PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Greene, NH; Kernic, MA; Vavilala, MS; Rivara, FP				Greene, Nathaniel. H.; Kernic, Mary A.; Vavilala, Monica S.; Rivara, Frederick P.			Variation in Pediatric Traumatic Brain Injury Outcomes in the United States	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference of the American-Society-of-Anesthesiologists	OCT 16, 2013	San Francisco, CA	Amer Soc Anesthesiologists		Healthcare disparities; Patient outcome assessment; Rehabilitation; Traumatic brain injury	FUNCTIONAL OUTCOMES; INSURANCE STATUS; CHILDREN; ADMISSION; REGISTRY; CARE	Objective: To ascertain the degree of variation, by state of hospitalization, in outcomes associated with traumatic brain injury (TBI) in a pediatric population. Design: A retrospective cohort study of pediatric patients admitted to a hospital with a TBI. Setting: Hospitals from states in the United States that voluntarily participate in the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project. Participants: Pediatric (age <= 19y) patients hospitalized for TBI (N = 71,476) in the United States during 2001, 2004, 2007, and 2010. Interventions: None. Main Outcome Measures: Primary outcome was proportion of patients discharged to rehabilitation after an acute care hospitalization among alive discharges. The secondary outcome was inpatient mortality. Results: The relative risk of discharge to inpatient rehabilitation varied by as much as 3-fold among the states, and the relative risk of inpatient mortality varied by as much as nearly 2-fold. In the United States, approximately 1981 patients could be discharged to inpatient rehabilitation care if the observed variation in outcomes was eliminated. Conclusions: There was significant variation between states in both rehabilitation discharge and inpatient mortality after adjusting for variables known to affect each outcome. Future efforts should be focused on identifying the cause of this state-to-state variation, its relationship to patient outcome, and standardizing treatment across the United States. (C) 2014 by the American Congress of Rehabilitation Medicine	[Greene, Nathaniel. H.; Vavilala, Monica S.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA USA; [Greene, Nathaniel. H.; Kernic, Mary A.; Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Kernic, Mary A.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA; [Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA		Greene, NH (corresponding author), Duke Univ Hosp, DUMC Box 3094, Durham, NC 27710 USA.	nathaniel.greene@duke.edu	Greene, Nathaniel/J-3450-2014	Greene, Nathaniel/0000-0003-0230-0499	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS072308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER		Clark DE., ICDPIC STATA MODULE; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cummings P, 2009, ARCH PEDIAT ADOL MED, V163, P438, DOI 10.1001/archpediatrics.2009.31; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Hamlat CA, 2012, ANN SURG, V255, P165, DOI 10.1097/SLA.0b013e31823840ca; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Rice-Townsend S, 2013, J PEDIATR SURG, V48, P104, DOI 10.1016/j.jpedsurg.2012.10.025; Scales CD, 2011, J UROLOGY, V186, P146, DOI 10.1016/j.juro.2011.03.018; Sears JM, 2014, INJURY, V45, P16, DOI 10.1016/j.injury.2012.12.024; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Stallion A, 2007, J TRAUMA, V62, P1262; Svenson JE, 2001, AM J EMERG MED, V19, P19, DOI 10.1053/ajem.2001.18041; Tepas JJ, 2009, J PEDIATR SURG, V44, P368, DOI 10.1016/j.jpedsurg.2008.10.089; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	16	45	45	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2014	95	6					1148	1155		10.1016/j.apmr.2014.02.020			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	AI3OY	WOS:000336773000020	24631594	Green Accepted, Green Submitted			2022-02-06	
J	Inui, TS; Parina, R; Chang, DC; Inui, TS; Coimbra, R				Inui, Tazo Stowe; Parina, Ralitza; Chang, David C.; Inui, Thomas S.; Coimbra, Raul			Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: A long-term analysis of risk versus benefit	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Warfarin; ground-level fall; head injury; mortality; population outcomes	TRAUMATIC INTRACRANIAL HEMORRHAGE; PREINJURY WARFARIN; BRAIN-INJURY; HEAD-INJURY; OUTCOMES; INTERVENTION; CLOPIDOGREL; ALCOHOL; ASPIRIN; STROKE	BACKGROUND Elderly patients with atrial fibrillation or flutter who experience ground-level falls are at risk for lethal head injuries. Patients on oral anticoagulation (OAC) for thromboprophylaxis may be at higher risk for these head injuries. Trauma surgeons treating these patients face a difficult choice: (1) continue OAC to minimize stroke risk while increasing the risk of a lethal head injury or (2) discontinue OAC to avoid intracranial hemorrhage while increasing the risk of stroke. To inform this choice, we conducted a retrospective cohort study to assess long-term outcomes and risk factors for mortality after presentation with a ground-level fall among patients with and without OAC. METHODS Retrospective analysis of the longitudinal version of the California Office of Statewide Planning and Development database was performed for years 1995 to 2009. Elderly anticoagulated patients (age > 65 years) with known atrial fibrillation or flutter who fell were stratified by CHA(2)DS(2)-VASc score and compared with a nonanticoagulated control cohort. Multivariable logistic regression including patient demographics, stroke risk, injury severity, and hospital type identified risk factors for mortality. RESULTS A total of 377,873 patient records met the inclusion criteria, 42,913 on OAC and 334,960 controls. The mean age was 82.4 and 80.6 years, respectively. Most were female, with CHA(2)DS(2)-VASc scores between 3 and 5. Mortality among OAC patients after a first fall was 6%, compared with 3.1% among non-OAC patients. Patients dying with a head injury constituted 31.6% of deaths within OAC patients compared with 23.8% among controls. Risk of eventual death with head injury exceeded annualized stroke risk for patients with CHA(2)DS(2)-VASc scores of 0 to 2. Predictors for mortality with head injury on the first admission included male sex, Asian ethnicity, a history of stroke, and trauma center admission. CONCLUSION Elderly patients on OAC for atrial fibrillation and/or flutter who fall have a greater risk for mortality compared with controls. Patients with low CHA(2)DS(2)-VASc scores (0-3) at high risk for falls with identified risk factors should speak to their prescribing physicians regarding the risk/benefits of continued use of OAC. LEVEL OF EVIDENCE Epidemiologic/prognostic study, level III.	[Inui, Tazo Stowe; Parina, Ralitza; Chang, David C.; Coimbra, Raul] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Inui, Thomas S.] Indiana Univ, Indianapolis, IN 46204 USA		Inui, TS (corresponding author), Univ Calif San Diego, Dept Surg, 200 W Arbor Dr,Mail Code 8400, San Diego, CA 92103 USA.	tinui@ucsd.edu; rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851	Haemonetics; TEM Systems, Inc.; LFB Biotechnologies	Ernest E. Moore, Editor: PI, research support, Haemonetics; PI, research support, TEM Systems, Inc. Ronald V. Maier, Associate editor: consultant, consulting fee, LFB Biotechnologies. Associate editors: David Hoyt and Steven Shackford have nothing to disclose. Editorial staff: Jennifer Crebs, Jo Fields, and Angela Sauaia have nothing to disclose.	Aguilar M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001925.pub2; Aguilar MI, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001927.pub2; Brewer ES, 2011, J TRAUMA, V70, pE1, DOI 10.1097/TA.0b013e3181e5e286; Bueno-Cavanillas A, 2000, EUR J EPIDEMIOL, V16, P849, DOI 10.1023/A:1007636531965; Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253; Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/europace/euq350, 10.1093/eurheartj/ehq278]; Chu LW, 2005, ANN ACAD MED SINGAP, V34, P60; Claudia C, 2011, J TRAUMA, V70, P906, DOI 10.1097/TA.0b013e3182031ab7; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Coppens M, 2013, EUR HEART J, V34, P170, DOI 10.1093/eurheartj/ehs314; Fang MC, 2011, J AM COLL CARDIOL, V58, P395, DOI 10.1016/j.jacc.2011.03.031; *FDA, WARF PROD LAB; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2006, AM HEART J, V151, P713, DOI 10.1016/j.ahj.2005.04.017; Gangavati AS, 2009, J AM GERIATR SOC, V57, P1470, DOI 10.1111/j.1532-5415.2009.02344.x; Hori M, 2011, CIRC J, V75, P800, DOI 10.1253/circj.CJ-11-0191; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Inamasu J, 2012, GERIATR GERONTOL INT, V12, P667, DOI 10.1111/j.1447-0594.2012.00838.x; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2006, J TRAUMA, V61, P318, DOI 10.1097/01.ta.0000223944.25922.91; Johnson JA, 2008, CIRCULATION, V118, P1383, DOI 10.1161/CIRCULATIONAHA.107.704023; Karni A, 2001, AM SURGEON, V67, P1098; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Leukhardt WH, 2010, AM J SURG, V199, P348, DOI 10.1016/j.amjsurg.2009.09.021; Lip GYH, 2011, J AM COLL CARDIOL, V57, P173, DOI 10.1016/j.jacc.2010.09.024; Luchette F, 2010, SURGERY, V148, P729; Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1; Medical Advisory Secretariat, 2008, Ont Health Technol Assess Ser, V8, P1; Meschia JF, 2010, STROKE, V41, P581, DOI 10.1161/STROKEAHA.109.573907; Moore MM, 2012, J TRAUMA ACUTE CARE, V73, P126, DOI 10.1097/TA.0b013e31824b01af; Moyer TP, 2009, MAYO CLIN PROC, V84, P1079, DOI 10.4065/mcp.2009.0278; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Ogawa S, 2010, CIRC J, V74, P2479, DOI 10.1253/circj.CJ-88-0001; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Pernod G, 2013, ARCH CARDIOVASC DIS, V106, P382, DOI 10.1016/j.acvd.2013.04.009; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Schermer CR, 2005, J TRAUMA, V59, pS119, DOI 10.1097/01.ta.0000174679.12567.7c; Siracuse JJ, 2010, SURGERY, V148, P724, DOI 10.1016/j.surg.2010.07.014; Sise MJ, 2005, J TRAUMA, V59, pS112, DOI 10.1097/01.ta.0000176045.95492.01; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	43	45	46	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2014	76	3					642	649		10.1097/TA.0000000000000138			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AB8YW	WOS:000332077100021	24553530				2022-02-06	
J	Sharma, J; Johnston, MV; Hossain, MA				Sharma, Jaswinder; Johnston, Michael V.; Hossain, Mir Ahamed			Sex differences in mitochondrial biogenesis determine neuronal death and survival in response to oxygen glucose deprivation and reoxygenation	BMC NEUROSCIENCE			English	Article						Hypoxia-ischemia; Mitochondrial DNA; Mitochondrial fusion and fission; Donut mitochondria; Sexual dimorphism	CEREBELLAR GRANULE NEURONS; TRAUMATIC BRAIN-INJURY; CELL-DEATH; HYPOXIA-ISCHEMIA; GROWTH-FACTOR; TRANSCRIPTION; EXPRESSION; APOPTOSIS; DYNAMICS; PATHWAY	Background: Mitochondrial dysfunction has been linked to neuronal death and a wide array of neurodegenerative diseases. Previously, we have shown sex differences in mitochondria-mediated cell death pathways following hypoxia-ischemia. However, the role of mitochondrial biogenesis in hypoxic-ischemic brain injury between male vs. female has not been studied yet. Results: Primary cerebellar granule neurons (CGNs), isolated from P7 male and female mice (CD-1) segregated based on visual inspection of sex, were exposed to 2 h of oxygen glucose deprivation (OGD) followed by 6-24 h of reoxygenation (Reox). Mitochondrial membrane potential (Delta psi(m)) and cellular ATP levels were reduced significantly in XX CGNs as compared to XY CGNs. Mitochondrial DNA (mtDNA) content was increased (>2-fold) at 2 h OGD in XY CGNs and remained increased up to 24 h of Reox compared to XX neurons and normoxia controls. The expression of mitochondrial transcription factor A (Tfam), the nuclear respiratory factor-1 (NRF-1) and the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha), a master regulator of mitochondrial biogenesis, were up-regulated (2-fold, ***p < 0.001) in XY CGNs but slightly reduced or remained unchanged in XX neurons. Similarly, the TFAM and PGC-1 alpha protein levels and the mitochondrial proteins HSP60 and COXIV were increased in XY neurons only. Supportively, a balanced stimulation of fusion (Mfn 1 and Mfn 2) and fission (Fis 1 and Drp 1) genes and enhanced formation of donut-shaped mitochondria were observed in XY CGNs vs. XX neurons (**p < 0.01). Conclusions: Our results demonstrate that OGD/Reox alters mitochondrial biogenesis and morphological changes in a sex-specific way, influencing neuronal injury/survival differently in both sexes.	[Sharma, Jaswinder; Johnston, Michael V.; Hossain, Mir Ahamed] Hugo W Moser Res Inst Kennedy Krieger, Dept Neurol, Baltimore, MD 21205 USA; [Sharma, Jaswinder; Johnston, Michael V.; Hossain, Mir Ahamed] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Johnston, Michael V.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA		Hossain, MA (corresponding author), Hugo W Moser Res Inst Kennedy Krieger, Dept Neurol, Baltimore, MD 21205 USA.	hossain@kennedykrieger.org			National Institutes of Health from National Institute of Neurological Disorders and Stroke [RO1 NS028208, RO1NS046030]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046030, R01NS028208] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grants RO1 NS028208 (MVJ) and RO1NS046030 (MAH) from the National Institute of Neurological Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.	Arnold S, 2008, J MOL ENDOCRINOL, V41, P289, DOI 10.1677/JME-08-0085; Bertoni-Freddari C, 2006, ANN NY ACAD SCI, V1090, P26, DOI 10.1196/annals.1378.003; Blomgren K, 2006, FREE RADICAL BIO MED, V40, P388, DOI 10.1016/j.freeradbiomed.2005.08.040; Carruth LL, 2002, NAT NEUROSCI, V5, P933, DOI 10.1038/nn922; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Chen H, 2001, STROKE, V32, P2382, DOI 10.1161/hs1001.097099; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Golomb MR, 2008, J CHILD NEUROL, V23, P279, DOI 10.1177/0883073807309246; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; Guo YF, 2008, ACTA BIOCH BIOPH SIN, V40, P426, DOI 10.1111/j.1745-7270.2008.00418.x; Gutsaeva DR, 2008, J NEUROSCI, V28, P2015, DOI 10.1523/JNEUROSCI.5654-07.2008; Hood DA, 2003, MED SCI SPORT EXER, V35, P86, DOI 10.1097/00005768-200301000-00015; Hossain MA, 2004, J NEUROSCI, V24, P4187, DOI 10.1523/JNEUROSCI.0347-04.2004; Hossain MA, 2002, J NEUROCHEM, V81, P365, DOI 10.1046/j.1471-4159.2002.00837.x; Kain KH, 2000, BBA-GENE STRUCT EXPR, V1494, P91, DOI 10.1016/S0167-4781(00)00223-2; Kaufman BA, 2003, J CELL BIOL, V163, P457, DOI 10.1083/jcb.200306132; Lagranha CJ, 2010, CIRC RES, V106, P1681, DOI 10.1161/CIRCRESAHA.109.213645; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Liu FD, 2011, STROKE, V42, P1090, DOI 10.1161/STROKEAHA.110.594861; Liu X, 2011, CELL DEATH DIFFER, V18, P1561, DOI 10.1038/cdd.2011.13; Mandemakers W, 2007, J CELL SCI, V120, P1707, DOI 10.1242/jcs.03443; Mecleiros DM, 2008, METHODS, V46, P288, DOI 10.1016/j.ymeth.2008.09.026; Osellame LD, 2012, BEST PRACT RES CL EN, V26, P711, DOI 10.1016/j.beem.2012.05.003; Penaloza C, 2009, FASEB J, V23, P1869, DOI 10.1096/fj.08-119388; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puka-Sundvall M, 2000, DEV BRAIN RES, V125, P31, DOI 10.1016/S0165-3806(00)00110-3; Renolleau S, 2008, NEUROSCIENTIST, V14, P46, DOI 10.1177/1073858407308889; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; Sharma J, 2011, ASN NEURO, V3, DOI 10.1042/AN20100032; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Soltys BJ, 1996, EXP CELL RES, V222, P16, DOI 10.1006/excr.1996.0003; Su B, 2010, BBA-MOL BASIS DIS, V1802, P135, DOI 10.1016/j.bbadis.2009.09.013; Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508; Vosler PS, 2009, STROKE, V40, P3149, DOI 10.1161/STROKEAHA.108.543769; Wang CX, 2009, ANNU REV GENET, V43, P95, DOI 10.1146/annurev-genet-102108-134850; Xu SC, 2010, BRAIN RES, V1311, P189, DOI 10.1016/j.brainres.2009.10.062; Yin W, 2008, STROKE, V39, P3057, DOI 10.1161/STROKEAHA.108.520114	46	45	45	0	11	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	JAN 10	2014	15								9	10.1186/1471-2202-15-9			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	294NW	WOS:000330054500001	24410996	gold, Green Published			2022-02-06	
J	Allen, BB; Chiu, YL; Gerber, LM; Ghajar, J; Greenfield, JP				Allen, Baxter B.; Chiu, Ya-lin; Gerber, Linda M.; Ghajar, Jamshid; Greenfield, Jeffrey P.			Age-Specific Cerebral Perfusion Pressure Thresholds and Survival in Children and Adolescents With Severe Traumatic Brain Injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cerebral perfusion pressure; head trauma; severe traumatic brain injury; traumatic brain injury management	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; INTRACRANIAL-PRESSURE; RISK-FACTORS; PREDICTORS; AUTOREGULATION; HYPERTENSION; MANAGEMENT; OUTCOMES; SCORE	Objectives: Evidence-based traumatic brain injury guidelines support cerebral perfusion pressure thresholds for adults at a class 2 level, but evidence is lacking in younger patients. The purpose of this study is to identify the impact of age-specific cerebral perfusion pressure thresholds on short-term survival among patients with severe traumatic brain injury. Design: Institutional review board-approved, prospective, observational cohort study. Setting: Level I or II trauma centers in New York State. Patients: Data on all patients with a postresuscitation Glasgow Coma Score less than 9 were added in the Brain Trauma Foundation prospective New York State TBI-trac database. Measurements and Main Results: We calculated the survival rates and relative risks of mortality for patients with severe traumatic brain injury based on predefined age-specific cerebral perfusion pressure thresholds. A higher threshold and a lower threshold were defined for each age group: 60 and 50mm Hg for 12 years old or older, 50 and 35mm Hg for 6-11 years, and 40 and 30mm Hg for 0-5 years. Patients were stratified into age groups of 0-11, 12-17, and 18 years old or older. Three exclusive groups of CPP-L (events below low cerebral perfusion pressure threshold), CPP-B (events between high and low cerebral perfusion pressure thresholds), and CPP-H (events above high cerebral perfusion pressure threshold) were defined. As an internal control, we evaluated the associations between cerebral perfusion pressure events and events of hypotension and elevated intracranial pressure. Survival was significantly higher in 0-11 and 18 years old or older age groups for patients with CPP-H events compared with those with CPP-L events. There was a significant decrease in survival with prolonged exposure to CPP-B events for the 0-11 and 18 years old and older age groups when compared with the patients with CPP-H events (p = 0.0001 and p = 0.042, respectively). There was also a significant decrease in survival with prolonged exposure to CPP-L events in all age groups compared with the patients with CPP-H events (p< 0.0001 for 0- to 11-yr olds, p = 0.0240 for 12- to 17-yr olds, and p < 0.0001 for 18-yr old and older age groups). The 12- to 17-year olds had a significantly higher likelihood of survival compared with adults with prolonged exposure to CPP-L events (< 50mm Hg). CPP-L events were significantly related to systemic hypotension for the 12- to 17-year-old group (p = 0.004) and the 18-year-old and older group (p < 0.0001). CPP-B events were significantly related to systemic hypotension in the 0- to 11-year-old group (p = 0.014). CPP-B and CPP-L events were significantly related to elevated intracranial pressure in all age groups. Conclusions: Our data provide new evidence that cerebral perfusion pressure targets should be age specific. Furthermore, cerebral perfusion pressure goals above 50 or 60mm Hg in adults, above 50mm Hg in 6- to 17-year olds, and above 40mm Hg in 0- to 5-year olds seem to be appropriate targets for treatment-based studies. Systemic hypotension had an inconsistent relationship to events of low cerebral perfusion pressure, whereas elevated intracranial pressure was significantly related to all low cerebral perfusion pressure events across all age groups. This may impart a clinically important difference in care, highlighting the necessity of controlling intracranial pressure at all times, while targeting systolic blood pressure in specific instances.	[Allen, Baxter B.] Weill Cornell Med Coll, Dept Neurol, New York, NY USA; [Chiu, Ya-lin] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA; [Gerber, Linda M.; Ghajar, Jamshid] Jamaica Hosp Med Ctr, Dept Surg, New York, NY USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA; [Greenfield, Jeffrey P.] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA		Allen, BB (corresponding author), Weill Cornell Med Coll, Dept Neurol, New York, NY USA.	bba2003@nyp.org	Allen, Baxter/X-3841-2019	Greenfield, Jeffrey/0000-0003-1904-1040	New York State Department of Health; New York Presbyterian Hospital TBI fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000457] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024996] Funding Source: NIH RePORTER	The authors thank the New York State Department of Health and the New York Presbyterian Hospital TBI fund for their financial support.	Adamo MA, 2009, J NEUROSURG-PEDIATR, V4, P414, DOI 10.3171/2009.6.PEDS0939; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Division of Vital Statistics National Center for Health Statistics Deaths, 2009, PERC TOT DEATHS DEAT; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Heron M, 2010, PEDIATRICS, V125, P4, DOI 10.1542/peds.2009-2416; Hutchison JS, 2010, DEV NEUROSCI-BASEL, V32, P406, DOI 10.1159/000323260; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS24, DOI 10.1097/PCC.0b013e31823f4450; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS18, DOI 10.1097/PCC.0b013e31823f4424; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Nijboer JMM, 2010, INJURY, V41, P52, DOI 10.1016/j.injury.2009.05.030; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Pearl GS, 1998, CLIN LAB MED, V18, P39; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Rhine T, 2012, J TRAUMA ACUTE CARE, V73, pS248, DOI 10.1097/TA.0b013e31826b0062; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Scaife ER, 2010, CURR OPIN PEDIATR, V22, P339, DOI 10.1097/MOP.0b013e3283395f2b; Schramm P, 2011, J NEUROSURG ANESTH, V23, P41, DOI 10.1097/ANA.0b013e3181f35854; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; Shein SL, 2012, J PEDIATR-US, V161, P716, DOI 10.1016/j.jpeds.2012.03.046; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]	52	45	48	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2014	15	1					62	70		10.1097/PCC.0b013e3182a556ea			9	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	285BS	WOS:000329368400014	24196011	Green Accepted			2022-02-06	
J	Conley, KM; Bolin, DJ; Carek, PJ; Konin, JG; Neal, TL; Violette, D				Conley, Kevin M.; Bolin, Delmas J.; Carek, Peter J.; Konin, Jeff G.; Neal, Timothy L.; Violette, Danielle			National Athletic Trainers' Association Position Statement: Preparticipation Physical Examinations and Disqualifying Conditions	JOURNAL OF ATHLETIC TRAINING			English	Article						medical history; family history; sudden cardiac death; concussion; sickle cell trait; diabetes; heat illness; hydration	SICKLE-CELL TRAIT; SUDDEN CARDIAC DEATH; EXERCISE-INDUCED ASTHMA; HIGH-SCHOOL; HYPERTROPHIC CARDIOMYOPATHY; CARDIOVASCULAR-DISEASE; UNITED-STATES; INDUCED BRONCHOSPASM; COLLISION ACTIVITIES; COMPETITIVE ATHLETE	Objective: To present athletic trainers with recommendations for the content and administration of the preparticipation physical examination (PPE) as well as considerations for determining safe participation in sports and identifying disqualifying conditions. Background: Preparticipation physical examinations have been used routinely for nearly 40 years. However, considerable debate exists as to their efficacy due to the lack of standardization in the process and the lack of conformity in the information that is gathered. With the continuing rise in sports participation at all levels and the growing number of reported cases of sudden death in organized athletics, the sports medicine community should consider adopting a standardized process for conducting the PPE to protect all parties. Recommendations: Recommendations are provided to equip the sports medicine community with the tools necessary to conduct the PPE as effectively and efficiently as possible using available scientific evidence and best practices. In addition, the recommendations will help clinicians identify those conditions that may threaten the health and safety of participants in organized sports, may require further evaluation and intervention, or may result in potential disqualification.	[Conley, Kevin M.] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Carek, Peter J.] Med Univ S Carolina, Charleston, SC USA; [Konin, Jeff G.] Univ S Florida, Tampa, FL USA; [Neal, Timothy L.] Syracuse Univ, Syracuse, NY 13244 USA; [Violette, Danielle] Washington Hosp, Dept Orthoped & Neurosci, Washington, PA 15301 USA		Conley, KM (corresponding author), Natl Athlet Trainers Assoc, Dept Commun, 1620 Valwood Pkway,Suite 115, Carrollton, TX 75006 USA.		Asad, Saeed A/J-9142-2017; Asad, Saeed A/E-6236-2019	Asad, Saeed A/0000-0002-9242-3806; Asad, Saeed A/0000-0002-9242-3806			American Academy of Family Physicians American Academy of Pediatrics American College of Sports Medicine American Medical Society for Sports Medicine American Orthopaedic Society for Sports Medicine American Osteopathic Academy of Sports Medicine, 2010, PPE PREP PHYS EV; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; [Anonymous], 2000, Am J Sports Med, V28, P440; [Anonymous], 2000, MED SCI SPORT EXER, V32, P877; [Anonymous], 1994, Arch Pediatr Adolesc Med, V148, P93; [Anonymous], 2010 11 HIGH SCH ATH; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Basavarajaiah S, 2008, J AM COLL CARDIOL, V51, P1033, DOI 10.1016/j.jacc.2007.10.055; Basso C, 2000, J AM COLL CARDIOL, V35, P1493, DOI 10.1016/S0735-1097(00)00566-0; Beckerman J, 2004, CLIN J SPORT MED, V14, P127, DOI 10.1097/00042752-200405000-00004; Blader JC, 2011, ARCH GEN PSYCHIAT, V68, P1276, DOI 10.1001/archgenpsychiatry.2011.84; Bonci CM, 2008, J ATHL TRAINING, V43, P80, DOI 10.4085/1062-6050-43.1.80; Boyajian-O'Neill L, 2004, PHYSICIAN SPORTSMED, V32, P29, DOI 10.1080/00913847.2004.11440756; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; Buyukyazi G, 2005, J SPORT MED PHYS FIT, V45, P112; Cantu RC, 1999, PHYSICIAN SPORTSMED, V27, P35, DOI 10.3810/psm.1999.08.945; Carek P J, 2001, J Med Liban, V49, P292; Carek PJ, 2003, J FAM PRACTICE, V52, P127; Carek PJ, 1999, CLIN J SPORT MED, V9, P124, DOI 10.1097/00042752-199907000-00002; Carek PJ, 1999, ARCH FAM MED, V8, P307, DOI 10.1001/archfami.8.4.307; Carek PJ, 2007, EVIDENCE BASED SPORT; Carroll JFX, 2001, ALCOHOL TREAT Q, V19, P33, DOI DOI 10.1300/J020v19n04_02; Casa DJ, 2000, J ATHL TRAINING, V35, P212; Casa DJ, 2009, J ATHL TRAINING, V44, P332, DOI 10.4085/1062-6050-44.3.332; Chizner MA, 2002, DM-DIS MON, V48, P7, DOI 10.1067/mda.2002.115501; Connes P, 2008, SPORTS MED, V38, P931, DOI 10.2165/00007256-200838110-00004; Corrado D, 2003, J AM COLL CARDIOL, V42, P1959, DOI 10.1016/j.jacc.2003.03.002; Corrado D, 1998, NEW ENGL J MED, V339, P364, DOI 10.1056/NEJM199808063390602; Corrado D, 2006, JAMA-J AM MED ASSOC, V296, P1593, DOI 10.1001/jama.296.13.1593; Corrigan B, 2003, CLIN J SPORT MED, V13, P33, DOI 10.1097/00042752-200301000-00007; Cowell BS, 2003, INT J SPORT NUTR EXE, V13, P277, DOI 10.1123/ijsnem.13.3.277; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crawford M H, 1979, Adv Intern Med, V24, P311; Di Santolo M, 2008, EUR J APPL PHYSIOL, V102, P703, DOI 10.1007/s00421-007-0647-9; DODGE WF, 1976, J PEDIATR-US, V88, P327, DOI 10.1016/S0022-3476(76)81012-8; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Eberman LE, 2011, J ATHL TRAINING, V46, P176, DOI 10.4085/1062-6050-46.2.176; Eberman LE, 2009, ATHLET THER TODAY, V14, P4, DOI 10.1123/att.14.4.4; Eisenmann JC, 2002, SPORTS MED, V32, P297, DOI 10.2165/00007256-200232050-00002; Eliakim A, 2002, J SPORT MED PHYS FIT, V42, P250; EPSTEIN SE, 1986, J AM COLL CARDIOL, V7, P220, DOI 10.1016/S0735-1097(86)80285-6; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Fallon KE, 2004, CLIN J SPORT MED, V14, P145, DOI 10.1097/00042752-200405000-00007; Fallon KE, 2008, J SCI MED SPORT, V11, P329, DOI 10.1016/j.jsams.2007.02.017; Feinstein RA, 1996, CLIN J SPORT MED, V6, P119; FRANCIS CK, 1980, CATHETER CARDIO DIAG, V6, P73, DOI 10.1002/ccd.1810060109; Fuller CM, 2000, MED SCI SPORT EXER, V32, P887; Fuller CM, 1997, MED SCI SPORT EXER, V29, P1131, DOI 10.1097/00005768-199709000-00003; GARRICK JG, 1980, PEDIATRICS, V66, P803; Garrick JG, 2004, CLIN J SPORT MED, V14, P123, DOI 10.1097/00042752-200405000-00003; Giese EA, 2007, AM FAM PHYSICIAN, V75, P1008; Glover DW, 1998, JAMA-J AM MED ASSOC, V279, P1817, DOI 10.1001/jama.279.22.1817; GOLDBERG B, 1980, PEDIATRICS, V66, P736; GOMEZ JE, 1993, AM J DIS CHILD, V147, P1109, DOI 10.1001/archpedi.1993.02160340095022; Grafe MW, 1997, CLIN SPORT MED, V16, P569, DOI 10.1016/S0278-5919(05)70043-0; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hedreville M, 2009, MED SCI SPORT EXER, V41, P13, DOI 10.1249/MSS.0b013e31818313d0; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; Huffman EA, 2008, J ATHL TRAINING, V43, P624, DOI 10.4085/1062-6050-43.6.624; HUSTON TP, 1985, NEW ENGL J MED, V313, P24, DOI 10.1056/NEJM198507043130106; Jimenez CC, 2007, J ATHL TRAINING, V42, P536; Joy EA, 2004, CLIN J SPORT MED, V14, P183, DOI 10.1097/00042752-200405000-00012; KARK JA, 1987, NEW ENGL J MED, V317, P781, DOI 10.1056/NEJM198709243171301; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; Kerle KK, 1996, AM FAM PHYSICIAN, V54, P237; Komatsu Y, 2009, RESPIROLOGY, V14, P217, DOI 10.1111/j.1440-1843.2008.01413.x; Kurowski K, 2000, AM FAM PHYSICIAN, V61, P2683; Le Gallais D, 2007, J APPL PHYSIOL, V103, P2137, DOI 10.1152/japplphysiol.00338.2007; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; Lippi G, 2006, CLIN CHEM LAB MED, V44, P322, DOI 10.1515/CCLM.2006.056; Lively MW, 1999, CLIN J SPORT MED, V9, P3, DOI 10.1097/00042752-199901000-00002; Lombardo J A, 2001, Clin Cornerstone, V3, P10, DOI 10.1016/S1098-3597(01)90066-3; LOMBARDO JA, 1984, PRIMARY CARE, V11, P3; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maron BJ, 2007, CARDIOL CLIN, V25, P399, DOI 10.1016/j.ccl.2007.07.006; Maron BJ, 2007, CIRCULATION, V115, P1643, DOI 10.1161/CIRCULATIONAHA.107.181423; Maron BJ, 2009, CIRCULATION, V119, P1085, DOI 10.1161/CIRCULATIONAHA.108.804617; Maron Barry J., 2003, Journal of the American College of Cardiology, V42, P1687, DOI 10.1016/S0735-1097(03)00941-0; Maron BJ, 2003, NEW ENGL J MED, V349, P1064, DOI 10.1056/NEJMra022783; Maron BJ, 2005, J AM COLL CARDIOL, V45, P1318, DOI 10.1016/j.jacc.2005.02.006; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; Maron BJ, 1998, NEW ENGL J MED, V339, P1632, DOI 10.1056/NEJM199811263392211; Maron BJ, 1998, J AM COLL CARDIOL, V32, P1881, DOI 10.1016/S0735-1097(98)00491-4; Maron BJ, 2003, J AM COLL CARDIOL, V41, P974, DOI 10.1016/S0735-1097(02)02976-5; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1994, J AM COLL CARDIOL, V24, P880, DOI 10.1016/0735-1097(94)90844-3; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1994, AM J CARDIOL, V73, P1098, DOI 10.1016/0002-9149(94)90290-9; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Matz SO, 2004, AM J SPORT MED, V32, P608, DOI 10.1177/0363546503262172; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Metzl JD, 2000, CLIN SPORT MED, V19, P577, DOI 10.1016/S0278-5919(05)70227-1; Miller MG, 2005, J ATHL TRAINING, V40, P224; Mitchell JH, 2005, J AM COLL CARDIOL, V45, P1364, DOI 10.1016/j.jacc.2005.02.015; Mitten MJ, 2005, J AM COLL CARDIOL, V45, P1373, DOI 10.1016/j.jacc.2005.02.019; Moulton MA, 1997, J ATHL TRAINING, V32, P148; Murphy RLH, 2008, RESP CARE, V53, P355; Myers A, 1998, PRIMARY CARE, V25, P225, DOI 10.1016/S0095-4543(05)70334-1; National Collegiate Athletic Association, 2011, 2011 12 NCAA SPORTS; National Collegiate Athletic Association, 2012, NCAA SPORTS SPONS PA; Nichols A W, 1995, Hawaii Med J, V54, P434; Parsons JP, 2007, MED SCI SPORT EXER, V39, P1487, DOI 10.1249/mss.0b013e3180986e45; Pelliccia A, 2000, CIRCULATION, V102, P278; PELLICCIA A, 1995, AM J CARDIOL, V75, P827, DOI 10.1016/S0002-9149(99)80421-4; Pelliccia A, 2008, NEW ENGL J MED, V358, P152, DOI 10.1056/NEJMoa060781; Pigozzi F, 2008, CLIN SPORT MED, V27, P153, DOI 10.1016/j.csm.2007.09.004; RICE SG, 1985, ANN ALLERGY, V55, P790; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; RIFAT SF, 1995, J FAM PRACTICE, V41, P42; RISSER WL, 1985, J SCHOOL HEALTH, V55, P270, DOI 10.1111/j.1746-1561.1985.tb04140.x; RISSER WL, 1985, TEX MED, V81, P35; Rodriguez JO, 2003, AM FAM PHYSICIAN, V67, P1481; Roh JLC, 2000, J ATHL TRAINING, V35, P458; Rundell KW, 2008, J ALLERGY CLIN IMMUN, V122, P238, DOI 10.1016/j.jaci.2008.06.014; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; RUPP NT, 1992, AM J DIS CHILD, V146, P941, DOI 10.1001/archpedi.1992.02160200063028; Sharma S, 1999, BRIT J SPORT MED, V33, P319, DOI 10.1136/bjsm.33.5.319; Shaskey DJ, 2000, SPORTS MED, V29, P27, DOI 10.2165/00007256-200029010-00003; Smith J, 1998, MAYO CLIN PROC, V73, P419; Substance Abuse and Mental Health Services Administration, 2010, RES 2009 NAT SURV DR; Szilagy P.G., 2003, BATES GUIDE PHYS EXA; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; Thompson PD, 2006, JAMA-J AM MED ASSOC, V296, P1648, DOI 10.1001/jama.296.13.1648; Torg JS, 1997, CLIN J SPORT MED, V7, P273, DOI 10.1097/00042752-199710000-00005; TORG JS, 1993, AM J SPORT MED, V21, P640, DOI 10.1177/036354659302100502; US Preventative Services Task Force, 1996, GUID CLIN PREV SERV, V2nd; Van Thuyne W, 2006, NUTR RES REV, V19, P147, DOI 10.1079/NRR2006122; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; Wingfield K, 2004, CLIN J SPORT MED, V14, P109, DOI 10.1097/00042752-200405000-00002; Yen KL, 2000, PEDIATR EMERG CARE, V16, P215, DOI 10.1097/00006565-200006000-00021; Zeppilli P, 1990, CARDIOLOGIA SPORT, P269	137	45	45	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-FEB	2014	49	1					102	120		10.4085/1062-6050-48.6.05			19	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	AQ3LX	WOS:000342696500015	24499039	Green Published			2022-02-06	
J	Jalloh, I; Helmy, A; Shannon, RJ; Gallagher, CN; Menon, DK; Carpenter, KLH; Hutchinson, PJ				Jalloh, Ibrahim; Helmy, Adel; Shannon, Richard J.; Gallagher, Clare N.; Menon, David K.; Carpenter, Keri L. H.; Hutchinson, Peter J.			Lactate Uptake by the Injured Human Brain: Evidence from an Arteriovenous Gradient and Cerebral Microdialysis Study	JOURNAL OF NEUROTRAUMA			English	Article						metabolism; microdialysis; traumatic brain injury (human)	MONOCARBOXYLATE TRANSPORTER-2 EXPRESSION; PENTOSE-PHOSPHATE PATHWAY; TRICARBOXYLIC-ACID CYCLE; COGNITIVE DEFICITS; GLUCOSE; BLOOD; METABOLISM; FLUX; RAT; DYSFUNCTION	Lactate has been regarded as a waste product of anaerobic metabolism of glucose. Evidence also suggests, however, that the brain may use lactate as an alternative fuel. Our aim was to determine the extent of lactate uptake from the circulation into the brain after traumatic brain injury (TBI) and to compare it with levels of lactate in the brain extracellular fluid. We recruited 19 patients with diffuse TBI, monitored with cerebral microdialysis and jugular bulb catheters. Serial arteriovenous (AV) concentration differences of glucose and lactate were calculated from arterial and jugular blood samples, providing a measure of net uptake or export by the brain. Microdialysis was used to measure brain extracellular glucose and lactate. In 17/19 patients studied for 5 days post-injury, there were periods of net lactate uptake into the brain, most frequently on day 3 after injury. Brain microdialysate lactate had a median (interquartile range [IQR]) concentration of 2.5 (1.5-3.2) mmol/L during lactate uptake and 2.2 (1.7-3.0) mmol/L during lactate export. Lactate uptake into the brain occurred at a median (IQR) arterial lactate concentration of 1.6 (1.0-2.2) mmol/L. Lactate uptake was associated with significantly higher AV difference in glucose values with a median (IQR) of 0.4 (0.03-0.7) mmol/L during uptake and 0.1 (-0.2-0.3) mmol/L during lactate export (Mann-Whitney U p=0.003). Despite relatively high brain lactate compared with arterial lactate concentrations, the brain appears to up-regulate lactate transport into the brain after TBI. This may serve to satisfy greater demands for energy substrate from the brain after TBI.	[Jalloh, Ibrahim; Helmy, Adel; Shannon, Richard J.; Carpenter, Keri L. H.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [Gallagher, Clare N.] Univ Calgary, Dept Clin Neurosci, Div Neurosurg, Calgary, AB, Canada; [Menon, David K.] Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge CB2 0QQ, England		Jalloh, I (corresponding author), Univ Cambridge, Sch Clin Med, Div Neurosurg, Dept Clin Neurosci, Box 167 Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	ij232@cam.ac.uk	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Carpenter, Keri/0000-0001-8236-7727; Hutchinson, Peter/0000-0002-2796-1835	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986 ID79068, G1002277 ID98489]; National Institute for Health Research Biomedical Research Centre CambridgeNational Institute for Health Research (NIHR); Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251]; Raymond and Beverly Sackler Fellowship; National Institute for Health Research Flexibility and Sustainability Fund; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251, G9439390, G1002277, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354, G0600986, G0802251, G9439390, G1002277, G0001354B, G1000183B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, ACF-2006-14-004] Funding Source: researchfish	We thank Mr. M. Guilfoyle for statistical advice. We gratefully acknowledge financial support as follows. Study support: Medical Research Council (Grant Nos. G0600986 ID79068 and G1002277 ID98489) and National Institute for Health Research Biomedical Research Centre Cambridge. Authors' support: I.J. - Medical Research Council (Grant no. G1002277 ID 98489) and National Institute for Health Research Biomedical Research Centre Cambridge; A. H. - Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship (Grant no. G0802251) and Raymond and Beverly Sackler Fellowship; K. L. H. C. - National Institute for Health Research Biomedical Research Centre Cambridge; RJS - National Institute for Health Research Flexibility and Sustainability Fund; P.J.H. - Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship and National Institute for Health Research Biomedical Research Centre Cambridge.	Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Beards SC, 1998, ANAESTHESIA, V53, P627; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; CMA Microdialysis AB, 2008, TECHN MAN ISCUS FLEX, P16; DAGER SR, 1992, LIFE SCI, V51, P973, DOI 10.1016/0024-3205(92)90404-D; Dalsgaard MK, 2006, J CEREBR BLOOD F MET, V26, P731, DOI 10.1038/sj.jcbfm.9600256; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; ENEVOLDSEN EM, 1977, CLIN NEUROL NEUROSUR, V80, P213; Espenell AEG, 2010, CAN J ANESTH, V57, P903, DOI 10.1007/s12630-010-9356-7; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gibbs EL, 1942, J BIOL CHEM, V144, P325; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Ide K, 2000, J PHYSIOL-LONDON, V522, P159, DOI 10.1111/j.1469-7793.2000.t01-2-00159.xm; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Larsen TS, 2008, J PHYSIOL-LONDON, V586, P2807, DOI 10.1113/jphysiol.2008.151449; Leegsma-Vogt G, 2001, J NEUROSCI RES, V66, P795, DOI 10.1002/jnr.10046; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Meierhans R, 2012, MINERVA ANESTESIOL, V78, P185; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Pierre K, 2003, J NEUROCHEM, V86, P1468, DOI 10.1046/j.1471-4159.2003.01964.x; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Quistorff B, 2008, FASEB J, V22, P3443, DOI 10.1096/fj.08-106104; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Sun FF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034525; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073	43	45	47	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2031	2037		10.1089/neu.2013.2947			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500004	23968221	Green Published			2022-02-06	
J	Fridman, L; Fraser-Thomas, JL; McFaull, SR; Macpherson, AK				Fridman, Liraz; Fraser-Thomas, Jessica L.; McFaull, Steven R.; Macpherson, Alison K.			Epidemiology of sports-related injuries in children and youth presenting to Canadian emergency departments from 2007-2010	BMC SPORTS SCIENCE MEDICINE AND REHABILITATION			English	Article						Epidemiology; Sports-related injuries; Pediatric injuries		Background: Although injuries related to sports and recreation represent a significant burden to children and youth, few studies have examined the descriptive epidemiology of sports-related injury since 2005, and some sports such as ringette have not been evaluated to date. The primary purpose of this study was to provide the descriptive epidemiology of sports-related injuries treated in emergency departments for children and youth aged 5 - 19. Methods: A retrospective data analysis was performed using data from the Canadian Hospitals Injury Reporting and Prevention Program [CHIRPP] from fiscal years (April -March) 2007/08 to 2009/10. CHIRPP is a computerized information system designed by the Public Health Agency of Canada that collects information about injuries to people evaluated in emergency departments across 11 pediatric hospitals and 5 general hospitals in Canada. Thirteen sports or activities were analyzed (baseball, basketball, cycling, football, ice hockey, lacrosse, ringette, rugby, skiing, sledding, snowboarding, soccer, and volleyball). Descriptive statistics, including frequency by sport, age and sex, as well as the percent of concussions within each sport were calculated. Results: Out of a total of 56, 691 reported sports and recreational injuries, soccer accounted for the largest proportion of injuries with 11,941 reported cases over the 3 year time period. Of these, approximately 30% were fractures. The 10 -14 year age group reported the greatest proportion of injuries in 10 out of the 13 sports analyzed. In addition, males reported a greater number of overall injuries than females in 11 out of the 13 sports analyzed. The largest percentage of concussions was reported in ringette; these injuries accounted for 17.1% of overall injuries within this sport. Conclusions: Injury prevention programs in Canada should focus on improving evidence-based programs to reduce the burden of injuries in all sports.	[Fridman, Liraz; Fraser-Thomas, Jessica L.; Macpherson, Alison K.] York Univ, Sch Kinesiol & Hlth Sci, 4700 Keele St, Toronto, ON M3J 1P3, Canada; [McFaull, Steven R.] Publ Hlth Agcy Canada, Ctr Chron Dis Prevent & Control, Hlth Surveillance & Epidemiol Div, Injury & Child Maltreatment Sect, Ottawa, ON K1A 0K9, Canada		Fridman, L (corresponding author), York Univ, Sch Kinesiol & Hlth Sci, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	liraz@yorku.ca					BEAULNE G, 1997, SAFETY CANADIAN CHIL; Billette J- M, INJURIES CANADA INSI; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; CHIRPP, UN SOURC CHILD INJ I; Clark W., KIDS SPORTS; Giannotti M, 2010, INJURY, V41, P907, DOI 10.1016/j.injury.2009.09.040; Howell CA, 2010, PEDIATRICS, V126, P517, DOI 10.1542/peds.2009-1499; Lawson BR, 2009, PEDIATRICS, V123, pE1028, DOI 10.1542/peds.2007-3796; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; Mello MJ, 2009, ACAD EMERG MED, V16, P243, DOI 10.1111/j.1553-2712.2009.00357.x; Monroe KW, 2011, CLIN PEDIATR, V50, P17, DOI 10.1177/0009922810378735; O'Rourke KP, 2007, INJURY, V38, P104, DOI 10.1016/j.injury.2006.06.010; Pakzad-Vaezi K, 2011, PAED CHILD HEALT-CAN, V16, P217, DOI 10.1093/pch/16.4.217; Pickett W, 2005, SPORTS MED; Randazzo C, 2010, PEDIATRICS, V126, P727, DOI 10.1542/peds.2009-2497; Taylor BL, 2000, ACAD EMERG MED, V7, P1376, DOI 10.1111/j.1553-2712.2000.tb00495.x; White HL, 2012, INJURY PREV, V18, P33, DOI 10.1136/injuryprev-2011-040006; Wood AM, 2010, INJURY, V41, P834, DOI 10.1016/j.injury.2010.04.008	18	45	47	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	2052-1847			BMC SPORTS SCI MED R	BMC Sports Sci. Med. Rehabil.	DEC	2013	5	1							30	10.1186/2052-1847-5-30			6	Rehabilitation; Sport Sciences	Emerging Sources Citation Index (ESCI)	Rehabilitation; Sport Sciences	V30QW	WOS:000215578100030	24364875	Green Published, gold, Green Submitted			2022-02-06	
J	Biderman, P; Einav, S; Fainblut, M; Stein, M; Singer, P; Medalion, B				Biderman, Philippe; Einav, Sharon; Fainblut, Michael; Stein, Michael; Singer, Pierre; Medalion, Benjamin			Extracorporeal life support in patients with multiple injuries and severe respiratory failure: A single-center experience?	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Extracorporeal membrane oxygenation; adult respiratory distress syndrome; multiple trauma; traumatic brain injury	MEMBRANE-OXYGENATION; LUNG ASSIST; PROFOUND HYPOTHERMIA; SUSPENDED ANIMATION; SWINE MODEL; INDUCTION; REVERSAL; ARREST; BLOOD; TRIAL	BACKGROUND: The use of extracorporeal life support in trauma casualties is limited by concerns regarding hemorrhage, particularly in the presence of traumatic brain injury (TBI). We report the use of extracorporeal membrane oxygenation (ECMO)/interventional lung assist (iLA) as salvage therapy in trauma patients. High-flow technique without anticoagulation was used in patients with coagulopathy or TBI. METHODS: Data were collected from all adult trauma patients referred to one center for ECMO/iLA treatment owing to severe hypoxemic respiratory failure. RESULTS: Ten casualties had a mean (SD) Injury Severity Score (ISS) of 50.3 (10.5) (mean [SD] age, 29.8 [7.7] years; 60% male) and were supported 9.5 (4.5) days on ECMO (n = 5) and 7.6 (6.5) days on iLA (n = 5). All experienced blunt injury with severe chest injuries, including one cardiac perforation. Most were coagulopathic before initiation of ECMO/iLA support. Among the seven patients with TBI, four had active intracranial hemorrhage. Complications directly related to support therapy were not lethal; these included hemorrhage from a cannulation site (n = 1), accidental removal of a cannula (n = 1), and pressure sores (n = 3). Deaths occurred owing to septic (n = 2) and cardiogenic shock (n = 1). Survival rates were 60% and 80% on ECMO and iLA, respectively. Follow-up of survivors detected no neurologic deterioration. CONCLUSION: ECMO/iLA therapy can be used as a rescue therapy in adult trauma patients with severe hypoxemic respiratory failure, even in the presence of coagulopathy and/or brain injury. The benefits of rewarming, acid-base correction, oxygenation, and circulatory support must be weighed individually against the risk of hemorrhage. Further research should determine whether ECMO therapy also confers survival benefit. (J Trauma Acute Care Surg. 2013;75:907-912. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Biderman, Philippe; Fainblut, Michael; Medalion, Benjamin] Tel Aviv Univ, Rabin Med Ctr, Dept Cardiothorac Surg, IL-69978 Tel Aviv, Israel; [Stein, Michael] Tel Aviv Univ, Rabin Med Ctr, Trauma Unit, IL-69978 Tel Aviv, Israel; [Singer, Pierre] Tel Aviv Univ, Rabin Med Ctr, Dept Gen Intens Care, IL-69978 Tel Aviv, Israel; [Einav, Sharon] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Gen Intens Care Unit, Jerusalem, Israel		Biderman, P (corresponding author), Tel Aviv Univ, Rabin Med Ctr, Dept Cardiothorac Surg, 39 Jabotinsky St, IL-49100 Petah Tiqwa, Israel.	philipb2@clalit.org.il					Alam HB, 2006, J TRAUMA, V61, P1321, DOI 10.1097/01.ta.0000244414.76523.d8; Arlt M, 2010, RESUSCITATION, V81, P804, DOI 10.1016/j.resuscitation.2010.02.020; Behringer W, 2003, CRIT CARE MED, V31, P1523, DOI 10.1097/01.CCM.0000063450.73967.40; Bein T, 2010, INT J EMERG MED, V3, P177, DOI 10.1007/s12245-010-0192-x; Bellamy R, 1996, CRIT CARE MED, V24, pS24; Brederlau J, 2004, J CARDIOTHOR VASC AN, V18, P777, DOI 10.1053/j.jvca.2004.08.022; Capone A, 1996, J TRAUMA, V40, P388, DOI 10.1097/00005373-199603000-00011; Casas F, 2005, ARTIF ORGANS, V29, P557, DOI 10.1111/j.1525-1594.2005.29092.x; Chaiwat O, 2009, ANESTHESIOLOGY, V110, P351, DOI 10.1097/ALN.0b013e3181948a97; GENTILELLO LM, 1992, J TRAUMA, V32, P316, DOI 10.1097/00005373-199203000-00009; Lambrechts DL, 2003, TEX HEART I J, V30, P65; Madershahian N, 2007, J CARDIAC SURG, V22, P180, DOI 10.1111/j.1540-8191.2007.00381.x; Masroor S, 2004, J TRAUMA, V57, P389, DOI 10.1097/01.TA.0000037285.52097.8C; Meduri GU, 2008, INTENS CARE MED, V34, P61, DOI 10.1007/s00134-007-0933-3; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; PERCHINSKY MJ, 1995, AM J SURG, V169, P488, DOI 10.1016/S0002-9610(99)80201-3; Petrucci N, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003844.pub3; Reng M, 2000, LANCET, V356, P219, DOI 10.1016/S0140-6736(00)02485-5; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Tagarakis Georgios I, 2009, Recent Pat Cardiovasc Drug Discov, V4, P177; TAYLOR MJ, 1995, CIRCULATION, V91, P431, DOI 10.1161/01.CIR.91.2.431; Wallace DJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8946; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193; Zimmermann M, 2006, BRIT J ANAESTH, V96, P63, DOI 10.1093/bja/aei274	25	45	46	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2013	75	5					907	912		10.1097/TA.0b013e3182a8334f			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	300IP	WOS:000330457900025	24158215				2022-02-06	
J	Ford, JH; Giovanello, KS; Guskiewicz, KM				Ford, Jaclyn H.; Giovanello, Kelly S.; Guskiewicz, Kevin M.			Episodic Memory in Former Professional Football Players with a History of Concussion: An Event-Related Functional Neuroimaging Study	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; head trauma; MRI	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN INJURY; ASSOCIATIVE INFORMATION; RELATIONAL RETRIEVAL; RECURRENT CONCUSSION; HIGH-SCHOOL; ITEM; RECOLLECTION; FAMILIARITY; HIPPOCAMPAL	Previous research has demonstrated that sport-related concussions can have short-term effects on cognitive processes, but the long-term consequences are less understood and warrant more research. This study was the first to use event-related functional magnetic resonance imaging (fMRI) to examine long-term differences in neural activity during memory tasks in former athletes who have sustained multiple sport-related concussions. In an event-related fMRI study, former football players reporting multiple sport-related concussions (i.e., three or more) were compared with players who reported fewer than three concussions during a memory paradigm examining item memory (i.e., memory for the particular elements of an event) and relational memory (i.e., memory for the relationships between elements). Behaviorally, we observed that concussion history did not significantly affect behavioral performance, because persons in the low and high concussion groups had equivalent performance on both memory tasks, and in addition, that concussion history was not associated with any behavioral memory measures. Despite demonstrating equivalent behavioral performance, the two groups of former players demonstrated different neural recruitment patterns during relational memory retrieval, suggesting that multiple concussions may be associated with functional inefficiencies in the relational memory network. In addition, the number of previous concussions significantly correlated with functional activity in a number of brain regions, including the medial temporal lobe and inferior parietal lobe. Our results provide important insights in understanding the long-term functional consequences of sustaining multiple sports-related concussions.	[Ford, Jaclyn H.; Giovanello, Kelly S.] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA; [Giovanello, Kelly S.] Univ N Carolina, Biomed Res Imaging Ctr, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Ctr Study Retired Athletes, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA		Ford, JH (corresponding author), Boston Coll, Dept Psychol, McGuinn Hall,Room 511, Brookline, MA 02467 USA.	JaclynHFord@gmail.com		Guskiewicz, Kevin/0000-0002-8682-2130	National Institutes on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG028774]; Martek Biosciences Corporation; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG028774] Funding Source: NIH RePORTER	The authors would like to thank Amy Matthews and Candice Goerger for their assistance in completing this work. This work was supported by National Institutes on Aging (AG028774 to KSG) and the Martek Biosciences Corporation (KMG).	Adjutant General's Office, 1944, ARM IND TEST BATT MA; Anderson ND, 2008, NEUROPSYCHOLOGY, V22, P177, DOI 10.1037/0894-4105.22.2.177; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benton L, 1976, MULTILINGUAL APHASIA; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Buckner RL, 2003, J NEUROSCI, V23, P3999; Burock MA, 1998, NEUROREPORT, V9, P3735, DOI 10.1097/00001756-199811160-00030; *CDCP, 2007, MORTALITY MORBIDITY, V0056; CLARK SE, 1992, MEM COGNITION, V20, P231, DOI 10.3758/BF03199660; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Donnell AJ, 2007, ARCH CLIN NEUROPSYCH, V22, P917, DOI 10.1016/j.acn.2007.06.007; Eichenbaum H, 2007, ANNU REV NEUROSCI, V30, P123, DOI 10.1146/annurev.neuro.30.051606.094328; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Fisher SRA, 1932, STAT METHODS RES WOR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fowler KS, 2002, J INT NEUROPSYCH SOC, V8, P58, DOI 10.1017/S1355617701020069; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giovanello KS, 2012, J INT NEUROPSYCH SOC, V18, P886, DOI 10.1017/S1355617712000689; Giovanello KS, 2012, J COGNITIVE NEUROSCI, V24, P159, DOI 10.1162/jocn_a_00113; Giovanello KS, 2009, HIPPOCAMPUS, V19, P111, DOI 10.1002/hipo.20491; Giovanello KS, 2004, HIPPOCAMPUS, V14, P5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gutchess AH, 2007, SOC NEUROSCI-UK, V2, P117, DOI 10.1080/17470910701399029; HOCKLEY WE, 1992, J EXP PSYCHOL LEARN, V18, P1321, DOI 10.1037/0278-7393.18.6.1321; Hockley WE, 1999, MEM COGNITION, V27, P657, DOI 10.3758/BF03211559; Ivanoiu A, 2005, J NEUROL, V252, P47, DOI 10.1007/s00415-005-0597-2; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Kaplan E, 1983, BOSTON NAMING TEST; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Lazar NA, 2002, NEUROIMAGE, V16, P538, DOI 10.1006/nimg.2002.1107; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lieberman MD, 2009, SOC COGN AFFECT NEUR, V4, P423, DOI 10.1093/scan/nsp052; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Talairach J., 1988, COPLANAR STEREOTAXIC; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Troyer AK, 2008, NEUROPSYCHOLOGY, V22, P10, DOI 10.1037/0894-4105.22.1.10; Tulving E., 1983, ELEMENTS EPISODIC ME; Vilberg KL, 2009, NEUROREPORT, V20, P1295, DOI 10.1097/WNR.0b013e3283306798; WechslerD, 2001, WECHSLER TEST ADULT; Wheeler ME, 2004, NEUROIMAGE, V21, P1337, DOI 10.1016/j.neuroimage.2003.11.001; Yonelinas AP, 1997, MEM COGNITION, V25, P747, DOI 10.3758/BF03211318; Yonelinas AP, 2001, J EXP PSYCHOL GEN, V130, P361, DOI 10.1037//0096-3445.130.3.361; Yonelinas AP, 2005, J NEUROSCI, V25, P3002, DOI 10.1523/JNEUROSCI.5295-04.2005	52	45	45	1	58	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1683	1701		10.1089/neu.2012.2535			19	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000001	23679098	Green Published, Green Submitted			2022-02-06	
J	Treble, A; Hasan, KM; Iftikhar, A; Stuebing, KK; Kramer, LA; Cox, CS; Swank, PR; Ewing-Cobbs, L				Treble, Amery; Hasan, Khader M.; Iftikhar, Amal; Stuebing, Karla K.; Kramer, Larry A.; Cox, Charles S., Jr.; Swank, Paul R.; Ewing-Cobbs, Linda			Working Memory and Corpus Callosum Microstructural Integrity after Pediatric Traumatic Brain Injury: A Diffusion Tensor Tractography Study	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; cognitive function; diffusion tensor imaging; pediatric brain injury	WHITE-MATTER INTEGRITY; MEDIAL TEMPORAL-LOBE; CLOSED-HEAD-INJURY; INTRUSION ERRORS; WATER DIFFUSION; AXONAL INJURY; CHILDREN; INFORMATION; MODERATE; DEFICITS	Deficits in working memory (WM) are a common consequence of pediatric traumatic brain injury (TBI) and are believed to contribute to difficulties in a range of cognitive and academic domains. Reduced integrity of the corpus callosum (CC) after TBI may disrupt the connectivity between bilateral frontoparietal neural networks underlying WM. In the present investigation, diffusion tensor imaging (DTI) tractography of eight callosal subregions (CC1-CC8) was examined in relation to measures of verbal and visuospatial WM in 74 children sustaining TBI and 49 typically developing comparison children. Relative to the comparison group, children with TBI demonstrated poorer visuospatial WM, but comparable verbal WM. Microstructure of the CC was significantly compromised in brain-injured children, with lower fractional anisotropy (FA) and higher axial and radial diffusivity metrics in all callosal subregions. In both groups of children, lower FA and/or higher radial diffusivity in callosal subregions connecting anterior and posterior parietal cortical regions predicted poorer verbal WM, whereas higher radial diffusivity in callosal subregions connecting anterior and posterior parietal, as well as temporal, cortical regions predicted poorer visuospatial WM. DTI metrics, especially radial diffusivity, in predictive callosal subregions accounted for significant variance in WM over and above remaining callosal subregions. Reduced microstructural integrity of the CC, particularly in subregions connecting parietal and temporal cortices, may act as a neuropathological mechanism contributing to long-term WM deficits. The future clinical use of neuroanatomical biomarkers may allow for the early identification of children at highest risk for WM deficits and earlier provision of interventions for these children.	[Treble, Amery] Univ Houston, Dept Psychol, Houston, TX USA; [Hasan, Khader M.; Iftikhar, Amal] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost Imaging, Houston, TX 77030 USA; [Stuebing, Karla K.] Univ Houston, Texas Inst Measurement Evaluat & Stat, Houston, TX USA; [Kramer, Larry A.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA; [Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Swank, Paul R.; Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, Houston, TX 77030 USA		Ewing-Cobbs, L (corresponding author), Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, 7000 Fannin,Suite 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu	Hasan, Khader M./ABB-5767-2020		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH-R01 NS046308, NIH-R01 NS052505]; Dunn Research Fund; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10-RR19186]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR019186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046308, R01NS052505] Funding Source: NIH RePORTER	This work was funded by the National Institutes of Health (NIH-R01 NS046308 [awarded to L. E. C.] and NIH-R01 NS052505) and the Dunn Research Fund (to K. M. H.). The purchase of the 3.0 T MRI Clinical Scanner was partially funded by the NIH (grant no.: S10-RR19186; to Dr. Ponnada A. Narayana). The content is solely the responsibility of the authors and does not necessarily represent the official views of the granting institutes. The authors thank Vipul Kumar Patel for helping in data acquisition.	Aboitiz F, 2003, BRAZ J MED BIOL RES, V36, P409, DOI 10.1590/S0100-879X2003000400002; ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baddeley A, 2003, NAT REV NEUROSCI, V4, P829, DOI 10.1038/nrn1201; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burzynska AZ, 2011, CEREB CORTEX, V21, P2261, DOI 10.1093/cercor/bhq293; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Charlton RA, 2008, NEUROBIOL AGING, V29, P1547, DOI 10.1016/j.neurobiolaging.2007.03.017; Charlton RA, 2010, CORTEX, V46, P474, DOI 10.1016/j.cortex.2009.07.005; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Cornoldi C, 2006, MEMORY, V14, P176, DOI 10.1080/09658210544000033; Cornoldi C, 2001, CHILD NEUROPSYCHOL, V7, P230, DOI 10.1076/chin.7.4.230.8735; Curtis CE, 2006, HDB FUNCTIONAL NEURO, P269; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; De Beni R, 1998, Q J EXP PSYCHOL-A, V51, P305, DOI 10.1080/713755761; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Engle RW, 2002, CURR DIR PSYCHOL SCI, V11, P19, DOI 10.1111/1467-8721.00160; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Gorman S, 2012, J INT NEUROPSYCH SOC, V18, P29, DOI 10.1017/S1355617711001251; Graham KS, 2010, NEUROPSYCHOLOGIA, V48, P831, DOI 10.1016/j.neuropsychologia.2010.01.001; Hasan KM, 2007, MAGN RESON IMAGING, V25, P1196, DOI 10.1016/j.mri.2007.02.011; Hasan KM, 2009, BRAIN RES, V1249, P91, DOI 10.1016/j.brainres.2008.10.026; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Huang H, 2005, NEUROIMAGE, V26, P195, DOI 10.1016/j.neuroimage.2005.01.019; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Karlsgodt KH, 2008, BIOL PSYCHIAT, V63, P512, DOI 10.1016/j.biopsych.2007.06.017; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Klingberg T, 2006, NEUROPSYCHOLOGIA, V44, P2171, DOI 10.1016/j.neuropsychologia.2005.11.019; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kwon H, 2002, P NATL ACAD SCI USA, V99, P13336, DOI 10.1073/pnas.162486399; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Miyake A., 1999, MODELS WORKING MEMOR; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Moseley M, 2002, BRAIN COGNITION, V50, P396, DOI 10.1016/S0278-2626(02)00524-9; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Nelson CA, 2000, DEV PSYCHOL, V36, P109, DOI 10.1037/0012-1649.36.1.109; O'Hare ED, 2008, NEUROIMAGE, V42, P1678, DOI 10.1016/j.neuroimage.2008.05.057; Olesen PJ, 2003, COGNITIVE BRAIN RES, V18, P48, DOI 10.1016/j.cogbrainres.2003.09.003; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Park HJ, 2008, HUM BRAIN MAPP, V29, P503, DOI 10.1002/hbm.20314; Passolunghi MC, 1999, MEM COGNITION, V27, P779; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pollmann S, 2004, NEUROPSYCHOLOGY, V18, P710, DOI 10.1037/0894-4105.18.4.710; Ranganath C, 2005, TRENDS COGN SCI, V9, P374, DOI 10.1016/j.tics.2005.06.009; Ranganath C, 2001, NEURON, V31, P865, DOI 10.1016/S0896-6273(01)00411-1; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schulte T, 2005, CEREB CORTEX, V15, P1384, DOI 10.1093/cercor/bhi020; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Shah, 1999, MODELS WORKING MEMOR, DOI DOI 10.1017/CBO9781139174909.005; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Zaidel E., 2003, PARALLEL BRAIN COGNI	95	45	45	0	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2013	30	19					1609	1619		10.1089/neu.2013.2934			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	227WQ	WOS:000325146800001	23627735	Green Published			2022-02-06	
J	Bradford, R; Choudhary, AK; Dias, MS				Bradford, Ray; Choudhary, Arabinda K.; Dias, Mark S.			Serial neuroimaging in infants with abusive head trauma: timing abusive injuries Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						abusive head trauma; shaken baby syndrome; infant; traumatic brain injury; magnetic resonance imaging; computed tomography	SHAKEN BABY SYNDROME; CRANIAL COMPUTED-TOMOGRAPHY; DIFFUSION-WEIGHTED MRI; CHILD-ABUSE; IMPACT SYNDROME; YOUNG-CHILDREN; SUBDURAL HEMATOMAS; BRAIN-DAMAGE; DIAGNOSIS; NEUROPATHOLOGY	Object. The appearance and evolution of neuroimaging abnormalities following abusive head trauma (AHT) is important for establishing the time frame over which these injuries might have occurred. From a legal perspective this frames the timing of the abuse and therefore identifies and excludes potential perpetrators. A previous pilot study involving 33 infants with AHT helped to refine the timing of these injuries but was limited by its small sample size. In the present study, the authors analyzed a larger group of 210 cases involving infants with AHT to chronicle the first appearance and evolution of radiological (CT, MRI) abnormalities. Methods. All children younger than 24 months admitted to the Penn State Hershey Medical Center with AHT over a 10-year period were identified from a medical record review; the time of injury was determined through an evaluation of the clinical records. All imaging studies were analyzed, and the appearance and evolution of abnormalities were chronicled on serial neuroimaging studies obtained in the days and weeks after injury. Results. One hundred five infants with specific injury dates and available imaging studies were identified; a subset of 43 children additionally had documented times of injury. In infants with homogeneously hyperdense subdural hematomas (SDHs) on initial CT scans, the first hypodense component appeared within the SDH between 0.3 and 16 days after injury, and the last hyperdense subdural component disappeared between 2 and 40 days after injury. In infants with mixed-density SDHs on initial scans, the last hyperdense component disappeared between 1 and 181 days. Parenchymal hypodensities appeared on CT scans performed as early as 1.2 hours, and all were visible within 27 hours after the injury. Rebleeding into SDHs was documented in 17 cases (16%) and was always asymptomatic. Magnetic resonance imaging of the brain was performed in 49 infants. Among those with SDH, 5 patterns were observed. Patterns I and II reflected homogeneous SDH; Pattern I (T1 hyperintensity and T2/FLAIR hypointensity, "early subacute") more commonly appeared on scans performed earlier after injury compared with Pattern II (T1 hyperintensity and T2/FLAIR hyperintensity, "late subacute"), although there was considerable overlap. Patterns III and IV reflected heterogeneous SDH; Pattern III contained relatively equal mixtures having different intensities, whereas Pattern IV had fluid that was predominantly T1 hypointense and T2/FLAIR hyperintense. Again, Pattern III more commonly appeared on scans performed earlier after injury compared with Pattern IV, although there was significant overlap. Conclusions. These data extend the preliminary data reported by Dias and colleagues and provide a framework upon which injuries in AHT can be timed as well as the limitations on such timing estimates.	[Bradford, Ray; Choudhary, Arabinda K.] Penn State Milton S Hershey Med Ctr, Penn State Coll Med, Dept Radiol, Hershey, PA USA; [Dias, Mark S.] Penn State Milton S Hershey Med Ctr, Penn State Coll Med, Dept Neurosurg, Hershey, PA USA		Dias, MS (corresponding author), Penn State Hershey Med Ctr, Dept Neurosurg EC110, 30 Hope Dr, Hershey, PA 17033 USA.	mdias@psu.edu	choudhary, arabinda/AAP-1220-2021	choudhary, arabinda/0000-0002-2338-5906	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; Pennsylvania Department of Health; New York State Children and Family Trust Fund	Dr. Dias testifies as an expert witness in child abuse cases and reports receiving non-study related clinical or research support from the Centers for Disease Control, the Pennsylvania Department of Health, and the New York State Children and Family Trust Fund.	BARKOVICH AJ, 1995, PEDIAT NEUROIMAGING, P107; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; Brennan LK, 2009, J NEUROS-PEDIATR, V3, P232, DOI 10.3171/2008.11.PEDS0835; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; Chabrol B, 1999, CHILD ABUSE NEGLECT, V23, P217, DOI 10.1016/S0145-2134(98)00128-8; Chan YL, 2003, PEDIATR RADIOL, V33, P574, DOI 10.1007/s00247-003-0949-y; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; FOBBEN ES, 1989, AM J ROENTGENOL, V153, P589, DOI 10.2214/ajr.153.3.589; Fox RJ, 1996, NEUROSURGERY, V39, P84, DOI 10.1097/00006123-199607000-00017; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Hymel Kent P, 2002, Child Maltreat, V7, P329, DOI 10.1177/107755902237263; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kesler H, 2008, J NEUROSURG-PEDIATR, V1, P351, DOI 10.3171/PED/2008/1/5/351; LEVIN A V, 1989, Pediatric Emergency Care, V5, P181, DOI 10.1097/00006565-198909000-00011; Parizel PM, 2003, PEDIATR RADIOL, V33, P868, DOI 10.1007/s00247-003-1025-3; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Uscinski RH, 2006, NEUROL MED-CHIR, V46, P57, DOI 10.2176/nmc.46.57; Uscinski RH, 2008, NEUROL MED-CHIR, V48, P151, DOI 10.2176/nmc.48.151; Vinchon M, 2004, J NEUROSURG, V101, P44, DOI 10.3171/ped.2004.101.2.0044; Vinchon M, 2002, PEDIATR NEUROSURG, V37, P245, DOI 10.1159/000066216; Vinchon M, 2010, CHILD NERV SYST, V26, P637, DOI 10.1007/s00381-009-1048-7; Willman KY, 1997, CHILD ABUSE NEGLECT, V21, P929, DOI 10.1016/S0145-2134(97)00054-9; Zimmerman R A, 1994, Neuroimaging Clin N Am, V4, P349; ZIMMERMAN RA, 1978, AM J ROENTGENOL, V131, P27, DOI 10.2214/ajr.131.1.27; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P39, DOI 10.1007/BF00395197; Zouros A, 2004, J NEUROSURG, V100, P512, DOI 10.3171/ped.2004.100.5.0512	39	45	45	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2013	12	2					110	119		10.3171/2013.4.PEDS12596			10	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	187CM	WOS:000322094500003	23799250	Bronze			2022-02-06	
J	Longhi, L; Perego, C; Ortolano, F; Aresi, S; Fumagalli, S; Zanier, ER; Stocchetti, N; De Simoni, MG				Longhi, Luca; Perego, Carlo; Ortolano, Fabrizio; Aresi, Silvia; Fumagalli, Stefano; Zanier, Elisa R.; Stocchetti, Nino; De Simoni, Maria-Grazia			Tumor necrosis factor in traumatic brain injury: effects of genetic deletion of p55 or p75 receptor	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; inflammation; microglia; pathophysiology; traumatic brain injury; tumor necrosis factor	CLOSED-HEAD INJURY; CONTROLLED CORTICAL IMPACT; FACTOR-ALPHA; CELL-DEATH; TNF-ALPHA; CONTUSION VOLUME; MICE; BCL-2; ACTIVATION; ISCHEMIA	The role of tumor necrosis factor (TNF) and its receptors after traumatic brain injury (TBI) remains unclear. We evaluated the effects of genetic deletion of either p55 or p75 TNF receptor on neurobehavioral outcome, histopathology, DNA damage and apoptosis-related cell death/survival gene expression (bcl-2/bax), and microglia/macrophage (M/M) activation in wild-type (WT) and knockout mice after TBI. Injured p55 (-/-) mice showed a significant attenuation while p75 (-/-) mice showed a significant worsening of sensorimotor deficits compared with WT mice over 4 weeks postinjury. At the same time point, contusion volume in p55 (-/-) mice (11.1 +/- 3.3 mm(3)) was significantly reduced compared with WT (19.7 +/- 3.4 mm(3)) and p75 (-/-) mice (20.9 +/- 3.2 mm(3)). At 4 hours postinjury, bcl-2/bax ratio mRNA expression was increased in p55 (-/-) compared with p75 (-/-) mice and was associated with reduced DNA damage terminal deoxynucleotidyl transferaseYmediated dUTP nick end labeling (TUNEL-positivity), reduced CD11b expression and increased Ym1 expression at 24 hours postinjury in p55 (-/-) compared with p75 (-/-) mice, indicative of a protective M/M response. These data suggest that TNF may exacerbate neurobehavioral deficits and tissue damage via p55 TNF receptor whose inhibition may represent a specific therapeutic target after TBI.	[Longhi, Luca; Ortolano, Fabrizio; Aresi, Silvia; Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplantat, Neurosurg Intens Care Unit, Fdn IRCCS Osped Maggiore Policlin, Milan, Italy; [Longhi, Luca; Perego, Carlo; Fumagalli, Stefano; Zanier, Elisa R.; De Simoni, Maria-Grazia] IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, I-20156 Milan, Italy		De Simoni, MG (corresponding author), IRCCS Ist Ric Farmacol Mario Negri, Lab Inflammat & Nervous Syst Dis, I-20156 Milan, Italy.	desimoni@marionegri.it	Zanier, Elisa/AAA-8095-2020; Perego, Carlo/AAA-6513-2020; De Simoni, Maria Grazia/I-6021-2012; Stocchetti, Nino/O-7444-2017; Fumagalli, Stefano/I-3097-2019; Longhi, Luca/AAF-9903-2021	Zanier, Elisa/0000-0002-3011-8718; Perego, Carlo/0000-0002-0259-0003; De Simoni, Maria Grazia/0000-0001-6695-5297; Stocchetti, Nino/0000-0003-3250-6834; Longhi, Luca/0000-0001-9894-8788; Fumagalli, Stefano/0000-0003-3598-6263; Ortolano, Fabrizio/0000-0003-1996-948X			Balosso S, 2005, ANN NEUROL, V57, P804, DOI 10.1002/ana.20480; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Genovese T, 2008, SHOCK, V29, P32, DOI 10.1097/shk.0b013e318059053a; Hallenbeck JM, 2002, NAT MED, V8, P1363, DOI 10.1038/nm1202-1363; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kitagaki M, 2012, J ATHEROSCLER THROMB, V19, P36, DOI 10.5551/jat.9746; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; RINK A, 1995, AM J PATHOL, V147, P1575; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Soares HD, 1995, J NEUROSCI, V15, P8223; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Taoufik E, 2008, P NATL ACAD SCI USA, V105, P6185, DOI 10.1073/pnas.0801447105; Taoufik E, 2007, J NEUROSCI, V27, P6633, DOI 10.1523/JNEUROSCI.1091-07.2007; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	56	45	48	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2013	33	8					1182	1189		10.1038/jcbfm.2013.65			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	193OQ	WOS:000322570000007	23611870	Green Published, Bronze			2022-02-06	
J	Coppi, E; Maraula, G; Fumagalli, M; Failli, P; Cellai, L; Bonfanti, E; Mazzoni, L; Coppini, R; Abbracchio, MP; Pedata, F; Pugliese, AM				Coppi, Elisabetta; Maraula, Giovanna; Fumagalli, Marta; Failli, Paola; Cellai, Lucrezia; Bonfanti, Elisabetta; Mazzoni, Luca; Coppini, Raffaele; Abbracchio, Maria P.; Pedata, Felicita; Pugliese, Anna Maria			UDP-glucose enhances outward K plus currents necessary for cell differentiation and stimulates cell migration by activating the GPR17 receptor in oligodendrocyte precursors	GLIA			English	Article						GPR17; K plus currents; migration; Ca2+currents; purinergic receptors; myelination	GLIAL PROGENITOR CELLS; CHANNEL EXPRESSION; MEMBRANE DEPOLARIZATION; POTASSIUM CURRENTS; GROWTH-FACTORS; IN-VITRO; MYELINATION; PROLIFERATION; LINEAGE; CA2+	In the developing and mature central nervous system, NG2 expressing cells comprise a population of cycling oligodendrocyte progenitor cells (OPCs) that differentiate into mature, myelinating oligodendrocytes (OLGs). OPCs are also characterized by high motility and respond to injury by migrating into the lesioned area to support remyelination. K+ currents in OPCs are developmentally regulated during differentiation. However, the mechanisms regulating these currents at different stages of oligodendrocyte lineage are poorly understood. Here we show that, in cultured primary OPCs, the purinergic G-protein coupled receptor GPR17, that has recently emerged as a key player in oligodendrogliogenesis, crucially regulates K+ currents. Specifically, receptor stimulation by its agonist UDP-glucose enhances delayed rectifier K+ currents without affecting transient K+ conductances. This effect was observed in a subpopulation of OPCs and immature pre-OLGs whereas it was absent in mature OLGs, in line with GPR17 expression, that peaks at intermediate phases of oligodendrocyte differentiation and is thereafter downregulated to allow terminal maturation. The effect of UDP-glucose on K+ currents is concentration-dependent, blocked by the GPR17 antagonists MRS2179 and cangrelor, and sensitive to the K+ channel blocker tetraethyl-ammonium, which also inhibits oligodendrocyte maturation. We propose that stimulation of K+ currents is responsible for GPR17-induced oligodendrocyte differentiation. Moreover, we demonstrate, for the first time, that GPR17 activation stimulates OPC migration, suggesting an important role for this receptor after brain injury. Our data indicate that modulation of GPR17 may represent a strategy to potentiate the post-traumatic response of OPCs under demyelinating conditions, such as multiple sclerosis, stroke, and brain trauma.	[Coppi, Elisabetta; Maraula, Giovanna; Failli, Paola; Cellai, Lucrezia; Mazzoni, Luca; Coppini, Raffaele; Pedata, Felicita; Pugliese, Anna Maria] Univ Florence, Div Pharmacol & Toxicol, Dept Neurosci Psychol Drug Res & Child Hlth Neuro, I-50139 Florence, Italy; [Fumagalli, Marta; Bonfanti, Elisabetta; Abbracchio, Maria P.] Univ Milan, Dept Pharmacol & Biomol Sci, Lab Mol & Cellular Pharmacol Purinerg Transmiss, I-20133 Milan, Italy; [Mazzoni, Luca] Univ Florence, Dept Clin & Expt Med, I-50139 Florence, Italy		Coppi, E (corresponding author), Univ Florence, Dept Hlth Sci, Viale Pieraccini 6, I-50139 Florence, Italy.	elisabetta.coppi@unifi.it	Coppi, Elisabetta/K-6705-2016; Coppini, Raffaele/K-4841-2016; Abbracchio, Maria Pia/B-9342-2014	Coppi, Elisabetta/0000-0003-4434-5919; Abbracchio, Maria Pia/0000-0002-7833-3388; Fumagalli, Marta/0000-0002-0158-842X; PUGLIESE, ANNA MARIA/0000-0001-7554-5740; Bonfanti, Elisabetta/0000-0003-1280-9109; Coppini, Raffaele/0000-0002-4096-3173; Failli, Paola/0000-0003-3879-9068; Pedata, Felicita/0000-0002-6841-3712	University of Florence; PRIN-COFINMinistry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN); Fondazione Italiana Sclerosi MultiplaFondazione Italiana Sclerosi Multipla (FISM) [FISM 2010/R2]	Grant sponsors: University of Florence, PRIN-COFIN 2008; Grant sponsor: Fondazione Italiana Sclerosi Multipla; Grant number: FISM 2010/R2.	Agresti C, 2005, GLIA, V50, P132, DOI 10.1002/glia.20160; ARMSTRONG RC, 1990, J NEUROSCI RES, V27, P400, DOI 10.1002/jnr.490270319; Attali B, 1997, J NEUROSCI, V17, P8234; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; BERGER T, 1992, EUR J NEUROSCI, V4, P1271, DOI 10.1111/j.1460-9568.1992.tb00153.x; Boda E, 2011, GLIA, V59, P1958, DOI 10.1002/glia.21237; Butt AM, 2002, J NEUROCYTOL, V31, P551, DOI 10.1023/A:1025751900356; Ceruti S, 2011, GLIA, V59, P363, DOI 10.1002/glia.21107; Ceruti S, 2009, BRAIN, V132, P2206, DOI 10.1093/brain/awp147; Chavalmane AK, 2010, J SEX MED, V7, P2698, DOI 10.1111/j.1743-6109.2010.01811.x; Chen Y, 2009, NAT NEUROSCI, V12, P1398, DOI 10.1038/nn.2410; Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; DUBOISDALCQ M, 1987, EMBO J, V6, P2587, DOI 10.1002/j.1460-2075.1987.tb02549.x; DUNLAP K, 1985, PFLUG ARCH EUR J PHY, V403, P170, DOI 10.1007/BF00584096; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Fulton D, 2010, GLIA, V58, P1292, DOI 10.1002/glia.21008; Fumagalli M, 2011, J BIOL CHEM, V286, P10593, DOI 10.1074/jbc.M110.162867; Gallo V, 1996, J NEUROSCI, V16, P2659, DOI 10.1523/jneurosci.16-08-02659.1996; GARD AL, 1989, DEVELOPMENT, V106, P119; Ghiani CA, 1999, J NEUROSCI, V19, P5380; GREGA DS, 1987, SCIENCE, V235, P345, DOI 10.1126/science.2432663; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; HENRY PD, 1980, AM J CARDIOL, V46, P1047, DOI 10.1016/0002-9149(80)90366-5; Hibino H, 2010, PHYSIOL REV, V90, P291, DOI 10.1152/physrev.00021.2009; Horner PJ, 2000, J NEUROSCI, V20, P2218; KETTENMANN H, 1991, ANN NY ACAD SCI, V633, P64; KIERNAN BW, 1993, DEVELOPMENT, P219; Knutson P, 1997, J NEUROSCI, V17, P2669, DOI 10.1523/jneurosci.17-08-02669.1997; Lecca D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003579; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Mann SA, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-39; McMorris FA, 1996, BRAIN PATHOL, V6, P313, DOI 10.1111/j.1750-3639.1996.tb00858.x; Melani A, 2005, NEUROCHEM INT, V47, P442, DOI 10.1016/j.neuint.2005.05.014; Melani A, 2012, EXP NEUROL, V233, P193, DOI 10.1016/j.expneurol.2011.09.036; Miller RH, 2002, PROG NEUROBIOL, V67, P451, DOI 10.1016/S0301-0082(02)00058-8; Milner R, 1997, GLIA, V19, P85, DOI 10.1002/(SICI)1098-1136(199701)19:1<85::AID-GLIA9>3.0.CO;2-9; Nawrath H, 1997, N-S ARCH PHARMACOL, V355, P79; Nishisho T, 1996, NEUROSURGERY, V39, P950, DOI 10.1097/00006123-199611000-00014; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Paez PM, 2009, J NEUROSCI RES, V87, P3259, DOI 10.1002/jnr.21938; Paez PM, 2010, J NEUROSCI, V30, P6422, DOI 10.1523/JNEUROSCI.5086-09.2010; Paez PM, 2009, ASN NEURO, V1, DOI 10.1042/AN20090003; Paez PM, 2009, J NEUROSCI, V29, P6663, DOI 10.1523/JNEUROSCI.5806-08.2009; Pugliese AM, 2009, AM J PHYSIOL-CELL PH, V297, pC1028, DOI 10.1152/ajpcell.00658.2008; Schmidt C, 1997, GLIA, V20, P284; SHRAGER P, 1995, DEV BRAIN RES, V88, P68, DOI 10.1016/0165-3806(95)00081-N; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; SOLIVEN B, 1989, DEV NEUROSCI-BASEL, V11, P118, DOI 10.1159/000111893; Soliven B, 2001, MICROSC RES TECHNIQ, V52, P672, DOI 10.1002/jemt.1051; SOLIVEN B, 1988, J NEUROSCI, V8, P2131; SONTHEIMER H, 1988, GLIA, V1, P415, DOI 10.1002/glia.440010609; SONTHEIMER H, 1989, NEURON, V2, P1135, DOI 10.1016/0896-6273(89)90180-3; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; STRONG JA, 1984, J NEUROSCI, V4, P2772; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; Temporini C, 2009, ANAL BIOCHEM, V384, P123, DOI 10.1016/j.ab.2008.09.010; Tiwari-Woodruff S, 2006, AM J PHYSIOL-CELL PH, V291, pC687, DOI 10.1152/ajpcell.00510.2005; Vautier F, 2004, GLIA, V48, P337, DOI 10.1002/glia.20088; VERKHRATSKY AN, 1990, NEUROSCI LETT, V112, P194, DOI 10.1016/0304-3940(90)90202-K; von Kugelgen I, 2006, PHARMACOL THERAPEUT, V110, P415, DOI 10.1016/j.pharmthera.2005.08.014; VONBLANKENFELD G, 1992, EUR J NEUROSCI, V4, P1035; Wake H, 2011, SCIENCE, V333, P1647, DOI 10.1126/science.1206998; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; Watanabe M, 2002, J NEUROSCI RES, V69, P826, DOI 10.1002/jnr.10338; Williamson AV, 1997, EUR J NEUROSCI, V9, P706, DOI 10.1111/j.1460-9568.1997.tb01419.x	71	45	46	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2013	61	7					1155	1171		10.1002/glia.22506			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	171NK	WOS:000320935900013	23640798				2022-02-06	
J	Simpson, GK; Sabaz, M; Daher, M				Simpson, Grahame K.; Sabaz, Mark; Daher, Maysaa			Prevalence, Clinical Features, and Correlates of Inappropriate Sexual Behavior After Traumatic Brain Injury: A Multicenter Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						challenging behavior; inappropriate sexual behavior; Overt Behavior Scale; prevalence; traumatic brain injury	HEAD-INJURY; SCALE; PEOPLE; DISABILITY; DAMAGE; ABI	Objective: Investigate the prevalence and clinical features of inappropriate sexual behavior (ISB) among a community-based cohort of clients of the New South Wales Brain Injury Rehabilitation program. Setting: All 11 community-based rehabilitation services of the statewide network. Participants: Five hundred seven clients with severe traumatic brain injury. Design: Cross-sectional multicentre study. Main Measures: Overt Behavior Scale, Disability Rating Scale, Sydney Psychosocial Reintegration Scale-2, Health of the Nation Outcome Scale-Acquired Brain Injury, Care and Needs Scale. Results: The point prevalence rate of ISBs was 8.9% (45/507) over the previous 3 months. Inappropriate sexual talk comprised 57.9% of all ISBs, followed by genital and nongenital touching behaviors (29.8%) and exhibitionism/public masturbation (10.5%). In 43 of 45 cases, ISBs were accompanied by other challenging behaviors, most often inappropriate social behavior, and/or aggression. Individuals who sustained more severe injuries and who were younger were significantly more likely to display ISBs. People displaying ISBs were more likely to display higher levels of challenging behaviors overall, lower levels of social participation, and more neuropsychiatric sequelae than 2 other groups: people displaying no challenging behaviors and people displaying challenging behaviors but no ISBs respectively. Conclusions: ISBs pose a complex clinical challenge among a minority of individuals with severe TBI.	[Simpson, Grahame K.; Sabaz, Mark; Daher, Maysaa] Liverpool Hosp, Liverpool Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Simpson, Grahame K.] Univ Sydney, Sydney Sch Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia		Simpson, GK (corresponding author), Liverpool Hosp, Liverpool Brain Injury Rehabil Unit, Locked Bag 7279, Liverpool Bc, NSW 1871, Australia.	grahame.simpson@sswahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060	New South Wales Agency for Clinical Innovation	The New South Wales Agency for Clinical Innovation funded the project. Dr Mark Sabaz was employed by the Agency for Clinical Innovation when working on the project. The authors thank Dr Jeffrey Rogers, Inika Gillis, and the Project steering committee.	ALDERMAN N, 1991, Brain Injury, V5, P77, DOI 10.3109/02699059108998516; Bezeau SC, 2004, BRAIN INJURY, V18, P299, DOI 10.1080/02699050310001617398; Britton KR, 1998, BRAIN INJURY, V12, P703, DOI 10.1080/026990598122269; Coetzer R., 2001, PSYCHIATR BULL, V25, P421, DOI [https://doi.org/10.1192/pb.25.11.421, DOI 10.1192/PB.25.11.421]; Elliott ML, 1996, BRAIN INJURY, V10, P703, DOI 10.1080/026990596123972; EMORY LE, 1995, J HEAD TRAUMA REHAB, V10, P47; Fleminger S, 2005, PSYCHIATR BULL, V29, P53, DOI 10.1192/pb.29.2.53; Guercio John M, 2002, Case Manager, V13, P55, DOI 10.1067/tcmg.2002.122043; Johnson C, 2006, BRAIN INJURY, V20, P687, DOI 10.1080/02699050600744137; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kelly G, 2011, SEX DISABIL, V29, P313, DOI 10.1007/s11195-011-9213-9; Knight C, 2008, NEUROPSYCHOL REHABIL, V18, P129, DOI 10.1080/09602010701822381; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Lawrie B, 2012, REHABIL NURS, V29, P9; Lebel C, 2011, J NEUROSCI, V31, P10937, DOI 10.1523/JNEUROSCI.5302-10.2011; LEHNE G, 1986, SEX DISABIL, V7, P145; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MONEY J, 1990, AM J PSYCHOTHER, V44, P26, DOI 10.1176/appi.psychotherapy.1990.44.1.26; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sabaz M, J HEAD TRAU IN PRESS; SABHESAN S, 1989, ARCH SEX BEHAV, V18, P349, DOI 10.1007/BF01541953; Schlund MW, 1999, BRAIN INJURY, V13, P55; Simpson G, 2001, J HEAD TRAUMA REHAB, V16, P556, DOI 10.1097/00001199-200112000-00004; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; Simpson G, 2001, BRAIN IMPAIR, V2, P97, DOI DOI 10.1375/BRIM.2.2.97; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tate RL, 2004, BRAIN INJURY, V18, P445, DOI 10.1080/02699050310001641183; Tate RL, 2011, J REHABIL MED, V43, P609, DOI 10.2340/16501977-0829; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; Wood R. L., 1987, BRAIN INJURY REHABIL; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163	35	45	45	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2013	28	3					202	210		10.1097/HTR.0b013e31828dc5ae			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	149PS	WOS:000319334000007	23661072				2022-02-06	
J	White, TE; Ford, GD; Surles-Zeigler, MC; Gates, AS; LaPlaca, MC; Ford, BD				White, Todd E.; Ford, Gregory D.; Surles-Zeigler, Monique C.; Gates, Alicia S.; LaPlaca, Michelle C.; Ford, Byron D.			Gene expression patterns following unilateral traumatic brain injury reveals a local pro-inflammatory and remote anti-inflammatory response	BMC GENOMICS			English	Article						Bioinformatics; Cytokine; Gene interaction hierarchy; Inflammation; Microarray; Rat; Traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; LONG-TERM DISABILITY; RAT CEREBRAL-CORTEX; UNITED-STATES; FOCAL STROKE; ISCHEMIA; NEUROPROTECTION; NEUREGULIN-1; HIPPOCAMPUS; CYTOKINES	Background: Traumatic brain injury (TBI) results in irreversible damage at the site of impact and initiates cellular and molecular processes that lead to secondary neural injury in the surrounding tissue. We used microarray analysis to determine which genes, pathways and networks were significantly altered using a rat model of TBI. Adult rats received a unilateral controlled cortical impact (CCI) and were sacrificed 24 h post-injury. The ipsilateral hemi-brain tissue at the site of the injury, the corresponding contralateral hemi-brain tissue, and naive (control) brain tissue were used for microarray analysis. Ingenuity Pathway Analysis (IPA) software was used to identify molecular pathways and networks that were associated with the altered gene expression in brain tissues following TBI. Results: Inspection of the top fifteen biological functions in IPA associated with TBI in the ipsilateral tissues revealed that all had an inflammatory component. IPA analysis also indicated that inflammatory genes were altered on the contralateral side, but many of the genes were inversely expressed compared to the ipsilateral side. The contralateral gene expression pattern suggests a remote anti-inflammatory molecular response. We created a network of the inversely expressed common (i.e., same gene changed on both sides of the brain) inflammatory response (IR) genes and those IR genes included in pathways and networks identified by IPA that changed on only one side. We ranked the genes by the number of direct connections each had in the network, creating a gene interaction hierarchy (GIH). Two well characterized signaling pathways, toll-like receptor/NF-kappaB signaling and JAK/STAT signaling, were prominent in our GIH. Conclusions: Bioinformatic analysis of microarray data following TBI identified key molecular pathways and networks associated with neural injury following TBI. The GIH created here provides a starting point for investigating therapeutic targets in a ranked order that is somewhat different than what has been presented previously. In addition to being a vehicle for identifying potential targets for post-TBI therapeutic strategies, our findings can also provide a context for evaluating the potential of therapeutic agents currently in development.	[White, Todd E.; Surles-Zeigler, Monique C.; Gates, Alicia S.; Ford, Byron D.] Morehouse Sch Med, Inst Neurosci, Dept Neurobiol, Atlanta, GA 30310 USA; [Ford, Gregory D.] Morehouse Coll, Dept Biol, Atlanta, GA 30314 USA; [LaPlaca, Michelle C.] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA		Ford, BD (corresponding author), Morehouse Sch Med, Inst Neurosci, Dept Neurobiol, 720 Westview Dr SW, Atlanta, GA 30310 USA.	bford@msm.edu		Surles-Zeigler, Monique/0000-0002-2308-8813	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01 NS 057993, U54 NS060659]; Department of DefenseUnited States Department of Defense [W81XWH-10-2-0055]; W.M. Keck FoundationW.M. Keck Foundation; BRIC NIH grant [5P20M006131-02]; NIH, National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR025008, KL2 RR025009, TL1 RR025010]; Morehouse School of Medicine Grants from the NCRR, a component of NIH [U54 RR026137, G12RR003034, S21MD000101]; Howard Hughes Medical InstituteHoward Hughes Medical Institute [52006306]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR000456, UL1TR000454, KL2TR000455] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025008, U54RR026137, G12RR003034, TL1RR025010, KL2RR025009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS057993, U54NS060659] Funding Source: NIH RePORTER; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [S21MD000101] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [T15LM007056] Funding Source: NIH RePORTER	The authors would like to thank Brock Wester, Kaelin Brewster, and Samantha Simon for their technical assistance. This work was supported by National Institutes of Health (NIH) grants U01 NS 057993 (BDF), U54 NS060659 (BDF), Department of Defense Contract #W81XWH-10-2-0055 (BDF), the W.M. Keck Foundation (BDF); BRIC NIH grant #5P20M006131-02 (GDF), Howard Hughes Medical Institute grant #52006306 (GDF) and PHS Grant (UL1 RR025008, KL2 RR025009 or TL1 RR025010) from the Clinical and Translational Science Award program, NIH, National Center for Research Resources (NCRR) (MCL). The project described was supported by Morehouse School of Medicine Grants Number U54 RR026137, G12RR003034 and S21MD000101 from the NCRR, a component of NIH, and its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH.	Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chavarria A, 2004, AUTOIMMUN REV, V3, P251, DOI 10.1016/j.autrev.2003.09.006; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Fahlenkamp AV, 2011, INFLAMM RES, V60, P379, DOI 10.1007/s00011-010-0281-6; FAN L, 1995, MOL BRAIN RES, V30, P125; Faul M, 2010, TRAUMATIC BRAIN INJU; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Ford G, 2006, BRAIN RES, V1071, P226, DOI 10.1016/j.brainres.2005.11.090; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kong Y, 2011, INT IMMUNOPHARMACOL, V11, P1407, DOI 10.1016/j.intimp.2011.04.025; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Ley EJ, 2011, J SURG RES, V170, P253, DOI 10.1016/j.jss.2011.03.006; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Li YG, 2011, TOXICOL APPL PHARM, V253, P261, DOI 10.1016/j.taap.2011.03.026; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Xu ZF, 2005, NEUROBIOL DIS, V19, P461, DOI 10.1016/j.nbd.2005.01.027; Xu ZF, 2004, BIOCHEM BIOPH RES CO, V322, P440, DOI 10.1016/j.bbrc.2004.07.149; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	36	45	45	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2164			BMC GENOMICS	BMC Genomics	APR 25	2013	14								282	10.1186/1471-2164-14-282			20	Biotechnology & Applied Microbiology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity	156KB	WOS:000319819600001	23617241	Green Published, gold			2022-02-06	
J	Luo, CL; Li, QQ; Chen, XP; Zhang, XM; Li, LL; Li, BX; Zhao, ZQ; Tao, LY				Luo, Cheng-Liang; Li, Qian-Qian; Chen, Xi-Ping; Zhang, Xin-Mu; Li, Li-Liang; Li, Bei-Xu; Zhao, Zi-Qin; Tao, Lu-Yang			Lipoxin A(4) attenuates brain damage and downregulates the production of pro-inflammatory cytokines and phosphorylated mitogen-activated protein kinases in a mouse model of traumatic brain injury	BRAIN RESEARCH			English	Article						Lipoxin A(4); Traumatic brain injury; Blood-brain barrier; Brain edema; Pro-inflammatory cytokines; Mitogen-activated protein kinases	ASPIRIN-TRIGGERED LIPOXIN; FOCAL CEREBRAL-ISCHEMIA; INDUCED CELL-DEATH; NF-KAPPA-B; AQUAPORIN-4 EXPRESSION; NITRIC-OXIDE; IN-VIVO; RAT; RECEPTOR; EDEMA	The present study was designed to investigate the effects of lipoxin A(4) (LXA(4)) on traumatic brain injury (TBI) and to analyze the possible mechanism. Outcome parameters consist of blood-brain barrier (BBB) breakdown, brain edema and lesion volume. Using western blot and quantitative real-time PCR, we examined the levels of pro-inflammatory cytokines (TNF-alpha, IL-1 beta, IL-6) and activation of mitogen-activated protein kinases (MAPKs) (including ERK, JNK, p38) following TBI. To investigate the cell types in which the LXA(4) receptor (ALXR) staining was localized, brain sections pulsed with ALXR were subjected to immunofluorescence staining with antibodies against cell type-specific antigens. Our findings show that LXA(4) decreases BBB permeability, attenuates brain edema, and reduces TBI-induced lesion volume. In addition, LXA(4) inhibits TBI-induced elevation of mRNA and protein levels of pro-inflammatory cytokines (TNF-alpha, IL-1 beta, IL-6). In the injured cortex at 24 h post-TBI, the phosphorylated-ERK (p-ERK) and -JNK (p-JNK), but not -p38 (p-p38) levels were increased. The p-ERK and p-JNK production were attenuated by their respective inhibitors (PD98059 and SP600125), as well as LXA(4). Moreover, ALXR was found to label more GFAP positive cells, whereas few CD11b-positive cells were labeled by ALXR within the layers of the injured cortex at 24 h post-TBI. The activation of ALXR in astrocytes was partially enhanced by LXA(4) treatment. Taken together, these data indicate that TBI activates pro-inflammatory cytokines, the MAPK pathways together with ALXR in astrocytes, and these mechanisms may be exploited by pharmacological interventions. (C) 2013 Elsevier B.V. All rights reserved.	[Luo, Cheng-Liang; Li, Qian-Qian; Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Dept Forens Med, Suzhou 215123, Peoples R China; [Luo, Cheng-Liang; Li, Li-Liang; Li, Bei-Xu; Zhao, Zi-Qin] Fudan Univ, Shanghai Med Coll, Dept Forens Med, Shanghai 200032, Peoples R China; [Li, Qian-Qian] Wannan Med Coll, Dept Forens Med, Wuhu, Peoples R China; [Zhang, Xin-Mu] Jilin Univ, Sch Pharm, Dept Biopharmaceut Sci, Changchun 130023, Peoples R China		Zhao, ZQ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Forens Med, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	zqzhao@shmu.edu.cn; luyang.tao@163.com	Li, Liliang/AAQ-9877-2020; Zhang, Xinmu/G-8128-2018	Li, Liliang/0000-0002-1933-134X	National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271379, 81172911, 81172897]; Shanghai Forensic Key Laboratory Foundation [KF1005]	This work was supported by the National Science Foundation of China (Nos. 81271379, 81172911, 81172897) and the Shanghai Forensic Key Laboratory Foundation (No. KF1005). We thank Dr. Jing Zhou in Department of Neurosurgery, Brigham and Women's Hospital/Harvard Medical School for polishing our manuscript.	Auger G, 2011, CYTOKINE, V56, P290, DOI 10.1016/j.cyto.2011.06.015; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Jozsef L, 2002, P NATL ACAD SCI USA, V99, P13266, DOI 10.1073/pnas.202296999; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Marmarou A, 1980, Adv Neurol, V28, P345; Marmarou A., 2007, NEUROSURG FOCUS, V22, P1; MASLIAH E, 1992, J NEUROPATH EXP NEUR, V51, P404, DOI 10.1097/00005072-199207000-00003; Medeiros R, 2008, MOL PHARMACOL, V74, P154, DOI 10.1124/mol.108.046870; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Qin ZH, 1999, J NEUROSCI, V19, P4023; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sigala I, 2011, AM J PHYSIOL-REG I, V300, pR1152, DOI 10.1152/ajpregu.00376.2010; Svensson CI, 2007, J EXP MED, V204, P245, DOI 10.1084/jem.20061826; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wada K, 2006, FASEB J, V20, P1785, DOI 10.1096/fj.06-5809com; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; Wu SH, 2007, PROSTAG LEUKOTR ESS, V76, P173, DOI 10.1016/j.plefa.2006.12.006; Wu Y, 2012, J MOL NEUROSCI, V46, P483, DOI 10.1007/s12031-011-9620-5; Wu Y, 2010, J MOL NEUROSCI, V42, P226, DOI 10.1007/s12031-010-9355-8; Ye XH, 2010, BRAIN RES, V1323, P174, DOI 10.1016/j.brainres.2010.01.079; Zhang HL, 2011, NEUROSCIENCE, V176, P381, DOI 10.1016/j.neuroscience.2010.12.029; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	39	45	47	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 28	2013	1502						1	10		10.1016/j.brainres.2013.01.037			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	126SG	WOS:000317640900001	23370001				2022-02-06	
J	Macdonald, RL; Cusimano, MD; Etminan, N; Hanggi, D; Hasan, D; Ilodigwe, D; Jaja, B; Lantigua, H; Le Roux, P; Lo, B; Louffat-Olivares, A; Mayer, S; Molyneux, A; Quinn, A; Schweizer, TA; Schenk, T; Spears, J; Todd, M; Torner, J; Vergouwen, MDL; Wong, GKC				Macdonald, R. Loch; Cusimano, Michael D.; Etminan, Nima; Hanggi, Daniel; Hasan, David; Ilodigwe, Don; Jaja, Blessing; Lantigua, Hector; Le Roux, Peter; Lo, Benjamin; Louffat-Olivares, Ada; Mayer, Stephan; Molyneux, Andrew; Quinn, Audrey; Schweizer, Tom A.; Schenk, Thomas; Spears, Julian; Todd, Michael; Torner, James; Vergouwen, Mervyn D. L.; Wong, George K. C.		SAHIT Collaboration	Subarachnoid Hemorrhage International Trialists Data Repository (SAHIT)	WORLD NEUROSURGERY			English	Article						Cerebral aneurysm; Clinical trial; Outcome; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; CEREBRAL INFARCTION; CLINICAL-TRIALS; INTENSIVE-CARE; DOUBLE-BLIND; VASOSPASM; STROKE; CLAZOSENTAN; ISCHEMIA; REGION	The outcome of patients with aneurysmal subarachnoid hemorrhage (SAH) has improved slowly over the past 25 years. This improvement may be due to early aneurysm repair by endovascular or open means, use of nimodipine, and better critical care management. Despite this improvement, mortality remains at about 40%, and many survivors have permanent neurologic, cognitive, and neuropsychologic deficits. Randomized clinical trials have tested pharmacologic therapies, but few have been successful. There are numerous explanations for the failure of these trials, including ineffective interventions, inadequate sample size, treatment side effects, and insensitive or inappropriate outcome measures. Outcome often is evaluated on a good-bad dichotomous scale that was developed for traumatic brain injury 40 years ago. To address these issues, we established the Subarachnoid Hemorrhage International Trialists (SAHIT) data repository. The primary aim of the SAHIT data repository is to provide a unique resource for prognostic analysis and for studies aimed at optimizing the design and analysis of phase III trials in aneurysmal SAH. With this aim in mind, we convened a multinational investigator meeting to explore merging individual patient data from multiple clinical trials and observational databases of patients with SAH and to create an agreement under which such a group of investigators could submit data and collaborate. We welcome collaboration with other investigators.	[Macdonald, R. Loch; Cusimano, Michael D.; Ilodigwe, Don; Jaja, Blessing; Lo, Benjamin; Louffat-Olivares, Ada; Schweizer, Tom A.; Spears, Julian] Univ Toronto, Toronto, ON, Canada; [Etminan, Nima; Hanggi, Daniel] Univ Dusseldorf, D-40225 Dusseldorf, Germany; [Hasan, David; Todd, Michael; Torner, James] Univ Iowa, Iowa City, IA USA; [Lantigua, Hector; Mayer, Stephan] Columbia Univ, New York, NY USA; [Le Roux, Peter] Univ Penn, Philadelphia, PA 19104 USA; [Molyneux, Andrew] Univ Oxford, Oxford, England; [Quinn, Audrey] Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; [Schenk, Thomas] Kings Coll London, London WC2R 2LS, England; [Vergouwen, Mervyn D. L.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Wong, George K. C.] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China		Macdonald, RL (corresponding author), Univ Toronto, Toronto, ON, Canada.		Wong, George Kwok Chu/L-4344-2016; Cusimano, Michael/X-4059-2019; Wong, George KC/A-6378-2011	Wong, George KC/0000-0002-6078-2548; hasan, david/0000-0002-8335-5442; Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Physicians Services Incorporated Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Brain Aneurysm Foundation; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Canadian Stroke Network; Medical Research Council UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Cerecyte Coil Trial; Ontario Ministry of Research and InnovationMinistry of Research and Innovation, Ontario; Netherlands Thrombosis Foundation; Netherlands Heart FoundationNetherlands Heart Foundation; Hong Kong Food and Health Bureau; Hong Kong University Grant Committee; Integra; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0700479, G9401611] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0700479, G9401611] Funding Source: researchfish	This work was funded by a grant from the Canadian Institutes for Health Research. Michael D. Cusimano receives grant support from the Canadian Institutes for Health Research. Nima Etminan receives grant support from Physicians Services Incorporated Foundation. David Hasan receives grant funding from National Institutes of Health and Brain Aneurysm Foundation. Peter Le Roux receives research funding from the National Institutes of Health and Integra and is a consultant for Cadman, Integra and Edge Therapeutics. R. Loch Macdonald receives grant funding from the Canadian Institutes for Health Research, Heart and Stroke Foundation of Canada, Canadian Stroke Network, Brain Aneurysm Foundation, and Physicians Services Incorporated Foundation and is a consultant for Actelion Pharmaceuticals, Ltd., and Chief Scientific Officer of Edge Therapeutics, Inc. Stephan Mayer is a consultant for Actelion Pharmaceuticals, Ltd. Andrew Molyneux is a consultant for Micrus Endovascular and receives grant support from the Medical Research Council UK and Cerecyte Coil Trial. Tom A. Schweizer receives grant support from the Heart and Stroke Foundation of Canada, the Canadian Institutes of Health Research, and the Ontario Ministry of Research and Innovation. Michael Todd receives grant support from the National Institutes of Health. James Torner receives grant support from the National Institutes of Health. Mervyn D. I. Vergouwen receives grant support from the Netherlands Thrombosis Foundation and Netherlands Heart Foundation. George K. C. Wong receives grant support from the Hong Kong Food and Health Bureau and the Hong Kong University Grant Committee.	Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Deans KJ, 2007, CRIT CARE MED, V35, P1509, DOI 10.1097/01.CCM.0000266584.40715.A6; Etminan N, 2011, J CEREBR BLOOD F MET, V31, P1443, DOI 10.1038/jcbfm.2011.7; Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B; JENNETT B, 1975, LANCET, V1, P480; KRAMER AH, 2011, ACTA NEUROCHIR SUPPL, V2, P193, DOI DOI 10.1007/978-3-7091-0356-2_36; Kreiter KT, 2009, STROKE, V40, P2362, DOI 10.1161/STROKEAHA.109.547331; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; Lovelock CE, 2010, NEUROLOGY, V74, P1494, DOI 10.1212/WNL.0b013e3181dd42b3; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; MEES SMD, 2007, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000277.PUB3; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7; Ospina-Tascon GA, 2008, CRIT CARE MED, V36, P1311, DOI 10.1097/CCM.0b013e318168ea3e; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; Sahs AL, 1969, INTRACRANIAL ANEURYS; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; Tobin MJ, 2008, CHEST, V133, P1071, DOI 10.1378/chest.08-0077; van der Schaaf IC, 2002, STROKE, V33, P2043, DOI 10.1161/01.STR.0000024110.82735.5A; Vergouwen MDI, 2011, J CEREBR BLOOD F MET, V31, P1545, DOI 10.1038/jcbfm.2011.56; Vincent JL, 2010, CRIT CARE MED, V38, pS534, DOI 10.1097/CCM.0b013e3181f208ac; Wong GKC, 2011, NEUROSURGERY, V68, P1556, DOI 10.1227/NEU.0b013e31820cd40d	28	45	45	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR-APR	2013	79	3-4					418	422		10.1016/j.wneu.2013.01.006			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	135CC	WOS:000318262600005	23295631				2022-02-06	
J	Griessenauer, CJ; Fleming, JB; Richards, BF; Cava, LP; Cure, JK; Younan, DS; Zhao, LM; Alexandrov, AV; Barlinn, K; Taylor, T; Harrigan, MR				Griessenauer, Christoph J.; Fleming, J. Brett; Richards, Boyd F.; Cava, Luis P.; Cure, Joel K.; Younan, Duraid S.; Zhao, Limin; Alexandrov, Andrei V.; Barlinn, Kristian; Taylor, Tracy; Harrigan, Mark R.			Timing and mechanism of ischemic stroke due to extracranial blunt traumatic cerebrovascular injury	JOURNAL OF NEUROSURGERY			English	Article						carotid artery; vertebral artery; blunt trauma; ischemic stroke; vascular disorders	INTERNAL CAROTID-ARTERY; VASCULAR NECK INJURIES; EARLY-DIAGNOSIS; FOLLOW-UP; OUTCOMES; THERAPY; ANGIOGRAPHY; DISSECTION; ANTICOAGULATION; HEAD	Object. Extracranial cerebrovascular injury is believed to be an important cause of neurological injury in patients who have suffered blunt trauma. The authors sought to determine the timing and mechanisms of ischemic stroke in patients who suffered traumatic cerebrovascular injury (TCVI). Methods. This is a prospective study of all patients with TCVI who were admitted to a Level I trauma center during a 28-month period. All patients who suffered blunt trauma and had risk factors for TCVI underwent screening CT angiography (CTA) of the head and neck on admission. All patients with either an ischemic stroke or CTA suggesting TCVI underwent confirmatory digital subtraction angiography (DSA). Patients with DSA-confirmed TCVI were treated with 325 mg aspirin daily; all patients were observed during their hospitalization for the occurrence of new ischemic stroke. In addition, a subset of patients with TCVI underwent transcranial Doppler ultrasonography monitoring for microembolic signals. Results. A total of 112 patients had CTA findings suggestive of TCVI; 68 cases were confirmed by DSA. Overall, 7 patients had an ischemic stroke in the territory of the affected artery prior to or during admission. Four of the patients had their event prior to diagnosis with CTA and 2 occurred prior to DSA. In 1 patient the ischemic stroke was found to be due to an extracranial atherosclerotic carotid plaque, and this patient was excluded from further analysis. All patients with ischemic stroke had brain CT findings consistent with an embolic mechanism. Two (8.7%) of 23 monitored patients with TCVI had microembolic signals on transcranial Doppler ultrasonography. Conclusions. Most ischemic strokes due to TCVI are embolic in nature and occur prior to screening CTA and initiation of treatment with aspirin. (http://thejns.org/doi/abs/10.3171/2012.11.JNS121038)	[Griessenauer, Christoph J.; Fleming, J. Brett; Richards, Boyd F.; Younan, Duraid S.; Taylor, Tracy; Harrigan, Mark R.] Univ Birmingham, Dept Surg, Birmingham, AL USA; [Cava, Luis P.; Cure, Joel K.] Univ Birmingham, Dept Radiol, Birmingham, AL USA; [Zhao, Limin; Alexandrov, Andrei V.; Barlinn, Kristian] Univ Birmingham, Dept Neurol, Birmingham, AL USA		Harrigan, MR (corresponding author), Fac Off Tower 1005,510 20th St S, Birmingham, AL 35294 USA.	mharrigan@uabmc.edu	Barlinn, Kristian/AAL-9340-2021	Alexandrov, Andrei V/0000-0001-8871-1023; Griessenauer, Christoph/0000-0002-2952-3812			Arthurs ZM, 2008, INJURY, V39, P1232, DOI 10.1016/j.injury.2008.02.042; Beletsky V, 2003, STROKE, V34, P2856, DOI 10.1161/01.STR.0000098649.39767.BC; Berne JD, 2009, J TRAUMA, V67, P1333, DOI 10.1097/TA.0b013e31818888c7; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Carrillo EH, 1999, J TRAUMA, V46, P1120, DOI 10.1097/00005373-199906000-00030; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; Diaz-Daza O, 2003, CARDIOVASC INTER RAD, V26, P213, DOI 10.1007/s00270-002-2619-0; DiPerna CA, 2002, AM SURGEON, V68, P441; Droste DW, 2001, CEREBROVASC DIS, V12, P181, DOI 10.1159/000047701; Eachempati SR, 1998, J TRAUMA, V45, P997, DOI 10.1097/00005373-199812000-00004; Eastman AL, 2009, J TRAUMA, V67, P551, DOI 10.1097/TA.0b013e3181b84408; Edwards NM, 2007, J AM COLL SURGEONS, V204, P1007, DOI 10.1016/j.jamcollsurg.2006.12.041; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FABIAN TC, 1990, J TRAUMA, V30, P953, DOI 10.1097/00005373-199008000-00003; Fleck SK, 2011, NEUROSURGERY, V69, P615, DOI 10.1227/NEU.0b013e31821a8701; Franz RW, 2010, VASC ENDOVASC SURG, V44, P198, DOI 10.1177/1538574409359429; Harrigan MR, 2011, WORLD J EMERG SURG, V6, DOI 10.1186/1749-7922-6-11; KRAJEWSKI LP, 1980, ANN SURG, V191, P341, DOI 10.1097/00000658-198003000-00014; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; McKevitt EC, 2002, J TRAUMA, V53, P472, DOI 10.1097/00005373-200209000-00013; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Miller PR, 2001, J TRAUMA, V51, P279, DOI 10.1097/00005373-200108000-00009; MOKRI B, 1988, J NEUROSURG, V68, P189, DOI 10.3171/jns.1988.68.2.0189; Molina CA, 2000, NEUROLOGY, V55, P1738, DOI 10.1212/WNL.55.11.1738; PERRY MO, 1980, ANN SURG, V192, P74, DOI 10.1097/00000658-198007000-00013; Redekop GJ, 2008, CAN J NEUROL SCI, V35, P146, DOI 10.1017/S0317167100008556; Ringelstein EB, 1998, STROKE, V29, P725; Rodriguez M, 2001, ACTA NEUROCHIR, V143, P939, DOI 10.1007/s007010170025; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Sliker CW, 2008, RADIOGRAPHICS, V28, P1689, DOI 10.1148/rg.286085521; Sliker CW, 2008, AM J ROENTGENOL, V190, P790, DOI 10.2214/AJR.07.2378; Srinivasan J, 1996, STROKE, V27, P1226, DOI 10.1161/01.STR.27.7.1226; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Wahl WL, 2002, J TRAUMA, V52, P896, DOI 10.1097/00005373-200205000-00012	41	45	48	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2013	118	2					397	404		10.3171/2012.11.JNS121038			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	076DY	WOS:000313937900025	23216467				2022-02-06	
J	Briones, TL; Woods, J; Rogozinska, M				Briones, Teresita L.; Woods, Julie; Rogozinska, Magdalena			Decreased neuroinflammation and increased brain energy homeostasis following environmental enrichment after mild traumatic brain injury is associated with improvement in cognitive function	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						IL-beta; TNF-alpha; IL10; AMPK; Non-matching-to-sample task	ACTIVATED PROTEIN-KINASE; CEREBRAL-ISCHEMIA; MICROGLIA; RECOVERY; IMPAIRMENT; PLASTICITY; INFLAMMATION; STIMULATION; HIPPOCAMPUS; INVOLVEMENT	Background: Persistent neuroinflammation and disruptions in brain energy metabolism is commonly seen in traumatic brain injury (TBI). Because of the lack of success of most TBI interventions and the documented benefits of environmental enrichment (EE) in enhancing brain plasticity, here we focused our study on use of EE in regulating injury-induced neuroinflammation and disruptions in energy metabolism in the prefrontal cortex and hippocampus. Adult male Wistar rats were used in the study and randomly assigned to receive either: mild TBI (mTBI) using the controlled cortical injury model or sham surgery. Following surgery, rats from each group were further randomized to either: EE housing or standard laboratory housing (CON). After 4 weeks of recovery, cognitive testing was performed using the non-matching-to-sample and delayed non-matching-to-sample tasks. After completion of behavioral testing, levels of the pro-inflammatory cytokines IL-1 beta and TNF-alpha and the anti-inflammatory cytokine IL-10 were measured. In addition, levels of AMPK (adenosine monophosphate-activated protein kinase), phosphorylated AMPK and uMtCK (ubiquitous mitochondrial creatine kinase) were assessed as measures of brain energy homeostasis. Results: Our results showed that EE: (1) decreased the pro-inflammatory cytokines IL-1 beta and TNF-alpha and enhanced levels of the anti-inflammatory cytokine IL-10 after mTBI; (2) mitigated mTBI-induced cognitive impairment; and (3) attenuated mTBI-induced downregulation in pAMPK/AMPK ratio and uMtCK levels. Conclusions: Our data demonstrated the potential of EE to modulate the persistent: (1) neuroinflammatory response seen following mTBI, and (2) persistent disturbance in brain energy homeostasis. It is possible that through the mechanism of modulating neuroinflammation, EE housing was able to restore the disruption in energy metabolism and enhanced functional recovery after mTBI.	[Briones, Teresita L.] Wayne State Univ, Dept Adult Hlth, Cohn Bldg,Rm 344,5557 Cass Ave, Detroit, MI 48202 USA; [Woods, Julie; Rogozinska, Magdalena] Univ Illinois, Dept Biobehav Hlth Sci, Chicago, IL 60612 USA		Briones, TL (corresponding author), Wayne State Univ, Dept Adult Hlth, Cohn Bldg,Rm 344,5557 Cass Ave, Detroit, MI 48202 USA.	tbriones@wayne.edu			National Institutes of Health, NINRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [RO1 NR007666]; University of Illinois at Chicago, College of Nursing Internal Research Program; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR007666] Funding Source: NIH RePORTER	This work was supported in part by the National Institutes of Health, NINR grant # RO1 NR007666 and the University of Illinois at Chicago, College of Nursing Internal Research Program. We are grateful for the assistance of Maggie Wadowska in animal handling.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; BACHYRITA P, 1990, NEUROPSYCHOLOGIA, V28, P547, DOI 10.1016/0028-3932(90)90033-K; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Boero J, 2003, MOL CELL BIOCHEM, V244, P69, DOI 10.1023/A:1022409101641; Briones T L, 2000, Biol Res Nurs, V1, P299, DOI 10.1177/109980040000100406; Briones Teresita L, 2005, Biol Res Nurs, V6, P167, DOI 10.1177/1099800404271328; Briones TL, 2009, J NEUROTRAUM, V26, P613, DOI 10.1089/neu.2008.0707; Briones TL, 2006, BEHAV BRAIN RES, V171, P17, DOI 10.1016/j.bbr.2006.03.011; Briones TL, 2006, BEHAV BRAIN RES, V168, P261, DOI 10.1016/j.bbr.2005.11.015; Briones TL, 2004, BRAIN RES, V997, P137, DOI 10.1016/j.brainres.2003.10.030; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Carling D, 2012, BIOCHEM J, V445, P11, DOI 10.1042/BJ20120546; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; Cunningham C, 2008, BRAIN BEHAV IMMUN, V22, P1117, DOI 10.1016/j.bbi.2008.05.007; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Faul M, 2010, TRAUMATIC BRAIN INJU; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Huang ZB, 2010, NEUROSCI BULL, V26, P455, DOI 10.1007/s12264-010-6023-5; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Johnson EM, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00044; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jurgens HA, 2012, BRAIN BEHAV IMMUN, V26, P1006, DOI 10.1016/j.bbi.2012.05.015; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kleman AM, 2008, J NEUROSCI METH, V167, P292, DOI 10.1016/j.jneumeth.2007.08.028; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Maesako M, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.10.028; Manwani B, 2013, J NEUROSCI RES, V91, P1018, DOI 10.1002/jnr.23207; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Rijntjes M, 2002, PROG NEUROBIOL, V66, P109, DOI 10.1016/S0301-0082(01)00027-2; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Tonelli LH, 2005, FRONT BIOSCI, V10, P675, DOI 10.2741/1562; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Yao ZH, 2012, CURR NEUROVASC RES, V9, P176, DOI 10.2174/156720212801618974; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	51	45	48	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.		2013	1								57	10.1186/2051-5960-1-57			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V9K2F	WOS:000422387200047	24252176	Green Published, gold			2022-02-06	
J	Song, SX; Gao, JL; Wang, KJ; Li, R; Tian, YX; Wei, JQ; Cui, JZ				Song, Si-Xin; Gao, Jun-Ling; Wang, Kai-Jie; Li, Ran; Tian, Yan-Xia; Wei, Jian-Qiang; Cui, Jian-Zhong			Attenuation of brain edema and spatial learning deficits by the inhibition of NADPH oxidase activity using apocynin following diffuse traumatic brain injury in rats	MOLECULAR MEDICINE REPORTS			English	Article						diffuse brain injury; nicotinamide adenine dinucleotide phosphate oxidase; NOX2; secondary brain damage; learning and memory ability	CELL-DEATH; ACTIVATION; HEMORRHAGE; ISCHEMIA; STROKE; VOLUME; DAMAGE; MODEL; NOX2; BETA	Diffuse brain injury (DBI) is a leading cause of mortality and disability among young individuals and adults worldwide. In specific cases, DBI is associated with permanent spatial learning dysfunction and motor deficits due to primary and secondary brain damage. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) is a major complex that produces reactive oxygen species (ROS) during the ischemic period. The complex aggravates brain damage and cell death following ischemia/reperfusion injury; however, its role in DBI remains unclear. The present study aimed to investigate the hypothesis that levels of NOX2 (a catalytic subunit of NOX) protein expression and the activation of NOX are enhanced following DBI induction in rats and are involved in aggravating secondary brain damage. A rat model of DBI was created using a modified weight-drop device. Our results demonstrated that NOX2 protein expression and NOX activity were enhanced in the CA1 subfield of the hippocampus at 48 and 72 h following DBI induction. Treatment with apocynin (50 mg/kg body weight), a specific inhibitor of NOX, injected intraperitoneally 30 min prior to DBI significantly attenuated NOX, protein expression and NOX activation. Moreover, treatment with apocynin reduced brain edema and improved spatial learning function assessed using the Morris water maze. These results reveal that treatment with apocynin may provide a new neuroprotective therapeutic strategy against DBI by diminishing the upregulation of NOX2 protein and NOX activity.	[Song, Si-Xin; Wei, Jian-Qiang; Cui, Jian-Zhong] Hebei Med Univ, Dept Surg, 361 E Zhongshan Rd, Shijiazhuang 050017, Peoples R China; [Gao, Jun-Ling; Li, Ran; Tian, Yan-Xia] Hebei United Univ, Sch Basic Med Sci, Tangshan, Hebei, Peoples R China; [Wang, Kai-Jie; Cui, Jian-Zhong] Tangshan Workers Hosp, Tangshan 063000, Peoples R China		Cui, JZ (corresponding author), Hebei Med Univ, Dept Surg, 361 E Zhongshan Rd, Shijiazhuang 050017, Peoples R China.	jzhcuidr2001@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2012401071]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (no. H2012401071).	Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bobba A, 2008, INT J MOL MED, V21, P737; Cairns B, 2012, CURR DRUG TARGETS, V13, P199, DOI 10.2174/138945012799201676; Connell BJ, 2011, FOOD CHEM TOXICOL, V49, P3063, DOI 10.1016/j.fct.2011.09.010; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Hur J, 2010, BIOCHEM BIOPH RES CO, V391, P1526, DOI 10.1016/j.bbrc.2009.12.114; Infanger DW, 2006, ANTIOXID REDOX SIGN, V8, P1583, DOI 10.1089/ars.2006.8.1583; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Jana A, 2004, J BIOL CHEM, V279, P51451, DOI 10.1074/jbc.M404635200; Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765; Kelly KA, 2009, BRAIN RES, V1292, P165, DOI 10.1016/j.brainres.2009.07.052; Kim MJ, 2005, BRAIN RES, V1040, P178, DOI 10.1016/j.brainres.2005.01.066; Lafeber FPJG, 1999, RHEUMATOLOGY, V38, P1088, DOI 10.1093/rheumatology/38.11.1088; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Lo W, 2007, NEUROSCI LETT, V414, P228, DOI 10.1016/j.neulet.2006.12.055; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046; Murillo MM, 2007, BIOCHEM J, V405, P251, DOI 10.1042/BJ20061846; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; Serrano F, 2003, BRAIN RES, V988, P193, DOI 10.1016/S0006-8993(03)03364-X; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Tang LL, 2007, J INT MED RES, V35, P517, DOI 10.1177/147323000703500411; Vallet P, 2005, NEUROSCIENCE, V132, P233, DOI 10.1016/j.neuroscience.2004.12.038; Woodfin A, 2011, FREE RADICAL BIO MED, V50, P518, DOI 10.1016/j.freeradbiomed.2010.12.010; Yoshioka H, 2011, J CEREBR BLOOD F MET, V31, P868, DOI 10.1038/jcbfm.2010.166; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhang Y, 2005, AM J HYPERTENS, V18, P910, DOI 10.1016/j.amjhyper.2005.02.017; Zia MT, 2009, STROKE, V40, P2191, DOI 10.1161/STROKEAHA.108.544759	30	45	46	0	5	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	JAN	2013	7	1					327	331		10.3892/mmr.2012.1147			5	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	052ZA	WOS:000312238000057	23128834	Bronze			2022-02-06	
J	Waldron, B; Casserly, LM; O'Sullivan, C				Waldron, Brian; Casserly, Lisa Marie; O'Sullivan, Clodagh			Cognitive behavioural therapy for depression and anxiety in adults with acquired brain injury. What works for whom?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Acquired brain injury; Traumatic brain injury; Cognitive behavioural therapy; Depression; Anxiety	OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; SELF-ASSESSMENT; AXIS I; SKILLS; STROKE; TRIAL; SCALE; INDIVIDUALS	This paper reviews treatment outcome studies on cognitive behavioural therapy (CBT) for depression and anxiety following acquired brain injury (ABI), including traumatic brain injury (TBI), cerebral vascular accident (CVA), anoxia and neurosurgery. Studies are included for review when the published paper included an anxiety disorder or depression as the treatment focus, or as part of outcome measurement. Relaxed criteria were used to select studies including relevant single-cases, case series and single group studies along with studies that employed control groups. Twenty-four studies were identified. Twelve papers were of a single-case design (with or without replication). Two papers used uncontrolled single groups and ten studies used a control group. There were a total of 507 people in the various treatment and control groups, which ranged in size from 6 to 67 persons. All participants in the study had an ABI. Our review indicates CBT often shows a within-group pre- to post-treatment statistical difference for depression and anxiety problems, or a statistical difference between CBT-treated and non-treated groups. For studies that targeted the treatment of depression with CBT, effect-sizes ranged from 0 to 2.39 with an average effect-size of 1.15 for depression (large effect). For studies that targeted the treatment of anxiety with CBT, effect-sizes ranged from 0 to 3.47 with an average effect-size of 1.04 for anxiety (large effect). However, it was not possible to submit all twenty-four studies identified to effect-size analysis. Additionally, it is clear that CBT is not a panacea, as studies frequently indicate only partial reduction in anxiety and depression symptoms. This review suggests that if CBT is aimed at, for example, anger management or coping, it can be effective for anger or coping, but will not generalise to have an effect on anxiety or depression. CBT interventions that target anxiety and depression specifically appear to generate better therapeutic effects on anxiety and depression. Gaps in the literature are highlighted with suggestions for future research.	[Waldron, Brian; Casserly, Lisa Marie; O'Sullivan, Clodagh] ABI Ireland, Dun Laoghaire, Co Dublin, Ireland		Waldron, B (corresponding author), ABI Ireland, Northumberland Ave, Dun Laoghaire, Co Dublin, Ireland.	bwaldron@abiireland.ie					Alford, 1999, SCI FDN COGNITIVE TH; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Arco L, 2008, NEUROPSYCHOL REHABIL, V18, P109, DOI 10.1080/09602010701656706; Arundine A, 2012, J HEAD TRAUMA REHAB, V27, P104, DOI 10.1097/HTR.0b013e3182125591; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Beck A. T., 1970, DEPRESSION CAUSES TR; Beck A.T., 1967, DEPRESSION CLIN; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bisson J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub3; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Clark DM., 1995, SOCIAL PHOBIA DIAGNO, P69; Cohen J., 2013, STAT POWER ANAL BEHA; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; COOPERSMITH S, 1975, SELF ESTEEM INVENTOR; Corneil W, 1999, J Occup Health Psychol, V4, P131, DOI 10.1037/1076-8998.4.2.131; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90, V3rd ed.; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Frydenberg E., 1996, COPING SCALE ADULTS; Hackett ML, 2005, STROKE, V36, P1330, DOI 10.1161/01.STR.0000165928.19135.35; Heimberg RG, 2002, BIOL PSYCHIAT, V51, P101, DOI 10.1016/S0006-3223(01)01183-0; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HODGSON J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; HODGSON RJ, 1977, BEHAV RES THER, V15, P389, DOI 10.1016/0005-7967(77)90042-0; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; King NS, 2002, BRAIN INJURY, V16, P65, DOI 10.1080/02699050110088263; Kneebone I, 2009, NEUROPSYCHOL REHABIL, V19, P86, DOI 10.1080/09602010802009623; Kneebone II, 2000, BRIT J CLIN PSYCHOL, V39, P53, DOI 10.1348/014466500163103; Koponen S, 2011, BRAIN INJURY, V25, P1029, DOI 10.3109/02699052.2011.607783; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lincoln NB, 2003, STROKE, V34, P111, DOI 10.1161/01.STR.0000044167.44670.55; Lincoln NB, 1997, CLIN REHABIL, V11, P114, DOI 10.1177/026921559701100204; Lovibond S.H., 1996, MANUAL DEPRESSION AN, V2nd ed.; Maher CG, 2003, PHYS THER REHABIL J, V83, P713, DOI 10.1093/ptj/83.8.713; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Marks I.M, 1986, BEHAV PSYCHOTHERAPY; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Novaco RW., 1975, ANGER CONTROL DEV EV; Perdices M, 2009, NEUROPSYCHOL REHABIL, V19, P904, DOI 10.1080/09602010903040691; Prigatano G., 1989, TRAUMATIC BRAIN INJU, P175; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rasquin SMC, 2009, NEUROPSYCHOL REHABIL, V19, P208, DOI 10.1080/09602010802091159; Resick P. A., 1993, COGNITIVE PROCESSING; Rosenberg M., 1965, SOC ADOLESCENT SELF; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SNAITH RP, 1971, PSYCHOL MED, V1, P143, DOI 10.1017/S0033291700000064; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; SooMeng K, 1997, INT J CLIN PRACT, V51, P336; Spielberger CD., 1988, STATE TRAIT ANGER EX; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Steer, 1993, MANUAL BECK ANXIETY; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Turner SM., 1989, PSYCHOL ASSESSMENT, V1, P35, DOI DOI 10.1037/1040-3590.1.1.35; van Dam-Baggen R, 2000, J ANXIETY DISORD, V14, P437, DOI 10.1016/S0887-6185(00)00038-4; WALLANDER JL, 1985, BEHAV ASSESS, V7, P137; Williams W H, 2003, Cogn Neuropsychiatry, V8, P1, DOI 10.1080/713752238; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; World Health Organization, 2008, ICD 10 INT STAT CLAS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	71	45	47	0	71	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN 1	2013	23	1					64	101		10.1080/09602011.2012.724196			38	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	096BD	WOS:000315377800004	23121258				2022-02-06	
J	Alwis, DS; Yan, EB; Morganti-Kossmann, MC; Rajan, R				Alwis, Dasuni S.; Yan, Edwin B.; Morganti-Kossmann, Maria-Cristina; Rajan, Ramesh			Sensory Cortex Underpinnings of Traumatic Brain Injury Deficits	PLOS ONE			English	Article							RAT BARREL CORTEX; VISUAL PROCESSING DEFICITS; DIFFUSE AXONAL INJURY; WHISKER VIBRATION; HIPPOCAMPAL CA1; CORTICAL INJURY; COMPLEX SOUNDS; LATE-ONSET; NEURONS; HYPEREXCITABILITY	Traumatic brain injury (TBI) can result in persistent sensorimotor and cognitive deficits including long-term altered sensory processing. The few animal models of sensory cortical processing effects of TBI have been limited to examination of effects immediately after TBI and only in some layers of cortex. We have now used the rat whisker tactile system and the cortex processing whisker-derived input to provide a highly detailed description of TBI-induced long-term changes in neuronal responses across the entire columnar network in primary sensory cortex. Brain injury (n = 19) was induced using an impact acceleration method and sham controls received surgery only (n = 15). Animals were tested in a range of sensorimotor behaviour tasks prior to and up to 6 weeks post-injury when there were still significant sensorimotor behaviour deficits. At 8-10 weeks post-trauma, in terminal experiments, extracellular recordings were obtained from barrel cortex neurons in response to whisker motion, including motion that mimicked whisker motion observed in awake animals undertaking different tasks. In cortex, there were lamina-specific neuronal response alterations that appeared to reflect local circuit changes. Hyper-excitation was found only in supragranular layers involved in intra-areal processing and long-range integration, and only for stimulation with complex, naturalistic whisker motion patterns and not for stimulation with simple trapezoidal whisker motion. Thus TBI induces long-term directional changes in integrative sensory cortical layers that depend on the complexity of the incoming sensory information. The nature of these changes allow predictions as to what types of sensory processes may be affected in TBI and contribute to post-trauma sensorimotor deficits.	[Alwis, Dasuni S.; Rajan, Ramesh] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia; [Alwis, Dasuni S.; Yan, Edwin B.; Morganti-Kossmann, Maria-Cristina] Alfred Hosp, Natl Trauma Res Inst, Prahran, Vic 3181, Australia		Rajan, R (corresponding author), Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia.	Ramesh.Rajan@monash.edu	rajan, ramesh/L-4842-2019	Morganti-Kossmann, Cristina/0000-0002-0807-2063; Rajan, Ramesh/0000-0001-9862-0520	NHMRC of AustraliaNational Health and Medical Research Council of Australia [APP 1029311]	This study was funded by the NHMRC of Australia Grant No. APP 1029311. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adcock RA, 2009, SCHIZOPHRENIA BULL, V35, P1132, DOI 10.1093/schbul/sbp068; Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Andermann ML, 2004, NEURON, V42, P451, DOI 10.1016/S0896-6273(04)00198-9; Arabzadeh E, 2004, J NEUROSCI, V24, P6011, DOI 10.1523/JNEUROSCI.1389-04.2004; Arabzadeh E, 2003, J NEUROSCI, V23, P9146; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Boddaert N, 2004, AM J PSYCHIAT, V161, P2117, DOI 10.1176/appi.ajp.161.11.2117; Boddaert N, 2003, AM J PSYCHIAT, V160, P2057, DOI 10.1176/appi.ajp.160.11.2057; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; Butler PD, 2009, SCHIZOPHRENIA BULL, V35, P1095, DOI 10.1093/schbul/sbp109; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Caeyenberghs K, 2009, BRAIN, V132, P684, DOI 10.1093/brain/awn344; Carmichael ST, 2012, ARCH NEUROL-CHICAGO, V69, P161, DOI 10.1001/archneurol.2011.1175; CARVELL GE, 1990, J NEUROSCI, V10, P2638; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chung S, 2002, NEURON, V34, P437, DOI 10.1016/S0896-6273(02)00659-1; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cook NL, 2010, J MOL NEUROSCI, V42, P192, DOI 10.1007/s12031-010-9347-8; Corbo J, 2004, ANN EMERG MED, V44, P57, DOI 10.1016/j.annemergmed.2003.11.010; Davis AS, 2010, APPL NEUROPSYCHOL, V17, P104, DOI 10.1080/09084281003708951; Ding MC, 2008, NEUROSCIENCE, V154, P551, DOI 10.1016/j.neuroscience.2008.03.088; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; Donkin JJ, 2011, J NEUROTRAUM, V28, P217, DOI 10.1089/neu.2010.1632; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Faul M, 2010, TRAUMATIC BRAIN INJU; Folmer RL, 2011, INT J PSYCHOPHYSIOL, V82, P4, DOI 10.1016/j.ijpsycho.2011.03.005; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Galvin J, 2009, AM J OCCUP THER, V63, P701, DOI 10.5014/ajot.63.6.701; Gao PH, 2001, J NEUROSCI, V21, P5374, DOI 10.1523/JNEUROSCI.21-14-05374.2001; Gibson JR, 2008, J NEUROPHYSIOL, V100, P2615, DOI 10.1152/jn.90752.2008; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hartmann MJ, 2003, J NEUROSCI, V23, P6510; Heath DL, 2001, J NEUROTRAUM, V18, P465, DOI 10.1089/089771501750171074; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Higley MJ, 2003, J NEUROSCI, V23, P10190; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Horton HK, 2011, SCHIZOPHRENIA BULL, V37, P716, DOI 10.1093/schbul/sbr055; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Imbrosci B, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/614329; Kalauzi Aleksandar, 2009, Nonlinear Biomed Phys, V3, P8, DOI 10.1186/1753-4631-3-8; Kim D, 2006, SCHIZOPHR RES, V82, P1, DOI 10.1016/j.schres.2005.10.008; Korostenskaja M, 2010, EPILEPSY RES, V92, P63, DOI 10.1016/j.eplepsyres.2010.08.008; Learoyd AE, 2012, BEHAV BRAIN RES, V226, P197, DOI 10.1016/j.bbr.2011.09.016; Leitman DI, 2007, AM J PSYCHIAT, V164, P474, DOI 10.1176/appi.ajp.164.3.474; Leitman DI, 2005, BIOL PSYCHIAT, V58, P56, DOI 10.1016/j.biopsych.2005.02.034; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lewis DA, 2012, TRENDS NEUROSCI, V35, P57, DOI 10.1016/j.tins.2011.10.004; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MANDELBROT BB, 1991, P ROY SOC LOND A MAT, V434, P79, DOI 10.1098/rspa.1991.0081; Marco EJ, 2011, PEDIATR RES, V69, p48R, DOI 10.1109/SPL.2011.5782616; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Paluszkiewicz SM, 2011, DEV NEUROSCI-BASEL, V33, P349, DOI 10.1159/000329420; Patel R, 2011, OPTOMETRY, V82, P284, DOI 10.1016/j.optm.2010.10.012; Pinto DJ, 2000, J NEUROPHYSIOL, V83, P1158, DOI 10.1152/jn.2000.83.3.1158; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Raghavendra BS, 2009, PHYSIOL MEAS, V30, P795, DOI 10.1088/0967-3334/30/8/005; Rajan R, 1998, NAT NEUROSCI, V1, P138, DOI 10.1038/388; Rajan R, 2007, EUR J NEUROSCI, V25, P2383, DOI 10.1111/j.1460-9568.2007.05481.x; Rajan R, 2006, J NEUROSCI METH, V157, P103, DOI 10.1016/j.jneumeth.2006.04.008; Rajan R, 2001, CEREB CORTEX, V11, P171, DOI 10.1093/cercor/11.2.171; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G; Raymond MJ, 1996, NEUROREHABILITATION, V6, P229, DOI 10.3233/NRE-1996-6309; Ritt JT, 2008, NEURON, V57, P599, DOI 10.1016/j.neuron.2007.12.024; Russo NM, 2008, CLIN NEUROPHYSIOL, V119, P1720, DOI 10.1016/j.clinph.2008.01.108; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Thomas TC, 2012, J NEUROTRAUM, V29, P187, DOI 10.1089/neu.2011.2091; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Wang JH, 2003, BRAIN RES BULL, V60, P53, DOI 10.1016/S0361-9230(03)00026-1; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wolf DH, 2008, BRAIN IMAGING BEHAV, V2, P132, DOI 10.1007/s11682-008-9022-7; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; YU Z, 2009, EMBC 2009 ANN INT C, P1135	96	45	45	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2012	7	12							e52169	10.1371/journal.pone.0052169			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	065OW	WOS:000313158800036	23284921	Green Published, Green Submitted, gold			2022-02-06	
J	Bao, HJ; Wang, T; Zhang, MY; Liu, R; Dai, DK; Wang, YQ; Wang, L; Zhang, L; Gao, YZ; Qin, ZH; Chen, XP; Tao, LY				Bao, Hai-Jun; Wang, Tao; Zhang, Ming-Yang; Liu, Ran; Dai, Ding-Kun; Wang, Yao-Qi; Wang, Long; Zhang, Lu; Gao, Yu-Zhen; Qin, Zheng-Hong; Chen, Xi-Ping; Tao, Lu-Yang			Poloxamer-188 Attenuates TBI-Induced Blood-Brain Barrier Damage Leading to Decreased Brain Edema and Reduced Cellular Death	NEUROCHEMICAL RESEARCH			English	Article						Traumatic brain injury; Poloxamer 188; Brain edema; Apoptosis; Neurovascular unit	CONTROLLED CORTICAL IMPACT; NF-KAPPA-B; WATER TRANSPORT; INJURY MODEL; AQUAPORIN-4; CELLS; PERMEABILITY; MECHANISMS; INHIBITION; CONTUSION	Plasmalemma permeability plays an important role in the secondary neuronal death induced by traumatic brain injury (TBI). Previous works showed that Poloxamer 188 (P188) could restore the intactness of the plasma membrane and play a cytoprotective action. However, the roles of P188 in blood-brain barrier (BBB) integrity and TBI-induced neural cell death are still not clear. In this study, mice were induced TBI by controlled cortical impact (CCI), and cerebral water content was measured to explore the profile of brain edema after CCI. Further, the regimen of P188 in mouse CCI models was optimized. The neurological test and BBB integrity assessment were performed, and the numbers of TBI-induced neural cell death were counted by propidium iodide (PI) labeling. The expression of apoptotic pathway associated proteins (Bax, cyt-c, caspase-8, caspase-9, caspase-3, P53) and aquaporin-4 (AQP4) was assessed by RT-PCR or immunoblotting. The data showed that the brain edema peaked at 24 h after TBI in untreated animals. Tail intravenous injection of P188 (4 mg/ml, 100 mu l) 30 min before TBI or within 30 min after TBI could attenuate TBI-induced brain edema. P188 pre-treatment restored BBB integrity, suppressed TBI-induced neural cell death, and improved neurological function. TBI induced an up-regulation of Bax, cyt-c, caspase-8, caspase-9, caspase-3, and the expression of p53 was down-regulated by P188 pre-treatment. AQP4 mainly located on endothelial cells and astrocytes, and its expression was also regulated by P188 pretreatment. All these results revealed that P188 attenuates TBI-induced brain edema by resealing BBB and regulating AQP4 expression, and suppressed apoptosis through extrinsic or intrinsic pathway. Plasmalemma permeability may be a potential target for TBI treatment.	[Bao, Hai-Jun; Wang, Tao; Zhang, Ming-Yang; Liu, Ran; Dai, Ding-Kun; Wang, Yao-Qi; Wang, Long; Zhang, Lu; Gao, Yu-Zhen; Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Inst Forens Sci, Suzhou 215123, Jiangsu, Peoples R China; [Zhang, Ming-Yang] Nantong Univ, Coll Med, Dept Forens Sci, Nantong 226001, Jiangsu, Peoples R China; [Qin, Zheng-Hong] Soochow Univ, Dept Pharmacol, Suzhou 215123, Jiangsu, Peoples R China		Chen, XP (corresponding author), Soochow Univ, Inst Forens Sci, Suzhou 215123, Jiangsu, Peoples R China.	xiping.chen@163.com; luyang.tao@163.com	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237	National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271379, 81172911, 30872666]	The work was supported by the National Science Foundation of China (No. 81271379, No. 81172911, No. 30872666). We thank Dr. Changhong Xing who polished this paper.	Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Baars DC, 2006, BIOMECH MODEL MECHAN, V5, P133, DOI 10.1007/s10237-006-0024-3; Bierbach B, 2008, STROKE, V39, P213, DOI 10.1161/STROKEAHA.107.496620; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Curry DJ, 2004, J NEUROSURG, V101, P91, DOI 10.3171/ped.2004.101.2.0091; Doelken M, 2007, DIAGN INTERV RADIOL, V13, P125; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Eghwrudjakpor PO, 2010, LIBYAN J MED, V5, DOI [10.4176/091104, 10.3402/ljm.v5i0.4620]; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Greenebaum B, 2004, BURNS, V30, P539, DOI 10.1016/j.burns.2004.02.009; Hunter RL, 2010, ANN CLIN LAB SCI, V40, P115; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; LaPlaca MC, 2009, IEEE ENG MED BIO, P1113, DOI 10.1109/IEMBS.2009.5334457; Lentsch AB, 1999, CLIN CHEM LAB MED, V37, P205, DOI 10.1515/CCLM.1999.038; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, NEURAL REGEN RES, V5, P706, DOI 10.3969/j.issn.1673-5374.2010.09.012; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Matsumoto Y, 2004, STROKE, V35, P185, DOI 10.1161/01.STR.0000106910.42815.C2; Nicchia GP, 2004, NEUROSCIENCE, V129, P935, DOI 10.1016/j.neuroscience.2004.07.055; Nielsen S, 1997, J NEUROSCI, V17, P171; Oliva AA, 2011, NEUROSCIENCE, V180, P272, DOI 10.1016/j.neuroscience.2011.02.020; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rangel-Castilla L, 2008, NEUROL CLIN, V26, px; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Robbins MA, 2003, ENDOCRINOLOGY, V144, P4616, DOI 10.1210/en.2003-0266; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tomkins O, 2011, CARDIOVASC PSYCHIAT, V2011; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yang Xiao-feng, 2005, Chin J Traumatol, V8, P96; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	48	45	47	0	17	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	DEC	2012	37	12					2856	2867		10.1007/s11064-012-0880-4			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	043IW	WOS:000311537300023	23011204				2022-02-06	
J	Heltemes, KJ; Holbrook, TL; MacGregor, AJ; Galarneau, MR				Heltemes, Kevin J.; Holbrook, Troy L.; MacGregor, Andrew J.; Galarneau, Michael R.			Blast-related mild traumatic brain injury is associated with a decline in self-rated health amongst US military personnel	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Mild traumatic brain injury; Self-rated health; Military; Combat casualty	QUALITY-OF-LIFE; OPERATION-IRAQI-FREEDOM; WHITEHALL-II; AFGHANISTAN; DEPLOYMENT; MORTALITY; SYMPTOMS; VALIDITY	Introduction: Mild traumatic brain injury (MTBI) has emerged as the preeminent injury of combat from the recent conflicts in Iraq and Afghanistan. Very little is known about short-and long-term outcomes after combat-related MTBI. As a measure of outcome after injury, self-rated health is a reliable, widely used measure that assesses perceived health. The primary aim of this study was to determine the effect of combat-related MTBI on self-reported health status after return from deployment. The secondary objective was to examine predictors of a decline in self-reported health status amongst US service members with MTBI, as compared to those service members with other minor non-TBI injuries. Patients and methods: MTBI cases and an injured comparison group were identified from the Expeditionary Medical Encounter Database records of 1129 male, US service members who experienced blast-related injuries in Iraq from March 2004 to March 2008. Self-rated health was assessed from the routinely administered pre- and post-deployment health assessment questionnaires by the following question, "Overall, how would you rate your health during the past month?" Possible responses were "poor", "fair", "good", "very good", or "excellent." A distinction was made between minor and major negative changes in health (i.e., very good to fair) based on these self-rated health outcomes captured post-injury. Results: For all personnel, post-injury levels of self-rated health were statistically significantly worse than pre-injury health rating. At 6 months post-injury, service members with MTBI were 5 times more likely to report a major negative change in health as compared to members with other mild injuries. This association was independent of age, rank, branch of service, Injury Severity Score, mental health diagnosis prior to injury, and having been referred to a health care professional. Discussion: Blast-related injuries, specifically MTBI, during deployment have negative consequences on service members' perception of health. Future research is needed to improve our understanding of the overall effects of MTBI on health and quality of life. (C) 2011 Elsevier Ltd. All rights reserved.	[Heltemes, Kevin J.; Holbrook, Troy L.; MacGregor, Andrew J.; Galarneau, Michael R.] USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, San Diego, CA 92106 USA		Heltemes, KJ (corresponding author), USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, 140 Sylvester Rd, San Diego, CA 92106 USA.	kevin.heltemes@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	US Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research CenterU.S. Army Medical Research & Materiel Command (USAMRMC)	The authors thank Dr. Mary Clouser for her assistance with data analysis and manuscript revision. The authors thank Science Applications International Corporation for its contributions to this work. Funding support for this research was provided through the US Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government. Approved for public release; distribution is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (Protocol NHRC.2003.0025).	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chandler D, 2006, ASHA LEADER, V11, p[8, 29]; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Haddock CK, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-57; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Larson GE, 2008, AM J EPIDEMIOL, V167, P1269, DOI 10.1093/aje/kwn084; Larsson D, 2002, SCAND J PUBLIC HEALT, V30, P259, DOI 10.1080/14034940210133997; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; REISTER FA, 1973, BATTLE CASUALTIES ME, pCH3; REVICKI DA, 1989, J FAM PRACTICE, V29, P377; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Singh-Manoux A, 2006, J EPIDEMIOL COMMUN H, V60, P364, DOI 10.1136/jech.2005.039883; Singh-Manoux A, 2007, PSYCHOSOM MED, V69, P138, DOI 10.1097/PSY.0b013e318030483a; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Voelker MD, 2002, AM J EPIDEMIOL, V155, P899, DOI 10.1093/aje/155.10.899; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Zhang SR, 2009, J REHABIL MED, V41, P1062, DOI 10.2340/16501977-0462	26	45	45	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	DEC	2012	43	12					1990	1995		10.1016/j.injury.2011.07.021			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	028XM	WOS:000310458600004	21855064				2022-02-06	
J	Cheng, JP; Shaw, KE; Monaco, CM; Hoffman, AN; Sozda, CN; Olsen, AS; Kline, AE				Cheng, Jeffrey P.; Shaw, Kaitlyn E.; Monaco, Christina M.; Hoffman, Ann N.; Sozda, Christopher N.; Olsen, Adam S.; Kline, Anthony E.			A Relatively Brief Exposure to Environmental Enrichment after Experimental Traumatic Brain Injury Confers Long-Term Cognitive Benefits	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; environmental enrichment; functional recovery; learning and memory; Morris water maze; traumatic brain injury	MEDIATED FUNCTIONAL IMPROVEMENT; RECEPTOR AGONIST 8-OH-DPAT; TREATMENT REGIMEN; CORTICAL IMPACT; DEFICITS; RECOVERY; HIPPOCAMPUS; ACQUISITION; GROWTH; CORTEX	It is well established that a relatively brief exposure to environmental enrichment (EE) enhances motor and cognitive performance after experimental traumatic brain injury (TBI), but it is not known whether the benefits can be sustained after EE is discontinued. To address this important rehabilitation-relevant concern, anesthetized rats received a controlled cortical impact (CCI) or sham injury, and for phase 1 of the experiment were randomly assigned to either 3 weeks of EE or standard (STD) housing. Neurobehavioral outcome was assessed by established motor and cognitive tests on postoperative days 1-5 and 14-18, respectively. Beam-balance and spatial learning were facilitated in the TBI + EE more than the TBI + STD group (p < 0.0001). In phase 2 of the experiment, half of the rats in EE were transferred to STD conditions (TBI + EE + STD and sham + EE + STD), and neurobehavior was re-assessed once per month for 6 months. The TBI + EE and TBI + EE + STD groups performed markedly better in the water maze than the TBI + STD group (p < 0.0001), and did not differ from one another (p = 0.53). These data replicate those of several studies from our laboratory showing that EE enhances recovery after CCI injury, and extend those findings by demonstrating that the cognitive benefits are maintained for at least 6 months post-rehabilitation. The persistent benefits shown with this paradigm provide further support for EE as a pre-clinical model of rehabilitation that can be further explored, either alone or in combination with pharmacotherapies, for optimal neurorehabilitation after TBI.	[Cheng, Jeffrey P.; Shaw, Kaitlyn E.; Monaco, Christina M.; Hoffman, Ann N.; Sozda, Christopher N.; Olsen, Adam S.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Hoffman, Ann N.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA; [Sozda, Christopher N.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Olsen, Adam S.] Univ Toledo, Coll Med, Toledo, OH 43606 USA		Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207; Olsen, Adam/0000-0003-0957-9867	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD043851, HD046700, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700, R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	Supported in part by National Institutes of Health grants HD043851, HD046700, and NS060005 (to A.E.K.)	BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	28	45	47	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	17					2684	2688		10.1089/neu.2012.2560			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	047QU	WOS:000311856400009	22774771	Green Published			2022-02-06	
J	Harrison-Felix, C; Kolakowsky-Hayner, SA; Hammond, FM; Wang, R; Englander, J; Dams-O'Connor, K; Kreider, SED; Novack, TA; Diaz-Arrastia, R				Harrison-Felix, Cynthia; Kolakowsky-Hayner, Stephanie A.; Hammond, Flora M.; Wang, Roberta; Englander, Jeffrey; Dams-O'Connor, Kristen; Kreider, Scott E. D.; Novack, Thomas A.; Diaz-Arrastia, Ramon			Mortality After Surviving Traumatic Brain Injury: Risks Based on Age Groups	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; chronic; epidemiology; life expectancy; mortality; rehabilitation; vital statistics	LONG-TERM SURVIVAL; HEAD TRAUMA; POPULATION; REHABILITATION; INDIVIDUALS; TRENDS; COMA	Objective: To assess mortality, life expectancy, risk factors, and causes of death by age groups among persons who received inpatient traumatic brain injury (TBI) rehabilitation. Design: Prospective cohort study. Setting: The TBI Model Systems. Participants: 8573 individuals injured between 1988 and 2009, with survival status per December 31, 2009, determined. Interventions: Not applicable. Main Outcome Measures: Standardized mortality ratio, life expectancy, and cause of death. Results: Moderate-severe TBI increases risk of mortality compared with the general population in all age groups, with the exception of those 85 years or older at the time of injury. Teenagers to middle-aged adults are at particular risk. Risk factors for death varied by age group and included gender, marital and employment status, year and cause of injury, and level of disability. External causes of death predominate in younger groups. For the youngest male participants in the sample, longevity was reduced up to 16 years. Conclusion: Risk factors and causes of death varied considerably by age group for individuals with moderate-severe TBI who were receiving acute care rehabilitation. Moderate-severe TBI is a chronic health condition.	[Kolakowsky-Hayner, Stephanie A.] Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; [Harrison-Felix, Cynthia; Kreider, Scott E. D.] Craig Hosp, Englewood, CO USA; [Hammond, Flora M.] Carolinas HealthCare Syst, Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN USA; [Dams-O'Connor, Kristen] Mt Sinai Sch Med, New York, NY USA; [Novack, Thomas A.] Univ Alabama Birmingham, Birmingham, AL USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA		Kolakowsky-Hayner, SA (corresponding author), Santa Clara Valley Med Ctr, Rehabil Res Ctr, 751 S Bascom Ave, San Jose, CA 95128 USA.	Stephanie.Hayner@hhs.sccgov.org	Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Diaz-Arrastia, Ramon/0000-0001-6051-3594	National Institute on Disability and Rehabilitation Research (NIDRR), Office of Special Education Services, Department of Education [H133A070038, HD133A020526, H133A070042, H133A070039, H133A070033, H133A110006, H133A070022]; Department of EducationUS Department of Education; NIDRR	This work was supported in part by grants from the National Institute on Disability and Rehabilitation Research (NIDRR), Office of Special Education Services, Department of Education grant numbers: H133A070038, HD133A020526, H133A070042, H133A070039, H133A070033, H133A110006, H133A070022. The contents of the study were developed under grants from the Department of Education, NIDRR, as specified under the Source of Funding section. However, those contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government. The authors thank the research participants, research assistants, and all project staff for their assistance in the success of this endeavor. In addition, the authors acknowledge the continued support of the project officers and program manager at NIDRR.	ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; [Anonymous], 1997, GUID UN DAT SET MED; Baguley I, 2000, BRAIN INJURY, V14, P505; Betz ME, 2008, J AM GERIATR SOC, V56, P2267, DOI 10.1111/j.1532-5415.2008.02001.x; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Centers for Disease Control and Prevention, COMPR MORT FIL UND C; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Faul M, 2010, TRAUMATIC BRAIN INJU; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hoff Clarissa J B, 2010, J La State Med Soc, V162, P352; Hoffman SW, 2010, NEUROREHABILITATION, V26, P257, DOI 10.3233/NRE-2010-0561; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Laing SP, 1999, DIABETIC MED, V16, P459, DOI 10.1046/j.1464-5491.1999.00075.x; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Nakase-Richardson R, 2009, ARCH PHYS MED REHAB, V90, P17, DOI 10.1016/j.apmr.2008.06.030; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; *SAS I INC, SAS SYST WIND COMP P; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle R, 2000, J Insur Med, V32, P163; Solana R, SEMIN IMMUNOL, DOI [10.1016/j.bbr.2011.03.031, DOI 10.1016/J.BBR.2011.03.031]; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; TBI Model Systems National Data and Statistical Center, TRAUM BRAIN INJ MOD; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Yeung JHH, 2011, ARCH SURG-CHICAGO, V146, P436, DOI 10.1001/archsurg.2011.46	36	45	45	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					E45	E56		10.1097/HTR.0b013e31827340ba			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200005	23131970				2022-02-06	
J	Walker, PA; Shah, SK; Jimenez, F; Aroom, KR; Harting, MT; Cox, CS				Walker, Peter A.; Shah, Shinil K.; Jimenez, Fernando; Aroom, Kevin R.; Harting, Matthew T.; Cox, Charles S., Jr.			Bone marrow-derived stromal cell therapy for traumatic brain injury is neuroprotective via stimulation of non-neurologic organ systems	SURGERY			English	Article							GROWTH-FACTOR	Bone marrow-derived mesenchymal stromal cells (MSCs) used as "MSC therapy" after traumatic brain injury act as remote "bioreactors" via stimulation of lung macrophages and augmention of T regulatory cell production by the spleen, leading to systemic increases in circulating anti-inflammatory cytokines and alteration of the locoregional milieu of the central nervous system. The altered intracerebral microenvironment leads to modulation of the resident microglia population, thereby stimulating an increase in the ratio of M2 (anti-inflammatory) macrophage to M1 (proinflammatory) macrophage, and it is this effect that accounts for the observed neuroprotection. (Surgery 2012; 152:790-3.)	[Walker, Peter A.; Shah, Shinil K.; Jimenez, Fernando; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Walker, Peter A.; Shah, Shinil K.; Aroom, Kevin R.; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Shah, Shinil K.; Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA; [Harting, Matthew T.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA		Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.s.cox@uth.tmc.edu		Harting, Matthew/0000-0002-8929-8311; Aroom, Kevin/0000-0003-1504-0585	Texas Higher Education Coordinating Board; Texas Emerging Technology Fund; Children's Memorial Hermann Hospital Foundation; Brown Foundation; Athersys Inc;  [NIH T32 GM 08 79201];  [M01 RR 02558]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER	Supported by grants NIH T32 GM 08 79201; M01 RR 02558; Texas Higher Education Coordinating Board; Texas Emerging Technology Fund; the Children's Memorial Hermann Hospital Foundation; The Brown Foundation; and Athersys Inc.	Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Sahin B., 2001, IMAGE ANAL STEREOL, V20, P9, DOI [10.5566/ias.v20.p9-13, DOI 10.5566/IAS.V20.P9-13]; Stroh M, 2003, BIOPHYS J, V85, P581, DOI 10.1016/S0006-3495(03)74502-0; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017	13	45	48	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	NOV	2012	152	5					790	793		10.1016/j.surg.2012.06.006			4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	035JY	WOS:000310943900002	22853856				2022-02-06	
J	Zhang, X; Wang, B; O'Callaghan, P; Hjertstrom, E; Jia, J; Gong, F; Zcharia, E; Nilsson, LNG; Lannfelt, L; Vlodavsky, I; Lindahl, U; Li, JP				Zhang, Xiao; Wang, Bo; O'Callaghan, Paul; Hjertstrom, Elina; Jia, Juan; Gong, Feng; Zcharia, Eyal; Nilsson, Lars N. G.; Lannfelt, Lars; Vlodavsky, Israel; Lindahl, Ulf; Li, Jin-Ping			Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-beta in murine brain	ACTA NEUROPATHOLOGICA			English	Article						Neuroinflammation; Heparan sulfate; Heparanase; Amyloid-beta; Clearance; Alzheimer's disease	CENTRAL-NERVOUS-SYSTEM; INTERCELLULAR-ADHESION MOLECULE-1; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; LEUKOCYTE ADHESION; MICROGLIAL CELLS; INTERFERON-GAMMA; SULFATE; EXPRESSION; MICE	Neuroinflammation is typically observed in neurodegenerative diseases such as Alzheimer's disease, as well as after traumatic injury and pathogen infection. Resident immune cells, microglia and astrocytes, are activated and joined by blood-borne monocytes that traverse the blood-brain barrier and convert into activated macrophages. The activated cells express various cytokines, chemokines and proteolytic enzymes. To study the role of heparan sulfate proteoglycans in neuroinflammation, we employed a transgenic mouse overexpressing heparanase, an endoglucuronidase that specifically degrades heparan sulfate side chains. Neuroinflammation was induced by systemic challenge with lipopolysaccharide, or by localized cerebral microinjection of aggregated amyloid-beta peptide, implicated in Alzheimer's disease. Lipopolysaccharide-treated control mice showed massive activation of resident microglia as well as recruitment of monocyte-derived macrophages into the brain parenchyma. Microinjection of aggregated amyloid-beta elicited a similar inflammatory response, albeit restricted to the injection site, which led to dispersion and clearance of the amyloid. In the heparanase-overexpressing mice, all aspects of immune cell recruitment and activation were significantly attenuated in both inflammation models, as was amyloid dispersion. Accordingly, an in vitro blood-brain barrier model constructed from heparanase-overexpressing cerebral vascular cells showed impaired transmigration of monocytes compared to a corresponding assembly of control cells. Our data indicate that intact heparan sulfate chains are required at multiple sites to mediate neuroinflammatory responses, and further point to heparanase as a modulator of this process, with potential implications for Alzheimer's disease.	[Wang, Bo; Hjertstrom, Elina; Jia, Juan; Gong, Feng; Lindahl, Ulf; Li, Jin-Ping] Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; [Zhang, Xiao; O'Callaghan, Paul; Nilsson, Lars N. G.; Lannfelt, Lars] Uppsala Univ, Rudbeck Lab, Dept Publ Hlth & Caring Sci, S-75185 Uppsala, Sweden; [Wang, Bo] Inst Pharmacol & Toxicol, Dept Pharmacol, Beijing 100850, Peoples R China; [Gong, Feng] Inst Transfus Med, Dept Blood Biochem & Mol Biol, Beijing 100850, Peoples R China; [Zcharia, Eyal; Vlodavsky, Israel] Technion Israel Inst Technol, Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; [Nilsson, Lars N. G.] Univ Oslo, Fac Med, Inst Clin Med, Dept Pharmacol, Oslo, Norway; [Nilsson, Lars N. G.] Oslo Univ Hosp, Oslo, Norway		Li, JP (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Box 582,Husargatan 3, S-75123 Uppsala, Sweden.	jin-ping.li@imbim.uu.se	O'Callaghan, Paul/T-5308-2018	O'Callaghan, Paul/0000-0003-3117-5367; nilsson, lars/0000-0002-8362-1042	Swedish Research CouncilSwedish Research CouncilEuropean Commission [K2009-67X-21128-01-3, K2012-67X-21128-04-4, K2010-61X-15383-06-3, 2009-4567]; Swedish Cancer Foundation; Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation [20110131]; European Commission (EURAMY)European CommissionEuropean Commission Joint Research Centre; Mizutani Foundation for Glycoscience; Polysackaridforskning AB (Uppsala); Alzheimerfonden; Stohnes Stiftelse; Stiftelsen for Gamla Tjanarinnor; Demensforbundet; Swedish Brain Foundation; Bertil Hallstens Forskningsstiftelse; Israel Science FoundationIsrael Science Foundation [549/06]; National Cancer Institute, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [RO1-CA106456]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA106456] Funding Source: NIH RePORTER	This work was supported by grants from the Swedish Research Council: K2009-67X-21128-01-3, K2012-67X-21128-04-4, K2010-61X-15383-06-3, #2009-4567, Swedish Cancer Foundation, Swedish Heart-Lung Foundation (20110131), The European Commission (EURAMY), the Mizutani Foundation for Glycoscience, Polysackaridforskning AB (Uppsala), Alzheimerfonden, Stohnes Stiftelse, Stiftelsen for Gamla Tjanarinnor, Demensforbundet, The Swedish Brain Foundation, Bertil Hallstens Forskningsstiftelse. The Israel Science Foundation (549/06), the National Cancer Institute, NIH (RO1-CA106456). I. Vlodavsky is a Research Professor of the ICRF.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Bates KA, 2009, MOL PSYCHIATR, V14, P469, DOI 10.1038/mp.2008.96; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; de Haas AH, 2007, MOL NEUROBIOL, V36, P137, DOI 10.1007/s12035-007-0036-8; DeVries HE, 1997, PHARMACOL REV, V49, P143; DUSTIN ML, 1986, J IMMUNOL, V137, P245; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; El Khoury J, 2008, TRENDS PHARMACOL SCI, V29, P626, DOI 10.1016/j.tips.2008.08.004; Fiala M, 2002, EUR J CLIN INVEST, V32, P360, DOI 10.1046/j.1365-2362.2002.00994.x; Fiala M, 2007, J ALZHEIMERS DIS, V11, P457; FORD AL, 1995, J IMMUNOL, V154, P4309; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Galvis MLE, 2007, NAT CHEM BIOL, V3, P773, DOI 10.1038/nchembio.2007.41; Gate D, 2010, J NEURAL TRANSM, V117, P961, DOI 10.1007/s00702-010-0422-7; Giulian D, 1998, J BIOL CHEM, V273, P29719, DOI 10.1074/jbc.273.45.29719; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Hickman SE, 2010, CNS NEUROL DISORD-DR, V9, P168, DOI 10.2174/187152710791011982; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Johnston B, 2002, SEMIN IMMUNOL, V14, P83, DOI 10.1006/smim.2001.0345; Kanekiyo T, 2011, J NEUROSCI, V31, P1644, DOI 10.1523/JNEUROSCI.5491-10.2011; Long EO, 2011, J IMMUNOL, V186, P5021, DOI 10.4049/jimmunol.1100646; MAIO M, 1989, J IMMUNOL, V143, P181; Malm TM, 2005, NEUROBIOL DIS, V18, P134, DOI 10.1016/j.nbd.2004.09.009; Martins IC, 2008, EMBO J, V27, P224, DOI 10.1038/sj.emboj.7601953; Massena S, 2010, BLOOD, V116, P1924, DOI 10.1182/blood-2010-01-266072; Miners JS, 2008, BRAIN PATHOL, V18, P240, DOI 10.1111/j.1750-3639.2008.00132.x; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Morise Z, 1999, INFLAMMATION, V23, P99, DOI 10.1023/A:1020232826906; MOST J, 1990, EUR J IMMUNOL, V20, P1661, DOI 10.1002/eji.1830200807; Nakanishi H, 2003, MOL NEUROBIOL, V27, P163, DOI 10.1385/MN:27:2:163; O'Callaghan P, 2008, BRAIN PATHOL, V18, P548, DOI 10.1111/j.1750-3639.2008.00152.x; Parish CR, 2005, NAT IMMUNOL, V6, P861, DOI 10.1038/ni0905-861; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Rezai-Zadeh K, 2009, J NEUROIMMUNE PHARM, V4, P462, DOI 10.1007/s11481-009-9166-2; Rogers J, 2007, INT REV NEUROBIOL, V82, P235, DOI 10.1016/S0074-7742(07)82012-5; Rummel C, 2010, MOL PSYCHIATR, V15, P523, DOI 10.1038/mp.2009.98; Sandwall E, 2010, GLYCOBIOLOGY, V20, P533, DOI 10.1093/glycob/cwp205; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Shafat I, 2006, BIOCHEM BIOPH RES CO, V341, P958, DOI 10.1016/j.bbrc.2006.01.048; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Solito E, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00014; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Steidl U, 2000, ANN HEMATOL, V79, P414, DOI 10.1007/s002770000168; Thompson WL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-35; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Town T, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-24; van Horssen J, 2003, LANCET NEUROL, V2, P482, DOI 10.1016/S1474-4422(03)00484-8; Wang LC, 2005, NAT IMMUNOL, V6, P902, DOI 10.1038/ni1233; WONG D, 1992, J NEUROIMMUNOL, V39, P11, DOI 10.1016/0165-5728(92)90170-P; Zcharia E, 2004, FASEB J, V18, P252, DOI 10.1096/fj.03-0572com; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	63	45	46	0	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	OCT	2012	124	4					465	478		10.1007/s00401-012-0997-1			14	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	008MY	WOS:000308962300002	22692572	hybrid, Green Published			2022-02-06	
J	Hou, ZG; Luo, W; Sun, XJ; Hao, SY; Zhang, Y; Xu, FF; Wang, ZC; Liu, BY				Hou, Zonggang; Luo, Wei; Sun, Xuejun; Hao, Shuyu; Zhang, Ying; Xu, Feifan; Wang, Zhongcheng; Liu, Baiyun			Hydrogen-rich saline protects against oxidative damage and cognitive deficits after mild traumatic brain injury	BRAIN RESEARCH BULLETIN			English	Article						Hydrogen-rich saline; Traumatic brain injury; Hippocampus; Oxidative stress; Antioxidant; Neuroprotection	NEUROTROPHIC FACTOR; LIPID-PEROXIDATION; HEAD-INJURY; RAT MODEL; FAT DIET; STRESS; HIPPOCAMPUS; ANTIOXIDANT; HOMEOSTASIS; CONSUMPTION	Oxidative stress is the principal factor in traumatic brain injury (TB!) that initiates events that result in protracted neuronal dysfunction and remodeling. Importantly, antioxidants can protect the brain against oxidative damage and modulate the capacity of the brain to cope with synaptic dysfunction and cognitive impairment. However, no studies have investigated the effects of hydrogen-rich saline on cognitive deficits after TBI. In the present study, rats with fluid percussion injury (FPI) were used to investigate the protective effects of hydrogen-rich saline. The results showed that hydrogen-rich saline reduced the level of malondialdehyde (MDA) and elevated the level of silent information regulator 2 (Sir2). In addition, treatment with hydrogen-rich saline, which elevated the levels of molecules associated with brain-derived neurotropic factor (BDNF)-mediated synaptic plasticity, improved cognitive performance in the Morris water maze after mild TBI. These results suggest that hydrogen-rich saline can protect the brain against the deleterious effects of mild TBI on synaptic plasticity and cognition and that hydrogen-rich saline could be an effective therapeutic strategy for patients with cognitive deficits after TBI. (C) 2012 Elsevier Inc. All rights reserved.	[Hou, Zonggang; Wang, Zhongcheng] Capital Med Univ, Beijing Neurosurg Inst, Beijing 100050, Peoples R China; [Hou, Zonggang; Luo, Wei; Hao, Shuyu; Zhang, Ying; Xu, Feifan; Liu, Baiyun] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Sun, Xuejun] Second Mil Med Univ, Fac Naval Med, Dept Diving Med, Shanghai 200433, Peoples R China; [Liu, Baiyun] Armed Police Force, Gen Hosp, Dept Nerve Trauma Surg, Beijing 100039, Peoples R China		Wang, ZC (corresponding author), Capital Med Univ, Beijing Neurosurg Inst, Tiantan Xili 6, Beijing 100050, Peoples R China.	wangzc1925@126.com; liubaiyun1964@163.com	sun, xuejun/C-2844-2013; sun, xuejun/A-5561-2010	sun, xuejun/0000-0003-2387-5531	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171144]; Beijing Municipal Education CommissionBeijing Municipal Commission of Education [KM 200910025019]; Special projects of Ministry of Health for public welfare fund industry research [200802093]; Health Technology Training Program of Beijing High-level Health Systems [2009-3-21]	This work was supported by research grants from the National Natural Science Foundation of China (No. 81171144); Project of Beijing Municipal Education Commission (KM 200910025019); Special projects of Ministry of Health for public welfare fund industry research (200802093); and the Health Technology Training Program of Beijing High-level Health Systems (2009-3-21).	Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ashman TA, 2006, MT SINAI J MED, V73, P999; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Cai JM, 2009, BRAIN RES, V1256, P129, DOI 10.1016/j.brainres.2008.11.048; Chen H, 2011, J SURG RES, V167, P316, DOI 10.1016/j.jss.2009.07.045; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Giese KP, 2011, BRAIN RES BULL, V85, P1, DOI 10.1016/j.brainresbull.2011.02.009; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Gu Y, 2010, J CLIN BIOCHEM NUTR, V46, P269, DOI 10.3164/jcbn.10-19; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Li J, 2010, BRAIN RES, V1328, P152, DOI 10.1016/j.brainres.2010.02.046; Mao YF, 2009, BIOCHEM BIOPH RES CO, V381, P602, DOI 10.1016/j.bbrc.2009.02.105; Marnett LJ, 1999, MUTAT RES-FUND MOL M, V424, P83, DOI 10.1016/S0027-5107(99)00010-X; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Nagata K, 2009, NEUROPSYCHOPHARMACOL, V34, P501, DOI 10.1038/npp.2008.95; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Shen L, 2011, NEUROCHEM RES, V36, P1501, DOI 10.1007/s11064-011-0476-4; Shingu C, 2010, J ANESTH, V24, P569, DOI 10.1007/s00540-010-0942-1; Sun Q, 2009, EXP BIOL MED, V234, P1212, DOI 10.3181/0812-RM-349; Vaynman S, 2007, NEUROSCIENCE, V144, P825, DOI 10.1016/j.neuroscience.2006.10.005; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu AG, 2006, EUR J NEUROSCI, V23, P2573, DOI 10.1111/j.1460-9568.2006.04807.x; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Zhou Y, 2012, NEUROSCIENCE, V209, P47, DOI 10.1016/j.neuroscience.2012.02.028	39	45	49	1	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	SEP 1	2012	88	6					560	565		10.1016/j.brainresbull.2012.06.006			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	995XT	WOS:000308049300003	22742936				2022-02-06	
J	Ponce, LL; Pillai, S; Cruz, J; Li, XQ; Julia, H; Gopinath, S; Robertson, CS				Ponce, Lucido L.; Pillai, Shibu; Cruz, Jovany; Li, Xiaoqi; Julia, H.; Gopinath, Shankar; Robertson, Claudia S.			Position of Probe Determines Prognostic Information of Brain Tissue PO2 in Severe Traumatic Brain Injury	NEUROSURGERY			English	Article						Brain tissue PO2; Head injury; PO2 monitoring; Traumatic brain injury	OXYGEN-TENSION; LICOX	BACKGROUND: Monitoring brain tissue PO2 (PbtO(2)) is part of multimodality monitoring of patients with traumatic brain injury (TBI). However, PbtO(2) measurement is a sampling of only a small area of tissue surrounding the sensor tip. OBJECTIVE: To examine the effect of catheter location on the relationship between PbtO(2) and neurological outcome. METHODS: A total of 405 patients who had PbtO(2) monitoring as part of standard management of severe traumatic brain injury were studied. The relationships between probe location and resulting PbtO(2) and outcome were examined. RESULTS: When the probe was located in normal brain, PbtO(2) averaged 30.8 +/- 18.2 compared with 25.6 +/- 14.8 mm Hg when placed in abnormal brain (P < .001). Factors related to neurological outcome in the best-fit logistic regression model were age, PbtO(2) probe position, postresuscitation motor Glasgow Coma Scale score, and PbtO(2) trend pattern. Although average PbtO(2) was significantly related to outcome in univariate analyses, it was not significant in the final logistic model. However, the interaction between PbtO(2) and probe position was statistically significant. When the PbtO(2) probe was placed in abnormal brain, the average PbtO(2) was higher in those with a favorable outcome, 28.8 +/- 12.0 mm Hg, compared with those with an unfavorable outcome, 19.5 +/- 13.7 mm Hg (P = .01). PbtO(2) and outcome were not related when the probe was placed in normal-appearing brain. CONCLUSION: These results suggest that the location of the PbtO(2) probe determines the PbtO2 values and the relationship of PbtO(2) to neurological outcome.	[Ponce, Lucido L.; Pillai, Shibu; Cruz, Jovany; Gopinath, Shankar; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Li, Xiaoqi] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Julia, H.] Univ Houston, Houston, TX USA		Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS38660]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	This work was funded by National Institutes of Health grant P01-NS38660. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Bardt TF, 1998, ACT NEUR S, V71, P153; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Haitsma I, 2008, ACTA NEUROCHIR SUPPL, V102, P197, DOI 10.1007/978-3-211-85578-2_39; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Kiening KL, 1998, ACT NEUR S, V71, P172; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Wartenberg KE, 2007, CRIT CARE CLIN, V23, P507, DOI 10.1016/j.ccc.2007.06.002	18	45	45	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2012	70	6					1492	1502		10.1227/NEU.0b013e31824ce933			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	946RV	WOS:000304372600040	22289784	Bronze, Green Accepted			2022-02-06	
J	Wilson, SM; Xiong, W; Wang, Y; Ping, X; Head, JD; Brittain, JM; Gagare, PD; Ramachandran, PV; Jin, X; Khanna, R				Wilson, S. M.; Xiong, W.; Wang, Y.; Ping, X.; Head, J. D.; Brittain, J. M.; Gagare, P. D.; Ramachandran, P. V.; Jin, X.; Khanna, R.			PREVENTION OF POSTTRAUMATIC AXON SPROUTING BY BLOCKING COLLAPSIN RESPONSE MEDIATOR PROTEIN 2-MEDIATED NEURITE OUTGROWTH AND TUBULIN POLYMERIZATION	NEUROSCIENCE			English	Article						epileptogenesis; posttraumatic sprouting; CRMP2; neurite outgrowth; tubulin polymerization; lacosamide	TEMPORAL-LOBE EPILEPSY; V PYRAMIDAL NEURONS; RAT BARREL CORTEX; ANTICONVULSANT LACOSAMIDE; IN-VITRO; SOMATOSENSORY CORTEX; SLOW INACTIVATION; BRAIN-INJURY; MODEL; EPILEPTOGENESIS	Epileptogenesis following traumatic brain injury (TBI) is likely due to a combination of increased excitability, disinhibition, and increased excitatory connectivity via aberrant axon sprouting. Targeting these pathways could be beneficial in the prevention and treatment of posttraumatic epilepsy. Here, we tested this possibility using the novel anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide ((R)-lacosamide [LCM]), which acts on both voltage-gated sodium channels and collapsin response mediator protein 2 (CRMP2), an axonal growth/guidance protein. LCM inhibited CRMP2-mediated neurite outgrowth, an effect phenocopied by CRMP2 knockdown. Mutation of LCM-binding sites in CRMP2 reduced the neurite inhibitory effect of LCM by similar to 8-fold. LCM also reduced CRMP2-mediated tubulin polymerization. Thus, LCM selectively impairs CRMP2-mediated microtubule polymerization, which underlies its neurite outgrowth and branching. To determine whether LCM inhibits axon sprouting in vivo, LCM was injected into rats subjected to partial cortical isolation, an animal model of posttraumatic epileptogenesis that exhibits axon sprouting in cortical pyramidal neurons. Two weeks following injury, excitatory synaptic connectivity of cortical layer V pyramidal neurons was mapped using patch clamp recordings and laser scanning photostimulation of caged glutamate. In comparison with injured control animals, there was a significant decrease in the map size of excitatory synaptic connectivity in LCM-treated rats, suggesting that LCM treatment prevented enhanced excitatory synaptic connectivity due to posttraumatic axon sprouting. These findings suggest, for the first time, that LCM's mode of action involves interactions with CRMP2 to inhibit posttraumatic axon sprouting. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Wilson, S. M.; Xiong, W.; Ping, X.; Brittain, J. M.; Jin, X.; Khanna, R.] Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Xiong, W.; Ping, X.; Jin, X.] Indiana Univ Sch Med, Dept Anat, Indianapolis, IN 46202 USA; [Xiong, W.; Ping, X.; Jin, X.] Indiana Univ Sch Med, Dept Cell Biol, Indianapolis, IN 46202 USA; [Xiong, W.; Ping, X.; Jin, X.; Khanna, R.] Indiana Univ Sch Med, Indiana Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA; [Wang, Y.; Khanna, R.] Indiana Univ Sch Med, Dept Pharmacol, Indianapolis, IN 46202 USA; [Wang, Y.; Khanna, R.] Indiana Univ Sch Med, Dept Pharmacol, Indianapolis, IN 46202 USA; [Head, J. D.] Indiana Univ Purdue Univ, Indianapolis, IN 46202 USA; [Gagare, P. D.; Ramachandran, P. V.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA		Khanna, R (corresponding author), 950 W Walnut St,R2 Room 478, Indianapolis, IN 46202 USA.	xijin@iupui.edu; khanna5@iupui.edu	Jin, Xiaoming/N-8545-2016; Ramachandran, P. Veeraraghavan/AAC-1852-2019; ping, xingjie/AAW-4597-2020; Jin, Xiaoming/AAH-3555-2020	Jin, Xiaoming/0000-0002-8671-8640; Khanna, Rajesh/0000-0002-9066-2969	Larry Kays Fellowship; Project Development Team within the ICTSI NIH/NCRR [RR025761, A70-9-079138]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057940]; Elwert Award in Medicine; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R00NS057940, K99NS057940] Funding Source: NIH RePORTER	We thank members of the SNRI for discussions, Dr. May Khanna (IUSM) for help with Pymol figures, Stephanie Martinez for acquiring some of the confocal images, and Nicole Ashpole for providing some of the cortical neurons. S.M.W. is a Stark Scholar. J.D.H. is supported by an undergraduate Life-Health Sciences Internship. J.M.B. is supported by a Larry Kays Fellowship. This project was supported by a Project Development Team within the ICTSI NIH/NCRR Grant Number RR025761 (A70-9-079138 to R.K.), NIH grant NS057940 (to X.J.), and the Elwert Award in Medicine (to X.J. and R.K.).	Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Beyreuther BK, 2007, CNS DRUG REV, V13, P21, DOI 10.1111/j.1527-3458.2007.00001.x; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Buckmaster PS, 2011, J NEUROSCI, V31, P2337, DOI 10.1523/JNEUROSCI.4852-10.2011; Bureau I, 2008, J NEUROSCI, V28, P5178, DOI 10.1523/JNEUROSCI.1076-08.2008; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; Chae YC, 2009, CELL SIGNAL, V21, P1818, DOI 10.1016/j.cellsig.2009.07.017; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Chen S, 2005, BRAIN RES, V1057, P88, DOI 10.1016/j.brainres.2005.07.039; Chi XX, 2009, J CELL SCI, V122, P4351, DOI 10.1242/jcs.053280; CHIAIA NL, 1994, DEV BRAIN RES, V79, P301, DOI 10.1016/0165-3806(94)90136-8; Choi D, 1996, BIOORGAN MED CHEM, V4, P2105, DOI 10.1016/S0968-0896(96)00225-8; Curia G, 2009, CNS DRUGS, V23, P555, DOI 10.2165/00023210-200923070-00002; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Doty P, 2007, NEUROTHERAPEUTICS, V4, P145, DOI 10.1016/j.nurt.2006.10.002; Errington AC, 2008, MOL PHARMACOL, V73, P157, DOI 10.1124/mol.107.039867; Errington AC, 2006, NEUROPHARMACOLOGY, V50, P1016, DOI 10.1016/j.neuropharm.2006.02.002; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Granacher RP., 2003, TRAUMATIC BRAIN INJU; Greenaway C, 2010, THER DRUG MONIT, V32, P448, DOI 10.1097/FTD.0b013e3181dcc5fb; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; Harris JA, 2009, ANN PHARMACOTHER, V43, P1809, DOI 10.1345/aph.1M303; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; Holtmaat AJGD, 2003, EXP NEUROL, V182, P142, DOI 10.1016/S0014-4886(03)00035-9; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Jin XM, 2011, CEREB CORTEX, V21, P1094, DOI 10.1093/cercor/bhq181; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Kelemen A, 2010, NEUROPSYCH DIS TREAT, V6, P465; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kimura T, 2005, J NEUROCHEM, V93, P1371, DOI 10.1111/j.1471-4159.2005.03063.x; Lees G, 2006, NEUROPHARMACOLOGY, V50, P98, DOI 10.1016/j.neuropharm.2005.08.016; Li HF, 2005, J NEUROPHYSIOL, V93, P146, DOI 10.1152/jn.00665.2004; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Nadler JV, 2003, NEUROCHEM RES, V28, P1649, DOI 10.1023/A:1026004904199; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Park KD, 2009, J MED CHEM, V52, P6897, DOI 10.1021/jm9012054; Perucca E, 2008, NAT REV DRUG DISCOV, V7, P973, DOI 10.1038/nrd2764; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Salin P, 1995, J NEUROSCI, V15, P8234; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Schubert D, 2001, J NEUROSCI, V21, P3580, DOI 10.1523/JNEUROSCI.21-10-03580.2001; Sheets PL, 2008, J PHARMACOL EXP THER, V326, P89, DOI 10.1124/jpet.107.133413; Shepherd GMG, 2003, NEURON, V38, P277, DOI 10.1016/S0896-6273(03)00152-1; SHOLL DA, 1953, J ANAT, V87, P387; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Wang YY, 2010, TRANSL NEUROSCI, V1, P106, DOI 10.2478/v10134-010-0025-8; Wang YY, 2011, TRANSL NEUROSCI, V2, P13, DOI 10.2478/s13380-011-0002-9; Wang YY, 2010, J BIOL CHEM, V285, P25296, DOI 10.1074/jbc.M110.128801; Xiong WH, 2011, JOVE-J VIS EXP, DOI 10.3791/2840; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009; Zhang W, 2012, J NEUROSCI, V32, P1183, DOI 10.1523/JNEUROSCI.5342-11.2012	59	45	47	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 17	2012	210						451	466		10.1016/j.neuroscience.2012.02.038			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	951ON	WOS:000304730000042	22433297	Green Accepted			2022-02-06	
J	Stengel, D; Ottersbach, C; Matthes, G; Weigeldt, M; Grundei, S; Rademacher, G; Tittel, A; Mutze, S; Ekkernkamp, A; Frank, M; Schmucker, U; Seifert, J				Stengel, Dirk; Ottersbach, Caspar; Matthes, Gerrit; Weigeldt, Moritz; Grundei, Simon; Rademacher, Grit; Tittel, Anja; Mutze, Sven; Ekkernkamp, Axel; Frank, Matthias; Schmucker, Uli; Seifert, Julia			Accuracy of single-pass whole-body computed tomography for detection of injuries in patients with major blunt trauma	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							RADIOGRAPHY; ROUTINE; METAANALYSIS; SPINE	Background: Contrast-enhanced whole-body computed tomography (also called "pan-scanning") is considered to be a conclusive diagnostic tool for major trauma. We sought to determine the accuracy of this method, focusing on the reliability of negative results. Methods: Between July 2006 and December 2008, a total of 982 patients with suspected severe injuries underwent single-pass pan-scanning at a metropolitan trauma centre. The findings of the scan were independently evaluated by two reviewers who analyzed the injuries to five body regions and compared the results to a synopsis of hospital charts, subsequent imaging and interventional procedures. We calculated the sensitivity and specificity of the pan-scan for each body region, and we assessed the residual risk of missed injuries that required surgery or critical care. Results: A total of 1756 injuries were detected in the 982 patients scanned. Of these, 360 patients had an Injury Severity Score greater than 15. The median length of follow-up was 39 (interquartile range 7-490) days, and 474 patients underwent a definitive reference test. The sensitivity of the initial pan-scan was 84.6% for head and neck injuries, 79.6% for facial injuries, 86.7% for thoracic injuries, 85.7% for abdominal injuries and 86.2% for pelvic injuries. Specificity was 98.9% for head and neck injuries, 99.1% for facial injuries, 98.9% for thoracic injuries, 97.5% for abdominal injuries and 99.8% for pelvic injuries. In total, 62 patients had 70 missed injuries, indicating a residual risk of 6.3% (95% confidence interval 4.9%-8.0%). Interpretation: We found that the positive results of trauma pan-scans are conclusive but negative results require subsequent confirmation. The pan-scan algorithms reduce, but do not eliminate, the risk of missed injuries, and they should not replace close monitoring and clinical follow-up of patients with major trauma.	[Stengel, Dirk; Ottersbach, Caspar; Grundei, Simon] Unfallkrankenhaus Berlin, Clin Res Ctr, Berlin, Germany; [Matthes, Gerrit; Weigeldt, Moritz; Seifert, Julia] Unfallkrankenhaus Berlin, Dept Trauma & Orthopaed Surg, Berlin, Germany; [Rademacher, Grit; Tittel, Anja; Mutze, Sven] Unfallkrankenhaus Berlin, Dept Radiol, Berlin, Germany; [Stengel, Dirk; Ottersbach, Caspar; Ekkernkamp, Axel; Frank, Matthias; Schmucker, Uli; Seifert, Julia] Ernst Moritz Arndt Univ Greifswald, Dept Trauma & Reconstruct Surg, Med Ctr, Greifswald, Germany		Stengel, D (corresponding author), Unfallkrankenhaus Berlin, Clin Res Ctr, Berlin, Germany.	dirk.stengel@ukb.de	Stengel, Dirk/AAF-6470-2019	Weigeldt, Moritz/0000-0002-0052-9604	Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF); European CommissionEuropean CommissionEuropean Commission Joint Research Centre; Johnson & Johnson MedicalJohnson & JohnsonJohnson & Johnson USA; Depuy; Medkon; Rehavital; German Advanced Trauma Life Support; NATONATO (North Atlantic Treaty Organisation)	Dirk Stengel is a board member of and a consultant for the German Trauma Association. He is a consultant, has provided expert testimony and received payment for lectures for the German Federal Statutory Accident Insurance, Biomet, DePuy, Stryker and the AO Foundation. He holds grants from these agencies, as well as from the Federal Ministry of Education and Research, and the European Commission. Gerrit Matthes is a board member and has received payment for providing lectures from the German Advanced Trauma Life Support. He has received compensation for travel expenses from NATO for providing a lecture on trauma management. Axel Ekkernkamp is a consultant for Pfizer, Stryker and Novo Nordisk. He has provided expert testimony for DePuy, Rehavital and Medkon, and he has received payment for lectures from Johnson & Johnson Medical, Depuy, Medkon and Rehavital. None declared for Caspar Ottersbach, Moritz Weigeldt, Simon Grundei, Grit Rademacher, Anja Tittel, Sven Mutze, Matthias Frank, Uli Schmucker and Julia Seifert.	Bossuyt PM, 2003, BRIT MED J, V326, P41, DOI 10.1136/bmj.326.7379.41; Brink M, 2008, AM J ROENTGENOL, V190, P1591, DOI 10.2214/AJR.07.3277; Cameron PA, 2011, INJURY, V42, P10, DOI 10.1016/j.injury.2010.11.035; Canadian Institute for Health Information, 2011, NAT TRAUM REG 2011 R; Chen CW, 2011, ACCIDENT ANAL PREV, V43, P823, DOI 10.1016/j.aap.2010.11.001; Deunk J, 2009, J TRAUMA, V66, P1108, DOI 10.1097/TA.0b013e31817e55c3; Deutsche Gesellschaft fur Unfallchirurgie, 2011, DGU MITTEIL NACHR, V33, P1; Elmali M, 2007, DIAGN INTERV RADIOL, V13, P179; Gennarelli TA., 2008, ABBREVIATED INJURY S; Hashem R, 2009, J TRAUMA, V66, P423, DOI 10.1097/TA.0b013e3181589fe5; Hilty MP, 2008, WORLD J EMERG SURG, V3, DOI 10.1186/1749-7922-3-11; Huber-Wagner S, 2009, LANCET, V373, P1455, DOI 10.1016/S0140-6736(09)60232-4; Hutter M, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-73; LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786; Lefering R, 2002, EUR J TRAUMA, P28, DOI DOI 10.1007/S00068-002-0170-Y; Leidner B, 1998, EUR RADIOL, V8, P1630, DOI 10.1007/s003300050601; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mutze S, 1999, EMERG RADIOL, V6, P77; Pfeifer R, 2008, PATIENT SAF SURG, V2, DOI 10.1186/1754-9493-2-20; Rutjes A W S, 2007, Health Technol Assess, V11, pix; Sierink JC, 2012, BRIT J SURG, V99, P52, DOI 10.1002/bjs.7760; Snyder GE, 2008, ANN EMERG MED, V52, P101, DOI 10.1016/j.annemergmed.2007.03.023; Stengel D, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004446.pub2; Stengel D, 2005, RADIOLOGY, V236, P102, DOI 10.1148/radiol.2361040791; Stengel D, 2009, INJURY, V40, pS36, DOI 10.1016/j.injury.2009.10.035; Tillou A, 2009, J TRAUMA, V67, P779, DOI 10.1097/TA.0b013e3181b5f2eb; van Vugt R, 2011, EUR J TRAUMA EMERG S, V37, P185, DOI 10.1007/s00068-010-0042-9; van Vugt R, 2011, J TRAUMA	28	45	48	0	6	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	MAY 15	2012	184	8					869	876		10.1503/cmaj.111420			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	001ZD	WOS:000308498400049	22392949	Green Published, gold			2022-02-06	
J	Kunio, NR; Differding, JA; Watson, KM; Stucke, RS; Schreiber, MA				Kunio, Nicholas R.; Differding, Jerome A.; Watson, Katherine M.; Stucke, Ryland S.; Schreiber, Martin A.			Thrombelastography-identified coagulopathy is associated with increased morbidity and mortality after traumatic brain injury	AMERICAN JOURNAL OF SURGERY			English	Article						Thrombelastography; Traumatic brain injury; Coagulopathy; Hypocoagulability	SEVERE HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; PROGNOSIS; COAGULATION; THERAPY; DEATH	BACKGROUND: The purpose of this study was to determine the relationship between coagulopathy and outcome after traumatic brain injury. METHODS: Patients admitted with a traumatic brain injury were enrolled prospectively and admission blood samples were obtained for kaolin-activated thrombelastogram and standard coagulation assays. Demographic and clinical data were obtained for analysis. RESULTS: Sixty-nine patients were included in the analysis. A total of 8.7% of subjects showed hypocoagulability based on a prolonged time to clot formation (R time, > 9 min). The mortality rate was significantly higher in subjects with a prolonged R time at admission (50.0% vs 11.7%). Patients with a prolonged R time also had significantly fewer intensive care unit-free days (8 vs 27 d), hospital-free days (5 vs 24 d), and increased incidence of neurosurgical intervention (83.3% vs 34.9%). CONCLUSIONS: Hypocoagulability as shown by thrombelastography after traumatic brain injury is associated with worse outcomes and an increased incidence of neurosurgical intervention. (c) 2012 Elsevier Inc. All rights reserved.	[Kunio, Nicholas R.; Differding, Jerome A.; Watson, Katherine M.; Stucke, Ryland S.; Schreiber, Martin A.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA		Kunio, NR (corresponding author), Oregon Hlth & Sci Univ, Dept Surg, 3181 SW Sam Jackson Pk Rd,Mail Code L-223, Portland, OR 97239 USA.	kunion@ohsu.edu					Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Huttner HB, 2006, STROKE, V37, P1465, DOI 10.1161/01.STR.0000221786.81354.d6; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; MCNICOL PL, 1994, ANAESTH INTENS CARE, V22, P659, DOI 10.1177/0310057X9402200603; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SPIESS BD, 1995, J CARDIOTHOR VASC AN, V9, P168, DOI 10.1016/S1053-0770(05)80189-2; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	23	45	52	0	7	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	MAY	2012	203	5					584	588		10.1016/j.amjsurg.2011.12.011			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	940ET	WOS:000303873500009	22425448				2022-02-06	
J	Perez, K; Novoa, AM; Santamarina-Rubio, E; Narvaez, Y; Arrufat, V; Borrell, C; Cabeza, E; Cirera, E; Ferrando, J; Garcia-Altes, A; Gonzalez-Luque, JC; Lizarbe, V; Martin-Cantera, C; Segui-Gomez, M; Suelves, JM				Perez, Katherine; Novoa, Ana M.; Santamarina-Rubio, Elena; Narvaez, Yislenz; Arrufat, Vita; Borrell, Carme; Cabeza, Elena; Cirera, Eva; Ferrando, Josep; Garcia-Altes, Anna; Carlos Gonzalez-Luque, Juan; Lizarbe, Vicenta; Martin-Cantera, Carlos; Segui-Gomez, Maria; Suelves, Josep M.		Spanish Soc Epidemiology	Incidence trends of traumatic spinal cord injury and traumatic brain injury in Spain, 2000-2009	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Spinal cord injury; Traumatic brain injury; Trauma; Epidemiology; Traffic accidents	ROAD TRAFFIC INJURIES; HEAD-INJURY; EPIDEMIOLOGY; PEOPLE; NUMBER; REDUCE	Aims: The The aim of the present study was to estimate the incidence of hospital discharges for traumatic spinal cord injury (TSCI) and traumatic brain injury (TBI) in Spain by injury circumstances (traffic crashes and others), injury severity, gender and age group and to describe its trends over the period 2000-2009. Methods: It is a study of trends that includes hospital discharges with a primary diagnosis of TSCI or TBI. Crude and age-standardised rates were calculated per million inhabitants. Changes in rates between 2000 and 2009 were assessed through calculation of the relative risk adjusted for age, using Poisson regression. Results: Between 2000 and 2009 in Spain, 10,274 patients were admitted for traumatic TSCI, and 206,503 for TBI. The annual incidence rate for TSCI was 23.5 per million, that for TBI was 472.6 per million. The overall incidence rate for TSCI fell significantly between 2000 and 2009 by 24.2% (traffic-related 40.9%, other 12.9%), as did that for TBI (23.8% overall, 60.2% traffic-related, with no change for other circumstances). Among people aged 65 years and over, no change was observed for TSCI, incidence of TBI fell significantly when due to traffic crashes, but there was a dramatic increase of 87% in men and 89.3% in women when due to other circumstances. Conclusions: Over the last decade the incidence of these types of injury has fallen significantly when the injury resulted from traffic crashes, and to a lesser extent when from other circumstances. However TBI incidence among people aged 65 and over injured in non-traffic-related circumstances has risen dramatically. (C) 2011 Elsevier Ltd. All rights reserved.	[Perez, Katherine; Novoa, Ana M.; Santamarina-Rubio, Elena; Narvaez, Yislenz; Borrell, Carme] Agencia Salut Pub Barcelona, Barcelona 08023, Spain; [Perez, Katherine; Novoa, Ana M.; Santamarina-Rubio, Elena; Borrell, Carme; Garcia-Altes, Anna] Inst Salud Carlos III, CIBER Epidemiol & Salud Publ CIBERESP, Madrid 28029, Spain; [Perez, Katherine; Novoa, Ana M.; Santamarina-Rubio, Elena; Borrell, Carme; Ferrando, Josep; Garcia-Altes, Anna] Inst Biomed Res IIB St Pau, Barcelona 08025, Spain; [Arrufat, Vita] Conselleria Sanitat Generalitat Valenciana, Negociat Programes Promocio Salut, Ctr Salut Publ Area 02, Castellon de La Plana 12003, Spain; [Cabeza, Elena] Conselleria Salut & Consum Illes Balears, Palma de Mallorca, Spain; [Cirera, Eva] Univ Vic, Fac Ciencies Salut & Benestar, Vic 08500, Spain; [Ferrando, Josep] IES Alexandre Satorras, Barcelona 08304, Spain; [Carlos Gonzalez-Luque, Juan] Direcc Gen Traf, Minist Interior, Observ Nacl Seguridad Vial, Madrid 28071, Spain; [Lizarbe, Vicenta] Minist Sanidad Polit Social & Igualdad, Madrid 28014, Spain; [Martin-Cantera, Carlos] IDIAP Jordi Gol, Unitat Suport Recerca Barcelona, Barcelona 08006, Spain; [Segui-Gomez, Maria] Univ Navarra, European Ctr Injury Prevent, Navarra 31080, Spain; [Suelves, Josep M.] Dept Salut Generalitat Catalunya, Barcelona 08005, Spain		Perez, K (corresponding author), Agencia Salut Pub Barcelona, Pl Lesseps 1, Barcelona 08023, Spain.	cperez@aspb.cat	Cirera, Eva/F-1407-2015; Suelves, Josep M/F-9080-2011; Martin Cantera, Carlos/D-2693-2011	Cirera, Eva/0000-0002-0381-358X; Suelves, Josep M/0000-0002-7716-6944; Martin Cantera, Carlos/0000-0003-0656-8126; Borrell, Carme/0000-0002-1170-2505; Narvaez-Martinez, Alejandra/0000-0002-0287-7653; Gonzalez-Luque, Juan Carlos/0000-0001-8081-0377; Perez, Katherine/0000-0001-5892-2807; GONZALEZ-LUQUE, JUAN CARLOS/0000-0002-4044-8403			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Benavides F.G., 2011, SEGURIDAD SALUD TRAB, V62, P22; Castillo-Manzano JI, 2011, J SAFETY RES, V42, P223, DOI 10.1016/j.jsr.2011.03.004; Castillo-Manzano JI, 2010, ACCIDENT ANAL PREV, V42, P1310, DOI 10.1016/j.aap.2010.02.009; Chiu WT, 2010, ASIA-PAC J PUBLIC HE, V22, P9, DOI 10.1177/1010539509355470; Clark D., 2011, ICDPIC STATA MODULE; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Direccion General de Trafico, 2006, MEM ACT SEG VIAL 200; Direccion General de Trafico, 2007, MEM ACT SEG VIAL 200; Direccion General de Trafico, 2009, BAL 2 AN PERM PUNT; Direccion General de Trafico, 2010, PRINC CIFR SEG VIAL; Dryden DM, 2003, CAN J NEUROL SCI, V30, P113, DOI 10.1017/S0317167100053373; Faul M, 2010, TRAUMATIC BRAIN INJU; Frick KD, 2010, J AM GERIATR SOC, V58, P136, DOI 10.1111/j.1532-5415.2009.02575.x; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Hu GQ, 2010, INJURY PREV, V16, P26, DOI 10.1136/ip.2009.023481; Jamieson LM, 2007, INJURY PREV, V13, P243, DOI 10.1136/ip.2007.015354; Kannus P, 2007, J GERONTOL A-BIOL, V62, P180, DOI 10.1093/gerona/62.2.180; Krug, 2002, INJURY LEADING CAUSE; Lieutaud T, 2010, J NEUROTRAUM, V27, P1101, DOI 10.1089/neu.2009.1197; Martins F, 1998, SPINAL CORD, V36, P574, DOI 10.1038/sj.sc.3100657; Nobunaga AI, 1999, ARCH PHYS MED REHAB, V80, P1372, DOI 10.1016/S0003-9993(99)90247-2; Novoa AM, 2011, B WORLD HEALTH ORGAN, V89, P422, DOI 10.2471/BLT.10.082180; Novoa AM, 2011, J EPIDEMIOL COMMUN H, V65, P218, DOI 10.1136/jech.2009.094029; Novoa AM, 2010, AM J PUBLIC HEALTH, V100, P2220, DOI 10.2105/AJPH.2010.192104; O'Connor PJ, 2006, ACCIDENT ANAL PREV, V38, P71, DOI 10.1016/j.aap.2005.03.025; Perez K., 2006, AM J PUBLIC HLTH; Rodriguez J.I., 2009, TRAFICO SEGURIDAD VI, V197, P42; Stephenson S, 2005, ACCIDENT ANAL PREV, V37, P825, DOI 10.1016/j.aap.2005.03.024; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; [United Nations WHO], 2011, WHO DEC ACT ROAD SAF; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Van Den Berg M, 2011, J NEUROTRAUM, V28, P469, DOI 10.1089/neu.2010.1608; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328	36	45	50	0	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAY	2012	46						37	44		10.1016/j.aap.2011.12.004			8	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	926MI	WOS:000302834700005	22310041				2022-02-06	
J	Lee, P; Kim, J; Williams, R; Sandhir, R; Gregory, E; Brooks, WM; Berman, NEJ				Lee, Phil; Kim, Jieun; Williams, Rachel; Sandhir, Rajat; Gregory, Eugene; Brooks, William M.; Berman, Nancy E. J.			Effects of aging on blood brain barrier and matrix metalloproteases following controlled cortical impact in mice	EXPERIMENTAL NEUROLOGY			English	Article						Controlled cortical impact; Traumatic brain injury; Aging; T1 mapping; Blood brain barrier; MMP-9; MMP-2; Occludin; ZO-1; Claudin-5	TIGHT JUNCTION PROTEINS; GENE KNOCK-OUT; CEREBRAL-ISCHEMIA; MICROGLIAL ACTIVATION; RAT-BRAIN; MEDIATED DISRUPTION; ENDOTHELIAL-CELLS; INJURY; EXPRESSION; MATRIX-METALLOPROTEINASE-9	Aging alters the ability of the brain to respond to injury. One of the major differences between the adult and aged brain is that comparable injuries lead to greater blood brain barrier disruption in the aged brain. The goals of these studies were to quantify the effects of age on BBB permeability using high field strength MRI T1 mapping and to determine whether activation of matrix metalloproteases, their inhibitors, or expression of blood brain barrier structural proteins, occludin, zonnula occludins-1 (ZO-1) and claudin-5 were altered following injury to the aged C57/BL6 mouse brain. T1 mapping studies revealed greater blood brain barrier permeability in the aged (21-24 months old) brain than in the adult (4-6 months old) following controlled cortical impact. The increased blood brain barrier permeability in the pericontusional region was confirmed with IgG immunohistochemistry. MMP-9 activity was increased following controlled cortical impact in the aged brain, and this was accompanied by increased MMP-9 gene expression. MMP-2 activity was higher in the uninjured aged brain than in the adult brain. Occludin and ZO-1 mRNA levels were unchanged following injury in either age group, but claudin-5 mRNA levels were lower in the aged than the adult brain following injury. These results demonstrate quantitative increases in blood brain barrier permeability in the aged brain following injury that are accompanied by increased MMP-9 activation and decreased blood brain barrier repair responses. (C) 2011 Published by Elsevier Inc.	[Lee, Phil; Brooks, William M.; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Lee, Phil; Kim, Jieun; Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA; [Williams, Rachel; Sandhir, Rajat; Gregory, Eugene; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Brooks, William M.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA		Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	nberman@kumc.edu	Brooks, William/AAF-8299-2019	Brooks, William/0000-0001-6227-7636; Lee, Phil/0000-0002-2087-8887	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AG31140, P30 HD02528, P20 RR016475]; Hoglund Family Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031140] Funding Source: NIH RePORTER	Supported by NIH grant R01AG31140, P30 HD02528, P20 RR016475, and the Hoglund Family Foundation. We would like to thank Dr. Y.Y. He for assistance with surgery.	Adams DD, 2001, MECH AGEING DEV, V122, P173, DOI 10.1016/S0047-6374(00)00230-X; Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI 10.1089/neu.2008-0765; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Berman NEJ, 1999, NEUROBIOL DIS, V6, P486, DOI 10.1006/nbdi.1999.0261; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Biron KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023789; Boda E, 2009, J MOL NEUROSCI, V37, P238, DOI 10.1007/s12031-008-9128-9; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Burek M, 2009, MOL CELL ENDOCRINOL, V298, P19, DOI 10.1016/j.mce.2008.09.041; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cross AK, 1999, GLIA, V28, P183, DOI 10.1002/(SICI)1098-1136(199912)28:3<183::AID-GLIA2>3.0.CO;2-3; del Zoppo GJ, 2007, STROKE, V38, P646, DOI 10.1161/01.STR.0000254477.34231.cb; Dobrogowska DH, 2004, J MOL HISTOL, V35, P529, DOI 10.1007/s10735-004-1318-3; Farrall AJ, 2009, NEUROBIOL AGING, V30, P337, DOI 10.1016/j.neurobiolaging.2007.07.015; Furuno T, 2002, PHARMACOGENETICS, V12, P529, DOI 10.1097/00008571-200210000-00004; Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Herrera AJ, 2008, J NEUROCHEM, V105, P750, DOI 10.1111/j.1471-4159.2007.05170.x; Hirase T, 1997, J CELL SCI, V110, P1603; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kim J, 2011, NEUROIMAGE, V56, P1286, DOI 10.1016/j.neuroimage.2011.02.039; Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Manaenko A, 2011, J NEUROSCI METH, V195, P206, DOI 10.1016/j.jneumeth.2010.12.013; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203, DOI 10.1152/ajpregu.1998.274.5.R1203; Nagaraja TN, 2011, NMR BIOMED, V24, P547, DOI 10.1002/nbm.1625; Narayana PA, 2004, J NEUROSCI RES, V78, P749, DOI 10.1002/jnr.20275; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Pugh TD, 1999, CANCER RES, V59, P1642; Rao HV, 2007, J NEUROCHEM, V101, P498, DOI 10.1111/j.1471-4159.2006.04389.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rohatgi T, 2004, NEUROSCIENTIST, V10, P501, DOI 10.1177/1073858404269955; Rosell A, 2008, STROKE, V39, P1121, DOI 10.1161/STROKEAHA.107.500868; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sood R, 2007, J MAGN RESON IMAGING, V25, P39, DOI 10.1002/jmri.20802; Sood RR, 2008, J CEREBR BLOOD F MET, V28, P431, DOI 10.1038/sj.jcbfm.9600534; Stephens EB, 2003, AIDS RES HUM RETROV, V19, P837, DOI 10.1089/088922203322493003; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Strupp JP, 1996, NEUROIMAGE, V3, pS607, DOI DOI 10.1016/S1053-8119(96)80609-4; Stucky NL, 2011, HEADACHE, V51, P674, DOI 10.1111/j.1526-4610.2011.01882.x; Suo Z., 2004, Current Drug Targets - Inflammation and Allergy, V3, P105, DOI 10.2174/1568010043483953; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tavelin S, 2003, MOL PHARMACOL, V64, P1530, DOI 10.1124/mol.64.6.1530; Tejima E, 2007, J CEREBR BLOOD F MET, V27, P460, DOI 10.1038/sj.jcbfm.9600354; Tejima E, 2009, J NEUROTRAUM, V26, P1935, DOI [10.1089/neu.2009-0959, 10.1089/neu.2009.0959]; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Van Itallie CM, 2009, MOL BIOL CELL, V20, P3930, DOI 10.1091/mbc.E09-04-0320; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yang Y, 2011, METHODS MOL BIOL, V762, P333, DOI 10.1007/978-1-61779-185-7_24; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	72	45	49	2	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2012	234	1					50	61		10.1016/j.expneurol.2011.12.016			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	910DN	WOS:000301617500007	22201549	Green Accepted			2022-02-06	
J	Lincoln, AE; Caswell, SV; Almquist, JL; Dunn, RE; Clough, MV; Dick, RW; Hinton, RY				Lincoln, Andrew E.; Caswell, Shane V.; Almquist, Jon L.; Dunn, Reginald E.; Clough, Mark V.; Dick, Randall W.; Hinton, Richard Y.			Effectiveness of the Women's Lacrosse Protective Eyewear Mandate in the Reduction of Eye Injuries	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						women's lacrosse; eye injuries; protective eyewear; injury prevention	HEAD; PLAYERS; FACE	Background: In an effort to minimize the risk of catastrophic eye injury, US Lacrosse initiated mandatory use of protective eyewear in women's lacrosse in the 2004-2005 season. Purpose: The authors compared eye injury rates in girls' scholastic lacrosse before and after implementation of protective eyewear. They also compared head/face injury rates, concussion rates, and overall injury rates before and after the rule change to assess possible unintended consequences of the change. Study Design: Cohort study; Level of evidence, 3. Methods: The study group included female scholastic lacrosse players in the 25 public high schools in Fairfax County, Virginia, during the 2004-2009 spring seasons. Injury rates were compared with those from the same data source for the 2000-2003 seasons. Premandate versus postmandate injury rates were adjusted for athlete exposures, or total opportunities for injury throughout the season. Results: The rate of eye injuries was reduced from 0.10 injuries per 1000 athlete exposures (AEs) in 2000 through 2003 before the use of protective eyewear to 0.016 injuries per 1000 AEs in 2004 through 2009 (incident rate ratio [IRR], 0.16; 95% confidence interval [CI], 0.06-0.42). The rate ratio of head/face injuries excluding concussion also decreased (IRR, 0.44; 95% CI, 0.26-0.76). There was no change in the rate ratio of total injuries involving all body parts (IRR, 0.93; 95% CI, 0.82-1.1) after introduction of protective eyewear. However, the rate ratio of concussion increased (IRR, 1.6; 95% CI, 1.1-2.3). Conclusion: The use of protective eyewear in women's lacrosse was associated with a reduction in the number of eye injuries. The number of head/face injuries decreased in this study group after introduction of protective eyewear, and there was no change in overall injury rates. The reason for the increase in concussion rate cannot be determined conclusively based on this study, but the authors speculate that this increase resulted largely from increased recognition and diagnosis because overall injury rates do not indicate rougher play with introduction of protective equipment.	[Lincoln, Andrew E.; Caswell, Shane V.; Almquist, Jon L.; Dunn, Reginald E.; Clough, Mark V.; Dick, Randall W.; Hinton, Richard Y.] MedStar Sports Med Res Ctr, Baltimore, MD USA		Lincoln, AE (corresponding author), Care of Camire L, Union Mem Orthopaed, Johnston Profess Bldg,Suite 400,3333 N Calvert St, Baltimore, MD 21218 USA.	lyn.camire@medstar.net			US Lacrosse Sports Science and Safety Committee	One or more of the authors has declared the following potential conflict of interest or source of funding: A nonrestrictive research support was provided by the US Lacrosse Sports Science and Safety Committee. The funding source had no other role in the study.	Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; Diamond PT, 2001, BRAIN INJURY, V15, P537, DOI 10.1080/02699050010007362; Goldenberg Michael S., 1995, Journal of Athletic Training, V30, P37; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; LAPIDUS CS, 1992, J TRAUMA, V32, P555, DOI 10.1097/00005373-199205000-00003; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Livingston LA, 1996, J TRAUMA, V40, P144, DOI 10.1097/00005373-199601000-00030; Matthews LS, 2001, SPORTS INJURIES MECH, P568; Perna FM, 2003, ANN BEHAV MED, V25, P66, DOI 10.1207/S15324796ABM2501_09; Schwarz A., 2011, NY TIMES        0216; Tyler TF, 2002, AM J SPORT MED, V30, P680, DOI 10.1177/03635465020300050801; Webster DA, 1999, MED SCI SPORT EXER, V31, P938, DOI 10.1097/00005768-199907000-00004	14	45	45	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	MAR	2012	40	3					611	614		10.1177/0363546511428873			4	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	902TV	WOS:000301065100016	22156171				2022-02-06	
J	Testa, R; Bennett, P; Ponsford, J				Testa, Renee; Bennett, Pauleen; Ponsford, Jennie			Factor Analysis of Nineteen Executive Function Tests in a Healthy Adult Population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Executive function; Executive dysfunction; Frontal lobe; Neuropsychological tests; Cognition	FRONTAL-LOBE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; DUAL-TASK PERFORMANCE; PREFRONTAL CORTEX; NEUROPSYCHOLOGICAL FINDINGS; DYSEXECUTIVE SYMPTOMS; STRATEGY APPLICATION; ANTERIOR CINGULATE; DECISION-MAKING; WORKING-MEMORY	Although there has been some progress in identifying the range of skills that comprise the executive neurocognitive system, their assessment has proved to be a challenge. Operationalization of executive functions (EFs) may be progressed by identifying the cognitive constructs that underlie EF test performance via principal components analysis. The underlying factor structure of 19 EF tests was examined in a non-clinical sample of 200 adults (mean age 30.8 [1864] years); the sample comprised 97 men. Findings revealed only weak correlations between various measures derived from the EF tests. Exploratory factor analysis revealed a model comprising six independent factors, consistent with previous reports, describing the functions of the EF system. The factors comprised: Prospective Working Memory, Set-Shifting and Interference Management, Task Analysis, Response Inhibition, Strategy Generation and Regulation, and Self-Monitoring and Set-Maintenance. Results confirm the diverse and heterogeneous nature of EFs and caution against conceptualizations that underestimate its complexity. Furthermore, variability within the normal executive system is evident, and further research is required to understand executive functioning in healthy populations.	[Testa, Renee] Univ Melbourne, Melbourne Neuropsychiat Ctr, Melbourne, Vic 3053, Australia; [Testa, Renee; Bennett, Pauleen; Ponsford, Jennie] Monash Univ, Dept Psychiat & Psychol, Melbourne, Vic 3004, Australia		Testa, R (corresponding author), Univ Melbourne, Melbourne Neuropsychiat Ctr, Alan Gilbert Bldg,161 Barry St, Melbourne, Vic 3053, Australia.	rtesta@unimelb.edu.au	Bennett, Pauleen/C-2138-2016	Bennett, Pauleen/0000-0001-5864-4464			Amieva H, 2003, BRAIN COGNITION, V53, P129, DOI 10.1016/S0278-2626(03)00094-0; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V., 2000, CLIN NEUROPSYCHOL, V1, P247; Ardila A, 2008, BRAIN COGNITION, V68, P92, DOI 10.1016/j.bandc.2008.03.003; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Australian Bureau of Statistics, 2001, 2001 NAT CONS POP HO; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 1996, PHILOS T ROY SOC B, V351, P1397, DOI 10.1098/rstb.1996.0123; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Benke T, 2003, NEUROCASE, V9, P70, DOI 10.1076/neur.9.1.70.14374; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Benson D.F., 1986, FRONTAL LOBES; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Brugger P, 1997, PERCEPT MOTOR SKILL, V84, P627, DOI 10.2466/pms.1997.84.2.627; Burgess P., 1997, METHODOLOGY FRONTAL, P81; Burgess PW, 1996, CORTEX, V32, P241, DOI 10.1016/S0010-9452(96)80049-9; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Carter CS, 1999, REV NEUROSCIENCE, V10, P49; CHALMERS D, 1993, INT J BEHAV DEV, V16, P191, DOI 10.1177/016502549301600206; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Charlton RA, 2006, NEUROLOGY, V66, P217, DOI 10.1212/01.wnl.0000194256.15247.83; Chayer C, 2001, Curr Neurol Neurosci Rep, V1, P547, DOI 10.1007/s11910-001-0060-4; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Cohen JD, 2000, NAT NEUROSCI, V3, P421, DOI 10.1038/74783; de Oliveira-Souza R, 2001, NEUROCASE, V7, P383, DOI 10.1076/neur.7.5.383.16244; De Vaus D., 2002, ANAL SOCIAL SCI DATA; Denckla M B, 1994, FRAMES REFERENCE ASS, P117; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Eslinger P. J, 1996, ATTENTION MEMORY EXE, P367; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; Fabrigar LR, 1999, PSYCHOL METHODS, V4, P272, DOI 10.1037/1082-989X.4.3.272; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286; FUSTER JM, 1991, PROG BRAIN RES, V87, P201; Godbout L, 2005, BRAIN INJURY, V19, P337, DOI 10.1080/02699050400005093; Golden CJ., 1978, STROOP COLOUR WORD T; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.2307/1130201; Gorsuch R. L., 1983, FACTOR ANAL; Gothelf D, 2005, MENT RETARD DEV D R, V11, P331, DOI 10.1002/mrdd.20089; Grafman J, 1995, ANN NY ACAD SCI, V769, P337, DOI 10.1111/j.1749-6632.1995.tb38149.x; Halstead W., 1947, BRAIN INTELLIGENCE C; Heaton R.K., 1981, WISCONSIN CARD SORTI; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Holmes AJ, 2005, SCHIZOPHR RES, V76, P199, DOI 10.1016/j.schres.2005.01.021; Hornak J, 2004, J COGNITIVE NEUROSCI, V16, P463, DOI 10.1162/089892904322926791; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; JASON GW, 1985, NEUROPSYCHOLOGIA, V23, P463, DOI 10.1016/0028-3932(85)90002-8; Kline P., 1998, NEW PSYCHOMETRICS SC; Kline P., 1994, EASY GUIDE FACTOR AN; Krasnegor N.A., 1996, ATTENTION MEMORY EXE, P263; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lezak MD., 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; McDonald CR, 2005, J INT NEUROPSYCH SOC, V11, P477, DOI 10.1017/S1355617705050484; Miller L., 1990, COGN REHABIL, V8, P14; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyake A, 2001, J EXP PSYCHOL GEN, V130, P621, DOI 10.1037/0096-3445.130.4.621; Mosher F.A., 1966, STUDIES COGNITIVE GR, P86; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; Nelson H.E., 1982, NATL ADULT READING T; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; Pantelis C, 2003, AUST NZ J PSYCHIAT, V37, P399, DOI 10.1046/j.1440-1614.2003.01193.x; PASSINGHAM RE, 1985, PHILOS T ROY SOC B, V308, P101, DOI 10.1098/rstb.1985.0013; Phillips L. H, 1997, METHODOLOGY FRONTAL, P191; Pineda DA, 2003, INT J NEUROSCI, V113, P397, DOI 10.1080/00207450390162164; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Reitan RM, 1992, TRAIL MAKING TEST MA; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; Roth RM, 2004, PSYCHIAT CLIN N AM, V27, P83, DOI 10.1016/S0193-953X(03)00112-6; Ruff RM, 1988, RUFF FIGURAL FLUENCY; Schnirman GM, 1998, ASSESSMENT, V5, P355, DOI 10.1177/107319119800500404; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SHALLICE T, 1991, PSYCHOL MED, V21, P661, DOI 10.1017/S0033291700022303; SHUTE GE, 1990, DEV NEUROPSYCHOL, V6, P1, DOI 10.1080/87565649009540445; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Storey E, 1999, ARCH NEUROL-CHICAGO, V56, P43, DOI 10.1001/archneur.56.1.43; Stuss D. T., 2007, HUMAN FRONTAL LOBES, V2, P292; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Szameitat AJ, 2002, J COGNITIVE NEUROSCI, V14, P1184, DOI 10.1162/089892902760807195; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Taylor SF, 2004, NEUROIMAGE, V21, P1045, DOI 10.1016/j.neuroimage.2003.10.032; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; TESTA R, 2009, NEUROPSYCHOLOGICAL M; TRANEL D, 1994, HDB NEUROPSYCHOLOGY, P125; van der Werf SP, 2000, NEUROPSY NEUROPSY BE, V13, P199; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Zimmerman ME, 2006, AM J GERIAT PSYCHIAT, V14, P823, DOI 10.1097/01.JGP.0000238502.40963.ac	99	45	46	2	40	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2012	27	2					213	224		10.1093/arclin/acr112			12	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	895HL	WOS:000300486900011	22314610	Bronze, Green Published			2022-02-06	
J	Finan, JD; Elkin, BS; Pearson, EM; Kalbian, IL; Morrison, B				Finan, John D.; Elkin, Benjamin S.; Pearson, Erica M.; Kalbian, Irene L.; Morrison, Barclay, III			Viscoelastic Properties of the Rat Brain in the Sagittal Plane: Effects of Anatomical Structure and Age	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Neurotrauma; Indentation; Relaxation function; Biomechanics; Injury	DIFFUSE AXONAL INJURY; ANGULAR-ACCELERATION; MECHANICAL RESPONSE; IN-VITRO; TISSUE; MODEL; HEAD; HETEROGENEITY; INDENTATION; ANISOTROPY	Rat is the most commonly used animal model for the study of traumatic brain injury. Recent advances in imaging and computational modeling technology offer the promise of biomechanical models capable of resolving individual brain structures and offering greater insight into the causes and consequences of brain injury. However, there is insufficient data on the mechanical properties of brain structures available to populate these models. In this study, we used microindentation to determine viscoelastic properties of different anatomical structures in sagittal slices of juvenile and adult rat brain. We find that the rat brain is spatially heterogeneous in this anatomical plane supporting previous results in the coronal plane. In addition, the brain becomes stiffer and more heterogeneous as the animal matures. This dynamic, region-specific data will support the development of more biofidelic computational models of brain injury biomechanics and the testing of hypotheses about the manner in which different anatomical structures are injured in a head impact.	[Finan, John D.; Elkin, Benjamin S.; Pearson, Erica M.; Kalbian, Irene L.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, Neurotrauma & Repair Lab, New York, NY 10027 USA		Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, Neurotrauma & Repair Lab, 351 Engn Terrace,1210 Amsterdam Ave MC 8904, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Finan, John/0000-0003-4626-9702	NHTSA [DTNH22-08-C-00088]	The authors wish to thank Dr. Ed X. Guo for laboratory space and equipment. This study was supported by NHTSA Project # DTNH22-08-C-00088.	ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Allen M.P., 1997, UNDERSTANDING REGRES; Begonia MT, 2010, ANN BIOMED ENG, V38, P3043, DOI 10.1007/s10439-010-0072-9; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Boretius S, 2004, MAGN RESON MATER PHY, V17, P339, DOI 10.1007/s10334-004-0069-1; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Christ AF, 2010, J BIOMECH, V43, P2986, DOI 10.1016/j.jbiomech.2010.07.002; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Davidsson Johan, 2011, Front Neurol, V2, P41, DOI 10.3389/fneur.2011.00041; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2011, J NEUROTRAUM, V28, P2235, DOI 10.1089/neu.2010.1604; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; Elliott DM, 2001, J BIOMECH ENG-T ASME, V123, P256, DOI 10.1115/1.1374202; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; HAYES WC, 1972, J BIOMECH, V5, P541, DOI 10.1016/0021-9290(72)90010-3; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Kaster T, 2011, J BIOMECH, V44, P1158, DOI 10.1016/j.jbiomech.2011.01.019; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schulze-Bauer CAJ, 2003, J BIOMECH ENG-T ASME, V125, P395, DOI 10.1115/1.1574331; Shulyakov AV, 2011, J MECH BEHAV BIOMED, V4, P484, DOI 10.1016/j.jmbbm.2010.12.012; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; WAHI KK, 1977, ANN BIOMED ENG, V5, P303, DOI 10.1007/BF02367311; Wang HC, 2010, J NEUROTRAUM, V27, P707, DOI 10.1089/neu.2009.1071	37	45	45	0	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		70	78		10.1007/s10439-011-0394-2			9	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	895HJ	WOS:000300486700006	22012082				2022-02-06	
J	Schroeder, RW; Baade, LE; Peck, CP; VonDran, EJ; Brockman, CJ; Webster, BK; Heinrichs, RJ				Schroeder, Ryan W.; Baade, Lyle E.; Peck, Caleb P.; VonDran, Emanuel J.; Brockman, Callie J.; Webster, Blake K.; Heinrichs, Robin J.			Validation of MMPI-2-RF Validity Scales in Criterion Group Neuropsychological Samples	CLINICAL NEUROPSYCHOLOGIST			English	Article						Validity scales; Minnesota Multiphasic Personality Inventory-2 Restructured Form; MMPI-2-RF; Malingering; Forensic neuropsychology	MALINGERED NEUROCOGNITIVE DYSFUNCTION; FAKE BAD SCALE; RESPONSE BIAS; UTILITY; RBS	This study utilized multiple criterion group neuropsychological samples to evaluate the "over-reporting" and "under-reporting" MMPI-2-RF validity scales. The five criterion groups included in this study were (1) litigating traumatic brain injury patients who failed Slick et al. criteria for probable malingering, (2) litigating traumatic brain injury patients who passed Slick et al. criteria, (3) mixed neuropsychological outpatients who passed SVTs and were diagnosed with primary neurological conditions, (4) mixed neuropsychological outpatients who passed SVTs and were diagnosed with primary psychiatric conditions, and (5) epileptic seizure disorder inpatients who were diagnosed via video-EEG. Using the data from these groups, cumulative percentages for all possible T-scores and sensitivity and specificity rates for optimal cutoff scores were determined. When specificity rates were set at 90% across all non-malingering neurological condition groups, sensitivity rates ranged from 48% (FBS-r) to 10% (K-r).	[Schroeder, Ryan W.; Baade, Lyle E.; Peck, Caleb P.; VonDran, Emanuel J.; Brockman, Callie J.; Webster, Blake K.; Heinrichs, Robin J.] Univ Kansas, Sch Med Wichita, Wichita, KS 67206 USA		Schroeder, RW (corresponding author), Univ Kansas, Sch Med Wichita, Room 105,7829 E Rockhill, Wichita, KS 67206 USA.	Ryan.W.Schroeder.PsyD@hotmail.com					Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Delis DC, 1987, CALIFORNIA VERBAL LE; Frederick R. I., 1997, VALIDITY INDICATOR P; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Green P., 2003, GREENS WORD MEMORY T; Green P, 2004, GREENS MED SYMPTOM V; Green P., 2004, MEMORY COMPLAINTS IN; Greiffenstein M.F., 2007, ASSESSMENT FEIGNED C, P210; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Kaemmer, 1989, MINNESOTA MULTIPHASI; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; Locke DEC, 2010, EPILEPSY BEHAV, V17, P252, DOI 10.1016/j.yebeh.2009.12.004; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2007, J CLIN EXP NEUROPSYC, V29, P67, DOI 10.1080/13803390500488546; Nelson NW, 2010, CLIN NEUROPSYCHOL, V24, P701, DOI 10.1080/13854040903482863; Pearson, 2009, ADV CLIN SOL WAIS 4; Rogers R, 2011, J PSYCHOPATHOL BEHAV, V33, P355, DOI 10.1007/s10862-011-9222-0; Sellbom M, 2010, PSYCHOL ASSESSMENT, V22, P757, DOI 10.1037/a0020825; Sellbom M, 2010, PSYCHOL ASSESSMENT, V22, P22, DOI 10.1037/a0018222; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tellegen, 2008, MMPI 2 RESTRUCTURED; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wygant D. B., 2010, PSYCHOL ASSESSMENT, V22, P1; Wygant DB, 2009, ARCH CLIN NEUROPSYCH, V24, P671, DOI 10.1093/arclin/acp073; Youngjohn JR, 2011, CLIN NEUROPSYCHOL, V25, P463, DOI [10.1080/13854046.2011.554444, 10.1080/13854046.2010.550635]	37	45	45	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	1					129	146		10.1080/13854046.2011.639314			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	922JN	WOS:000302543300011	22150551				2022-02-06	
J	Theadom, A; Barker-Collo, S; Feigin, VL; Starkey, NJ; Jones, K; Jones, A; Ameratunga, S; Barber, PA				Theadom, A.; Barker-Collo, S.; Feigin, V. L.; Starkey, N. J.; Jones, K.; Jones, A.; Ameratunga, S.; Barber, P. A.		BIONIC Res Grp	The Spectrum Captured: A Methodological Approach to Studying Incidence and Outcomes of Traumatic Brain Injury on a Population Level	NEUROEPIDEMIOLOGY			English	Article						Traumatic brain injury; Epidemiology; Longitudinal; Outcomes; Assessment; Methods; New Zealand; Incidence	MILD HEAD-INJURY; YOUNG-CHILDREN; NEW-ZEALAND; COMA SCALE; FOLLOW-UP; QUESTIONNAIRE; RECOVERY; CONSCIOUSNESS; EPIDEMIOLOGY; RELIABILITY	Objective: Drawing on the experience of conducting the Brain Injury Incidence and Outcomes New Zealand in the Community study, this article aims to identify the issues arising from the implementation of proposed guidelines for population-based studies of incidence and outcomes in traumatic brain injury (TBI). Study Design and Setting: All new cases of TBI (all ages and severities) were ascertained over a 1-year period, using overlapping prospective and retrospective sources of case ascertainment in New Zealand. All eligible TBI cases were invited to participate in a comprehensive assessment at baseline and at 1-month follow-up. Results: Our experience to date has revealed the feasibility of case ascertainment methods. Consultation with community health services and professionals resulted in feasible referral pathways to support the identification of TBI cases. 'Hot pursuit' methods of recruitment were essential to ensure complete case ascertainment for this population with few additional cases of TBI identified through cross-checks. Conclusion: This review of proposed guidelines in relation to practical study methodology provides a framework for future comparable population-based epidemiological studies of TBI incidence and outcomes in developed countries. Copyright (C) 2011 S. Karger AG, Basel	[Theadom, A.] Auckland Univ Technol, Fac Hlth & Environm Sci, Sch Rehabil & Occupat Studies, Natl Inst Stroke & Appl Neurosci, Auckland 1142, New Zealand; [Barker-Collo, S.] Univ Auckland, Dept Psychol, Fac Sci, Auckland, New Zealand; [Ameratunga, S.] Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand; [Barber, P. A.] Univ Auckland, Dept Med, Auckland, New Zealand; [Starkey, N. J.] Univ Waikato, Fac Arts & Social Sci, Sch Psychol, Hamilton, New Zealand		Theadom, A (corresponding author), Auckland Univ Technol, Fac Hlth & Environm Sci, Sch Rehabil & Occupat Studies, Natl Inst Stroke & Appl Neurosci, AUT N Shore Campus,AA254C,90 Akoranga Dr,Private, Auckland 1142, New Zealand.	alice.theadom@aut.ac.nz	Starkey, Nicola/AAJ-3795-2020; Feigin, Valery/AAF-2313-2019; Jones, Kelly/I-5199-2019; Jones, Kelly/G-4127-2015	Starkey, Nicola/0000-0002-4370-8186; Feigin, Valery L./0000-0002-6372-1740; Ameratunga, Shanthi/0000-0001-8042-2251; Theadom, Alice/0000-0003-0351-6216; Barber, P Alan/0000-0003-2469-9023; Jones, Kelly/0000-0001-5692-653X	Health Research Council of New Zealand (HRC)Health Research Council of New Zealand [09/063A]; ABI Rehabilitation Management, NZ	This study is funded by the Health Research Council of New Zealand (HRC 09/063A). The lead author's position is supported by ABI Rehabilitation Management, NZ. The authors would also like to thank all those who have supported the study through advertising and referring eligible participants, the research assistants working on the BIONIC study and all participants for taking part. Without their contribution this study would not have been possible.	Anderson CS, 2005, STROKE, V36, P2087, DOI 10.1161/01.STR.0000181079.42690.bf; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bakas T, 1999, NURS RES, V48, P250, DOI 10.1097/00006199-199909000-00005; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Broadbent E, 2006, J PSYCHOSOM RES, V60, P631, DOI 10.1016/j.jpsychores.2005.10.020; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Coen AS, 1996, EVAL PROGRAM PLANN, V19, P309, DOI 10.1016/S0149-7189(96)00024-9; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Feigin V. L., 2007, HDB CLIN NEUROEPIDEM, P197; Fletcher JM, 1990, VARIABILITY OUTCOMES; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; GRIGSBY J, 1992, PERCEPT MOTOR SKILL, V74, P883, DOI 10.2466/PMS.74.3.883-892; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JENNETT B, 1975, LANCET, V1, P480; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; *NZ GUID GROUP, 2005, DIAGN AC MAN REH PEO; Petrie KJ, 2007, CURR OPIN PSYCHIATR, V20, P163, DOI 10.1097/YCO.0b013e328014a871; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Reynolds C. R., 2002, CLIN GUIDE BEHAV ASS; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; *STAT NZ, 2006, NZ CENS 2006; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torner JC, 1996, HEAD INJURY POSTCONC; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Varni JW, 1999, J CLIN OUTCOMES MANA, V6, P33; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WOODCOCK RW, 2001, WOODCOCKJOHNSON III; World Health Organization, 2005, 55 SESS WHO REG COMM; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]	56	45	46	1	13	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350	1423-0208		NEUROEPIDEMIOLOGY	Neuroepidemiology		2012	38	1					18	29		10.1159/000334746			12	Public, Environmental & Occupational Health; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Neurosciences & Neurology	879DI	WOS:000299309500002	22179412	Bronze			2022-02-06	
J	Datta, A; Qian, JR; Khor, TH; Teo, MT; Heese, K; Sze, SK				Datta, Arnab; Qian Jingru; Khor, Tze Hsin; Teo, Muh Tyng; Heese, Klaus; Sze, Siu Kwan			Quantitative Neuroproteomics of an In Vivo Rodent Model of Focal Cerebral Ischemia/Reperfusion Injury Reveals a Temporal Regulation of Novel Pathophysiological Molecular Markers	JOURNAL OF PROTEOME RESEARCH			English	Article						cerebral ischemia; iTRAQ; MCAO model; neuroproteomics; temporal profiling; glutamate excitotoxicity; neuro-inflammation; transferrin; stroke	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; ACUTE ISCHEMIC-STROKE; ARTERY OCCLUSION; GLUTAMATE-DEHYDROGENASE; INTRALUMINAL SUTURE; PROTEOMICS APPROACH; UP-REGULATION; RATS; IDENTIFICATION	Cerebral ischemia or stroke, an acute neurological injury lacking an effective therapy, is the second leading cause of death globally. The unmet need in stroke research is to identify viable targets and to understand their interplay during the temporal evolution of ischemia/reperfusion (I/R) injury. Here we report a temporal signature of the ischemic hemisphere revealed by the isobaric tag for relative and absolute quantification (iTRAQ)-based 2D-LC-MS/MS strategy in an in vivo middle cerebral artery occlusion (MCAO) model of focal cerebral I/R injury. To recapitulate clinical stroke, two hours of MCAO was followed by 0, 4, and 24 h of reperfusion to capture ischemia with an acute and subacute durations of reperfusion injury. The subsequent iTRAQ experiment identified 2242 proteins from the ischemic hemisphere with <1.0% false discovery rate. Data mining revealed that (1) about 2.7% of detected proteins were temporally perturbed having an involvement in the energy metabolism (Pygb, Atp5b), glutamate excitotoxicity (Slc1a3, Glud1), neuro-inflammation (Tf, C3, Alb), and cerebral plasticity (Gfap, Vim, Gap43); (2) astrocytes participated actively in the neurometabolic coupling underlining the importance of a cerebro-protective rather than a neuro-protective approach; and (3) hyper-acute yet progressive opening of the blood brain barrier (BBB), accompanied by stimulation of an innate immune response and late activation of a regenerative response, which provides an extended therapeutic window for intervention. Several regulated proteins (Caskin1, Shank3, Kpnb1, Uchl1, Mtap6, Epb4.1l1, Apba1, and Ube1x) novel in the context of stroke were also discovered. In conclusion, our result supports a dynamic multitarget therapy rather than the traditional approach of a unilateral and sustained modulation of a single target to address the phasic regulation of an ischemic proteome.	[Datta, Arnab; Qian Jingru; Khor, Tze Hsin; Teo, Muh Tyng; Heese, Klaus; Sze, Siu Kwan] Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore		Sze, SK (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	sksze@ntu.edu.sg	Sze, Siu_kwan Newman/A-2199-2011; Datta, Arnab/H-2755-2013; Heese, Klaus/H-3128-2013; Sze, Siu Kwan/AAO-3342-2020	Sze, Siu_kwan Newman/0000-0002-5652-1687; Datta, Arnab/0000-0002-9220-7812; Heese, Klaus/0000-0002-0027-6993; Sze, Siu Kwan/0000-0002-5652-1687	Agency for Science, Technology and Research of SingaporeAgency for Science Technology & Research (ASTAR) [BMRC: 08/1/22/19/575]; Nanyang Technological UniversityNanyang Technological University [AcRF: RG 51/10]	We thank Lokesh Bhatt, Prashant Jamadarkhana, Anookh Mohanan, Salil Kumar Bose, Jung Eun Park, Xin Li, Anindya Basu for the experimental assistance and/or critical reading of the manuscript. The work was supported by grants from the Agency for Science, Technology and Research of Singapore (BMRC: 08/1/22/19/575) and Nanyang Technological University (AcRF: RG 51/10).	AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Altamura C, 2009, STROKE, V40, P1282, DOI 10.1161/STROKEAHA.108.536714; AOKI C, 1987, J NEUROSCI RES, V18, P305, DOI 10.1002/jnr.490180207; Arikkath J, 2009, J NEUROSCI, V29, P5435, DOI 10.1523/JNEUROSCI.0835-09.2009; Arranz AM, 2010, NEUROBIOL DIS, V37, P156, DOI 10.1016/j.nbd.2009.09.019; Bao XD, 2009, J NEUROSCI, V29, P13929, DOI 10.1523/JNEUROSCI.4413-09.2009; Bayes A, 2009, NAT REV NEUROSCI, V10, P635, DOI 10.1038/nrn2701; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 1999, BRAIN RES, V833, P181, DOI 10.1016/S0006-8993(99)01528-0; Bosc C, 2003, BIOCHEMISTRY-US, V42, P12125, DOI 10.1021/bi0352163; Brown AM, 2005, J NEUROSCI RES, V79, P74, DOI 10.1002/jnr.20335; Carmichael S Thomas, 2005, NeuroRx, V2, P396; Chemerinski E, 2006, MT SINAI J MED, V73, P1006; Chen A, 2007, NEUROCHEM INT, V50, P1078, DOI 10.1016/j.neuint.2006.11.008; Chong PK, 2006, J PROTEOME RES, V5, P1232, DOI 10.1021/pr060018u; Cid C, 2007, PROTEOMICS, V7, P3207, DOI 10.1002/pmic.200700214; Datta A, 2010, J PROTEOME RES, V9, P472, DOI 10.1021/pr900829h; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; Dhodda VK, 2004, J NEUROCHEM, V89, P73, DOI 10.1111/j.1471-4159.2004.02316.x; Dittmar M, 2003, STROKE, V34, P2252, DOI 10.1161/01.STR.0000083625.54851.9A; Dominguez C, 2010, STROKE, V41, P653, DOI 10.1161/STROKEAHA.109.571935; Duan SM, 1999, J NEUROSCI, V19, P10193; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Foley LM, 2010, TRANSL STROKE RES, V1, P220, DOI 10.1007/s12975-010-0032-6; Gong YS, 2009, BRAIN RES, V1292, P191, DOI 10.1016/j.brainres.2009.07.056; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Horonchik L, 2008, CHEM BIOL, V15, P647, DOI 10.1016/j.chembiol.2008.05.011; Huang PY, 2009, J NEUROL, V256, P625, DOI 10.1007/s00415-009-0133-x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ishii T, 2010, BRAIN RES, V1321, P164, DOI 10.1016/j.brainres.2010.01.039; Joshi CN, 2004, BRAIN RES PROTOC, V13, P11, DOI 10.1016/j.brainresprot.2003.12.001; Kersey PJ, 2004, PROTEOMICS, V4, P1985, DOI 10.1002/pmic.200300721; Koh PO, 2010, J VET MED SCI, V72, P181, DOI 10.1292/jvms.09-0364; Leiser SF, 2010, MOL CELL, V38, P779, DOI 10.1016/j.molcel.2010.06.015; Li FH, 1999, STROKE, V30, P2464, DOI 10.1161/01.STR.30.11.2464; LIPTON P, 1989, J NEUROSCI METH, V28, P147, DOI 10.1016/0165-0270(89)90019-8; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lo EH, 2005, STROKE, V36, P189, DOI 10.1161/01.STR.0000153069.96296.fd; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Magistretti PJ, 2009, AM J CLIN NUTR, V90, p875S, DOI 10.3945/ajcn.2009.27462CC; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Nagaraja TN, 2008, MICROCIRCULATION, V15, P1, DOI 10.1080/10739680701409811; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pendlebury ST, 2009, MATURITAS, V64, P165, DOI 10.1016/j.maturitas.2009.09.010; Prajapati KD, 2010, BRAIN RES, V1327, P118, DOI 10.1016/j.brainres.2010.02.063; Schroeder JM, 2003, AM J PHYSIOL-RENAL, V285, pF258, DOI 10.1152/ajprenal.00422.2002; Sung JH, 2009, J PINEAL RES, V46, P300, DOI 10.1111/j.1600-079X.2008.00661.x; Swistowski A, 2009, J NEUROSCI, V29, P15703, DOI 10.1523/JNEUROSCI.4351-09.2009; Tabuchi K, 2002, J NEUROSCI, V22, P4264, DOI 10.1523/JNEUROSCI.22-11-04264.2002; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Vaslin A, 2009, ANN NEUROL, V65, P337, DOI 10.1002/ana.21584; Wang XY, 2003, MOL NEUROBIOL, V28, P229, DOI 10.1385/MN:28:3:229; Wardlaw JM, 2010, J INTERN MED, V267, P172, DOI 10.1111/j.1365-2796.2009.02200.x; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weinstein PR, 2004, STROKE, V35, P2666, DOI 10.1161/01.STR.0000144052.10644.ed; Whiteley W, 2009, STROKE, V40, pE380, DOI 10.1161/STROKEAHA.108.528752; YAMADA K, 1994, ACTA NEUROPATHOL, V88, P553; Yamamoto H, 2007, MOL ENDOCRINOL, V21, P1745, DOI 10.1210/me.2007-0079; Zaleska MM, 2009, NEUROPHARMACOLOGY, V56, P329, DOI 10.1016/j.neuropharm.2008.10.006; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4; Zhang XM, 2010, BRAIN RES, V1343, P143, DOI 10.1016/j.brainres.2010.04.027; Zhang ZJ, 2009, NEUROCHEM INT, V54, P488, DOI 10.1016/j.neuint.2009.02.005	69	45	45	0	15	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	NOV	2011	10	11					5199	5213		10.1021/pr200673y			15	Biochemical Research Methods	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840CA	WOS:000296414700028	21950801	Green Accepted			2022-02-06	
J	Cope, EC; Morris, DR; Scrimgeour, AG; VanLandingham, JW; Levenson, CW				Cope, Elise C.; Morris, Deborah R.; Scrimgeour, Angus G.; VanLandingham, Jacob W.; Levenson, Cathy W.			Zinc supplementation provides behavioral resiliency in a rat model of traumatic brain injury	PHYSIOLOGY & BEHAVIOR			English	Article						Zinc; TBI; Depression; Anxiety; Anhedonia; Spatial memory	LOWER SERUM ZINC; MAJOR DEPRESSION; DEFICIENCY; CHELATION; MEMORY	Depression, anxiety, and impairments in learning and memory are all associated with traumatic brain injury (TBI). Because of the strong link between zinc deficiency, depression, and anxiety, in both humans and rodent models, we hypothesized that dietary zinc supplementation prior to injury could provide behavioral resiliency to lessen the severity of these outcomes after TBI. Rats were fed a marginal zinc deficient (5 ppm), zinc adequate (30 ppm), or zinc supplemented (180 ppm) diet for 4 weeks followed by a moderately-severe TBI using the well-established model of controlled cortical impact (CCI). Following CCI, rats displayed depression-like behaviors as measured by the 2-bottle saccharin preference test for anhedonia. Injury also resulted in evidence of stress and impairments in Morris water maze (MWM) performance compared to sham-injured controls. While moderate zinc deficiency did not worsen outcomes following TBI, rats that were fed the zinc supplemented diet for 4 weeks showed significantly attenuated increases in adrenal weight (p < 0.05) as well as reduced depression-like behaviors (p < 0.001). Supplementation prior to injury improved resilience such that there was not only significant improvements in cognitive behavior compared to injured rats fed an adequate diet (p < 0.01), there were no significant differences between supplemented and sham-operated rats in MWM performance at any point in the 10-day trial. These data suggest a role for supplemental zinc in preventing cognitive and behavioral deficits associated with TBI. (C) 2011 Elsevier Inc. All rights reserved.	[Cope, Elise C.; Morris, Deborah R.; VanLandingham, Jacob W.; Levenson, Cathy W.] Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA; [VanLandingham, Jacob W.; Levenson, Cathy W.] Florida State Univ, Coll Med, Program Neurosci, Tallahassee, FL 32306 USA; [Scrimgeour, Angus G.] USA, Environm Med Res Inst, Mil Nutr Div, Natick, MA USA		Levenson, CW (corresponding author), Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA.	cathy.levenson@med.fsu.edu		Cope, Elise/0000-0001-6239-690X; Levenson, Cathy W/0000-0003-4463-3136	U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM081382] Funding Source: NIH RePORTER	The authors would like to thank Dr. Vincent Salters at the National High Magnetic Field Laboratory (Tallahassee, FL) for his assistance with the brain zinc measurements, Shannon Gower-Winter, MS for excellent technical and editorial assistance, and the U.S. Army Medical Research and Material Command who funded this work.	Boroujeni ST, 2009, BIOL TRACE ELEM RES, V130, P48, DOI 10.1007/s12011-008-8312-7; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Chu Y, 2003, PHYSIOL BEHAV, V78, P569, DOI 10.1016/S0031-9384(03)00041-6; Cope EC, 2010, CURR OPIN CLIN NUTR, V13, P685, DOI 10.1097/MCO.0b013e32833df61a; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Hellmich HL, 2008, NEUROSCI LETT, V440, P155, DOI 10.1016/j.neulet.2008.05.068; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; IOM, 2006, MIN REQ MIL PERS LEV; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; MAES M, 1994, J AFFECT DISORDERS, V31, P135, DOI 10.1016/0165-0327(94)90117-1; Maes M, 1999, J AFFECT DISORDERS, V56, P189, DOI 10.1016/S0165-0327(99)00011-7; Maes M, 1997, BIOL PSYCHIAT, V42, P349, DOI 10.1016/S0006-3223(96)00365-4; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Rich NJ, 2010, J NEUROSCI RES, V88, P2933, DOI 10.1002/jnr.22443; Salters VJM, 2010, CHEM GEOL, V273, P151, DOI 10.1016/j.chemgeo.2010.02.010; Siwek M, 2009, J AFFECT DISORDERS, V118, P187, DOI 10.1016/j.jad.2009.02.014; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Takeda A, 2007, BEHAV BRAIN RES, V177, P1, DOI 10.1016/j.bbr.2006.11.023; Tassabehji NM, 2008, PHYSIOL BEHAV, V95, P365, DOI 10.1016/j.physbeh.2008.06.017; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Yeiser EC, 2002, NUTR NEUROSCI, V5, P345, DOI 10.1080/1028415021000033811; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25	25	45	48	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	OCT 24	2011	104	5					942	947		10.1016/j.physbeh.2011.06.007			6	Psychology, Biological; Behavioral Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Behavioral Sciences	837MP	WOS:000296208200040	21699908	Green Accepted			2022-02-06	
J	Eckner, JT; Sabin, M; Kutcher, JS; Broglio, SP				Eckner, James T.; Sabin, Matthew; Kutcher, Jeffrey S.; Broglio, Steven P.			No Evidence for a Cumulative Impact Effect on Concussion Injury Threshold	JOURNAL OF NEUROTRAUMA			English	Article						acceleration; biomechanics; concussion; helmet; injury tolerance	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; HEAD IMPACTS; SPORTS; STATEMENT; MAGNITUDE; SEVERITY; LOCATION; HOCKEY	Recent studies using a helmet-based accelerometer system (Head Impact Telemetry System [HITS]) have demonstrated that concussions result from a wide range of head impact magnitudes. Variability in concussion thresholds has been proposed to result from the cumulative effect of non-concussive head impacts prior to injury. We used the HITS to collect biomechanical data representing > 100,000 head impacts in 95 high school football players over 4 years. The cumulative impact histories prior to 20 concussive impacts in 19 athletes were compared to the cumulative impact histories prior to the three largest magnitude non-concussive head impacts in the same athletes. No differences were present in any impact history variable between the concussive and non-concussive high magnitude impacts. These analyses included the number of head impacts, cumulative HIT severity profile value, cumulative linear acceleration, and cumulative rotational acceleration during the same practice or game session, as well as over the 30 min and 1 week preceding these impacts. Our data do not support the proposal that impact volume or intensity influence concussion threshold in high school football athletes.	[Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Neurotrauma Res Lab, Ann Arbor, MI 48109 USA; [Eckner, James T.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; [Sabin, Matthew] Eastern Kentucky Univ, Dept Exercise & Sport Sci, Richmond, KY 40475 USA		Broglio, SP (corresponding author), Univ Michigan, Sch Kinesiol, Neurotrauma Res Lab, 1402 Washington Hts, Ann Arbor, MI 48109 USA.	broglio@umich.edu			Unity Rockets football team (Tolono, IL); Rehabilitation Medicine Scientist Training Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	We thank Scott Hamilton and the Unity Rockets football team (Tolono, IL), John Storsved, and Susan Mantel, all of whose support made this project possible. We also thank James A. Ashton-Miller and James K. Richardson for their advice regarding our data analysis. Dr. Eckner also thanks the Rehabilitation Medicine Scientist Training Program for its support of his research.	Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Giza CC, 2001, J ATHL TRAINING, V36, P228; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Gwin J. T., 2009, J ASTM INT, V6, P1; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	25	45	45	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2079	2090		10.1089/neu.2011.1910			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500009	21815783	Green Published, Green Submitted			2022-02-06	
J	Readnower, RD; Pandya, JD; McEwen, ML; Pauly, JR; Springer, JE; Sullivan, PG				Readnower, Ryan D.; Pandya, Jignesh D.; McEwen, Melanie L.; Pauly, James R.; Springer, Joseph E.; Sullivan, Patrick G.			Post-Injury Administration of the Mitochondrial Permeability Transition Pore Inhibitor, NIM811, Is Neuroprotective and Improves Cognition after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; mitochondria; neurodegeneration; neuroprotection; TBI	SPINAL-CORD CONTUSION; CYCLOSPORINE-A ANALOG; CELL-DEATH; OXIDATIVE DAMAGE; SYNAPTIC MITOCHONDRIA; FREE-RADICALS; MOUSE MODEL; DYSFUNCTION; MEMBRANE; TISSUE	Mitochondrial dysfunction is known to play a pivotal role in cell death mechanisms following traumatic brain injury (TBI). N-methyl-4-isoleucine-cyclosporin (NIM811), a non-immunosuppressive cyclosporin A (CsA) analog, inhibits the mitochondrial permeability transition pore (mPTP) and has been shown to be neuroprotective following TBI in mice. However, the translation of the neuroprotective effects of mPTP inhibitors, including CsA and NIM811, into improved cognitive end points has yet to be fully investigated. Therefore, to build upon these results, a severe unilateral controlled cortical impact model of TBI was used in the present study to establish a dose-response curve for NIM811 in rats. The findings demonstrate that the neuroprotection afforded by NIM811 is dose dependent, with the 10 mg/kg dose being the most effective dose. Once the dose response was established, we evaluated the effect of the optimal dose of NIM811 on behavior, mitochondrial bioenergetics, and mitochondrial oxidative damage following TBI. For behavioral studies, rats were administered NIM811 at 15 min and 24 h post-injury, with cognitive testing beginning 10 days post-injury. Mitochondrial studies involved a single injection of NIM811 at 15 min post-injury followed by mitochondrial isolation at 6 h post-injury. The results revealed that the optimal dose of NIM811 improves cognition, improves mitochondrial functioning, and reduces oxidative damage following TBI.	[Sullivan, Patrick G.] Univ Kentucky, Chandler Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Readnower, Ryan D.; McEwen, Melanie L.; Springer, Joseph E.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [McEwen, Melanie L.; Springer, Joseph E.] Univ Kentucky, Dept Phys Med & Rehabil, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA		Sullivan, PG (corresponding author), Univ Kentucky, Chandler Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 South Limestone,BBSRB 475, Lexington, KY 40536 USA.	patsull@email.uky.edu	springer, joe/B-2581-2014	springer, joe/0000-0001-9611-8107	National Institutes of Health, United States Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [R01 NS48191, R01 NS062993, P30 NS051220, T32 DA022738]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062993, P30NS051220, R01NS048191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health, United States Public Health Service grants R01 NS48191 (P.G.S.), R01 NS062993 (J.W.G, P.G.S.), P30 NS051220 (E.D.H), T32 DA022738 (E.D.H), and funding from the Kentucky Spinal Cord and Head Injury Research Trust.	Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Andreeva L, 1999, INT J EXP PATHOL, V80, P305, DOI 10.1046/j.1365-2613.1999.00128.x; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cook AM, 2009, EXPERT OPIN DRUG SAF, V8, P411, DOI 10.1517/14740330903066742; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Giacomello M, 2007, CELL DEATH DIFFER, V14, P1267, DOI 10.1038/sj.cdd.4402147; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hansson MJ, 2008, FREE RADICAL BIO MED, V45, P284, DOI 10.1016/j.freeradbiomed.2008.04.021; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Jordan J, 2003, J PHYSIOL BIOCHEM, V59, P129, DOI 10.1007/BF03179878; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Komary Z, 2010, BBA-BIOENERGETICS, V1797, P922, DOI 10.1016/j.bbabio.2010.03.010; Korde AS, 2007, J NEUROTRAUM, V24, P895, DOI 10.1089/neu.2006.0122; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141, DOI 10.1152/ajpcell.1995.269.1.C141; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; Ravikumar R, 2007, J NEUROTRAUM, V24, P1618, DOI 10.1089/neu.2007.0329; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Redell JB, 2007, J NEUROSCI RES, V85, P1980, DOI 10.1002/jnr.21324; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	61	45	49	0	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1845	1853		10.1089/neu.2011.1755			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000015	21875332	Green Published			2022-02-06	
J	Werman, HA; Erskine, T; Caterino, J; Riebe, JF; Valasek, T				Werman, Howard A.; Erskine, Timothy; Caterino, Jeffrey; Riebe, Jane F.; Valasek, Tricia		State Ohio EMS Board	Development of Statewide Geriatric Patients Trauma Triage Criteria	PREHOSPITAL AND DISASTER MEDICINE			English	Article						emergency medical services; geriatric; Ohio; trauma; trauma center; trauma registry		Introduction: The geriatric population is unique in the type of traumatic injuries sustained, physiological responses to those injuries, and an overall higher mortality when compared to younger adults. No published, evidence-based, geriatric-specific field destination criteria exist as part of a statewide trauma system. The Trauma Committee of the Ohio Emergency Medical Services (EMS) Board sought to develop specific criteria for geriatric trauma victims. Methods: A literature search was conducted for all relevant literature to determine potential, geriatric-specific, field-destination criteria. Data from the Ohio Trauma Registry were used to compare elderly patients, defined as age >70 years, to all patients between the ages of 16 to 69 years with regards to mortality risk in the following areas: (1) Glasgow Coma Scale (GCS) score; (2) systolic blood pressure (SBP); (3) falls associated with head, chest, abdominal or spinal injury; (4) mechanism of injury; (5) involvement of more than one body system as defined in the Barell matrix; and (6) co-morbidities and motor vehicle collision with one or more long bone fracture. For GCS score and SBP, those cut-off points with equal or greater risk of mortality as compared to current values were chosen as proposed triage criteria. For other measures, any criterion demonstrating a statistically significant increase in mortality risk was included in the proposed criteria. Results: The following criteria were identified as geriatric-specific criteria: (1) GCS score <14 in the presence of known or suspected traumatic brain trauma; (2) SBP < 100 mmHg; (3) fall from any height with evidence of traumatic brain injury: (4) multiple body-system injuries; (5) struck by a moving vehicle; and (6) the presence of any proximal long bone fracture following motor vehicle trauma. In addition, these data suggested that elderly patients with specific co-morbidities be given strong consideration for evaluation in a trauma center. Conclusions: The state of Ohio is the first state to develop evidence-based geriatric-specific field-destination criteria using data from its state-mandated trauma registry. Further analysis of these criteria will help determine their effects on over-triage and under-triage of geriatric victims of traumatic injuries and the impact on the overall mortality in the elderly.	[Werman, Howard A.; Caterino, Jeffrey] Ohio State Univ, Columbus, OH 43210 USA; [Erskine, Timothy] Ohio Dept Publ Safety, Columbus, OH 43223 USA; [Riebe, Jane F.] Hosp Council Northwest Ohio, Toledo, OH USA; [Valasek, Tricia] Natl Assoc Local Boards Hlth, Bowling Green, OH USA		Erskine, T (corresponding author), Ohio Dept Publ Safety, EMS Div, 1970 West Broad St, Columbus, OH 43223 USA.	terskine@dps.state.oh.us					[Anonymous], 2007, COMMUNICATION; Baez AA, 2003, J TRAUMA, V54, P344, DOI 10.1097/01.TA.0000046258.81127.E1; Ballentine NH, 2008, CRIT CARE NURS Q, V31, P40, DOI 10.1097/01.CNQ.0000306395.86905.8b; Caterino JM, 2010, AM J EMERG MED, V28, P151, DOI 10.1016/j.ajem.2008.10.027; CDC. National Center for Health Statistics, BAR INJ DIAGN MATR C; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; Chang DC, 2008, ARCH SURG-CHICAGO, V143, P776, DOI 10.1001/archsurg.143.8.776; CLARK DE, NATL TRAUMA DATA BAN; Cushman JT, 2009, PREHOSP EMERG CARE, V13, P117; Demetriades D, 2001, J TRAUMA, V51, P754, DOI 10.1097/00005373-200110000-00022; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; Fulton Maryann M, 2005, J Am Acad Nurse Pract, V17, P123, DOI 10.1111/j.1041-2972.2005.0020.x; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; Helling TS, 1999, J TRAUMA, V46, P453, DOI 10.1097/00005373-199903000-00019; Jacobs DG, 2003, J TRAUMA, V54, P391, DOI 10.1097/01.TA.0000042015.54022.BE; LONNER JH, 1995, CLIN ORTHOP RELAT R, P136; Ma MHM, 1999, J TRAUMA, V46, P168; McGwin G, 2004, J TRAUMA, V56, P1291, DOI 10.1097/01.TA.0000089354.02065.D0; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; MUELLER MS, 1976, SOC SECUR BULL, V39, P18; Mullins RJ, 1998, JAMA-J AM MED ASSOC, V279, P1727, DOI 10.1001/jama.279.21.1727; National Diabetes Statistics, 2007 NAT DIAB INF CL, P1; Ohio Department of Public Safety, 2004, OH TRAUM REG DICT 20; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Phillips S, 1996, J TRAUMA, V40, P278, DOI 10.1097/00005373-199602000-00018; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Scheetz Linda J, 2003, J Emerg Nurs, V29, P109, DOI 10.1067/men.2003.59; SMITH DP, 1990, SOUTHERN MED J, V83, P171, DOI 10.1097/00007611-199002000-00010; Sugimoto K, 1999, Prehosp Disaster Med, V14, P186; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; US Centers for Disease Control and Prevention (CDC), 2003, 10 LEAD CAUS INJ DEA; Victorino GP, 2003, ARCH SURG-CHICAGO, V138, P1093, DOI 10.1001/archsurg.138.10.1093; Zautcke JL, 2002, AM J EMERG MED, V20, P14, DOI 10.1053/ajem.2002.30107; ZIMMERGEMBECK MJ, 1995, J TRAUMA, V39, P922, DOI 10.1097/00005373-199511000-00017	38	45	45	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1049-023X	1945-1938		PREHOSP DISASTER MED	Prehospital Disaster Med.	JUN	2011	26	3					170	179		10.1017/S1049023X11006315			10	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	VG0ZV	WOS:000445115900008	22107767				2022-02-06	
J	Goforth, PB; Ren, JH; Schwartz, BS; Satin, LS				Goforth, Paulette B.; Ren, Jianhua; Schwartz, Benjamin S.; Satin, Leslie S.			Excitatory synaptic transmission and network activity are depressed following mechanical injury in cortical neurons	JOURNAL OF NEUROPHYSIOLOGY			English	Article						traumatic brain injury; alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors; N-methyl-D-aspartate; oscillations	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; CA2+-PERMEABLE AMPA RECEPTORS; FLUID PERCUSSION INJURY; IMPROVES FUNCTIONAL RECOVERY; STRETCH-INDUCED ENHANCEMENT; D-ASPARTATE RECEPTORS; V PYRAMIDAL NEURONS; CLOSED-HEAD INJURY; IN-VITRO	Goforth PB, Ren J, Schwartz BS, Satin LS. Excitatory synaptic transmission and network activity are depressed following mechanical injury in cortical neurons. J Neurophysiol 105: 2350-2363, 2011. First published February 23, 2011; doi:10.1152/jn.00467.2010.-In vitro and in vivo traumatic brain injury (TBI) alter the function and expression of glutamate receptors, yet the combined effect of these alterations on cortical excitatory synaptic transmission is unclear. We examined the effect of in vitro mechanical injury on excitatory synaptic function in cultured cortical neurons by assaying synaptically driven intracellular free calcium ([ Ca(2+)](i)) oscillations in small neuronal networks as well as spontaneous and miniature excitatory postsynaptic currents (mEPSCs). We show that injury decreased the incidence and frequency of spontaneous neuronal [Ca(2+)](i) oscillations for at least 2 days post-injury. The amplitude of the oscillations was reduced immediately and 2 days post-injury, although a transient rebound at 4 h post-injury was observed due to increased activity of N-methyl-D-aspartate (NMDARs) and calcium-permeable alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (CP-AMPARs). Increased CP-AMPAR function was abolished by the inhibition of protein synthesis. In parallel, mEPSC amplitude decreased immediately, 4 h, and 2 days post-injury, with a transient increase in the contribution of synaptic CP-AMPARs observed at 4 h post-injury. Decreased mEPSC amplitude was evident after injury, even if NMDARs and CP-AMPARs were blocked pharmacologically, suggesting the decrease reflected alterations in synaptic Glur2-containing, calcium-impermeable AMPARs. Despite the transient increase in CP-AMPAR activity that we observed, the overriding effect of mechanical injury was long-term depression of excitatory neurotransmission that would be expected to contribute to the cognitive deficits of TBI.	[Satin, Leslie S.] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48105 USA		Satin, LS (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1000 Wall St, Ann Arbor, MI 48105 USA.	lsatin@umich.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS49519]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049519] Funding Source: NIH RePORTER	This work was supported by RO1 NS49519 from the National Institutes of Health (to L. Satin).	Ashman TA, 2006, MT SINAI J MED, V73, P999; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Calderone A, 2003, J NEUROSCI, V23, P2112; Chung HJ, 2003, SCIENCE, V300, P1751, DOI 10.1126/science.1082915; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; Cull-Candy S, 2006, CURR OPIN NEUROBIOL, V16, P288, DOI 10.1016/j.conb.2006.05.012; Cull-Candy Stuart G, 2004, Sci STKE, V2004, pre16, DOI 10.1126/stke.2552004re16; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Grosskreutz J, 2003, EUR J NEUROSCI, V17, P1173, DOI 10.1046/j.1460-9568.2003.02531.x; Guire ES, 2008, J NEUROSCI, V28, P6000, DOI 10.1523/JNEUROSCI.0384-08.2008; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Jones TL, 2004, J PHARMACOL EXP THER, V310, P223, DOI 10.1124/jpet.103.064741; Ju W, 2004, NAT NEUROSCI, V7, P244, DOI 10.1038/nn1189; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Koike M, 1997, NEUROSCI RES, V29, P27, DOI 10.1016/S0168-0102(97)00067-9; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Kurz JE, 2005, BRAIN RES, V1048, P153, DOI 10.1016/j.brainres.2005.04.062; Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004; Lea PM, 2003, J NEUROTRAUM, V20, P1233, DOI 10.1089/089771503770802907; Lea PM, 2002, PHARMACOL BIOCHEM BE, V73, P287, DOI 10.1016/S0091-3057(02)00825-0; Li G, 2003, BIOCHEMISTRY-US, V42, P12358, DOI 10.1021/bi0347961; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Liu SJ, 2007, TRENDS NEUROSCI, V30, P126, DOI 10.1016/j.tins.2007.01.006; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MURPHY TH, 1992, J NEUROSCI, V12, P4834; Nakanishi K, 1998, BRAIN RES, V795, P137, DOI 10.1016/S0006-8993(98)00283-2; Oh MC, 2005, NAT NEUROSCI, V8, P853, DOI 10.1038/nn1476; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B; REEVES TM, 1995, EXP BRAIN RES, V106, P248; ROBINSON HPC, 1993, J NEUROPHYSIOL, V70, P1606, DOI 10.1152/jn.1993.70.4.1606; Rogawski M A, 1999, Adv Neurol, V79, P947; Salin P, 1995, J NEUROSCI, V15, P8234; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santos SD, 2009, NEUROSCIENCE, V158, P105, DOI 10.1016/j.neuroscience.2008.02.037; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Seidenman KJ, 2003, J NEUROSCI, V23, P9220; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Sutton MA, 2006, CELL, V125, P785, DOI 10.1016/j.cell.2006.03.040; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Takazawa A, 1996, BRAIN RES, V706, P173, DOI 10.1016/0006-8993(95)01334-2; Terashima A, 2008, NEURON, V57, P872, DOI 10.1016/j.neuron.2008.01.028; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Turrigiano GG, 2008, CELL, V135, P422, DOI 10.1016/j.cell.2008.10.008; Vikman KS, 2008, J PHYSIOL-LONDON, V586, P515, DOI 10.1113/jphysiol.2007.145581; Wang XS, 1997, BRAIN RES, V767, P239, DOI 10.1016/S0006-8993(97)00585-4; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	72	45	45	0	11	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	MAY	2011	105	5					2350	2363		10.1152/jn.00467.2010			14	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	765MF	WOS:000290710300036	21346214	Green Published			2022-02-06	
J	Hartholt, KA; van Lieshout, EMM; Polinder, S; Panneman, MJM; van der Cammen, TJM; Patka, P				Hartholt, Klaas A.; van Lieshout, Esther M. M.; Polinder, Suzanne; Panneman, Martien J. M.; van der Cammen, Tischa J. M.; Patka, Peter			Rapid Increase in Hospitalizations Resulting from Fall-Related Traumatic Head Injury in Older Adults in the Netherlands 1986-2008	JOURNAL OF NEUROTRAUMA			English	Article						guidelines; hospitalizations; older adults; time trend; traumatic head injuries	BRAIN-INJURIES; UNITED-STATES; TRENDS; MILD; PREVENTION; GUIDELINES; ADMISSIONS; MANAGEMENT; DISABILITY; PEOPLE	Falls occur frequently in older adults. With ageing populations worldwide, an increase in fall-related traumatic head injuries can be expected. The aim of our study was to determine trends in traumatic head-injury-related hospitalizations among older adults. Therefore, a secular trend analysis of fall-related traumatic head injuries in the older Dutch population between 1986 and 2008 was performed, using the National Hospital Discharge Registry. All significant fall-related traumatic head injury hospitalizations in persons aged >= 65 years were extracted from this database. During the study period, traumatic head-injury-related hospitalizations increased by 213% to 3,010 in 2008. The incidence rate increased annually by 1.2% (95% CI: 0.6; 1.9) between 1986 and 2000. Since 2001, the increase has accelerated up to 11.6% (95% CI: 9.5; 13.8) per year. Overall, the age-adjusted incidence rate increased from 53.1 in 1986 to 119.1 per 100,000 older persons in 2008. Age-specific incidence rates increased in all age groups, especially in persons aged >= 85 years. Despite an overall reduction in the length of hospital stay per admission, the total number of hospital-bed-days increased with 31.5% to 20,250 between 1991 and 2008. In conclusion, numbers and incidence rates of significant traumatic head-injury-related hospitalization after a fall are increasing rapidly in the older Dutch population, especially in the oldest old, resulting in an increased health care demand. The recent increase might be explained by the ageing population, but also other factors may have contributed to the increase, such as an increased awareness of traumatic head injuries, the implementation of renewed guidelines for traumatic head injuries, and improved radiographic tools.	[Hartholt, Klaas A.; van Lieshout, Esther M. M.; Patka, Peter] Univ Med Ctr Rotterdam, Erasmus MC, Dept Surg Traumatol, NL-3000 CA Rotterdam, Netherlands; [Hartholt, Klaas A.; van der Cammen, Tischa J. M.] Univ Med Ctr Rotterdam, Erasmus MC, Geriatr Med Sect, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands; [Polinder, Suzanne] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [Panneman, Martien J. M.] Consumer & Safety Inst, Amsterdam, Netherlands		van Lieshout, EMM (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Surg Traumatol, Room H822k,POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.vanlieshout@erasmusmc.nl	Hartholt, Klaas A/Q-1782-2016	Hartholt, Klaas A/0000-0001-5019-9239	"The Netherlands Organization for Health Research and Development" (ZonMw)Netherlands Organization for Health Research and Development [170.885.607]	Klaas Hartholt is a research fellow at the Erasmus MC, appointed on a research grant from "The Netherlands Organization for Health Research and Development" (ZonMw), project number 170.885.607.	BRUGGINK JW, 2010, NATIONAAL KOMPAS VOL, P3; *COMM HEALTHC IMPR, 2001, GUID DIAGN TREATM PA; Faul M, 2010, TRAUMATIC BRAIN INJU; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; HARTHOLT KA, 2010, J TRAUMA, DOI DOI 10.1097/TA.0B013E3181F6F5E5; Hartholt KA, 2010, ARCH INTERN MED, V170, P905, DOI 10.1001/archinternmed.2010.106; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HOEYMANS N, 2009, NATIONAAL KOMPAS VOL; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Kannus P, 2005, LANCET, V366, P1885, DOI 10.1016/S0140-6736(05)67604-0; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Logan PA, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2102; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MCNEIL DR, 1977, DEMOGRAPHY, V14, P245, DOI 10.2307/2060581; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Scuffham P, 2003, J EPIDEMIOL COMMUN H, V57, P740, DOI 10.1136/jech.57.9.740; Stamatakis E, 2008, BRIT J SPORT MED, V42, P601; Statistics Netherlands, 2009, POP PROGN 1969 2040; Stevens J. A., 2006, Morbidity and Mortality Weekly Report, V55, P1221; Stevens JA, 2005, INJURY PREV, V11, P115, DOI 10.1136/ip.2004.005835; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Stegen RPJ, 2009, DESCRIPTION METHODS; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	28	45	45	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					739	744		10.1089/neu.2010.1488			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100274	21355818	Green Submitted			2022-02-06	
J	Stein, DM; Lindell, A; Murdock, KR; Kufera, JA; Menaker, J; Keledjian, K; Bochicchio, GV; Aarabi, B; Scalea, TM				Stein, Deborah M.; Lindell, Allison; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Keledjian, Kaspar; Bochicchio, Grant V.; Aarabi, Bizhan; Scalea, Thomas M.			Relationship of Serum and Cerebrospinal Fluid Biomarkers With Intracranial Hypertension and Cerebral Hypoperfusion After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Biomarkers; Neuroinflammation; Intracranial hypertension; Cerebral hypoperfusion	TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; FRACTURE FIXATION; SECONDARY INSULTS; PROGNOSTIC VALUE; CARDIAC-ARREST; TNF-ALPHA; PRESSURE; PLASMA; INTERLEUKIN-8	Background: There is little that can be done to treat or reverse the primary injury that occurs at the time of a traumatic brain injury (TBI). Initial management of the patient with severe TBI focuses on prevention of subsequent secondary insults, namely, intracranial hypertension (ICH) and cerebral hypoperfusion (CH). Currently, there is no reliable way to predict which patients will develop ICH and CH other than clinical acumen; therefore, indicators of impending secondary intracranial insults may be useful in predicting these events and allowing for prevention and early intervention. This study was undertaken to investigate the relationship of cytokine levels with intracranial pressure (ICP) and cerebral perfusion pressure (CPP) in patients with severe TBI. Methods: Patients at the R Adams Cowley Shock Trauma Center were prospectively enrolled for a 6-month period. Inclusion criteria were older than 17 years, admission within the first 6 hours after injury, Glasgow Coma Scale <9 on admission, and placement of a clinically indicated ICP monitor. Serum and cerebrospinal fluid, when available, were collected on admission and twice daily for 7 days. Cytokine levels of interleukin (IL)-1 beta, IL-6, IL-8, IL-10, and tumor necrosis factor (TNF)-alpha were analyzed by multiplex bead array assays. Hourly values for ICP and CPP were recorded, and means, minimum (for CPP) or maximum (for ICP) values, percentage time ICP >20 mm Hg (% ICP20) and CPP <60 mm Hg (% CPP60), and cumulative Pressure Times Time Dose (PTD; mm Hg . h) for ICP >20 mm Hg (PTD ICP20) and CPP <60 mm Hg (PTD CPP60) were compared with the serum and cerebrospinal fluid levels that were drawn before 12-hour time periods (PRE) and after 12-hour time periods (POST) of monitoring. Results: Twenty-four patients were enrolled. In-hospital mortality was 12.5%, and good functional outcome was noted in 58%. Two hundred and seventy-five serum samples were taken and analyzed. IL-6 levels in the serum were found in the highest concentration of the cytokines measured. PTD ICP20 and PTD CPP60 were moderately correlated with increased PRE IL-8 levels (r = 0.34, p < 0.001; r = 0.53, p < 0.001). PTD ICP20 was also correlated with PRE TNF-alpha levels (r = 0.27, p < 0.001) as was PTD CPP60 (r = 0.25, p < 0.001). POST IL-8 levels were found to be correlated with PTD ICP20 (r = 0.46, p < 0.001) and PTD CPP60 (r = 0.54, p < 0.001). POST TNF-alpha was associated with PTD ICP20 (r = 0.45, p < 0.001). PTD CPP60 was also moderately correlated with POST TNF-alpha levels (r = 0.26, p < 0.001). When comparing patients with good versus poor outcome, median daily serum IL-8 levels were associated with poor outcome. Conclusions: IL-8 and, to a lesser extent, TNF-alpha demonstrated the most promise in this study to be candidate serum markers of impending ICH and CH. The clinical relevance of this is the suggestion that we may be able to predict impending secondary insults after TBI before the clinical manifestation of these events. Given the known morbidity of ICH and CH, early intervention and prevention may have a significant impact on outcome. This becomes even more important when decisions must be made about timing of interventions. Increased levels of IL-8 and TNF-alpha in the serum during episodes of ICH and CH imply there are significant systemic effects of these events. These serum biomarkers are promising as diagnostic targets. In addition, further study of the precise role of these molecules may have significant implications for inflammatory system manipulation in the management of severe TBI.	[Stein, Deborah M.] Univ Maryland, Div Crit Care, Program Trauma, R Adams Cowley Shock Trauma Ctr,Med Ctr,Sch Med, Baltimore, MD 21201 USA; [Stein, Deborah M.; Lindell, Allison; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Keledjian, Kaspar; Bochicchio, Grant V.; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Organized Res Ctr, Baltimore, MD 21201 USA		Stein, DM (corresponding author), Univ Maryland, Div Crit Care, Program Trauma, R Adams Cowley Shock Trauma Ctr,Med Ctr,Sch Med, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963	US ArmyUnited States Department of Defense [W81XWH-07-2-0118]	Supported by W81XWH-07-2-0118, US Army.	Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bridges E, 2010, AACN ADV CRIT CARE, V21, P260, DOI 10.1097/NCI.0b013e3181e67385; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; CHIARETTI A, 2005, CHILD NERV SYST, V32, P194; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Dziurdzik P, 2004, INFLAMM RES, V53, P338, DOI 10.1007/s00011-004-1265-1; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FaberElman A, 1995, FASEB J, V9, P1605, DOI 10.1096/fasebj.9.15.8529840; FAN L, 1995, MOL BRAIN RES, V30, P125; Flierl MA, 2010, J ORTHOP TRAUMA, V24, P107, DOI 10.1097/BOT.0b013e3181b6bdfc; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Gopcevic A, 2007, TOHOKU J EXP MED, V211, P387, DOI 10.1620/tjem.211.387; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Jawa Randeep S, 2006, J Intensive Care Med, V21, P63, DOI 10.1177/0885066605284325; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; KENNEDY CS, 2004, CLIN PEDIAT EMERG ME, V5, P224; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kraus J, 1996, NEUROTRAUMA, P13; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LOTZ M, 1993, CANCER INVEST, V11, P732, DOI 10.3109/07357909309046948; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scalea TM, 2007, J TRAUMA, V62, P647, DOI 10.1097/TA.0b013e31802ee542; Scalea TM, 2008, J TRAUMA, V65, P253, DOI 10.1097/TA.0b013e31817fa475; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; TCHELINGERIAN JL, 1995, J NEUROCHEM, V65, P2377; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; van der Meer JWM, 1998, ANN NY ACAD SCI, V856, P243; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	69	45	46	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2011	70	5					1096	1103		10.1097/TA.0b013e318216930d			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	762LQ	WOS:000290480300028	21610426				2022-02-06	
J	Hindman, BJ; Palecek, JP; Posner, KL; Traynelis, VC; Lee, LA; Sawin, PD; Tredway, TL; Todd, MM; Domino, KB				Hindman, Bradley J.; Palecek, John P.; Posner, Karen L.; Traynelis, Vincent C.; Lee, Lorri A.; Sawin, Paul D.; Tredway, Trent L.; Todd, Michael M.; Domino, Karen B.			Cervical Spinal Cord, Root, and Bony Spine Injuries A Closed Claims Analysis	ANESTHESIOLOGY			English	Article							POSTERIOR-FOSSA SURGERY; SITTING POSITION; NEUROLOGIC DETERIORATION; ATLANTOAXIAL INSTABILITY; ENDOTRACHEAL INTUBATION; SIPHON CONTROVERSY; AIRWAY MANAGEMENT; MYELOPATHY; ANTERIOR; TETRAPLEGIA	Background: The aim of this study was to characterize cervical cord, root, and bony spine claims in the American Society of Anesthesiologists Closed Claims database to formulate hypotheses regarding mechanisms of injury. Methods: All general anesthesia claims (1970-2007) in the Closed Claims database were searched to identify cervical injuries. Three independent teams, each consisting of an anesthesiologist and neurosurgeon, used a standardized review form to extract data from claim summaries and judge probable contributors to injury. Results: Cervical injury claims (n = 48; mean +/- SD age 47 +/- 15 yr; 73% male) comprised less than 1% of all general anesthesia claims. When compared with other general anesthesia claims (19%), cervical injury claims were more often permanent and disabling (69%; P < 0.001). In addition, cord injuries (n = 37) were more severe than root and/or bony spine injuries (n = 10; P < 0.001), typically resulting in quadriplegia. Although anatomic abnormalities (e.g., cervical stenosis) were often present, cord injuries usually occurred in the absence of traumatic injury (81%) or cervical spine instability (76%). Cord injury occurred with cervical spine (65%) and noncervical spine (35%) procedures. Twenty-four percent of cord injuries were associated with the sitting position. Probable contributors to cord injury included anatomic abnormalities (81%), direct surgical complications (24% [38%, cervical spine procedures]), preprocedural symptomatic cord injury (19%), intraoperative head/neck position (19%), and airway management (11%). Conclusion: Most cervical cord injuries occurred in the absence of traumatic injury, instability, and airway difficulties. Cervical spine procedures and/or sitting procedures appear to predominate. In the absence of instability, cervical spondylosis was the most common factor associated with cord injury.	[Hindman, Bradley J.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Fac Dev, Iowa City, IA USA; [Todd, Michael M.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anesthesia, Iowa City, IA USA; [Palecek, John P.] Iowa Methodist Med Ctr, Des Moines, IA USA; [Posner, Karen L.; Lee, Lorri A.; Domino, Karen B.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA USA; [Tredway, Trent L.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA USA; [Traynelis, Vincent C.] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA; [Sawin, Paul D.] Orlando Neurosurg PA, Winter Pk, FL USA		Hindman, BJ (corresponding author), Univ Iowa Hosp & Clin, Dept Anesthesia, Iowa City, IA 52242 USA.	brad-hindman@uiowa.edu		Hindman, Bradley/0000-0003-2242-7980	American Society of Anesthesiologists (Park Ridge, Illinois); Department of Anesthesia, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City; Medtronic, Inc. (Minneapolis, Minnesota)Medtronic; Globus Medical, Inc. (Audubon, Pennsylvania); Neurosurgery Research and Education Foundation of the American Association of Neurological Surgeons (Rolling Meadows, Illinois)	Received from the Department of Anesthesia, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa, and the Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, Washington. Submitted for publication August 30, 2010. Accepted for publication December 28, 2010. Supported in part by the American Society of Anesthesiologists (Park Ridge, Illinois) and the Department of Anesthesia, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City. Dr. Traynelis has received research and educational grants from Medtronic, Inc. (Minneapolis, Minnesota), Globus Medical, Inc. (Audubon, Pennsylvania), and the Neurosurgery Research and Education Foundation of the American Association of Neurological Surgeons (Rolling Meadows, Illinois) for management of cervical spine disease. He is also a paid consultant for United HealthCare Services, Inc. (Minneapolis, Minnesota) and Medtronic, Inc. In addition, Dr. Traynelis holds the following patents from which he has received patent and/or licensing royalties: U. S. patent 7 727 266, Method and apparatus for retaining screws in a plate; U. S. patent 7 276 082, Artificial spinal discs and associated implantation and revision methods; U. S. patent 7 300 441, Technique and instrumentation for preparation of vertebral members. Dr. Sawin is a paid consultant for NuVasive, Inc. (San Diego, California). Dr. Tredway has received honoraria from Synthes, Inc. (West Chester, Pennsylvania) and Medtronic, Inc., for lecturing on related topics. The remaining authors are not supported by, nor maintain any financial interest in, any commercial activity that may be associated with the topic of this article. Presented in part at the annual Midwest Anesthesia Residents Conference, Saint Louis, Missouri, April 14, 2007, and at the annual meeting of the American Society of Anesthesiologists, San Diego, California, October 18, 2010.	American College of Surgeons Committee on Tauma, 2008, ADV TRAUM LIF SUPP S; Baron EM, 2007, NEUROSURGERY, V60, P35, DOI 10.1227/01.NEU.0000215383.64386.82; BLACK S, 1988, ANESTHESIOLOGY, V69, P49, DOI 10.1097/00000542-198807000-00008; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; Bose Bikash, 2004, Spine J, V4, P202, DOI 10.1016/j.spinee.2003.06.001; Buchowski JM, 2005, SPINE, V30, pE103, DOI 10.1097/01.brs.0000153704.92369.f7; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; Cheney FW, 1999, ANESTHESIOLOGY, V91, P552, DOI 10.1097/00000542-199908000-00030; Crosby ET, 2006, ANESTHESIOLOGY, V104, P1293, DOI 10.1097/00000542-200606000-00026; Drummond JC, 2009, APSF NEWSLETTER, V24, P6; Dunham CM, 2003, J TRAUMA, V55, P162, DOI 10.1097/01.ta.0000083335.93868.2c; Emery SE, 1998, J BONE JOINT SURG AM, V80A, P941, DOI 10.2106/00004623-199807000-00002; Farmer J, 1998, J SPINAL DISORD, V11, P192; FIROOZNIA H, 1985, SURG NEUROL, V23, P165, DOI 10.1016/0090-3019(85)90337-4; Fujioka S, 2003, ANESTH ANALG, V97, P979, DOI 10.1213/01.ANE.0000078585.67412.FE; Gisolf J, 2005, AM J PHYSIOL-REG I, V289, pR627, DOI 10.1152/ajpregu.00709.2004; Haisa T, 1996, NEUROSURGERY, V38, P819, DOI 10.1227/00006123-199604000-00037; HARLEY EH, 1994, ARCH OTOLARYNGOL, V120, P159; HARROP JS, 2007, NEUROSURGERY S, V60, pS1, DOI DOI 10.1227/01.NEU.0000215380.71097.EC; Hashimoto M, 2010, EUR SPINE J, V19, P1702, DOI 10.1007/s00586-010-1427-5; HASTINGS RH, 1993, ANESTHESIOLOGY, V78, P580, DOI 10.1097/00000542-199303000-00022; Hata T, 2005, ANESTHESIOLOGY, V102, P680, DOI 10.1097/00000542-200503000-00030; Hayes AF, 2007, COMMUN METHODS MEAS, V1, P77, DOI 10.1080/19312450709336664; Hicks JW, 2005, AM J PHYSIOL-REG I, V289, pR629, DOI 10.1152/ajpregu.00810.2004; Hilibrand AS, 2004, J BONE JOINT SURG AM, V86A, P1248, DOI 10.2106/00004623-200406000-00018; Hirose Hitoshi, 2005, Ann Thorac Cardiovasc Surg, V11, P270; HITSELBERGER WE, 1980, ARCH OTOLARYNGOL, V106, P69; Houten JK, 2008, J NEUROSURG-SPINE, V9, P237, DOI 10.3171/SPI/2008/9/9/237; HUKUDA S, 1972, J NEUROSURG, V37, P631, DOI 10.3171/jns.1972.37.6.0631; Jones SJ, 2003, J NEUROL NEUROSUR PS, V74, P273, DOI 10.1136/jnnp.74.2.273; Kelleher MO, 2008, J NEUROSURG-SPINE, V8, P215, DOI 10.3171/SPI/2008/8/3/215; Khan MH, 2006, SPINE, V31, pE105, DOI 10.1097/01.brs.0000200163.71909.1f; Koyanagi I, 2000, J NEUROSURG, V93, P15, DOI 10.3171/spi.2000.93.1.0015; KRIPPENDORFF K, 2004, CONTENT ANAL INTRO I, P238; LAROCHE M, 1992, CLIN RHEUMATOL, V11, P533, DOI 10.1007/BF02283114; Lee JY, 2006, SPINE, V31, P1916, DOI 10.1097/01.brs.0000228724.01795.a2; Lee L, 2010, ANESTHESIA PATIENT S, V24, P45; Lee Lorri A, 2002, Anesthesiol Clin North Am, V20, P485; Lee MJ, 2007, J BONE JOINT SURG AM, V89A, P376, DOI 10.2106/JBJS.F.00437; Lewandrowski KU, 2006, SPINE, V31, P1056, DOI 10.1097/01.brs.0000214968.58581.44; Liang BA, 1999, J CLIN ANESTH, V11, P349, DOI 10.1016/S0952-8180(99)00050-1; MATJASKO J, 1985, NEUROSURGERY, V17, P695, DOI 10.1227/00006123-198511000-00001; Matsumoto M, 1998, J BONE JOINT SURG BR, V80B, P19, DOI 10.1302/0301-620X.80B1.7929; McLeod ADM, 2000, BRIT J ANAESTH, V84, P705, DOI 10.1093/bja/84.6.705; MENEZES AH, 1992, PEDIATR NEUROSURG, V18, P24, DOI 10.1159/000120638; Mercieri M, 2009, ANAESTHESIA, V64, P1010, DOI 10.1111/j.1365-2044.2009.05944.x; Morandi X, 2004, NEUROSURGERY, V54, P1512, DOI 10.1227/01.NEU.0000125008.93625.5E; Muckart DJJ, 1997, ANESTHESIOLOGY, V87, P418, DOI 10.1097/00000542-199708000-00029; Muhle C, 1998, INVEST RADIOL, V33, P444, DOI 10.1097/00004424-199808000-00004; Muhle C, 1998, AM J NEURORADIOL, V19, P1763; MUNIS J, 2008, APSF NEWSL, V22, P82; Naja Z, 2005, ANESTH ANALG, V101, P1883, DOI 10.1213/01.ANE.0000180255.62444.7A; Nitta H, 1997, NEUROSURGERY, V40, P1082, DOI 10.1097/00006123-199705000-00039; Nowak DD, 2009, J AM ACAD ORTHOP SUR, V17, P756, DOI 10.5435/00124635-200912000-00004; Okada E, 2009, SPINE, V34, P706, DOI 10.1097/BRS.0b013e31819c2003; PATEL A, 1993, AM HEART J, V126, P184, DOI 10.1016/S0002-8703(07)80027-5; Patil PG, 2005, NEUROSURGERY, V57, P753, DOI 10.1227/01.NEU.0000175729.79119.1d; Pohl A, 2005, J CLIN ANESTH, V17, P463, DOI 10.1016/j.jclinane.2004.09.012; POSNER KL, 1990, STAT MED, V9, P1103, DOI 10.1002/sim.4780090917; Posner KL, 1996, ANESTHESIOLOGY, V85, P1049, DOI 10.1097/00000542-199611000-00013; POWELL JF, 1990, ANAESTHESIA, V45, P1049, DOI 10.1111/j.1365-2044.1990.tb14886.x; Powell R M, 1996, J R Army Med Corps, V142, P79; Rao R, 2002, J BONE JOINT SURG AM, V84A, P1872, DOI 10.2106/00004623-200210000-00021; Redl G, 1998, ANESTHESIOLOGY, V89, P1262, DOI 10.1097/00000542-199811000-00031; Resnick DK, 2009, J NEUROSURG-SPINE, V11, P245, DOI 10.3171/2009.2.SPINE08730; SALATHE M, 1989, ANESTHESIOLOGY, V70, P869, DOI 10.1097/00000542-198905000-00027; Sebastian C, 1997, Eur Spine J, V6, P316, DOI 10.1007/BF01142677; Shamji MF, 2008, J NEUROSURG-SPINE, V9, P10, DOI 10.3171/SPI/2008/9/7/010; Shedid D, 2007, NEUROSURGERY, V60, P7, DOI 10.1227/01.NEU.0000215430.86569.C4; Smith PN, 2007, SPINE J, V7, P83, DOI 10.1016/j.spinee.2006.04.008; Sung RD, 2001, SPINE, V26, P67, DOI 10.1097/00007632-200101010-00013; Taunt CJ, 2005, SPINE, V30, P1970, DOI 10.1097/01.brs.0000176321.02963.72; TERESI LM, 1987, RADIOLOGY, V164, P83, DOI 10.1148/radiology.164.1.3588931; Tsirikos AI, 2004, J SPINAL DISORD TECH, V17, P385, DOI 10.1097/01.bsd.0000095825.98982.1a; Wang MC, 2007, SPINE, V32, P342, DOI 10.1097/01.brs.0000254120.25411.ae; Westerveld LA, 2009, EUR SPINE J, V18, P145, DOI 10.1007/s00586-008-0764-0; WILDER BL, 1982, NEUROSURGERY, V11, P530; Woodward LJ, 2009, ANAESTHESIA, V64, P540, DOI 10.1111/j.1365-2044.2008.05794.x; YASZEMSKI MJ, 1990, SPINE, V15, P338, DOI 10.1097/00007632-199004000-00017; YOUNG ML, 1986, NEUROSURGERY, V18, P157, DOI 10.1227/00006123-198602000-00007; Zeidman SM, 1997, J SPINAL DISORD, V10, P523	81	45	47	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2011	114	4					782	795		10.1097/ALN.0b013e3182104859			14	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	739DT	WOS:000288694400009	21326090	Bronze			2022-02-06	
J	Vakili, A; Mojarrad, S; Akhavan, MM; Rashidy-Pour, A				Vakili, Abedin; Mojarrad, Somye; Akhavan, Maziar Mohammad; Rashidy-Pour, Ali			Pentoxifylline attenuates TNF-alpha protein levels and brain edema following temporary focal cerebral ischemia in rats	BRAIN RESEARCH			English	Article						Pentoxifylline; Focal cerebral ischemia; Blood-brain barrier permeability; Brain edema; TNF-alpha; Rat	TUMOR-NECROSIS-FACTOR; SPONTANEOUSLY HYPERTENSIVE-RATS; CLOSED-HEAD INJURY; BARRIER PERMEABILITY; BLOOD-FLOW; ARTERY OCCLUSION; TRANSIENT MODEL; INFARCT VOLUME; MACROPHAGES; INHIBITION	Cerebral edema is the most common cause of neurological deterioration and mortality during acute ischemic stroke. Despite the clinical importance of cerebral ischemia, the underlying mechanisms remain poorly understood. Recent studies suggest a role for TNF-alpha in the brain edema formation. To further investigate whether TNF-alpha would play a role in brain edema formation, we examined the effects of pentoxifylline (PTX, an inhibitor of TNF-alpha synthesis) on the brain edema and TNF-alpha levels in a model of transient focal cerebral ischemia. The right middle cerebral artery (MCA) of rats was occluded for 60 min using the intraluminal filament method. The animals received PTX (60 mg/kg) immediately, 1, 3, or 6 h post-ischemic induction. Twenty-four hours after induction of ischemic injury, permeability of the blood-brain barrier (BBB) and brain edema were determined by in situ brain perfusion of Evans Blue (EB) and wet-to-dry weight ratio, respectively. TNF-alpha protein levels in ischemic cortex were also measured at 1, 4, and 24 h after the beginning of an ischemic stroke by using an enzyme-linked immunosorbent assay method. The administration of PTX up to 6 h after occlusion of the MCA significantly reduced the brain edema. Moreover, PTX significantly reduced the concentration of TNF-alpha in ischemic brain cortex up to 4 h post-transient focal stroke (P<0.002). Finally, treatment by PTX led to a significant decrease in EB extravasations (P<0.001). Our data demonstrate that PTX administration up to 6 h after ischemia can reduce brain edema in a model of transient focal cerebral ischemia. The beneficial effects of PTX may be mediated, at least in part, through a decline in TNF-alpha production and BBB breakdown. (C) 2011 Elsevier B.V. All rights reserved.	[Vakili, Abedin; Mojarrad, Somye] Semnan Univ Med Sci, Sch Med, Lab Cerebrovasc Res, Dept Physiol, Semnan, Iran; [Akhavan, Maziar Mohammad] Shahid Beheshti Univ MC, Shohadae Tajrish Hosp, Skin Res Ctr, Lab Prot & Enzyme, Tehran 1989934148, Iran; [Rashidy-Pour, Ali] Semnan Univ Med Sci, Res Ctr Physiol, Lab Learning & Memory, Semnan, Iran; [Rashidy-Pour, Ali] Semnan Univ Med Sci, Dept Physiol, Lab Learning & Memory, Semnan, Iran; [Vakili, Abedin; Mojarrad, Somye] Semnan Univ Med Sci, Sch Med, Lab Cerebrovasc Res, Res Ctr Physiol, Semnan, Iran		Vakili, A (corresponding author), Semnan Univ Med Sci, Sch Med, Lab Cerebrovasc Res, Dept Physiol, Semnan, Iran.	Abvakili@yahoo.com	Rashidy-Pour, Ali/B-5696-2018; Vakili, Abedin/G-7934-2017	Rashidy-Pour, Ali/0000-0001-5006-1408; Vakili, Abedin/0000-0002-4269-9978	Semnan University of Medical Sciences, Semnan, Iran [243]	This work was financially supported (Grant No. 243) by Semnan University of Medical Sciences, Semnan, Iran. We would like to thank Dr. P. Kokhaei for his critical reading of the manuscript.	Bemeur C, 2010, NEUROCHEM INT, V56, P213, DOI 10.1016/j.neuint.2009.11.010; Bhat VB, 2001, BIOCHEM BIOPH RES CO, V288, P1212, DOI 10.1006/bbrc.2001.5922; BOWTON DL, 1989, STROKE, V20, P1662, DOI 10.1161/01.STR.20.12.1662; FUJIMOTO K, 1976, CHEM PHARM BULL, V24, P1137; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Harada H, 2005, BRAIN RES PROTOC, V14, P165, DOI 10.1016/j.brainresprot.2004.12.007; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Hoie EB, 2004, BIOL PHARM BULL, V27, P1670, DOI 10.1248/bpb.27.1670; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Jacoby D, 2004, DRUGS, V64, P1657, DOI 10.2165/00003495-200464150-00004; JOHANSSON BB, 1989, ACTA NEUROL SCAND, V80, P259, DOI 10.1111/j.1600-0404.1989.tb03872.x; JOHANSSON BB, 1986, STROKE, V17, P744, DOI 10.1161/01.STR.17.4.744; KAMBAYASHI T, 1995, J IMMUNOL, V155, P4909; Kimura H, 2003, BRAIN RES, V990, P148, DOI 10.1016/S0006-8993(03)03450-4; Kondo T, 1997, J NEUROSCI, V17, P4180; KUCUK M, 2002, LIFE SCI, V12, P496; LAUTERBACH R, 1995, BIOL NEONATE, V67, P72; Lecrux C, 2007, STROKE, V38, P3007, DOI 10.1161/STROKEAHA.107.491126; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Maddahi A, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-14; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Marcinkiewicz J, 2000, IMMUNOPHARMACOLOGY, V49, P335, DOI 10.1016/S0162-3109(00)00249-6; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; NATAF S, 1993, ACTA NEUROL SCAND, V88, P97; Nekooeian AA, 2005, IRAN J MED SCI, V30, P169; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Rao KVR, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-66; ROCCI ML, 1987, PHARMACEUT RES, V4, P433; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SLIVKA A, 1995, STROKE, V26, P1061, DOI 10.1161/01.STR.26.6.1061; Strbian D, 2008, NEUROSCIENCE, V153, P175, DOI 10.1016/j.neuroscience.2008.02.012; TOUNG TJK, 1994, CRIT CARE MED, V22, P273, DOI 10.1097/00003246-199402000-00019; Tsao N, 2001, J MED MICROBIOL, V50, P812, DOI 10.1099/0022-1317-50-9-812; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Vakili A, 2007, BRAIN RES, V1170, P97, DOI 10.1016/j.brainres.2007.07.016; Vakili A, 2007, BRAIN RES, V1144, P186, DOI 10.1016/j.brainres.2007.01.096; Watkins LR, 2003, ADV EXP MED BIOL, V521, P1; Yang GY, 1999, MOL BRAIN RES, V69, P135, DOI 10.1016/S0169-328X(99)00007-8; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7	44	45	52	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 4	2011	1377						119	125		10.1016/j.brainres.2011.01.001			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	733YH	WOS:000288299900012	21219888				2022-02-06	
J	Todis, B; Glang, A; Bullis, M; Ettel, D; Hood, D				Todis, Bonnie; Glang, Ann; Bullis, Michael; Ettel, Deborah; Hood, Donald			Longitudinal Investigation of the Post-High School Transition Experiences of Adolescents With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community adjustment; employment; post-secondary education; transition outcomes; traumatic brain injury	TO-COMMUNITY TRANSITION; QUALITY-OF-LIFE; INCARCERATED YOUTH; BEHAVIOR PROBLEMS; HEAD-INJURY; CHILDREN; CHILDHOOD; TERM; OUTCOMES; PERFORMANCE	Objective: To describe outcomes for youth with traumatic brain injury (TBI) transitioning from high school to adulthood. Design: Longitudinal design using univariate and multivariate analyses, including survival analysis to predict time to outcomes of interest and longitudinal growth modeling to evaluate factors that predict rates and levels of outcomes over time. Main Outcome Measures: employment, post-secondary education, and independent living status. Participants: Eighty-nine youth and young adults (aged 19-25 years) with TBI (19 mild-moderate TBI and 70 severe TBI). Results: Individuals entering adulthood following childhood TBI experienced fluctuations in rates of employment, enrollment in post-secondary education, and independent living. A higher likelihood of being enrolled in post-secondary education following graduation from high school was associated with being female, later age at injury, and higher socioeconomic status. Overall greater likelihood of employment was associated with higher socioeconomic status, while employment upon high school graduation was associated with more severe injury and lack of rehabilitations services. Greater likelihood of independent living was associated with later age at injury and nonreceipt of rehabilitation services, while shorter time until independent living was associated with less severe injury. Conclusion: Knowledge of how specific factors affect transition outcomes can be used to tailor transition interventions and resources to the needs of students with TBI. Findings related to special education and medical rehabilitation services should be interpreted with caution as the criteria for receipt of both types of services and the links between such services and functional outcomes are unclear.	[Todis, Bonnie; Glang, Ann; Ettel, Deborah; Hood, Donald] Teaching Res Inst, Eugene, OR 97401 USA; [Bullis, Michael] Univ Oregon, Coll Educ, Eugene, OR 97403 USA		Todis, B (corresponding author), Teaching Res Inst, 99 W 10th Ave,Ste 370, Eugene, OR 97401 USA.	todisb@wou.edu			US Department of Education, Office of Special Education and Rehabilitation ServicesUS Department of Education [H324C980115]	This study was funded by the US Department of Education, Office of Special Education and Rehabilitation Services Grant H324C980115 Resilience in Students with Traumatic Brain Injury: A Longitudinal Investigation.	Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Blackorby J, 1996, EXCEPT CHILDREN, V62, P399, DOI 10.1177/001440299606200502; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Bullis M, 2004, J SPEC EDUC, V38, P80, DOI 10.1177/00224669040380020201; Bullis M, 2002, EXCEPT CHILDREN, V69, P7, DOI 10.1177/001440290206900101; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; *CDCP, 2004, TRAUM BRAIN INJ TBI; Centers for Disease Control and Prevention, 2005, INT DAT TABL; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; EISENMAN LT, 2003, EXCEPTIONALITY, V0011, P00089; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; GARMEZY N, 1988, STUDIES PSYCHOSOCIAL, P29; Gioia GA IP, 2000, BEHAV RATING INVENTO; GLANG A, 2003, RESILIENCE STUDENTS; Halpern A. S., 1994, CAREER DEV EXCEPTION, V17, P115, DOI DOI 10.1177/088572889401700201; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Heinrich CJ, 2001, J PUBL ADM RES THEOR, V11, P109, DOI 10.1093/oxfordjournals.jpart.a003490; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; Keogh B. K., 1993, LEARNING DISABILITIE, V8, P3; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRIEL RL, 1988, PEDIATR NEUROL, V4, P337, DOI 10.1016/0887-8994(88)90079-3; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; Nybo T, 2005, ACTA NEUROL SCAND, V112, P338, DOI 10.1111/j.1600-0404.2005.00489.x; Nybo T, 1999, BRAIN INJURY, V13, P759; Oregon Department of Human Services Health Services, 1999, HOSP DISCH IND; Pew Research Center for the People and the Press, 2007, PORT GEN NEXT YOUNG; Raudenbus S, 2004, HLM6 HIERARCHICAL LI; Rivara Frederick P, 2004, Arch Pediatr Adolesc Med, V158, P513, DOI 10.1001/archpedi.158.6.513; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rusch FR, 1998, HIGH SCH TRANSITIONS; Rutter M. E., 1988, STUDIES PSYCHOSOCIAL; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Shandra CL, 2008, J VOCAT REHABIL, V29, P117; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; The American Academy of Physical Medicine and Rehabilitation, 2004, HOT STOR TOP BRAIN I; TODIS B, 1998, RESILIENCE STUDENTS; Todis B, 2008, J HEAD TRAUMA REHAB, V23, P252, DOI 10.1097/01.HTR.0000327257.84622.bc; US Census Bureau, STAT COUNT QUICKFACT; Van Heugten CM, 2006, BRAIN INJURY, V20, P895, DOI 10.1080/02699050600832015; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wagner M., 2005, HIGH SCH 1 LOOK POST; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; NATL LONGITUDINAL ST; [No title captured]	59	45	46	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2011	26	2					138	149		10.1097/HTR.0b013e3181e5a87a			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	732OR	WOS:000288197200004	20631630				2022-02-06	
J	Woodrome, SE; Yeates, KO; Taylor, HG; Rusin, J; Bangert, B; Dietrich, A; Nuss, K; Wright, M				Woodrome, Stacey E.; Yeates, Keith Owen; Taylor, H. Gerry; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn; Wright, Martha			Coping Strategies as a Predictor of Post-concussive Symptoms in Children with Mild Traumatic Brain Injury versus Mild Orthopedic Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Children; Coping; Longitudinal study; Moderator variable; Post-concussive symptoms; Traumatic brain injury	POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; PSYCHOLOGICAL ADJUSTMENT; NEUROBEHAVIORAL SYMPTOMS; STRESS; ADOLESCENTS; CHILDHOOD; COMPLAINTS; MINORITY; VALIDITY	This study examined whether children's coping strategies are related to post-concussive symptoms following mild traumatic brain injury (TBI) versus orthopedic injury (OD. Participants were 8- to 15-year-old children with mild TB! (n = 167) or 01 (n = 84). They rated their current preferred coping strategies and post-injury symptoms at 2 weeks (baseline) and 1, 3, and 12 months post-injury. Children's reported use of coping strategies did not vary significantly over time, so their baseline coping ratings were examined as predictors of post-concussive symptoms across time. Self-ratings of symptoms were positively related to emotion-focused strategies and negatively related to problem-focused engagement after both mild TBI and OI. Higher problem-focused disengagement predicted larger group differences in children's ratings of symptoms, suggesting that problem-focused disengagement moderates the effects of mild TBI. Coping strategies collectively accounted for approximately 10-15% of the variance in children's post-concussive symptoms over time. The findings suggest that coping may play an important role in accounting for children's perceptions of post-concussive symptoms after mild TBI. (JINS, 2011, 17, 317-326)	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA; [Woodrome, Stacey E.] Childrens Healthcare Atlanta, Dept Neuropsychol, Atlanta, GA USA; [Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD39834, K02 HD44099]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER	The larger project from which the research was derived was supported by grants R01 HD39834 and K02 HD44099 from the National Institute of Child Health and Human Development to the second author. The authors have no conflicts of interest.	*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bachanas PJ, 2001, J PEDIATR PSYCHOL, V26, P343, DOI 10.1093/jpepsy/26.6.343; BAND EB, 1988, DEV PSYCHOL, V24, P247, DOI 10.1037/0012-1649.24.2.247; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Campbell LK, 2009, J PEDIATR PSYCHOL, V34, P317, DOI 10.1093/jpepsy/jsn080; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casey R, 2000, REHABIL PSYCHOL, V45, P155, DOI 10.1037/0090-5550.45.2.155; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cauce AM, 1998, STUDYING MINORITY ADOLESCENTS, P147; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; Compas BE, 2001, PSYCHOL BULL, V127, P87, DOI 10.1037//0033-2909.127.1.87; COMPAS BE, 1987, PSYCHOL BULL, V101, P393, DOI 10.1037/0033-2909.101.3.393; Compas BE, 2001, J DEV BEHAV PEDIATR, V22, P323, DOI 10.1097/00004703-200110000-00007; Compas BE, 2006, J CONSULT CLIN PSYCH, V74, P1132, DOI 10.1037/0022-006X.74.6.1132; Donaldson D, 2000, AM J ORTHOPSYCHIAT, V70, P351, DOI 10.1037/h0087689; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Folkman S., 1984, STRESS; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Grey Margaret, 2004, Curr Diab Rep, V4, P126, DOI 10.1007/s11892-004-0068-7; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Losoya S, 1998, INT J BEHAV DEV, V22, P287, DOI 10.1080/016502598384388; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Mallery P., 2003, SPSS WINDOWS STEP ST, V4th; Martinez, 1993, CHILDRENS HLTH CARE, V22, P189, DOI 10.1207/s15326888chc2203_2; MCCALL RB, 1973, CHILD DEV, V44, P401; Miller KS, 2009, J PEDIATR PSYCHOL, V34, P1135, DOI 10.1093/jpepsy/jsp037; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mittenberg W., 1997, CLIN NEUROPSYCHOL, V11, P305; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Rollnik JD, 2001, HEADACHE, V41, P297, DOI 10.1046/j.1526-4610.2001.111006297.x; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; STEVENS G, 1985, SOC SCI RES, V14, P142, DOI 10.1016/0049-089X(85)90008-0; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RJ, 1993, J CONSULT CLIN PSYCH, V61, P468, DOI 10.1037/0022-006X.61.3.468; Tobin D.L., 1984, USERS MANUAL COPING; TOBIN DL, 1989, COGNITIVE THER RES, V13, P343, DOI 10.1007/BF01173478; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Yancey AK, 2006, ANNU REV PUBL HEALTH, V27, P1, DOI 10.1146/annurev.publhealth.27.021405.102113; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	65	45	45	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2011	17	2					317	326		10.1017/S1355617710001700			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	738DY	WOS:000288620900012	21241531	Green Accepted			2022-02-06	
J	Loane, DJ; Washington, PM; Vardanian, L; Pocivavsek, A; Hoe, HS; Duff, KE; Cernak, I; Rebeck, GW; Faden, AI; Burns, MP				Loane, David J.; Washington, Patricia M.; Vardanian, Lilit; Pocivavsek, Ana; Hoe, Hyang-Sook; Duff, Karen E.; Cernak, Ibolja; Rebeck, G. William; Faden, Alan I.; Burns, Mark P.			Modulation of ABCA1 by an LXR Agonist Reduces Beta-Amyloid Levels and Improves Outcome after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						A beta clearance; amyloid precursor protein processing; beta-amyloid; liver X receptor; traumatic brain injury	LIVER-X-RECEPTORS; ALZHEIMERS-DISEASE PATHOLOGY; TRANSGENIC MOUSE MODEL; LONG-TERM ACCUMULATION; PRECURSOR PROTEIN; A-BETA; NEURONAL APOPTOSIS; INDUCED INCREASES; OXIDATIVE STRESS; APP23 MICE	Traumatic brain injury (TBI) increases brain beta-amyloid (A beta) in humans and animals. Although the role of A beta in the injury cascade is unknown, multiple preclinical studies have demonstrated a correlation between reduced A beta and improved outcome. Therefore, therapeutic strategies that enhance A beta clearance may be beneficial after TBI. Increased levels of ATP-binding cassette A1 (ABCA1) transporters can enhance A beta clearance through an apolipoprotein E (apoE)-mediated pathway. By measuring A beta and ABCA1 after experimental TBI in C57BL/6J mice, we found that A beta peaked early after injury (1-3 days), whereas ABCA1 had a delayed response (beginning at 3 days). As ABCA1 levels increased, A beta levels returned to baseline levels-consistent with the known role of ABCA1 in A beta clearance. To test if enhancing ABCA1 levels could block TBI-induced A beta, we treated TBI mice with the liver X-receptor (LXR) agonist T0901317. Pre- and post-injury treatment increased ABCA1 levels at 24 h post-injury, and reduced the TBI-induced increase in A beta. This reduction in A beta was not due to decreased amyloid precursor protein processing, or a shift in the solubility of A beta, indicating enhanced clearance. T0901317 also limited motor coordination deficits in injured mice and reduced brain lesion volume. These data indicate that activation of LXR can reduce A beta accumulation after TBI, and is accompanied by improved functional recovery.	[Washington, Patricia M.; Vardanian, Lilit; Pocivavsek, Ana; Hoe, Hyang-Sook; Rebeck, G. William; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res, Natl Study Ctr Trauma & EMS, Baltimore, MD 21201 USA; [Duff, Karen E.] Columbia Univ, Dept Pathol, Taub Inst Alzheimer Dis Res, Med Ctr, New York, NY USA; [Duff, Karen E.] Columbia Univ, Integrat Neurosci New York State Psychiat Inst, Med Ctr, New York, NY USA; [Cernak, Ibolja] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD USA		Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Bldg WP22A,3970 Reservoir Rd NW, Washington, DC 20007 USA.	mpb37@georgetown.edu	Pocivavsek, Ana/AAW-8923-2020; Loane, David/ABD-5177-2021; Rebeck, George William/J-2192-2012	Loane, David/0000-0003-0393-3503; Rebeck, George William/0000-0001-6276-248X; Pocivavsek, Ana/0000-0002-3817-3201; Ibolja, Cernak/0000-0003-3214-698X; Burns, Mark P/0000-0003-4750-2000; Duff, Karen/0000-0002-6177-868X	Wright Family;  [R03NS057635]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS057635] Funding Source: NIH RePORTER	This research was supported by grant no. R03NS057635 (to M.P.B.), and funding from the Wright Family through the Memory Disorders Program at Georgetown University (to M.P.B.). We would like to thank Marie Hanscom for technical support; the Small Animal Imaging Laboratory at Georgetown University; Dr. Guojon Bu (Washington University); and Dr. Paul Mathews (Nathan S. Kline Institute) for antibodies; and Dr. Yasuji Matsuoka for helpful comments and discussion.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Boyd-Kimball D, 2004, J ALZHEIMERS DIS, V6, P515; Brera B, 2000, NEUROBIOL DIS, V7, P395, DOI 10.1006/nbdi.2000.0313; Burns M, 2003, J NEUROSCI, V23, P5645; Burns MP, 2006, J NEUROCHEM, V98, P792, DOI 10.1111/j.1471-4159.2006.03925.x; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Combs CK, 2001, J NEUROSCI, V21, P1179; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; Eckert GP, 2007, NEUROSCI LETT, V423, P47, DOI 10.1016/j.neulet.2007.05.063; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Fitz NF, 2010, J NEUROSCI, V30, P6862, DOI 10.1523/JNEUROSCI.1051-10.2010; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200; Hoe HS, 2007, J NEUROSCI, V27, P10895, DOI 10.1523/JNEUROSCI.3135-07.2007; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Kobayashi S, 2010, NEUROCHEM INT, V56, P387, DOI 10.1016/j.neuint.2009.11.005; Koldamova R, 2005, J BIOL CHEM, V280, P43224, DOI 10.1074/jbc.M504513200; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; MARK RJ, 1995, J NEUROSCI, V15, P6239; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Morales JR, 2008, CIRCULATION, V118, P1450, DOI 10.1161/CIRCULATIONAHA.108.782300; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Paterniti I, 2010, J NEUROCHEM, V112, P611, DOI 10.1111/j.1471-4159.2009.06471.x; Repa JJ, 2007, J NEUROSCI, V27, P14470, DOI 10.1523/JNEUROSCI.4823-07.2007; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sironi L, 2008, FEBS LETT, V582, P3396, DOI 10.1016/j.febslet.2008.08.035; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wahrle SE, 2005, J BIOL CHEM, V280, P43236, DOI 10.1074/jbc.M508780200; Wahrle SE, 2008, J CLIN INVEST, V118, P671, DOI 10.1172/JCI33622; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Zelcer N, 2007, P NATL ACAD SCI USA, V104, P10601, DOI 10.1073/pnas.0701096104; Zhang X, 2007, J BIOL CHEM, V282, P10873, DOI 10.1074/jbc.M608856200	53	45	45	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					225	236		10.1089/neu.2010.1595			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700006	21175399	Green Published			2022-02-06	
J	Faux, S; Sheedy, J; Delaney, R; Riopelle, R				Faux, Steven; Sheedy, Jo; Delaney, R.; Riopelle, Richard			Emergency department prediction of post-concussive syndrome following mild traumatic brain injury-an international cross-validation study	BRAIN INJURY			English	Article						Mild traumatic brain injury; concussion; post-concussive syndrome; mild head injury; prognosis	BLOOD-ALCOHOL CONCENTRATIONS; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RAPID SCREEN; CHRONIC PAIN; ADULTS; TRIAL; CARE	Background: Between 20-50% of those suffering a mild traumatic brain injury (MTBI) will suffer symptoms beyond 3 months or post-concussive disorder (PCD). Researchers in Sydney conducted a prospective controlled study which identified that bedside recordings of memory impairment together with recordings of moderate or severe pain could predict those who would suffer PCS with 80% sensitivity and specificity of 76%. Primary objective: This study is a cross-validation study of the Sydney predictive model conducted at Montreal General Hospital, Montreal, Canada. Methods: One hundred and seven patients were assessed in the Emergency Department following a MTBI and followed up by phone at 3 months. The Rivermead Post-Concussive Questionnaire was the main outcome measure. Results: Regression analysis showed that immediate verbal recall and quantitative recording of headache was able to predict PCD with a sensitivity of 71.4% and a specificity of 63.3%. In the combined MTBI groups from Sydney and Montreal the sensitivity was 70.2% and the specificity was 64.2%. Conclusion: This is the first study to compare populations from different countries with diverse language groups using a predictive model for identifying PCD following MTBI. The model may be able to identify an 'at risk' population to whom pre-emptive treatment can be offered.	[Faux, Steven] St Vincents Hosp, Sydney, NSW 2010, Australia; [Delaney, R.] McGill Univ, Montreal Gen Hosp, Med Ctr, Dept Emergency Med, Montreal, PQ H3G 1A4, Canada; [Riopelle, Richard] McGill Univ, Montreal Gen Hosp, Med Ctr, Dept Neurol Neurosurg, Montreal, PQ H3G 1A4, Canada		Faux, S (corresponding author), St Vincents Hosp, 170 Darlinghurst Rd, Sydney, NSW 2010, Australia.	sfaux@stvincents.com.au	Faux, Steven/Y-3409-2019	Faux, Steven/0000-0001-8846-216X	Stroke Society of Australia; Australian Faculty of Rehabilitation Medicine Ipsen Research FellowshipIpsen	Dr Faux's travel to Canada was supported by two grants; (1) Short Traveling Grant from the Stroke Society of Australia and (2) Australian Faculty of Rehabilitation Medicine Ipsen Research Fellowship. There was no direct funding of this research. The assistance, kind advice and cooperation of Dr R. Primavesi, Director of Emergency Medicine at Montreal General Hospital/Hopital General de Montreal, Canada is acknowledged.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; *AUSTR BUR STAT, 2004, CENS; Australian Acute Musculoskeletal Pain Guidelines Group, 2004, EV BAS MAN AC MUSC P; *COLL MED QUEB, 2005, OR MIN TRAUM CRAN CE; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; COPES WS, 1997, P 33 ANN M ASS ADV A, P205; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; De Monte VE, 2004, J CLIN EXP NEUROPSYC, V26, P628, DOI 10.1080/13803390490504443; Hillier SL, 1997, BRAIN INJURY, V11, P649; *I STAT QUEB, 2001, CENS; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JONES AW, 1991, FORENSIC SCI PROGR, V5, P31; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Noble B, 2005, J PAIN SYMPTOM MANAG, V29, P14, DOI 10.1016/j.jpainsymman.2004.08.007; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Paniak C, 2000, BRAIN INJURY, V14, P219; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; STATISTICS CANADA, 2001, CENS; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stowell AR, 1998, J FORENSIC SCI, V43, P14, DOI 10.1520/JFS16083J; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454; WATSON PE, 1981, J STUD ALCOHOL, V42, P547, DOI 10.15288/jsa.1981.42.547; Weschler D., 1981, MANUAL WECHSLER ADUL	46	45	48	1	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2011	25	1					14	22		10.3109/02699052.2010.531686			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700003	21142827				2022-02-06	
J	Putukian, M				Putukian, Margot			The Acute Symptoms of Sport-Related Concussion: Diagnosis and On-field Management	CLINICS IN SPORTS MEDICINE			English	Article						Sport-related concussion; Sideline management; Concussion protocol; Symptoms; Diagnosis; Mild traumatic brain injury; Head injury; Sports	MILD HEAD-INJURY; COLLEGIATE FOOTBALL PLAYERS; NEUROPSYCHOLOGICAL ASSESSMENT; INTERNATIONAL-CONFERENCE; CEREBRAL CONCUSSION; POSTURAL STABILITY; STATEMENT; RETURN; RELIABILITY; VALIDATION	Sport-related concussion is a common injury that occurs in a variety of sports. In recent years, more attention has been focused on the importance of this injury as well as the long-term complications of unrecognized, repetitive, and/or severe injury. The acute presentation of concussion as well as the diagnosis of concussion is often straightforward and obvious, but it can also be subtle and difficult to discern. Most injuries are short lived with complete recovery within a couple of weeks, with a small minority taking several months to resolve. Unfortunately, it is difficult to predict which injuries will linger. This article discusses the on-field presentation, diagnosis, and management of sport-related concussion. It is important to have a concussion protocol for high-risk sports, including a preseason and postinjury assessment, and an individualized yet comprehensive approach that includes evaluating symptoms, and a neurologic examination that includes cognitive function and balance testing. A multifaceted approach to the evaluation and diagnosis of concussion is endorsed for the optimal management of this injury.	[Putukian, Margot] Univ Med & Dent New Jersey, New Brunswick, NJ 08901 USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA		Putukian, M (corresponding author), Univ Med & Dent New Jersey, 125 Paterson St, New Brunswick, NJ 08901 USA.	putukian@princeton.edu					Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; [Anonymous], 2009, BRIT J SPORT MED, V43, pi85; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J ATHL TRAINING, V36, P297; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Barth JT, 1989, MILD HEAD INJURY, P257; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Bruce JM, 2004, NEUROLOGY, V63, P1516; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Colorado Medical Society School and Sports Medicine Committee, 1990, COLO MED, V87, P4; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Echemendia R., 2006, SPORTS NEUROPSYCHOLO; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hecht S, 2004, CLIN J SPORT MED, V14, P310; HERRING S, 2001, MED SCI SPORTS EXERC, V33, P846; HERRING SA, 2005, MED SCI SPORTS EXERC, V37, P2012; JENNETT B, 1975, LANCET, V1, P480; Kelly JP, 1997, NEUROLOGY, V48, P581; LECLERC S, 2004, ASSESSMENT CONCUSSIO; Lovell M. R., 2007, IMMEDIATE POSTCONCUS; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; *NAT FED HIGH SCH, 2009 NFHS CONS BROCH; *NCAA HLTH SAF, NCAA REQ CONC MAN PL; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Piland SG, 2003, J ATHL TRAINING, V38, P104; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Randolph C, 2005, J ATHL TRAINING, V40, P139; RANDOLPH C, CONCUSSION SYMPTOM I; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rubin Aaron L, 2004, Curr Sports Med Rep, V3, P141; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; VALVOLICHMCLEOD TC, 2006, J ATHL TRAINING, V41, P399; Van Kampen D., 2006, AM J SPORTS MED, V34, P1	62	45	45	0	23	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					49	+		10.1016/j.csm.2010.09.005			14	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	691XR	WOS:000285114800006	21074081				2022-02-06	
J	Reinhardt, JD; Li, JA; Gosney, J; Rathore, FA; Haig, AJ; Marx, M; DeLisa, JA				Reinhardt, Jan D.; Li, Jianan; Gosney, James; Rathore, Farooq A.; Haig, Andrew J.; Marx, Michael; DeLisa, Joel A.		Int Soc Phys Rehabil Med	Disability and health-related rehabilitation in international disaster relief	GLOBAL HEALTH ACTION			English	Article							SPINAL-CORD INJURIES; 2008 WENCHUAN EARTHQUAKE; SUB-SAHARAN AFRICA; GREAT HANSHIN EARTHQUAKE; PHYSICAL MEDICINE; WHITE PAPER; BLACK MARK; CONCEPTUAL DESCRIPTION; NORTHERN PAKISTAN; UNIFYING MODEL	Background: Natural disasters result in significant numbers of disabling impairments. Paradoxically, however, the traditional health system response to natural disasters largely neglects health-related rehabilitation as a strategic intervention. Objectives: To examine the role of health-related rehabilitation in natural disaster relief along three lines of inquiry: (1) epidemiology of injury and disability, (2) impact on health and rehabilitation systems, and (3) the assessment and measurement of disability. Design: Qualitative literature review and secondary data analysis. Results: Absolute numbers of injuries as well as injury to death ratios in natural disasters have increased significantly over the last 40 years. Major impairments requiring health-related rehabilitation include amputations, traumatic brain injuries, spinal cord injuries (SCI), and long bone fractures. Studies show that persons with pre-existing disabilities are more likely to die in a natural disaster. Lack of health-related rehabilitation in natural disaster relief may result in additional burdening of the health system capacity, exacerbating baseline weak rehabilitation and health system infrastructure. Little scientific evidence on the effectiveness of health-related rehabilitation interventions following natural disaster exists, however. Although systematic assessment and measurement of disability after a natural disaster is currently lacking, new approaches have been suggested. Conclusion: Health-related rehabilitation potentially results in decreased morbidity due to disabling injuries sustained during a natural disaster and is, therefore, an essential component of the medical response by the host and international communities. Significant systematic challenges to effective delivery of rehabilitation interventions during disaster include a lack of trained responders as well as a lack of medical recordkeeping, data collection, and established outcome measures. Additional development of health-related rehabilitation following natural disaster is urgently required.	[Reinhardt, Jan D.] Swiss Parapleg Res, CH-6207 Nottwil, Switzerland; [Reinhardt, Jan D.; Li, Jianan; Gosney, James; Rathore, Farooq A.; Haig, Andrew J.; DeLisa, Joel A.] Rehabil Disaster Relief Comm, ISPRM, Ghent, Belgium; [Reinhardt, Jan D.] Univ Lucerne, Dept Hlth Sci & Hlth Policy, Luzern, Switzerland; [Li, Jianan] Nanjing Med Univ, Affiliated Hosp 1, Dept Rehabil Med, Nanjing, Peoples R China; [Li, Jianan; Gosney, James; Rathore, Farooq A.; Haig, Andrew J.] Int Rehabil Forum Emergency Rehabil Work Grp, Ann Arbor, MI USA; [Rathore, Farooq A.] Combined Mil Hosp, Dept Rehabil Med, Sindh, Pakistan; [Haig, Andrew J.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Marx, Michael] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany; [DeLisa, Joel A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; [DeLisa, Joel A.] Univ Hosp, Newark, NJ USA		Reinhardt, JD (corresponding author), Swiss Parapleg Res, Guido A Zach Str 4, CH-6207 Nottwil, Switzerland.	jan.reinhardt@paranet.ch	Rathore, Farooq Azam/B-8232-2008	Rathore, Farooq Azam/0000-0002-4759-0453			[Anonymous], 1980, WHO CHRON, V34, P96; Anonymous, 2011, Morbidity and Mortality Weekly Report, V59, P1673; Armenian HK, 2000, ACTA PSYCHIAT SCAND, V102, P58, DOI 10.1034/j.1600-0447.2000.102001058.x; Armenian HK, 1998, AM J EPIDEMIOL, V148, P1077, DOI 10.1093/oxfordjournals.aje.a009585; Armenian HK, 1997, INT J EPIDEMIOL, V26, P806, DOI 10.1093/ije/26.4.806; Bai XD, 2009, CHIN J TRAUMATOL, V12, P122, DOI 10.3760/cma.j.issn.1008-1275.2009.02.012; Centre for Research on the Epidemiology of Disasters (CRED), 2011, EM DAT INT DIS DAT; Chan E Y Y, 2007, Asia Pac J Public Health, V19 Spec No, P45; Chan EYY, 2009, PREHOSPITAL DISASTER, V24, P365, DOI 10.1017/S1049023X00007159; Chiou-Tan FY, 2007, AM J PHYS MED REHAB, V86, P762, DOI 10.1097/PHM.0b013e31813e61cc; Chou YJ, 2004, AM J EPIDEMIOL, V160, P688, DOI 10.1093/aje/kwh270; Cohen ME, 2000, ARCH PHYS MED REHAB, V81, pS21, DOI 10.1053/apmr.2000.20620; de Goyet CD, 2007, PREHOSP DISASTER MED, V22, P152, DOI 10.1017/S1049023X00004556; DUNNETT CW, 1980, J AM STAT ASSOC, V75, P796, DOI 10.2307/2287161; Eldar R, 1997, DISABIL REHABIL, V19, P547, DOI 10.3109/09638289709166048; Fan F, 2011, J TRAUMA STRESS, V24, P44, DOI 10.1002/jts.20599; Gosney JE, 2010, DISASTER MED PUBLIC, V4, P110, DOI 10.1001/dmphp.4.2.110; Gosselin RA, 2009, INT ORTHOP, V33, P1445, DOI 10.1007/s00264-009-0798-x; Grosse SD, 2009, PUBLIC HEALTH REP, V124, P197, DOI 10.1177/003335490912400206; Guha-Sapir D, 2011, ADV NAT TECHNOL HAZA, P13, DOI DOI 10.1007/978-90-481-9455-1_2; Haig AJ, 2009, EUR J PHYS REHAB MED, V45, P185; Haig AJ, 2009, CHINESE J REHABILITA, V24, P385; Haig AJ, 2009, PM&R, V1, P421, DOI 10.1016/j.pmrj.2008.12.012; Haig AJ, 2009, DISABIL REHABIL, V31, P1031, DOI 10.1080/09638280902803765; Haig AJ, 2009, J REHABIL MED, V41, P401, DOI 10.2340/16501977-0367; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Huang Ming-jin, 2010, Zhonghua Liu Xing Bing Xue Za Zhi, V31, P167; Iezzoni LI, 2010, ANN INTERN MED, V152, P812, DOI 10.7326/0003-4819-152-12-201006150-00234; Ingstad B., 1995, DISABILITY CULTURE; Ke X, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-573; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelen GD, 2006, LANCET, V368, P1984, DOI 10.1016/S0140-6736(06)69808-5; King JC, 2005, PHYS MED REHABILITAT, P1051; LECHAT MF, 1979, B WORLD HEALTH ORGAN, V57, P11; Li S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004964; Li WF, 2009, CRIT CARE, V13, DOI 10.1186/cc8160; Loar J, 2011, DISABIL REHABIL, V33, P319, DOI 10.3109/09638288.2010.490870; Majchrzak A, 2007, ORGAN SCI, V18, P147, DOI 10.1287/orsc.1060.0228; MICRODIS, 2007, MICRODIS INT S HLTH; Mont D, 2007, LANCET, V369, P1658, DOI 10.1016/S0140-6736(07)60752-1; Mori Kikuko, 2007, Disaster Manag Response, V5, P8, DOI 10.1016/j.dmr.2006.11.002; MURRAY CJL, 1990, GLOBAL BURDEN DIS CO, V1; Nufer KE, 2006, J EMERG MED, V30, P183, DOI 10.1016/j.jemermed.2005.03.020; OCHA ROMENACA, 2010, HUM RESP HAIT; Osaki Y, 1999, Nihon Koshu Eisei Zasshi, V46, P175; Phalkey R, 2011, INJURY EPIDEMIOLOGY; Priestley M, 2007, J SOC WORK DISABIL R, V5, P23, DOI 10.1300/J198v05n03_02; Qiu J, 2010, CHIN J TRAUMATOL, V13, P297, DOI 10.3760/cma.j.issn.1008-1275.2010.05.009; Raissi GR, 2007, AM J PHYS MED REHAB, V86, P912, DOI 10.1097/PHM.0b013e3181583abc; Raissi GR, 2007, J SPINAL CORD MED, V30, P369, DOI 10.1080/10790268.2007.11753954; Rathore FA, 2008, ARCH PHYS MED REHAB, V89, P579, DOI 10.1016/j.apmr.2007.09.027; Rathore FA, 2011, ARCH PHYS MED REHAB, V92, P161, DOI 10.1016/j.apmr.2010.10.004; Rathore MFA, 2008, SPINAL CORD, V46, P461, DOI 10.1038/sj.sc.3102162; Rathore MFA, 2007, SPINAL CORD, V45, P658, DOI 10.1038/sj.sc.3102023; Rathore MFA, 2008, J SPINAL CORD MED, V31, P118; Redmond AD, 2011, EMERG MED J, V28, P516, DOI 10.1136/emj.2009.089920; Smith K, 2009, ENV HAZARDS ASSESSIN, VFifth; Stucki G, 2007, J REHABIL MED, V39, P279, DOI 10.2340/16501977-0041; Stucki G, 2007, J REHABIL MED, V39, P286, DOI 10.2340/16501977-0044; Takahashi A, 1997, J INTELL DISABIL RES, V41, P193, DOI 10.1111/j.1365-2788.1997.tb00695.x; Tanida N, 1996, BRIT MED J, V313, P1133, DOI 10.1136/bmj.313.7065.1133; Tauqir SF, 2007, J SPINAL CORD MED, V30, P373, DOI 10.1080/10790268.2007.11753955; Teal GE, 1965, TRAINING REQUIREMENT; Tinney MJ, 2007, DISABIL REHABIL, V29, P921, DOI 10.1080/09638280701240482; United Nations ESCAP, 2010, STAT YB AS PAC 2009; WHO, 2009, WHODAS 2 0 WHO DIS A; Wisner B., 2003, ENV HLTH EMERGENCIES; World Health Organization, 2008, GUID PROV MAN WHEELC; World Health Organization, 2007, INT CLASS FUNCT DIS; World Heath Organisation (WHO), 2005, DIS DIS REH; Yang C, 2009, INJURY, V40, P488, DOI 10.1016/j.injury.2009.01.102; Yun K, 2010, NEW ENGL J MED, V363, P1193, DOI 10.1056/NEJMp1008304; Zhang LL, 2011, EMERG MED J, V28, P618, DOI 10.1136/emj.2009.087296	73	45	46	1	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1654-9880			GLOBAL HEALTH ACTION	Glob. Health Action		2011	4				SI				7191	10.3402/gha.v4i0.7191			9	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	875EH	WOS:000299012700052		Green Published, gold			2022-02-06	
J	Simblett, SK; Bateman, A				Simblett, Sara K.; Bateman, Andrew			Dimensions of the Dysexecutive Questionnaire (DEX) examined using Rasch analysis	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Dysexecutive Questionnaire; DEX; Acquired brain injury; Rasch analysis	TRAUMATIC BRAIN-INJURY; EXECUTIVE DYSFUNCTION; ECOLOGICAL VALIDITY; MEASUREMENT MODEL; GOAL MANAGEMENT; REHABILITATION; DEFICITS; PROGRAM; RATINGS; SKILLS	Executive dysfunction is very broad term used to capture a range of interacting high-level cognitive, emotional and behavioural difficulties, commonly seen after acquired brain injury (ABI). Many argue that the concept of executive functioning should be subdivided into several separate dimensions. In this study we explore the dimensional structure of a tool designed to assess level of executive functioning, the Dysexecutive (DEX) Questionnaire (Burgess, Alderman, Wilson, Evans, Emslie, 1996), in order to inform theoretical conceptualisations of executive functioning and improve measurement precision in rehabilitation centres. Rasch analysis was undertaken on the responses of 363 people with ABI to the DEX. Overall, the questionnaire did not perform as a unidimensional, interval-level scale of executive functioning, suggesting that it measures more than one psychological construct. Most subscales previously proposed using factor analysis, including those suggested in the DEX manual, did not perform as unidimensional interval-level scales either. Several new subscales in keeping with theoretical conceptualisations of the different dimensions of executive functioning are proposed, alongside suggestions for revision of the wording and scoring of some of the items in the DEX. These results provide a platform for future evaluation of executive function rehabilitation programmes.	[Simblett, Sara K.] Univ Cambridge, Dept Psychiat, Cambridge Intellectual & Dev Disabil Res Grp, Cambridge CB2 8AH, England; [Simblett, Sara K.] CLAHRC, NIHR, Peterborough, Cambs, England; [Bateman, Andrew] Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, Cambs, England		Simblett, SK (corresponding author), Univ Cambridge, Dept Psychiat, Cambridge Intellectual & Dev Disabil Res Grp, Douglas House,18B,Trumpington Rd, Cambridge CB2 8AH, England.	ss879@medschl.cam.ac.uk		Bateman, Andrew/0000-0002-2547-5921; Simblett, Sara/0000-0002-8075-8238	NIHR CLAHRC for Cambridgeshire; Peterborough PhD award	The data reported here were collected by clinicians at the Oliver Zangwill Centre for Neuropsychological Rehabilitation. The preparation this paper was funded by an NIHR CLAHRC for Cambridgeshire and Peterborough PhD award to the first author; we are grateful for their support.	ALDERMAN N, 1995, NEUROPSYCHOL REHABIL, V5, P193, DOI 10.1080/09602019508401467; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; ANDRICH D, 1982, PSYCHOMETRIKA, V47, P105, DOI 10.1007/BF02293856; Andrich D., 2005, RUMM2020 VERSION 4 W; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Baghaei P., 2008, MELBOURNE PAPERS LAN, V13, P32; Bateman A, 2009, NEUROPSYCHOL REHABIL, V19, P941, DOI 10.1080/09602010903021170; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Bodenburg S, 2008, J NERV MENT DIS, V196, P75, DOI 10.1097/NMD.0b013e31815faa2b; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess P.W., 1996, BEHAV ASSESSMENT DYS, P18; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chan RCK, 2008, J NEUROL NEUROSUR PS, V79, P86, DOI 10.1136/jnnp.2007.117184; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Damasio A., 1994, DESCARTES ERROR EMOT; DZURILLA TJ, 1999, PROBLEM SOLVING THEA; Evans J. J., 1996, SELECTING ADM INTERP; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fisher W., 1992, RASCH MEAS T, V6, P238; Gilbert SJ, 2010, BRAIN RES, V1312, P79, DOI 10.1016/j.brainres.2009.11.045; Hambleton RK., 1991, FUNDAMENTALS ITEM RE; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hobart J, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13120; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Linacre J, 2007, RASCH MEASUREMENT T, V21, P1096; Magar ECE, 2008, PERS INDIV DIFFER, V45, P153, DOI 10.1016/j.paid.2008.03.014; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; NOVICK MR, 1966, J MATH PSYCHOL, V3, P1, DOI 10.1016/0022-2496(66)90002-2; Oikawa N., 2006, JPN J NEUROPSYCHOL, V22, P138; Pallant JF, 2007, BRIT J CLIN PSYCHOL, V46, P1, DOI 10.1348/014466506X96931; Rasch G., 1960, PROBABALISTIC MODELS; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Smith Everett V Jr, 2002, J Appl Meas, V3, P205; Smith R. M., 2006, J APPL MEASUREMENT; Stuss D. T., 1983, LOCALIZATION NEUROPS; STUSS DT, 2007, HUMAN FRONTAL LOBES, P292; Tennant A., 2006, RASCH MEAS T, V20, P1048; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; Wright B. D., 1995, RASCH MEASUREMENT T, V9, P430	47	45	45	0	19	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	1					1	25	PII 931444558	10.1080/09602011.2010.531216			25	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	715RE	WOS:000286900800001	21919559				2022-02-06	
J	Kaen, A; Jimenez-Roldan, L; Alday, R; Gomez, PA; Lagares, A; Alen, JF; Lobato, RD				Kaen, Ariel; Jimenez-Roldan, Luis; Alday, Rafael; Gomez, Pedro A.; Lagares, Alfonso; Fernandez Alen, Jose; Lobato, Ramiro D.			Interhemispheric hygroma after decompressive craniectomy: does it predict posttraumatic hydrocephalus? Clinical article	JOURNAL OF NEUROSURGERY			English	Article						head injury; decompressive craniectomy; hydrocephalus; subdural hygroma	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; EXTERNAL HYDROCEPHALUS; SUBDURAL HYGROMA; TOMOGRAPHY; HEMICRANIECTOMY; CLASSIFICATION; DIAGNOSIS; LESION	Object. The aim of this study was to determine the incidence of posttraumatic hydrocephalus in severely head-injured patients who required decompressive craniectomy (DC). Additional objectives were to determine the relationship between hydrocephalus and several clinical and radiological features, with special attention to subdural hygromas as a sign of distortion of the CSF circulation. Methods. The authors conducted a retrospective study of 73 patients with severe head injury who required DC. The patients were admitted to the authors' department between January 2000 and January 2006. Posttraumatic hydrocephalus was defined as: 1) modified frontal horn index greater than 33%, and 2) the presence of Gudeman CT criteria. Hygromas were diagnosed based on subdural fluid collection and classified according to location of the craniectomy. Results. Hydrocephalus was diagnosed in 20 patients (27.4%). After uni- and multivariate analysis, the presence of interhemispheric hygromas (IHHs) was the only independent prognostic factor for development of posttraumatic hydrocephalus (p < 0.0001). More than 80% of patients with IHHs developed hydrocephalus within the first 50 days of undergoing DC. In all cases the presence of hygromas preceded the diagnosis of hydrocephalus. The IHH predicts the development of hydrocephalus after DC with 94% sensitivity and 96% specificity. The presence of an IHH showed an area under the receiver-operator characteristic of 0.951 (95% CI 0.87-1.00; p < 0.0001). Conclusions. Hydrocephalus was observed in 27.4% of the patients with severe traumatic brain injury who required DC. The presence of IHHs was a predictive radiological sign of hydrocephalus development within the first 6 months of DC in patients with severe head injury. (DOI: 10.3171/2010.4.JNS10132)	[Kaen, Ariel] Hosp Univ Virgen del Rocio, Dept Neurosurg, Seville, Spain; [Jimenez-Roldan, Luis; Alday, Rafael; Gomez, Pedro A.; Lagares, Alfonso; Fernandez Alen, Jose; Lobato, Ramiro D.] Hosp 12 Octubre, Dept Neurosurg, E-28041 Madrid, Spain		Kaen, A (corresponding author), Hosp Virgen del Rocio, Dept Neurosurg, Avda Manuel Siurot S-N, Seville 41013, Spain.	kaenariel@hotmail.com	Jimenez-Roldan, Luis/K-2298-2017; Gomez, Pedro/N-5051-2019; KAEN, ARIEL/F-1338-2015; ALEN, JOSE A FERNANDEZ/G-4990-2018; kaen, ariel/G-3786-2015; Lagares, Alfonso/B-2969-2011	Jimenez-Roldan, Luis/0000-0002-9864-0385; Gomez, Pedro/0000-0002-4185-5238; ALEN, JOSE A FERNANDEZ/0000-0002-3321-983X; Lagares, Alfonso/0000-0003-3996-0554; KAEN, ARIEL/0000-0002-0595-9515			Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Cardoso ER, 1996, J NEUROSURG, V85, P1143, DOI 10.3171/jns.1996.85.6.1143; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Choi I, 2008, J KOREAN NEUROSURG S, V43, P227, DOI 10.3340/jkns.2008.43.5.227; Czosnyka M, 2000, J NEUROL NEUROSUR PS, V68, P246; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; Huh PW, 2006, J NEUROSURG, V105, P65, DOI 10.3171/jns.2006.105.1.65; Licata C, 2001, J Neurosurg Sci, V45, P141; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Miranda P, 2004, NEUROCIRUGIA, V15, P67; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	23	45	64	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	2010	113	6					1287	1293		10.3171/2010.4.JNS10132			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	684QX	WOS:000284565500033	20486895				2022-02-06	
J	Hendricks, HT; Heeren, AH; Vos, PE				Hendricks, H. T.; Heeren, A. H.; Vos, P. E.			Dysautonomia after severe traumatic brain injury	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						cohort study; diffuse axonal injury; dysautonomia; incidence; traumatic brain injury	SEVERE HEAD-INJURY; DIENCEPHALIC SEIZURES	Background: Dysautonomia after traumatic brain injury (TBI) is characterized by episodes of increased heart rate, respiratory rate, temperature, blood pressure, muscle tone, decorticate or decerebrate posturing, and profuse sweating. This study addresses the incidence of dysautonomia after severe TBI, the clinical variables that are associated with dysautonomia, and the functional outcome of patients with dysautonomia. Methods: A historic cohort study in patients with severe TBI [Glasgow Coma Scale (GCS) < 8 on admission]. Results: Seventy-six of 119 patients survived and were eligible for follow-up. The incidence of dysautonomia was 11.8%. Episodes of dysautonomia were prevalent during a mean period of 20.1 days (range 3-68) and were often initiated by discomfort. Patients with dysautonomia showed significant longer periods of coma (24.78 vs. 7.99 days) and mechanical ventilation (22.67 vs. 7.21 days). Dysautonomia was associated with diffuse axonal injury (DAI) [relative risk (RR) 20.83, CI 4.92-83.33] and the development of spasticity (RR 16.94, CI 3.96-71.42). Patients with dysautonomia experienced more secondary complications. They tended to have poorer outcome. Conclusions: Dysautonomia occurs in approximately 10% of patients surviving severe TBI and is associated with DAI and the development of spasticity at follow-up. The initiation of dysautonomia by discomfort supports the Excitatory: Inhibitory Ratio model as pathophysiological mechanism.	[Hendricks, H. T.] Rehabil Ctr, Arnhem, Netherlands; [Hendricks, H. T.; Heeren, A. H.] Radboud Univ Nijmegen Med Ctr, Dept Rehabil Med, NL-6500 HB Nijmegen, Netherlands; [Vos, P. E.] Radboud Univ Nijmegen Med Ctr, Inst Neurol, NL-6500 HB Nijmegen, Netherlands		Hendricks, HT (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Rehabil Med, PO 9011, NL-6500 HB Nijmegen, Netherlands.	h.hendricks@reval.umcn.nl	Vos, Pieter/A-6043-2012				American College of Surgeons, 1997, ADV TRAUM LIF SUPP D, V6th ed; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BRATTON SL, 2007, J NEUROTRAUM, V1, pS1; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTRY LR, 1994, RADIOLOGY, V191, P1; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	20	45	48	0	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1351-5101			EUR J NEUROL	Eur. J. Neurol.	SEP	2010	17	9					1172	1177		10.1111/j.1468-1331.2010.02989.x			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	639TG	WOS:000280996800011	20298427				2022-02-06	
J	Oddo, M; Nduom, E; Frangos, S; MacKenzie, L; Chen, I; Maloney-Wilensky, E; Kofke, WA; Levine, JM; LeRoux, PD				Oddo, Mauro; Nduom, Edjah; Frangos, Suzanne; MacKenzie, Larami; Chen, Isaac; Maloney-Wilensky, Eileen; Kofke, W. Andrew; Levine, Joshua M.; LeRoux, Peter D.			Acute Lung Injury Is an Independent Risk Factor for Brain Hypoxia After Severe Traumatic Brain Injury	NEUROSURGERY			English	Article						Acute lung injury; Brain hypoxia; Brain tissue oxygen tension; Lung function; Systemic oxygenation; Traumatic brain injury	RESPIRATORY-DISTRESS-SYNDROME; SEVERE HEAD-INJURY; END-EXPIRATORY PRESSURE; TISSUE OXYGEN-TENSION; CEREBRAL PERFUSION-PRESSURE; HIGH TIDAL VOLUME; MECHANICAL VENTILATION; LONGITUDINAL DATA; INSPIRED OXYGEN; DELIVERY	BACKGROUND: Pulmonary complications are frequently observed after severe traumatic brain injury (TBI), but little is known about the consequences of lung injury on brain tissue oxygenation and metabolism. OBJECTIVE: We examined the association between lung function and brain tissue oxygen tension (PbtO(2)) in patients with severe TBI. METHODS: We analyzed data from 78 patients with severe, nonpenetrating TBI who underwent continuous PbtO(2) and intracranial pressure monitoring. Acute lung injury was defined by the presence of pulmonary infiltrates with a PaO2/FiO(2) (PF) ratio less than 300 and the absence of left ventricular failure. A total of 587 simultaneous measurements of PbtO(2) and PF ratio were examined using longitudinal data analysis. RESULTS: PbtO(2) correlated strongly with PaO2 and PF ratio (P < .05) independent of PaCO2, brain temperature, cerebral perfusion pressure, and hemoglobin. Acute lung injury was associated with lower PbtO(2) (34.6 +/- 13.8 mm Hg at PF ratio > 300 vs 30.2 +/- 10.8 mm Hg [ PF ratio 200-300], 28.9 +/- 9.8 mm Hg [ PF ratio 100-199], and 21.1 +/- 7.4 mm Hg [ PF ratio < 100], all P values <. 01). After adjusting for intracranial pressure, Marshall computed tomography score, and APACHE II (Acute Physiology and Chronic Health Evaluation) score, acute lung injury was an independent risk factor for compromised PbtO(2) (PbtO(2) < 20 mm Hg; adjusted odds ratio: 2.13, 95% confidence interval: 1.21-3.77; P < .01). CONCLUSION: After severe TBI, PbtO(2) correlates with PF ratio. Acute lung injury is associated with an increased risk of compromised PbtO(2), independent from intracerebral and systemic injuries. Our findings support the use of lung-protective strategies to prevent brain hypoxia in TBI patients.	[LeRoux, Peter D.] Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg, Philadelphia, PA 19107 USA; [MacKenzie, Larami; Levine, Joshua M.] Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19107 USA; [Kofke, W. Andrew; Levine, Joshua M.] Univ Penn, Med Ctr, Dept Anesthesiol & Crit Care, Philadelphia, PA 19107 USA		LeRoux, PD (corresponding author), Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg, 330 S 9th St, Philadelphia, PA 19107 USA.	Peter.LeRoux@uphs.upenn.edu	Oddo, Mauro/R-3370-2016; Nduom, Edjah/K-3171-2019	Oddo, Mauro/0000-0002-6155-2525; Nduom, Edjah/0000-0001-9882-0899	SICPA Foundation, Switzerland; Integra Foundation; Integra Neurosciences; Mary Elisabeth Groff Surgical and Medical Research Trust	Supported by research grants from the SICPA Foundation, Switzerland (M.O.), the Integra Foundation (P.D.L.R.), Integra Neurosciences (PDLR), and the Mary Elisabeth Groff Surgical and Medical Research Trust (P.D.L.R.). Dr. Le Roux is a member of Integra Neurosciences Speaker's Bureau. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Bullock RM, 2000, J NEUROTRAUM, V17, P449; BURCHIEL KJ, 1981, NEUROSURGERY, V8, P443, DOI 10.1227/00006123-198104000-00007; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Crossley DJ, 1997, CRIT CARE MED, V25, P1522, DOI 10.1097/00003246-199709000-00019; Dings J, 1998, NEUROL RES, V20, pS71; Gajic O, 2004, CRIT CARE MED, V32, P1817, DOI 10.1097/01.CCM.0000133019.52531.30; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Huynh T, 2002, J TRAUMA, V53, P488, DOI 10.1097/00005373-200209000-00016; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Lowe GJ, 2006, CURR OPIN CRIT CARE, V12, P3, DOI 10.1097/01.ccx.0000198055.29600.4b; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mascia L, 2008, MINERVA ANESTESIOL, V74, P325; Mascia L, 2005, INTENS CARE MED, V31, P373, DOI 10.1007/s00134-004-2491-2; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Moore F, 2002, J TRAUMA, V53, P492; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2008, CRIT CARE MED, V36, P1984, DOI 10.1097/CCM.0b013e318176a9f6; Offner PJ, 2003, J TRAUMA, V55, P285, DOI 10.1097/01.TA.0000078695.35172.79; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; SHAPIRO HM, 1978, J TRAUMA, V18, P254, DOI 10.1097/00005373-197804000-00005; SPIOTTA A, 2010, J NEUROSURG     0423; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tobin MJ, 2000, NEW ENGL J MED, V342, P1360, DOI 10.1056/NEJM200005043421808; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Yildirim E, 2004, EUR J CARDIO-THORAC, V25, P523, DOI 10.1016/j.ejcts.2003.12.021; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; ZEGER SL, 1992, STAT MED, V11, P1825, DOI 10.1002/sim.4780111406	51	45	49	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2010	67	2					338	344		10.1227/01.NEU.0000371979.48809.D9			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	628HI	WOS:000280105800025	20644419				2022-02-06	
J	Preece, MHW; Horswill, MS; Geffen, GM				Preece, Megan H. W.; Horswill, Mark S.; Geffen, Gina M.			Driving After Concussion: The Acute Effect of Mild Traumatic Brain Injury on Drivers' Hazard Perception	NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury; driving; fitness-to-drive; hazard perception skill	FIELD-OF-VIEW; HEAD-INJURY; OLDER-ADULTS; ACCIDENT INVOLVEMENT; EXPERIENCED DRIVERS; TRAFFIC ACCIDENT; WORD REPETITION; VISUAL-SEARCH; EYE-MOVEMENTS; RAPID SCREEN	Objective: No research has examined whether individuals recovering from a recent mild traumatic brain injury (MTBI) are safe to drive, despite cognitive impairment being a common consequence soon after MTBI. This study examined the acute effect of MTBI on drivers' hazard perception, which is defined as drivers' ability to search the road ahead to rapidly identify potentially dangerous traffic situations. Poorer hazard perception has been associated with higher crash rate's in a number of studies. Method: Forty-two patients with MTBI and 43 patients with minor orthopedic injuries were recruited from the emergency department of a large metropolitan hospital within 24 hours of injury. Participants completed a computerized hazard perception test, in which they watched videos of genuine traffic scenes filmed from the driver's point of view. They were required to use the computer mouse to click on potential traffic hazards as early as possible. Results: Participants with MTBI were significantly slower to respond to traffic hazards than participants with minor orthopedic injuries (p = .03, d = .48). Conclusions: This study provides the first indication that within the acute stage postinjury, MTBI is associated with impairment in a crash-related component of driving. This suggests that patients with MTBI should be advised to refrain from driving for at least the first 24 hours' postinjury.	[Preece, Megan H. W.; Horswill, Mark S.; Geffen, Gina M.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia		Preece, MHW (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.	m.preece@psy.uq.edu.au	Horswill, Mark/J-9029-2019; Preece, Megan/A-7186-2013	Horswill, Mark/0000-0002-0286-6292; Preece, Megan/0000-0003-4852-8712	Department of Emergency Medicine, Royal Brisbane & Women's Hospital	The research reported here forms part of the doctoral thesis of Megan H. W. Preece, to be submitted to The University of Queensland. These data were also presented in a poster session at the inaugural Mild Traumatic Brain Injury Conference. August. 2009, Vancouver. British Columbia. Canada. We thank Emmaline Falconer and Felicia Tay for testing some of the participants; Mark Wetton for preparing the Hazard Perception Test; and Dr Kevin Chu and staff from the Department of Emergency Medicine, Royal Brisbane & Women's Hospital for supporting the researchers to complete the study.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BAILEY IL, 1993, OPTOMETRY VISION SCI, V70, P299, DOI 10.1097/00006324-199304000-00008; BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chapman PR, 1998, PERCEPTION, V27, P951, DOI 10.1068/p270951; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; Crundall D, 2003, J EXP PSYCHOL-APPL, V9, P163, DOI 10.1037/1076-898X.9.3.163; Crundall D, 1999, PERCEPTION, V28, P1075, DOI 10.1068/p2894; Crundall DE, 1998, ERGONOMICS, V41, P448, DOI 10.1080/001401398186937; Darby P, 2009, SAFETY SCI, V47, P436, DOI 10.1016/j.ssci.2008.05.004; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; De Monte VE., 2005, BRAIN IMPAIR, V6, P109, DOI [10.1375/brim.2005.6.2.109, DOI 10.1375/BRIM.2005.6.2.109]; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Falconer EK, 2006, BRAIN INJURY, V20, P1251, DOI 10.1080/02699050601049601; Fisk GD, 1998, BRAIN INJURY, V12, P683; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Garay-Vega L, 2007, TRANSPORT RES REC, P1, DOI 10.3141/2009-01; Goode KT, 1998, J CLIN PSYCHOL MED S, V5, P425, DOI 10.1023/A:1026206927686; Graydon FX, 2004, TRANSPORT RES F-TRAF, V7, P271, DOI 10.1016/j.trf.2004.09.006; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hirth VA, 2007, DEMENT GERIATR COGN, V24, P335, DOI 10.1159/000108606; Horikawa E, 2005, BRAIN COGNITION, V58, P166, DOI 10.1016/j.bandc.2004.10.002; Horswill M. S., 2004, COGNITIVE APPROACH S, P155; Horswill MS, 2008, J GERONTOL B-PSYCHOL, V63, pP212, DOI 10.1093/geronb/63.4.P212; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; KWAPIL KJ, 2003, BRAIN IMPAIR, V4, P155; Lawton R, 1997, J APPL SOC PSYCHOL, V27, P1258, DOI 10.1111/j.1559-1816.1997.tb01805.x; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lovibond SH., 1995, MANUAL DEPRESSION AN, V2nd; Marrington SA, 2008, OPTOMETRY VISION SCI, V85, P1121, DOI 10.1097/OPX.0b013e31818e8d00; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; MCCULLOUGH CM, 2006, BRAIN IMPAIR, V7, P16; McKenna F.P., 1999, BEHAV RES ROAD SAFET BEHAV RES ROAD SAFET; McKenna F.P., 1999, J INT ASS TRAFFIC SA, V23, P26; McKenna F.P., 1991, HAZARD PERCEPTION DR; McKenna FP, 2006, J EXP PSYCHOL-APPL, V12, P1, DOI 10.1037/1076-898X.12.1.1; Mesken J, 2002, ERGONOMICS, V45, P469, DOI 10.1080/00140130210129682; MILLS KL, 1998, EFFECTS HAZARD PERCE; Motor Accident Authorithies New South Wales, 2008, GUID MILD TRAUM BRAI; MOURANT RR, 1972, HUM FACTORS, V14, P325, DOI 10.1177/001872087201400405; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; PARKER D, 1995, ERGONOMICS, V38, P1036, DOI 10.1080/00140139508925170; PARKER D, 1995, ACCIDENT ANAL PREV, V27, P571, DOI 10.1016/0001-4575(95)00005-K; Pelz D.C., 1974, ACCIDENT ANAL PREV, V6, P45, DOI [10.1016/0001-4575(74)90015-3., DOI 10.1016/0001-4575(74)90015-3]; Pollatsek A, 2006, CURR DIR PSYCHOL SCI, V15, P255, DOI 10.1111/j.1467-8721.2006.00447.x; Pradhan AK, 2005, HUM FACTORS, V47, P840, DOI 10.1518/001872005775570961; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Preece MHW, 2007, BRAIN INJURY, V21, P951, DOI 10.1080/02699050701481647; QUIMBY AR, 1986, PERCEPTUAL ABILITIES, V27; Renge K., 1998, IATSS RES, V22, P103; Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432; Schneider JJ, 2005, APPL NEUROPSYCHOL, V12, P138, DOI 10.1207/S15324826AN1203_3; Smith SS, 2009, ACCIDENT ANAL PREV, V41, P729, DOI 10.1016/j.aap.2009.03.016; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Underwood G, 2002, ERGONOMICS, V45, P1, DOI 10.1080/00140130110110610; Underwood G., 2002, TRANSPORT RES F-TRAF, V5, P87, DOI [10.1016/S1369-8478(02)00008-6, DOI 10.1016/S1369-8478(02)00008-6]; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wald JL, 2000, CYBERPSYCHOL BEHAV, V3, P643, DOI 10.1089/109493100420232; Wallis TSA, 2007, ACCIDENT ANAL PREV, V39, P1177, DOI 10.1016/j.aap.2007.03.003; Watts G., 1979, DESIGN VALIDATION DR; Wechsler D, 1981, WESCHLER ADULT INTEL; WELLS P, 2008, COHORT 2 STUDY LEARN, V81	76	45	47	1	21	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2010	24	4					493	503		10.1037/a0018903			11	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	619HN	WOS:000279420500008	20604623				2022-02-06	
J	Kaen, A; Jimenez-Roldan, L; Arrese, I; Delgado, MA; Lopez, PG; Alday, R; Alen, JF; Lagares, A; Lobato, RD				Kaen, Ariel; Jimenez-Roldan, Luis; Arrese, Ignacio; Delgado, Manuel Amosa; Lopez, Pedro Gomez; Alday, Rafael; Alen, Jose Fernandez; Lagares, Alfonso; Lobato, Ramiro D.			The Value of Sequential Computed Tomography Scanning in Anticoagulated Patients Suffering From Minor Head Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Anticoagulation; Outcome; Mild head trauma	TRAUMATIC BRAIN-INJURY; PREINJURY WARFARIN USE; ELDERLY-PATIENTS; COMPLICATIONS; GUIDELINES; MANAGEMENT; ADULTS; RISK; CT	Background: Since 1999, the Italian guidelines have been used at our department for the management of patients with mild head injury (MHI). According to these guidelines, a computed tomography (CT) scan should be obtained in all patients with coagulopathy and these should routinely undergo strict observation during the first 24 hours after injury; in addition they should have a control CT scan before discharge. With the increased use of anticoagulant therapy in the elderly population, admitting patients in such treatment with a MHI to the emergency rooms has become very common. The aim of our study was to evaluate the need of performing a control CT scan in patients on anticoagulation treatment who showed neither intracranial pathology on the first CT-scan nor neurologic worsening during the observation period. Methods: We prospectively analyzed the course of all patients on anticoagulation treatment consecutively admitted to our unit between October 2005 and December 2006 who suffered from a MHI and showed a normal initial CT scan. All patients underwent strict observation during the first 24 hours after admission and had a control CT scan performed before discharge. Results: One hundred thirty-seven patients were included in this study. Only two patients (1.4%) showed hemorrhagic changes. However, neither of them developed concomitant neurologic worsening nor needed admitting or surgery. Conclusion: According with our data, patients on anticoagulation treatment suffering from MHI could be managed with strict neurologic observation without routinely performing a control CT scan that can be reserved for the rare patients showing new clinical symptoms.	[Kaen, Ariel] Hosp 12 Octubre, Serv Neurocirugia, Dept Neurosurg, E-28041 Madrid, Spain		Kaen, A (corresponding author), Hosp 12 Octubre, Serv Neurocirugia, Dept Neurosurg, Avda Cordoba S-N, E-28041 Madrid, Spain.	kaenariel@hotmail.com	KAEN, ARIEL/F-1338-2015; ALEN, JOSE A FERNANDEZ/G-4990-2018; Lagares, Alfonso/B-2969-2011; Jimenez-Roldan, Luis/K-2298-2017; kaen, ariel/G-3786-2015; Gomez, Pedro/N-5051-2019	ALEN, JOSE A FERNANDEZ/0000-0002-3321-983X; Lagares, Alfonso/0000-0003-3996-0554; Jimenez-Roldan, Luis/0000-0002-9864-0385; Gomez, Pedro/0000-0002-4185-5238; Amosa Delgado, Manuel/0000-0003-0748-7627; KAEN, ARIEL/0000-0002-0595-9515			Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; Gomez PA, 2000, NEUROCIRUGIA, V11, P351; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Itshayek E, 2006, NEUROSURGERY, V58, P851, DOI 10.1227/01.NEU.0000209653.B2936.96; Karni A, 2001, AM SURGEON, V67, P1098; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; Saab M, 1996, J ACCID EMERG MED, V13, P208; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Volans AP, 1998, J ACCID EMERG MED, V15, P159; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	23	45	46	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2010	68	4					895	898		10.1097/TA.0b013e3181b28a76			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	583GY	WOS:000276663100028	20016390				2022-02-06	
J	MacDonald, S; Wiseman-Hakes, C				MacDonald, Sheila; Wiseman-Hakes, Catherine			Knowledge translation in ABI rehabilitation: A model for consolidating and applying the evidence for cognitive-communication interventions	BRAIN INJURY			English	Article						Communication; cognitive-communication; speech-language pathology; speech-language therapy; speech therapy; communication therapy; intervention; treatment evidence; efficacy; evidence based practice; knowledge translation; knowledge transfer	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; PRACTICE GUIDELINES; VERBAL IMPAIRMENT; WORKING-MEMORY; LANGUAGE; DEFICITS; ADOLESCENTS; DISORDERS; CHILDREN	Primary objectives: (1) To propose a model for consolidating and disseminating existing evidence relevant to cognitive-communication interventions after ABI. (2) To present the Cognitive-Communication Intervention Review Framework (CCIRF). (3) To outline future considerations for applying evidence to clinical practice. Research design: Employment of a model for knowledge translation. Methods and procedures: Application of evidence requires synthesis and dissemination of information in an accessible format for end users. A literature search identified 20 systematic reviews (1997-2007) with a complex array of 72 practice recommendations relevant to cognitive-communication interventions. The CCIRF was used to synthesize the evidence within 11 intervention categories. Reviews were analysed according to: organization, population, intervention, comparison and outcome, with a focus on communication outcomes. Main outcomes and results: Consolidated evidence revealed support for interventions relating to: social communication, behavioural regulation, verbal formulation, attention, external memory aids, executive functions and communication partner training. Research gaps were noted in the areas of comprehension (auditory/reading), written expression and vocational communication interventions. Similar recommendations emerge across reviews. Conclusions: Implementation of the growing body of evidence for cognitive-communication interventions is challenged by variability in study populations, interventions, and research focus on communication. The CCIRF provides a means of promoting consistency in knowledge translation and application.	[MacDonald, Sheila] Sheila MacDonald & Associates, Guelph, ON N1H 6J2, Canada; [Wiseman-Hakes, Catherine] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada		MacDonald, S (corresponding author), Sheila MacDonald & Associates, Suite 26,5420 Hwy 6 N, Guelph, ON N1H 6J2, Canada.	sheilamacdonald@rogers.com	Wiseman-Hakes, Catherine/AAC-8303-2021	Wiseman-Hakes, Catherine/0000-0001-8441-884X	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Ministry of Health and Long-Term Care in OntarioMinistry of Health and Long-Term Care, Ontario	The authors wish to express sincere gratitude to Dr Lyn Turkstra and Dr Mark Ylvisaker for their editorial expertise in reviewing this paper at various stages of its evolution. Appreciation is also extended to Dr Mary Kennedy and Dr Leanne Togher who provided resources during the earlier stages of the paper. The second author gratefully acknowledges the support of the Canadian Institutes for Health Research through a Fellowship in Clinical Research, and the Toronto Rehabilitation Institute who receive funding under the Provincial Rehabilitation Research Program from the Ministry of Health and Long-Term Care in Ontario. The views expressed do not necessarily reflect those of the Ministry.	*AM SPEECH LANG HE, 2006, ASHA EV BAS PRACT; American Speech-Language-Hearing Association (ASHA), 2005, ROL SPEECH LANG PATH; *ASHA, 2006, STEPS PROC EV BAS PR; *ASHA, 1987, LANG SUBC COGN LANG; Barreca S, 2003, BRAIN INJURY, V17, P1065, DOI 10.1080/0269905031000110535; Beeson PM, 2006, NEUROPSYCHOL REV, V16, P161, DOI 10.1007/s11065-006-9013-7; BIGLER ED, 1988, J LEARN DISABIL, V21, P325, DOI 10.1177/002221948802100602; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Carlson PM, 2006, BRAIN INJURY, V20, P1111, DOI 10.1080/02699050600955337; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CARNEY N, 1999, 2 AG HLTHHC POL RES; CASLPO, 2002, PREF PRACT GUID COGN; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cirrin FM, 2008, LANG SPEECH HEAR SER, V39, pS110, DOI 10.1044/0161-1461(2008/012); Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; COHEN M, NEUROPSYCHO IN PRESS; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; Dobbins M, 2002, ONLINE J KNOWL SYN N, V9; Docking K, 1999, BRAIN INJURY, V13, P953; Dodd B, 2007, FOLIA PHONIATR LOGO, V59, P118, DOI 10.1159/000101770; Dolloghan C., 2007, HDB EVIDENCE BASED P; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; GIROLAMETTO L, 1994, J EARLY INTERVENTION, V18, P155, DOI 10.1177/105381519401800204; Glang A, 2008, J HEAD TRAUMA REHAB, V23, P243, DOI 10.1097/01.HTR.0000327256.46504.9f; Golper L., 2001, EVIDENCE BASED PRACT; Graham Ian D, 2007, Healthc Q, V10, P20; GREENER J, 1998, INT J LANGUAGE COM S, V33, P148; HAGEN C, 1986, HDB SPEECH LANGUAGE; Halper AS, 1991, CLIN MANAGEMENT COMM; HALPERN H, 1973, J SPEECH HEAR DISORD, V38, P162, DOI 10.1044/jshd.3802.162; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Jurado MA, 2000, BRAIN INJURY, V14, P789; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); KATZ R, 2002, EVIDENCE BASED PRACT; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; King KA, 2006, BRAIN INJURY, V20, P725, DOI 10.1080/02699050600743824; KUNTZ R, 2008, J CLIN EPIDEMIOL, V61, P207; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Larkins Brigette, 2007, Seminars in Speech and Language, V28, P334, DOI 10.1055/s-2007-986530; LIPPERT C, 2007, 13 ERABI; LOMAS J, 1997, C971 MCMASTER U CTR; Macdonald S, 2005, BRAIN INJURY, V19, P895, DOI 10.1080/02699050400004294; Malec JF, 2005, REHABILITATION TRAUM, P176; MARQUARDT TP, 1988, J LEARN DISABIL, V21, P340, DOI 10.1177/002221948802100605; MARSHALL S, 2007, 6 ERABI; Martin Randi C., 2008, Seminars in Speech and Language, V29, P201, DOI 10.1055/s-0028-1082884; MCCORMICK A, 2007, 14 ERABI; McDonald S., 2003, BRAIN IMPAIR, V4, P36, DOI [10.1375/brim.4.1.36.27032, DOI 10.1375/BRIM.4.1.36.27032, DOI 10.1375/brim.4.1.36.27032]; MCDONALD S, 2006, BRAIN IMPAIR, V7, P169; Montgomery EB, 2003, J MED SPEECH-LANG PA, V11, pIX; Moran CA, 2006, BRAIN INJURY, V20, P417, DOI 10.1080/02699050500488223; Nail-Chiwetalu BJ, 2006, LANG SPEECH HEAR SER, V37, P157, DOI 10.1044/0161-1461(2006/018); National Reading Panel, 2000, TEACH CHILDR READ EV; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; PERDICES M, 2006, BRAIN IMPAIR, V2, P119; *PSYCBITE, PSYCBITE DAT ACQ BRA; Ratner NB, 2006, LANG SPEECH HEAR SER, V37, P257, DOI 10.1044/0161-1461(2006/029); REES L, 2007, 8 ERABI; Richardson W. S., 2000, EVIDENCE BASED MED P, V2nd; ROBEY RR, 1994, BRAIN LANG, V47, P582, DOI 10.1006/brln.1994.1060; Robey RR, 1998, J SPEECH LANG HEAR R, V41, P172, DOI 10.1044/jslhr.4101.172; RUSK H, 1969, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SCOLLON J, 2000, PUBLICATION WORKERS; SOHLBERG M, 2007, J MED SPEECH PATHOLO, V15; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Struchen M. A., 2005, REHABILITATION TRAUM, P88; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; TOGHER L, 1999, COMMUNICATION DISORD, P14; TURKIBENALI Y, 2005, PHYSICA E, V26, P222; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra Lyn S, 2005, Semin Speech Lang, V26, P213, DOI 10.1055/s-2005-922100; Turkstra Lyn S., 2001, Seminars in Speech and Language, V22, P147; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Vingilis E, 2003, CAN J PUBLIC HEALTH, V94, P468, DOI 10.1007/BF03405087; WELCHWEST P, 2007, COMMUNICATION DEFICI; Wiseman-Hakes C, 1998, J HEAD TRAUMA REHAB, V13, P23, DOI 10.1097/00001199-199812000-00005; WISEMANHAKES C, NEUROREHABI IN PRESS; World Health Organization, 2007, INT CLASS FUNCT DIS; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; YLVISAKER M, 2005, REHABILITATION TRAUM; Ylvisaker M., 2006, BRAIN IMPAIR, V7, P246, DOI [10.1375/brim.7.3.246, DOI 10.1375/BRIM.7.3.246]; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Ylvisaker Mark, 1996, Seminars in Speech and Language, V17, P217, DOI 10.1055/s-2008-1064100; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951; Zipoli RP, 2005, AM J SPEECH-LANG PAT, V14, P208, DOI 10.1044/1058-0360(2005/021)	103	45	46	0	32	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2010	24	3					486	508		10.3109/02699050903518118			23	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	574JR	WOS:000275985800005	20184406				2022-02-06	
J	Kozak, LR; Bango, M; Szabo, M; Rudas, G; Vidnyanszky, Z; Nagy, Z				Kozak, L. R.; Bango, M.; Szabo, M.; Rudas, G.; Vidnyanszky, Z.; Nagy, Z.			Using diffusion MRI for measuring the temperature of cerebrospinal fluid within the lateral ventricles	ACTA PAEDIATRICA			English	Article						Asphyxia; Diffusion; Magnetic resonance imaging; Temperature; Thermometry	MODERATE HYPOTHERMIA; HUMAN MUSCLE; BRAIN; THERMOMETRY; HYPERTHERMIA; SYSTEMS; INJURY	Aim: Hypothermia is often induced to reduce brain injury in newborns, following perinatal hypoxic-ischaemic events, and in adults following traumatic brain injury, stroke or cardiac arrest. We aimed to devise a method, based on diffusion-weighted MRI, to measure non-invasively the temperature of the cerebrospinal fluid in the lateral ventricles. Methods: The well-known temperature dependence of the water diffusion constant was used for the estimation of temperature. We carried out diffusion MRI measurements on a 3T Philips Achieva Scanner involving phantoms (filled with water or artificial cerebrospinal fluid while slowly cooling from 41 to 32 degrees C) and healthy adult volunteers. Results: The estimated temperature of water phantoms followed that measured using a mercury thermometer, but the estimates for artificial cerebrospinal fluid were 1.04 degrees C lower. After correcting for this systematic difference, the estimated temperature within the lateral ventricles of volunteers was 39.9 degrees C. Using diffusion directions less sensitive to cerebrospinal fluid flow, it was 37.7 degrees C, which was in agreement with the literature. Conclusion: Although further improvements are needed, measuring the temperature within the lateral ventricles using diffusion MRI is a viable method that may be useful for clinical applications. We introduced the method, identified sources of error and offered remedies for each.	[Kozak, L. R.; Bango, M.; Rudas, G.; Vidnyanszky, Z.] Semmelweis Univ, Szentagothai J Knowledge Ctr, MR Res Ctr, H-1083 Budapest, Hungary; [Bango, M.; Szabo, M.] Semmelweis Univ, Dept Pediat 1, H-1083 Budapest, Hungary; [Vidnyanszky, Z.] Semmelweis Univ, Pazmany Peter Catholic Univ, Hungarian Acad Sci, Neurob Res Grp, H-1083 Budapest, Hungary; [Nagy, Z.] UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London, England; [Nagy, Z.] Karolinska Univ Hosp, Neonatal Unit, Dept Woman & Child Hlth, Stockholm, Sweden		Kozak, LR (corresponding author), Semmelweis Univ, Szentagothai J Knowledge Ctr, MR Res Ctr, Balassa U 6, H-1083 Budapest, Hungary.	lkozak@mrkk.sote.hu	Kozak, Lajos R/B-4194-2011; Nagy, Zoltan/AAI-2485-2019	Kozak, Lajos R/0000-0003-0368-3663; Nagy, Zoltan/0000-0001-6611-6362	Hungarian Scientific Research FundOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [T048949]; Bolyai FellowshipHungarian Academy of Sciences; Wellcome Trust (UK)Wellcome Trust	The authors thank Dr Attila Ambrus, PhD, from the Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary and Dr Gabor Vass, PhD, from the Institute of Chemistry, Eotvos Lorand University, Budapest, Hungary for their kind assistance in the preparation of the artificial cerebrospinal fluid that was used in the phantom experiments. This study was supported by the Hungarian Scientific Research Fund (T048949) and by the Bolyai Fellowship to ZV. ZN enjoys support from the Wellcome Trust (UK).	Berkow Robert, 1999, MERCK MANUAL DIAGNOS; Bevington P.R., 2003, DATA REDUCTION ERROR; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CADY EB, 1995, MAGN RESON MED, V33, P862, DOI 10.1002/mrm.1910330620; CARR HY, 1954, PHYS REV, V94, P630, DOI 10.1103/PhysRev.94.630; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Cheung Ka Wai, 2006, CJEM, V8, P329; DAVSON H, 1987, PHYSL PATHOPHYSIOLOG; den Hertog Heleen, 2007, Expert Rev Neurother, V7, P155, DOI 10.1586/14737175.7.2.155; DEPOORTER J, 1995, MAGNET RESON MED, V33, P74; Einstein A., 1956, INVESTIGATIONS THEOR; Il'yasov KA, 1998, J MAGN RESON IMAGING, V8, P1296; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Kingsley PB, 2004, MAGNET RESON MED, V51, P996, DOI 10.1002/mrm.20059; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1989, RADIOLOGY, V171, P853, DOI 10.1148/radiology.171.3.2717764; Mcilvoy Laura, 2004, J Neurosci Nurs, V36, P23; Mcilvoy LH, 2005, AACN ADV CRIT CARE, V16, P488, DOI 10.1097/00044067-200510000-00006; MILLS R, 1973, J PHYS CHEM-US, V77, P685, DOI 10.1021/j100624a025; MORVAN D, 1993, MAGNET RESON MED, V29, P371, DOI 10.1002/mrm.1910290313; Nagy Z, 2007, MAGN RESON MED, V58, P763, DOI 10.1002/mrm.21379; Rieke V, 2008, J MAGN RESON IMAGING, V27, P376, DOI 10.1002/jmri.21265; ROBERTSON NJ, 2007, P PEAD AC SOC C TOR; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Tofts PS, 2008, MAGN RESON MED, V59, P190, DOI 10.1002/mrm.21456; Tumani H, 2009, NEUROBIOL DIS, V35, P117, DOI 10.1016/j.nbd.2009.04.010; Whitelaw A, 2002, NEWBORN BRAIN: NEUROSCIENCE AND CLINICAL APPLICATIONS, P415; Xing D, 1997, MAGN RESON IMAGING, V15, P771, DOI 10.1016/S0730-725X(97)00037-4; Zougman A, 2008, J PROTEOME RES, V7, P386, DOI 10.1021/pr070501k	31	45	47	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253			ACTA PAEDIATR	Acta Paediatr.	FEB	2010	99	2					237	243		10.1111/j.1651-2227.2009.01528.x			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	541VS	WOS:000273449700018	19845565	Green Published			2022-02-06	
J	Saljo, A; Bolouri, H; Mayorga, M; Svensson, B; Hamberger, A				Saljo, Annette; Bolouri, Hayde; Mayorga, Maria; Svensson, Berndt; Hamberger, Anders			Low-Level Blast Raises Intracranial Pressure and Impairs Cognitive Function in Rats: Prophylaxis with Processed Cereal Feed	JOURNAL OF NEUROTRAUMA			English	Article						blast; intracranial pressure; cognitive function; traumatic brain injury treatment	TRAUMATIC BRAIN-INJURY; HUMAN CEREBROSPINAL-FLUID; CLOSED-HEAD INJURY; ATRIAL-NATRIURETIC-PEPTIDE; ANTISECRETORY FACTOR; KETOGENIC DIET; NA+/K+ PUMP; CELL-DEATH; MODEL; DEFICITS	There is increasing evidence that even low levels of blast cause brain injury, but little is known about their thresholds and mechanisms. Exposure of rats to 10-60 kPa blasts elevate intracranial pressure (ICP) in a dose-dependent manner and impair cognitive function. We have evaluated a prophylactic measure against these brain injuries in a rat animal model, consisting of feeding them processed cereal. This type of feed is known to ameliorate disturbances in secretion of body fluids and to have anti-inflammatory effects. In humans, intake of processed cereals is effective against intestinal diarrhea and also reduces the symptoms of Meniere's disease. Rats were given either standard laboratory feed or processed cereal feed for 2 weeks before exposure to blast in a shock tube. The ICP was monitored at different time points up to 1 week after exposure to a 60-kPa blast, and for up to 24 h after exposure to a 30-kPa blast. Maximal ICP elevation was reached at 10 h in both groups. In the group of rats on standard feed exposed to 60 kPa, an ICP increase of 145% was noted at 10 h, and the corresponding increase in the rats fed processed cereal feed was only 50%. In rats exposed to a 30-kPa blast, those fed standard feed and processed cereal feed demonstrated increases of ICP of 80% and 40%, respectively. Cognitive function as measured by the Morris water maze was assessed in other groups of rats at 2 days after exposure to 10- or 30-kPa blasts. Their performance was significantly impaired at both exposure levels in rats on standard feed, but no functional impairment was seen in rats fed processed cereal feed.	[Saljo, Annette] Univ Gothenburg, Inst Biomed, Sect Med Chem & Cell Biol, Sahlgren Acad,Dept Med Chem & Cell Biol, SE-40530 Gothenburg, Sweden		Saljo, A (corresponding author), Univ Gothenburg, Inst Biomed, Sect Med Chem & Cell Biol, Sahlgren Acad,Dept Med Chem & Cell Biol, Box 440, SE-40530 Gothenburg, Sweden.	annette.saljo@anatcell.gu.se			Swedish Armed ForcesFMV and Svenska Militarlakareforeningen	The authors want to express their gratitude to Svante Hojer, Samba Sensors AB, Vastra Frolunda, Sweden, for sharing with us his knowledge of pressure sensors and pressure recording; to Stefan Lange, Department of Infectious Medicine, Sahlgrenska Academy, Goteborg, Sweden; and Lantmannen AS-Faktor AB, Stockholm, Sweden, for providing advice and the cereal feed. This study was supported by grants from the Swedish Armed ForcesFMV and Svenska Militarlakareforeningen.	Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bjorck S, 2000, GUT, V46, P824, DOI 10.1136/gut.46.6.824; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; CLERICO A, 1992, CLIN CHEM, V38, P504; DOCZI T, 1993, ACTA NEUROCHIR, V121, P1, DOI 10.1007/BF01405174; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; HALPERIN JA, 1985, LIFE SCI, V37, P561, DOI 10.1016/0024-3205(85)90469-2; HALPERIN JA, 1988, J BIOL CHEM, V263, P646; Hamberger A, 2003, NEUROCHEM RES, V28, P177, DOI 10.1023/A:1022364830421; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hanner P, 2004, HEARING RES, V190, P31, DOI 10.1016/S0378-5955(03)00368-X; HANNER P, 2009, ACTA OTO-LARYNGOL, P1; Hoane MR, 2008, MAGNESIUM RES, V21, P29; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Jamali S, 1998, BRAIN INJURY, V12, P525, DOI 10.1080/026990598122485; Jantzen JPAH, 2007, BEST PRACT RES-CLIN, V21, P517, DOI 10.1016/j.bpa.2007.09.001; Jennische E, 2008, BRAIN RES, V1227, P189, DOI 10.1016/j.brainres.2008.05.083; JOHANSSON E, 1995, J BIOL CHEM, V270, P20615, DOI 10.1074/jbc.270.35.20615; Johansson E, 1997, BBA-MOL BASIS DIS, V1362, P177, DOI 10.1016/S0925-4439(97)00066-5; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Lange S, 2001, INT REV CYTOL, V210, P39; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; LONNROTH I, 1988, COMP BIOCHEM PHYS A, V90, P611, DOI 10.1016/0300-9629(88)90675-5; LORENZO AV, 1989, Z KINDERCHIR, V44, P24; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAYORGA MA, 2008, SPANISH J NEUROPSYCH, V10, P109; Mendelson WB, 1999, NEUROREPORT, V10, P3237, DOI 10.1097/00001756-199910190-00021; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NEWMAN LA, 2003, CARING OUR SOLDIERS, P10; Orban JC, 2007, ANN FR ANESTH, V26, P440, DOI 10.1016/j.annfar.2007.03.001; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; PRUSACZYK WK, 2008, ANN BATTL HEALTHC C; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; ROSENBERG GA, 1995, STROKE, V26, P874, DOI 10.1161/01.STR.26.5.874; SALJO A, 2009, J NEUROTRAUMA; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Vajda Z, 2001, NEUROSURGERY, V49, P697, DOI 10.1097/00006123-200109000-00031; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Westhout FD, 2008, SURG NEUROL, V70, P70, DOI 10.1016/j.surneu.2007.04.020; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599; Zohar O, 2006, NEUROSCI LETT, V394, P239, DOI 10.1016/j.neulet.2005.10.099	61	45	45	0	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					383	389		10.1089/neu.2009.1053			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800011	19852583				2022-02-06	
J	Bortnik, KE; Boone, KB; Marion, SD; Amano, S; Ziegler, E; Cottingham, ME; Victor, TL; Zeller, MA				Bortnik, Kirsty E.; Boone, Kyle B.; Marion, Sarah D.; Amano, Stacy; Ziegler, Elizabeth; Cottingham, Maria E.; Victor, Tara L.; Zeller, Michelle A.			EXAMINATION OF VARIOUS WMS-III LOGICAL MEMORY SCORES IN THE ASSESSMENT OF RESPONSE BIAS	CLINICAL NEUROPSYCHOLOGIST			English	Article						Logical Memory; Wechsler Memory Scale - III; Malingering; Rarely Missed Index; Effort	RARELY MISSED INDEX; TRAUMATIC BRAIN-INJURY; SUSPECT EFFORT; RECOGNITION TRIAL; SENSITIVITY; SPECIFICITY; PERFORMANCE; VALIDITY; SCALE	The assessment of response validity during neuropsychological evaluation is an integral part of the testing process. Research has increasingly focused on the use of "embedded'' effort measures (derived from standard neuropsychological tasks) because they do not require additional administration time and are less likely to be identified as effort indicators by test takers because of their primary focus as measures of cognitive function. The current study examined the clinical utility of various WMS-III Logical Memory scores in detecting response bias, as well as the Rarely Missed Index, an embedded effort indicator derived from the WMS-III Logical Memory Delayed Recognition subtest. The Rarely Missed Index cut-off only identified 24.1% of 63 non-credible participants (at >= 90% specificity in 125 credible patients), and cut-offs for other Logical Memory variables were in fact found to be more sensitive to non-credible performance. A new indicator, consisting of the weighted combination of the two most sensitive Logical Memory subtest scores (Logical Memory II raw score and Logical Memory Delayed Recognition raw score), was associated with 53% to 60% sensitivity, and thus may be an effective adjunct when utilized in conjunction with other validated effort indicators and collateral information in identifying non-credible performance.	[Bortnik, Kirsty E.; Marion, Sarah D.; Amano, Stacy] Fuller Grad Sch Psychol, Pasadena, CA USA; [Boone, Kyle B.] Alliant Int Univ, Los Angeles, CA USA; [Ziegler, Elizabeth] Spokane VA Med Ctr, Spokane, WA USA; [Victor, Tara L.] Calif State Univ Dominguez Hills, Carson, CA 90747 USA; [Zeller, Michelle A.] W LA VA Med Ctr, Los Angeles, CA USA		Bortnik, KE (corresponding author), Fuller Grad Sch Psychol, Pasadena, CA USA.	kirstybortnik@fuller.edu	Victor, Tara/K-6581-2019				Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Arnold G., 2007, ASSESSMENT FEIGNED C, P178; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; BABIKIAN T, 2007, ASSESSMENT FEIGNED C, P00103; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Boone K., 2002, DOT COUNTING TEST; Boone K., CLIN NEUROP IN PRESS; Boone K. B., 2002, B TEST; Boone K. B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; BOONE KB, 2007, ASSESSMENT MALINGERE, P27; BRANDT J, 1988, CLIN ASSESSMENT MALI, P65; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Haines ME, 2001, CLIN NEUROPSYCHOL, V15, P171, DOI 10.1076/clin.15.2.171.1891; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; Lange RT, 2006, J CLIN EXP NEUROPSYC, V28, P294, DOI 10.1080/13803390490918156; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P412, DOI 10.1080/13803390490520319; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P80; LARRABEE GJ, 2007, ASSESSMENT MALINGERE, P3; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; Lu P. H., 2007, ASSESSMENT FEIGNED C, P128; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Ross SR, 1999, CLIN NEUROPSYCHOL, V13, P112, DOI 10.1076/clin.13.1.112.1973; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J.A., 2007, ASSESSMENT MALINGERE, P131; Swihart AA, 2008, J CLIN EXP NEUROPSYC, V30, P120, DOI 10.1080/13803390701249044; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler D., 1997, WECHSLER MEMORY SCAL	43	45	45	1	8	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	2					344	357		10.1080/13854040903307268			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	566HR	WOS:000275361200011	19921593				2022-02-06	
J	Huckans, M; Pavawalla, S; Demadura, T; Kolessar, M; Seelye, A; Roost, N; Twamley, EW; Storzbach, D				Huckans, Marilyn; Pavawalla, Shital; Demadura, Theresa; Kolessar, Michael; Seelye, Adriana; Roost, Noah; Twamley, Elizabeth W.; Storzbach, Daniel			A pilot study examining effects of group-based Cognitive Strategy Training treatment on self-reported cognitive problems, psychiatric symptoms, functioning, and compensatory strategy use in OIF/OEF combat veterans with persistent mild cognitive disorder and history of traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast injury; cognitive aids; cognitive rehabilitation; combat veterans; compensatory strategies; Operation Enduring Freedom (OEF); Operation Iraqi Freedom (OIF); postconcussive syndrome; posttraumatic stress disorder; traumatic brain injury	REHABILITATION OUTCOMES; HEAD TRAUMA; BLAST; IRAQ; WAR; SCHIZOPHRENIA; QUESTIONNAIRE; METAANALYSIS; PERSONNEL; MEMORY	We aimed to determine whether group-based Cognitive Strategy Training (CST) for combat veterans with mild cognitive disorder and a history of traumatic brain injury (TBI) has significant posttreatment effects on self-reported compensatory strategy usage, functioning, and psychiatric symptoms. Participants included 21 veterans returning from conflicts in Iraq or Afghanistan with a diagnosis of Cognitive Disorder, Not Otherwise Specified and a history of combat-related TBI. Participants attended 6- to 8-week structured CST groups designed to provide them training in and practice with a variety of compensatory cognitive strategies, including day planner usage. Of the participants, 16 completed pre- and posttreatment assessment measures. Following CST, participants reported significantly increased use of compensatory cognitive strategies and day planners; an increased perception that these strategies were useful to them; increased life satisfaction; and decreased depressive, memory, and cognitive symptom severity. Group-based CST is a promising intervention for veterans with mild cognitive disorder, and randomized controlled trials are required to further evaluate its efficacy.	[Huckans, Marilyn; Kolessar, Michael; Storzbach, Daniel] Portland Dept Vet Affairs VA Med Ctr, Div Res, Portland, OR USA; [Huckans, Marilyn; Demadura, Theresa; Roost, Noah; Storzbach, Daniel] Portland Dept Vet Affairs VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA; [Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Pavawalla, Shital; Seelye, Adriana] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA; [Pavawalla, Shital] VA Palo Alto Hlth Care Syst, Psychol Serv, Palo Alto, CA USA; [Kolessar, Michael] Pacific Univ, Sch Profess Psychol, Portland, OR USA; [Twamley, Elizabeth W.] VA San Diego Healthcare Syst, San Diego, CA USA; [Twamley, Elizabeth W.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA		Huckans, M (corresponding author), Portland VA Med Ctr P3MHN, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	marilyn.huckans@va.gov			VA Rehabilitation Research and Development Service Merit Review Study [B5060R]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080150] Funding Source: NIH RePORTER	This material was based on work supported in part by a VA Rehabilitation Research and Development Service Merit Review Study (grant B5060R) to Dr. Storzbach and a VA Career Development Award to Dr. Huckans.	Beck AT, 1996, BDI 2 BECK DEPRESSIO; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bell C.C., 2001, DIAGNOSTIC STAT MANU, VFourth; Benedict RHB, 2004, MULT SCLER J, V10, P675, DOI 10.1191/1352458504ms1098oa; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dixon RA, 2001, J CLIN EXP NEUROPSYC, V23, P650, DOI 10.1076/jcen.23.5.650.1242; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gossop M, 2002, ADDICTION, V97, P169, DOI 10.1046/j.1360-0443.2002.00028.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; RITCHIE EC, 2006, COMBAT DISASTER PSYC; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Siddharthan K, 2008, REHABIL NURS, V33, P221, DOI 10.1002/j.2048-7940.2008.tb00231.x; Singer Pierre, 2005, Crit Care Med, V33, pS61, DOI 10.1097/01.CCM.0000151068.33935.3E; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Twamley EW, 2008, AM J PSYCHIATR REHAB, V11, P144, DOI 10.1080/15487760801963678; Twamley EW, 2003, SCHIZOPHRENIA BULL, V29, P359, DOI 10.1093/oxfordjournals.schbul.a007011; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Weathers FW, 1996, MEASUREMENT STRESS T, P250; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	40	45	45	0	17	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2010	47	1					43	60		10.1682/JRRD.2009.02.0019			18	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	577HH	WOS:000276212700006	20437326	Bronze, Green Accepted			2022-02-06	
J	Franschman, G; Peerdeman, SM; Greuters, S; Vieveen, J; Brinkman, ACM; Christiaans, HMT; Toor, EJ; Jukema, GN; Loer, SA; Boer, C				Franschman, G.; Peerdeman, S. M.; Greuters, S.; Vieveen, J.; Brinkman, A. C. M.; Christiaans, H. M. T.; Toor, E. J.; Jukema, G. N.; Loer, S. A.; Boer, C.		ALARM-TBI Investigators	Prehospital endotracheal intubation in patients with severe traumatic brain injury: Guidelines versus reality	RESUSCITATION			English	Article						Brain injury; Prehospital; Emergency medical service; Airway management; Guideline adherence	SEVERE HEAD-INJURY; RAPID-SEQUENCE INTUBATION; CEREBRAL-ISCHEMIA; HYPERVENTILATION; MANAGEMENT; OUTCOMES; HYPERGLYCEMIA; PREDICTORS; PHYSICIANS; HYPOXEMIA	The international Brain Trauma Foundation guidelines recommend prehospital endotracheal intubation in all patients with traumatic brain injury (TBI) and a Glasgow Coma Scale (GCS) <= 8. Close adherence to these guidelines is associated with improved outcome, but not all severely injured TBI patients receive adequate prehospital airway support. Here we hypothesized that guideline adherence varies when skills are involved that rely on training and expertise, such as endotracheal intubation. We retrospectively studied the medical records of CT-confirmed TBI patients with a GCS <= 8 who were referred to a level 1 trauma centre in Amsterdam (n = 127). Records were analyzed for demographic parameters, prehospital treatment modalities, involvement of an emergency medical service (EMS) and respiratory and metabolic parameters Upon arrival at the hospital. Patients were mostly male, aged 45 +/- 21 years with a median injury severity score (ISS) of 26. Of all patients for whom guidelines recommend endotracheal intubation, only 56% were intubated. In 21 out of 106 severe cases an EMS was not called for, suggesting low guideline adherence. Especially those TBI patients treated by paramedics tended to develop higher levels of stress markets like glucose and lactate. We observed a low degree of adherence to intubation guidelines in a Dutch urban area. Main reasons for low adherence were the unavailability of specialized care, scoop and run strategies and absence of a specialist physician in cases where intubation was recommended. The discrepancy between guidelines and reality warrants changing practice to improve guideline compliance and optimize outcome in TBI patients. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Franschman, G.; Greuters, S.; Vieveen, J.; Brinkman, A. C. M.; Christiaans, H. M. T.; Loer, S. A.; Boer, C.] Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, NL-1081 HV Amsterdam, Netherlands; [Peerdeman, S. M.] Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, NL-1081 HV Amsterdam, Netherlands; [Toor, E. J.; Jukema, G. N.] Vrije Univ Amsterdam, Med Ctr, Dept Traumatol, NL-1081 HV Amsterdam, Netherlands		Franschman, G (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	g.franschman@vumc.nl		Boer, Christa/0000-0002-7781-6951			Ausina A, 1998, ACT NEUR S, V71, P1; Bouamra O, 2006, J TRAUMA, V61, P701, DOI 10.1097/01.ta.0000197175.91116.10; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DF, 2008, CURR OPIN CRIT CARE, V14, P142, DOI 10.1097/MCC.0b013e3282f63c40; Davis DP, 2008, RESUSCITATION, V76, P333, DOI 10.1016/j.resuscitation.2007.08.004; Davis DP, 2007, RESUSCITATION, V73, P354, DOI 10.1016/j.resuscitation.2006.09.015; Davis DP, 2005, J TRAUMA, V59, P794; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; *FDN NAT AMB EM RO, 2007, LAND PROT AMB LPA7; FLORES EA, 1990, METABOLISM, V39, P738, DOI 10.1016/0026-0495(90)90110-X; Garner A, 1999, AUST NZ J SURG, V69, P697, DOI 10.1046/j.1440-1622.1999.01688.x; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; HILL M, 1991, J CLIN INVEST, V88, P811, DOI 10.1172/JCI115381; Huizenga JE, 2002, ACAD EMERG MED, V9, P806, DOI 10.1197/aemj.9.8.806; Khani S, 2001, CLIN SCI, V101, P739, DOI [10.1042/CS20010180, 10.1042/cs1010739]; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Neumann JO, 2008, INTENS CARE MED, V34, P1676, DOI 10.1007/s00134-008-1123-7; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Parr M, 2008, RESUSCITATION, V76, P321, DOI 10.1016/j.resuscitation.2008.01.001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Timmermann A, 2008, CURR OPIN ANESTHESIO, V21, P222, DOI 10.1097/ACO.0b013e3282f5f4f7; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Watt MJ, 2001, J PHYSIOL-LONDON, V534, P269, DOI 10.1111/j.1469-7793.2001.t01-1-00269.x; Watts Dorraine D, 2004, Prehosp Emerg Care, V8, P254; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	36	45	46	1	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	OCT	2009	80	10					1147	1151		10.1016/j.resuscitation.2009.06.029			5	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	513PX	WOS:000271336400013	19632024				2022-02-06	
J	Anderson, J; Sandhir, R; Hamilton, ES; Berman, NEJ				Anderson, Joshua; Sandhir, Rajat; Hamilton, Eric S.; Berman, Nancy E. J.			Impaired Expression of Neuroprotective Molecules in the HIF-1 alpha Pathway following Traumatic Brain Injury in Aged Mice	JOURNAL OF NEUROTRAUMA			English	Article						aging; erythropoietin; HIF-1 alpha; heme oxygenase-1; neuroprotection; traumatic brain injury; VEGF	HYPOXIA-INDUCIBLE FACTOR; CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; ENDOTHELIAL GROWTH-FACTOR; HEME OXYGENASE-1; FACTOR-I; INTRALUMINAL SUTURE; NEURONAL APOPTOSIS; UNITED-STATES; OLDER-ADULTS	Elderly traumatic brain injury (TBI) patients have higher rates of mortality and worse functional outcome than non-elderly TBI patients. The mechanisms involved in poor outcomes in the elderly are not well understood. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a basic helix-loop-helix transcription factor that modulates expression of key genes involved in neuroprotection. In this study, we studied the expression of HIF-1 alpha and its target survival genes, heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and erythropoietin (EPO) in the brains of adult versus aged mice following controlled cortical impact (CCI) injury. Adult (5-6 months) and aged (23-24 months) C57Bl/6 mice were injured using a CCI device. At 72 h post-injury, mice were sacrificed and the injured cortex was used for mRNA and protein analysis using real-time reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting protocols. Following injury, HIF-1 alpha, HO-1, and VEGF showed upregulation in both the young and aged mice, but in the aged animals the increase in HIF-1 alpha and VEGF in response to injury was much lower than in the adult injured animals. EPO was upregulated in the adult injured brain, but not in the aged injured brain. These results support the hypothesis that reduced expression of genes in the HIF-1 alpha neuroprotective pathway in aging may contribute to poor prognosis in the elderly following TBI.	[Sandhir, Rajat; Hamilton, Eric S.; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Anderson, Joshua; Sandhir, Rajat; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Steve Palermo Nerve Regenerat Lab, Kansas City, KS 66160 USA; [Anderson, Joshua; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66160 USA		Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Dept Anat & Cell Biol, 3901 Rainbow Blvd,Mail Stop 3038, Kansas City, KS 66160 USA.	nberman@kumc.edu			Steve Palermo Endowment; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG026482, P30 NICHD HD 02528]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG026482] Funding Source: NIH RePORTER	We acknowledge the assistance of Eugene Gregory in carrying out the work and Eileen Roach with processing of the images. Special thanks go to Dr. Y. Y. He for his help with controlled cortical impact injury. This study was supported in part by the Steve Palermo Endowment and the National Institutes of Health (AG026482 and research core support P30 NICHD HD 02528).	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Alam J, 2007, AM J RESP CELL MOL, V36, P166, DOI 10.1165/rcmb.2006-0340TR; Anderson RM, 1998, AM J FOREN MED PATH, V19, P1, DOI 10.1097/00000433-199803000-00001; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Belayev L, 1997, J CEREBR BLOOD F MET, V17, P1266, DOI 10.1097/00004647-199712000-00002; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Campbell SJ, 2007, NEUROPATH APPL NEURO, V33, P108, DOI 10.1111/j.1365-2990.2006.00773.x; Carmeliet P, 2002, SEMIN CELL DEV BIOL, V13, P39, DOI 10.1006/scdb.2001.0290; Chang EF, 2003, J NEUROSCI, V23, P3689; Chavez JC, 2003, ADV EXP MED BIOL, V510, P337; Chavez JC, 2002, J NEUROSCI, V22, P8922; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ferrandiz ML, 2008, CURR PHARM DESIGN, V14, P473, DOI 10.2174/138161208783597399; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Frenkel-Denkberg G, 1999, FEBS LETT, V462, P341, DOI 10.1016/S0014-5793(99)01552-5; GALBRAITH S, 1987, BRIT MED J, V294, P325, DOI 10.1136/bmj.294.6568.325; Geddes JF, 2004, FORENSIC SCI INT, V146, P83, DOI 10.1016/S0379-0738(03)00283-4; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Heiss WD, 1997, J CEREBR BLOOD F MET, V17, P388, DOI 10.1097/00004647-199704000-00004; Hwang ISS, 2007, J GERONTOL A-BIOL, V62, P41, DOI 10.1093/gerona/62.1.41; Ito Y, 2009, BIOGERONTOLOGY, V10, P173, DOI 10.1007/s10522-008-9164-4; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; LaManna JC, 2004, J EXP BIOL, V207, P3163, DOI 10.1242/jeb.00976; LaManna JC, 2007, ESSAYS BIOCHEM, V43, P139; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leblanc N, 2006, BRAIN COGNITION, V60, P208; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Liu Xin, 2004, J Bioinform Comput Biol, V2, P343, DOI 10.1142/S0219720004000594; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Maes OC, 2008, MECH AGEING DEV, V129, P534, DOI 10.1016/j.mad.2008.05.004; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Rapino C, 2005, AGING CELL, V4, P177, DOI 10.1111/j.1474-9726.2005.00161.x; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Shan Y, 2007, GASTROENTEROLOGY, V133, P1166, DOI 10.1053/j.gastro.2007.08.002; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Sharp FR, 2001, ADV EXP MED BIOL, V502, P273; Siddiq A, 2005, J BIOL CHEM, V280, P41732, DOI 10.1074/jbc.M504963200; Sinor AD, 2000, NEUROSCI LETT, V290, P213, DOI 10.1016/S0304-3940(00)01361-6; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Stokely ME, 2008, J NEUROTRAUM, V25, P52, DOI 10.1089/neu.2007.0397; Stowe AM, 2008, J CEREBR BLOOD F MET, V28, P612, DOI 10.1038/sj.jcbfm.9600560; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Suzuki R, 2006, ACTA NEUROCHIR SUPPL, V96, P398; Taoufik E, 2008, P NATL ACAD SCI USA, V105, P6185, DOI 10.1073/pnas.0801447105; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thomas S, 2000, ACT NEUR S, V76, P397; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Unterberg AW, 1997, ACT NEUR S, V70, P106; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wang XG, 2003, AM J PHYSIOL-HEART C, V284, pH613, DOI 10.1152/ajpheart.00449.2002; Williams BJ, 2006, PSYCHOPHARMACOLOGY, V188, P605, DOI 10.1007/s00213-006-0477-1; Xiaowei H, 2006, SPINAL CORD, V44, P35, DOI 10.1038/sj.sc.3101813; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhao WZ, 1997, J CEREBR BLOOD F MET, V17, P1281, DOI 10.1097/00004647-199712000-00003	68	45	47	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1557	1566		10.1089/neu.2008.0765			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200012	19203226	Green Published			2022-02-06	
J	Kleindienst, A; Brabant, G; Bock, C; Maser-Gluth, C; Buchfelder, M				Kleindienst, Andrea; Brabant, Georg; Bock, Christoph; Maser-Gluth, Christiane; Buchfelder, Michael			Neuroendocrine Function following Traumatic Brain Injury and Subsequent Intensive Care Treatment: A Prospective Longitudinal Evaluation	JOURNAL OF NEUROTRAUMA			English	Article						critical illness; endocrine dysfunction; pituitary; traumatic brain injury	ANTERIOR-PITUITARY INSUFFICIENCY; GROWTH-HORMONE DEFICIENCY; CRITICAL ILLNESS; POSTTRAUMATIC HYPOPITUITARISM; SUBARACHNOID HEMORRHAGE; SELLA TURCICA; ACUTE-PHASE; LONG-TERM; HIGH-RISK; DYSFUNCTION	Neuroendocrine dysfunction following traumatic brain injury (TBI) has been described extensively. However, few studies are longitudinal and most lack subtle radiological, clinical, and repetitive endocrine assessment in the acute phase. Accordingly, we prospectively assessed neuroendocrine function in 71 patients after TBI. Injury was documented by a computed tomography (CT). During the first week, critical clinical data (Glasgow Coma Score, APACHE score), treatment variables such as duration of analgosedation for mechanical ventilation, were related to basal pituitary function. More than 2 years later, a subgroup of patients was re-evaluated using dynamic testing with ACTH and GHRH-arginine tests. The Pearson's correlation analysis and Mann-Whitney rank sum test for group differences were used for statistical analysis. None of the CT findings predicted neuroendocrine dysfunction following TBI. The adaptive response to critical illness with significantly elevated cortisol levels on admission and decreased levels thereafter in patients ventilated for more than 24 h (p < 0.05) was attenuated following severe TBI (p < 0.05). However, the coincidence of low serum cortisol and increased urinary excretion of glucocorticoid metabolites in about 80% of patients challenges the relevance of basal hormone measurements. In ventilated patients, total T3 and free T4 were decreased (p < 0.05), TSH was low on day 3 (p < 0.05), and a gonadotropic insufficiency was present (p < 0.05). The thyrotropic and gonadotropic system recovered completely within the follow-up period. With regard to the somatotropic system, neither brain injury severity nor mechanical ventilation was associated with an insufficiency during the acute phase post-injury. However, initially low GH levels predicted a persistent deficiency (r = 0.731, p < 0.001). We conclude that both severe TBI and prolonged mechanical ventilation result in hormonal disturbances early after injury, suggesting a pathophysiological response to brain injury and subsequent intensive care treatment rather than morphological damage.	[Kleindienst, Andrea; Buchfelder, Michael] Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany; [Brabant, Georg] Christie Hosp, Dept Endocrinol, Manchester, Lancs, England; [Bock, Christoph] Univ Gottingen, Dept Neurosurg, Gottingen, Germany; [Maser-Gluth, Christiane] Heidelberg Univ, Inst Pharmacol, D-6900 Heidelberg, Germany		Kleindienst, A (corresponding author), Univ Erlangen Nurnberg, Dept Neurosurg, Schwabachanlage 6, D-91054 Erlangen, Germany.	andrea.kleindienst@uk-erlangen.de	Kleindienst, Andrea/F-1674-2014	Kleindienst, Andrea/0000-0003-4758-0324			Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; AGHA A, 2005, AM J MED, V188, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Arafah BM, 2006, J CLIN ENDOCR METAB, V91, P3725, DOI 10.1210/jc.2006-0674; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; DUSICK JR, 2008, PITUITARY IN PRESS; EDWARDS OM, 1986, MEDICINE, V65, P281; Fliers E, 2001, BEST PRACT RES CL EN, V15, P453, DOI 10.1053/beem.2001.0163; Ghigo E, 2001, ENDOCRINE, V15, P29, DOI 10.1385/ENDO:15:1:029; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; Gittoes NJL, 1998, CLIN ENDOCRINOL, V48, P331; Jennett B, 1975, Ciba Found Symp, P3; KAPTEIN EM, 1982, J CLIN INVEST, V69, P526, DOI 10.1172/JCI110478; KAWAI K, 1995, J NEUROSURG, V83, P368, DOI 10.3171/jns.1995.83.2.0368; KEELING FP, 1986, CLIN RADIOL, V37, P233, DOI 10.1016/S0009-9260(86)80323-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2008, PITUITARY, V11, P255, DOI 10.1007/s11102-008-0102-x; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Koea JB, 2006, ANZ J SURG, V76, P959, DOI 10.1111/j.1445-2197.2006.03944.x; KOJIMA T, 1985, NEUROSURGERY, V16, P225, DOI 10.1227/00006123-198502000-00018; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LILJEDAHL STEN-OTTO, 1961, ACTA CHIR SCAND, V122, P1; Lusk B, 2005, DIMENS CRIT CARE NUR, V24, P25, DOI 10.1097/00003465-200501000-00004; McIver B, 1997, THYROID, V7, P125, DOI 10.1089/thy.1997.7.125; NOMIKOS P, 1997, ANN ENDOCRINOL S, V58; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; SAEZ JMG, 1982, MED CLIN-BARCELONA, V78, P159; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; SCHNEIDER HJ, 2004, DTSCH ARZTEBL, V101, pA712; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Segal-Lieberman G, 2000, Pituitary, V3, P181, DOI 10.1023/A:1011407910913; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Tanriverdi F, 2007, CLIN ENDOCRINOL, V67, P931, DOI 10.1111/j.1365-2265.2007.02989.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; VandenBerghe G, 1997, CLIN ENDOCRINOL, V47, P599, DOI 10.1046/j.1365-2265.1997.3371118.x; Vanhorebeek I, 2006, NAT CLIN PRACT ENDOC, V2, P20, DOI 10.1038/ncpendmet0071; Vanhorebeek I, 2006, CRIT CARE CLIN, V22, P1, DOI 10.1016/j.ccc.2005.09.004; VOERMAN HJ, 1992, ANN SURG, V216, P648, DOI 10.1097/00000658-199212000-00006; WEST OC, 1993, RADIOLOGY, V188, P329, DOI 10.1148/radiology.188.2.8327674; YOUNG HA, 1980, NEUROSURGERY, V7, P23, DOI 10.1227/00006123-198007000-00004; Zaloga GP, 2001, CRIT CARE CLIN, V17, P25, DOI 10.1016/S0749-0704(05)70150-0	56	45	49	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1435	1446		10.1089/neu.2008.0601			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200001	19459759				2022-02-06	
J	Johnson, VE; Stewart, W; Graham, DI; Stewart, JE; Praestgaard, AH; Smith, DH				Johnson, Victoria E.; Stewart, William; Graham, David I.; Stewart, Janice E.; Praestgaard, Amy H.; Smith, Douglas H.			A Neprilysin Polymorphism and Amyloid-beta Plaques after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; human beta-amyloid; neprilysin; polymorphism; traumatic brain injury	SPORADIC ALZHEIMERS-DISEASE; LONG-TERM ACCUMULATION; DIFFUSE AXONAL INJURY; HEAD-INJURY; PROMOTER REGION; A-BETA; ASSOCIATION; GENE; DEPOSITION; PEPTIDE	Traumatic brain injury (TBI) induces the rapid formation of Alzheimer's disease (AD)-like amyloid-beta (AB) plaques in about 30% of patients. However, the mechanisms behind this selective plaque formation are unclear. We investigated a potential association between amyloid deposition acutely after TBI and a genetic polymorphism of the AB-degrading enzyme, neprilysin (n = 81). We found that the length of the GT repeats in AB-accumulators was longer than in non-accumulators. Specifically, there was an increased risk of AB plaques for patients with more than 41 total repeats (p < 0.0001; OR: 10.1). In addition, the presence of 22 repeats in at least one allele was independently associated with plaque deposition (p = 0.03; OR: 5.2). In contrast, the presence of 20GT repeats in one allele was independently associated with a reduced incidence of AB deposition (p = 0.003). These data suggest a genetically linked mechanism that determines which TBI patients will rapidly form AB plaques. Moreover, these findings provide a potential genetic screening test for individuals at high risk of TBI, such as participants in contact sports and military personnel.	[Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; [Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Praestgaard, Amy H.] Univ Penn, Biostat Anal Ctr, Sch Med, Philadelphia, PA 19104 USA; [Johnson, Victoria E.; Stewart, William; Graham, David I.; Stewart, Janice E.] So Gen Hosp NHS Trust, Inst Neurol Sci, Div Clin Neurosci, Acad Unit Neuropathol, Glasgow, Lanark, Scotland		Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007	Stewart, William/0000-0003-2199-2582	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038104]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104] Funding Source: NIH RePORTER	This work was supported by a grant from the National Institutes of Health (NS038104).	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Comings DE, 1998, MOL PSYCHIATR, V3, P21, DOI 10.1038/sj.mp.4000289; Comings DE, 1999, NEUROREPORT, V10, P2283, DOI 10.1097/00001756-199908020-00011; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1989, HISTOCHEMISTRY, V92, P355, DOI 10.1007/BF00500553; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAOUAS H, 1995, BIOCHEM BIOPH RES CO, V207, P933, DOI 10.1006/bbrc.1995.1275; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; ISHIMARU F, 1995, BLOOD, V85, P3199, DOI 10.1182/blood.V85.11.3199.bloodjournal85113199; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Iwata N, 2005, PHARMACOL THERAPEUT, V108, P129, DOI 10.1016/j.pharmthera.2005.03.010; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; LI CW, 1995, GENE, V164, P363, DOI 10.1016/0378-1119(95)00464-H; Lilius L, 2003, NEUROSCI LETT, V337, P111, DOI 10.1016/S0304-3940(02)01300-9; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Mohajeri MH, 2002, J BIOL CHEM, V277, P35460, DOI 10.1074/jbc.M202899200; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oda M, 2002, NEUROSCI LETT, V320, P105, DOI 10.1016/S0304-3940(02)00057-5; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Sakai A, 2004, DEMENT GERIATR COGN, V17, P164, DOI 10.1159/000076351; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Sodeyama N, 2001, J NEUROL NEUROSUR PS, V71, P817, DOI 10.1136/jnnp.71.6.817; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wood LS, 2007, NEUROSCI LETT, V427, P103, DOI 10.1016/j.neulet.2007.09.019; Yamada M, 2003, J NEUROL NEUROSUR PS, V74, P749, DOI 10.1136/jnnp.74.6.749; Yasojima K, 2001, NEUROSCI LETT, V297, P97, DOI 10.1016/S0304-3940(00)01675-X	39	45	45	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1197	1202		10.1089/neu.2008.0843			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900003	19326964	Green Published			2022-02-06	
J	Nagel, A; Graetz, D; Schink, T; Frieler, K; Sakowitz, O; Vajkoczy, P; Sarrafzadeh, A				Nagel, Alexandra; Graetz, Daniela; Schink, Tania; Frieler, Katja; Sakowitz, Oliver; Vajkoczy, Peter; Sarrafzadeh, Asita			Relevance of intracranial hypertension for cerebral metabolism in aneurysmal subarachnoid hemorrhage Clinical article	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; intracranial hypertension; microdialysis; cerebral metabolism; outcome	TRAUMATIC BRAIN-INJURY; MICRODIALYSIS; PRESSURE; ISCHEMIA; IMPAIRMENT; VASOSPASM; GLUTAMATE; COMA	Object. Intracranial hypertension, defined as intracranial pressure (ICP) >= 20 mm Hg, is a complication typically associated with head injury. Its impact on cerebral metabolism, ICP therapy, and outcome has rarely been studied in patients with aneurysmal subarachnoid hemorrhage (aSAH); such an assessment is the authors' goal in the present study. Methods. Cerebral metabolism was prospectively studied in 182 patients with aSAH. The database was retrospectively analyzed with respect to ICP. Patients were classified into 2 groups based on ICP. There were 164 with low ICP (< 20 mm Hg) and 18 with high ICP (>= 20 mm Hg, measured > 6 hours/day). Cerebral microdialysis parameters of energy metabolism, glycerol, and glutamate levels were analyzed hourly from the brain parenchyma of interest for 7 days. The 12-month outcome in these patients was evaluated. Results. In the high ICP group, extended ICP therapy including decompressive craniectomy was necessary in 7 patients (39%). Cerebral glycerol levels and the lactate/pyruvate ratio were pathologically increased on Days 1-7 after aSAH (p < 0.001). The excitotoxic neurotransmitter glutamate and glycerol, a marker of membrane degradation, further increased on Days 5-7, probably reflecting the development of secondary brain damage. An ICP a 20 mm Hg was shown to have a significant influence on the 12-month Glasgow Outcome Scale (GOS) score (p = 0.001) and was a strong predictor of mortality (OR = 24.6; p < 0.001). Glutamate (p = 0.012), the lactate/pyruvate ratio as a marker of anaerobic metabolism (p = 0.028), age (p < 0.001), and Fisher grade (p = 0.001) also influenced the GOS score at 12 months. Conclusions. The authors confirmed the relevance of intracranial hypertension as a severe complication in patients with aSAH. Because high ICP is associated with a severely deranged cerebral metabolism and poor outcome, future studies focusing on metabolism-guided, optimized ICP therapy could help minimize secondary brain damage and improve prognosis in patients with aSAH. (DOI: 10.3171/2009.1.JNS08587)	[Sarrafzadeh, Asita] Charite, Clin Neurosurg, Charite Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany; [Schink, Tania; Frieler, Katja] Charite Campus Mitte, Dept Med Stat & Clin Epidemiol, Berlin, Germany; [Sakowitz, Oliver] Heidelberg Univ, Dept Neurosurg, D-6900 Heidelberg, Germany		Sarrafzadeh, A (corresponding author), Charite, Clin Neurosurg, Charite Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de	Schink, Tania/A-4585-2017	Schink, Tania/0000-0002-0224-1866; Sakowitz, Oliver/0000-0003-3248-6335; Frieler, Katja/0000-0003-4869-3013			Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Brunner E., 2002, NONPARAMETRIC ANAL L; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Clausen T, 2005, J NEUROSURG, V103, P233, DOI 10.3171/jns.2005.103.2.0233; DRAKE CG, 1988, J NEUROSURG, V68, P985; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fukuhara T, 1998, NEUROL MED-CHIR, V38, P710, DOI 10.2176/nmc.38.710; Gambardella G, 1998, ACT NEUR S, V71, P215; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HAYASHI M, 1984, J NEUROSURG, V61, P30, DOI 10.3171/jns.1984.61.1.0030; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Heuer GG, 2004, J NEUROSURG, V101, P408, DOI 10.3171/jns.2004.101.3.0408; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; JENNETT B, 1975, LANCET, V1, P480; Lanzino G, 1999, J NEUROSURG, V90, P1018, DOI 10.3171/jns.1999.90.6.1018; LeRoux PD, 1996, NEUROSURGERY, V38, P887, DOI 10.1097/00006123-199605000-00006; Liu HL, 2005, EXP BRAIN RES, V167, P666, DOI 10.1007/s00221-005-0243-3; Mayer SA, 2002, NEUROLOGY, V59, P1750, DOI 10.1212/01.WNL.0000035748.91128.C2; Nelder JA., 1998, GEN LINEAR MODELS, V37; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; ROMNER B, 1991, British Journal of Neurosurgery, V5, P31, DOI 10.3109/02688699108998444; Sarrafzadeh AS, 2005, ACT NEUR S, V95, P89; Sarrafzadeh AS, 2004, STROKE, V35, P638, DOI 10.1161/01.STR.0000116101.66624.F1; Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2; Stover JF, 1999, CRIT CARE MED, V27, P1351, DOI 10.1097/00003246-199907000-00028; TEASDALE G, 1974, LANCET, V2, P81; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073	30	45	47	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2009	111	1					94	101		10.3171/2009.1.JNS08587			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	462VA	WOS:000267383900021	19284237				2022-02-06	
J	Malcolm, D				Malcolm, Dominic			Medical Uncertainty and Clinician-Athlete Relations: The Management of Concussion Injuries in Rugby Union	SOCIOLOGY OF SPORT JOURNAL			English	Article							SPORT; RISK; PAIN	This article addresses clinical practice in sport medicine. Combining notions of medical uncertainty with a figurational sociological emphasis oil interdependence. the article illustrates how uncertainty characterizes the medical understanding, clinical treatment, and patient experience of concussion. Faced With uncertainty, the clinician's desire for recognition and validation through athletes' dependence oil them enables medically based diagnostic and treatment guidelines to be replaced by the understanding and definition of concussion dominant in file sport subculture. Clinicians further invoke strategies that protect their professional status and therefore Secure their interdependence with others in the sport club figuration. The study advances Our understanding by illuminating the basis Oil which clinicians and athletes negotiate treatment and the impact of these experiences oil clinicians' actions and beliefs.	Loughborough Univ Technol, Sch Sport & Exercise Sci, Loughborough LE11 3TU, Leics, England		Malcolm, D (corresponding author), Loughborough Univ Technol, Sch Sport & Exercise Sci, Loughborough LE11 3TU, Leics, England.			Malcolm, Dominic/0000-0002-5898-2911			Adamson C, 1997, SOCIOL HEALTH ILL, V19, P133, DOI 10.1111/1467-9566.ep10934391; Albrecht, 2000, HDB SOCIAL STUDIES H, P409, DOI DOI 10.4135/9781848608412.N26; CALNAN M, 1984, SOCIOL HEALTH ILL, V6, P74, DOI 10.1111/1467-9566.ep10777367; COCKERHAM WC, 2004, MED SOCIOLOGY; CONRAD P, 1987, RES SOCIOLOGY HLTH C, V6, P1; CURRY TJ, 1993, SYMB INTERACT, V16, P273, DOI 10.1525/si.1993.16.3.273; DeVaus DA, 1996, SURVEYS SOCIAL RES; Elias N., 1978, WHAT IS SOCIOLOGY; Fox RC., 1957, STUDENT PHYS INTRO S, V3, P207; HOWE P. D., 2004, SPORT PROFESSIONALIS; HUGHES R, 1991, SOCIOL SPORT J, V8, P307, DOI 10.1123/ssj.8.4.307; IRB, 2008, REG REL GAM; LIGHT D, 1979, J HEALTH SOC BEHAV, V20, P310, DOI 10.2307/2955407; Malcolm D, 2002, SOCIOL SPORT J, V19, P149, DOI 10.1123/ssj.19.2.149; MALCOLM D, 2004, SPORT SOC, V7, P95; MALCOLM D, 2005, FOOTBALL STUDIES, V8, P58; Malcolm D, 2006, SOCIOL SPORT J, V23, P376, DOI 10.1123/ssj.23.4.376; Malcolm D, 2005, ETHICS SPORT, P165; May T., 2001, SOCIAL RES ISSUES ME, V3rd ed; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, BRIT J SPORT MED, V35, P380, DOI 10.1136/bjsm.35.6.380; McCrory PR, 1999, BRIT J SPORT MED, V33, P297; MESSNER M, 1992, POWER PLAY SPORT PRO; MURPHY P, 2008, MATTERS SPORT ESSAYS, P40; Nixon H. L. II, 1992, Journal of Sport and Social Issues, V16, P127, DOI 10.1177/019372359201600208; Pike ECJ, 2003, SOCIOL SPORT J, V20, P232, DOI 10.1123/ssj.20.3.232; Rafalovich A, 2005, SOCIOL HEALTH ILL, V27, P305, DOI 10.1111/j.1467-9566.2005.00444.x; *RFU, 1998, RFU HDB SAF RUGB; Roderick M., 2000, International Review for the Sociology of Sport, V35, P165, DOI 10.1177/101269000035002003; Roderick M., 2006, WORK PROFESSIONAL FO; Roderick M, 2005, ETHICS SPORT, P17; Roderick Martin, 2004, SPORTING BODIES DAMA, P137; Safai P, 2003, SOCIOL SPORT J, V20, P127, DOI 10.1123/ssj.20.2.127; Safai P, 2004, SPORTING BODIES DAMA, P269; SCHWARZ A, 2007, NY TIMES        0915; Stroh M, 2000, RES TRAINING SOCIAL, P196, DOI DOI 10.4135/9780857028051.D23; Theberge N, 2008, SOCIOL HEALTH ILL, V30, P19, DOI 10.1111/j.1467-9566.2007.01026.x; Theberge N, 2007, ROUTL CRIT STUD SPOR, P176; Waddington I, 2002, BRIT J SPORT MED, V36, P118, DOI 10.1136/bjsm.36.2.118; Waddington I., 2000, SPORT HLTH DRUGS CRI; Walk SR, 1997, SOCIOL SPORT J, V14, P22, DOI 10.1123/ssj.14.1.22; Yair G, 2007, SOCIOLOGY, V41, P681, DOI 10.1177/0038038507078923; YOUNG K, 1993, SOCIOL SPORT J, V10, P373, DOI 10.1123/ssj.10.4.373; Young K., 2004, SPORTING BODIES DAMA, P1; YOUNG K, 2000, MASCULINITIES GENDER, P108, DOI DOI 10.4135/9781452233963	46	45	45	0	20	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	0741-1235	1543-2785		SOCIOL SPORT J	Sociol. Sport J.	JUN	2009	26	2					191	210		10.1123/ssj.26.2.191			20	Hospitality, Leisure, Sport & Tourism; Sociology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Sociology; Sport Sciences	465GV	WOS:000267571700001		Green Published, Green Submitted, Green Accepted			2022-02-06	
J	Chiesa, A; Duhaime, AC				Chiesa, Antonia; Duhaime, Ann-Christine			Abusive Head Trauma	PEDIATRIC CLINICS OF NORTH AMERICA			English	Article						Child abuse; Abusive head trauma; Pediatric traumatic brain injury; Shaken baby syndrome; Nonaccidental trauma	SHAKEN BABY SYNDROME; PERMANENT BRAIN-DAMAGE; SUSPECTED CHILD-ABUSE; RETINAL HEMORRHAGES; CARDIOPULMONARY-RESUSCITATION; OPHTHALMOLOGIC FINDINGS; SUBDURAL HEMORRHAGES; CRANIAL INJURIES; YOUNG-CHILDREN; INFANTS	Child physical abuse that results in injury to the head or brain has been described using many terms, including battered child syndrome, whiplash injuries, shaken infant or shaken impact syndrome, and nonmechanistic terms such as abusive head trauma or nonaccidental trauma. These injuries sustained by child abuse victims are discussed in detail in this article, including information about diagnosis, management and outcomes. The use of forensics, the use imaging studies, and associated injuries are also detailed.	[Chiesa, Antonia] Childrens Hosp, Kempe Child Protect Team, Dept Pediat, Denver, CO 80045 USA; [Duhaime, Ann-Christine] Childrens Hosp Dartmouth, Dartmouth Hitchcock Med Ctr, Dept Pediat Neurosurg, Lebanon, NH 03756 USA		Chiesa, A (corresponding author), Childrens Hosp, Kempe Child Protect Team, Dept Pediat, 13123 E 16th Ave,Box 138, Denver, CO 80045 USA.	Chiesa.Antonia@tchden.org					ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bonnier C, 2003, PEDIATRICS, V112, P808, DOI 10.1542/peds.112.4.808; Boos SC, 2006, ABUSIVE HEAD TRAUMA, P191; BRENNAN LK, J NEUROSURG IN PRESS; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Butchart A, 2008, AM J PREV MED, V34, pS103, DOI 10.1016/j.amepre.2008.01.006; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CANTU RC, 1991, ATHLETIC INJURIES HE, P323; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Chadwick DL, 2008, PEDIATRICS, V121, P1213, DOI 10.1542/peds.2007-2281; Cory CZ, 2003, MED SCI LAW, V43, P317, DOI 10.1258/rsmmsl.43.4.317; Demaerel P, 2002, EUR RADIOL, V12, P849, DOI 10.1007/s00330-001-1145-9; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUHAIME AC, 1998, GELLIS KAGANS CURREN, P436; Duhaime AC, 2007, PROG BRAIN RES, V161, P293, DOI 10.1016/S0079-6123(06)61020-0; DURFEE MJ, 1992, JAMA-J AM MED ASSOC, V267, P3172, DOI 10.1001/jama.267.23.3172; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Fernando S, 2008, PEDIATR RADIOL, V38, P827, DOI 10.1007/s00247-007-0729-1; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Glick JC, 2007, PEDIATR NEUROSURG, V43, P436, DOI 10.1159/000106400; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; Gulino SP, 2006, ABUSIVE HEAD TRAUMA, P297; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HAN BK, 1990, AM J ROENTGENOL, V154, P361, DOI 10.2214/ajr.154.2.2105031; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Hughes LA, 2006, J AAPOS, V10, P102, DOI 10.1016/j.jaapos.2005.12.005; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Jaspan T, 2008, PEDIATR RADIOL, V38, pS378, DOI 10.1007/s00247-008-0896-8; Jayawant S, 2007, ARCH DIS CHILD, V92, P343, DOI 10.1136/adc.2005.084988; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jones R, 2008, PEDIATRICS, V122, P259, DOI 10.1542/peds.2007-2312; Judkins AR, 2004, AM J FOREN MED PATH, V25, P29, DOI 10.1097/01.paf.0000113811.85110.54; Kairys SW, 2001, PEDIATRICS, V108, P206; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Kesler H, 2008, J NEUROSURG-PEDIATR, V1, P351, DOI 10.3171/PED/2008/1/5/351; Kivlin JD, 2001, CURR OPIN OPHTHALMOL, V12, P158, DOI 10.1097/00055735-200106000-00002; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Kleinman PK, 1998, DIAGNOSTIC IMAGING C, P237; Kleinman PK, 1998, DIAGNOSTIC IMAGING C, P285; Kleinman PL, 2004, RADIOLOGY, V233, P477, DOI 10.1148/radiol.2332031640; Labbe J, 2005, CHILD ABUSE NEGLECT, V29, P311, DOI 10.1016/j.chiabu.2005.03.002; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; LEVIN AV, 2000, RECENT ADV PAEDIAT, V18, P151; Libby AM, 2003, PEDIATRICS, V112, P58, DOI 10.1542/peds.112.1.58; Looney CB, 2007, RADIOLOGY, V242, P535, DOI 10.1148/radiol.2422060133; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Odom A, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.6.e3; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Salehi-Had H, 2006, PEDIATRICS, V117, pE1039, DOI 10.1542/peds.2005-0811; Sane SM, 2000, PEDIATRICS, V105, P1345; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shugerman RP, 1996, PEDIATRICS, V97, P664; SILVERMAN FN, 1953, AM J ROENTGENOL, V69, P413; SIROTNAK AP, 2006, ABUSIVE HEAD TRAUMA, P191; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; STARLING SP, 1995, PEDIATRICS, V95, P259; Steinbok P, 2007, NEUROSURGERY, V60, P689, DOI 10.1227/01.NEU.0000255398.00410.6B; Swift DM, 2000, NEUROSURG CLIN N AM, V11, P439, DOI 10.1016/S1042-3680(18)30106-2; Vinchon M, 2004, J NEUROSURG, V101, P44, DOI 10.3171/ped.2004.101.2.0044; Whitby EH, 2004, LANCET, V363, P846, DOI 10.1016/S0140-6736(04)15730-9; Willman KY, 1997, CHILD ABUSE NEGLECT, V21, P929, DOI 10.1016/S0145-2134(97)00054-9; YAIR M, 2004, J AAPOS, V8, P521; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; [No title captured]	90	45	45	1	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0031-3955	1557-8240		PEDIATR CLIN N AM	Pediatr. Clin. N. Am.	APR	2009	56	2					317	+		10.1016/j.pcl.2009.02.001			16	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	441CA	WOS:000265745700002	19358918				2022-02-06	
J	Compagnone, C; d'Avella, D; Servadei, F; Angileri, FF; Brambilla, G; Conti, C; Cristofori, L; Delfini, R; Denaro, L; Ducati, A; Gaini, SM; Stefini, R; Tomei, G; Tagliaferri, F; Trincia, G; Tomasello, F				Compagnone, Christian; d'Avella, Domenico; Servadei, Franco; Angileri, Filippo F.; Brambilla, Gianluigi; Conti, Carlo; Cristofori, Luciano; Delfini, Roberto; Denaro, Luca; Ducati, Alessandro; Gaini, Sergio M.; Stefini, Roberto; Tomei, Giustino; Tagliaferri, Fernanda; Trincia, Giuseppe; Tomasello, Francesco			PATIENTS WITH MODERATE HEAD INJURY: A PROSPECTIVE MULTICENTER STUDY OF 315 PATIENTS	NEUROSURGERY			English	Article						Computed tomographic scan; Moderate head injury; Neuroworsening; Outcome	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; COMPUTERIZED-TOMOGRAPHY; INITIAL MANAGEMENT; MILD; MORTALITY; SEVERITY; ADULTS; TRIAL; SCORE	OBJECTIVE: To analyze the risk factors of worst outcome associated with moderate head injury. METHODS: Data on patients with moderate head injury were collected prospectively in 11 Italian neurosurgical units over a period of 18 months. Patients older than 18 years with blunt head injury and at least one Glasgow Coma Scale (GCS) score between 9 and 13 were enrolled. The outcome was determined at 6 months using the Glasgow Outcome Scale. RESULTS: We analyzed 315 patients. Initial computed tomographic scans showed a diffuse injury type I or 11 in 63%, a mass lesion in 35%, and traumatic subarachnoid hemorrhage in 42% of the patients. The risk of progression toward a mass lesion was 23% when the admission computed tomographic scan showed diffuse injury type I or II. An emergency craniotomy was performed in 22% of the patients, delayed surgery was performed in 14%, and both were performed in 25%. A favorable outcome was obtained in 74% of the patients. When the GCS score was 9 or 10, the predictor of worst outcome was a motor GCS score of 4 or lower (odds ratio [OR], 8.08; 95% confidence interval [CI], 1.22-67.35; P = 0.008), but when the GCS score was 11 to 13, the factors associated with worst outcome were neuroworsening (OR, 3.43; 95% Cl, 1.45-8.17; P = 0.002), seizures (OR, 7.94; 95% Cl, 1.18-64.48; P = 0.02), and medical complications (OR, 4.24; 95% Cl, 1.74-10.33; P = 0.0006). CONCLUSION: There is a high percentage of surgery and worsening on computed tomographic scans in patients with moderate head injury. Neuroworsening, seizures, and medical complications as outcome predictors were more strongly associated with a GCS score of 11 to 13, whereas a low motor GCS score was more outcome-related in patients with GCS scores of 9 and 10.	[d'Avella, Domenico] Univ Padua, Sch Med, Dept Neurosci, I-35128 Padua, Italy; [Compagnone, Christian; Tagliaferri, Fernanda] Bufalini Hosp, Intens Care Unit, Cesena, Italy; [Servadei, Franco] Azienda Osped Univ, Div Neurosurg, Parma, Italy; [Angileri, Filippo F.; Tomasello, Francesco] Univ Messina, Clin Neurochirurg, Messina, Italy; [Brambilla, Gianluigi] IRCCS Policlin S Matteo, Pavia, Italy; [Conti, Carlo; Trincia, Giuseppe] Azienda Osped Mestre, Div Neurosurg, Venice, Italy; [Cristofori, Luciano] Azienda Osped Verona, Dept Neurosurg, Verona, Italy; [Delfini, Roberto] Univ Roma La Sapienza, Dept Neurosurg, Rome, Italy; [Denaro, Luca] Univ Cattolica Sacro Cuore, Inst Neurosurg, Rome, Italy; [Ducati, Alessandro] Univ Turin, Clin Neurochirurg, Turin, Italy; [Gaini, Sergio M.] Osped Policlin IRCCS, Clin Neurochirurg, Milan, Italy; [Stefini, Roberto] Univ Brescia, Clin Neurochirurg, Brescia, Italy; [Tomei, Giustino] Univ Insubria Varese, Clin Neurochirurg, Varese, Italy		d'Avella, D (corresponding author), Univ Padua, Sch Med, Dept Neurosci, Via Giustiniani 2, I-35128 Padua, Italy.	domenico.davella@unipd.it	Angileri, Filippo Flavio/J-3533-2012; Angileri, Filippo/N-8556-2019; Angileri, Filippo/AAL-4851-2021	Angileri, Filippo Flavio/0000-0002-1107-4115; Angileri, Filippo/0000-0002-1107-4115; D'AVELLA, Domenico/0000-0001-9077-412X; Compagnone, Christian/0000-0001-9951-5503; Servadei, Franco/0000-0002-3595-3464			Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; JENNETT B, 1975, LANCET, V1, P480; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MILLER JD, 1985, LANCET, V1, P1141; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1	36	45	46	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2009	64	4					690	696		10.1227/01.NEU.0000340796.18738.F7			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	427MN	WOS:000264783500028	19197220				2022-02-06	
J	Bonilla, C; Zurita, M; Otero, L; Aguayo, C; Vaquero, J				Bonilla, Celia; Zurita, Mercedes; Otero, Laura; Aguayo, Concepcion; Vaquero, Jesus			Delayed intralesional transplantation of bone marrow stromal cells increases endogenous neurogenesis and promotes functional recovery after severe traumatic brain injury	BRAIN INJURY			English	Article						Stem cells; bone marrow stromal cells; brain trauma; cell therapy	MESENCHYMAL STEM-CELLS; SUBVENTRICULAR ZONE; NEURAL STEM; INTRACEREBRAL TRANSPLANTATION; NEURONAL DIFFERENTIATION; ADULT RATS; PROLIFERATION; THERAPY; STROKE; NEUROTROPHINS	Primary objective: To investigate the utility of delayed transplantation of bone marrow stromal cells (BMSC) to improve the neurological sequels after traumatic brain injury (TBI). Methods: Adult Wistar rats were subjected to weight-drop impact causing severe brain injury, and 2 months later, BMSC in saline, or saline alone, were injected into injured brain tissue. Both experimental groups were evaluated by means of rotarod and modified neurologic severity scores (mNSS) tests in the course of the two following months. At this time, the animal were sacrificed and their brains were studied by means of histological and immunohistochemical techniques. Results: Rotarod and mNSS tests showed progressive functional recovery in the BMSC- transplanted rats, compared with controls. Two months after transplantation, BMSC survived in the host tissue, and some of them showed expression of Neu-N or GFAP, suggesting neuronal and astroglial transdifferentiation. Furthermore, significant increase of endogenous neurogenesis was found in BMSC-transplanted rats, compared with controls. Conclusions: These findings suggest the utility of delayed intracerebral transplantation of BMSC for the treatment of established sequels after TBI.	[Vaquero, Jesus] Autonomous Univ Madrid, Hosp Puerta Hierro Majadahonda, Neurosci Res Unit, Madrid 28222, Spain; Autonomous Univ Madrid, Hosp Puerta Hierro Majadahonda, Mapfre UAM Chair Brain Injury Res, Madrid 28222, Spain		Vaquero, J (corresponding author), Autonomous Univ Madrid, Hosp Puerta Hierro Majadahonda, Neurosci Res Unit, Manuel Falla 1, Madrid 28222, Spain.	jvaqueroc@telefonica.net		Otero Ortega, Laura/0000-0001-8765-6341	Carlos III Institute, Ministry of Health, SpainInstituto de Salud Carlos III [FIS: PI 06/0650]	The present study was performed with financial support from Carlos III Institute, Ministry of Health (FIS: PI 06/0650), Spain.	Andres RH, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E15; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; GARCIACASTRO J, 2008, CELL THERAPY, P58; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2001, CELL TRANSPLANT, V10, P31; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Masuda T, 2007, NEUROSCI LETT, V425, P114, DOI 10.1016/j.neulet.2007.08.039; Miles DK, 2006, PROG BRAIN RES, V157, P187, DOI 10.1016/S0079-6123(06)57012-8; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Romanko MJ, 2004, PROG NEUROBIOL, V74, P77, DOI 10.1016/j.pneurobio.2004.07.001; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vaquero J, 2009, HISTOL HISTOPATHOL, V24, P107, DOI 10.14670/HH-24.107; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yoo SW, 2008, EXP MOL MED, V40, P387, DOI 10.3858/emm.2008.40.4.387; Zhang HB, 2006, NEUROL RES, V28, P104, DOI 10.1179/016164106X91960; Zimmet JM, 2005, BASIC RES CARDIOL, V100, P471, DOI 10.1007/s00395-005-0553-4; Zurita M, 2005, NEUROREPORT, V16, P505, DOI 10.1097/00001756-200504040-00017; Zurita M, 2004, NEUROREPORT, V15, P1105, DOI 10.1097/00001756-200405190-00004; Zurita M, 2008, TRANSPLANTATION, V86, P845, DOI 10.1097/TP.0b013e318186198f; Zurita M, 2007, NEUROREPORT, V18, P1713, DOI 10.1097/WNR.0b013e3282f0d3b0; Zurita M, 2006, NEUROSCI LETT, V402, P51, DOI 10.1016/j.neulet.2006.03.069	44	45	47	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	9					760	769	PII 913448048	10.1080/02699050903133970			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	475UR	WOS:000268387600007	19637001				2022-02-06	
J	Dichter, MA				Dichter, Marc A.			Posttraumatic epilepsy: The challenge of translating discoveries in the laboratory to pathways to a cure	EPILEPSIA			English	Article						Epileptogenesis; Antiepileptogenesis; Epilepsy prevention; Posttraumatic epilepsy	FLUID PERCUSSION INJURY; RAT; RECOVERY; SEIZURES	Translating laboratory discoveries into successful therapies for preventing epilepsy is a difficult task, but preventing epilepsy in those who are known to be at high risk needs to be one of our highest priorities. At present, we need to approach this task as a parallel set of research endeavors-one concentrating on laboratory experiments designed to learn how to prevent epilepsy after brain trauma and the other focusing on how to perform the appropriate clinical research in humans to demonstrate that whatever is discovered in the laboratory can be appropriately tested. It is too important to let the second process await conclusion of the first. Initially, we need to create a consortium of groups in trauma centers that are dedicated to antiepileptogenic studies and develop funding sources for long-term studies. We need to experiment with clinical protocols, making the studies as cost-effective as possible, while performing continuous data mining of outcomes and surrogate markers. The limitations of current technology to assist in antiepileptogenesis trials must be acknowledged: There is no currently available method for continuously monitoring electroencephalography (EEG) over prolonged periods, and there are no validated biomarkers for the process of epileptogenesis. As we learn more about the process of epileptogenesis and its underlying mechanisms, it is hoped that we will be able to prevent the development of epilepsy after traumatic brain injury (TBI) and after many other known epileptogenic lesions.	[Dichter, Marc A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA		Dichter, MA (corresponding author), Univ Penn, Dept Neurol, Hosp Univ Penn, 3 W Gates,3400 Spruce St, Philadelphia, PA 19104 USA.	dichter@mail.med.upenn.edu					Blumenfeld H, 2008, EPILEPSIA, V49, P400, DOI 10.1111/j.1528-1167.2007.01458.x; Bragin A, 2004, EPILEPSIA, V45, P1017, DOI 10.1111/j.0013-9580.2004.17004.x; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dube C, 2004, ANN NEUROL, V56, P709, DOI 10.1002/ana.20266; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; Goldstein LB, 1998, ARCH NEUROL-CHICAGO, V55, P454, DOI 10.1001/archneur.55.4.454; Grohn O, 2007, EPILEPSIA, V48, P3, DOI 10.1111/j.1528-1167.2007.01236.x; Perna R, 2006, J HEAD TRAUMA REHAB, V21, P82, DOI 10.1097/00001199-200601000-00009; STEAD M, 2007, EPILEPSIA S6, V46; Temkin N R, 1998, Adv Neurol, V76, P179; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801	12	45	47	0	6	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0013-9580			EPILEPSIA	Epilepsia		2009	50						41	45		10.1111/j.1528-1167.2008.02009.x			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	399VN	WOS:000262827500007	19187293	Bronze			2022-02-06	
J	Draper, K; Ponsford, J				Draper, Kristy; Ponsford, Jennie			Long-term outcome following traumatic brain injury: A comparison of subjective reports by those injured and their relatives	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Outcome measurement; TBI versus close-other report	SEVERE HEAD-INJURY; SELF-AWARENESS; COGNITIVE DEFICITS; IMPAIRED AWARENESS; CLOSE RELATIVES; ADULTS; REHABILITATION; MODERATE; VALIDATION; DEPRESSION	Many long-term outcome studies have documented changes following injury using subjective reports from TBI patients and close others. It is known that factors such as self-awareness and emotional adjustment can influence subjective reports, but there has been limited research comparing reports by those injured with those of their close others at longer periods post-injury. The aims of the present study were to compare TBI participants' and close others' subjective reports of cognitive and behavioural problems 10 years following TBI and to investigate the relationship between subjective reports of cognitive impairments and TBI participants' performances on cognitive tests. Fifty-four participants who had sustained mild to very severe TBI were followed up a mean of 10 years post-injury and 54 close others also participated. Measures included the Neurobehavioural Functioning Inventory (NFI), the Hospital Anxiety and Depression Scale (HADS), and cognitive measures of attention, memory and executive function. TBI participants and close others showed strong agreement in their reporting of problems on the NFI. However, there was no strong relationship between subjective reports of cognitive problems and test performances. Much stronger relationships were found between subjective reports of cognitive change and emotional state. This study highlights the importance of assessing emotional state when utilising subjective report data, as well as the need to use objective measures of cognitive impairment.	[Ponsford, Jennie] Monash Univ, Sch Psychol Psychiat & Psychol Med, Monash Epworth Rehabil Res Ctr, Epworth Hosp,Natl Trauma Res Inst, Melbourne, Vic 3004, Australia		Ponsford, J (corresponding author), Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Arlinghaus KA, 2005, TXB TRAUMATIC BRAIN, P59; BADDELEY A, 1994, DOORS PEOPLE; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Burgess P.W., 1997, HAYLING BRIXTON TEST; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dixon R.A., 1999, COGNITIVE NEUROREHAB, P59; ELSASS L, 1991, THESIS TROBE U MELBO; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Fischer, 2004, NEUROPSYCHOL ASSESSM; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Hoofien D, 2001, BRAIN INJURY, V15, P189; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lezak MD, 1976, NEUROPSYCHOLOGICAL A; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Markova IS, 2005, AGING MENT HEALTH, V9, P386, DOI 10.1080/13607860500142945; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rey A, 1958, LEXAMEN CLINIQUE PSY; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; Snaith R., 1994, HOSP ANXIETY DEPRESS; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P239, DOI 10.1016/j.acn.2005.12.004; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	67	45	45	0	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	5					645	661		10.1080/17405620802613935			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	539EK	WOS:000273236200002	19629849				2022-02-06	
J	Katz-Leurer, M; Rotem, H; Keren, O; Meyer, S				Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley			Balance abilities and gait characteristics in post-traumatic brain injury, cerebral palsy and typically developed children	DEVELOPMENTAL NEUROREHABILITATION			English	Article						Cerebral palsy; children; traumatic brain injury; step variability; balance		Objectives: To quantify the differences in gait variability and balance performance between children with cerebral palsy (CP), children with post-traumatic brain injury (TBI) and typically developed (TD) children and to determine the association between gait variability and functional balance in these groups. Design: Cross-sectional study. Setting: Physical therapy department of a paediatric and adolescent rehabilitation hospital. Participants: A convenience sample of 15 children post-TBI, 15 children with CP and 30 TD age-and sex-matched controls. Intervention: Not applicable. Main outcome measure: Step length and step time variability measured by an electronic walkway; timed up and go (TUG) test and functional reach test (FRT) were used as functional balance tests. Results: The functional balance abilities of children post-TBI and children with CP were significantly limited compared to TD children. Children post-TBI had significantly greater variability in step length in comparison to healthy controls. A significant linear inverse correlation between balance performance and step length variability was found only among children with TBI. Conclusion: Brain damage is associated with restricted balance performance and increased step variability. It might be that in a child born with brain damage, as opposed to acquired damage, the developmental process has a restraining effect on gait variability.	[Katz-Leurer, Michal] Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Phys Therapy Dept, IL-69978 Ramat Aviv, Israel; [Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley] Alyn Hosp, Pediat & Adolescent Rehabil Ctr, Jerusalem, Israel		Katz-Leurer, M (corresponding author), Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Phys Therapy Dept, IL-69978 Ramat Aviv, Israel.	michalkz@post.tau.ac.il					BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Donahoe B, 1994, PEDIAT PHYSICAL THER, V6, P189, DOI DOI 10.1097/00001577-199400640-00004; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Hausdorff JM, 1999, J APPL PHYSIOL, V86, P1040, DOI 10.1152/jappl.1999.86.3.1040; Hausdorff JM, 1997, ARCH PHYS MED REHAB, V78, P278, DOI 10.1016/S0003-9993(97)90034-4; Hausdorff JM, 1998, MOVEMENT DISORD, V13, P428, DOI 10.1002/mds.870130310; Katz-Leurer M, 2008, BRAIN INJURY, V22, P153, DOI 10.1080/02699050801895399; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Lowes LP, 1996, PEDIATR PHYS THER, V8, P176; LOWES LP, 1997, THESIS ALLEGHENY U H; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; McDonough AL, 2001, ARCH PHYS MED REHAB, V82, P419, DOI 10.1053/apmr.2001.19778; Niznik Theresa M., 1995, Physical and Occupational Therapy in Pediatrics, V15, P1; Rosano C, 2007, NEUROEPIDEMIOLOGY, V29, P193, DOI 10.1159/000111582; TEASDALE G, 1974, LANCET, V2, P81; Thorpe DE, 2005, ARCH PHYS MED REHAB, V86, P2342, DOI 10.1016/j.apmr.2005.07.301; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2	19	45	46	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1751-8423			DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	2					100	105		10.1080/17518420902800928			6	Clinical Neurology; Pediatrics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FM	WOS:000207787900005	19340662				2022-02-06	
J	Sander, AM; Pappadis, MR; Davis, LC; Clark, AN; Evans, G; Struchen, MA; Mazzei, DM				Sander, Angelle M.; Pappadis, Monique R.; Davis, Lynne Cole; Clark, Allison N.; Evans, Gina; Struchen, Margaret A.; Mazzei, Diana M.			Relationship of race/ethnicity and income to community integration following traumatic brain injury: Investigation in a non-rehabilitation trauma sample	NEUROREHABILITATION			English	Article						Traumatic brain injury; race/ethnicity; income; community integration	SEVERE HEAD-INJURY; ETHNIC DISPARITIES; PRACTICAL SCALE; OUTCOMES; WORK; TBI; QUESTIONNAIRE; EMPLOYMENT; VIOLENT; PEOPLE	The purpose of the current study was to determine the contribution of race/ethnicity and income to community integration at approximately 6 months following traumatic brain injury (TBI). Participants were 151 persons with mild to severe TBI (38% Black; 38% Hispanic; 24% White) recruited from consecutive admissions to the Neurosurgery service of a county Level I trauma center. A large number of participants had low income and low education. Community integration was assessed using the Community Integration Questionnaire (CIQ), Craig Handicap Assessment and Reporting Technique - Short Form (CHART-SF), and Community Integration Measure (CIM). Results of analysis of covariance (ANCOVA) indicated that, after accounting for injury severity, age, education, and income, race/ethnicity contributed significantly to the variance in CIQ Total score, Home Integration Scale, and Productive Activity Scale scores. Blacks had lower CIQ Total scores compared to Whites. Black and Hispanic participants had lower scores than Whites on the Home Integration Scale, and Blacks had lower scores than Whites and Hispanics on the CIQ Productive Activity Scale. Low income (<= $20,000) was related to lower scores on the CIQ and CHART-SF Social Integration Scales, and scores on the CIM Total, Belonging, and Independent Participation scales. These results indicate that racial/ethnic differences in community integration exist, even after accounting for income. However, income was more predictive than race/ethnicity for certain aspects of community integration, indicating that it should be accounted for in all studies investigating racial/ethnic differences in outcomes.	[Sander, Angelle M.; Pappadis, Monique R.; Davis, Lynne Cole; Clark, Allison N.; Struchen, Margaret A.; Mazzei, Diana M.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sander, Angelle M.; Davis, Lynne Cole; Clark, Allison N.; Evans, Gina; Struchen, Margaret A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle M.] Harris Cty Hosp Dist, Ctr Trauma Rehabil Res, Houston, TX USA; [Pappadis, Monique R.] Univ Houston, Dept Hlth & Human Performance, Houston, TX USA; [Evans, Gina] Baylor Coll Med, Chron Dis Prevent & Control Ctr, Dept Med, Houston, TX 77030 USA		Sander, AM (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bcm.edu	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B031117, H133A070043] Funding Source: Medline		Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; AXELROD D, 1986, HEAD INJURY NEW YORK; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Cicerone KD, 2004, J HEAD TRAUMA REHAB, V19, P494, DOI 10.1097/00001199-200411000-00006; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; *CRAIG HOSP RES DE, 1999, CRAIG HAND ASS REP T; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85, DOI 10.1097/01.HTR.0000265096.44683.6b; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gosling J, 1999, BRAIN INJURY, V13, P785; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KRAUS JF, 1999, REHABILITATION ADULT, P156; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1984, CLOSED HEAD INJURY P; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SANDER AM, 2007, INCLUSION MINORITIES; Schopp LH, 2006, J HEAD TRAUMA REHAB, V21, P213, DOI 10.1097/00001199-200605000-00002; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Tamietto M, 2006, NEUROREHABILITATION, V21, P81; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	57	45	45	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2009	24	1					15	27		10.3233/NRE-2009-0450			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	412DS	WOS:000263704400003	19208954				2022-02-06	
J	Shi, JX; Xiang, HY; Wheeler, K; Smith, GA; Stallones, L; Groner, J; Wang, ZZ				Shi, Junxin; Xiang, Huiyun; Wheeler, Krista; Smith, Gary A.; Stallones, Lorann; Groner, Jonathan; Wang, Zengzhen			Costs, mortality likelihood and outcomes of hospitalized US children with traumatic brain injuries	BRAIN INJURY			English	Article						Children; costs; outcome; traumatic brain injury; predictive mortality likelihood level	UNITED-STATES; RISK-FACTORS; SHORT-TERM; POPULATION; CLASSIFICATION; HYPERACTIVITY; ADOLESCENTS; PREVALENCE; CHILDHOOD; SEVERITY	Primary objective: To examine the hospitalization costs and discharge outcomes of US children with TBI and to evaluate a severity measure, the predictive mortality likelihood level. Research design: Data from the 2006 Healthcare Cost and Utilization Project Kids' Inpatient Database (KID) were used to report the national estimates and characteristics of TBI-associated hospitalizations among US children 20 years of age. The percentage of children with TBI caused by motor vehicle crashes (MVC) and falls was calculated according to the predictive mortality likelihood levels (PMLL), death in hospital and discharge into long-term rehabilitation facilities. Associations with the PMLL, discharge outcomes and average hospital charges were examined. Results: In 2006, there were an estimated 58 900 TBI-associated hospitalizations among US children, accounting for $2.56 billion in hospital charges. MVCs caused 38.9% and falls caused 21.2% of TBI hospitalizations. The PMLL was strongly associated with TBI type, length of hospital stay, hospital charges and discharge disposition. About 4% of children with fall or MVC related TBIs died in hospital and 9% were discharged into long-term facilities. Conclusion: The PMLL may provide a useful tool to assess characteristics and treatment outcomes of hospitalized TBI children, but more research is still needed.	[Shi, Junxin; Xiang, Huiyun; Wheeler, Krista; Smith, Gary A.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA; [Groner, Jonathan] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Trauma Program, Columbus, OH 43205 USA; [Stallones, Lorann] Colorado State Univ, Colorado Injury Control Res Ctr, Ft Collins, CO 80523 USA; [Wang, Zengzhen] Tongji Med Coll, Sch Publ Hlth, Wuhan, Hubei, Peoples R China		Xiang, HY (corresponding author), Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	huiyun.xiang@nationwidechildrens.org	Stallones, Lorann/AAC-6248-2021; Xiang, Huiyun/E-4335-2011; Groner, Jonathan/E-3156-2011	Stallones, Lorann/0000-0001-7616-582X; Groner, Jonathan/0000-0002-0998-593X; Wheeler, Krista/0000-0003-3728-8928	National Institutes of Health Fogarty International CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [1D43TW007257-01A2]; National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE001172-01]; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW007257] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025755] Funding Source: NIH RePORTER	Dr J. Shi was a trainee of the USA-China Agricultural Injury Research Training project, funded by a grant from the National Institutes of Health Fogarty International Center (PIs: L. Stallones and H. Xiang, Grant #: 1D43TW007257-01A2).r This study was supported by grants from the National Institutes of Health Fogarty International Center (PIs: L. Stallones and H. Xiang, Grant #: 1D43TW007257-01A2) and the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (PI: H. Xiang, Grant #: R49/CE001172-01).	Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; CATALE C, 2008, J CLIN EXPT NEUROPSY, V31, P1; *CDCP, 2001, TRAUM BRAIN INJ US A; *CDCP, REC FRAM E COD GROUP; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Dedoukou X, 2004, ARCH PEDIAT ADOL MED, V158, P1002, DOI 10.1001/archpedi.158.10.1002; DePompei R, 2008, J HEAD TRAUMA REHAB, V23, P191, DOI 10.1097/01.HTR.0000327251.16010.3b; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Guice KS, 2007, J TRAUMA, V63, pS68, DOI 10.1097/TA.0b013e31815acbb6; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; HCUP Kids' Inpatient Database (KID), 2006, HEALTHC COST UT PROJ; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Kendrick D, 2008, AM J PREV MED, V35, P370, DOI 10.1016/j.amepre.2008.06.038; Khambalia A, 2006, INJURY PREV, V12, P378, DOI 10.1136/ip.2006.012161; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Marr A., 2004, CENTRAL NERVOUS SYST; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; *MEDST GROUP INC, 2001, DIS STAG SOFTW US GU; *NAT HIGHW TRANSP, 2006, TRAFF SAF FACTS 2005; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; *POSTCR TRAUM CAR, 2003, REP POSTCR TRAUM CAR; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Runyan CW, 2005, AM J PREV MED, V28, P116, DOI 10.1016/j.amepre.2004.09.018; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; *SAS I, 2004, STAT AN SOFTW SAS VE; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Simons-Morton B, 2007, J SAFETY RES, V38, P193, DOI 10.1016/j.jsr.2007.02.007; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; *US BUR CENS, 2008, MONTHL POSTC CIV NON; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Verger K, 2000, BRAIN INJURY, V14, P495; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	45	45	46	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					602	611	PII 912685334	10.1080/02699050903014907			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600003	19557562	Green Accepted			2022-02-06	
J	Rinder, CS				Rinder, Christine Stowe			Fire safety in the operating room	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						fire triad; monitored anesthesia care liability; operating-room fires; oxygen-enriched atmospheres	MONITORED ANESTHESIA CARE; SURGICAL FIRES; NITROUS-OXIDE; INJURY	Purpose of review Elimination of flammable anesthetic gases has had little effect on operating-room fires except to change their etiology. Electrocautery and lasers, in an oxygen-enriched environment, can ignite even the most fire-resistant materials, including the patient, and the fire triad possibilities in the operating room are nearly limitless. This review will: identify operating room contents capable of acting as ignition/oxidizer/fuel sources, highlight operating room items that are uniquely potent fire triad contributors, and operating room identify settings where fire risk is enhanced by proximity of triad components in time or space. Recent findings Anesthesiologists are cognizant of the risk of airway surgery fires due to laser ignition of the endotracheal tube and/or its contents. Recently, however, head/neck surgery under monitored anesthesia care has emerged as a high-risk setting for operating room fires; burn injuries represent 20% of monitored anesthesia care-related malpractice claims, 95% of which involved head/neck surgery. Summary Operating room fires are infrequent but catastrophic. Operating room fire prevention depends on: (a) understanding how fire triad elements interact to create a fire, (b) recognizing how standard operating-room equipment, materials, and supplemental oxygen can become one of those elements, and (c) vigilance for circumstances that bring fire triad elements into close proximity.	[Rinder, Christine Stowe] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06520 USA; [Rinder, Christine Stowe] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA		Rinder, CS (corresponding author), Yale Univ, Sch Med, Dept Anesthesiol, Tompkins 3, New Haven, CT 06520 USA.	christine.rinder@yale.edu					Barker SJ, 2001, ANESTH ANALG, V93, P960, DOI 10.1097/00000539-200110000-00031; Barnes A M, 2000, AANA J, V68, P153; Bhananker SM, 2006, ANESTHESIOLOGY, V104, P228, DOI 10.1097/00000542-200602000-00005; *ECRI, 1992, HLTH DEVICES, V21, P3; EHRENWERTH JE, 2006, CLIN ANESTH, P169; GL W, 2000, J CLIN MONITOR COMPU, V16, P237; Goldberg Jessica, 2006, AANA J, V74, P352; *JCAHO, NAT PAT SAF GOALS; Lampotang S, 2005, ANESTH ANALG, V101, P1407, DOI 10.1213/01.ANE.0000180215.50589.02; Meneghetti SC, 2007, PLAST RECONSTR SURG, V120, P1701, DOI 10.1097/01.prs.0000282729.23202.da; NEUMAN GG, 1993, ANESTHESIOLOGY, V78, P875, DOI 10.1097/00000542-199305000-00011; Niskanen M, 2007, ACTA ANAESTH SCAND, V51, P509, DOI 10.1111/j.1399-6576.2007.01280.x; RINDER CS, 2005, ANESTHESIOLOGY S, V105, pC46; SaRego MM, 1997, ANESTH ANALG, V85, P1020, DOI 10.1097/00000539-199711000-00012; Smyth ETM, 2005, J HOSP INFECT, V61, P112, DOI 10.1016/j.jhin.2005.02.010; Sommers JR., 1998, SSM, V2, P41; Sosis M B, 1992, J Clin Anesth, V4, P217, DOI 10.1016/0952-8180(92)90069-D; Weber SM, 2005, HEAD NECK-J SCI SPEC, V28, P649; Williams DM, 2006, ACTA ANAESTH SCAND, V50, P505, DOI 10.1111/j.1399-6576.2006.00975.x; WOLF GL, 1987, ANESTHESIOLOGY, V67, P236, DOI 10.1097/00000542-198708000-00014	20	45	45	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0952-7907			CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	DEC	2008	21	6					790	795		10.1097/ACO.0b013e328318693a			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	398ES	WOS:000262716000017	18997531				2022-02-06	
J	Kirchhoff, C; Buhmann, S; Bogner, V; Stegmaier, J; Leidel, BA; Braunstein, V; Mutschler, W; Biberthaler, P				Kirchhoff, C.; Buhmann, S.; Bogner, V.; Stegmaier, J.; Leidel, B. A.; Braunstein, V.; Mutschler, W.; Biberthaler, P.			CEREBROSPINAL IL-10 CONCENTRATION IS ELEVATED IN NON-SURVIVORS AS COMPARED TO SURVIVORS AFTER SEVERE TRAUMATIC BRAIN INJURY	EUROPEAN JOURNAL OF MEDICAL RESEARCH			English	Article							SYSTEMIC INTERLEUKIN-10 RELEASE; CENTRAL-NERVOUS-SYSTEM; FLUID; ACTIVATION; EXPRESSION; CYTOKINES; SERUM; CELL; SUPPRESSES; PRESSURE	Objective: The intrathecal posttraumatic inflammation contributes to secondary brain damage as well as to the induction of neuroreparative mechanisms. In this context release of interleukin-10 (IL-10) has been reported to play a major role. However, initial IL-10 concentration in CSF remains incompletely characterized. Therefore, the aim was to analyze Il-10 in CSF and serum of patients early after TBI. Methods: For control, 10 Volunteers receiving spinal puncture were enrolled. In patients with severe TBI (GCS<8pts.), CSF and serum was drawn within 90 +/- 45min after intraventricular catheter insertion (0h), as well as 12h, 24h and 48h after TBI. Albumin for assessing Blood-Brain-Barrier (BBB) function and IL-10 (IMMULITE, DPC Biermann, Bad Nauheim, Germany) were analyzed. Results: 23 patients were enrolled. 15 survived and 8 deceased within 24h. In controls, CSF IL-10 was below detection limit (<5pg/ml). In contrast, IL-10 was elevated significantly in non-survivors at 0h vs. survivors and controls (30 +/- 6 vs. 9 +/- 1 vs. <5pg/mL). This was accompanied by a significant increase of serum If.-H in both groups at Oh vs. controls (survivors: 30 +/- 6pg/mL, non-survivors: 48 +/- 8pg/mL, controls: 10 +/- 7pg/mL, p <0.001). Survivors revealed signs of a mild BBB dysfunction during the entire observation period. In contrast, non-survivors presented a severe BBB breakage. Conclusions: We demonstrated an analysis of IL-10 CSF and serum concentration after TBI. These data Support an intrathecal IL-10 synthesis. Although the significant increase of IL-10 might indicate a bad outcome of TBI, responsible mechanisms still have to be elucidated.	[Kirchhoff, C.] Tech Univ Munich, Klinikum Rechts Isar, Abt Sportorthopad, D-80809 Munich, Germany; [Buhmann, S.] Univ Munich, Inst Klin Radiol, Munich, Germany; [Bogner, V.; Stegmaier, J.; Leidel, B. A.; Braunstein, V.; Mutschler, W.; Biberthaler, P.] Univ Munich, Chirurg Klin Innenstadt, Munich, Germany		Kirchhoff, C (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Abt Sportorthopad, Conollystr 32, D-80809 Munich, Germany.	chlodwig.kirchhoff@med.uni-muenchen.de		LEIDEL, Bernd A./0000-0002-5149-8764			Balasingam V, 1996, J NEUROSCI, V16, P2945; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; Dziurdzik P, 2004, INFLAMM RES, V53, P338, DOI 10.1007/s00011-004-1265-1; Elenkov IJ, 2002, ANN NY ACAD SCI, V966, P290, DOI 10.1111/j.1749-6632.2002.tb04229.x; FREI K, 1994, J IMMUNOL, V152, P2720; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P339; LACKI JK, 1995, INFLAMM RES, V44, P24, DOI 10.1007/BF01630483; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Maskin B, 2001, MEDICINA-BUENOS AIRE, V61, P573; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mussack T, 2005, EUR J MED RES, V10, P426; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; Scott MJ, 2006, CYTOKINE, V33, P79, DOI 10.1016/j.cyto.2005.12.002; SEITZ M, 1995, EUR J IMMUNOL, V25, P1129, DOI 10.1002/eji.1830250443; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; The Brain Trauma Foundation The American Association of Neurological Surgeons The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P497; Woiciechowsky C, 2005, ACT NEUR S, V95, P373; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Wu DF, 1999, P NATL ACAD SCI USA, V96, P254, DOI 10.1073/pnas.96.1.254	29	45	47	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0949-2321	2047-783X		EUR J MED RES	Eur. J. Med. Res.	OCT 27	2008	13	10					464	468					5	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	370LJ	WOS:000260763400004	19008173				2022-02-06	
J	Yuh, EL; Gean, AD; Manley, GT; Callen, AL; Wintermark, M				Yuh, Esther L.; Gean, Alisa D.; Manley, Geoffrey T.; Callen, Andrew L.; Wintermark, Max			Computer-Aided Assessment of Head Computed Tomography (CT) Studies in Patients with Suspected Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	International Symposium on Traumatic Brain Injury Research Priorities	OCT 13-16, 2005	Johnstown, PA	John P Murtha Neursci & Pain Inst, Natl Brain Injury Res, Treatments & Training Fdn, Brain Injury Assoc Amer		adult brain injury; animal studies; blood-brain barrier dysfunction; intracranial pressure; therapeutic approaches for the treatment of CNS injury	ACUTE INTRACRANIAL HEMORRHAGE; SCAN INTERPRETATION; PULMONARY NODULES; CLASSIFICATION; SENSITIVITY; PERFORMANCE; PREDICTION	In this study, we sought to determine the accuracy of a computer algorithm that automatically assesses head computed tomography (CT) studies in patients with suspected traumatic brain injury (TBI) for features of intracranial hemorrhage and mass effect, employing a neuroradiologist's interpretation as the gold standard. To this end, we designed a suite of computer algorithms that evaluates in a fully automated fashion the presence of intracranial blood and/or mass effect based on the following CT findings: (1) presence or absence of a subdural or epidural hematoma, (2) presence or absence of subarachnoid hemorrhage, (3) presence or absence of an intraparenchymal hematoma, (4) presence or absence of clinically significant midline shift (>= 5 mm), and (5) normal, partly effaced, or completely effaced basal cisterns. The algorithm displays abnormal findings as color overlays on the original head CT images, and calculates the volume of each type of blood collection, the midline shift, and the volume of the basal cisterns, based on the above-described features. Thresholds and parameters yielding optimal accuracy of the computer algorithm were determined using a development sample of 33 selected, nonconsecutive patients. The software was then applied to a validation sample of 250 consecutive patients evaluated for suspicion of acute TBI at our institution in 2006 -2007. Software detection of the presence of at least one noncontrast CT (NCT) feature of acute TBI demonstrated high sensitivity of 98% and high negative predictive value (NPV) of 99%. There was actually only one false negative case, where a very subtle subdural hematoma, extending exclusively along the falx, was diagnosed by the neuroradiologist, while the case was considered as normal by the computer algorithm. The software was excellent at detecting the presence of mass effect and intracranial hemorrhage, but showed some disagreements with the neuroradiologist in quantifying the degree of mass effect and characterizing the type of intracranial hemorrhage. In summary, we have developed a fully automated computer algorithm that demonstrated excellent sensitivity for acute intracranial hemorrhage and clinically significant midline shift, while maintaining intermediate specificity. Further studies are required to evaluate the potential favorable impact of this software on facilitating workflow and improving diagnostic accuracy when used as a screening aid by physicians with different levels of experience.	[Yuh, Esther L.; Gean, Alisa D.; Callen, Andrew L.; Wintermark, Max] Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, San Francisco, CA 94143 USA; [Yuh, Esther L.; Gean, Alisa D.; Manley, Geoffrey T.; Callen, Andrew L.; Wintermark, Max] San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Gean, Alisa D.; Manley, Geoffrey T.; Wintermark, Max] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA		Wintermark, M (corresponding author), Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA.	Max.Wintermark@radiology.ucsf.edu		Wintermark, Max/0000-0002-6726-3951			ALFARO D, 1995, ANN EMERG MED, V25, P169, DOI 10.1016/S0196-0644(95)70319-5; Baker ME, 2007, RADIOLOGY, V245, P140, DOI 10.1148/radiol.2451061116; Beyer F, 2007, EUR RADIOL, V17, P2941, DOI 10.1007/s00330-007-0667-1; BRANCATO B, 2007, BREAST CANC IN PRESS; Chan T, 2008, ACAD RADIOL, V15, P290, DOI 10.1016/j.acra.2007.09.022; Chan T, 2007, COMPUT MED IMAG GRAP, V31, P285, DOI 10.1016/j.compmedimag.2007.02.010; CHANTAL WPM, 2006, J CLIN EPIDEMIOL, V59, P132; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Das M, 2006, RADIOLOGY, V241, P564, DOI 10.1148/radiol.2412051139; Erly WK, 2003, AM J ROENTGENOL, V180, P1727, DOI 10.2214/ajr.180.6.1801727; Fenton JJ, 2007, NEW ENGL J MED, V356, P1399, DOI 10.1056/NEJMoa066099; Khoo NC, 2007, EMERG MED AUSTRALAS, V19, P122, DOI 10.1111/j.1742-6723.2007.00914.x; Lal NR, 2000, AM J NEURORADIOL, V21, P124; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wysoki MG, 1998, RADIOLOGY, V208, P125, DOI 10.1148/radiology.208.1.9646802	19	45	45	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2008	25	10					1163	1172		10.1089/neu.2008.0590			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	370XK	WOS:000260796200004	18986221				2022-02-06	
J	Tanriverdi, F; Taheri, S; Ulutabanca, H; Caglayan, AO; Ozkul, Y; Dundar, M; Selcuklu, A; Unluhizarci, K; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Taheri, Serpil; Ulutabanca, Halil; Caglayan, Ahmet Okay; Ozkul, Yusuf; Dundar, Munis; Selcuklu, Ahmet; Unluhizarci, Kursad; Casanueva, Felipe F.; Kelestimur, Fahrettin			Apolipoprotein E3/E3 Genotype Decreases the Risk of Pituitary Dysfunction after Traumatic Brain Injury due to Various Causes: Preliminary Data	JOURNAL OF NEUROTRAUMA			English	Article						APO E; hypopituitarism; polymorphism; pituitary; traumatic brain injury	E POLYMORPHISM; HEAD-INJURY; APOE GENOTYPE; HYPOPITUITARISM; DISEASE; INSUFFICIENCY; HEMORRHAGE; SEIZURES; PROTEIN; ALLELE	Traumatic brain injury (TBI) is a devastating public health problem which may result in hypopituitarism. However, the mechanisms and the risk factors responsible for hypothalamo-pituitary dysfunction due to TBI are still unclear. Although APO E is one of the most abundant protein in hypothalamo-pituitary region, there is no study investigating the relation between APO E polymorphism and TBI-induced hypopituitarism. This study was undertaken to determine whether APO E genotypes modulate the pituitary dysfunction risk after TBI due to various causes, including traffic accident, boxing, and kickboxing. Ninety-three patients with TBI (mean age, 30.61 +/- 1.25 years) and 27 healthy controls (mean age, 29.03 +/- 1.70 years) were included in the study. Pituitary functions were evaluated, and APO E genotypes (E2/E2; E3/E3; E4/E4; E2/E3; E2/E4; E3/E4) were screened. Twenty-four of 93 subjects (25.8%) had pituitary dysfunction after TBI. The ratio of pituitary dysfunction was significantly lower in subjects with APO E3/E3 (17.7%) than the subjects without APO E3/E3 genotype (41.9%; p = 0.01), and the corresponding odds ratio was 0.29 (95% confidence interval [CI], 0.11-0.78). In conclusion, this study provides strong evidence for the first time that APO E polymorphism is associated with the development of TBI-induced pituitary dysfunction. Present data demonstrated that APO E3/E3 genotype decreases the risk of hypopituitarism after TBI. The demonstration of the association between the APO E polymorphism and TBI may provide a new point of view in this field and promote further studies.	[Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [Taheri, Serpil; Caglayan, Ahmet Okay; Ozkul, Yusuf; Dundar, Munis] Erciyes Univ, Sch Med, Dept Genet, TR-38039 Kayseri, Turkey; [Ulutabanca, Halil; Selcuklu, Ahmet] Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; [Casanueva, Felipe F.] Univ Santiago, Sch Med, Dept Med, Santiago De Compostela, Spain; [Casanueva, Felipe F.] Univ Santiago, Complejo Hosp, Santiago De Compostela, Spain		Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr	Dundar, Munis/B-3150-2011; Ozkul, Yusuf/AAT-3574-2021; Caglayan, Ahmet O/D-1066-2012; kelestimur, f/ABE-9873-2021; Taheri, Serpil/AAL-8870-2021	Dundar, Munis/0000-0003-0969-4611; Caglayan, Ahmet O/0000-0002-2332-322X; 	Scientific and Technical Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [SBAG-3017]	This study was funded by the Scientific and Technical Research Council of Turkey (TUBITAK, project no. SBAG-3017).	Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Ballerini S, 2002, CLIN CHIM ACTA, V317, P71, DOI 10.1016/S0009-8981(01)00769-0; Barger SW, 1997, J NEUROCHEM, V69, P60; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Lamberts SWJ, 1998, LANCET, V352, P127; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nishida Y, 2005, GENE, V344, P133, DOI 10.1016/j.gene.2004.09.007; Schauwecker PE, 1998, EXP NEUROL, V149, P87, DOI 10.1006/exnr.1997.6679; Schiefermeier M, 2000, BRAIN, V123, P585, DOI 10.1093/brain/123.3.585; Schmidt R, 1997, STROKE, V28, P951, DOI 10.1161/01.STR.28.5.951; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; WelshBohmer KA, 1997, ANN NEUROL, V42, P319, DOI 10.1002/ana.410420308; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	38	45	46	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1071	1077		10.1089/neu.2007.0456			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900003	18707245				2022-02-06	
J	Chen, SJ; Pipinos, I; Johanning, J; Radovic, M; Huisinga, JM; Myers, SA; Stergiou, N				Chen, Shing-Jye; Pipinos, Iraklis; Johanning, Jason; Radovic, Matija; Huisinga, Jessie M.; Myers, Sara A.; Stergiou, Nick			Bilateral claudication results in alterations in the gait biomechanics at the hip and ankle joints	JOURNAL OF BIOMECHANICS			English	Article						peripheral arterial disease; claudication; joint moment; biomechanics; gait	PERIPHERAL ARTERIAL-DISEASE; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; INTERMITTENT CLAUDICATION; OCCLUSIVE DISEASE; PHYSICAL-ACTIVITY; WALKING IMPAIRMENT; TIBIAL ROTATION; MUSCLE; STRENGTH	claudication is the most common symptomatic manifestation of peripheral arterial disease (PAD), producing significant ambulatory compromise. The purpose of this study was to use advanced biomechanical gait analysis to determine the gait alterations occurring in claudicating patients both before and after onset of claudication pain in their legs. Hip, knee, and ankle joint moments were measured in claudicating patients (age: 64.46 +/- 8.47 years: body mass: 80.70 +/- 12.64 kg; body height: 1.72 +/- 0.08 m) and were compared to gender-age-body mass-height-matched healthy controls (age 66.27 +/- 9.22 years; body mass: 77.89 +/- 10.65kg; body height: 1.74 +/- 0.08 m). The claudicating patients were evaluated both before (pain-free (PF) condition) and after (pain condition) onset of claudication pain in their legs. Thirteen symptomatic PAD patients (26 claudicating limbs) with bilateral intermittent claudication (IC) and 11 healthy controls (22 control limbs) were tested during level walking at their self-selected speed. Compared to controls, PAD hip and ankle joints demonstrated significant angular kinematics and net internal moment changes. Alterations were present both in PF and pain conditions with several of them becoming worse in the pain condition. Both PF and pain conditions resulted in significantly reduced peak hip extensor moment (5.62 +/- 1.40 and 5.63 +/- 1.33% BW x BH, respectively) during early stance as compared to controls (7.53 +/- 1.16% BW x BH). In the pain condition, PAD patients had a significantly reduced ankle plantar flexor moment (7.56 +/- 1.41 % BW x BH) during late stance as compared to controls (8.65 +/- 1.27% BW x BH). Furthermore, when comparing PF to pain conditions, there was a decreased peak plantar flexor moment (PF condition: 8.23 +/- 1.37 vs. pain condition: 7.56 +/- 1.41% BW x BH) during late stance. The findings point to a weakness in the posterior compartment muscles of the hip and calf as being the key factor underlying the PAD gait adaptations. Our findings establish a detailed baseline description of the changes present in PAD patient's joint angles and moments during walking. Since IC is primarily a gait disability, better understanding of the abnormalities in joint and muscle function will enhance our understanding of the gait impairment and may lead to novel, gait-specific treatments. (c) 2008 Elsevier Ltd. All rights reserved.	[Chen, Shing-Jye; Radovic, Matija; Huisinga, Jessie M.; Myers, Sara A.; Stergiou, Nick] Univ Nebraska, HPER Biomech Lab, Sch Hlth Phys Educ & Recreat, Omaha, NE 68182 USA; [Pipinos, Iraklis; Johanning, Jason; Stergiou, Nick] Univ Nebraska Med Ctr, Omaha, NE USA; [Pipinos, Iraklis; Johanning, Jason] Vet Affairs Med Ctr, Omaha, NE USA		Chen, SJ (corresponding author), Univ Nebraska, HPER Biomech Lab, Sch Hlth Phys Educ & Recreat, 6001 Dodge St, Omaha, NE 68182 USA.	shingjychen@mail.unomaha.edu	Chen, Shing-Jye/T-3135-2019; Myers, Sara/E-1460-2015	Pipinos, Iraklis/0000-0001-6873-6346; Myers, Sara/0000-0002-2934-2624	American Geriatrics Society's Hartford Foundation Dennis W. Jahnigen Award; Nebraska Research Initiative; University of Community on Research and Creative Activity at UNO; AHA Scientific Councils' Student scholarshipAmerican Heart Association	We would like to acknowledge the support that was provided by the American Geriatrics Society's Hartford Foundation Dennis W. Jahnigen Award (to JMJ), the Nebraska Research Initiative (to NS), the University of Community on Research and Creative Activity at UNO (to SJC), and the AHA Scientific Councils' Student scholarship in cardiovascular disease and stroke (to SAM).	Atkins LM, 2004, ANGIOLOGY, V55, P347, DOI 10.1177/000331970405500401; Baker R, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-4; Barker SP, 2006, GAIT POSTURE, V24, P448, DOI 10.1016/j.gaitpost.2005.09.008; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bauman H C, 1997, J Vasc Nurs, V15, P21, DOI 10.1016/S1062-0303(97)90049-2; Benedetti MG, 1998, CLIN BIOMECH, V13, P204, DOI 10.1016/S0268-0033(97)00041-7; Bhat HK, 1999, CIRCULATION, V99, P807, DOI 10.1161/01.CIR.99.6.807; Brass EP, 2000, VASC MED, V5, P55, DOI 10.1177/1358836X0000500109; Chang FM, 2006, J PEDIATR ORTHOPED, V26, P612, DOI 10.1097/01.bpo.0000229970.55694.5c; Coyne KS, 2003, J VASC SURG, V38, P296, DOI 10.1016/S0741-5214(03)00312-4; Crowther RG, 2007, J VASC SURG, V45, P1172, DOI 10.1016/j.jvs.2007.01.060; DIBIANCO R, 1984, AM HEART J, V108, P1121, DOI 10.1016/0002-8703(84)90592-1; Fosang A, 2006, GAIT POSTURE, V24, P406, DOI 10.1016/j.gaitpost.2005.09.015; Gardner AW, 2006, ANGIOLOGY, V57, P539, DOI 10.1177/0003319706293114; Gardner AW, 1997, ANGIOLOGY, V48, P883, DOI 10.1177/000331979704801005; Gardner AW, 2001, VASC MED, V6, P31, DOI 10.1191/135886301677047365; Georgoalis AD, 2007, CLIN ORTHOP RELAT R, P89, DOI 10.1097/BLO.0b013e31802b4a0a; Green S, 2002, CLIN PHYSIOL FUNCT I, V22, P81, DOI 10.1046/j.1365-2281.2002.00400.x; Houck J, 2004, GAIT POSTURE, V19, P76, DOI 10.1016/S0966-6362(03)00033-X; Izquierdo-Porrera AM, 2005, J VASC SURG, V41, P625, DOI 10.1016/j.jvs.2005.01.012; Jobges M, 2004, J NEUROL NEUROSUR PS, V75, P1682, DOI 10.1136/jnnp.2003.016550; Judge JO, 1996, J GERONTOL A-BIOL, V51, pM303, DOI 10.1093/gerona/51A.6.M303; Kaufman KR, 2001, J BIOMECH, V34, P907, DOI 10.1016/S0021-9290(01)00036-7; Kemp GJ, 2004, MITOCHONDRION, V4, P629, DOI 10.1016/j.mito.2004.07.017; Kerrigan DC, 1998, ARCH PHYS MED REHAB, V79, P317, DOI 10.1016/S0003-9993(98)90013-2; Koopman JP, 1996, EUR J SURG, V162, P443; Liles DR, 2006, J SURG RES, V136, P294, DOI 10.1016/j.jss.2006.06.008; LUNDGREN F, 1988, AM J PHYSIOL, V255, pH1156; MARBINI A, 1986, ACTA NEUROL BELG, V86, P304; McDermott Mary McGrae, 2002, Am J Geriatr Cardiol, V11, P258, DOI 10.1111/j.1076-7460.2002.00031.x; McDermott MM, 2001, J AM GERIATR SOC, V49, P747, DOI 10.1046/j.1532-5415.2001.49151.x; McGibbon CA, 2001, CLIN BIOMECH, V16, P324, DOI 10.1016/S0268-0033(01)00004-3; McGinley JL, 2006, ARCH PHYS MED REHAB, V87, P779, DOI 10.1016/j.apmr.2006.02.022; MCKENNA M, 1991, ATHEROSCLEROSIS, V87, P119, DOI 10.1016/0021-9150(91)90014-T; Menard JR, 2004, J VASC SURG, V39, P1186, DOI 10.1016/j.jvs.2004.01.034; Meru AV, 2006, ATHEROSCLEROSIS, V187, P221, DOI 10.1016/j.atherosclerosis.2005.11.027; Neptune RR, 2001, J BIOMECH, V34, P1387, DOI 10.1016/S0021-9290(01)00105-1; Norgren L, 2007, J ENDOVASC THER, V14, P743, DOI 10.1583/1545-1550(2007)14[743:TISFOR]2.0.CO;2; Oka RK, 2005, VASC MED, V10, P265, DOI 10.1191/1358863x05vm637oa; Pipinos II, 2006, FREE RADICAL BIO MED, V41, P262, DOI 10.1016/j.freeradbiomed.2006.04.003; Riley PO, 2001, GAIT POSTURE, V14, P264, DOI 10.1016/S0966-6362(01)00133-3; Runge M., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P167; Scott-Okafor HR, 2001, ANGIOLOGY, V52, P7, DOI 10.1177/000331970105200102; Scott-Pandorf MM, 2007, J VASC SURG, V46, P491, DOI 10.1016/j.jvs.2007.05.029; Stergiou N, 2007, SPORTS MED, V37, P601, DOI 10.2165/00007256-200737070-00004; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Weber F, 2002, MUSCLE NERVE, V26, P471, DOI 10.1002/mus.10235; Winter DA, 2005, BIOMECHANICS MOTOR C, P86; Yavuzer G, 2006, CLIN REHABIL, V20, P960, DOI 10.1177/0269215506070315	49	45	46	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	AUG 7	2008	41	11					2506	2514		10.1016/j.jbiomech.2008.05.011			9	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	347GQ	WOS:000259129000022	18586253	Green Published			2022-02-06	
J	Donders, J; Janke, K				Donders, Jacobus; Janke, Kelly			Criterion validity of the Wechsler Intelligence Scale for Children-Fourth Edition after pediatric traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						intelligence; assessment; processing speed; sensitivity; specificity	HEAD-INJURY; WISC-III; SCORES	The performance of 40 children with complicated mild to severe traumatic brain injury on the Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV; Wechsler, 2003) was compared with that of 40 demographically matched healthy controls. Of the four WISC-IV factor index scores, only Processing Speed yielded a statistically significant group difference (p <.001) as well as a statistically significant negative correlation with length of coma (p <.01). Logistic regression, using Processing Speed to classify individual children, yielded a sensitivity of 72.50% and a specificity of 62.50%, with false positive and false negative rates both exceeding 30%. We conclude that Processing Speed has acceptable criterion validity in the evaluation of children with complicated mild to severe traumatic brain injury but that the WISC-IV should be supplemented with other measures to assure sufficient accuracy in the diagnostic process.	[Donders, Jacobus] Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; [Janke, Kelly] Calvin Coll, Dept Psychol, Grand Rapids, MI 49506 USA		Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					American Educational Research Association American Psychological Association National Council on Measurement in Education, 1999, STAND ED PSYCH TEST; Bigler ED, 2007, PEDIATRIC NEUROPSYCHOLOGICAL INTERVENTION: A CRITICAL REVIEW OF SCIENCE AND PRACTICE, P415; Calhoun SL, 2005, PSYCHOL SCHOOLS, V42, P333, DOI 10.1002/pits.20067; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Doyle AE, 2000, J CONSULT CLIN PSYCH, V68, P477, DOI [10.1037//0022-006X.68.3.477, 10.1037/0022-006X.68.3.477]; GREEN P, 2003, GREENS WORD MEMORY; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Keith TZ, 2006, SCHOOL PSYCHOL REV, V35, P108; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Naglieri JA, 2005, APPL NEUROPSYCHOL, V12, P208, DOI 10.1207/s15324826an1204_4; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Reinecke MA, 1999, J AM ACAD CHILD PSY, V38, P322, DOI 10.1097/00004583-199903000-00020; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Wechsler D, 2003, WECHSLER INTELLIGENC; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Yeates KO., 2005, WISC 4 CLIN USE INTE, P415, DOI 10.1016/B978-012564931-5/50014-1	20	45	45	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2008	14	4					651	655		10.1017/S1355617708080752			5	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	338VL	WOS:000258537400016	18577295	Bronze			2022-02-06	
J	Tehranian, R; Rose, ME; Vagni, V; Pickrell, AM; Griffith, RP; Liu, H; Clark, RSB; Dixon, CE; Kochanek, PM; Graham, SH				Tehranian, Roya; Rose, Marie E.; Vagni, Vincent; Pickrell, Alicia M.; Griffith, Raymond P.; Liu, Hao; Clark, Robert S. B.; Dixon, C. Edward; Kochanek, Patrick M.; Graham, Steven H.			Disruption of Bax protein prevents neuronal cell death but produces cognitive impairment in mice following traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; Bax; TBI; transgenic mice	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; TRANSGENIC MICE; BCL-2 PROTEIN; CEREBRAL-ISCHEMIA; GLOBAL-ISCHEMIA; APOPTOSIS; RATS; MITOCHONDRIA; EXPRESSION	Apoptosis contributes to delayed neuronal cell death in traumatic brain injury (TBI). To investigate if Bax plays a role in neuronal cell death and functional outcome after TBI, Bax gene disrupted (null) mice and wild-type (WT) controls were subjected to the controlled cortical impact (CCI) model of TBI. Motor function in WT and Bax null mice was evaluated using the round beam balance and the wire grip test on days 0-5. Spatial memory was assessed using a Morris Water Maze adopted for mice on days 14-18 post-injury. For histopathological analysis, animals were sacrificed 24 h and 21 days post-injury. In all three behavioral tests, the sham and TBI-injured Bax null mice performed significantly worse than their WT sham and TBI-injured counterparts. However, Bax null mice exhibited a higher percentage of surviving neurons in the CA1 and CA3 regions of hippocampus measured at 21 days post-injury. At 24 h after trauma, Bax null mice had fewer TUNEL positive cells in the CA1 and dentate regions of hippocampus as compared to WT mice, suggesting that deletion of the Bax gene ameliorates hippocampal cell death after TBI. Sham-operated Bax null mice had significantly greater brain volume as compared to WT mice. Thus, it is possible that Bax deficiency in the transgenic mice produces developmental behavioral effects, perhaps due to Bax's role in regulating cell death during development.	[Tehranian, Roya; Rose, Marie E.; Pickrell, Alicia M.; Liu, Hao; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA; [Tehranian, Roya; Rose, Marie E.; Liu, Hao; Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Griffith, Raymond P.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA; [Vagni, Vincent; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA		Graham, SH (corresponding author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, 7108 Highland Dr, Pittsburgh, PA 15206 USA.	sgra@pitt.edu	Kochanek, Patrick M/D-2371-2015; Pickrell, Alicia/B-8494-2018	Kochanek, Patrick M/0000-0002-2627-913X; Pickrell, Alicia/0000-0002-8470-6056	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS030318-10, P50 NS030318, NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER		Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Chen J, 1996, J NEUROCHEM, V67, P64; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Conti AC, 1998, J NEUROSCI, V18, P5663; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1992, NEUROCHEMICAL CORREL, P161; Fiskum G, 1983, Am J Emerg Med, V1, P147, DOI 10.1016/0735-6757(83)90082-7; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hetz C, 2005, J BIOL CHEM, V280, P42960, DOI 10.1074/jbc.M505843200; Hochhauser E, 2003, AM J PHYSIOL-HEART C, V284, pH2351, DOI 10.1152/ajpheart.00783.2002; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OLTVAI ZN, 1993, CELL, V74, P619; Polster BM, 2003, J NEUROSCI, V23, P2735; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Young C, 2003, CELL DEATH DIFFER, V10, P1148, DOI 10.1038/sj.cdd.4401277	50	45	53	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					755	767		10.1089/neu.2007.0441			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000004	18627254	Green Published, Green Accepted			2022-02-06	
J	Dhar, R; Diringer, MN				Dhar, Rajat; Diringer, Michael N.			The burden of the systemic inflammatory response predicts vasospasm and outcome after subarachnoid hemorrhage	NEUROCRITICAL CARE			English	Article						subarachnoid hemorrhage; inflammation; vasospasm; sepsis syndrome	DELAYED ISCHEMIC DEFICITS; C-REACTIVE PROTEIN; ACUTE BRAIN-INJURY; BLOOD-CELL COUNT; CEREBRAL VASOSPASM; CEREBROSPINAL-FLUID; ORGAN DYSFUNCTION; INTENSIVE-CARE; SEPSIS; SIMVASTATIN	Introduction Subarachnoid hemorrhage (SAH) can trigger immune activation sufficient to induce the systemic inflammatory response syndrome (SIRS). This may promote both extra-cerebral organ dysfunction and delayed cerebral ischemia, contributing to worse outcome. We ascertained the frequency and predictors of SIRS after spontaneous SAH, and determined whether degree of early systemic inflammation predicted the occurrence of vasospasm and clinical outcome. Methods Retrospective analysis of prospectively collected data on 276 consecutive patients admitted to a neurosciences intensive care unit with acute, non-traumatic SAH between 2002 and 2005. A daily SIRS score was derived by summing the number of variables meeting standard criteria (HR > 90, RR > 20, Temperature > 38 degrees C, or < 36 degrees C, WBC count < 4,000 or > 12,000). SIRS was considered present if two or more criteria were met, while SIRS burden over the first four days was calculated by averaging daily scores. Regression modeling was used to determine the relationship among SIRS burden (after controlling for confounders including infection, surgery, and corticosteroid use), symptomatic vasospasm, and outcome, determined by hospital disposition. Results SIRS was present in over half the patients on admission and developed in 85% within the first four days. Factors associated with SIRS included poor clinical grade, thick cisternal blood, larger aneurysm size, higher admission blood pressure, and surgery for aneurysm clipping. Higher SIRS burden was independently associated with death or discharge to nursing home (OR 2.20/point, 95% CI 1.27-3.81). All of those developing clinical vasospasm had evidence of SIRS, with greater SIRS burden predicting increased risk for delayed ischemic neurological deficits (OR 1.77/point, 95% CI 1.12-2.80). Conclusions Systemic inflammatory activation is common after SAH even in the absence of infection; it is more frequent in those with more severe hemorrhage and in those who undergo surgical clipping. Higher burden of SIRS in the initial four days independently predicts symptomatic vasospasm and is associated with worse outcome.	[Dhar, Rajat; Diringer, Michael N.] Washington Univ, Sch Med, Dept Neurol & Neurol Surg, Neurol Neurosurg Intens Care Unit, St Louis, MO 63110 USA		Dhar, R (corresponding author), Washington Univ, Sch Med, Dept Neurol & Neurol Surg, Neurol Neurosurg Intens Care Unit, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	dharr@neuro.wustl.edu	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537; Dhar, Rajat/0000-0002-5167-5097	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS035966, P01 NS035966-09] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [N535906] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035966] Funding Source: NIH RePORTER		Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Bavbek M, 1998, STROKE, V29, P1930, DOI 10.1161/01.STR.29.9.1930; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BOWTON DL, 1989, CRIT CARE MED, V17, P399, DOI 10.1097/00003246-198905000-00004; Chello M, 2006, CRIT CARE MED, V34, P660, DOI 10.1097/01.CCM.0000201407.89977.EA; Choileain NN, 2006, ARCH SURG-CHICAGO, V141, P1132, DOI 10.1001/archsurg.141.11.1132; CHYATTE D, 1989, STROKE, V20, P1021, DOI 10.1161/01.STR.20.8.1021; Clatterbuck RE, 2003, J NEUROSURG, V99, P376, DOI 10.3171/jns.2003.99.2.0376; de Oliveira JG, 2007, NEUROSURG REV, V30, P22, DOI 10.1007/s10143-006-0045-5; DILRAJ A, 1992, NEUROSURGERY, V31, P42, DOI 10.1227/00006123-199207000-00007; Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E; Fassbender K, 2000, STROKE, V31, P2971, DOI 10.1161/01.STR.31.12.2971; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; German JW, 1996, NEUROSURGERY, V39, P141, DOI 10.1097/00006123-199607000-00028; Gosling P, 2006, CRIT CARE MED, V34, P2158, DOI 10.1097/01.CCM.0000228914.73550.BD; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Gruber A, 2000, J NEUROSURG ANESTH, V12, P297, DOI 10.1097/00008506-200010000-00001; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; HUGHES JT, 1978, J NEUROSURG, V48, P515, DOI 10.3171/jns.1978.48.4.0515; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; Malham GM, 2001, BRIT J NEUROSURG, V15, P381, DOI 10.1080/02688690120082378; McGirt MJ, 2006, NEUROSURGERY, V58, P945, DOI 10.1227/01.NEU.0000210262.67628.7E; McGirt MJ, 2003, J NEUROSURG, V98, P1222, DOI 10.3171/jns.2003.98.6.1222; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; MILLER JA, 1995, STROKE, V26, P2260, DOI 10.1161/01.STR.26.12.2260; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Moynihan J, 2004, J NEUROIMMUNOL, V147, P87, DOI 10.1016/j.jneuroim.2003.10.018; Napolitano LM, 2000, J TRAUMA, V49, P647, DOI 10.1097/00005373-200010000-00011; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Naredi S, 2006, INTENS CARE MED, V32, P1955, DOI 10.1007/s00134-006-0408-y; NEILDWYER G, 1985, EUR J CLIN PHARMACOL, V28, P25, DOI 10.1007/BF00543706; O'Connor E, 2004, ANAESTH INTENS CARE, V32, P465, DOI 10.1177/0310057X0403200402; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; PARKINSON D, 1984, SURG NEUROL, V21, P132, DOI 10.1016/0090-3019(84)90330-6; PETERSON JW, 1989, J NEUROSURG, V71, P718, DOI 10.3171/jns.1989.71.5.0718; Rothoerl RD, 2006, J NEUROSURG ANESTH, V18, P68, DOI 10.1097/01.ana.0000181693.30750.af; Sehba FA, 2006, NEUROL RES, V28, P381, DOI 10.1179/016164106X114991; Suarez JI, 2002, CRIT CARE MED, V30, P1348, DOI 10.1097/00003246-200206000-00035; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Vincent JL, 2003, INTENS CARE MED, V29, pS74; WEIR B, 1989, NEUROSURGERY, V25, P161, DOI 10.1227/00006123-198908000-00002; Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646	46	45	47	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2008	8	3					404	412		10.1007/s12028-008-9054-2			9	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	301DT	WOS:000255877300014	18196475	Green Accepted			2022-02-06	
J	Matsui, T; Kakeda, T				Matsui, Tomohiro; Kakeda, Takahiro			IL-10 production is reduced by hypothermia but augmented by hyperthermia in rat microglia	JOURNAL OF NEUROTRAUMA			English	Article						hyperthermia; hypothermia; interleukin-10; microglia; nitric oxide	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; CEREBROSPINAL-FLUID; MILD HYPOTHERMIA; CYTOKINE PRODUCTION; PROTEIN-LEVELS; INTERLEUKIN-10; TEMPERATURE	Pro-inflammatory cytokines and nitric oxide (NO) are considered responsible for exacerbating brain injury. Activated microglia produce these potentially cytotoxic factors during neuron destruction. The beneficial effects of hypothermia on neuroprotection are considered to be due, in part, to suppression of post-injury inflammatory factors by microglia. However, the underlying mechanisms remain unclear. In particular, the hypothermia's role in modulating anti-inflammatory cytokines is unknown. We examined whether altering culture temperature modifies microglial production of cytokines and NO. Microglia isolated from neonatal rats were cultured with 1 mu g/mL lipopolysaccharide (LPS) under hypothermic, normothermic, and hyperthermic conditions for 72 h. Interleukin (IL)-6 and IL-10 levels in supernatants were measured by enzyme-linked immunosorbent assay (ELISA). NO production was analyzed by colorimetric assay of nitrite accumulated in the medium. Compared to normothermia, hypothermia decreased LPS-induced IL-6 production at 6 h of culture. In contrast, hyperthermia reduced IL-6 production throughout culture. IL-10 production was reduced by hypothermia but augmented by hyperthermia at 24-72 h. NO production was reduced by hypothermia throughout culture, while no significant differences in NO production were observed between normothermia and hyperthermia. In this study, hypothermia reduced production of IL-6, IL-10, and NO by LPS-activated microglia, suggesting that the neuroprotective effects of hypothermia might involve not only the inhibition of inflammatory factors, but also anti-inflammatory factor(s). Hyperthermia specifically increased IL-10 production in these cells. These temperature-dependent changes in IL-10 production may imply an important clinical marker for this cytokine in hypothermia-related neuronal protection and in hyperthermia-related neuronal injury.	[Matsui, Tomohiro] Yamaguchi Univ, Grad Sch Med, Dept Lab Sci, Yamaguchi, Japan; [Kakeda, Takahiro] Kawasaki Univ Med Welf, Fac Hlth & Welf, Dept Nursing, Okayama, Japan		Matsui, T (corresponding author), 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.	giants-ygc@umin.ac.jp	Kakeda, Takahiro/T-1063-2019				Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; FREI K, 1994, J IMMUNOL, V152, P2720; Gibbons H, 2003, MOL BRAIN RES, V110, P63, DOI 10.1016/S0169-328X(02)00585-5; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lancelot E, 1998, NEUROSCI LETT, V242, P131, DOI 10.1016/S0304-3940(98)00095-0; Maekawa S, 2002, CRIT CARE MED, V30, P2700, DOI 10.1097/00003246-200212000-00014; MALEFYT RD, 1991, J EXP MED, V174, P1209; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsui T, 2004, ACTA ANAESTH SCAND, V48, P205, DOI 10.1111/j.0001-5172.2004.00293.x; Matsui T, 2006, J NEUROSURG ANESTH, V18, P189, DOI 10.1097/01.ana.0000188639.39844.f6; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Nakamura Y, 1999, NEUROSCI RES, V35, P95, DOI 10.1016/S0168-0102(99)00071-1; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; Si QS, 1997, NEUROSCIENCE, V81, P223, DOI 10.1016/S0306-4522(97)00172-3; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	35	45	47	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					709	715		10.1089/neu.2007.0482			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900012	18533891				2022-02-06	
J	Arango-Lasprilla, JC; Ketchum, JM; Williams, K; Kreutzer, JS; de la Plata, CAM; O'Neil-Pirozzi, TM; Wehman, P				Arango-Lasprilla, Juan Carlos; Ketchum, Jessica M.; Williams, Kelli; Kreutzer, Jeffrey S.; de la Plata, Carlos A. Marquez; O'Neil-Pirozzi, Therese M.; Wehman, Paul			Racial differences in employment outcomes after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; outcomes research; race; rehabilitation	QUALITY-OF-LIFE; FUNCTIONAL OUTCOMES; WORK; RACE	Objective: To examine racial differences in employment status and occupational status I year after a traumatic brain injury (TBI). Design: Retrospective study. Setting: Longitudinal dataset of the Traumatic Brain Injury Model Systems national database. Participants: Subjects with primarily moderate to severe TBI (3468 whites vs 1791 minorities) hospitalized between 1989 and 2005. Interventions: Not applicable. Main Outcome Measures: Employment status (competitively employed or unemployed) and occupational status (professional/managerial, skilled, or manual labor) at 1 year postinjury. Results: Race and/or ethnicity has a significant effect on employment status at 1 year postinjury (chi(2)(1) = 58.23, P <.001), after adjusting for preinjury employment status, sex, Disability Rating Scale at discharge, marital status, cause of injury, age, and education. The adjusted odds of being unemployed versus competitively employed are 2.17 times (95% confidence interval, 1.78-2.65) greater for minorities than for whites. Race and ethnicity does not have a significant effect on occupational status at I year postinjury. Conclusions: With this empirical evidence supporting racial differences in employment outcomes between minorities and whites at I year postinjury, priority should be given to tailoring interventions to maximize minority survivors' work-related productivity.	[Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA 23219 USA; [Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23219 USA; [de la Plata, Carlos A. Marquez] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [de la Plata, Carlos A. Marquez] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [O'Neil-Pirozzi, Therese M.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA		Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Theater Row Bldg,730 Broad St, Richmond, VA 23219 USA.	jcarangolasp@vcu.edu	Ketchum, Jessica/AAE-8200-2020	Ketchum, Jessica/0000-0002-5566-3691	National Institute on Disability and Rehabilitation Research; U.S. Department of EducationUS Department of Education [H133A020516, H133B040011]	Supported by the National Institute on Disability and Rehabilitation Research. U.S. Department of Education (grant nos. H133A020516, H133B040011).	Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Finkelstein E., 2006, INCIDENCE EC BURDEN; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; INGE KJ, 2007, REAL WORK REAL PLAY, P117; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lemeshow S, 2000, APPL LOGISTIC REGRES; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M., 1996, J HEAD TRAUMA REHAB, V11, P69; RUTLANDBROWN W, 2003, J HEAD TRAUMA REHAB, V2, P544; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001	23	45	45	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					988	995		10.1016/j.apmr.2008.02.012			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	341ST	WOS:000258735900027	18452750				2022-02-06	
J	Grond-Ginsbach, C; Hummel, M; Wiest, T; Horstmann, S; Pfleger, K; Hergenhahn, M; Hollstein, M; Mansmann, U; Grau, AJ; Wagner, S				Grond-Ginsbach, C.; Hummel, M.; Wiest, T.; Horstmann, S.; Pfleger, K.; Hergenhahn, M.; Hollstein, M.; Mansmann, U.; Grau, A. J.; Wagner, S.			Gene expression in human peripheral blood mononuclear cells upon acute ischemic stroke	JOURNAL OF NEUROLOGY			English	Article						acute ischemic stroke; acute traumatic brain injury; gene expression; blood	MICROARRAY; BRAIN; INTERLEUKIN-1; NEUTROPHILS; PROFILES; PATTERNS; GENOMICS; INJURY	Background and purpose Ischemic stroke provokes a systemic inflammatory response. The purpose of this study was to characterize this response on the gene expression level in circulating mononuclear leukocytes from acute ischemic stroke (AIS) patients. Methods RNA from peripheral blood mononuclear cells (PBMCs) of AIS patients (24 +/- 2 hours after onset of symptoms) was analyzed with Affymetrix U133A GeneChips using a pooled design. We compared the gene expression signature from AIS patients (n = 20), stroke survivors (n = 15), patients with acute traumatic brain injury (ATBI, n = 15) and healthy control subjects without vascular risk factors (n = 15). Results Expression levels of 9682 probe sets with present calls on each GeneChip were compared. Between AIS patients and stroke survivors or between AIS patients and ATBI patients there were no significant differences in expression values of single genes after correction for multiple testing. However, comparison of the PBMC expression profiles from AIS patients and healthy subjects revealed significantly different expression (p = 0.012) of a single probe set, specific for phosphodiesterase 4 D (PDE4D). In order to detect modest expression differences in multiple genes with a presumed cumulative effect we studied the gene expression of functional groups of genes by global statistical tests. Analysis of 11 gene groups revealed differential expression between AIS patients and healthy subjects for genes involved in the inflammatory response (GeneOntology GO:0006954). Genes encoding the N-formyl peptide receptor-like 1 (FPRL1), interleukin-1 receptor antagonist (IL1RN) and complement component 3a receptor 1 (C3AR1) contributed most to the observed difference. Conclusions This transcriptome analysis did not identify significant changes between circulating mononuclear cells from AIS patients 24 hours after stroke and closely matched stroke survivors. However, comparing AIS patients with healthy control subjects revealed measurable differences in PDE4D and in inflammatory response genes when considered as a set.	[Grond-Ginsbach, C.; Wiest, T.; Horstmann, S.; Pfleger, K.; Wagner, S.] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; [Hummel, M.; Mansmann, U.] LMU Munchen, Sch Med, IBE, Munich, Germany; [Hergenhahn, M.; Hollstein, M.] German Canc Res Ctr, Dept Genet Alterat Carcinogenesis, D-6900 Heidelberg, Germany; [Grau, A. J.] Klinikum Stadt Ludwigshafen, Dept Neurol, D-6700 Ludwigshafen, Germany		Grond-Ginsbach, C (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Caspar_Grond_Ginsbach@med.uni-heidelberg.de					Baird AE, 2007, STROKE, V38, P694, DOI 10.1161/01.STR.0000250431.99687.7b; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Barnum SR, 2002, GLIA, V38, P169, DOI 10.1002/glia.10069; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Chtanova T, 2005, J IMMUNOL, V175, P7837, DOI 10.4049/jimmunol.175.12.7837; Connolly PH, 2004, J APPL PHYSIOL, V97, P1461, DOI 10.1152/japplphysiol.00316.2004; Cowell RM, 2003, J NEUROSCI, V23, P9459; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Feezor RJ, 2004, PHYSIOL GENOMICS, V19, P247, DOI 10.1152/physiolgenomics.00020.2004; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Gretarsdottir S, 2002, AM J HUM GENET, V70, P593, DOI 10.1086/339252; GRONDGINSBACH C, 2007, GENE EXPRESSIO UNPUB; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Jolly RA, 2005, PHYSIOL GENOMICS, V22, P346, DOI 10.1152/physiolgenomics.00260.2004; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Liu J, 2006, J MOL DIAGN, V8, P551, DOI 10.2353/jmoldx.2006.060021; Malcolm KC, 2003, AM J PHYSIOL-LUNG C, V284, pL663, DOI 10.1152/ajplung.00094.2002; Mansmann U, 2005, METHOD INFORM MED, V44, P449; Mocco J, 2006, CIRC RES, V99, P209, DOI 10.1161/01.RES.0000232544.90675.42; Moore DF, 2005, CIRCULATION, V111, P212, DOI 10.1161/01.CIR.0000152105.79665.C6; Rosand J, 2006, NAT GENET, V38, P1091, DOI 10.1038/ng1006-1091; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Sebastiani P, 2005, NAT GENET, V37, P435, DOI 10.1038/ng1533; Sharp FR, 2007, STROKE, V38, P691, DOI 10.1161/01.STR.0000247940.27518.38; Sharp FR, 2006, EPILEPSIA, V47, P1603, DOI 10.1111/j.1528-1167.2006.00809.x; Subrahmanyam YVBK, 2001, BLOOD, V97, P2457, DOI 10.1182/blood.V97.8.2457; Tang Y, 2006, J CEREBR BLOOD F MET, V26, P1089, DOI 10.1038/sj.jcbfm.9600264; Wang Y, 2001, STROKE, V32, P2170, DOI 10.1161/hs0901.095650; Worrall BB, 2007, STROKE, V38, P1189, DOI 10.1161/01.STR.0000260099.42744.b0; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yue L, 2005, CURR MOL MED, V5, P11, DOI 10.2174/1566524053152906; Zakharkin SO, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-214	35	45	47	0	5	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	MAY	2008	255	5					723	731		10.1007/s00415-008-0784-z			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	311EH	WOS:000256583000017	18465111				2022-02-06	
J	Minns, RA; Jones, PA; Mok, JYQ				Minns, Robert A.; Jones, Patricia A.; Mok, Jacqueline Y-Q			Incidence and demography of non-accidental head injury in southeast Scotland from a national database	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							RISK-FACTORS; CHILD-ABUSE; INFANTS	Background: This study utilized an existing national database of cases of non-accidental head injury (NAHI; also called inflicted traumatic brain injury [inflicted TBI] and shaken baby syndrome [SBS]) in Scotland to report the incidence, confidence intervals, and demography of such cases in Southeast Scotland. Methods: This prospective population-based study was conducted from January 1998 to September 2006. Data from the Lothian region of Scotland, where there is known full ascertainment of infant head injuries, including NAHI have been used to calculate the incidence rate for this region of Scotland, with government statistics providing the normal annual infant population as the denominator. A new Scottish Index of Multiple Deprivation (SIMD), which assesses a very focused area (data zone population size=750) and provides novel information about social demography for education, housing, employment, health, crime, income, and geographic accessibility to services, was applied to the identified cases of NAHI during this study period. Results: The mean incidence of NAHI in southeast Scotland for 8.75 years was 33.8/100,000 infants per year. The cases of NAHI were mostly located in the lowest 1 (or 2) quintiles for all SIMD domains (education, housing, employment, health, crime, income), although they had good accessibility to medical and other community services. Conclusions: The incidence rates from this prospective study for NAHI are considerably higher than other published UK surveys and are not considered to reflect a cluster effect. The perpetrators in this study fit a strongly skewed profile aggregating to the lowest socioeconomic groups in the community.	[Minns, Robert A.; Jones, Patricia A.; Mok, Jacqueline Y-Q] Univ Edinburgh, Dept Child Life & Hlth, Edinburgh EH9 1UW, Midlothian, Scotland; [Minns, Robert A.; Mok, Jacqueline Y-Q] Lothian Univ Hosp NHS Trust, Royal Hosp Sick Children, Edinburgh, Midlothian, Scotland		Minns, RA (corresponding author), Univ Edinburgh, Dept Child Life & Hlth, 20 Sylvan Pl, Edinburgh EH9 1UW, Midlothian, Scotland.	Robert.Minns@ed.ac.uk					BALLIN JC, 1985, JAMA-J AM MED ASSOC, V254, P796; Barlow KM, 1998, SCOT MED J, V43, P112, DOI 10.1177/003693309804300407; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; DUHAIME AC, 1992, PEDIATRICS, V90, P179; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; HUNTER RS, 1978, PEDIATRICS, V61, P629; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; KAPLUN D, 1976, AM J PSYCHIAT, V133, P809; Keenan H, 2003, INFLICTED CHILDHOOD, P3; Minns RA, 2004, BRIT MED J, V328, P766, DOI 10.1136/bmj.328.7442.766; Minns RA, 2005, CLIN DEV MED, P1; Mok JYQ, 2005, CLIN DEV MED, P415; Nagler J, 2002, CURR OPIN PEDIATR, V14, P251, DOI 10.1097/00008480-200204000-00019; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; Rao P, 1999, CLIN RADIOL, V54, P11, DOI 10.1016/S0009-9260(99)91234-5; Rao P, 1999, CLIN RADIOL, V54, P495, DOI 10.1016/S0009-9260(99)90845-0; SEDLAK A, 1996, EXECUTIVE SUMMARY, V3; Wu SS, 2004, CHILD ABUSE NEGLECT, V28, P1253, DOI 10.1016/j.chiabu.2004.07.005	19	45	47	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	APR	2008	34	4		S			S126	S133		10.1016/j.amepre.2008.01.016			8	Public, Environmental & Occupational Health; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; General & Internal Medicine	279TT	WOS:000254378300006	18374262				2022-02-06	
J	Brown, AW; Elovic, EP; Kothari, S; Flanagan, SR; Kwasnica, C				Brown, Allen W.; Elovic, Elie P.; Kothari, Sunil; Flanagan, Steven R.; Kwasnica, Christina			Congenital and acquired brain injury. 1. Epidemiology, pathophysiology, prognostication, innovative treatments, and prevention	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						diffuse axonal injury; economics; guidelines [publication type]; mortality; preventive measures; rehabilitation	PEDIATRIC TRAUMA; UNITED-STATES; HEAD-INJURY; MORTALITY; MANAGEMENT; TRENDS; DEATH; MODEL	This self-directed learning module reviews the cur-rent epidemiology of traumatic brain injury (TBI), its pathophysiology, prognostication after injury, currently available innovative early approaches to diagnosis and treatment, and effective methods of prevention. It is intended to provide the rehabilitation clinician with current knowledge to accurately inform patients, families, significant others, referring physicians, and payers and to aid in clinical decision making while caring for patients after TBI. Overall Article Objective: To describe current knowledge in traumatic brain injury epidemiology, pathophysiology, prognostication, acute treatment, and prevention.	[Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; [Elovic, Elie P.] Kessler Med Rehabil Res & Educ Ctr, W Orange, NJ USA; [Kothari, Sunil] Inst Rehabil & Res, Houston, TX USA; [Flanagan, Steven R.] Mt Sinai Hosp, New York, NY 10029 USA; [Kwasnica, Christina] Barrow Neurol Inst, Phoenix, AZ 85013 USA		Brown, AW (corresponding author), Mayo Clin, Dept Phys Med & Rehabil, 200 1st SW, Rochester, MN 55905 USA.	brown.allen@mayo.edu		Brown, Allen W./0000-0001-7228-3351; Flanagan, Steven/0000-0001-9005-5897			Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Benoit R, 2000, J TRAUMA, V49, P477, DOI 10.1097/00005373-200009000-00015; *BRAIN TRAUM FDN, 2003, GUID MAN SEV TRAUM B; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Everett SA, 2001, J ADOLESCENT HEALTH, V28, P228, DOI 10.1016/S1054-139X(00)00177-4; Finkelstein E., 2006, INCIDENCE EC BURDEN; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Kim DH, 2006, NEUROCRIT CARE, V4, P83, DOI 10.1385/NCC:4:1:083; Kochanek PM, 2007, BRAIN INJURY MED PRI, P81; Kothari S., 2007, BRAIN INJURY MED PRI, P169; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Napolitano E, 2007, BRAIN INJURY MED PRI, P57; NHTSA, 1996, 3 REP C EFF OCC PROT; Plautz B, 1996, AM J PREV MED, V12, P33, DOI 10.1016/S0749-3797(18)30256-3; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; STYLIANOS S, 1993, PEDIATR CLIN N AM, V40, P1359; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Vitaz TW, 2001, J TRAUMA, V51, P369, DOI 10.1097/00005373-200108000-00025; Winter CD, 2005, SURG-J R COLL SURG E, V3, P329, DOI 10.1016/S1479-666X(05)80112-X	31	45	48	1	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2008	89	3		1			S3	S8		10.1016/j.apmr.2007.12.001			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	276TX	WOS:000254167100002	18295647				2022-02-06	
J	Stein, DM; Dutton, RP; Kramer, ME; Handley, C; Scalea, TM				Stein, Deborah M.; Dutton, Richard P.; Kramer, Mary E.; Handley, Christopher; Scalea, Thomas M.			Recombinant factor VIIa: Decreasing time to intervention in coagulopathic patients with severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	66th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 27-29, 2007	Las Vegas, NV	Amer Assoc Surg Trauma		trauma; traumatic brain injury; coagulopathy; rFVIIa	ACTIVATED FACTOR-VII; CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; WARFARIN; REVERSAL; THERAPY; ANTICOAGULATION; MANAGEMENT; MORTALITY; NOVOSEVEN	Background: Treatment of coagulopathy is often needed before neurosurgical intervention in patients with traumatic brain injury (TBI). Typically, this is accomplished with administration of plasma. We hypothesized that the off-label use of recombinant factor VIIa (rFVIIa) to normalize the coagulation profile would allow for earlier intervention than conventional therapy. Methods: The trauma registry was used to identify patients with severe TBI who were admitted during a 4-year period and were coagulopathic at admission (international normalized ratio, INR >= 1.4) and required a neurosurgical procedure. Severe TBI was defined as head abbreviated injury scale (AIS) >3 and admission Glasgow coma score (GCS) <9. Demographics, injury, blood bank and laboratory data, time of intervention, rFVIIa use, and complications were abstracted. Characteristics of the group who received rFVIIa were compared against those treated with plasma alone with a Student's t test and chi(2) analysis, as well as nonparametric methods for comparison of medians. Results: Of 681 patients with severe TBI, 63 were coagulopathic at admission and needed an emergent neurosurgical procedure. Twenty-nine patients who received rFVIIa were compared against 34 patients who were treated with only plasma. Mean age, injury severity score (ISS), and admission GCS and INR were not different between the two groups. Time to neurosurgical intervention was less in the rFVIIa group (median = 144 vs. 446 minutes, p = 0.0003) as were the number of units of plasma administered before intervention (median = 2 vs. 6, p = 0.0006). The rate of thromboembolic complications was not different between groups. In patients with isolated TBI, mortality was 33.3% in the rFVIIa group and 52.9% in controls (p 0.24). Conclusions: rFVIIa rapidly and effectively reversed coagulopathy in patients with severe TBI. rFVIIa decreased the time to intervention and decreased the use of blood products without increasing the rate of thromboembolic complications.	[Stein, Deborah M.; Dutton, Richard P.; Kramer, Mary E.; Scalea, Thomas M.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Natl Study Ctr Trauma & Emergency Med Syst, Baltimore, MD 21201 USA		Stein, DM (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Brody DL, 2005, NEUROCRIT CARE, V2, P263, DOI 10.1385/NCC:2:3:263; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cortiana M, 1986, J Neurosurg Sci, V30, P133; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Freeman WD, 2004, MAYO CLIN PROC, V79, P1495, DOI 10.4065/79.12.1495; Harrison TD, 2005, J TRAUMA, V59, P150, DOI 10.1097/01.TA.0000171470.39742.8E; Hedner U, 2006, SEMIN THROMB HEMOST, V32, P77, DOI 10.1055/s-2006-939557; Henzler D, 2007, CRIT CARE MED, V35, P1027, DOI 10.1097/01.CCM.0000259526.45894.08; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Karadimov D, 2003, J NEUROSURG ANESTH, V15, P330, DOI 10.1097/00008506-200310000-00008; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; Levy JH, 2006, TRANSFUSION, V46, P919, DOI 10.1111/j.1537-2995.2006.00824.x; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Lu J, 2005, ACT NEUR S, V95, P281; May AK, 1997, AM SURGEON, V63, P233; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; MOHR JP, 2007, 16 EUR STROK C GLASG; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Perkins JG, 2007, J TRAUMA, V62, P1095, DOI 10.1097/TA.0b013e31804798a4; Powner DJ, 2005, NEUROSURGERY, V57, P823, DOI 10.1227/01.NEU.0000179915.74429.b2; Rizoli SB, 2006, J TRAUMA, V61, P1419, DOI 10.1097/01.ta.0000243045.56579.74; Roitberg B, 2005, NEUROSURGERY, V57, P832, DOI 10.1227/01.NEU.0000180816.80626.C2; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Sorensen B, 2003, BLOOD COAGUL FIBRIN, V14, P469, DOI 10.1097/00001721-200307000-00007; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; TAWIL S, IN PRESS J TRAUMA; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Valadka A, 2000, TRAUMA, P377; White Christopher E, 2006, Curr Surg, V63, P310, DOI 10.1016/j.cursur.2006.04.013; Yusim Y, 2006, J CLIN ANESTH, V18, P545, DOI 10.1016/j.jclinane.2006.02.012; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	44	45	48	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2008	64	3					620	627		10.1097/TA.0b013e3181650fc7			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	274JE	WOS:000253996800013	18332801				2022-02-06	
J	Murphy, B; Dunleavy, M; Shinoda, S; Schindler, C; Meller, R; Bellver-Estelles, C; Hatazaki, S; Dicker, P; Yamamoto, A; Koegel, I; Chu, XP; Wang, WZ; Xiong, ZG; Prehn, J; Simon, R; Henshall, D				Murphy, Brona; Dunleavy, Mark; Shinoda, Sachiko; Schindler, Clara; Meller, Robert; Bellver-Estelles, Carmen; Hatazaki, Seiji; Dicker, Patrick; Yamamoto, Akitaka; Koegel, Ina; Chu, Xiangping; Wang, Weizhen; Xiong, Zhigang; Prehn, Jochen; Simon, Roger; Henshall, David			Bcl-w protects hippocampus during experimental status epilepticus	AMERICAN JOURNAL OF PATHOLOGY			English	Article							EVOKED LIMBIC SEIZURES; INDUCED NEURONAL DEATH; TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; PROGRAMMED CELL-DEATH; ISCHEMIC BRAIN; DEFICIENT MICE; APOPTOSIS; PROTEINS; EXPRESSION	Experimentally evoked seizures can activate the intrinsic mitochondrial cell death pathway, components of which are modulated in the hippocampus of patients with temporal lobe epilepsy. Bcl-2 family proteins are critical regulators of mitochondrial dysfunction, but their significance in this setting remains primarily untested. Presently, we investigated the mitochondrial pathway and role of anti-apoptotic Bcl-2 proteins using a mouse model of seizure-induced neuronal death. Status epilepticus was evoked in mice by intra-amygdala kainic acid, causing cytochrome c release, processing of caspases 9 and 7, and death of ipsilateral hippocampal pyramidal neurons. Seizures caused a rapid decline in hippocampal Bcl-w levels not seen for either Bcl-2 or Bcl-xl. To test whether endogenous Bcl-w was functionally significant for neuronal survival, we investigated hippocampal injury after seizures in Bcl-w-deficient mice. Seizures induced significantly more hippocampal CA3 neuronal loss and DNA fragmentation in Bcl-w-deficient mice compared with wild-type mice. Quantitative electroencephalography analysis also revealed that Bcl-w-deficient mice display a neurophysiological phenotype whereby there was earlier polyspike seizure onset. Finally, we detected higher levels of Bcl-w in hippocampus from temporal lobe epilepsy patients compared with autopsy controls. These data identify Bcl-w as an endogenous neuroprotectant that may have seizure-suppressive functions.	Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; Legacy Res, Robert S Dow Neurobiol Labs, Portland, OR USA; Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 514, Japan		Henshall, D (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	dhenshall@rcsi.ie	Dunleavy, Mark/B-4260-2012; Dicker, Patrick/ABA-9881-2021; Murphy, Brona/D-4873-2012; Prehn, Jochen HM/A-3928-2010; Murphy, Brona/P-2544-2019	Dunleavy, Mark/0000-0001-5916-9722; Murphy, Brona/0000-0002-6740-8858; Prehn, Jochen HM/0000-0003-3479-7794; Murphy, Brona/0000-0002-6740-8858; Henshall, David/0000-0001-6237-9632; Chu, Xiang-Ping/0000-0002-6781-0468	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047622, R01NS039016, R01NS041935] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41935, NS47622, R01 NS039016, R01 NS041935, NS39016, R01 NS047622] Funding Source: Medline; Wellcome TrustWellcome TrustEuropean Commission [gr076576] Funding Source: Medline		Araki T, 2002, J NEUROSCI RES, V69, P614, DOI 10.1002/jnr.10356; Briellmann RS, 2000, NEUROLOGY, V55, P1479, DOI 10.1212/WNL.55.10.1479; Cao GD, 2002, J NEUROSCI, V22, P5423; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Fujikawa DG, 2002, J NEUROCHEM, V83, P229, DOI 10.1046/j.1471-4159.2002.01152.x; Hamner S, 1999, NEUROSCIENCE, V91, P673, DOI 10.1016/S0306-4522(98)00642-3; Henshall DC, 2005, J CEREBR BLOOD F MET, V25, P1557, DOI 10.1038/sj.jcbfm.9600149; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Henshall DC, 2002, NEUROBIOL DIS, V10, P71, DOI 10.1006/nbdi.2002.0505; Henshall DC, 2001, CELL DEATH DIFFER, V8, P1169, DOI 10.1038/sj.cdd.4400921; Henshall DC, 2001, NEUROSCI LETT, V305, P153, DOI 10.1016/S0304-3940(01)01849-3; Hochman A, 1998, J NEUROCHEM, V71, P741; Jia ZP, 1996, NEURON, V17, P945, DOI 10.1016/S0896-6273(00)80225-1; Jonas EA, 2003, J NEUROSCI, V23, P8423; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kondratyev A, 2001, MOL BRAIN RES, V91, P1, DOI 10.1016/S0169-328X(01)00099-7; Lai Y, 2005, J NEUROCHEM, V94, P360, DOI 10.1111/j.1471-4159.2005.03212.x; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Tian-Fu, 2005, Shengli Xuebao, V57, P310; Lindsten T, 2006, CELL DEATH DIFFER, V13, P1272, DOI 10.1038/sj.cdd.4401953; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu XM, 2006, J BIOL CHEM, V281, P17432, DOI 10.1074/jbc.M513490200; Meldrum BS, 2002, PROG BRAIN RES, V135, P487; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Pitkanen A, 2002, NEUROLOGY, V59, pS27, DOI 10.1212/WNL.59.9_suppl_5.S27; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; Schindler CK, 2004, NEUROSCI LETT, V356, P163, DOI 10.1016/j.neulet.2003.11.048; Shinoda S, 2004, J NEUROSCI RES, V76, P121, DOI 10.1002/jnr.20064; Shinoda S, 2004, J CLIN INVEST, V113, P1059, DOI 10.1172/JCI200419971; Sun Y, 2003, GENE THER, V10, P115, DOI 10.1038/sj.gt.3301868; Vocero-Akbani A, 2000, METHOD ENZYMOL, V322, P508; Weise J, 2005, NEUROBIOL DIS, V18, P582, DOI 10.1016/j.nbd.2004.10.025; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Xiong ZG, 1999, J NEUROSCI, V19; Yamamoto A, 2006, J NEUROPATH EXP NEUR, V65, P217, DOI 10.1097/01.jnen.0000202886.22082.2a; Yan CH, 2000, J CEREBR BLOOD F MET, V20, P620, DOI 10.1097/00004647-200003000-00020	47	45	45	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	OCT	2007	171	4					1258	1268		10.2353/ajpath.2007.070269			11	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	217TJ	WOS:000249969900017	17702891	Green Published			2022-02-06	
J	Tate, CC; Garcia, AJ; LaPlaca, MC				Tate, Ciara C.; Garcia, Andres J.; LaPlaca, Michelle C.			Plasma fibronectin is neuroprotective following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						fibronectin; traumatic brain injury; neurotraurna; neuroprotection; apoptosis; extracellular matrix; inflammation; controlled cortical impact	CONTROLLED CORTICAL IMPACT; EXTRACELLULAR-MATRIX PROTEINS; RAT; EXPRESSION; MOUSE; MACROPHAGES; CELLS; IMMUNOREACTIVITY; ANGIOGENESIS; ACTIVATION	Promotion of repair and regeneration following traumatic brain injury remains a challenging clinical problem. While significant efforts have been made to reduce inhibitory extracellular matrix expression following central nervous system injury, much less attention has been given to the role of endogenous reparative matrix proteins, such as fibronectin. Traumatic brain injury leads to increased levels of plasma-derived fibronectin in the brain tissue, though the specific function of this protein following neurotrauma was unknown. In this study, we utilized conditional plasma fibronectin (pFN) knockout mice to examine the role of fibronectin following a traumatic insult. Injured mice deficient in pFN performed significantly worse on both motor and cognitive tasks, had significantly increased lesion volume and apoptotic cell death, and had significantly less phagocytic cells in the injured cortex compared to injured mice with normal pFN levels. Moreover, intravenous injections of fibronectin prior to the injury restored the neural deficits seen in the pFN deficient mice to that of wild type injured mice. These results demonstrate that fibronectin is neuroprotective to the traumatically injured brain and identify a novel target for therapeutic interventions. (c) 2007 Elsevier Inc. All rights reserved.	Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, Woodruff Sch Mech Engn, Atlanta, GA 30332 USA		LaPlaca, MC (corresponding author), Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu					DIXON CE, 1991, J NEUROSCI METH, V39, P253; EGAN RA, 1991, BRAIN RES, V568, P330, DOI 10.1016/0006-8993(91)91421-V; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fukai F, 1998, EXP CELL RES, V242, P92, DOI 10.1006/excr.1998.4076; GAUPERAA T, 1985, ACTA CHIR SCAND, V151, P193; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gibson RM, 2005, MOL CELL NEUROSCI, V28, P588, DOI 10.1016/j.mcn.2004.11.004; GRINNELL F, 1984, J CELL BIOCHEM, V26, P107, DOI 10.1002/jcb.240260206; Hoyte JS, 1997, INFLAMMATION, V21, P335, DOI 10.1023/A:1027354001187; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JONES TR, 1982, CANCER RES, V42, P168; KIENER JL, 1986, AM J PHYSIOL, V251, pR724, DOI 10.1152/ajpregu.1986.251.4.R724; King VR, 2001, J NEUROCYTOL, V30, P243, DOI 10.1023/A:1012753808599; KRUM JM, 1991, EXP NEUROL, V111, P152, DOI 10.1016/0014-4886(91)90002-T; Langlios JA, 2004, TRAUMATIC BRAIN INJU; Liao H, 2005, J BIOL CHEM, V280, P8316, DOI 10.1074/jbc.M412730200; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; MADDOX DE, 1982, P NATL ACAD SCI-BIOL, V79, P166, DOI 10.1073/pnas.79.1.166; Maenpaa A, 1997, ACTA NEUROPATHOL, V94, P216, DOI 10.1007/s004010050696; MARTIN DE, 1988, ARCH DERMATOL, V124, P226, DOI 10.1001/archderm.124.2.226; Milner R, 2003, J IMMUNOL, V170, P3850, DOI 10.4049/jimmunol.170.7.3850; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nasu-Tada K, 2005, GLIA, V52, P98, DOI 10.1002/glia.20224; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OWENS MR, 1982, BLOOD, V59, P1305; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; PENNELL NA, 1994, HISTOCHEMISTRY, V102, P483, DOI 10.1007/BF00269580; Properzi F, 2003, BIOCHEM SOC T, V31, P335, DOI 10.1042/BST0310335; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schwartz M, 2000, ANN NY ACAD SCI, V917, P341; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tate CC, 2007, J NEUROTRAUM, V24, P226, DOI 10.1089/neu.2006.0043; Yanaka K, 1996, J NEUROSURG, V85, P125, DOI 10.3171/jns.1996.85.1.0125; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhao LR, 2005, BRAIN RES, V1054, P1, DOI 10.1016/j.brainres.2005.04.056	39	45	47	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2007	207	1					13	22		10.1016/j.expneurol.2007.05.008			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	210TB	WOS:000249477400003	17599836				2022-02-06	
J	Fijalkowski, RJ; Stemper, BD; Pintar, FA; Yoganandan, N; Crowe, MJ; Gennarelli, TA				Fijalkowski, Ronald J.; Stemper, Brian D.; Pintar, Frank A.; Yoganandan, Narayan; Crowe, Maria J.; Gennarelli, Thomas A.			New rat model for diffuse brain injury using coronal plane angular acceleration	JOURNAL OF NEUROTRAUMA			English	Article						concussion; craniocerebral trauma; diffuse brain injury; experimental rat model; mild traumatic brain injury	CLOSED-HEAD INJURY; AXONAL INJURY; CEREBRAL CONCUSSION; IMPACT; PATHOPHYSIOLOGY; MEDETOMIDINE; ATIPAMEZOLE; DAMAGE; MECHANICS; REVERSAL	A new experimental model was developed to induce diffuse brain injury (DBI) in rats through pure coronal plane angular acceleration. An impactor was propelled down a guide tube toward the lateral extension of the helmet fixture. Upon impactor-helmet contact, helmet and head were constrained to rotate in the coronal plane. In the present experimental series, the model was optimized to generate rotational kinematics necessary for concussion. Twenty-six rats were subjected to peak angular accelerations of 368 +/- 30 krad/sec(2) ( mean +/- standard deviation) with 2.1 +/- 0.5-msec durations. Following rotational loading, unconsciousness was defined as time between reversal agent administration and return of corneal reflex. All experimental rats demonstrated transient unconsciousness lasting 8.8 +/- 3.7 min that was significantly longer than control rats. Macroscopic damage was noted in 51% of experimental animals: 38% subarachnoid hemorrhage, and 15% intraparenchymal lesion. Microscopic analysis indicated no evidence of axonal swellings at sacrifice times of 24, 48, 72, and 96 h. All rats survived rotational loading without skull fracture. Injuries were classified as concussion based on transient unconsciousness, scaled biomechanics, limited macroscopic damage, and minimal histological abnormalities. The experimental methodology remains adjustable, permitting investigation of increasing DBI severities through modulation of model parameters, and inclusion of further functional and histological outcome measures.	Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA		Pintar, FA (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	fpintar@mcw.edu	Stemper, Brian/AAX-7611-2020				ABEL JM, 1978, 22 STAPP CAR CRASH C; Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Buki A, 2000, J NEUROSCI, V20, P2825; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ellingson Benjamin M., 2005, V41, P86; Fijalkowski RJ, 2006, BIOMED SCI INSTRUM, V42, P108; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; Gennarelli T., 2003, ANN P ASS ADV AUTOMO, V47, P624; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1987, 31 STAPP CAR CRASH C; GENNARELLI TA, 1982, NATO AGARD C; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hahn N, 2005, LAB ANIMAL, V34, P48, DOI 10.1038/laban0205-48; Hirsch A.E., 1968, TOLERANCE SUBHUMAN P; Holbourn AHS, 1943, LANCET, V2, P438; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARGULIES SS, 1985, STUDY SCALING HEAD I; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MCLEAN AJ, 1995, J NEUROTRAUM, V12, P621, DOI 10.1089/neu.1995.12.621; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; NEWMAN J, 2000, NEW BIOMECHANICAL AS; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1967, 11 STAPP CAR CRASH C; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; PINCEMAILLE Y, 1989, 33 STAPP CAR CRASH C; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Sleeman JM, 2000, J ZOO WILDLIFE MED, V31, P28, DOI 10.1638/1042-7260(2000)031[0028:SACEOM]2.0.CO;2; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; STRICH SJ, 1961, LANCET, V2, P443; Sun FJ, 2003, CONTEMP TOP LAB ANIM, V42, P32; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yamashita K, 1996, J VET MED SCI, V58, P1049, DOI 10.1292/jvms.58.10_1049	61	45	46	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1387	1398		10.1089/neu.2007.0268			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500010	17711400				2022-02-06	
J	Verhaeghe, STL; van Zuuren, FJ; Defloor, T; Duijnstee, MSH; Grypdonck, MHF				Verhaeghe, Sofie T. L.; van Zuuren, Florence J.; Defloor, Tom; Duijnstee, Mia S. H.; Grypdonck, Mieke H. F.			How does information influence hope in family members of traumatic coma patients in intensive care unit?	JOURNAL OF CLINICAL NURSING			English	Article						coma; family members; hope; information; intensive care unit; nursing	CRITICALLY ILL PATIENTS; OF-THE-LITERATURE; PERCEIVED NEEDS; ADULT PATIENTS; BRAIN INJURY; RELATIVES; NURSES; PERCEPTIONS; EXPERIENCES	Aims. To assess the interplay between hope and the information provided by health care professionals. Background. Earlier research learned that hope is crucial for relatives of traumatic coma patients. Also it has been reported that the need for information is extremely important for relatives of critically ill patients. Design. A qualitative approach according to the 'grounded theory' method with constant comparison was used. Method. We held 24 in-depth interviews with 22 family members of 16 patients with traumatic coma. Data processing and data analysis took place in a cyclic process wherein the induction of themes was alternated by confrontation with new material. Results. Family members of traumatic coma patients want information that is as accurate as possible, provided by doctors and nurses in an understandable manner and leaving room for hope. At first, family members can do no more than passively absorb the information they receive. After some time, they actively start working with information and learn what to build their hope on. In this way, concrete hope evolves and seems to be strongly determined by information. Information that is more positive than warranted is not appreciated at all. It leads to false hope and once its real nature becomes apparent, to increased distress and loss of trust in the professionals. Conclusion. The process of hope is crucial in coping with traumatic coma and information can facilitate this process. Relevance to clinical practice. If professionals, especially nurses, keep the process in mind that family members go through in handling information, they can not only facilitate this process but also help them to establish realistic hope.	Univ Ghent, B-9000 Ghent, Belgium; Univ Amsterdam, Amsterdam, Netherlands; Univ Utrecht, Med Ctr, Utrecht, Netherlands; Univ Ghent, B-9000 Ghent, Belgium		Verhaeghe, STL (corresponding author), Univ Ghent, UZ Blok A2o De Pintelaan 185, B-9000 Ghent, Belgium.	sofie.verhaeghe@ugent.be		Verhaeghe, Sofie/0000-0002-2063-5033; Beeckman, Dimitri/0000-0003-3080-8716			Azoulay E, 2004, CRIT CARE MED, V32, P2323, DOI 10.1097/01.CCM.0000145950.57614.04; Bijttebier P, 2001, INTENS CARE MED, V27, P160, DOI 10.1007/s001340000750; Bijttebier P, 2000, HEART LUNG, V29, P278, DOI 10.1067/mhl.2000.107918; Burr G, 1997, Aust Crit Care, V10, P124, DOI 10.1016/S1036-7314(97)70415-6; Campbell C H, 1988, Rehabil Nurs, V13, P320; COULTER M, 1989, INTENSIVE CARE NURSI, V5, P5; DALEY L, 1984, HEART LUNG, V13, P231; DAVISMARTIN S, 1994, HEART LUNG, V23, P515; DOCKTER B, 1988, PATIENT EDUC COUNS, V12, P29, DOI 10.1016/0738-3991(88)90035-3; Engli M, 1993, J Neurosci Nurs, V25, P78; Engstrom Asa, 2004, Intensive Crit Care Nurs, V20, P299; FORRESTER DA, 1990, HEART LUNG, V19, P655; FREICHELS T A, 1991, Critical Care Nursing Quarterly, V14, P16; Fulbrook P, 1999, Nurs Crit Care, V4, P138; GELLING I, 2002, NURSING CRITICAL CAR, V7, P271; Gelling L., 1999, NURSING CRITICAL CAR, V4, P214; Glaser B., 1967, DISCOVERY GROUNDED T; HAMPE SO, 1975, NURS RES, V24, P113; HICKEY M, 1990, HEART LUNG, V19, P401; JACONO J, 1990, HEART LUNG, V19, P72; Jamerson PA, 1996, HEART LUNG, V25, P467, DOI 10.1016/S0147-9563(96)80049-5; Johnson L H, 1996, J Trauma Nurs, V3, P72; Johnson L H, 1996, J Neurosci Nurs, V28, P259; Johnson S K, 1995, Image J Nurs Sch, V27, P238, DOI 10.1111/j.1547-5069.1995.tb00866.x; Kleiber C, 1994, Am J Crit Care, V3, P70; Kleinpell R M, 1992, Appl Nurs Res, V5, P2; Koller P A, 1991, AACN Clin Issues Crit Care Nurs, V2, P338; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kuyper MB, 1998, QUAL HEALTH RES, V8, P237, DOI 10.1177/104973239800800207; LESKE JS, 1986, HEART LUNG, V15, P189; LYNNMCHALE DJ, 1988, HEART LUNG, V17, P447; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mendonca D, 1998, Crit Care Nurs Q, V21, P58; Miller J F, 1991, AACN Clin Issues Crit Care Nurs, V2, P307; Miller J F, 1989, Appl Nurs Res, V2, P23; MOLTER NC, 1979, HEART LUNG, V8, P332; Morse J. M., 1996, NURSING RES APPL QUA; MORSE JM, 1995, J ADV NURS, V21, P886, DOI 10.1046/j.1365-2648.1995.21050886.x; MURPHY PA, 1992, HEART LUNG, V21, P25; Neabel B, 2000, HEART LUNG, V29, P196, DOI 10.1067/mhl.2000.106938; NORRIS LO, 1986, HEART LUNG, V15, P194; OMALLEY P, 1991, HEART LUNG, V20, P189; Plowfield L A, 1999, J Neurosci Nurs, V31, P231; PRICE DM, 1991, HEART LUNG, V20, P183; RUKHOLM E, 1991, J ADV NURS, V16, P920, DOI 10.1111/j.1365-2648.1991.tb01796.x; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Spatt L, 1986, QRB Qual Rev Bull, V12, P16; STILLWELL SB, 1984, HEART LUNG, V13, P238; Takman Christina A S, 2004, Intensive Crit Care Nurs, V20, P22, DOI 10.1016/j.iccn.2003.09.003; Testani-Dufour L, 1992, J Neurosci Nurs, V24, P317; Verhaeghe S, 2005, J CLIN NURS, V14, P501, DOI 10.1111/j.1365-2702.2004.01081.x; Verhaeghe STL, 2007, QUAL HEALTH RES, V17, P730, DOI 10.1177/1049732307303242; Warren N A, 1993, Crit Care Nurs Q, V16, P56; WERTZ FJ, 1987, ADV QUALITATIVE PSYC, P1; Wester F., 1987, STRATEGIEEN KWALITAT	55	45	45	1	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1067	1365-2702		J CLIN NURS	J. Clin. Nurs.	AUG	2007	16	8					1488	1497		10.1111/j.1365-2702.2006.01807.x			10	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	196LM	WOS:000248483000013	17655537				2022-02-06	
J	Beschorner, R; Dietz, K; Schauer, K; Mittelbronn, M; Schluesener, HJ; Trautmann, K; Meyermann, R; Simon, P				Beschorner, R.; Dietz, K.; Schauer, K. N.; Mittelbronn, M.; Schluesener, H. J.; Trautmann, K.; Meyermann, R.; Simon, P.			Expression of EAAT1 reflects a possible neuroprotective function of reactive astrocytes and activated microglia following human traumatic brain injury	HISTOLOGY AND HISTOPATHOLOGY			English	Article						microglial activation; neuroprotection; traumatic brain injury; excitatory amino acid transporters	GLIAL GLUTAMATE TRANSPORTER; AMINO-ACID TRANSPORTER-1; FOCAL CEREBRAL-ISCHEMIA; GLT-1 EXPRESSION; CELL-DEATH; CLINICAL-TRIALS; CORTICAL IMPACT; MICE LACKING; SPINAL-CORD; RAT MODEL	Glutamate-mediated excitotoxicity is known to cause secondary brain damage following stroke and traumatic brain injury (TBI). However, clinical trials using NMDA antagonists failed. Thus, glial excitatory amino acid transporters (EAATs) might be a promising target for therapeutic intervention. Methods and Results. We examined expression of EAAT1 (GLAST) and EAAT2 (Glt-1) in 36 TBI cases by immunohistochemistry. Cortical expression of both EAATs decreased rapidly and widespread throughout the brain (in lesional, adjacent and remote areas) following TBI. In the white matter numbers of EAAT1+ parenchymal cells increased 39-fold within 24h (p < 0.001) and remained markedly elevated till later stages in the lesion (90-fold, p < 0.01) and in peri-lesional regions (86-fold, p < 0.01). In contrast, EAAT2+ parenchymal cells and EAAT1+ or EAAT2+ perivascular cells did not increase significantly. Within the first days following TBI mainly activated microglia and thereafter mainly reactive astrocytes expressed EAAT1. Perivascular monocytes and foamy macrophages lacked EAAT1 immunoreactivity. We conclude that following TBI i) loss of cortical EAATs contributes to secondary brain damage, ii) glial EAAT1 expression reflects a potential neuroprotective function of microglia and astrocytes, iii) microglial EAAT1 expression is restricted to an early stage of activation, iv) blood-derived monocytes do not express EAAT1 and v) pharmacological modification of glial EAAT expression might further limit neuronal damage.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Univ Tubingen, Dept Med Biometry, D-72076 Tubingen, Germany; Univ Tubingen, Clin Internal Med, Dept Sports Med, D-72076 Tubingen, Germany		Beschorner, R (corresponding author), Univ Tubingen, Inst Brain Res, Calwestr 3, D-72076 Tubingen, Germany.	rudi.beschorner@med.uni-tuebingen.de	Dietz, Klaus/R-9268-2016; Beschorner, Rudi/M-6397-2014; Simon, Perikles D/B-2293-2013	Dietz, Klaus/0000-0001-8503-9737; Simon, Perikles D/0000-0002-7996-4034; Beschorner, Rudi/0000-0003-1109-915X; Mittelbronn, Michel/0000-0002-2998-052X			ANDERSON KJ, 1991, BRAIN RES, V562, P285, DOI 10.1016/0006-8993(91)90633-7; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Banner SJ, 2002, NEUROSCIENCE, V109, P27, DOI 10.1016/S0306-4522(01)00437-7; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Bonde C, 2003, NEUROCHEM INT, V43, P371, DOI 10.1016/S0197-0186(03)00024-X; BONDOLI A, 1981, RESUSCITATION, V9, P119, DOI 10.1016/0300-9572(81)90021-6; Cakir E, 2005, J CLIN NEUROSCI, V12, P923, DOI 10.1016/j.jocn.2005.03.013; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Chen WH, 2005, NEUROSCI LETT, V384, P117, DOI 10.1016/j.neulet.2005.04.070; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Chretien F, 2002, NEUROPATH APPL NEURO, V28, P410, DOI 10.1046/j.1365-2990.2002.00426.x; Chretien F, 2004, J NEUROPATH EXP NEUR, V63, P1058, DOI 10.1093/jnen/63.10.1058; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Duan SM, 1999, J NEUROSCI, V19, P10193; Eisenstein M, 2005, LAB ANIMAL, V34, P10; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165-3806(01)00303-0; Ginsberg SD, 1996, J NEUROCHEM, V67, P1208; Gras G, 2003, BRAIN PATHOL, V13, P211; Hoyte L, 2004, CURR MOL MED, V4, P131, DOI 10.2174/1566524043479248; Hurtado O, 2005, NEUROBIOL DIS, V18, P336, DOI 10.1016/j.nbd.2004.10.006; Ikematsu K, 2002, FORENSIC SCI INT, V130, P83, DOI 10.1016/S0379-0738(02)00344-4; Ikematsu K, 2001, FORENSIC SCI INT, V118, P49, DOI 10.1016/S0379-0738(00)00378-9; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Knecht K, 1997, NEUROSCI LETT, V229, P201, DOI 10.1016/S0304-3940(97)00444-8; Krum JM, 2002, EXP NEUROL, V174, P137, DOI 10.1006/exnr.2002.7867; Lopez-Bayghen E, 2004, J NEUROCHEM, V91, P200, DOI 10.1111/j.1471-4159.2004.02706.x; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; Matsuura S, 2002, GLIA, V37, P178, DOI 10.1002/glia.10020; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249; Mori T, 2004, NEUROCHEM INT, V45, P381, DOI 10.1016/j.neuint.2003.06.001; Muir KW, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001244; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; Namura S, 2002, NEUROSCI LETT, V324, P117, DOI 10.1016/S0304-3940(02)00193-3; Niederberger E, 2003, NEUROSCIENCE, V116, P81, DOI 10.1016/S0306-4522(02)00547-X; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pawlak J, 2005, MOL BRAIN RES, V138, P1, DOI 10.1016/j.molbrainres.2004.10.043; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson M, 2005, GLIA, V51, P111, DOI 10.1002/glia.20191; Phillis JW, 2000, BRAIN RES, V868, P105, DOI 10.1016/S0006-8993(00)02303-9; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, NEUROCHEM RES, V26, P497; Rimaniol AC, 2000, J IMMUNOL, V164, P5430, DOI 10.4049/jimmunol.164.10.5430; Robelet S, 2004, EUR J NEUROSCI, V20, P1255, DOI 10.1111/j.1460-9568.2004.03591.x; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Rozyczka J, 2004, BRAIN PATHOL, V14, P406; Shimada F, 1999, EUR J PHARMACOL, V386, P263, DOI 10.1016/S0014-2999(99)00735-9; Simantov R, 1999, J NEUROCHEM, V73, P1828; Simantov R, 1999, MOL BRAIN RES, V65, P112, DOI 10.1016/S0169-328X(98)00349-0; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TORP R, 1995, EXP BRAIN RES, V103, P51; Umemura K, 1996, STROKE, V27, P1624, DOI 10.1161/01.STR.27.9.1624; Vallat-Decouvelaere AV, 2003, J NEUROPATH EXP NEUR, V62, P475, DOI 10.1093/jnen/62.5.475; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Vera-Portocarrero LP, 2002, BRAIN RES, V927, P104, DOI 10.1016/S0006-8993(01)03329-7; Voutsinos-Porche B, 2003, CEREB CORTEX, V13, P1110, DOI 10.1093/cercor/13.10.1110; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wang CX, 2005, CNS NEUROL DISORD-DR, V4, P143, DOI 10.2174/1568007053544183; Werner P, 2001, ANN NEUROL, V50, P169, DOI 10.1002/ana.1077; Williams SM, 2005, GLIA, V49, P520, DOI 10.1002/glia.20139; [No title captured]	76	45	50	0	3	F HERNANDEZ	MURCIA	PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN	0213-3911	1699-5848		HISTOL HISTOPATHOL	Histol. Histopath.	MAY	2007	22	5					515	526					12	Cell Biology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Pathology	145TA	WOS:000244886200005	17330806				2022-02-06	
J	Catroppa, C; Anderson, V				Catroppa, Cathy; Anderson, Vicki			Recovery in memory function, and its relationship to academic success, at 24 months following pediatric TBI	CHILD NEUROPSYCHOLOGY			English	Article						traumatic brain injury; children; memory; recovery	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; 1ST YEAR; CHILDREN; ADOLESCENTS; CHILDHOOD; SEVERITY	While a number of research papers have reported findings on memory deficits following traumatic brain injury (TBI), only limited studies have monitored the recovery of these skills over time. The present study examined memory ability and its effect on academic success in a group of children who had sustained a mild, moderate, or severe traumatic brain injury (TBI). Results showed that the severe TBI group exhibited greater deficits on memory tasks, irrespective of modality, in the acute, 6-, 12-, and 24-month postinjury stages, in comparison to mild and moderate TBI groups. Performance on academic measures was dependent on both injury severity and task demands. Preinjury academic ability and verbal memory indices best predicted academic success.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; Univ Melbourne, Parkville, Vic 3052, Australia		Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			ANDERSON RL, 1996, CRC HDB LIE GR ANAL, V3, P3; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; ANDERSON VA, 1997, NEUROPSYCHOLOGICAL A; Baddeley, 1990, HUMAN MEMORY THEORY; BADDELEY A, 2000, HUMAN MEMORY THEORY; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BARON I, 1996, PEDIAT NEUROPSYCHOLO; BERGERGROSS P, 1985, PERCEPT MOTOR SKILL, V61, P254, DOI 10.2466/pms.1985.61.1.254; BJORKLUND DF, 1984, CHILDRENS THINKING D; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 1999, Pediatr Rehabil, V3, P167; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHORAZY AJL, 1985, HEAD INJURY REHABILI; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COLOMBO M, 1994, BEHAV NEUROSCI, V108, P443, DOI 10.1037/0735-7044.108.3.443; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Cowan N., 1995, ATTENTION MEMORY INT; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M., 1989, CLIN NEUROPSYCHOLOGY; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Fidell L.S., 2000, USING MULTIVARIATE S; Goldstein B, 1994, Pediatr Rev, V15, P213, DOI 10.1542/pir.15-6-213; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hanten G, 2004, DEV NEUROPSYCHOL, V25, P85, DOI 10.1207/s15326942dn2501&2_6; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Harris JR, 1996, J COMMUN DISORD, V29, P79, DOI 10.1016/0021-9924(94)00035-2; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kaufman A. S, 1983, KAUFMAN ASSESSMENT B; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Pressley M, 1997, INTRO MEMORY DEV CHI; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; ROWE JK, 1995, ROWE BEHAV RATING IN; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Siegler R. S., 1991, CHILDRENS THINKING, V2nd; TEASDALE G, 1974, LANCET, V2, P81; VANZOMERON AH, 1994, CLIN NEUROPSYCHOLOGY; WALSH K, 1994, NEUROPSYCHOLOGY CLIN; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; Warschausky S, 2005, NEUROPSYCHOLOGY, V19, P193, DOI 10.1037/0894-4105.19.2.193; Wechsler D., 1991, MANUAL WECHSLER INTE, VIII; WECHSLER D, 1992, WECHSLER INDIVIDUAL; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	63	45	45	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	MAY	2007	13	3					240	261		10.1080/09297040600837362			22	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	164BR	WOS:000246208100003	17453832				2022-02-06	
J	Simosa, HF; Petersen, DJ; Agarwal, SK; Burke, PA; Hirsch, EF				Simosa, Hector F.; Petersen, Dustin J.; Agarwal, Suresh K.; Burke, Peter A.; Hirsch, Erwin F.			Increased risk of deep venous thrombosis with endovascular cooling in patients with traumatic head injury	AMERICAN SURGEON			English	Article							BRAIN-INJURY; INDUCED HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; CARDIAC-ARREST; HEMORRHAGE; EFFICACY; STROKE; FEVER	Endovascular therapeutic hypothermia has been shown to preserve neurological function and improve outcomes; however, its use and potential complications have not been fully described in patients with traumatic head injuries. We believe that the use of endovascular cooling leads to deep venous thrombosis (DVT) in this high-risk population. We performed a retrospective review of 11 patients with severe head injuries admitted to our Level I trauma center surgical intensive care unit who underwent intravascular cooling. Duplex sonograms were obtained after 4 days at catheter removal or with clinical symptoms that were suspicious for DVT. Patients had a mean age of 23.2 (range, 16-42) years and an Injury Severity Score of 31.9 (range, 25-43). The overall incidence of DVT was 50 per cent. The DVT rate was 33 per cent if catheters were removed in 4 days or less and 75 per cent if removed after 4 days (risk ratio = 2.25; odds ratio = 6; P = ns). An elevated international normalized ratio upon admission was protective against DVT (no DVT = 1.26 vs DVT = 1.09; P = 0.02). Inferior vena cava filters were placed in most patients with DVT. The use of endovascular cooling catheters is associated with increased risk of DVT in patients with traumatic head injuries. Therefore, we discourage the use of endovascular cooling devices in this patient population.	Boston Univ, Dept Gen Surg Trauma & Crit Care, Boston Med Ctr, Boston, MA 02215 USA		Hirsch, EF (corresponding author), Boston Med Ctr, 850 Harrison Ave,Dowling 2, S Boston, MA 02118 USA.			Burke, Peter/0000-0002-0329-5436			Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernard SA, 1999, CRIT CARE, V3, P167, DOI 10.1186/cc371; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Dohi K, 2006, ACTA NEUROCHIR SUPPL, V96, P409; FAY T, 1945, RES PUBL ASS NERV ME, V24, P611; FAY T, 1940, NY STATE J MED, V40, P1351; Georgiadis D, 2001, STROKE, V32, P2550, DOI 10.1161/hs1101.097382; Holzer M, 2002, NEW ENGL J MED, V346, P549; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Lindenblatt N, 2005, AM J PHYSIOL-HEART C, V289, pH2680, DOI 10.1152/ajpheart.00425.2005; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Polderman KH, 2004, CRIT CARE MED, V32, P2558, DOI 10.1097/01.CCM.0000148087.41418.0A; Schmutzhard E, 2002, CRIT CARE MED, V30, P2481, DOI 10.1097/00003246-200211000-00013; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Wijdicks EFM, 1997, NEUROLOGY, V49, P1342, DOI 10.1212/WNL.49.5.1342	19	45	49	0	1	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	MAY	2007	73	5					461	464					4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	163VP	WOS:000246191600008	17520999				2022-02-06	
J	Gouveia, PAR; Brucki, SMD; Malheiros, SMF; Bueno, OFA				Rodrigues Gouveia, Paula Adriana; Dom Brucki, Sonia Maria; Fleury Malheiros, Suzana Maria; Amodeo Bueno, Orlando Francisco			Disorders in planning and strategy application in frontal lobe lesion patients	BRAIN AND COGNITION			English	Article						executive functions; planning; neuropsychological tests; frontal lobe lesion; ecological tests	TOWER-OF-LONDON; TRAUMATIC BRAIN-INJURY; CARD SORTING TEST; DYSEXECUTIVE SYNDROME; PERFORMANCE; DAMAGE; TASK; IMPAIRMENTS; ACTIVATION; DEFICITS	The aim of this study was to investigate deficits in planning ability using an adapted version of the Modified Six Elements Test, from the Behavioral Assessment of the Dysexecutive Syndrome-BADS [Wilson, B. A., Alderman, N., Burgess, P. W., Emslie, H., & Evans, J. J. (1996). Behavioural Assessment of the Dysexecutiue Syndrome (BADS). Bury St Edmunds, U.K.: Thames Valley Test Company. Trans. Ricardo O Souza, Sergio L Schmidt. Rio de Janeiro: Cognicao]. Subjects were left- and right-frontal lobe lesion patients. Other measures of executive dysfunctions used were verbal fluency, the Wisconsin Card Sorting Test, and the Trail Making Test. These other instruments were sensitive to detect executive deficits in the left frontal lobe lesion group, except the Wisconsin Card Sorting Test, which showed impairment only for the frontal lobe lesion group as a whole. The Modified Six Elements Test detected planning disorders in left frontal lobe lesion patients. The deficit of these patients was due to a greater likelihood to break the rules of the task, that is, in plan-following processes, rather than in planning the strategic approach to solve it. (c) 2006 Elsevier Inc. All rights reserved.	Univ Fed Sao Paulo, Sao Paulo, Brazil; Hosp Santa Marcelina, Sao Paulo, Brazil		Gouveia, PAR (corresponding author), Univ Fed Sao Paulo, Sao Paulo, Brazil.	paula-gouveia@uol.com.br	Malheiros, Suzana M. F./O-2620-2013; Brucki, Sonia MD/B-5736-2014; Brucki, Sonia/L-4201-2019	Brucki, Sonia MD/0000-0002-8303-6732; Brucki, Sonia/0000-0002-8303-6732			Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; ARMSTRONG C, 1993, NEUROLOGY, V43, P1961, DOI 10.1212/WNL.43.10.1961; AXELROD BN, 1993, CLIN NEUROPSYCHOL, V7, P205, DOI 10.1080/13854049308401523; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Barcelo F, 2000, REV NEUROLOGIA, V30, P855, DOI 10.33588/rn.3009.99451; Beauchamp MH, 2003, NEUROIMAGE, V20, P1649, DOI 10.1016/j.neuroimage.2003.07.003; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; BRANDAO E, 1987, THESIS PONTIFICIA U; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Carlin D, 2000, NEUROPSYCHOLOGIA, V38, P655, DOI 10.1016/S0028-3932(99)00102-5; Cazalis F, 2003, EUR J NEUROSCI, V17, P2219, DOI 10.1046/j.1460-9568.2003.02633.x; Chan RCK, 2004, EUR ARCH PSY CLIN N, V254, P256, DOI 10.1007/s00406-00-0492-3; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J INT NEUROPSYCH SOC, V8, P771, DOI 10.1017/S1355617702860052; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Garden SE, 2001, NEUROPSYCHOLOGY, V15, P472, DOI 10.1037//0894-4105.15.4.472; GOEL V, 1995, NEUROPSYCHOLOGIA, V33, P623, DOI 10.1016/0028-3932(95)90866-P; Goethals I, 2004, NUCL MED COMMUN, V25, P177, DOI 10.1097/00006231-200402000-00015; Heaton R.K., 1981, WISCONSIN CARD SORTI; Ihara H, 2000, J NEUROL NEUROSUR PS, V68, P731, DOI 10.1136/jnnp.68.6.731; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Morris RG, 1997, NEUROPSYCHOLOGIA, V35, P1147, DOI 10.1016/S0028-3932(97)00009-2; Newman SD, 2003, NEUROPSYCHOLOGIA, V41, P1668, DOI 10.1016/S0028-3932(03)00091-5; Nilsson JP, 2005, J SLEEP RES, V14, P1, DOI 10.1111/j.1365-2869.2005.00442.x; Owen AM, 1996, EUR J NEUROSCI, V8, P353, DOI 10.1111/j.1460-9568.1996.tb01219.x; Reitan R, 1985, HALSTEAD REITAN NEUR; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Spreen O., 1969, NEUROSENSORY CTR COM; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; van den Heuvel OA, 2003, NEUROIMAGE, V18, P367, DOI 10.1016/S1053-8119(02)00010-1; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED	39	45	50	0	27	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	APR	2007	63	3					240	246		10.1016/j.bandc.2006.09.001			7	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	154SF	WOS:000245527200004	17049704				2022-02-06	
J	Yan, HQ; Ma, XC; Chen, XB; Li, Y; Shao, LF; Dixon, CE				Yan, Hong Qu; Ma, Xiecheng; Chen, Xianybai; Li, Youming; Shao, Lifang; Dixon, C. Edward			Delayed increase of tyrosine hydroxylase expression in rat nigrostriatal system after traumatic brain injury	BRAIN RESEARCH			English	Article						immunohistochemistry; nigrostriatal; rat; traumatic brain injury (TBI); tyrosine hydroxylase (TH); western blot	CONTROLLED CORTICAL IMPACT; NEOSTRIATAL DOPAMINE NEURONS; WORKING-MEMORY DEFICITS; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; GENE-EXPRESSION; COMPENSATORY RESPONSE; FRONTAL-CORTEX; LESIONS; STRIATUM	Tyrosine hydroxylase (TH) is the key enzyme for synthesizing dopamine (DA) in dopaminergic neurons and its terminals. Emerging experimental and clinical evidence support the hypothesis of a disturbance in dopamine neurotransmission following traumatic brain injury (TBI). However, the effect of controlled cortical impact (CCI) injury on TH in the nigrostriatal system is currently unknown. To determine if there is an alteration in TH after CCI injury, we examined TH levels at 1 day, 7 days, and 28 days post-injury by utilizing a commercially available antibody specific to TH. Rats were anesthetized and surgically prepared for CCI injury (4 m/s, 3.2 mm) or sham surgery. Injured (N=6) and sham animals (N=6) were sacrificed and coronally sectioned (35 mu m thick) through the striatum and substantia nigra (SN) for immunohistochemistry. Additionally, semiquantitative measurements of TH protein in striatal and SN homogenates from injured (N=6) and sham (N=6) rats sacrificed at the appropriate time post-surgery were assessed using Western blot analysis. TH protein is bilaterally increased at 28 days post-injury in nigrostriatal system revealed by immunohistochemistry in injured rats compared to sham controls. Western blot analysis confirms the findings of immunohistochemistry in both striatum and SN. We speculate that the increase in TH in the nigrostriatal system may reflect a compensatory response of dopaminergic neurons to upregulate their synthesizing capacity and a delayed increase in the efficiency of DA neurotransmission after TBI. (c) 2006 Elsevier B.V. All rights reserved.	Univ Pittsburgh, Safar Ctr, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA		Dixon, CE (corresponding author), Univ Pittsburgh, Safar Ctr, Brain Trauma Res Ctr, Dept Neurosurg, 201 Hill Bldg,3434 5th Ave, Pittsburgh, PA 15260 USA.	dixonec@upmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, P01NS030318, R01NS079061, P50NS030318, P20NS030318, R01NS040125, R01NS060672] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS033150, NS 40125, P50 NS030318, NS 33150, R01 NS040125, R01 NS079061, P01 NS030318, R01 NS060672, NS 30318] Funding Source: Medline		ANDEN NE, 1964, LIFE SCI, V3, P523, DOI 10.1016/0024-3205(64)90161-4; Backman L, 1997, BRAIN, V120, P2207, DOI 10.1093/brain/120.12.2207; BANKIEWICZ KS, 1990, J NEUROSURG, V72, P231, DOI 10.3171/jns.1990.72.2.0231; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; BERTLER A, 1959, ACTA PHYSIOL SCAND, V47, P350; BLANCHARD V, 1995, J NEUROCHEM, V64, P1669; Blanchard V, 1996, BRAIN RES, V709, P319, DOI 10.1016/0006-8993(95)01391-1; CARLSSON A, 1959, PHARMACOL REV, V11, P490; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIVAC I, 1967, J COMP PHYSIOL PSYCH, V63, P184, DOI 10.1037/h0024348; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doder M, 1999, J NEUROL NEUROSUR PS, V66, P380, DOI 10.1136/jnnp.66.3.380; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; DRAVID A, 1984, BRAIN RES, V311, P361, DOI 10.1016/0006-8993(84)90101-X; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FIANDACA MS, 1988, EXP NEUROL, V102, P76, DOI 10.1016/0014-4886(88)90080-5; FRIEDMAN JH, 1989, SOUTHERN MED J, V82, P543, DOI 10.1097/00007611-198905000-00002; FRITSCHY JM, 1992, J COMP NEUROL, V321, P421, DOI 10.1002/cne.903210309; GILAD GM, 1979, BRAIN RES, V160, P17, DOI 10.1016/0006-8993(79)90597-3; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HIRSCH EC, 1990, ANN NEUROL, V27, P676, DOI 10.1002/ana.410270615; HOKFELT T, 1977, MED BIOL, V55, P21; HOKFELT T, 1976, MED BIOL, V54, P427; HOKFELT T, 1969, ACTA PHYSIOL SCAND, V76, P415, DOI 10.1111/j.1748-1716.1969.tb04488.x; HORNYKIEWICZ O, 1993, ADV NEUROL, V60, P140; HOWELLS DW, 1993, BRAIN RES, V622, P285, DOI 10.1016/0006-8993(93)90830-G; JAEGER CB, 1983, J COMP NEUROL, V218, P74, DOI 10.1002/cne.902180105; JOH TH, 1975, BRAIN RES, V85, P146, DOI 10.1016/0006-8993(75)91021-5; Joyce JN, 1997, MOVEMENT DISORD, V12, P885, DOI 10.1002/mds.870120609; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; KATZMAN R, 1971, BRAIN RES, V25, P579, DOI 10.1016/0006-8993(71)90462-8; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; KOPIN IJ, 1993, ADV NEUROL, V60, P707; KORDOWER JH, 1991, ANN NEUROL, V29, P405, DOI 10.1002/ana.410290411; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Miyoshi E, 2002, BRAIN RES BULL, V58, P41, DOI 10.1016/S0361-9230(02)00754-2; Muller U, 2000, J NEURAL TRANSM, V107, P303, DOI 10.1007/s007020050025; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; ONN SP, 1986, BRAIN RES, V376, P8, DOI 10.1016/0006-8993(86)90894-2; OTTO D, 1990, J NEUROSCI, V10, P1912; PASINETTI GM, 1992, MOL BRAIN RES, V13, P63, DOI 10.1016/0169-328X(92)90045-D; PICKEL VM, 1975, J HISTOCHEM CYTOCHEM, V23, P1, DOI 10.1177/23.1.234988; Pifl C, 2006, NEUROCHEM INT, V49, P519, DOI 10.1016/j.neuint.2006.03.013; PLUNKETT RJ, 1990, J NEUROSURG, V73, P918, DOI 10.3171/jns.1990.73.6.0918; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; PRZEDBORSKI S, 1991, BRAIN RES, V550, P231, DOI 10.1016/0006-8993(91)91323-S; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Rinne JO, 2000, ARCH NEUROL-CHICAGO, V57, P470, DOI 10.1001/archneur.57.4.470; ROSIN DL, 1992, NEUROSCIENCE, V48, P831, DOI 10.1016/0306-4522(92)90271-3; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; Soriano MA, 1997, NEUROBIOL DIS, V4, P376, DOI 10.1006/nbdi.1997.0166; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Von Voigtlander P F, 1971, J Pharm Pharmacol, V23, P381; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008; Williams AJ, 2006, NEUROCHEM INT, V49, P106, DOI 10.1016/j.neuint.2006.03.018; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Yao XL, 2006, NEUROSCI LETT, V409, P65, DOI 10.1016/j.neulet.2006.09.015	69	45	48	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 23	2007	1134	1					171	179		10.1016/j.brainres.2006.11.087			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	142GZ	WOS:000244638700020	17196177	Green Accepted			2022-02-06	
J	Iverson, GL; Le Page, J; Koehler, BE; Shojania, K; Badii, M				Iverson, Grant L.; Le Page, Judy; Koehler, Barry E.; Shojania, Kamran; Badii, Maziar			Test of memory malingering (TOMM) scores are not affected by chronic pain or depression in patients with fibromyalgia	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	24th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 17-20, 2004	Seattle, WA	Natl Acad Neuropsychol		chronic pain; depression; effort; malingering; Test of Memory Malingering	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; NEUROPSYCHOLOGICAL TESTS; HEAD-INJURY; COGNITIVELY INTACT; NORMATIVE DATA; RESPONSE BIAS; INVENTORY-II; BACK-PAIN; PERFORMANCE	Neuropsychologists routinely give effort tests, such as the Test of Memory Malingering (TOMM). When a person fails one of these tests, the clinician must try to determine whether the poor performance was due to suboptimal effort or to chronic pain, depression, or other problems. Participants were 54 community-dwelling patients who met American College of Rheumatology criteria for fibromyalgia (FM). In addition to the TOMM, they completed the Beck Depression Inventory-Second Edition, Multidimensional Pain Inventory-Version 1, Oswestry Disability Index-2.0, British Columbia Cognitive Complaints Inventory, and the Fibromyalgia Impact Questionnaire. The majority endorsed at least mild levels of depressive symptoms (72%), and 22% endorsed "severe'' levels of depression. The average scores on the TOMM were 48.8 (SD = 1.9, range = 40-50) for Trial 1, 49.8 (SD = 0.5, range 48-50) for Trial 2, and 49.6 (SD = 0.9, range 45-50) for Retention. Despite relatively high levels of self-reported depression, chronic pain, and disability, not a single patient failed the TOMM. In this study, the TOMM was not affected by chronic pain, depression, or both.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC, Canada; Arthrit Res Ctr Canada, Vancouver, BC, Canada		Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Allen L., 1997, CARB 97 MANUAL COMPU; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Arnau RC, 2001, HEALTH PSYCHOL, V20, P112, DOI 10.1037//0278-6133.20.2.112; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Baker D.J., 1989, BACK PAIN NEW APPROA, P174; Beck A., 1996, MANUAL BDI 2; BECK AT, 1979, COGNITIVE THERAPY DE; BERNSTEIN IH, 1995, SPINE, V20, P956, DOI 10.1097/00007632-199504150-00014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Bolan B, 2002, J CLIN EXP NEUROPSYC, V24, P154, DOI 10.1076/jcen.24.2.154.1000; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Delain SL, 2003, ASSESSMENT, V10, P370, DOI 10.1177/1073191103259156; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Doss R.C., 1999, J FORENSIC NEUROPSYC, V1, P5, DOI [https://doi.org/10.1300/J151v01n04_02, DOI 10.1300/J151V01N04_02, 10.1300/J151v01n04_02]; Duncan A, 2005, ASSESSMENT, V12, P123, DOI 10.1177/1073191105275512; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Fairbank J C, 1980, Physiotherapy, V66, P271; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gierok SD, 2005, ARCH CLIN NEUROPSYCH, V20, P755, DOI 10.1016/j.acn.2005.04.008; Green P, 2001, CLIN NEUROPSYCHOL, V15, P492, DOI 10.1076/clin.15.4.492.1887; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P117, DOI 10.1016/j.acn.2005.06.009; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Grotle M, 2004, PAIN, V112, P343, DOI 10.1016/j.pain.2004.09.020; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; Hassett AL, 2000, ARTHRITIS RHEUM-US, V43, P2493, DOI 10.1002/1529-0131(200011)43:11<2493::AID-ANR17>3.0.CO;2-W; Hayes JS, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P249; Hill S. K., 2003, J FORENSIC NEUROPSYC, P1, DOI [10.1300/J151v03n03_01, DOI 10.1300/J151V03N03_01]; HOM J, 2003, DETECTION RESPONSE B; Iverson G. L., 2003, CAN PSYCH ASS HAL NO; Iverson GL, 2005, ARCH CLIN NEUROPSYCH, V20, P882; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P735; IVERSON GL, 1994, ARCH CLIN NEUROPSYCH, V9, P437, DOI 10.1016/0887-6177(94)90006-X; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; IVERSON GL, 1999, J COGNITIVE REHABILI, V2, P4; IVERSON GL, 2003, HDB FORENSIC NEUROPS; IVERSON GL, 1998, UNPUB BC COGNITIVE C; Ju D, 2000, Appl Neuropsychol, V7, P201, DOI 10.1207/S15324826AN0704_1; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; King RA, 1999, ARCH CLIN NEUROPSYCH, V14, P651, DOI 10.1016/S0887-6177(99)80063-8; Lousberg R, 1996, J CLIN PSYCHOL, V52, P161, DOI 10.1002/(SICI)1097-4679(199603)52:2<161::AID-JCLP6>3.0.CO;2-X; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Morley S, 2002, PAIN, V99, P289, DOI 10.1016/S0304-3959(02)00137-9; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; REYNOLDS C, 1998, DETECTION MALINGERIN; Rogers R., 1997, CLIN ASSESSMENT MALI; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; Rudy TE, 1989, MULTIAXIAL ASSESSMEN; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Suter PB, 2002, PAIN, V100, P249, DOI 10.1016/S0304-3959(02)00238-5; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Thieme K, 2004, PSYCHOSOM MED, V66, P837, DOI 10.1097/01.psy.0000146329.63158.40; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Turk DC, 1996, J RHEUMATOL, V23, P1255; van Hout MSE, 2003, NEUROTOXICOLOGY, V24, P547, DOI 10.1016/S0161-813X(03)00054-8; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Viljoen JL, 2003, J CLIN PSYCHOL MED S, V10, P289, DOI 10.1023/A:1026353404839; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481; Wesley AL, 1999, CLIN J PAIN, V15, P117, DOI 10.1097/00002508-199906000-00008; White KP, 2002, ARTHRIT RHEUM-ARTHR, V47, P260, DOI 10.1002/art.10400; Wittink H, 2004, CLIN J PAIN, V20, P133, DOI 10.1097/00002508-200405000-00002; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Yanez YT, 2006, ARCH CLIN NEUROPSYCH, V21, P161, DOI 10.1016/j.acn.2005.07.009	90	45	46	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2007	21	3					532	546		10.1080/13854040600611392			15	Psychology, Clinical; Clinical Neurology; Psychology	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	158HA	WOS:000245781200090	17455036				2022-02-06	
J	Lippert-Gruner, M; Maegele, M; Haverkamp, H; Klug, N; Wedekind, C				Lippert-Gruener, Marcela; Maegele, Marc; Haverkamp, Heinz; Klug, Norfrid; Wedekind, Christoph			Health-related quality of life during the first year after severe brain trauma with and without	BRAIN INJURY			English	Article						traumatic brain injury; polytrauma; quality of life; SF-36	SEVERE HEAD-INJURY; SURVEY QUESTIONNAIRE; MULTIPLE TRAUMA; SF-36; RECOMMENDATIONS	Objective: The increasing number of patients surviving severe traumatic brain injury ( sTBI) but with significant sensorimotor and neuropsychological deficits is a challenge to rehabilitation medicine. So far, most research initiatives have focused on mortality rates, physiological or economic parameters to estimate therapeutic effects of rehabilitation strategies. Investigations on health-related quality of life ( HRQoL) after TBI with and without concomitant polytrauma are rare compared to other disorders. Design/patients: A prospective study was conducted to investigate HRQoL using the SF-36 questionnaire in 49 patients with sTBI ( Glasgow Coma Scale < 9 for more than 24 hours) with and without concomitant polytrauma 6 and 12 months after injury. Results: The SF-36 score profiles 6 and 12 months after trauma were similar. Scores 12 months after trauma, however, were higher in 7/8 dimensions indicating an improvement over time. Similar observations were made for physical and mental sum scores. There was no difference in the SF-36 scoring pattern between the patients with isolated TBI and the patients with concomitant polytrauma, except for physical functioning after 12 months. Conclusion: While there is significant overall improvement of HRQoL over time, sTBI appears to bear major influence on post-traumatic HRQoL and outcome.	Univ Cologne, Dept Neurosurg, Cologne, Germany; Klinikum Koln Merheim, Chirurg Klin Kliniken Stadt Koln, Cologne, Germany; Univ Cologne, Coordinating Ctr Clin Trials, Cologne, Germany		Lippert-Gruner, M (corresponding author), Klinikum Univ Koln, Klin Allgemeine Neurochirurg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	marcela.lippert.gruener@medizin.uni-koeln.de		Haverkamp, Heinz/0000-0001-6895-4132			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; BAZIL K, 1992, INT J REHABILITATION, V15, P93; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Frowein R A, 1992, Acta Neurochir Suppl (Wien), V55, P72; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Lippert-Gruner M, 2002, ZBL NEUROCHIR, V63, P116, DOI 10.1055/s-2002-35825; Lippert-Gruner M, 2002, J REHABIL MED, V34, P211, DOI 10.1080/165019702760279198; Lippert-Gruner M, 2001, PHYS MED REHAB KUROR, V11, P233, DOI 10.1055/s-2001-19069; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Thurman DJ, 1996, WESTERN J MED, V165, P192; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005	20	45	48	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	5					451	455		10.1080/02699050701343961			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	175FI	WOS:000246998000001	17522984				2022-02-06	
J	Shore, PM; Berger, RP; Varma, S; Janesko, KL; Wisniewski, SR; Clark, RSB; Adelson, PD; Thomas, NJ; Lai, YC; Bayir, H; Kochanek, PM				Shore, Paul M.; Berger, Rachel P.; Varma, Sumeeta; Janesko, Keri L.; Wisniewski, Stephen R.; Clark, Robert S. B.; Adelson, P. David; Thomas, Neal J.; Lai, Yi-Chen; Bayir, Hulya; Kochanek, Patrick M.			Cerebrospinal fluid biomarkers versus Glasgow Coma Scale and Glasgow Outcome Scale in pediatric traumatic brain injury: The role of young age and inflicted injury	JOURNAL OF NEUROTRAUMA			English	Article						child abuse; clinical research; correlation; inflicted traumatic brain injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; CHILD-ABUSE; BIOCHEMICAL MARKERS; PRACTICAL SCALE; PROTEIN S-100B; SERUM; INFANTS; S100B; DAMAGE	The Glasgow Coma Scale (GCS) and Glasgow Outcome Scale (GOS) are widely used clinical scoring systems to measure the severity of neurologic injury after traumatic brain injury (TBI), but have recognized limitations in infants and small children. Cerebrospinal fluid (CSF) concentrations of neuron-specific enolase (NSE) and S100B show promise as markers of brain injury. We hypothesized that the initial GCS and 6-month GOS scores would be inversely associated with CSF NSE and/or S100B concentrations after severe pediatric TBI. Using banked CSF obtained during ongoing studies of pediatric TBI, NSE and S100B were determined in CSF collected within 24 h of trauma from 88 infants and children with severe TBI (GCS <= 8) versus 20 non-injured controls. Victims of inflicted (iTBI) and non-inflicted TBI (nTBI) showed similar (> 10-fold) increases in both NSE and S100B versus control. Both markers showed overall significant, inverse correlation with GCS and GOS scores. In subgroup analysis, both markers correlated significantly with GCS and GOS scores only in older (> 4 years) victims of nTBI; no correlation was found for patients <= 4 years old or victims of iTBI. While confirming the overall correlations between GCS/GOS score and CSF NSE and S100B seen in prior studies, we conclude that these clinical and CSF biomarkers of brain injury do not correlate in children <= 4 years of age and/or victims of iTBI. Although further, prospective study is warranted, these findings suggest important limitations in our current ability to assess injury severity in this important population.	Univ Texas, SW Med Ctr, Childrens Med Ctr Dallas, Dept Pediat,Div Crit Care Serv, Dallas, TX 75235 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Penn State Univ, Childrens Hosp, Coll Med, Hershey, PA 17033 USA		Shore, PM (corresponding author), Univ Texas, SW Med Ctr, Childrens Med Ctr Dallas, Dept Pediat,Div Crit Care Serv, 1935 Motor St, Dallas, TX 75235 USA.	paul.shore@childrens.com	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Thomas, Neal/0000-0002-7991-7510; Varma, Sumeeta/0000-0002-6955-2634; Lai, Yi-Chen/0000-0002-9450-5506; Wisniewski, Stephen/0000-0002-3877-9860	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000005] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD 40686] Funding Source: Medline		Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Berger RP, 2004, CHILD ABUSE NEGLECT, V28, P739, DOI 10.1016/j.chiabu.2004.01.007; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Brown RL, 2001, J PEDIATR SURG, V36, P1107, DOI 10.1053/jpsu.2001.25665; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Guan Wei, 2003, Chin J Traumatol, V6, P218; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; JENNETT B, 1975, LANCET, V1, P480; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; McIntosh TK, 1996, LAB INVEST, V74, P315; McKeating EG, 1998, ACT NEUR S, V71, P117; MOLYNEUX ME, 1989, Q J MED, V71, P441; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Portela LVC, 2002, CLIN CHEM, V48, P950; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Ruppel RA, 2002, NEUROSURG CLIN N AM, V13, P169, DOI 10.1016/S1042-3680(01)00005-5; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SEGATORE M, 1992, HEART LUNG, V21, P548; Shore PM, 2003, CRIT CARE MED, V31, pA91; Shore PM, 2004, J NEUROTRAUM, V21, P1113; SHORE PM, 2003, PEDIATR CRIT CARE ME, V4, pA143; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Ucar T, 2004, J TRAUMA, V57, P95, DOI 10.1097/01.TA.0000071352.95491.75; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	58	45	45	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					75	86		10.1089/neu.2006.0062			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100007	17263671				2022-02-06	
J	Cremer, OL; Moons, KGM; van Dijk, GW; van Balen, P; Kalkman, CJ				Cremer, Olaf L.; Moons, Karel G. M.; van Dijk, Gert W.; van Balen, Peter; Kalkman, Cor J.			Prognosis following severe head injury: Development and validation of a model for prediction of death, disability, and functional recovery	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injuries, closed; outcome prediction; ordinal logistic regression analysis; prognosis	TRAUMATIC BRAIN-INJURY; GLASGOW OUTCOME SCALE; STRUCTURED INTERVIEWS; CLINICAL-TRIALS; MORTALITY; MANAGEMENT; SURVIVAL; PATIENT; DETERMINANTS; GUIDELINES	Background: A prognostic model for head trauma patients is useful only if it predicts clinically relevant outcomes accurately on new subjects in various settings. Most existing models consider only dichotomous outcome and have not been tested externally. We developed and validated a rule for prediction of three functional outcome states after severe head injury, using information from day 1. Methods: The model was developed in a cohort of 304 adults who were admitted to a Dutch trauma center and had survived and remained comatose for > 24 hours following severe head injury. We used ordinal logistic regression analysis to predict the extended Glasgow Outcome Scale after 2:12 months, merged into three categories. We preselected five known predictors of outcome and used bootstrapping techniques to avoid statistical overfitting. The performance of the model was subsequently tested in a cohort of 122 patients from an unrelated hospital. Results: The model contained age (p < 0.0001), best motor response on day 1 (p = 0.002), pupil response after resuscitation (p = 0.005), computed tomography findings (p = 0.004), and presence of arterial hypotension (p = 0.37) as predictor variables. In the external validation cohort the model showed adequate agreement between observed and predicted outcome probabilities (calibration). The model had a good ability to discriminate patients with different outcomes (c-statistic 0.808). The predictive accuracy was 66% when the model was used to classify patients across the three outcome categories. Conclusions: We have developed a practical model for predicting the probability of death, survival with major disability, and functional recovery in patients who are comatose 24 hours after severe head injury. The model performed well in an external setting, indicating that measures to avoid statistical overfitting were successful.	Univ Utrecht, Med Ctr, Div Perioperat Care & Emergency Med, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Neurol, Utrecht, Netherlands		Cremer, OL (corresponding author), Acad Med Ctr C3, Dept Intens Care 423, POB 22660, NL-1100 DD Amsterdam, Netherlands.	o.l.cremer@amc.uva.nl	Kalkman, Cor/O-3215-2019; Cremer, Olaf L/G-3855-2016	Kalkman, Cor/0000-0002-8372-6960; Cremer, Olaf L/0000-0003-4264-1108			Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/BF01709556; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Efron B., 1993, INTRO BOOTSTRAP; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FELDMAN Z, 1991, LANCET, V337, P1451, DOI 10.1016/0140-6736(91)93137-X; GIBSON RM, 1989, LANCET, V2, P369; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Harrell FE, 1998, STAT MED, V17, P909, DOI 10.1002/(SICI)1097-0258(19980430)17:8<909::AID-SIM753>3.0.CO;2-O; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Maas AIR, 2004, ACT NEUR S, V89, P113; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nissen JJ, 1999, J NEUROL NEUROSUR PS, V67, P796, DOI 10.1136/jnnp.67.6.796; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; [No title captured]	39	45	47	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2006	61	6					1484	1491		10.1097/01.ta.0000195981.63776.ba			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	119CI	WOS:000242989400038	16983303				2022-02-06	
J	Timofeev, I; Hutchinson, PJ				Timofeev, I.; Hutchinson, P. J.			Outcome after surgical decompression of severe traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						head injury; trauma; decompressive craniectomy; brain oedema; intracranial pressure; neurosurgery; neurological outcome; neuromonitoring; intensive care	SEVERE HEAD-INJURIES; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; CEREBRAL-ARTERY INFARCTION; ISCHEMIC-STROKE; EUROPEAN BRAIN; CRANIECTOMY; MANAGEMENT; EDEMA; CRANIOTOMY; PRESSURE	One of the factors that affects outcome following severe traumatic brain injury is development and progression of cerebral oedema with associated increase in intracranial pressure (ICP). Uncontrolled elevations of ICP may compromise energy metabolism of the injured brain and lead to secondary injury, affecting neurological outcome of the patient. Decompressive craniectomy has been used for over a century as a treatment of refractory brain swelling in a variety of neurological conditions. However, conclusive evidence of whether it has a beneficial or adverse affect on outcome is tacking. This article reviews the existing evidence on the role of decornpressive craniectomy in management of patients with traumatic brain injury and stresses the need for randomised controlled trials. (C) 2006 Elsevier Ltd. All rights reserved.	Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England		Hutchinson, PJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Box 167, Cambridge CB2 2QQ, England.	pjah2@cam.ac.uk	Timofeev, Ivan/AAE-7019-2019		MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G9439390] Funding Source: Medline		Abdullah J, 2005, ACT NEUR S, V95, P311; Agrawal D, 2005, EUR J CLIN MICROBIOL, V24, P772, DOI 10.1007/s10096-005-0017-7; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Ausman J I, 1976, Surg Neurol, V6, P97; Bor-Seng-Shu E, 2004, ARQ NEURO-PSIQUIAT, V62, P715, DOI 10.1590/S0004-282X2004000400028; Boret H, 2006, ACTA ANAESTH SCAND, V50, P252, DOI 10.1111/j.1399-6576.2005.00862.x; Cho DY, 2003, SURG NEUROL, V60, P227, DOI 10.1016/S0090-3019(03)00266-0; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; Csokay A, 2002, SURG NEUROL, V57, P126, DOI 10.1016/S0090-3019(01)00686-3; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; DIERSSEN G, 1983, ACTA NEUROCHIR, V69, P53, DOI 10.1007/BF02055853; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Fandino Y, 2004, SWISS MED WKLY, V134, P423; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; GAAB MR, 1990, ACT NEUR S, V51, P326; GERL A, 1980, Zentralblatt fuer Neurochirurgie, V41, P125; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Harrington ML, 1996, AM J VET RES, V57, P1659; Harscher S, 2006, ACTA NEUROCHIR, V148, P31, DOI 10.1007/s00701-005-0617-0; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; Lu J, 2005, ACT NEUR S, V95, P281; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Meier U, 2005, ACT NEUR S, V95, P55; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Mitchell P, 2004, ACTA NEUROCHIR, V146, P159, DOI 10.1007/s00701-003-0186-z; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Mussack T, 2005, J TRAUMA, V58, P1061, DOI 10.1097/01.TA.0000171989.63817.8c; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ong YK, 2002, CHILD NERV SYST, V18, P340, DOI 10.1007/s00381-002-0597-9; Oyelese AA, 2005, NEUROSURGERY, V57, P594, DOI 10.1227/01.NEU.0000170437.79760DF; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PEREIRA WC, 1977, ARQ NEURO-PSIQUIAT, V35, P99, DOI 10.1590/S0004-282X1977000200002; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Reithmeier T, 2005, ACTA NEUROCHIR, V147, P947, DOI 10.1007/s00701-005-0543-1; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Schneider GH, 2002, ACT NEUR S, V81, P77; Schwab S, 1998, NERVENARZT, V69, P896, DOI 10.1007/s001150050360; Strege RJ, 2003, NEUROL RES, V25, P510, DOI 10.1179/016164103101201742; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; WHITFIELD P, 1995, STROKE, V26, P1125; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005; [No title captured]	60	45	52	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	DEC	2006	37	12					1125	1132		10.1016/j.injury.2006.07.031			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	123TQ	WOS:000243319200006	17081545				2022-02-06	
J	Reeves, DL; Bleiberg, J; Roebuck-Spencer, T; Cernich, AN; Schwab, K; Ivins, B; Salazar, AM; Harvey, SC; Brown, FH; Warden, D				Reeves, Dennis L.; Bleiberg, Joseph; Roebuck-Spencer, Tresa; Cernich, Alison N.; Schwab, Karen; Ivins, Brian; Salazar, Andres M.; Harvey, Sally C.; Brown, Fred H., Jr.; Warden, Deborah			Reference values for performance on the Automated Neuropsychological Assessment Metrics V3.0 in an active duty military sample	MILITARY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; REACTION-TIME	The Automated Neuropsychological Assessment Metrics (ANAM) is a computerized measure of processing speed, cognitive efficiency, and memory. This study describes performance and psychometric properties of ANAM in an active duty, healthy military sample (N = 2,371) composed primarily of young (18-46 years) adult males. Rarely have neuropsychological reference values for use with individuals in the military been derived from a large, active duty military population, and this is the first computerized neuropsychological test battery with military-specific reference values. Although these results do not provide demographically corrected, formal normative data, they provide reference points for neuropsychologists and other health care providers who are using ANAM data in research or clinical settings, with patients of comparable demographics to the present sample.	ClinVest Inc, Springfield, MO 65807 USA; Natl Rehabil Hosp, Ctr Cognit Neurosci, Washington, DC 20010 USA; Univ Maryland, Med Ctr, Dept Neurol, Baltimore, MD 21201 USA; Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20012 USA; Oncovir Inc, Washington, DC 20008 USA; 902nd Mil Intelligence Grp, Ft George G Meade, MD 20755 USA; Psychol Applicat Directorate, Special Operat Command, Ft Bragg, NC 28310 USA		Reeves, DL (corresponding author), ClinVest Inc, 3805 S Kansas Expressway, Springfield, MO 65807 USA.			Bleiberg, Joseph/0000-0003-0867-5494			Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Farmer K, 2001, HEADACHE, V41, P377, DOI 10.1046/j.1526-4610.2001.111006377.x; GASTALDO E, 1997, ANAM NORMATIVE DATA; Gestaldo E, 2001, ARCH CLIN NEUROPSYCH, V16, P825; GOLDSTONE A, 1995, ANAM V3 11 GERIATRIC; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; KABAT MH, 2000, J INT NEUROPSYCH SOC, V6, P146; Kane R. L., 1997, NEUROPSYCHOLOGY HDB; LEVINSON DM, 1994, AUTOMATED NEUROPSYCH; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; REEVES D, IN PRESS NEUROPSYCHO; REEVES DL, 1996, ANAM USMC NORMATIV 1; ROEBUCKSPENCER TM, IN PRESS NEUROPSYCHO; Salthouse TA, 2002, J CLIN EXP NEUROPSYC, V24, P858, DOI 10.1076/jcen.24.7.858.8392; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wilken JA, 2003, MULT SCLER, V9, P119, DOI 10.1191/1352458503ms893oa	19	45	45	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	OCT	2006	171	10					982	994		10.7205/MILMED.171.10.982			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	096JH	WOS:000241372900012	17076451	Bronze			2022-02-06	
J	Sheedy, J; Geffen, G; Donnelly, J; Faux, S				Sheedy, Joanne; Geffen, Gina; Donnelly, James; Faux, Steven			Emergency department assessment of mild traumatic brain injury and prediction of post-concussion symptoms at one month post injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							RAPID SCREEN; HEAD-INJURY; SEVERITY; RECOVERY; MODERATE; STRESS	Mild traumatic brain injury (mTBI) is a common injury and a significant proportion of those affected report chronic symptoms. This study investigated prediction of post-concussion symptoms using an Emergency Department (ED) assessment that examined neuropsychological and balance deficits and pain severity of 29 concussed individuals. Thirty participants with minor orthopedic injuries and 30 ED visitors were recruited as control subjects. Concussed and orthopedically injured participants were followed up by telephone at one month to assess symptom severity. In the ED, concussed subjects performed worse on some neuropsychological tests and had impaired balance compared to controls. They also reported significantly more post-concussive symptoms at follow-up. Neurocognitive impairment, pain and balance deficits were all significantly correlated with severity of post-concussion symptoms. The findings suggest that a combination of variables assessable in the ED may be useful in predicting which individuals will suffer persistent post-concussion problems.	St Vincents Hosp, Darlinghurst, NSW 2010, Australia; Univ Queensland, Sch Psychol, Cognit Psychophysiol Lab, Brisbane, Qld, Australia; Univ New England, Sch Psychol, Armidale, NSW, Australia		Sheedy, J (corresponding author), St Vincents Hosp, Victoria St, Darlinghurst, NSW 2010, Australia.	jsheedy@stvincents.com.au	Faux, Steven/Y-3409-2019; Donnelly, James F/P-5932-2015	Faux, Steven/0000-0001-8846-216X; Donnelly, James F/0000-0002-2052-7948			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Baddeley A., 1992, SPEED CAPACITY LANGU; BIGLER ED, 2000, UNPUB LESIONS TRAUMA; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; De Monte VE, 2004, J CLIN EXP NEUROPSYC, V26, P628, DOI 10.1080/13803390490504443; DEMONTE V, IN PRESS J CLIN EXPT; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HINTONBAYRE AD, 1997, SPORT HLTH, V15, P4; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Malec JF, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P15; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; *NAT HLTH MED RES, 1992, IS THER SAF LEV DAIL; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; RUBIN AM, 1995, AM J OTOL, V16, P216; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Uzzell BP, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P1; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454; Wechsler, 1997, WECHSLER ADULT INTEL; Wrisley DM, 2000, J ORTHOP SPORT PHYS, V30, P755, DOI 10.2519/jospt.2000.30.12.755	37	45	45	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	2006	28	5					755	772		10.1080/13803390591000864			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	046AS	WOS:000237784400011	16723323				2022-02-06	
J	Armin, SS; Colohan, ART; Zhang, JH				Armin, Sean S.; Colohan, Austin R. T.; Zhang, John H.			Traumatic subarachnoid hemorrhage: our current understanding and its evolution over the past half century	NEUROLOGICAL RESEARCH			English	Article						traumatic subarachnoid hemorrhage; vasospasm; secondary injury	SEVERE HEAD-INJURY; TRANSCRANIAL DOPPLER ULTRASOUND; CEREBRAL ARTERIAL SPASM; ISCHEMIC BRAIN-DAMAGE; COMPUTERIZED-TOMOGRAPHY; FLOW VELOCITIES; INTRAVENOUS NIMODIPINE; PROGNOSTIC VALUE; DOUBLE-BLIND; BLOOD-FLOW	Traumatic brain injury (TBI) is a common cause of morbidity and mortality in the US, especially among the young. Primary injury in TBI is preventable, whereas secondary injury is treatable. As a result, considerable research efforts have been focused on elucidating the pathophysiology of secondary injury and determining various prognosticators in the hopes of improving final outcome by minimizing secondary injury. One such variable, traumatic subarachnoid hemorrhage (tSAH), has been the focus of many discussions over the past half century as numerous clinical studies have shown tSAH to be associated with adverse outcome. Whether the relationship of tSAH with poorer outcome in TBI is merely an epiphenomenon or a result of direct cause and effect is unclear. Some investigators believe that tSAH is merely a marker of severer TBI, while others argue that it directly causes deleterious effects such as vasospasm and ischemia. At the present time, no proven treatment regimen aimed specifically at decreasing the detrimental effects of tSAH exists, although calcium channel blockers traditionally thought to target vasospasm have shown some promises. Given that tSAH may primarily be an early indicator of associated and evolving brain injury, vigilant diagnostic surveillance including serial head CT and prevention of secondary brain damage owing to hypotension, hypoxia and intracranial hypertension may be more cost-effective than attempting to treat potential adverse sequelae associated with tSAH.	Loma Linda Univ, Med Ctr, Div Neurosurg, Loma Linda, CA 92354 USA		Colohan, ART (corresponding author), 11234 Anderson St, Loma Linda, CA 92354 USA.	acolohan@ahs.llumc.edu		Zhang, John H./0000-0002-4319-4285			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; AUER LM, 1981, DRUG RES, V31, P1423; Barker FG, 1996, J NEUROSURG, V84, P405, DOI 10.3171/jns.1996.84.3.0405; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BROWN ST, 1990, ANNU REV PUBL HEALTH, V11, P251; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Chen Guangxin, 2002, Chin J Traumatol, V5, P169; Chestnut RM, 1993, P 8 INT S INTR PRESS, P503; Chhabra R, 2001, NEUROL INDIA, V49, P138; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Collier BR, 2004, J NEUROSURG ANESTH, V16, P196, DOI 10.1097/00008506-200407000-00003; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; COOPER PR, 1982, HEAD INJURY, P321; COURVILLE CB, 1950, PATHOLOGY CENTRAL NE, P112; DALE J, 1983, AM HEART J, V105, P103, DOI 10.1016/0002-8703(83)90285-5; DEMIRCIVI F, 1993, ACTA NEUROCHIR, V122, P45, DOI 10.1007/BF01446985; DOWLING G, 1988, AM J FOREN MED PATH, V9, P23, DOI 10.1097/00000433-198803000-00007; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FORD R, 1956, J FORENSIC SCI, V1, P117; FREYTAG E, 1963, ARCH PATHOL, V75, P402; Fukuda T, 1998, NEUROSURGERY, V43, P1040, DOI 10.1097/00006123-199811000-00022; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Grcevic N, 1983, Acta Neurochir Suppl (Wien), V32, P79; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Greene KA, 1996, J TRAUMA, V41, P964, DOI 10.1097/00005373-199612000-00004; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; Hanlon RE, 2005, BRAIN INJURY, V19, P257, DOI 10.1080/02699050400004955; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; JAN M, 1988, NEUROSURGERY, V23, P154, DOI 10.1227/00006123-198808000-00004; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; KAKARIEKA A, 1994, J NEURAL TRANSM-SUPP, P13; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KAOUTZANIS M, 1993, J NEUROSCI METH, V50, P301, DOI 10.1016/0165-0270(93)90037-R; KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562; Kobayashi S, 1988, No To Shinkei, V40, P1131; Langham J, 2003, COCHRANE DB SYST REV, V4, DOI [10.1002/14651858.CD000565, DOI 10.1002/14651858.CD000565]; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LEEDS NE, 1966, ACTA RADIOL DIAGN, V5, P320, DOI 10.1177/02841851660050P135; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Megyesi JF, 2000, NEUROSURGERY, V46, P448, DOI 10.1097/00006123-200002000-00035; Miller J D, 1979, Acta Neurochir Suppl (Wien), V28, P86; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Morris GF, 1997, ACTA NEUROCHIR S, V71, P382; NEIL-DWYER G, 1987, European Heart Journal, V8, P41; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; OHMAN J, 1988, J NEUROSURG, V69, P683, DOI 10.3171/jns.1988.69.5.0683; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; Patel HC, 1999, HOSP MED, V60, P497, DOI 10.12968/hosp.1999.60.7.1155; PETRUK KC, 1988, J NEUROSURG, V68, P505, DOI 10.3171/jns.1988.68.4.0505; PHILIPPON J, 1986, ACTA NEUROCHIR, V82, P110, DOI 10.1007/BF01456369; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Radhakrishnan D, 1997, ANAESTHESIA, V52, P489, DOI 10.1111/j.1365-2044.1997.112-az0105.x; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROBINSON MJ, 1990, CEREBROVAS BRAIN MET, V2, P205; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; Sahuquillo J, 2000, REV NEUROLOGIA, V30, P401, DOI 10.33588/rn.3005.99063; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; Schmieder K, 1996, ACTA NEUROL SCAND, V93, P123, DOI 10.1111/j.1600-0404.1996.tb00573.x; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SHIGEMORI M, 1990, Neurologia Medico-Chirurgica, V30, P396, DOI 10.2176/nmc.30.396; SIMONSEN J, 1963, J Forensic Sci, V8, P97; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Suarez JI, 2002, CRIT CARE MED, V30, P1348, DOI 10.1097/00003246-200206000-00035; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; SYMON L, 1967, J NEUROL NEUROSUR PS, V30, P497, DOI 10.1136/jnnp.30.6.497; TAKIZAWA T, 1984, Neurologia Medico-Chirurgica, V24, P390, DOI 10.2176/nmc.24.390; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; TEASDALE G, 1974, LANCET, V2, P81; Thomas S, 1998, ACT NEUR S, V71, P135; Thomas S, 2000, ACTA NEUROCHIR SUPPL, V76, P203; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WADWORTH AN, 1992, DRUG AGING, V2, P262, DOI 10.2165/00002512-199202040-00002; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626	94	45	55	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2006	28	4					445	452		10.1179/016164106X115053			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	058HR	WOS:000238656600009	16759448				2022-02-06	
J	Rapoport, MJ; Kiss, A; Feinstein, A				Rapoport, Mark J.; Kiss, Alexander; Feinstein, Anthony			The impact of major depression on outcome following mild-to-moderate traumatic brain injury in older adults	JOURNAL OF AFFECTIVE DISORDERS			English	Article; Proceedings Paper	18th Annual Meeting of the American-Association-for-Geriatric-Psychiatry	MAR 03-06, 2005	San Diego, CA	Amer Assoc Geriatr Psychiat		traumatic brain injury; older adults; major depression	HEAD-INJURY; QUESTIONNAIRE; DISORDERS; MORTALITY; SYMPTOMS	Background: Major depression is common following traumatic brain injury (TBI), yet no studies to date have explored its relationship to psychosocial outcome in older adults with TBI. Methods: A consecutive sample of seventy-seven older patients with mild-to-moderate TBI was assessed for the presence of major depression within 2 months of injury, and followed prospectively for 1 year. Those with major depression were compared with those without on measures of psychosocial outcome, instrumental activities of daily living (IADL). Results: Patients with major depression (15.6%) reported higher degrees of psychological distress, psychosocial dysfunction, and post-concussive symptoms than those without, and were rated as having poorer IADL performance. Limitations: The present study was limited to a clinical population, and there were significant attrition rates. Conclusions: Major depression in the first few months after TBI in older adults has persisting adverse effects on outcome, highlighting its significance in this population, and suggesting early attention to treatment. (c) 2006 Elsevier B.V. All rights reserved.	Univ Toronto, Hlth Sci Ctr, Sunnybrook & Womens Coll, Toronto, ON, Canada		Rapoport, MJ (corresponding author), Univ Toronto, Hlth Sci Ctr, Sunnybrook & Womens Coll, Toronto, ON, Canada.	mark.rapoport@sw.ca	Rapoport, Mark/AAD-8581-2020				Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FIELDS RB, 1994, TXB GERIATRIC NEUROP, P479; First M.B., 1996, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lyness JM, 2002, AM J GERIAT PSYCHIAT, V10, P275, DOI 10.1176/appi.ajgp.10.3.275; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004	21	45	45	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	JUN	2006	92	2-3					273	276		10.1016/j.jad.2005.05.022			4	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Neurosciences & Neurology; Psychiatry	050ZS	WOS:000238130500016	16504305				2022-02-06	
J	Schonberger, M; Humle, F; Zeeman, P; Teasdale, TW				Schonberger, M; Humle, F; Zeeman, P; Teasdale, TW			Working alliance and patient compliance in brain injury rehabilitation and their relation to psychosocial outcome	NEUROPSYCHOLOGICAL REHABILITATION			English	Article								Employment and physical activity at follow up of 98 patients who underwent a holistic neuropsychological outpatient rehabilitation programme were examined in relation to therapeutic process factors. The patients had suffered a traumatic brain injury (n = 26), a cerebrovascular accident ( n 58) or another neurological insult (n = 14). Two staff members, a neuropsychologist and a physiotherapist, retrospectively rated patients' compliance with the therapeutic regime and their working alliances. They completed the ratings separately, but had some degree of common knowledge about the patients. While the compliance ratings were closely associated, working alliance ratings differed between the raters. The working alliance ratings were predictive of employment, but not physical activity. Both compliance ratings predicted physical training, but only the neuropsychologist's compliance rating was associated with follow-up employment. Post-hoc analysis showed that high compliance ratings given by the physiotherapist were also a predictor of employment. Overall, there was a tendency for the neuropsychologist's ratings to be more closely associated with employment than the physiotherapist's ratings. These results indicate that employment and physical activity are differentially predictable from different process measures rated from different professional perspectives.	Univ Copenhagen, Ctr Rehabil Brain Injury, DK-2300 Copenhagen S, Denmark		Schonberger, M (corresponding author), Univ Copenhagen, Ctr Rehabil Brain Injury, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	michael.schoenberger@psy.ku.dk					BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P33; CAETANO C, 2000, INT HDB NEUROPSYCHOL; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; CHRISTENSEN AL, 1999, COGNITIVE NEUROREHAB; Constantino M. J., 2002, COUNSELING BASED PRO; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Hilsenroth MJ, 2002, PSYCHOTHERAPY, V39, P309, DOI 10.1037//0033-3204.39.4.309; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; HORVATH AO, 1994, THEWORKING ALLIANCE, P259; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Meichenbaum D., 1987, FACILITATING TREATME; Norcross, 2002, PSYCHOTHERAPY RELATI, P17; Petermann F., 1998, COMPLIANCE SELBSTMAN, P73; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RASMUSSESN G, 1994, BRAIN INJURY NEUROPS; Rogers CR, 1952, SCI AM, V187, P66; Shirk SR, 2003, J CONSULT CLIN PSYCH, V71, P452, DOI 10.1037/0022-006X.71.3.452; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; VOLMER T, 1998, COMPLIANCE SELBSTMAN, P45	22	45	46	0	11	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUN	2006	16	3					298	314		10.1080/09602010500176476			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	054XR	WOS:000238412400004	16835153				2022-02-06	
J	Ewing-Cobbs, L; Hasan, KM; Prasad, MR; Kramer, L; Bachevalier, J				Ewing-Cobbs, L; Hasan, KM; Prasad, MR; Kramer, L; Bachevalier, J			Corpus callosum diffusion anisotropy correlates with neuropsychological outcomes in twins disconcordant for traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	12th Annual Meeting of the International-Society-for-Magnetic-Resonance-in-Medicine	MAY 15-21, 2004	Kyoto, JAPAN	Int Soc Magnet Resonance Med				Conventional and diffusion tensor MR imaging studies in twins sustaining severe pediatric traumatic brain injury identified reduction in fractional anisotropy (FA) in all regions of the corpus callosum, particularly the posterior body, rostral body, and genu, relative to healthy cotwins. FA from the rostrum, genu, anterior body, posterior body, and isthmus were correlated with measures of reading speed and comprehension; verbal working memory and math fact retrieval scores were correlated only with the rostral body FA.	Univ Texas, Houston Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Dept Intervent & Diagnost Imaging, Houston, TX 77030 USA; Emory Univ, Dept Psychol, Atlanta, GA 30322 USA		Ewing-Cobbs, L (corresponding author), Univ Texas, Houston Hlth Sci Ctr, Dept Pediat, 7000 Fannin UCT 2401, Houston, TX 77030 USA.		Hasan, Khader M./ABB-5767-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS029462, R01 NS046308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046308, R01NS029462] Funding Source: NIH RePORTER		Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baumgardner TL, 1996, NEUROLOGY, V47, P477, DOI 10.1212/WNL.47.2.477; Chepuri NB, 2002, AM J NEURORADIOL, V23, P803; Cohen J., 1998, STAT POWER ANAL BEHA, V2nd; Constable RT, 2004, NEUROIMAGE, V22, P11, DOI 10.1016/j.neuroimage.2004.01.001; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Hasan KM, 2003, MAGNET RESON MED, V50, P589, DOI 10.1002/mrm.10552; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; HASAN KM, 2004, P 12 INT SOC MAGN RE, P338; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Mather N., 2001, WOODCOCK JOHNSON 3 T; Menon V, 2002, HUM BRAIN MAPP, V16, P119, DOI 10.1002/hbm.10035; Rashotte C.A., 1999, TEST WORD READING EF; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Simos PG, 2002, CEREB CORTEX, V12, P297, DOI 10.1093/cercor/12.3.297; STRICH SJ, 1970, PATHOLOGY TRAUMA, P166; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799	18	45	48	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2006	27	4					879	881					3	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	033BY	WOS:000236822500034	16611782				2022-02-06	
J	High, WM; Roebuck-Spencer, T; Sander, AM; Struchen, MA; Sherer, M				High, WM; Roebuck-Spencer, T; Sander, AM; Struchen, MA; Sherer, M			Early versus later admission to postacute rehabilitation: Impact on functional outcome after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; treatment effectiveness; treatment outcome	DISABILITY RATING-SCALE; COMMUNITY INTEGRATION QUESTIONNAIRE; CLOSED-HEAD-INJURY; COGNITIVE REHABILITATION; PREDICTION; RECOVERY; PROGRAM; COMA	Early versus later admission to postacute rehabilitation: impact on functional outcome after traumatic brain injury. Arch Phys Med Rehabil 2006;87:334-42. Objective: To examine the impact of participation in a postacute community reentry program on functional outcome after traumatic brain injury (TBI). Design: Cohort, nonrandomized, intervention study. Pretest-posttest, follow-up design. Setting: Nonprofit outpatient community reentry program affiliated with an inpatient rehabilitation hospital. Participants: Three groups of persons with moderate to severe TBI differing in length of time between injury and admission. The first group entered postacute rehabilitation within 6 months of injury (n= 115); the second group, between 6 and 12 months (n=23); and the third group, greater than 12 months (n=29). Interventions: Persons with TBI participated in a postacute community reentry program (average, 4.3mo) that emphasized (1) teaching compensatory strategies to address residual cognitive deficits; (2) arranging environmental supports to maximize functioning; (3) counseling and education to address personal and family adjustment and to improve accurate self-awareness; and (4) transition from simulated activities in the clinic to productive activities in the community. Main Outcome Measures: Disability Rating Scale, Supervision Rating Scale, and the Community Integration Questionnaire. Results: All groups showed improvements between admission and discharge on measures of overall disability, independence, home competency, and productivity, and these gains were maintained at follow-up. For the group beginning postacute rehabilitation the earliest (< 6mo postinjury) independence continued to improve after discharge. Community integration total score and home competency also continued to improve even after discharge. Conclusions: The results point toward the effectiveness of postacute rehabilitation in improving functional outcome after TBI even for persons who have reached stable neurologic recovery at 12 or more months postinjury.	Inst Rehabil & Res, Brain Injury Res Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Natl Rehabil Hosp, Washington, DC USA; Methodist Rehabil Ctr, Jackson, MS USA; Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Psychiat, Jackson, MS 39216 USA		High, WM (corresponding author), Inst Rehabil & Res, Brain Injury Res Ctr, 1333 Moursund Ave, Houston, TX 77030 USA.	whigh@bcm.tmc.edu					Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; HIGH WM, 2005, REHABILITATION TRAUM, P14; Johnson J, 2001, INT J PSYCHIAT CLIN, V5, P141, DOI 10.1080/136515001300374894; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; Pastorek NJ, 2004, J INT NEUROPSYCH SOC, V10, P807, DOI 10.1017/S1355617704106012; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Sherer M, 1997, CANCER, V80, P250, DOI 10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T; Sherer M, 1999, BRAIN INJURY, V13, P973; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; TEASDALE G, 1974, LANCET, V2, P81; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	32	45	45	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2006	87	3					334	342		10.1016/j.apmr.2005.11.028			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	021XZ	WOS:000236020500005	16500166				2022-02-06	
J	Skelton, RW; Ross, SP; Nerad, L; Livingstone, SA				Skelton, RW; Ross, SP; Nerad, L; Livingstone, SA			Human spatial navigation deficits after traumatic brain injury shown in the arena maze, a virtual Morris water maze	BRAIN INJURY			English	Article						topographical disorientation; spatial cognition; cognitive map; place learning; allocentric; closed head injury	UNILATERAL TEMPORAL LOBECTOMY; TOPOGRAPHICAL DISORIENTATION; HEAD-INJURY; PLACE NAVIGATION; HIPPOCAMPAL-LESIONS; STIMULUS-CONTROL; MEMORY DEFICITS; LOBE LESIONS; OPTIC FLOW; RATS	Objective: Survivors of traumatic brain injury (TBI) often have spatial navigation deficits. This study examined such deficits and conducted a detailed analysis of navigational behaviour in a virtual environment. Design: TBI survivors were tested in a computer simulation of the Morris water maze task that required them to find and remember the location of an invisible platform that was always in the same location. A follow-up questionnaire assessed everyday spatial ability. Method: Fourteen survivors of moderate-to-severe TBI were compared to 12 non-injured participants. Results: TBI survivors navigated to a visible platform but could not learn the location of the invisible platform. The difference between TBI survivors and uninjured participants was best indicated by two new dependent variables, path efficacy and spatial scores. Conclusion: This study confirms the capacity of virtual environments to reveal spatial navigation deficits after TBI and establishes the best way to identify such deficits.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada		Skelton, RW (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	skelton@uvic.ca	Skelton, Ronald/E-5605-2012	Ross, Shelley/0000-0001-9581-3191			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Aguirre GK, 1999, BRAIN, V122, P1613, DOI 10.1093/brain/122.9.1613; Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; Barrash J, 1998, J CLIN EXP NEUROPSYC, V20, P807, DOI 10.1076/jcen.20.6.807.1114; Barrash J, 2000, NEUROPSYCHOLOGIA, V38, P820, DOI 10.1016/S0028-3932(99)00131-1; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bohbot VD, 2004, NEUROPSYCHOLOGY, V18, P418, DOI 10.1037/0894-4105.18.3.418; Bohbot VD, 2002, PHYSIOL RES, V51, pS49; Bohbot VD, 2000, ANN NY ACAD SCI, V911, P355; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; CORKIN S, 1965, NEUROPSYCHOLOGIA, V3, P339, DOI 10.1016/0028-3932(65)90006-0; Darken RP, 2002, HUM FAC ER, P493; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; Feigenbaum JD, 1996, NEUROPSYCHOLOGIA, V34, P163, DOI 10.1016/0028-3932(95)00107-7; GAGE FH, 1986, J NEUROSCI, V6, P2837; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Iaria G, 2003, J NEUROSCI, V23, P5945; Jacobs WJ, 1998, LEARN MOTIV, V29, P288, DOI 10.1006/lmot.1998.1008; Jacobs WJ, 1997, LEARN MOTIV, V28, P521, DOI 10.1006/lmot.1997.0977; Kearns MJ, 2002, PERCEPTION, V31, P349, DOI 10.1068/p3311; Kirschen MP, 2000, PERCEPTION, V29, P801, DOI 10.1068/p3096; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; Kolb B, 2000, NEUROPHARMACOLOGY, V39, P756, DOI 10.1016/S0028-3908(99)00260-9; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1998, J COGNITIVE NEUROSCI, V10, P61, DOI 10.1162/089892998563789; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; MCDANIEL WF, 1991, BEHAV BRAIN RES, V44, P107, DOI 10.1016/S0166-4328(05)80245-1; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; MILNER B, 1970, BIOL MEM, V23, P31; Moffat SD, 2002, BEHAV NEUROSCI, V116, P851, DOI 10.1037//0735-7044.116.5.851; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Nadel L, 2000, HIPPOCAMPUS, V10, P352, DOI 10.1002/1098-1063(2000)10:4<352::AID-HIPO2>3.3.CO;2-4; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; OLSEN GM, 1994, BEHAV NEUROSCI, V108, P681, DOI 10.1037/0735-7044.108.4.681; Paterson A, 1944, BRAIN, V67, P331, DOI 10.1093/brain/67.4.331; Pizzamiglio L, 1998, CORTEX, V34, P719, DOI 10.1016/S0010-9452(08)70775-5; Previc FH, 1998, PSYCHOL BULL, V124, P123, DOI 10.1037/0033-2909.124.2.123; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; ROD MR, 1990, CAN J PSYCHOL, V44, P196, DOI 10.1037/h0084242; Rose FD, 1999, DISABIL REHABIL, V21, P548; Sandstrom NJ, 1998, COGNITIVE BRAIN RES, V6, P351, DOI 10.1016/S0926-6410(98)00002-0; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Spiers HJ, 2001, BRAIN, V124, P2476, DOI 10.1093/brain/124.12.2476; Spiers HJ, 2001, NEUROCASE, V7, P357, DOI 10.1076/neur.7.5.357.16245; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUZUKI S, 1980, LEARN MOTIV, V11, P1, DOI 10.1016/0023-9690(80)90018-1; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; Trullier O, 1999, EUR J NEUROSCI, V11, P4381, DOI 10.1046/j.1460-9568.1999.00839.x; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	68	45	45	0	15	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2006	20	2					189	203		10.1080/02699050500456410			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	003KX	WOS:000234681700009	16421068				2022-02-06	
J	Ling, CY; Sandor, M; Suresh, M; Fabry, Z				Ling, CY; Sandor, M; Suresh, M; Fabry, Z			Traumatic injury and the presence of antigen differentially contribute to T-cell recruitment in the CNS	JOURNAL OF NEUROSCIENCE			English	Article						antigen specificity; CD8(+) T-cell homing; traumatic brain injury; neuroimmunology; ovalbumin antigen; intracerebral injection	CENTRAL-NERVOUS-SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE-SCLEROSIS LESIONS; FACIAL MOTONEURON LOSS; BLOOD-BRAIN-BARRIER; DENDRITIC CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; CD40-CD40L INTERACTION; HEMATOGENOUS CELLS; IMMUNE-RESPONSES	T-cell recruitment into the brain is critical in inflammatory and autoimmune diseases of the CNS. We use intracerebral antigen microinjection and tetramer technology to track antigen-specific CD8(+) T-cells in the CNS and to clarify the contribution of antigen deposition or traumatic injury to the accumulation of T-cells in the brain. We demonstrate that, after intracerebral microinjection of ovalbumin, ovalbumin-specific CD8(+) T-cells expand systemically and then migrate into the brain where they complete additional proliferation cycles. T-cells in the brain are activated and respond to in vitro secondary antigen challenge. CD8(+) T-cells accumulate and persist in sites of antigen in the brain without replenishment from the periphery. Persistent survival of CD8(+) T-cells at sites of cognate antigen is significantly reduced by blocking CD154 molecules. A small traumatic injury itself does not lead to recruitment of CD8(+) T-cells into the brain but attracts activated antigen-specific CD8(+) T-cells from cognate antigen injection sites. This process is presumably antigen independent and cannot be inhibited by blocking CD154 molecules. These data show that activated antigen-specific CD8(+) T-cells accumulate in the CNS at both cognate antigen-containing and traumatic injury sites after intracerebral antigen delivery. The accumulation of activated antigen-specific T-cells at traumatic injury sites, in addition to antigen-containing areas, could amplify local inflammatory processes in the CNS. Combination therapies in neuroinflammatory diseases to block both of these processes should be considered.	Univ Wisconsin, Madison Med Sch, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Pathol Sci, Madison, WI 53706 USA		Fabry, Z (corresponding author), Univ Wisconsin, Dept Pathol, 1300 Univ Ave,6130 Med Sci Ctr, Madison, WI 53706 USA.	zfabry@facstaff.wisc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037570, R01-NS 37570-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037570] Funding Source: NIH RePORTER		Aktas O, 2005, NEURON, V46, P421, DOI 10.1016/j.neuron.2005.03.018; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Azukizawa H, 2003, EUR J IMMUNOL, V33, P1879, DOI 10.1002/eji.200323630; Babbe H, 2000, J EXP MED, V192, P393, DOI 10.1084/jem.192.3.393; BALZASCIA T, 2005, IMMUNITY, V22, P175; BOOSS J, 1983, J NEUROL SCI, V62, P219, DOI 10.1016/0022-510X(83)90201-0; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; Brabb T, 2000, J EXP MED, V192, P871, DOI 10.1084/jem.192.6.871; Byram SC, 2004, J NEUROSCI, V24, P4333, DOI 10.1523/JNEUROSCI.5276-03.2004; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; CSERR HF, 1992, J NEUROIMMUNOL, V41, P195, DOI 10.1016/0165-5728(92)90070-2; Darabi K, 2004, J IMMUNOL, V173, P92, DOI 10.4049/jimmunol.173.1.92; FABRY Z, 1992, J NEUROIMMUNOL, V36, P1, DOI 10.1016/0165-5728(92)90026-H; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Fee DB, 2004, BRAIN RES, V1012, P52, DOI 10.1016/j.brainres.2004.03.028; FONTANA A, 1987, IMMUNOL REV, V100, P185, DOI 10.1111/j.1600-065X.1987.tb00532.x; Gay FW, 1997, BRAIN, V120, P1461, DOI 10.1093/brain/120.8.1461; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; HAYASHI T, 1988, ANN NEUROL, V24, P523, DOI 10.1002/ana.410240408; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; Hofstetter HH, 2003, J NEUROIMMUNOL, V134, P25, DOI 10.1016/S0165-5728(02)00358-2; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hulshof S, 2002, GLIA, V38, P24, DOI 10.1002/glia.10050; Ingulli E, 2002, J IMMUNOL, V169, P2247, DOI 10.4049/jimmunol.169.5.2247; Irani DN, 1997, J IMMUNOL, V158, P2318; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; JUSTICIA C, 2005, IN PRESS J CEREB BLO; Karman J, 2004, IMMUNOL LETT, V92, P107, DOI 10.1016/j.imlet.2003.10.017; Karman J, 2004, J IMMUNOL, V173, P2353, DOI 10.4049/jimmunol.173.4.2353; KELLY JM, 1993, EUR J IMMUNOL, V23, P3318, DOI 10.1002/eji.1830231239; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Ling CY, 2003, J NEUROIMMUNOL, V141, P90, DOI 10.1016/S0165-5728(03)00249-2; Liu JSH, 2001, AM J PATHOL, V158, P2057, DOI 10.1016/S0002-9440(10)64677-9; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lyons AB, 1999, IMMUNOL CELL BIOL, V77, P509, DOI 10.1046/j.1440-1711.1999.00864.x; MATSUMOTO Y, 1993, IMMUNOLOGY, V79, P381; McGavern DB, 2004, J IMMUNOL, V173, P4779, DOI 10.4049/jimmunol.173.8.4779; McGavern DB, 2002, J INFECT DIS, V186, pS145, DOI 10.1086/344264; Moalem G, 2000, J NEUROIMMUNOL, V106, P189, DOI 10.1016/S0165-5728(00)00240-X; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mullins DW, 2003, J EXP MED, V198, P1023, DOI 10.1084/jem.20021348; Nitsch R, 2004, J NEUROSCI, V24, P2458, DOI 10.1523/JNEUROSCI.4703-03.2004; Obst R, 2005, J EXP MED, V201, P1555, DOI 10.1084/jem.20042521; Qing Z, 2000, J NEUROIMMUNOL, V105, P169, DOI 10.1016/S0165-5728(99)00265-9; Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reinhardt RL, 2003, J EXP MED, V197, P751, DOI 10.1084/jem.20021690; RODRIGUE.LA, 1968, J COMP NEUROL, V132, P109, DOI 10.1002/cne.901320106; Schwartz M, 2001, CELL MOL NEUROBIOL, V21, P617, DOI 10.1023/A:1015139718466; Serpe CJ, 2000, J NEUROSCI RES, V62, P273, DOI 10.1002/1097-4547(20001015)62:2<273::AID-JNR11>3.3.CO;2-3; Serpe CJ, 2003, BRAIN BEHAV IMMUN, V17, P393, DOI 10.1016/S0889-1591(03)00028-X; Serpe CJ, 1999, J NEUROSCI, V19; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Sorensen TL, 2002, J NEUROIMMUNOL, V127, P59, DOI 10.1016/S0165-5728(02)00097-8; Sun DM, 2001, J IMMUNOL, V166, P7579, DOI 10.4049/jimmunol.166.12.7579; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; Tan J, 2002, CURR OPIN PHARMACOL, V2, P445, DOI 10.1016/S1471-4892(02)00180-7; TRAUGOTT U, 1989, CELL IMMUNOL, V119, P114, DOI 10.1016/0008-8749(89)90228-1; VASS K, 1986, ACTA NEUROPATHOL, V70, P149, DOI 10.1007/BF00691433; Whitney LW, 1999, ANN NEUROL, V46, P425; Williams KC, 1995, CURR TOP MICROBIOL, V202, P221; WOODROOFE MN, 1986, J NEUROL SCI, V74, P135, DOI 10.1016/0022-510X(86)90100-0; Xiao BG, 1999, CELL MOL LIFE SCI, V56, P5, DOI 10.1007/s000180050002; Yan SS, 2003, NAT MED, V9, P287, DOI 10.1038/nm831	69	45	46	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JAN 18	2006	26	3					731	741		10.1523/JNEUROSCI.3502-05.2006			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	003XG	WOS:000234715000004	16421293	Green Published, Bronze			2022-02-06	
J	Willison, J; Tombaugh, TN				Willison, J; Tombaugh, TN			Detecting simulation of attention deficits using reaction time tests	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						simulation; malingering; reaction time tests	INJURY	The current study examined if a newly developed series of reaction time tests, the Computerized Tests of Information Processing (CTIP) [Tombaugh, T. N., & Rees, L. (2000). Manual for the Computerized Tests of Information Processing (CTIP). Ottawa, Ontario: Carleton University (unpublished test)], were sensitive to simulation of attention deficits commonly caused by traumatic brain injury (TBI). The CTIP consists of three reaction time tests: Simple RT, Choice RT, and Semantic Search RT. These tests were administered to four groups: Control, Simulator, Mild TBI, and Severe TBI. Individuals attempting to simulate attention deficits produced longer reaction time scores, made more incorrect responses, and exhibited greater variability than cognitively-intact individuals and those with TBI. Sensitivity and specificity values were comparable or exceeded those obtained on the Test of Memory Malingering [Tombaugh, T. N. (1996). The Test of Memory Malingering (TOMM). Toronto, Canada: Multi-Health Systems Inc.]. As such, the CTIP offers considerable promise of serving as a viable malingering test that uses a distinctively different paradigm than the two-item, forced-choice procedure employed by traditional symptom validity tests. (c) 2005 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Carleton Univ, Dept Psychol, Ottawa, ON K1S 5B6, Canada; Royal Ottawa Hosp, Ottawa, ON, Canada		Tombaugh, TN (corresponding author), Carleton Univ, Dept Psychol, 1125 Colonel By Dr, Ottawa, ON K1S 5B6, Canada.	ttombaug@ccs.carleton.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BAIRD BJ, 2004, THESIS OTTAWA ONTARI; Berry E., 2002, BOSTON GLOBE, pA1; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Bolan B, 2002, J CLIN EXP NEUROPSYC, V24, P154, DOI 10.1076/jcen.24.2.154.1000; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; Resnick P. J., 1988, CLIN ASSESSMENT MALI, P84; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; STRAUSS E, 1994, ARCH CLIN NEUROPSYCH, V9, P483, DOI 10.1016/0887-6177(94)90039-6; Strauss E, 1999, CLIN NEUROPSYCHOL, V13, P420, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT420; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 2000, MANUAL COMPUTERIZED; TOMBAUGH TN, 1998, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Trueblood W, 1997, ARCH CLIN NEUROPSYCH, V12, P13, DOI 10.1016/S0887-6177(96)00027-3; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245; VANZOMEREN AH, 1994, ASSESSMENT ATTENTION, P159; VANZOMEREN AH, 1989, NEUROBEHAVIORAL RECO, P398; Weschler D., 1997, WESCHLER ADULT INTEL; WESCHLER D, 1981, WESCHLER ADULT INTEL; Wogar MA, 1998, BRIT J CLIN PSYCHOL, V37, P327, DOI 10.1111/j.2044-8260.1998.tb01389.x; [No title captured]	43	45	45	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2006	21	1					41	52		10.1016/j.acn.2005.07.005			12	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	006EA	WOS:000234877100005	16280230	Bronze			2022-02-06	
J	Schultke, E; Kamencic, H; Zhao, M; Tian, GF; Baker, AJ; Griebel, RW; Juurlink, BHJ				Schultke, E; Kamencic, H; Zhao, M; Tian, GF; Baker, AJ; Griebel, RW; Juurlink, BHJ			Neuroprotection following fluid percussion brain trauma: A pilot study using quercetin	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; compound action potential; electrophysiology; fluid percussion model; glutathione; inflammation; oxidative stress	HYDROGEN-PEROXIDE; QUINONE REDUCTASE; AXONAL INJURY; KAPPA-B; FLAVONOID QUERCETIN; EPITHELIAL-CELLS; MARKER ENZYME; IN-VITRO; MYELOPEROXIDASE; RAT	Previously, we were able to demonstrate the neuroprotective effect of quercetin in an animal model of acute traumatic spinal cord injury. The objective of the present study was to determine whether any neuroprotective effect is seen when quercetin is administered in an animal model of traumatic brain injury. Twenty-six adult male Sprague-Dawley rats were submitted to moderate fluid percussion injury in the anterior midline position. Animals were divided into two experimental groups: one group received 25 mu mol/kg quercetin starting 1 h after injury, while animals in the second group received saline vehicle (n = 13 per group). Eight animals were used as uninjured healthy controls. Eight animals in each experimental group were sacrificed at 24 h, while five animals per group were allowed to recover for 72 h following injury. Compound action potential amplitudes (CAPAs) were recorded on 400-mu m vibrotome sections of the corpus callosum superfused with oxygenated artificial CSF (n = 3 per animal) in 20 experimental animals and five healthy controls. Three brains from animals in each experimental group and healthy controls were used for histological, immunocytochemical and biochemical analysis after sacrifice at 24 h. CAPAs in uninjured animals had a mean of 1.12 mV. This decreased to 0.55 mV in saline vehicle-treated injured animals by 24 h and changed little over the next 3 days. CAPAs were significantly better at 0.82 mV at 24 h and 0.76 mV at 3 days in quercetin-treated injured animals when compared to injured saline vehicle controls. Quercetin significantly prevented decrease of glutathione levels and decreased myeloperoxidase activity. We conclude that this dietary flavonoid has therapeutic potential following brain trauma.	Univ Saskatchewan, Dept Anat & Cell Biol, Div Neurosurg, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Surg, Div Neurosurg, Saskatoon, SK S7N 5E5, Canada; St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada		Juurlink, BHJ (corresponding author), Univ Saskatchewan, Dept Anat & Cell Biol, Div Neurosurg, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	juurlink@duke.usask.ca	Schultke, Elisabeth/M-3959-2013				Arabbi PR, 2004, J AGR FOOD CHEM, V52, P1124, DOI 10.1021/jf0499525; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; BLACKBURN WD, 1987, BIOCHEM BIOPH RES CO, V144, P1229, DOI 10.1016/0006-291X(87)91442-2; BUSSE WW, 1984, J ALLERGY CLIN IMMUN, V73, P801, DOI 10.1016/0091-6749(84)90450-0; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cheng IF, 2000, BIOMETALS, V13, P77, DOI 10.1023/A:1009229429250; Cho SY, 2003, MOL CELL BIOCHEM, V243, P153, DOI 10.1023/A:1021624520740; Christman JW, 2000, BRAIN PATHOL, V10, P153; CLARK RA, 1981, J IMMUNOL, V126, P1295; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Conquer JA, 1998, J NUTR, V128, P593, DOI 10.1093/jn/128.3.593; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; deVries JHM, 1997, CANCER LETT, V114, P141, DOI 10.1016/S0304-3835(97)04645-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Donnelly LE, 2004, AM J PHYSIOL-LUNG C, V287, pL774, DOI 10.1152/ajplung.00110.2004; Dugas AJ, 2000, J NAT PROD, V63, P327, DOI 10.1021/np990352n; Erlund I, 2003, EUR J CLIN NUTR, V57, P37, DOI 10.1038/sj.ejcn.1601513; Ferrali M, 1997, FEBS LETT, V416, P123, DOI 10.1016/S0014-5793(97)01182-4; Furtmuller PC, 2000, EUR J BIOCHEM, V267, P5858, DOI 10.1046/j.1432-1327.2000.01491.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hakkinen SH, 1999, J AGR FOOD CHEM, V47, P2274, DOI 10.1021/jf9811065; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Hollman PCH, 1997, FEBS LETT, V418, P152, DOI 10.1016/S0014-5793(97)01367-7; HOLLMAN PCH, 1995, AM J CLIN NUTR, V62, P1276, DOI 10.1093/ajcn/62.6.1276; Hollman PCH, 1996, FREE RADICAL BIO MED, V21, P703, DOI 10.1016/0891-5849(96)00129-3; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; IARC, 1999, IARC MON EV CARC RIS, P1597; Ishikawa Y, 1999, J AM SOC NEPHROL, V10, P2290; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Juurlink BHJ, 1999, NEUROTOX RES, V1, P119, DOI 10.1007/BF03033276; Kamencic H, 2000, ANAL BIOCHEM, V286, P35, DOI 10.1006/abio.2000.4765; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kobuchi H, 1999, AM J PHYSIOL-CELL PH, V277, pC403, DOI 10.1152/ajpcell.1999.277.3.C403; Lucisano-Valim YM, 2002, J PHARMACOL TOX MET, V47, P53, DOI 10.1016/S1056-8719(02)00206-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moon JH, 2000, AM J PHYSIOL-REG I, V279, pR461, DOI 10.1152/ajpregu.2000.279.2.R461; Myhrstad MCW, 2002, FREE RADICAL BIO MED, V32, P386, DOI 10.1016/S0891-5849(01)00812-7; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; PAGONIS C, 1986, BIOCHEM PHARMACOL, V35, P237, DOI 10.1016/0006-2952(86)90520-4; Peet GW, 1999, J BIOL CHEM, V274, P32655, DOI 10.1074/jbc.274.46.32655; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PINCEMAIL J, 1988, EXPERIENTIA, V44, P450, DOI 10.1007/BF01940544; Raby CA, 1998, J NEUROCHEM, V71, P2505; Reiterer G, 2004, J NUTR, V134, P771, DOI 10.1093/jn/134.4.771; Rodrigues MR, 2002, BIOCHEM BIOPH RES CO, V292, P869, DOI 10.1006/bbrc.2002.6724; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schultke E, 2003, J NEUROTRAUM, V20, P583, DOI 10.1089/089771503767168500; Selloum L, 2001, ARCH BIOCHEM BIOPHYS, V395, P49, DOI 10.1006/abbi.2001.2562; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; THART BA, 1990, CHEM-BIOL INTERACT, V73, P323, DOI 10.1016/0009-2797(90)90012-C; Tian GF, 2000, J NEUROPHYSIOL, V83, P1830, DOI 10.1152/jn.2000.83.4.1830; TORDERA M, 1994, Z NATURFORSCH C, V49, P235; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Uda Y, 1997, CANCER LETT, V120, P213, DOI 10.1016/S0304-3835(97)00311-X; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Valerio LG, 2001, TOXICOL LETT, V119, P49, DOI 10.1016/S0378-4274(00)00302-7; Wang LM, 2002, NEPHRON, V91, P142, DOI 10.1159/000057616; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; Williamson G, 1996, CARCINOGENESIS, V17, P2385, DOI 10.1093/carcin/17.11.2385; Winterbourn CC, 2000, FREE RADICAL BIO MED, V29, P403, DOI 10.1016/S0891-5849(00)00204-5; Yannai S, 1998, FOOD CHEM TOXICOL, V36, P623, DOI 10.1016/S0278-6915(98)00022-2; Yoshino M, 1998, ANAL BIOCHEM, V257, P40, DOI 10.1006/abio.1997.2522; Yoshizumi M, 2001, MOL PHARMACOL, V60, P656	77	45	50	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1475	1484		10.1089/neu.2005.22.1475			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500009	16379584				2022-02-06	
J	van Donkelaar, P; Langan, J; Rodriguez, E; Drew, A; Halterman, C; Osternig, LR; Chou, LS				van Donkelaar, P; Langan, J; Rodriguez, E; Drew, A; Halterman, C; Osternig, LR; Chou, LS			Attentional deficits in concussion	BRAIN INJURY			English	Article						concussion; attention; ANT; reaction time	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; CLOSED-HEAD INJURY; SPATIAL ATTENTION; RIGHT-HEMISPHERE; REACTION-TIME; PARIETAL; CONFLICT; CORTEX; SYMPTOMS	Primary objective: The purpose of the present study was to examine deficits in the alerting, orienting and executive components of attention in individuals who have recently suffered a concussion. Research design: A group design was used in which the performance by individuals with concussion was compared to control subjects matched for age, height, weight and activity level. Methods and procedures: Participants completed the Attentional Network Test ( ANT) that breaks down attention into alerting, orienting and executive components. Reaction time and response accuracy were the dependent variables. Main outcomes and results: It was found that only the orienting and executive components of attention were affected by concussion, whereas the alerting component was normal. Furthermore, participants with concussion required a significantly longer time than controls to initiate correct responses. Conclusions: These results suggest that the orienting and executive components of attention are most susceptible to the effects of concussion.	Univ Oregon, Inst Neurosci, Dept Human Physiol, Eugene, OR 97403 USA		van Donkelaar, P (corresponding author), Univ Oregon, Inst Neurosci, Dept Human Physiol, 122C Esslinger Hall, Eugene, OR 97403 USA.	paulvd@darkwing.uoregon.edu	Rodriguez-Torres, Erika Elizabeth/A-3843-2019	Rodriguez-Torres, Erika Elizabeth/0000-0002-7738-1863; Langan, Jeanne/0000-0003-1417-2180	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49CCR 021735-01] Funding Source: Medline		Casey BJ, 2000, P NATL ACAD SCI USA, V97, P8728, DOI 10.1073/pnas.97.15.8728; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fan J, 2003, NEUROIMAGE, V18, P42, DOI 10.1006/nimg.2002.1319; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Giza CC, 2001, J ATHL TRAINING, V36, P228; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; LANGAN J, 2003, SOC NEUR ABSTR, P363; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; Nobre AC, 2004, J COGNITIVE NEUROSCI, V16, P363, DOI 10.1162/089892904322926700; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, NEUROPSYCHOLOGIA, V25, P135, DOI 10.1016/0028-3932(87)90049-2; Ruff RM, 1999, BRAIN INJURY, V13, P943; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Sturm W, 1999, NEUROPSYCHOLOGIA, V37, P797, DOI 10.1016/S0028-3932(98)00141-9; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; Vandenberghe R, 2001, NEUROIMAGE, V14, P661, DOI 10.1006/nimg.2001.0860; Weissman DH, 2003, NEUROIMAGE, V19, P1361, DOI 10.1016/S1053-8119(03)00167-8; Yantis S, 2002, NAT NEUROSCI, V5, P995, DOI 10.1038/nn921	32	45	45	1	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2005	19	12					1031	1039		10.1080/02699050500110363			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	983ZA	WOS:000233269700010	16263646				2022-02-06	
J	Brown, TH; Mount, J; Rouland, BL; Kautz, KA; Barnes, RM; Kim, J				Brown, TH; Mount, J; Rouland, BL; Kautz, KA; Barnes, RM; Kim, J			Body weight-supported treadmill training versus conventional gait training for people with chronic traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						body weight support; gait training; head injury; physical therapy; rehabilitation; traumatic brain injury; treadmill	LOCOMOTION; RELIABILITY; RECOVERY	Objectives: To compare body weight support treadmill training (BWSTT) to conventional over-ground gait training (COGT). Design: Randomized controlled trial. Setting: Residential rehabilitation center. Participants: Twenty subjects with chronic traumatic brain injury (TBI). Intervention: The BWSTT or COGT for 15 minutes plus 30 minutes of exercise 2 days per week, for 3 months. Main Outcome Measures: Functional Ambulation Category (FAC), Functional Reach (FR), Timed Up and Go; gait velocity, step width (BOS) and step length differential using instrumented gait mat. Results: Step width approached the norm Without between-group differences. Step length differential improved significantly more for the COGT Conclusions: Physical therapy can improve gait for patients more than 6 years post-TBL. The COGT is more effective than the BWSTT for improving gait symmetry during overground walking.	Beechwood Rehabil Serv, Dept Phys Therapy, Langhorne, PA 19047 USA; Thomas Jefferson Univ, Coll Hlth Profess, Dept Phys Therapy, Philadelphia, PA 19107 USA		Brown, TH (corresponding author), Beechwood Rehabil Serv, Dept Phys Therapy, Langhorne, PA 19047 USA.						BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Gardner MB, 1998, PHYS THER, V78, P361, DOI 10.1093/ptj/78.4.361; Grillner S, 1979, Prog Brain Res, V50, P227; Hassid E, 1997, J NEUROL REHABIL, V11, P21; HEITMANN DK, 1989, PHYS THER, V69, P923, DOI 10.1093/ptj/69.11.923; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HESSE S, 1994, ARCH PHYS MED REHAB, V75, P1087, DOI 10.1016/0003-9993(94)90083-3; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; McDonough AL, 2001, ARCH PHYS MED REHAB, V82, P419, DOI 10.1053/apmr.2001.19778; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Miller EW, 2002, PHYS THER, V82, P53, DOI 10.1093/ptj/82.1.53; Miyai I, 2000, ARCH PHYS MED REHAB, V81, P849, DOI 10.1053/apmr.2000.4439; Moseley A, 2003, COCHRANE DB SYST REV; Murray M P, 1970, Arch Phys Med Rehabil, V51, P637; MURRAY MP, 1964, J BONE JOINT SURG AM, V46, P335, DOI 10.2106/00004623-196446020-00009; Nymark J, 1998, J NEUROL REHABIL, V12, P119; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; OSULLIVAN S, 1994, PHYS REHABILITATION, P454; Perry J, 1992, GAIT ANAL NORMAL PAT, P432; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; ROVNER BW, 1987, HOSP PRACT, V22, P99; Schindl MR, 2000, ARCH PHYS MED REHAB, V81, P301, DOI 10.1053/apmr.2000.0810301; Seif-Naraghi AH, 1999, J HEAD TRAUMA REHAB, V14, P146, DOI 10.1097/00001199-199904000-00005; SHUMWAYCOOK A, 1995, MOTOR CONTROL THEORY, P198; Stolze H, 2002, J NEUROL NEUROSUR PS, V73, P310, DOI 10.1136/jnnp.73.3.310; Sullivan KJ, 2002, ARCH PHYS MED REHAB, V83, P683, DOI 10.1053/apmr.2002.32488; VISINTIN M, 1994, PARAPLEGIA, V32, P540, DOI 10.1038/sc.1994.86; VISINTIN M, 1989, CAN J NEUROL SCI, V16, P315, DOI 10.1017/S0317167100029152; WERNIG A, 1995, EUR J NEUROSCI, V7, P823, DOI 10.1111/j.1460-9568.1995.tb00686.x; Wilson DJ, 2002, BRAIN INJURY, V16, P259, DOI 10.1080/02699050110103922	36	45	47	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2005	20	5					402	415		10.1097/00001199-200509000-00002			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	965NO	WOS:000231957600003	16170249				2022-02-06	
J	Gagnon, I; Swaine, B; Friedman, D; Forget, R				Gagnon, I; Swaine, B; Friedman, D; Forget, R			Exploring children's self-efficacy related to physical activity performance after a mild traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	7th Annual Conference of the Euroacademia Multidisciplinaria Neurotraumatologica	JUN, 2002	Newcastle upon Tyne, ENGLAND			adolescents; children; physical activity; self-efficacy; traumatic brain injury	ACTIVITY QUESTIONNAIRE; VALIDATION; PEOPLE; SCALE	Objective: To evaluate children's self-efficacy related to their practice of physical activities prior to and after a mild traumatic brain injury (mTBI), and compare these to those of noninjured children matched for age, sex, and premorbid level of physical activity. Participants and Methods: Thirty-four children (mean age: 12 +/- 3 years) in each group. Children with mTBI were assessed I day postinjury (to document preinjury status) and at 12 weeks post-mTBI using a self-efficacy questionnaire, the Physical Activity Questionnaire, the Athletic Competence subscale of the Self-Perception Profile for Children or Adolescents, and the Rivermead Post-Concussion Symptoms Questionnaire. Noninjured children underwent the same assessments at a corresponding time interval. Results: At 12 weeks postinjury, self-efficacy scores of children with mTBI were significantly lower than initial (ie, pretraumatic) values and those of noninjured children. The children with mTBI had, however, returned to their preinjury level of participation in physical activities and maintained their athletic competence. Conclusions: After mTBI, children appear to lack confidence in their ability to perform during physical activities as compared to before their injury, Intervention strategies such as information or counseling sessions targeting children and their parents may minimize the impact of the mTBI on children's confidence in their performance in physical activities.	McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada; Univ Montreal, Fac Med, Ecole Readapt, Montreal, PQ H3H 1P3, Canada; Montreal Metropolitain Site Inst Readapt Montreal, Ctr Rech Interdisciplinaire Readapt, Montreal, PQ, Canada		Gagnon, I (corresponding author), McGill Univ, Ctr Hlth, Montreal Childrens Hosp, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.	Isabelle.gagnon6@sympatico.ca		Gagnon, Isabelle/0000-0003-2043-1644			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bandura A, 1986, SOCIAL FDN THOUGHT A; Bass B. L., 2005, J APPL SPORT PSYCHOL, V78, P155, DOI DOI 10.1080/10413209008406426; Crocker PRE, 1997, MED SCI SPORT EXER, V29, P1344, DOI 10.1097/00005768-199710000-00011; Dilorio C, 1992, J Neurosci Nurs, V24, P9; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Gagnon I, 2001, J HEAD TRAUMA REHAB, V16, P595, DOI 10.1097/00001199-200112000-00007; GAGNON I, 2002, ARCH PHYS MED REHAB, V83, P1481; GAGNON I, 2002, NEROREHABIL NEURAL R, V16, P22; HARTER S, 1982, CHILD DEV, V53, P87, DOI 10.1111/j.1467-8624.1982.tb01295.x; Harter S., 1988, MANUAL SELF PERCEPTI; Harter S., 1985, MANUAL SELF PERCEPTI; Kelly JP, 1997, NEUROLOGY, V48, P581; KILGORE JM, 1998, INVESTIGATION EFFECT; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kowalski KC, 1997, PEDIATR EXERC SCI, V9, P342, DOI 10.1123/pes.9.4.342; Kowalski KC, 1997, PEDIATR EXERC SCI, V9, P174, DOI 10.1123/pes.9.2.174; Levin HS, 1996, NEUROTRAUMA, P749; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; Maehr M. L., 1984, ADV MOTIVATION ACHIE, V3, P219; MAIBACH E, 1995, HEALTH EDUC RES, V10, P37, DOI 10.1093/her/10.1.37; SALLIS JF, 1993, MED SCI SPORT EXER, V25, P99, DOI 10.1249/00005768-199301000-00014; SALLIS JF, 1988, AM J EPIDEMIOL, V127, P933, DOI 10.1093/oxfordjournals.aje.a114896; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P394, DOI 10.1016/S0003-9993(96)90091-X; Streiner D.L., 1989, HLTH MEASUREMENT SCA; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008	27	45	45	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2005	20	5					436	449		10.1097/00001199-200509000-00005			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Neurosciences & Neurology; Rehabilitation	965NO	WOS:000231957600006	16170252				2022-02-06	
J	Clausen, T; Alves, OL; Reinert, M; Doppenberg, E; Zauner, A; Bullock, R				Clausen, T; Alves, OL; Reinert, M; Doppenberg, E; Zauner, A; Bullock, R			Association between elevated brain tissue glycerol levels and poor outcome following severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						glycerol; oxygenation; cerebral perfusion pressure; traumatic brain injury; microdialysis; multimodal monitoring	CEREBRAL PERFUSION-PRESSURE; MEMBRANE PHOSPHOLIPID DEGRADATION; HUMAN HEAD-INJURY; INTERSTITIAL GLYCEROL; FREE-RADICALS; SUBDURAL-HEMATOMA; OXYGEN-TENSION; ACID RELEASE; RAT-BRAIN; MICRODIALYSIS	Object. Glycerol is considered to be a marker of cell membrane degradation and thus cellular lysis. Recently, it has become feasible to measure via microdialysis cerebral extracellular fluid (ECF) glycerol concentrations at the patient's bedside. Therefore the aim of this study was to investigate the ECF concentration and time course of glycerol after severe traumatic brain injury (TBI) and its relationship to patient outcome and other monitoring parameters. Methods. As soon as possible after injury for up to 4 days, 76 severely head-injured patients were monitored using a microdialysis probe (cerebral glycerol) and a Neurotrend sensor (brain tissue PO,) in uninjured brain tissue confirmed by computerized tomography scanning. The mean brain tissue glycerol concentration in all monitored patients decreased significantly from 206 +/- 31 mu mol/L on Day 1 to 9 +/- 3 mu mol/L on Day 4 after injury (p < 0.0001). Note, however, that there was no significant difference in the time course between patients with a favorable outcome (Glasgow Outcome Scale [GOS] Scores 4 and 5) and those with an unfavorable outcome (GOS Scores 1-3). Significantly increased glycerol concentrations were observed when brain tissue PO2 was less than 10 mm Hg or when cerebral perfusion pressure was less than 70 mm Hg. Conclusions. Based on results in the present study one can infer that microdialysate glycerol is a marker of severe tissue damage, as seen immediately after brain injury or during profound tissue hypoxia. Given that brain tissue glycerol levels do not yet add new clinically significant information, however, routine monitoring of this parameter following traumatic brain injury needs further validation.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Univ Halle Wittenberg, Dept Anesthesiol & Intens Care Med, Halle Saale, Germany; Univ Porto, Fac Med, Ctr Hosp Gaia, Serv Neurocirurg, Oporto, Portugal; Inselspital Bern, Dept Neurosurg, CH-3010 Bern, Switzerland; Univ Miami, Lois Pope Life Ctr, Dept Neurosurg, Miami, FL 33152 USA		Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.	robulloc@hsc.vcu.edu	Reinert, Michael/AAA-3929-2019; Reinert, Michael/E-4964-2011	Reinert, Michael/0000-0002-0971-9543; 	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [12587] Funding Source: Medline		ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; Alessandri B, 1999, ACT NEUR S, V75, P21; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Berger C, 1999, STROKE, V30, P460, DOI 10.1161/01.STR.30.2.460; BERTRAND N, 1992, NEUROSCI LETT, V148, P81, DOI 10.1016/0304-3940(92)90809-L; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; Chesnut R M, 1995, New Horiz, V3, P366; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; Farooqui AA, 2001, BRAIN RES REV, V38, P61, DOI 10.1016/S0169-328X(01)00214-5; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Gasparovic C, 1998, J NEUROCHEM, V71, P1727; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Grande P O, 1997, Acta Anaesthesiol Scand Suppl, V110, P36; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJA, 2000, ZBL NEUROCHIR, V61, P88, DOI 10.1055/s-2000-8265; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; Lang E W, 1995, New Horiz, V3, P400; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lipton SA, 1998, CELL CALCIUM, V23, P165, DOI 10.1016/S0143-4160(98)90115-4; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; MUIZELAAR JP, 1995, J NEUROSURG, V83, P942; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; Peerdeman SM, 2003, INTENS CARE MED, V29, P1825, DOI 10.1007/s00134-003-1850-8; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1995, ANN THORAC SURG, V59, P1316, DOI 10.1016/0003-4975(95)00077-X; Stahl N, 2003, ACTA NEUROL SCAND, V108, P211, DOI 10.1034/j.1600-0404.2003.00095.x; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P507; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	41	45	46	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2005	103	2					233	238		10.3171/jns.2005.103.2.0233			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	957KI	WOS:000231368300007	16175851				2022-02-06	
J	Coughlan, T; Gibson, C; Murphy, S				Coughlan, T; Gibson, C; Murphy, S			Modulatory effects of progesterone on inducible nitric oxide synthase expression in vivo and in vitro	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; inducible nitric oxide synthase; neuroprotection; progesterone; progesterone response element; transcription	HORMONE REPLACEMENT THERAPY; TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY OCCLUSION; BREAST-CANCER CELLS; INTERFERON-GAMMA; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; BACTERIAL LIPOPOLYSACCHARIDE; MURINE MACROPHAGES; RECEPTOR ISOFORMS	Nitric oxide (NO) is produced in the CNS following injury-induced expression of inducible nitric oxide synthase (iNOS), yet its role as protective or damaging is unclear. Previous studies investigating the therapeutic potential of female sex steroids in stroke and trauma suggest that NO from this source is harmful, since oestradiol and progesterone decreased the level of iNOS expression in vitro and improved neurological outcome. We investigated the effects of progesterone on stroke-induced expression of iNOS in mice, as well as cytokine-induced expression of iNOS and its transcriptional activators in cells relevant to injury. We observed a significant reduction in stroke-induced iNOS transcript in progesterone-treated mice and in cultured macrophages. In contrast, progesterone significantly amplifed cytokine-induced iNOS mRNA in cultured primary astrocytes, although the expression of protein was decreased. We sequenced upstream of the 1.5 kb reported iNOS promoter region and identified a potential progesterone response element (PRE). Astrocytes transiently transfected with iNOS promoter/CAT reporter gene constructs containing the PRE displayed a significant increase in induction of CAT expression after progesterone treatment, and this was diminished in cells transfected with a construct containing a disrupted PRE. These observations suggest the involvement of iNOS in the neuroprotective effects of progesterone.	Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England		Murphy, S (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Clifton Blvd, Nottingham NG7 2UH, England.	sean.murphy@nottingham.ac.uk			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029226] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29226] Funding Source: Medline		Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Bechtel MK, 2001, GYNECOL ONCOL, V82, P127, DOI 10.1021/gyno.2001.6221; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bushnell CD, 2001, NEUROLOGY, V56, P1304, DOI 10.1212/WNL.56.10.1304; Camacho-Arroyo I, 1998, NEUROREPORT, V9, P3993, DOI 10.1097/00001756-199812210-00001; Cheng KW, 2001, MOL ENDOCRINOL, V15, P2078, DOI 10.1210/me.15.12.2078; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Garcia-Duran M, 1999, CIRC RES, V85, P1020; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; GIBSON CL, 2004, 34372004 SOC NEUR; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Guo FQ, 2003, SCIENCE, V302, P100, DOI 10.1126/science.1086770; Hayashi T, 1998, J CARDIOVASC PHARM, V31, P292, DOI 10.1097/00005344-199802000-00016; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kassel O, 1998, MOL PHARMACOL, V54, P1073, DOI 10.1124/mol.54.6.1073; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kauser K, 1998, BRIT J PHARMACOL, V123, P1089, DOI 10.1038/sj.bjp.0701715; Kohmura Y, 2000, INT J IMMUNOPHARMACO, V22, P765, DOI 10.1016/S0192-0561(00)00038-2; Kouretas D, 1999, CELL MOL BIOL, V45, P219; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Li XT, 2003, J BIOL CHEM, V278, P39261, DOI 10.1074/jbc.R300024200; Lieb K, 2003, NEUROCHEM INT, V42, P131, DOI 10.1016/S0197-0186(02)00076-1; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; Loihl AK, 1999, J BIOL CHEM, V274, P8844, DOI 10.1074/jbc.274.13.8844; Loihl AK, 1999, BRAIN RES, V830, P155, DOI 10.1016/S0006-8993(99)01388-8; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LUSS H, 1994, BIOCHEM BIOPH RES CO, V204, P635, DOI 10.1006/bbrc.1994.2506; Miller L, 1996, J LEUKOCYTE BIOL, V59, P442, DOI 10.1002/jlb.59.3.442; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; Neugarten J, 1997, J AM SOC NEPHROL, V8, P1240; Nuedling S, 1999, CARDIOVASC RES, V43, P666, DOI 10.1016/S0008-6363(99)00093-0; Pedersen AT, 1997, LANCET, V350, P1277, DOI 10.1016/S0140-6736(97)06005-4; Perusquia M, 1996, GEN PHARMACOL, V27, P181, DOI 10.1016/0306-3623(95)00091-7; Petitti DB, 1998, STROKE, V29, P23, DOI 10.1161/01.STR.29.1.23; Prefontaine GG, 1999, J BIOL CHEM, V274, P26713, DOI 10.1074/jbc.274.38.26713; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rowan BG, 2000, STEROIDS, V65, P545, DOI 10.1016/S0039-128X(00)00112-4; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Taylor BS, 1997, ARCH SURG-CHICAGO, V132, P1177; Weisz A, 1996, BIOCHEM J, V316, P209, DOI 10.1042/bj3160209; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Xu R, 1999, LIFE SCI, V64, P2451, DOI 10.1016/S0024-3205(99)00202-7; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; Yamamoto T, 2001, MOL CELL ENDOCRINOL, V182, P215, DOI 10.1016/S0303-7207(01)00580-9; Zancan V, 1999, ENDOCRINOLOGY, V140, P2004, DOI 10.1210/en.140.5.2004; Zemojtel T, 2004, TRENDS BIOCHEM SCI, V29, P224, DOI 10.1016/j.tibs.2004.03.005; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	71	45	48	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2005	93	4					932	942		10.1111/j.1471-4159.2005.03068.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	920WB	WOS:000228721200015	15857396				2022-02-06	
J	Zebrack, M; Kadish, H; Nelson, D				Zebrack, M; Kadish, H; Nelson, D			The pediatric hybrid observation unit: An analysis of 6477 consecutive patient encounters	PEDIATRICS			English	Article						emergency department; emergency medicine; hospitalization; pediatric; observation unit	DEPARTMENT OBSERVATION UNIT; OBSERVATION MEDICINE; OBSERVATION WARD; SHORT-STAY; EMERGENCY; MANAGEMENT; DESIGN; CARE	Objectives. Pediatric observation units (OUs) are becoming more common in hospitals throughout the United States, providing physicians with a new disposition option for children who are judged to be too ill for home management. Some OUs function as "hybrid" units, serving both acutely ill and injured observation patients as well as scheduled elective procedure patients. How best to utilize this new resource is not yet defined. We studied the utilization of our pediatric hybrid OU during the first 2 years of operation to determine ( 1) the spectrum and frequency of diagnoses treated, ( 2) diagnoses and procedures most ( and least) likely to attain discharge successfully within 24 hours, and ( 3) whether age was associated with inability to be discharged from the OU within 24 hours. Methods. The study setting was a 20-bed hybrid OU located in a pediatric tertiary care hospital in Salt Lake City, Utah. The records of all patients admitted during the first 2 years of OU operation, from August 1999 through July 2001, were examined retrospectively. Results. There were 6477 OU admissions: 4189 (65%) for acutely ill and injured observation patients and 2288 (35%) for scheduled elective procedure patients. For the observation patients, median age was 2.5 years and median length of stay was 15.5 hours. Common admission diagnoses in these patients included enteritis/dehydration (n = 722), orthopedic injuries ( n = 362), asthma ( n = 327), closed head injury ( n = 289), urgent transfusion/ infusion ( n = 221), bronchiolitis ( n = 212), croup ( n = 207), abdominal pain ( n = 199), cellulitis ( n = 177), and nonfebrile seizure ( n = 98). Overall, 15% of observation patients required subsequent inpatient admission for > 24-hour stay. Observation diagnoses that were most likely to require inpatient admission were hematochezia (60%), viral pneumonia (46%), and bronchiolitis (43%). We demonstrated successful OU discharge rates (> 85%) for several diagnoses not commonly reported: neonatal hyperbilirubinemia, aseptic meningitis, and diabetic ketoacidosis in the patient with known diabetes. Among the scheduled elective procedure patients, median age was 5.0 years and median length of stay was 3.0 hours. Only 1% of these patients required subsequent inpatient admission. In both populations, age <= 30 days was associated with increased need for inpatient admission, with a relative risk of 1.9 (95% confidence interval: 1.4 - 2.6) among the observation patients and 13.9 (95% confidence interval: 3.0 - 65.0) among scheduled procedure patients. Conclusion. Our pediatric hybrid OU played an important role in the treatment of children who were admitted for observation as a result of acute illness or injury, as well as children who required scheduled procedures. For both patient types, we identified diagnoses that are most and least likely to attain successful discharge within 24 hours. The majority (85%) of observation patients were discharged successfully within 24 hours. Successful discharge rates for diagnoses that are not commonly managed in other pediatric OUs were reported. We identified certain age groups within selected diagnoses that may not have been appropriate for the OU.	Univ Utah, Primary Childrens Med Ctr, Div Pediat Emergency Med, Salt Lake City, UT 84113 USA		Zebrack, M (corresponding author), Univ Utah, Primary Childrens Med Ctr, Div Pediat Emergency Med, 100 N Med Dr, Salt Lake City, UT 84113 USA.	michelle.zebrack@hsc.utah.edu					*ACEP PRACT MAN CO, 1994, MAN OBS UN; BOBZIEN WF, 1979, JACEP-J AM COLL EMER, V8, P508, DOI 10.1016/S0361-1124(79)80296-8; Browne GJ, 2000, PEDIATR EMERG CARE, V16, P223, DOI 10.1097/00006565-200008000-00001; DAWSON KP, 1991, NEW ZEAL MED J, V104, P185; DeCoster C, 1996, MANITOBA CTR HLTH PO; FARRELL RG, 1982, ANN EMERG MED, V11, P353, DOI 10.1016/S0196-0644(82)80360-0; HENNEMAN PL, 1989, ANN EMERG MED, V18, P647, DOI 10.1016/S0196-0644(89)80519-0; *HLTH CAR FIN ADM, MED HOSP MAN TRANSM; Holsti M, 2003, ANN EMERG MED, V42, pS85; Johnson ME, 2002, AEROSPACE AM, V40, P76; KLEIN B L, 1991, Emergency Medicine Clinics of North America, V9, P669; Lateef F, 2000, AM J EMERG MED, V18, P629, DOI 10.1053/ajem.2000.9291; Mace SE, 2003, AM J EMERG MED, V21, P529, DOI 10.1016/j.ajem.2003.08.012; Mace SE, 2001, EMERG MED CLIN N AM, V19, P239, DOI 10.1016/S0733-8627(05)70178-4; MACE SE, 1999, OBS MED RED COSTS UN; MALLORY MD, 2003, PED AC SOC ANN M MAY; Miescier MJ, 2003, ANN EMERG MED, V42, pS107; NUMA A, 1991, MED J AUSTRALIA, V155, P395, DOI 10.5694/j.1326-5377.1991.tb101318.x; Rentz AC, 2004, PEDIATR EMERG CARE, V20, P430, DOI 10.1097/01.pec.0000132214.19858.71; Ross MA, 2001, EMERG MED CLIN N AM, V19, P1, DOI 10.1016/S0733-8627(05)70165-6; Ross MA, 2001, ANN EMERG MED, V37, P267, DOI 10.1067/mem.2001.111519; Rydman RJ, 1998, MED CARE, V36, P599, DOI 10.1097/00005650-199804000-00015; Scribano PV, 2001, PEDIATR EMERG CARE, V17, P321, DOI 10.1097/00006565-200110000-00001; Wiley JF, 1998, PEDIATR EMERG CARE, V14, P444, DOI 10.1097/00006565-199812000-00019; Wiley JF, 2001, CLIN PEDIAT EMERG ME, V2, P247; Zebrack MM, 2003, ANN EMERG MED, V42, pS87; ZUN L, 1990, Journal of Emergency Medicine, V8, P485, DOI 10.1016/0736-4679(90)90180-4	27	45	45	0	1	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAY	2005	115	5					E535	E542		10.1542/peds.2004-0391			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	922JM	WOS:000228833500005	15867018				2022-02-06	
J	Lehtonen, S; Stringer, AY; Millis, S; Boake, C; Englander, J; Hart, T; High, W; Macciocchi, S; Meythaler, J; Novack, T; Whyte, J				Lehtonen, S; Stringer, AY; Millis, S; Boake, C; Englander, J; Hart, T; High, W; Macciocchi, S; Meythaler, J; Novack, T; Whyte, J			Neuropsychological outcome and community re-integration following traumatic brain injury: The impact of frontal and non-frontal lesions	BRAIN INJURY			English	Article						TBI; lesion location; neuropsychological outcome; community re-integration	CLOSED-HEAD-INJURY; SORTING TEST-PERFORMANCE; DIFFUSE AXONAL INJURY; PRACTICAL SCALE; FOCAL LESIONS; LOBE DAMAGE; CT; SPECT; MR; SEVERITY	Primary objective: To examine the relationship between cortical lesion location and brain injury outcome. It was hypothesized that focal frontal lesions after traumatic brain injury (TBI) would result in decreased executive and memory functioning and poor community participation outcome. Research design: Three quasi-experimental, prospective studies employed a total of 643 patients with focal frontal, frontotemporal, non-frontal or no lesions in CT scans. Methods and procedures: CT scan analysis, neuropsychological assessment, the Neurobehavioural Functioning Inventory (NFI), the Community Integration Questionnaire (CIQ). Main results: In study 1, frontal and fronto-temporal groups performed worse in executive functioning and better in constructional ability. Study 2 found no differences in neuropsychological and community re-integration measures at 1-year follow-up. Study 3 found comparable neuropsychological test score improvement across groups over 1 year. Conclusions: Results are consistent with previous findings and document the potential for test score improvement with rehabilitation and suggest that lesion location needs to be considered when individual rehabilitation plans are being implemented in the post-acute stage of TBI.	Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Brain Injury Res Ctr, Houston, TX USA; Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Moss Rehabil Res Inst, Philadelphia, PA USA; Shepherd Ctr, Atlanta, GA USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA		Stringer, AY (corresponding author), Emory Univ, Dept Rehabil Med, 1441 Clifton Rd NE, Atlanta, GA 30322 USA.	astring@emory.edu		Whyte, John/0000-0002-4381-1474			ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; De Renzi E., 1982, DISORDERS SPACE EXPL; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; FORMISANO R, 1991, ACTA NEUROCHIR, V109, P1, DOI 10.1007/BF01405688; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Hamsher K., 1989, MULTILINGUAL APHASIA; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton RK, 1991, COMPREHENSIVE NORMS; HUBERTY CJ, 1989, PSYCHOL BULL, V105, P302, DOI 10.1037/0033-2909.105.2.302; ICHISE M, 1994, J NUCL MED, V35, P217; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P171; LUCAS JA, 1998, CLIN NEUROPSYCHOLOGY, P243; Matthews CG., 1964, INSTRUCTION MANUAL A; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Miller GA, 2001, J ABNORM PSYCHOL, V110, P40, DOI 10.1037//0021-843X.110.1.40; Millis S R, 1994, Int J Neurosci, V79, P165; Milner B, 1963, ARCH NEUROL-CHICAGO, V9, P100, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; MITTL RL, 2000, AM J NEURORADIOL, V15, P808; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; PRAYER L, 1993, ACTA RADIOL, V34, P593; Raininko R K, 1986, Acta Radiol Suppl, V369, P374; Rey A., 1964, EXAMEN CLIN PSYCHOL; ROSENTHAL M, 1993, J HEAD TRAUMA REHABI, V8; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Stringer A. Y., 1996, GUIDE ADULT NEUROPSY; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; TEASDALE G, 1974, LANCET, V2, P81; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VILKKI J, 1988, CORTEX, V24, P119, DOI 10.1016/S0010-9452(88)80020-0; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wechsler D., 1981, WAIS R MANUAL; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILSON J T L, 1990, Brain Injury, V4, P349	49	45	48	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2005	19	4					239	256		10.1080/0269905040004310			18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	917MN	WOS:000228466400002	15832870				2022-02-06	
J	Loy, DN; Sroufe, AE; Pelt, JL; Burke, DA; Cao, QL; Talbott, JF; Whittemore, SR				Loy, DN; Sroufe, AE; Pelt, JL; Burke, DA; Cao, QL; Talbott, JF; Whittemore, SR			Serum biomarkers for experimental acute spinal CORD injury: Rapid elevation ofneuron-specific enolase and S-100 beta	NEUROSURGERY			English	Article						adult rat; biomarkers; neuron-specific enolase; S-100 beta; spinal cord injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; TRAUMATIC BRAIN-INJURY; ACUTE STROKE; ADULT-RAT; NEUROBIOCHEMICAL MARKERS; CARDIOPULMONARY BYPASS; EVOKED-POTENTIALS; DAMAGE MARKERS; PROTEIN	OBJECTIVE: We evaluated whether serum levels of neuron-specific enolase (NSE) and S-100beta protein are biomarkers for traumatic injury in an animal model of spinal cord injury (SCI). METHODS: Enzyme-linked immunosorbent assay serum measurements of NSE and S-100beta and assays of serum protein were compared at 6 and 24 hours after a graded contusive SCI (150 or 200 kdyn IH impactor injury (Infinite Horizons, L.L.C., Lexington, KY) or sham laminectomy at T9 in 30 female Sprague-Dawley rats. Serum from control animals was also analyzed. RESULTS: Increases in serum levels of NSE were observed for 200-kdyn (3.1 -fold,:P <0.001) and 150-kdyn (2.3-fold, P < 0.001) injury groups at 6 hours after injury, which decreased by 73.7%, (P < 0.001). and 65.2% (P < 0.001) at 24 hours after SCI, respectively; the levels were still greater than in sham animals (P < 0.001, P,= 0.001)., The 200- and 150-kdyn injury groups were not different at either time point. S-100beta serum levels increased at 6 hours-in the 200-kdyn injury group (P <0.05), and no differences from sham levels, were seen at 24 hours. No differences in total protein concentrations were observed between the injury and control groups. CONCLUSION: Present data suggest that NSE and S-100beta serum,levels may, be useful, experimental tools for the acute measurement of tissue loss after SCI. Despite significant shortcomings, NSE and S-100beta serum measurements in acute, SCI patients with clinically defined functional deficits should allow, comparisons, with well-characterized SCI animal models. Future efforts to develop biomarkers that predict functional outcomes in the acute phase should focus on axon-specific proteins as markers of secondary axonal loss and regeneration.	Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; Univ Louisville, Sch Med, MD PhD Program, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA		Whittemore, SR (corresponding author), Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR 616, Louisville, KY 40292 USA.	swhittemore@louisville.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038665, U54NS039405] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR-15576] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-38665, NS-39405] Funding Source: Medline		Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; BALENTINE JD, 1977, ANN NEUROL, V2, P520, DOI 10.1002/ana.410020612; Bilgen M, 2000, MAGN RESON MED, V43, P594; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Burns AS, 2003, J NEUROTRAUM, V20, P477, DOI 10.1089/089771503765355540; Butterworth RJ, 1998, STROKE, V29, P730, DOI 10.1161/01.STR.29.3.730; Butterworth RJ, 1996, STROKE, V27, P2064, DOI 10.1161/01.STR.27.11.2064; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; CAO QL, IN PRESS EXP NEUROL; CHABOT R, 1985, J NEUROSURG, V63, P544, DOI 10.3171/jns.1985.63.4.0544; Cunningham RT, 1996, EUR J CLIN INVEST, V26, P298, DOI 10.1046/j.1365-2362.1996.129282.x; de Vries J, 2003, MINIM INVAS NEUROSUR, V46, P33, DOI 10.1055/s-2003-37963; de Vries J, 2001, J NEUROL NEUROSUR PS, V71, P671, DOI 10.1136/jnnp.71.5.671; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Ditunno J., 2002, SPINAL CORD MED, P108; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; Fan M, 2001, CELL MOL NEUROBIOL, V21, P497, DOI 10.1023/A:1013867306555; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Grossman SD, 2000, J NEUROCHEM, V75, P174, DOI 10.1046/j.1471-4159.2000.0750174.x; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; Hauben E, 2003, TRENDS PHARMACOL SCI, V24, P7, DOI 10.1016/S0165-6147(02)00013-5; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jonsson H, 1998, ANN THORAC SURG, V65, P1639, DOI 10.1016/S0003-4975(98)00229-X; KATZ RT, 1991, SPINE, V16, P730, DOI 10.1097/00007632-199107000-00007; KURIHARA M, 1985, J NEUROSURG, V62, P743, DOI 10.3171/jns.1985.62.5.0743; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Liu Cheng-long, 2003, Chin J Traumatol, V6, P18; Loy DN, 2002, EXP NEUROL, V177, P575, DOI 10.1006/exnr.2002.7959; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Loy DN, 2002, J NEUROSCI, V22, P315, DOI 10.1523/JNEUROSCI.22-01-00315.2002; Ma JJ, 2001, SCAND J PLAST RECONS, V35, P355; Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016; Marangos P J, 1980, Essays Neurochem Neuropharmacol, V4, P211; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Oh SH, 2002, YONSEI MED J, V43, P357, DOI 10.3349/ymj.2002.43.3.357; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; RIVLIN AS, 1978, J NEUROSURG, V49, P844, DOI 10.3171/jns.1978.49.6.0844; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Shepard MJ, 1999, SPINAL CORD, V37, P833, DOI 10.1038/sj.sc.3100927; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Toupalik P, 2001, Soud Lek, V46, P34; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x	66	45	53	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2005	56	2					391	396		10.1227/01.NEU.0000148906.83616.D2			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	895UO	WOS:000226889400041	15670387				2022-02-06	
J	Platz, T; Kim, IH; Engel, U; Pinkowski, C; Eickhof, C; Kutzner, M				Platz, T; Kim, IH; Engel, U; Pinkowski, C; Eickhof, C; Kutzner, M			Amphetamine fails to facilitate motor performance and to enhance recovery among stroke patients with mild arm paresis: Interim analysis and termination of a double blind, randomised, placedo-controlled trial	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						arm; stroke; rehabilitation; training; recovery; amphetamine; clinical trial	KINEMATIC MOTION ANALYSIS; TRAUMATIC BRAIN INJURY; PROGNOSTIC-FACTORS; PHYSIOTHERAPY	Purpose. To assess the effects of d-amphetamine on motor facilitation and recovery in stroke patients with mild arm paresis receiving the Arm Ability training. Methods. Thirty-one stroke patients with mild arm paresis were randomly assigned to either (a.) receiving placebo or (b.) d-amphetamine twice a week 2 hours before Arm Ability training sessions for three weeks. Main outcome measure: time needed to perform TEMPA tasks, a measure of upper extremity performance reflecting everyday life tasks. Secondary measures: aimed movements, tapping, and a 10 in walkway as well as motor performance during training sessions. Results: The interim efficacy analysis of 26 stroke patients who completed the study intervention showed overall ann motor recovery both from pre to post test after 3 weeks of training and from pre test to follow-up 1 year later. No superior effect of d-amphetamine over placebo could be substantiated for either motor facilitation during training or motor recovery (post training or long-term). D-amphetamine exerted mild effects on blood pressure. Serious adverse events were not observed. Conclusions. d-Amphetamine failed to facilitate motor performance during training sessions, to promote skill acquisition with training tasks, and most importantly to enhance motor recovery among patients with mild arm paresis after stroke.	Klin Berlin, Dept Neurol Rehabil, D-14089 Berlin, Germany; Segeberger Klin, Neurol Zentrum, Bad Segeberg, Germany		Platz, T (corresponding author), Klin Berlin, Dept Neurol Rehabil, Kladower Damm 223, D-14089 Berlin, Germany.	tplatz@zedat.fu-berlin.de		Platz, Thomas/0000-0003-2629-9744			BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Desrosiers J, 1993, CAN J OCCUP THER, V60, P9, DOI DOI 10.1177/000841749306000104; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gladstone DJ, 2004, STROKE, V35, P239; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P318; Hankey GJ, 2002, STROKE, V33, P1034, DOI 10.1161/01.STR.0000012515.66889.24; Martinsson L, 2003, CEREBROVASC DIS, V16, P338, DOI 10.1159/000072555; MARTINSSON L, 2004, COCHRANE LIB; Meijer R, 2003, CLIN REHABIL, V17, P119, DOI 10.1191/0269215503cr585oa; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; PLATZ T, 1994, NEUROPSYCHOLOGIA, V32, P1209, DOI 10.1016/0028-3932(94)90103-1; Platz T, 2004, RESTOR NEUROL NEUROS, V22, P301; Platz T, 2001, NEUROPSYCHOLOGIA, V39, P687, DOI 10.1016/S0028-3932(01)00005-7; Platz T, 2002, RESTOR NEUROL NEUROS, V20, P37; Platz T, 2001, ARCH PHYS MED REHAB, V82, P961, DOI 10.1053/apmr.2001.23982; Platz T, 1999, ARCH PHYS MED REHAB, V80, P270, DOI 10.1016/S0003-9993(99)90137-5; Schmidt R. A., 1999, MOTOR CONTROL LEARNI; Sonde L, 2001, CEREBROVASC DIS, V12, P253, DOI 10.1159/000047712; Treig T, 2003, CLIN REHABIL, V17, P590, DOI 10.1191/0269215503cr653oa; Unnebrink K, 2001, STAT MED, V20, P3931, DOI 10.1002/sim.1149.abs; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; WADE DT, 1992, MEASUREMENT NEUROLOG, P53; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254	25	45	46	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2005	23	5-6					271	280					10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	007HS	WOS:000234960200002	16477089				2022-02-06	
J	Starkstein, SE; Jorge, R				Starkstein, SE; Jorge, R			Dementia after traumatic brain injury	INTERNATIONAL PSYCHOGERIATRICS			English	Article						traumatic brain injury; dementia; cognition; Alzheimer's disease	AMYLOID PROTEIN DEPOSITION; CHILDHOOD HEAD-INJURY; ALZHEIMERS-DISEASE; RISK-FACTOR; CEREBROSPINAL-FLUID; EPISODIC MEMORY; WORKING-MEMORY; MILD; PERFORMANCE; ATTENTION	Early retrospective studies suggested that individuals with a history of a traumatic brain injury (TBI) had a higher risk for dementia than those without a history of TBI. Two meta-analyses demonstrated that the risk for dementia is higher among men, but not women, with a history of TBI. More recent prospective studies, however, are providing discrepant findings, probably due to important methodological differences. TBI is usually associated with significant neuropsychological deficits, primarily in the domains of attention, executive functioning and memory. These deficits may not improve with time. TBI may also lower the threshold for the clinical expression of dementia among predisposed individuals, and the onset of Alzheimer's disease (AD)like neuropathological and biochemical changes immediately after severe TBI may play an important role in this mechanism.	Fremantle Hosp, Fremantle, WA 6959, Australia; Univ Western Australia, Sch Psychiat & Clin Neurosci, Nedlands, WA 6009, Australia; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA		Starkstein, SE (corresponding author), Fremantle Hosp, Educ Bldg T-7, Fremantle, WA 6959, Australia.	ses@cyllene.uwa.edu.au					Alexander MP, 2003, BRAIN, V126, P1493, DOI 10.1093/brain/awg128; Alexander MP, 2000, SEMIN NEUROL, V20, P427, DOI 10.1055/s-2000-13175; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Burke R, 2004, BRAIN INJURY, V18, P497, DOI 10.1080/02699050310001645784; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Dritschel BH, 1998, BRAIN INJURY, V12, P875; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Isaki E, 2000, BRAIN INJURY, V14, P441; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jurado MA, 2000, BRAIN INJURY, V14, P789; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCDOWELL I, 1994, NEUROLOGY, V44, P2073; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Moran C, 2004, BRAIN INJURY, V18, P273, DOI 10.1080/02699050310001617415; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1147, DOI 10.1097/00005072-199911000-00004; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TULVING E, 1988, BRAIN COGNITION, V8, P3, DOI 10.1016/0278-2626(88)90035-8; Wheeler MA, 2003, CORTEX, V39, P827, DOI 10.1016/S0010-9452(08)70866-9; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	73	45	45	1	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1041-6102	1741-203X		INT PSYCHOGERIATR	Int. Psychogeriatr.		2005	17			1			S93	S107		10.1017/S1041610205001973			15	Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Geriatrics & Gerontology; Psychiatry	977WH	WOS:000232833700009	16240486				2022-02-06	
J	Broglio, SP; Guskiewicz, KM; Sell, TC; Lephart, SM				Broglio, SP; Guskiewicz, KM; Sell, TC; Lephart, SM			No acute changes in postural control after soccer heading	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; PLAYERS; CONCUSSION; STABILITY; FOOTBALL; BALANCE; SWAY; DEFICITS; IMPACT	Background: Soccer heading has been proposed as a potential cause of cerebral dysfunction. Objective: To examine the acute effects of two types of soccer heading on postural control. Methods: Collegiate soccer players were randomly assigned to one of four groups: control, linear heading, simulated rotational heading, or rotational heading. Each subject completed a baseline postural stability assessment on day 1. On day 2 the same assessment was completed for the control subjects. The simulated rotational heading group completed a simulated heading drill before postural stability testing. The linear and rotational heading groups performed a heading drill with 20 balls at 88.71 km/h (55 mph), before postural stability testing. Separate one between (group), three within (surface, eyes, and day), mixed model, repeated measures analyses of variance were conducted on values for total sway and mean centre of pressure. Results: The mixed model analysis of variance of results showed no significant differences (p > 0.05) for the interactions of interest for either variable. Results suggest no acute changes in measures of postural control in soccer players completing either a linear or rotational soccer heading drill of 20 balls at a fixed speed. Conclusion: Non-significant interactions between surface, eyes, day, and group indicate that sensory interaction of the balance mechanism components are not be compromised by the heading drill. This research supports previous studies suggesting that there are no acute risks associated with routine soccer heading. A direct comparison between these findings and those suggesting long term chronic deficits, however, cannot be made. Other studies that report chronic cerebral deficits in soccer players may have resulted from factors other than soccer heading and warrant further examination.	Univ Pittsburgh, Pittsburgh, PA USA; Univ N Carolina, Chapel Hill, NC USA		Broglio, SP (corresponding author), Univ Georgia, Ramsey Ctr, 300 River Rd, Athens, GA 30602 USA.	sbroglio@coe.uga.edu		Guskiewicz, Kevin/0000-0002-8682-2130			Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Brandt T. H., 1986, DISORDERS POSTURE GA, P157; BYL NN, 1991, SPINE, V16, P325, DOI 10.1097/00007632-199103000-00012; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; GUYTON A, 2000, TXB MED PHYSL, P622; HORAK FB, 1990, EXP BRAIN RES, V82, P167; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Keselman HJ, 1998, PSYCHOPHYSIOLOGY, V35, P470, DOI 10.1017/S0048577298000237; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Kuo AD, 1998, EXP BRAIN RES, V122, P185, DOI 10.1007/s002210050506; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; LOVELL M, 1989, CLIN J SPORT MED, V9, P193; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser EJT, 2000, PHYSICIAN SPORTSMED, V28, P87, DOI 10.3810/psm.2000.01.645; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 2001, J ATHL TRAINING, V36, P274; NASHNER LM, 1982, J NEUROSCI, V2, P536; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; RICCIO GE, 1993, VARIABILITY AND MOTOR CONTROL, P317; Riemann BL, 2000, J ATHL TRAINING, V35, P19; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; TSYVAER AT, 1989, AM J SPORTS MED, V17, P573; Tsyvaer AT, 1981, BRIT J SPORT MED, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; 1976, LANCET          0221, P401	38	45	45	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	OCT 1	2004	38	5					561	567		10.1136/bjsm.2003.004887			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	856PE	WOS:000224056300011	15388539	Green Submitted, Green Published, Bronze			2022-02-06	
J	Carlesimo, GA; Casadio, P; Caltagirone, C				Carlesimo, GA; Casadio, P; Caltagirone, C			Prospective and retrospective components in the memory for actions to be performed in patients with severe closed-head injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						prospective memory; retrospective memory; closed-head injury; time monitoring; executive functions	RETRIEVAL; DAMAGE; EVENT	This study investigated the basic mechanisms of the impairment of memory for actions to be performed in a group of 16 chronic survivors of severe closed-head injury (CHI). The experimental paradigm allowed discrimination between the deficit in spontaneously remembering the intention at the appropriate moment (prospective component of the task) and the deficit in remembering the specific actions to perform (retrospective component). The experimental procedure also contrasted a condition in which the time expiration was marked by the ringing of a timer (event-based condition) and one in which the time expiration was not marked by any event and the patient had to monitor the passing of time and completely self-activate the recall of the intention (time-based condition). Two other experimental manipulations were concerned with the duration of the delay interval from the examiner's instructions to the time expiration ( 10 vs. 45 min) and the fact that the three actions to be performed could be functionally related or not. With respect to a group of 16 normal controls. the patients with CHI were impaired in both the prospective and retrospective components of the memory for actions. Although an impairment of episodic memory is a plausible explanation for the poor retrieval of specific actions to perform, it is unlikely that this deficit played a major role in the CHI patients' reduced accuracy in spontaneously recalling the intention when the event occurred or the time expired. Instead, reduced frequency and less strategic utilization of time monitoring and/or self-reminding likely played a significant role in this sense.	IRCCS, Fdn S Lucia, I-00179 Rome, Italy; Univ Roma Tor Vergata, Neurol Clin, Rome, Italy		Carlesimo, GA (corresponding author), IRCCS, Fdn S Lucia, V Ardeatina 306, I-00179 Rome, Italy.	memolab@hsantalucia.it	Caltagirone, Carlo/B-4930-2013				BISIACCHI PS, 1995, TRAUMA CRANICO CONSE, P92; BISIACCHI PS, 1992, RIV PSICOLOGIA SOCIA, V17, P77; BRANDIMONTE MA, 1994, Q J EXP PSYCHOL-A, V47, P565, DOI 10.1080/14640749408401128; BRNADIMONTE MA, 1996, PROSPECTIVE MEMORY T; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burgess P. W., 1997, COGNITIVE MODELS MEM, P247; Burgess PW, 2003, NEUROPSYCHOLOGIA, V41, P906, DOI 10.1016/S0028-3932(02)00327-5; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Carlesimo G, 2002, NUOVA RIV NEUROLOGIA, V12, P1; Carlesimo GA, 1997, CORTEX, V33, P131, DOI 10.1016/S0010-9452(97)80009-3; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Guynn MJ, 1998, MEM COGNITION, V26, P287, DOI 10.3758/BF03201140; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KVAVILASHVILI L, 1987, BRIT J PSYCHOL, V78, P507, DOI 10.1111/j.2044-8295.1987.tb02265.x; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Leynes PA, 2003, CONSCIOUS COGN, V12, P1, DOI 10.1016/S1053-8100(02)00002-8; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; McDaniel MA., 1996, PROSPECTIVE MEMORY T, P1; Otani H, 1997, MEMORY, V5, P343, DOI 10.1080/741941393; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Tognoni G., 1987, ITALIAN J NEUROLOG S, V8, P44	28	45	45	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2004	10	5					679	688		10.1017/S1355617704105079			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	848XZ	WOS:000223502700004	15327715				2022-02-06	
J	Nathoo, N; Narotam, PK; Agrawal, DK; Connolly, CA; Van Dellen, JR; Barnett, GH; Chetty, R				Nathoo, N; Narotam, PK; Agrawal, DK; Connolly, CA; Van Dellen, JR; Barnett, GH; Chetty, R			Influence of apoptosis on neurological outcome following traumatic cerebral contusion	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral contusion; apoptosis; outcome	PROGRAMMED CELL-DEATH; FATAL HEAD-INJURY; BRAIN-INJURY; NEURONAL APOPTOSIS; MOLECULAR MECHANISMS; CEREBROSPINAL-FLUID; PRACTICAL SCALE; TRANSGENIC MICE; FOCAL ISCHEMIA; BCL-2	Object. Apoptosis has increasingly been implicated in the pathobiology of traumatic brain injury (TBI). The present study was undertaken to confirm the presence of apoptosis in the periischemic zone (PIZ) of traumatic cerebral contusions and to determine the role of apoptosis, if any, in neurological outcome. Methods. Brain tissue harvested at Wentworth Hospital from the PIZ in 29 patients with traumatic supratentorial contusions was compared with brain tissue resected in patients with epilepsy. Immunohistochemical analyses were performed on the tissues to see if they contained the apoptosis-related proteins p53, bcl-2, bax, and caspase-3. The findings were then correlated to demographic, clinical, surgical, neuroimaging, and outcome data. In the PIZ significant increases of bax (18-fold; p < 0.005) and caspase-3 (20-fold; p < 0.005) were recorded, whereas bcl-2 was upregulated in only 14 patients (48.3%; 2.9-fold increase) compared with control tissue. Patients in the bcl-2-positive group exhibited improved outcomes at the 18-month follow-up examination despite an older mean age and lower mean admission Glasgow Coma Scale score (p < 0.03). Caspase-3 immunostaining was increased in those patients who died (Glasgow Outcome Scale [GOS] Score 1, 12 patients) when compared with those who experienced a good outcome (GOS Score 4 or 5, 17 patients) (p < 0.005). Regression analysis identified bcl-2-negative status (p < 0.04, odds ratio [OR] 5.5; 95% confidence interval [CI] 1.1-28.4) and caspase-3-positive status (p < 0.01, OR 1.4, 95% Cl 1.1-1.8) as independent predictors of poor outcome. No immunostaining for p53 was recorded in the TBI specimens. Conclusions. The present findings confirm apoptosis in the PIZ of traumatic cerebral contusions and indicate that this form of cell death can influence neurological outcome following a TBI.	Dept Neurosurg, Durban, South Africa; Wentworth Provincial Hosp, Nelson R Mandela Sch Med, Durban, South Africa; Univ KwaZulu Natal, ZA-4001 Durban, South Africa; Med Res Council S Africa, Div Biostat, Durban, South Africa; Cleveland Clin, Brain Tumor Inst, Cleveland, OH 44106 USA; Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA; Creighton Univ, Med Ctr, Dept Neurosurg, Omaha, NE 68178 USA; W London Neurosci Ctr, London, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Charing Cross Hosp, London SW7 2AZ, England; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada		Nathoo, N (corresponding author), Cleveland Clin Fdn, Dept Neurosurg S80, 9500 Euclid Ave, Cleveland, OH 44195 USA.	nathoon@ccf.org		Agrawal, Deepak/0000-0002-5499-0746			BULLOCK R, 1990, ACT NEUR S, V51, P286; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen J, 1997, J NEUROCHEM, V69, P232; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Conti AC, 1998, J NEUROSCI, V18, P5663; GOLD R, 1994, LAB INVEST, V71, P219; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; JENNETT B, 1975, LANCET, V1, P480; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Maclennan KA, 1990, THEORY PRACTISE HIST, P437; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MAXWELL WL, 1994, ACTA NEUROCHIR, P465; MIYASHITA T, 1995, CELL, V80, P293; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; ROBINSON G, 1990, THEORY PRACTICE HIST, P413; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; TEASDALE G, 1974, LANCET, V2, P81; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhao JS, 2003, CHINESE MED J-PEKING, V116, P1923; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	38	45	53	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2004	101	2					233	240		10.3171/jns.2004.101.2.0233			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	842JQ	WOS:000223000600010	15309913				2022-02-06	
J	Byrd, DA; Touradji, P; Tang, MX; Manly, JJ				Byrd, DA; Touradji, P; Tang, MX; Manly, JJ			Cancellation test performance, in African American, Hispanic, and White elderly	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						cancellation tests; cognitive style; ethnicity differences	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; VISUAL-SEARCH; STIMULUS; ATTENTION; NEGLECT; SPEED; AGE; EDUCATION; MEMORY	Shape and letter cancellation test performance was investigated among large samples of African American, Hispanic, and White non-demented elders. Ethnic minority elders took significantly longer to complete both tasks compared to Whites. An index of task efficiency, which simultaneously measures time and accuracy, suggested that slower time by minority elders was not related to a measurable effort to achieve greater accuracy. The frequency of commission errors was greater in our sample than in previous reports, especially among ethnic minority elders. Although significant differences were observed between the ethnic groups when matched for years of education, equating for literacy level eliminated all performance differences between African Americans and Whites on both cancellation tasks.	Columbia Univ, Coll Phys & Surg, GH Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA; Columbia Univ, Coll Phys & Surg, Cognit Neurosci Div, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Biostat, New York, NY USA		Manly, JJ (corresponding author), Columbia Univ, Coll Phys & Surg, GH Sergievsky Ctr, 630 W 168th St P & S Box 16, New York, NY 10032 USA.	jjm71@columbia.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG07232, T32 AG000261, AG16206] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG016206, P01AG007232, T32AG000261] Funding Source: NIH RePORTER		Aglioti S, 1997, BRAIN COGNITION, V34, P388, DOI 10.1006/brcg.1997.0915; Amieva H, 1999, BRAIN COGNITION, V40, P26; Baddeley AD, 2001, BRAIN, V124, P1492, DOI 10.1093/brain/124.8.1492; Benton A. L., 1955, VISUAL RETENTION TES; Berry J.W., 2002, CROSS CULTURAL PSYCH; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; DELLASALA S, 1992, PSYCHOL MED, V22, P805; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; Filley C M, 1994, Appl Neuropsychol, V1, P29, DOI 10.1207/s15324826an0101&2_6; FOLDI NS, 1992, J GERONTOL B-PSYCHOL, V47, P146; Foster JK, 1995, AGING COGNITION, V2, P279, DOI 10.1080/13825589508256604; Geldmacher DS, 1997, BRAIN INJURY, V11, P59, DOI 10.1080/026990597123818; Geldmacher DS, 1999, NEUROPSY NEUROPSY BE, V12, P28; Geldmacher DS, 2000, AGING NEUROPSYCHOL C, V7, P194, DOI 10.1076/1382-5585(200009)7:3;1-Q;FT194; GELDMACHER DS, 1995, NEUROPSY NEUROPSY BE, V8, P259; Geldmacher DS, 1998, BRAIN COGNITION, V36, P346, DOI 10.1006/brcg.1997.0978; Heaton RK, 1991, COMPREHENSIVE NORMS; HELMS JE, 1992, AM PSYCHOL, V47, P1083, DOI 10.1037/0003-066X.47.9.1083; Hills EC, 1998, BRAIN INJURY, V12, P69, DOI 10.1080/026990598122872; Jacobs DM, 1997, J CLIN EXP NEUROPSYC, V19, P331, DOI 10.1080/01688639708403862; JONES J, 1998, SOCIAL PSYCHOL TIME, P21; KELLAND DZ, 1996, CLIN NEUROPSYCHOLOGY, V11, P339; KLINEBERG O, 1928, ARCH PSYCHOL; Levine Robert, 1997, GEOGRAPHY TIME TEMPO; Lewis R, 1979, MANUAL REPEATABLE CO; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LLABRE MM, 1987, J EXP EDUC, V55, P137, DOI 10.1080/00220973.1987.10806446; LLABRE MM, 1991, ASSESSMENT ACCESS HI, P95; Lockwood KA, 2001, J CLIN EXP NEUROPSYC, V23, P317, DOI 10.1076/jcen.23.3.317.1179; Manly JJ, 2002, J INT NEUROPSYCH SOC, V8, P341, DOI 10.1017/S1355617702813157; MARSHALL JC, 1989, COGNITIVE NEUROPSYCH, V6, P403, DOI 10.1080/02643298908253290; Mennemeier M, 1998, BRAIN COGNITION, V37, P439, DOI 10.1006/brcg.1998.1007; MILLER EN, 1993, J CLIN EXP NEUROPSYC, V15, P66; Perry RJ, 1999, BRAIN, V122, P383, DOI 10.1093/brain/122.3.383; Perry RJ, 2000, NEUROPSYCHOLOGIA, V38, P252, DOI 10.1016/S0028-3932(99)00079-2; SANO M, 1984, ATTENTION DEFICITS A; SHOR RE, 1971, J GEN PSYCHOL, V85, P187, DOI 10.1080/00221309.1971.9920672; *SPSS INC, 1998, SPSS WIND REL 9 0 0; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; *US BUR CENS, 1991, CENS POP HOUS 1990 S; WEINTRAUB S, 1988, J NEUROL NEUROSUR PS, V51, P1481, DOI 10.1136/jnnp.51.12.1481; WEINTRAUB S, 1987, ARCH NEUROL-CHICAGO, V44, P621, DOI 10.1001/archneur.1987.00520180043014; WILKINSON GS, 1993, WIDE RANGE ACHIEVEMN; Willis M.G., 1989, J BLACK PSYCHOL, V16, P47, DOI 10.1177/009579848901600105	45	45	47	1	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2004	10	3					401	411		10.1017/S1355617704103081			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	817MB	WOS:000221180500010	15147598				2022-02-06	
J	Bedi, A; Murray, JM; Dingley, J; Stevenson, MA; Fee, JPH				Bedi, A; Murray, JM; Dingley, J; Stevenson, MA; Fee, JPH			Use of xenon as a sedative for patients receiving critical care	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	2000	SAN FRANCISCO, CALIFORNIA	Amer Soc Anesthesiologists		noble gases; sedatives; critical care	CLOSED-CIRCUIT ANESTHESIA; NITROUS-OXIDE; STABLE XENON; SUBANAESTHETIC CONCENTRATIONS; INTRACRANIAL-PRESSURE; PROPOFOL INFUSION; DELIVERY SYSTEM; HEAD-INJURY; ACCUMULATION; BLOOD	Objective. Many sedative regimens are used in the intensive care setting, but none are wholly without adverse effect. Xenon is a noble gas with sedative and analgesic properties. It has been used successfully as a general anesthetic and has many desirable properties, not least of which is a minimal effect on the myocardium. In theory, xenon may provide sedation without adverse effect for certain groups of critically ill patients. The objective of this study was to assess the feasibility of using xenon as an intensive care sedative. Design: Double-blind, randomized study. Setting. Tertiary-level intensive care unit. Subjects. Twenty-one patients admitted to an intensive care unit following elective thoracic surgery. Interventions. A standard intensive care sedation regimen (intravenous propofol at 0-5 mg(.)kg(-1.)hr(-1) and alfentanil 30 mug(.)kg(-1.)hr(-1)) was compared with a xenon sedation regimen delivered using a novel bellows-in-bottle delivery system. Measurements and Main Results., Each sedative regimen was continued for 8 hrs. The hemodynamic effects, additional analgesic requirements, recovery from sedation, and effect on hematological and biochemical variables were compared for the two sedation regimens. All patients were successfully sedated during the xenon regimen. The mean +/- SD end-tidal xenon concentration required to provide sedation throughout the duration of the study was 28 +/- 9.0% (range, 9-62%). Arterial systolic, diastolic, and mean pressures showed a greater tendency for negative gradients in patients receiving the propofol regimen (p < .05, p < .1, and p < .01, respectively). Recovery following xenon was significantly faster than from the standard sedation regimen (p < .0001). Hematological and biochemical laboratory markers were within normal clinical limits in both groups. Conclusions. Xenon provided satisfactory sedation in our group of patients. It was well tolerated with minimal hemodynamic effect. Recovery from this agent is extremely rapid. We have demonstrated the feasibility of using xenon within the critical care setting, without adverse effect.	Royal Grp Hosp, Belfast, Antrim, North Ireland; Queens Univ Belfast, Dept Anaesthet & Intens Care Med, Belfast, Antrim, North Ireland; Morriston Hosp, Swansea, W Glam, Wales; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast, Antrim, North Ireland		Bedi, A (corresponding author), Royal Grp Hosp, Belfast, Antrim, North Ireland.						Bedi A, 2002, ANAESTHESIA, V57, P233, DOI 10.1046/j.0003-2409.2001.02455.x; BOOMSMA F, 1990, ANAESTHESIA, V45, P273, DOI 10.1111/j.1365-2044.1990.tb14731.x; BUROV NE, 1993, ANESTEZIOL REANIMAT, V5, P57; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; DARBY JM, 1989, SURG NEUROL, V32, P343, DOI 10.1016/0090-3019(89)90136-5; Dingley J, 1999, CRIT CARE MED, V27, P2435, DOI 10.1097/00003246-199911000-00019; Dingley J, 2001, ANESTHESIOLOGY, V94, P173, DOI 10.1097/00000542-200101000-00034; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Goto T, 1997, BRIT J ANAESTH, V79, P595, DOI 10.1093/bja/79.5.595; Goto T, 1998, BRIT J ANAESTH, V80, P255, DOI 10.1093/bja/80.2.255; Goto T, 2000, BRIT J ANAESTH, V85, P359, DOI 10.1093/bja/85.3.359; LACHMANN B, 1990, LANCET, V335, P1413; LUTTROPP HH, 1993, ANAESTHESIA, V48, P1045; MARION DW, 1991, J CEREBR BLOOD F MET, V11, P347, DOI 10.1038/jcbfm.1991.69; Marx T, 1997, BRIT J ANAESTH, V78, P326, DOI 10.1093/bja/78.3.326; MORITA S, 1985, ANESTH ANALG, V64, P343; Murdoch S, 2000, INTENS CARE MED, V26, P922, DOI 10.1007/s001340051282; Nakata Y, 1999, J CLIN ANESTH, V11, P477, DOI 10.1016/S0952-8180(99)00087-2; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Petersen-Felix S, 1998, BRIT J ANAESTH, V81, P742, DOI 10.1093/bja/81.5.742; Petzelt C, 1999, PFLUG ARCH EUR J PHY, V437, P737, DOI 10.1007/s004240050840; Petzelt C, 1999, LIFE SCI, V65, P901, DOI 10.1016/S0024-3205(99)00320-3; PHILLIPS AS, 1993, ANAESTHESIA, V48, P661, DOI 10.1111/j.1365-2044.1993.tb07173.x; PLOUGMANN J, 1994, J NEUROSURG, V81, P822, DOI 10.3171/jns.1994.81.6.0822; PUNTILLO KA, 1990, HEART LUNG, V19, P526; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; REVELL S, 1988, ANAESTHESIA, V43, P477, DOI 10.1111/j.1365-2044.1988.tb06636.x; ROLLY G, 1994, ANESTH ANALG, V79, P545; SCHOENBORN BP, 1965, NATURE, V208, P760, DOI 10.1038/208760a0; STRAUSS JM, 1993, BRIT J ANAESTH, V70, P363, DOI 10.1093/bja/70.3.363; Suzuki A, 2000, EUR J ANAESTH, V17, P359, DOI 10.1046/j.1365-2346.2000.00697.x; Trudell JR, 1998, ANESTH ANALG, V87, P411, DOI 10.1097/00000539-199808000-00034; Versichelen L, 1996, BRIT J ANAESTH, V76, P668, DOI 10.1093/bja/76.5.668; WILLATTS SM, 1994, ANAESTHESIA, V49, P422; YAGI M, 1995, BRIT J ANAESTH, V74, P670, DOI 10.1093/bja/74.6.670	35	45	49	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	OCT	2003	31	10					2470	2477		10.1097/01.CCM.0000089934.66049.76			8	Critical Care Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	733LZ	WOS:000186003100008	14530753				2022-02-06	
J	Lendon, CL; Harris, JM; Pritchard, AL; Nicoll, JAR; Teasdale, GM; Murray, G				Lendon, CL; Harris, JM; Pritchard, AL; Nicoll, JAR; Teasdale, GM; Murray, G			Genetic variation of the APOE promoter and outcome after head injury	NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; APOLIPOPROTEIN-E GENE; ALZHEIMERS-DISEASE; POLYMORPHISMS	The APOE-epsilon4 allele is associated with risk for Alzheimer's disease (AD) and poorer outcome after head injury. Several studies show that polymorphisms in the promoter that influence APOE expression also increase risk for AD. The authors' data from a study of 92 patients are consistent with a possible influence of the G-219T promoter polymorphism on outcome after head injury. The group with unfavorable outcome had a genotype frequency distribution similar to that found in AD.	Univ Birmingham, Dept Psychiat, Birmingham, W Midlands, England; Univ Birmingham, Dept Neurosci, Birmingham, W Midlands, England; Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Southampton, Div Clin Neurosci, Southampton SO9 5NH, Hants, England; Univ Glasgow, So Gen Hosp, Dept Neurosurg, Glasgow G12 8QQ, Lanark, Scotland		Lendon, CL (corresponding author), Univ Birmingham, Dept Psychiat, Birmingham, W Midlands, England.		Pritchard, Antonia L/F-4288-2010; Nicoll, James/I-9253-2017	Pritchard, Antonia L/0000-0001-5336-0454; Murray, Gordon/0000-0001-9866-4734; Nicoll, James/0000-0002-9444-7246			Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Bullido MJ, 2000, MICROSC RES TECHNIQ, V50, P261, DOI 10.1002/1097-0029(20000815)50:4<261::AID-JEMT2>3.0.CO;2-B; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Lambert JC, 2002, NEUROLOGY, V59, P59, DOI 10.1212/WNL.59.1.59; Lambert JC, 2001, LANCET, V357, P608, DOI 10.1016/S0140-6736(00)04063-0; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3	10	45	53	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	SEP 9	2003	61	5					683	685		10.1212/01.WNL.0000078033.81925.80			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	719CX	WOS:000185187000019	12963763				2022-02-06	
J	Mills, JD; Stone, JR; Rubin, DG; Melon, DE; Okonkwo, DO; Periasamy, A; Helm, GA				Mills, JD; Stone, JR; Rubin, DG; Melon, DE; Okonkwo, DO; Periasamy, A; Helm, GA			Illuminating protein interactions in tissue using confocal and two-photon excitation fluorescent resonance energy transfer microscopy	JOURNAL OF BIOMEDICAL OPTICS			English	Article						fluorescent resonance energy transfer; confocal and two-photon fluorescent resonance energy transfer; BAD; Bcl-xL; traumatic axonal injury; tissue fluorescent; resonance energy transfer	TRAUMATIC BRAIN-INJURY; FRET MICROSCOPY; LIVING CELLS; APOPTOSIS; DEPHOSPHORYLATION; VISUALIZATION; ACTIVATION; ASSAY; BAD	Traumatic brain injury (TBI) remains the most common cause of death in persons under age 45 in the Western world. One of the principal determinants of morbidity and mortality following TBI is traumatic axonal injury (TAI). Current hypotheses on the pathogenesis of TAI involve activation of apoptotic cascades secondary to TBI. While a number of studies have demonstrated direct evidence for the activation of apoptotic cascades in TAI, the precise pathway by which these cascades are initiated remains a subject of intense investigation. As axolemmal disruption with the subsequent intra-axonal influx of large molecular weight species has been demonstrated to occur in relation to local axonal breakdown, attention has focused on cascades that may occur as a result of loss of ionic homeostasis. One proposed pathway by which this has been hypothesized to occur is the Ca2+-mediated activation of calmodulin and subsequent activation of the phosphatase calcineurin with dephosphorylation of a protein known as BAD, leading to a proapoptotic interaction between BAD and the mitochondrial protein Bcl-xL. While this pathway is an intriguing route for traumatic axonal pathogenesis, neither conventional irnmunocytochemical/histochemical nor ultrastructural approaches have had the capacity to shed insight on whether BAD and Bcl-xL interact in TAI in vivo. We describe the implementation of confocal and two-photon excitation fluorescence resonance energy transfer (FRET) microscopy techniques through which we demonstrate interaction between the proapoptotic protein BAD and the prosurvival protein Bcl-xL within TAI following TBI. Further, we report on a method to reliably detect protein interactions within aldehyde fixed tissue sections through conventional immunohistochemical approaches. (C) 2003 society of Photo-Optical Instrumentation Engineers.	Univ Virginia, Hlth Sci Ctr, Dept Neurosurg, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Neurosci, Charlottesville, VA 22908 USA; Univ Virginia, WM Keck Ctr Cellular Imaging, Charlottesville, VA 22904 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22904 USA		Mills, JD (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Neurosurg, Charlottesville, VA 22908 USA.		Periasamy, Ammasi/B-1279-2010				Bai YL, 2003, MOL ENDOCRINOL, V17, P589, DOI 10.1210/me.2002-0351; Bruno JG, 2001, BIOCHEM BIOPH RES CO, V287, P875, DOI 10.1006/bbrc.2001.5669; Buki A, 2000, J NEUROSCI, V20, P2825; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Elangovan M, 2003, METHODS, V29, P58, DOI 10.1016/S1046-2023(02)00283-9; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Everett H, 2002, J EXP MED, V196, P1127, DOI 10.1084/jem.20011247; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Jones J, 2000, J BIOMOL SCREEN, V5, P307, DOI 10.1177/108705710000500502; KAM Z, 1995, J CELL SCI, V108, P1051; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; KOKSCH M, 1995, J IMMUNOL METHODS, V187, P53, DOI 10.1016/0022-1759(95)00166-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Periasamy A, 1999, MICROSC RES TECHNIQ, V47, P172, DOI 10.1002/(SICI)1097-0029(19991101)47:3<172::AID-JEMT3>3.0.CO;2-A; Periasamy A, 2001, J BIOMED OPT, V6, P287, DOI 10.1117/1.1383063; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Sharma N, 2001, AM J PATHOL, V159, P339, DOI 10.1016/S0002-9440(10)61700-2; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Springer JE, 2000, J NEUROSCI, V20, P7246; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509	29	45	46	0	5	SPIE-INT SOCIETY OPTICAL ENGINEERING	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668			J BIOMED OPT	J. Biomed. Opt.	JUL	2003	8	3					347	356		10.1117/1.1584443			10	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	709CD	WOS:000184606400004	12880338				2022-02-06	
J	Vanderploeg, RD; Curtiss, G; Duchnick, JJ; Luis, CA				Vanderploeg, RD; Curtiss, G; Duchnick, JJ; Luis, CA			Demographic, medical, and psychiatric factors in work and marital status after mild head injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						health status; marital status; mild head injury-minor; sequelae; work	TRAUMATIC BRAIN-INJURY; DIAGNOSTIC INTERVIEW SCHEDULE; COMMUNITY INTEGRATION; MENTAL-HEALTH; PREDICTION; REHABILITATION; MINORITY; SYMPTOMS; HISTORY; RETURN	Objective. To explore factors associated with long-term outcomes of work and marital status in individuals who had experienced a mild head injury (MHI), as well as those who had not. Design: Population-based study using logistical regression analyses to investigate the impact of preinjury characteristics on work and marital status. Participants: Two groups of Vietnam-era Army veterans: 626 who had experienced a MHI an average of 8 years before examination, and 3,896 who had not. Main outcome measures: Demographic characteristics, concurrent medical conditions, early life psychiatric problems, loss of consciousness (LOC), and interactions among these variables were used to predict current work and marital status. Results: Multiple variables were associated with work and marital status in the sample with MHI, accounting for approximately 23% and 17% of the variance in these two outcome variables, respectively. In contrast, the same factors accounted for significantly less variance in outcome in the sample without a head injury-13.3% and 9.4% for work and marital status, respectively. Conclusions: These findings suggest a more potent role for and increased vulnerability to the influence of demographic, medical, and psychiatric factors on outcomes after a MHI. That is, MHI itself moderates the influence of preinjury characteristics on work and marital status. In addition, in those who had a MHI, moderator relationships were found between education and LOC for both work and marital status. Similarly, complex moderator relationships among race, region of residence, and LOC were found for both work and marital status outcomes.	James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA; Def & Vet Head Injury Program, Tampa, FL USA; Univ S Florida, Dept Psychiat & Behav Sci, Tampa, FL USA; Univ S Florida, Dept Psychol, Tampa, FL USA; Mt Sinai Med Ctr, Miami Heart Inst, Wien Ctr Alzheimers Dis & Mem Disorders, Miami Beach, FL 33140 USA		Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, Tampa, FL 33612 USA.	Rodney.Vanderploeg@med.va.gov	Curtiss, Glenn/ABB-5566-2020				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; [Anonymous], 1988, JAMA, V259, P2701; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; *CDC, 1989, HLTH STAT VIETN VET, V4; DeMaris A, 2002, SOCIOL METHOD RES, V31, P27, DOI 10.1177/0049124102031001002; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Fleming J, 1999, BRAIN INJURY, V13, P417; FRANK RG, 1991, INT J LAW PSYCHIAT, V14, P377, DOI 10.1016/0160-2527(91)90016-G; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Gosling J, 1999, BRAIN INJURY, V13, P785; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; GUTMANN MC, 1982, CIRCULATION, V66, P33; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KREIDER RM, 2001, P7080 US CENS BUR; Leonard KE, 1999, J STUD ALCOHOL, P139, DOI 10.15288/jsas.1999.s13.139; LUIS CA, 2001, ANN CONV AM PSYCH AS; MCKELVEY RD, 1975, J MATH SOCIOL, V4, P103, DOI 10.1080/0022250X.1975.9989847; MONTAGUE E K, 1957, U S Armed Forces Med J, V8, P883; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Panting A, 1972, REHABILITATION, V38, P33; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schretlen DJ, 2000, REHABIL PSYCHOL, V45, P260, DOI 10.1037/0090-5550.45.3.260; SHAFFER D, 1993, J AM ACAD CHILD PSY, V32, P643, DOI 10.1097/00004583-199305000-00023; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; STILWELL J, 1998, NATL TRAUMATIC BRAIN; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; Webster G, 1999, BRAIN INJURY, V13, P593; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	47	45	45	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2003	18	2					148	163		10.1097/00001199-200303000-00006			16	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	663DU	WOS:000181991600006	12802224				2022-02-06	
J	Williams, WH; Evans, JJ; Fleminger, S				Williams, WH; Evans, JJ; Fleminger, S			Neurorehabilitation and cognitive-behaviour therapy of anxiety disorders after brain injury: An overview and a case illustration of obsessive-compulsive disorder	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							OUTCOME MEASURES	Survivors of acquired and traumatic brain injuries may often experience anxiety states. Psychological reactions to neurological trauma may be caused by a complex interaction of a host of factors. We explore how anxiety states may be understood in terms of a biopsychosocial formulation of such factors. We also review the current evidence for the presence of specific anxiety disorders after brain injury. We then describe how cognitive-behaviour therapy (CBT), a treatment of choice for many anxiety disorders, may be integrated with cognitive rehabilitation (CR), for the management of anxiety disorders in brain injury. We illustrate how CBT and CR may be delivered with a case of a survivor of traumatic brain injury (TBI) who had developed obsessive compulsive disorder and health anxiety. We show how CBT plus CR allows a biopsychosocial formulation to be developed of the survivor's concerns for guiding a goal-based intervention. The survivor made significant gains from intervention in terms of goals achieved and changes on clinical measures. We argue that large-scale research is needed for developing an evidence base for managing emotional disorders in brain injury.	Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter, Devon, England; Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, England; Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, London SE5 8AZ, England		Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter, Devon, England.			williams, huw/0000-0003-0670-2620			*AM PSYCH ASS, 1994, DIAGN STAT MAN, V4; *AM PSYCH ASS, 2000, DIAGN STAT MAN, V4; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Bond M. R., 1990, REHABILITATION ADULT, P179; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BRADSHAW JL, 2001, DEV DISORDERS FRONTO; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; DAVEY GL, 1994, NEW WORRYING PERSPEC; Eells T. D., 1997, HDB PSYCHOTHERAPY CA; HARRIS DP, 1997, J OUTCOMES MEASUREME, V1, P23; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HODGSON RJ, 1977, BEHAV RES THER, V15, P389, DOI 10.1016/0005-7967(77)90042-0; Holzer JC, 1998, J NEUROPSYCH CLIN N, V10, P113, DOI 10.1176/jnp.10.1.113; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lishman WA, 1998, ORGANIC PSYCHIAT; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MANCHESTER D, 2001, NEUROBEHAVIOURAL DIS; MARCH JS, 1994, J AM ACAD CHILD PSY, V33, P333, DOI 10.1097/00004583-199403000-00006; MCKEON J, 1984, BRIT J PSYCHIAT, V144, P190, DOI 10.1192/bjp.144.2.190; Pender N, 1999, NEUROPSYCHOL REHABIL, V9, P345, DOI 10.1080/096020199389428; PONSFORD J, 1998, TRAUMATIC BRAIN INJU; Rauch SL, 1997, BIOL PSYCHIAT, V42, P446, DOI 10.1016/S0006-3223(97)00145-5; ROTH A, 1996, WHAT WORKS WHOM CRIT; SALKOVSKIS PM, 2001, HYPOCHONDRIASIS MODE; SAPOLSKY RM, 1990, J NEUROSCI, V10, P2897, DOI 10.1523/jneurosci.10-09-02897.1990; Scheutzow MH, 1999, BRAIN INJURY, V13, P705; Spinella M, 2002, BRAIN INJURY, V16, P359, DOI 10.1080/02699050110103319; Tallis F, 1997, BRIT J CLIN PSYCHOL, V36, P3, DOI 10.1111/j.2044-8260.1997.tb01226.x; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; WILLIAMS WH, 1997, COGNITIVE THERAPY PE; WILLIAMS WH, IN PRESS STUDIES NEU; WILLIAMS WH, IN PRESS BRAIN INJUR; Wise M G, 1999, Semin Clin Neuropsychiatry, V4, P98; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zitterl W, 2001, PSYCHOPATHOLOGY, V34, P113, DOI 10.1159/000049292	37	45	46	0	5	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		133	148		10.1080/09602010244000417			16	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500008	21854331				2022-02-06	
J	Kline, AE; Yu, JY; Massucci, JL; Zafonte, RD; Dixon, CE				Kline, AE; Yu, JY; Massucci, JL; Zafonte, RD; Dixon, CE			Protective effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin against traumatic brain injury-induced cognitive deficits and neuropathology in adult male rats	NEUROSCIENCE LETTERS			English	Article						8-hydroxy-2-(di-n-propylamino)tetralin; controlled cortical impact; Morris water maze; recovery; spatial learning and memory	GLUTAMATE RELEASE; HIPPOCAMPUS; 8-OH-DPAT	To further investigate the efficacy of 5-HT1A receptor agonism on functional and histological outcome in traumatically-brain injured (TBI) rats, a single intraperitoneal injection of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.1, 0.5, or 1.0 mg/kg) or vehicle was given 15 min after controlled cortical impact or sham injury. Function was assessed by established motor and cognitive tests on post-operative days 1-5 and 14-18, respectively. Cortical lesion volume and hippocampal CA(1)/CA(3) cell survival were quantified at 4 weeks. The administration of 8-OH-DPAT (0.5 mg/kg) attenuated spatial acquisition deficits and reduced hippocampal CA(3) cell loss vs. vehicle (P < 0.05). These data augment published reports that 5-HT1A receptor agonists confer neuroprotective effects after experimental TBI. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA		Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 201 Lillian Kaufmann Bldg, Pittsburgh, PA 15260 USA.	klineae@msx.upmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 33150, NS 40125, NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, R01NS033150, P50NS030318, R01NS040125, P20NS030318] Funding Source: NIH RePORTER		ANDRADE R, 1992, DRUG DEVELOP RES, V26, P275, DOI 10.1002/ddr.430260307; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fujii T, 1997, BRAIN RES, V761, P244, DOI 10.1016/S0006-8993(97)00325-9; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Koyama T, 1999, NEUROSCI LETT, V265, P33, DOI 10.1016/S0304-3940(99)00200-1; Matsuyama S, 1996, BRAIN RES, V728, P175, DOI 10.1016/0006-8993(96)00395-2; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; Melena J, 2000, EUR J PHARMACOL, V406, P319, DOI 10.1016/S0014-2999(00)00688-9; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; RAITERI M, 1991, J PHARMACOL EXP THER, V257, P1184; Sakaue M, 2000, BRIT J PHARMACOL, V129, P1028, DOI 10.1038/sj.bjp.0703139; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X	17	45	48	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 29	2002	333	3					179	182	PII S0304-3940(02)01101-1	10.1016/S0304-3940(02)01101-1			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	619MR	WOS:000179480200007	12429377				2022-02-06	
J	Nakahara, S; Yone, K; Setoguchi, T; Yamaura, I; Arishima, Y; Yoshino, S; Komiya, S				Nakahara, S; Yone, K; Setoguchi, T; Yamaura, I; Arishima, Y; Yoshino, S; Komiya, S			Changes in nitric oxide and expression of nitric oxide synthase in spinal cord after acute traumatic injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						microdialysis; nitric oxide; nitric oxide synthase; spinal cord injury	METHYL-D-ASPARTATE; FOCAL CEREBRAL-ISCHEMIA; BRAIN; APOPTOSIS; NEUROTOXICITY; MECHANISMS; NOS; INHIBITION; CULTURES; NEURONS	The aim of this study was to observe the time course of NO production and NOS expression in the spinal cord following acute traumatic injury. Rat spinal cord was injured by extradural static weight-compression, which resulted in an incomplete transverse spinal cord lesion with paralysis of, the lower extremities. Using this model, measurement of NO by microdialysis and Griess reaction and histological and immunohistochemical examinations using polyclonal antibodies to nNOS and iNOS were performed from immediately to 14 days after injury. In injured cord, the amount of, NO markedly increased immediately after injury and gradually decreased between 1 and 12 h after injury. A second wave of increase in NO level was observed at 24 h and 3 days after injury. Histologically, hematomas and necrotic changes were observed after injury and demyelination of nerve fibers increased with time in the compressed segment. Immunohistochemically, the number of cells with expression of nNOS was increased immediately to 12 h after injury. Expression of iNOS was observed from 12 h to 3 days after injury. These findings suggested that the initial maximal increase of NO production might be caused mainly by nNOS and that the second wave of increase in NO might be due mainly to iNOS.	Kagoshima Univ, Fac Med, Dept Orthopaed Surg, Kagoshima 8908520, Japan		Yone, K (corresponding author), Kagoshima Univ, Fac Med, Dept Orthopaed Surg, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.						AKIRA T, 1994, BRAIN RES, V645, P285, DOI 10.1016/0006-8993(94)91662-4; Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; ANDERSON DK, 1980, J NEUROSURG, V52, P387, DOI 10.3171/jns.1980.52.3.0387; BLACK P, 1986, NEUROSURGERY, V19, P752, DOI 10.1227/00006123-198611000-00006; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brunetti L, 1994, Clin Ter, V144, P147; BUISSON A, 1993, J NEUROCHEM, V61, P690; CHI OZ, 1994, PHARMACOLOGY, V48, P367, DOI 10.1159/000139202; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEMEDIUK P, 1989, J NEUROCHEM, V52, P1529, DOI 10.1111/j.1471-4159.1989.tb09204.x; Esch F, 1998, J NEUROSCI, V18, P4083; Estevez AG, 1998, J NEUROSCI, V18, P923; FAIRHOLM DJ, 1971, J NEUROSURG, V35, P277, DOI 10.3171/jns.1971.35.3.0277; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRIFFITHS IR, 1975, J NEUROSURG, V42, P155, DOI 10.3171/jns.1975.42.2.0155; Guizar-Sahagun G, 1998, NEUROREPORT, V9, P2899, DOI 10.1097/00001756-199808240-00040; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; LI P, 1994, BRAIN RES, V637, P287, DOI 10.1016/0006-8993(94)91246-7; NAGAFUJI T, 1993, EUR J PHARM-ENVIRON, V248, P325; NOVIKOV L, 1995, NEUROSCI LETT, V200, P45, DOI 10.1016/0304-3940(95)12078-I; PETERSON PK, 1994, J INFECT DIS, V170, P457, DOI 10.1093/infdis/170.2.457; RUDA MA, 1994, ANN NY ACAD SCI, V738, P181; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; SAXON DW, 1994, NEUROREPORT, V5, P809, DOI 10.1097/00001756-199403000-00018; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.ne.17.030194.001101; SELGERSTAHL K, 1985, NEUROCHEM RES, V10, P563; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P271, DOI 10.1001/archneurpsyc.1954.02320390001001; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; WU W, 1994, NEUROSCIENCE, V61, P719, DOI 10.1016/0306-4522(94)90394-8; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Yamada K, 1997, J NEUROCHEM, V68, P1234; YANASE M, 1995, J NEUROSURG, V83, P884, DOI 10.3171/jns.1995.83.5.0884; Yick LW, 1998, NEUROSCI LETT, V241, P155; Yoshino S, 1998, J Orthop Sci, V3, P54, DOI 10.1007/s007760050021; Young W, 1985, Cent Nerv Syst Trauma, V2, P109; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	49	45	47	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1467	1474		10.1089/089771502320914697			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500007	12490011				2022-02-06	
J	Paolin, A; Nardin, L; Gaetani, P; Baena, RRY; Pansarasa, O; Marzatico, F				Paolin, A; Nardin, L; Gaetani, P; Baena, RRY; Pansarasa, O; Marzatico, F			Oxidative damage after severe head injury and its relationship to neurological outcome	NEUROSURGERY			English	Article						Glasgow Outcomes Scale; malonylaldehyde; oxidative damage; severe brain injury; superoxide dismutase; vitamin E	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; VITAMIN-E; ALPHA-TOCOPHEROL; FREE-RADICALS; SUPEROXIDE-DISMUTASE; TIRILAZAD MESYLATE; PREDICTIVE-VALUE; BLOOD-FLOW	OBJECTIVE: We sought to establish the time course of reactive oxygen species after severe head injuries in humans and to investigate the relationship with clinical outcomes. METHODS: Both the markers of oxidative damage-malonylaldehyde (MDA) and the enzymatic and nonenzymatic antioxidant defenses (i.e., superoxide dismutase [SOD] and vitamin E [VE], respectively)-were studied. To assess the time course of MDA, SOD, and VE, jugular bulb (JB) and peripheral venous blood samples were obtained from 30 patients within 8 hours of severe head trauma onset (T-0) and 6 (T-1), 12 (T-2), 24(T-3), and 48 hours (T-4) after trauma onset. Patients were divided into good and poor outcome groups according to their 6-month neurological outcome as determined on the basis of their Glasgow Outcome Scale scores and biochemical profiles. RESULTS: In JB samples, MDA levels increased significantly at T-2 and T-3 as compared with T-0; and VE levels decreased significantly at T-1, T-2, and T-3 as compared with T-0. The same variables did not change significantly over time in peripheral venous blood samples. Moreover, the MDA levels and SOD activity detected in JB samples were significantly higher in the poor outcome at T-1 and T-2. No significant difference in VE levels was observed between the two outcome groups. CONCLUSION: Reactive oxygen species-mediated oxidative damage can play an important role in determining the prognosis of severe brain injury in humans.	Gen Hosp Treviso, Neurosurg Intens Care Unit, Treviso, Italy; Humanitas Clin, Dept Neurosurg, Rozzano, MI, Italy; Univ Pavia, Dept Pharmacol & Physiol Sci, Pharmacol Sect, I-27100 Pavia, Italy		Paolin, A (corresponding author), Osped Ca Foncello, Anesthesiol & Intens Care Med, P Osped 1, I-31100 Treviso, Italy.	apaolin@ulss.tv.it	Pansarasa, Orietta/A-2012-2019	Gaetani, Paolo/0000-0003-0662-5872			BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BUSTO R, 1984, ANN NEUROL, V15, P441, DOI 10.1002/ana.410150507; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CATIGNANI GL, 1986, METHOD ENZYMOL, V123, P215, DOI 10.1016/S0076-6879(86)23025-6; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRISAR JM, 1995, J MED CHEM, V38, P453, DOI 10.1021/jm00003a008; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1992, J NEUROTRAUM, V9, pS425; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Ikeda Y, 2000, ACT NEUR S, V76, P343; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; JOHNSON D, 1993, BRIT J NEUROSURG, V7, P53, DOI 10.3109/02688699308995056; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KIRSCH JR, 1992, J NEUROTRAUM, V9, pS157; KNIGHT JA, 1993, ANN CLIN LAB SCI, V23, P51; Koc PK, 1999, RES EXP MED, V199, P21, DOI 10.1007/s004330050129; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Layton ME, 1997, NEUROSCI LETT, V236, P63, DOI 10.1016/S0304-3940(97)00765-9; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; STRAW RN, 1995, PRELIMINARY EFFICACY; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YOSHIDA S, 1983, NEUROLOGY, V33, P166, DOI 10.1212/WNL.33.2.166; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	47	45	47	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0148-396X			NEUROSURGERY	Neurosurgery	OCT	2002	51	4					949	954		10.1227/01.NEU.0000027881.33381.3F			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	598ZV	WOS:000178308500027	12234402				2022-02-06	
J	Baker, AJ; Phan, N; Moulton, RJ; Fehlings, MG; Yucel, Y; Zhao, M; Liu, E; Tian, GF				Baker, AJ; Phan, N; Moulton, RJ; Fehlings, MG; Yucel, Y; Zhao, M; Liu, E; Tian, GF			Attenuation of the electrophysiological function of the corpus callosum after fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						corpus callosum; electrophysiology; fluid percussion injury model; traumatic brain injury; white matter injury	TRAUMATIC BRAIN INJURY; AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; SPINAL-CORD INJURY; WHITE-MATTER INJURY; PIG OPTIC-NERVE; HEAD-INJURY; GLUTAMATE RECEPTORS; BLOOD-FLOW; IN-VITRO	This study describes a new method used to evaluate axonal physiological dysfunction following fluid percussion induced traumatic brain injury (TBI) that may facilitate the study of the mechanisms and novel therapeutic strategies of posttraumatic diffuse axonal injury (DAI). Stimulated compound action potentials (CAP) were recorded extracellularly in the corpus callosum of superfused brain slices at 3 h, and 1, 3, and 7 days following central fluid percussion injury and demonstrated a temporal pattern of functional deterioration. The maximal CAP amplitude (CAPA) covaried with the intensity of impact 1 day following sham, mild (1.0-1.2 atm), and moderate (1.8-2.0 atm) injury (p < 0.05; 1.11 +/- 0.10, 0.82 +/- 0.11, and 0.49 +/- 0.08 mV, respectively). The CAPA in sham animals were approximately 1.1 mV and did not vary with survival interval (3 h, and 1, 3, and 7 days); however, they were significantly decreased at each time point following moderate injury (p < 0.05; 0.51 +/- 0.11, 0.49 +/- 0.08, 0.46 +/- 0.10, and 0.75 +/- 0.13 mV, respectively). The CAPA at 7 days in the injured group were higher than at 3 h, and 1 and 3 days. H&E and amyloid precursor protein (APP) light microscopic analysis confirmed previously reported trauma-induced axonal injury in the corpus callosum seen after fluid percussion injury. Increased APP expression was confirmed using Western blotting showing significant accumulation at 1 day (IOD 913.0 +/- 252.7; n = 3; p = 0.05), 3 days (IOD 753.1 +/- 159.1; n = 3; p = 0.03), and at 7 days (IOD 1093.8 +/- 105.0; n = 3; p = 0.001) compared to shams (IOD 217.6 +/- 20.4; n = 3). Thus, we report the characterization of white matter axonal dysfunction in the corpus callosum following TBI. This novel method was easily applied, and the results were consistent and reproducible. The electrophysiological changes were sensitive to the early effects of impact intensity, as well as to delayed changes occurring several days following injury. They also indicated a greater degree of attenuation than predicted by APP expression changes alone.	Univ Toronto, Dept Anaesthesia, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON, Canada		Baker, AJ (corresponding author), Univ Toronto, Dept Anaesthesia, Toronto, ON, Canada.			Fehlings, Michael/0000-0002-5722-6364			AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEHLINGS MG, 1995, BRAIN RES, V677, P291, DOI 10.1016/0006-8993(95)00141-C; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Koszyca B, 1998, J NEUROTRAUM, V15, P675, DOI 10.1089/neu.1998.15.675; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LI S, 1999, J NEUROSCI, V19, P1; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; Marmarou A, 1990, Adv Neurol, V52, P233; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; PETERSEN G, 1977, ANAL BIOCHEM, V3, P346; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; RANSOM BR, 1992, J CEREBR BLOOD F MET, V12, P593, DOI 10.1038/jcbfm.1992.83; Rosenberg LJ, 1997, J NEUROTRAUM, V14, P823, DOI 10.1089/neu.1997.14.823; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; STYS PK, 1995, J CEREBR BLOOD F MET, V15, P425, DOI 10.1038/jcbfm.1995.53; Swanson TH, 1998, BRAIN RES, V784, P188, DOI 10.1016/S0006-8993(97)01323-1; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Tian GF, 2000, J NEUROPHYSIOL, V83, P1830, DOI 10.1152/jn.2000.83.4.1830; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WAXMAN SG, 1989, J NEUROL SCI, V91, P1, DOI 10.1016/0022-510X(89)90072-5; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; [No title captured]	65	45	46	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2002	19	5					587	599		10.1089/089771502753754064			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557PA	WOS:000175915900004	12042094				2022-02-06	
J	Stamatakis, EA; Wilson, JTL; Hadley, DM; Wyper, DJ				Stamatakis, EA; Wilson, JTL; Hadley, DM; Wyper, DJ			SPECT imaging in head injury interpreted with statistical parametric mapping	JOURNAL OF NUCLEAR MEDICINE			English	Article						SPECT; regional cerebral blood flow; head injury; statistical parametric mapping	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; ANTERIOR CINGULATE CORTEX; CEREBRAL-BLOOD-FLOW; HM-PAO-SPECT; TECHNETIUM-99M-HMPAO SPECT; CT; MILD; MRI; DISEASE	This study investigated regional cerebral blood flow in head-injured patients using statistical parametric mapping (SPM) to detect hypoperfusion on Tc-99m-hexamethylpropyleneamine oxime (HMPAO) SPECT scans. Methods: Acute and follow-up SPECT and MRI scans from 61 patients who were admitted to a regional neurosurgical unit were examined. Patients had acute MRI and SPECT at 2-18 d after injury and on follow-up between 130 and 366 d after injury. Thirty-two scans from non-head-injured patients were used as a SPECT control group. The SPECT images were first aligned to the Talairach-Tournoux atlas and then analzed statistically with SPM. Results: SPECT detected more extensive abnormality than MRI in acute and follow-up stages. This effect was more pronounced on follow-up of patients with diffuse injury. Examination of a focal injury group indicated the involvement of frontal and temporal lobes and the anterior cingulate. Blood flow abnormalities persist, to a lesser extent, on follow-up scans, The diffuse group displayed low blood flow in the frontal and temporal lobes, including cingulate involvement, which persists at follow-up with additional involvement of the thalamus. Conclusion: SPM has a role in SPECT image interpretation because it allows better visualization than other methods of quantitative analysis of the spatial distribution of abnormalities in focal and diffuse head injury. Frontal lobe blood flow abnormality (particulary anterofrontal regions and mesiofrontal areas) is common after head injury.	Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; So Gen Hosp, Inst Neurol Sci, Dept Neuroradiol, Glasgow, Lanark, Scotland; So Gen Hosp, Inst Neurol Sci, Dept Clin Phys, Glasgow, Lanark, Scotland		Stamatakis, EA (corresponding author), Univ Cambridge, Ctr Speech & Language, Dept Expt Psychol, Cambridge CB2 3BE, England.	emmanuel@csl.psychol.cam.ac.uk	Wilson, Lindsay/O-8883-2019; Wilson, Lindsay/A-3659-2009	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601			ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; BAVETTA S, 1994, NUCL MED COMMUN, V15, P961, DOI 10.1097/00006231-199412000-00007; BULLOCK R, 1990, ACT NEUR S, V51, P286; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; COSTA DC, 1988, J CEREBR BLOOD F MET, V8, pS109, DOI 10.1038/jcbfm.1988.40; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friston K.J., 1994, FUNCTIONAL NEUROIMAG, P79; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAY BG, 1992, J NUCL MED, V33, P52; HADLEY DM, 1988, CLIN RADIOL, V39, P131; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; Johnson LS, 1999, J NUCL MED, V40, p270P; KARBE H, 1994, NEURORADIOLOGY, V36, P1, DOI 10.1007/BF00599183; Lee JS, 1999, J NUCL MED, V40, p276P; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; ODER W, 1991, INTENS CARE MED, V17, P149, DOI 10.1007/BF01704718; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; PRAYER L, 1993, ACTA RADIOL, V34, P593; ROPER SN, 1991, J NUCL MED, V32, P1684; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Stamatakis EA, 1999, NEUROIMAGE, V10, P397, DOI 10.1006/nimg.1999.0477; Stamatakis EA, 2001, NEUROIMAGE, V14, P844, DOI 10.1006/nimg.2001.0884; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Tikofsky RS, 1999, J NUCL MED, V40, p272P; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WILSON JTL, 1997, SPECT IMAGING BRAIN	39	45	47	0	1	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	APR	2002	43	4					476	483					8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	540BA	WOS:000174907300013	11937590				2022-02-06	
J	Downs, DS; Abwender, D				Downs, DS; Abwender, D			Neuropsychological impairment in soccer athletes	JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS			English	Article; Proceedings Paper	107th Annual Convention of the American-Psychological-Association	JUN, 1999	Denver, CO	Amer Psychol Assoc		soccer; swimming; neurophysiology; brain	BRAIN-INJURY; BALL	Background. Soccer reportedly places participants at risk for neuropsychological. impairment, although it is unknown if the risk is associated primarily with concussion, subconcussive blows from heading the ball, or some combination thereof. Moreover, the extent to which younger versus older athletes are at risk for soccer-related cognitive impairment is unclear. We hypothesized that soccer athletes, especially older ones, would show poorer neuropsychological test performance than comparable swimmers. Methods. Thirty-two soccer (26 college and 6 professional) and 29 swimmers (22 college and 7 masters level), all involved for at least 4 years in their sport at collegiate or national levels, participated. In a 2 X 2 (sport X age category) factorial design, all participants underwent 4 neuropsychological tests with 11 outcome measures assessing motor speed, attention, concentration, reaction time, and conceptual thinking. Results. Soccer athletes performed worse than swimmers on measures of conceptual thinking. The older soccer group in particular performed poorly on measures of conceptual thinking, reaction time, and concentration. Among non-goaltender soccer athletes, estimates of career exposure to brain trauma (based on length of career and level of play) predicted significantly poorer test performance on 6 of 11 measures, even after statistically controlling for age. Conclusions. Results provide additional evidence that participation in soccer may be associated with poorer neuropsychological performance, although the observed pattern of findings does not specifically implicate heading as the cause. Although deficits were most apparent among older soccer players, serial neuropsychological testing for early detection of impairment is recommended for younger players as well.	Univ Florida, Dept Exercise & Sport Sci, Gainesville, FL 32611 USA; SUNY Coll Brockport, Dept Psychol, Brockport, NY USA		Downs, DS (corresponding author), Univ Florida, Dept Exercise & Sport Sci, POB 118205,Room 110 Florida Gym, Gainesville, FL 32611 USA.	symons@ufl.edu	Abwender, David/AAG-1837-2021				Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Asken MJ, 1998, PHYSICIAN SPORTSMED, V26, P37, DOI 10.3810/psm.1998.11.1190; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Gean AD, 1994, IMAGING HEAD TRAUMA; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GRONWALL D, 1975, LANCET, V2, P995; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Levin H.S., 1989, MILD HEAD INJURY; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	15	45	45	0	10	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0022-4707	1827-1928		J SPORT MED PHYS FIT	J. Sports Med. Phys. Fit.	MAR	2002	42	1					103	107					5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	541KG	WOS:000174983300017	11832883				2022-02-06	
J	Gerring, JP; Slomine, B; Vasa, RA; Grados, M; Chen, A; Rising, W; Christensen, JR; Denckla, MB; Ernst, M				Gerring, JP; Slomine, B; Vasa, RA; Grados, M; Chen, A; Rising, W; Christensen, JR; Denckla, MB; Ernst, M			Clinical predictors of posttraumatic stress disorder after closed head injury in children	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						posttraumatic stress disorder; posttraumatic stress symptoms; closed head injury	TRAUMATIC BRAIN INJURY; AMNESIA TEST; SYMPTOMATOLOGY; ADOLESCENTS; ORIENTATION; ACCIDENTS; SEQUELAE; SCALE; RISK	Objective: To describe injury, demographic, and neuropsychiatric characteristics of children who develop posttraumatic stress disorder (PTSD) and posttraumatic stress symptoms (PTSS) after closed head injury (CHI). Method: Ninety-five children with severe CHI and amnesia for the event were prospectively followed for 1 year. Structured interviews were administered twice to the parents: shortly after injury to cover the child's premorbid status, and 1 year after injury. The child was also interviewed twice: shortly after injury to cover current status, and 1 year after injury. Outcome measures were diagnostic status (PTSD by parent or child) and symptom severity (PTSS by parent or child). Results: Twelve children developed PTSD by 1 year after injury, 5 according to parent report, 5 according to child report, and 2 according to both parent and child report. Predictors of PTSD at 1 year post-CHI included female gender and early post-CHI anxiety symptoms. Predictors of PTSS at 1 year post-CHI were (1) premorbid psychosocial adversity, premorbid anxiety symptoms, and injury severity; and (2) early post-CHI depression symptoms and nonanxiety psychiatric diagnoses. Conclusions: PTSD developed in 13% of children with severe CHI accompanied by traumatic amnesia. Predictors of PTSD and PTSS after CHI, according to parent and child report, are consistent with predictors of PTSD and PTSS that develop after non-head injury trauma.	Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Duke Univ, Clin Res Inst, Durham, NC USA; NIMH, Mood & Anxiety Disorders Program, NIH, Bethesda, MD 20892 USA		Gerring, JP (corresponding author), Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.			Grados, Marco/0000-0002-6189-6264	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO-RR00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline		Achenbach TM, 1991, MANUAL CHILD BEHAV C; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; Asarnow J, 1999, J AM ACAD CHILD PSY, V38, P1016, DOI 10.1097/00004583-199908000-00018; BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; EDELBROCK C, 1985, CHILD DEV, V56, P265, DOI 10.1111/j.1467-8624.1985.tb00104.x; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FOA EB, 1995, AM J PSYCHIAT, V152, P116; Foy DW, 1996, J SCHOOL PSYCHOL, V34, P133, DOI 10.1016/0022-4405(96)00003-9; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Jensen PS, 1999, J AM ACAD CHILD PSY, V38, P1569, DOI 10.1097/00004583-199912000-00019; Klein D.N., 1993, BASIC ISSUES PSYCHOP, Vix; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LONIGAN CJ, 1994, J AM ACAD CHILD PSY, V33, P94, DOI 10.1097/00004583-199401000-00013; March JS, 1998, J AM ACAD CHILD PSY, V37, P585, DOI 10.1097/00004583-199806000-00008; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050118030; Newport DJ, 2000, CURR OPIN NEUROBIOL, V10, P211, DOI 10.1016/S0959-4388(00)00080-5; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; Sattler JM, 1992, ASSESSMENT CHILDREN, Vthird; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; [No title captured], DOI DOI 10.1037/1040-3590.6.4.372	35	45	45	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	FEB	2002	41	2					157	165		10.1097/00004583-200202000-00009			9	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	514PZ	WOS:000173451400009	11837405				2022-02-06	
J	Thompson, JS; Brown, SA; Khurdayan, V; Zeynalzadedan, A; Sullivan, PG; Scheff, SW				Thompson, JS; Brown, SA; Khurdayan, V; Zeynalzadedan, A; Sullivan, PG; Scheff, SW			Early effects of tribromoethanol, ketamine/xylazine, pentobarbitol, and isoflurane anesthesia on hepatic and lymphoid tissue in ICR mice	COMPARATIVE MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; TOXICITY; XYLAZINE; AVERTIN; RATS	We investigated the effects of various anesthetic agents on hepatic and splenic injury in mice. Three and six hours after intraperitoneal injection of TBE, intramuscular injection of ketamine/xylazine combination (K/X), intraperitoneal injection of pentobarbital (PB), and inhalation of isoflurane (IF), or intraperitoneal and intramuscular injection of control saline, mice were exsanguinated and serum was obtained for measurement of hepatic aspartate transaminase (AST), alanine transaminase (ALT) and gamma-glutamyltransferase (GGT). The spleen and liver also were obtained, and sections were examined by use of routine light microscopy for pathologic changes and for apoptosis, as determined by use of the in situ terminal deoxynucleotidyl transferase-mediated dUPT nick-end-labeling (TUNEL) histochemical analysis. Three hours after TBE or K/X administration, AST activity increased three- to fourfold above that in untreated and saline-injected control animals, and remained high at six hours. Administration of PB did not effect AST activity at three hours, but there was a significant increase at six hours. Activity of ALT was non-significantly increased three hours after TBE and K/X, but not PB administration. Administration of IF had no effect on hepatic enzyme activities, and GGT was not increased after administration of any of the agents. Markedly increased apoptosis was observed in splenic follicles and in hepatic Kupffer and endothelial cells at three hours after TBE and K/X administration, but apoptosis decreased to control levels by six hours. Increased apoptosis was not observed after IF administration. Administration of TBE and K/X causes injury to lymphocytes and to hepatic Kupffer and endothelial cells within three hours, and PB administration induces changes within six hours. Thus, use of these anesthetic agents should be avoided when experiments are being designed to test short-term effects of an experimental intervention on the spleen and possibly on all lymphoid tissues. In addition, they also should be avoided in experiments testing effects on hepatic tissue.	Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Thompson, JS (corresponding author), Univ Kentucky, Dept Internal Med, Room MN644A, Lexington, KY 40536 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER		CHANGTSUI YYH, 1980, CLIN TOXICOL, V16, P41, DOI 10.3109/15563658008989922; CLEMENT JG, 1983, BIOCHEM PHARMACOL, V32, P1411, DOI 10.1016/0006-2952(83)90455-0; ERHARDT W, 1984, RES EXP MED, V184, P159, DOI 10.1007/BF01852390; GARDNER DJ, 1995, LAB ANIM SCI, V45, P199; Kimbro JR, 2000, ANESTHESIOLOGY, V92, P806, DOI 10.1097/00000542-200003000-00024; NIEDERWIESER D, 1990, TRANSPLANTATION, V50, P620, DOI 10.1097/00007890-199010000-00019; RAPER SE, 1987, ANAT RECORD, V218, P116, DOI 10.1002/ar.1092180204; Reid WC, 1999, LAB ANIM SCI, V49, P665; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TAKEDA T, 1987, Journal of Toxicological Sciences, V12, P57; Weiss J, 1999, LAB ANIM, V33, P192, DOI 10.1258/002367799780578417; WIXSON SK, 1987, LAB ANIM SCI, V37, P743; Zeller W, 1998, LAB ANIM, V32, P407, DOI 10.1258/002367798780599811	14	45	45	0	2	AMER ASSOC LABORATORY ANIMAL SCIENCE	MEMPHIS	9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA	1532-0820			COMPARATIVE MED	Comparative Med.	FEB	2002	52	1					63	67					5	Veterinary Sciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Veterinary Sciences; Zoology	527PH	WOS:000174194200009	11900415				2022-02-06	
J	Spikman, JM; Kiers, HAL; Deelman, BG; van Zomeren, AH				Spikman, JM; Kiers, HAL; Deelman, BG; van Zomeren, AH			Construct validity of concepts of attention in healthy controls and patients with CHI	BRAIN AND COGNITION			English	Article							CLOSED-HEAD-INJURY; REACTION-TIME; INTELLIGENCE; DEFICITS; RECOVERY	The present study aimed to examine the construct validity of three aspects of attention, namely focused, divided, and supervisory control of attention. Factor-analytic techniques were applied to scores of healthy subjects on a series of neuropsychological tests tapping these aspects of attention. The two components found did not match the hypothesized aspects and were labeled as Memory-driven Action and Stimulus-driven Reaction. The second question was whether the same components could be found in a group of patients with CHI. The pattern of attentional functions found in healthy subjects had changed qualitatively in patients with CHI. A possible explanation for this result in terms of a shift from automatic to controlled processing is discussed. (C) 2001 Elsevier Science.	Groningen State Univ, Dept Neuropsychol, Groningen, Netherlands; Acad Hosp Groningen, Dept Neuropsychol, NL-9713 EZ Groningen, Netherlands; Groningen State Univ, Heymans Inst Psychol, Groningen, Netherlands		Spikman, JM (corresponding author), Acad Hosp Groningen, Dept Neuropsychol, Poortweg 4,Hanzeplein 1, NL-9713 EZ Groningen, Netherlands.		Kiers, Henk/D-2900-2012	Kiers, Henk/0000-0002-4995-9349; Spikman, Jacoba/0000-0002-6477-0763			Benson D.F., 1986, FRONTAL LOBES; BROUWER WH, 1985, LIMITATIONS ATTENTIO; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; COOK DT, 1979, QUASI EXPT DESIGN AN; DAVIES DR, 1983, PHYSL CORRELATED HUM; Deelman B. G., 1980, NEUROPSYCHOLOGIE NED, P253; DEJONG PF, 1991, THESIS FREE U AMST N; DELAND N, 1995, THESIS U MONTREAL; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; HOCKEY GRJ, 1979, HUMAN STRESS COGNITI; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KIERS HAL, 1989, PSYCHOMETRIKA, V54, P467, DOI 10.1007/BF02294629; KIERS HAL, 1990, USERS MANUAL SCA PRO; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Leonberger FT, 1992, NEUROPSYCHOLOGY, V6, P239, DOI DOI 10.1037/0894-4105.6.3.239; Mesulam M., 1985, PRINCIPLES BEHAV NEU; Miller E, 1970, Cortex, V6, P121; MILLSAP RE, 1988, PSYCHOMETRIKA, V53, P123, DOI 10.1007/BF02294198; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; POGGE DL, 1994, J CLIN EXP NEUROPSYC, V16, P344, DOI 10.1080/01688639408402645; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P182; PRIBRAM KH, 1975, PSYCHOL REV, V82, P116, DOI 10.1037/h0076780; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHUM DHK, 1990, CLIN NEUROPSYCHOL, V4, P163; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STANKOV L, 1988, PSYCHOL AGING, V3, P59, DOI 10.1037/0882-7974.3.1.59; STANOV L, 1983, J EDUC PSYCHOL, V4, P471; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; TANBERGE JMF, 1986, MULTIVARIATE BEHAV R, V21, P41; TENBERGE JMF, 1986, MULTIVAR BEHAV RES, V21, P262; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VELTMAN JC, 1996, NEUROPSYCHOLOGY, V10, P1; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Walsh KW., 1991, UNDERSTANDING BRAIN	45	45	46	1	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	DEC	2001	47	3					446	460		10.1006/brcg.2001.1320			15	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	502BG	WOS:000172723400006	11748900				2022-02-06	
J	Kirkendall, DT; Garrett, WE				Kirkendall, DT; Garrett, WE			Heading in soccer: Integral skill or grounds for cognitive dysfunction?	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; mild traumatic brain injury	TRAUMATIC BRAIN INJURY; FOOTBALL PLAYERS; CONCUSSION; DAMAGE	Objective: To critically review the literature concerning the effect of purposeful heading of a soccer ball and head injuries on reported cognitive dysfunction in soccer players. Data Sources: We searched MEDLINE (1965-2001) and SPORTDiscus (1975-2001) for refereed articles in English combining key words for soccer (eg, soccer, football, association football) with key words for head injuries (eg, concussion, head injury). In addition, literature on cognition and head injuries was obtained. We reviewed reference lists of current literature for pertinent citations that might not have been found in the search procedures. Data Synthesis: The fact that soccer players (and other athletes) have selected cognitive deficits is not questioned, and the popular press is quick to publicize results of questionable validity. The reasons for such deficits are many. Much of the early data implied that heading was the culprit; however, subsequent research has suggested that other interpretations and factors may be potential explanations for these deficits. The current focus is on concussions, a known factor in cognitive dysfunction and a common head injury in soccer. Conclusions/Recommendations: It is difficult to blame purposeful heading for the reported cognitive deficits when actual heading exposure and details of the nature of head-ball impact are unknown. Concussions are a common head injury in soccer (mostly from head-head or head-ground impact) and a factor in cognitive deficits and are probably the mechanism of the reported dysfunction.	Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; US Soccer Federat, Chicago, IL USA		Kirkendall, DT (corresponding author), Univ N Carolina, Dept Orthopaed, CB 7055, Chapel Hill, NC 27599 USA.						ARMSTRONG C, 1994, SCI FOOTBALL, P493; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Frith U, 1998, SCAND J PSYCHOL, V39, P191, DOI 10.1111/1467-9450.393078; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HOLBOURN AHS, 1943, LANCET, P438; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lees K., 1988, SCI FOOTBALL, P385; Lohnes JH, 1994, SPORTS INJURIES MECH, P603; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Luhtanen P, 1994, FOOTBALL SOCCER, P59; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; Neiman J, 1998, ALCOHOL CLIN EXP RES, V22, p346S, DOI 10.1111/j.1530-0277.1998.tb04389.x; Nigg JT, 1998, J ABNORM PSYCHOL, V107, P468, DOI 10.1037/0021-843X.107.3.468; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Reilly TT, 1976, J HUM MOV STUD, V2, P87; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P258; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; VICTOR M, 1989, WERNICKEKORSAKOFF S; 2001, SITE FOOTBALL ALGERI	36	45	45	0	4	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					328	333					6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	557NC	WOS:000175913800019	12937505				2022-02-06	
J	Reid, SR; Roesler, JS; Gaichas, AM; Tsai, AK				Reid, SR; Roesler, JS; Gaichas, AM; Tsai, AK			The epidemiology of pediatric traumatic brain injury in Minnesota	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article; Proceedings Paper	Annual Congress of the American-Academy-of-Pediatrics	OCT 16-19, 1998	SAN FRANCISCO, CALIFORNIA	Amer Acad Pediat			HEAD-INJURY; POPULATION; TRENDS; COMMUNITY; CHILDREN; COUNTY; URBAN	Objectives: To determine the epidemiology of pediatric traumatic brain injury (TBI) in a midwestern state and to examine differences between metropolitan and nonmetropolitan residents. Design: Population-based case series. Participants: Patients aged 0-19 years sustaining TBI in 1993 that resulted in hospitalization or death. Interventions: None. Main Outcome Measures: Incidence, mortality and case-fatality rates, length of hospital stay, discharge status, and Glasgow Outcome Scale score. Results: Nine hundred seventy-seven patients met inclusion criteria. Incidence, mortality, and case-fatality rates were 73.5 per 100 000, 9.3 per 100 000, and 12.8 per 100, respectively. Higher median household incomes and percentages of adult high-school graduates in a patient's census block group correlated with lower incidence. Median length of stay was 2 days. Of those included in the study, 720 patients (74%) were discharged home with self-care. Three hundred fifty-seven patients met criteria for severe TBI; 346 (97%) were assigned Glasgow Outcome Scale scores, of which 161 (47%) had disabilities or died. Severe TBI was associated with nonmetropolitan residence, higher median household income, and certain injury mechanisms. Incidence was similar for metropolitan and nonmetropolitan residents. Median head-region Abbreviated Injury Score, Injury Severity Score, and mortality and case-fatality rates were higher for nonmetropolitan residents. Conclusions: This study reports the lowest incidence of pediatric TBI that results in death or hospitalization to date. One half of severely injured patients suffered poor outcomes. A greater proportion of nonmetropolitan than metropolitan residents suffered severe TBI and had higher mortality and case-fatality rates.	Childrens Hosp & Clin, Dept Emergency Med, St Paul, MN 55102 USA; Univ Minnesota, Dept Hlth, St Paul, MN 55108 USA; Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA		Reid, SR (corresponding author), Childrens Hosp & Clin, Dept Emergency Med, 245 N Smith Ave, St Paul, MN 55102 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BROWN DSO, 1991, SOC SCI MED, V33, P283, DOI 10.1016/0277-9536(91)90362-G; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; *CTR HLTH PROM, 1995, OV TRAUM BRAIN SPIN, P27; *CTR HLTH STAT, 1994, 1993 MINN HLTH STAT, P107; DUNN KA, 1999, REP NIH CONS DEV C R, pB1; Edna T H, 1987, J Oslo City Hosp, V37, P101; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; GABELLA B, 1997, MMWR-MORBID MORTAL W, V46, P8; GAICHAS A, 2000, P NAT C HLTH STAT WA, P29; GOLDSMITH HF, 1993, IMPROVING OPERATIONA, P1; HOROWITZ I, 1982, INT REHABIL MED, V5, P32; Hwang H C, 1997, Inj Prev, V3, P35, DOI 10.1136/ip.3.1.35; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KALSBEEK WD, 1980, J NEUROSURG, V53, P519; KING WD, 1994, PEDIATR EMERG CARE, V10, P34, DOI 10.1097/00006565-199402000-00010; KLAUBER MR, 1981, NEUROSURGERY, V9, P236, DOI 10.1227/00006123-198109000-00003; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LAPORTE RE, 1995, AM J EPIDEMIOL, V142, P1069, DOI 10.1093/oxfordjournals.aje.a117560; MacKenzie E J, 1989, Md Med J, V38, P725; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; *OFF TRAFF SAF, 1999, MINN MOT VEH CRASH F, P1; SINGH GK, 1996, MON VITAL STAT REP, V45, P75; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ., 1995, GUIDELINES SURVEILLA; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; YIP PSF, 1995, AM J EPIDEMIOL, V142, P1059, DOI 10.1093/oxfordjournals.aje.a117559; YIP PSF, 1995, AM J EPIDEMIOL, V142, P1047	38	45	45	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JUL	2001	155	7					784	789		10.1001/archpedi.155.7.784			6	Pediatrics	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	450WF	WOS:000169767300006	11434844	Bronze			2022-02-06	
J	Floyd, CL; Rzigalinski, BA; Weber, JT; Sitterding, HA; Willoughby, KA; Ellis, EF				Floyd, CL; Rzigalinski, BA; Weber, JT; Sitterding, HA; Willoughby, KA; Ellis, EF			Traumatic injury of cultured astrocytes alters inositol (1,4,5) trisphosphate-mediated signaling	GLIA			English	Article						calcium signaling; glutamate; tACPD; neomycin; U73122	CAPACITATIVE CALCIUM-ENTRY; EXPERIMENTAL BRAIN INJURY; STRETCH-INDUCED INJURY; PHOSPHOLIPASE-C; 1,4,5-TRISPHOSPHATE RECEPTOR; COGNITIVE IMPAIRMENT; GLUTAMATE RECEPTORS; CORTICAL-NEURONS; PLASMA-MEMBRANE; GAP-JUNCTIONS	Our previous studies using an in vitro model of traumatic injury have shown that stretch injury of astrocytes causes a rapid elevation in intracellular free calcium ([Ca2+](i)), which returns to near normal by 15 min postinjury. We have also shown that after injury astrocyte intracellular calcium stores are no longer able to release Ca2+ in response to signal transduction events mediated by the second messenger inositol (1,4,5)-trisphosphate (IP3, Rzigalinski et al., 1998). Therefore, we tested the hypothesis that in vitro injury perturbs astrocyte IP3 levels. Astrocytes grown on Silastic membranes were labeled with [H-3]-myo-inositol and stretch-injured. Cells and media were acid-extracted and inositol phosphates isolated using anion-exchange columns. Alter injury, inositol polyphosphate (IP3) levels increased up to 10-fold over uninjured controls. Significant injury-induced increases were seen at 5, 15, and 30 min and at 24 and 48 h postinjury. Injury-induced increases in IPx were equivalent to the maximal glutamate and trans-(1S,3R)-1-amino-1,3-cyclopentanedicarboxylic acid-stimulated IPx production, however injury-induced increases in IPx were sustained through 24 and 48 h postinjury. Injury-induced increases in IPx were attenuated by pretreatment with the phospholipase C inhibitors neomycin (100 muM) or U73122 (1.0 muM). Since we have previously shown that astrocyte [Ca2+](i) returns to near basal levels by 15 min postinjury, the current results suggest that IP3-mediated signaling is uncoupled from its target, the intracellular Ca2+ store. Uncoupling of IP3-mediated signaling may contribute to the pathological alterations seen after traumatic brain injury. GLIA 33:12-23, 2001. (C) 2001 Wiley-Liss, Inc.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Richmond, VA 23298 USA		Rzigalinski, BA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 07288, NS 27214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER		Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Cotrina ML, 1998, J NEUROSCI, V18, P2520; CUNNINGHAM AM, 1993, NEUROSCIENCE, V57, P339, DOI 10.1016/0306-4522(93)90067-P; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DI X, 1999, IN PRESS BRAIN EDEMA; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAROOQUI AA, 1994, J NEUROSCI RES, V38, P6, DOI 10.1002/jnr.490380103; Fisher Stpehen K., 1999, P415; GINSBERG MD, 1993, RES P ARNMD, V71, P207; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hoffman SW, 2000, J NEUROTRAUM, V17, P415, DOI 10.1089/neu.2000.17.415; HUGHES AR, 1990, ENVIRON HEALTH PERSP, V84, P141, DOI 10.2307/3430715; IMAZAWA M, 1989, JPN J PSYCHIAT NEUR, V43, P465; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KIM WT, 1994, GLIA, V11, P173, DOI 10.1002/glia.440110211; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LEVITZKI A, 1987, FEBS LETT, V211, P113, DOI 10.1016/0014-5793(87)81419-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Marmarou A, 1997, ACT NEUR S, V70, P68; McIntosh TK, 1996, LAB INVEST, V74, P315; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; NEDERGAARD M, 1995, J NEUROBIOL, V28, P433, DOI 10.1002/neu.480280404; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OCONNOR ER, 1993, J NEUROSCI, V13, P2638, DOI 10.1523/JNEUROSCI.13-06-02638.1993; OLIVER JM, 1978, AM J PATHOL, V93, P221; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Parsons JT, 1997, J NEUROCHEM, V68, P1124; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PRASAD MR, 1994, J NEUROCHEM, V63, P773; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Roberts RE, 1997, J NEUROCHEM, V69, P1291; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHREIBER D, 1995, P 1995 INT RES C BIO; SHAO Y, 1995, CELL CALCIUM, V17, P187, DOI 10.1016/0143-4160(95)90033-0; Smith RJ, 1996, J PHARMACOL EXP THER, V278, P320; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; Wang JP, 1996, J BIOL CHEM, V271, P8387, DOI 10.1074/jbc.271.14.8387; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WU DQ, 1992, J BIOL CHEM, V267, P25798; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	71	45	47	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	JAN	2001	33	1					12	23		10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	389MY	WOS:000166243200002	11169788				2022-02-06	
J	Hodgkinson, A; Veerabangsa, A; Drane, D; McCluskey, A				Hodgkinson, A; Veerabangsa, A; Drane, D; McCluskey, A			Service utilization following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						follow-up; psychosocial disability; service utilization; traumatic brain injury	BLUNT HEAD-INJURY	Objectives: To document service utilization by people with a traumatic brain injury at different times postinjury and to identify factors that predict service use. Design: Cross-sectional study design. Four groups of subjects were randomly selected from a regional database, according to their time postinjury: 6-18 months; 2-4 years; 6-9 years; and 10-17 years. Subjects: A total of 119 adults with a traumatic brain injury (TBI) Setting: Hospital and community-based clients in Sydney Australia. Outcome measures: Glasgow Outcome Scale, Disability Rating Scale; Functional Independence Measure; Lidcombe Psychosocial Disability Scale; number, type, and frequency of services used in the previous 12 months. Results: Subjects in all four groups used a variety of services. The mean number of services used was 4.2, and there was only a moderate decline in service use over time. The use of medical and allied health services remained high in all four groups. Severity of injury, physical and cognitive disability, and psychosocial disability were all predictors of service utilization. Psychosocial disability was strongly associated with ongoing service utilization. Conclusion: In this study, people with TBI used services well beyond the early stage of recovery Psychosocial disability may be a better predictor of service use than physical and cognitive disability alone.	Liverpool Hlth Serv, Brain Injury Rehabil Med, Liverpool, NSW, Australia; Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL USA; Univ Western Sydney Macarthur, Fac Hlth, Div Occupat Therapy, Campbelltown, NSW 2560, Australia		Hodgkinson, A (corresponding author), Liverpool Hlth Serv, Brain Injury Rehabil Med, Liverpool, NSW, Australia.						BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Fricke J, 1993, AUST OCCUP THER J, V40, P7; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hamilton BB, 1987, REHABILITATION OUTCO; HIGHTOWER CM, 1995, SPE DRILL COMPLETION, V10, P4, DOI 10.2118/26335-PA; JENNETT B, 1975, LANCET, V1, P480; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340	16	45	46	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2000	15	6					1208	1226		10.1097/00001199-200012000-00003			19	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	378ZX	WOS:000165617400003	11056404				2022-02-06	
J	Warden, DL; Salazar, AM; Martin, EM; Schwab, KA; Coyle, M; Walter, J				Warden, DL; Salazar, AM; Martin, EM; Schwab, KA; Coyle, M; Walter, J		DVHIP Study Grp	A home program of rehabilitation for moderately severe traumatic brain injury patients	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; home activities; home rehabilitation; outcome; telephone monitoring	COMMUNITY-BASED REHABILITATION	We have recently reported the results of a prospective controlled randomized trial comparing home versus inpatient cognitive rehabilitation for patients with model-ate to severe head injury. That study showed no overall difference in outcomes between the two groups.(1) In this article, we provide further details of the home program arm of the study ALI patients in the home program received medical treatment as needed. a multidisciplinary in-hospital evaluation, and TBI counseling before entering the eight-week home program, which then included guidance on home activities, as well as weekly telephone calls from a psychiatric nurse.	Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Walter Reed AMC, Def & Vet Head Injury Program, Washington, DC USA; Walter Reed AMC, Neurosurg Serv, Washington, DC USA		Warden, DL (corresponding author), Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.						Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Braverman SE, 1999, BRAIN INJURY, V13, P405; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; CHESTNUT R, 1999, 9E0006 AHCPR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Freeman EA, 1997, BRAIN INJURY, V11, P143, DOI 10.1080/026990597123746; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Pace GM, 1999, BRAIN INJURY, V13, P535; Portnow J, 1991, Clin Geriatr Med, V7, P695; PRIGATANO G, 1984, J NEUROL NEUROSRUG P, V47, P503; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sargent M, 1993, Rehabil Nurs, V18, P380; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Stonnington HH, 1997, BRAIN INJURY, V11, P155, DOI 10.1080/026990597123755; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; Wing J. K., 1974, MEASUREMENT CLASSIFI	17	45	45	1	10	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2000	15	5					1092	1102		10.1097/00001199-200010000-00003			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	359DT	WOS:000089596800003	10970930				2022-02-06	
J	Kirkwood, M; Janusz, J; Yeates, KO; Taylor, HG; Wade, SL; Stancin, T; Drotar, D				Kirkwood, M; Janusz, J; Yeates, KO; Taylor, HG; Wade, SL; Stancin, T; Drotar, D			Prevalence and correlates of depressive symptoms following traumatic brain injuries in children	CHILD NEUROPSYCHOLOGY			English	Article; Proceedings Paper	28th Annual Meeting of the International-Neuropsychological-Society	FEB 09-12, 2000	DENVER, CO	Int Neuropsychol Soc			PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; HEAD-INJURY; ADOLESCENTS; RECOVERY; RELIABILITY; CHILDHOOD; SEVERITY; VALIDITY; STRESS	The prevalence and correlates of depressive symptoms following childhood traumatic brain injuries (TBI), were examined using data drawn from a prospective longitudinal study. Participants included 38 children with severe TBI, 51 with moderate TBI, and 55 with orthopedic injuries (OI). Assessments occurred shortly after injury (baseline) and at 6- and 12-month follow-ups. Children completed the Child Depression Inventory (CDI). Parents rated depressive symptoms using the Child Behavior Checklist (CBC); with baseline ratings reflecting premorbid status. Assessments also included measures of children's neurocognitive functioning and the family environment. The three groups did not differ overall in self-reported symptoms on the CDI, but did display different trends over time. The three groups did not differ on parent ratings of premorbid depressive symptoms on the CBC, but parents reported more depressive symptoms in the TBI groups than in the OI group at 6- and 12-month follow-ups. Child and parent reports were correlated for children in the TBI groups, but not for those in the OI group. Depressive symptoms were related to socioeconomic status in all groups. Socioeconomic status also was a significant moderator of group differences, such that the effects of TBI were exacerbated in children from more disadvantaged homes. Although self-reports of depressive symptoms were related inconsistently to children's verbal memory, parent reports of depressive symptoms were unrelated to IQ or verbal memory. The findings suggest that TBI increases the risk of depressive symptoms, especially among more socially disadvantaged children, and that depressive symptoms are not strongly related to post-injury neurocognitive deficits.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Univ Cincinnati, Dept Phys Med & Rehabil Med, Cincinnati, OH USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Metrohlth Med Ctr, Cleveland, OH USA		Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeates.1@osu.edu	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892; Janusz, Jennifer/0000-0002-6877-0947	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 RO1 NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ 390611] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		Achenbach TM., 1991, MANUAL CHILD BEHAV C; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BENNETT DS, 1994, J PEDIATR PSYCHOL, V19, P149, DOI 10.1093/jpepsy/19.2.149; BIRD HR, 1988, ARCH GEN PSYCHIAT, V45, P1120; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Cohen J., 2013, STAT POWER ANAL BEHA; Cole DA, 2000, PSYCHOL ASSESSMENT, V12, P174, DOI 10.1037//1040-3590.12.2.174; CRAIGHEAD WE, 1995, PSYCHOL ASSESSMENT, V7, P171, DOI 10.1037/1040-3590.7.2.171; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEDEROFF JP, 1993, DEPRESSION NEUROLOGI, P139; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GORE S, 1992, J HEALTH SOC BEHAV, V33, P97, DOI 10.2307/2137249; Hodges K., 1990, PSYCHOL ASSESSMENT J, V2, P489; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KASLOW NJ, 1984, J ABNORM CHILD PSYCH, V12, P605, DOI 10.1007/BF00916853; KENDALL PC, 1989, COGNITIVE THER RES, V13, P109, DOI 10.1007/BF01173268; Kovacs M., 1992, CHILDRENS DEPRESSION; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LARSON RW, 1990, J ABNORM PSYCHOL, V99, P92, DOI 10.1037/0021-843X.99.1.92; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; REINHERZ HZ, 1993, J AM ACAD CHILD PSY, V32, P1155, DOI 10.1097/00004583-199311000-00007; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUTTER M, 1983, DEV NEUROPSYCHIATRY, P83; Sattler JM, 1992, ASSESSMENT CHILDREN, Vthird; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; YEATES KO, IN PRESS J PEDIAT PS; [No title captured]	54	45	45	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	SEP	2000	6	3					195	208		10.1076/chin.6.3.195.3157			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	437EU	WOS:000168978600004	11402397				2022-02-06	
J	Knoblach, SM; Susan, MKC				Knoblach, SM; Susan, MKC			Cortical interleukin-1 beta elevation after traumatic brain injury in the rat: no effect of two selective antagonists on motor recovery	NEUROSCIENCE LETTERS			English	Article						interleukin-1; interleukin-1 receptor antagonist; soluble receptors; expression; neurological dysfunction; brain injury	TUMOR-NECROSIS-FACTOR; RECEPTOR ANTAGONIST; MESSENGER-RNA; HEAD-INJURY; EXPRESSION; CONTRIBUTES; APOPTOSIS; INCREASE; DAMAGE	Interleukin-1 is an inflammatory cytokine implicated in secondary responses to traumatic brain injury. We utilized a specific IL-beta enzyme-linked immunoadsorbant assay to examine the expression of IL-beta after lateral fluid percussion brain injury in the rat. IL-beta was significantly elevated in the ipsilateral injured cortex at 4 h after injury. Increased levels of IL-beta were also observed at 12, 24 and 72 h after injury, although such changes did not reach statistical significance. To determine whether injury-induced IL-beta expression may contribute to subsequent neurological impairment, we treated rats with either of two structurally different, selective IL-1 antagonists and monitored neurological recovery 1,7 and 14 days later. Intracerebroventricular treatment with either the endogenous interleukin-1 receptor antagonist (10 mu g) at 15 min, 2, 4, 6, and 8 h after injury or soluble IL-1 receptors (10 mu g) at 15 min, 4 and 8 h after injury did not significantly alter outcome in a series of motor tasks. These data suggest that cortical elevations of IL-beta follow traumatic brain injury, but they may not contribute to subsequent neurological impairment. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurosci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurol, Washington, DC 20007 USA		Knoblach, SM (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Dept Neurosci, 3970 Reservoir Rd, Washington, DC 20007 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007459] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32HD07459] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR30664-07] Funding Source: Medline		Bagetta G, 1999, NEUROSCIENCE, V89, P1051, DOI 10.1016/S0306-4522(98)00363-7; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FREIDLANDER RM, 1996, J EXP MED, V184, P717; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; JACOBS CA, 1993, INT REV EXP PATHOL, V34, P123; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rothwell NJ, 1997, INT REV NEUROBIOL, V40, P281; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676	19	45	46	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUL 28	2000	289	1					5	8		10.1016/S0304-3940(00)01263-5			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	339EZ	WOS:000088465800002	10899395				2022-02-06	
J	Copland, DA; Chenery, HJ; Murdoch, BE				Copland, DA; Chenery, HJ; Murdoch, BE			Persistent deficits in complex language function following dominant nonthalamic subcortical lesions	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							CLOSED-HEAD-INJURY; LEFT BASAL GANGLIA; STROKE PATIENTS; APHASIA; HEMORRHAGE; INFARCTION; IMPAIRMENT; SUBSEQUENT; THALAMUS; PROFILES	The language abilities of 14 subjects with chronic nonthalamic subcortical (NS) lesions following stroke was assessed using a test battery probing a broad range of language functions. The language battery included the Boston Naming Test (BNT), the Western Aphasia Battery (WAB), and subtests from the Test of language Competence-Expanded Edition, the Test of Word Knowledge, and The Word Test-Revised. The performance of the subjects with NS lesions did not differ significantly from a group of matched non-neurologically impaired subjects on most aspects of the WAB, whereas subjects with NS lesions evidenced deficits on the BNT and in word-list generation, recreating sentences, interpreting ambiguous or figurative passages, and in providing definitions, synonyms, and antonyms. These results suggest that standard aphasia batteries may be largely insensitive to subtle deficits in more cognitively demanding aspects of language function which can occur following NS lesions. The implications of these findings are considered in terms of current theories of subcortical language function.	Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia		Copland, DA (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia.		Copland, David A/F-1409-2010; Copland, David/AAE-5334-2020; Chenery, Helen J/F-5194-2010; Murdoch, Bruce E/C-1397-2012	Copland, David A/0000-0002-2257-4270; Copland, David/0000-0002-2257-4270; 			Aglioti S, 1997, J NEUROLINGUIST, V10, P255, DOI 10.1016/S0911-6044(97)00020-1; Alexander M., 1989, HDB NEUROPSYCHOLOGY, V2, P47; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; ALEXANDER MP, 1987, BRAIN, V110, P961, DOI 10.1093/brain/110.4.961; ALEXANDER MP, 1980, NEUROLOGY, V30, P1193, DOI 10.1212/WNL.30.11.1193; ALEXANDER MP, 1992, NEUROPSYCHOLOGICAL D, P455; ARAM DM, 1990, DEV NEUROPSYCHOL, V6, P301, DOI 10.1080/87565649009540469; ARAM DM, 1989, DEV DYSLEXIA DYSPHAS; Benson D.F., 1986, FRONTAL LOBES; BOCK JK, 1982, PSYCHOL REV, V89, P1, DOI 10.1037/0033-295X.89.1.1; Bowey J., 1984, METALINGUISTIC AWARE, V15, P73; BRUNNER RJ, 1982, BRAIN LANG, V16, P281, DOI 10.1016/0093-934X(82)90087-6; CAPLAN LR, 1990, ARCH NEUROL-CHICAGO, V47, P133, DOI 10.1001/archneur.1990.00530020029011; CAPPA SF, 1983, CORTEX, V19, P227, DOI 10.1016/S0010-9452(83)80016-1; CARAMAZZA A, 1989, BRAIN COGNITION, V10, P256, DOI 10.1016/0278-2626(89)90056-0; CROSSON B, 1985, BRAIN LANG, V25, P257, DOI 10.1016/0093-934X(85)90085-9; Crosson B, 1997, J NEUROLINGUIST, V10, P277, DOI 10.1016/S0911-6044(97)00018-3; Crosson B., 1992, SUBCORTICAL FUNCTION; DAMASIO AR, 1982, ARCH NEUROL-CHICAGO, V39, P15, DOI 10.1001/archneur.1982.00510130017003; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DESPOSITO M, 1995, NEUROLOGY, V45, P38, DOI 10.1212/WNL.45.1.38; DUBOIS B, 1995, ADV NEUROLOGY, V65; Fabbro F, 1996, PERCEPT MOTOR SKILL, V82, P1291, DOI 10.2466/pms.1996.82.3c.1291; FLICKER C, 1987, BRAIN LANG, V31, P187, DOI 10.1016/0093-934X(87)90069-1; Frazier L., 1989, LEXICAL REPRESENTATI, P505; FROMM D, 1985, ARCH NEUROL-CHICAGO, V42, P943, DOI 10.1001/archneur.1985.04060090025009; GODEFROY O, 1994, J NEUROL NEUROSUR PS, V57, P480, DOI 10.1136/jnnp.57.4.480; Gold M, 1997, BRAIN LANG, V57, P374, DOI 10.1006/brln.1997.1750; GURD JM, 1988, NEUROPSYCHOLOGIA, V26, P237, DOI 10.1016/0028-3932(88)90077-2; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; Huisingh R, 1990, WORD TEST REVISED; Kaplan E, 1983, BOSTON NAMING TEST; KENNEDY M, 1993, BRAIN LANG, V44, P284, DOI 10.1006/brln.1993.1019; KENNEDY M, 1989, APHASIOLOGY, V3, P221, DOI 10.1080/02687038908248997; Keppel G., 1992, DESIGN ANAL RES HDB, V2; Kertesz A., 1982, W APHASIA BATTERY; KIRKEVOLD M, 1994, SCAND J CARING SCI, V8, P1; Lethlean JB, 1997, APHASIOLOGY, V11, P39, DOI 10.1080/02687039708248454; Lewis FM, 1998, APHASIOLOGY, V12, P193, DOI 10.1080/02687039808249446; MACDONALD MC, 1994, PSYCHOL REV, V101, P676, DOI 10.1037/0033-295X.101.4.676; MAZZOCCHI F, 1979, CORTEX, V15, P627, DOI 10.1016/S0010-9452(79)80051-9; MEGA MS, 1994, NEUROLOGY, V44, P1824, DOI 10.1212/WNL.44.10.1824; MENDEZ MF, 1989, NEUROLOGY, V39, P349, DOI 10.1212/WNL.39.3.349; METTER EJ, 1988, ARCH NEUROL-CHICAGO, V45, P1229, DOI 10.1001/archneur.1988.00520350067018; MOHR JP, 1975, BRAIN LANG, V2, P3, DOI 10.1016/S0093-934X(75)80050-2; MURDOCH BE, 1986, AUSTR J HUMAN COMMUN, V14, P5; Nadeau SE, 1997, BRAIN LANG, V58, P355, DOI 10.1006/brln.1997.1707; NAESER MA, 1982, ARCH NEUROL-CHICAGO, V39, P2, DOI 10.1001/archneur.1982.00510130004002; NICHOLAS LE, 1989, APHASIOLOGY, V3, P569, DOI 10.1080/02687038908249023; PERFETTI CA, 1990, COMPREHENSION PROCESSES IN READING, P205; PUEL M, 1984, REV NEUROL-FRANCE, V140, P695; Raymer AM, 1997, NEUROPSYCHOLOGIA, V35, P211, DOI 10.1016/S0028-3932(96)00069-3; ROBIN DA, 1990, J SPEECH HEAR DISORD, V55, P90, DOI 10.1044/jshd.5501.90; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; SKYHOJOLSEN T, 1986, BRAIN, V109, P393; TANRIDAG O, 1987, APHASIOLOGY, V1, P107; VALLAR G, 1988, APHASIOLOGY, V2, P463, DOI 10.1080/02687038808248953; Wallesch C-W., 1988, APHASIA, P256; WALLESCH CW, 1983, BRAIN LANG, V20, P286, DOI 10.1016/0093-934X(83)90046-9; WALLESCH CW, 1985, BRAIN LANG, V25, P357, DOI 10.1016/0093-934X(85)90090-2; Wallesch CW, 1997, J NEUROLINGUIST, V10, P267, DOI 10.1016/S0911-6044(97)00019-5; WEILLER C, 1993, BRAIN, V116, P1509, DOI 10.1093/brain/116.6.1509; Wiig E. H., 1989, TEST LANGUAGE COMPET; Wiig EH., 1992, TEST WORD KNOWLEDGE; Winner E., 1988, POINT WORDS CHILDREN; YANG BJ, 1989, BRAIN LANG, V37, P145, DOI 10.1016/0093-934X(89)90105-3	66	45	45	0	4	SINGULAR PUBLISHING GROUP INC	SAN DIEGO	401 WEST A ST, STE 325, SAN DIEGO, CA 92101-7904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	MAR	2000	8	1					1	14					14	Audiology & Speech-Language Pathology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Neurosciences & Neurology	290LH	WOS:000085677400002					2022-02-06	
J	Saatman, KE; Zhang, C; Bartus, RT; McIntosh, TK				Saatman, KE; Zhang, C; Bartus, RT; McIntosh, TK			Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						calcium-activated protease; cytoskeleton; histology; rat; traumatic brain injury	TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; CELL-DEATH; RAT; CYTOSKELETAL; ACTIVATION; BREAKDOWN; RECOVERY	Administration of the selective calpain inhibitor AK295 has been shown to attenuate motor and cognitive dysfunction after brain trauma in rats. To explore mechanisms underlying the behavioral efficacy of posttraumatic calpain inhibition, we investigated histologic consequences of AK295 administration. Anesthetized Sprague-Dawley rats received lateral fluid percussion brain injury of moderate severity (2.2 to 2.4 arm) or served as uninjured controls. At 15 minutes after injury, animals were randomly assigned to receive a 48-hour infusion of either 2 mmol/L AK295 (120 to 140 mg/kg) or saline via the carotid artery. At 48 hours and 1 week after injury, spectrin fragments generated specifically by calpain were detected by Western blotting and immunohistochemistry, respectively, in saline-treated, brain-injured animals. Interestingly, equivalent spectrin breakdown was observed in AK295-treated animals when cortical and hippocampal regions were evaluated. Similarly. administration of the calpain inhibitor did not attenuate cortical lesion size or the numbers of apoptotic cells in the cortex, subcortical white matter, or hippocampus, as verified by terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick-end labeling and morphology, at 48 hours after injury. These data suggest that an overt reduction in spectrin proteolysis, cortical lesion, or apoptotic cell death at 48 hours or 1 week is not required for behavioral improvements associated with calpain inhibition by AK295 after experimental brain injury in rats.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Alkermes Inc, Cambridge, MA USA		Saatman, KE (corresponding author), Univ Penn, Dept Neurosurg, 120 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818] Funding Source: NIH RePORTER		ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BARTH W, 1993, MATH ANN, V295, P25, DOI 10.1007/BF01444875; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; BEHRENS MM, 1995, CELL GROWTH DIFFER, V6, P1375; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Gressner AM, 1997, BIOCHEM BIOPH RES CO, V231, P457, DOI 10.1006/bbrc.1996.5777; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HIRAMATSU K, 1993, STROKE, V24, P1725, DOI 10.1161/01.STR.24.11.1725; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; IWASAKI Y, 1987, BRAIN RES, V406, P99, DOI 10.1016/0006-8993(87)90773-6; James T, 1998, J NEUROSCI RES, V51, P218, DOI 10.1002/(SICI)1097-4547(19980115)51:2<218::AID-JNR10>3.0.CO;2-4; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEWCOMB JK, 1997, J NEUROTRAUM, V14, P369; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sabel BA, 1997, NEUROSCIENTIST, V3, P366, DOI 10.1177/107385849700300609; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Shoeman RL, 1990, INTRACELLULAR CALCIU, P191; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; WANG KKW, 1995, TRENDS PHARMACOL SCI, V15, P412; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	44	45	46	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2000	20	1					66	73		10.1097/00004647-200001000-00010			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	281PJ	WOS:000085169600010	10616794	Bronze			2022-02-06	
J	Hellawell, DJ; Taylor, R; Pentland, B				Hellawell, DJ; Taylor, R; Pentland, B			Persisting symptoms and carers' views of outcome after subarachnoid haemorrhage	CLINICAL REHABILITATION			English	Article							BLUNT HEAD-INJURY; QUALITY-OF-LIFE; EARLY OPERATION; RELATIVES VIEW; HEMORRHAGE; DEFICITS; DEPRESSION; IMPAIRMENT; ADJUSTMENT; COGNITION	Objective: To report the outcome of aneurysmal subarachnoid haemorrhage (SAH) in terms of subjective symptoms and carers' perspective over a period of two years. Design: Forty-four consecutive patients admitted to a Regional Neurosurgical Unit and who survived aneurysmal SAH were invited for outpatient assessment at 6, 12 and 24 months post haemorrhage. Measures: The Glasgow Outcome Scale (GOS) was used to measure global outcome; the Hospital Anxiety and Depression Scale (HAD) to screen for affective symptoms; the Head Injury Symptom Checklist (HISC) to detect symptoms commonly reported after head trauma; and information was collected from a close friend or relative of the patient using the Relative's Questionnaire (RO). Results: GOS outcome was significantly related to the severity of the original haemorrhage, as classified by the World Federation of Neurological Surgeons (WFNS) Grading Scale, on admission to hospital. However, even in cases where patients had made a good recovery according to the GOS, a variety of problems were frequently reported by patients and relatives, and many of these persisted for the duration of the study. The three most common and persistent symptoms were tiredness (63%, 59% and 59% at 6, 12 and 24 months respectively), memory disturbance (50%, 52% and 56%) and passivity (61%, 47% and 46%). In contrast, the prevalence of disturbed mood, as reported using the HAD, was similar to that of the general population. Conclusions: Studies of outcome following SAH should address these subtle disturbances, and information pertaining to potential long-term problems should be provided to patients and relevant others.	Univ Edinburgh, Rehabil Studies Unit, Edinburgh, Midlothian, Scotland; Western Gen Hosp NHS Trust, Edinburgh, Midlothian, Scotland; Scottish Brain Injury Rehabil Serv, Edinburgh, Midlothian, Scotland		Pentland, B (corresponding author), Astley Ainslie Hosp, Grange Loan, Edinburgh EH9 2HL, Midlothian, Scotland.						ANDERSON SI, 1994, CLIN REHABIL, V8, P301; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DRAKE CG, 1988, J NEUROSURG, V68, P985; GOLDBERG RJ, 1995, AM J MED, V98, P278, DOI 10.1016/S0002-9343(99)80375-1; Gray J.M, 1994, CLIN REHABIL, V8, P188, DOI [10.1177/026921559400800302, DOI 10.1177/026921559400800302, DOI 10.1080/09602010902949207]; HELLAWELL DJ, 1997, ADV NEUROTRAUMA RES, P115; Hop JW, 1998, STROKE, V29, P798, DOI 10.1161/01.STR.29.4.798; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; HUTTER BO, 1995, BRIT J NEUROSURG, V9, P465, DOI 10.1080/02688699550041106; HUTTER BO, 1993, NEUROSURGERY, V33, P999; JENNETT B, 1975, LANCET, V1, P80; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LINDSAY K, 1991, NEUROLOGY NEUROSURGE; LJUNGGREN B, 1985, J NEUROSURG, V62, P673, DOI 10.3171/jns.1985.62.5.0673; MCKENNA P, 1989, BRIT MED J, V299, P485, DOI 10.1136/bmj.299.6697.485; MCKENNA P, 1989, NEUROSURGERY, V24, P361, DOI 10.1227/00006123-198903000-00009; Ogden J. A., 1990, NEUROPSY NEUROPSY BE, V3, P260; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; OSullivan MG, 1996, BRIT J NEUROSURG, V10, P445, DOI 10.1080/02688699647069; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; SONESSON B, 1987, NEUROSURGERY, V21, P279, DOI 10.1227/00006123-198709000-00001; SORYAL I, 1992, CLIN REHABIL, V6, P103; VANGIJN J, 1994, STROKE, V25, P1623, DOI 10.1161/01.STR.25.8.1623; VILKKI J, 1990, NEUROSURGERY, V26, P579, DOI 10.1227/00006123-199004000-00004; Wade D, 1992, MEASUREMENT NEUROLOG; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	45	45	0	3	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	AUG	1999	13	4					333	340		10.1191/026921599669500092			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	223NB	WOS:000081846200008	10460121				2022-02-06	
J	Tellier, A; Della Malva, LC; Cwinn, A; Grahovac, S; Morrish, W; Brennan-Barnes, M				Tellier, A; Della Malva, LC; Cwinn, A; Grahovac, S; Morrish, W; Brennan-Barnes, M			Mild head injury: a misnomer	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; CEREBRAL PERFUSION; CT; SEQUELAE; RISK; CLASSIFICATION; TOMOGRAPHY; SPECT; MRI	Despite controversy surrounding the concept of mild head injury (MHI), it is becoming evident that even a head trauma termed 'mild' may result in significant behavioural sequelae. The present study was an attempt at documenting structural cerebral damage, by way of computerized tomography, in a group of patients having suffered a MHI as defined by the Glasgow Coma Scale (GCS) score. A 1-year retrospective chart review identified 80 MHI patients who presented to the Emergency department of a lead hospital for trauma. Sixty-six per cent of these MHI patients were scanned. Evidence of intracranial abnormalities was obtained in 31% of the overall sample. Patients with a lower GCS score had a higher percentage of abnormal scans than those with a GCS score of either 14 or 15. The present findings suggest that a MHI can be associated with significant morbidity, and that a MHI group does not constitute a homogeneous pool of patients.	Ottawa Hosp, Dept Psychol, Neuropsychol Serv, Ottawa, ON K1H 8L6, Canada; Ottawa Hosp, Trauma Serv, Ottawa, ON K1H 8L6, Canada; Ottawa Hosp, Dept Radiol, Ottawa, ON K1H 8L6, Canada; Rehabil Ctr, Psychol Serv, Ottawa, ON, Canada		Tellier, A (corresponding author), Ottawa Hosp, Dept Psychol, Neuropsychol Serv, Module Q,Gen Campus,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Ardila A, 1989, NEUROPSYCHOLOGY, V3, P23, DOI 10.1037//0894-4105.3.1.23; Bailey B. N., 1989, TXB HEAD INJURY, P308; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT, 1989, MILD HEAD INJURY, P257; BECKER DP, 1990, NEUROLOGICAL SURG, P2017; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; BINDER LM, 1994, 22 ANN M INT NEUR SO; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Colohan A. R. T., 1986, J HEAD TRAUMA REHAB, V1, P13; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; FISCHER RP, 1981, J TRAUMA, V21, P920, DOI 10.1097/00005373-198111000-00002; GEVINS A, 1992, J HEAD TRAUMA REHAB, V7, P78; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GRAY C, 1992, EARTH ISL J, V7, P33; HAAS DC, 1988, J NEUROSURG, V68, P181, DOI 10.3171/jns.1988.68.2.0181; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; ICHISE M, 1994, J NUCL MED, V35, P217; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Jennett B, 1981, MANAGEMENT HEAD INJU; JOSEPH R, 1990, NEUROPSYCHOLOGY NEUR, P277; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1977, CORTEX, V13, P119, DOI 10.1016/S0010-9452(77)80003-8; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; Lidvall H., 1974, ACTA NEUROL SCAND, V50, P3; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; Newberg AB, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199612000-00009; NEWTON MR, 1989, NUCL MED COMMUN, V10, P254; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF RM, 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199309000-00008; RUFF RM, 1990, NEUROPSYCHOLOGICAL F, P161; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stewart DP, 1996, ACAD EMERG MED, V3, P21, DOI 10.1111/j.1553-2712.1996.tb03297.x; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; TEASDALE G, 1974, LANCET, V2, P81; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13, DOI 10.1097/00001199-199309000-00004	59	45	45	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1999	13	7					463	475					13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	215GT	WOS:000081374100001	10462145				2022-02-06	
J	Aronowski, J; Cho, KH; Strong, R; Grotta, JC				Aronowski, J; Cho, KH; Strong, R; Grotta, JC			Neurofilament proteolysis after focal ischemia; When do cells die after experimental stroke?	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						neurofilament proteolysis; focal ischemia; reperfusion injury; infarct maturation	CEREBRAL-ARTERY OCCLUSION; CALCIUM-ACTIVATED PROTEOLYSIS; TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN INJURY; CYTOSKELETAL DERANGEMENTS; NEURONAL NECROSIS; INFARCT VOLUME; RATS; DEGRADATION; TRANSPORT	To determine the occurrence and time-course of presumably irreversible subcellular damage after moderate focal ischemia, rats were subjected to 1, 3, 6, 9, or 24 hours of permanent unilateral middle cerebral and common carotid occlusion or 3 hours of reversible occlusion followed by 3, 6, or 21 hours of reperfusion. The topography and the extent of damage were analyzed with tetrazolium staining and immunoblot using an antibody capable of detecting breakdown of neurofilament. Neurofilament proteolysis began after 3 hours in the infarct core but was still incomplete in penumbral regions up to 9 hours. Similarly, tetrazolium-staining abnormalities were observed in the core of 50% of animals after 3 hours of ischemia. At 6 hours of permanent ischemia, infarct volume was maximal, and further prolongation of occlusion to 9 or 24 hours did nor increase abnormal tetrazolium staining. In contrast to permanent ischemia and in agreement with the authors' previous demonstration of "reperfusion injury" in this model, prolongation of reperfusion from 3 hours to 6 and 21 hours after 3 hours of reversible occlusion gradually augmented infarct volume by 203% and 324%, respectively. Neurofilament proteolysis initiated approximately 3 hours after ischemia was quantitatively greatest in the core and extended during reperfusion to incorporate penumbra with a similar time course to that of tetrazolium abnormalities. These data demonstrate that, at least as measured by neurofilament breakdown and mitochondrial failure, extensive cellular damage is not present in penumbral regions for up to 9 hours, suggesting the potential for rescuing these regions by appropriate and timely neuroprotective strategies.	Univ Texas, Sch Med, Dept Neurol, Houston, TX 77030 USA; Chonnam Univ, Sch Med, Dept Neurol, Kwangju, South Korea		Grotta, JC (corresponding author), Univ Texas, Sch Med, Dept Neurol, 6431 Fannin,Rm 7-044, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023979] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS23979] Funding Source: Medline		ARONOWSKI J, 1992, J NEUROCHEM, V58, P1743, DOI 10.1111/j.1471-4159.1992.tb10049.x; Aronowski J, 1997, J CEREBR BLOOD F MET, V17, P1048, DOI 10.1097/00004647-199710000-00006; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; GARCIA JH, 1993, AM J PATHOL, V142, P623; GARCIA JH, 1995, STROKE, V26, P636, DOI 10.1161/01.STR.26.4.636; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; GRIFFIN JW, 1988, ANN NEUROL, V23, P3, DOI 10.1002/ana.410230103; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; MORRIS JR, 1982, J CELL BIOL, V92, P192, DOI 10.1083/jcb.92.1.192; NAKAMURA M, 1992, EXP BRAIN RES, V89, P31; OGATA N, 1989, J NEUROSURG, V70, P103, DOI 10.3171/jns.1989.70.1.0103; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SCHLAEPFER WW, 1985, PROG BRAIN RES, V63, P185; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; YANG GY, 1994, STROKE, V25, P1658, DOI 10.1161/01.STR.25.8.1658; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	28	45	46	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	1999	19	6					652	660		10.1097/00004647-199906000-00008			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	277TB	WOS:000084948700008	10366195	Bronze			2022-02-06	
J	Watt, KJ; O'Carroll, RE				Watt, KJ; O'Carroll, RE			Evaluating methods for estimating premorbid intellectual ability in closed head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						NART; CCRT; STW; assessment; cognitive; premorbid	CONTEXTUAL READING TEST; DEMOGRAPHIC-VARIABLES; BRAIN INJURY; UK SAMPLE; INTELLIGENCE; DEPRESSION; PERFORMANCE; DEMENTIA; IQ	Objectives-The present study examines the utility of three measures of premorbid intellectual functioning in closed head injury, the National adult reading test (NART), the Cambridge contextual reading test (CCRT), and the spot the word test (STW). Methods-In the first experiment, a group of 25 patients with closed head injury were compared with 50 healthy controls and 20 orthopaedic trauma controls. In the second experiment, the strength of correlation between the premorbid measures and current intellectual level were assessed in 114 healthy adults. Results-The head injured group performed significantly more poorly than both control groups on measures of current intellectual ability. However, no significant differences emerged between the groups on any of the premorbid measures. In the large control sample, both the NART and the CCRT accounted for about 50% of the variance in current verbal intelligence. However, by contrast, the STW only accounted for 29% of the variability in verbal intelligence. Adding demographic variables to the prediction of current intellectual level increased the amount of variance explained to 60% for the NART, 62% for the CCRT, but only 41% for the STW. Conclusion-The results provide supportive evidence for the use of the CCRT and NART in estimating premorbid intellectual functioning in patients who have sustained closed head injuries, but suggest caution when employing the STW.	Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; St Johns Hosp, Dept Clin Psychol, Livingston EH54 6PP, West Lothian, Scotland		O'Carroll, RE (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.		O'Carroll, Ronan E/A-5040-2009	O'Carroll, Ronan E/0000-0002-5130-291X			AUSTIN MP, 1992, J AFFECT DISORDERS, V25, P21, DOI 10.1016/0165-0327(92)90089-O; BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; BEARDSALL L, 1994, J CLIN EXP NEUROPSYC, V16, P232, DOI 10.1080/01688639408402634; Benton A., 1978, MULTILINGUAL APHASIA; Conway SC, 1997, BRIT J CLIN PSYCHOL, V36, P623, DOI 10.1111/j.2044-8260.1997.tb01267.x; Crawford J.R., 1992, HDB NEUROPSYCHOLOGIC, P21; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P192, DOI 10.1080/13854049708407050; CRAWFORD JR, 1989, BRIT J CLIN PSYCHOL, V28, P275, DOI 10.1111/j.2044-8260.1989.tb01377.x; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; CRAWFORD JR, 1992, BRIT J CLIN PSYCHOL, V31, P327, DOI 10.1111/j.2044-8260.1992.tb00999.x; CRAWFORD JR, 1987, BRIT J CLIN PSYCHOL, V26, P313, DOI 10.1111/j.2044-8260.1987.tb01366.x; CRAWFORD JR, 1988, BRIT J CLIN PSYCHOL, V27, P181, DOI 10.1111/j.2044-8260.1988.tb00770.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HART S, 1986, BRIT J CLIN PSYCHOL, V25, P119, DOI 10.1111/j.2044-8260.1986.tb00680.x; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; Nelson H.E., 1982, NATL ADULT READING T; NELSON HA, 1978, CORTEX, V14, P233; NELSON HE, 1975, BRIT J SOC CLIN PSYC, V14, P259, DOI 10.1111/j.2044-8260.1975.tb00178.x; Nelson HE, 1991, REVISED NATL ADULT R; OCarroll R, 1995, NEUROCASE, V1, P83, DOI 10.1080/13554799508402350; Perez SA, 1996, ARCH CLIN NEUROPSYCH, V11, P491; SHARPE K, 1991, BRIT J CLIN PSYCHOL, V30, P381, DOI 10.1111/j.2044-8260.1991.tb00962.x; Trenerry M., 1988, STROOP NEUROPSYCHOLO; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; Williams JM, 1997, ARCH CLIN NEUROPSYCH, V12, P745, DOI 10.1016/S0887-6177(97)00048-6; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	45	46	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	1999	66	4					474	479		10.1136/jnnp.66.4.474			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	181TA	WOS:000079457400011	10201419	Green Published, Bronze			2022-02-06	
J	Bell, MJ; Kochanek, PM; Heyes, MP; Wisniewski, SR; Sinz, EH; Clark, RSB; Blight, AR; Marion, DW; Adelson, PD				Bell, MJ; Kochanek, PM; Heyes, MP; Wisniewski, SR; Sinz, EH; Clark, RSB; Blight, AR; Marion, DW; Adelson, PD			Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						head injury; inflammation; shaken infant syndrome; neurotoxin; child abuse; macrophage; quinolinic acid; NMDA; head trauma; excitotoxicity	INTRAVENTRICULAR INFUSION; NEUROLOGICAL DISEASE; L-TRYPTOPHAN; SPINAL-CORD; AMINO-ACIDS; HEAD-INJURY; RAT; MODEL; EXCITOTOXICITY; ACCUMULATION	Objective: To measure quinolinic acid, a macrophage-derived neurotoxin, in the cerebrospinal fluid (CSF) of children after traumatic brain injury (TBI) and to correlate CSF quinolinic acid concentrations to clinically important variables. Design: A prospective, observational study. Setting: The pediatric intensive care unit in Children's Hospital of Pittsburgh, a tertiary care, university based children's hospital. Patients: Seventeen critically ill children following severe TBI (Glasgow Coma Scale score <8) whose care required the place ment of an intraventricular catheter for continuous drainage of CSF, interventions: None, Measurements and Main Results: Patients ranged in age from 2 mos to 16 yrs (mean 6.0 yrs), CSF was collected immediately on placement of the ventricular catheter and daily thereafter, Quinolinic acid concentration was measured by gas chromatography/mass spectroscopy in 69 samples (4.0 +/- 0.4 [SEM] samples per patient), CSF quinolinic acid concentration progressively increased after injury (p = .034, multivariate analysis) and was increased in nonsurvivors vs, survivors (p = .002, multivariate analysis). CSF quinolinic acid concentration was not associated with age. Although overall CSF quinolinic acid concentration was not associated with shaken injury (p = .16, multivariate analysis), infants suffering with shaken infant syndrome had increased admission CSF quinolinic acid concentrations compared with children with accidental mechanisms of injury (p = .027, Mann-Whitney Rank Sum test), Conclusions: A large and progressive increase in the macrophage-derived neurotoxin quinolinic acid is seen following severe TBI in children, The increase is strongly associated with increased mortality, Increased CSF quinolinic acid concentration on admission in children with shaken infant syndrome could reflect a delay in presentation to medical attention or age-related differences in quinolinic acid production, These findings raise the possibility that quinolinic acid may play a role in secondary injury after TBI in children and suggest an interaction between inflammatory and excitotoxic mechanisms of injury following TBI.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA USA; Childrens Natl Med Ctr, Dept Pediat & Crit Care Med, Washington, DC 20010 USA; Univ N Carolina, Dept Neurol Surg, Chapel Hill, NC USA; NIMH, Lab Neurotoxicol, Bethesda, MD 20892 USA		Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Adelson, David/W-2083-2019; Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Sinz, Elizabeth/0000-0001-7129-6193	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; Blight AR, 1997, J NEUROTRAUM, V14, P89, DOI 10.1089/neu.1997.14.89; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GIULIAN D, 1993, J NEUROSCI, V13, P29; HEYES MP, 1995, J NEUROL SCI, V133, P112, DOI 10.1016/0022-510X(95)00164-W; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1993, BRAIN, V116, P1425, DOI 10.1093/brain/116.6.1425; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LAPIN IP, 1982, NEUROPHARMACOLOGY, V21, P1227, DOI 10.1016/0028-3908(82)90125-3; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Misztal M, 1996, NEUROPHARMACOLOGY, V35, P449, DOI 10.1016/0028-3908(96)00005-6; Misztal M, 1996, EUR J PHARMACOL, V296, P1, DOI 10.1016/0014-2999(95)00682-6; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; SAITO K, 1993, J NEUROCHEM, V61, P2061, DOI 10.1111/j.1471-4159.1993.tb07443.x; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; SUSEL Z, 1991, NEUROSCI LETT, V121, P234, DOI 10.1016/0304-3940(91)90693-N; THOMAS SR, 1994, J BIOL CHEM, V269, P14457; WALKER ML, 1984, CHILD BRAIN, V11, P387; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5	24	45	47	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	1999	27	3					493	497		10.1097/00003246-199903000-00023			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182LH	WOS:000079500100022	10199527				2022-02-06	
J	Martelli, MF; Grayson, RL; Zasler, ND				Martelli, MF; Grayson, RL; Zasler, ND			Posttraumatic headache: Neuropsychological and psychological effects and treatment implications	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						chronic pain; head trauma; neuropsychological tests; posttraumatic headache; treatment	CHRONIC PAIN; TEMPOROMANDIBULAR DISORDERS; STRESS-DISORDER; INJURY PATIENTS; CERVICAL-SPINE; ATTENTION; WHIPLASH; DEFICITS; MIGRAINE; TRAUMA	Posttraumatic headache (PTHA) is a frequent occurrence following trauma to the head, brain, and/or neck. Estimates of persistence for 6 months are as high as 44%. Review of available studies examining the effect of headache on neuropsychological test findings reveals that chronic headache pain, and chronic pain generally, exerts a significant and negative effect that poses a challenge to differential diagnostic efforts in the evaluation of mild brain injury. Given that PTHA is the most common postconcussive symptom and most frequent type of posttraumatic pain associated with mild traumatic brain injury (TBI), it follows that resolution of the postconcussion syndrome, and successful posttraumatic adaptation, may frequently rely on success in coping with PTHA symptomatology. Viewing PTHA from a biopsychosocial perspective, a general outline is offered for improving both assessment and treatment of PTHA. In addition, the most promising psychology-based treatment interventions are reviewed.	Concuss Care Ctr Virginia, Glen Allen, VA 23060 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychiat, Dept Psychiat, Richmond, VA 23298 USA; Malcolm Grow Med Ctr, Andrews AFB, MD USA; Tree Life, Glenn Allen, VA USA		Martelli, MF (corresponding author), Concuss Care Ctr Virginia, 10120 W Broad St,Suites G& H, Glen Allen, VA 23060 USA.						Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANDRASIK F, 1990, NEUROL CLIN, V8, P961, DOI 10.1016/S0733-8619(18)30329-3; ANDRASIK F, 1987, BIOFEEDBACK STUDIES; ARENA JG, 1997, ELECTROMYOGRAPHY APP; Auerbach SM, 1998, STRESS MANAGEMENT PS; BAKAL DA, 1982, PSYCHOBIOLOGY CHRONI; Bennett TL, 1988, COGNITIVE REHABILIAT, V6, P34; BLANCHARD EB, 1994, HDB PSYCHOTHERAPY BE; DALY E, 1987, BRIT J MED PSYCHOL, V60, P85; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; DeBoever JA, 1996, J ORAL REHABIL, V23, P91; DEVORE JR, 1998, PHYSICAL MED REHABIL, V12, P111; Di Stefano G, 1993, Z Unfallchir Versicherungsmed, V86, P97; DIPIERO V, 1991, PAIN, V46, P9, DOI 10.1016/0304-3959(91)90026-T; DISTEFANO G, 1995, ACTA NEUROL SCAND, V91, P346; Dodrill CB, 1997, CLIN NEUROPSYCHOL, V11, P1, DOI 10.1080/13854049708407025; DUCKRO PN, 1985, HEADAHCE, V25, P180; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; Epstein J B, 1992, J Can Dent Assoc, V58, P488; FLOR H, 1985, J CONSULT CLIN PSYCH, V53, P354, DOI 10.1037/0022-006X.53.3.354; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; Gimse R, 1997, J CLIN EXP NEUROPSYC, V19, P838, DOI 10.1080/01688639708403764; Goldberg Michael B., 1996, Journal of Orofacial Pain, V10, P126; GOLDSTEIN J, 1991, MED CLIN N AM, V75, P641, DOI 10.1016/S0025-7125(16)30439-4; Gramling SE, 1996, J BEHAV THER EXP PSY, V27, P245, DOI 10.1016/S0005-7916(96)00027-4; GRAYSON EL, 1997, ASS ADV BEH THER AAB; GREEN R, 1991, DYNAMICS HLTH WELLNE; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; HAAS DC, 1993, HEADACHES; Ham LP, 1996, BIOFEEDBACK SELF-REG, V21, P93, DOI 10.1007/BF02284689; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; HINNANT DW, 1994, HDB CHRONIC PAIN MAN; HOLROYD KA, 1978, J CONSULT CLIN PSYCH, V46, P1036; JARVIS P, 1998, B NATL ACAD NEUROPSY, V14, P7; JENSEN MP, 1991, PAIN, V47, P249, DOI 10.1016/0304-3959(91)90216-K; Karlsborg M, 1997, ACTA NEUROL SCAND, V95, P65, DOI 10.1111/j.1600-0404.1997.tb00071.x; KAY T, 1992, REHABILITATION POSTC; Keidel M, 1997, NERVENARZT, V68, P769, DOI 10.1007/s001150050193; KEWMAN DG, 1991, INT J PSYCHIAT MED, V21, P253, DOI 10.2190/FRYK-TMGA-AULW-BM5G; LASKIN DM, 1969, J AM DENT ASSOC, V79, P147, DOI 10.14219/jada.archive.1969.0234; LEIJDEKKERS MLA, 1990, HEADACHE, V30, P352, DOI 10.1111/j.1526-4610.1990.hed3006352.x; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; MARTELLI MF, IN PRESS GUIDE FUNCT; MARTIN PR, 1993, PSYCHOL MANAGEMENT C; MEDINA JL, 1992, HEADACHE, V32, P180, DOI 10.1111/j.1526-4610.1992.hed3204180.x; MILLER L, 1993, PSYCHOTHERAPY BRAIN; MOSS RA, 1987, J CRANIOMANDIB PRACT, V5, P196; MOUNTZ JM, 1995, ARTHRITIS RHEUM, V38, P926, DOI 10.1002/art.1780380708; Mountz JM, 1998, AM J MED SCI, V315, P385, DOI 10.1097/00000441-199806000-00007; MUSE M, 1986, PAIN, V25, P389, DOI 10.1016/0304-3959(86)90243-5; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PACKARD RC, 1994, SEMIN NEUROL, V14, P40, DOI 10.1055/s-2008-1041057; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; PARKER RS, 1995, J COGNITIVE REHABILI, V13, P14; Penzien DB, 1993, HEADACHE DIAGNOSIS T; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RADANOV BP, 1992, ACTA NEUROL SCAND, V85, P358; Rudy TE, 1989, MULTIAXIAL ASSESSMEN; SCHIFFMAN E, 1995, HEADACHE, V35, P121, DOI 10.1111/j.1526-4610.1995.hed3503121.x; SCHREIBER S, 1993, PAIN, V54, P107, DOI 10.1016/0304-3959(93)90105-X; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; Sendrowski DP, 1997, OPTOMETRY VISION SCI, V74, P660, DOI 10.1097/00006324-199708000-00027; TOBIN DL, 1988, COGNITIVE THER RES, V12, P325, DOI 10.1007/BF01173301; Todd D., 1998, COGNIPHOBIA SCALE C, pdomain; Todd D, 1998, FORENSIC EXAMINER, V7, P14; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; Tsushima WT, 1996, HEADACHE, V36, P613, DOI 10.1046/j.1526-4610.1996.3610613.x; TURK DC, 1990, PAIN, V43, P27, DOI 10.1016/0304-3959(90)90047-H; TURK DC, 1986, PAIN MANAGEMENT HDB; TURK DC, 1978, COGNITIVE BEHAV THER; ZEIGLER DK, 1995, ARCH NEUROL-CHICAGO, V52, P602; 1995, BEHAV THER RES, V33, P391	72	45	46	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1999	14	1					49	69		10.1097/00001199-199902000-00007			21	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	165LT	WOS:000078523100007	9949246				2022-02-06	
J	Uysal, S; Hibbard, MR; Robillard, D; Pappadopulos, E; Jaffe, M				Uysal, S; Hibbard, MR; Robillard, D; Pappadopulos, E; Jaffe, M			The effect of parental traumatic brain injury on parenting and child behavior	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							BLUNT HEAD-INJURY; DEPRESSED MOTHERS; SOCIAL SUPPORT; FAMILY; PERCEPTIONS; RELATIVES; PSYCHOPATHOLOGY; INVENTORY; DISORDER; SPOUSES	Objectives: To examine (1) the parenting skills of individuals with traumatic brain injury (TBI) and their spouses, (2) the effects of parental TBI on children, and (3) the effects of parental TBI on levels of depression for all family members. Design: Independent two-tailed t tests and Pearson chi-square analyses were utilized to compare parents with TBI versus parents without TBI, spouses of parents with TBI versus spouses of parents without TBI, and children of parents with TBI versus children of parents without TBI. Setting: Urban, suburban, and rural New York State. Participants: 32 families participated in the study; in 16 families one parent had a TBI and in the remaining 16 families, no parent had a TBI. Eighteen children from families with parental TBI and 26 children from families without TBI were interviewed. On average, parents with TBI were 9 years post-onset of injury at the time of interview. Main Outcome Measures: The parents' battery explored parents' perspectives of their own parenting skills (Parent Behavior Form, Parent Practices Questionnaire, Parenting Dimensions Inventory), their mood (Beck Depression Inventory), and the behaviors of their children (Children's Problem Checklist, Behavior Rating Profile). The child's battery tapped the children's perspective of their own behaviors (Behavior Rating Profile), their mood (Children's Depression Inventory), and the parental abilities of both parents (Parent Behavior Form, Parent Practices Questionnaire). Results: Although parents with TBI and their spouses were similar to their comparison group in many parenting skills, parents with TBI reported less goal setting, less encouragement of skill development, less emphasis on obedience to rules and orderliness, less promotion of work values, less nurturing, and lower levels of active involvement with their children. Spouses of individuals with TBI, compared to their counterparts, reported less feelings of warmth, love, and acceptance toward their children. Children from families in which a parent had a TBI perceived both parents as more lax in their discipline, with the parent without TBI perceived as less actively involved in parenting roles. No differences in the frequency of behavioral problems were found between children of parents with TBI and children of parents without TBI. Parents with TBI and their children experienced more symptoms of depression relative to their respective comparison groups. Conclusion: Parental TBI has select consequences for all family members: individuals with TBI, their spouses, and their children. Prospective clinical evaluations of family members and proactive interventions to maximize family adjustment and minimize affective distress are indicated.	Mt Sinai Med Ctr, New York, NY 10029 USA; CUNY Hunter Coll, Educ Fdn Program, New York, NY 10021 USA; CUNY Hunter Coll, Counseling Program, New York, NY 10021 USA; Long Isl Jewish Med Ctr, Hillside Hosp, Glen Oaks, NY 11004 USA		Hibbard, MR (corresponding author), Mt Sinai Med Ctr, 1 Gustave Levy Pl,Box 1240, New York, NY 10029 USA.						BEARDSLEE WR, 1983, AM J PSYCHIAT, V140, P825; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1984, CLOSED HEAD INJURY P; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown L, 1990, BEHAV RATING PROFILE; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; CUMMINGS EM, 1995, DEV PSYCHOL, V31, P425, DOI 10.1037/0012-1649.31.3.425; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; DODGE KA, 1990, DEV PSYCHOL, V26, P3, DOI 10.1037/0012-1649.26.1.3; FRANKEL F, 1983, J PEDIAT NURS, V8, P177; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GELFAND DM, 1990, CLIN PSYCHOL REV, V10, P329, DOI 10.1016/0272-7358(90)90065-I; GILBERT LA, 1983, J MARRIAGE FAM, V45, P203, DOI 10.2307/351309; GOODMAN SH, 1990, DEV PSYCHOL, V26, P31, DOI 10.1037/0012-1649.26.1.31; HAMILTON EB, 1993, FAM PROCESS, V32, P329, DOI 10.1111/j.1545-5300.1993.00329.x; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HU XH, 1993, CAN MED ASSOC J, V149, P421; KASHANI JH, 1985, CHILD PSYCHIAT HUM D, V15, P234, DOI 10.1007/BF00706367; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; Kovacs M., 1992, CHILDRENS DEPRESSION; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUTTER M, 1984, PSYCHOL MED, V14, P853, DOI 10.1017/S0033291700019838; Scherer DG, 1996, J CLIN CHILD PSYCHOL, V25, P156, DOI 10.1207/s15374424jccp2502_4; SCHINCKA JA, 1985, CHILDRENS PROBLEMS C; Slater M. A., 1987, ADV FAMILY INTERVENT; STRAYHORN JM, 1988, J AM ACAD CHILD PSY, V27, P613, DOI 10.1097/00004583-198809000-00016; Urbach J R, 1989, Psychiatr Med, V7, P17; URBACH JR, 1991, PSYCHOSOMATICS, V32, P24, DOI 10.1016/S0033-3182(91)72108-7; WEISSMAN MM, 1984, J AM ACAD CHILD PSY, V23, P78, DOI 10.1097/00004583-198401000-00011; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WORELL J, COMMUNICATION; ZEIGLER EA, 1987, J REHABIL, V53, P50	42	45	46	0	10	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1998	13	6					57	71		10.1097/00001199-199812000-00007			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	141KF	WOS:000077142300007	9885318				2022-02-06	
J	Sato, M; Noble, LJ				Sato, M; Noble, LJ			Involvement of the endothelin receptor subtype A in neuronal pathogenesis after traumatic brain injury	BRAIN RESEARCH			English	Article						traumatic brain injury; endothelin-1; Ro 61-1790; heat shock protein; microglia	CEREBRAL BLOOD-FLOW; ANEURYSMAL SUBARACHNOID HEMORRHAGE; SPINAL CORD BARRIER; CEREBROSPINAL-FLUID; ET(A) RECEPTORS; TIME COURSE; RAT; VASOSPASM; RESPONSES; BREAKDOWN	Endothelin-1 (ET-1) is a 21 amino acid peptide that has been closely linked to cerebral vasospasm and more recently to oxidative stress after traumatic brain injury. In this study, we have examined the effects of the endothelin receptor subtype A antagonist, Ro 61-1790, on acute cortical neuronal injury and delayed neuronal death in the cerebellum after mild traumatic brain injury. Rats were administered Ro 61-1790 or vehicle for 24 h after injury and euthanized at 1 day, 3 days, or 7 days. Heat shock protein70 (HSP70), a marker of neuronal stress/injury, was immunolocalized in the cortex. Induction of heme oxygenase-1 (HO-1) and enhanced immunoexpression of the complement C3bi receptor, both of which are indicators of cerebellar glial reactivity, and Purkinje cell loss were evaluated in the cerebellum. There was maximal induction of HSP70 in cortical neurons at 24 h postinjury in all animals. Drug treated animals showed significantly fewer HSP70 labeled cortical neurons at this time point. There were fewer reactive glia in the cerebellum of drug treated animals as compared to vehicle controls at 3 days postinjury. However, at 7 days postinjury glial reactivity and Purkinje cell loss were similar in both groups. These findings demonstrate that Ro 61-1790, when administered for the first 24 h postinjury, limits acute neuronal injury in the cortex, transiently influences glial reactivity in the cerebellum, and does not attenuate delayed Purkinje cell death. The latter finding may reflect the duration of infusion of the drug. (C) 1998 Elsevier Science B.V. All rights reserved.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA		Noble, LJ (corresponding author), Univ Calif San Francisco, Dept Neurosurg, 521 Parnassus Ave,Room C224, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; ASANO T, 1989, BIOCHEM BIOPH RES CO, V159, P1345, DOI 10.1016/0006-291X(89)92258-4; CLOZEL M, 1993, LIFE SCI, V52, P825, DOI 10.1016/0024-3205(93)90081-D; COSENTINO F, 1994, STROKE, V25, P904, DOI 10.1161/01.STR.25.4.904; DEOLIVEIRA AM, 1995, PEPTIDES, V16, P139, DOI 10.1016/0196-9781(94)00169-7; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; FILEP JG, 1993, BRIT J PHARMACOL, V109, P880, DOI 10.1111/j.1476-5381.1993.tb13657.x; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GAETANI P, 1994, J NEUROL NEUROSUR PS, V57, P66, DOI 10.1136/jnnp.57.1.66; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GREENBERG DA, 1992, NEUROLOGY, V42, P25, DOI 10.1212/WNL.42.1.25; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; KARNE S, 1993, J BIOL CHEM, V268, P19126; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; KINOUCHI H, 1993, BRAIN RES, V619, P334, DOI 10.1016/0006-8993(93)91630-B; Kurokawa K, 1997, J COMP NEUROL, V389, P348, DOI 10.1002/(SICI)1096-9861(19971215)389:2<348::AID-CNE11>3.0.CO;2-H; LYSKO PG, 1995, DEV BRAIN RES, V88, P96, DOI 10.1016/0165-3806(95)00087-T; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; McIntosh T K, 1986, NIDA Res Monogr, V75, P527; MCKENZIE AL, 1995, J NEUROTRAUM, V12, P257, DOI 10.1089/neu.1995.12.257; MUGNAINI E, 1987, ARCH ITAL BIOL, V126, P41; Nakagomi T, 1989, Neurol Med Chir (Tokyo), V29, P967, DOI 10.2176/nmc.29.967; Nayler W G, 1990, Trends Pharmacol Sci, V11, P96, DOI 10.1016/0165-6147(90)90188-E; Nilsson T, 1997, NEUROSURGERY, V40, P346, DOI 10.1097/00006123-199702000-00023; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; POHL U, 1989, J CARDIOVASC PHAR S5, V13, P188; ROBINSON MJ, 1990, J CEREBR BLOOD F MET, V10, P285, DOI 10.1038/jcbfm.1990.46; Roux S, 1997, J PHARMACOL EXP THER, V283, P1110; SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; SHIRAKAMI G, 1994, ACTA ANAESTH SCAND, V38, P457, DOI 10.1111/j.1399-6576.1994.tb03929.x; STANIMIROVIC DB, 1994, J NEUROCHEM, V62, P592; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VIGNE P, 1993, EUR J PHARM-MOLEC PH, V245, P229, DOI 10.1016/0922-4106(93)90101-E; WESTMARK R, 1995, NEUROSCI LETT, V192, P173, DOI 10.1016/0304-3940(95)11638-D; YAMADA G, 1995, J CARDIOVASC PHARM, V26, pS486; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YAMASHITA K, 1993, CELL MOL NEUROBIOL, V13, P15, DOI 10.1007/BF00712986; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	48	45	48	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 26	1998	809	1					39	49		10.1016/S0006-8993(98)00817-8			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	134BJ	WOS:000076722700006	9795123				2022-02-06	
J	Gagnon, I; Forget, R; Sullivan, SJ; Friedman, D				Gagnon, I; Forget, R; Sullivan, SJ; Friedman, D			Motor performance following a mild traumatic brain injury in children: an exploratory study	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; PROFICIENCY; ADOLESCENTS; ATTENTION; COHORT	Mild Traumatic Brain Injury (TBI) is a common occurrence in the paediatric population and, as the concept of motor performance has not been assessed specifically in this population, the purpose of this study was to determine if motor performance deficits are present and can be objectively identified in a sample of children having sustained a mild TBI (Glasgow Coma Scale score 13-15). Twenty-eight children aged between 5 and 15 years were recruited immediately post-trauma. Subjects were considered normal on standard neurological exam at the time of discharge. They were assessed 13-18 days post-trauma using the Bruininks-Oseretsky Test of Motor Proficiency, a norm referenced clinical standardized assessment tool. Compared to published norms, motor performance was significantly lower in domains of balance, response speed and running speed an agility (t-test p < 0.01), and significantly higher in domains of upper extremity coordination and visual motor control (t-test p < 0.01). Although excellent performance can be observed in domains requiring upper limb coordination, motor planning and execution of motor tasks, deficits in balance and response speed can be identified in a significant number of children even after mild TBI. More specific and sensitive evaluations are necessary to identify the exact nature of the problems and evaluate their functional impact on daily activities.	Montreal Childrens Hosp, Phys Therapy Dept, Montreal, PQ H3H 1P3, Canada; Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; Univ Otago, Sch Phys Therapy, Dunedin, New Zealand		Gagnon, I (corresponding author), Montreal Childrens Hosp, Phys Therapy Dept, 2300 Tupper St, Montreal, PQ H3H 1P3, Canada.			Gagnon, Isabelle/0000-0003-2043-1644			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BAWDEN HN, 1991, BRAIN INJURY, V5, P339; Bruininks, 1978, BRUININKS OSERETSKY; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; CONNOLLY BH, 1986, PHYS THER, V66, P344, DOI 10.1093/ptj/66.3.344; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Gabbard C, 1995, J GENET PSYCHOL, V156, P411, DOI 10.1080/00221325.1995.9914833; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HARRINGTON DE, 1993, ARCH PHYS MED REHAB, V74, P579, DOI 10.1016/0003-9993(93)90155-4; HATTIE J, 1987, BRIT J EDUC PSYCHOL, V57, P104, DOI 10.1111/j.2044-8279.1987.tb03065.x; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; LEVIN HS, 1979, CHILD BRAIN, V5, P281; McCordie W. R., 1988, CLIN NEUROPSYCHOL, V2, P198; Miller L, 1996, J COGNITIVE REHABILI, V15, P8; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; PALISANO R J, 1989, Physical and Occupational Therapy in Pediatrics, V9, P79; PLIMPTON CE, 1992, PERCEPT MOTOR SKILL, V74, P399, DOI 10.2466/PMS.74.2.399-402; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; Rodger S, 1994, AUSTR OCCUPATIONAL T, V41, P137; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81	34	45	45	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1998	12	10					843	853		10.1080/026990598122070			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	121FR	WOS:000076003100004	9783083				2022-02-06	
J	Sarapatta, M; Herrmann, D; Johnson, T; Aycock, R				Sarapatta, M; Herrmann, D; Johnson, T; Aycock, R			The role of head injury in cognitive functioning, emotional adjustment and criminal behaviour	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; VIOLENCE	In two investigations, 50% of non-violent convicted felons, who avoided incarceration by participating in a day reporting progranune, reported a prior history of head injury and current problems in cognitive and emotional functioning. Only 5% of a college sample in the first investigation and 15% of a community sample in the second investigation reported prior head injury. In a third investigation, 83% of felons who had reported a history of head injury also reported a date for their head injury that preceded the dale of their first encounter with law enforcement. Some participants reported no trouble with the law until after experiencing a head injury that occurred in their late thirties. Considering the research reported here and elsewhere in the literature, it appears that many serious crimes follow a head injury. One implication of the findings reported here is that many crimes might not occur if people with head injury were given prompt and comprehensive treatment after the injury.	Indiana State Univ, Terre Haute, IN 47809 USA; Vigo Cty Community Correct, Terre Haute, IN USA		Sarapatta, M (corresponding author), 7940 Greenwood Court, Terre Haute, IN 47802 USA.						Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; CLUM MS, 1981, J NEUROSURGICAL NURS, V13, P165; DUNWAY G, 1991, CRIME DELINQUENCY, P536; Eysenck H.J., 1964, CRIME PERSONALITY; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HERRMANN D, 1996, RETRAINING COGNITION; HODGINS S, BIOL CONTRIBUTIONS C, P161; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Langevin R., 1987, BEHAVIORAL SCI LAW, V5, P77; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; MCGUE M, BEHAV GENETICS, P607; Modestin J, 1996, SCHIZOPHRENIA BULL, V22, P69, DOI 10.1093/schbul/22.1.69; NESTOR PG, 1995, B AM ACAD PSYCH LAW, V23, P331; PINCUS JH, 1991, SEMIN NEUROL, V11, P146, DOI 10.1055/s-2008-1041216; ROSENBAUM M, 1986, AM J PSYCHIAT, V143, P267; SCHEPANK H, 1974, MONOGRAPHIEN GESAMTG; Winer BJ, 1962, STAT PRINCIPLES EXPT; YEUDALL LT, 1977, CAN MENT HEALTH, V25, P7	20	45	45	0	15	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1998	12	10					821	842		10.1080/026990598122061			22	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	121FR	WOS:000076003100003	9783082				2022-02-06	
J	Tucker, FM; Hanlon, RE				Tucker, FM; Hanlon, RE			Effects of mild traumatic brain injury on narrative discourse production	BRAIN INJURY			English	Article							HEAD-INJURY; DEFICITS	Mild traumatic brain injury (MTBI) and postconcussive syndrome can result in difficult to document complaints regarding subtle language use. Narrative discourse production has been shown to be a sensitive index of linguistic and cognitive deficits in the more severe TBI population. The narrative discourse production of MTBI subjects was investigated to determine whether cognitive changes were reflected in linguistic production Eight MTBI, five moderate TBI, and five neurologically normal subjects were matched for age, education, and gender. The TBI subjects were matched on a number of neuropsychological measures. The subjects produced marratives about their correct picture sequences on five items from the Wechsler Adult Intelligenbce Scale-Revised picture arrangement subtest. The narratives were scored for correct arrangement, content: essential information, correct story, and implied meaning. Significant differences were found between the normal control group and both the TBI groups on accuracy of narrative description of the correct picture sequences. Although differences in generation of implied meaning failed to reach significance, a trend was noted for both the TBI groups to produce fewer implied meanings than the control group. The results suggest that cognitive disruptions associated with MTBI may affect the quality of narrative discourse.	So Illinois Univ, Dept Special Educ & Commun Disorders, Edwardsville, IL 62026 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA		Tucker, FM (corresponding author), So Illinois Univ, Dept Special Educ & Commun Disorders, Campus Box 1776, Edwardsville, IL 62026 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Cherney L., 1993, CLIN APHASIOLOGY, V21, P123; CICERONE K, 1995, J HEAT TRAUMA REHABI, V19, P1; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Coelho C. A., 1994, DISCOURSE ANAL APPL, P95; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; GLOSSER G, 1993, DISCOURSE ABILITY BR, P191; HAGAN C, 1979, REHABILITATION HEAD, P87; Kaplan E., 1991, WAIS R NI MANUAL; KENNEDY MRT, 1991, COMMUNICATION DISORD, P123; Levin H.S., 1989, MILD HEAD INJURY; Levin HS., 1982, NEUROBEHAVIORAL CONS; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Myers PS, 1996, J SPEECH HEAR RES, V39, P870, DOI 10.1044/jshr.3904.870; Ulatowska Hanna K., 1990, DISCOURSE ABILITY BR, P180, DOI 10.1007/978-1-4612-3262-9_8; ULATOWSKA HK, 1994, DISCOURSE ANAL APPL, P26; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wechsler, 1997, WECHSLER ADULT INTEL	21	45	47	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1998	12	9					783	792		10.1080/026990598122179			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	117ET	WOS:000075768500006	9755369				2022-02-06	
J	Chendrasekhar, A; Moorman, DW; Timberlake, GA				Chendrasekhar, A; Moorman, DW; Timberlake, GA			An evaluation of the effects of semirigid cervical collars in patients with severe closed head injury	AMERICAN SURGEON			English	Article; Proceedings Paper	Midwest-Surgical-Association Meeting	AUG 10-13, 1997	HURON, OHIO	Midwest Surg Assoc			SPINE	The use of a semirigid cervical collar has been recommended to prevent further cervical spine injury in the management of trauma patients. These cervical collars are kept on obtunded patients for prolonged periods. We assessed the incidence of cervical collar related decubiti in patients with severe closed head injury (SCHI). We also assessed the utility of fluoroscopy in clearing the cervical spine of patients with SCHI, A retrospective chart review was performed on 52 consecutive patients with SCHI at a community hospital-based Level II trauma center over an 8-month period. Thirteen of 34 patients (38%) who survived >24 hours after admission developed decubiti related to the cervical collar. The patients who developed decubiti had a significantly greater duration of cervical collar placement (21.15 +/- 0.99 days) as compared with patients who did not develop decubiti (4.42 +/- 0.79 days; P = 0,001). Eight patients had their cervical spine assessed for ligamentous injury by bedside fluoroscopy. All eight patients had early collar removal; none of these patients developed decubiti, Patients with SCHI with semirigid cervical collars kept in place for prolonged periods of time are at risk for developing decubiti. Fluoroscopy in addition to standard radiographs may "clear" the cervical spine and allow early removal of these collars.	Iowa Methodist Med Ctr, Dept Surg Educ, Des Moines, IA USA		Chendrasekhar, A (corresponding author), 1221 Pleasant St,Suite 550, Des Moines, IA 50309 USA.						*AM COLL SURG SPIN, 1993, ADV TRAUM LIF SUPP I, P191; CLINE JR, 1985, J TRAUMA, V25, P649, DOI 10.1097/00005373-198507000-00013; DAVIS JW, 1995, J TRAUMA, V39, P435; DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006; FISCHER RP, 1984, ANN EMERG MED, V13, P905, DOI 10.1016/S0196-0644(84)80667-8; GERRELTS BD, 1991, J TRAUMA, V31, P1622, DOI 10.1097/00005373-199112000-00010; GRADY MS, 1986, NEUROSURGERY, V18, P151; PLAISIER B, 1994, J TRAUMA, V37, P714, DOI 10.1097/00005373-199411000-00004; ROSEN PB, 1992, ANN EMERG MED, V21, P1189, DOI 10.1016/S0196-0644(05)81744-5; ROSS SE, 1987, J TRAUMA, V27, P1055, DOI 10.1097/00005373-198709000-00017	10	45	46	1	2	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	JUL	1998	64	7					604	606					3	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	ZW842	WOS:000074453800002	9655267				2022-02-06	
J	Klonoff, PS; Lamb, DG; Henderson, SW; Shepherd, SW				Klonoff, PS; Lamb, DG; Henderson, SW; Shepherd, SW			Outcome assessment after milieu-oriented rehabilitation: New considerations	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	16th Annual Meeting of the National-Academy-of-Neuropsychology	OCT 30-NOV 02, 1996	NEW ORLEANS, LA	Natl Acad Neuropsychol			TRAUMATIC BRAIN INJURY; WORK; PREDICTORS; RETURN	Objective: This study incorporated level of functional impairment ratings at program admission into rehabilitation outcome (return to work/school) at the time of program discharge. Hypotheses: (1) Patients and families with better working alliance ratings will show better adjusted outcome; (2) patients seeking compensation will have poorer outcome than those not seeking compensation or receiving benefits; (3) speed of information processing and memory will relate to the level of adjusted outcome. Design: Consecutive neurorehabilitation admissions from March 1992 to May 1996. Setting: Outpatient milieu-based interdisciplinary day treatment program. Subjects: Sixty-four patients with heterogeneous brain injury etiologies. Main Outcome Measures: Adjusted outcome, defined as level of discharge productivity adjusted by staff ratings of functional severity of impairment at program admission; work readiness and work eagerness, based on average staff ratings. Results: At discharge, 89.5% of patients showed fair or good adjusted outcome; 62% were gainfully employed/full-time students; 15.6% resumed preinjury status. Better working alliance predicted better adjusted outcome. Patients seeking compensation showed significantly lower work eagerness ratings. Poorer outcome was associated with better neuropsychological status. Conclusions: Efficacy of neurorehabilitation was demonstrated for patients with better working alliance who were not seeking compensation. Adjusted outcome demonstrated greater sensitivity and utility by incorporating the variable of functional severity of impairment at program admission, Inclusion of "process" variables addressing working alliance, motivation, and capacity to work provide important contributions to understanding rehabilitation outcome. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	St Josephs Hosp, Barrow Neurol Inst, Adult Day Hosp Neurol Rehabil, Phoenix, AZ 85013 USA; Med Ctr, Phoenix, AZ USA		Klonoff, PS (corresponding author), 222 W Thomas Rd,Suite 115, Phoenix, AZ 85013 USA.						Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BENYISHAY Y, 1970, J ABNORM PSYCHOL, V75, P248, DOI 10.1037/h0029368; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Delis DC, 1987, CALIFORNIA VERBAL LE; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1997, CLIN NEUROPSYCHOLOGY, P219; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; Reitan R, 1985, HALSTEAD REITAN NEUR; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; Wechsler, 1997, WECHSLER ADULT INTEL; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355	24	45	46	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1998	79	6					684	690		10.1016/S0003-9993(98)90045-4			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	ZT554	WOS:000074099500015	9630150				2022-02-06	
J	Yam, PS; Dewar, D; McCulloch, J				Yam, PS; Dewar, D; McCulloch, J			Axonal injury caused by focal cerebral ischemia in the rat	JOURNAL OF NEUROTRAUMA			English	Article						cytoskeleton; focal ischemia; MAPS; NF68kD; rats; SNAP25	AMYLOID PRECURSOR PROTEIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN; HEAD-INJURY; OPTIC-NERVE; CALPAIN INHIBITOR; ANOXIC INJURY; BRAIN INJURY; WHITE-MATTER; NEUROFILAMENT SUBUNITS; EXTRACELLULAR CALCIUM	The susceptibility of axons to blunt head injury is well established. However, axonal injury following cerebral ischemia has attracted less attention than damage in gray matter. We have employed immunocytochemical methods to assess the vulnerability of axons to cerebral ischemia in vivo. Immunocytochemistry was performed using antibodies to a synaptosomal-associated protein of 25 kDa (SNAP25), which is transported by fast anterograde transport; the 68-kDa neurofilament subunit (NF68kD); and microtubule-associated protein 5 (MAPS) on sections from rats subjected to 30 min and 1, 2, and 4 h of ischemia induced by permanent middle cerebral artery (MCA) occlusion. After 4 h of occlusion, there was increased SNAP25 immunoreactivity, which was bulbous in appearance, reminiscent of the axonal swellings that occur following blunt head injury. Increased SNAP25 immunoreactivity was present in circumscribed zones in the subcortical white matter and in the axonal tracts at the border of infarction, a pattern similar to that previously described for amyloid precursor protein. Although less marked, similar changes in immunoreactivity in axons were evident following 2 h of ischemia. MAPS and NF68kD had striking changes in immunoreactivity in axonal tracts permeating the caudate nucleus within the MCA territory at 4 h. The appearance was roughened and disorganized compared with the smooth regular staining in axons within the nonischemic areas. Profiles reminiscent of axonal bulbs were evident in MAPS-stained sections. The changes seen with NF68kD and MAP5 were also evident at 2 h but were more subtle at 1 h. There were no changes in axonal immunoreactivity with SNAP25 or NF68kD at 30 min after MCA occlusion. Altered immunoreactivity following ischemia using SNAP25, MAPS, and NF68kD provides further evidence for the progressive breakdown of the axonal cytoskeleton following an ischemic insult. NF68kD and MAP5 appear to be sensitive markers of the structural disruption of the cytoskeleton, which precedes the subsequent accumulation of SNAP25 within the damaged axons. Axonal cytoskeletal breakdown and disruption of fast axonal transport, which are well-recognized features of traumatic brain injury, are also sequalae of an ischemic insult.	Univ Glasgow, Wellcome Surg Inst, Glasgow, Lanark, Scotland; Univ Glasgow, Hugh Fraser Neurosci Labs, Glasgow G61 1QH, Lanark, Scotland		Yam, PS (corresponding author), Univ Glasgow, Wellcome Surg Inst, Garscube Estate, Glasgow, Lanark, Scotland.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; Dewar D, 1997, ACTA NEUROPATHOL, V93, P71, DOI 10.1007/s004010050584; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; HESS DT, 1992, J NEUROSCI, V12, P4634; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LUDIN B, 1993, HIPPOCAMPUS, V3, P61; Maxwell W. L., 1995, Journal of Neurotrauma, V12, P363; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCKENZIE KJ, 1996, ACTA NEUROPATHOL, V92, P609; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; OCHS S, 1972, J PHYSIOL-LONDON, V227, P627, DOI 10.1113/jphysiol.1972.sp010051; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Povlishock John T., 1995, P504; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; SHIGEMATSU K, 1992, J NEUROSCI RES, V31, P443, DOI 10.1002/jnr.490310306; SHIGENO T, 1985, SURG NEUROL, V24, P47, DOI 10.1016/0090-3019(85)90063-1; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; STYS PK, 1990, P NATL ACAD SCI USA, V87, P4212, DOI 10.1073/pnas.87.11.4212; SUENAGA T, 1994, ACTA NEUROPATHOL, V87, P450; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; WAXMAN SG, 1992, BRAIN RES, V574, P105, DOI 10.1016/0006-8993(92)90806-K; WAXMAN SG, 1994, BRAIN RES, V644, P197, DOI 10.1016/0006-8993(94)91680-2; WAXMAN SG, 1993, BRAIN RES, V614, P137, DOI 10.1016/0006-8993(93)91027-P; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610	55	45	45	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1998	15	6					441	450		10.1089/neu.1998.15.441			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZR931	WOS:000074030700006	9624629				2022-02-06	
J	Brouwer, WH; Withaar, FK				Brouwer, WH; Withaar, FK			Fitness to drive after traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY; DAMAGE; PERFORMANCE; PREDICTION; SAFETY; SKILLS	This paper deals with the issue of fitness to drive in patients suffering from traumatic brain injury (TBI). Guidelines for assessment are proposed and three types of studies are reviewed: studies about impairments of attention and information processing, studies of driving competence, and driver selection studies, applying and evaluating the procedures for assessing fitness to drive. From these reviews a relicensing rate emerges of slightly over 50% for very severe TBI patients. Failures in relicensing particularly occur in patients with a very long duration of post-traumatic amnesia (exceeding 1 month), and with severe impairments of perception and judgement. Furthermore, a review of studies describing training of driving competence in traumatically brain-injured patients is presented. It is argued that graded procedures for (re)training should be developed and assessment should extend to training advice and prediction of training success. When expanding assessments according to this suggestion, evaluation procedures should not only focus on operational capacities, but should include measures of executive functions and learning potential as well.	UNIV GRONINGEN HOSP, DEPT NEUROPSYCHOL, CMCI 3, NL-9700 RB GRONINGEN, NETHERLANDS								Bardach J L, 1971, Arch Phys Med Rehabil, V52, P328; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brouwer W H, 1994, Disabil Rehabil, V16, P149; BROUWER WH, 1990, TRAUMATIC BRAIN INJU, P89; BROUWER WH, 1988, ROAD USER BEHAV THEO, P296; Engum E., 1988, COGNITIVE REMEDI SEP, P34; ENGUM ES, 1990, COGNITIVE REHABI MAR, P20; ENGUM ES, 1989, COGNITIVE REHABI JUL, P22; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; GURGOLD GD, 1978, AM J OCCUP THER, V32, P41; HOPEWELL CA, 1985, J CLIN EXP NEUROPSYC, V7, P148; HOPEWELL CA, 1990, NEUROPSYCHOLOGY EVER, P307; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; KEWMAN DG, 1985, REHABIL PSYCHOL, V30, P11; Klebelsberg D., 1982, VERKEHRSPSYCHOLOGIE; KORTELING H, 1988, ROAD USER BEHAV THEO, P319; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Lambert EW, 1992, COGNITIVE REHABI MAY, V10, P32; ODENHEIMER GL, 1994, J GERONTOL, V49, pM153, DOI 10.1093/geronj/49.4.M153; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; QUIGLEY FL, 1983, AM J OCCUP THER, V37, P474, DOI 10.5014/ajot.37.7.474; SCHMIDT IW, 1996, APPL NEUROPSYCHOLOGY; SHORE D, 1980, ARCH PHYSICAL MED RE, V62, P163; SIVAK M, 1984, ARCH PHYS MED REHAB, V65, P163; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; Stevens J.P., 1992, APPL MULTIVARIATE ST, V2nd; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANWOLFFELAAR PC, 1990, DRIVING BEHAV SOCIAL, P564; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357	37	45	48	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL	1997	7	3					177	193		10.1080/713755536			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	XL513	WOS:A1997XL51300001					2022-02-06	
J	Katoh, H; Sima, K; Nawashiro, H; Wada, K; Chigasaki, H				Katoh, H; Sima, K; Nawashiro, H; Wada, K; Chigasaki, H			The effect of MK-801 on extracellular neuroactive amino acids in hippocampus after closed head injury followed by hypoxia in rats	BRAIN RESEARCH			English	Article						closed head injury; hypoxia; vulnerability; hippocampus; glutamate; GABA; microdialysis	TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; GLUTAMATE RELEASE; FOREBRAIN ISCHEMIA; SELECTIVE VULNERABILITY; SPREADING DEPRESSION; GLOBAL-ISCHEMIA; MICRODIALYSIS; ASPARTATE; ANTAGONISTS	Increased neuronal vulnerability to ischemia or hypoxia has been demonstrated following traumatic brain injury but not explained. Animal data suggest that neuronal damage after traumatic brain injury is caused mainly by massive glutamate release that activates N-methyl-D-aspartate (NMDA) receptors. Using rat models with controlled closed head injury (CHI) followed by hypoxia, we investigated extracellular concentrations of neuroactive amino acids in the hippocampus by in vivo microdialysis. CHI alone produced an immediate increase of glutamate and taurine; hypoxia alone did not alter amino acid concentrations. CHI followed by hypoxia produced a biphasic increase in extracellular glutamate and taurine, with an immediate peak after CHI and a prolonged plateau after hypoxia. Though changes in gamma-aminobutylic acid (GABA) concentration is also prolonged by combined traumatic and hypoxic insults, it showed less alteration than glutamate. Pre-treatment with dizocilpine maleate (MK-801), a non-competitive NMDA antagonist, did not affect the immediate peak of glutamate after CHI but significantly diminished the prolonged plateau after hypoxia. These findings suggest that traumatic brain injury may increase hypoxic release of glutamate, contributing to increased vulnerability to hypoxia. Our data suggest that MK-801 may be beneficial in preventing secondary neuronal damages by hypoxia.			Katoh, H (corresponding author), NATL DEF MED COLL, DEPT NEUROSURG, 3-2 NAMIKI, TOKOROZAWA, SAITAMA 359, JAPAN.						ADAMSON P, 1990, J NEUROCHEM, V55, P1850, DOI 10.1111/j.1471-4159.1990.tb05767.x; BECKER DP, 1986, MECH SECONDARY BRAIN, P47; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P49; CONNICK JH, 1988, BRIT J PHARMACOL, V93, P863, DOI 10.1111/j.1476-5381.1988.tb11473.x; DELPINO MMS, 1995, J BIOL CHEM, V270, P14913, DOI 10.1074/jbc.270.25.14913; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GEMBA T, 1992, NEUROSCI LETT, V135, P184, DOI 10.1016/0304-3940(92)90432-7; GHRIBI O, 1995, FUNDAM CLIN PHARM, V9, P141, DOI 10.1111/j.1472-8206.1995.tb00273.x; GLOBUS MYT, 1991, NEUROSCI LETT, V127, P39, DOI 10.1016/0304-3940(91)90889-2; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAHARA N, 1995, NEUROL RES, V17, P9, DOI 10.1080/01616412.1995.11740281; KITA H, 1994, ACTA NEUROCHIR, P452; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; LEKIEFFRE D, 1992, NEUROSCI LETT, V137, P78, DOI 10.1016/0304-3940(92)90303-O; LIN BW, 1992, J NEUROCHEM, V59, P2213; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTIN D, 1991, J NEUROCHEM, V56, P1647, DOI 10.1111/j.1471-4159.1991.tb02063.x; MATSUMOTO M, 1992, ANESTHESIOLOGY, V77, P764, DOI 10.1097/00000542-199210000-00022; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MITANI A, 1990, J NEUROCHEM, V54, P709, DOI 10.1111/j.1471-4159.1990.tb01930.x; MIYASHITA K, 1992, NEUROCHEM RES, V17, P147, DOI 10.1007/BF00966792; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; SEGAL MB, 1990, BLOOD BRAIN BARRIER, P31; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHIBANOKI S, 1993, J NEUROCHEM, V61, P1698, DOI 10.1111/j.1471-4159.1993.tb09806.x; SHIMA K, 1993, ADV NEUROTRAUMA RES, V5, P53; SHIMA K, 1990, ADV EXPT NEUROTRAUMA, V2, P53; SZERB JC, 1991, BRAIN RES, V542, P259, DOI 10.1016/0006-8993(91)91576-M; Tan WKM, 1996, PEDIATR RES, V39, P791, DOI 10.1203/00006450-199605000-00008	40	45	47	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 30	1997	758	1-2					153	162		10.1016/S0006-8993(97)00213-8			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XE606	WOS:A1997XE60600019	9203544				2022-02-06	
J	Busto, R; Dietrich, WD; Globus, MYT; Alonso, O; Ginsberg, MD				Busto, R; Dietrich, WD; Globus, MYT; Alonso, O; Ginsberg, MD			Extracellular release of serotonin following fluid-percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; serotonin; microdialysis	CEREBRAL BLOOD-FLOW; EXPERIMENTAL SPINAL TRAUMA; MODERATE HYPOTHERMIA; NEWBORN PIGS; CORD INJURY; AMINO-ACIDS; HEAD-INJURY; 5-HYDROXYTRYPTAMINE; DAMAGE; MODEL	Serotonin has been implicated in the pathobiology of central nervous system trauma. Using microdialysis techniques, we performed measurements of extracellular serotonin release within the traumatized cerebral cortex of rats subjected to moderate fluid-percussion (F-P) brain injury. Twenty-four hours prior to TBI, a F-P interface was positioned parasagitally over the right cerebral cortex. On the second day, fasted rats were anesthetized with 70% nitrous oxide, 1% halothane, and 30% oxygen. Under controlled physiological conditions and normothermic brain temperature (37-37.5 degrees C), rats were injured (n = 6) with a F-P pulse ranging from 1.8 to 2.0 atm. Following trauma, brain temperature was maintained for 4 h at 37 degrees C. Sham trauma animals (n = 7) were treated in an identical manner. Brain trauma induced acute elevations in the extracellular levels of serotonin (p < 0.01, ANOVA) compared to sham-operated controls. For example, serotonin levels increased from 18.85 +/- 7.12 pm/mL (mean +/- SD) in baseline samples to 65.78 +/- 11.36 in the first 10 min after trauma. The levels of serotonin remained significantly higher than control for the first 90-min sampling period. In parallel to the increase in serotonin levels after TBI, a significant 71.1% decrease (i.e., 182.29 +/- 30.08 vs 52.75 +/- 16.92) in extracellular 5-hydroxyindoleacetic acid (5-HIAA) levels was observed during the first 10 min after TBI. These data indicate that TBI is followed by a prompt increase in the extracellular levels of serotonin in cortical regions adjacent to the impact site. These neurochemical findings indicate that serotonin may play a significant role in the pathophysiology of TBI.			Busto, R (corresponding author), UNIV MIAMI,SCH MED,DEPT NEUROL D4 5,NEUROTRAUMA RES CTR,POB 016960,MIAMI,FL 33101, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline		ALAFACI C, 1990, ACTA PHYSIOL SCAND, V138, P317, DOI 10.1111/j.1748-1716.1990.tb08852.x; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORTEZ SC, 1989, BRAIN RES, V482, P272; DAPRADA M, 1979, BRIT J PHARMACOL, V65, P653; DELALANDE JS, 1989, PERIPHERAL ACTION 5, P123; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DIETRICH WD, 1989, J CEREBR BLOOD F MET, V9, P812, DOI 10.1038/jcbfm.1989.115; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EDVINSSON L, 1977, NEUROLOGY, V27, P878, DOI 10.1212/WNL.27.9.878; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1988, BRAIN RES, V450, P94, DOI 10.1016/0006-8993(88)91548-X; FENIUK W, 1989, PERIPHERAL ACTIONS 5, P100; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GINSBERG MD, 1995, J CEREB BLOOD FLOW S, V15, pS31; GLOBUS MYT, 1992, STROKE, V23, P1595, DOI 10.1161/01.STR.23.11.1595; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HOLMSEN H, 1985, SEROTONIN CARDIOVASC, P75; IVERSEN LL, 1974, BIOCHEM PHARMACOL, V23, P1927, DOI 10.1016/0006-2952(74)90250-0; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMBELBERG HK, 1985, SCIENCE, V228, P889; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LIU D, 1990, Journal of Neurotrauma, V7, P219, DOI 10.1089/neu.1990.7.219; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOHANTY S, 1978, INDIAN J MED RES, V67, P1029; NAYAK AK, 1980, J NEUROL SCI, V47, P211, DOI 10.1016/0022-510X(80)90005-2; NEDERGAARD S, 1987, CELL MOL NEUROBIOL, V7, P367, DOI 10.1007/BF00733789; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OSBORNE NN, 1982, BIOL SEROTONERGIC TR, P1; OSTERHOLM JL, 1969, J NEUROSURG, V31, P408, DOI 10.3171/jns.1969.31.4.0408; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAPPIUS HM, 1987, J NEUROCHEM, V49, P321, DOI 10.1111/j.1471-4159.1987.tb03433.x; PAPPIUS HM, 1988, J CEREBR BLOOD F MET, V8, P324, DOI 10.1038/jcbfm.1988.67; PARFENOVA H, 1993, STROKE, V24, P1729, DOI 10.1161/01.STR.24.11.1729; Peroutka S. J., 1991, SEROTONIN RECEPTOR S, P65; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; REYNOLDS JN, 1988, BRAIN RES, V456, P286, DOI 10.1016/0006-8993(88)90230-2; Salzman S K, 1987, Cent Nerv Syst Trauma, V4, P181; SALZMAN SK, 1991, ANN NEUROL, V30, P533, DOI 10.1002/ana.410300405; SALZMAN SK, 1987, J NEUROSURG, V66, P431, DOI 10.3171/jns.1987.66.3.0431; SALZMAN SK, 1994, NEUROBIOLOGY CENTRAL, P182; Salzman SK, 1991, J NEUROTRAUM, V8, P45, DOI 10.1089/neu.1991.8.45; SHARMA HS, 1989, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1988, P317; SHARMA HS, 1990, ACTA NEUROPATHOL, V80, P12, DOI 10.1007/BF00294216; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; SINGH S, 1986, J EXP BIOL, V24, P503; SMITH D R, 1969, Journal of Neurosurgery, V30, P664, DOI 10.3171/jns.1969.30.6.0664; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; VANHOUTTE PM, 1985, CIRCULATION, V72, P728, DOI 10.1161/01.CIR.72.4.728; VANNUETEN JM, 1985, SEROTONIN CARDIOVASC, P95; WESTER P, 1992, STROKE, V23, P870, DOI 10.1161/01.STR.23.6.870; YAKUBU MA, 1994, PEDIATR RES, V36, P589, DOI 10.1203/00006450-199411000-00009; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG BC, 1992, AM J PHYSIOL, V262, pH931, DOI 10.1152/ajpheart.1992.262.4.H931; YOUNG HA, 1986, NEUROSURGERY, V19, P502, DOI 10.1227/00006123-198610000-00003; ZILLES L, 1985, CORTEX RAT STEREOTAX; ZIVIN JA, 1976, NEUROLOGY, V26, P99, DOI 10.1212/WNL.26.2.99; ZIVIN JA, 1985, NEUROLOGY, V35, P584, DOI 10.1212/WNL.35.4.584; ZIVIN JA, 1984, NEUROLOGY, V34, P469, DOI 10.1212/WNL.34.4.469	69	45	45	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1997	14	1					35	42		10.1089/neu.1997.14.35			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WK032	WOS:A1997WK03200004	9048309				2022-02-06	
J	Gonul, E; Baysefer, A; Kahraman, S; Ciklatekerlioglu, O; Gezen, F; Yayla, O; Seber, N				Gonul, E; Baysefer, A; Kahraman, S; Ciklatekerlioglu, O; Gezen, F; Yayla, O; Seber, N			Causes of infections and management results in penetrating craniocerebral injuries	NEUROSURGICAL REVIEW			English	Article						craniocerebral injury; penetrating wound; retained bone fragments; surgical infection	INTRACRANIAL BONE FRAGMENTS; MISSILE WOUNDS; LEBANESE CONFLICT; HEAD WOUNDS; BRAIN; VIETNAM	From February 1992 to December 1994, 148 patients with penetrating craniocerebral injuries were treated surgically with primary and secondary debridement including repair of dural defects and removal of retained intracranial bone and metal fragments. Dural defects were closed primarily or with temporalis fascia, pericranium, and cadaver graft. Cerebrospinal fluid fistulas were observed in 11 (7.3 %) patients: 7 of these were infected. Central nervous system (CNS) infection was seen in 2 patients without CSF fistula. Excluding those 11 patients with CSF fistula, CNS infection was shown in 2 of the 137 cases (1.5 %). All patients underwent CT scans periodically In 51 (34 %) of 148 patients, bone and metal fragments were determined on control CT scans. During this time, 12 patients died (8 %). Most of deaths were caused by the direct effect of brain injury and occured within the first month after injury. Fragments retained after first debridement were followed periodically by CT scan. Surgery was not performed until infection developed. Retained fragments did not increase the infection risk, but high rates of infection did occur in cases with CSF fistula.			Gonul, E (corresponding author), GATA,FAC MED,DEPT NEUROSURG,ANKARA,TURKEY.		Kahraman, Serdar/K-4658-2019	Kahraman, Serdar/0000-0003-2489-3854			AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; AARABI B, 1989, NEUROSURGERY, V25, P923, DOI 10.1227/00006123-198912000-00011; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAREY ME, 1971, J NEUROSURG, V34, P145, DOI 10.3171/jns.1971.34.2part1.0145; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HAMMON WM, 1971, J NEUROSURG, V34, P142, DOI 10.3171/jns.1971.34.2part1.0142; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; MEIROWSKY AM, 1982, J NEUROSURG, V57, P617, DOI 10.3171/jns.1982.57.5.0617; MEIROWSKY AM, 1981, J NEUROSURG, V54, P44, DOI 10.3171/jns.1981.54.1.0044; MYERS PW, 1989, J NEUROSURG, V70, P319; PITLYK PJ, 1970, J NEUROSURG, V33, P19, DOI 10.3171/jns.1970.33.1.0019; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007	16	45	46	0	1	WALTER DE GRUYTER & CO	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0344-5607			NEUROSURG REV	Neurosurg. Rev.		1997	20	3					177	181		10.1007/BF01105561			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	XT017	WOS:A1997XT01700003	9297719				2022-02-06	
J	Asikainen, I; Kaste, M; Sarna, S				Asikainen, I; Kaste, M; Sarna, S			Patients with traumatic brain injury referred to a rehabilitation and re-employment programme: Social and professional outcome for 508 Finnish patients 5 or more years after injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; POPULATION; MANAGEMENT; DISABILITY; PROGNOSIS; SURVIVAL; FEATURES; COUNTY; SCALE	We studied influence of age and educational level before injury on the social and vocational outcome among a group of traumatic brain injury (TBI) patients with post-injury problems in their education and employment. Patients with TBI, followed up for at least 5 years, and who were admitted to a rehabilitation and re-employment programme, were selected for evaluation of long-term outcome. We used the Glasgow Coma Scale (GCS) scores at the time of emergency admission to the hospital to measure brain injury severity. Age at the time of TBI and educational status before TBI were correlated with the outcome measures at the end of follow-up separately in each category of brain injury severity. The study was carried out at the Kauniala outpatient neurological clinic, which specializes in brain injuries in Finland; it works closely with the Departments of Neurology and Neurosurgery at the Helsinki University Central Hospital. Main outcome measures were functional outcome measured by the Glasgow Outcome Scale (GOS), the educational level reached, and postinjury occupation, as well as the incapacity for work at the end of follow-up. In the severe category of brain injuries, children 7 years or younger at the time of injury suffered severe disability as measured by the GOS scores more often than did the older age groups (p = 0.010, chi(2)). They were less often capable of independent employment (p = 0.011, chi(2)) than the children injured at the age of 8-16. Patients with a higher education usually had a better outcome. In the category of mild brain injuries the majority of the patients, regardless of age, recovered well according to the GOS, and were capable of independent employment at the end of follow-up. Our patients were selected from the TBI population as survivors with problems in education and re-employment. Those with severe injury sustained early in life (childhood and early teens) coupled with poor educational attainment had relatively worse social and vocational outcome; better outcomes were enjoyed by those severely injured individuals whose injuries were sustained later Gate teens or early adulthood). In the groups of patients with moderate and mild br;un injuries such a relationship was not found between age or pre-injury education and outcome.	UNIV HELSINKI,DEPT NEUROL,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT HLTH,HELSINKI,FINLAND		Asikainen, I (corresponding author), KAUNIALA HOSP,DEPT NEUROL,KYLPYLANTIE 19,KAUNIAINEN 02700,FINLAND.			Sarna, Seppo/0000-0003-3458-1627; Kaste, Markku/0000-0001-6557-6412			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHRISTENSEN AL, 1992, SCAND J REHABIL MED, P34; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Clifton GL, 1993, NEUROSURGERY, V33, P8; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Frowein R A, 1979, Acta Neurochir Suppl (Wien), V28, P3; GUATIERI CT, 1988, BRAIN INJURY, V2, P101; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HAGEL KH, 1982, UNFALLHEILKUNDE, V85, P192; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1987, HEAD INJURY, V2, P1; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCKENZIE EJ, 1981, MARYLAND MED J, V38, P725; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PARENTE R, 1990, COMMUNITY INTEGRATIO, P216; Parente R., 1989, J HEAD TRAUMA REHAB, V4, P55; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P793; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUCKERT RF, 1985, UNFALLCHIRURG, V88, P99; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1993, HEAD INJURY, P553; Vollmer DG, 1991, NEUROSURGERY, V75, P37; WEHMAN P, 1990, COMMUNITY INTEGRATIO, P110; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WHEATLY C, 1989, WORK PROGR OCCUPATIO, P141; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955	48	45	47	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	DEC	1996	10	12					883	899		10.1080/026990596123864			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	VU408	WOS:A1996VU40800003	8939307				2022-02-06	
J	Bernard, LC; McGrath, MJ; Houston, W				Bernard, LC; McGrath, MJ; Houston, W			The differential effects of simulating malingering, closed head injury, and other CNS pathology on the Wisconsin Card Sorting Test: Support for the ''pattern of performance'' hypothesis	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							AGE	We investigated the effects of faking bad on the Wisconsin Card Sorting Test, comparing the performance of simulating malingerers (M; n = 24) to controls (C; n = 21), closed head-injured patients (CHI; n = 70), and patients with mired CNS pathology other than CHI alone (CNS; n = 89). Stepwise discriminant functions achieved good accuracy (91-96%), sensitivity (58-100%), and specificity (92-100%) in differentiating simulating malingerers from these groups. The Categories score was a consistent significant independent discriminating variable. Categories alone could differentiate between the M and C groups. However; in discriminating between simulating malingerers and both CHI or CNS patients, more complex patterns of performance emerged, consisting of relatively poorer performance ratios on Categories compared to Perseverative Errors. This supported the Fatten of Performance theory of the effects of simulating malingering on neuropsychological tests, which holds that people simulating malingering do more poorly on obvious vs. subtle tasks compared to people with verified brain damage. Due to the difficulty of tracking one's performance on several different indices simultaneously, known patterns of performance for patients with verified brain dysfunction should be very difficult to fake, even with coaching.	ROYAL C JOHNSON VET MEM HOSP,SIOUX FALLS,SD		Bernard, LC (corresponding author), LOYOLA MARYMOUNT UNIV,DEPT PSYCHOL,LOYOLA BLVD & W 80TH ST,LOS ANGELES,CA 90045, USA.						ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; AXELROD BN, 1992, CLIN NEUROPSYCHOLOGI, V6, P142; AXELROD BN, 1992, CLIN NEUROPSYCHOL, V6, P16; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; BERNARD LC, 1993, ARCH CLIN NEUROPSYCH, V8, P539, DOI 10.1016/0887-6177(93)90054-5; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; BOONE KB, 1993, J CLIN PSYCHOL, V49, P54, DOI 10.1002/1097-4679(199301)49:1<54::AID-JCLP2270490108>3.0.CO;2-6; DAIGNEAULT S, 1992, DEV NEUROPSYCHOL, V8, P99, DOI 10.1080/87565649209540518; DANNENBAUM SE, 1993, J PERS ASSESS, V61, P501, DOI 10.1207/s15327752jpa6103_6; DUSH DM, 1994, J PERS ASSESS, V62, P299, DOI 10.1207/s15327752jpa6202_10; Flashman LA., 1991, CLIN NEUROPSYCHOL, V5, P190, DOI [DOI 10.1080/13854049108403303, 10.1080/13854049108403303]; GOLDSTEIN H, 1945, PSYCHOL BULL, V42, P104, DOI 10.1037/h0056446; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.7.1120-1122; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Harris M.E., 1990, WISCONSIN CARD SORTI, VVolume 4; Heaton R.K., 1981, WISCONSIN CARD SORTI; HEATON RK, 1993, COMPREHENSIVE NORMS; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MOUNTAIN MA, 1993, CLIN NEUROPSYCHOL, V7, P108, DOI 10.1080/13854049308401893; Powell K. H., 1991, THESIS U S CAROLINA; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; ROGERS R, 1988, CLIN ASSESSMENT MALI, P293; Russell E. W., 1970, ASSESSMENT BRAIN DAM; Spreen O, 1991, COMPENDIUM NEUROPSYC; Tabachnick B. G., 1989, USING MULTIVARIATE S; Wechsler D, 1987, MEMORY SCALE REVISED; Wolfson, 1993, HALSTEAD REITAN NEUR; Wolfson, 1988, TRAUMATIC BRAIN INJU, VII	30	45	47	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1996	11	3					231	245		10.1016/0887-6177(95)00025-9			15	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	UB662	WOS:A1996UB66200007	14588927				2022-02-06	
J	DIRUSSO, SM; NELSON, LD; SAFCSAK, K; MILLER, RS				DIRUSSO, SM; NELSON, LD; SAFCSAK, K; MILLER, RS			SURVIVAL IN PATIENTS WITH SEVERE ADULT-RESPIRATORY-DISTRESS-SYNDROME TREATED WITH HIGH-LEVEL POSITIVE END-EXPIRATORY PRESSURE	CRITICAL CARE MEDICINE			English	Article						ADULT RESPIRATORY DISTRESS SYNDROME; OXYGENATION; VENTILATION; OXYGEN; HYPOXEMIA; HYPOXIA; MECHANICAL VENTILATION; POSITIVE END-EXPIRATORY PRESSURE; PULMONARY EMERGENCIES; LUNG INJURY	MECHANICAL VENTILATION; AIRWAY PRESSURE; FAILURE; PEEP; PROGNOSIS; MORTALITY; OXYGEN; RISK	Objective: To assess the mortality rate and complications in a population of surgical patients with severe adult respiratory distress syndrome (ARDS) treated with positive end-expiratory pressure (PEEP) of >15 cm H2O in an attempt to reduce intrapulmonary shunt to similar to 0.20 and reduce FIO2 to <0.50. Design: Retrospective review of patients treated by a standardized ventilatory support protocol at the time of their illness. Setting: A 24-bed surgical intensive care unit in a university medical center. Patients: All patients admitted to the surgical intensive care unit during a 34-month period who met the criteria for severe ARDS (PaO2 of less than or equal to 70 torr [less than or equal to 9.3 kPa] on an FIO2 of greater than or equal to 0.50, diffuse interstitial and/or alveolar infiltrates on chest radiograph, decreased lung compliance, no evidence of congestive heart failure, and a likely predisposing etiology) were evaluated. Patients treated with PEEP of >15 cm H2O were selected for this review. Interventions: Patients were treated by a protocol to achieve oxygenation end points, which consisted of maintaining arterial oxyhemoglobin saturation (as determined by pulse oximetry of greater than or equal to 0.92), while reducing FIO2 to <0.50 and decreasing intrapulmonary shunt fraction to less than or equal to 0.20 by adding PEEP. With the exception of patients with suspected intracranial hypertension related to closed-head injury, low-rate intermittent mandatory ventilation was the primary mode of ventilation. Pressure-support ventilation was added, when needed, to improve patient comfort, enhance spontaneous tidal volume, or improve CO2 excretion. Measurements and Main Results: Eighty-six patients with severe ARDS were treated with a PEEP of >15 cm H2O. Nineteen of these patients died early of severe closed-head injury or massive uncontrollable hemorrhage and were excluded from the evaluation. The remaining 67 patients had a mean Lung Injury Score of 3.3 during their treatment with high PEEP. Twenty (30%) of 67 patients died. Eight of the deaths occurred after decrease of ventilatory support and with acceptable blood gases. The other 12 patients who died had continued oxygenation deficits and received increased levels of ventilatory support at the time of death. Twenty-six (39%) of 67 patients had radiographic manifestations of barotrauma (pneumothorax, subcutaneous emphysema, etc.) related to their primary injuries or to complications related to central venous catheter placement. Seven (17%) of 41 patients developed clinical or radiographic signs of barotrauma while receiving high-level PEEP. The hemodynamic effects of increased airway pressure were managed with fluids and inotropic agents, when necessary, and did not limit the application of PEEP to reach the defined end point of treatment. Conclusions: This subset of patients with severe ARDS treated with high-level PEEP had a mortality rate lower than those rates previously reported by other researchers using more conventional ventilatory support and resuscitation techniques. FIO2 may be significantly reduced and PaO2 may be maintained at acceptable values by decreasing intrapulmonary shunt fraction using high-level PEEP.	VANDERBILT UNIV,SCH MED,DEPT SURG,SURG CRIT CARE SERV,NASHVILLE,TN 37212								ASHBAUGH DG, 1967, LANCET, V2, P319; ASHBAUGH DG, 1969, J THORAC CARDIOV SUR, V57, P31, DOI 10.1016/S0022-5223(19)42760-8; BARTLETT RH, 1986, CHEST, V89, P684, DOI 10.1378/chest.89.5.684; BAUMANN WR, 1986, CRIT CARE MED, V14, P1, DOI 10.1097/00003246-198601000-00001; BERNARD GR, 1983, CHEST, V89, P594; BOLIN R W, 1986, Critical Care Clinics, V2, P585; BONE RC, 1980, ARCH INTERN MED, V140, P85, DOI 10.1001/archinte.140.1.85; CHEATHAM ML, 1993, CRIT CARE MED, V21, pS244; CIVETTA JM, 1976, SOUTH MED J, V69, P749, DOI 10.1097/00007611-197606000-00026; CULLEN DJ, 1979, ANESTHESIOLOGY, V50, P185, DOI 10.1097/00000542-197903000-00003; DENKE SM, 1980, NEW ENGL J MED, V303, P76; DOUGLAS ME, 1977, CHEST, V71, P18, DOI 10.1378/chest.71.1.18; DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; FEIN AM, 1983, CHEST, V83, P40, DOI 10.1378/chest.83.1.40; FOWLER AA, 1985, AM REV RESPIR DIS, V132, P472; GALLAGHER TJ, 1978, CRIT CARE MED, V6, P323, DOI 10.1097/00003246-197809000-00005; JARDIN F, 1981, INTENS CARE MED, V7, P171, DOI 10.1007/BF01724837; JARDIN F, 1981, NEW ENGL J MED, V304, P387, DOI 10.1056/NEJM198102123040703; KAPLAN RL, 1979, ARCH INTERN MED, V139, P867, DOI 10.1001/archinte.139.8.867; KIRBY RR, 1975, CHEST, V67, P156, DOI 10.1378/chest.67.2.156; Kumar A, 1973, Crit Care Med, V1, P181, DOI 10.1097/00003246-197307000-00001; LAURENZI GA, 1968, NEW ENGL J MED, V279, P333, DOI 10.1056/NEJM196808152790701; MANNING HL, 1994, CHEST, V105, P242, DOI 10.1378/chest.105.1.242; MAUNDER R J, 1989, American Review of Respiratory Disease, V139, pA220; MEYRICK B, 1986, Critical Care Clinics, V2, P405; MILLER RS, 1992, J TRAUMA, V33, P284, DOI 10.1097/00005373-199208000-00020; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MORAN JF, 1981, SURGERY, V89, P575; MURRAY JF, 1978, AM REV RESPIR DIS, V138, P720; NELSON LD, 1987, CRIT CARE MED, V15, P14, DOI 10.1097/00003246-198701000-00003; NORWOOD SH, 1986, CRIT CARE MED, V14, P376; PEPE PE, 1984, NEW ENGL J MED, V311, P281, DOI 10.1056/NEJM198408023110502; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PERSCHAU RA, 1979, CIRCULATION, V59, P1312, DOI 10.1161/01.CIR.59.6.1312; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; PRATT PC, 1974, AM REV RESPIR DIS, V110, P51; RALPH DD, 1985, AM REV RESPIR DIS, V131, P54; RAPPAPORT SH, 1994, CRIT CARE MED, V22, P22, DOI 10.1097/00003246-199401000-00009; REGISTER SD, 1987, CRIT CARE MED, V15, P598, DOI 10.1097/00003246-198706000-00012; SHAPIRO BA, 1980, CHEST, V77, P138, DOI 10.1378/chest.77.2.138; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; SMITH PK, 1982, ANN SURG, V195, P121, DOI 10.1097/00000658-198202000-00001; SNIDER MT, 1990, CRIT CARE CLIN, V6, P103; STEVENS PM, 1985, ANN NY ACAD SCI, V384, P477; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; TOUNG TJK, 1978, SURG GYNECOL OBSTET, V147, P518; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; WINTER PM, 1972, ANESTHESIOLOGY, V37, P210, DOI 10.1097/00000542-197208000-00010; WOLF WG, 1979, ANN SURG, V188, P530; WOLFE WG, 1972, SURGERY, V72, P246; WOODRING JH, 1985, CRIT CARE MED, V13, P786, DOI 10.1097/00003246-198510000-00003; ZWILLICH CW, 1974, AM J MED, V57, P161, DOI 10.1016/0002-9343(74)90440-9	53	45	47	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	SEP	1995	23	9					1485	1496		10.1097/00003246-199509000-00008			12	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU202	WOS:A1995RU20200008	7664550				2022-02-06	
J	SNOW, P; DOUGLAS, J; PONSFORD, J				SNOW, P; DOUGLAS, J; PONSFORD, J			DISCOURSE ASSESSMENT FOLLOWING TRAUMATIC BRAIN INJURY - A PILOT-STUDY EXAMINING SOME DEMOGRAPHIC AND METHODOLOGICAL ISSUES	APHASIOLOGY			English	Article							CLOSED-HEAD-INJURY; ADULTS; DEFICITS; APPRAISAL; LANGUAGE	With the shift away from evaluation of isolated aspects of linguistic performance, discourse assessment has become an important tool in assessing the communication skills of individuals who have sustained traumatic brain injury (TBI). Given the substantial evidence that the brain-injured represent a largely preselected population, it would seem relevant that speech pathologists acquire a greater understanding of the role of premorbid sociolinguistic and demographic characteristics in determining the clinical presentation of these patients. This demands that close consideration be given to the selection of control subjects for research with this population. Further, there needs to be clarification about which discourse tasks (by virtue of their cognitive/linguistic demands) are sensitive to brain injury. The pilot study described here compared the discourse skills of three TBI subjects with those of three non-TBI orthopaedic patients, on a range of discourse tasks thought to make differing cognitive and/or linguistic demands on the speaker. The results appear to confirm the need to examine discourse skills within a sociolinguistic context. The importance of examining different discourse parameters is also borne out. Finally, the results suggest that there is some merit in tapping sources other than direct discourse analysis in order to determine how verbal skills have altered as a consequence of brain injury.	BETHESDA HOSP,MELBOURNE,AUSTRALIA		SNOW, P (corresponding author), LA TROBE UNIV,FAC HLTH SCI,SCH COMMUN DISORDERS,BUNDOORA,VIC 3083,AUSTRALIA.		Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624; Snow, Pamela/0000-0002-2426-8349			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BELLACK AS, 1983, BEHAV RES THER, V21, P29, DOI 10.1016/0005-7967(83)90123-7; BENJAMIN L, 1989, THEORY FUNCTION BRID; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; CAMPBELL TF, 1992, TOP LANG DISORD, V12, P42, DOI 10.1097/00011363-199202000-00006; CANNITO M P, 1988, Seminars in Speech and Language, V9, P117, DOI 10.1055/s-0028-1082459; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COEHLO CA, 1991, ARCH PHYSICAL MED RE, V72, P465; COEHLO CA, 1990, J PSYCHOLINGUISTIC R, V19, P405; COEHLO CA, 1991, J HEAD TRAUMA REHAB, V6, P92; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Damico J. S., 1985, COMMUNICATION SKILLS, P165; DILLER L, 1981, J CONSULT CLIN PSYCH, V49, P822, DOI 10.1037/0022-006X.49.6.822; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; GILLIES S, 1990, UNPUB PERCEPTIONS CO; Goldstein H, 1990, TREATMENT EFFICACY R, P91; Grice H. P., 1975, SYNTAX SEMANTICS, P41; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HAGEN C, 1981, TOPICS LANGUAGE  SEP, P73; HARTLEY L, 1989, J SPEECH LANGUAGE PA, V13, P51; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hartley L. L., 1990, NEUROPSYCHOLOGY EVER, P125; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; HUNT KW, 1970, MONOGR SOC RES CHILD, V35, P1; Jennett B, 1981, MANAGEMENT HEAD INJU; JORDAN F, 1990, AUSTR J HUMAN COMMUN, V19, P69; KEARNS KJ, 1990, TREATMENT EFFICACY R, P79; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levin HS., 1982, NEUROBEHAVIORAL CONS; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LOBAN WD, 1963, NATIONAL COUNCIL TEA; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milton S. B., 1986, CLIN NEUROPSYCHOLOGY, P223, DOI [10.1007/978-1-4613-2291-7_11, DOI 10.1007/978-1-4613-2291-7_11]; MISLER EG, 1979, HARVARD EDUC REV, V49, P1; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; Penn C, 1985, S Afr J Commun Disord, V32, P18; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POOLE ME, 1976, SOCIAL CLASS LANGUAG; Prigatano G. P., 1985, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Rimel RW, 1990, REHABILITATION ADULT, P8; SARNO MT, 1984, FUNCTIONAL ASSESSMEN, P210; SLOAN S, 1989, THEORY FUNCTION BRID, P36; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SNOW P, 1987, BRAIN IMPAIRMENT P 1, P87; STUBBS M, 1983, DISCOURSE ANAL; Suls J., 1983, HDB HUMOR RES BASIC, VVol. 56, P39, DOI [https://doi.org/10.1007/978-1-4612-5572-7_3, DOI 10.1007/978-1-4612-5572-7_3]; SWINDELL CS, 1982, CLIN APHASIOLOGY C P, P50; TRUDGILL P, 1983, INTRO LANGUAGE SOC; ULTATOWSKA HK, 1988, NEUROPSYCHOLOGIAL ST, P108; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WILSON, 1989, BOUNDARIES CONVERSAT; Ylvisaker M., 1985, CLIN MANAGEMENT NEUR, V2nd, P243; [No title captured]	61	45	47	0	3	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0268-7038			APHASIOLOGY	Aphasiology	JUL-AUG	1995	9	4					365	380		10.1080/02687039508248210			16	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	RE390	WOS:A1995RE39000004					2022-02-06	
J	BOAKE, C; FREELAND, JC; RINGHOLZ, GM; NANCE, ML; EDWARDS, KE				BOAKE, C; FREELAND, JC; RINGHOLZ, GM; NANCE, ML; EDWARDS, KE			AWARENESS OF MEMORY LOSS AFTER SEVERE CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							EVERYDAY MEMORY	This study investigated unawareness of memory loss in 48 severe closed-head injury patients. Awareness was measured as the correlation of patients' memory test scores with their self-ratings on the Everyday Memory Questionnaire (EMQ). Patients who endorsed atypical memory failures on the EMQ were classified as invalid responders. Invalid responders had poorer memory test performances and a higher rate of focal left hemispheric lesions, but did not report greater emotional symptoms. Correlations between memory test scores and memory self-ratings were weaker among invalid responders or those classified as depressed, and stronger among valid responders, especially those classified as non-depressed. The results indicate that the validity of memory self-reports is influenced by both neurogenic and psychogenic factors, and suggest that invalid responding is an important problem with self-reports by brain-injured patients.	INST REHABIL & RES, HOUSTON, TX USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; CASA COLINA CTR REHABIL, POMONA, CA USA; VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA; DALLAS CTY MENTAL HLTH & MENTAL RETARDAT CTR, DALLAS, TX USA								ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; DAHLSTROM WG, 1975, MMPI HDB GUIDE USE C, V1; DAHLSTROM WG, 1975, MMPI HDB GUIDE USE C, V2; Delis DC, 1987, CALIFORNIA VERBAL LE; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; HERRMANN DJ, 1982, PSYCHOL BULL, V92, P434, DOI 10.1037/0033-2909.92.2.434; Larrabee GJ, 1988, NEUROPSYCHOLOGY, V2, P173, DOI 10.1037//0894-4105.2.3-4.173; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Najenson T, 1980, Int Rehabil Med, V2, P17; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Wade D, 1992, MEASUREMENT NEUROLOG; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; Wilson BA., 1985, RIVERMEAD BEHAVIOURA; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	24	45	47	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	1995	9	3					273	283		10.3109/02699059509008198			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QR499	WOS:A1995QR49900005	7606238				2022-02-06	
J	EDDY, VA; VITSKY, JL; RUTHERFORD, EJ; MORRIS, JA				EDDY, VA; VITSKY, JL; RUTHERFORD, EJ; MORRIS, JA			AGGRESSIVE USE OF ICP MONITORING IS SAFE AND ALTERS PATIENT-CARE	AMERICAN SURGEON			English	Article; Proceedings Paper	62nd Annual Scientific Meeting of the Southeastern Surgical Conference	FEB 06-10, 1994	LAKE BUENA VISTA, FL				CEREBRAL PERFUSION-PRESSURE; INTRA-CRANICAL PRESSURE; INTRACRANIAL-PRESSURE; CLINICAL-EVALUATION; FIBEROPTIC DEVICE; RISK-FACTORS; HEAD-INJURY; COMA; COMPLICATIONS; LESIONS	Objective: To identify complications and interventions resulting from fiberoptic ICP monitoring in a large series of patients with closed head injury (CHI). Setting/Design: Level I trauma center/Consecutive case series. Methods: Of 11,962 consecutive trauma admissions from 1984-1991, 279 patients underwent fiberoptic ICP monitoring for CHI. We identified the last 100 consecutive blunt trauma patients who had received ICP monitoring. Ninety-eight of these patients had charts available and constitute the study group. We examined mortality, Glasgow Coma Score (GCS), and admission CT findings for the group. Indications, interventions, and complications (bleeding, meningitis, and wound infections) associated with ICP monitoring were identified. Results: Mortality for the group was 24%. Reasons for ICP monitoring included GCS less than or equal to 8 and/or abnormal CT findings; 83% had GCS less than or equal to 8. Admission CT findings included subarachnoid hemorrhage (48%), intracerebral hemorrhage (47%), edema (31%), intraventricular hemorrhage (20%), subdural hematoma (18%), and epidural hematoma (9%). Eighty-one per cent of patients had interventions based on ICP monitoring: osmolar therapy (81%), emergency CT (22%), surgical decompression (3%), or pentobarbital coma (2%). No complications resulted from ICP monitoring. Mean duration of monitoring was 4 days (maximum 13 days). Twenty patients (20%) required two or more monitors. Reasons for placing a second monitor included duration >5 days (50%), questionable accuracy (20%), and accidental removal of the first monitor (10%). Conclusions: 1) Fiberoptic intracranial pressure monitoring leads to specific interventions in the majority of patients. 2) The procedure is safe. 3) Prospective studies are needed to determine the impact of coagulopathy on the safety of fiberoptic intracranial pressure monitoring and to define those factors responsible for the low infection rate.			EDDY, VA (corresponding author), VANDERBILT UNIV,SCH MED,DEPT SURG,DIV TRAUMA,243 MED CTR S,2100 PIERCE AVE,NASHVILLE,TN 37212, USA.						ARTRU F, 1992, ANN FR ANESTH, V11, P424, DOI 10.1016/S0750-7658(05)80342-9; AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; CHAMBERS IR, 1990, NEUROSURGERY, V26, P421, DOI 10.1227/00006123-199003000-00007; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CLARK WC, 1989, NEUROSURGERY, V25, P20; CRUTCHFIELD JS, 1990, J NEUROSURG, V72, P482, DOI 10.3171/jns.1990.72.3.0482; DOYLE J, 1992, J CLIN MONITOR, V8, P81, DOI 10.1007/BF01618093; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; HICKMAN KM, 1990, HEART LUNG, V19, P84; HOLLINGSWORTHFR.P, 1988, HEART LUNG, V17, P111; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; OSTRUP RC, 1987, J NEUROSURG, V67, P26; ROSENWASSER RH, 1992, TRAUUMA Q, V8, P30; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; TASKER RC, 1991, NEUROPEDIATRICS, V22, P47, DOI 10.1055/s-2008-1071416; TEASDALE G, 1974, LANCET, V2, P81; TRUNKEY D, 1985, TRAUMA CENTRAL NERVO, P9; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; WEINSTABL C, 1992, J CLIN MONITOR, V8, P116, DOI 10.1007/BF01617429; YALON JS, 1993, J CLIN MONITOR, V9, P71; YANO M, 1987, NEUROSURGERY, V21, P688, DOI 10.1227/00006123-198711000-00015	24	45	46	0	2	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352	0003-1348			AM SURGEON	Am. Surg.	JAN	1995	61	1					24	29					6	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	QC078	WOS:A1995QC07800006	7832377				2022-02-06	
J	SCHNEIDER, GH; VONHELDEN, A; LANKSCH, WR; UNTERBERG, A				SCHNEIDER, GH; VONHELDEN, A; LANKSCH, WR; UNTERBERG, A			CONTINUOUS MONITORING OF JUGULAR BULB OXYGEN-SATURATION IN COMATOSE PATIENTS - THERAPEUTIC IMPLICATIONS	ACTA NEUROCHIRURGICA			English	Article; Proceedings Paper	Joint Meeting of the Belgian, Dutch, and German Neurosurgical Societies on Modern Trends and Innovative Techniques in Clinical Neurosurgery in Adults	FEB 11-13, 1993	MAASTRICHT, NETHERLANDS			JUGULAR VENOUS OXYGEN SATURATION; HYPERVENTILATION; CEREBRAL PERFUSION PRESSURE; DESATURATION EPISODE	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; HYPERVENTILATION; METABOLISM; PRESSURE; INSULTS	Comatose patients run a high risk of developing cerebral ischaemia which may considerably influence final outcome. It would therefore be extremely useful if one could monitor cerebral blood flow in these patients. Since there is a close correlation between the arteriovenous difference of oxygen and cerebral blood flow, it was a logical step to place a fiberoptic catheter in the jugular bulb for continuous measurement of cerebrovenous oxygen saturation. We have monitored cerebral oxygenation in 54 patients, comatose because of severe head injury, intracerebral haemorrhage or subarachnoid haemorrhage. Normal jugular venous oxygen saturation (SJVO(2)) ranges between 60 and 90%. A decline to below 50% is considered indicative of cerebral ischaemia. Spontaneous episodes of desaturation (SJVO(2) < 50% for at least 15 min) were frequent during the acute phase of these insults. Many of these desaturation episodes could be attributed to hyperventilation, even though considered moderate. Likewise, insufficient cerebral perfusion pressure and severe vasospasm were found to be important causes of desaturation episodes. In many instances, tailoring of ventilation or induced hypervolaemia and hypertension were capable of reversing these low flow states. The new method of continuous cerebrovenous oximetry is expected to contribute to a better outcome by enabling timely detection and treatment of insufficient cerebral perfusion.	FREE UNIV BERLIN,RUDOLF VIRCHOW MED CTR,DEPT NEUROSURG,W-1000 BERLIN,GERMANY								ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BAETHMANN A, 1986, MECHANISMS SECONDARY; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1985, CRIT CARE MED, V4, P284; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Miller J.D., 1987, CEREBRAL BLOOD FLOW, P119; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; PATEL PM, 1993, J NEUROSURG ANESTH, V5, P62; PRAKASH S, 1992, J NEUROSURG, V76, pA398; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SCHEINBERG M, 1992, J NEUROSURG, V76, P212; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; von Helden A, 1993, Acta Neurochir Suppl (Wien), V59, P102	18	45	46	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1995	134	1-2					71	75		10.1007/BF01428507			5	Clinical Neurology; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	QZ277	WOS:A1995QZ27700014	7668132				2022-02-06	
J	PHILLIPS, LL; LYETH, BG; HAMM, RJ; POVLISHOCK, JT				PHILLIPS, LL; LYETH, BG; HAMM, RJ; POVLISHOCK, JT			COMBINED FLUID PERCUSSION BRAIN INJURY AND ENTORHINAL CORTICAL LESION - A MODEL FOR ASSESSING THE INTERACTION BETWEEN NEUROEXCITATION AND DEAFFERENTATION	JOURNAL OF NEUROTRAUMA			English	Article							DENTATE GYRUS; HIPPOCAMPAL FORMATION; CORTEX LESIONS; ADULT-RAT; EXTRACELLULAR POTASSIUM; REACTIVE SYNAPTOGENESIS; REINNERVATION; DENERVATION; RECOVERY; SYNAPTOPHYSIN	Laboratory studies suggest that excessive neuroexcitation and deafferentation contribute to long-term morbidity following human head injury. Because no current animal model of traumatic brain injury (TBI) has been shown to combine excessive neuroexcitation and significant levels of deafferentation, we developed a rat model combining the neuroexcitation of fluid percussion TBI with subsequent entorhinal cortical (EC) deafferentation. In this paradigm, moderate fluid percussion TBI was induced in each rat, followed 24 h later by bilateral EC lesion (BEG). Six conditions were examined: (1) fluid percussion TBI followed 24 h later by bilateral EC lesion (TBEC), (2) fluid percussion TBI (TBI), (3) bilateral EC lesion (BEG), (4) sham fluid percussion TBI (SHAM), (5) TBI followed 24 h later by unilateral EC lesion (TUEC), and (6) unilateral EC lesion (UEC). The first four groups were assessed for motor (with beam-balance and beam-walk testing) and cognitive deficits (with the Morris water maze) and hippocampal morphology (with immunocytochemistry and electron microscopy). The TUEC and UEC groups were assessed for cognitive deficits alone. Motor deficits were greater in the TBEC injury than in TBI or sham alone; however, no significant difference was observed between the TBEC and BEC conditions in motor performance. Cognitive deficits were of a greater magnitude in the combined TBEC injury model relative to each individual insult. These cognitive deficits appeared to be additive for the two experimental injuries, BEC deafferentation producing deficits intermediate between TBI and TBEC insults. Morphologic analysis of the dentate gyrus molecular layer at 15 days after TBEC showed that the distribution of synaptophysin-positive presynaptic terminals was distinct from that observed after either TBI or BEC alone. Specifically, the laminar pattern of presynaptic rearrangement induced by BEC lesion did not occur after TBEC injury. The present results show that axonal injury and its attendant deafferentation, when coupled with traumatically induced neuroexcitation, produce an enhancement of the morbidity associated with TBI. Moreover, they indicate that this model can effectively be used to study the interaction between neuroexcitation and synaptic plasticity.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23284		PHILLIPS, LL (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,BOX 693,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, P50NS012587, P01NS012587] Funding Source: NIH RePORTER		CALBAKA LM, 1992, NEUROBIOL AGING, V13, P283; Cotman C.W., 1978, NEURONAL PLASTICITY, P227; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GRADY MS, 1989, J NEUROSURG, V71, P534, DOI 10.3171/jns.1989.71.4.0534; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hamm RJ, 1993, BRAIN RES COGN BRAIN, V1, P223, DOI [10.1016/0926-6410(93)90006-Q, DOI 10.1016/0926-6410(93)90006-Q]; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HOVDA DA, 1990, ACT NEUR S, V51, P331; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1990, Society for Neuroscience Abstracts, V16, P778; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYNCH G, 1976, BRAIN RES, V110, P57, DOI 10.1016/0006-8993(76)90208-0; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, J NEUROCHEM, V55, P1170; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Nagahara A. H., 1992, Society for Neuroscience Abstracts, V18, P1421; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; PHILLIPS LL, 1993, SOC NEUR ABSTR, V19, P1993; PKA MJ, 1992, ACTA NEUROPATHOL BER, V83, P530; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; REEVES TM, 1987, BEHAV NEUROSCI, V101, P179; REEVES TM, 1988, EXP NEUROL, V102, P37, DOI 10.1016/0014-4886(88)90076-3; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; SMITH D H, 1990, Society for Neuroscience Abstracts, V16, P779; STEWARD O, 1988, J COMP NEUROL, V267, P203, DOI 10.1002/cne.902670205; STEWARD O, 1977, BRAIN RES BULL, V2, P41, DOI 10.1016/0361-9230(77)90023-5; STEWARD O, 1983, J COMP NEUROL, V214, P370, DOI 10.1002/cne.902140403; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; STORMMAT.J, 1974, BRAIN RES, V80, P181, DOI 10.1016/0006-8993(74)90683-0; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; VES TM, 1986, EXP BRAIN RES, V102, P167; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	48	45	45	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1994	11	6					641	656		10.1089/neu.1994.11.641			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	QD215	WOS:A1994QD21500002	7723064				2022-02-06	
J	DUNNMEYNELL, A; PAN, SJ; LEVIN, BE				DUNNMEYNELL, A; PAN, SJ; LEVIN, BE			FOCAL TRAUMATIC BRAIN INJURY CAUSES WIDESPREAD REDUCTIONS IN RAT-BRAIN NOREPINEPHRINE TURNOVER FROM 6 TO 24 H	BRAIN RESEARCH			English	Article						BRAIN INJURY; HEAD TRAUMA; RECOVERY OF FUNCTION; PLASTICITY; CATECHOLAMINE	SENSORIMOTOR CORTEX INJURY; CEREBRAL OXIDATIVE-METABOLISM; LOCUS COERULEUS; MOTOR RECOVERY; BEAM-WALKING; CEREBELLAR NOREPINEPHRINE; GLUCOSE-UTILIZATION; CORTICAL INJURY; BARREL CORTEX; AMPHETAMINE	The effect of right sensorimotor traumatic brain injury (TBI) in male Sprague-Dawley rats on brain norepinephrine (NE) turnover was assessed by measuring the decline of endogenous NE levels following tyrosine hydroxylase inhibition produced with alpha-methyl-p-tyrosine. Right sensorimotor cortex contusions were produced by a pneumatically driven piston which depressed the dural surface by 2 mm at 3.2 m/s. TBI rats were compared to uninjured, anesthetized controls at 6 h and 24 h after surgery. While NE turnover was not affected at the lesion site at 6 h after TBI, it was either abolished or decreased by 33-75% bilaterally in the hypothalamus and in the cerebral cortex surrounding and rostral to the lesion site. In the cortex caudal to the lesion site, NE turnover was completely abolished. NE turnover in cerebral cortex opposite the lesion site and in the contralateral cerebellum was decreased by 51 and 43%, respectively, at 6 h. At 24 h, NE turnover was either abolished or decreased bilaterally by 45-92% in all cortical areas, in the hypothalamus, cerebellum, locus coeruleus and medulla. Thus, right sensorimotor cortex contusion causes a marked, early and widespread depression of brain NE turnover. Since amphetamine increases NE turnover, this may explain the dramatic improvement in behavioral deficits which occurs following amphetamine administration at 24 h after such lesions.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT NEUROSCI,NEWARK,NJ 07103		DUNNMEYNELL, A (corresponding author), DEPT VET AFFAIRS MED CTR,NEUROL SERV 127,385 TREMONT AVE,E ORANGE,NJ 07018, USA.						BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1993, PHARMACOL BIOCHEM BE, V44, P297, DOI 10.1016/0091-3057(93)90465-6; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; BRODIE BB, 1966, J PHARMACOL EXP THER, V154, P493; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CRAIK RL, 1987, BRAIN RES BULL, V19, P495, DOI 10.1016/0361-9230(87)90154-7; DIETRICH WD, 1990, STROKE S, V3, P147; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FULHAM MJ, 1992, NEUROLOGY, V42, P2267, DOI 10.1212/WNL.42.12.2267; GLOBUS MYT, 1989, J CEREBR BLOOD F MET, V9, P892, DOI 10.1038/jcbfm.1989.123; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GOLDSTEIN LB, 1993, RESTOR NEUROL NEUROS, V5, P371, DOI 10.3233/RNN-1993-55608; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GUSTAFSON I, 1989, J CEREBR BLOOD F MET, V9, P171, DOI 10.1038/jcbfm.1989.25; HARIK SI, 1984, ANN NEUROL, V15, P568, DOI 10.1002/ana.410150609; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; KATAYAMA Y, 1981, BRAIN RES, V21, P173; LAMANNA JC, 1981, BRAIN RES, V204, P87, DOI 10.1016/0006-8993(81)90654-5; LEVIN BE, 1983, BRAIN RES, V289, P205, DOI 10.1016/0006-8993(83)90021-5; LEVIN BE, 1991, EXP NEUROL, V113, P237, DOI 10.1016/0014-4886(91)90180-K; LEVIN BE, IN PRESS RESTOR NEUR; LEVITT P, 1979, J COMP NEUROL, V186, P505, DOI 10.1002/cne.901860402; LOUGHLIN SE, 1982, BRAIN RES BULL, V9, P287, DOI 10.1016/0361-9230(82)90142-3; LOWRY O, 1934, J BIOL CHEM, P265; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MIYAUCHI Y, 1989, J NEUROCHEM, V53, P408, DOI 10.1111/j.1471-4159.1989.tb07349.x; MOURADIAN RD, 1991, BRAIN RES, V546, P83, DOI 10.1016/0006-8993(91)91162-T; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PAPPIUS HM, 1988, METAB BRAIN DIS, V3, P303, DOI 10.1007/BF00999542; PEARLSON GD, 1981, BRAIN RES, V218, P233, DOI 10.1016/0006-8993(81)91303-2; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; RAICHLE ME, 1975, P NATL ACAD SCI USA, V72, P3726, DOI 10.1073/pnas.72.9.3726; ROBINSON RG, 1980, BRAIN RES, V188, P63, DOI 10.1016/0006-8993(80)90557-0; SLUKA KA, 1992, BRAIN RES, V579, P67, DOI 10.1016/0006-8993(92)90742-R; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUTTON RL, 1993, J NEUROTRAUM, V10, pS181; Ungerstedt U, 1971, ACTA PHYSIOL SC S367, V82, P1; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	49	45	46	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 10	1994	660	1					88	95		10.1016/0006-8993(94)90842-7			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PJ969	WOS:A1994PJ96900011	7828006				2022-02-06	
J	DEANGELIS, MM; HAYES, RL; LYETH, BG				DEANGELIS, MM; HAYES, RL; LYETH, BG			TRAUMATIC BRAIN INJURY CAUSES A DECREASE IN M2 MUSCARINIC CHOLINERGIC RECEPTOR-BINDING IN THE RAT-BRAIN	BRAIN RESEARCH			English	Article						FLUID PERCUSSION; AFDX384; ACETYLCHOLINE; PIRENZIPINE; AUTORADIOGRAPHY; HIPPOCAMPUS; TRAUMATIC BRAIN INJURY; RECEPTOR BINDING	AMINO-ACIDS; DEFICITS; BEHAVIOR; RELEASE; M1	Numerous studies indicate that an acute, excessive activation of muscarinic acetylcholine receptors (mAChR) contributes to the pathophysiological sequela of TBI. The present study examined the effect of moderate fluid percussion traumatic brain injury (TBI) on binding to M1 and M2 mAChR subtypes in the hippocampal formation and adjacent cortex using quantitative autoradiography. Injured animals along with concurrent controls were sacrificed by in situ freezing at 3 h or 24 h following TBI. Slide-mounted tissue sections were incubated in either [H-3]pirenzipine (23 nM) for M1 or [H-3]AFDX384 (9 nM) for M2 mAChR subtype labeling. Binding of [H-3]pirenzipine to the M1 mAChR subtype was not significantly altered by TBI when compared to sham-injured animals. [H-3]AFDX384 binding to the M2 mAChR subtype was significantly decreased at 24 h in hippocampal CA2-3 region and dorsal blade of the dentate gyrus (P < 0.05). The differences observed between M1 and M2 subtypes suggests that these muscarinic subtypes may differentially contribute to the pathophysiology of TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,RICHMOND,VA 23298; UNIV TEXAS,SCH MED,DEPT SURG,DIV NEUROSURG,HOUSTON,TX 77030				DeAngelis, e/J-7863-2015	Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, R01NS021458, R01NS029995, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS21458, R01 NS29995, NS12587] Funding Source: Medline		AUBERT I, 1992, EUR J PHARMACOL, V217, P173, DOI 10.1016/0014-2999(92)90843-S; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DELAHUNTY TM, 1992, 10TH P ANN NUEUR SOC; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAYES RL, 1992, J NEUROTRAUM, V9, P5173; HEPPNER F, 1958, Monatsschr Unfallheilkd Versicherungsmed, V61, P257; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LAPCHAK PA, 1989, BRAIN RES, V496, P285, DOI 10.1016/0006-8993(89)91075-5; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYETH BG, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P253; MAKIYAMA Y, 1990, 8TH P ANN M SOC NEUR; MASH DC, 1986, NEUROSCIENCE, V19, P551, DOI 10.1016/0306-4522(86)90280-0; MASH DC, 1985, SCIENCE, V228, P1115, DOI 10.1126/science.3992249; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PERRY DC, 1992, MOL CHEM NEUROPATHOL, V16, P95, DOI 10.1007/BF03159963; POTTER LT, 1984, TRENDS PHARM SCI S, V5, P22; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; TONNAER JAD, 1990, EUR J PHARMACOL, V207, P183; WAMSLEY JK, 1984, LIFE SCI, V34, P1375; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398	32	45	47	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 8	1994	653	1-2					39	44		10.1016/0006-8993(94)90369-7			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PA036	WOS:A1994PA03600006	7982073				2022-02-06	
J	CREMONAMETEYARD, SL; GEFFEN, GM				CREMONAMETEYARD, SL; GEFFEN, GM			PERSISTENT VISUOSPATIAL ATTENTION DEFICITS FOLLOWING MILD HEAD-INJURY IN AUSTRALIAN RULES FOOTBALL PLAYERS	NEUROPSYCHOLOGIA			English	Article							COVERT ORIENTATION; VISUAL-ATTENTION; NEUROPSYCHOLOGICAL DEFICITS; REACTION-TIME; SYMPTOMS; CONCUSSION; SEQUELAE; RECOVERY; LONG	The ability to direct visuospatial attention covertly was studied in two groups of Australian Rules football players who had sustained mild head injuries (MHI) during competition. Their performance was compared to 12 non-injured sportsmen using a cued reaction time (RT) task which measured the RT benefit of valid directional cueing and the RT cost of miscueing. In Experiment 1, nine footballers tested within 2 weeks of sustaining their injury showed the same cost as normals in speed of response to targets in the unexpected visual field. However, their responses to targets in the expected location (following valid cues) showed only a minor benefit compared to controls. Moderate to severely injured patients also show a normal cost but a reduced or absent benefit (CREMONA-METEYARD and GEFFEN, Neuropsychologia 30, 123-132, 1992). When subjects were retested 1 year later their pattern of performance had not altered but overall RT had improved. Experiment 2 replicated these findings in another eight footballers tested at least 1 year after sustaining their MHI. A persistent consequence of MHI might be an inability to take action quickly in response to expected events.	UNIV QUEENSLAND,DEPT PSYCHOL,COGNIT PSYCHOPHYSIOL LAB,ST LUCIA,QLD 4067,AUSTRALIA; UNIV QUEENSLAND,CLIN STUDIES UNIT,ST LUCIA,QLD 4067,AUSTRALIA; QUEENSLAND HLTH,BRISBANE,QLD 4072,AUSTRALIA								BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT, 1989, MILD HEAD INJURY, P257; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1987, ASSESSMENT BEHAVIOUR, P37; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BROOKS N, 1984, CLOSED HEAD INJURY P; CASTIELLO U, 1988, RIV CULTURA SPORTIVA, V13, P28; CLARK CR, 1989, NEUROPSYCHOLOGIA, V27, P131, DOI 10.1016/0028-3932(89)90166-8; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; CREMONAMETEYARD SL, IN PRESS BRAIN INJUR; DENCKER SJ, 1958, ACTA PSYCHIAT N S122, V33; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GANDY SE, 1984, NEUROLOGY, V16, P114; GEFFEN GM, 1991, J CLIN EXP NEUROPSYC, V13, P423; GEFFEN GM, UNPUB TEST RETEST RE; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTILINI M, 1989, MILD HEAD INJURY, P163; GREENWOOD PM, 1993, NEUROPSYCHOLOGIA, V31, P471, DOI 10.1016/0028-3932(93)90061-4; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JACKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341; KEPPEL S, 1982, DESIGN ANAL RES HDB; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NOUGIER V, 1992, J EXP CHILD PSYCHOL, V54, P315, DOI 10.1016/0022-0965(92)90023-Y; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1988, SCIENCE, V240, P1727; Posner MI., 1978, MODES PERCEIVING PRO, P137; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P64; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHT MJ, 1990, NEUROPSYCHOLOGIA, V28, P151, DOI 10.1016/0028-3932(90)90097-8; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; [No title captured]; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	51	45	45	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	JUN	1994	32	6					649	662		10.1016/0028-3932(94)90026-4			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	NU235	WOS:A1994NU23500002	8084421				2022-02-06	
J	HENRIKSSON, R; FROJD, O; GUSTAFSSON, H; JOHANSSON, S; YIQING, C; FRANZEN, L; BJERMER, L				HENRIKSSON, R; FROJD, O; GUSTAFSSON, H; JOHANSSON, S; YIQING, C; FRANZEN, L; BJERMER, L			INCREASE IN MAST-CELLS AND HYALURONIC-ACID CORRELATES TO RADIATION-INDUCED DAMAGE AND LOSS OF SEROUS ACINAR-CELLS IN SALIVARY-GLANDS - THE PAROTID AND SUBMANDIBULAR GLANDS DIFFER IN RADIATION SENSITIVITY	BRITISH JOURNAL OF CANCER			English	Article							BREAST-CANCER PATIENTS; BRONCHOALVEOLAR LAVAGE; IRRADIATION; SMOKING; INJURY; LUNG; RADIOSENSITIVITY; AMYLASE	The detailed mechanisms which can explain the inherent radiosensitivity of salivary glands remain to be elucidated. Although DNA is the most plausible critical target for the lethal effects of irradiation, interactions with other constituents, such as cell membrane and neuropeptides, have been suggested to cause important physiological changes. Moreover, mast cells seem to be closely linked to radiation-induced pneumonitis. Therefore, in the present study the effects of fractionated irradiation on salivary glands have been assessed with special regard to the appearance of mast cells and its correlation with damage to gland parenchyma. Sprague-Dawley strain rats were unilaterally irradiated to the head and neck with the salivary glands within the radiation field. The irradiation was delivered once daily for 5 days to a total dose of 20, 35 and 45 Gy. The contralateral parotid and submandibular glands served as intra-animal controls and parallel analysis of glands was performed 2, 4, IO or 180 days following the last radiation treatment. Morphological analysis revealed no obvious changes up to 10 days after the irradiation. At 180 days a radiation dose-dependent loss of gland parenchyma was seen, especially with regard to serous acinar cells in parotid gland and acinar cells and serous CGT (convoluted granular tubule) cells in the submandibular gland. These changes displayed a close correlation with a concomitant dose-dependent enhanced density of mast cells and staining for hyaluronic acid. This cell population seems to conform with the features of the connective tissue mast cell type. The parotid seems to be more sensitive to irradiation than the submandibular gland. Thus, the present results further strengthen the role of and the potential interaction of mast cells with radiation-induced tissue injury and alterations in normal tissue integrity.	UNIV HOSP UMEA,DEPT OTO RHINO LARYNGOL,S-90187 UMEA,SWEDEN; UNIV HOSP TRONDHEIM,DEPT LUNG MED,TRONDHEIM,NORWAY		HENRIKSSON, R (corresponding author), UNIV HOSP UMEA,DEPT ONCOL,S-90187 UMEA,SWEDEN.		Bjermer, Leif H/I-4899-2014	Bjermer, Leif H/0000-0002-3441-8099			ABOK K, 1984, VIRCHOWS ARCH B, V45, P443, DOI 10.1007/BF02889885; Alper T, 1977, Adv Exp Med Biol, V84, P139; BJERMER L, 1990, CANCER RES, V50, P2027; BJERMER L, 1992, EUR RESPIR J, V5, P785; CREASY NA, 1960, BIOCHIM BIOPHYS ACTA, V38, P181; DESAI ID, 1964, BIOCHIM BIOPHYS ACTA, V86, P277, DOI 10.1016/0304-4165(64)90054-6; ELMOFTY SK, 1981, INT J RADIAT BIOL, V39, P55, DOI 10.1080/09553008114550071; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; Enerback L., 1986, P405; ENEROTH CM, 1972, CANCER, V30, P1147, DOI 10.1002/1097-0142(197211)30:5<1147::AID-CNCR2820300502>3.0.CO;2-0; FORSGREN S, 1992, NEUROSCIENCE, V46, P233, DOI 10.1016/0306-4522(92)90023-U; FRANZEN L, 1991, LAB INVEST, V64, P279; FRANZEN L, 1989, INT J RADIAT BIOL, V56, P721, DOI 10.1080/09553008914551961; FRANZEN L, 1993, CELL TISSUE RES, V271, P529, DOI 10.1007/BF02913737; GRAHAM MM, 1990, INT J RADIAT ONCOL, V19, P329, DOI 10.1016/0360-3016(90)90541-Q; HENRIKSSON R, 1982, AM J PHYSIOL, V242, pG481, DOI 10.1152/ajpgi.1982.242.5.G481; JUNGLEE D, 1986, CLIN CHEM, V32, P609; MIRA JG, 1982, ACTA RADIOL ONCOL, V21, P151, DOI 10.3109/02841868209133999; NETTELBLAD O, 1989, AM REV RESPIR DIS, V139, P756; NILSSON K, 1990, AM J RESP CELL MOL, V2, P199, DOI 10.1165/ajrcmb/2.2.199; NILSSON K, 1992, IN PRESS INT J RAD B; READE PC, 1985, J BIOL BUCCALE, V13, P307; Rubin P, 1972, FRONT RADIAT THER ON, V6, P1; SHANNON IL, 1978, P SOC EXP BIOL MED, V157, P50; STEPHENS LC, 1986, AM J PATHOL, V124, P469; STEPHENS LC, 1986, RADIOTHER ONCOL, V7, P165; SUTHERLAND RM, 1967, INT J RADIAT BIOL RE, V12, P551, DOI 10.1080/09553006714551161; WEIBEL ER, 1979, STEREOLOGICAL METHOD	28	45	47	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0007-0920			BRIT J CANCER	Br. J. Cancer	FEB	1994	69	2					320	326		10.1038/bjc.1994.58			7	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	MU507	WOS:A1994MU50700019	8297728	Green Published, Bronze			2022-02-06	
J	MCDONALD, S; VANSOMMERS, P				MCDONALD, S; VANSOMMERS, P			PRAGMATIC LANGUAGE-SKILLS AFTER CLOSED-HEAD INJURY - ABILITY TO NEGOTIATE REQUESTS	COGNITIVE NEUROPSYCHOLOGY			English	Article							DEFICITS	Closed head injuries (CHI) frequently result in a constellation of frontal lobe deficits such as poor abstraction, poor regulation of behaviour, and disinhibition. These deficits have ramifications for communication abilities despite intact primary language processes. This study focused on the ability of 2 CHI subjects to make requests in social contexts compared to 12 non-brain-damaged controls. The CHI subjects were found to retain a sensitivity to the various social factors influencing the form a request takes and to use these normally when the request was simple, conventional, and straightforward. They had difficulty, however, formulating their request indirectly in the form of a hint. Their attempts reflected a failure to appreciate logically related aspects of the request context and to use these in their request formulation. Alternatively, if they managed to formulate an indirect hint, they were unable to avoid completing the argument to the point of stating their requests baldly. These features were discussed in relationship to their known frontal lobe deficits.	MACQUARIE UNIV,N RYDE,NSW 2113,AUSTRALIA		MCDONALD, S (corresponding author), UNIV NEW S WALES,DEPT PSYCHOL,POB 1,KENSINGTON,NSW 2033,AUSTRALIA.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Benson D.F., 1986, FRONTAL LOBES; BOWDEN S, 1992, CLIN NEUROPSYCHOLOGI, V6, P45; CLARK HH, 1979, COGNITIVE PSYCHOL, V11, P430, DOI 10.1016/0010-0285(79)90020-3; CLARK HH, 1975, J VERB LEARN VERB BE, V14, P56, DOI 10.1016/S0022-5371(75)80006-5; CLARK HH, 1980, COGNITION, V8, P111, DOI 10.1016/0010-0277(80)90009-8; Courville C. B., 1945, PATHOLOGY NERVOUS SY; Cronbach L.J., 1972, DEPENDABILITY BEHAVI; CROWE SF, 1992, J CLIN EXP NEUROPSYC, V14, P327, DOI 10.1080/01688639208402832; FRANCIK EP, 1985, J MEM LANG, V24, P560, DOI 10.1016/0749-596X(85)90046-4; Halliday Michael Alexander Kirkwood, 1989, LANGUAGE CONTEXT TEX; Holbourn AHS, 1943, LANCET, V2, P438; Kertesz A, 1979, W APHASIA BATTERY; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Levinson, 1987, POLITENESS SOME UNIV; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Luria AR., 1976, BASIC PROBLEMS NEURO; LURIA AR, 1976, HIGHER CORTICAL FUNC; Milner B., 1964, FRONTAL GRANULAR COR; Milton S. B., 1984, CLIN APHASIOLOGY, V14, P114; PILLON B, 1981, NEUROPSYCHOLOGIA, V19, P375, DOI 10.1016/0028-3932(81)90067-1; SEIGEL S, 1988, NONPARAMETRIC STATIS; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Spreen O, 1991, COMPENDIUM NEUROPSYC; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TATE RL, 1992, UNPUB DATA 40 NORMAL; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Walsh K. W., 1985, UNDERSTANDING BRAIN; Walsh K. W., 1978, NEUROPSYCHOLOGY CLIN; Wilson D., 1986, RELEVANCE COMMUNICAT; [No title captured]	34	45	50	0	3	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.	AUG	1993	10	4					297	315		10.1080/02643299308253466			19	Psychology; Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	LT369	WOS:A1993LT36900001					2022-02-06	
J	KITCHENER, PD; VANDERZEE, CEEM; DIAMOND, J				KITCHENER, PD; VANDERZEE, CEEM; DIAMOND, J			LESION-INDUCED NADPH-DIAPHORASE REACTIVITY IN NEOCORTICAL PYRAMIDAL NEURONS	NEUROREPORT			English	Article						BRAIN INJURY; NEURONAL PLASTICITY; NEOCORTEX; NITRIC OXIDE SYNTHASE	LONG-TERM POTENTIATION; NITRIC-OXIDE; MESSENGER	PYRAMIDAL neurones of the rat neocortex do not normally express NADPH-diaphorase reactivity. However, after stab lesions which extended through the entire depth of the neocortex, strong NADPH-diaphorase reactivity was observed in pyramidal neurones at 7 and 14 days post-lesion. At 3 and 21 days post-lesion fewer and less reactive pyramidal neurones were observed, and no reactive pyramidal neurones were seen at 2 and 26 days post-lesion. The great majority of reactive pyramidal neurones were in layers V and VI and most were situated medial to the lesion. The induction of NADPH-diaphorase implies that the capability to synthesize nitric oxide may be a component of the pyramidal neurones' response to traumatic injury.	MCMASTER UNIV,DEPT BIOMED SCI,DIV NEUROSCI,HAMILTON L8N 3Z5,ONTARIO,CANADA		KITCHENER, PD (corresponding author), UNIV QUEENSLAND,DEPT ANAT SCI,CEREBRAL SENSORY FUNCT UNIT,BRISBANE,QLD 4072,AUSTRALIA.		Van der Zee, Catharina E.E.M./L-4773-2015	Kitchener, Peter/0000-0003-4324-5270			BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BROWN IR, 1990, J NEUROSCI RES, V27, P47; CHAPMAN PF, 1992, NEUROREPORT, V3, P567, DOI 10.1097/00001756-199207000-00005; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; FERRIERO DM, 1988, ANN NEUROL, V24, P670, DOI 10.1002/ana.410240512; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GOADSBY PJ, 1992, BRAIN RES, V595, P167, DOI 10.1016/0006-8993(92)91470-Y; GONZALEZ MF, 1987, BRAIN RES BULL, V18, P417, DOI 10.1016/0361-9230(87)90016-5; HOPE BT, 1992, TRENDS NEUROSCI, V15, P108; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; Jones EG, 1984, CELLULAR COMPONENTS, P521; KITCHENER PD, 1993, IN PRESS NEUROSCI; KITCHENER PD, 1991, P AUST PHYSL PHARM S, V22, pP186; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POW DV, 1992, J NEUROENDOCRINOL, V4, P377, DOI 10.1111/j.1365-2826.1992.tb00183.x; SAGAR SM, 1987, BRAIN RES, V400, P348, DOI 10.1016/0006-8993(87)90633-0; SCHERERSINGLER U, 1983, J NEUROSCI METH, V9, P229, DOI 10.1016/0165-0270(83)90085-7; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; SOLODKIN A, 1992, NEUROSCIENCE, V51, P495, DOI 10.1016/0306-4522(92)90290-I; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; WALLACE MN, 1992, NEUROREPORT, V3, P953, DOI 10.1097/00001756-199211000-00001; WALLIS RA, 1992, NEUROREPORT, V3, P645, DOI 10.1097/00001756-199207000-00026	25	45	49	0	0	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	MAY	1993	4	5					487	490		10.1097/00001756-199305000-00006			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LB076	WOS:A1993LB07600006	8513123				2022-02-06	
J	PHILLIPS, LL; BELARDO, ET				PHILLIPS, LL; BELARDO, ET			EXPRESSION OF C-FOS IN THE HIPPOCAMPUS FOLLOWING MILD AND MODERATE FLUID PERCUSSION BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							LONG-TERM POTENTIATION; RAT-BRAIN; DENTATE GYRUS; ORNITHINE DECARBOXYLASE; UNANESTHETIZED RATS; INDUCED SEIZURES; MAMMALIAN BRAIN; GENE-EXPRESSION; NMDA RECEPTORS; MESSENGER-RNA	An oncoprotein mediator of gene expression, c-fos, was evaluated in the central fluid percussion model of traumatic brain injury (TBI). Since hippocampal CA1 neurons are particularly vulnerable to TBI, we hypothesized that TBI may produce pathobiologic changes in CA1, in part, by alterations in gene expression through c-fos. Sprague-Dawley rats were subjected to mild (1.0 atm) or moderate (2.1 atm) fluid percussion TBI or sham injury. At 15 min, 1 h, and 24 h after injury (or sham injury), sections from middorsal hippocampus were immunostained with antibodies to c-fos, and c-fos-positive CA1 neurons were counted. As predicted, c-fos was localized in the nuclei of CA1 pyramidal neurons. However, the intensity of label was not equal over all CA1 neurons. Cells with high-intensity c-fos label were more prevalent after mild TBI. The number of c-fos-labeled CA1 neurons was increased at 15 min after both mild and moderate TBI relative to paired sham controls. Counts of c-fos-positive neurons remained significantly elevated at 1 h postinjury only after mild TBI. By 24 h postinjury, the number of c-fos-positive cells at both injury levels was not different from sham controls. No difference was observed between the number of c-fos-positive cells in naive and sham controls. However, label intensity was slightly less in the naive cases. These results suggest that the pathobiologic changes at early intervals following mild or moderate TBI may involve c-fos alteration of gene expression and that c-fos expression may be differentially regulated as a function of injury level.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298		PHILLIPS, LL (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,BOX 693,MCV STN,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027225, R01NS019550, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27225, NS21458, NS19550] Funding Source: Medline		BELT BS, 1989, IMMUNOCYTOCHEMICAL T, P90; CHIARUGI VP, 1989, NEUROCHEM INT, V14, P1, DOI 10.1016/0197-0186(89)90002-8; COLE AJ, 1990, J NEUROCHEM, V55, P1920, DOI 10.1111/j.1471-4159.1990.tb05777.x; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DRAGUNOW M, 1989, NEUROSCI LETT, V101, P274, DOI 10.1016/0304-3940(89)90545-4; DRAGUNOW M, 1990, NEUROSCI LETT, V109, P128, DOI 10.1016/0304-3940(90)90550-S; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HAYES RL, 1992, CENTRAL NERVOUS SYST, P173; HERRERA DG, 1989, BRAIN RES, V503, P205, DOI 10.1016/0006-8993(89)91665-X; JEFFERY KJ, 1990, MOL BRAIN RES, V8, P267, DOI 10.1016/0169-328X(90)90039-G; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; PERRY DC, 1992, MOL CHEM NEUROPATHOL, V16, P95, DOI 10.1007/BF03159963; POPOVICI T, 1990, BRAIN RES, V536, P183, DOI 10.1016/0006-8993(90)90024-6; RAYTER SI, 1989, ONCOGENES, P113; SAITOH T, 1991, LAB INVEST, V64, P596; SHARP FR, 1989, NEUROSCI LETT, V100, P117, DOI 10.1016/0304-3940(89)90670-8; SHARP JW, 1990, EXP NEUROL, V109, P323, DOI 10.1016/S0014-4886(05)80023-8; Siesj? BK., 1978, BRAIN ENERGY METABOL; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; VENDRELL M, 1991, BRAIN RES, V544, P291, DOI 10.1016/0006-8993(91)90067-6; WESSEL TC, 1991, BRAIN RES, V567, P231, DOI 10.1016/0006-8993(91)90800-B; ZAWIA NH, 1990, MOL BRAIN RES, V7, P243, DOI 10.1016/0169-328X(90)90034-B	34	45	49	1	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	WIN	1992	9	4					323	333		10.1089/neu.1992.9.323			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	KH753	WOS:A1992KH75300002	1291692				2022-02-06	
J	BROOKE, MM; QUESTAD, KA; PATTERSON, DR; VALOIS, TA				BROOKE, MM; QUESTAD, KA; PATTERSON, DR; VALOIS, TA			DRIVING EVALUATION AFTER TRAUMATIC BRAIN INJURY	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						AUTOMOBILE DRIVING; BRAIN INJURY; PSYCHOMOTOR PERFORMANCE	DAMAGE	Traumatic closed head injury results in a variety of cognitive and behavioral deficits that may be difficult to assess fully. Adequately evaluating driving safety is a common and important problem for health care professionals. The purpose of this study was to examine the relationship between standardized measures of cognitive function and measures of driving performance in patients with closed head injuries and in their age-matched relative or friend cohorts. Thirteen patients were evaluated. They had each sustained a closed head injury (followed by more than 1 h of coma) 3 to 6 months before testing. Their scores were analyzed along with those of seven cohorts. Assessments of cognitive function and behind-the-wheel driving performance were conducted by examiners blinded to subjects' group membership and medical condition. There was a significant relationship (r = 0.44) between the sum of rated scores of the Tactual Performance Test and Trail Making Test and the global pass/fail ratings of the behind-the-wheel driving test, but it was not related to the driving performance score. The difference between the verbal and performance IQs, and the difference between the block design and other performance tests of the Wechsler Adult Intelligence Scale-Revised were also not significantly related to driving performance. These results suggest that tests of cognitive function alone are not adequate to predict driving performance, and should be used along with standardized driving performance evaluations before recommendations are made.	UNIV WASHINGTON,SCH MED,DEPT REHABIL MED,SEATTLE,WA 98195		BROOKE, MM (corresponding author), TUFTS UNIV,SCH MED,DEPT REHABIL MED,136 HARRISON AVE,BOSTON,MA 02111, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR002570-03] Funding Source: Medline		COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Reitan RM, 1985, HALSTEADREITAN NEURO; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; SULLIVAN RA, 1975, PREDRIVING EVALUATIO; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	8	45	45	0	6	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUN	1992	71	3					177	182		10.1097/00002060-199206000-00009			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	HY972	WOS:A1992HY97200009	1627283				2022-02-06	
J	RISLING, M; FRIED, K; LINDA, H; CULLHEIM, S; MEIER, M				RISLING, M; FRIED, K; LINDA, H; CULLHEIM, S; MEIER, M			CHANGES IN NERVE GROWTH-FACTOR RECEPTOR-LIKE IMMUNOREACTIVITY IN THE SPINAL-CORD AFTER VENTRAL FUNICULUS LESION IN ADULT CATS	JOURNAL OF NEUROCYTOLOGY			English	Article							ELECTRON-MICROSCOPIC OBSERVATIONS; HYALURONATE-BINDING PROTEIN; MOTOR-NEURON INJURY; SENSORY NEURONS; NEUROTROPHIC FACTOR; NGF-RECEPTOR; AXONAL REGENERATION; OPTIC-NERVE; RAT-BRAIN; PERIVASCULAR CELLS	Spinal motoneurons have a capability to regenerate CNS-type axons after intramedullary lesions in the adult cat. Regrowing axons have been traced through CNS-type scar tissue in the ventral funiculus of the spinal cord and into adjacent ventral root fascicles. This scar tissue, which appears to support and sustain regenerating axons, has been shown to have a persistent defect in the blood-brain barrier. It has been suggested that the blood-brain barrier may play a vital role in CNS regeneration by regulating the access of blood-borne trophic factors to the lesion area. In the present study, the binding of antibodies to the human nerve growth factor receptor in the cat spinal cord was examined with immunohistochemical methods 2 days to 8 weeks after a ventral funiculus lesion. The results show that, while no neurons in the ventral horn of the control material contained nerve growth factor receptor-like immunoreactivity as revealed by fluorescence microscopy, affected motoneurons expressed nerve growth factor receptor after ventral funiculus lesion. Nerve growth factor receptor-like immunoreactivity associated to both capillaries and interstitium was present in the scar tissue. Electron microscopic examination of sections labelled with the immunogold-silver method showed that perivascular nerve growth factor receptor-like immunoreactivity was located exclusively to non-pericytic perivascular cells. These cells were abundant in the expanded capillary perivascular spaces adjacent to the traumatic lesion. Similar cells, with or without relation to blood vessels, were observed in the scar tissue and in the pia mater. In a separate set of specimens it was observed that a ventral funiculus lesion combined with ventral root avulsion, which removes denervated PNS tissue, resulted in an expression of nerve growth factor receptor-like immunoreactivity which was similar to the one observed after ventral funiculus lesion only. The results of the present study show that affected motoneurons and cells in the scar tissue express nerve growth factor receptor after ventral funiculus lesion which implies that neurotrophic factors related to nerve growth factor may be of importance for the regenerative response.			RISLING, M (corresponding author), KAROLINSKA INST, DEPT ANAT, POB 60400, S-10401 STOCKHOLM 60, SWEDEN.						ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; ALETTA JM, 1988, J CELL BIOL, V106, P1573, DOI 10.1083/jcb.106.5.1573; ALLEN SJ, 1989, J COMP NEUROL, V289, P626, DOI 10.1002/cne.902890408; BABA M, 1988, N-S ARCH PHARMACOL, V337, P423; BALIN BJ, 1986, J COMP NEUROL, V251, P260, DOI 10.1002/cne.902510209; BASBAUM AI, 1989, J HISTOCHEM CYTOCHEM, V37, P1811, DOI 10.1177/37.12.2479673; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BERRY M, 1988, BRAIN RES BULL, V20, P223, DOI 10.1016/0361-9230(88)90182-7; BIGNAMI A, 1988, EXP NEUROL, V100, P253, DOI 10.1016/0014-4886(88)90218-X; BROWN MC, 1991, NEURON, V6, P359, DOI 10.1016/0896-6273(91)90245-U; CARLSTEDT T, 1977, ACTA PHYSIOL SCAND, P5; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CAVICCHIOLI L, 1989, EUR J NEUROSCI, V1, P258, DOI 10.1111/j.1460-9568.1989.tb00793.x; CULLHEIM S, 1989, NEUROSCIENCE, V29, P725, DOI 10.1016/0306-4522(89)90144-9; D'MELLO SR, 1990, J NEUROCHEM, V55, P718, DOI 10.1111/j.1471-4159.1990.tb04192.x; DAVID S, 1984, J NEUROCYTOL, V13, P961, DOI 10.1007/BF01148596; DAVID S, 1988, J NEUROCYTOL, V17, P131, DOI 10.1007/BF01735385; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DUNCAN D, 1948, TEX REP BIOL MED, V6, P461; ECKENSTEIN F, 1988, BRAIN RES, V446, P149, DOI 10.1016/0006-8993(88)91305-4; ERNFORS P, 1989, NEURON, V2, P1605, DOI 10.1016/0896-6273(89)90049-4; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; EVELETH DD, 1988, NEURON, V1, P929, DOI 10.1016/0896-6273(88)90150-X; FRANSON P, 1985, J COMP NEUROL, V231, P490, DOI 10.1002/cne.902310407; FRIED K, 1991, CELL TISSUE RES, V264, P321, DOI 10.1007/BF00313969; FRIED K, 1990, BRAIN RES, V536, P321, DOI 10.1016/0006-8993(90)90043-B; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GRAEBER MB, 1989, J NEUROSCI RES, V22, P103, DOI 10.1002/jnr.490220114; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; HAGG T, 1991, EXP NEUROL, V112, P79, DOI 10.1016/0014-4886(91)90116-T; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, RECENT PROG HORM RES, V45, P441; HILDEBRAND C, 1985, J NEUROCYTOL, V14, P597, DOI 10.1007/BF01200800; HILDEBRAND C, 1976, J COMP NEUROL, V170, P191, DOI 10.1002/cne.901700205; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1989, BRAIN RES, V478, P166, DOI 10.1016/0006-8993(89)91491-1; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; KIERNAN JA, 1979, BIOL REV, V54, P155, DOI 10.1111/j.1469-185X.1979.tb00871.x; KIERNAN JA, 1980, ACTA NEUROPATHOL, V51, P39, DOI 10.1007/BF00688848; KIERNAN JA, 1985, J ANAT, V141, P139; KOLIATSOS VE, 1991, BRAIN RES, V541, P121, DOI 10.1016/0006-8993(91)91084-E; KOLIATSOS VE, 1991, BRAIN RES, V549, P297, DOI 10.1016/0006-8993(91)90471-7; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LIESI P, 1988, DEV BIOL, V130, P774, DOI 10.1016/0012-1606(88)90366-1; LINDA H, 1990, BRAIN RES, V534, P352, DOI 10.1016/0006-8993(90)90157-7; LINDA H, 1985, BRAIN RES, V358, P329, DOI 10.1016/0006-8993(85)90978-3; LINDHOLM D, 1990, EUR J NEUROSCI, V2, P795, DOI 10.1111/j.1460-9568.1990.tb00471.x; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LINDSAY RM, 1990, EUR J NEUROSCI, V2, P389, DOI 10.1111/j.1460-9568.1990.tb00431.x; LINDSAY RM, 1989, NEUROSCIENCE, V33, P53, DOI 10.1016/0306-4522(89)90310-2; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; MANNEN T, 1977, J NEUROL NEUROSUR PS, V40, P464, DOI 10.1136/jnnp.40.5.464; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; MANTHORPE M, 1983, J CELL BIOL, V97, P1882, DOI 10.1083/jcb.97.6.1882; MARCHETTI D, 1990, J NEUROSCI RES, V27, P211, DOI 10.1002/jnr.490270211; MORGAN B, 1989, J NEUROSCI RES, V23, P41, DOI 10.1002/jnr.490230106; Peters A, 1976, FINE STRUCTURE NERVO, V3rd; PIORO EP, 1990, NEUROSCIENCE, V34, P89, DOI 10.1016/0306-4522(90)90305-N; PRIESTLEY JV, 1984, IMMUNOLABELLING ELEC, P37; RAGSDALE C, 1991, NATURE, V350, P660, DOI 10.1038/350660a0; RAIVICH G, 1985, EMBO J, V4, P637, DOI 10.1002/j.1460-2075.1985.tb03677.x; Ramon y Cajal S., 1959, DEGENERATION REGENER; RICH KM, 1987, J NEUROCYTOL, V16, P261, DOI 10.1007/BF01795309; RISLING M, 1983, BRAIN RES, V280, P15, DOI 10.1016/0006-8993(83)91169-1; RISLING M, 1989, BRAIN RES, V494, P13, DOI 10.1016/0006-8993(89)90138-8; RISLING M, 1990, FERNS FOUND SERIES, V14, P555; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SAIKA T, 1991, MOL BRAIN RES, V9, P157, DOI 10.1016/0169-328X(91)90142-K; SCHWAB ME, 1990, EXP NEUROL, V109, P2, DOI 10.1016/S0014-4886(05)80003-2; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SJOGREN A, 1991, BRAIN RES, V559, P276, DOI 10.1016/0006-8993(91)90012-K; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STEPHANI U, 1987, J NEUROSCI RES, V17, P25, DOI 10.1002/jnr.490170105; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOMSON TM, 1988, EXP CELL RES, V174, P533, DOI 10.1016/0014-4827(88)90323-0; TSUDA T, 1990, INT ARCH ALLER A IMM, V91, P15, DOI 10.1159/000235083; VARNDELL IM, 1986, IMMUNOCYTOCHEMISTRY, P147; WADDELL WR, 1972, LANCET, V1, P1365; WOOD SJ, 1990, EUR J NEUROSCI, V2, P650, DOI 10.1111/j.1460-9568.1990.tb00454.x; YAN Q, 1989, J COMP NEUROL, V290, P585, DOI 10.1002/cne.902900411; YAN Q, 1988, NEURON, V1, P335; YAN Q, 1988, J NEUROSCI, V8, P3481; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	90	45	45	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-4864			J NEUROCYTOL	J. Neurocytol.	FEB	1992	21	2					79	93		10.1007/BF01189007			15	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	HE544	WOS:A1992HE54400001	1313859				2022-02-06	
J	PECHADRE, JC; LAUXEROIS, M; COLNET, G; COMMUN, C; DIMICOLI, C; BONNARD, M; GIBERT, J; CHABANNES, J				PECHADRE, JC; LAUXEROIS, M; COLNET, G; COMMUN, C; DIMICOLI, C; BONNARD, M; GIBERT, J; CHABANNES, J			PREVENTION OF LATE POSTTRAUMATIC EPILEPSY BY PHENYTOIN IN SEVERE BRAIN INJURIES - 2 YEARS FOLLOW-UP	PRESSE MEDICALE			French	Article						PHENYTOIN; EPILEPSY	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; PHARMACOLOGICAL PROPHYLAXIS; INTRAVENOUS PHENYTOIN; SEIZURES; CAT	The high incidence rate and the invalidating nature of post-traumatic epilepsy after severe brain injury have encouraged the authors to review the prophylactic treatment of this type of epilepsy. Thirty-four out of 86 randomised patients with brain injuries admitted into a neurotraumatology intensive care unit were treated prophylactically, immediately after the injury, with an intravenous hydantoin injection in a dose sufficient to provide stable and effective blood levels. This was followed by dose-adjusted oral administration maintained for a minimum period of 3 months. After a 2 years' follow-up, there was a significant difference between treated and untreated patients, since only 6 per cent of the patients treated suffered from post-traumatic epilepsy, as against 42 percent in the untreated group.	CTR HOSP REG & UNIV CLERMONT FERRAND HOTEL DIEU,SERV NEUROTRAUMATOL,F-63003 CLERMONT FERRAND,FRANCE; CTR HOSP REG & UNIV CLERMONT FERRAND,HOTEL DIEU,SERV ANESTHESIE REANIMAT,F-69003 CLERMONT FERRAND,FRANCE		PECHADRE, JC (corresponding author), CTR HOSP REG & UNIV CLERMONT FERRAND,HOTEL DIEU,SERV EXPLORAT FONCT SYST NERVEUX,BP 69,F-63003 CLERMONT FERRAND,FRANCE.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BRICOLO E, 1974, IL FRACASTORO, V67, P225; BUCHTHAL F, 1972, ANTIEPILEPTIC DRUGS, P193; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; COURJON J, 1966, CAH MED LYON, V42, P1343; CRANFORD RE, 1978, NEUROLOGY, V28, P874, DOI 10.1212/WNL.28.9.874; De Santis A, 1979, J Neurosurg Sci, V23, P207; EARNEST MP, 1983, JAMA-J AM MED ASSOC, V249, P762, DOI 10.1001/jama.249.6.762; GLAZKO AJ, 1972, ANTIEPILEPTIC DRUGS, P103; HAGEL KH, 1983, UNFALLHEILKUNDE, V86, P331; JANZ D, 1982, NERVENARZT, V53, P238; Jennett W. B., 1969, LATE EFFECTS HEAD IN, P201; KARBOWSKI K, 1981, SCHWEIZ RUNDSCH MED, V70, P1546; KUTT H, 1972, ANTIEPILEPTIC DRUGS, P211; LAUXEROIS M, 1983, NEUROCHIRURGIE, V30, P241; LAUXEROIS M, 1990, EPILEPSIES, V2, P5; LOCKARD JS, 1976, EPILEPSIA, V17, P37, DOI 10.1111/j.1528-1157.1976.tb03380.x; MAUGUIERE F, 1979, REV EEG NEUROPHYSIOL, V9, P149, DOI 10.1016/S0370-4475(79)80069-6; Mauguiere F, 1984, Rev Electroencephalogr Neurophysiol Clin, V14, P207, DOI 10.1016/S0370-4475(84)80006-4; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; MEIROWSKY AM, 1982, MIL MED, V147, P632, DOI 10.1093/milmed/147.8.632; RAPPORT RL, 1975, ARCH NEUROL-CHICAGO, V32, P539, DOI 10.1001/archneur.1975.00490500059007; RAPPORT RL, 1973, J NEUROSURG, V38, P159, DOI 10.3171/jns.1973.38.2.0159; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SERVIT Z, 1972, 4TH P EUR C NEUR AMS; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TURNER IM, 1977, ANN NEUROL, V2, P221, DOI 10.1002/ana.410020307; VANDERVELDE GA, 1972, CHEM PHYS LETT, V13, P409, DOI 10.1016/0009-2614(72)80112-X; WADA JA, 1976, ARCH NEUROL-CHICAGO, V33, P426, DOI 10.1001/archneur.1976.00500060032008; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x	32	45	48	0	2	MASSON EDITEUR	PARIS 06	120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE	0755-4982			PRESSE MED	Presse Med.	MAY 11	1991	20	18					841	845					5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM026	WOS:A1991FM02600006	1829177				2022-02-06	
J	SPETTELL, CM; ELLIS, DW; ROSS, SE; SANDEL, ME; OMALLEY, KF; STEIN, SC; SPIVACK, G; HURLEY, KE				SPETTELL, CM; ELLIS, DW; ROSS, SE; SANDEL, ME; OMALLEY, KF; STEIN, SC; SPIVACK, G; HURLEY, KE			TIME OF REHABILITATION ADMISSION AND SEVERITY OF TRAUMA - EFFECT ON BRAIN INJURY OUTCOME	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURIES; GLASGOW OUTCOME SCALE; HEAD INJURIES; HOSPITALIZATION; MULTIPLE TRAUMA; REHABILITATION	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; PROGNOSIS	Outcome after traumatic brain injury, defined by the Glasgow Outcome Scale (GOS) and length of stay in acute rehabilitation, was measured in 59 patients admitted to an intensive rehabilitation program to examine the effects of severity of the initial brain injury, severity of multiple trauma, and length of stay in the acute care hospital. Severity of initial brain injury, best measured by length of coma, was the most significant predictor of GOS outcome. Length of acute hospitalization was a small, but significant, predictor of GOS. Severity of initial brain injury, length of acute hospitalization, and gender emerged as predictors of length of rehabilitation hospital stay. Although length of acute hospitalization is apparently affected by severity of brain injury, it adds significantly - more than severity of brain injury - to the prediction of length of rehabilitation.	COOPER HOSP UNIV MED CTR,ROBERT WOOD JOHNSON MED SCH,CAMDEN,NJ		SPETTELL, CM (corresponding author), MEDIPLEX REHAB CAMDEN,INST BRAIN INJURY RES & TRAINING,2 COOPER PLAZA,CAMDEN,NJ 08103, USA.						ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; BERGMAN TA, 1987, MINN MED, V70, P397; BLACK P, 1975, OUTCOME SEVERE DAMAG, P65; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; EDWARDS AL, 1972, EXPT PSYCHOL RES; EISENBERG HM, 1987, NEUROBEHAVIORAL RECO, P13; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; GIANNOTTA SL, 1987, HEAD INJURY, P464; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Jones C, 1981, J Neurosurg Nurs, V13, P178; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; Kraus JF, 1987, HEAD INJURY, V2, P1; Levin H., 1987, HEAD INJURY, P442; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MAYER T, 1981, CHILD BRAIN, V8, P189; OVERGAARD J, 1973, LANCET, V2, P631; PAZZAGLIA D, 1975, J NEUROL NEUROSUR PS, V38, P149; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rosenzwelg M., 1980, RECOVERY FUNCTION TH, P127; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STEIN DG, 1974, PLASTICITY RECOVERY, P373; TEASDALE G, 1974, LANCET, V2, P81; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; YU J, 1976, ARCH PHYS MED REHAB, V57, P38; 1985, ABBREVIATED INJURY S	37	45	46	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1991	72	5					320	325					6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	FF342	WOS:A1991FF34200011	2009049				2022-02-06	
J	BAKSHI, R; NEWMAN, AH; FADEN, AI				BAKSHI, R; NEWMAN, AH; FADEN, AI			DYNORPHIN-A-(1-17) INDUCES ALTERATIONS IN FREE FATTY-ACIDS, EXCITATORY AMINO-ACIDS, AND MOTOR FUNCTION THROUGH AN OPIATE-RECEPTOR-MEDIATED MECHANISM	JOURNAL OF NEUROSCIENCE			English	Article							SPINAL-CORD INJURY; KAPPA-OPIOID RECEPTOR; RAT-BRAIN; BINDING-SITES; LIQUID-CHROMATOGRAPHY; INTRATHECAL INJECTION; NOR-BINALTORPHIMINE; TRAUMATIC INJURY; IMPACT TRAUMA; BLOOD-FLOW	The endogenous opioid dynorphin A-(1-17) (Dyn A) has been implicated as a mediator of tissue damage after traumatic spinal cord injury (TSCI) and causes hindlimb paralysis when administered intrathecally. Motor impairment following intrathecal Dyn A is attenuated by antagonists of excitatory amino acids (EAAs); where opioid receptors mediate such injury has been questioned. TSCI causes various biochemical changes associated with secondary tissue damage, including alterations in tissue amino acids, phospholipids, and fatty acids. Such changes reflect injury severity and correlate with motor dysfunction. The present studies examined whether dynorphin administration causes similar biochemical alterations and whether effects of Dyn A can be modified by treatment with opioid-receptor antagonists. At 24 hr after intrathecal Dyn A, there were significant declines in tissue levels of glutamate, aspartate, and glycine. Increase in total free fatty acids were found at 2 and 24 hr, reflecting changes in both saturated and unsaturated components, which were associated with significant decreases in tissue cholesterol and phospholipid phosphorus at the earlier time point. Each of these neurochemical changes, as well as corresponding motor deficits, were limited by pretreatment with the opioid antagonist nalmefene. In separate experiments, both nalmefene and the selective kappa-opioid antagonist nor-binaltorphimine (nor-BNI) limited dynorphin-induced motor dysfunction; effects of nor-BNI were dose related, and those of nalmefene were stereospecific. Therefore, behavioral and neurochemical consequences of Dyn A administration are mediated in part through opiate receptors, most likely kappa-receptors. These studies indicate that phospholipid hydrolysis and release of EAAs may contribute to dynorphin-induced tissue damage, suggesting for the first time a potential linkage among opioid, excitotoxin, and membrane lipid mechanisms of secondary injury after neurotrauma.	DEPT VET AFFAIRS, NEUROL SERV 127, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, CTR NEURAL INJURY, DEPT NEUROL, SAN FRANCISCO, CA 94121 USA; WALTER REED ARMY MED CTR, DEPT APPL BIOCHEM, WASHINGTON, DC 20307 USA						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS23422] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023422] Funding Source: NIH RePORTER		AGARDH CD, 1981, J NEUROCHEM, V36, P490, DOI 10.1111/j.1471-4159.1981.tb01619.x; ALLEN KG, 1984, J CHROMATOGR, V309, P33, DOI 10.1016/0378-4347(84)80003-1; ALLISON LA, 1984, ANAL CHEM, V56, P1089, DOI 10.1021/ac00271a010; ARIAS MJ, 1985, SURG NEUROL, V23, P440, DOI 10.1016/0090-3019(85)90226-5; ATTALI B, 1982, NEUROPEPTIDES, V3, P53, DOI 10.1016/0143-4179(82)90065-8; BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BAKSHI R, 1990, NEUROSCI LETT, V110, P113, DOI 10.1016/0304-3940(90)90797-D; BLOK MC, 1977, BIOCHIM BIOPHYS ACTA, V464, P509, DOI 10.1016/0005-2736(77)90026-8; BOWMAN RE, 1962, CLIN CHEM, V8, P302; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAUDLE RM, 1988, BRAIN RES, V443, P329, DOI 10.1016/0006-8993(88)91628-9; CAUDLE RM, 1987, BRAIN RES, V435, P1, DOI 10.1016/0006-8993(87)91579-4; CHAN PH, 1983, ANN NEUROL, V13, P625, DOI 10.1002/ana.410130608; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; CHOI D W, 1989, Society for Neuroscience Abstracts, V15, P1113; CHOI DW, 1988, J NEUROSCI, V8, P185; CZLONKOWSKI A, 1983, BRAIN RES, V267, P392, DOI 10.1016/0006-8993(83)90897-1; DANYSZ W, 1989, BRAIN RES, V479, P270, DOI 10.1016/0006-8993(89)91628-4; DEMEDIUK P, 1989, J NEUROCHEM, V52, P1529, DOI 10.1111/j.1471-4159.1989.tb09204.x; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; ERECINSKA M, 1984, BRAIN RES, V304, P9, DOI 10.1016/0006-8993(84)90857-6; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1984, BRIT J PHARMACOL, V81, P271, DOI 10.1111/j.1476-5381.1984.tb10074.x; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1985, REGUL PEPTIDES, V11, P35, DOI 10.1016/0167-0115(85)90029-1; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GARDINER M, 1981, J NEUROCHEM, V36, P1500, DOI 10.1111/j.1471-4159.1981.tb00592.x; GOUARDERES C, 1985, NEUROPEPTIDES, V6, P331, DOI 10.1016/0143-4179(85)90006-X; GOUARDERES C, 1984, NEUROPEPTIDES, V5, P113, DOI 10.1016/0143-4179(84)90040-4; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; HAN JS, 1982, LIFE SCI, V31, P1781, DOI 10.1016/0024-3205(82)90209-0; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; Houslay MD, 1982, DYNAMICS BIOL MEMBRA, P71; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; INOUE Y, 1986, Journal of the Japanese Orthopaedic Association, V60, P777; IYENGAR S, 1985, Journal of Neurochemistry, V44, pS89; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JONES M, 1982, J CHROMATOGR, V237, P522, DOI 10.1016/S0021-9673(00)97644-1; KWO S, 1989, Journal of Neurotrauma, V6, P13, DOI 10.1089/neu.1989.6.13; LAZAREWICZ JW, 1972, B ACAD POL SCI BIOL, V20, P599; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; LEMKE M, 1990, IN PRESS MOL CHEM NE; LONG JB, 1987, BRAIN RES, V436, P374, DOI 10.1016/0006-8993(87)91683-0; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1167; LONG JB, 1989, BRAIN RES, V497, P155, DOI 10.1016/0006-8993(89)90982-7; LONG JB, 1989, J NEUROTRAUM, V6, P59; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; LUCY JA, 1970, NATURE, V227, P815, DOI 10.1038/227815a0; MACK KJ, 1984, LIFE SCI, V34, P281, DOI 10.1016/0024-3205(84)90600-3; MASSARDIER D, 1989, EUR J PHARMACOL, V170, P125, DOI 10.1016/0014-2999(89)90149-0; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MICHEL ME, 1985, METHOD FIND EXP CLIN, V7, P175; NOCK B, 1988, EUR J PHARMACOL, V154, P27, DOI 10.1016/0014-2999(88)90359-7; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PRZEWLOCKI R, 1983, NEUROPEPTIDES, V3, P233, DOI 10.1016/0143-4179(83)90019-7; RAZ A, 1973, BIOCHIM BIOPHYS ACTA, V311, P222, DOI 10.1016/0005-2736(73)90269-1; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; RHOADS DE, 1982, J NEUROCHEM, V38, P1255, DOI 10.1111/j.1471-4159.1982.tb07898.x; RICE KC, 1986, TOTAL SYNTHESIS NORT; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SAUNDERS RD, 1984, ANAL BIOCHEM, V143, P71, DOI 10.1016/0003-2697(84)90559-1; SEGLERSTAHL K, 1985, NEUROCHEM RES, V10, P563, DOI 10.1007/BF00964658; SPAMPINATO S, 1985, EUR J PHARMACOL, V110, P21, DOI 10.1016/0014-2999(85)90024-X; STEVENS CW, 1986, J PHARMACOL EXP THER, V238, P833; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; THORNHILL JA, 1989, BRAIN RES, V490, P174, DOI 10.1016/0006-8993(89)90447-2; TRAYNOR JR, 1982, LIFE SCI, V31, P1377, DOI 10.1016/0024-3205(82)90385-X; WALKER JM, 1982, SCIENCE, V218, P1136, DOI 10.1126/science.6128791; WOJTCZAK L, 1976, J BIOENERG BIOMEMBR, V8, P293; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; YOSHIDA S, 1982, BRAIN RES, V245, P307, DOI 10.1016/0006-8993(82)90813-7; YOSHIMURA K, 1982, J PHARMACOL EXP THER, V222, P71; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	86	45	45	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	DEC	1990	10	12					3793	3800		10.1523/JNEUROSCI.10-12-03793.1990			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EP042	WOS:A1990EP04200004	1980130	Green Published, Bronze			2022-02-06	
J	WISNER, D; BUSCHE, F; STURM, J; GAAB, M; MEYER, H				WISNER, D; BUSCHE, F; STURM, J; GAAB, M; MEYER, H			TRAUMATIC SHOCK AND HEAD-INJURY - EFFECTS OF FLUID RESUSCITATION ON THE BRAIN	JOURNAL OF SURGICAL RESEARCH			English	Article									HANOVER UNIV MED,DEPT NEUROSURG,D-3000 HANOVER 61,FED REP GER; HANOVER UNIV MED,DEPT TRAUMA SURG,D-3000 HANOVER 61,FED REP GER		WISNER, D (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT SURG,SACRAMENTO,CA 95817, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007860] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5T32 GM07860-05] Funding Source: Medline		ALBRIGHT AL, 1984, J NEUROSURG, V60, P481, DOI 10.3171/jns.1984.60.3.0481; ALBRIGHT AL, 1982, ACTA NEUROCHIR, V60, P257, DOI 10.1007/BF01406311; ARTURSON G, 1961, Acta Chir Scand Suppl, VSuppl 274, P1; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BLASBERG RG, 1976, DYNAMICS BRAIN EDEMA, P98; DELOSREYES RA, 1980, CLIN NEUROSURG, V28, P98; Fenstermacher J.D., 1976, DYNAMICS BRAIN EDEMA, P87; FENSTERMACHER JD, 1966, AM J PHYSIOL, V211, P341, DOI 10.1152/ajplegacy.1966.211.2.341; GARBOW JD, 1984, AM J PUBLIC HEALTH, V74, P710; GARDNER AE, 1971, ANESTHESIOLOGY, V35, P226, DOI 10.1097/00000542-197108000-00029; GO KG, 1981, BRAIN EDEMA, P3; GORIS RJA, 1982, J TRAUMA, V22, P141, DOI 10.1097/00005373-198202000-00011; GURDJIAN ES, 1978, SURG GYNECOL OBSTET, V146, P805; GUYTON AC, 1982, HUMAN PHYSL MECHANIS, P30; JUPAMARCINKOWSK.V, 1981, BRAIN EDEMA, P155; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KLATZO I, 1972, STEROIDS BRAIN EDEMA, P1; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KNOBLICH OE, 1979, EXP NEUROL, V66, P30, DOI 10.1016/0014-4886(79)90060-8; KWAPINSKI JB, 1965, METHODS SEROLOGICAL, P168; Lentner C, 1984, GEIGY SCI TABLES, V3, P78; LEVISON M, 1982, SURG CLIN N AM, V62, P9; MARTYN JAJ, 1979, CHEST, V76, P374, DOI 10.1378/chest.76.4.374; Meeh K, 1879, Z BIOL, V15, P425; ODOM GL, 1981, DAVISCHRISTOPHER TXB, P1484; PAPPIUS HM, 1965, ARCH NEUROL-CHICAGO, V13, P395, DOI 10.1001/archneur.1965.00470040061010; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PRUITT BA, 1978, SURG CLIN N AM, V58, P1291; REULEN HJ, 1981, BRAIN EDEMA, P31; SCHMIDT K, 1972, HIRNKREISLAUF, P715; SHAPIRO HM, 1973, BRIT J ANAESTH, V45, P1057, DOI 10.1093/bja/45.10.1057; SHIRES GT, 1985, PRINCIPLES TRAUMA CA, P3; SMITH AL, 1977, ANESTHESIOLOGY, V47, P285, DOI 10.1097/00000542-197709000-00010; SMITH SD, 1982, J TRAUMA, V22, P588, DOI 10.1097/00005373-198207000-00011; Snedecor G.W., 1967, STAT METHODS, V6th ed., P91; STURM JA, 1985, TRAUMATISCHER SCHOCK, P32; TOMMASINO C, 1982, Anesthesiology (Hagerstown), V57, pA109, DOI 10.1097/00000542-198209001-00109; TRANBAUGH RF, 1984, SURG GYNECOL OBSTET, V158, P193; TRUNKEY DD, 1983, SCI AM, V249, P20; WARD RE, 1981, RADIOL CLIN N AM, V19, P3; WYTE SR, 1972, ANESTHESIOLOGY, V36, P174, DOI 10.1097/00000542-197202000-00021; YOUNG EG, 1963, COMPREHENSIVE BIOCH, P1; 1977, STANDARD MED ALMANAC, P488	44	45	46	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0022-4804			J SURG RES	J. Surg. Res.	JAN	1989	46	1					49	59		10.1016/0022-4804(89)90181-9			11	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	R9450	WOS:A1989R945000009	2915535				2022-02-06	
J	SHAW, CM; ALVORD, EC				SHAW, CM; ALVORD, EC			INJURY OF BASILAR ARTERY ASSOCIATED WITH CLOSED HEAD TRAUMA	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article																	Birley JL, 1928, BRAIN, V51, P184, DOI 10.1093/brain/51.2.184; BOTS G. T. A. M., 1964, ACTA NEUROPATHOL, V3, P416; BRASS K, 1957, Frankf Z Pathol, V68, P254; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CAIRNS H, 1942, LISBOA MED, V19, P375; CALDWELL HW, 1948, ANN INTERN MED, V28, P1132, DOI 10.7326/0003-4819-28-6-1132; CARMICHAEL R, 1950, J PATHOL BACTERIOL, V62, P1, DOI 10.1002/path.1700620102; CARPENTER S, 1961, J NEUROSURG, V18, P849, DOI 10.3171/jns.1961.18.6.0849; CHATRIAN GE, 1964, ELECTROEN CLIN NEURO, V16, P285, DOI 10.1016/0013-4694(64)90111-7; CLARKE PRR, 1955, BRIT J SURG, V43, P215, DOI 10.1002/bjs.18004317816; De Veer JA, 1942, J NEUROPATH EXP NEUR, V1, P24; DRATZ HM, 1947, J NEUROPATH EXP NEUR, V6, P286, DOI 10.1097/00005072-194707000-00009; Forbus WD, 1930, B JOHNS HOPKINS HOSP, V47, P239; FORD FR, 1956, B JOHNS HOPKINS HOSP, V98, P37; Glynn LE, 1940, J PATHOL BACTERIOL, V51, P213, DOI 10.1002/path.1700510206; GRECO T, 1935, ARCH ITAL CHIR, V39, P757; GURDJIAN ES, 1963, J NEUROSURG, V20, P418, DOI 10.3171/jns.1963.20.5.0418; HIRSCH JF, 1962, NEURO-CHIR, V8, P189; HOCKADAY TDR, 1959, J NEUROL NEUROSUR PS, V22, P229, DOI 10.1136/jnnp.22.3.229; HOUCK WS, 1964, ANN SURG, V159, P219, DOI 10.1097/00000658-196402000-00006; HUGHES JT, 1968, J NEUROL NEUROSUR PS, V31, P307, DOI 10.1136/jnnp.31.4.307; HUMPHREY JG, 1960, BRAIN, V83, P565, DOI 10.1093/brain/83.4.565; Kleyn AD, 1933, DTSCH Z NERVENHEILK, V132, P157; KUNKLE EC, 1952, ANN INTERN MED, V36, P1329, DOI 10.7326/0003-4819-36-5-1329; LINDENBERG R, 1955, J NEUROPATH EXP NEUR, V14, P223, DOI 10.1097/00005072-195507000-00001; LINDENBERG R, 1966, J NEUROSURG, V24, P908, DOI 10.3171/jns.1966.24.5.0908; LOCKSLEY HB, 1966, J NEUROSURG, V25, P219, DOI 10.3171/jns.1966.25.2.0219; LOOP JW, 1964, RADIOLOGY, V83, P36, DOI 10.1148/83.1.36; MASTAGLIA FL, 1969, J NEUROL NEUROSUR PS, V32, P383, DOI 10.1136/jnnp.32.5.383; MILLER JDR, 1967, RADIOLOGY, V89, P95, DOI 10.1148/89.1.95; MURRAY DS, 1957, BRIT J SURG, V44, P556, DOI 10.1002/bjs.18004418803; NORTHCROFT GB, 1945, BRITISH J SURGERY, V32, P105; PITNER SE, 1966, NEW ENGL J MED, V274, P764, DOI 10.1056/NEJM196604072741403; PRATTTHOMAS HR, 1947, JAMA-J AM MED ASSOC, V133, P600, DOI 10.1001/jama.1947.02880090022005; RANEY AA, 1948, ARCH NEURO PSYCHIATR, V60, P425, DOI 10.1001/archneurpsyc.1948.02310050002001; SCHNEIDER RC, 1952, J NEUROSURG, V9, P495, DOI 10.3171/jns.1952.9.5.0495; SEDZIMIR CB, 1955, J NEUROL NEUROSUR PS, V18, P293, DOI 10.1136/jnnp.18.4.293; SHAW CM, 1968, J NEUROSURG, V28, P475, DOI 10.3171/jns.1968.28.5.0475; SIGHTS WP, 1968, J NEUROSURG, V28, P588, DOI 10.3171/jns.1968.28.6.0588; SMITH DE, 1961, 7 ANN SCIENT M HOUST, P367; SMITH KR, 1968, J NEUROSURG, V29, P551, DOI 10.3171/jns.1968.29.5.0551; THERKELSEN J, 1963, CIRCULATION, V28, P101, DOI 10.1161/01.CIR.28.1.101; THOMSON JLG, 1963, BRIT J RADIOL, V36, P840, DOI 10.1259/0007-1285-36-431-840; TOAKLEY G, 1965, Aust N Z J Surg, V34, P261, DOI 10.1111/j.1445-2197.1965.tb04371.x; VERBIEST H, 1959, Folia Psychiatr Neurol Neurochir Neerl, V62, P371; VERNEUIL, 1972, B ACADEMIE MEDICIN 2, V1, P45; WALTON JN, 1956, SUBARCHNOID HAEMORRH; WINTERNITZ MC, 1938, BIOLOGY ARTERIOSCLER	48	45	45	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1972	35	2					247	&		10.1136/jnnp.35.2.247			0	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	M4206	WOS:A1972M420600017	5037036	Green Published, Bronze			2022-02-06	
J	TORRES, F; SHAPIRO, SK				TORRES, F; SHAPIRO, SK			ELECTROENCEPHALOGRAMS IN WHIPLASH INJURY - A COMPARISON OF ELECTROENCEPHALOGRAPHIC ABNORMALITIES WITH THOSE PRESENT IN CLOSED HEAD INJURIES	ARCHIVES OF NEUROLOGY			English	Article																	COBB WA, 1950, SVA; DENKER PG, 1954, NEUROLOGY, V4, P912, DOI 10.1212/WNL.4.12.912; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FRANKEL CJ, 1959, JAMA-J AM MED ASSOC, V169, P216, DOI 10.1001/jama.1959.03000200014004; Gibbs FA, 1943, ARCH NEURO PSYCHIATR, V50, P111, DOI 10.1001/archneurpsyc.1943.02290200011001; HOEFER PF, 1943, ECHIISBSC; LEWIS RC, 1956, MISSOURI MED, V53, P1059; NIELSEN J M, 1959, Bull Los Angel Neuro Soc, V24, P27; SELETZ E, 1958, JAMA-J AM MED ASSOC, V168, P1750, DOI 10.1001/jama.1958.03000130016005; SHAPIRO SK, 1960, MINN MED, V43, P473; TORRES F, 1959, NEUROLOGY, V9, P147; TORRES F, UPSNCUM; Walter WG, 1942, J MENT SCI, V88, P110; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P257, DOI 10.1136/jnnp.4.3-4.257; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P131, DOI 10.1136/jnnp.4.2.131	16	45	45	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.		1961	5	1					28	&		10.1001/archneur.1961.00450130030005			0	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	5677A	WOS:A19615677A00013	13777563				2022-02-06	
J	Cook, AM; Jones, GM; Hawryluk, GWJ; Mailloux, P; McLaughlin, D; Papangelou, A; Samuel, S; Tokumaru, S; Venkatasubramanian, C; Zackol, C; Zimmermann, LL; Hirsch, K; Shutter, L				Cook, Aaron M.; Jones, G. Morgan; Hawryluk, Gregory W. J.; Mailloux, Patrick; McLaughlin, Diane; Papangelou, Alexander; Samuel, Sophie; Tokumaru, Sheri; Venkatasubramanian, Chitra; Zackol, Christopher; Zimmermann, Lara L.; Hirsch, Karen; Shutter, Lori			Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients	NEUROCRITICAL CARE			English	Article						Intracranial pressure; Neurocritical care; Osmotherapy; Hyperventilation; Hypertonic; Mannitol	TRAUMATIC BRAIN-INJURY; INCREASED INTRACRANIAL-PRESSURE; ACUTE BACTERIAL-MENINGITIS; ACUTE KIDNEY INJURY; SEVERE HEAD-INJURY; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; ADJUNCTIVE DEXAMETHASONE THERAPY; HYPERTONIC SALINE RESUSCITATION; CEREBROSPINAL-FLUID DRAINAGE; ISCHEMIC-STROKE PATIENTS	Background Acute treatment of cerebral edema and elevated intracranial pressure is a common issue in patients with neurological injury. Practical recommendations regarding selection and monitoring of therapies for initial management of cerebral edema for optimal efficacy and safety are generally lacking. This guideline evaluates the role of hyperosmolar agents (mannitol, HTS), corticosteroids, and selected non-pharmacologic therapies in the acute treatment of cerebral edema. Clinicians must be able to select appropriate therapies for initial cerebral edema management based on available evidence while balancing efficacy and safety. Methods The Neurocritical Care Society recruited experts in neurocritical care, nursing, and pharmacy to create a panel in 2017. The group generated 16 clinical questions related to initial management of cerebral edema in various neurological insults using the PICO format. A research librarian executed a comprehensive literature search through July 2018. The panel screened the identified articles for inclusion related to each specific PICO question and abstracted necessary information for pertinent publications. The panel used GRADE methodology to categorize the quality of evidence as high, moderate, low, or very low based on their confidence that the findings of each publication approximate the true effect of the therapy. Results The panel generated recommendations regarding initial management of cerebral edema in neurocritical care patients with subarachnoid hemorrhage, traumatic brain injury, acute ischemic stroke, intracerebral hemorrhage, bacterial meningitis, and hepatic encephalopathy. Conclusion The available evidence suggests hyperosmolar therapy may be helpful in reducing ICP elevations or cerebral edema in patients with SAH, TBI, AIS, ICH, and HE, although neurological outcomes do not appear to be affected. Corticosteroids appear to be helpful in reducing cerebral edema in patients with bacterial meningitis, but not ICH. Differences in therapeutic response and safety may exist between HTS and mannitol. The use of these agents in these critical clinical situations merits close monitoring for adverse effects. There is a dire need for high-quality research to better inform clinicians of the best options for individualized care of patients with cerebral edema.	[Cook, Aaron M.] Univ Kentucky, Coll Pharm, UK Healthcare, Lexington, KY 40506 USA; [Jones, G. Morgan] Methodist Le Bonheur Healthcare, Memphis, TN USA; [Hawryluk, Gregory W. J.] Univ Manitoba, Winnipeg, MB, Canada; [Mailloux, Patrick] Maine Med Ctr, Portland, ME 04102 USA; [McLaughlin, Diane] Ohio State Univ, Columbus, OH 43210 USA; [Papangelou, Alexander] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA; [Samuel, Sophie] Mem Hermann Texas Med Ctr, Houston, TX USA; [Tokumaru, Sheri] Univ Hawaii Hilo, Daniel K Inouye Coll Pharm, Honolulu, HI USA; [Venkatasubramanian, Chitra; Hirsch, Karen] Stanford Univ, Med Ctr, Stanford, CA 94305 USA; [Zackol, Christopher] Penn State Univ Hlth, Milton S Hershey Med Ctr, Hershey, PA USA; [Zimmermann, Lara L.] Univ Calif Davis, Sacramento, CA 95817 USA; [Shutter, Lori] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA		Cook, AM (corresponding author), Univ Kentucky, Coll Pharm, UK Healthcare, Lexington, KY 40506 USA.	amcook0@email.uky.edu	Shutter, Lori A/G-2957-2013	McLaughlin, Diane/0000-0002-0648-7847; Venkatasubramanian, Chitra/0000-0002-7917-6142; Shutter, Lori/0000-0002-1390-0628; Cook, Aaron/0000-0001-8539-902X	Neurocritical Care Society	The Neurocritical Care Society partially supported travel and virtual meetings.	Achinger SG, 2017, CRIT CARE MED, V45, P1762, DOI 10.1097/CCM.0000000000002595; Ahsan T, 2002, J Pak Med Assoc, V52, P233; Ajdukiewicz KMB, 2011, LANCET INFECT DIS, V11, P293, DOI 10.1016/S1473-3099(10)70317-0; Al-Rawi PG, 2005, ACTA NEUROCHIR SUPPL, V95, P123; Al-Rawi PG, 2010, STROKE, V41, P122, DOI 10.1161/STROKEAHA.109.560698; Aminmansour Bahram, 2017, Adv Biomed Res, V6, P75, DOI 10.4103/2277-9175.192628; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Asehnoune K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1918-4; Assiri AM, 2009, MAYO CLIN PROC, V84, P403, DOI [10.1016/S0025-6196(11)60558-2, 10.4065/84.5.403]; Auburtin M, 2002, AM J RESP CRIT CARE, V165, P713, DOI 10.1164/ajrccm.165.5.2105110; Ayaz C, 2008, NEUROSCIENCES, V13, P146; BADEMOSI O, 1979, TROP GEOGR MED, V31, P53; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Baunbaek-Knudsen G, 2016, INFECT DIS-NOR, V48, P281, DOI 10.3109/23744235.2015.1109705; Becker D.P., 1972, INTRACRANIAL PRESSUR; Bennett IL, 1963, JAMA-J AM MED ASSOC, V183, P462, DOI [DOI 10.1001/JAMA.1963.63700060029012, 10.1001/jama.1963.63700060029012]; Bentsen G, 2004, ACTA ANAESTH SCAND, V48, P1089, DOI 10.1111/j.1399-6576.2004.00497.x; Bentsen G, 2008, CRIT CARE MED, V36, P2414, DOI 10.1097/CCM.0b013e318180fe04; Bentsen G, 2006, CRIT CARE MED, V34, P2912, DOI 10.1097/01.CCM.0000245665.46789.7C; Bereczki D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001153.pub2; Bereczki D, 2003, STROKE, V34, P1730, DOI 10.1161/01.STR.0000078658.52316.E8; Berger-Pelleiter E, 2016, CAN J EMERG MED, V18, P112, DOI 10.1017/cem.2016.12; Bhaumik S, 1998, NEUROL INDIA, V46, P225; Biestro A, 1997, ACTA NEUROCHIR, V139, P725, DOI 10.1007/BF01420045; Bodilsen J, 2014, SCAND J INFECT DIS, V46, P418, DOI 10.3109/00365548.2014.887223; Boland T, 2016, NEUROCRIT CARE, V25, P110, DOI 10.1007/s12028-015-0234-6; Bourdeaux CP, 2011, NEUROCRIT CARE, V15, P42, DOI 10.1007/s12028-011-9512-0; Brouwer MC, 2010, NEUROLOGY, V75, P1533, DOI 10.1212/WNL.0b013e3181f96297; Brouwer MC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub5; Buchholz G, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1498-8; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; Candanedo C, 2019, NEUROCRIT CARE, V30, P340, DOI 10.1007/s12028-018-0612-y; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chatterjee N, 2007, INDIAN J NEUROTRAUM, V4, P101, DOI 10.1016/S0973-0508(07)80023-2; Cheng F, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00631; Chotmongkol Verajit, 1996, Journal of the Medical Association of Thailand, V79, P83; Colton K, 2016, J INTENSIVE CARE MED, V31, P263, DOI 10.1177/0885066614555692; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Corry Jesse J, 2014, World J Crit Care Med, V3, P61, DOI 10.5492/wjccm.v3.i2.61; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334; Desai P, 1998, J NEUROL NEUROSUR PS, V65, P799; Diringer MN, 2011, NEUROCRIT CARE, V14, P11, DOI 10.1007/s12028-010-9465-8; DORMAN HR, 1990, MEDICINE, V69, P153, DOI 10.1097/00005792-199005000-00003; Dunham CM, 2018, INT J BURNS TRAUMA, V8, P40; DURWARD QJ, 1983, J NEUROSURG, V59, P938, DOI 10.3171/jns.1983.59.6.0938; Dziedzic T, 2003, CLIN NEUROL NEUROSUR, V105, P87, DOI 10.1016/S0303-8467(02)00106-3; Erdman MJ, 2017, NEUROHOSPITALIST, V7, P9, DOI 10.1177/1941874416665744; Feigin VL, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004583.pub2; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Fernandes D, 2014, J CRIT CARE, V29, P347, DOI 10.1016/j.jcrc.2013.12.001; Fisher LA, 2006, NEUROCRIT CARE, V5, P180, DOI 10.1385/NCC:5:3:180; Flores-Cordero JM, 2003, INTENS CARE MED, V29, P1967, DOI 10.1007/s00134-003-1935-4; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Fritz D, 2012, NEUROLOGY, V79, P2177, DOI 10.1212/WNL.0b013e31827595f7; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; GADALLAH MF, 1995, AM J MED SCI, V309, P219, DOI 10.1097/00000441-199504000-00006; Garcia-Morales EJ, 2004, CRIT CARE MED, V32, P986, DOI 10.1097/01.CCM.0000120057.04528.60; Gijwani D, 2002, NEUROL INDIA, V50, P63; GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004; GIRGIS NI, 1991, PEDIATR INFECT DIS J, V10, P179, DOI 10.1097/00006454-199103000-00002; Glimaker M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091976; Gondim FDA, 2005, J NEUROSURG, V103, P444; Gudina EK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200067; Gupta A, 1996, J Assoc Physicians India, V44, P90; HANID MA, 1980, GUT, V21, P866, DOI 10.1136/gut.21.10.866; Hartl R, 1997, ZBL CHIR, V122, P181; Hartl R, 1997, ACT NEUR S, V70, P40; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Hauer EM, 2011, CRIT CARE MED, V39, P1766, DOI 10.1097/CCM.0b013e318218a390; Heckenberg SGB, 2012, NEUROLOGY, V79, P1563, DOI 10.1212/WNL.0b013e31826e2684; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Hoogman M, 2007, J NEUROL NEUROSUR PS, V78, P1092, DOI 10.1136/jnnp.2006.110023; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hosoglu S, 2002, INT J TUBERC LUNG D, V6, P64; Hsu PC, 2010, J MICROBIOL IMMUNOL, V43, P111, DOI 10.1016/S1684-1182(10)60018-7; Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Jagannatha AT, 2016, J CLIN NEUROSCI, V27, P68, DOI 10.1016/j.jocn.2015.08.035; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kalita J, 2001, NEUROL INDIA, V49, P267; Keller E, 2002, J NEUROSURG ANESTH, V14, P130, DOI 10.1097/00008506-200204000-00007; KENNING JA, 1981, SURG NEUROL, V15, P148, DOI 10.1016/0090-3019(81)90037-9; Kerr M E, 2001, Neurosurg Focus, V11, pE1; Kerr ME, 2000, J NEUROSURG ANESTH, V12, P324, DOI 10.1097/00008506-200010000-00005; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; KUMARVELU S, 1994, TUBERCLE LUNG DIS, V75, P203, DOI 10.1016/0962-8479(94)90009-4; Larive LL, 2004, NEUROCRIT CARE, V1, P435, DOI 10.1385/NCC:1:4:435; Lazzarini L, 2008, J CHEMOTHERAPY, V20, P478, DOI 10.1179/joc.2008.20.4.478; Ledwith MB, 2010, J NEUROSCI NURS, V42, P280, DOI 10.1097/JNN.0b013e3181ecafd4; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; LEVIN AB, 1979, NEUROSURGERY, V5, P570, DOI 10.1227/00006123-197911000-00005; Lewandowski-Belfer JJ, 2014, NEUROCRIT CARE, V20, P436, DOI 10.1007/s12028-013-9907-1; Li M, 2015, MEDICINE, V94; Lin SY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002032; Liotta E, 2015, CRIT CARE MED, V43; Maguigan KL, 2017, J CLIN NEUROSCI, V39, P147, DOI 10.1016/j.jocn.2017.01.025; Mahfoud F, 2010, ACTA NEUROCHIR, V152, P443, DOI 10.1007/s00701-009-0520-1; Mai NTH, 2007, NEW ENGL J MED, V357, P2431, DOI 10.1056/NEJMoa070852; Malhotra HS, 2009, ANN TROP MED PARASIT, V103, P625, DOI 10.1179/000349809X12502035776315; Mangat HS, 2020, NEUROSURGERY, V86, P221, DOI 10.1093/neuros/nyz046; Mangat HS, 2015, J NEUROSURG, V122, P202, DOI 10.3171/2014.10.JNS132545; Manno EM, 1999, NEUROLOGY, V52, P583, DOI 10.1212/WNL.52.3.583; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Midgley S., 1993, P 8 INT S INTR PRESS, P558; Misra UK, 2005, J NEUROL SCI, V234, P41, DOI 10.1016/j.jns.2005.03.038; Moon SY, 2012, J NEUROL, V259, P1453, DOI 10.1007/s00415-011-6373-6; Moraine JJ, 2000, J NEUROSURG, V92, P606, DOI 10.3171/jns.2000.92.4.0606; Morrison LJ, 2011, J CRIT CARE, V26, P363, DOI 10.1016/j.jcrc.2010.08.021; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; Nwachuku EL, 2014, NEUROCRIT CARE, V20, P49, DOI 10.1007/s12028-013-9885-3; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Ogun S A, 2001, West Afr J Med, V20, P1; Onar M., 1997, CLIN NEUROPHYSIOL, V37, P213; Ong CJ, 2015, NEUROCRIT CARE, V23, P285, DOI 10.1007/s12028-015-0173-2; OTOOLE RD, 1969, ANN INTERN MED, V70, P39, DOI 10.7326/0003-4819-70-1-39; Papagianni M, 2018, AM J CARDIOVASC DRUG, V18, P397, DOI 10.1007/s40256-018-0285-0; Patil H, 2019, WORLD NEUROSURG, V125, pE221, DOI 10.1016/j.wneu.2019.01.051; POUNGVARIN N, 1987, NEW ENGL J MED, V316, P1229, DOI 10.1056/NEJM198705143162001; Prasad K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002244.pub4; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Rahman M L, 2009, Mymensingh Med J, V18, P47; Riha HM, 2017, CRIT CARE MED, V45, pE947, DOI 10.1097/CCM.0000000000002522; Roberts I, 2007, BRIT MED J, V334, P392, DOI 10.1136/bmj.39118.480023.BE; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; RUBINSTEIN MK, 1965, J NERV MENT DIS, V141, P291, DOI 10.1097/00005053-196509000-00005; Sadan O, 2017, CRIT CARE MED, V45, P1382, DOI 10.1097/CCM.0000000000002497; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; SANTAMBROGIO S, 1978, STROKE, V9, P130, DOI 10.1161/01.STR.9.2.130; Saraswat VA, 2008, WORLD J GASTROENTERO, V14, P4168, DOI 10.3748/wjg.14.4168; Sayre MR, 1996, ACAD EMERG MED, V3, P840, DOI 10.1111/j.1553-2712.1996.tb03528.x; Scarborough M, 2007, NEW ENGL J MED, V357, P2441, DOI 10.1056/NEJMoa065711; Schatzmann C, 1998, ACT NEUR S, V71, P31; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Shah M, 2018, J STROKE CEREBROVASC, V27, P1061, DOI 10.1016/j.jstrokecerebrovasdis.2017.11.013; Sharafadinzadeh N, 2008, PAK J MED SCI, V24, P502; Singhi S, 2008, PEDIATR INFECT DIS J, V27, P892, DOI 10.1097/INF.0b013e318175d177; Smedema RJ, 1993, INTRACRANIAL PRESSUR, V1993, P605; SMITH HP, 1986, J NEUROSURG, V65, P820, DOI 10.3171/jns.1986.65.6.0820; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Stelfox HT, 2010, CAN J ANAESTH, V57, P650, DOI 10.1007/s12630-010-9309-1; Strbian D, 2013, INT J STROKE, V8, P529, DOI 10.1111/j.1747-4949.2012.00781.x; Suarez JI, 1999, J NEUROSURG ANESTH, V11, P178, DOI 10.1097/00008506-199907000-00004; Sun SW, 2019, WORLD NEUROSURG, V124, P386, DOI 10.1016/j.wneu.2018.11.249; Tan SKR, 2016, CAN J ANESTH, V63, P664, DOI 10.1007/s12630-016-0633-y; Tellez H, 1973, STROKE, V4, P541, DOI 10.1161/01.STR.4.4.541; TEMES SP, 1975, SURG GYNECOL OBSTET, V141, P223; Thomas R, 1999, INTENS CARE MED, V25, P475, DOI 10.1007/s001340050883; Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573; Torok ME, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027821; Tolaj Ilir, 2010, Med Arh, V64, P228; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368; van de Beek D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub2; van de Beek D, 2010, LANCET NEUROL, V9, P254, DOI 10.1016/S1474-4422(10)70023-5; Vardakas KZ, 2009, EUR J NEUROL, V16, P662, DOI 10.1111/j.1468-1331.2009.02615.x; Viale P, 2015, ANN PHARMACOTHER, V49, P978, DOI 10.1177/1060028015586012; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Videen TO, 2001, NEUROLOGY, V57, P2120, DOI 10.1212/WNL.57.11.2120; Wagner I, 2011, STROKE, V42, P1540, DOI 10.1161/STROKEAHA.110.609479; Wang X, 2015, STROKE, V46, P2762, DOI 10.1161/STROKEAHA.115.009357; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Weisfelt M, 2006, EUR J CLIN MICROBIOL, V25, P73, DOI 10.1007/s10096-006-0089-z; Weisfelt M, 2006, ANN NEUROL, V60, P456, DOI 10.1002/ana.20944; Wells DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11678; Winkelman C, 2000, Am J Crit Care, V9, P373; Yechoor VK, 1996, ARCH INTERN MED, V156, P1710, DOI 10.1001/archinte.156.15.1710; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Zaganas I, 2011, STROKE, V42, P3640, DOI 10.1161/STROKEAHA.111.632174; Zuliani G, 2004, DRUG AGING, V21, P273, DOI 10.2165/00002512-200421040-00005	186	44	45	5	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2020	32	3					647	666		10.1007/s12028-020-00959-7		MAR 2020	20	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	LV6MP	WOS:000522175300001	32227294	Green Published, hybrid	Y	N	2022-02-06	
J	Kerr, ZY; Chandran, A; Nedimyer, AK; Arakkal, A; Pierpoint, LA; Zuckerman, SL				Kerr, Zachary Y.; Chandran, Avinash; Nedimyer, Aliza K.; Arakkal, Alan; Pierpoint, Lauren A.; Zuckerman, Scott L.			Concussion Incidence and Trends in 20 High School Sports	PEDIATRICS			English	Article							COLLEGIATE FOOTBALL PLAYERS; HEALTH-CARE UTILIZATION; TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; UNITED-STATES; RECURRENT CONCUSSION; GENDER-DIFFERENCES; SEX-DIFFERENCES; EPIDEMIOLOGY; RATES	This epidemiological study uses sports injury surveillance data to describe concussion incidence and trends in high school sports during the 2013-2014 to 2017-2018 academic years. BACKGROUND: Ongoing monitoring of concussion rates and distributions is important in assessing temporal patterns. Examinations of high school sport-related concussions need to be updated. This study describes the epidemiology of concussions in 20 high school sports during the 2013-2014 to 2017-2018 school years. METHODS: In this descriptive epidemiology study, a convenience sample of high school athletic trainers provided injury and athlete exposure (AE) data to the National High School Sports-Related Injury Surveillance Study (High School Reporting Information Online). Concussion rates per 10 000 AEs with 95% confidence intervals (CIs) and distributions were calculated. Injury rate ratios and injury proportion ratios examined sex differences in sex-comparable sports (soccer, basketball, baseball and softball, cross country, track, and swimming). We also assessed temporal trends across the study period. RESULTS: Overall, 9542 concussions were reported for an overall rate of 4.17 per 10 000 AEs (95% CI: 4.09 to 4.26). Football had the highest concussion rate (10.40 per 10 000 AEs). Across the study period, football competition-related concussion rates increased (33.19 to 39.07 per 10 000 AEs); practice-related concussion rates decreased (5.47 to 4.44 per 10 000 AEs). In all sports, recurrent concussion rates decreased (0.47 to 0.28 per 10 000 AEs). Among sex-comparable sports, concussion rates were higher in girls than in boys (3.35 vs 1.51 per 10 000 AEs; injury rate ratio = 2.22; 95% CI: 2.07 to 2.39). Also, among sex-comparable sports, girls had larger proportions of concussions that were recurrent than boys did (9.3% vs 6.4%; injury proportion ratio = 1.44; 95% CI: 1.11 to 1.88). CONCLUSIONS: Rates of football practice-related concussions and recurrent concussions across all sports decreased. Changes in concussion rates may be associated with changes in concussion incidence, diagnosis, and management. Future research should continue to monitor trends and examine the effect of prevention strategies.	[Nedimyer, Aliza K.] Univ North Carolina Chapel Hill, Human Movement Sci Curriculum, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Chandran, Avinash] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Chandran, Avinash; Nedimyer, Aliza K.] Univ North Carolina Chapel Hill, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27599 USA; [Arakkal, Alan] Univ Colorado Denver, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA; [Pierpoint, Lauren A.] Steadman Philippon Res Inst, Vail, CO USA; [Zuckerman, Scott L.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37212 USA; [Zuckerman, Scott L.] Vanderbilt Univ, Sch Med, Sports Concuss Ctr, Nashville, TN 37212 USA		Kerr, ZY (corresponding author), Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2 RR025754]; National Federation of High School Associations; National Operating Committee on Standards for Athletic Equipment, DonJoy Orthotics, and EyeBlack	This report represents data collection from High School Reporting Information Online. These data were provided by Dr R. Dawn Comstock of the Colorado School of Public Health and the University of Colorado School of Medicine. High School Reporting Information Online was funded in part by the Centers for Disease Control and Prevention (grants R49/CE000674-01 and R49/CE001172-01) and the National Center for Research Resources (award KL2 RR025754). The authors also acknowledge the research funding contributions of the National Federation of High School Associations, National Operating Committee on Standards for Athletic Equipment, DonJoy Orthotics, and EyeBlack. The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the funding organizations.	Baker DR, 2018, AM J SPORT MED, V46, P396, DOI 10.1177/0363546517738742; Brenner JS, 2015, PEDIATRICS, V136, pe1419; Brett BL, 2018, SPORTS MED-OPEN, V4, DOI 10.1186/s40798-018-0121-8; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Comstock RD, 2018, CONVENIENCE SAMPLE S; Covassin T, 2018, AM J SPORT MED, V46, P2270, DOI 10.1177/0363546518780225; Currie DW, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2447; de Courten-Myers GM, 1999, J NEUROPATH EXP NEUR, V58, P217; Esposito G, 1996, J NUCL MED, V37, P559; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Green L., 2014, LEGAL PERSPECTIVES R; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harvey HH, 2015, J LAW MED ETHICS, V43, P87, DOI 10.1111/jlme.12225; Jones B., 2015, STATES ADOPT PLANS L; Jones CM, 2017, SPORTS MED, V47, P943, DOI 10.1007/s40279-016-0619-5; Kerr ZY, 2021, CLIN J SPORT MED, V31, pE21, DOI 10.1097/JSM.0000000000000697; Kerr ZY, 2018, J ATHL TRAINING, V53, P738, DOI 10.4085/1062-6050-144-17; Kerr ZY, 2017, AM J PREV MED, V53, P914, DOI 10.1016/j.amepre.2017.05.017; Kerr ZY, 2017, NEUROL CLIN, V35, P409, DOI 10.1016/j.ncl.2017.03.001; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Lombardi NJ, 2016, ORTHOPEDICS, V39, pE944, DOI 10.3928/01477447-20160623-10; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; National Federation of State High School Associations, 2020, PART STAT; National Federation of State High School Associations, 2018, RUL REV HIGH SCH VOL; O'Connor KL, 2017, J ATHL TRAINING, V52, P175, DOI 10.4085/1062-6050-52.1.15; Pfaller AY, 2019, AM J SPORT MED, V47, P2294, DOI 10.1177/0363546519860120; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; The Aspen Institute: Project Play, 2018, STAT PLAY 2018 TREND; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; United States Census Bureau, 2009, CENS REG US; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002; Wiebe DJ, 2018, JAMA-J AM MED ASSOC, V320, P2035, DOI 10.1001/jama.2018.14165; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Yang JZ, 2017, AM J PUBLIC HEALTH, V107, P1916, DOI 10.2105/AJPH.2017.304056; Yard EE, 2009, J ATHL TRAINING, V44, P645, DOI 10.4085/1062-6050-44.6.645; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	48	44	43	1	17	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2019	144	5							e20192180	10.1542/peds.2019-2180			13	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	JK2MP	WOS:000494681400023	31615955	Bronze			2022-02-06	
J	Gotzl, JK; Brendel, M; Werner, G; Parhizkar, S; Monasor, LS; Kleinberger, G; Colombo, AV; Deussing, M; Wagner, M; Winkelmann, J; Diehl-Schmid, J; Levin, J; Fellerer, K; Reifschneider, A; Bultmann, S; Bartenstein, P; Rominger, A; Tahirovic, S; Smith, ST; Madore, C; Butovsky, O; Capell, A; Haass, C				Goetzl, Julia K.; Brendel, Matthias; Werner, Georg; Parhizkar, Samira; Monasor, Laura Sebastian; Kleinberger, Gernot; Colombo, Alessio-Vittorio; Deussing, Maximilian; Wagner, Matias; Winkelmann, Juliane; Diehl-Schmid, Janine; Levin, Johannes; Fellerer, Katrin; Reifschneider, Anika; Bultmann, Sebastian; Bartenstein, Peter; Rominger, Axel; Tahirovic, Sabina; Smith, Scott T.; Madore, Charlotte; Butovsky, Oleg; Capell, Anja; Haass, Christian			Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism	EMBO MOLECULAR MEDICINE			English	Article						disease-associated and homeostatic microglial signatures; microglia; neurodegeneration; progranulin; TREM2	FRONTOTEMPORAL LOBAR DEGENERATION; TRAUMATIC BRAIN-INJURY; PROGRANULIN DEFICIENCY; ALZHEIMERS-DISEASE; BINDING-AFFINITY; MOUSE MODEL; PROTEIN; MICE; NEUROINFLAMMATION; CELLS	Microglia adopt numerous fates with homeostatic microglia (HM) and a microglial neurodegenerative phenotype (MGnD) representing two opposite ends. A number of variants in genes selectively expressed in microglia are associated with an increased risk for neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD). Among these genes are progranulin (GRN) and the triggering receptor expressed on myeloid cells 2 (TREM2). Both cause neurodegeneration by mechanisms involving loss of function. We have now isolated microglia from Grn(-/-) mice and compared their transcriptomes to those of Trem2(-/-) mice. Surprisingly, while loss of Trem2 enhances the expression of genes associated with a homeostatic state, microglia derived from Grn(-/-) mice showed a reciprocal activation of the MGnD molecular signature and suppression of gene characteristic for HM. The opposite mRNA expression profiles are associated with divergent functional phenotypes. Although loss of TREM2 and progranulin resulted in opposite activation states and functional phenotypes of microglia, FDG (fluoro-2-deoxy-d-glucose)-mu PET of brain revealed reduced glucose metabolism in both conditions, suggesting that opposite microglial phenotypes result in similar wide spread brain dysfunction.	[Goetzl, Julia K.; Werner, Georg; Parhizkar, Samira; Fellerer, Katrin; Reifschneider, Anika; Capell, Anja; Haass, Christian] Ludwig Maximilians Univ Munchen, Fac Med, Chair Metab Biochem, Biomed Ctr BMC, Munich, Germany; [Brendel, Matthias; Deussing, Maximilian; Bartenstein, Peter; Rominger, Axel] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Nucl Med, Munich, Germany; [Monasor, Laura Sebastian; Colombo, Alessio-Vittorio; Levin, Johannes; Tahirovic, Sabina; Haass, Christian] German Ctr Neurodegenerat Dis DZNE, Munich, Germany; [Kleinberger, Gernot; Bartenstein, Peter; Rominger, Axel; Haass, Christian] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Kleinberger, Gernot; Bartenstein, Peter; Rominger, Axel; Haass, Christian] Helmholtz Zentrum Munchen, Inst Neurogenom, Munich, Germany; [Wagner, Matias; Winkelmann, Juliane] Tech Univ Munich, Inst Human Genet, Munich, Germany; [Wagner, Matias; Winkelmann, Juliane] Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, Germany; [Diehl-Schmid, Janine] Tech Univ Munich, Dept Psychiat, Munich, Germany; [Levin, Johannes] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Neurol, Munich, Germany; [Bultmann, Sebastian] Ludwig Maximilians Univ Munchen, Dept Biol & Ctr Integrated Prot Sci Munich CIPSM, Munich, Germany; [Smith, Scott T.; Madore, Charlotte; Butovsky, Oleg] Harvard Med Sch, Brigham & Women Hosp, Dept Neurol, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA; [Butovsky, Oleg] Harvard Med Sch, Brigham & Womens Hosp, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA		Capell, A; Haass, C (corresponding author), Ludwig Maximilians Univ Munchen, Fac Med, Chair Metab Biochem, Biomed Ctr BMC, Munich, Germany.; Haass, C (corresponding author), German Ctr Neurodegenerat Dis DZNE, Munich, Germany.; Haass, C (corresponding author), Munich Cluster Syst Neurol SyNergy, Munich, Germany.; Haass, C (corresponding author), Helmholtz Zentrum Munchen, Inst Neurogenom, Munich, Germany.	anja.capell@mail03.med.uni-muenchen.de; christian.haass@mail03.med.uni-muenchen.de	Rominger, Axel/K-5891-2019; Levin, Johannes/E-4052-2010; Bultmann, Sebastian/AAC-7729-2020; Madore, Charlotte/AAK-8735-2021; Levin, Johannes/W-8686-2019; Butovsky, Oleg/ABG-9086-2020	Levin, Johannes/0000-0001-5092-4306; Madore, Charlotte/0000-0002-0704-6496; Levin, Johannes/0000-0001-5092-4306; Butovsky, Oleg/0000-0003-0186-8867; Parhizkar, Samira/0000-0001-5807-190X; Diehl-Schmid, Janine/0000-0002-7745-1382	Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [EXC 1010 SyNergy]; Koselleck Project [HA1737/16-1]; Cure Alzheimer's fund; NOMIS Foundation; PET imaging grant [BR4580/1-1, RO5194/1-1]; German Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF) [FTLDc 01GI1007A]; Hans and Ilse Breuer Foundation; US National Institutes of Health (NIH) NIH-NINDS [R01 NS088137, R21 NS104609, R21 NS101673]; NIH-NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG051812, R01 AG054672]; NIH-NEY [R01 EY027921]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [5092A1]; Nancy Davis Foundation Faculty Award; Cure Alzheimer's Fund Award; Amyotrophic Lateral Sclerosis Association; Sanofi; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY027921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088137, R21NS101673, R21NS104609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG054672, R01AG051812] Funding Source: NIH RePORTER	This work was supported by the Deutsche Forschungsgemeinschaft (DFG) within the framework of the Munich Cluster for Systems Neurology (EXC 1010 SyNergy), the Koselleck Project HA1737/16-1, the Cure Alzheimer's fund and the NOMIS Foundation (to C.H.), by a dedicated PET imaging grant to M.B. & A. Ro. (BR4580/1-1 & RO5194/1-1) and the German Federal Ministry of Education and Research (project: FTLDc 01GI1007A; to J.D.-S.), and a PhD stipend of the Hans and Ilse Breuer Foundation to A. Re. We would like to thank Dr. M. Nishihara (Department of Veterinary Physiology, The University of Tokyo) for providing the founder of the Grn<SUP>-/-</SUP> mouse strain, Dr. David M. Holtzman (Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA) for providing the ApoE antibody, Dr. Feng Zhang (Broad Institute) for providing PX458 and acknowledge the Core Facility Flow Cytometry at the Biomedical Center, Ludwig-Maximilians-Universitat, Munchen, for providing equipment and services and Christian Behrends (Ludwig-Maximilians-Universitat, Munchen) for providing assistance with flow cytometry analysis of cultivated primary microglia. The Trem2<SUP>-/-</SUP> mice were kindly provided by Marco Colonna (Washington University, School of Medicine), and the APPPS1 colony was established from a breeding pair kindly provided by Mathias Jucker (Hertie-Institute for Clinical Brain Research, University of Tubingen and DZNE-Tubingen). GE made GE-180 cassettes available through an early access model. O.B. is supported by the US National Institutes of Health (NIH) NIH-NINDS (R01 NS088137, R21 NS104609, R21 NS101673), NIH-NIA (R01 AG051812, R01 AG054672), NIH-NEY (R01 EY027921), National Multiple Sclerosis Society (5092A1), Nancy Davis Foundation Faculty Award, Cure Alzheimer's Fund Award, and Amyotrophic Lateral Sclerosis Association and Sanofi.	Abduljaleel Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092648; Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Albert NL, 2017, EUR J NUCL MED MOL I, V44, P2230, DOI 10.1007/s00259-017-3799-9; Atagi Y, 2015, J BIOL CHEM, V290, P26043, DOI 10.1074/jbc.M115.679043; Bailey CC, 2015, J BIOL CHEM, V290, P26033, DOI 10.1074/jbc.M115.677286; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; Beel S, 2017, HUM MOL GENET, V26, P2850, DOI 10.1093/hmg/ddx162; BELCOURT DR, 1993, J BIOL CHEM, V268, P9230; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Borroni B, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.09.017; Brendel M, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00008; Brendel M, 2016, J NUCL MED, V57, P954, DOI 10.2967/jnumed.115.167858; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Capell A, 2011, J NEUROSCI, V31, P1885, DOI 10.1523/JNEUROSCI.5757-10.2011; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Chang MC, 2017, J EXP MED, V214, P2611, DOI 10.1084/jem.20160999; Cruts M, 2008, TRENDS GENET, V24, P186, DOI 10.1016/j.tig.2008.01.004; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Cuyvers E, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.09.009; Daria A, 2017, EMBO J, V36, P583, DOI 10.15252/embj.201694591; Deussing M, 2018, NEUROIMAGE, V165, P83, DOI 10.1016/j.neuroimage.2017.10.006; Gotzl JK, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0281-5; Gotzl JK, 2016, AGEING RES REV, V32, P122, DOI 10.1016/j.arr.2016.04.008; Gotzl JK, 2014, ACTA NEUROPATHOL, V127, P845, DOI 10.1007/s00401-014-1262-6; Gosselin D, 2017, SCIENCE, V356, DOI 10.1126/science.aal3222; Guerreiro RJ, 2013, JAMA NEUROL, V70, P78, DOI 10.1001/jamaneurol.2013.579; Holtman IR, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0203-5; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Jonsson T, 2013, NEW ENGL J MED, V369, P1568, DOI 10.1056/NEJMc1306509; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Kim J, 2012, J EXP MED, V209, P2149, DOI 10.1084/jem.20121274; Kleinberger G, 2017, EMBO J, V36, P1837, DOI 10.15252/embj.201796516; Kleinberger G, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009093; Krabbe G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060921; Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008; Kremer LS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15824; Liu B, 2015, J NEUROSCI, V35, P15716, DOI 10.1523/JNEUROSCI.0996-15.2015; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Mazaheri F, 2017, EMBO REP, V18, P1186, DOI 10.15252/embr.201743922; Mizrahi R, 2012, J CEREBR BLOOD F MET, V32, P968, DOI 10.1038/jcbfm.2012.46; Overhoff F, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00045; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Parhizkar S, 2019, NAT NEUROSCI, V22, P191, DOI 10.1038/s41593-018-0296-9; Radde R, 2006, EMBO REP, V7, P940, DOI 10.1038/sj.embor.7400784; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Ransohoff RM, 2016, SCIENCE, V353, P777, DOI 10.1126/science.aag2590; Rayaprolu S, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-19; Rominger A, 2013, J NUCL MED, V54, P1127, DOI 10.2967/jnumed.112.114660; Schlepckow K, 2017, EMBO MOL MED, V9, P1356, DOI 10.15252/emmm.201707672; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Song WM, 2018, J EXP MED, V215, P745, DOI 10.1084/jem.20171529; Takahashi H, 2017, ACTA NEUROPATHOL, V133, P785, DOI 10.1007/s00401-017-1668-z; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; Ulland TK, 2017, CELL, V170, P649, DOI 10.1016/j.cell.2017.07.023; Ulrich JD, 2017, NEURON, V94, P237, DOI 10.1016/j.neuron.2017.02.042; Ulrich JD, 2016, ACS CHEM NEUROSCI, V7, P420, DOI 10.1021/acschemneuro.5b00313; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; Wang YM, 2016, J EXP MED, V213, P667, DOI 10.1084/jem.20151948; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Ward ME, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5642; Wils H, 2012, J PATHOL, V228, P67, DOI 10.1002/path.4043; Xiang XY, 2016, EMBO MOL MED, V8, P992, DOI 10.15252/emmm.201606370; Yeh FL, 2017, TRENDS MOL MED, V23, P512, DOI 10.1016/j.molmed.2017.03.008; Yeh FL, 2016, NEURON, V91, P328, DOI 10.1016/j.neuron.2016.06.015; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; Zhang N, 2014, EXP THER MED, V8, P1643, DOI 10.3892/etm.2014.1981; Zhou XL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15277; Zhou XL, 2015, J CELL BIOL, V210, P991, DOI 10.1083/jcb.201502029	75	44	45	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1757-4676	1757-4684		EMBO MOL MED	EMBO Mol. Med.	JUN	2019	11	6							e9711	10.15252/emmm.201809711			15	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	IC2MH	WOS:000470793600002	31122931	Green Published, gold			2022-02-06	
J	Majidinia, M; Reiter, RJ; Shakouri, SK; Mohebbi, I; Rastegar, M; Kaviani, M; Darband, SG; Jahanban-Esfahlan, R; Nabavi, SM; Yousefi, B				Majidinia, Maryam; Reiter, Russel J.; Shakouri, Seyed Kazem; Mohebbi, Iraj; Rastegar, Mojgan; Kaviani, Mojtaba; Darband, Saber Ghazizadeh; Jahanban-Esfahlan, Rana; Nabavi, Seyed Mohammad; Yousefi, Bahman			The multiple functions of melatonin in regenerative medicine	AGEING RESEARCH REVIEWS			English	Article						Circadian rhythm; Stem cell; Tissue engineering; Neuroregeneration; Liver regeneration; Kidney regeneration; Bone regeneration; Muscle regeneration	MESENCHYMAL STEM-CELLS; SPINAL-CORD-INJURY; RENAL ISCHEMIA-REPERFUSION; ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; OXIDATIVE LIVER-INJURY; SCIATIC-NERVE INJURY; NF-KAPPA-B; SKELETAL-MUSCLE; BONE-GRAFT	Melatonin research has been experiencing hyper growth in the last two decades; this relates to its numerous physiological functions including anti-inflammation, oncostasis, circadian and endocrine rhythm regulation, and its potent antioxidant activity. Recently, a large number of studies have focused on the role of melatonin in the regeneration of cells or tissues after their partial loss. In this review, we discuss the recent findings on the molecular involvement of melatonin in the regeneration of various tissues including the nervous system, liver, bone, kidney, bladder, skin, and muscle, among others.	[Majidinia, Maryam] Urmia Univ Med Sci, Solid Tumor Res Ctr, Orumiyeh, Iran; [Reiter, Russel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Shakouri, Seyed Kazem] Tabriz Univ Med Sci, Aging Res Inst, Phys Med & Rehabil Res Ctr, Tabriz, Iran; [Mohebbi, Iraj] Urmia Univ Med Sci, Dept Occupat Hlth, Orumiyeh, Iran; [Rastegar, Mojgan] Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Regenerat Med Program,Dept Biochem & Med Genet, Winnipeg, MB, Canada; [Kaviani, Mojtaba] Acadia Univ, Sch Nutr & Dietet, Wolfville, NS, Canada; [Darband, Saber Ghazizadeh] Urmia Univ Med Sci, Hlth Technol Dev Ctr, Danesh Pey Hadi Co, Orumiyeh, Iran; [Jahanban-Esfahlan, Rana] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran; [Jahanban-Esfahlan, Rana] Tabriz Univ Med Sci, Students Res Comm, Tabriz, Iran; [Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran, Iran; [Yousefi, Bahman] Tabriz Univ Med Sci, Stem Cell & Regenerat Med Inst, Tabriz, Iran		Yousefi, B (corresponding author), Tabriz Univ Med Sci, Stem Cell & Regenerat Med Inst, Tabriz, Iran.	yousefib@tbzmed.ac.ir	Mohebbi, Iraj/G-1494-2017; Nabavi, Seyed Mohammad/G-5335-2010; Rastegar, Mojgan/T-9394-2019; Kaviani, Mojtaba/L-4940-2019; majidinia, maryam/V-7187-2019; Kaviani, Mohammad Javad/T-9205-2019	Nabavi, Seyed Mohammad/0000-0001-8859-5675; Rastegar, Mojgan/0000-0003-3619-6116; Kaviani, Mojtaba/0000-0002-1186-3384; Majidinia, Maryam/0000-0001-9776-5816; Shakouri, Seyed Kazem/0000-0003-3815-4091; Mohebbi, Iraj/0000-0001-9158-5742; Ghazizadeh Darband, Saber/0000-0002-7217-753X	Clinical Research Development Unit, Shohada Hospital, Tabriz University of Medical Sciences	The authors would like to thank Clinical Research Development Unit, Shohada Hospital, Tabriz University of Medical Sciences for kind supports.	ABBASOGLU O, 1995, J HEPATOL, V23, P578, DOI 10.1016/0168-8278(95)80065-4; Abdel-Wahab WM, 2012, LIFE SCI J, V9, P1173; Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2; Gonzalez MA, 2012, CELL BIOCHEM FUNCT, V30, P701, DOI 10.1002/cbf.2855; Aktoz T, 2007, RENAL FAILURE, V29, P535, DOI 10.1080/08860220701391738; Albrektsson T, 2001, EUR SPINE J, V10, pS96, DOI 10.1007/s005860100282; Alghasham A. A., 2013, PHARM PHARM, V4, P590; Ambrosio F, 2009, AM J PHYS MED REHAB, V88, P145, DOI 10.1097/PHM.0b013e3181951fc5; Angelini F, 2016, BIOIMPACTS, V6, P14, DOI 10.15171/bi.2016.03; Aranda M, 2010, J PINEAL RES, V49, P78, DOI 10.1111/j.1600-079X.2010.00769.x; Aranda ML, 2016, J PINEAL RES, V60, P360, DOI 10.1111/jpi.12318; ARMSTRONG SM, 1991, MED HYPOTHESES, V34, P300, DOI 10.1016/0306-9877(91)90046-2; Atala A, 2006, CURR OPIN PEDIATR, V18, P167, DOI 10.1097/01.mop.0000193294.94646.be; Atik B, 2011, J SURG RES, V166, P330, DOI 10.1016/j.jss.2009.06.002; Aydin G, 2003, HUM EXP TOXICOL, V22, P383, DOI 10.1191/0960327103ht354oa; Bach AD, 2004, J CELL MOL MED, V8, P413, DOI 10.1111/j.1582-4934.2004.tb00466.x; Back K, 2016, J PINEAL RES, V61, P426, DOI 10.1111/jpi.12364; Bai XZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32199; Banaei S, 2016, TRAUMA MON, V21, DOI 10.5812/traumamon.23005; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bauer TW, 2000, CLIN ORTHOP RELAT R, P10; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Belanger K, 2016, MACROMOL BIOSCI, V16, P472, DOI 10.1002/mabi.201500367; Berthiaume F, 2011, ANNU REV CHEM BIOMOL, V2, P403, DOI 10.1146/annurev-chembioeng-061010-114257; Bijonowski BM, 2013, CURR OPIN CHEM ENG, V2, P32, DOI 10.1016/j.coche.2012.12.001; Bliss TM, 2010, NEUROBIOL DIS, V37, P275, DOI 10.1016/j.nbd.2009.10.003; Bonandrini B, 2014, TISSUE ENG PT A, V20, P1486, DOI [10.1089/ten.tea.2013.0269, 10.1089/ten.TEA.2013.0269]; Bostrom Mathias P G, 2005, HSS J, V1, P9, DOI 10.1007/s11420-005-0111-5; Bruck R, 2004, J HEPATOL, V40, P86, DOI 10.1016/S0168-8278(03)00504-X; Calvo JR, 2001, J CELL BIOCHEM, V80, P461, DOI 10.1002/1097-4644(20010315)80:4<461::AID-JCB1000>3.0.CO;2-P; Calvo-Guirado J. L., 2016, CLIN ORAL IMPLANTS R; Calvo-Guirado JL, 2010, J PINEAL RES, V49, P356, DOI 10.1111/j.1600-079X.2010.00801.x; Calvo-Guirado JL, 2015, CLIN ORAL IMPLAN RES, V26, P399, DOI 10.1111/clr.12364; Canaud G, 2015, NEPHROL DIAL TRANSPL, V30, P575, DOI 10.1093/ndt/gfu230; Cao ZW, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12389; Carloni S, 2016, J PINEAL RES, V61, P370, DOI 10.1111/jpi.12354; Carnovale CE, 2000, J HEPATOL, V32, P798, DOI 10.1016/S0168-8278(00)80249-4; Carretero M, 2009, J PINEAL RES, V47, P192, DOI 10.1111/j.1600-079X.2009.00700.x; Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje; Carrillo-Vico A, 2005, J CLIN ENDOCR METAB, V90, P992, DOI 10.1210/jc.2004-1429; Carrillo-Vico A, 2006, CURR OPIN INVEST DR, V7, P423; Cattin AL, 2016, CURR OPIN NEUROBIOL, V39, P38, DOI 10.1016/j.conb.2016.04.005; Cetinel S, 2005, J UROLOGY, V173, P267, DOI 10.1097/01.ju.0000145891.35810.56; Chalfoun CT, 2006, J CELL MOL MED, V10, P309, DOI 10.1111/j.1582-4934.2006.tb00401.x; Chang HM, 2000, BRAIN RES, V873, P243, DOI 10.1016/S0006-8993(00)02489-6; Chang HM, 2008, J PINEAL RES, V44, P172, DOI 10.1111/j.1600-079X.2007.00505.x; Chang HM, 2014, J PINEAL RES, V56, P322, DOI 10.1111/jpi.12125; Chang YC, 2016, EXP BIOL MED, V241, P1588, DOI 10.1177/1535370216642528; Chang YS, 2016, J UROLOGY, V195, pE375, DOI 10.1016/j.juro.2016.02.1060; Chawla SL, 2008, FLUORIDE, V41, P44; Chen FM, 2010, BIOMATERIALS, V31, P6279, DOI 10.1016/j.biomaterials.2010.04.053; Chen HH, 2014, J PINEAL RES, V57, P16, DOI 10.1111/jpi.12140; Chen YT, 2014, J PINEAL RES, V57, P248, DOI 10.1111/jpi.12164; Cho YA, 2015, J PINEAL RES, V58, P127, DOI 10.1111/jpi.12198; Clafshenkel WP, 2012, J PINEAL RES, V53, P206, DOI 10.1111/j.1600-079X.2012.00989.x; Clavien P, 2007, NEW ENGL J MED, V356, P1545, DOI 10.1056/NEJMra065156; Colman A, 2000, TRENDS BIOTECHNOL, V18, P192, DOI 10.1016/S0167-7799(00)01434-7; Cosovic E., 2017, Veterinaria (Sarajevo), V66, P21; CUNNANE SC, 1979, MED HYPOTHESES, V5, P403, DOI 10.1016/0306-9877(79)90107-5; Dalamagkas K, 2016, MAT SCI ENG C-MATER, V65, P425, DOI 10.1016/j.msec.2016.04.048; Daly W., 2011, J R SOC INTERFACE; Demirbag B, 2011, BIOTECHNOL J, V6, P1437, DOI 10.1002/biot.201100261; Deumens R, 2010, PROG NEUROBIOL, V92, P245, DOI 10.1016/j.pneurobio.2010.10.002; Develioglu H, 2009, DENT MATER J, V28, P396, DOI 10.4012/dmj.28.396; Di Martino Alberto, 2011, Musculoskelet Surg, V95, P69, DOI 10.1007/s12306-011-0097-8; Drobnik Jacek, 1996, Cytobios, V85, P51; Duda GN, 2008, EXERC SPORT SCI REV, V36, P64, DOI 10.1097/JES.0b013e318168eb88; Duffy JF, 2015, SLEEP MED CLIN, V10, P423, DOI 10.1016/j.jsmc.2015.08.002; Duncan AW, 2013, CURR OPIN ORGAN TRAN, V18, P197, DOI 10.1097/MOT.0b013e32835f07e2; Dziedzic K., SEMINARS CELL DEV BI; Ebaid H, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-20; Ehrler DM, 2000, CLIN ORTHOP RELAT R, P38; Ek RO, 2007, NEUROENDOCRINOL LETT, V28, P666; El-Sokkary G.H., 2009, OPEN NEUROENDOCRINOL, V2, P1; El-Sokkary GH, 2007, TOXICOLOGY, V239, P60, DOI 10.1016/j.tox.2007.06.092; El-Sokkary GH, 2010, ECOTOX ENVIRON SAFE, V73, P456, DOI 10.1016/j.ecoenv.2009.09.014; El-Sokkary GH, 2005, TOXICOLOGY, V213, P25, DOI 10.1016/j.tox.2005.05.003; Elkwood AI, 2011, J SPINAL CORD MED, V34, P241, DOI 10.1179/107902611X12972448729521; Esposito E, 2008, J PINEAL RES, V45, P149, DOI 10.1111/j.1600-079X.2008.00569.x; Esposito E, 2009, J PINEAL RES, V46, P79, DOI 10.1111/j.1600-079X.2008.00633.x; Finkemeier CG, 2002, J BONE JOINT SURG AM, V84A, P454, DOI 10.2106/00004623-200203000-00020; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fortun J, 2009, NEUROSCI LETT, V456, P124, DOI 10.1016/j.neulet.2008.08.092; Fujimoto T, 2000, SPINE, V25, P769, DOI 10.1097/00007632-200004010-00003; Gao YH, 2016, J PINEAL RES, V60, P303, DOI 10.1111/jpi.12311; Garcia-Maurino S, 1998, J NEUROIMMUNOL, V92, P76, DOI 10.1016/S0165-5728(98)00179-9; Garcia-Rubio L, 2005, HUM EXP TOXICOL, V24, P475, DOI 10.1191/0960327105ht548oa; Genovese T, 2005, J PINEAL RES, V38, P198, DOI 10.1111/j.1600-079X.2004.00194.x; Genovese T, 2007, J PINEAL RES, V43, P140, DOI 10.1111/j.1600-079X.2007.00454.x; Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029; Gomes KU, 2008, J ORAL MAXIL SURG, V66, P2335, DOI 10.1016/j.joms.2008.06.006; Gomes ME, 2017, TISSUE ENG PART B-RE, V23, P211, DOI [10.1089/ten.teb.2017.0081, 10.1089/ten.TEB.2017.0081]; Gomez-Pinilla PJ, 2008, J PINEAL RES, V44, P416, DOI 10.1111/j.1600-079X.2007.00544.x; Gomez-Pinilla PJ, 2007, J UROLOGY, V177, P1558, DOI 10.1016/j.juro.2006.11.071; Goradel NH, 2015, ADV PHARM BULL, V5, P293, DOI 10.5681/apb.2015.041; Greenwald AS, 2001, J BONE JOINT SURG AM, V83A, P98, DOI 10.2106/00004623-200100022-00007; Gu XS, 2014, BIOMATERIALS, V35, P6143, DOI 10.1016/j.biomaterials.2014.04.064; Gu XS, 2011, PROG NEUROBIOL, V93, P204, DOI 10.1016/j.pneurobio.2010.11.002; Gul S, 2005, SURG NEUROL, V64, P355, DOI 10.1016/j.surneu.2005.03.036; Guo BL, 2014, SCI CHINA CHEM, V57, P490, DOI 10.1007/s11426-014-5086-y; Guo P., 2014, TOXICOL SCI; Guo Y, 2010, BRIT J NEUROSURG, V24, P62, DOI 10.3109/02688690903506077; Harari-Steinberg O, 2011, ORGANOGENESIS, V7, P123, DOI 10.4161/org.7.2.15783; Hardeland R, 2017, MELATONIN HLTH AGING, P209, DOI 10.1007/978-3-319- 63001-4_10; Hardeland R, 2013, J PINEAL RES, V55, P325, DOI 10.1111/jpi.12090; Hevia D, 2015, J PINEAL RES, V58, P234, DOI 10.1111/jpi.12210; Hibaoui Y, 2009, J PINEAL RES, V47, P238, DOI 10.1111/j.1600-079X.2009.00707.x; Hill SM, 2015, ENDOCR-RELAT CANCER, V22, pR183, DOI 10.1530/ERC-15-0030; Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027; Hong Y, 2014, J PINEAL RES, V56, P175, DOI 10.1111/jpi.12110; Hosseinzadeh A, 2016, J PINEAL RES, V61, P411, DOI 10.1111/jpi.12362; Huo XK, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12390; Itoh T, 2014, HEPATOLOGY, V59, P1617, DOI 10.1002/hep.26753; Jaenisch R., 2015, NUCL CLONING STEM CE; Jahanban-Esfahlan R, 2018, BRIT J PHARMACOL, V175, P3230, DOI 10.1111/bph.13898; Jana S, 2016, ADV MATER, V28, P10588, DOI 10.1002/adma.201600240; Janicki P, 2011, INJURY, V42, pS77, DOI 10.1016/j.injury.2011.06.014; Jiang X, 2010, EXP NEUROL, V223, P86, DOI 10.1016/j.expneurol.2009.09.009; Johnson EO, 2008, INJURY, V39, pS37, DOI 10.1016/j.injury.2008.06.015; Johnson EO, 2008, INJURY, V39, pS30, DOI 10.1016/j.injury.2008.05.018; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Jung KH, 2009, J PINEAL RES, V47, P173, DOI 10.1111/j.1600-079X.2009.00698.x; Kandemir YB, 2015, FOLIA MORPHOL, V74, P283, DOI 10.5603/FM.2015.0043; Kaplan S, 2011, MICROSURG, V31, P306, DOI 10.1002/micr.20876; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Karimaian A, 2017, DNA REPAIR, V51, P14, DOI 10.1016/j.dnarep.2017.01.003; KAUFMANN PM, 1994, TRANSPL P, V26, P3343; Kaya Y, 2013, J CHEM NEUROANAT, V53, P18, DOI 10.1016/j.jchemneu.2013.08.002; Kaya Y, 2013, CHILD NERV SYST, V29, P389, DOI 10.1007/s00381-012-1936-0; Keating JF, 2001, J BONE JOINT SURG BR, V83B, P3, DOI 10.1302/0301-620X.83B1.11952; Keeffe EB, 2001, GASTROENTEROLOGY, V120, P749, DOI 10.1053/gast.2001.22583; Kelestemur T, 2016, NEUROSCI LETT, V612, P92, DOI 10.1016/j.neulet.2015.11.043; Kode JA, 2009, CYTOTHERAPY, V11, P377, DOI 10.1080/14653240903080367; Koh CJ, 2004, J AM SOC NEPHROL, V15, P1113, DOI 10.1097/01.ASN.0000119683.59068.F0; Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163; Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219; Kramann R, 2015, NEPHROL DIAL TRANSPL, V30, P903, DOI 10.1093/ndt/gfu281; Krityakiarana W, 2016, J NEUROSCI RES, V94, P1451, DOI 10.1002/jnr.23930; Kumar A, 2012, IN VITRO CELL DEV-AN, V48, P625, DOI 10.1007/s11626-012-9556-2; Kunak ZI, 2012, J SURG RES, V175, pE17, DOI 10.1016/j.jss.2011.11.002; Kuraitis D, 2012, BIOMATERIALS, V33, P428, DOI 10.1016/j.biomaterials.2011.09.078; Kurcer Z, 2007, J PINEAL RES, V43, P42, DOI 10.1111/j.1600-079X.2007.00441.x; Kus I, 2005, CELL BIOCHEM FUNCT, V23, P169, DOI 10.1002/cbf.1136; Kwon YJ, 2015, CLIN MOL HEPATOL, V21, P7, DOI 10.3350/cmh.2015.21.1.7; Lacoste B, 2015, J PINEAL RES, V58, P397, DOI 10.1111/jpi.12224; Lad SP, 2010, NEUROSURGERY, V66, P953, DOI 10.1227/01.NEU.0000368545.83463.91; Laliena A, 2012, J PINEAL RES, V53, P270, DOI 10.1111/j.1600-079X.2012.00995.x; Lardone PJ, 2011, J PINEAL RES, V51, P454, DOI 10.1111/j.1600-079X.2011.00909.x; Lee MS, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12372; Lee SJ, 2014, J PINEAL RES, V57, P393, DOI 10.1111/jpi.12179; Lee Seunghoon, 2012, Lab Anim Res, V28, P47, DOI 10.5625/lar.2012.28.1.47; Lepper C, 2011, DEVELOPMENT, V138, P3639, DOI 10.1242/dev.067595; Lerou PH, 2005, BLOOD REV, V19, P321, DOI 10.1016/j.blre.2005.01.005; Liang R, 2009, J PINEAL RES, V46, P8, DOI 10.1111/j.1600-079X.2008.00596.x; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Lin MY, 2013, HAND CLIN, V29, P331, DOI 10.1016/j.hcl.2013.04.003; Liu FuRong, 2009, China Tropical Medicine, V9, P2069; Liu JB, 2004, CHINESE MED J-PEKING, V117, P571; Loi P, 2016, TRENDS BIOTECHNOL, V34, P791, DOI 10.1016/j.tibtech.2016.03.008; Luchetti F, 2014, J PINEAL RES, V56, P382, DOI 10.1111/jpi.12133; Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10-154450; Calvo-Guirado JL, 2015, CLIN ORAL IMPLAN RES, V26, P1421, DOI 10.1111/clr.12472; Calvo-Guirado JL, 2010, J PINEAL RES, V48, P194, DOI 10.1111/j.1600-079X.2009.00743.x; Calvo-Guirado JL, 2009, J PINEAL RES, V47, P164, DOI 10.1111/j.1600-079X.2009.00696.x; Mackinnon SE, 2001, PLAST RECONSTR SURG, V107, P1419, DOI 10.1097/00006534-200105000-00016; Mahieu S, 2009, TOXICOL LETT, V190, P9, DOI 10.1016/j.toxlet.2009.06.852; Majidinia M, 2018, J CELL PHYSIOL, V233, P5598, DOI 10.1002/jcp.26265; Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042; Majidinia M, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12416; Majidinia M, 2017, CHEM BIOL DRUG DES, V89, P309, DOI 10.1111/cbdd.12893; Majidinia M, 2016, DNA REPAIR, V47, P1, DOI 10.1016/j.dnarep.2016.09.003; Malafaya PB, 2007, ADV DRUG DELIVER REV, V59, P207, DOI 10.1016/j.addr.2007.03.012; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Maria S, 2014, J PINEAL RES, V56, P115, DOI 10.1111/jpi.12116; Markus RP, 2013, INT J MOL SCI, V14, P10979, DOI 10.3390/ijms140610979; Pereira-Junior OCM, 2007, J BIOMATER APPL, V21, P283, DOI 10.1177/0885328206063526; Mayo J.C., 2017, J PINEAL RES, V62; Mayo JC, 2002, CELL MOL LIFE SCI, V59, P1706, DOI 10.1007/PL00012498; McKay WF, 2017, GOOGLE PATENTS; Mehanna RA, 2017, INT J CLIN EXP MED, V10, P1490; Mehmet K., 2006, ARCH TOXICOL, V80, P362; Meki ARMA, 2004, TOXICON, V43, P93, DOI 10.1016/j.toxicon.2003.10.026; Meki ARMA, 2001, NEUROENDOCRINOL LETT, V22, P417; Meki ARMA, 2001, COMP BIOCHEM PHYS C, V130, P305, DOI 10.1016/S1532-0456(01)00248-4; Menovsky T, 2001, J NEUROSURG, V95, P694, DOI 10.3171/jns.2001.95.4.0694; Mias C, 2008, STEM CELLS, V26, P1749, DOI 10.1634/stemcells.2007-1000; Mohammadian M, 2013, ADV PHARM BULL, V3, P433, DOI 10.5681/apb.2013.070; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Morsy FA, 2006, INT J TOXICOL, V25, P523, DOI 10.1080/10915810600961648; Moshiri A., 2012, HARD TISSUE, V1, P11, DOI [10.13172/2050-2303-1-2-291., DOI 10.13172/2050-2303-1-2-291]; Muir D, 2010, EXP NEUROL, V223, P102, DOI 10.1016/j.expneurol.2009.05.038; Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94; Najafi M, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/s40200-014-0106-1; Nakade O, 1999, J PINEAL RES, V27, P106, DOI 10.1111/j.1600-079X.1999.tb00603.x; Nava M, 2000, AM J PHYSIOL-RENAL, V279, pF910, DOI 10.1152/ajprenal.2000.279.5.F910; Nomiya M, 2013, BJU INT, V112, pE221, DOI 10.1111/j.1464-410X.2012.11746.x; Odaci E, 2009, INT REV NEUROBIOL, V87, P317, DOI 10.1016/S0074-7742(09)87016-5; Oguz E, 2015, RENAL FAILURE, V37, P318, DOI 10.3109/0886022X.2014.991263; Ohta Y, 2004, J PINEAL RES, V36, P10, DOI 10.1046/j.1600-079X.2003.00091.x; Ohta Y, 2001, J PINEAL RES, V31, P370, DOI 10.1034/j.1600-079X.2001.310413.x; Ohta Y, 2000, J PINEAL RES, V28, P119, DOI 10.1034/j.1600-079X.2001.280208.x; Ohta Y, 2000, J PINEAL RES, V29, P15, DOI 10.1034/j.1600-079X.2000.290103.x; Okamoto M, 2013, PROG POLYM SCI, V38, P1487, DOI 10.1016/j.progpolymsci.2013.06.001; Oner J, 2008, ANAT REC, V291, P448, DOI 10.1002/ar.20659; Orive G, 2009, NAT REV NEUROSCI, V10, P682, DOI 10.1038/nrn2685; Orlando G, 2013, BIOMATERIALS, V34, P5915, DOI 10.1016/j.biomaterials.2013.04.033; Orlando G, 2012, ANN SURG, V256, P363, DOI 10.1097/SLA.0b013e31825a02ab; Oryan A, 2012, CELL TISSUE BANK, V13, P639, DOI 10.1007/s10561-011-9285-x; Oryan A, 2013, HARD TISSUE, V2, P1, DOI DOI 10.13172/2050-2303-2-2-374; Oryan A, 2012, J TISSUE VIABILITY, V21, P88, DOI 10.1016/j.jtv.2012.06.002; Pakulska MM, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/2/024101; Pandi-Perumal SR, 2013, NEUROTOX RES, V23, P267, DOI 10.1007/s12640-012-9337-4; Panseri S, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-39; Paradies G, 2017, CELL MOL LIFE SCI, V74, P3897, DOI 10.1007/s00018-017-2619-5; Parikh S N, 2002, J Postgrad Med, V48, P142; Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600-079X.2011.00875.x; Patschan D, 2012, AM J PHYSIOL-RENAL, V302, pF1305, DOI 10.1152/ajprenal.00445.2011; Peyrot F, 2008, J PINEAL RES, V45, P235, DOI 10.1111/j.1600-079X.2008.00580.x; Ramirez-Fernandez MP, 2013, CLIN ORAL INVEST, V17, P147, DOI 10.1007/s00784-012-0684-6; Ping ZC, 2017, ACTA BIOMATER, V51, P513, DOI 10.1016/j.actbio.2017.01.034; Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/nmat2441, 10.1038/NMAT2441]; Pugazhenthi K, 2008, J PINEAL RES, V44, P387, DOI 10.1111/j.1600-079X.2007.00541.x; Qiu TT, 2016, INT J CLIN EXP MED, V9, P8014; Quertainmont R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039500; Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600-079X.2006.00318.x; Raggi Chiara, 2012, Muscles Ligaments Tendons J, V2, P239; Rajaram A, 2012, TISSUE ENG PART B-RE, V18, P454, DOI [10.1089/ten.teb.2012.0006, 10.1089/ten.TEB.2012.0006]; Ramirez-Garcia G, 2015, ELECTROCHIM ACTA, V166, P88, DOI 10.1016/j.electacta.2015.03.063; Ramis MR, 2015, CURR MED CHEM, V22, P2690, DOI 10.2174/0929867322666150619104143; Ramis MR, 2015, MECH AGEING DEV, V146, P28, DOI 10.1016/j.mad.2015.03.008; Rateb EE, 2017, EXCLI J, V16, P138, DOI 10.17179/excli2016-763; Reiter R., 2007, ADV MED SCI, V52, P52; Reiter RJ, 2002, J PHARM PHARMACOL, V54, P1299, DOI 10.1211/002235702760345374; REITER RJ, 1969, NEUROENDOCRINOLOGY, V5, P219, DOI 10.1159/000121862; Reiter RJ, 2000, ANN NY ACAD SCI, V917, P376; Reiter RJ, 2017, HEALTHY AGEING LONG, V7, P1, DOI 10.1007/978-3-319-64543-8_1; Reiter RJ, 2016, J PINEAL RES, V61, P253, DOI 10.1111/jpi.12360; Reiter RJ, 2014, PHYSIOLOGY, V29, P325, DOI 10.1152/physiol.00011.2014; Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4; Reule S, 2011, ORGANOGENESIS, V7, P135, DOI 10.4161/org.7.2.16285; Ringe J, 2002, NATURWISSENSCHAFTEN, V89, P338, DOI 10.1007/s00114-002-0344-9; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rodriguez MI, 2007, FREE RADICAL RES, V41, P15, DOI 10.1080/10715760600936359; Rogerio F, 2002, BRAIN RES, V926, P33, DOI 10.1016/S0006-8993(01)03286-3; Romagnani P, 2013, NAT REV NEPHROL, V9, P137, DOI 10.1038/nrneph.2012.290; Romero A, 2014, J PINEAL RES, V56, P343, DOI 10.1111/jpi.12132; Ross EA, 2012, ORGANOGENESIS, V8, P49, DOI 10.4161/org.20209; Ross EA, 2009, J AM SOC NEPHROL, V20, P2338, DOI 10.1681/ASN.2008111196; Sainz RM, 2003, CELL MOL LIFE SCI, V60, P1407, DOI 10.1007/s00018-003-2319-1; Salucci S, 2016, MICROSC RES TECHNIQ, V79, P532, DOI 10.1002/jemt.22663; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; Sato M, 2011, J BIOSCI BIOENG, V112, P273, DOI 10.1016/j.jbiosc.2011.05.007; Satomura K, 2007, J PINEAL RES, V42, P231, DOI 10.1111/j.1600-079X.2006.00410.x; Sayan H, 2004, J PINEAL RES, V37, P143, DOI 10.1111/j.1600-079X.2004.00145.x; Scheer FAJL, 2006, SPINAL CORD, V44, P78, DOI 10.1038/sj.sc.3101784; Schiaffino S, 2017, FEBS J, V284, P517, DOI 10.1111/febs.13827; Schmidt CE, 2003, ANNU REV BIOMED ENG, V5, P293, DOI 10.1146/annurev.bioeng.5.011303.120731; Seidlits S. K., 2008, NANOSTRUCTURED SCAFF; Sethi S, 2010, J PINEAL RES, V49, P222, DOI 10.1111/j.1600-079X.2010.00784.x; Sharfuddin AA, 2011, NAT REV NEPHROL, V7, P189, DOI 10.1038/nrneph.2011.16; Sharma S, 2013, ARH HIG RADA TOKSIKO, V64, P219, DOI 10.2478/10004-1254-64-2013-2248; Shino H, 2016, MED ORAL PATOL ORAL, V21, pE122, DOI 10.4317/medoral.20904; Shoichet Molly S., 2008, P221; Shokouhi G, 2008, CHILD NERV SYST, V24, P111, DOI 10.1007/s00381-007-0366-x; Sidhu S, 2010, EUR J PHARMACOL, V628, P282, DOI 10.1016/j.ejphar.2009.11.058; Son JH, 2017, LASER MED SCI, V32, P533, DOI 10.1007/s10103-017-2145-6; Son JH, 2014, J PINEAL RES, V57, P385, DOI 10.1111/jpi.12177; Song JJ, 2013, NAT MED, V19, P646, DOI 10.1038/nm.3154; Song J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/854359; Stavisky RC, 2005, NEUROSCI LETT, V376, P98, DOI 10.1016/j.neulet.2004.11.033; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Stratos I, 2012, J PINEAL RES, V52, P62, DOI 10.1111/j.1600-079X.2011.00919.x; Sullivan DC, 2012, BIOMATERIALS, V33, P7756, DOI 10.1016/j.biomaterials.2012.07.023; Sutken E, 2007, INT J TOXICOL, V26, P81, DOI 10.1080/10915810601122893; Tabar V, 2014, NAT REV GENET, V15, P82, DOI 10.1038/nrg3563; Takahashi H, 2016, ADV HEALTHC MATER, V5, P1931, DOI 10.1002/adhm.201600197; Takebe T, 2013, NATURE, V499, P481, DOI 10.1038/nature12271; Tam RY, 2014, NEUROPSYCHOPHARMACOL, V39, P169, DOI 10.1038/npp.2013.237; Tan DX, 2016, J PINEAL RES, V61, P27, DOI 10.1111/jpi.12336; Tan DX, 2013, J PINEAL RES, V54, P127, DOI 10.1111/jpi.12026; Tan DX, 2003, EXPERT OPIN THER PAT, V13, P1513, DOI 10.1517/eotp.13.10.1513.22913; Tas U, 2011, TOXICOL IND HEALTH, V27, P465, DOI 10.1177/0748233710389853; Taskiran D, 2000, INT J NEUROSCI, V104, P63, DOI 10.3109/00207450009035009; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Teixeira CFP, 2003, MUSCLE NERVE, V28, P449, DOI 10.1002/mus.10453; Topsakal C, 2003, SPINE, V28, P1643, DOI 10.1097/00007632-200308010-00004; Tripathi DN, 2010, J PINEAL RES, V48, P324, DOI 10.1111/j.1600-079X.2010.00756.x; Turgut M, 2005, J PINEAL RES, V38, P284, DOI 10.1111/j.1600-079X.2004.00205.x; Turgut M, 2005, ACTA NEUROCHIR, V147, P67, DOI 10.1007/s00701-004-0426-x; Turgut M, 2006, J CLIN NEUROSCI, V13, P753, DOI 10.1016/j.jocn.2005.07.019; Uygun BE, 2010, NAT MED, V16, P814, DOI 10.1038/nm.2170; Uygur R, 2016, TOXICOL IND HEALTH, V32, P848, DOI 10.1177/0748233713512891; Uzarski JS, 2014, CURR OPIN NEPHROL HY, V23, P399, DOI 10.1097/01.mnh.0000447019.66970.ea; Venegas C, 2012, J PINEAL RES, V52, P217, DOI 10.1111/j.1600-079X.2011.00931.x; Vogelstein B, 2002, SCIENCE, V295, P1237, DOI 10.1126/science.1070247; Wang L, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12429; Wang WZ, 2005, J PINEAL RES, V39, P57, DOI 10.1111/j.1600-079X.2005.00215.x; WEICHSELBAUM R, 1975, NATURE, V254, P349, DOI 10.1038/254349a0; White RE, 2008, RESTOR NEUROL NEUROS, V26, P197; Willerth SM, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt58; Witt-Enderby PA, 2012, J PINEAL RES, V53, P374, DOI 10.1111/j.1600-079X.2012.01007.x; Wobma H, 2016, TISSUE ENG PART B-RE, V22, P101, DOI [10.1089/ten.teb.2015.0535, 10.1089/ten.TEB.2015.0535]; Wright LS, 2003, J NEUROCHEM, V86, P179, DOI 10.1046/j.1471-4159.2003.01826.x; Wu QB, 2014, J MOL NEUROSCI, V54, P714, DOI 10.1007/s12031-014-0430-4; Yang F, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12422; Yanilmaz M, 2015, J CRANIOFAC SURG, V26, P667, DOI 10.1097/SCS.0000000000001503; Yildirim ME, 2016, CENT EUR J UROL, V69, P225, DOI 10.5173/ceju.2016.770; Yoe YM, 2011, BRAIN RES, V1385, P1, DOI 10.1016/j.brainres.2011.02.047; Yousefi B, 2014, BIOL TRACE ELEM RES, V158, P276, DOI 10.1007/s12011-014-9956-0; Yousefi B, 2012, BIOIMPACTS, V2, P145, DOI 10.5681/bi.2012.019; Zandstra PW, 2001, ANNU REV BIOMED ENG, V3, P275, DOI 10.1146/annurev.bioeng.3.1.275; Zaouali MA, 2013, J PINEAL RES, V55, P65, DOI 10.1111/jpi.12051; Zeitzer JM, 2000, J CLIN ENDOCR METAB, V85, P2189, DOI 10.1210/jc.85.6.2189; Zencirci SG, 2010, J NEUROSCI METH, V191, P277, DOI 10.1016/j.jneumeth.2010.07.008; Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162; Zhang JJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040673; Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600-079X.2010.00803.x; Zhang S, 2017, PHARMACOL RES, V117, P252, DOI 10.1016/j.phrs.2016.12.035; Zhao J, 2015, AM J PHYSIOL-RENAL, V308, pF1474, DOI 10.1152/ajprenal.00512.2014; Zheng BL, 2017, SAUDI PHARM J, V25, P570, DOI 10.1016/j.jsps.2017.04.025; Zhu FM, 2017, AM J TRANSL RES, V9, P1694; Zimmermann G, 2011, INJURY, V42, pS16, DOI 10.1016/j.injury.2011.06.199; Zochodne DW, 2012, J PERIPHER NERV SYST, V17, P1, DOI 10.1111/j.1529-8027.2012.00378.x; Zupancic D, 2008, J PINEAL RES, V44, P299, DOI 10.1111/j.1600-079X.2007.00530.x; Zupancic D, 2009, VIRCHOWS ARCH, V454, P657, DOI 10.1007/s00428-009-0765-3	326	44	46	2	35	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1568-1637	1872-9649		AGEING RES REV	Ageing Res. Rev.	AUG	2018	45						33	52		10.1016/j.arr.2018.04.003			20	Cell Biology; Geriatrics & Gerontology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Geriatrics & Gerontology	GO8YU	WOS:000440390000004	29630951				2022-02-06	
J	Brennan, PM; Murray, GD; Teasdale, GM				Brennan, Paul M.; Murray, Gordon D.; Teasdale, Graham M.			Simplifying the use of prognostic information in traumatic brain injury. Part 1: The GCS-Pupils score: an extended index of clinical severity	JOURNAL OF NEUROSURGERY			English	Article						Glasgow Coma Scale; head injury; traumatic brain injury; trauma; prognosis; pupil reactivity	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; PREDICTION; VALIDATION; CONSCIOUSNESS; POPULATION; REFLEXES	OBJECTIVE Glasgow Coma Scale (GCS) scores and pupil responses are key indicators of the severity of traumatic brain damage. The aim of this study was to determine what information would be gained by combining these indicators into a single index and to explore the merits of different ways of achieving this. METHODS Information about early GCS scores, pupil responses, late outcomes on the Glasgow Outcome Scale, and mortality were obtained at the individual patient level by reviewing data from the CRASH (Corticosteroid Randomisation After Significant Head Injury; n = 9,045) study and the IMPACT (International Mission for Prognosis and Clinical Trials in TBI; n = 6855) database. These data were combined into a pooled data set for the main analysis. Methods of combining the Glasgow Coma Scale and pupil response data varied in complexity from using a simple arithmetic score (GCS score [range 3-15] minus the number of nonreacting pupils [0, 1, or 2]), which we call the GCS-Pupils score (GCS-P; range 1-15), to treating each factor as a separate categorical variable. The content of information about patient outcome in each of these models was evaluated using Nagelkerke's R-2. RESULTS Separately, the GCS score and pupil response were each related to outcome. Adding information about the pupil response to the GCS score increased the information yield. The performance of the simple GCS-P was similar to the performance of more complex methods of evaluating traumatic brain damage. The relationship between decreases in the GCS-P and deteriorating outcome was seen across the complete range of possible scores. The additional 2 lowest points offered by the GCS-Pupils scale (GCS-P 1 and 2) extended the information about injury severity from a mortality rate of 51% and an unfavorable outcome rate of 70% at GCS score 3 to a mortality rate of 74% and an unfavorable outcome rate of 90% at GCS-P 1. The paradoxical finding that GCS score 4 was associated with a worse outcome than GCS score 3 was not seen when using the GCS-P. CONCLUSIONS A simple arithmetic combination of the GCS score and pupillary response, the GCS-P, extends the information provided about patient outcome to an extent comparable to that obtained using more complex methods. The greater range of injury seventies that are identified and the smoothness of the stepwise pattern of outcomes across the range of scores may be useful in evaluating individual patients and identifying patient subgroups. The GCS-P may be a useful platform onto which information about other key prognostic features can be added in a simple format likely to be useful in clinical practice.	[Brennan, Paul M.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Murray, Gordon D.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Teasdale, Graham M.] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland		Brennan, PM (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland.	paul.brennan@ed.ac.uk		Brennan, Paul/0000-0002-7347-830X			BARLOW P, 1986, NEUROSURGERY, V19, P989, DOI 10.1227/00006123-198612000-00014; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Brain Trauma Foundation American Association of Neurological Surgeons, 2000, MAN PROGN SEV TRAUM; Eken C, 2009, EUR J EMERG MED, V16, P29, DOI 10.1097/MEJ.0b013e32830346ab; JENNETT B, 1976, LANCET, V1, P1031; Latronico N, 2015, CRIT CARE MED, V43, P505, DOI 10.1097/CCM.0000000000000795; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Moore NA, 2013, BRIT J NEUROSURG, V27, P340, DOI 10.3109/02688697.2012.754402; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; MOULTON C, 1994, LANCET, V343, P1261, DOI 10.1016/S0140-6736(94)92155-5; Murray GD, 2018, J NEUROSURG, V128, P1621, DOI 10.3171/2017.12.JNS172782; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; Osler T, 2016, INJURY, V47, P1879, DOI 10.1016/j.injury.2016.04.016; Peng J, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0508-9; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Reith FCM, 2017, INJURY, V48, P1932, DOI 10.1016/j.injury.2017.05.038; Reith FCM, 2016, INTENS CARE MED, V42, P3, DOI 10.1007/s00134-015-4124-3; Rotheray KR, 2012, RESUSCITATION, V83, P86, DOI 10.1016/j.resuscitation.2011.07.017; Royston P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b604; Steyerberg EW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001381; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1983, LANCET, V2, P678; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611	32	44	47	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2018	128	6					1612	1620		10.3171/2017.12.JNS172780			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	GP2IM	WOS:000440653000002	29631516	Bronze, Green Submitted			2022-02-06	
J	Lu, Y; Zhang, XS; Zhang, ZH; Zhou, XM; Gao, YY; Liu, GJ; Wang, H; Wu, LY; Li, W; Hang, CH				Lu, Yue; Zhang, Xiang-Sheng; Zhang, Zi-Huan; Zhou, Xiao-Ming; Gao, Yong-Yue; Liu, Guang-Jie; Wang, Han; Wu, Ling-Yun; Li, Wei; Hang, Chun-Hua			Peroxiredoxin 2 activates microglia by interacting with Toll-like receptor 4 after subarachnoid hemorrhage	JOURNAL OF NEUROINFLAMMATION			English	Article						Subarachnoid hemorrhage; Peroxiredoxin 2; Microglial activation; Toll-like receptor 4; Neuronal apoptosis	DUAL ROLE; INTRACEREBRAL HEMORRHAGE; FUNCTIONAL DIFFERENCES; ISCHEMIC-STROKE; CELL-TYPES; BRAIN; INFLAMMATION; PROTEINS	Background: Peroxiredoxin (Prx) protein family have been reported as important damage-associated molecular patterns (DAMPs) in ischemic stroke. Since peroxiredoxin 2 (Prx2) is the third most abundant protein in erythrocytes and the second most protein in the cerebrospinal fluid in traumatic brain injury and subarachnoid hemorrhage (SAH) patients, we assessed the role of extracellular Prx2 in the context of SAH. Methods: We introduced a co-culture system of primary neurons and microglia. Prx2 was added to culture medium with oxyhemoglobin (OxyHb) to mimic SAH in vitro. Neuronal cell viability was assessed by lactate dehydrogenase (LDH) assay, and neuronal apoptosis was determined by TUNEL staining. Inflammatory factors in culture medium were measured by ELISA, and their mRNA levels in microglia were determined by qPCR. Toll-like receptor 4 knockout (TLR4-KO) mice were used to provide TLR4-KO microglia; ST-2825 was used to inhibit MyD88, and pyrrolidine dithiocarbamate (PDTC) was used to inhibit NF-kappa B. Related cellular signals were analyzed by Western blot. Furthermore, we detected the level of Prx2 in aneurysmal SAH patients' cerebrospinal fluids (CSF) and compared its relationship with Hunt-Hess grades. Results: Prx2 interacted with TLR4 on microglia after SAH and then activated microglia through TLR4/MyD88/NF-kappa B signaling pathway. Pro-inflammatory factors were expressed and released, eventually caused neuronal apoptosis. The levels of Prx2 in SAH patients positively correlated with Hunt-Hess grades. Conclusions: Extracellular Prx2 in CSF after SAH is a DAMP which resulted in microglial activation via TLR4/MyD88/NF-kappa B pathway and then neuronal apoptosis. Prx2 in patients' CSF may be a potential indicator of brain injury and prognosis.	[Lu, Yue; Zhang, Xiang-Sheng; Gao, Yong-Yue; Liu, Guang-Jie; Wu, Ling-Yun; Li, Wei; Hang, Chun-Hua] Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Zhang, Zi-Huan] Zhongdu Hosp, Dept Neurosurg, Bengbu, Peoples R China; [Zhou, Xiao-Ming] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Wang, Han] South Med Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China		Li, W; Hang, CH (corresponding author), Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.	lwxzlw@126.com; hang_neurosurgery@163.com	Li, Wei/ABE-4301-2021	LU, Yue/0000-0001-9111-5943	National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81371294, 81501022, 81401029, 81771291]	This work was supported by the National Natural Science Foundation of China (NSFC) [grant numbers 81371294, 81501022, 81401029, 81771291].	Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Buttgereit A, 2016, NAT IMMUNOL, V17, P1397, DOI 10.1038/ni.3585; Connor David E Jr, 2017, Pathophysiology, V24, P169, DOI 10.1016/j.pathophys.2017.04.003; Conway JP, 2006, J BIOL CHEM, V281, P27991, DOI 10.1074/jbc.M605026200; Jin MH, 2005, NEUROSCI LETT, V381, P252, DOI 10.1016/j.neulet.2005.02.048; Lan X, 2017, NAT REV NEUROL, V13, P420, DOI 10.1038/nrneurol.2017.69; Lee WS, 2007, J BIOL CHEM, V282, P22011, DOI 10.1074/jbc.M610330200; Li Q, 2017, NAT REV IMMUNOL; Liu DL, 2016, INT IMMUNOPHARMACOL, V41, P82, DOI 10.1016/j.intimp.2016.10.025; Lucke-Wold BP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040497; Matcovitch-Natan O, 2016, SCIENCE, V353, DOI 10.1126/science.aad8670; Matte A, 2007, BLOOD, V110, p529A; Nakagawa Y, 2014, PHARMACEUTICALS, V7, P1028, DOI 10.3390/ph7121028; Park MH, 2016, PHARMACOL THERAPEUT, V163, P1, DOI 10.1016/j.pharmthera.2016.03.018; Ritzel RM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0329-1; Sarafian TA, 1999, J NEUROSCI RES, V56, P206, DOI 10.1002/(SICI)1097-4547(19990415)56:2<206::AID-JNR1>3.0.CO;2-X; Shichita T, 2017, NAT MED, V23, P723, DOI 10.1038/nm.4312; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Smolinska MJ, 2011, J IMMUNOL, V187, P6043, DOI 10.4049/jimmunol.1100967; Sun Q, 2014, J NEUROINFLAMM, V11; Watanabe Y, 2017, BIOCHEM BIOPH RES CO, V483, P930, DOI 10.1016/j.bbrc.2017.01.034; Xu XM, 2017, J NEUROSCI, V37, P10498, DOI 10.1523/JNEUROSCI.1139-17.2017; Yu L, 2010, J CELL MOL MED, V14, P2592, DOI 10.1111/j.1582-4934.2010.01127.x; Zhang DD, 2016, NEUROL SCI, V37, P219, DOI 10.1007/s10072-015-2391-y; Zhang XS, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00611	26	44	46	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAR 19	2018	15								87	10.1186/s12974-018-1118-4			10	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	FZ9BR	WOS:000427905100001	29554978	Green Published, gold			2022-02-06	
J	Zhou, J; Wang, HD; Shen, RM; Fang, J; Yang, YQ; Dai, W; Zhu, YH; Zhou, ML				Zhou, Jian; Wang, Handong; Shen, Ruiming; Fang, Jiang; Yang, Youqin; Dai, Wei; Zhu, Yihao; Zhou, Mengliang			Mitochondrial-targeted antioxidant MitoQ provides neuroprotection and reduces neuronal apoptosis in experimental traumatic brain injury possibly via the Nrf2-ARE pathway	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						Mitoquinone (MitoQ); traumatic brain injury; nuclear factor erythroid 2-related factor 2; oxidative stress; apoptosis; neuroprotection	INDUCED OXIDATIVE STRESS; ISCHEMIA-REPERFUSION INJURY; CLOSED-HEAD INJURY; CELL-DEATH; RAT-BRAIN; DISEASE; DAMAGE; MODEL; TOXICITY; MITOQUINONE	Mitoquinone (MitoQ) is a powerful mitochondrial-targeted antioxidant whose neuroprotective effects have been shown in a variety of animal models of neurological diseases. However, its roles in traumatic brain injury (TBI) remain unexplored. The primary objective of this study was to investigate the neuroprotection afforded by MitoQ in a mouse model of TBI, and the involvement of the Nrf2-ARE signaling pathway in the putative neuroprotective mechanism. Mice were randomly divided into four groups: sham group, TBI group, TBI + vehicle group, and TBI + MitoQ group. MitoQ (4 mg/kg, administered intraperitoneally) or an equal volume of vehicle was given at 30 min after TBI. After 24 h, brain samples were harvested for analysis. The results demonstrated that treatment with MitoQ significantly improved neurological deficits, alleviated brain edema and inhibited cortical neuronal apoptosis. Furthermore, MitoQ administration increased the activity of antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GPx), whereas it decreased the malondialdehyde (MDA) content. In addition, MitoQ treatment reduced Bax protein translocation to mitochondria and cytochrome c release into the cytosol. Moreover, MitoQ greatly accelerated the Nrf2 nuclear translocation and subsequently upregulated the expression of Nrf2 downstream proteins, including heme oxygenase-1 (HO-1) and quinone oxidoreductase 1 (Nqo1). In conclusion, the results in the study demonstrate that MitoQ exerts neuroprotective effects in the mouse model of TBI, possibly by activating the Nrf2-ARE pathway.	[Zhou, Jian; Wang, Handong; Dai, Wei] Nanjing Med Univ, Jinling Hosp, Jinling Clin Med Coll, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China; [Zhou, Jian] Hainan Med Coll, Affiliated Hosp 1, Dept Neurosurg, Haikou 570102, Hainan, Peoples R China; [Shen, Ruiming] Hainan Med Coll, Affiliated Hosp 1, Dept Rheumatol, Haikou 570102, Hainan, Peoples R China; [Fang, Jiang] Southeast Univ, Med Coll, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Yang, Youqin] Xinxiang Med Univ, Affiliated Hosp 1, Dept Neurosurg, Xinxiang 453100, Henan, Peoples R China; [Zhu, Yihao; Zhou, Mengliang] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China		Wang, HD (corresponding author), Nanjing Med Univ, Jinling Hosp, Jinling Clin Med Coll, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Fundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81571162, 81401026]	This study was grant-supported by the National Natural Science Fundation of China (No. 81371357, No. 81571162 and No. 81401026).	Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; Ahmed E, 2015, J NEUROL NEUROSCI, V6; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Cahill J, 2007, NEUROSURGERY, V60, P531, DOI 10.1227/01.NEU.0000249287.99878.9B; Cho HY, 2005, FREE RADICAL BIO MED, V38, P325, DOI 10.1016/j.freeradbiomed.2004.10.013; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Escribano-Lopez I, 2016, REDOX BIOL, V10, P200, DOI 10.1016/j.redox.2016.10.017; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gonzalez Y, 2014, ONCOTARGET, V5, P1526, DOI 10.18632/oncotarget.1715; Graham D, 2009, HYPERTENSION, V54, P322, DOI 10.1161/HYPERTENSIONAHA.109.130351; James AM, 2007, J BIOL CHEM, V282, P14708, DOI 10.1074/jbc.M611463200; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Ma T, 2011, J NEUROSCI, V31, P5589, DOI 10.1523/JNEUROSCI.6566-10.2011; Manczak M, 2010, J ALZHEIMERS DIS, V20, pS609, DOI 10.3233/JAD-2010-100564; Neuzil J, 2007, REDOX REP, V12, P148, DOI 10.1179/135100007X200227; Oyewole AO, 2015, FASEB J, V29, P4766, DOI 10.1096/fj.15-275404; Paradies G, 2014, WORLD J GASTROENTERO, V20, P14205, DOI 10.3748/wjg.v20.i39.14205; Rao VA, 2010, J BIOL CHEM, V285, P34447, DOI 10.1074/jbc.M110.133579; Rehman Hasibur, 1800, Int J Physiol Pathophysiol Pharmacol, V8, P14; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Ross MF, 2008, BIOCHEM J, V411, P633, DOI 10.1042/BJ20080063; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Smith RAJ, 2010, ANN NY ACAD SCI, V1201, P96, DOI 10.1111/j.1749-6632.2010.05627.x; Smith RAJ, 2008, ANN NY ACAD SCI, V1147, P105, DOI 10.1196/annals.1427.003; Solesio ME, 2013, BBA-MOL BASIS DIS, V1832, P174, DOI 10.1016/j.bbadis.2012.07.009; Szeto HH, 2006, AAPS J, V8, pE521, DOI 10.1208/aapsj080362; Wang R, 2014, CELL PHYSIOL BIOCHEM, V34, P854, DOI 10.1159/000366304; Wani WY, 2011, NEUROPHARMACOLOGY, V61, P1193, DOI 10.1016/j.neuropharm.2011.07.008; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiao L, 2017, REDOX BIOL, V11, P297, DOI 10.1016/j.redox.2016.12.022; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yin XL, 2016, HUM MOL GENET, V25, P1739, DOI 10.1093/hmg/ddw045	43	44	45	0	6	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2018	10	6					1887	1899					13	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	GL8HJ	WOS:000437458800028	30018728				2022-02-06	
J	Vergouwe, Y; Nieboer, D; Oostenbrink, R; Debray, TPA; Murray, GD; Kattan, MW; Koffijberg, H; Moons, KGM; Steyerberg, EW				Vergouwe, Yvonne; Nieboer, Daan; Oostenbrink, Rianne; Debray, Thomas P. A.; Murray, Gordon D.; Kattan, Michael W.; Koffijberg, Hendrik; Moons, Karel G. M.; Steyerberg, Ewout W.			A closed testing procedure to select an appropriate method for updating prediction models	STATISTICS IN MEDICINE			English	Article						model updating; logistic regression; prediction model; closed testing procedure	INDIVIDUAL PARTICIPANT DATA; VALIDATION; FRAMEWORK	Prediction models fitted with logistic regression often show poor performance when applied in populations other than the development population. Model updating may improve predictions. Previously suggested methods vary in their extensiveness of updating the model. We aim to define a strategy in selecting an appropriate update method that considers the balance between the amount of evidence for updating in the new patient sample and the danger of overfitting. We consider recalibration in the large (re-estimation of model intercept); recalibration (re-estimation of intercept and slope) and model revision (re-estimation of all coefficients) as update methods. We propose a closed testing procedure that allows the extensiveness of the updating to increase progressively from a minimum (the original model) to a maximum (a completely revised model). The procedure involves multiple testing with maintaining approximately the chosen type I error rate. We illustrate this approach with three clinical examples: patients with prostate cancer, traumatic brain injury and children presenting with fever. The need for updating the prostate cancer model was completely driven by a different model intercept in the update sample (adjustment: 2.58). Separate testing of model revision against the original model showed statistically significant results, but led to overfitting (calibration slope at internal validation=0.86). The closed testing procedure selected recalibration in the large as update method, without overfitting. The advantage of the closed testing procedure was confirmed by the other two examples. We conclude that the proposed closed testing procedure may be useful in selecting appropriate update methods for previously developed prediction models. Copyright (c) 2016 John Wiley & Sons, Ltd.	[Vergouwe, Yvonne; Nieboer, Daan; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, Rotterdam, Netherlands; [Oostenbrink, Rianne] Erasmus MC Sophia Childrens Hosp, Dept Gen Paediat, Rotterdam, Netherlands; [Debray, Thomas P. A.; Koffijberg, Hendrik; Moons, Karel G. M.] UMC Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Murray, Gordon D.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Kattan, Michael W.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA		Vergouwe, Y (corresponding author), Erasmus MC, Dept Publ Hlth, NA 2322, NL-3000 CA Rotterdam, Netherlands.	y.vergouwe@erasmusmc.nl	Steyerberg, Ewout W/C-1509-2018; Debray, Thomas/J-7413-2012; Kattan, Michael/AAF-9735-2021	Steyerberg, Ewout W/0000-0002-7787-0122; Debray, Thomas/0000-0002-1790-2719; Kattan, Michael/0000-0002-3840-4161; Koffijberg, Hendrik/0000-0002-1753-0652	Netherlands Organization for Scientific ResearchNetherlands Organization for Scientific Research (NWO) [ZonMw 1709.925.039, 9120.8004]	The Netherlands Organization for Scientific Research (ZonMw 1709.925.039 and 9120.8004)	Abo-Zaid G, 2013, J CLIN EPIDEMIOL, V66, P865, DOI 10.1016/j.jclinepi.2012.12.017; Ambler G, 2001, J STAT COMPUT SIM, V69, P89, DOI 10.1080/00949650108812083; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Debray TPA, 2015, J CLIN EPIDEMIOL, V68, P280, DOI 10.1016/j.jclinepi.2014.06.018; Debray TPA, 2013, STAT MED, V32, P3158, DOI 10.1002/sim.5732; Debray TPA, 2012, STAT MED, V31, P2697, DOI 10.1002/sim.5412; Goeman JJ, 2014, STAT MED, V33, P1946, DOI 10.1002/sim.6082; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harrell FE Jr, 2017, REGRESSION MODELING; HOLM S, 1979, SCAND J STAT, V6, P65; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Kattan MW, 2003, J UROLOGY, V170, P1792, DOI 10.1097/01.ju.0000091806.70171.41; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.2307/2335748; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MILLER ME, 1993, MED DECIS MAKING, V13, P49, DOI 10.1177/0272989X9301300107; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Oostenbrink R, 2001, ACTA PAEDIATR, V90, P611, DOI 10.1080/080352501750258649; Roobol MJ, 2003, BJU INT, V92, P48, DOI 10.1111/j.1464-410X.2003.04390.x; STEIN CM, 1981, ANN STAT, V9, P1135, DOI 10.1214/aos/1176345632; Steyerberg EW, 2004, STAT MED, V23, P2567, DOI 10.1002/sim.1844; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; van Houwelingen HC, 2000, STAT MED, V19, P3401, DOI 10.1002/1097-0258(20001230)19:24<3401::AID-SIM554>3.0.CO;2-2; VANSHOUWELINGEN. H, 1995, STATISTICS IN MEDICI, V14, P1999; Vickers AJ, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-13; Zou H, 2007, ANN STAT, V35, P2173, DOI 10.1214/009053607000000127	28	44	44	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-6715	1097-0258		STAT MED	Stat. Med.	DEC 10	2017	36	28					4529	4539		10.1002/sim.7179			11	Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED)	Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics	FN3BA	WOS:000415869400016	27891652				2022-02-06	
J	Yang, JZ; Comstock, RD; Yi, HG; Harvey, HH; Xun, PC				Yang, Jingzhen; Comstock, R. Dawn; Yi, Honggang; Harvey, Hosea H.; Xun, Pengcheng			New and Recurrent Concussions in High-School Athletes Before and After Traumatic Brain Injury Laws, 2005-2016	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							PROFESSIONAL FOOTBALL PLAYERS; UNITED-STATES; SPORTS; EDUCATION; SYMPTOMS; ENCEPHALOPATHY; EPIDEMIOLOGY; LEGISLATION; CHILDREN; COACHES	Objectives. To examine the trends of new and recurrent sports-related concussions in high-school athletes before and after youth sports traumatic brain injury laws. Methods. We used an interrupted time-series design and analyzed the concussion data (2005-2016) from High School Reporting Injury Online. We examined the trends of new or recurrent concussion rates among US representative high-school athletes participating in 9 sports across prelaw, immediate-postlaw, and postlaw periods by using general linear models. We defined 1 athlete exposure as attending 1 competition or practice. Results. We included a total of 8043 reported concussions (88.7% new, 11.3% recurrent). The average annual concussion rate was 39.8 per 100 000 athlete exposures. We observed significantly increased trends of reported new and recurrent concussions from the prelaw, through immediate-postlaw, into the postlaw period. However, the recurrent concussion rate showed a significant decline 2.6 years after the laws went into effect. Football exhibited different trends compared with other boys' sports and girls' sports. Conclusions. Observed trends of increased concussion rates are likely attributable to increased identification and reporting. Additional research is needed to evaluate intended long-term impact of traumatic brain injury laws.	[Yang, Jingzhen] Ohio State Univ, Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43210 USA; [Yang, Jingzhen] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Yang, Jingzhen] Ohio State Univ, Coll Publ Hlth, Dept Epidemiol, Columbus, OH 43210 USA; [Comstock, R. Dawn] Univ Colorado Anschutz, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Comstock, R. Dawn] Univ Colorado Anschutz, Sch Med, Dept Pediat, Emergency Med, Aurora, CO USA; [Yi, Honggang] Nanjing Med Univ, Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Nanjing, Jiangsu, Peoples R China; [Yi, Honggang] Nanjing Med Univ, Sch Publ Hlth, Dept Biostat, Nanjing, Jiangsu, Peoples R China; [Harvey, Hosea H.] Temple Univ, Beasley Sch Law, Philadelphia, PA 19122 USA; [Xun, Pengcheng] Indiana Univ, Sch Publ Hlth Bloomington, Dept Epidemiol & Biostat, Bloomington, IN USA		Yang, JZ (corresponding author), Ohio State Univ, Coll Med, Dept Pediat, Ctr Injury Res & Policy,Res Inst,Nationwide Child, 700 Childrens Dr,RB3-WB5403, Columbus, OH 43205 USA.	ginger.yang@nationwidechildrens.org	pengcheng, xun/D-3411-2013	pengcheng, xun/0000-0002-6245-4505	Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF) [30822]	This research work was supported by the Robert Wood Johnson Foundation (grant 30822).	Baugh CM, 2014, J LAW MED ETHICS, V42, P297, DOI 10.1111/jlme.12147; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bompadre V, 2014, J ATHL TRAINING, V49, P486, DOI 10.4085/1062-6050-49.3.30; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Esquivel A, 2013, SPORTS HEALTH, V5, P258, DOI 10.1177/1941738113476850; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harvey HH, 2015, J LAW MED ETHICS, V43, P87, DOI 10.1111/jlme.12225; Harvey Hosea H, 2014, Yale J Health Policy Law Ethics, V14, P66; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; LawAtlas, POL SURV PORT PUBL H; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lowrey Kerri McGowan, 2016, J Health Care Law Policy, V19, P99; Lowrey KM, 2014, J LAW MED ETHICS, V42, P290, DOI 10.1111/jlme.12146; Lowrey KM, 2014, J BUSINESS TECH L, V10, P61; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; National Center for Injury Prevention and Control, 2013, IMPL RET PLAY LEARN; National Centre for Injury Prevention and Control Division of Unintentional Injury Prevention (US), 2013, GET HEADS CONC SPORT; Program for Injury Prevention Education & Research (PIPER), HIGH SCH RIO REP FOR; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Trojian Thomas, 2015, Inj Epidemiol, V2, P2	33	44	44	0	12	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	DEC	2017	107	12					1916	1922		10.2105/AJPH.2017.304056			7	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	FR7HU	WOS:000419239300040	29048967	Green Submitted, Green Published			2022-02-06	
J	Crompton, EM; Lubomirova, I; Cotlarciuc, I; Han, TS; Sharma, SD; Sharma, P				Crompton, Ellie M.; Lubomirova, Irina; Cotlarciuc, Ioana; Han, Thang S.; Sharma, Sapna D.; Sharma, Pankaj			Meta-Analysis of Therapeutic Hypothermia for Traumatic Brain Injury in Adult and Pediatric Patients	CRITICAL CARE MEDICINE			English	Article						adult; hypothermia; morbidity; mortality; pediatric; traumatic brain injury	RANDOMIZED CONTROLLED-TRIAL; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; INTRACRANIAL-PRESSURE; CEREBRAL HYPOTHERMIA; HEAD-INJURY; PHASE-II; CEREBROSPINAL-FLUID; ENERGY-EXPENDITURE; PROTEIN-LEVELS	Objective: Therapeutic hypothermia has been used to attenuate the effects of traumatic brain injuries. However, the required degree of hypothermia, length of its use, and its timing are uncertain. We undertook a comprehensive meta-analysis to quantify benefits of hypothermia therapy for traumatic brain injuries in adults and children by analyzing mortality rates, neurologic outcomes, and adverse effects. Data Sources: Electronic databases PubMed, Google Scholar, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov and manual searches of studies were conducted for relevant publications up until February 2016. Study Selection: Forty-one studies in adults (n= 3,109; age range, 18-81 yr) and eight studies in children (n = 454; age range, 3 mo to 18 yr) met eligibility criteria. Data Extraction: Baseline patient characteristics, enrollment time, methodology of cooling, target temperature, duration of hypothermia, and rewarming protocols were extracted. Data Synthesis: Risk ratios with 95% Cls were calculated. Compared with adults who were kept normothermic, those who underwent therapeutic hypothermia were associated with 18% reduction in mortality (risk ratio, 0.82; 95% CI, 0.70-0.96; p = 0.01) and a 35% improvement in neurologic outcome (risk ratio, 1.35; 95% CI, 1.18-1.54; p < 0.00001). The optimal management strategy for adult patients included cooling patients to a minimum of 33 degrees C for 72 hours, followed by spontaneous, natural rewarming. In contrast, adverse outcomes were observed in children who underwent hypothermic treatment with a 66% increase in mortality (risk ratio, 1.66; 95% CI, 1.06-2.59; p= 0.03) and a marginal deterioration of neurologic outcome (risk ratio, 0.90; 95% CI, 0.80-1.01; p= 0.06). Conclusions: Therapeutic hypothermia is likely a beneficial treatment following traumatic brain injuries in adults but cannot be recommended in children. (Crit Care Med 2017; 45:575-583)	[Crompton, Ellie M.; Cotlarciuc, Ioana; Han, Thang S.; Sharma, Sapna D.; Sharma, Pankaj] Royal Holloway Univ London ICR2UL, Inst Cardiovasc Res, Egham, Surrey, England; [Lubomirova, Irina] Imperial Coll London, Dept Med, London, England; [Han, Thang S.; Sharma, Pankaj] Ashford & St Peters NHS Fdn Trust, Chertsey, Surrey, England		Sharma, P (corresponding author), Royal Holloway Univ London ICR2UL, Inst Cardiovasc Res, Egham, Surrey, England.; Sharma, P (corresponding author), Ashford & St Peters NHS Fdn Trust, Chertsey, Surrey, England.	pankaj.sharma@rhul.ac.uk	Crompton, Ellie/M-3164-2015	Han, Thang/0000-0003-2570-0938; Chilcott, Ellie/0000-0002-8362-8850			Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Bergman KS, 2015, CRIT CARE NURS CLIN, V27, P225, DOI 10.1016/j.cnc.2015.02.009; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS21; Chen L, 2001, Chin J Traumatol, V4, P164; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; DEMPSEY DT, 1985, SURG GYNECOL OBSTET, V160, P128; Dennis L J, 2001, Neurol India, V49 Suppl 1, pS37; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Faul M, 2010, TRAUMATIC BRAIN INJU; Frieden T.R., 2015, REPORT C TRAUMATIC B; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Galvin IM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006638.pub3; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Harris OA, 2009, J NEUROSURG, V110, P1256, DOI 10.3171/2009.1.JNS081320; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Hayashi S, 2005, ACT NEUR S, V95, P269; Hayashi S, 2002, ACT NEUR S, V81, P83; Hirayama TKY, 1994, INTRACRANIAL PRESSUR, VIX, P233; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Idris Zamzuri, 2014, Asian J Neurosurg, V9, P115, DOI 10.4103/1793-5482.142690; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; Jiang Jiyao, 1998, Chin J Traumatol, V1, P17; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Lee HC, 2010, WORLD NEUROSURG, V74, P654, DOI 10.1016/j.wneu.2010.06.019; Li H, 2009, J NEUROTRAUM, V26, P1905, DOI [10.1089/neu.2008.0828, 10.1089/neu.2008-0828]; Li PC, 2014, BRAIN INJURY, V28, P1036, DOI 10.3109/02699052.2014.910609; Liu J, 1999, CHIN J TRAUMATOL, V15, P35; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; Ma CK, 2013, CHILD NERV SYST, V29, P979, DOI 10.1007/s00381-013-2076-x; Maekawa T, 2015, J NEUROTRAUM, V32, P422, DOI 10.1089/neu.2013.3197; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Meissner W, 2003, INTENS CARE MED, V29, P44, DOI 10.1007/s00134-002-1556-3; Mtaweh H, 2014, PEDIATR CRIT CARE ME, V15, P242, DOI 10.1097/PCC.0000000000000041; Nara I, 1997, ACTA NEUROCHIR WIE S, V71, P22; Papile LA, 2014, PEDIATRICS, V133, P1146, DOI 10.1542/peds.2014-0899; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Puvanachandra P, 2009, PAK J NEUROL SCI, V4, P27; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; ROSOMOFF HL, 1956, SURGERY, V40, P328; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smrcka M, 2005, ACT NEUR S, V95, P273; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Suehiro E, 2014, J NEUROTRAUM, V31, P315, DOI 10.1089/neu.2013.3057; Tagin MA, 2012, ARCH PEDIAT ADOL MED, V166, P558, DOI 10.1001/archpediatrics.2011.1772; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tisherman SA, 1999, SURG CLIN N AM, V79, P1269, DOI 10.1016/S0039-6109(05)70077-3; Tokutomi T, 2004, NEUROCRIT CARE, V1, P171, DOI 10.1385/NCC:1:2:171; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Whiteneck G, 2001, COLORADO TRAUMATIC B; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Yamamoto T, 2002, NEUROL RES, V24, P789, DOI 10.1179/016164102101200906; Yan Y, 2010, J CLIN NEUROSCI, V17, P196, DOI 10.1016/j.jocn.2009.05.022; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010; Zhang BF, 2015, WORLD NEUROSURG, V83, P567, DOI 10.1016/j.wneu.2014.12.010; Zhang XW, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1133-0; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4; Zhu Yan-xiang, 2003, Chin J Traumatol, V6, P152	89	44	48	1	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2017	45	4					575	583		10.1097/CCM.0000000000002205			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EO6JQ	WOS:000396798700002	27941370				2022-02-06	
J	Yu, FS; Shukla, DK; Armstrong, RC; Marion, CM; Radomski, KL; Selwyn, RG; Dardzinski, BJ				Yu, Fengshan; Shukla, Dinesh K.; Armstrong, Regina C.; Marion, Christina M.; Radomski, Kryslaine L.; Selwyn, Reed G.; Dardzinski, Bernard J.			Repetitive Model of Mild Traumatic Brain Injury Produces Cortical Abnormalities Detectable by Magnetic Resonance Diffusion Imaging, Histopathology, and Behavior	JOURNAL OF NEUROTRAUMA			English	Article						concussion; diffusion kurtosis imaging; diffusion tensor imaging; microglia; Thy1-YFP	WHITE-MATTER; AXONAL INJURY; DIFFERENTIAL DETECTION; CHRONIC DEMYELINATION; COGNITIVE IMPAIRMENT; CORPUS-CALLOSUM; GLUCOSE-UPTAKE; MOUSE MODEL; HEAD-INJURY; TRACK-TBI	Noninvasive detection of mild traumatic brain injury (mTBI) is important for evaluating acute through chronic effects of head injuries, particularly after repetitive impacts. To better detect abnormalities from mTBI, we performed longitudinal studies (baseline, 3, 6, and 42 days) using magnetic resonance diffusion tensor imaging (DTI) and diffusion kurtosis imaging (DKI) in adult mice after repetitive mTBI (r-mTBI; daily x 5) or sham procedure. This r-mTBI produced righting reflex delay and was first characterized in the corpus callosum to demonstrate low levels of axon damage, astrogliosis, and microglial activation, without microhemorrhages. High-resolution DTI-DKI was then combined with post-imaging pathological validation along with behavioral assessments targeted for the impact regions. In the corpus callosum, only DTI fractional anisotropy at 42 days showed significant change post-injury. Conversely, cortical regions under the impact site (M1-M2, anterior cingulate) had reduced axial diffusivity (AD) at all time points with a corresponding increase in axial kurtosis (K-a) at 6 days. Post-imaging neuropathology showed microglial activation in both the corpus callosum and cortex at 42 days after r-mTBI. Increased cortical microglial activation correlated with decreased cortical AD after r-mTBI (r=-0.853; n = 5). Using Thy1-YFP-16 mice to fluorescently label neuronal cell bodies and processes revealed low levels of axon damage in the cortex after r-mTBI. Finally, r-mTBI produced social deficits consistent with the function of this anterior cingulate region of cortex. Overall, vulnerability of cortical regions is demonstrated after mild repetitive injury, with underlying differences of DTI and DKI, microglial activation, and behavioral deficits.	[Yu, Fengshan; Shukla, Dinesh K.; Armstrong, Regina C.; Marion, Christina M.; Radomski, Kryslaine L.; Selwyn, Reed G.; Dardzinski, Bernard J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Yu, Fengshan; Radomski, Kryslaine L.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Armstrong, Regina C.; Marion, Christina M.] Uniformed Serv Univ Hlth Sci, Program Neurosci, Bethesda, MD 20814 USA; [Dardzinski, Bernard J.] Uniformed Serv Univ Hlth Sci, Dept Radiol & Radiol Sci, Bethesda, MD 20814 USA; [Shukla, Dinesh K.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA; [Selwyn, Reed G.] Univ New Mexico, Dept Radiol, Albuquerque, NM 87131 USA		Yu, FS (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	fengshan.yu.ctr@usuhs.edu	Marion, Christina M/B-8120-2015	Marion, Christina M/0000-0003-0381-4109; Dardzinski, Bernard/0000-0001-7098-9131; Radomski, Kryslaine/0000-0001-9624-623X; Yu, Fengshan/0000-0001-8620-3084	Department of Defense within the Center for Neuroscience and Regenerative Medicine	This study was funded by the Department of Defense within the Center for Neuroscience and Regenerative Medicine. We appreciate the assistance of Dr. Amanda Mierzwa, Laurel Beer, Tuan Le, and the Pre-clinical Core and Translational Imaging Core of the Center for Neuroscience and Regenerative Medicine. We thank Drs. R. P. Gullapalli and J. Zhuo (University of Maryland, Baltimore, MD) for providing the MATLAB code for DKI processing.	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Allen B, 2002, J NEUROSCI, V22, P9340; Armstrong RC, 2002, J NEUROSCI, V22, P8574; Armstrong RC, 2006, J NEUROPATH EXP NEUR, V65, P245, DOI 10.1097/01.jnen.0000205142.08716.7e; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Davenport EM, 2016, J NEUROTRAUM, V33, P2133, DOI 10.1089/neu.2015.4267; Delano-Wood L, 2015, BRAIN IMAGING BEHAV, V9, P500, DOI 10.1007/s11682-015-9432-2; Edlow BL, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-015-0525-8; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Glenn GR, 2016, AM J NEURORADIOL, V37, P1216, DOI 10.3174/ajnr.A4714; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Harris NG, 2016, NEUROIMAGE, V133, P129, DOI 10.1016/j.neuroimage.2016.03.012; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hernandez A, 2016, J NEUROCHEM, V136, P18, DOI 10.1111/jnc.13402; Hibbits N, 2009, ASN NEURO, V1, DOI 10.1042/AN20090032; Hong S, 2016, CURR OPIN NEUROBIOL, V36, P128, DOI 10.1016/j.conb.2015.12.004; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Hughes EG, 2013, NAT NEUROSCI, V16, P668, DOI 10.1038/nn.3390; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kou Z, 2010, GLIA, V62, P1831; Lavin Claudio, 2013, Front Neurosci, V7, P64, DOI 10.3389/fnins.2013.00064; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Lindner M, 2008, NEUROPATH APPL NEURO, V34, P105, DOI 10.1111/j.1365-2990.2007.00879.x; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKenzie IA, 2014, SCIENCE, V346, P318, DOI 10.1126/science.1254960; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meier TB, 2016, J NEUROTRAUM, V33, P330, DOI 10.1089/neu.2015.3919; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Mierzwa AJ, 2014, ASN NEURO, V6, DOI 10.1177/1759091414551782; Mierzwa AJ, 2013, NEUROSCI LETT, V548, P280, DOI 10.1016/j.neulet.2013.05.010; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-1848.2004.00076.x; Nadler JJ, 2004, GENES BRAIN BEHAV, V3, P303, DOI 10.1111/j.1601-183X.2004.00071.x; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ojo JO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00213; Olmos-Alonso A, 2016, BRAIN, V139, P891, DOI 10.1093/brain/awv379; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.3.CO;2-A; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Pierpaoli C., 2010, ISMRM 18 ANN M STOCK, P1597; Robinson S, 2017, J NEUROSCI RES, V95, P1025, DOI 10.1002/jnr.23848; Sekar A, 2016, NATURE, V530, P177, DOI 10.1038/nature16549; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Selwyn RG, 2016, J NEUROTRAUM, V33, P1479, DOI 10.1089/neu.2015.4129; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Silverman JL, 2010, NAT REV NEUROSCI, V11, P490, DOI 10.1038/nrn2851; Singh K, 2016, EXP NEUROL, V275, P427, DOI 10.1016/j.expneurol.2015.07.016; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Srivastava DP, 2012, J NEUROSCI, V32, P11864, DOI 10.1523/JNEUROSCI.1349-12.2012; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Stemper BD, 2015, ANN BIOMED ENG, V43, P1071, DOI 10.1007/s10439-014-1171-9; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Tobin JE, 2011, J NEUROPATH EXP NEUR, V70, P157, DOI 10.1097/NEN.0b013e31820937e4; Tu TW, 2016, ANN NEUROL, V79, P907, DOI 10.1002/ana.24641; Ware JB, 2016, RADIOLOGY, V280, P212, DOI 10.1148/radiol.2016151013; Yang ST, 2015, J NEUROL SCI, V349, P99, DOI 10.1016/j.jns.2014.12.032; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	76	44	45	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	7					1364	1381		10.1089/neu.2016.4569			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ER0FB	WOS:000398461600007	27784203	Green Published, Bronze, Green Submitted			2022-02-06	
J	Holleran, L; Kim, JH; Gangolli, M; Stein, T; Alvarez, V; McKee, A; Brody, DL				Holleran, Laurena; Kim, Joong Hee; Gangolli, Mihika; Stein, Thor; Alvarez, Victor; McKee, Ann; Brody, David L.			Axonal disruption in white matter underlying cortical sulcus tau pathology in chronic traumatic encephalopathy	ACTA NEUROPATHOLOGICA			English	Article						Chronic traumatic encephalopathy; Radiological-pathological correlations; White matter; Phosphorylated tau; Diffusion MRI; Fractional anisotropy; Diffusion tensor imaging	EX-VIVO MRI; BRAIN-INJURY; DIFFUSION ANISOTROPY; RELAXATION-TIMES; MEAN DIFFUSIVITY; IN-VIVO; QUANTIFICATION; REGISTRATION; RESOLUTION; DIAGNOSIS	Chronic traumatic encephalopathy (CTE) is a progressive degenerative disorder associated with repetitive traumatic brain injury. One of the primary defining neuropathological lesions in CTE, based on the first consensus conference, is the accumulation of hyperphosphorylated tau in gray matter sulcal depths. Post-mortem CTE studies have also reported myelin loss, axonal injury and white matter degeneration. Currently, the diagnosis of CTE is restricted to post-mortem neuropathological analysis. We hypothesized that high spatial resolution advanced diffusion MRI might be useful for detecting white matter microstructural changes directly adjacent to gray matter tau pathology. To test this hypothesis, formalin-fixed post-mortem tissue blocks from the superior frontal cortex of ten individuals with an established diagnosis of CTE were obtained from the Veterans Affairs-Boston University-Concussion Legacy Foundation brain bank. Advanced diffusion MRI data was acquired using an 11.74 T MRI scanner at Washington University with 250 x 250 x 500 A mu m(3) spatial resolution. Diffusion tensor imaging, diffusion kurtosis imaging and generalized q-sampling imaging analyses were performed in a blinded fashion. Following MRI acquisition, tissue sections were tested for phosphorylated tau immunoreactivity in gray matter sulcal depths. Axonal disruption in underlying white matter was assessed using two-dimensional Fourier transform analysis of myelin black gold staining. A robust image co-registration method was applied to accurately quantify the relationship between diffusion MRI parameters and histopathology. We found that white matter underlying sulci with high levels of tau pathology had substantially impaired myelin black gold Fourier transform power coherence, indicating axonal microstructural disruption (r = -0.55, p = 0.0015). Using diffusion tensor MRI, we found that fractional anisotropy (FA) was modestly (r = 0.53) but significantly (p = 0.0012) correlated with axonal disruption, where lower FA was associated with greater axonal disruption in white matter directly adjacent to hyperphosphorylated tau positive sulci. In summary, our findings indicate that axonal disruption and tau pathology are closely associated, and high spatial resolution ex vivo diffusion MRI has the potential to detect microstructural alterations observed in CTE tissue. Future studies will be required to determine whether this approach can be applied to living people.	[Holleran, Laurena; Kim, Joong Hee; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Gangolli, Mihika] Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO USA; [Stein, Thor; Alvarez, Victor; McKee, Ann] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Brody, David L.] Hope Ctr Neurol Disorders, St Louis, MO 63110 USA		Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.; Brody, DL (corresponding author), Hope Ctr Neurol Disorders, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UO1 NS086659-02]	NIH UO1 NS086659-02 (Overall PI: A. McKee, Subproject 3 PI: Brody).	ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Calabrese E, 2014, HUM BRAIN MAPP, V35, P5667, DOI 10.1002/hbm.22578; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Currie S., 2016, MED J, V92, P41, DOI [10.1136/postgradmedj-2014-133211, DOI 10.1136/POSTGRADMEDJ-2014-133211]; D'Arceuil H, 2007, NEUROIMAGE, V36, P64, DOI 10.1016/j.neuroimage.2007.02.039; Dawe RJ, 2009, MAGN RESON MED, V61, P810, DOI 10.1002/mrm.21909; Gajawelli N, 2013, WORLD NEUROSURG, V80, P824, DOI 10.1016/j.wneu.2013.10.020; Gangolli M, 2016, NAT NEUR SOC S LEX K; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goubran M, 2015, J NEUROSCI METH, V241, P53, DOI 10.1016/j.jneumeth.2014.12.005; Goubran M, 2013, NEUROIMAGE, V83, P770, DOI 10.1016/j.neuroimage.2013.07.053; Hasan KM, 2006, MAGN RESON MED, V56, P130, DOI 10.1002/mrm.20935; Hasan KM, 2003, MAGNET RESON MED, V50, P589, DOI 10.1002/mrm.10552; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Kamnaksh A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04809; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Koay CG, 2006, J MAGN RESON, V182, P115, DOI 10.1016/j.jmr.2006.06.020; Lawrenz M, 2015, MAGN RESON MED, V73, P773, DOI 10.1002/mrm.25140; Le Bihan D, 2012, NEUROIMAGE, V61, P324, DOI 10.1016/j.neuroimage.2011.11.006; Lee Bruce, 2005, NeuroRx, V2, P372; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mandelkow EM, 2003, NEUROBIOL AGING, V24, P1079, DOI 10.1016/j.neurobiolaging.2003.04.007; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Millspaugh JA, 1937, US NAVAL MED B, V35, P297; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Robinson S, 2017, J NEUROSCI RES, V95, P1025, DOI 10.1002/jnr.23848; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Shahim P, 2015, BRAIN INJURY, V29, P872, DOI 10.3109/02699052.2015.1018324; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shively SB, 2017, ACTA NEUROPATHOL, V133, P353, DOI 10.1007/s00401-016-1649-7; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Wang Y, 2015, BRAIN, V138, P1223, DOI 10.1093/brain/awv046; Wansapura JP, 1999, JMRI-J MAGN RESON IM, V9, P531, DOI 10.1002/(SICI)1522-2586(199904)9:4<531::AID-JMRI4>3.0.CO;2-L; Weiss M, 2015, BRAIN STRUCT FUNCT, V220, P1695, DOI 10.1007/s00429-014-0754-4; Yeh FC, 2011, NEUROIMAGE, V55, P1054, DOI 10.1016/j.neuroimage.2010.11.087; Yeh FC, 2010, IEEE T MED IMAGING, V29, P1626, DOI 10.1109/TMI.2010.2045126	54	44	45	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2017	133	3					367	380		10.1007/s00401-017-1686-x			14	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	EL9ST	WOS:000394961100003	28214960				2022-02-06	
J	Sufrinko, AM; Mucha, A; Covassin, T; Marchetti, G; Elbin, RJ; Collins, MW; Kontos, AP				Sufrinko, Alicia M.; Mucha, Anne; Covassin, Tracey; Marchetti, Greg; Elbin, R. J.; Collins, Michael W.; Kontos, Anthony P.			Sex Differences in Vestibular/Ocular and Neurocognitive Outcomes After Sport-Related Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; adolescents; vestibular; ocular; sex differences	POSTURAL STABILITY; NEUROPSYCHOLOGICAL DEFICITS; HIGH-SCHOOL; BASE-LINE; SYMPTOMS; MANAGEMENT; BALANCE; SUSCEPTIBILITY; SPECIFICITY; SENSITIVITY	Objective:To examine sex differences in vestibular and oculomotor symptoms and impairment in athletes with sport-related concussion (SRC). The secondary purpose was to replicate previously reported sex differences in total concussion symptoms, and performance on neurocognitive and balance testing.Design:Prospective cross-sectional study of consecutively enrolled clinic patients within 21 days of a SRC.Setting:Specialty Concussion Clinic.Participants:Included male (n = 36) and female (n = 28) athletes ages 9 to 18 years.Interventions:Vestibular symptoms and impairment was measured with the Vestibular/Ocular Motor Screening (VOMS). Participants completed the Immediate Post-concussion Assessment and Cognitive Test (ImPACT), Post-concussion Symptom Scale (PCSS), and Balance Error Scoring System (BESS).Main Outcomes Measures:Sex differences on clinical measures.Results:Females had higher PCSS scores (P = 0.01) and greater VOMS vestibular ocular reflex (VOR) score (P = 0.01) compared with males. There were no sex differences on BESS or ImPACT. Total PCSS scores together with female sex accounted for 45% of the variance in VOR scores.Conclusions:Findings suggest higher VOR scores after SRC in female compared with male athletes. Findings did not extend to other components of the VOMS tool suggesting that sex differences may be specific to certain types of vestibular impairment after SRC. Additional research on the clinical significance of the current findings is needed.	[Sufrinko, Alicia M.; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA; [Mucha, Anne] UPMC, Centers Rehabil Serv, Pittsburgh, PA USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Marchetti, Greg] Duquesne Univ, Dept Phys Therapy, Pittsburgh, PA 15219 USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Fayetteville, AR 72701 USA		Kontos, AP (corresponding author), UPMC Ctr Sports Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders [1K01DC012332-01A1]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	Supported in part by a grant to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1).	Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Black FO, 2002, AM J OBSTET GYNECOL, V186, pS204, DOI 10.1067/mob.2002.122602; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Buse DC, 2013, HEADACHE, V53, P1278, DOI 10.1111/head.12150; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2013, SPORT PSYCHOL, V27, P372, DOI 10.1123/tsp.27.4.372; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2013, TRANSL STROKE RES, V4, P420, DOI 10.1007/s12975-012-0228-z; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P81, DOI 10.1017/S1355617713001288; Ferrari S, 2014, PSYCHOSOMATICS, V55, P280, DOI 10.1016/j.psym.2013.02.005; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Furman JM, 2010, CURR OPIN OTOLARYNGO, V18, P386, DOI 10.1097/MOO.0b013e32833ce5a6; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hammar ML, 1996, OBSTET GYNECOL, V88, P955; Helm MR, 2005, HEADACHE, V45, P332, DOI 10.1111/j.1526-4610.2005.05070.x; Hormones Haybach P., 2006, HORMONES, V3, P6; Jokerst MD, 1999, AVIAT SPACE ENVIR MD, V70, P962; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee AJY, 2007, J APPL BIOMECH, V23, P173, DOI 10.1123/jab.23.3.173; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mickle KJ, 2011, J SCI MED SPORT, V14, P243, DOI 10.1016/j.jsams.2010.11.002; Monzani D, 2001, J PSYCHOSOM RES, V50, P319, DOI 10.1016/S0022-3999(01)00208-2; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; von Brevern M., 2014, VESTIBULAR MIGRAINE, P83; Zhou GW, 2015, OTOLARYNG HEAD NECK, V152, P1133, DOI 10.1177/0194599815576720; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	36	44	44	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2017	27	2					133	138		10.1097/JSM.0000000000000324			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	EM8PJ	WOS:000395573100007	27379660	Green Accepted			2022-02-06	
J	Westerlind, E; Persson, HC; Sunnerhagen, KS				Westerlind, Emma; Persson, Hanna C.; Sunnerhagen, Katharina S.			Return to Work after a Stroke in Working Age Persons; A Six-Year Follow Up	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SICK LEAVE; HEALTH; SCALE; DISABILITY; BEHAVIOR; PEOPLE; EQ-5D; CARE	Objectives Stroke is one of the most common and resource intensive diseases for society. Stroke in the working age population is increasing in different parts of the world. An incomplete return to work (RTW) after sick leave post stroke entails negative consequences for the affected person and an economical burden for society. The aim of this study was to explore the RTW rate and factors associated with RTW in a six-year follow up post stroke. Methods Data from 174 persons 63 years or younger, with first ever stroke in 2009-2010 in Gothenburg were analyzed. Baseline characteristics were collected through medical records and the Swedish Health Insurance Office provided information on sick leave up to 6 years post stroke. Time-to-event was presented and cox regression as well as logistic regression were used to analyze risk factors for no-RTW. Results The RTW rate was 74.7%, at the end of follow up. Participants continued to RTW until just over 3 years post stroke. Dependency at discharge (in the modified Rankin Scale) and sick leave prior to the stroke were significant risk factors for no-RTW after 1 year with odds ratio 4.595 and 3.585, respectively. The same factors were significant in time-to-event within six years post stroke with hazard ratio 2.651 and 1.929, respectively. Conclusions RTW after a stroke is incomplete, however RTW is possible over a longer period of time than previously thought. More severe disability at discharge from hospital and sick leave prior to the stroke were shown to be risk factors for no-RTW. This knowledge can contribute to more individualized vocational rehabilitation.	[Westerlind, Emma; Persson, Hanna C.; Sunnerhagen, Katharina S.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden		Westerlind, E (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden.	westerlind.emma@gmail.com	Sunnerhagen, Katharina Stibrant/AAE-2405-2020; Westerlind, Emma/AAN-7227-2021	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400; 	Swedish Heart and Lung FoundationSwedish Heart-Lung Foundation; Swedish Brain Foundation	This study was funded in part by the Swedish Heart and Lung Foundation and the Swedish Brain Foundation.	Altman D.G., 1990, PRACTICAL STAT MED R; Anema JR, 2009, J OCCUP REHABIL, V19, P419, DOI 10.1007/s10926-009-9202-3; Ayis SA, 2013, J NEUROL NEUROSUR PS, V84, P604, DOI 10.1136/jnnp-2012-303525; Bonner B, 2016, EUR J NEUROL, V23, P548, DOI 10.1111/ene.12887; Burstrom K, 2014, QUAL LIFE RES, V23, P431, DOI 10.1007/s11136-013-0496-4; Busch MA, 2009, J NEUROL NEUROSUR PS, V80, P888, DOI 10.1136/jnnp.2008.163295; Chang WH, 2016, J REHABIL MED; Cioncoloni D, 2012, NEUROREHABILITATION, V30, P315, DOI 10.3233/NRE-2012-0761; Clayton S, 2012, EUR J PUBLIC HEALTH, V22, P434, DOI 10.1093/eurpub/ckr101; Cumming TB, 2010, CEREBROVASC DIS, V30, P7, DOI 10.1159/000313438; de Groot V, 2003, J CLIN EPIDEMIOL, V56, P221, DOI 10.1016/S0895-4356(02)00585-1; Endo M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009682; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Ghatnekar O, 2014, INT J TECHNOL ASSESS, V30, P203, DOI 10.1017/S0266462314000075; Hackett ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041795; Hannerz H, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000180; Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5; Larsen LP, 2016, J REHABIL MED, V48, P339, DOI 10.2340/16501977-2061; Larsson J, 2010, SCAND J PUBLIC HEALT, V38, P541, DOI 10.1177/1403494810371143; Maruthappu M, 2015, INT J STROKE, V10, P364, DOI 10.1111/ijs.12408; Medin J, 2007, BRAIN INJURY, V21, P457, DOI 10.1080/02699050701317643; Mishra NK, 2010, STROKE, V41, P2612, DOI 10.1161/STROKEAHA.110.589317; Nielsen MBD, 2015, EUR J PUBLIC HEALTH, V25, P96, DOI 10.1093/eurpub/cku016; Persson HC, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-162; Peters GO, 2013, DISABIL REHABIL, V35, P455, DOI 10.3109/09638288.2012.697251; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Riks-Stroke (the Swedish Stroke Register), 2015, ETT EFT STROK; Roding J, 2010, J REHABIL MED, V42, P155, DOI 10.2340/16501977-0497; Rosengren A, 2013, STROKE, V44, P2388, DOI 10.1161/STROKEAHA.113.001170; Singam A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144344; Stam M, 2013, WORK, V46, P207, DOI 10.3233/WOR-131747; Tanaka H, 2011, ARCH PHYS MED REHAB, V92, P743, DOI 10.1016/j.apmr.2010.12.009; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Treger I, 2007, DISABIL REHABIL, V29, P1397, DOI 10.1080/09638280701314923; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vestling M, 2003, J REHABIL MED, V35, P127, DOI 10.1080/16501970310010475; Vikholmen K, 2015, ACTA NEUROL SCAND, V132, P329, DOI 10.1111/ane.12404; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang YC, 2014, WORK, V47, P553, DOI 10.3233/WOR-131627; Wolfenden B, 2009, INT J REHABIL RES, V32, P93, DOI 10.1097/MRR.0b013e328325a358; Wozniak MA, 2002, NEUROEPIDEMIOLOGY, V21, P159, DOI 10.1159/000059516; Young FB, 2005, STROKE, V36, P2187, DOI 10.1161/01.STR.0000181089.41324.70	42	44	44	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2017	12	1							e0169759	10.1371/journal.pone.0169759			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EH3AX	WOS:000391641500135	28061507	gold, Green Submitted, Green Published			2022-02-06	
J	Barnard, E; Yates, D; Edwards, A; Fragoso-Iniguez, M; Jenks, T; Smith, JE				Barnard, Ed; Yates, David; Edwards, Antoinette; Fragoso-Iniguez, Marisol; Jenks, Tom; Smith, Jason E.			Epidemiology and aetiology of traumatic cardiac arrest in England and Wales - A retrospective database analysis	RESUSCITATION			English	Article						Trauma; Cardiac arrest; Traumatic cardiac arrest; Epidemiology	RESUSCITATION COUNCIL GUIDELINES; SPECIAL CIRCUMSTANCES; INJURY; ALGORITHM; OUTCOMES	Background: Historically, reported survival from traumatic cardiac arrest (TCA) was extremely low. More recent publications have recorded survival to discharge of up to 8%. This improvement is likely to be multi-factorial; however, there are currently no published data describing the epidemiology or aetiology of TCA in England and Wales to guide future practice improvement. Methods: Population-based analysis of 2009-2015 Trauma Audit and Research Network (TARN) data. The primary aim was to describe the 30-day survival following TCA. Patients of all ages with traumatic cardiac arrest pre-hospital or in the emergency department (ED) were included. Data are described as number (%), and median [interquartile range]. Two-group analysis with Chi-squared test was performed. Results: During the study period 227,944 patients were included in the TARN database. Seven hundred and five (0.3%) suffered TCA: 74.3% were male, aged 44.3 [25.2-83.2] years, ISS 29 [21-75], and 601 (85.2%) had blunt injuries. 612 (86.8%) had a severe traumatic brain injury and or severe haemorrhage. Overall 30-day survival was 7.5% (95%CI 5.6-9.5) 'pre-hospital only' TCA 11.5%, 'ED only' TCA 3.9%, p < 0.02. No patients who were in TCA both pre-hospital and in the ED survived. Conclusion: This study has shown that short-term survival from TCA in this large civilian registry is 7.5%. Early and aggressive management of patients with TCA, using protocols that target the reversible causes of TCA, should be initiated. Further work to establish novel ways to manage patients with reversible causes of TCA is indicated. Resuscitation in this patient group is not futile. Crown Copyright (C) 2016 Published by Elsevier Ireland Ltd. All rights reserved.	[Barnard, Ed] Inst Naval Med, Crescent Rd, Gosport PO12 2DL, Hants, England; [Barnard, Ed; Smith, Jason E.] Royal Ctr Def Med Res & Acad, Acad Dept Mil Emergency Med, Birmingham, W Midlands, England; [Yates, David; Edwards, Antoinette; Fragoso-Iniguez, Marisol; Jenks, Tom] Univ Manchester, Salford Royal NHS Fdn Trust, Trauma Audit & Res Network, Manchester, Lancs, England; [Smith, Jason E.] Derriford Hosp, Emergency Dept, Plymouth, Devon, England		Barnard, E (corresponding author), Inst Naval Med, Crescent Rd, Gosport PO12 2DL, Hants, England.	ukbarnard@gmail.com	Smith, Jason Edward/H-9380-2013	Smith, Jason Edward/0000-0002-6143-0421; Edwards, Antoinette/0000-0003-1427-0725			Barnard EBG, 2015, EMERG MED J, V32, P926, DOI 10.1136/emermed-2015-205217; Battistella FD, 1999, ARCH SURG-CHICAGO, V134, P742, DOI 10.1001/archsurg.134.7.742; Bodnar D, 2014, EMERG MED J, V31, P93, DOI 10.1136/emermed-2012-201969; Leis CC, 2013, J TRAUMA ACUTE CARE, V74, P634, DOI 10.1097/TA.0b013e31827d5d3c; Cureton EL, 2012, J TRAUMA ACUTE CARE, V73, P102, DOI 10.1097/TA.0b013e3182569ebc; Hayashi M, 2015, CIRC RES, V116, P1887, DOI 10.1161/CIRCRESAHA.116.304521; Huber-Wagner S, 2007, RESUSCITATION; HUSSAIN LM, 1994, BRIT MED J, V308, P1077, DOI 10.1136/bmj.308.6936.1077; Intercollegiate Board for Training in Pre-hospital Emergency Medicine, 2015, GUID SUBSP TRAIN; JENNETT B, 1975, LANCET, V1, P480; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Lockey D, 2006, ANN EMERG MED, V48, P240, DOI 10.1016/j.annemergmed.2006.03.015; Lockey DJ, 2013, RESUSCITATION, V84, P738, DOI 10.1016/j.resuscitation.2012.12.003; Morrison JJ, 2013, J TRAUMA ACUTE CARE, V74, P825, DOI 10.1097/TA.0b013e31827e1d26; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; Russell RJ, 2011, PHILOS T R SOC B, V366, P171, DOI 10.1098/rstb.2010.0232; Sherren PB, 2013, CRIT CARE, V17, DOI 10.1186/cc12504; SHIMAZU S, 1983, J TRAUMA, V23, P213, DOI 10.1097/00005373-198303000-00006; Smith JE, 2015, J ROY SOC MED, V108, P11, DOI 10.1177/0141076814560837; Soar J, 2010, RESUSCITATION, V81, P1400, DOI 10.1016/j.resuscitation.2010.08.015; Tarmey NT, 2011, RESUSCITATION, V82, P1194, DOI 10.1016/j.resuscitation.2011.04.018; Truhlar A, 2015, RESUSCITATION, V95, P148, DOI 10.1016/j.resuscitation.2015.07.017; Wang HC, 2014, BRAIN INJURY, V28, P1491, DOI 10.3109/02699052.2014.943288	23	44	44	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JAN	2017	110						90	94		10.1016/j.resuscitation.2016.11.001			5	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	EO0HX	WOS:000396380000021	27855275				2022-02-06	
J	Sun, LH; Perakyla, J; Holm, K; Haapasalo, J; Lehtimaki, K; Ogawa, KH; Peltola, J; Hartikainen, KM				Sun, Lihua; Perakyla, Jari; Holm, Katri; Haapasalo, Joonas; Lehtimaki, Kai; Ogawa, Keith H.; Peltola, Jukka; Hartikainen, Kaisa M.			Vagus nerve stimulation improves working memory performance	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Attention; Cognition; Executive functions; Frontal alpha asymmetry; Vagus nerve stimulation	TREATMENT-RESISTANT DEPRESSION; EMOTION-ATTENTION INTERACTION; ANTERIOR THALAMIC NUCLEI; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; SELECTIVE ATTENTION; LOCUS-COERULEUS; ALZHEIMERS-DISEASE; VAGAL-STIMULATION; PARTIAL SEIZURES	Vagus nerve stimulation (VNS) is used for treating refractory epilepsy and major depression. While the impact of this treatment on seizures has been established, its impact on human cognition remains equivocal. The goal of this study is to elucidate the immediate effects of vagus nerve stimulation on attention, cognition, and emotional reactivity in patients with epilepsy. Twenty patients (12 male and 8 female; 45 +/- 13years old) treated with VNS due to refractory epilepsy participated in the study. Subjects performed a computer-based test of executive functions embedded with emotional distractors while their brain activity was recorded with electroencephalography. Subjects' cognitive performance, early visual event-related potential N1, and frontal alpha asymmetry were studied when cyclic vagus nerve stimulation was on and when it was off. We found that vagus nerve stimulation improved working memory performance as seen in reduced errors on a subtask that relied on working memory, odds ratio (OR)=0.63 (95% confidence interval, CI [0.47, 0.85]) and increased N1 amplitude, F(1, 15)=10.17, p=.006. In addition, vagus nerve stimulation resulted in longer reaction time, F(1, 16)=8.23, p=.019, and greater frontal alpha asymmetry, F(1, 16)=11.79, p=.003, in response to threat-related distractors. This is the first study to show immediate improvement in working memory performance in humans with clinically relevant vagus nerve stimulation. Furthermore, vagus nerve stimulation had immediate effects on emotional reactivity evidenced in behavior and brain physiology.	[Sun, Lihua; Perakyla, Jari; Holm, Katri; Hartikainen, Kaisa M.] Tampere Univ Hosp, Behav Neurol Res Unit, Tampere, Finland; [Perakyla, Jari; Holm, Katri; Peltola, Jukka; Hartikainen, Kaisa M.] Univ Tampere, Fac Med & Life Sci, Tampere, Finland; [Haapasalo, Joonas; Lehtimaki, Kai; Peltola, Jukka] Tampere Univ Hosp, Dept Neurosci & Rehabil, Tampere, Finland; [Ogawa, Keith H.] St Marys Coll Calif, John Magaddino Neurosci Lab, Moraga, CA USA		Hartikainen, KM (corresponding author), Tampere Univ Hosp, Behav Neurol Res Unit, Tampere, Finland.	kaisa.hartikainen@uta.fi		Sun, Lihua/0000-0002-9931-9497; Hartikainen, Kaisa/0000-0001-7278-9635	Academy of FinlandAcademy of FinlandEuropean Commission; Competitive Research Fund of Pirkanmaa Hospital District	This work was supported by the Academy of Finland and the Competitive Research Fund of Pirkanmaa Hospital District.	Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; ASTONJONES G, 1991, PROG BRAIN RES, V88, P47; Awh E, 2006, NEUROSCIENCE, V139, P201, DOI 10.1016/j.neuroscience.2005.08.023; BENMENACHEM E, 1994, EPILEPSIA, V35, P616, DOI 10.1111/j.1528-1157.1994.tb02482.x; Bishop SJ, 2008, ANN NY ACAD SCI, V1129, P141, DOI 10.1196/annals.1417.016; Chamberlain SR, 2006, PSYCHOPHARMACOLOGY, V188, P397, DOI 10.1007/s00213-006-0391-6; CLARK KB, 1995, NEUROBIOL LEARN MEM, V63, P213, DOI 10.1006/nlme.1995.1024; Clark KB, 1999, NAT NEUROSCI, V2, P94, DOI 10.1038/4600; DALGLEISH T, 1990, CLIN PSYCHOL REV, V10, P589, DOI 10.1016/0272-7358(90)90098-U; Davidson R.J., 1995, CEREBRAL ASYMMETRY E, P361; Dodrill CB, 2001, EPILEPSY BEHAV, V2, P46, DOI 10.1006/ebeh.2000.0148; Elger G, 2000, EPILEPSY RES, V42, P203, DOI 10.1016/S0920-1211(00)00181-9; Goddard AW, 2010, DEPRESS ANXIETY, V27, P339, DOI 10.1002/da.20642; Grimonprez A, 2015, NEUROSCI BIOBEHAV R, V56, P26, DOI 10.1016/j.neubiorev.2015.06.019; Grimonprez A, 2015, J PSYCHIATR RES, V68, P1, DOI 10.1016/j.jpsychires.2015.05.002; Hartikainen KM, 2007, NEUROREPORT, V18, P1929, DOI 10.1097/WNR.0b013e3282f1ca18; Hartikainen KM, 2014, J CLIN EXP NEUROPSYC, V36, P540, DOI 10.1080/13803395.2014.913554; Hartikainen KM, 2012, NEUROREPORT, V23, P447, DOI 10.1097/WNR.0b013e3283531e74; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hartikainen KM, 2010, NEUROREPORT, V21, P344, DOI 10.1097/WNR.0b013e328336eeb3; Hartikainen KM, 2000, NEUROPSYCHOLOGIA, V38, P1576, DOI 10.1016/S0028-3932(00)00072-5; Hassert DL, 2004, BEHAV NEUROSCI, V118, P79, DOI 10.1037/0735-7044.118.1.79; Javed A, 2015, SEIZURE-EUR J EPILEP, V29, P34, DOI 10.1016/j.seizure.2015.03.013; KALIA M, 1982, J COMP NEUROL, V211, P248, DOI 10.1002/cne.902110304; Kindt M, 2001, J PSYCHOPATHOL BEHAV, V23, P193, DOI 10.1023/A:1010921405496; Klinkenberg S, 2012, CLIN NEUROL NEUROSUR, V114, P336, DOI 10.1016/j.clineuro.2011.11.016; Liimatainen J, 2016, INTERACT CARDIOV TH, V23, P630, DOI 10.1093/icvts/ivw170; Luck SJ, 1998, P NATL ACAD SCI USA, V95, P825, DOI 10.1073/pnas.95.3.825; MACLEOD C, 1988, Q J EXP PSYCHOL-A, V40, P653, DOI 10.1080/14640748808402292; Maki-Marttunen V, 2017, J NEUROTRAUM, V34, P400, DOI 10.1089/neu.2015.4390; Maki-Marttunen V, 2015, J NEUROTRAUM, V32, P272, DOI 10.1089/neu.2014.3557; Maki-Marttunen V, 2014, NEUROREPORT, V25, P1038, DOI 10.1097/WNR.0000000000000223; MANGUN GR, 1991, J EXP PSYCHOL HUMAN, V17, P1057, DOI 10.1037/0096-1523.17.4.1057; Marangell LB, 2002, BIOL PSYCHIAT, V51, P280, DOI 10.1016/S0006-3223(01)01343-9; McGlone J, 2008, CAN J NEUROL SCI, V35, P287, DOI 10.1017/S0317167100008854; Merrill CA, 2006, J CLIN PSYCHIAT, V67, P1171, DOI 10.4088/JCP.v67n0801; O'Dell TJ, 2015, LEARN MEMORY, V22, P461, DOI 10.1101/lm.031088.113; PENRY JK, 1990, EPILEPSIA, V31, pS40, DOI 10.1111/j.1528-1157.1990.tb05848.x; Perez-Edgar K, 2013, BRAIN COGNITION, V82, P337, DOI 10.1016/j.bandc.2013.05.009; Raedt R, 2011, J NEUROCHEM, V117, P461, DOI 10.1111/j.1471-4159.2011.07214.x; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Rush AJ, 2000, BIOL PSYCHIAT, V47, P276, DOI 10.1016/S0006-3223(99)00304-2; Sackeim HA, 2001, NEUROPSY NEUROPSY BE, V14, P53; Sackeim HA, 2001, NEUROPSYCHOPHARMACOL, V25, P713, DOI 10.1016/S0893-133X(01)00271-8; Sjogren MJC, 2002, J CLIN PSYCHIAT, V63, P972, DOI 10.4088/JCP.v63n1103; Sun LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149525; Sun LH, 2015, NEUROPSYCHOLOGIA, V78, P88, DOI 10.1016/j.neuropsychologia.2015.10.001; Van Bockstaele EJ, 1999, J COMP NEUROL, V412, P410, DOI 10.1002/(SICI)1096-9861(19990927)412:3<410::AID-CNE3>3.0.CO;2-F; van Stegeren AH, 2008, ACTA PSYCHOL, V127, P532, DOI 10.1016/j.actpsy.2007.10.004; Vonck K, 2014, NEUROSCI BIOBEHAV R, V45, P63, DOI 10.1016/j.neubiorev.2014.05.005; Vuilleumier P, 2001, NEUROREPORT, V12, P1119, DOI 10.1097/00001756-200105080-00014	51	44	46	2	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2017	39	10					954	964		10.1080/13803395.2017.1285869			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	FN2VJ	WOS:000415853000004	28492363				2022-02-06	
J	Gerson, J; Castillo-Carranza, DL; Sengupta, U; Bodani, R; Prough, DS; DeWitt, DS; Hawkins, BE; Kayed, R				Gerson, Julia; Castillo-Carranza, Diana L.; Sengupta, Urmi; Bodani, Riddhi; Prough, Donald S.; DeWitt, Douglas S.; Hawkins, Bridget E.; Kayed, Rakez			Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice	JOURNAL OF NEUROTRAUMA			English	Article						neurodegeneration; tau oligomers; traumatic brain injury	ALZHEIMERS-DISEASE; ENDOGENOUS TAU; HEAD-INJURY; MODEL; BLAST; RAT; NEURODEGENERATION; EPIDEMIOLOGY; AGGREGATION; PROPAGATION	Tau aggregation is a pathological feature of numerous neurodegenerative disorders and has also been shown to occur under certain conditions of traumatic brain injury (TBI). Currently, no effective treatments exist for the long-term effects of TBI. In some cases, TBI not only induces cognitive changes immediately post-injury, but also leads to increased incidence of neurodegeneration later in life. Growing evidence from our lab and others suggests that the oligomeric forms of tau initiate the onset and spread of neurodegenerative tauopathies. Previously, we have shown increased levels of brain-derived tau oligomers in autopsy samples from patients diagnosed with Alzheimer's disease. We have also shown similar increases in tau oligomers in animal models of neurodegenerative diseases and TBI. In the current study, we evaluated the presence of tau oligomers in blast-induced TBI. To test the direct impact of TBI-derived tau oligomer toxicity, we isolated tau oligomers from brains of rats that underwent either a blast-or a fluid percussion injury-induced TBI. Oligomers were characterized biochemically and morphologically and were then injected into hippocampi of mice overexpressing human tau (Htau). Mice were cognitively evaluated and brains were collected for immunological analysis after testing. We found that tau oligomers form as a result of brain injury in two different models of TBI. Additionally, these oligomers accelerated onset of cognitive deficits when injected into brains of Htau mice. Tau oligomer levels increased in the hippocampal injection sites and cerebellum, suggesting that tau oligomers may be responsible for seeding the spread of pathology post-TBI. Our results suggest that tau oligomers play an important role in the toxicity underlying TBI and may be a viable therapeutic target.	[Gerson, Julia; Castillo-Carranza, Diana L.; Sengupta, Urmi; Bodani, Riddhi; Kayed, Rakez] Univ Texas Med Branch, Mitchell Ctr Neurodegenerat Dis, 301 Univ Blvd,Med Res Bldg,Room 10-138C, Galveston, TX 77555 USA; [Gerson, Julia; Castillo-Carranza, Diana L.; Sengupta, Urmi; Bodani, Riddhi; Kayed, Rakez] Univ Texas Med Branch, Dept Neurol, Galveston, TX 77555 USA; [Gerson, Julia; Castillo-Carranza, Diana L.; Sengupta, Urmi; Bodani, Riddhi; Kayed, Rakez] Univ Texas Med Branch, Dept Neurosci, Galveston, TX 77555 USA; [Gerson, Julia; Castillo-Carranza, Diana L.; Sengupta, Urmi; Bodani, Riddhi; Kayed, Rakez] Univ Texas Med Branch, Dept Cell Biol, Galveston, TX 77555 USA; [Prough, Donald S.; DeWitt, Douglas S.; Hawkins, Bridget E.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Hawkins, Bridget E.; Kayed, Rakez] Univ Texas Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA; [Prough, Donald S.; DeWitt, Douglas S.; Hawkins, Bridget E.; Kayed, Rakez] Univ Texas Med Branch, Dept Anesthesiol, Moody Project Translat Traumat Brain Injury Res, Galveston, TX 77555 USA		Kayed, R (corresponding author), Univ Texas Med Branch, Mitchell Ctr Neurodegenerat Dis, 301 Univ Blvd,Med Res Bldg,Room 10-138C, Galveston, TX 77555 USA.	rakayed@utmb.edu	Prough, Donald S/G-5793-2013; Gerson, Julia/L-3275-2019; Hawkins, Bridget/H-4933-2015	Prough, Donald S/0000-0001-7994-532X; Hawkins, Bridget/0000-0002-1887-3657; Castillo-Carranza, Diana/0000-0003-2511-949X	Mitchell Center for Neurodegenerative Disease; Sealy Center for Vaccine Development; Darrell K. Royal Research Fund for Alzheimer's Disease; Institute for Rehabilitation and Research/Mission Connect; Moody Project for Translational Traumatic Brain Injury Research	This work was supported, in part, by the Mitchell Center for Neurodegenerative Disease, the Sealy Center for Vaccine Development, Darrell K. Royal Research Fund for Alzheimer's Disease, and the Institute for Rehabilitation and Research/Mission Connect. Additionally, these studies were completed as part of an interdisciplinary research team funded by The Moody Project for Translational Traumatic Brain Injury Research. The authors thank Prof. Giulio Taglialatela and Prof. Yogesh Wairkar for their valuable assistance with this project.	Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Castillo-Carranza DL, 2014, J ALZHEIMERS DIS, V40, pS97, DOI 10.3233/JAD-132477; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; FRIEDLANDER FG, 1946, PROC R SOC LON SER-A, V186, P322, DOI 10.1098/rspa.1946.0046; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gerson JE, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-73; Gerson JE, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00093; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lasagna-Reeves CA, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-56; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Lasagna-Reeves CA, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-39; Lasagna-Reeves CA, 2010, BIOCHEMISTRY-US, V49, P10039, DOI 10.1021/bi1016233; Liliang PC, 2010, RESUSCITATION, V81, P1205, DOI 10.1016/j.resuscitation.2010.05.016; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Maeda S, 2006, NEUROSCI RES, V54, P197, DOI 10.1016/j.neures.2005.11.009; Maeda S, 2007, BIOCHEMISTRY-US, V46, P3856, DOI 10.1021/bi061359o; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; Patterson KR, 2011, J BIOL CHEM, V286, P23063, DOI 10.1074/jbc.M111.237974; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Sengupta U, 2015, BIOL PSYCHIAT, V78, P672, DOI 10.1016/j.biopsych.2014.12.019; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thruman D., 1999, JAMA-J AM MED ASSOC, V282, P954; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Wu JW, 2013, J BIOL CHEM, V288, P1856, DOI 10.1074/jbc.M112.394528	49	44	44	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2016	33	22					2034	2043		10.1089/neu.2015.4262			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EC4OL	WOS:000388112300007	26729399	Green Published			2022-02-06	
J	Pischiutta, F; Brunelli, L; Romele, P; Silini, A; Sammali, E; Paracchini, L; Marchini, S; Talamini, L; Bigini, P; Boncoraglio, GB; Pastorelli, R; De Simoni, MG; Parolini, O; Zanier, ER				Pischiutta, Francesca; Brunelli, Laura; Romele, Pietro; Silini, Antonietta; Sammali, Eliana; Paracchini, Lara; Marchini, Sergio; Talamini, Laura; Bigini, Paolo; Boncoraglio, Giorgio B.; Pastorelli, Roberta; De Simoni, Maria-Grazia; Parolini, Ornella; Zanier, Elisa R.			Protection of Brain Injury by Amniotic Mesenchymal Stromal Cell-Secreted Metabolites	CRITICAL CARE MEDICINE			English	Article						brain protection; human amniotic mesenchymal stromal cells; metabolites; secretome; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; ALPHA-AMINOADIPIC ACID; MEMBRANE-DERIVED CELLS; STEM-CELLS; BONE-MARROW; CONDITIONED MEDIUM; FUNCTIONAL RECOVERY; INDUCED NEURODEGENERATION; KYNURENINE PATHWAY; EFFECTOR FUNCTIONS	Objectives: To define the features of human amniotic mesenchymal stromal cell secretome and its protective properties in experimental models of acute brain injury. Design: Prospective experimental study. Setting: Laboratory research. Subjects: C57Bl/6 mice. Interventions: Mice subjected to sham or traumatic brain injury by controlled cortical impact received human amniotic mesenchymal stromal cells or phosphate-buffered saline infused intracerebroventricularly or intravenously 24 hours after injury. Organotypic cortical brain slices exposed to ischemic injury by oxygen-glucose deprivation were treated with human amniotic mesenchymal stromal cells or with their secretome (conditioned medium) in a transwell system. Measurements and Main Results: Traumatic brain injured mice receiving human amniotic mesenchymal stromal cells intravenously or intracerebroventricularly showed early and lasting functional and anatomical brain protection. cortical slices injured by oxigen-glucose deprivation and treated with human amniotic mesenchymal stromal cells or conditioned medium showed comparable protective effects (neuronal rescue, promotion of M2 microglia polarization, induction of trophic factors) indicating that the exposure of human amniotic mesenchymal stromal cells to the injured tissue is not necessary for the release of bioactive factors. Using sequential size-exclusion and gel-filtration chromatography, we identified a conditioned medium subfraction, which specifically displays these highly protective properties and we found that this fraction was rich in bioactive molecules with molecular weight smaller than 700 Da. Quantitative RNA analysis and mass spectrometry-based peptidomics showed that the active factors are not proteins or RNAs. The metabolomic profiling of six metabolic classes identified a list of molecules whose abundance was selectively elevated in the active conditioned medium fraction. Conclusions: Human amniotic mesenchymal stromal cell-secreted factors protect the brain after acute injury. Importantly, a fraction rich in metabolites, and containing neither proteic nor ribonucleic molecules was protective. This study indicates the profiling of protective factors that could be useful in cell-free therapeutic approaches for acute brain injury.	[Pischiutta, Francesca; Sammali, Eliana; De Simoni, Maria-Grazia; Zanier, Elisa R.] IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy; [Brunelli, Laura; Pastorelli, Roberta] IRCCS Ist Ric Farmacol Mario Negri, Dept Environm Hlth Sci, Milan, Italy; [Romele, Pietro; Silini, Antonietta; Parolini, Ornella] Fdn Poliambulanza, Ist Osped, Ctr Ric E Menni, Brescia, Italy; [Sammali, Eliana; Boncoraglio, Giorgio B.] Fdn IRCCS, Ist Neurol Carlo Besta, Dept Cerebrovasc Dis, Milan, Italy; [Paracchini, Lara; Marchini, Sergio] IRCCS Ist Ric Farmacol Mario Negri, Dept Oncol, Milan, Italy; [Talamini, Laura; Bigini, Paolo] IRCCS Ist Ric Farmacol Mario Negri, Dept Biochem, Milan, Italy		Zanier, ER (corresponding author), IRCCS Ist Ric Farmacol Mario Negri, Dept Neurosci, Milan, Italy.	elisa.zanier@marionegri.it	De Simoni, Maria Grazia/I-6021-2012; Romele, Pietro/AAC-1911-2022; Pastorelli, Roberta/AAA-6736-2020; PAROLINI, ORNELLA/C-7946-2013; PAROLINI, ORNELLA/ABI-7862-2020; Pischiutta, Francesca/AAA-7927-2020; Paracchini, Lara/AAH-4149-2021; Marchini, sergio/J-3968-2018; Sammali, Eliana/AAA-2464-2019; Brunelli, Laura/J-8664-2018; Zanier, Elisa/AAA-8095-2020; Bigini, Paolo/AAB-2901-2020; Boncoraglio, Giorgio Battista/B-8647-2011; Silini, Antonietta Rosa/K-7638-2016	De Simoni, Maria Grazia/0000-0001-6695-5297; Romele, Pietro/0000-0003-0721-3300; Pastorelli, Roberta/0000-0001-5097-600X; PAROLINI, ORNELLA/0000-0002-5211-6430; PAROLINI, ORNELLA/0000-0002-5211-6430; Pischiutta, Francesca/0000-0002-7151-0812; Paracchini, Lara/0000-0003-1832-5471; Marchini, sergio/0000-0003-1783-7651; Brunelli, Laura/0000-0002-5465-9586; Zanier, Elisa/0000-0002-3011-8718; Bigini, Paolo/0000-0002-0239-9532; Boncoraglio, Giorgio Battista/0000-0002-2551-525X; Silini, Antonietta Rosa/0000-0001-6208-3583; Talamini, Laura/0000-0001-6010-2947	Competitiveness Regional Operational Programme of the European Regional Development Fund (ROP ERDF) of the Lombardy Region (ROP ERDF-Progetto NUTEC-NUoveTECnologie) [30263049]; Societa Italiana di Farmacologia, SIF-MSD Italia; Fondazione Umberto Veronesi (FUV)Fondazione Umberto Veronesi	Supported, in part, by Competitiveness Regional Operational Programme of the European Regional Development Fund (ROP ERDF) 2007-2013 of the Lombardy Region (ROP ERDF-Progetto NUTEC-NUoveTECnologie-ID:n.30263049).; Dr. Pischiutta received a fellowship by "Societa Italiana di Farmacologia, SIF-MSD Italia." Dr. Brunelli received a fellowship from Fondazione Umberto Veronesi (FUV2014-2015). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Acosta SA, 2015, STROKE, V46, P2616, DOI 10.1161/STROKEAHA.115.009854; Adibhatla RM, 2002, BRAIN RES, V938, P81, DOI 10.1016/S0006-8993(02)02447-2; Ajmo CT, 2008, J NEUROSCI RES, V86, P2227, DOI 10.1002/jnr.21661; Amori L, 2009, J NEUROCHEM, V109, P316, DOI 10.1111/j.1471-4159.2009.05893.x; Antonucci I, 2012, CURR PHARM DESIGN, V18, P1846, DOI 10.2174/138161212799859602; Baglio SR, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00359; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Cargnoni A, 2014, CYTOTHERAPY, V16, P17, DOI 10.1016/j.jcyt.2013.07.002; Cargnoni A, 2012, CYTOTHERAPY, V14, P153, DOI 10.3109/14653249.2011.613930; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Chen JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115316; Chen ZY, 2009, J NEUROTRAUM, V26, P1987, DOI 10.1089/neu.2008.0863; Chuang TJ, 2012, J TRAUMA ACUTE CARE, V73, P1161, DOI 10.1097/TA.0b013e318265d128; Clark EA, 2014, STEM CELLS, V32, P1074, DOI 10.1002/stem.1623; de Girolamo L, 2013, CURR PHARM DESIGN, V19, P2459, DOI 10.2174/1381612811319130015; Dela Pena I, 2014, J NEUROSURG SCI, V58, P145; Deng-Bryant Y, 2015, RESTOR NEUROL NEUROS, V33, P189, DOI 10.3233/RNN-140455; Deng-Bryant Y, 2012, J TRAUMA ACUTE CARE, V73, pS156, DOI 10.1097/TA.0b013e3182625f5f; Dossi E, 2013, CEREB CORTEX, V23, P2905, DOI 10.1093/cercor/bhs275; Drago D, 2013, BIOCHIMIE, V95, P2271, DOI 10.1016/j.biochi.2013.06.020; Fierabracci A, 2015, EXPERT OPIN BIOL TH, V15, P613, DOI 10.1517/14712598.2015.1000856; Gesuete R, 2011, STROKE, V42, P1445, DOI 10.1161/STROKEAHA.110.603266; Gibb SL, 2015, STEM CELLS, V33, P3530, DOI 10.1002/stem.2189; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Groh ME, 2005, EXP HEMATOL, V33, P928, DOI 10.1016/j.exphem.2005.05.002; Guidetti P, 2003, MOL BRAIN RES, V118, P132, DOI 10.1016/j.molbrainres.2003.08.004; Gutierrez-Fernandez M, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt159; HALL JG, 1977, J PHYSIOL-LONDON, V272, pP52; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Hegyi B, 2014, STEM CELLS DEV, V23, P2600, DOI 10.1089/scd.2014.0088; HUCK S, 1984, NEUROSCIENCE, V12, P783, DOI 10.1016/0306-4522(84)90170-2; Hung SC, 2007, STEM CELLS, V25, P2363, DOI 10.1634/stemcells.2006-0686; Johnson TV, 2014, BRAIN, V137, P503, DOI 10.1093/brain/awt292; KATO S, 1990, NEUROSCIENCE, V36, P145, DOI 10.1016/0306-4522(90)90357-A; Kondoh T, 2010, FRONT INTEGR NEUROSC, V4, DOI 10.3389/fnint.2010.00018; Kumar A., 2015, J NEUROTRAUMA; Lakshmipathy U, 2008, STEM CELLS, V26, P356, DOI 10.1634/stemcells.2007-0625; Li F, 2012, MOL MED REP, V6, P625, DOI 10.3892/mmr.2012.968; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709; Lovaas E, 1997, Adv Pharmacol, V38, P119; Magatti M, 2015, MESENCHYMAL STEM CEL, P233; Magatti M, 2008, STEM CELLS, V26, P182, DOI 10.1634/stemcells.2007-0491; Magatti M, 2015, CELL TRANSPLANT, V24, P1733, DOI 10.3727/096368914X684033; Magatti M, 2012, J CELL MOL MED, V16, P2208, DOI 10.1111/j.1582-4934.2012.01531.x; Magatti M, 2009, CELL TRANSPLANT, V18, P899, DOI 10.3727/096368909X471314; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Menzie J, 2013, BRAIN SCI, V3, P877, DOI 10.3390/brainsci3020877; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Nakano N, 2010, NEUROSCI LETT, V483, P57, DOI 10.1016/j.neulet.2010.07.062; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Offner H, 2012, TRANSL STROKE RES, V3, P324, DOI 10.1007/s12975-012-0187-4; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Ooi YY, 2015, NEUROIMMUNOMODULAT, V22, P233, DOI 10.1159/000365483; Parolini O, 2014, ARTHRITIS RHEUMATOL, V66, P327, DOI 10.1002/art.38206; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Pianta S, 2015, STEM CELL REV REP, V11, P394, DOI 10.1007/s12015-014-9558-4; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Rossi D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046956; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tao J, 2012, BRAIN RES, V1448, P1, DOI 10.1016/j.brainres.2012.01.069; Teixeira FG, 2013, CELL MOL LIFE SCI, V70, P3871, DOI 10.1007/s00018-013-1290-8; Tsai MJ, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-5; Vecsei L, 2013, NAT REV DRUG DISCOV, V12, P64, DOI 10.1038/nrd3793; Vendrame M, 2005, STEM CELLS DEV, V14, P595, DOI 10.1089/scd.2005.14.595; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Verderio Claudia, 2013, Front Physiol, V4, P163, DOI 10.3389/fphys.2013.00163; Wakabayashi K, 2010, J NEUROSCI RES, V88, P1017, DOI 10.1002/jnr.22279; WAKAKURA M, 1992, DOC OPHTHALMOL, V80, P385, DOI 10.1007/BF00154389; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yan EB, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0328-2; Yan ZJ, 2013, NEUROCHEM RES, V38, P1022, DOI 10.1007/s11064-013-1012-5; Yoo SW, 2008, EXP MOL MED, V40, P387, DOI 10.3858/emm.2008.40.4.387; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zahedi K, 2010, J NEUROTRAUM, V27, P515, DOI 10.1089/neu.2009.1097; Zanier ER, 2016, J NEUROTRAUM, V33, P1060, DOI 10.1089/neu.2015.4041; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	89	44	45	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2016	44	11					E1118	E1131		10.1097/CCM.0000000000001864			14	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU1ZL	WOS:000400824800012	27441900				2022-02-06	
J	Lynall, RC; Clark, MD; Grand, EE; Stucker, JC; Littleton, AC; Aguilar, AJ; Petschauer, MA; Teel, EF; Mihalik, JP				Lynall, Robert C.; Clark, Michael D.; Grand, Erin E.; Stucker, Jaclyn C.; Littleton, Ashley C.; Aguilar, Alain J.; Petschauer, Meredith A.; Teel, Elizabeth F.; Mihalik, Jason P.			Head Impact Biomechanics in Women's College Soccer	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; FOOTBALL; SPORTS INJURY; INJURY PREVENTION; SPORTS SAFETY	SPORTS-RELATED CONCUSSION; FOOTBALL PLAYERS; ACCELERATION MEASUREMENT; CLINICAL MEASURES; KINEMATICS; HISTORY; BRAIN; BALL	Introduction: There are limited nonlaboratory soccer head impact biomechanics data. This is surprising given soccer's global popularity. Epidemiological data suggest that female college soccer players are at a greater concussion injury risk than their male counterparts. Therefore, the purposes of our study were to quantify head impact frequency and magnitude during women's soccer practices and games in the National Collegiate Athletic Association and to characterize these data across event type, playing position, year on the team, and segment of game (first and second halves). Methods: Head impact biomechanics were collected from female college soccer players (n = 22; mean+/-SD age = 19.1+/-0.1 yr, height = 168.0+/-3.5 cm, mass = 63.7+/-6.0 kg). We employed a helmetless head impact measurement device (X2 Biosystems xPatch) before each competition and practice across a single season. Peak linear and rotational accelerations were categorized based on impact magnitude and subsequently analyzed using appropriate nonparametric analyses. Results: Overall, women's college soccer players experience approximately seven impacts per 90 min of game play. The overwhelming majority (similar to 90 %) of all head impacts were categorized into our mildest linear acceleration impact classification (10g-20g). Interestingly, a higher percentage of practice impacts in the 20g-40g range compared with games (11% vs 7%) was observed. Conclusion: Head impact biomechanics studies have provided valuable insights into understanding collision sports and for informing evidence-based rule and policy changes. These have included changing the football kickoff, ice hockey body checking ages, and head-to-head hits in both sports. Given soccer's global popularity, and the growing public concern for the potential long-term neurological implications of collision and contact sports, studying soccer has the potential to impact many athletes and the sports medicine professionals caring for them.	[Lynall, Robert C.; Clark, Michael D.; Grand, Erin E.; Stucker, Jaclyn C.; Teel, Elizabeth F.; Mihalik, Jason P.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Lynall, Robert C.; Clark, Michael D.; Teel, Elizabeth F.; Mihalik, Jason P.] Univ North Carolina Chapel Hill, Dept Allied Hlth Sci, Human Movement Sci Curriculum, Chapel Hill, NC USA; [Littleton, Ashley C.] Towson Univ, Dept Kinesiol, Towson, MD USA; [Aguilar, Alain J.; Petschauer, Meredith A.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, Chapel Hill, NC USA		Mihalik, JP (corresponding author), 2201 Stallings Evans Sports Med Ctr, Campus Box 8700, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu	Lynall, Robert/M-2888-2014	Lynall, Robert/0000-0002-0785-6640; Clark, Michael/0000-0002-5019-0290; Teel, Elizabeth/0000-0002-2846-5884	Princeton UniversityPrinceton University; National Operating Committee on Standards for Athletic Equipment (NOCSAE)	The authors acknowledge Dr. Margot Putukian (Princeton University) for her assistance with funding. This work was indirectly supported with funding by the National Operating Committee on Standards for Athletic Equipment (NOCSAE). The opinions expressed herein are those of the authors and do not necessarily reflect the opinions of the committee.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Dezman ZDW, 2013, SPORTS HEALTH, V5, P320, DOI 10.1177/1941738113480935; Dorminy M, 2015, BRAIN INJURY, V29, P1158, DOI 10.3109/02699052.2015.1035324; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Gutierrez GM, 2014, PEDIATR EXERC SCI, V26, P33, DOI 10.1123/pes.2013-0102; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Harpham JA, 2014, ANN BIOMED ENG, V42, P1, DOI 10.1007/s10439-013-0881-8; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Meehan WP, 2016, J NEUROTRAUM, V33, P254, DOI 10.1089/neu.2015.3930; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; National Federation of State High School Associations, 2015, PART STAT; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	34	44	43	0	56	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	SEP	2016	48	9					1772	1778		10.1249/MSS.0000000000000951			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DU5NX	WOS:000382259600017	27187102				2022-02-06	
J	Posti, JP; Takala, RSK; Runtti, H; Newcombe, VF; Outtrim, J; Katila, AJ; Frantzen, J; Ala-Seppala, H; Coles, JP; Hossain, MI; Kyllonen, A; Maanpaa, HR; Tallus, J; Hutchinson, PJ; van Gils, M; Menon, DK; Tenovuo, O				Posti, Jussi P.; Takala, Riikka S. K.; Runtti, Hilkka; Newcombe, Virginia F.; Outtrim, Joanne; Katila, Ari J.; Frantzen, Janek; Ala-Seppala, Henna; Coles, Jonathan P.; Hossain, Md. Iftakher; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi; Hutchinson, Peter J.; van Gils, Mark; Menon, David K.; Tenovuo, Olli		TBIcare Investigators	The Levels of Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 During the First Week After a Traumatic Brain Injury: Correlations With Clinical and Imaging Findings	NEUROSURGERY			English	Article						Biomarker; GFAP; Severity; Traumatic brain injury; UCH-L1	GLASGOW COMA SCALE; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; SERUM-LEVELS; BIOMARKERS; MILD; GFAP	BACKGROUND: Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) are promising biomarkers of traumatic brain injury (TBI). OBJECTIVE: We investigated the relation of the GFAP and UCH-L1 levels to the severity of TBI during the first week after injury. METHODS: Plasma UCH-L1 and GFAP were measured from 324 consecutive patients with acute TBI and 81 control subject enrolled in a 2-center prospective study. The baseline measures included initial Glasgow Coma Scale (GCS), head computed tomographic (CT) scan at admission, and blood samples for protein biomarkers that were collected at admission and on days 1, 2, 3, and 7 after injury. RESULTS: Plasma levels of GFAP and UCH-L1 during the first 2 days after the injury strongly correlated with the initial severity of TBI as assessed with GCS. Additionally, levels of UCH-L1 on the seventh day after the injury were significantly related to the admission GCS scores. At admission, both biomarkers were capable of distinguishing mass lesions from diffuse injuries in CT, and the area under the curve of the receiver-operating characteristic curve for prediction of any pathological finding in CT was 0.739 (95% confidence interval, 0.636-0.815) and 0.621 (95% confidence interval, 0.517-0.713) for GFAP and UCH-L1, respectively. CONCLUSION: These results support the prior findings of the potential role of GFAP and UCH-L1 in acute-phase diagnostics of TBI. The novel finding is that levels of GFAP and UCH-L1 correlated with the initial severity of TBI during the first 2 days after the injury, thus enabling a window for TBI diagnostics with latency.	[Posti, Jussi P.; Frantzen, Janek] Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, POB 52, FI-20521 Turku, Finland; [Posti, Jussi P.; Frantzen, Janek; Tenovuo, Olli] Turku Univ Hosp, Dept Rehabil & Brain Trauma, Div Clin Neurosci, Turku, Finland; [Posti, Jussi P.; Ala-Seppala, Henna; Hossain, Md. Iftakher; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi] Univ Turku, Dept Neurol, Turku, Finland; [Takala, Riikka S. K.; Katila, Ari J.] Turku Univ Hosp, Perioperat Serv, Intens Care Med & Pain Management, Turku, Finland; [Takala, Riikka S. K.; Katila, Ari J.] Univ Turku, Turku, Finland; [Runtti, Hilkka; van Gils, Mark] VTT Tech Res Ctr Finland, Syst Med, Tampere, Finland; [Newcombe, Virginia F.; Outtrim, Joanne; Menon, David K.; Tenovuo, Olli] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Dept Med, Cambridge, England; [Coles, Jonathan P.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Neurosurg Unit, Dept Clin Neurosci, Cambridge, England		Posti, JP (corresponding author), Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, POB 52, FI-20521 Turku, Finland.	jussi.posti@utu.fi	Posti, Jussi P./Y-2908-2019	Posti, Jussi P./0000-0002-5925-5193; Newcombe, Virginia/0000-0001-6044-9035; van Gils, Mark/0000-0002-0029-1771; Liedes, Hilkka/0000-0003-4655-7675; Coles, Jonathan/0000-0003-4013-679X; Ala-Seppala, Henna/0000-0002-1577-3028; Hossain, Iftakher/0000-0003-4836-1158	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [FP7-270259-TBIcare]; EVO; Maire Taponen Foundation; Skulle Implants Ltd.; AbbottAbbott Laboratories; Fresenius-Kabi; UCBUCB Pharma SA; PfizerPfizer; NIHR Research Professorship; NIHR Cambridge BRC; Orion Corp.; Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090, ACF-2009-14-007] Funding Source: researchfish	This work was partially funded by the European Commission under the 7th Framework Programme (FP7-270259-TBIcare). Dr Posti has received personal EVO funding and a grant from Maire Taponen Foundation and financial support in form of a congress fee and travel expenses paid by Skulle Implants Ltd. Dr Takala has received speaker fees from Abbott, Fresenius-Kabi, and UCB and conference funding from Pfizer. Dr Takala is a stockholder in Orion. Dr Newcombe has a Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship. Dr Frantzen is chief medical officer at Skulle Implants Ltd. Dr Hutchinson is a director of Technicam and is supported by an NIHR Research Professorship and the NIHR Cambridge BRC. Dr Tenovuo has received speaker fees from Orion Corp. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Majdan M, 2015, J NEUROTRAUM, V32, P101, DOI 10.1089/neu.2014.3438; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McMahon PJ, 2014, J NEUROTRAUM, V32, P527; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Takala RSK, 2015, WORLD NEUROSURG; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000	22	44	46	1	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2016	79	3					456	463		10.1227/NEU.0000000000001226			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DV9PX	WOS:000383274400030	26963330				2022-02-06	
J	Logsdon, AE; Lucke-Wold, BP; Nguyen, L; Matsumoto, RR; Turner, RC; Rosen, CL; Huber, JD				Logsdon, Aric E.; Lucke-Wold, Brandon P.; Nguyen, Linda; Matsumoto, Rae R.; Turner, Ryan C.; Rosen, Charles L.; Huber, Jason D.			Salubrinal reduces oxidative stress, neuroinflammation and impulsive-like behavior in a rodent model of traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Oxidative stress; Endoplasmic reticulum stress; Neuroinflammation; Impulsive-like behavior	ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; IMPROVES FUNCTIONAL RECOVERY; NADPH-OXIDASE; MOUSE MODEL; ER STRESS; SIGNALING PATHWAYS; ACTIVATION; INHIBITION; JNK	Traumatic brain injury (TBI) is the leading cause of trauma related morbidity in the developed world. TBI has been shown to trigger secondary injury cascades including endoplasmic reticulum (ER) stress, oxidative stress, and neuroinflammation. The link between secondary injury cascades and behavioral outcome following TBI is poorly understood warranting further investigation. Using our validated rodent blast TBI model, we examined the interaction of secondary injury cascades following single injury and how these interactions may contribute to impulsive-like behavior after a clinically relevant repetitive TBI paradigm. We targeted these secondary pathways acutely following single injury with the cellular stress modulator, salubrinal (SAL). We examined the neuroprotective effects of SAL administration on significantly reducing ER stress: janus-N-terminal kinase (JNK) phosphorylation and C/EBP homology protein (CHOP), oxidative stress: superoxide and carbonyls, and neuroinflammation: nuclear factor kappa beta (NF kappa B) activity, inducible nitric oxide synthase (iNOS) protein expression, and pro-inflammatory cytokines at 24 h post-TBI. We then used the more clinically relevant repeat injury paradigm and observed elevated NF kappa B and iNOS activity. These injury cascades were associated with impulsive-like behavior measured on the elevated plus maze. SAL administration attenuated secondary iNOS activity at 72 h following repetitive TBI, and most importantly prevented impulsive-like behavior. Overall, these results suggest a link between secondary injury cascades and impulsive-like behavior that can be modulated by SAL administration. (c) 2016 Elsevier B.V. All rights reserved.	[Logsdon, Aric E.; Nguyen, Linda; Huber, Jason D.] W Virginia Univ, Dept Pharmaceut Sci, Sch Pharm, Hlth Sci Ctr, One Med Ctr Dr, Morgantown, WV 26506 USA; [Logsdon, Aric E.; Lucke-Wold, Brandon P.; Turner, Ryan C.; Rosen, Charles L.; Huber, Jason D.] W Virginia Univ, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA; [Matsumoto, Rae R.] Touro Univ Calif, Deans Off, Coll Pharm, Vallejo, CA USA; [Logsdon, Aric E.; Lucke-Wold, Brandon P.; Turner, Ryan C.; Rosen, Charles L.; Huber, Jason D.] W Virginia Univ, Centers Neurosci, Sch Med, Morgantown, WV 26506 USA		Huber, JD (corresponding author), W Virginia Univ, Dept Pharmaceut Sci, Sch Pharm, Hlth Sci Ctr, One Med Ctr Dr, Morgantown, WV 26506 USA.	alogsdol@mix.wvu.edu; bwold@mix.wvu.edu; Inguyenl@mix.wvu.edu; rae.matsumoto@tu.edu; rcturner@hsc.wvu.edu; crosen@hsc.wvu.edu; jdhuber@hsc.wvu.edu	Lucke-Wold, Brandon/AAW-1881-2021; Lucke-Wold, Brandon/AAW-3525-2021; Nguyen, Linda/AAQ-1755-2021	Lucke-Wold, Brandon/0000-0001-6577-4080; Turner, Ryan/0000-0001-5523-0645	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 RR016550, P30 RR032138/GM103488, P20 RR016477]; West Virginia University Health Sciences Center Office of Research and Graduate Education; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32GM08174]; American Foundation of Pharmaceutical Education; American Medical Association Foundation Seed Grant; Neurosurgery Research AMP; Education Foundation Medical Student Summer Research Fellowship; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016455, P20RR016477, P30RR032138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM081740, U54GM104942, P30GM103488] Funding Source: NIH RePORTER	We thank Dr. James P. O'Callaghan and Dr. Diane B. Miller of the Center for Disease Control (CDC) and the National Institute for Occupational Safety and Health (NIOSH). We appreciate guidance of Dr. James W. Simpkins during manuscript preparation (Director of Stroke Center). The authors acknowledge the assistance with animal work done by Xinlan Li (Dept. of Neurosurgery). The authors acknowledge the technical assistance performed by Kelly E. Smith. The authors are grateful for the assistance of Dr. Robert T.T. Gettens and Nicholas St. John of Western New England University for their help with design of the blast model and Mr. Peter Bennett and Mr. James Edward Robson for model construction. Imaging experiments and image analysis were performed in the West Virginia University Microscope Imaging Facility, which has been supported by the National Institutes of Health (NIH) Grants P20 RR016550, P30 RR032138/GM103488 and P20 RR016477. This work was supported by a Research Funding and Development (RFDG) grant from the West Virginia University Health Sciences Center Office of Research and Graduate Education (to JDH and CLR), a training grant from the NIH (to RCT) (5T32GM08174), and an American Foundation of Pharmaceutical Education pre-doctoral fellowship (to AFL and BPL). An American Medical Association Foundation Seed Grant and Neurosurgery Research & Education Foundation Medical Student Summer Research Fellowship was awarded (to BPL).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Abdul-Muneer PM, 2014, MOL NEUROBIOL; Abdullah Z, 2014, MOL CELL NEUROSCI, V61, P72, DOI 10.1016/j.mcn.2014.06.002; Adhikari A, 2011, NEURON, V71, P898, DOI 10.1016/j.neuron.2011.07.027; Ansari MA, 2014, FREE RADICAL BIO MED, V77, P21, DOI 10.1016/j.freeradbiomed.2014.08.025; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Banks SJ, 2014, J NEUROPSYCH CLIN N, V26, P44, DOI 10.1176/appi.neuropsych.12070185; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Bellezza I, 2014, INT J BIOCHEM CELL B, V51, P159, DOI 10.1016/j.biocel.2014.03.023; Bidzan L, 2012, MED SCI MONITOR, V18, pCR182, DOI 10.12659/MSM.882523; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Bracchi-Ricard V, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-92; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Colla E, 2012, J NEUROSCI, V32, P3306, DOI 10.1523/JNEUROSCI.5367-11.2012; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Damjanac M, 2007, BRAIN RES, V1128, P40, DOI 10.1016/j.brainres.2006.05.050; Dash P. K., 2015, J NEUROTRAUMA; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Deslauriers AM, 2011, J IMMUNOL, V187, P4788, DOI 10.4049/jimmunol.1004111; Faden A. I., 2015, BR J PHARM; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fenn AM, 2015, J NEUROTRAUM, V32, P127, DOI 10.1089/neu.2014.3514; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Hayashi T, 2015, PSYCHIAT CLIN NEUROS, V69, P179, DOI 10.1111/pcn.12262; Hong Y, 2016, INT IMMUNOPHARMACOL, V33, P83, DOI 10.1016/j.intimp.2016.02.002; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Hsieh YH, 2007, BIOCHEM BIOPH RES CO, V359, P643, DOI 10.1016/j.bbrc.2007.05.154; Hu YC, 2014, INFLAMM RES, V63, P109, DOI 10.1007/s00011-013-0677-1; Huang X., 2012, NEUROBIOL AGING, V33, pe1009; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Johnson EM, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00044; Kumar R. G., 2014, BRAIN BEHAV IMMUN; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Liu HD, 2013, NEUROL SCI, V34, P1173, DOI 10.1007/s10072-012-1214-7; Liu Y, 2014, CAN J CARDIOL, V30, P368, DOI 10.1016/j.cjca.2013.11.001; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Logsdon AF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00421; Lucke-Wold B.P., 2014, J NEUROTRAUMA; Lucke-Wold B. P., 2014, MOL NEUROBIOL; Lucke-Wold BP, 2015, TRANSL RES, V166, P509, DOI 10.1016/j.trsl.2015.08.005; Lucke-Wold BP, 2016, J NEUROSURG, V124, P687, DOI 10.3171/2015.3.JNS141802; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; Mar AC, 2011, J NEUROSCI, V31, P6398, DOI 10.1523/JNEUROSCI.6620-10.2011; Uranga RM, 2009, TOXICOL SCI, V111, P331, DOI 10.1093/toxsci/kfp152; Michael A. P., 2015, J NEUROTRAUMA; Mosienko V, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.44; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Nisenbaum EJ, 2014, J NEUROTRAUM, V31, P301, DOI 10.1089/neu.2013.3102; Ohri SS, 2013, NEUROBIOL DIS, V58, P29, DOI 10.1016/j.nbd.2013.04.021; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Prell T, 2014, J NEUROIMMUNOL, V270, P29, DOI 10.1016/j.jneuroim.2014.03.005; Quan X., 2015, BIOCH BIOPHYS RES CO; Rebetez MML, 2015, BRAIN INJURY, V29, P1175, DOI 10.3109/02699052.2015.1035326; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Ruan J, 2015, BIOCHEM BIOPH RES CO, V456, P122, DOI 10.1016/j.bbrc.2014.11.045; Rubovitch V, 2015, NEUROMOL MED, V17, P58, DOI 10.1007/s12017-015-8340-3; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Sominsky L, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00201; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; Toklu HZ, 2015, BRAIN NEUROTRAUMA MO; Tsai KH, 2012, J CELL PHYSIOL, V227, P1347, DOI 10.1002/jcp.22847; Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Wu LL, 2014, LIFE SCI, V110, P44, DOI 10.1016/j.lfs.2014.06.020; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	84	44	45	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 15	2016	1643						140	151		10.1016/j.brainres.2016.04.063			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DP4EE	WOS:000378448200015	27131989	Green Accepted			2022-02-06	
J	Chamard, E; Lefebvre, G; Lassonde, M; Theoret, H				Chamard, Emilie; Lefebvre, Genevieve; Lassonde, Maryse; Theoret, Hugo			Long-Term Abnormalities in the Corpus Callosum of Female Concussed Athletes	JOURNAL OF NEUROTRAUMA			English	Article						athletes; corpus callosum; diffusion tensor imaging; female; sports concussion	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; DIFFUSIVITY MEASURES; AXONAL INJURY; MILD; MOTOR; TRACTOGRAPHY; GENDER	Concussion is an injury affecting millions of individuals annually that can be associated with long-term sequelae. Recent studies have reported long-term abnormalities in the white matter (WM) tracts of male athletes. The corpus callosum (CC) and corticospinal tract (CST) have been shown to be particularly vulnerable to concussion, which may be related to abnormal interhemispheric functional connectivity and motor impairments. These anatomical pathways, however, have not been investigated in female athletes despite the functional significance of the CC and CST to adequate sports performance. In the present study, 8 healthy, unconcussed female athletes (soccer, hockey) were compared with 10 female athletes (soccer, hockey, water polo) 6 months post-concussion. Diffusion tensor imaging (DTI) of the CC and CST was conducted in a 3T magnetic resonance imaging (MRI) scanner. DTI analysis showed no significant differences between groups within the CST but revealed differences between groups in the CC. The concussed group had lower mean diffusivity (t = 2.14; p = 0.048) and lower radial diffusivity (t = 2.91; p = 0.010) in the region of the CC projecting to the prefrontal cortex. A lower volume of WM fibers was found in the region projecting to the premotor and supplementary motor areas (t = 2.14; p = 0.048). Finally, lower axial diffusivity (AD) was observed in the CC area projecting mainly to the parietal and temporal area (t = 2.23; p = 0.041). Long-term alterations in the CC of female athletes appear to affect mostly the anterior part of the CC projecting to the prefrontal and premotor areas. Further studies are needed to determine whether these alterations are associated with a higher risk of sustaining a subsequent concussive injury.	[Chamard, Emilie; Lefebvre, Genevieve; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Lassonde, Maryse; Theoret, Hugo] CHU St Justine, Ctr Rech, Montreal, PQ, Canada		Theoret, H (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit CERNEC, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	hugo.theoret@umontreal.ca		Theoret, Hugo/0000-0002-7458-8797	CIHRCanadian Institutes of Health Research (CIHR) Funding Source: Medline		Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Avants B., 2009, ADV NORMALIZATION TO; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barr M., 2005, HUMAN NERVOUS SYSTEM; Bear M.F., 2007, NEUROSCIENCE EXPLORI; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Chamard E, 2016, J NEUROTRAUM, V33, P1220, DOI 10.1089/neu.2015.3948; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chamberland M, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00059; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; Descoteaux M, 2008, LECT NOTES COMPUT SC, V5242, P122, DOI 10.1007/978-3-540-85990-1_15; Echemendia R., 2006, SPORTS NEUROPSYCHOLO; Ennis DB, 2006, MAGN RESON MED, V55, P136, DOI 10.1002/mrm.20741; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Garyfallidis E, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00008; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gooijers J, 2014, NEUROSCI BIOBEHAV R, V43, P1, DOI 10.1016/j.neubiorev.2014.03.008; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harsan LA, 2006, J NEUROSCI RES, V83, P392, DOI 10.1002/jnr.20742; Henry LC, 2014, PROG NEUROL SURG, V28, P63, DOI 10.1159/000358763; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Herweh Christian, 2016, NEURORADIOLOGY; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Major BP, 2015, CLIN EXP PHARMACOL P, V42, P394, DOI 10.1111/1440-1681.12363; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2008, ACTA NEUROCHIR SUPPL, V102, P247, DOI 10.1007/978-3-211-85578-2_47; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Pinel J., 2013, BIOPSYCHOLOGY; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sponheim S. R., 2011, NEUROIMAGE, P1; Toga A.W., 2002, BRAIN MAPPING METHOD, Vsecond; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; Wassermann D, 2013, LECT NOTES COMPUT SC, V8149, P647, DOI 10.1007/978-3-642-40811-3_81; Whittingstall K, 2014, CORTEX, V56, P85, DOI 10.1016/j.cortex.2013.02.004; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	61	44	45	1	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2016	33	13					1220	+		10.1089/neu.2015.3948			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DP2QY	WOS:000378336200388	26414496				2022-02-06	
J	Ercole, A; Thelin, EP; Holst, A; Bellander, BM; Nelson, DW				Ercole, A.; Thelin, E. P.; Holst, A.; Bellander, B. M.; Nelson, D. W.			Kinetic modelling of serum S100b after traumatic brain injury	BMC NEUROLOGY			English	Article						S100b protein; Human; Traumatic brain injury; Biomarkers; Kinetics	PROGNOSTIC BIOMARKER; CEREBROSPINAL-FLUID; PROTEIN; BLOOD; MARKER; S-100B; RELEASE; DAMAGE; HEAD; IMMUNOASSAY	Background: An understanding of the kinetics of a biomarker is essential to its interpretation. Despite this, little kinetic modelling of blood biomarkers can be found in the literature. S100b is an astrocyte related marker of brain injury used primarily in traumatic brain injury (TBI). Serum levels are expected to be the net result of a multi-compartmental process. The optimal sample times for TBI prognostication, and to follow injury development, are unclear. The purpose of this study was to develop a kinetic model to characterise the temporal course of serum S100b concentration after primary traumatic brain injury. Methods: Data of serial serum S100b samples from 154 traumatic brain injury patients in a neurointensive care unit were retrospectively analysed, including only patients without secondary peaks of this biomarker. Additionally, extra-cranial S100b can confound samples earlier than 12 h after trauma and were therefore excluded. A hierarchical, Bayesian gamma variate kinetic model was constructed and the parameters estimated by Markov chain Monte Carlo sampling. Results: We demonstrated that S100b concentration changes dramatically over timescales that are clinically important for early prognostication with a peak at 27.2 h (95 % credible interval [25.6, 28.8]). Baseline S100b levels was found to be 0.11 mu g/L (95 % credible interval [0.10, 0.12]). Conclusions: Even small differences in injury to sample time may lead to marked changes in S100b during the first days after injury. This must be taken into account in interpretation. The model offers a way to predict the peak and trajectory of S100b from 12 h post trauma in TBI patients, and to identify deviations from this, possibly indicating a secondary event. Kinetic modelling, providing an equation for the peak and projection, may offer a way to reduce the ambiguity in interpretation of, in time, randomly sampled acute biomarkers and may be generally applicable to biomarkers with, in time, well defined hits.	[Ercole, A.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Thelin, E. P.; Bellander, B. M.] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden; [Holst, A.] KTH Royal Inst Technol, Sch Comp Sci & Commun, Stockholm, Sweden; [Nelson, D. W.] Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, Stockholm, Sweden		Nelson, DW (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, Stockholm, Sweden.	david.nelson@karolinska.se	Ercole, Ari/B-6288-2009; Thelin, Eric Peter/K-2144-2012	Ercole, Ari/0000-0001-8350-8093; Thelin, Eric Peter/0000-0002-2338-4364; Nelson, David/0000-0003-2530-8207	Stockholm City Council; Swedish Institute of Computer Science; SICS; Karolinska InstituteKarolinska Institutet	AE would like to acknowledge the assistance of Carmen Lopez-Soto in preparing the data for initial evaluation. DN would like to acknowledge the assistance of Gunilla Malmborg-Bornhall for maintenance of the Karolinska traumatic injury database. The study was financed in part the Stockholm City Council (ET, BMB), Swedish Institute of Computer Science, SICS (AH) and the Karolinska Institute (DN).	Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Carpenter KLH, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00026; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; DAVENPORT R, 1983, J NUCL MED, V24, P945; Development Core Team R, 2008, R LANG ENV STAT COMP; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Martenson ED, 2001, J CLIN ONCOL, V19, P824, DOI 10.1200/JCO.2001.19.3.824; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Mussack T, 2006, CLIN BIOCHEM, V39, P349, DOI 10.1016/j.clinbiochem.2005.12.007; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Plummer M., 2003, P 3 INT WORKSH DISTR, P1; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; SHANNON CE, 1949, P IRE, V37, P10, DOI 10.1109/JRPROC.1949.232969; SHEPPARD C W, 1954, Minn Med, V37, P93; Smit LHM, 2005, INT J BIOL MARKER, V20, P34, DOI 10.1177/172460080502000106; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; USUI A, 1989, CLIN CHEM, V35, P1942; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127	36	44	45	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	JUN 17	2016	16								93	10.1186/s12883-016-0614-3			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO8PN	WOS:000378045700001	27315805	Green Published, gold			2022-02-06	
J	Nakae, R; Takayama, Y; Kuwamoto, K; Naoe, Y; Sato, H; Yokota, H				Nakae, Ryuta; Takayama, Yasuhiro; Kuwamoto, Kentaro; Naoe, Yasutaka; Sato, Hidetaka; Yokota, Hiroyuki			Time Course of Coagulation and Fibrinolytic Parameters in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						coagulopathy; D-dimer; fibrinolysis; prognosis; traumatic brain injury	SEVERE HEAD-INJURY; ACTIVATED FACTOR-VII; HEMOSTATIC ABNORMALITIES; INTRACRANIAL HEMORRHAGE; D-DIMER; COAGULOPATHY; PROGRESSION; TALK; COMA; DETERIORATE	Traumatic brain injury (TBI) has long been associated with coagulopathy; however, the time course of coagulation/fibrinolytic parameters in the acute phase of TBI remains unclear. The purpose of the study was to analyze the time course of coagulation/fibrinolytic parameters in the acute phase of TBI and to elucidate parameter relationships to prognosis. We retrospectively evaluated 234 patients with severe isolated TBI with initial blood samples obtained no more than 1 h after injury. Platelet count, prothrombin time, activated partial thromboplastin time (aPTT), plasma levels of fibrinogen, and D-dimer were measured on arrival in the emergency department and 3, 6, and 12 h after injury. Multivariate logistic regression analysis was performed to identify risk factors for poor prognosis at each time point. From hospital admission to 12 h after injury, an elevated D-dimer level was a significant negative prognostic indicator (admission: p < 0.0001; 3 h after injury: p = 0.0005; 6 h after injury: p = 0.005; 12 h after injury: p = 0.0009). An upward trend of aPTT on admission and 3 h after injury was also a significant negative prognostic indicator (admission: p = 0.0011; 3 h after injury: p = 0.013). On multivariate logistic regression analysis, which included all initial variables, independent risk factors for poor prognosis included older age (p = 0.0005), low Glasgow Coma Scale score (p < 0.0001), high Abbreviated Injury Score (p = 0.015), aPTT >30.2 sec (p = 0.019), and elevated D-dimer level (p = 0.0005). We concluded that D-dimer is the best coagulation/fibrinolytic parameter to monitor for prediction of outcome.	[Nakae, Ryuta; Naoe, Yasutaka] Kawaguchi Municipal Med Ctr, Emergency & Crit Care Ctr, 180 Nishiaraijuku, Kawaguchi, Saitama 3330833, Japan; [Takayama, Yasuhiro; Kuwamoto, Kentaro; Sato, Hidetaka; Yokota, Hiroyuki] Nippon Med Sch, Dept Emergency & Crit Care Med, 1-1-5 Sendagi, Tokyo 113, Japan		Nakae, R (corresponding author), Kawaguchi Municipal Med Ctr, Emergency & Crit Care Ctr, 180 Nishiaraijuku, Kawaguchi, Saitama 3330833, Japan.	nakae@nms.ac.jp		Nakae, Ryuta/0000-0003-1820-2463			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; *ASS ADV AUT MED, 1998, ABBR INJ SCAL AIS 19; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; ClinicalTrials. gov, PREH TRAN AC US TRAU; CRASH 2 trial collaborators, 2011, BMJ-BRIT MED J, V343, pd3795; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Goldschlager T, 2007, J CLIN NEUROSCI, V14, P618, DOI 10.1016/j.jocn.2006.02.018; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JAMJOOM A, 1992, Acta Neurochirurgica, V115, P86, DOI 10.1007/BF01406363; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241; KARIO K, 1991, THROMB RES, V62, P501, DOI 10.1016/0049-3848(91)90023-P; KARIO K, 1993, ATHEROSCLEROSIS, V103, P131, DOI 10.1016/0021-9150(93)90256-T; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; MacCallum PK, 2000, THROMB HAEMOSTASIS, V83, P421; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; MARI D, 1995, BLOOD, V85, P3144, DOI 10.1182/blood.V85.11.3144.bloodjournal85113144; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; May AK, 1997, AM SURGEON, V63, P233; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Morenski JD, 2003, J NEUROSURG, V98, P611, DOI 10.3171/jns.2003.98.3.0611; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; PHONPRASERT C, 1980, J TRAUMA, V20, P679, DOI 10.1097/00005373-198008000-00008; Ratanalert S, 2002, J CLIN NEUROSCI, V9, P640, DOI 10.1054/jocn.2002.1085; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Shigemori M, 2012, NEUROL MED-CHIR, V52, P1; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Sun YR, 2011, BRIT J NEUROSURG, V25, P363, DOI 10.3109/02688697.2011.552650; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; WINTER JP, 1989, ANN EMERG MED, V18, P553, DOI 10.1016/S0196-0644(89)80842-X; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929	60	44	45	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2016	33	7					688	695		10.1089/neu.2015.4039			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DI6QK	WOS:000373624700008	26414158				2022-02-06	
J	Boccia, M; D'Amico, S; Bianchini, F; Marano, A; Giannini, AM; Piccardi, L				Boccia, Maddalena; D'Amico, Simonetta; Bianchini, Filippo; Marano, Assunta; Giannini, Anna Maria; Piccardi, Laura			Different neural modifications underpin PTSD after different traumatic events: an fMRI meta-analytic study	BRAIN IMAGING AND BEHAVIOR			English	Article						PTSD; fMRI; ALE meta-analysis	POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD SEXUAL-ABUSE; SCRIPT-DRIVEN IMAGERY; FUNCTIONAL CONNECTIVITY; HIPPOCAMPAL VOLUME; AUTOBIOGRAPHICAL MEMORY; DISSOCIATIVE RESPONSES; NEUROCIRCUITRY MODELS; SYMPTOM PROVOCATION; DECLARATIVE MEMORY	Post-traumatic stress disorder (PTSD) is an anxiety condition that can develop after exposure to trauma such as physical or sexual assault, injury, combat-related trauma, natural disaster or death. Although an increasing number of neurobiological studies carried out over the past 20 years have allowed clarifying the neural substrate of PTSD, the neural modifications underpinning PTSD are still unclear. Here we used activation likelihood estimation meta-analysis (ALE) to determine whether PTSD has a consistent neural substrate. We also explored the possibility that different traumatic events produce different alterations in the PTSD neural network. In neuroimaging studies of PTSD, we found evidence of a consistent neural network including the bilateral insula and cingulate cortex as well as the parietal, frontal and limbic areas. We also found that specific networks of brain areas underpin PTSD after different traumatic events and that these networks may be related to specific aspects of the traumatic events. We discuss our results in light of the functional segregation of the brain areas involved in PTSD.	[Boccia, Maddalena; Bianchini, Filippo; Piccardi, Laura] IRCCS Fdn Santa Lucia Rome, Neuropsychol Unit, Rome, Italy; [Boccia, Maddalena; Bianchini, Filippo; Giannini, Anna Maria] Univ Roma La Sapienza, Dept Psychol, Via Marsi 78, I-00185 Rome, Italy; [D'Amico, Simonetta; Marano, Assunta; Piccardi, Laura] Univ Aquila, Dept Life Hlth & Environm Sci, I-67100 Laquila, Italy		Boccia, M (corresponding author), IRCCS Fdn Santa Lucia Rome, Neuropsychol Unit, Rome, Italy.; Boccia, M (corresponding author), Univ Roma La Sapienza, Dept Psychol, Via Marsi 78, I-00185 Rome, Italy.	maddalena.boccia@uniroma1.it	Boccia, Maddalena/I-4575-2018; GIANNINI, Anna Maria/AAE-5896-2021; Piccardi, laura/AAC-7587-2022	Boccia, Maddalena/0000-0002-2044-8326; Piccardi, Laura/0000-0002-1322-5538; D'AMICO, SIMONETTA/0000-0002-4418-4978	Italian Association of Psychology (AIP); ANIA Foundation	This research was supported by a grant from the Italian Association of Psychology (AIP) to the Faculty of Psychology, University of L'Aquila, after the earthquake of April 6, 2009 and ANIA Foundation.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Boccia M, 2014, NEUROPSYCHOL REV, V24, P236, DOI 10.1007/s11065-014-9247-8; Bohbot VD, 2007, HIPPOCAMPUS, V17, P863, DOI 10.1002/hipo.20313; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Bremner JD, 2003, BIOL PSYCHIAT, V53, P879, DOI 10.1016/S0006-3223(02)01891-7; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Britton JC, 2005, BIOL PSYCHIAT, V57, P832, DOI 10.1016/j.biopsych.2004.12.025; Bustamante V, 2001, J TRAUMA STRESS, V14, P791, DOI 10.1023/A:1013050423901; Chen SL, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-39; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Critchley HD, 2005, J COMP NEUROL, V493, P154, DOI 10.1002/cne.20749; Damasio A., 1999, FEELING WHAT HAPPENS; Ditlevsen DN, 2012, ANN GEN PSYCHIATR, V11, DOI 10.1186/1744-859X-11-26; Eickhoff SB, 2009, HUM BRAIN MAPP, V30, P2907, DOI 10.1002/hbm.20718; EKMAN P, 1993, AM PSYCHOL, V48, P384, DOI 10.1037/0003-066X.48.4.384; Elzinga BM, 2002, J AFFECT DISORDERS, V70, P1, DOI 10.1016/S0165-0327(01)00351-2; Epstein RA, 2012, NEUROPSYCHOLOGIA, V50, P530, DOI 10.1016/j.neuropsychologia.2011.09.042; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Etkin A, 2006, NEURON, V51, P871, DOI 10.1016/j.neuron.2006.07.029; Falconer E, 2008, J PSYCHIATR NEUROSCI, V33, P413; Fox PT, 2014, ANNU REV NEUROSCI, V37, P409, DOI 10.1146/annurev-neuro-062012-170320; Geuze E, 2007, ARCH GEN PSYCHIAT, V64, P76, DOI 10.1001/archpsyc.64.1.76; Gil T., 1990, J TRAUMA STRESS, V3, P29, DOI DOI 10.1002/JTS.2490030104; Gilbertson MW, 2001, J TRAUMA STRESS, V14, P413, DOI 10.1023/A:1011181305501; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Gurvits TV, 2002, PSYCHIAT RES, V112, P263, DOI 10.1016/S0165-1781(02)00234-2; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P500, DOI 10.1037/0022-006X.66.3.500; Hassabis D, 2007, TRENDS COGN SCI, V11, P299, DOI 10.1016/j.tics.2007.05.001; Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9; Herry C, 2010, EUR J NEUROSCI, V31, P599, DOI 10.1111/j.1460-9568.2010.07101.x; Hopper JW, 2007, J TRAUMA STRESS, V20, P713, DOI 10.1002/jts.20284; Hou CL, 2007, BRAIN RES, V1144, P165, DOI 10.1016/j.brainres.2007.01.089; Husarewycz MN, 2014, GEN HOSP PSYCHIAT, V36, P26, DOI 10.1016/j.genhosppsych.2013.06.003; Jenkins MA, 2000, CLIN NEUROPSYCHOL, V14, P7, DOI 10.1076/1385-4046(200002)14:1;1-8;FT007; Kalisch R, 2005, J COGNITIVE NEUROSCI, V17, P874, DOI 10.1162/0898929054021184; Kandel E.R., 1991, PRINCIPLES NEURAL SC, V3rd ed.; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kitayama N, 2005, J AFFECT DISORDERS, V88, P79, DOI 10.1016/j.jad.2005.05.014; Koenen KC, 2001, BRAIN COGNITION, V45, P64, DOI 10.1006/brcg.2000.1256; Lanius RA, 2002, BIOL PSYCHIAT, V52, P305, DOI 10.1016/S0006-3223(02)01367-7; Lanius RA, 2005, BIOL PSYCHIAT, V57, P873, DOI 10.1016/j.biopsych.2005.01.011; Lanius RA, 2004, AM J PSYCHIAT, V161, P36, DOI 10.1176/appi.ajp.161.1.36; Lanius RA, 2003, BIOL PSYCHIAT, V53, P204, DOI 10.1016/S0006-3223(02)01466-X; Lanius RA, 2007, PSYCHIAT RES-NEUROIM, V155, P45, DOI 10.1016/j.pscychresns.2006.11.006; Mazza M, 2012, BRAIN IMAGING BEHAV, V6, P374, DOI 10.1007/s11682-012-9151-x; MCNALLY RJ, 1995, BEHAV RES THER, V33, P619, DOI 10.1016/0005-7967(95)00007-K; Milad MR, 2012, ANNU REV PSYCHOL, V63, P129, DOI 10.1146/annurev.psych.121208.131631; Milner B, 2005, PSYCHIAT CLIN N AM, V28, P599, DOI 10.1016/j.psc.2005.06.002; Misra G, 2014, CEREB CORTEX; Morey RA, 2008, PSYCHIAT RES-NEUROIM, V162, P59, DOI 10.1016/j.pscychresns.2007.07.007; Morrow BA, 1999, NEUROSCIENCE, V92, P553, DOI 10.1016/S0306-4522(99)00014-7; Moscovitch M, 2005, J ANAT, V207, P35, DOI 10.1111/j.1469-7580.2005.00421.x; Moscovitch M, 2006, CURR OPIN NEUROBIOL, V16, P179, DOI 10.1016/j.conb.2006.03.013; Patel R, 2012, NEUROSCI BIOBEHAV R, V36, P2130, DOI 10.1016/j.neubiorev.2012.06.003; Perrin M, 2013, SOC PSYCHIAT PSYCHIA; Pissiota A, 2002, EUR ARCH PSY CLIN N, V252, P68, DOI 10.1007/s004060200014; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Polak A. R., 2012, BMC PSYCHIAT, V12; Portas CM, 1998, J NEUROSCI, V18, P8979; Protopopescu X, 2005, BIOL PSYCHIAT, V57, P464, DOI 10.1016/j.biopsych.2004.12.026; Rabinak Christine A, 2011, Front Psychiatry, V2, P62, DOI 10.3389/fpsyt.2011.00062; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SAM, 2012, J REHABIL RES DEV, V49, P679, DOI 10.1682/JRRD.2011.08.0152; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Robinson JL, 2010, HUM BRAIN MAPP, V31, P173, DOI 10.1002/hbm.20854; Sakamoto H, 2005, NEUROIMAGE, V26, P813, DOI 10.1016/j.neuroimage.2005.02.032; Santiago PN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059236; Shaw ME, 2002, NEUROIMAGE, V15, P661, DOI 10.1006/nimg.2001.1024; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; Shin LM, 1999, AM J PSYCHIAT, V156, P575; Shin LM, 2004, HIPPOCAMPUS, V14, P292, DOI 10.1002/hipo.10183; Shin LM, 1997, ARCH GEN PSYCHIAT, V54, P233; Simmons AN, 2008, BIOL PSYCHIAT, V64, P681, DOI 10.1016/j.biopsych.2008.05.027; Simmons AN, 2011, BIOL MOOD ANXIETY DI, V1, DOI 10.1186/2045-5380-1-6; Smith ME, 2005, HIPPOCAMPUS, V15, P798, DOI 10.1002/hipo.20102; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Sullivan K, 2003, J PSYCHOPATHOL BEHAV, V25, P95, DOI 10.1023/A:1023342915425; Taylor SF, 2003, NEUROIMAGE, V18, P650, DOI 10.1016/S1053-8119(02)00051-4; Vann SD, 2009, NAT REV NEUROSCI, V10, P792, DOI 10.1038/nrn2733; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Vincent JL, 2006, J NEUROPHYSIOL, V96, P3517, DOI 10.1152/jn.00048.2006; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704	87	44	44	2	23	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	MAR	2016	10	1					226	237		10.1007/s11682-015-9387-3			12	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO5NJ	WOS:000377829500024	25913645				2022-02-06	
J	Miller, DR; Hayes, JP; Lafleche, G; Salat, DH; Verfaellie, M				Miller, Danielle R.; Hayes, Jasmeet P.; Lafleche, Ginette; Salat, David H.; Verfaellie, Mieke			White Matter Abnormalities are Associated With Chronic Postconcussion Symptoms in Blast-Related Mild Traumatic Brain Injury	HUMAN BRAIN MAPPING			English	Article						diffusion tensor imaging; OEF/OIF; PTSD; loss of consciousness	POSTTRAUMATIC-STRESS-DISORDER; HIPPOCAMPAL VOLUME; WAR VETERANS; HEAD-INJURY; COMBAT; CONCUSSION; IRAQ; PTSD; PERSISTENT; AFGHANISTAN	Blast-related mild traumatic brain injury (mTBI) is a common injury among Iraq and Afghanistan military veterans due to the frequent use of improvised explosive devices. A significant minority of individuals with mTBI report chronic postconcussion symptoms (PCS), which include physical, emotional, and cognitive complaints. However, chronic PCS are nonspecific and are also associated with mental health disorders such as posttraumatic stress disorder (PTSD). Identifying the mechanisms that contribute to chronic PCS is particularly challenging in blast-related mTBI, where the incidence of comorbid PTSD is high. In this study, we examined whether blast-related mTBI is associated with diffuse white matter changes, and whether these neural changes are associated with chronic PCS. Ninety Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans were assigned to one of three groups including a blast-exposed no - TBI group, a blast-related mTBI without loss of consciousness (LOC) group (mTBI - LOC), and a blast-related mTBI with LOC group (mTBI + LOC). PCS were measured with the Rivermead Postconcussion Questionnaire. Results showed that participants in the mTBI + LOC group had more spatially heterogeneous white matter abnormalities than those in the no - TBI group. These white matter abnormalities were significantly associated with physical PCS severity even after accounting for PTSD symptoms, but not with cognitive or emotional PCS severity. A mediation analysis revealed that mTBI + LOC significantly influenced physical PCS severity through its effect on white matter integrity. These results suggest that white matter abnormalities are associated with chronic PCS independent of PTSD symptom severity and that these abnormalities are an important mechanism explaining the relationship between mTBI and chronic physical PCS. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.	[Miller, Danielle R.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Miller, Danielle R.; Lafleche, Ginette; Verfaellie, Mieke] VA Boston Healthcare Syst, Memory Disorders Res Ctr, 151A,150 South,Huntington Ave, Boston, MA 02130 USA; [Hayes, Jasmeet P.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA; [Hayes, Jasmeet P.; Lafleche, Ginette; Verfaellie, Mieke] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Hayes, Jasmeet P.; Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA 02130 USA; [Salat, David H.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Salat, David H.] Harvard Univ, Sch Med, Boston, MA USA		Miller, DR (corresponding author), VA Boston Healthcare Syst, Memory Disorders Res Ctr, 151A,150 South,Huntington Ave, Boston, MA 02130 USA.	dmiller3@bu.edu	Hayes, Jasmeet/AAN-4150-2020	Hayes, Jasmeet/0000-0002-5157-0666; Verfaellie, Mieke/0000-0001-5535-4584; Sullivan, Danielle R./0000-0002-0141-5887	VA Rehabilitation Research Development [RX000216]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23MH084013]; National Center for PTSD; VA Clinical Science Research and Development Service; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH084013] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000216] Funding Source: NIH RePORTER	Contract grant sponsor: VA Rehabilitation Research & Development; Contract grant number: RX000216; Contract grant sponsor: NIH; Contract grant number: K23MH084013; Contract grant sponsor: National Center for PTSD; Contract grant sponsor: VA Clinical Science Research and Development Service.	Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Corbo V, 2005, BIOL PSYCHIAT, V58, P119, DOI 10.1016/j.biopsych.2005.02.032; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Hayes AF, 2014, BRIT J MATH STAT PSY, V67, P451, DOI 10.1111/bmsp.12028; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Hayes JP, 2011, J PSYCHIATR RES, V45, P660, DOI 10.1016/j.jpsychires.2010.10.007; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2008, MILD TRAUMATIC BRAIN; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; O'Doherty DCM, 2015, PSYCHIAT RES-NEUROIM, V232, P1, DOI 10.1016/j.pscychresns.2015.01.002; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Sadeh N, 2015, HUM BRAIN MAPP, V36, P3076, DOI 10.1002/hbm.22829; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Smith ME, 2005, HIPPOCAMPUS, V15, P798, DOI 10.1002/hipo.20102; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; St Jacques PL, 2013, COGN AFFECT BEHAV NE, V13, P554, DOI 10.3758/s13415-013-0157-7; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tombaugh T.N., 1996, TEST MEMORY MALINGER; van Wingen GA, 2012, P NATL ACAD SCI USA, V109, P15508, DOI 10.1073/pnas.1206330109; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; WechslerD, 2001, WECHSLER TEST ADULT; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Xydakis MS, 2012, ANN NEUROL, V72, P673, DOI 10.1002/ana.23757; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358	61	44	44	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JAN	2016	37	1					220	229		10.1002/hbm.23022			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DC3WU	WOS:000369150500015	26497829	Green Accepted, Green Published			2022-02-06	
J	van den Heuvel, TLA; van der Eerden, AW; Manniesing, R; Ghafoorian, M; Tan, T; Andriessen, TMJC; Vyvere, TV; van den Hauwe, L; Romeny, BMT; Goraj, BM; Platel, B				van den Heuvel, T. L. A.; van der Eerden, A. W.; Manniesing, R.; Ghafoorian, M.; Tan, T.; Andriessen, T. M. J. C.; Vyvere, T. Vande; van den Hauwe, L.; Romeny, B. M. ter Haar; Goraj, B. M.; Platel, B.			Automated detection of cerebral microbleeds in patients with traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Computer Aided Detection; Cerebral Microbleeds; Traumatic Brain Injury; Susceptibility Weighted Imaging	DIFFUSE AXONAL INJURY; MR-IMAGES; OPTIMIZATION; REGISTRATION; RELIABILITY; ROBUST	In this paper a Computer Aided Detection (CAD) system is presented to automatically detect Cerebral Microbleeds (CMBs) in patients with Traumatic Brain Injury (TBI). It is believed that the presence of CMBs has clinical prognostic value in TBI patients. To study the contribution of CMBs in patient outcome, accurate detection of CMBs is required. Manual detection of CMBs in TBI patients is a time consuming task that is prone to errors, because CMBs are easily overlooked and are difficult to distinguish from blood vessels. This study included 33 TBI patients. Because of the laborious nature of manually annotating CMBs, only one trained expert manually annotated the CMBs in all 33 patients. A subset of ten TBI patients was annotated by six experts. Our CAD systemmakes use of both Susceptibility Weighted Imaging (SWI) and T1 weighted magnetic resonance images to detect CMBs. After pre-processing these images, a two-step approach was used for automated detection of CMBs. In the first step, each voxel was characterized by twelve features based on the dark and spherical nature of CMBs and a random forest classifier was used to identify CMB candidate locations. In the second step, segmentations were made from each identified candidate location. Subsequently an object-based classifier was used to remove false positive detections of the voxel classifier, by considering seven object-based features that discriminate between spherical objects (CMBs) and elongated objects (blood vessels). A guided user interface was designed for fast evaluation of the CAD system result. During this process, an expert checked each CMB detected by the CAD system. A Fleiss' kappa value of only 0.24 showed that the inter-observer variability for the TBI patients in this study was very large. An expert using the guided user interface reached an average sensitivity of 93%, which was significantly higher (p=0.03) than the average sensitivity of 77% (sd 12.4%) that the six experts manually detected. Furthermore, with the use of this CAD system the reading time was substantially reduced from one hour to 13 minutes per patient, because the CAD system only detects on average 25.9 false positives per TBI patient, resulting in 0.29 false positives per definite CMB finding. (C) 2016 The Authors. Published by Elsevier Inc.	[van den Heuvel, T. L. A.; van der Eerden, A. W.; Manniesing, R.; Tan, T.; Goraj, B. M.; Platel, B.] Radboudumc, Dept Radiol & Nucl Med, Nijmegen, Netherlands; [van den Heuvel, T. L. A.; Romeny, B. M. ter Haar] Eindhoven Univ Technol, Dept Biomed Image Anal, Eindhoven, Netherlands; [Ghafoorian, M.] Radboud Univ Nijmegen, Inst Comp & Informat Sci, Nijmegen, Netherlands; [Andriessen, T. M. J. C.] Rivas Healthcare Grp, Dept Psychol, Gorinchem, Netherlands; [Vyvere, T. Vande; van den Hauwe, L.] Univ Antwerp, Univ Antwerp Hosp, Dept Radiol, Antwerp, Belgium; [Vyvere, T. Vande; van den Hauwe, L.] Icometrix, Leuven, Belgium; [Romeny, B. M. ter Haar] Northeastern Univ, Shenyang, Peoples R China; [Goraj, B. M.] Med Ctr Postgrad Educ Warsaw, Dept Diagnost Imaging, Warsaw, Poland		van den Heuvel, TLA (corresponding author), Geert Grootepl 10, NL-6500 HB Nijmegen, Netherlands.	Thomas.vandenHeuvel@radboudumc.nl	Ghafoorian, Mohsen/AAH-7397-2019; Romenij, Bart M. ter Haar/A-5323-2013; van den Heuvel, Thomas/N-7185-2015; Vande Vyvere, Thijs/AAB-5180-2022; Manniesing, Rashindra/G-9728-2015; Platel, Bram/D-2132-2009; van der Eerden, Anke/H-9413-2017	van den Heuvel, Thomas/0000-0003-3736-7693; Vande Vyvere, Thijs/0000-0003-4032-5443; Manniesing, Rashindra/0000-0002-4616-6298; Platel, Bram/0000-0002-1936-6825; van der Eerden, Anke/0000-0002-9182-9089			Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Barnes SRS, 2011, MAGN RESON IMAGING, V29, P844, DOI 10.1016/j.mri.2011.02.028; Bian W, 2013, NEUROIMAGE-CLIN, V2, P282, DOI 10.1016/j.nicl.2013.01.012; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Cheng AL, 2013, STROKE, V44, P2782, DOI 10.1161/STROKEAHA.113.002267; Dou Q, 2016, IEEE T MED IMAGING, V35, P1182, DOI 10.1109/TMI.2016.2528129; Faziollahi A, 2014, I S BIOMED IMAGING, P113, DOI 10.1109/ISBI.2014.6867822; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Ghafaryasl B, 2012, 2012 9TH IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI), P138, DOI 10.1109/ISBI.2012.6235503; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Gregoire SM, 2009, NEUROLOGY, V73, P1759, DOI 10.1212/WNL.0b013e3181c34a7d; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kuijf HJ, 2012, NEUROIMAGE, V59, P2266, DOI 10.1016/j.neuroimage.2011.09.061; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Romeny BMT, 2011, BIOL MED PHYS BIOMED, P177, DOI 10.1007/978-3-642-15816-2_7; Sato Y, 1998, Med Image Anal, V2, P143, DOI 10.1016/S1361-8415(98)80009-1; Sato Y., 1997, CVRMED MRCAS; Seghier ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017547; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Werring DJ, 2011, CEREBRAL MICROBLEEDS; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	25	44	44	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2016	12						241	251		10.1016/j.nicl.2016.07.002			11	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EF3AI	WOS:000390196400028	27489772	Green Published, gold			2022-02-06	
J	Halaweish, I; Bambakidis, T; Chang, ZG; Wei, H; Liu, BL; Li, YQ; Bonthrone, T; Srinivasan, A; Bonham, T; Chtraklin, K; Alam, HB				Halaweish, Ihab; Bambakidis, Ted; Chang, Zhigang; Wei, He; Liu, Baoling; Li, Yongqing; Bonthrone, Toby; Srinivasan, Ashok; Bonham, Tess; Chtraklin, Kiril; Alam, Hasan B.			Addition of low-dose valproic acid to saline resuscitation provides neuroprotection and improves long-term outcomes in a large animal model of combined traumatic brain injury and hemorrhagic shock	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	45th Annual Meeting of the Western-Trauma-Association	MAR 01-06, 2015	Telluride, CO	Western Trauma Assoc		Traumatic brain injury; hemorrhagic shock; HDACI; valproic acid; swine	HISTONE DEACETYLASE INHIBITOR; PHARMACOLOGICAL RESUSCITATION; SWINE MODEL; PLATELET ACTIVATION; BARRIER DISRUPTION; ISCHEMIA; HYPOTHERMIA; STRATEGIES; LETHALITY; PROFILES	BACKGROUND Combined traumatic brain injury (TBI) and hemorrhagic shock (HS) is highly lethal. In a nonsurvival model of TBI + HS, addition of high-dose valproic acid (VPA) (300 mg/kg) to hetastarch reduced brain lesion size and associated swelling 6 hours after injury; whether this would have translated into better neurologic outcomes remains unknown. It is also unclear whether lower doses of VPA would be neuroprotective. We hypothesized that addition of low-dose VPA to normal saline (NS) resuscitation would result in improved long-term neurologic recovery and decreased brain lesion size. METHODS TBI was created in anesthetized swine (40-43 kg) by controlled cortical impact, and volume-controlled hemorrhage (40% volume) was induced concurrently. After 2 hours of shock, animals were randomized (n = 5 per group) to NS (3x shed blood) or NS + VPA (150 mg/kg). Six hours after resuscitation, packed red blood cells were transfused, and animals were recovered. Peripheral blood mononuclear cells were analyzed for acetylated histone-H3 at lysine-9. A Neurological Severity Score (NSS) was assessed daily for 30 days. Brain magnetic resonance imaging was performed on Days 3 and 10. Cognitive performance was assessed by training animals to retrieve food from color-coded boxes. RESULTS There was a significant increase in histone acetylation in the NS + VPA-treated animals compared with NS treatment. The NS + VPA group demonstrated significantly decreased neurologic impairment and faster speed of recovery as well as smaller brain lesion size compared with the NS group. Although the final cognitive function scores were similar between the groups, the VPA-treated animals reached the goal significantly faster than the NS controls. CONCLUSION In this long-term survival model of TBI + HS, addition of low-dose VPA to saline resuscitation resulted in attenuated neurologic impairment, faster neurologic recovery, smaller brain lesion size, and a quicker normalization of cognitive functions.	[Halaweish, Ihab; Bambakidis, Ted; Liu, Baoling; Li, Yongqing; Bonthrone, Toby; Bonham, Tess; Chtraklin, Kiril; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Srinivasan, Ashok] Univ Michigan, Dept Radiol, Neuroradiol Sect, Ann Arbor, MI 48109 USA; [Chang, Zhigang] Beijing Hosp, Minist Hlth, Dept Surg Crit Care, Beijing, Peoples R China; [Wei, He] Southeast Univ, Sch Med, Dept Cardiothorac Surg, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China		Alam, HB (corresponding author), Univ Michigan Hosp, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu			US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; Joyce and Don Massey Family Foundation	This research was funded by a grant from the US Army Medical Research and Materiel Command (GRANTT00521959) to H.B.A. and supported by a research endowment from the Joyce and Don Massey Family Foundation.	Alam HB, 2011, J TRAUMA, V70, P636, DOI 10.1097/TA.0b013e31820d0dcc; Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Alam HB, 2004, RESUSCITATION, V60, P91, DOI 10.1016/j.resuscitation.2003.08.006; Alam HB, 2002, SURGERY, V132, P278, DOI 10.1067/msy.2002.125787; [Anonymous], 1999, JAMA, V282, P974; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Brain Trauma Founction, GUID PREH MAN TRAUM; Burns JW, 2012, INT J BURNS TRAUMA, V2, P59; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Causey MW, 2013, J SURG RES, V184, P533, DOI 10.1016/j.jss.2013.03.087; Chen S, 2014, NEUROCHEM RES, V39, P1621, DOI 10.1007/s11064-014-1241-2; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Dekker SE, 2014, J TRAUMA ACUTE CARE, V77, P906, DOI 10.1097/TA.0000000000000345; Dekker SE, 2014, J SURG RES, V190, P312, DOI 10.1016/j.jss.2014.02.049; Difede J, 2010, ANN NY ACAD SCI, V1208, P1, DOI 10.1111/j.1749-6632.2010.05795.x; Engelhardt B, 2008, J NEUROL SCI, V274, P23, DOI 10.1016/j.jns.2008.05.019; Faul M, 2010, TRAUMATIC BRAIN INJU; Fuss Ivan J, 2009, Curr Protoc Immunol, VChapter 7, DOI 10.1002/0471142735.im0701s85; Gonzales E, 2006, SHOCK, V25, P395, DOI 10.1097/01.shk.0000209522.28120.c8; Gonzales ER, 2008, J TRAUMA, V65, P554, DOI 10.1097/TA.0b013e31818233ef; Halaweish I, 2015, SHOCK; Hwabejire JO, 2014, J SURG RES, V186, P363, DOI 10.1016/j.jss.2013.09.016; Hwabejire JO, 2013, SURGERY, V154, P234, DOI 10.1016/j.surg.2013.04.008; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Lee JY, 2012, J NEUROCHEM, V121, P818, DOI 10.1111/j.1471-4159.2012.07731.x; Li YQ, 2008, J TRAUMA, V64, P863, DOI 10.1097/TA.0b013e318166b822; Liu ZC, 2014, SHOCK, V41, P104, DOI 10.1097/SHK.0000000000000074; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Meyer S, 2005, KLIN PADIATR, V217, P82, DOI 10.1055/s-2004-822676; Morland C, 2004, J CEREBR BLOOD F MET, V24, P1226, DOI 10.1097/01.WCB.0000138666.25305.A7; Nanau RM, 2013, CLIN BIOCHEM, V46, P1323, DOI 10.1016/j.clinbiochem.2013.06.012; Navarro JC, 2012, J NEUROTRAUM, V29, P322, DOI 10.1089/neu.2011.1979; Nichol AD, 2009, INJURY, V40, P471, DOI 10.1016/j.injury.2009.01.002; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Shults C, 2008, J TRAUMA, V64, P629, DOI 10.1097/TA.0b013e3181650ff3; Sztajnkrycer MD, 2002, J TOXICOL-CLIN TOXIC, V40, P789, DOI 10.1081/CLT-120014645; Tai YT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/980657; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Zhang C, 2014, BRAIN RES, V1555, P1, DOI 10.1016/j.brainres.2014.01.051	50	44	44	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2015	79	6					911	919		10.1097/TA.0000000000000789			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	CX4TD	WOS:000365692300005	26680134				2022-02-06	
J	Han, ZP; Liu, XR; Luo, YM; Ji, XM				Han, Ziping; Liu, Xiangrong; Luo, Yumin; Ji, Xunming			Therapeutic hypothermia for stroke: Where to go?	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	3rd Pangu Stroke Conference	OCT 10-12, 2014	Beijing, PEOPLES R CHINA			Hypothermia; Ischemic stroke; Neuroprotection	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; TISSUE-PLASMINOGEN ACTIVATOR; RANDOMIZED CONTROLLED-TRIAL; ADMISSION BODY-TEMPERATURE; COMBINATION-DRUG THERAPY; UPPER RESPIRATORY-TRACT; LOCAL MILD HYPOTHERMIA; COLD SALINE INFUSION; DAMAGE COOL AID	Ischemic stroke is a major cause of death and long-term disability worldwide. Thrombolysis with recombinant tissue plasminogen activator is the only proven and effective treatment for acute ischemic stroke; however, therapeutic hypothermia is increasingly recognized as having a tissue-protective function and positively influencing neurological outcome, especially in cases of ischemia caused by cardiac arrest or hypoxic-ischemic encephalopathy in newborns. Yet, many aspects of hypothermia as a treatment for ischemic stroke remain unknown. Large-scale studies examining the effects of hypothermia on stroke are currently underway. This review discusses the mechanisms underlying the effect of hypothermia, as well as trends in hypothermia induction methods, methods for achieving optimal protection, side effects, and therapeutic strategies combining hypothermia with other neuroprotective treatments. Finally, outstanding issues that must be addressed before hypothermia treatment is implemented at a clinical level are also presented. (C) 2015 Elsevier Inc. All rights reserved.	[Han, Ziping; Liu, Xiangrong; Luo, Yumin; Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing 100053, Peoples R China; [Luo, Yumin; Ji, Xunming] Beijing Inst Brain Disorders, Ctr Stroke, Beijing 100053, Peoples R China; [Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing 100053, Peoples R China		Ji, XM (corresponding author), Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, 45 Changchun St, Beijing 100053, Peoples R China.	jixm@ccmu.edu.cn	Ji, Xunming/AAN-3370-2021		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171241, 81325007, 81471340]; Ministry of Science and Technology [2011CB707804]	This work was supported by the National Natural Science Foundation of China (81171241, 81325007, and 81471340) and the Ministry of Science and Technology (2011CB707804).	Ahmad M, 2010, TRANSL STROKE RES, V1, P74, DOI 10.1007/s12975-010-0023-7; An CR, 2014, PROG NEUROBIOL, V115, P6, DOI 10.1016/j.pneurobio.2013.12.002; Andrews PJD, 2005, BRIT J ANAESTH, V94, P330, DOI 10.1093/bja/aei025; Ao HS, 2001, RESUSCITATION, V51, P83, DOI 10.1016/S0300-9572(01)00380-X; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Badjatia N, 2009, CRIT CARE MED, V37, P1893, DOI 10.1097/CCM.0b013e31819fffd3; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Berger C, 2004, EXP NEUROL, V185, P305, DOI 10.1016/j.expneurol.2003.10.008; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bi M, 2011, CLIN NEUROL NEUROSUR, V113, P768, DOI 10.1016/j.clineuro.2011.08.010; BRISTOW GK, 1994, AVIAT SPACE ENVIR MD, V65, P220; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; Chen F, 2014, PROG NEUROBIOL, V115, P246, DOI 10.1016/j.pneurobio.2013.12.007; Chen J, 2013, STROKE, V44, P260, DOI 10.1161/STROKEAHA.112.675462; CHENG C, 1995, ANESTHESIOLOGY, V82, P1160, DOI 10.1097/00000542-199505000-00011; Cheng HK, 2009, NEUROL RES, V31, P340, DOI 10.1179/174313209X443982; Choi JH, 2010, AM J NEURORADIOL, V31, P928, DOI 10.3174/ajnr.A1961; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; Clark DL, 2009, EXP NEUROL, V220, P391, DOI 10.1016/j.expneurol.2009.10.002; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; Covaciu L, 2011, INTENS CARE MED, V37, P1277, DOI 10.1007/s00134-011-2264-7; Dae MW, 2003, STROKE, V34, P734, DOI 10.1161/01.STR.0000057461.56040.FE; Dai Da-wei, 2006, Zhonghua Yi Xue Za Zhi, V86, P906; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; De Witte JL, 1998, ANESTH ANALG, V87, P173, DOI 10.1097/00000539-199807000-00036; Den Hertog HM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001247.pub2; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Deng J, 2014, PROG NEUROBIOL, V115, P210, DOI 10.1016/j.pneurobio.2014.01.001; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Ding YC, 2003, NEUROSCI LETT, V353, P173, DOI 10.1016/j.neulet.2003.09.055; Ding YC, 2002, STROKE, V33, P2492, DOI 10.1161/01.STR.0000028237.15541.CC; Ding YC, 2002, J NEUROSURG, V96, P310, DOI 10.3171/jns.2002.96.2.0310; Ding YC, 2004, NEUROSURGERY, V54, P956, DOI 10.1227/01.NEU.0000114513.96704.29; Dirks M, 2011, STROKE, V42, P1325, DOI 10.1161/STROKEAHA.110.596940; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Ehrlich MP, 2002, ANN THORAC SURG, V73, P191, DOI 10.1016/S0003-4975(01)03273-8; Els T, 2006, CEREBROVASC DIS, V21, P79, DOI 10.1159/000090007; Emsley HC, 2008, LANCET NEUROL, V7, P341, DOI 10.1016/S1474-4422(08)70061-9; Esposito E, 2014, J CEREBR BLOOD F MET, V34, P743, DOI 10.1038/jcbfm.2014.29; Feng JF, 2010, NEUROSURGERY, V67, P730, DOI 10.1227/01.NEU.0000378023.81727.6E; Fukuda H, 2001, BRAIN RES, V910, P187, DOI 10.1016/S0006-8993(01)02659-2; Georgiadis D, 2002, STROKE, V33, P1584, DOI 10.1161/01.STR.0000016970.51004.D9; Georgiadis D, 2001, STROKE, V32, P2550, DOI 10.1161/hs1101.097382; Gerdeman G, 2001, J NEUROPHYSIOL, V85, P468, DOI 10.1152/jn.2001.85.1.468; Giraud R, 2013, CRIT CARE, V17, DOI 10.1186/cc12523; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; Gong P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067476; Gonzalez-Ibarra Fernando Pavel, 2011, Front Neurol, V2, P4, DOI 10.3389/fneur.2011.00004; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grigore AM, 2002, ANESTH ANALG, V94, P4, DOI 10.1097/00000539-200201000-00002; Gu LJ, 2014, CNS NEUROSCI THER, V20, P67, DOI 10.1111/cns.12160; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Hampson AJ, 2001, EUR J NEUROSCI, V13, P1529, DOI 10.1046/j.0953-816x.2001.01536.x; Han F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069340; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Harris BA, 2007, BRIT J ANAESTH, V98, P93, DOI 10.1093/bja/ael308; Hemmen TM, 2010, STROKE, V41, P2265, DOI 10.1161/STROKEAHA.110.592295; Hong JM, 2014, STROKE, V45, P134, DOI 10.1161/STROKEAHA.113.003143; Horiguchi T, 2003, J NEUROTRAUM, V20, P511, DOI 10.1089/089771503765355577; Horstmann S, 2003, STROKE, V34, P2165, DOI 10.1161/01.STR.0000088062.86084.F2; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Imada S, 2010, J NEUROSCI RES, V88, P3457, DOI 10.1002/jnr.22520; Ji XM, 2007, FRONT BIOSCI, V12, P1737, DOI 10.2741/2185; Ji YB, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.5.FOCUS1215; Ji YB, 2012, NEUROL RES, V34, P657, DOI 10.1179/1743132812Y.0000000061; Kammersgaard LP, 2002, STROKE, V33, P1759, DOI 10.1161/01.STR.0000019910.90280.F1; Karnatovskaia LV, 2014, NEUROHOSPITALIST, V4, P153, DOI 10.1177/1941874413519802; Khanna A, 2014, TRANSL STROKE RES, V5, P3, DOI 10.1007/s12975-013-0307-9; Kim JY, 2011, TRANSL STROKE RES, V2, P195, DOI 10.1007/s12975-011-0082-4; Kimberger O, 2007, CRIT CARE, V11, DOI 10.1186/cc5709; Kollmar R, 2007, STROKE, V38, P1585, DOI 10.1161/STROKEAHA.106.475897; Kollmar R, 2009, STROKE, V40, P1907, DOI 10.1161/STROKEAHA.108.530410; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Kurasako T, 2007, J CEREBR BLOOD F MET, V27, P1919, DOI 10.1038/sj.jcbfm.9600492; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lee JE, 2005, J NEUROSURG, V103, P289, DOI 10.3171/jns.2005.103.2.0289; Lee SL, 2001, J SURG RES, V100, P150, DOI 10.1006/jsre.2001.6230; Leng TD, 2014, PROG NEUROBIOL, V115, P189, DOI 10.1016/j.pneurobio.2013.12.008; Li HY, 2014, TRANSL STROKE RES, V5, P618, DOI 10.1007/s12975-014-0354-x; Li J, 2004, NEUROL RES, V26, P677, DOI 10.1179/016164104225015903; Liu L, 2008, J NEUROCHEM, V106, P541, DOI 10.1111/j.1471-4159.2008.05411.x; Liu XR, 2014, TRANSL STROKE RES, V5, P692, DOI 10.1007/s12975-014-0359-5; Liu XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053431; Luan XD, 2004, ACTA NEUROPATHOL, V107, P227, DOI 10.1007/s00401-003-0802-2; Luo YM, 2007, FRONT BIOSCI, V12, P1852, DOI 10.2741/2193; Lyden Patrick D, 2005, J Stroke Cerebrovasc Dis, V14, P107, DOI 10.1016/j.jstrokecerebrovasdis.2005.01.001; Lyden PD, 2006, INT J STROKE, V1, P9, DOI 10.1111/j.1747-4949.2005.00011.x; Mack WJ, 2003, STROKE, V34, P1994, DOI 10.1161/01.STR.0000079813.31539.6D; Macleod MR, 2010, INT J STROKE, V5, P489, DOI 10.1111/j.1747-4949.2010.00520.x; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Martin-Schild S, 2009, J STROKE CEREBROVASC, V18, P86, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.015; Matsui T, 2008, J NEUROTRAUM, V25, P709, DOI 10.1089/neu.2007.0482; Matsuwaka R, 1998, J CARDIAC SURG, V13, P463, DOI 10.1111/j.1540-8191.1998.tb01083.x; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meloni BP, 2009, STROKE, V40, P2236, DOI 10.1161/STROKEAHA.108.542381; Mirzoyev SA, 2010, RESUSCITATION, V81, P1632, DOI 10.1016/j.resuscitation.2010.08.007; Mohr J, 2013, J TRAUMA ACUTE CARE, V74, P1014, DOI 10.1097/TA.0b013e3182826edd; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Mueller-Burke D, 2008, INT J DEV NEUROSCI, V26, P67, DOI 10.1016/j.ijdevneu.2007.08.015; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Nagel Simon, 2008, Expert Rev Neurother, V8, P1255, DOI 10.1586/14737175.8.8.1255; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Nunnally ME, 2011, CRIT CARE MED, V39, P1113, DOI 10.1097/CCM.0b013e318206bab2; Patel MD, 2006, AGE AGEING, V35, P273, DOI 10.1093/ageing/afj074; Perrone S, 2010, PEDIATR NEUROL, V43, P236, DOI 10.1016/j.pediatrneurol.2010.05.009; Phanithi PB, 2000, NEUROPATHOLOGY, V20, P273, DOI 10.1046/j.1440-1789.2000.00346.x; Piehl S, 2011, ENDOCR REV, V32, P64, DOI 10.1210/er.2009-0040; Piironen K, 2014, STROKE, V45, P486, DOI 10.1161/STROKEAHA.113.003180; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Reed SD, 2001, STROKE, V32, P1832, DOI 10.1161/01.STR.32.8.1832; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Roelfsema V, 2004, J CEREBR BLOOD F MET, V24, P877, DOI 10.1097/01.WCB.0000123904.17746.92; Rogalewski A, 2006, STROKE, V37, P1129, DOI 10.1161/01.STR.0000209330.73175.34; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; Russwurm S, 2002, J INTERF CYTOK RES, V22, P215, DOI 10.1089/107999002753536185; Sánchez-Casado M., 2007, Med. Intensiva, V31, P113; Schmid-Elsaesser R, 1999, STROKE, V30, P1891, DOI 10.1161/01.STR.30.9.1891; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmitt KRL, 2010, BRAIN PATHOL, V20, P771, DOI 10.1111/j.1750-3639.2009.00358.x; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Seifert HA, 2014, TRANSL STROKE RES, V5, P543, DOI 10.1007/s12975-014-0349-7; Sessler DI, 2009, CRIT CARE MED, V37, pS203, DOI 10.1097/CCM.0b013e3181aa5568; Silasi G, 2012, J CEREBR BLOOD F MET, V32, P1525, DOI 10.1038/jcbfm.2012.38; Silasi G, 2011, J CEREBR BLOOD F MET, V31, P1725, DOI 10.1038/jcbfm.2011.25; Song MK, 2014, TRANSL STROKE RES, V5, P17, DOI 10.1007/s12975-013-0314-x; Staikou C, 2011, W INDIAN MED J, V60, P513; Stetler RA, 2014, PROG NEUROBIOL, V114, P58, DOI 10.1016/j.pneurobio.2013.11.005; Taggart R, 2012, J VET EMERG CRIT CAR, V22, P219, DOI 10.1111/j.1476-4431.2012.00729.x; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017; Tang XN, 2011, ANN NEUROL, V70, P606, DOI 10.1002/ana.22476; Tang XN, 2009, J NEUROTRAUM, V26, P325, DOI 10.1089/neu.2008.0594; Tokutomi T, 2004, NEUROCRIT CARE, V1, P171, DOI 10.1385/NCC:1:2:171; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Van Hemelrijck A, 2005, J NEUROCHEM, V95, P1287, DOI 10.1111/j.1471-4159.2005.03450.x; Wang D, 2013, NEUROSCIENCE, V237, P130, DOI 10.1016/j.neuroscience.2013.01.056; Wang Qiong, 2007, Chin J Traumatol, V10, P246; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Wartenberg KE, 2012, CURR OPIN CRIT CARE, V18, P152, DOI 10.1097/MCC.0b013e32835075c5; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; Wolberg AS, 2004, J TRAUMA, V56, P1221, DOI 10.1097/01.TA.0000064328.97941.FC; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Xiao F, 2004, ACAD EMERG MED, V11, P1001, DOI 10.1197/j.aem.2004.05.026; Xie YC, 2007, NEUROSCI LETT, V422, P87, DOI 10.1016/j.neulet.2007.03.072; Xiong M, 2011, NEUROCHEM INT, V58, P625, DOI 10.1016/j.neuint.2011.01.026; Xiong M, 2009, BRAIN RES BULL, V79, P351, DOI 10.1016/j.brainresbull.2009.03.011; Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720; Yenari MA, 2013, FRONT NEUROL NEUROSC, V32, P122, DOI 10.1159/000346428; Yenari MA, 2002, J CEREBR BLOOD F MET, V22, P29, DOI 10.1097/00004647-200201000-00004; YENARI MA, 1995, THROMB RES, V77, P475, DOI 10.1016/0049-3848(95)93883-2; Yenari M, 2008, STROKE, V39, P2910, DOI 10.1161/STROKEAHA.108.514471; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yenari MA, 2010, STROKE, V41, pS72, DOI 10.1161/STROKEAHA.110.595371; Zhang F, 2009, J CEREBR BLOOD F MET, V29, P1022, DOI 10.1038/jcbfm.2009.28; Zhang MJ, 2013, CNS NEUROL DISORD-DR, V12, P371, DOI 10.2174/1871527311312030010; Zhang ZJ, 2001, MOL BRAIN RES, V95, P75, DOI 10.1016/S0169-328X(01)00247-9; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhao WH, 2009, NEUROL RES, V31, P43, DOI 10.1179/174313208X327982; Zhou JQ, 2011, EXPERT OPIN DRUG MET, V7, P803, DOI 10.1517/17425255.2011.574127; Zweifler Richard M, 2003, J Stroke Cerebrovasc Dis, V12, P237, DOI 10.1016/j.jstrokecerebrovasdis.2003.09.006	178	44	47	1	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2015	272				SI		67	77		10.1016/j.expneurol.2015.06.006			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	CV6AS	WOS:000364353700009	26057949				2022-02-06	
J	Villasana, LE; Kim, KN; Westbrook, GL; Schnell, E				Villasana, Laura E.; Kim, Kristine N.; Westbrook, Gary L.; Schnell, Eric			Functional Integration of Adult-Born Hippocampal Neurons after Traumatic Brain Injury	ENEURO			English	Article						adult neurogenesis; functional integration; hippocampus; maturation; synaptic integration; traumatic brain injury	INDUCED CELL-PROLIFERATION; DENTATE GRANULE CELLS; COGNITIVE RECOVERY; ABERRANT NEUROGENESIS; ENHANCES NEUROGENESIS; SYNAPTIC INTEGRATION; GENERATED NEURONS; NEWBORN NEURONS; DIFFERENTIATION; GYRUS	Traumatic brain injury (TBI) increases hippocampal neurogenesis, which may contribute to cognitive recovery after injury. However, it is unknown whether TBI-induced adult-born neurons mature normally and functionally integrate into the hippocampal network. We assessed the generation, morphology, and synaptic integration of new hippocampal neurons after a controlled cortical impact (CCI) injury model of TBI. To label TBI-induced newborn neurons, we used 2-month-old POMC-EGFP mice, which transiently and specifically express EGFP in immature hippocampal neurons, and doublecortin-CreERT2 transgenic mice crossed with Rosa26-CAGtdTomato reporter mice, to permanently pulse-label a cohort of adult-born hippocampal neurons. TBI increased the generation, outward migration, and dendritic complexity of neurons born during post-traumatic neurogenesis. Cells born after TBI had profound alterations in their dendritic structure, with increased dendritic branching proximal to the soma and widely splayed dendritic branches. These changes were apparent during early dendritic outgrowth and persisted as these cells matured. Whole-cell recordings from neurons generated during posttraumatic neurogenesis demonstrate that they are excitable and functionally integrate into the hippocampal circuit. However, despite their dramatic morphologic abnormalities, we found no differences in the rate of their electrophysiological maturation, or their overall degree of synaptic integration when compared to age-matched adult-born cells from sham mice. Our results suggest that cells born after TBI participate in information processing, and receive an apparently normal balance of excitatory and inhibitory inputs. However, TBI-induced changes in their anatomiclocalization and dendritic projection patterns could result in maladaptive network properties.	[Villasana, Laura E.; Schnell, Eric] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA; [Kim, Kristine N.; Schnell, Eric] VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,P3ANES, Portland, OR 97239 USA; [Westbrook, Gary L.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA		Schnell, E (corresponding author), VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,P3ANES, Portland, OR 97239 USA.	schneler@ohsu.edu		Kim, Kristine/0000-0001-9747-6547; Schnell, Eric/0000-0002-5623-5015; Westbrook, Gary/0000-0002-8108-5223	Department of Veterans Affairs Career Development Award (VA BLRD)US Department of Veterans Affairs [CDA-2 005-10S]; PVARF Summer Fellowship; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32-NS083109 NRSA]; Ellison Medical FoundationLawrence Ellison Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS080979, P30-NS061800]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS080979] Funding Source: NIH RePORTER	This work was funded by a Department of Veterans Affairs Career Development Award (VA BLR&D CDA-2 005-10S; E.S.), a PVARF Summer Fellowship (K.N.K.), National Institutes of Health (NIH) Grant F32-NS083109 NRSA (L.E.V.), an Ellison Medical Foundation Award (G.L.W.), and NIH Grants R01-NS080979 (GLW) and P30-NS061800 (Oregon Health & Science University Imaging Center). We thank Drs. Zhi-Qi Xiong and Xuewen Cheng for providing Dcx-CreERT2 mice; and Dr. Stefanie Kaech-Petrie of the Oregon Health & Science University Advanced Light Microscopy Core for assistance with imaging.	Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Carlson SW, 2014, J NEUROPATH EXP NEUR, V73, P734, DOI 10.1097/NEN.0000000000000092; Chancey JH, 2013, J NEUROSCI, V33, P6614, DOI 10.1523/JNEUROSCI.0781-13.2013; Cheng XW, 2011, CELL RES, V21, P338, DOI 10.1038/cr.2010.141; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chohan MO, 2015, NEUROSURGERY, V76, P201, DOI 10.1227/NEU.0000000000000577; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; El-Hassar L, 2007, J PHYSIOL-LONDON, V578, P193, DOI 10.1113/jphysiol.2006.119297; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gupta A, 2012, J NEUROSCI, V32, P2523, DOI 10.1523/JNEUROSCI.4141-11.2012; Hunt RF, 2012, J NEUROSCI, V32, P12862, DOI 10.1523/JNEUROSCI.1286-12.2012; Jackson J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035557; Jessberger S, 2007, J NEUROSCI, V27, P9400, DOI 10.1523/JNEUROSCI.2002-07.2007; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Lisman JE, 2007, PROG BRAIN RES, V163, P615, DOI 10.1016/S0079-6123(07)63033-7; Liu JL, 1998, J NEUROSCI, V18, P7768; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Nakashiba T, 2012, CELL, V149, P188, DOI 10.1016/j.cell.2012.01.046; Niv F, 2012, STROKE, V43, P2468, DOI 10.1161/STROKEAHA.112.660977; Overstreet LS, 2004, J NEUROSCI, V24, P3251, DOI 10.1523/JNEUROSCI.5173-03.2004; Overstreet W. L., 2005, J NEUROPHYSIOL, V94, P4528, DOI DOI 10.1152/JN.00633.2005; Overstreet-Wadiche LS, 2006, J NEUROSCI, V26, P4095, DOI 10.1523/JNEUROSCI.5508-05.2006; Parent JM, 2002, PROG BRAIN RES, V135, P121; Parent JM, 1997, J NEUROSCI, V17, P3727; Perederiy JV, 2013, J NEUROSCI, V33, P4754, DOI 10.1523/JNEUROSCI.4785-12.2013; Pugh P, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00045; Quadrato G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00017; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Scharfman HE, 2007, SCIENCE, V315, P336, DOI 10.1126/science.1138711; Shapiro LA, 2008, EPILEPSIA, V49, P13, DOI 10.1111/j.1528-1167.2008.01633.x; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2015, J NEUROTRAUM, V32, P495, DOI 10.1089/neu.2014.3545; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Varela-Nallar L, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00017; Villasana LE, 2014, EXP NEUROL, V261, P156, DOI 10.1016/j.expneurol.2014.05.016; Xie CC, 2015, BRAIN RES, V1602, P1, DOI 10.1016/j.brainres.2014.03.021; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zhu LL, 2005, BRAIN RES, V1055, P1, DOI 10.1016/j.brainres.2005.04.075	60	44	44	1	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA		2373-2822		ENEURO	eNeuro	SEP-OCT	2015	2	5							0056-15.2015	10.1523/ENEURO.0056-15.2015			17	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	V3T5V	WOS:000218574600005	26478908	gold, Green Published			2022-02-06	
J	Meizoso, JP; Valle, EJ; Allen, CJ; Ray, JJ; Jouria, JM; Teisch, LF; Shatz, DV; Namias, N; Schulman, CI; Proctor, KG				Meizoso, Jonathan P.; Valle, Evan J.; Allen, Casey J.; Ray, Juliet J.; Jouria, Jassin M.; Teisch, Laura F.; Shatz, David V.; Namias, Nicholas; Schulman, Carl I.; Proctor, Kenneth G.			Decreased mortality after prehospital interventions in severely injured trauma patients	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 09-13, 2014	Philadelphia, PA	Amer Assoc Surg Trauma		Prehospital; interventions; lifesaving; scoop and run; stay and play	SEVERE HEAD-INJURY; FLUID RESUSCITATION; INTUBATION; ASSOCIATION; MANAGEMENT; GUIDELINE; SURVIVAL; OUTCOMES; SYSTEM	BACKGROUND We test the hypothesis that prehospital interventions (PHIs) performed by skilled emergency medical service providers during ground or air transport adversely affect outcome in severely injured trauma patients. METHODS Consecutive trauma activations (March 2012 to June 2013) transported from the scene by air or ground emergency medical service providers were reviewed. PHI was defined as intubation, needle decompression, tourniquet, cricothyroidotomy, or advanced cardiac life support. RESULTS In 3,733 consecutive trauma activations (71% blunt, 25% penetrating, 4% burns), age was 39 years, 74% were male, Injury Severity Score (ISS) was 5, and Glasgow Coma Score (GCS) was 15, with 32% traumatic brain injury (TBI) and 7% overall mortality. Those who received PHI (n = 130, 3.5% of the trauma activations) were more severely injured: ISS (26 vs. 5), GCS (3 vs. 15), TBI (57% vs. 31%), Revised Trauma Score (RTS, 5.45 vs. 7.84), Trauma and Injury Severity Score (TRISS, 1.32 vs. 4.89), and mortality (56% vs. 5%) were different (all p < 0.05) than those who received no PHI. Air crews transported 22% of the patients; more had TBI, blunt injury, high ISS, and long prehospital times (all p < 0.05), but mortality was similar to those transported by ground. In the most severely injured patients with signs of life who received a PHI, the ISS, prehospital times, and proportions of TBI, blunt trauma, and air transport were similar, but mortality was significantly lower (43% vs. 23%, p= 0.021). CONCLUSION In our urban trauma system, PHIs are associated with a lower incidence of mortality in severely injured trauma patients and do not delay transport to definitive care. LEVEL OF EVIDENCE Prognostic/epidemiologic study, level III; therapeutic study, level IV.	[Meizoso, Jonathan P.; Valle, Evan J.; Allen, Casey J.; Ray, Juliet J.; Jouria, Jassin M.; Teisch, Laura F.; Namias, Nicholas; Schulman, Carl I.; Proctor, Kenneth G.] Univ Miami, Leonard M Miller Sch Med, DeWitt Daughtry Family Dept Surg, Div Trauma Surg Crit Care & Burns, Miami, FL 33136 USA; [Shatz, David V.] UC Davis Hlth Syst, Div Trauma Acute Care Surg & Surg Crit Care, Sacramento, CA USA		Proctor, KG (corresponding author), Univ Miami, Leonard M Miller Sch Med, Ryder Trauma Ctr, Div Trauma,DeWitt Daughtry Family Dept Surg, 1800 NW 10th Ave,Suite T-215 D-40, Miami, FL 33136 USA.	kproctor@miami.edu; kproctor@miami.edu	Meizoso, Jonathan/AAF-5777-2019; Schulman, Carl/AAE-7448-2021; Proctor, Kenneth/AAA-2199-2022	Meizoso, Jonathan/0000-0002-6616-6682; Proctor, Kenneth/0000-0003-1326-6628; Schulman, Carl/0000-0001-8899-4350; Namias, Nicholas/0000-0001-7021-2250	Office of Naval ResearchOffice of Naval Research [N140610670]; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [09078015]	This study was supported in part by Grants #N140610670 from the Office of Naval Research and #09078015 from US Army Medical Research and Materiel Command.	Ball CG, 2010, CAN J SURG, V53, P184; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BORDER JR, 1983, J TRAUMA, V23, P708, DOI 10.1097/00005373-198308000-00005; Bulger EM, 2014, PREHOSP EMERG CARE, V18, P163, DOI 10.3109/10903127.2014.896962; Bulger EM, 2012, J TRAUMA ACUTE CARE, V72, P567, DOI 10.1097/TA.0b013e31824baddf; Cotton BA, 2009, J TRAUMA, V67, P389, DOI 10.1097/TA.0b013e3181a8b26f; Davis DP, 2010, J TRAUMA, V69, P294, DOI 10.1097/TA.0b013e3181dc6c7f; Demetriades D, 1996, ARCH SURG-CHICAGO, V131, P133; Hampton DA, 2013, J TRAUMA ACUTE CARE, V75, pS9, DOI 10.1097/TA.0b013e318290cd52; Johnson NJ, 2013, AM J EMERG MED, V31, P275, DOI 10.1016/j.ajem.2012.07.023; Karamanos E, 2014, PREHOSP DISASTER MED, V29, P32, DOI 10.1017/S1049023X13008947; Mayglothling J, 2012, J TRAUMA ACUTE CARE, V73, pS333, DOI 10.1097/TA.0b013e31827018a5; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Papa L, 2006, J TRAUMA, V61, P261, DOI 10.1097/01.ta.0000221789.53864.ba; Taghavi S, 2014, AM SURGEON, V80, P9; Talving P, 2009, WORLD J SURG, V33, P2469, DOI 10.1007/s00268-009-0185-1; Warner KJ, 2008, PREHOSP EMERG CARE, V12, P162, DOI 10.1080/10903120801907299; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	18	44	45	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2015	79	2					227	231		10.1097/TA.0000000000000748			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	CS2II	WOS:000361892800010	26218690				2022-02-06	
J	Ponsford, J; Schonberger, M; Rajaratnam, SMW				Ponsford, Jennie; Schoenberger, Michael; Rajaratnam, Shantha M. W.			A Model of Fatigue Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							PSYCHIATRIC-DISORDERS; SLEEP; DEPRESSION; SCALE; DISTURBANCES; NEUROENDOCRINE; ASSOCIATION; PREVALENCE; ANXIETY	Objective: Fatigue is one of the most frequent sequelae of traumatic brain injury (TBI), although its causes are poorly understood. This study investigated the interrelationships between fatigue and sleepiness, vigilance performance, depression, and anxiety, using a structural equation modeling approach. Methods: Seventy-two participants with moderate to severe TBI (78% males) were recruited a median of 305 days postinjury. They completed the Fatigue Severity Scale, a vigilance task, the Epworth Sleepiness Scale, and Hospital Anxiety and Depression Scale. A model of the interrelationships between the study variables was developed, tested, and modified with path analysis. Results: The modified model had a good overall fit (chi(2)(2) = 1.3, P = .54; comparative fit index = 1.0; root-mean square error of approximation = 0.0; standardized root-mean square residual = 0.02). Most paths in this model were significant (P < .05). Fatigue predicted anxiety, depression, and daytime sleepiness. Depression predicted daytime sleepiness and poor vigilance, whereas anxiety tended to predict reduced daytime sleepiness. Conclusions: This model confirms the complexity of fatigue experience. It supports the hypothesis that fatigue after TBI is a cause, not a consequence, of anxiety, depression, and daytime sleepiness, which, in turn (especially depression), may exacerbate fatigue by affecting cognitive functioning. These findings suggest that to alleviate fatigue, it is important to address each of these factors. However, the findings need to be confirmed with a longitudinal research design.	[Ponsford, Jennie; Schoenberger, Michael; Rajaratnam, Shantha M. W.] Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol & Psychotherapy, D-79106 Freiburg, Germany		Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu		Rajaratnam, Shantha/0000-0001-7527-8558	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [334002]; Monash UniversityMonash University; Vanda Pharmaceuticals; Takeda Pharmaceuticals North AmericaTakeda Pharmaceutical Company Ltd; Philips Lighting; Philips Respironics; Cephalon; ResMed Foundation	This work was supported by the National Health and Medical Research Council (project ID 334002) and Monash University. The authors acknowledge the contributions of Monique Roper to data collection for this study and Carlo Ziino for design of the vigilance task.; Jennie Ponsford has received royalties from Psychology Press and Guilford Press for textbooks on traumatic brain injury, has received an honorarium, travel, and accommodation support to present a lecture on fatigue and sleep disturbance at the TBI Interagency Conference in Washington, District of Columbia, May 2011. Michael Schonberger reports no conflicts of interest. Shantha Rajaratnam has served as a consultant through his institution to Vanda Pharmaceuticals, Philips Respironics, EdanSafe, The Australian Workers' Union, and National Transport Commission and has through his institution received research grants and/or unrestricted educational grants from Vanda Pharmaceuticals, Takeda Pharmaceuticals North America, Philips Lighting, Philips Respironics, Cephalon, and ResMed Foundation and reimbursements for conference travel expenses from Vanda Pharmaceuticals. His institution has received equipment donations or other support from Optalert, Compumedics, and Tyco Healthcare. He has also served as an expert witness and/or consultant to shift work organizations.	Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Arnett PA, 2002, CLIN NEUROPSYCHOL, V16, P341, DOI 10.1076/clin.16.3.341.13852; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; DeLuca J, 2005, ISS CLIN COGN NEUROP, P319; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Folkman S., 1984, STRESS; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jansson M, 2006, PSYCHOL HEALTH, V21, P383, DOI 10.1080/14768320500129015; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Parasuraman R, 1998, ATTENTIVE BRAIN, P221; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Parkes JD, 1998, J SLEEP RES, V7, P41, DOI 10.1046/j.1365-2869.1998.00093.x; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Snaith R., 1994, HOSP ANXIETY DEPRESS; Strober LB, 2005, ARCH CLIN NEUROPSYCH, V20, P631, DOI 10.1016/j.acn.2005.04.002; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	41	44	44	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2015	30	4					277	282		10.1097/HTR.0000000000000049			6	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CM8JA	WOS:000357944700006	24721811				2022-02-06	
J	Ahmed, F; Plantman, S; Cernak, I; Agoston, DV				Ahmed, Farid; Plantman, Stefan; Cernak, Ibolja; Agoston, Denes V.			The temporal pattern of changes in serum biomarker levels reveals complex and dynamically changing pathologies after exposure to a single low-intensity blast in mice	FRONTIERS IN NEUROLOGY			English	Article						blast; traumatic brain injury; mouse; serum; biomarkers	TRAUMATIC BRAIN-INJURY; VON-WILLEBRAND-FACTOR; TIME-DEPENDENT CHANGES; LIPID-PEROXIDATION; CLEAVED-TAU; MOUSE MODEL; MOLECULAR-MECHANISMS; OXIDATIVE STRESS; CNS INJURY; INFLAMMATION	Time-dependent changes in blood-based protein biomarkers can help identify the pathological processes in blast-induced traumatic brain injury (bTBI), assess injury severity, and monitor disease progression. We obtained blood from control and injured mice (exposed to a single, low-intensity blast) at 2-h, 1-day, 1-week, and 1-month post-injury. We then determined the serum levels of biomarkers related to metabolism (4-HNE, HIF-1 alpha, ceruloplasmin), vascular function (AQP1, AQP4, VEGF, vWF, Flk-1), inflammation (OPN, CINC1, fibrinogen, MIP-1a, OX-44, p38, MMP-8, MCP-1 CCR5, CRP, galectin-1), cell adhesion and the extracellular matrix (integrin alpha 6, TIMP1, TIMP4, Ncad, connexin-43), and axonal (NF-H, Tau), neuronal (NSE, CK-BB) and glial damage (GFAP, S100 beta, MBP) at various post-injury time points. Our findings indicate that the exposure to a single, low-intensity blast results in metabolic and vascular changes, altered cell adhesion, and axonal and neuronal injury in the mouse model of bTBI. Interestingly, serum levels of several inflammatory and astroglial markers were either unchanged or elevated only during the acute and subacute phases of injury. Conversely, serum levels of the majority of biomarkers related to metabolic and vascular functions, cell adhesion, as well as neuronal and axonal damage remained elevated at the termination of the experiment (1 month), indicating long-term systemic and cerebral alterations due to blast. Our findings show that the exposure to a single, low-intensity blast induces complex pathological processes with distinct temporal profiles. Hence, monitoring serum biomarker levels at various post-injury time points may provide enhanced diagnostics in blast-related neurological and multi-system deficits.	[Ahmed, Farid; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Plantman, Stefan; Agoston, Denes V.] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Cernak, Ibolja] Univ Alberta, Fac Rehabil Med, Canadian Mil & Vet Clin Rehabil Res, Edmonton, AB, Canada		Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	denes.agoston@usuhs.edu		Ibolja, Cernak/0000-0003-3214-698X	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G170AZ]	This work was supported by the Center for Neuroscience and Regenerative Medicine, grant G170AZ. We thank Ms. Alaa Kamnaksh and Mr. John Olson for their editorial help.	Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Agre P, 2003, FEBS LETT, V555, P72, DOI 10.1016/S0014-5793(03)01083-4; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI 10.1089/neu.2008-0765; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; [Anonymous], 1944, LANCET, V1, P788; Appelboom G, 2012, ACTA NEUROCHIR, V154, P131, DOI 10.1007/s00701-011-1210-3; Ayton S, 2014, FREE RADICAL BIO MED, V69, P331, DOI 10.1016/j.freeradbiomed.2014.01.041; Badaut J, 2014, BBA-GEN SUBJECTS, V1840, P1554, DOI 10.1016/j.bbagen.2013.10.032; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Bickel C, 2002, AM J CARDIOL, V89, P901, DOI 10.1016/S0002-9149(02)02236-1; Borkakoti N, 1998, PROG BIOPHYS MOL BIO, V70, P73, DOI 10.1016/S0079-6107(98)00003-0; Bowen I.G., 1968, ESTIMATE MANS TOLERA, P1; Braitch Manjit, 2010, Inflammation & Allergy Drug Targets, V9, P249; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brill A, 2012, J THROMB HAEMOST, V10, P1662, DOI 10.1111/j.1538-7836.2012.04820.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; CARAYON A, 1963, Mem Acad Chir (Paris), V89, P509; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2015, BRAIN NEUROTRAUMA MO, P629; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00128; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen WQ, 2008, NEUROBIOL DIS, V31, P433, DOI 10.1016/j.nbd.2008.05.020; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Croll SD, 2004, ADV EXP MED BIOL, V548, P57; Dash PK, 2010, J NEUROSCI RES, V88, P1719, DOI 10.1002/jnr.22336; Davalos D, 2012, SEMIN IMMUNOPATHOL, V34, P43, DOI 10.1007/s00281-011-0290-8; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; De Oliveira CO, 2007, J NEUROTRAUM, V24, P1331, DOI 10.1089/neu.2006.0159; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; Gardner J, 2006, J NEUROSCI RES, V83, P1281, DOI 10.1002/jnr.20823; Gatson J, 2014, JAMA NEUROL, V71, P677, DOI 10.1001/jamaneurol.2014.443; Gerstner ER, 2009, NAT REV CLIN ONCOL, V6, P229, DOI 10.1038/nrclinonc.2009.14; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hsieh CH, 2008, J IMMUNOL, V181, P2806, DOI 10.4049/jimmunol.181.4.2806; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Jang YN, 2009, J NEUROSCI, V29, P5974, DOI 10.1523/JNEUROSCI.6178-08.2009; Jean A, 2014, P NATL ACAD SCI USA, V111, P15310, DOI 10.1073/pnas.1415743111; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kamnaksh A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04809; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kanemaru K, 2013, P NATL ACAD SCI USA, V110, P11612, DOI 10.1073/pnas.1300378110; Katayama T, 2009, J PHARMACOL SCI, V109, P88, DOI 10.1254/jphs.08298FP; Kawa L., 2014, J NEUROTRAUMA; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Lakis N, 2013, NEUROL RES, V35, P290, DOI 10.1179/1743132813Y.0000000177; Lenting PJ, 2012, J THROMB HAEMOST, V10, P2428, DOI 10.1111/jth.12008; Li AH, 2013, J MOL NEUROSCI, V51, P1052, DOI 10.1007/s12031-013-0084-7; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Mendez MF, 2013, BRAIN INJURY, V27, P10, DOI 10.3109/02699052.2012.722252; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Muradashvili N, 2013, BRAIN INJURY, V27, P1508, DOI 10.3109/02699052.2013.823562; Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514; Niki E, 2008, BIOFACTORS, V34, P171, DOI 10.1002/biof.5520340208; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Rauch A, 2013, MEDITERR J HEMATOL I, V5, DOI 10.4084/MJHID.2013.046; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shin T, 2012, ACTA HISTOCHEM, V114, P749, DOI 10.1016/j.acthis.2012.08.004; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Tsai YD, 2013, BRAIN INJURY, V27, P361, DOI 10.3109/02699052.2012.750738; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Versace A, 2014, MOL PSYCHIATR, V19, P200, DOI 10.1038/mp.2012.188; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Xie K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064907; Yelverton JT, 1996, J TRAUMA, V40, pS111, DOI 10.1097/00005373-199603001-00025	107	44	44	5	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUN 12	2015	6								114	10.3389/fneur.2015.00114			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CU9FC	WOS:000363848400001	26124743	Green Published, gold			2022-02-06	
J	Kabu, S; Jaffer, H; Petro, M; Dudzinski, D; Stewart, D; Courtney, A; Courtney, M; Labhasetwar, V				Kabu, Shushi; Jaffer, Hayder; Petro, Marianne; Dudzinski, Dave; Stewart, Desiree; Courtney, Amy; Courtney, Michael; Labhasetwar, Vinod			Blast-Associated Shock Waves Result in Increased Brain Vascular Leakage and Elevated ROS Levels in a Rat Model of Traumatic Brain Injury	PLOS ONE			English	Article							OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; BARRIER DISRUPTION; HUMAN NEURONS; MOUSE MODEL; EDEMA; DEFICITS; DIFFUSE; OVERPRESSURE; BREAKDOWN	Blast-associated shock wave-induced traumatic brain injury (bTBI) remains a persistent risk for armed forces worldwide, yet its detailed pathophysiology remains to be fully investigated. In this study, we have designed and characterized a laboratory-scale shock tube to develop a rodent model of bTBI. Our blast tube, driven by a mixture of oxygen and acetylene, effectively generates blast overpressures of 20-130 psi, with pressure-time profiles similar to those of free-field blast waves. We tested our shock tube for brain injury response to various blast wave conditions in rats. The results show that blast waves cause diffuse vascular brain damage, as determined using a sensitive optical imaging method based on the fluorescence signal of Evans Blue dye extravasation developed in our laboratory. Vascular leakage increased with increasing blast overpressures and mapping of the brain slices for optical signal intensity indicated nonhomogeneous damage to the cerebral vasculature. We confirmed vascular leakage due to disruption in the blood-brain barrier (BBB) integrity following blast exposure. Reactive oxygen species (ROS) levels in the brain also increased with increasing blast pressures and with time post-blast wave exposure. Immunohistochemical analysis of the brain sections analyzed at different time points post blast exposure demonstrated astrocytosis and cell apoptosis, confirming sustained neuronal injury response. The main advantages of our shock-tube design are minimal jet effect and no requirement for specialized equipment or facilities, and effectively generate blast-associated shock waves that are relevant to battle-field conditions. Overall data suggest that increased oxidative stress and BBB disruption could be the crucial factors in the propagation and spread of neuronal degeneration following blast injury. Further studies are required to determine the interplay between increased ROS activity and BBB disruption to develop effective therapeutic strategies that can prevent the resulting cascade of neurodegeneration.	[Kabu, Shushi; Jaffer, Hayder; Petro, Marianne; Stewart, Desiree; Labhasetwar, Vinod] Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44106 USA; [Dudzinski, Dave] Cleveland Clin, Med Device Solut, Lerner Res Inst, Cleveland, OH 44106 USA; [Courtney, Amy; Courtney, Michael] BTG Res, Colorado Springs, CO USA		Labhasetwar, V (corresponding author), Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44106 USA.	labhasv@ccf.org	Labhasetwar, Vinod/J-9660-2016	Labhasetwar, Vinod/0000-0001-7950-1542; Courtney, Amy/0000-0002-1925-8736			Ahn HY, 2012, J AM CHEM SOC, V134, P4721, DOI 10.1021/ja210315x; Alley M., 2009, THESIS PURDUE U W LA; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Blixt J, 2015, BRAIN RES; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen Y, 2013, J NEUROPSYCH CLIN N, V25, P103, DOI 10.1176/appi.neuropsych.12030058; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00117; Chen Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039353; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney AC, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3702803; Courtney E, 2014, DEF TECHNOL, V10, P245, DOI 10.1016/j.dt.2014.04.003; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; Her H, 2012, QUANTIFYING MOMENTUM; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iffland PH, 2013, NEUROBIOL DIS, V59, P206, DOI 10.1016/j.nbd.2013.07.006; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jaffer H, 2013, SCI REP-UK, V3, DOI 10.1038/srep03117; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Mediavilla Varas Jesus, 2011, Front Neurol, V2, P58, DOI 10.3389/fneur.2011.00058; Newman AJ, 2015, J NEUROSCI METH, V242, P82, DOI 10.1016/j.jneumeth.2015.01.009; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1; Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Singhal A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.362; Stuhmiller JH, 2008, MILITARY QUANTITATIV, P267; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7	64	44	46	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2015	10	5							e0127971	10.1371/journal.pone.0127971			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CJ2MQ	WOS:000355319400062	26024446	Green Published, gold			2022-02-06	
J	Haring, RS; Narang, K; Canner, JK; Asemota, AO; George, BP; Selvarajah, S; Haider, AH; Schneider, EB				Haring, R. Sterling; Narang, Kunal; Canner, Joseph K.; Asemota, Anthony O.; George, Benjamin P.; Selvarajah, Shalini; Haider, Adil H.; Schneider, Eric B.			Traumatic brain injury in the elderly: morbidity and mortality trends and risk factors	JOURNAL OF SURGICAL RESEARCH			English	Article						Older adult; TBI; Mortality; Morbidity; Risk factors	UNITED-STATES; SEVERITY SCORE; OLDER; DISABILITY; OUTCOMES; CARE; TBI; AGE	An estimated 1.7 million people sustain a traumatic brain injury (TBI) annually in the United States. We sought to examine factors contributing to mortality among TBI patients aged >= 65 y in the United States. TBI data from the Nationwide Inpatient Sample were combined from 2000-2010. Patients were stratified by age, sex, mechanism of injury, payer status, comorbidity, injury severity, and other factors. Odds of death were explored using an adjusted multivariable logistic regression. A total of 950,132 TBI-related hospitalizations and 107,666 TBI-related deaths occurred among adults aged >= 65 y from 2000-2010. The most common mechanism of injury was falling, and falls were more common among the oldest age groups. Logistic regression analysis showed highest odds of death among male patients, those whose mechanism of injury was motor vehicle related, patients with three or more comorbidities, and patients who were designated as self-paying. (C) 2015 Elsevier Inc. All rights reserved.	[Haring, R. Sterling; Haider, Adil H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Haring, R. Sterling] Lake Erie Coll Osteopath Med, Dept Osteopath Med, Bradenton, FL USA; [Haring, R. Sterling; Narang, Kunal; Canner, Joseph K.; Asemota, Anthony O.; George, Benjamin P.; Selvarajah, Shalini; Haider, Adil H.; Schneider, Eric B.] Johns Hopkins Univ, CSTOR, Dept Surg, Baltimore, MD USA; [Asemota, Anthony O.] Johns Hopkins Univ, Dept Neurol & Neurosurg, Baltimore, MD USA; [George, Benjamin P.] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA		Schneider, EB (corresponding author), Johns Hopkins Univ Hosp, Dept Surg, CSTOR, 600 N Wolfe St,Blalock 618, Baltimore, MD 21287 USA.	eschnei1@jhmi.edu		Narang, Kunal/0000-0001-5980-4845; Haring, R. Sterling/0000-0002-5417-3914	Patient-Centered Outcomes Research InstitutePatient-Centered Outcomes Research Institute - PCORI [AD-1306-03980]; American College of Surgeons; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112-01]; World Health Organization, Geneva, SwitzerlandWorld Health Organization; Karolinska Institutet, Stockholm, Sweden; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112] Funding Source: NIH RePORTER	R.S.H., K.N., J.K.C., A.O.A., B.P.G., and S.S. had no competing interests. A.H.H. receives funding from the Patient-Centered Outcomes Research Institute, (AD-1306-03980) the American College of Surgeons, (C. James Carrico Fellowship) and the National Institute of General Medical Sciences (K23GM093112-01). E.B.S. has pending patents regarding central nervous system trauma, is amember of Bergeim, LLC, and receives support for consulting from the World Health Organization, Geneva, Switzerland and Karolinska Institutet, Stockholm, Sweden.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P33; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clark DE, 2010, ICDPIC STATA MODULE; Committee on Injury Scaling, 1980, AM ASS AUTOMOT MED; Coronado V, 2012, EPIDEMIOLOG IN PRESS; Coronado V, 2006, JAMA-J AM MED ASSOC, V295, P201; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cuthbert J, 2011, ARCH PHYS MED REHABI, V92; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Day JC, 1996, POPULATION PROJECTIO; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Haider A, 2007, ARCH SURG-CHICAGO, V143, P945; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; HCUP National Inpatient Sample (NIS), 2000, HEALTHC COST UT PROJ; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; MACKENZIE EJ, 1985, MED CARE, V23, P823, DOI 10.1097/00005650-198506000-00008; Michael YL, 2010, ANN INTERN MED, V153, P815, DOI 10.7326/0003-4819-153-12-201012210-00008; O'Keefe G, 2001, INJ CONTROL; Ortman J.M., 2009, US POPULATION PROJEC; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Quigley P, 2007, ONLINE J ISSUES NURS, V12, P1; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schneider EB, 2012, J SURG RES, V177, P295, DOI 10.1016/j.jss.2012.06.022; Sears JM, 2013, J OCCUP REHABIL, V23, P19, DOI 10.1007/s10926-012-9377-x; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; StataCorp, 2011, STAT STAT SOFTW; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; THURMAN D, 2001, HEAD TRAUMA BASIC PR; U.S. Census Bureau DID, POP EST; Xian Y, 2011, ANN INTERN MED, V154, P152, DOI 10.7326/0003-4819-154-3-201102010-00004	36	44	45	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY 1	2015	195	1					1	9		10.1016/j.jss.2015.01.017			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	CE9CA	WOS:000352139900001	25724764				2022-02-06	
J	Montenigro, PH; Bernick, C; Cantu, RC				Montenigro, Philip H.; Bernick, Charles; Cantu, Robert C.			Clinical Features of Repetitive Traumatic Brain Injury and Chronic Traumatic Encephalopathy	BRAIN PATHOLOGY			English	Article						chronic traumatic encephalopathy; concussion; mild traumatic brain injury; football; boxing; neuropathology	PROFESSIONAL FOOTBALL PLAYERS; NATIONAL INSTITUTE; LEAGUE PLAYERS; HEAD-INJURIES; WHITE-MATTER; CONCUSSION; DEMENTIA; SPECTRUM; DISEASE; BOXERS	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease characterized by a distinct pattern of hyperphosphorylated tau (p-tau). Thought to be caused by repetitive concussive and subconcussive injuries, CTE is considered largely preventable. The majority of neuropathologically confirmed cases have occurred in professional contact sport athletes (eg, boxing, football). A recent post-mortem case series has magnified concerns for the public's health following its identification in six high school level athletes. CTE is diagnosed with certainty only following a post-mortem autopsy. Efforts to define the etiology and clinical progression during life are ongoing. The goal of this article is to characterize the clinical concepts associated with short- and long-term effects of repetitive traumatic brain injury, with a special emphasis on new clinical diagnostic criteria for CTE. Utilizing these new diagnostic criteria, two cases of neuropathologically confirmed CTE, one in a professional football player and one in a professional boxer, are reported. Differences in cerebellar pathology in CTE confirmed cases in boxing and football are discussed.	[Montenigro, Philip H.; Cantu, Robert C.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Ctr, Boston, MA 02118 USA; [Montenigro, Philip H.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurol & Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA 01742 USA; [Bernick, Charles] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA; [Cantu, Robert C.] Sports Legacy Inst, Waltham, MA USA		Cantu, RC (corresponding author), Emerson Hosp, John Cuming Bldg,Suite 820, Concord, MA 01742 USA.	rcantu@emersonhosp.org		Montenigro, Philip/0000-0003-4442-9207	Top Rank Promotions; Golden Boy Promotions; Bellator/Spike TV; Zuffa	P. Montenigro reports no disclosures. C. Bernick receives research support for the Professional Fighters Brain Health study from Top Rank Promotions, Golden Boy Promotions, Bellator/Spike TV, Zuffa. R. Cantu receives compensation from the National Football League as Senior Advisor to the Head Neck and Spine Committee, from the National Operating Committee on Safety of Athletic Equipment as Chairman of the Scientific Advisory Committee and from Sports Legacy Institute as co-founder and Medical Director for some talks given and research conducted. He receives royalties from Houghton Mifflin Harcourt and compensation from expert legal opinion.	Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Bernick C, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt177; Bernick C, 2013, AM J EPIDEMIOL, V178, P280, DOI 10.1093/aje/kws456; BETTI O O, 1969, Acta Neurologica Latinoamericana, V15, P47; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; BRANDENBURG W, 1954, Virchows Arch Pathol Anat Physiol Klin Med, V325, P680, DOI 10.1007/BF00955101; Brown LM, 2005, INT J GERIATR PSYCH, V20, P911, DOI 10.1002/gps.1375; Cantu R., 2012, CONCUSSIONS OUR KIDS; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2000, NEUROLOGIC ATHLETIC, P2; Cantu RC, 2006, NEUROSURG FOCUS, V21, P1, DOI [10.3171/foc.2006.21.4.4, DOI 10.3171/FOC.2006.21.4.4]; Cantu RC, 2013, JAMA NEUROL, V70, P1481, DOI 10.1001/jamaneurol.2013.3231; Cantu RC, 2013, WORLD NEUROSURG, V80, P792, DOI 10.1016/j.wneu.2013.10.011; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; Constantinidis J, 1967, Schweiz Arch Neurol Neurochir Psychiatr, V100, P117; Cordeiro Q, 2001, ARQ NEURO-PSIQUIAT, V59, P283, DOI 10.1590/S0004-282X2001000200029; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Critchley M., 1949, HOMMAGE CLOVIS VINCE, P131; Crook T, 1983, ASSESSMENT GERIATRIC; Galvin JE, 2005, NEUROLOGY, V65, P559, DOI 10.1212/01.wnl.0000172958.95282.2a; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; Grinnon ST, 2012, CLIN TRIALS, V9, P322, DOI 10.1177/1740774512438980; Handratta V, 2010, NEUROCASE, V16, P125, DOI 10.1080/13554790903329166; HARVEY PKP, 1974, LANCET, V2, P928; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Jayarao M, 2010, PHYSICIAN SPORTSMED, V38, P18, DOI 10.3810/psm.2010.10.1804; JEDLINSKI J, 1971, Acta Medica Polona, V12, P443; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; Jordan BD, 1998, NEUROBIOLOGY OF PRIMARY DEMENTIA, P191; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan BD, 1992, MED ASPECTS BOXING, P150; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; La Cava G, 1952, DTSCH SPORTEIRZTE K, V79, P817; Lehman EJ, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt188; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Levin B, 2014, NEUROCRIT CARE, V20, P334, DOI 10.1007/s12028-013-9931-1; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Margulies SS, 2015, BRAIN PATHOL, V25, P289, DOI 10.1111/bpa.12247; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; MEYERS KR, 1974, ARCH NEUROL-CHICAGO, V30, P84, DOI 10.1001/archneur.1974.00490310086013; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, NEUROLOGY, V83, P1992; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Otero Siliceo E, 2004, ARCH NEUROCIENC, V9, P114; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Roberts A, 1969, BRIAN DAMAGE BOXERS; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Sinnott RA, 2012, J INT SOC SPORTS S1, V9, pP28; Slobounov S, 2014, BRIT J SPORT MED, V48, P75, DOI 10.1136/bjsports-2013-092362; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith C, 2015, BRAIN PATHOL, V25, P287, DOI 10.1111/bpa.12251; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Spitznagel MB, 2005, ARCH CLIN NEUROPSYCH, V20, P505, DOI 10.1016/j.acn.2004.11.003; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2015, NEUROLOGY, V85, P1008; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; THORNDIKE A, 1952, NEW ENGL J MED, V247, P554, DOI 10.1056/NEJM195210092471504; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; UHL GR, 1982, ANN NEUROL, V12, P99; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Victoroff J, 2013, NEUROREHABILITATION, V32, P211, DOI 10.3233/NRE-130839; Weir DR., 2009, NATL FOOTBALL LEAGUE; World Health Organization, 1992, ICD 10 CLASSIFICATIO	97	44	45	5	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	MAY	2015	25	3					304	317		10.1111/bpa.12250			14	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	CG6CX	WOS:000353384200008	25904046	Green Published			2022-02-06	
J	Laccheo, I; Sonmezturk, H; Bhatt, AB; Tomycz, L; Shi, YP; Ringel, M; DiCarlo, G; Harris, D; Barwise, J; Abou-Khalil, B; Haas, KF				Laccheo, Ikuko; Sonmezturk, Hasan; Bhatt, Amar B.; Tomycz, Luke; Shi, Yaping; Ringel, Marianna; DiCarlo, Gina; Harris, DeAngelo; Barwise, John; Abou-Khalil, Bassel; Haas, Kevin F.			Non-convulsive Status Epilepticus and Non-convulsive Seizures in Neurological ICU Patients	NEUROCRITICAL CARE			English	Article						Neurological ICU; Critical care; Altered mental status; Non-convulsive seizures; Non-convulsive status epilepticus; EEG	INTENSIVE-CARE-UNIT; REFRACTORY STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; CONTINUOUS EEG; ELECTROGRAPHIC SEIZURES; NEUROCRITICAL CARE; CLINICAL-FEATURES; MANAGEMENT; PREVALENCE; MORTALITY	Non-convulsive seizures (NCS) or non-convulsive status epilepticus (NCSE) has been reported in 8-20 % of critically ill patient populations, and delayed diagnosis and treatment of NCSE may lead to increased mortality. This study seeks to better understand the risk factors, characteristics, and outcome of NCS/NCSE in the neurological ICU. This is a prospective observational study, recruiting consecutive patients admitted to the adult neurological ICU with altered mental status. Patients with anoxic brain injury were excluded from the study. Data were collected and analyzed for prevalence of NCSE/NCS, EEG patterns, associated risk factors, treatment response, and final outcome. NCSE/NCS was detected in 21 % of 170 subjects. Clinical seizures preceded EEG diagnosis of NCSE/NCS in 25 % of cases. Significant risk factors for NCSE/NCS were a past medical history of intracranial tumor, epilepsy, or meningitis/encephalitis, or MRI evidence of encephalomalacia. Subtle clinical findings such as twitching of oral or ocular muscles and eye deviations were found on exam in 50 % of the NCSE/NCS group. Mortality was increased in NCSE cases as 31 % of NCSE/NCS patients died compared to 14 % in non-NCSE/NCS group. Specific clinical features along with history and imaging findings may be used to identify patients at high risk of NCSE/NCS in the neurological ICU.	[Laccheo, Ikuko] Vet Affairs Med Ctr, Epilepsy Ctr Excellence, Richmond, VA 23224 USA; [Laccheo, Ikuko] Virginia Commonwealth Univ, Richmond, VA USA; [Sonmezturk, Hasan; Bhatt, Amar B.; Shi, Yaping; Ringel, Marianna; DiCarlo, Gina; Harris, DeAngelo; Barwise, John; Abou-Khalil, Bassel; Haas, Kevin F.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Tomycz, Luke] Seattle Childrens Hosp, Seattle, WA USA		Laccheo, I (corresponding author), Vet Affairs Med Ctr, Epilepsy Ctr Excellence, Richmond, VA 23224 USA.	ikuko.laccheo@gmail.com					Benbadis SR, 2000, NEUROLOGY, V55, P1421, DOI 10.1212/WNL.55.9.1421-a; Beniczky S, 2013, EPILEPSIA, V54, P28, DOI 10.1111/epi.12270; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2005, J CLIN NEUROPHYSIOL, V22, P92, DOI 10.1097/01.WNP.0000145006.02048.3A; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Cocito L, 2001, ARCH NEUROL-CHICAGO, V58, P1310, DOI 10.1001/archneur.58.8.1310; Cooper AD, 2009, ARCH NEUROL-CHICAGO, V66, P1505, DOI 10.1001/archneurol.2009.273; DeLorenzo RJ, 1999, EPILEPSIA, V40, P164, DOI 10.1111/j.1528-1157.1999.tb02070.x; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Dennis LJ, 2002, NEUROSURGERY, V51, P1136, DOI 10.1097/00006123-200211000-00006; Drislane FW, 2008, J CLIN NEUROPHYSIOL, V25, P181, DOI 10.1097/WNP.0b013e31817be70e; Flores-Cordero JM, 2003, INTENS CARE MED, V29, P1967, DOI 10.1007/s00134-003-1935-4; Holtkamp M, 2005, J NEUROL NEUROSUR PS, V76, P534, DOI 10.1136/jnnp.2004.041947; Husain AM, 2003, J NEUROL NEUROSUR PS, V74, P189, DOI 10.1136/jnnp.74.2.189; Jordan Kenneth G, 2009, Am J Electroneurodiagnostic Technol, V49, P94; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Kaplan PW, 2007, EPILEPSIA, V48, P39, DOI 10.1111/j.1528-1167.2007.01345.x; Khan SF, 2005, CLIN NEUROPHYSIOL, V116, P2454, DOI 10.1016/j.clinph.2005.06.024; Kramer AH, 2012, CAN J NEUROL SCI, V39, P328, DOI 10.1017/S0317167100013469; Little AS, 2007, J NEUROSURG, V106, P805, DOI 10.3171/jns.2007.106.5.805; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; Maschio M, 2012, J NEURO-ONCOL, V109, P1, DOI 10.1007/s11060-012-0867-7; Mecarelli O, 2011, CEREBROVASC DIS, V31, P191, DOI 10.1159/000321872; Meierkord H, 2010, EUR J NEUROL, V17, P348, DOI 10.1111/j.1468-1331.2009.02917.x; Mirski MA, 2008, CRIT CARE CLIN, V24, P115, DOI 10.1016/j.ccc.2007.11.005; Narayanan JT, 2007, EPILEPSIA, V48, P900, DOI 10.1111/j.1528-1167.2007.01099.x; Ney JP, 2013, NEUROLOGY, V81, P2002, DOI 10.1212/01.wnl.0000436948.93399.2a; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Rossetti AO, 2005, ARCH NEUROL-CHICAGO, V62, P1698, DOI 10.1001/archneur.62.11.1698; Spindler M, 2013, J CLIN NEUROPHYSIOL, V30, P339, DOI 10.1097/WNP.0b013e31829ddcdb; Sutter R, 2014, NEUROLOGY, V82, P656, DOI 10.1212/WNL.0000000000000009; TOWNE AR, 1994, EPILEPSIA, V35, P27, DOI 10.1111/j.1528-1157.1994.tb02908.x; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Treiman DM, 2006, EPILEPSY RES, V68, pS77, DOI 10.1016/j.eplepsyres.2005.07.020; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2005, CURR OPIN CRIT CARE, V11, P133, DOI 10.1097/01.ccx.0000155353.01489.58; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Walker MC, 2003, J NEUROL, V250, P401, DOI 10.1007/s00415-003-1042-z; Waterhouse EJ, 1999, EPILEPSIA, V40, P752, DOI 10.1111/j.1528-1157.1999.tb00774.x; Young GB, 1999, J CLIN NEUROPHYSIOL, V16, P354, DOI 10.1097/00004691-199907000-00008; Young GB, 1996, NEUROLOGY, V47, P83; Zoons E, 2008, NEUROLOGY, V70, P2109, DOI 10.1212/01.wnl.0000288178.91614.5d	49	44	47	0	15	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2015	22	2					202	211		10.1007/s12028-014-0070-0			10	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CD9VK	WOS:000351447100005	25246236				2022-02-06	
J	Cui, HJ; Yang, AL; Zhou, HJ; Wang, C; Luo, JK; Lin, Y; Zong, YX; Tang, T				Cui, Han-Jin; Yang, A-Li; Zhou, Hua-Jun; Wang, Cong; Luo, Jie-Kun; Lin, Yuan; Zong, Yan-Xia; Tang, Tao			Buyang huanwu decoction promotes angiogenesis via vascular endothelial growth factor receptor-2 activation through the PI3K/Akt pathway in a mouse model of intracerebral hemorrhage	BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE			English	Article						Intracerebral hemorrhage; Angiogenesis; Vascular endothelial growth factor receptor-2; Phosphorylation; PI3K/Akt; Buyang huanwu decoction	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CELL-PROLIFERATION; SHEAR-STRESS; EXPRESSION; STROKE; VEGF; RECOVERY; RATS; INHIBITOR	Background: Intracerebral hemorrhage (ICH) is a fatal subtype of stroke that lacks effective treatments. Angiogenesis following ICH is an important response mediating brain recovery and repair. Phosphorylation of vascular endothelial growth factor receptor 2 (pVEGFR2) via PI3K/Akt signaling plays a key role in mediating cellular processes involved in repair, such as mitogenesis, angiogenesis, and vascular permeability. This study aimed to investigate the potential effects of Buyang Huanwu Decoction (BYHWD), a traditional Chinese medicine formula, on angiogenesis by VEGFR2 activation through the phosphatidylinositol 3 kinase (PI3K)/Akt signaling pathway in a mouse model of ICH. Methods: Adult male Kunming mice (n = 50) were randomly assigned into sham and ICH-operated groups and treated with one of the followings SU5416 (VEGFR2 inhibitor), BYHWT and BYHWT + SU5416. ICH was induced in mice by injecting collagenase (type VII) into the right globus pallidus of the mouse brain. BYHWD (4.36 g/kg) was administrated in mice by intragastric infusion. Neurological function was evaluated in mice by a modified Neurological Severity Scores (mNSS) as well as corner turn and foot-fault tests. Angiogenesis was examined by intraperitoneal injection of 5-bromodeoxyuridine (BrdU) in mice to quantify new brain vessel growth. SU5416 treatment and assessment of VEGFR2 phosphorylation as well as alterations in PI3K/Akt signaling were performed to determine whether the effect of BYHWD on angiogenesis was partly mediated by phosphorylation of VEGFR2 via the PI3K/Akt signaling pathway. Results: We show that BYHWD treated mice exhibited (i) significantly better recovery from neurological dysfunction, (ii) increased BrdU(+) nuclei in vWF(+) dilated brain vessels and (iii) higher VEGFR2 phosphorylation immunoreactivity in brain microvessels (P<0.05), (iv) higher expression of PI3K and pAkt at the protein level (P<0.05) when compared to untreated ICH mice. These beneficial effects were reversed by SU5416 (P<0.05). Conclusions: BYHWD promoted neurological recovery and angiogenesis after ICH in mice by enhancing VEGFR2 phosphorylation through the PI3K/Akt signaling pathway.	[Cui, Han-Jin; Wang, Cong; Luo, Jie-Kun; Zong, Yan-Xia; Tang, Tao] Cent S Univ, Inst Integrat Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Yang, A-Li] Cent S Univ, Inst Neurol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Cui, Han-Jin; Yang, A-Li; Zhou, Hua-Jun; Wang, Cong; Luo, Jie-Kun; Lin, Yuan; Zong, Yan-Xia; Tang, Tao] Key Lab Chinese Gan SATCM, Changsha 410008, Hunan, Peoples R China; [Zhou, Hua-Jun] China Three Gorges Univ, Inst Neurol, Coll Clin Med Sci 1, Yichang 443003, Hubei, Peoples R China		Tang, T (corresponding author), Cent S Univ, Inst Integrat Med, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.	falcontang@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81473573, 81173175, 81202625]; Project for New Century Excellent Talent [NCET-11-0522]; Hunan Provincial Natural Science FoundationNatural Science Foundation of Hunan Province [14JJ2024]; Hunan TCM Project [201424]	This study was supported by grants from the National Natural Science Foundation of China (Grant Nos. 81473573, 81173175, 81202625), the Project for New Century Excellent Talent (NCET-11-0522), the Hunan Provincial Natural Science Foundation (Grant Nos. 14JJ2024), and Hunan TCM Project (Grant Nos. 201424)	Adeoye O, 2010, NAT REV NEUROL, V6, P593, DOI 10.1038/nrneurol.2010.146; Adjei AA, 2007, CLIN LUNG CANCER, V8, pS74, DOI 10.3816/CLC.2007.s.005; Andaluz N, 2009, J NEUROSURG, V110, P403, DOI 10.3171/2008.5.17559; Cai GX, 2007, J ETHNOPHARMACOL, V113, P292, DOI 10.1016/j.jep.2007.06.007; Cecatto RB, 2014, AM J PHYS MED REHAB, V93, P791, DOI 10.1097/PHM.0000000000000104; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Del Bigio MR, 1999, NEUROL RES, V21, P415, DOI 10.1080/01616412.1999.11740953; Dellinger MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028947; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fournier NM, 2012, NEUROPHARMACOLOGY, V63, P642, DOI 10.1016/j.neuropharm.2012.04.033; Gharbi SI, 2007, BIOCHEM J, V404, P15, DOI 10.1042/BJ20061489; Hao CZ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/630124; Imbe H, 2010, BRAIN RES, V1329, P103, DOI 10.1016/j.brainres.2010.03.006; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444; Kieran MW, 2009, PEDIATR BLOOD CANCER, V52, P169, DOI 10.1002/pbc.21873; Kleim JA, 2007, ILAR J, V48, P374, DOI 10.1093/ilar.48.4.374; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Krafft PR, 2014, BEHAV BRAIN RES, V264, P151, DOI 10.1016/j.bbr.2014.01.052; Lakshmikanthan S, 2011, BLOOD, V118, P2015, DOI 10.1182/blood-2011-04-349282; Lee Hyoshin, 2007, Plant Biology (Rockville), V2007, P156; Li WL, 2011, EXP BRAIN RES, V214, P503, DOI 10.1007/s00221-011-2849-y; Liu Hua, 2005, Chin J Integr Med, V11, P167; Narantuya D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011746; O'Farrell AM, 2004, LEUKEMIA RES, V28, P679, DOI 10.1016/j.leukres.2003.11.004; Reshef A, 2008, J NEUROTRAUM, V25, P569, DOI 10.1089/neu.2007.0341; Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Shimotake J, 2010, STROKE, V41, P343, DOI 10.1161/STROKEAHA.109.564229; Sho E, 2003, EXP MOL PATHOL, V75, P1, DOI 10.1016/S0014-4800(03)00032-7; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Smith JK, 2004, ONCOL RES, V14, P175, DOI 10.3727/000000003772462298; Tang T, 2007, BRAIN RES, V1175, P134, DOI 10.1016/j.brainres.2007.08.028; Tiwari A, 2012, HEMATOLOGY SCI PRACT, P253; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Urbich C, 2003, FEBS LETT, V535, P87, DOI 10.1016/S0014-5793(02)03879-6; Urschel K, 2011, ATHEROSCLEROSIS, V219, P499, DOI 10.1016/j.atherosclerosis.2011.09.045; van der Meer AD, 2010, BIORHEOLOGY, V47, P179, DOI 10.3233/BIR-2010-0569; Wang DZ, 2009, CURR NEUROL NEUROSCI, V9, P13, DOI 10.1007/s11910-009-0003-z; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wei RL, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/138484; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu XG, 2011, NEURAL REGEN RES, V6, P656, DOI 10.3969/j.issn.1673-5374.2011.09.003; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Zan L, 2014, NEUROSCIENCE, V262, P118, DOI 10.1016/j.neuroscience.2013.12.060; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang L, 2011, J PHARMACOL EXP THER, V338, P485, DOI 10.1124/jpet.111.180992; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhang ZQ, 2007, CHIN J INTEGR MED, V13, P285, DOI 10.1007/s11655-007-0285-4; Zhao LD, 2012, J ETHNOPHARMACOL, V140, P339, DOI 10.1016/j.jep.2012.01.026; Zhong XS, 2004, BIOCHEM BIOPH RES CO, V324, P471, DOI 10.1016/j.bbrc.2004.09.082	52	44	47	2	32	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1472-6882			BMC COMPLEM ALTERN M	BMC Complement. Altern. Med.	MAR 28	2015	15								91	10.1186/s12906-015-0605-8			10	Integrative & Complementary Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Integrative & Complementary Medicine	CE5TT	WOS:000351899300001	25886469	Green Published, gold			2022-02-06	
J	Chun, IY; Mao, X; Breedlove, EL; Leverenz, LJ; Nauman, EA; Talavage, TM				Chun, I. Y.; Mao, X.; Breedlove, E. L.; Leverenz, L. J.; Nauman, E. A.; Talavage, T. M.			DTI Detection of Longitudinal WM Abnormalities Due to Accumulated Head Impacts	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	2nd Annual Meeting of the CIC/Big Ten/Ivy League Traumatic Brain Injury Summit	JUL 16-17, 2014	Philadelphia, PA				TRAUMATIC BRAIN-INJURY; WHITE-MATTER	Longitudinal evaluation using diffusion-weighted imaging and collision event monitoring was performed on high school athletes who participate in American football. Observed changes in white matter health were suggestive of injury and found to be correlated with accumulation of head collision events during practices and games.	[Chun, I. Y.; Mao, X.; Talavage, T. M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Breedlove, E. L.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Leverenz, L. J.] Purdue Univ, Dept Hlth Kinesiol, W Lafayette, IN 47907 USA; [Nauman, E. A.] Purdue Univ, Sch Mech Engn, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Nauman, E. A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Talavage, T. M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA		Chun, IY (corresponding author), Purdue Univ, Sch Elect & Comp Engn, 465 Northwestern Ave, W Lafayette, IN 47907 USA.	chuni@purdue.edu	Chun, Il Yong/AAL-2113-2021	Chun, Il Yong/0000-0002-4226-3760; Talavage, Thomas/0000-0003-4977-6398	Indiana State Department of Health Spinal Cord and Brain Injury Research Fund	This work was supported by the Indiana State Department of Health Spinal Cord and Brain Injury Research Fund.	Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett CM, 2009, SOC COGN AFFECT NEUR, V4, P417, DOI 10.1093/scan/nsp053; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024	12	44	44	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	FEB 17	2015	40	2			SI		92	97		10.1080/87565641.2015.1020945			6	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology	CH6UW	WOS:000354172800008	25961592				2022-02-06	
J	Borich, M; Babul, AN; Yuan, PH; Boyd, L; Virji-Babul, N				Borich, Michael; Babul, Aliya-Nur; Yuan, Po Hsiang; Boyd, Lara; Virji-Babul, Naznin			Alterations in Resting-State Brain Networks in Concussed Adolescent Athletes	JOURNAL OF NEUROTRAUMA			English	Article						fMRI; resting-state networks; concussion; adolescents	INDEPENDENT COMPONENT ANALYSIS; SPORTS-RELATED CONCUSSION; CEREBRAL BLOOD-FLOW; HEAD-INJURED CHILDREN; DEFAULT-MODE; FUNCTIONAL CONNECTIVITY; HIGH-SCHOOL; HYPOTHESIS; CORTEX; FMRI	Sports-related concussion in adolescents is a major public health issue; however, little is known about the underlying changes in functional brain connectivity. We evaluated connectivity of resting-state brain networks to determine whether alterations in specific networks distinguish adolescents with sports-related concussion from a group of healthy, active control adolescents. Twelve adolescents with a clinical diagnosis of subacute concussion and ten healthy adolescents matched for age, gender, and physical activity completed functional magnetic resonance imaging (fMRI) scanning. Functional connectivity of resting-state brain networks was evaluated in both groups using probabilistic independent component analysis (ICA). Altered functional connectivity was found within three resting-state networks in adolescents with concussion. Specifically, we noted: a) alterations within the default mode network; b) increased connectivity in the right frontal pole in the executive function network; and c) increased connectivity in the left frontal operculum cortex associated with the ventral attention network. This preliminary report shows that whole-brain functional connectivity is altered in networks related to cognition and attention in adolescents in the subacute phase following sports-related concussion. This first report in adolescents should be used to inform future studies in larger cohorts of adolescents with sports-related concussion. Increased knowledge of these changes may lead to improvements in clinical management and help to develop rehabilitation programs.	[Borich, Michael; Babul, Aliya-Nur; Yuan, Po Hsiang; Boyd, Lara; Virji-Babul, Naznin] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V6T 1Z3, Canada; [Virji-Babul, Naznin] Child & Family Res Inst, Vancouver, BC, Canada		Virji-Babul, N (corresponding author), Univ British Columbia, Dept Phys Therapy, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	nvb31@mail.ubc.ca	Meijer, Anna/K-5118-2016	Virji-Babul, Naznin/0000-0002-8984-5848	Martha Piper Research Fund, University of British Columbia; Brain Research Centre, University of British Columbia; BC Hockey; Heart and Stroke FoundationHeart & Stroke Foundation of Canada; Canada Research ChairNatural Resources CanadaCanadian Forest ServiceCanada Research Chairs; Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research	This research was supported by the Martha Piper Research Fund, University of British Columbia and the Brain Research Centre, University of British Columbia. We would like to thank BC Hockey for their support and all the participants, trainers and coaches who took part in this study. We would also like to thank Suejin Lin for her help with the initial fMRI analysis. MRB received salary support from the Heart and Stroke Foundation. LAB is supported by a Canada Research Chair and Michael Smith Foundation for Health Research awards. Dr. Naznin Virji-Babul had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Burgess PW, 2007, TRENDS COGN SCI, V11, P290, DOI 10.1016/j.tics.2007.05.004; Cordes D, 2000, AM J NEURORADIOL, V21, P1636; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Faul M, 2010, TRAUMATIC BRAIN INJU, P891, DOI [10.1016/B978-0-444-52910-7.00011-8, DOI 10.1016/B978-0-444-52910-7.00011-8]; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2006, P NATL ACAD SCI USA, V103, P10046, DOI 10.1073/pnas.0604187103; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Higo T, 2011, P NATL ACAD SCI USA, V108, P4230, DOI 10.1073/pnas.1013361108; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Lehericy S, 2004, ANN NEUROL, V55, P522, DOI 10.1002/ana.20030; Maddock RJ, 1999, TRENDS NEUROSCI, V22, P310, DOI 10.1016/S0166-2236(98)01374-5; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005	50	44	45	0	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2015	32	4					265	271		10.1089/neu.2013.3269			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CB0KN	WOS:000349314900007	25010041				2022-02-06	
J	Genova, HM; Rajagopalan, V; Chiaravalloti, N; Binder, A; Deluca, J; Lengenfelder, J				Genova, Helen M.; Rajagopalan, Venkateswaran; Chiaravalloti, Nancy; Binder, Allison; Deluca, John; Lengenfelder, Jeannie			Facial affect recognition linked to damage in specific white matter tracts in traumatic brain injury	SOCIAL NEUROSCIENCE			English	Article						Inferior-fronto-occipital fasciculus; Emotional processing; Facial affect recognition; Traumatic brain injury; Inferior longitudinal fasciculus; Diffusion tensor imaging	EMOTION RECOGNITION; EXPRESSIONS; IMAGES; METAANALYSIS; ASSOCIATION; EXTRACTION; DISORDER; FACES; FSL; SAD	Emotional processing deficits have recently been identified in individuals with traumatic brain injury (TBI), specifically in the domain of facial affect recognition. However, the neural networks underlying these impairments have yet to be identified. In the current study, 42 individuals with moderate to severe TBI and 23 healthy controls performed a task of facial affect recognition (Facial Emotion Identification Test (FEIT)) in order to assess their ability to identify and discriminate six emotions: happiness, sadness, anger, surprise, shame, and fear. These individuals also underwent structural neuroimaging including diffusion tensor imaging to examine white matter (WM) integrity. Correlational analyses were performed to determine where in the brain WM damage was associated with performance on the facial affect recognition task. Reduced performance on the FEIT was associated with reduced WM integrity (fractional anisotropy, mean diffusivity, axial diffusivity, and radial diffusivity) in the inferior longitudinal fasciculus and inferior-fronto-occipital fasciculus in individuals with TBI. Poor performance on the task was additionally associated with reduced gray matter (GM) volume in lingual gyrus and parahippocampal gyrus. The results implicate a pattern of WM and GM damage in TBI that may play a role in emotional processing impairments.	[Genova, Helen M.; Rajagopalan, Venkateswaran; Chiaravalloti, Nancy; Deluca, John; Lengenfelder, Jeannie] Kessler Fdn Res Ctr, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; [Genova, Helen M.; Rajagopalan, Venkateswaran; Chiaravalloti, Nancy; Deluca, John; Lengenfelder, Jeannie] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [Binder, Allison] Univ Massachusetts, Dept Psychol, Amherst, MA 01003 USA; [Binder, Allison] Suffolk Univ, Dept Clin Psychol, Boston, MA 02114 USA		Genova, HM (corresponding author), Kessler Fdn Res Ctr, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA.	hgenova@kesslerfoundation.org		Chiaravalloti, Nancy/0000-0003-2943-7567	New Jersey Commission on Brain Injury Research (NJCBIR) [10-3218-BIR-E-0, CBIR13IRG026]	This work was supported by the New Jersey Commission on Brain Injury Research (NJCBIR), Research Grants [10-3218-BIR-E-0] to JL and [CBIR13IRG026] to JL and HG.	Adolphs R, 2010, ANN NY ACAD SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x; Aldinger M, 2013, PSYCHIAT RES, V205, P59, DOI 10.1016/j.psychres.2012.08.032; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Baggio HC, 2012, NEUROPSYCHOLOGIA, V50, P2121, DOI 10.1016/j.neuropsychologia.2012.05.020; Bessette KL, 2014, BRAIN IMAGING BEHAV, V8, P531, DOI 10.1007/s11682-013-9274-8; Catani M, 2003, BRAIN, V126, P2093, DOI 10.1093/brain/awg203; Fu CHY, 2008, BIOL PSYCHIAT, V64, P505, DOI 10.1016/j.biopsych.2008.04.033; Fusar-Poli P, 2009, NEUROSCI LETT, V452, P262, DOI 10.1016/j.neulet.2009.01.065; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Grieve SM, 2013, NEUROIMAGE-CLIN, V3, P332, DOI 10.1016/j.nicl.2013.08.016; Gur RC, 2002, NEUROIMAGE, V16, P651, DOI 10.1006/nimg.2002.1097; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jou RJ, 2011, AUST NZ J PSYCHIAT, V45, P153, DOI 10.3109/00048674.2010.534069; Kennedy DP, 2012, TRENDS COGN SCI, V16, P559, DOI 10.1016/j.tics.2012.09.006; KERR SL, 1993, J ABNORM PSYCHOL, V102, P312, DOI 10.1037/0021-843X.102.2.312; Martino J, 2010, CORTEX, V46, P691, DOI 10.1016/j.cortex.2009.07.015; Mike A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082422; Miyahara M, 2013, SOC COGN AFFECT NEUR, V8, P181, DOI 10.1093/scan/nsr085; Nyenhuis DL, 1998, J PERS ASSESS, V70, P386, DOI 10.1207/s15327752jpa7002_14; Philippi CL, 2009, J NEUROSCI, V29, P15089, DOI 10.1523/JNEUROSCI.0796-09.2009; Polyack S., 1957, VERTEBRATE VISUAL SY; Popescu V, 2012, NEUROIMAGE, V61, P1484, DOI 10.1016/j.neuroimage.2012.03.074; Puce A, 1996, J NEUROSCI, V16, P5205; Shukla DK, 2011, J CHILD PSYCHOL PSYC, V52, P286, DOI 10.1111/j.1469-7610.2010.02342.x; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Surguladze S, 2005, BIOL PSYCHIAT, V57, P201, DOI 10.1016/j.biopsych.2004.10.028; Suslow T, 2010, BIOL PSYCHIAT, V67, P155, DOI 10.1016/j.biopsych.2009.07.023; Trautmann SA, 2009, BRAIN RES, V1284, P100, DOI 10.1016/j.brainres.2009.05.075; WechslerD, 2001, WECHSLER TEST ADULT; Yim J, 2013, BRAIN INJURY, V27, P1155, DOI 10.3109/02699052.2013.804203; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	37	44	44	0	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1747-0919	1747-0927		SOC NEUROSCI-UK	Soc. Neurosci.	JAN 2	2015	10	1					27	34		10.1080/17470919.2014.959618			8	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	AU3GW	WOS:000345501400004	25223759				2022-02-06	
J	Rom, S; Zuluaga-Ramirez, V; Dykstra, H; Reichenbach, NL; Ramirez, SH; Persidsky, Y				Rom, Slava; Zuluaga-Ramirez, Viviana; Dykstra, Holly; Reichenbach, Nancy L.; Ramirez, Servio H.; Persidsky, Yuri			Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						BBB; PARP; endothelial dysfunction	CANNABINOID RECEPTOR 2; TRANSCRIPTION FACTORS; CEREBRAL-ISCHEMIA; KINASE; ACTIVATION; EXPRESSION; PARP-1; MIGRATION; OCCLUDIN; PATHWAY	Blood-brain barrier (BBB) dysfunction seen in neuroinflammation contributes to mortality and morbidity in multiple sclerosis, encephalitis, traumatic brain injury, and stroke. Identification of molecular targets maintaining barrier function is of clinical relevance. We used a novel in vivo model of localized aseptic meningitis where tumor necrosis factor alpha (TNF alpha) was introduced intracerebrally and surveyed cerebral vascular changes and leukocyte-endothelium interactions by intravital videomicroscopy. Poly (ADP-ribose) polymerase-1 (PARP) inhibition significantly reduced leukocyte adhesion to and migration across brain endothelium in cortical microvessels. PARP inactivation diminished BBB permeability in an in vivo model of systemic inflammation. PARP suppression in primary human brain microvascular endothelial cells (BMVEC), an in vitro model of BBB, enhanced barrier integrity and augmented expression of tight junction proteins. PARP inhibition in BMVEC diminished human monocyte adhesion to TNF alpha-activated BMVEC (up to 65%) and migration (80-100%) across BBB models. PARP suppression decreased expression of adhesion molecules and decreased activity of GTPases (controlling BBB integrity and monocyte migration across the BBB). PARP inhibitors down-regulated expression of inflammatory genes and dampened secretion of pro-inflammatory factors increased by TNF alpha in BMVEC. These results point to PARP suppression as a novel approach to BBB protection in the setting of endothelial dysfunction caused by inflammation.	[Rom, Slava; Zuluaga-Ramirez, Viviana; Dykstra, Holly; Reichenbach, Nancy L.; Ramirez, Servio H.; Persidsky, Yuri] Temple Univ, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19122 USA		Rom, S (corresponding author), MERB, Dept Pathol, 3500 N Broad St,Room 880, Philadelphia, PA 19140 USA.	srom@temple.edu	Rom, Slava/AAF-6872-2020	ramirez, servio/0000-0002-4609-5653; Rom, Slava/0000-0002-1050-1955	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AA015913, MH65151, R21NS087385, NS086570-01]; Shriners Hospitals for Children [85110-PHI-14]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087385, R01NS086570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R37AA015913, R01AA015913] Funding Source: NIH RePORTER	This work was supported in part by NIH research grants AA015913 (YP) and MH65151 (YP), R21NS087385 (SR), NS086570-01 (SHR), and The Shriners Hospitals for Children 85110-PHI-14 (SHR).	Aslam M, 2012, CYTOKINE, V57, P269, DOI 10.1016/j.cyto.2011.10.016; Aychek T, 2011, MAGN RESON MED, V66, P235, DOI 10.1002/mrm.22798; Birukov KG, 2009, MICROVASC RES, V77, P46, DOI 10.1016/j.mvr.2008.09.006; Booth G, 2001, AM J PHYSIOL-ENDOC M, V280, pE848, DOI 10.1152/ajpendo.2001.280.6.E848; Boudaoud A, 2014, NAT PROTOC, V9, P457, DOI 10.1038/nprot.2014.024; Bruewer M, 2004, AM J PHYSIOL-CELL PH, V287, pC327, DOI 10.1152/ajpcell.00087.2004; Cavone L, 2011, MULT SCLER J, V17, P794, DOI 10.1177/1352458511399113; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Doggett TM, 2011, JOVE-J VIS EXP, V57, P3187, DOI [10.3791/3187, DOI 10.3791/3187]; Erdelyi K, 2005, MOL PHARMACOL, V68, P895, DOI 10.1124/mol.105.012518; Farez MF, 2009, NAT IMMUNOL, V10, P958, DOI 10.1038/ni.1775; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Haddad M, 2006, BRIT J PHARMACOL, V149, P23, DOI 10.1038/sj.bjp.0706837; Hay T, 2009, CANCER RES, V69, P3850, DOI 10.1158/0008-5472.CAN-08-2388; Janzen DM, 2013, MOL CANCER THER, V12, P2917, DOI 10.1158/1535-7163.MCT-13-0572; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Koedel U, 2002, J CEREBR BLOOD F MET, V22, P39, DOI 10.1097/00004647-200201000-00005; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Lenzser G, 2007, J CEREBR BLOOD F MET, V27, P1318, DOI 10.1038/sj.jcbfm.9600437; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Liu LL, 2012, HUM IMMUNOL, V73, P439, DOI 10.1016/j.humimm.2012.02.002; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; Moroni F, 2008, CURR OPIN PHARMACOL, V8, P96, DOI 10.1016/j.coph.2007.10.005; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Ramirez SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055972; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Ramirez SH, 2010, J NEUROSCI, V30, P9454, DOI 10.1523/JNEUROSCI.5796-09.2010; Ramirez SH, 2010, AM J PATHOL, V176, P881, DOI 10.2353/ajpath.2010.090671; Rolfe BE, 2005, ATHEROSCLEROSIS, V183, P1, DOI 10.1016/j.atherosclerosis.2005.04.023; Rom S, 2013, AM J PATHOL, V183, P1548, DOI 10.1016/j.ajpath.2013.07.033; Rom S, 2012, AM J PATHOL, V181, P1414, DOI 10.1016/j.ajpath.2012.06.018; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Spindler V, 2010, CARDIOVASC RES, V87, P243, DOI 10.1093/cvr/cvq086; Veres B, 2003, BIOCHEM PHARMACOL, V65, P1373, DOI 10.1016/S0006-2952(03)00077-7; Vestweber D, 2008, ERNST SCHERING FOUND, V3, P151, DOI 10.1007/2789_2007_063; Wu XL, 2014, J MOL NEUROSCI, V53, P1, DOI 10.1007/s12031-013-0175-5; Yamamoto M, 2008, AM J PATHOL, V172, P521, DOI 10.2353/ajpath.2008.070076; Zhang CX, 2004, AM J PHYSIOL-HEART C, V287, pH659, DOI 10.1152/ajpheart.00162.2004	40	44	44	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2015	35	1					28	36		10.1038/jcbfm.2014.167			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AY2AZ	WOS:000347392200005	25248836	Green Published, Bronze			2022-02-06	
J	Reid, MW; Miller, KJ; Lange, RT; Cooper, DB; Tate, DF; Bailie, J; Brickell, TA; French, LM; Asmussen, S; Kennedy, JE				Reid, Matthew W.; Miller, Kelly J.; Lange, Rael T.; Cooper, Douglas B.; Tate, David F.; Bailie, Jason; Brickell, Tracey A.; French, Louis M.; Asmussen, Sarah; Kennedy, Jan E.			A Multisite Study of the Relationships between Blast Exposures and Symptom Reporting in a Post-Deployment Active Duty Military Population with Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						post-concussion; blast; post-traumatic stress; neurobehavioral symptom inventory; mild traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; OIF/OEF SERVICE MEMBERS; POSTCONCUSSIVE SYMPTOMS; IRAQI FREEDOM; HEALTH; VETERANS; TBI; ASSOCIATIONS; PTSD	Explosive devices have been the most frequent cause of traumatic brain injury (TBI) among deployed contemporary U.S. service members. The purpose of this study was to examine the influence of previous cumulative blast exposures (that did or did not result in TBI) on later post-concussion and post-traumatic symptom reporting after sustaining a mild TBI (MTBI). Participants were 573 service members who sustained MTBI divided into four groups by number of blast exposures (1, 2, 3, and 4-10) and a nonblast control group. Post-concussion symptoms were measured using the Neurobehavioral Symptom Inventory (NSI) and post-traumatic stress disorder (PTSD) symptoms using the Post-traumatic Checklist-Civilian version (PCL-C). Results show groups significantly differed on total NSI scores (p<0.001), where symptom endorsement increased as number of reported blast exposures increased. Total NSI scores were significantly higher for the 3- and 4-10 blast groups compared with the 1- and 2-blast groups with effect sizes ranging from small to moderate (d=0.31 to 0.63). After controlling for PTSD symptoms using the PCL-C total score, NSI total score differences remained between the 4-10-blast group and the 1- and 2-blast groups, but were less pronounced (d=0.35 and d=0.24, respectively). Analyses of NSI subscale scores using PCL-C scores as a covariate revealed significant between-blast group differences on cognitive, sensory, and somatic, but not affective symptoms. Regression analyses revealed that cumulative blast exposures accounted for a small but significant amount of the variance in total NSI scores (4.8%; p=0.009) and total PCL-C scores (2.3%; p<0.001). Among service members exposed to blast, post-concussion symptom reporting increased as a function of cumulative blast exposures. Future research will need to determine the relationship between cumulative blast exposures, symptom reporting, and neuropathological changes.	[Reid, Matthew W.; Miller, Kelly J.; Lange, Rael T.; Cooper, Douglas B.; Tate, David F.; Bailie, Jason; Brickell, Tracey A.; French, Louis M.; Asmussen, Sarah; Kennedy, Jan E.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA; [Reid, Matthew W.; Cooper, Douglas B.; Tate, David F.; Kennedy, Jan E.] San Antonio Mil Med Ctr, San Antonio, TX USA; [Miller, Kelly J.; Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Bailie, Jason; Asmussen, Sarah] Naval Med Ctr San Diego, San Diego, CA USA; [Asmussen, Sarah] Marine Corps Base Camp Pendleton, Camp Pendleton, CA USA		Reid, MW (corresponding author), Brooke Army Med Ctr, MCHE MDU DVBIC, 3551 Roger Brooke Dr, Jbsa Ft Sam Houston, TX 78234 USA.	matthew.w.reid2.ctr@mail.mil	french, louis/AAB-2083-2020; Tate, David F/I-3963-2013	Tate, David F/0000-0003-0213-1920; french, louis/0000-0002-9451-0604	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [L30 NS063444] Funding Source: Medline		[Anonymous], 2013, MSMR, V20, P9; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Defense and Veteran Brain Injury Center, 2014, DOD WORLDW NUMB TBI; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; MERTON RK, 1968, SCIENCE, V159, P56, DOI 10.1126/science.159.3810.56; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Taber KH, 2014, J HEAD TRAUMA REHABI; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023	26	44	44	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1899	1906		10.1089/neu.2014.3455			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500001	25036531	Green Published			2022-02-06	
J	Wu, QB; Jing, YL; Yuan, XC; Zhang, XY; Li, BW; Liu, MM; Wang, B; Li, HW; Liu, SY; Xiu, RJ				Wu, Qingbin; Jing, Yingli; Yuan, Xiaochen; Zhang, Xiaoyan; Li, Bingwei; Liu, Mingming; Wang, Bing; Li, Hongwei; Liu, Shuying; Xiu, Ruijuan			Melatonin Treatment Protects Against Acute Spinal Cord Injury-Induced Disruption of Blood Spinal Cord Barrier in Mice	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Spinal cord injury; Microcirculation; Blood spinal cord barrier; Permeability; Melatonin	BRAIN-BARRIER; FUNCTIONAL RECOVERY; MATRIX METALLOPROTEINASES; TRAUMATIC INJURY; OXIDATIVE DAMAGE; GENE-EXPRESSION; RATS; PERMEABILITY; COMPRESSION; IMPACT	The spinal cord microcirculation plays a critically important role in maintaining the normal function of spinal cord neurons, glial cells, and axons. Previous researches were largely focused on improved neurological manifestations of spinal cord injury (SCI) while ignoring to improve spinal cord microcirculation disorder after melatonin treatment. Therefore, the mechanism of melatonin that affects blood spinal cord barrier (BSCB) integrity and microcirculation in SCI remains unclear. The present study was performed to investigate the effect of melatonin on the BSCB in a SCI mice model. Melatonin (5, 10, 25, 50, 100 mg/kg i.p.) was administered to mice immediately following SCI. Compared to the 48 h post-SCI group, mice treated with melatonin (50 mg/kg) exhibited significantly reduced BSCB permeability. Additionally, melatonin treatment restrained microvessel loss; attenuated edema; protected the tight junction proteins, endothelial cells, and pericytes; decreased the number of cell apoptosis; and reduced MMP3/AQP4/HIF-1 alpha/VEGF/VEGFR2 expression after SCI. Above all, our results clearly demonstrated that melatonin could stabilize microvascular barrier function and microcirculation of SCI, whose mechanism was to promote the repair of the damaged BSCB.	[Wu, Qingbin; Jing, Yingli; Yuan, Xiaochen; Zhang, Xiaoyan; Li, Bingwei; Liu, Mingming; Wang, Bing; Li, Hongwei; Liu, Shuying; Xiu, Ruijuan] Chinese Acad Med Sci, Inst Microcirculat, Key Lab Microcirculat, Minist Natl Hlth China, Beijing 100005, Peoples R China; [Wu, Qingbin; Jing, Yingli; Yuan, Xiaochen; Zhang, Xiaoyan; Li, Bingwei; Liu, Mingming; Wang, Bing; Li, Hongwei; Liu, Shuying; Xiu, Ruijuan] Peking Union Med Coll, Beijing 100005, Peoples R China		Xiu, RJ (corresponding author), Chinese Acad Med Sci, Inst Microcirculat, Key Lab Microcirculat, Minist Natl Hlth China, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	xiurj@aliyun.com	LIU, Mingming/ABA-6770-2020	Liu, Mingming/0000-0002-6750-5068; Xiu, Ruijuan/0000-0002-1446-2711	Chinese Academy of Medical Sciences; Peking Union Medical College [1012012X17]	This work was supported by the innovation fund of Chinese Academy of Medical Sciences and Peking Union Medical College (No. 1012012X17).	Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Alvarez C, 2007, HUM REPROD, V22, P3210, DOI 10.1093/humrep/dem315; Casella GTB, 2006, EXP NEUROL, V202, P8, DOI 10.1016/j.expneurol.2006.05.028; Chen HY, 2006, J PINEAL RES, V41, P175, DOI 10.1111/j.1600-079X.2006.00351.x; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Dulmovits BM, 2012, INT J BIOCHEM CELL B, V44, P1800, DOI 10.1016/j.biocel.2012.06.031; Echeverry S, 2011, J NEUROSCI, V31, P10819, DOI 10.1523/JNEUROSCI.1642-11.2011; Ersahin M, 2009, J PINEAL RES, V46, P324, DOI 10.1111/j.1600-079X.2009.00664.x; Espino J, 2010, FERTIL STERIL, V94, P1915, DOI 10.1016/j.fertnstert.2009.12.082; Esposito E, 2008, J PINEAL RES, V45, P149, DOI 10.1111/j.1600-079X.2008.00569.x; Fan ZK, 2013, J MOL NEUROSCI, V51, P986, DOI 10.1007/s12031-013-0083-8; Fan ZK, 2013, J NEUROTRAUM, V30, P473, DOI 10.1089/neu.2012.2574; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Goldberg AL, 2010, J SPINAL CORD MED, V33, P105, DOI 10.1080/10790268.2010.11689685; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V41, P33, DOI 10.1007/BF00689554; Haddadi G, 2013, CELL J, V14, P246; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; Imaizumi T, 1997, J NEUROTRAUM, V14, P299, DOI 10.1089/neu.1997.14.299; Josko J, 2004, MED SCI MONITOR, V10, pRA89; Jung F, 2010, CLIN HEMORHEOL MICRO, V45, P79, DOI 10.3233/CH-2010-1312; Kaur C, 2008, CURR NEUROVASC RES, V5, P71, DOI 10.2174/156720208783565645; Lee JY, 2012, J NEUROCHEM, V121, P818, DOI 10.1111/j.1471-4159.2012.07731.x; Liebner S, 2011, INT J DEV BIOL, V55, P467, DOI 10.1387/ijdb.103224sl; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; Noble LJ, 2002, J NEUROSCI, V22, P7526; Oudega M, 2012, CELL TISSUE RES, V349, P269, DOI 10.1007/s00441-012-1440-6; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Park K, 2010, J PINEAL RES, V48, P270, DOI 10.1111/j.1600-079X.2010.00751.x; Qiu J, 2009, LANCET NEUROL, V8, P606, DOI 10.1016/S1474-4422(09)70162-0; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2011, NEUROTHERAPEUTICS, V8, P180, DOI 10.1007/s13311-011-0037-1; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Schiaveto-de-Souza A, 2013, BRAZ J MED BIOL RES, V46, P348, DOI 10.1590/1414-431X20132322; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Sharma HS, 2011, J NEURAL TRANSM, V118, P155, DOI 10.1007/s00702-010-0514-4; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; Shibuya Masaubmi, 2006, Angiogenesis, V9, P225, DOI 10.1007/s10456-006-9055-8; Sommansson A, 2013, J PINEAL RES, V54, P282, DOI 10.1111/jpi.12013; Strazielle N, 2013, MOL PHARMACEUT, V10, P1473, DOI 10.1021/mp300518e; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xu WB, 2008, BRAIN RES, V1246, P11, DOI 10.1016/j.brainres.2008.09.087; Ye S, 1996, J BIOL CHEM, V271, P13055, DOI 10.1074/jbc.271.22.13055; Yuan XC, 2011, J PINEAL RES, V51, P220, DOI 10.1111/j.1600-079X.2011.00882.x	48	44	47	0	18	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	DEC	2014	54	4					714	722		10.1007/s12031-014-0430-4			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AW0PP	WOS:000345995700013	25303856				2022-02-06	
J	Brown, FL; Whittingham, K; Boyd, RN; McKinlay, L; Sofronoff, K				Brown, Felicity L.; Whittingham, Koa; Boyd, Roslyn N.; McKinlay, Lynne; Sofronoff, Kate			Improving child and parenting outcomes following paediatric acquired brain injury: a randomised controlled trial of Stepping Stones Triple P plus Acceptance and Commitment Therapy	JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY			English	Article						Acquired brain injury; acceptance and commitment therapy; Stepping Stones Triple P: Positive Parenting Program; behavioural and emotional functioning; parenting style; randomised controlled trial	SKILLS PROGRAM; INTERVENTION; FEASIBILITY; DISORDERS; EFFICACY; MOTHERS; STRESS; MOOD	Background: Persistent behavioural difficulties are common following paediatric acquired brain injury (ABI). Parents and families also experience heightened stress, psychological symptoms and burden, and there is evidence of a reciprocal relationship between parent and child functioning, which may be mediated by the adoption of maladaptive parenting practices. Despite this, there is currently a paucity of research in family interventions in this population. The aim of this study was to determine the efficacy of Stepping Stones Triple P: Positive Parenting Program (SSTP), with an Acceptance and Commitment Therapy (ACT) workshop, in improving child outcomes and parenting practices following paediatric ABI. Methods: Fifty-nine parents of children (mean age 7 years, SD 3 years, 1 month; 35 males, 24 females) with ABI (Traumatic injuries 58%, Tumour 17%, Encephalitis or meningitis 15%, Cardiovascular accident 7%, Hypoxia 3%) who were evidencing at least mild behaviour problems were randomly assigned to treatment or care-as-usual conditions over 10 weeks. Mixed-model repeated-measures linear regression analyses were conducted to compare conditions from pre- to postintervention on child behavioural and emotional functioning (Eyberg Child Behavior Inventory, Strengths and Difficulties Questionnaire) and dysfunctional parenting style (Parenting Scale). Assessment of maintenance of change was conducted at a 6-month follow-up. The trial was registered on Australian New Zealand Clinical Trials Registry (ID: ACTRN12610001051033, www.anzctr.org.au). Results: Significant time-by-condition interactions were identified on number and intensity of child behaviour problems, child emotional symptoms and parenting laxness and overreactivity, indicating significant improvements in the treatment condition, with medium-to-large effect sizes. Most improvements were maintained at 6 months. Conclusions: Group parenting interventions incorporating Triple P and ACT may be efficacious in improving child and parenting outcomes following paediatric ABI.	[Brown, Felicity L.; Whittingham, Koa; Sofronoff, Kate] Univ Queensland, Sch Psychol, Fac Hlth & Behav Sci, Brisbane, Qld, Australia; [Brown, Felicity L.; Whittingham, Koa; Boyd, Roslyn N.; McKinlay, Lynne] Univ Queensland, Sch Med, Fac Med & Biomed Sci, Queensland Cerebral Palsy & Rehabil Res Ctr, Brisbane, Qld, Australia; [Brown, Felicity L.; McKinlay, Lynne] Univ Queensland, Fac Med & Biomed Sci, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [McKinlay, Lynne] Royal Childrens Hosp, Queensland Paediat Rehabil Serv, Brisbane, Qld, Australia		Brown, FL (corresponding author), Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia.	felicity.brown@uqconnect.edu.au	Boyd, Roslyn N/A-4498-2011; Whittingham, Koa L/C-6766-2009	Boyd, Roslyn N/0000-0002-4919-5975; Whittingham, Koa L/0000-0002-5344-9907; McKinlay, Lynne/0000-0002-6677-0628; Brown, Felicity/0000-0001-6800-1657	Queensland Children's Medical Research Institute Science PhD Scholarship [50002]; National Health and Medical Research Council postdoctoral fellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [631712]; National Health and Medical Research Council Career Development FellowshipNational Health and Medical Research Council of Australia [473840]; Smart State Fellowship	This study was supported by a Queensland Children's Medical Research Institute Science PhD Scholarship (F.B., grant number 50002); a National Health and Medical Research Council postdoctoral fellowship (K.W., grant number 631712); a National Health and Medical Research Council Career Development Fellowship (R.B., grant number 473840) and a Smart State Fellowship (R.B).	Acker M.M., 1993, PSYCHOL ASSESSMENT, V5, P137, DOI DOI 10.1037/1040-3590.5.2.137; Anderson V, 2006, AM J PHYS MED REHAB, V85, P767, DOI 10.1097/01.phm.0000233176.08480.22; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Antonini TN, 2012, J TELEMED TELECARE, V18, P333, DOI 10.1258/jtt.2012.120404; Biglan A, 2012, AM PSYCHOL, V67, P257, DOI 10.1037/a0026796; Blackledge JT, 2006, CHILD FAM BEHAV THER, V28, P1, DOI 10.1300/J019v28n01_01; Brown FL, 2013, BRAIN IMPAIR, V14, P253, DOI 10.1017/BrImp.2013.18; Brown FL, 2013, J HEAD TRAUMA REHAB, V28, P349, DOI 10.1097/HTR.0b013e318245fed5; Cheron DM, 2009, CHILD PSYCHIAT HUM D, V40, P383, DOI 10.1007/s10578-009-0135-z; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cole WR, 2009, DEV DISABIL RES REV, V15, P159, DOI 10.1002/ddrr.58; de Graaf I, 2008, BEHAV MODIF, V32, P714, DOI 10.1177/0145445508317134; de Graaf I, 2008, FAM RELAT, V57, P553, DOI 10.1111/j.1741-3729.2008.00522.x; Eyberg S.M., 1999, ECBI SESBI R EYBERG; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Hastings RP, 2004, J CHILD PSYCHOL PSYC, V45, P1338, DOI 10.1111/j.1469-7610.2004.00357.x; Hayes SC, 2006, BEHAV RES THER, V44, P1, DOI 10.1016/j.brat.2005.06.006; Hedeker D., 2006, LONGITUDINAL DATA AN; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Lloyd T, 2008, J INTELL DISABIL RES, V52, P37, DOI 10.1111/j.1365-2788.2007.00974.x; Lovibond SH., 1995, MANUAL DEPRESSION AN, V2nd; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Micklewright JL, 2012, J INT NEUROPSYCH SOC, V18, P343, DOI 10.1017/S1355617711001792; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; Ost LG, 2008, BEHAV RES THER, V46, P296, DOI 10.1016/j.brat.2007.12.005; Powers MB, 2009, PSYCHOTHER PSYCHOSOM, V78, P73, DOI 10.1159/000190790; Rhoades KA, 2007, J CLIN CHILD ADOLESC, V36, P137, DOI 10.1080/15374410701274157; Sanders MR, 2012, ANNU REV CLIN PSYCHO, V8, P345, DOI 10.1146/annurev-clinpsy-032511-143104; Sanders MR, 2009, FACILITATORS MANUAL; Shea SE, 2011, CHILD FAM BEHAV THER, V33, P231, DOI 10.1080/07317107.2011.596004; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Tellegen CL, 2013, RES DEV DISABIL, V34, P1556, DOI 10.1016/j.ridd.2013.01.022; Wackerley D. D., 2008, MATH STAT APPL; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Weiss JA, 2012, AUTISM, V16, P261, DOI 10.1177/1362361311422708; Whittingham K, 2013, CHILD CARE HLTH DEV, V39, P366, DOI 10.1111/j.1365-2214.2012.01396.x; Whittingham K., 2010, STRESS MANAGEM UNPUB; Woods DT, 2012, NEUROREHABILITATION, V30, P189, DOI 10.3233/NRE-2012-0744; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	45	44	46	2	55	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9630	1469-7610		J CHILD PSYCHOL PSYC	J. Child Psychol. Psychiatry	OCT	2014	55	10					1172	1183		10.1111/jcpp.12227			12	Psychology, Developmental; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	AR8KS	WOS:000343824600014	24635872				2022-02-06	
J	Rodrigues, EM; Simon, D; Ikuta, N; Klovan, C; Dannebrock, FA; de Oliveira, CO; Regner, A				Rodrigues Filho, Edison Moraes; Simon, Daniel; Ikuta, Nilo; Klovan, Caroline; Dannebrock, Fernando Augusto; de Oliveira, Carla Oliveira; Regner, Andrea			Elevated Cell-Free Plasma DNA Level as an Independent Predictor of Mortality in Patients with Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; outcome; plasma DNA; real-time PCR; traumatic brain injury	SEVERE HEAD-INJURY; SERUM S-100B PROTEIN; GLASGOW COMA SCALE; MATERNAL PLASMA; FETAL DNA; INTRACRANIAL-PRESSURE; PROGNOSTIC MARKER; MULTIPLE TRAUMA; CANCER-PATIENTS; CARDIAC-ARREST	Trauma is the leading cause of death in individuals less than 45 years old worldwide, and up to 50% of trauma fatalities are because of brain injury. Prediction of outcome is one of the major problems associated with severe traumatic brain injury (TBI), and research efforts have focused on the investigation of biomarkers with prognostic value after TBI. Therefore, our aim was to investigate whether cell-free DNA concentrations correlated to short-term primary outcome (survival or death) and Glasgow Coma Scale (GCS) scores after severe TBI. A total of 188 patients with severe TBI were enrolled in this prospective study; outcome variables comprised survival and neurological assessment using the GCS at intensive care unit (ICU) discharge. Control blood samples were obtained from 25 healthy volunteers. Peripheral venous blood was collected at admission to the ICU. Plasma DNA was measured using a real-time quantitative polymerase chain reaction (PCR) assay for the beta-globin gene. There was correlation between higher DNA levels and both fatal outcome and lower hospital admission GCS scores. Plasma DNA concentrations at the chosen cutoff point (>= 171,381 kilogenomes-equivalents/L) predicted mortality with a specificity of 90% and a sensitivity of 43%. Logistic regression analysis showed that elevated plasma DNA levels were independently associated with death (p < 0.001). In conclusion, high cell-free DNA concentration was a predictor of short-term mortality after severe TBI.	[Rodrigues Filho, Edison Moraes; Simon, Daniel; Ikuta, Nilo; de Oliveira, Carla Oliveira; Regner, Andrea] Univ Luterana Brasil, Lab Biomarcadores Trauma, Canoas, Brazil; [Simon, Daniel; Ikuta, Nilo; Regner, Andrea] Univ Luterana Brasil, Programa Posgrad Biol Celular & Mol Aplicada Saud, Canoas, Brazil; [Ikuta, Nilo] Simbios Biotecnol, Canoas, RS, Brazil; [Klovan, Caroline; Dannebrock, Fernando Augusto; Regner, Andrea] Univ Luterana Brasil, Curso Med, Canoas, Brazil		Regner, A (corresponding author), Univ Luterana Brasil, Ctr Pesquisa Ciencias Med, Ave Farroupilha,8001 Predio 22,5 Andar, BR-92425900 Canoas, RS, Brazil.	regner@uol.com.br	Regner, Andrea/M-2596-2014; Simon, Daniel/A-9087-2011	Regner, Andrea/0000-0002-6657-7991; Simon, Daniel/0000-0003-1122-8468; Dannebrock, Fernando Augusto/0000-0002-7640-8956	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [568691/2008-3]; Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [PPSUS 09/0041-5]	The present study received financial support from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; research Grant 568691/2008-3) and Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS; research Grant PPSUS 09/0041-5).	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Arnalich F, 2010, CRIT CARE, V14, DOI 10.1186/cc8934; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; De Oliveira CO, 2007, J NEUROTRAUM, V24, P1331, DOI 10.1089/neu.2006.0159; Diringer MN, 1997, ARCH NEUROL-CHICAGO, V54, P606, DOI 10.1001/archneur.1997.00550170078017; Faul M, 2010, TRAUMATIC BRAIN INJU; Gahan PB, 2008, ANN NY ACAD SCI, V1137, P7, DOI 10.1196/annals.1448.046; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Jahr S, 2001, CANCER RES, V61, P1659; Johnson PJ, 2002, CLIN CHEM, V48, P1186; Lam NYL, 2004, CLIN CHEM, V50, P213, DOI 10.1373/clinchem.2003.025783; Lam NYL, 2003, CLIN CHEM, V49, P1286, DOI 10.1373/49.8.1286; Lo YMD, 1998, LANCET, V351, P1329, DOI 10.1016/S0140-6736(05)79055-3; Lo YMD, 2000, CLIN CHEM, V46, P319; Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Macher H, 2012, CLIN CHIM ACTA, V414, P12, DOI 10.1016/j.cca.2012.08.001; MANDEL P, 1948, C R Seances Soc Biol Fil, V142, P241; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rainer TH, 2003, CLIN CHEM, V49, P562, DOI 10.1373/49.4.562; Rainer TH, 2006, CLIN CHIM ACTA, V368, P110, DOI 10.1016/j.cca.2005.12.021; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Rhodes A, 2006, CRIT CARE, V10, DOI 10.1186/cc4894; Rodrigues E., 2008, BRAIN INJ S1, V22, P165; Saukkonen K, 2008, CLIN CHEM, V54, P1000, DOI 10.1373/clinchem.2007.101030; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; TEASDALE G, 1974, LANCET, V2, P81; Toschlog EA, 2003, AM SURGEON, V69, P491; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; van der Vaart M, 2008, ANN NY ACAD SCI, V1137, P18, DOI 10.1196/annals.1448.022; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Wang BG, 2003, CANCER RES, V63, P3966; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Yurgel VC, 2007, J NEUROTRAUM, V24, P1172, DOI 10.1089/neu.2006.0160; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	55	44	45	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2014	31	19					1639	1646		10.1089/neu.2013.3178			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AP5VI	WOS:000342146400006	24827371	Green Published			2022-02-06	
J	Fraas, MR; Coughlan, GE; Hart, EC; McCarthy, C				Fraas, Michael R.; Coughlan, Garrett E.; Hart, Emily C.; McCarthy, Conor			Concussion history and reporting rates in elite Irish rugby union players	PHYSICAL THERAPY IN SPORT			English	Article						Head injury; Epidemiology; Ireland; Rugby union; Concussion reporting rates	FOOTBALL PLAYERS; RECURRENT CONCUSSION; PERFORMANCE PROJECT; CONSENSUS STATEMENT; RISK-FACTORS; INJURIES; EPIDEMIOLOGY; SCHOOL; HEAD; KNOWLEDGE	Objectives: To determine the self-reported, seasonal rates of concussion and the reporting practices among Irish rugby union players. Design: Descriptive epidemiology study. Setting: The study was conducted at the training grounds of four professional Irish rugby union clubs. Participants: One hundred seventy-two players (24.97 +/- 4.11 years of age, 13.49 +/- 5.79 years playing experience) gave consent to participate. Main outcome measures: Number of concussions reported during the 2010-2011 season, reasons for not reporting, and positions of concussed players. Results: Forty-five percent of players reported at least one concussion during the 2010-2011 season, but only 46.6% of these presented to medical staff. The reasons for not reporting their concussions included, not thinking the injury was serious enough, and not wanting to be removed from the game. The relative proportion of concussions was higher for backs than forwards; however, the severity of injury was greater for forwards. Scrum-halves (12.0%) and flankers (10.9%) accounted for the majority of concussions reported. Conclusions: The self-reported rate of concussion in elite rugby union players in Ireland is higher than reported in other countries or other sports. Many concussions remain unreported and, therefore, unmanaged. However, recent changes in concussion management guidelines by the International Rugby Board may impact future reporting practices of players. (C) 2013 Elsevier Ltd. All rights reserved.	[Fraas, Michael R.] Western Washington Univ, Dept Commun Sci & Disorders, Bellingham, WA 98225 USA; [Fraas, Michael R.; Hart, Emily C.] Elmhurst Coll, Dept Commun Arts & Sci, Chicago, IL USA; [Coughlan, Garrett E.; McCarthy, Conor] Irish Rugby Football Union, Dept Med, Dublin, Ireland; [McCarthy, Conor] Chicago Sch, Dept Psychol, Chicago, IL USA		Fraas, MR (corresponding author), Western Washington Univ, Dept Commun Sci & Disorders, 516 High St, Bellingham, WA 98225 USA.	fraasm@gmail.com					Baker JF, 2013, IRISH J MED SCI, V182, P121, DOI 10.1007/s11845-012-0846-1; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; Broglio SP, 2010, J SPORT SCI MED, V9, P418; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Coughlan GF, 2011, J ORTHOP SPORT PHYS, V41, P600, DOI 10.2519/jospt.2011.3508; Council for International Organizations of Medical Sciences (CIOMS), 2002, INT ETH GUID BIOM RE; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Holtzhausen LJ, 2006, SAMJ S AFR MED J, V96, P1260; IRB, 2010, LAWS GAM RUGB UN 201; IRFU, 2011, IR RUGB FOOTB UN ANN; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Marshall SW, 2002, INT J EPIDEMIOL, V31, P587, DOI 10.1093/ije/31.3.587; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Shuttleworth-Edwards AB, 2008, CLIN J SPORT MED, V18, P403, DOI 10.1097/JSM.0b013e3181895910; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	34	44	44	1	37	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1466-853X			PHYS THER SPORT	Phys. Ther. Sport	AUG	2014	15	3					136	142		10.1016/j.ptsp.2013.08.002			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	AL3NL	WOS:000339035300002	24035483				2022-02-06	
J	Alhilali, LM; Yaeger, K; Collins, M; Fakhran, S				Alhilali, Lea M.; Yaeger, Karl; Collins, Michael; Fakhran, Saeed			Detection of Central White Matter Injury Underlying Vestibulopathy after Mild Traumatic Brain Injury	RADIOLOGY			English	Article							BLAST; HEAD; REHABILITATION; IMPAIRMENT; ACTIVATION; LOCOMOTION; PATTERNS; RECOVERY; VERTIGO; STANCE	Purpose: To determine if central axonal injury underlies vestibulopathy and ocular convergence insufficiency after mild traumatic brain injury (TBI) by using tract-based spatial statistics (TBSS) analysis of diffusion-tensor imaging (DTI). Materials and Methods: The institutional review board approved this study, and the requirement to obtain informed consent was waived. Diffusion-tensor images were retrospectively reviewed in 30 patients with mild TBI and vestibular symptoms and 25 patients with mild TBI and ocular convergence insufficiency. Control subjects consisted of 39 patients with mild TBI without vestibular abnormalities and 17 patients with mild TBI and normal ocular convergence. Fractional anisotropy (FA) maps were generated as a measure of white matter integrity and were analyzed with TBSS regression analysis by using a general linear model. DTI abnormalities were correlated with symptom severity, neurocognitive test scores, and time to recovery with the Pearson correlation coefficient. Results: Compared with control subjects, patients with mild TBI and vestibular symptoms had decreased neurocognitive test scores (P < .05) and FA values in the cerebellum and fusiform gyri (P < .05). Patients with ocular convergence insufficiency had diminished neurocognitive test scores (P < .05) and FA values in the right anterior thalamic radiation and right geniculate nucleus optic tracts (P < .0001). Cerebellar injury showed an inverse correlation with recovery time (R = -0.410, P = .02). Anterior thalamic radiation injury showed correlation with decreased processing speed (R = 0.402, P < .05). Conclusion: DTI findings in patients with mild TBI and vestibulopathy support the hypothesis that posttraumatic vestibulopathy has a central axonal injury component. Peripheral vestibular structures were not assessed, and a superimposed peripheral contribution may exist. DTI evaluation of central vestibular structures may provide a diagnostic imaging tool in these patients and a quantitative biomarker to aid in prognosis.	[Alhilali, Lea M.; Yaeger, Karl; Fakhran, Saeed] Univ Pittsburgh, Med Ctr, Dept Radiol, Div Neuroradiol, Pittsburgh, PA 15213 USA; [Collins, Michael] Univ Pittsburgh, Med Ctr, Dept Orthoped, Div Sports Med, Pittsburgh, PA 15213 USA		Alhilali, LM (corresponding author), Univ Pittsburgh, Med Ctr, Dept Radiol, Div Neuroradiol, 8th Floor,8 North,Presby South Tower, Pittsburgh, PA 15213 USA.	alhilalilm@upmc.edu			ImPACT Applications	L.M.A. No relevant conflicts of interest to disclose. K.Y. No relevant conflicts of interest to disclose. M.C. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: is co-founder and board member of ImPACT Applications. Other relationships: none to disclose. S. F. No relevant conflicts of interest to disclose.	Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Biesbroek JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060541; BRANDT T, 1991, BRAIN, V114, P2159, DOI 10.1093/brain/114.5.2159; Capo-Aponte JE, 2012, J REHABIL RES DEV, V49, P1377, DOI 10.1682/JRRD.2011.07.0128; Coffman KA, 2011, P NATL ACAD SCI USA, V108, P16068, DOI 10.1073/pnas.1107904108; Dlugaiczyk J, 2011, OTOL NEUROTOL, V32, P1285, DOI 10.1097/MAO.0b013e31822e94d9; Duering M, 2013, NEUROIMAGE, V66, P177, DOI 10.1016/j.neuroimage.2012.10.084; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Jahn K, 2004, NEUROIMAGE, V22, P1722, DOI 10.1016/j.neuroimage.2004.05.017; Jahn K, 2009, ANN NY ACAD SCI, V1164, P229, DOI 10.1111/j.1749-6632.2009.03770.x; Karim AKMR, 2010, ADV COGN PSYCHOL, V6, P103, DOI 10.2478/v10053-008-0080-6; Katsarkas A, 1999, ACTA OTO-LARYNGOL, V119, P745, DOI 10.1080/00016489950180360; KERR AG, 1980, J LARYNGOL OTOL, V94, P107, DOI 10.1017/S0022215100088538; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mahone EM, 2009, J AM ACAD CHILD PSY, V48, P749, DOI 10.1097/CHI.0b013e3181a565f1; Marzo SJ, 2004, LARYNGOSCOPE, V114, P1720, DOI 10.1097/00005537-200410000-00008; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; RUBIN AM, 1995, AM J OTOL, V16, P216; Salimi-Khorshidi G, 2011, NEUROIMAGE, V54, P2006, DOI 10.1016/j.neuroimage.2010.09.088; SCHUKNECHT HF, 1956, ARCHIV OTOLARYNGOL, V63, P513; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Sexton CE, 2012, PSYCHOL MED, V42, P1195, DOI 10.1017/S0033291711002352; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Stoodley CJ, 2012, NEUROIMAGE, V59, P1560, DOI 10.1016/j.neuroimage.2011.08.065; Straube Andreas, 2007, V40, P1; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; YLIKOSKI J, 1982, AM J OTOL, V3, P343	33	44	44	0	7	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	JUL	2014	272	1					224	232		10.1148/radiol.14132670			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	AM7GU	WOS:000340034300024	24735411	Bronze			2022-02-06	
J	Bompadre, V; Jinguji, TM; Yanez, ND; Satchell, EK; Gilbert, K; Burton, M; Conrad, EU; Herring, SA				Bompadre, Viviana; Jinguji, Thomas M.; Yanez, N. David; Satchell, Emma K.; Gilbert, Kaiulani; Burton, Monique; Conrad, Ernest U., III; Herring, Stanley A.			Washington State's Lystedt Law in Concussion Documentation in Seattle Public High Schools	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion incidence; sports injuries; adolescents	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; SEX-DIFFERENCES; UNITED-STATES; EPIDEMIOLOGY; LEGISLATION; PREVENTION; COACHES; IMPACT; YOUTH	Context: The Lystedt law requires high school athletes who have sustained a concussion to be removed from practice and play and not to be allowed to return until cleared by a medical professional. Objective: To determine the effect of the Lystedt law on injury and concussion documentation in the Seattle public high schools. Design: Cross-sectional study. Setting: Seattle public high schools. Patients or Other Participants: The numbers of students, aged 13 to 19 years in the 2008-2009, 2009-2010, and 2010-2011 school years, were 4348, 4925, and 4806, respectively. Main Outcome Measure(s): All injuries documented in SportsWare by athletic trainers in Seattle public high schools. We evaluated all injuries, including concussions recorded during the 2008-2009 school year, before the Lystedt law, and during the 2 school years after the law took effect (2009-2010 and 2010-2011). Incidence rates before and after the law were estimated and compared. Results: The concussion rate was -1.09% in 2008-2009, 2.26% in 2009-2010, and 2.26% in 2010-2011. A comparison of relative risks showed that the incidence rates of concussions were different before and 1 year after the Lystedt law (relative risk = 2.10; 95% confidence interval [CI] = 1.50, 2.93) and 2 years after the law (relative risk = 2.10; 95% CI = 1.49, 2.93). Overall, the mean number of days out of play after 2008-2009 was almost 7 days greater after the law took effect (difference = 6.9 days; 95% CI = 0.70, 13.1). For females, the mean number of days out of play after 2008-2009 was more than 17 days in 2009-2010 (difference = 17.2 days; 95% CI = 4.81, 29.5) and was more than 6 days in 2010-2011 (difference = 6.3 days; 95% CI = 1.62, 11.0). Conclusions: The number of documented concussions more than doubled after the institution of the Lystedt law, which may be attributed to heightened awareness and closer monitoring.	[Bompadre, Viviana; Jinguji, Thomas M.; Yanez, N. David; Satchell, Emma K.; Gilbert, Kaiulani; Burton, Monique; Conrad, Ernest U., III; Herring, Stanley A.] Seattle Childrens Hosp, Seattle, WA 98105 USA; [Yanez, N. David; Burton, Monique; Conrad, Ernest U., III; Herring, Stanley A.] Univ Washington, Seattle, WA 98195 USA		Bompadre, V (corresponding author), Seattle Childrens Hosp, 4800 Sand Point Way NE,M-S W-7706, Seattle, WA 98105 USA.	viviana.bompadre@seattlechildrens.org			Center for Clinical and Translational Research at Seattle Children's Research Institute; National Institutes of Health's National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025014]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000423] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025014] Funding Source: NIH RePORTER	We acknowledge all ATs working in the Seattle Public Schools system for their commitment in keeping the students safe. The Seattle, Washington, Children's Core for Biomedical Statistics is supported by the Center for Clinical and Translational Research at Seattle Children's Research Institute and by grant UL1RR025014 from the National Institutes of Health's National Center for Research Resources.	Adler RH, 2011, PM&R, V3, pS468, DOI 10.1016/j.pmrj.2011.08.006; Almquist J, 2008, J ATHL TRAINING, V43, P416, DOI 10.4085/1062-6050-43.4.416; [Anonymous], ZACK LYST LAW SPORTS; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Covassin T, 2003, J ATHL TRAINING, V38, P238; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Murphy A, 2012, PM&R, V4, P419, DOI 10.1016/j.pmrj.2012.03.013; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Shields BJ, 2009, J ATHL TRAINING, V44, P586, DOI 10.4085/1062-6050-44.6.586; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	28	44	43	0	6	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2014	49	4					486	492		10.4085/1062-6050-49.3.30			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	AQ4LO	WOS:000342768700008	24870293	Green Published, Bronze			2022-02-06	
J	Han, JL; King, NKK; Neilson, SJ; Gandhi, MP; Ng, I				Han, Julian; King, Nicolas K. K.; Neilson, Sam J.; Gandhi, Mihir P.; Ng, Ivan			External Validation of the CRASH and IMPACT Prognostic Models in Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						external validation; prediction models; prognosis; TBI	INTRACEREBRAL HEMORRHAGE; PREDICTION; MORTALITY; TRIAL	An accurate prognostic model is extremely important in severe traumatic brain injury (TBI) for both patient management and research. Clinical prediction models must be validated both internally and externally before they are considered widely applicable. Our aim is to independently externally validate two prediction models, one developed by the Corticosteroid Randomization After Significant Head injury (CRASH) trial investigators, and the other from the International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) group. We used a cohort of 300 patients with severe TBI (Glasgow Coma Score [GCS] <= 8) consecutively admitted to the National Neuroscience Institute (NNI), Singapore, between February 2006 and December 2009. The CRASH models (base and CT) predict 14 day mortality and 6 month unfavorable outcome. The IMPACT models (core, extended, and laboratory) estimate 6 month mortality and unfavorable outcome. Validation was based on measures of discrimination and calibration. Discrimination was assessed using the area under the receiving operating characteristic curve (AUC), and calibration was assessed using the Hosmer-Lemeshow (H-L) goodness-of-fit test and Cox calibration regression analysis. In the NNI database, the overall observed 14 day mortality was 47.7%, and the observed 6 month unfavorable outcome was 71.0%. The CRASH base model and all three IMPACT models gave an underestimate of the observed values in our cohort when used to predict outcome. Using the CRASH CT model, the predicted 14 day mortality of 46.6% approximated the observed outcome, whereas the predicted 6 month unfavorable outcome was an overestimate at 74.8%. Overall, both the CRASH and IMPACT models showed good discrimination, with AUCs ranging from 0.80 to 0.89, and good overall calibration. We conclude that both the CRASH and IMPACT models satisfactorily predicted outcome in our patients with severe TBI.	[Han, Julian; King, Nicolas K. K.; Ng, Ivan] Natl Inst Neurosci, Dept Neurosurg, Singapore 308433, Singapore; [Neilson, Sam J.] Univ Manchester, Manchester Med Sch, Manchester, Lancs, England; [Gandhi, Mihir P.] Duke Natl Univ Singapore, Ctr Quantitat Med, Grad Sch Med, Singapore, Singapore; [Gandhi, Mihir P.] Singapore Clin Res Inst, Dept Biostat, Singapore, Singapore		King, NKK (corresponding author), Natl Inst Neurosci, Dept Neurosurg, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	nkkk@gmx.net		Kon Kam King, Nicolas/0000-0002-6009-4411			COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Skrobik Y, 2006, CAN J ANAESTH, V53, P432, DOI 10.1007/BF03022613; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1974, LANCET, V2, P81; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd; Zahuranec DB, 2007, NEUROLOGY, V68, P1651, DOI 10.1212/01.wnl.0000261906.93238.72	22	44	45	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1146	1152		10.1089/neu.2013.3003			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500003	24568201				2022-02-06	
J	Liesemer, K; Riva-Cambrin, J; Bennett, KS; Bratton, SL; Tran, H; Metzger, RR; Bennett, TD				Liesemer, Kate; Riva-Cambrin, Jay; Bennett, Kimberly Statler; Bratton, Susan L.; Tran, Henry; Metzger, Ryan R.; Bennett, Tellen D.			Use of Rotterdam CT Scores for Mortality Risk Stratification in Children With Traumatic Brain Injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						brain injuries; craniocerebral trauma; intracranial hypertension; neuroradiography; pediatric intensive care unit; pediatrics	SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; OUTCOME PREDICTION; MODEL; CLASSIFICATION; EXPERIENCE; CARE	Objectives: The Rotterdam CT score refined features of the Marshall score and was designed to categorize traumatic brain injury type and severity in adults. The objective of this study was to determine whether the Rotterdam CT score can be used for mortality risk stratification after pediatric traumatic brain injury. Design: In children with moderate to severe traumatic brain injury, a comparison of observed versus predicted mortality was calculated using published model probabilities of adult mortality. Development and validation of a new pediatric mortality model using randomly selected prediction and validation samples from our cohort. Setting: A single level 1 pediatric trauma center. Subjects: Six hundred thirty-two children with moderate or severe traumatic brain injury. Interventions: None. Measurements and Main Results: Sixteen percent of the patients (101 of 632) died prior to hospital discharge. The predicted mortality based on Rotterdam score for adults with moderate or severe traumatic brain injury discriminated pediatric observed mortality well (area under the curve = 0.85; 95% CI, 0.80-0.89) but had poor calibration, overestimating or underestimating mortality for children in several Rotterdam categories. A predictive model based on children with moderate or severe traumatic brain injury from the single center discriminated mortality well (area under the curve, 0.80; 95% CI, 0.68-0.91) and showed good calibration and overall fit. Conclusions: Children with traumatic brain injury have better survival than adults in Rotterdam CT score categories representing less severe injuries but worse survival than adults in higher score categories. A novel, validated pediatric mortality model based on the Rotterdam score is accurate in children with moderate or severe traumatic brain injury and can be used for risk stratification.	[Liesemer, Kate; Riva-Cambrin, Jay; Bennett, Kimberly Statler; Bratton, Susan L.; Metzger, Ryan R.; Bennett, Tellen D.] Univ Utah, Sch Med, Salt Lake City, UT 84158 USA; [Liesemer, Kate; Riva-Cambrin, Jay; Bennett, Kimberly Statler; Bratton, Susan L.; Metzger, Ryan R.; Bennett, Tellen D.] Primary Childrens Med Ctr, Salt Lake City, UT 84158 USA; [Tran, Henry] Univ Rochester, Sch Med, Rochester, NY USA		Bennett, TD (corresponding author), Univ Utah, Sch Med, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	tell.bennett@hsc.utah.edu	Bratton, Susan L./O-2353-2013	Bratton, Susan L./0000-0002-4605-8078; Bennett, Tellen/0000-0003-1483-4236	National Institutes of Health/National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K23HD074620]; CDC-Spina Bifida Registry; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074620] Funding Source: NIH RePORTER	Dr. Bennett received grant support from the National Institutes of Health/National Cancer Institute (K23HD074620). Dr. Riva-Cambrin received grant support from the CDC-Spina Bifida Registry. Dr. Bratton received support for travel for speaking at the European Academic Society Meeting. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS9; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; Brier GW, 1950, MON WEATHER REV, V78, P1, DOI DOI 10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2; Chun KA, 2010, J NEUROTRAUM, V27, P325, DOI 10.1089/neu.2009.1115; Teruel GC, 2007, J PEDIATR SURG, V42, P1903, DOI 10.1016/j.jpedsurg.2007.07.020; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Corral L, 2009, BRAIN INJURY, V23, P403, DOI 10.1080/02699050902788477; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Hirsch W, 2002, PAEDIATR ANAESTH, V12, P337, DOI 10.1046/j.1460-9592.2002.00837.x; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Lemeshow S, 2000, APPL LOGISTIC REGRES; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, NEUROSURGERY, P443; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Manktelow BN, 2010, ARCH DIS CHILD-FETAL, V95, pF9, DOI 10.1136/adc.2008.148015; Manktelow BN, 2013, PEDIATRICS, V131, pE425, DOI 10.1542/peds.2012-2189; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Straney L, 2013, PEDIATR CRIT CARE ME, V14, P673, DOI 10.1097/PCC.0b013e31829760cf; Tasaki O, 2009, J TRAUMA, V66, P304, DOI 10.1097/TA.0b013e31815d9d3f; Tasker RC, 2011, BRIT J NEUROSURG, V25, P68, DOI 10.3109/02688697.2010.538770; The Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P597; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006	35	44	44	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUL	2014	15	6					554	562		10.1097/PCC.0000000000000150			9	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	AK8WK	WOS:000338709100012	24751786	Green Accepted			2022-02-06	
J	Wang, Y; Yue, XY; Kiesewetter, DO; Niu, G; Teng, GJ; Chen, XY				Wang, Yu; Yue, Xuyi; Kiesewetter, Dale O.; Niu, Gang; Teng, Gaojun; Chen, Xiaoyuan			PET imaging of neuroinflammation in a rat traumatic brain injury model with radiolabeled TSPO ligand DPA-714	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING			English	Article						Traumatic brain injury (TBI); Translocator protein (TSPO); [F-18]DPA-714; PET; Molecular imaging	PERIPHERAL BENZODIAZEPINE-RECEPTOR; POSITRON-EMISSION-TOMOGRAPHY; TRANSLOCATOR PROTEIN; IN-VIVO; ACTIVATED MICROGLIA; NERVOUS-SYSTEM; ASTROCYTES; EXPRESSION; ALZHEIMERS; DISEASE	Purpose The inflammatory response in injured brain parenchyma after traumatic brain injury (TBI) is crucial in the pathological process. In order to follow microglia activation and neuroinflammation after TBI, we performed PET imaging in a rat model of TBI using F-18-labeled DPA-714, a ligand of the 18-kDa translocator protein (TSPO). Methods TBI was induced in male SD rats by a controlled cortical impact. The success of the TBI model was confirmed by MRI. [F-18]DPA-714 was synthesized using a slightly modified TRACERLab FX-FN module and an automated procedure. In vivo PET imaging was performed at different time points after surgery using an Inveon small-animal PET scanner. The specificity of [F-18]DPA-714 was confirmed by a displacement study with an unlabeled competitive TSPO ligand, PK11195. Ex vivo autoradiography as well as immunofluorescence staining was carried out to confirm the in vivo PET results. Results Both in vivo T-2-weighted MR images and ex vivo TTC staining results revealed successful establishment of the TBI model. Compared with the sham-treated group, [F-18]DPA-714 uptake was significantly higher in the injured brain area on PET images. Increased lesion-to-normal ratios of [F-18]DPA-714 were observed in the brain of TBI rats on day 2 after surgery. Ratios peaked around day 6 (2.65 +/- 0.36) and then decreased gradually to nearly normal levels on day 28. The displacement study using PK11195 confirmed the specific binding of [F-18]DPA-714 to TSPO. The results of ex vivo autoradiography were consistent with in vivo PET results. Immunofluorescence staining showed the time course of TSPO expression after TBI and the temporal and the spatial distribution of microglia in the damaged brain area. Conclusion TSPO-targeted PET using [F-18]DPA-714 as the imaging probe can be used to dynamically monitor the inflammatory response after TBI in a noninvasive manner. This method will not only facilitate a better understanding of the inflammatory process after TBI, but also provide a useful in vivo monitoring strategy for antiinflammation therapy of TBI.	[Wang, Yu; Teng, Gaojun] Southeast Univ, Jiangsu Key Lab Mol Imaging & Funct Imaging, Dept Radiol, Zhongda Hosp,Med Sch, Nanjing 210009, Jiangsu, Peoples R China; [Wang, Yu; Yue, Xuyi; Kiesewetter, Dale O.; Niu, Gang; Chen, Xiaoyuan] NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD 20892 USA		Teng, GJ (corresponding author), 87 Dingjiaqiao Rd, Nanjing 210009, Jiangsu, Peoples R China.	niug@mail.nih.gov; gjteng@vip.sina.com; shawn.chen@nih.gov	Chen, Xiaoyuan/D-1860-2014; yue, xuyi/AAE-9006-2020	Chen, Xiaoyuan/0000-0002-9622-0870; yue, xuyi/0000-0002-3783-6392	National Basic Research Program of China (973 program)National Basic Research Program of China [2013CB733803, 2013CB733802]; Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000073] Funding Source: NIH RePORTER	This work was supported by the National Basic Research Program of China (973 program, 2013CB733803, 2013CB733802), and the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH).	[Anonymous], 2010, GUIDE CARE USE LAB A; Arlicot N, 2012, NUCL MED BIOL, V39, P570, DOI 10.1016/j.nucmedbio.2011.10.012; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boutin H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056441; Cai WB, 2009, STROKE, V40, P270, DOI 10.1161/STROKEAHA.108.517474; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; Chauveau F, 2009, J NUCL MED, V50, P468, DOI 10.2967/jnumed.108.058669; Chen DL, 2004, AM J PHYSIOL-LUNG C, V286, pL834, DOI 10.1152/ajplung.00339.2003; Chen MK, 2004, BRAIN, V127, P1379, DOI 10.1093/brain/awh161; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Doorduin J, 2009, MOL IMAGING BIOL, V11, P386, DOI 10.1007/s11307-009-0211-6; Folkersma H, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-67; GALAN X, 1993, BIOL NEONATE, V64, P295; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; James ML, 2008, J NUCL MED, V49, P814, DOI 10.2967/jnumed.107.046151; James ML, 2006, CURR MED CHEM, V13, P1991, DOI 10.2174/092986706777584979; Ji B, 2008, J NEUROSCI, V28, P12255, DOI 10.1523/JNEUROSCI.2312-08.2008; Kuhnast B, 2012, APPL RADIAT ISOTOPES, V70, P489, DOI 10.1016/j.apradiso.2011.10.015; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Martin A, 2010, J CEREBR BLOOD F MET, V30, P230, DOI 10.1038/jcbfm.2009.205; Radu CG, 2007, P NATL ACAD SCI USA, V104, P1937, DOI 10.1073/pnas.0610544104; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Scarf AM, 2011, J NUCL MED, V52, P667, DOI 10.2967/jnumed.110.086629; Schilling M, 2005, EXP NEUROL, V196, P290, DOI 10.1016/j.expneurol.2005.08.004; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Tardy M, 1990, Adv Exp Med Biol, V265, P41; Venneti S, 2007, J NEUROCHEM, V102, P2118, DOI 10.1111/j.1471-4159.2007.04690.x; Venneti S, 2009, NEUROBIOL AGING, V30, P1217, DOI 10.1016/j.neurobiolaging.2007.11.005; Winkeler A, 2012, EUR J NUCL MED MOL I, V39, P811, DOI 10.1007/s00259-011-2041-4; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196	34	44	45	0	22	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1619-7070	1619-7089		EUR J NUCL MED MOL I	Eur. J. Nucl. Med. Mol. Imaging	JUL	2014	41	7					1440	1449		10.1007/s00259-014-2727-5			10	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	AI9UR	WOS:000337286200020	24615467	Green Accepted			2022-02-06	
J	Guo, J; Lin, P; Zhao, X; Zhang, J; Wei, X; Wang, Q; Wang, C				Guo, J.; Lin, P.; Zhao, X.; Zhang, J.; Wei, X.; Wang, Q.; Wang, C.			ETAZOLATE ABROGATES THE LIPOPOLYSACCHARIDE (LPS)-INDUCED DOWNREGULATION OF THE cAMP/pCREB/BDNF SIGNALING, NEUROINFLAMMATORY RESPONSE AND DEPRESSIVE-LIKE BEHAVIOR IN MICE	NEUROSCIENCE			English	Article						lipopolysaccharide (LPS); etazolate; depression; phosphodiesterase-4 (PDE4); cyclic adenosine monophosphate (cAMP); interleukin-1 beta (IL-1 beta)	PHOSPHODIESTERASE-4 INHIBITOR ROLIPRAM; ELEMENT-BINDING PROTEIN; TRAUMATIC BRAIN-INJURY; ANTIDEPRESSANT-LIKE; HIPPOCAMPAL NEUROGENESIS; CYTOKINE EXPRESSION; NEUROTROPHIC FACTOR; SICKNESS BEHAVIOR; 5-HT7 RECEPTOR; MESSENGER-RNA	Increasing evidence has indicated that immune challenge by bacterial lipopolysaccharide (LPS) induces depressive-like behavior, neuroinflammatory response and upregulates phosphodiesterase-4 (PDE4), an enzyme that specifically hydrolyzes cyclic adenosine monophosphate (cAMP). However, whether the potential PDE4 inhibitor etazolate prevents the LPS-induced depressive-like behavior remains unclear. Here using a model of depression induced by the repeated administration of LPS during 16 days, and then investigated the influence of LPS on the expression of PDE4, interleukin-1 beta (IL-1 beta) and antidepressant action of etazolate in mice through forced swimming, novelty suppressed feeding, sucrose preference and open-field tests. Our results showed that etazolate pretreatment facilitated the recovery from weight loss and prevented the depressive-like behavior induced by repeated LPS administration. Moreover, the antidepressant action of etazolate was paralleled by significantly reducing the expression levels of PDE4A, PDE4B, PDE4D and IL-1 beta and up-regulating the cAMP/phosphorylated cAMP response-element binding protein (pCREB)/brain-derived neurotrophic factor (BDNF) signaling in the hippocampus and prefrontal cortex of mice. These results indicate that the effects of etazolate on the depressive-like behavior induced by repeated LPS treatment may partially depend on the inhibition of PDE4 subtypes, the activation of the cAMP/pCREB/BDNF signaling and the anti-inflammatory responses in the hippocampus and prefrontal cortex. Crown Copyright (C) 2014 Published by Elsevier Ltd. on behalf of IBRO. All rights reserved.	Ningbo Univ, Sch Med, Ningbo 315211, Zhejiang, Peoples R China; [Wang, Q.] Ningbo Univ, Sch Med, Zhejiang Prov Key Lab Pathophysiol, Ningbo 315211, Zhejiang, Peoples R China		Wang, C (corresponding author), Ningbo Univ, Sch Med, Ningbo 315211, Zhejiang, Peoples R China.	wangqinwen@nbu.edu.cn; wangchuang@nbu.edu.cn	Wei, Xiaofei/V-5512-2019	Wei, Xiaofei/0000-0002-1173-4734	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81201050, 30901802, 81100822]; Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LQ12H09001, LY12H09002]; Natural Science Foundation of Ningbo [2012A610249, 2011A610064]; Natural Science Foundation of Ningbo University [XKL11D2111]; Ningbo University	This work was supported by National Natural Science Foundation of China (No. 81201050 to Dr. Chuang Wang; No. 30901802 to Dr. Xin Zhao; No. 81100822 to Dr. Xiaowei Chen); Natural Science Foundation of Zhejiang Province (No. LQ12H09001 to Chuang Wang and No. LY12H09002 to Dr. Xin Zhao); Natural Science Foundation of Ningbo (No. 2012A610249 to Dr. Chuang Wang and No. 2011A610064 to Dr. Xiaowei Chen); Natural Science Foundation of Ningbo University (No. XKL11D2111 to Dr. Chuang Wang) and Student Research and Innovation Program (SRIP) of Ningbo University. This project also sponsored by K. C. Wong Magna funded at Ningbo University.	Anderson GM, 2005, PSYCHOPHARMACOLOGY, V178, P339, DOI 10.1007/s00213-004-2011-7; Bekris S, 2005, BEHAV BRAIN RES, V161, P45, DOI 10.1016/j.bbr.2005.01.005; Breuillaud L, 2012, BIOL PSYCHIAT, V72, P528, DOI 10.1016/j.biopsych.2012.04.011; Cheng YF, 2010, PSYCHOPHARMACOLOGY, V212, P181, DOI 10.1007/s00213-010-1943-3; Ching S, 2007, J NEUROSCI, V27, P10476, DOI 10.1523/JNEUROSCI.3357-07.2007; D'Sa C, 2002, BIPOLAR DISORD, V4, P183, DOI 10.1034/j.1399-5618.2002.01203.x; Dagyte G, 2011, J NEUROSCI RES, V89, P1646, DOI 10.1002/jnr.22697; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Dantzer R, 2006, NEUROL CLIN, V24, P441, DOI 10.1016/j.ncl.2006.03.003; Dantzer R, 2012, BIOL PSYCHIAT, V71, P4, DOI 10.1016/j.biopsych.2011.10.025; Drott J, 2010, EUR J PHARMACOL, V634, P95, DOI 10.1016/j.ejphar.2010.02.036; Dworkin S, 2009, STEM CELLS, V27, P1347, DOI 10.1002/stem.56; Dyke HJ, 2002, EXPERT OPIN INV DRUG, V11, P1; Fan LW, 2013, NEUROSCIENCE, V240, P27, DOI 10.1016/j.neuroscience.2013.02.041; Fujimaki K, 2000, NEUROPSYCHOPHARMACOL, V22, P42, DOI 10.1016/S0893-133X(99)00084-6; Fuller-Thomson E, 2006, INFLAMM BOWEL DIS, V12, P697, DOI 10.1097/00054725-200608000-00005; Galecki P, 2012, J AFFECT DISORDERS, V138, P360, DOI 10.1016/j.jad.2012.01.016; Garate I, 2013, BIOL PSYCHIAT, V73, P32, DOI 10.1016/j.biopsych.2012.07.005; Gobejishvili L, 2013, J PHARMACOL EXP THER, V347, P80, DOI 10.1124/jpet.113.204933; Goltser-Dubner T, 2010, ISR J PSYCHIATR REL, V47, P72; Hasler G, 2010, WORLD PSYCHIATRY, V9, P155; Hedayati SS, 2010, JAMA-J AM MED ASSOC, V303, P1946, DOI 10.1001/jama.2010.619; Hedlund PB, 2005, BIOL PSYCHIAT, V58, P831, DOI 10.1016/j.biopsych.2005.05.012; Ji WW, 2013, PHARM BIOCH BEHAV; Jindal A, 2012, EUR J PHARMACOL, V689, P125, DOI 10.1016/j.ejphar.2012.05.051; Kentner AC, 2010, ENDOCRINOLOGY, V151, P2689, DOI 10.1210/en.2009-1101; KREISS DS, 1995, J PHARMACOL EXP THER, V274, P866; Krogh J, 2013, BRAIN BEHAV IMMUN; Lawson MA, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-87; Leonard B, 2012, NEUROSCI BIOBEHAV R, V36, P764, DOI 10.1016/j.neubiorev.2011.12.005; Li YF, 2011, J NEUROSCI, V31, P172, DOI 10.1523/JNEUROSCI.5236-10.2011; Li YF, 2009, NEUROPSYCHOPHARMACOL, V34, P2404, DOI 10.1038/npp.2009.66; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P287; Maes M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-66; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P664, DOI 10.1016/j.pnpbp.2010.06.014; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Manji H K, 2001, Psychopharmacol Bull, V35, P5; Marsden WN, 2013, PROG NEURO-PSYCHOPH, V43, P168, DOI 10.1016/j.pnpbp.2012.12.012; Miro X, 2002, SYNAPSE, V45, P259, DOI 10.1002/syn.10100; MOORE AR, 1995, CLIN EXP IMMUNOL, V101, P387; Moreau M, 2005, J INFECT DIS, V192, P537, DOI 10.1086/431603; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; Nemeroff Charles B, 2007, Expert Rev Neurother, V7, pS11, DOI 10.1586/14737175.7.11s.S11; Niciu MJ, 2013, CNS SPECTRUMS, P1; O'Connor JC, 2009, MOL PSYCHIATR, V14, P511, DOI 10.1038/sj.mp.4002148; O'Donnell JM, 1999, PHARMACOL BIOCHEM BE, V63, P185, DOI 10.1016/S0091-3057(98)00267-6; Park SE, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-12; Patki G, 2013, BRAIN RES, VS0006-8993; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Reneerkens OAH, 2009, PSYCHOPHARMACOLOGY, V202, P419, DOI 10.1007/s00213-008-1273-x; Richter W, 2013, EXPERT OPIN THER TAR, V17, P1011, DOI 10.1517/14728222.2013.818656; Robichaud A, 2002, J CLIN INVEST, V110, P1045, DOI 10.1172/JCI200215506; Robichaud A, 2001, NEUROPHARMACOLOGY, V40, P262, DOI 10.1016/S0028-3908(00)00142-8; RUTTER JJ, 1994, NEUROSCI LETT, V171, P183, DOI 10.1016/0304-3940(94)90635-1; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sarkisyan G, 2010, BEHAV BRAIN RES, V209, P99, DOI 10.1016/j.bbr.2010.01.022; Shalaby AM, 2012, J PHARMACOL PHARMACO, V3, P132, DOI 10.4103/0976-500X.95509; Siopi E, 2013, NEUROPHARMACOLOGY, V67, P183, DOI 10.1016/j.neuropharm.2012.11.009; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Rojas PS, 2011, PSYCHIAT RES, V189, P239, DOI 10.1016/j.psychres.2011.04.032; Sumegi Andras, 2008, Neuropsychopharmacol Hung, V10, P131; Takano K, 2012, J PHARMACOL SCI, V120, P176, DOI 10.1254/jphs.12039FP; Tonelli LH, 2008, NEUROPSYCHOPHARMACOL, V33, P1038, DOI 10.1038/sj.npp.1301488; Vellas B, 2011, CURR ALZHEIMER RES, V8, P203, DOI 10.2174/156720511795256053; Wang C, 2012, INT J NEUROPSYCHOPH, V15, P749, DOI 10.1017/S1461145711000836; Wang P, 1997, BIOCHEM BIOPH RES CO, V234, P320, DOI 10.1006/bbrc.1997.6636; Wang ZZ, 2013, BRIT J PHARMACOL, V168, P1001, DOI 10.1111/j.1476-5381.2012.02225.x; Wolfe F, 2009, ARTHRIT RHEUM-ARTHR, V61, P667, DOI 10.1002/art.24428; Zeugmann S, 2013, PSYCHIAT DANUB, V25, P227; Zhang HT, 2009, CURR PHARM DESIGN, V15, P1688, DOI 10.2174/138161209788168092; Zhang HT, 2002, NEUROPSYCHOPHARMACOL, V27, P587; Zhang HT, 2006, PSYCHOPHARMACOLOGY, V186, P209, DOI 10.1007/s00213-006-0369-4; Zhang JF, 2013, BEHAV BRAIN RES, V250, P230, DOI 10.1016/j.bbr.2013.05.017; Zhang KYJ, 2005, EXPERT OPIN THER TAR, V9, P1283, DOI 10.1517/14728222.9.6.1283	74	44	48	2	26	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 28	2014	263						1	14		10.1016/j.neuroscience.2014.01.008			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AC3GF	WOS:000332403400001	24434771				2022-02-06	
J	Madinier, A; Quattromani, MJ; Sjolund, C; Ruscher, K; Wieloch, T				Madinier, Alexandre; Quattromani, Miriana Jlenia; Sjolund, Carin; Ruscher, Karsten; Wieloch, Tadeusz			Enriched Housing Enhances Recovery of Limb Placement Ability and Reduces Aggrecan-Containing Perineuronal Nets in the Rat Somatosensory Cortex after Experimental Stroke	PLOS ONE			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; INDUCED MOVEMENT THERAPY; TRAUMATIC BRAIN-INJURY; FORCED ARM USE; ENVIRONMENTAL ENRICHMENT; PHOTOTHROMBOTIC STROKE; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; NEUROTROPHIC FACTOR; MOTOR RECOVERY	Stroke causes life long disabilities where few therapeutic options are available. Using electrical and magnetic stimulation of the brain and physical rehabilitation, recovery of brain function can be enhanced even late after stroke. Animal models support this notion, and housing rodents in an enriched environment (EE) several days after experimental stroke stimulates lost brain function by multisensory mechanisms. We studied the dynamics of functional recovery of rats with a lesion to the fore and hind limb motor areas induced by photothrombosis (PT), and with subsequent housing in either standard (STD) or EE. In this model, skilled motor function is not significantly enhanced by enriched housing, while the speed of recovery of sensori-motor function substantially improves over the 9-week study period. In particular, this stroke lesion completely obliterates the fore and hind limb placing ability when visual and whisker guidance is prevented, a deficit that persists for up to 9 weeks of recovery, but that is markedly restored within 2 weeks by enriched housing. Enriched housing after stroke also leads to a significant loss of perineuronal net (PNN) immunoreactivity; detection of aggrecan protein backbone with AB1031 antibody was decreased by 13-22%, and labelling of a glycan moiety of aggrecan with Cat-315 antibody was reduced by 25-30% in the peri-infarct area and in the somatosensory cortex, respectively. The majority of these cells are parvalbumin/GABA inhibitory interneurons that are important in sensori-information processing. We conclude that damage to the fore and hind limb motor areas provides a model of loss of limb placing response without visual guidance, a deficit also seen in more than 50% of stroke patients. This loss is amenable to recovery induced by multiple sensory stimulation and correlates with a decrease in aggrecan-containing PNNs around inhibitory interneurons. Modulating the PNN structure after ischemic damage may provide new therapies enhancing tactile/proprioceptive function after stroke.	[Madinier, Alexandre; Quattromani, Miriana Jlenia; Sjolund, Carin; Ruscher, Karsten; Wieloch, Tadeusz] Lund Univ, Dept Clin Sci, Expt Brain Res Lab, Div Neurosurg, Lund, Sweden		Wieloch, T (corresponding author), Lund Univ, Dept Clin Sci, Expt Brain Res Lab, Div Neurosurg, Lund, Sweden.	tadeusz.wieloch@med.lu.se		Wieloch, Tadeusz/0000-0002-7669-2520	Swedish Research CouncilSwedish Research CouncilEuropean Commission [2011-2652, 2011-2684]; EU through the European Stroke Network [201024]; Hans-Christian and Alice Wachtmeister Foundation; Swedish Brain Fund; Greta och Johan Kocks Stiftelser; Thorsten och Elsa Segerfalk Stiftelse; Crafoord Foundation	This study was supported by the Swedish Research Council grants no. 2011-2652 (TW) and no. 2011-2684 (KR), the EU 7th work program through the European Stroke Network grant no. 201024, the Hans-Christian and Alice Wachtmeister Foundation (TW, KR), the Swedish Brain Fund (TW), the Greta och Johan Kocks Stiftelser (KR), the Thorsten och Elsa Segerfalk Stiftelse (KR) and the Crafoord Foundation (KR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arendash GW, 2004, NEUROREPORT, V15, P1751, DOI 10.1097/01.wnr.0000137183.68847.4e; Ballermann M, 2001, J NEUROSCI METH, V106, P39, DOI 10.1016/S0165-0270(01)00326-0; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bezard E, 2003, J NEUROSCI, V23, P10999; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Carey LM, 2011, NEUROREHAB NEURAL RE, V25, P443, DOI 10.1177/1545968310395777; Carey LM, 1996, ARCH PHYS MED REHAB, V77, P1271, DOI 10.1016/S0003-9993(96)90192-6; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Celio MR, 1998, TRENDS NEUROSCI, V21, P510, DOI 10.1016/S0166-2236(98)01298-3; Dahlqvist P, 2003, NEUROSCIENCE, V119, P643, DOI 10.1016/S0306-4522(03)00195-7; Dancause N, 2006, REV NEUROSCIENCE, V17, P561; DERYCK M, 1992, BRAIN RES, V573, P44; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; Diederich K, 2012, STROKE, V43, P185, DOI 10.1161/STROKEAHA.111.622159; Dino MR, 2006, NEUROSCIENCE, V142, P1055, DOI 10.1016/j.neuroscience.2006.07.054; DONOGHUE JP, 1994, J CLIN NEUROPHYSIOL, V11, P382; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; Edwardson MA, 2013, EXP BRAIN RES, V224, P335, DOI 10.1007/s00221-012-3315-1; Encarnacion A, 2011, J NEUROSCI METH, V196, P247, DOI 10.1016/j.jneumeth.2011.01.010; Foscarin S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016666; Freund TF, 2007, NEURON, V56, P33, DOI 10.1016/j.neuron.2007.09.012; Frischknecht R, 2012, ADV EXP MED BIOL, V970, P153, DOI 10.1007/978-3-7091-0932-8_7; Gherardini L., 2013, CEREB CORTEX; Giamanco KA, 2010, NEUROSCIENCE, V170, P1314, DOI 10.1016/j.neuroscience.2010.08.032; GUIMARAES A, 1990, J NEUROSCI, V10, P3014; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; HARTIG W, 1994, BRAIN RES, V635, P307, DOI 10.1016/0006-8993(94)91452-4; Hebb, 1947, AM PSYCHOL, V2, P306, DOI DOI 10.1037/H0028720; Hill JJ, 2012, P NATL ACAD SCI USA, V109, P9155, DOI 10.1073/pnas.1205697109; Hobohm C, 2005, J NEUROSCI RES, V80, P539, DOI 10.1002/jnr.20459; HOCKFIELD S, 1990, COLD SH Q B, V55, P505; HOCKFIELD S, 1983, P NATL ACAD SCI-BIOL, V80, P5758, DOI 10.1073/pnas.80.18.5758; Hockly E, 2002, ANN NEUROL, V51, P235, DOI 10.1002/ana.10094; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; Inacio AR, 2011, NEUROBIOL DIS, V41, P270, DOI 10.1016/j.nbd.2010.09.015; Jablonka JA, 2010, NEUROSCIENCE, V165, P90, DOI 10.1016/j.neuroscience.2009.09.074; Janssen H, 2010, NEUROREHAB NEURAL RE, V24, P802, DOI 10.1177/1545968310372092; Jin Z, 2010, BRAIN RES, V1363, P191, DOI 10.1016/j.brainres.2010.09.081; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Karetko-Sysa M, 2011, EXP NEUROL, V231, P113, DOI 10.1016/j.expneurol.2011.05.022; Katsman D, 2003, J CEREBR BLOOD F MET, V23, P997, DOI 10.1097/01.WCB.0000084252.20114.BE; Keyvani K, 2004, J NEUROPATH EXP NEUR, V63, P598, DOI 10.1093/jnen/63.6.598; Kitago T, 2013, NEUROREHAB NEURAL RE, V27, P99, DOI 10.1177/1545968312452631; Knieling M, 2009, NEUROSCIENCE, V163, P759, DOI 10.1016/j.neuroscience.2009.07.004; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Lander C, 1997, J NEUROSCI, V17, P1928; Lendvai D, 2013, ACTA NEUROPATHOL, V125, P215, DOI 10.1007/s00401-012-1042-0; Lenzlinger PM, 2004, RESTOR NEUROL NEUROS, V22, P73; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Martinez-Cue C, 2005, BEHAV BRAIN RES, V163, P174, DOI 10.1016/j.bbr.2005.04.016; Matthews RT, 2002, J NEUROSCI, V22, P7536; McRae PA, 2007, J NEUROSCI, V27, P5405, DOI 10.1523/JNEUROSCI.5425-06.2007; Moon SK, 2009, EXP NEUROL, V218, P145, DOI 10.1016/j.expneurol.2009.04.021; Morawski M, 2012, INT J BIOCHEM CELL B, V44, P690, DOI 10.1016/j.biocel.2012.01.010; Muller HD, 2008, STROKE, V39, P1012, DOI 10.1161/STROKEAHA.107.495069; Muntner P, 2002, STROKE, V33, P1209, DOI 10.1161/01.STR.0000015031.57955.D1; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Overman JJ, 2014, NEUROSCIENTIST, V20, P15, DOI 10.1177/1073858413491146; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Restivo L, 2005, P NATL ACAD SCI USA, V102, P11557, DOI 10.1073/pnas.0504984102; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Rogers DC, 1997, PHARMACOL BIOCHEM BE, V56, P747, DOI 10.1016/S0091-3057(96)00430-3; Rosell A, 2008, CURR OPIN PHARMACOL, V8, P82, DOI 10.1016/j.coph.2007.12.001; Ruscher K, 2011, BRAIN, V134, P732, DOI 10.1093/brain/awq367; Ruscher K, 2009, J CEREBR BLOOD F MET, V29, P1796, DOI 10.1038/jcbfm.2009.96; Sale A, 2007, NAT NEUROSCI, V10, P679, DOI 10.1038/nn1899; Schabitz WR, 2004, STROKE, V35, P992, DOI 10.1161/01.STR.0000119754.85848.0D; Schulz R, 2013, NEUROPHARMACOLOGY, V64, P579, DOI 10.1016/j.neuropharm.2012.05.016; Shanina EV, 2006, NEUROSCIENCE, V139, P1495, DOI 10.1016/j.neuroscience.2006.01.016; Sigler A, 2008, J NEUROSCI METH, V170, P35, DOI 10.1016/j.jneumeth.2007.12.015; Soleman S, 2013, NEUROSCIENCE, V253, P194, DOI 10.1016/j.neuroscience.2013.08.050; Starkey ML, 2012, BRAIN, V135, P3265, DOI 10.1093/brain/aws270; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vandeputte C, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-92; Viapiano MS, 2006, TRENDS MOL MED, V12, P488, DOI 10.1016/j.molmed.2006.08.007; Wang DF, 2012, CELL TISSUE RES, V349, P147, DOI 10.1007/s00441-012-1375-y; Wang YG, 2008, J CEREBR BLOOD F MET, V28, P1936, DOI 10.1038/jcbfm.2008.82; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Wood NI, 1996, BEHAV BRAIN RES, V78, P113, DOI 10.1016/0166-4328(95)00237-5; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690	89	44	45	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2014	9	3							e93121	10.1371/journal.pone.0093121			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AD7QO	WOS:000333459900155	24664200	Green Published, Green Submitted, gold			2022-02-06	
J	Forbes, CE; Poore, JC; Krueger, F; Barbey, AK; Solomon, J; Grafman, J				Forbes, Chad E.; Poore, Joshua C.; Krueger, Frank; Barbey, Aron K.; Solomon, Jeffrey; Grafman, Jordan			The role of executive function and the dorsolateral prefrontal cortex in the expression of neuroticism and conscientiousness	SOCIAL NEUROSCIENCE			English	Article						Personality; DLPC; Executive function; Neuroticism; Conscientiousness; Self-control	GENERAL INTELLIGENCE; PERSONALITY-TRAITS; EMOTION REGULATION; BRAIN VOLUME; EXTROVERSION; FMRI; METAANALYSIS; SOFTWARE; AMYGDALA; INJURY	The current study examined how specific neurological systems contribute to the expression of multiple personality dimensions. We used individuals with traumatic brain injuries to examine the contribution of the dorsolateral prefrontal cortex (DLPFC)a region important for executive function and attentionto the expression of neuroticism and conscientiousness factors and facets. Results from Voxel-Based Lesion-Symptom Mapping analyses revealed that focal damage to the left DLPFC (Brodmann's area 9) was associated with high neuroticism and low conscientious factor and facet scores (anxiety and self-discipline, respectively). Compared with lesioned and normal controls, veterans with damage in left DLPFC also reported higher neuroticism and lower conscientiousness facet scores, slower reaction times on the California Computerized Assessment Package assessment, and lower scores on the Delis-Kaplan executive function battery. Findings suggest that while neuroticism and conscientiousness remain psychometrically independent personality dimensions, their component facets may rely on a common neurocognitive infrastructure and executive function resources in general.	[Forbes, Chad E.; Poore, Joshua C.; Krueger, Frank; Barbey, Aron K.; Solomon, Jeffrey; Grafman, Jordan] NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Forbes, Chad E.] Univ Delaware, Dept Psychol, Newark, DE 19716 USA; [Forbes, Chad E.] Ctr Clin, Bethesda, MD USA; [Forbes, Chad E.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD USA; [Poore, Joshua C.] Charles Stark Draper Lab Inc, Boston, MA USA; [Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Solomon, Jeffrey] Expert Image Anal LLC, Potomac, MD USA; [Grafman, Jordan] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Alzheimers Dis Res Ctr, Dept Phys Med & Rehabil, Evanston, IL 60208 USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Alzheimers Dis Res Ctr, Dept Psychiat & Behav Sci, Evanston, IL 60208 USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Alzheimers Dis Res Ctr, Dept Cognit Neurol, Evanston, IL 60208 USA; [Grafman, Jordan] Northwestern Univ, Dept Psychol, Evanston, IL 60208 USA		Forbes, CE (corresponding author), Univ Delaware, Dept Psychol, 111 Wolf Hall, Newark, DE 19716 USA.	cforbes@psych.udel.edu; jgrafman@northwestern.edu	Barbey, Aron/L-7312-2015	Barbey, Aron/0000-0002-6092-0912; Grafman, Jordan H./0000-0001-8645-4457	Intramural Research Training Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health; US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD17-01-1-0675]	This work was supported by the Intramural Research Training Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, and a project grant from the US Army Medical Research and Material Command administrated by the Henry M. Jackson Foundation [Vietnam Head Injury Study Phase III: A 30-year post-injury follow-up study: Grant number: DAMD17-01-1-0675]. The authors are grateful to all the Vietnam veterans who participated in this study.	Badre D, 2008, TRENDS COGN SCI, V12, P193, DOI 10.1016/j.tics.2008.02.004; Banich MT, 2009, CURR DIR PSYCHOL SCI, V18, P89, DOI 10.1111/j.1467-8721.2009.01615.x; Banks SJ, 2007, SOC COGN AFFECT NEUR, V2, P303, DOI 10.1093/scan/nsm029; Barbey AK, 2014, SOC COGN AFFECT NEUR, V9, P265, DOI 10.1093/scan/nss124; Barbey AK, 2012, BRAIN, V135, P1154, DOI 10.1093/brain/aws021; Barrett LF, 2006, CURR DIR PSYCHOL SCI, V15, P79, DOI 10.1111/j.0963-7214.2006.00411.x; Barrett LF, 2009, PERSPECT PSYCHOL SCI, V4, P326, DOI 10.1111/j.1745-6924.2009.01134.x; Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; Blankstein U, 2009, NEUROPSYCHOLOGIA, V47, P599, DOI 10.1016/j.neuropsychologia.2008.10.014; Costa Jr P.T., 1992, NEO PI R PROFESSIONA; Deckersbach T, 2006, DEPRESS ANXIETY, V23, P133, DOI 10.1002/da.20152; Defense Do, 1960, ARMED FORCES QUALIF; Delis DC., 2001, DELIS KAPLAN EXECUTI; DeYoung CG, 2010, PSYCHOL SCI, V21, P820, DOI 10.1177/0956797610370159; DeYoung CG, 2009, CAMBRIDGE HANDBOOK OF PERSONALITY PSYCHOLOGY, P323; Eisenberger NI, 2005, COGN AFFECT BEHAV NE, V5, P169, DOI 10.3758/CABN.5.2.169; Fuster, 2015, PREFRONTAL CORTEX; Giedd JN, 2010, NEURON, V67, P728, DOI 10.1016/j.neuron.2010.08.040; Glascher J, 2010, P NATL ACAD SCI USA, V107, P4705, DOI 10.1073/pnas.0910397107; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Gross JJ, 2003, J PERS SOC PSYCHOL, V85, P348, DOI 10.1037/0022-3514.85.2.348; Jackson J, 2011, NEUROBIOL AGING, V32, P2162, DOI 10.1016/j.neurobiolaging.2009.12.009; John OP., 2008, HDB PERSONAL THEORY, P114; Knutson B, 2001, BIOL PSYCHIAT, V50, P685, DOI 10.1016/S0006-3223(01)01220-3; Kotov R, 2010, PSYCHOL BULL, V136, P768, DOI 10.1037/a0020327; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Krueger F, 2009, P NATL ACAD SCI USA, V106, P22486, DOI 10.1073/pnas.0912568106; Kumari V, 2007, BEHAV NEUROSCI, V121, P643, DOI 10.1037/0735-7044.121.4.643; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lewis MD, 2007, COGNITIVE DEV, V22, P406, DOI 10.1016/j.cogdev.2007.08.004; Lieberman MD, 2009, SOC COGN AFFECT NEUR, V4, P423, DOI 10.1093/scan/nsp052; Lindquist KA, 2012, BEHAV BRAIN SCI, V35, P121, DOI 10.1017/S0140525X11000446; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; McCrae Robert R., 2008, HDB PERSONALITY THEO, DOI DOI 10.3905/JPE.2000.319978; MCCRAE RR, 1992, J PERS, V60, P175, DOI 10.1111/j.1467-6494.1992.tb00970.x; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MILLER EN, 1990, CALIFORNIA COMPUTERI; Muller D, 2005, J PERS SOC PSYCHOL, V89, P852, DOI 10.1037/0022-3514.89.6.852; Murphy FC, 2003, COGN AFFECT BEHAV NE, V3, P207, DOI 10.3758/CABN.3.3.207; Naragon-Gainey K, 2011, PSYCHOL MED, V41, P1437, DOI 10.1017/S0033291710002096; Omura K, 2005, NEUROREPORT, V16, P1905, DOI 10.1097/01.wnr.0000186596.64458.76; Roberts BW, 2000, PSYCHOL BULL, V126, P3, DOI 10.1037/0033-2909.126.1.3; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Vul E, 2009, PERSPECT PSYCHOL SCI, V4, P274, DOI 10.1111/j.1745-6924.2009.01125.x; Wager TD, 2003, NEUROIMAGE, V19, P513, DOI 10.1016/S1053-8119(03)00078-8; Wagner AD, 2001, NEUROIMAGE, V14, P1337, DOI 10.1006/nimg.2001.0936; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wood JN, 2003, NAT REV NEUROSCI, V4, P139, DOI 10.1038/nrn1033; Wright CI, 2007, NEUROIMAGE, V35, P263, DOI 10.1016/j.neuroimage.2006.11.039; Wright CI, 2006, CEREB CORTEX, V16, P1809, DOI 10.1093/cercor/bhj118; Zuckerman M., 1991, PERSONALITY INDIVIDU, V54, P96	52	44	46	0	47	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1747-0919	1747-0927		SOC NEUROSCI-UK	Soc. Neurosci.	MAR 4	2014	9	2					139	151		10.1080/17470919.2013.871333			13	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	AA2NZ	WOS:000330932600004	24405294				2022-02-06	
J	Joseph, B; Pandit, V; Aziz, H; Kulvatunyou, N; Hashmi, A; Tang, A; O'Keeffe, T; Wynne, J; Vercruysse, G; Friese, RS; Rhee, P				Joseph, Bellal; Pandit, Viraj; Aziz, Hassan; Kulvatunyou, Narong; Hashmi, Ammar; Tang, Andrew; O'Keeffe, Terence; Wynne, Julie; Vercruysse, Gary; Friese, Randall S.; Rhee, Peter			Clinical outcomes in traumatic brain injury patients on preinjury clopidogrel: A prospective analysis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Clopidogrel therapy; progression on repeat head computed tomography; neurosurgical intervention	PLATELET TRANSFUSION; ANTIPLATELET THERAPY; ELDERLY-PATIENTS; HEAD-INJURIES; ASPIRIN	BACKGROUND Patients receiving antiplatelet medications are considered to be at an increased risk for traumatic intracranial hemorrhage after blunt head trauma. However, most studies have categorized all antiplatelet drugs into one category. The aim of our study was to evaluate clinical outcomes and the requirement of a repeat head computed tomography (RHCT) in patients on preinjury clopidogrel therapy. METHODS Patients with traumatic brain injury with intracranial hemorrhage on initial head CT were prospectively enrolled. Patients on preinjury clopidogrel were matched with patients exclusive of antiplatelet and anticoagulation therapy using a propensity score in a 1:1 ratio for age, Glasgow Coma Scale (GCS), head Abbreviated Injury Scale (h-AIS), Injury Severity Score (ISS), neurologic examination, and platelet transfusion. Outcome measures were progression on RHCT scan and need for neurosurgical intervention. RESULTS A total of 142 patients with intracranial hemorrhage on initial head CT scan (clopidogrel, 71; no clopidogrel, 71) were enrolled. The mean (SD) age was 70.5 (15.1) years, 66% were male, median GCS score was 14 (range, 3-15), and median h-AIS (ISS) was 3 (range, 2-5). The mean (SD) platelet count was 210 (101), and 61% (n = 86) of the patients received platelet transfusion. Patients on preinjury clopidogrel were more likely to have progression on RHCT (odds ratio [OR], 5.1; 95% confidence interval [CI], 3.1-7.1) and RHCT as a result of clinical deterioration (OR, 2.1; 95% CI, 1.8-3.5). The overall rate of neurosurgical intervention was 4.2% (n = 6). Patients on clopidogrel therapy were more likely to require a neurosurgical intervention (OR, 1.8; 95% CI, 1.4-3.1). CONCLUSION Preinjury clopidogrel therapy is associated with progression of initial insult on RHCT scan and need for neurosurgical intervention. Preinjury clopidogrel therapy as an independent variable should warrant the need for a routine RHCT scan in patients with traumatic brain injury. LEVEL OF EVIDENCE Prognostic study, level I; therapeutic study, level II.	[Joseph, Bellal; Pandit, Viraj; Aziz, Hassan; Kulvatunyou, Narong; Hashmi, Ammar; Tang, Andrew; O'Keeffe, Terence; Wynne, Julie; Vercruysse, Gary; Friese, Randall S.; Rhee, Peter] Univ Arizona, Div Trauma Crit Care Emergency Surg & Burns, Dept Surg, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Div Trauma Crit Care Emergency Surg & Burns, Dept Surg, 1501 N Campbell Ave,Room 5411, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021	Aziz, Hassan/0000-0003-0406-1946			Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Fabbri A, 2013, CRIT CARE, V17, DOI 10.1186/cc12575; Faul M, 2010, TRAUMATIC BRAIN INJU; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Joseph B, 2013, J TRAUMA AC IN PRESS; Joseph B, 2014, AM SURG IN PRESS; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; MILLS DCB, 1992, ARTERIOSCLER THROMB, V12, P430, DOI 10.1161/01.ATV.12.4.430; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Serebruany VL, 2003, AM HEART J, V146, P713, DOI 10.1016/S0002-8703(03)00260-6; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	15	44	44	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2014	76	3					817	820		10.1097/TA.0b013e3182aafcf0			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AB8YW	WOS:000332077100050	24553554				2022-02-06	
J	Stewart, TC; Gilliland, J; Fraser, DD				Stewart, Tanya Charyk; Gilliland, Jason; Fraser, Douglas D.			An epidemiologic profile of pediatric concussions: Identifying urban and rural differences	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Epidemiology-injury; concussion; mild traumatic brain injury; urban; rural	SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; HEAD-INJURIES; UNITED-STATES; BRAIN; ADOLESCENTS; EMERGENCY; FOOTBALL; CHILDREN	BACKGROUND The objective of this study was to describe the epidemiology of concussions presenting to the emergency department (ED). METHODS A retrospective cohort of concussions for pediatric (age < 18 years) patients treated in the ED of a regional pediatric Level 1 trauma center from 2006 to 2011 was examined. Descriptive and geographic analyses were completed, with comparisons by age groups and residence (urban/rural). RESULTS There were a total of 2,112 treated pediatric concussions. Two thirds of the concussions occurred in males (67%), with a median age of 13 years (interquartile range [IQR], 6). Nearly half of the pediatric concussions were sports related (48%); 36% of these concussions were from hockey. Significant differences were found in the distribution of the mechanism of injury across age groups (p < 0.001). Falls were most prevalent among young children, and sports concussions, for children 10 years and older. Two fifths of concussions occurred during winter months. Discharge disposition significantly differed by age (p < 0.001), with home discharge increasing with age up to 14 years. There were a total of 387 rural (19%) and 1,687 urban (81%) concussed patients, for a mean ED concussion visit rate of 2.2 per 1,000 and 3.5 per 1,000, respectively. Rural patients were older (14 [IQR, 6] vs. 13 [IQR, 6], p = 0.019] and sustained 2.5 times more concussions from a motor vehicle crash compared with urban youth patients (p < 0.001). CONCLUSION Males in early adolescence are at highest risk for concussion, particularly from sport-related activities. Urban and rural children have differences in their etiology and severity of concussions. Concussions are predictable, and their prevention should be targeted based on epidemiologic and environmental data. LEVEL OF EVIDENCE Epidemiologic, study, level III.	[Stewart, Tanya Charyk] London Hlth Sci Ctr, Trauma Program, London, ON N6A 5W9, Canada; [Stewart, Tanya Charyk] Univ Western Ontario, Dept Surg, London, ON N6A 3K7, Canada; [Gilliland, Jason] Univ Western Ontario, Dept Geog, London, ON N6A 5C2, Canada; [Gilliland, Jason; Fraser, Douglas D.] Univ Western Ontario, Dept Pediat, London, ON N6A 3K7, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Gilliland, Jason] Univ Western Ontario, Sch Hlth Studies, London, ON, Canada; [Gilliland, Jason; Fraser, Douglas D.] Childrens Hlth Res Inst, London, ON, Canada; [Fraser, Douglas D.] Ctr Crit Illness Res, London, ON, Canada		Stewart, TC (corresponding author), London Hlth Sci Ctr, Trauma Program, 800 Commissioners Rd East, London, ON N6A 5W9, Canada.	tanya.charyk@lhsc.on.ca	Gilliland, Jason A/E-3393-2019; El-Bagdady, Moe/S-8621-2019; University, HEAL Western/T-1323-2019	Gilliland, Jason A/0000-0002-2909-2178; 	Children's Health Foundation, London, Ontario, Canada	Financial support was provided by The Children's Health Foundation (www.childhealth.ca), London, Ontario, Canada.	[Anonymous], 2012, INJ PREV CONTR TRAUM; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barzarian JJ, 2005, EMERG MED J, V22, P473; Brain Injury Association of Canada, 2012, CONC HITT YOUTH EV; Canadian Institute for Health Information, 2012, INT STAT CLASS DIS R; Canadian Institute for Health Information, 2008, NAT TRAUM REG 2007 I; Centers for Disease Control and Prevention, 2012, PROT ON YOU LOV CHIL; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Forward K, 2010, J TRAUMA, V69, P1294, DOI 10.1097/TA.0b013e3181fa7e25; Franklin CC, 2012, CURR OPIN PEDIATR, V24, P64, DOI 10.1097/MOP.0b013e32834ec618; Fung M, 2006, PEDIATRICS, V126, P597; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Joffe Ari R, 2006, J Intensive Care Med, V21, P227, DOI 10.1177/0885066606288944; JOLY MF, 1991, REV EPIDEMIOL SANTE, V39, P345; Jones CS, 2005, J RURAL HEALTH, V21, P70, DOI 10.1111/j.1748-0361.2005.tb00064.x; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Katcher MJ, 1996, PEDIATRICS, V97, P765; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Laflamme L, 2000, Inj Prev, V6, P293, DOI 10.1136/ip.6.4.293; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Morrison Gavin, 2013, Pathophysiology, V20, P49, DOI 10.1016/j.pathophys.2012.02.006; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Patel DR, 2010, PEDIATR CLIN N AM, V57, P649, DOI 10.1016/j.pcl.2010.03.006; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Puderer HA, 2009, URBAN PERSPECTIVES M; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Upshaw JE, 2012, PEDIATR EMERG CARE, V28, P926, DOI 10.1097/PEC.0b013e318267f674; Vogt KN, 2009, BOYS THEIR TOYS REGI	37	44	44	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2014	76	3					736	742		10.1097/TA.0b013e3182aafdf5			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AB8YW	WOS:000332077100038	24553542				2022-02-06	
J	Rostami, E; Krueger, F; Plantman, S; Davidsson, J; Agoston, D; Grafman, J; Risling, M				Rostami, Elham; Krueger, Frank; Plantman, Stefan; Davidsson, Johan; Agoston, Denes; Grafman, Jordan; Risling, Marten			Alteration in BDNF and its receptors, full-length and truncated TrkB and p75(NTR) following penetrating traumatic brain injury	BRAIN RESEARCH			English	Article						BDNF; Traumatic brain injury; TrkB; p75(NTR); Neurotrophins	NERVE GROWTH-FACTOR; P75 NEUROTROPHIN RECEPTOR; TYROSINE PROTEIN-KINASE; MESSENGER-RNA; ENVIRONMENTAL ENRICHMENT; RAT HIPPOCAMPUS; INCREASED EXPRESSION; GENE-EXPRESSION; MULTIPLE ROLES; UP-REGULATION	The evidence that BDNF is involved in neuroprotection, neuronal repair and recovery after traumatic brain injury (TBI) is substantial. We have previously shown that the polymorphism of the human BDNF gene predicts cognitive recovery and outcome following penetrating TBI. The distribution of expression of BONE and its receptors after penetrating TBI has not been investigated. In this study we examined the expression of these genes in a rat model of penetrating TBI. The injury is produced by a controlled penetration of a 2 mm thick needle-shaped object, which is accelerated with a pellet from an air gun. We used in situ hybridization and investigated the mRNA expression of BDNF and its receptors: the full-length and the truncated TrkB and p75(NTR), from 1 day to 8 weeks following penetrating TBI. In addition, the protein level of BDNF in frontal cortex and hippocampus was measured by reverse phase protein microarray (RPPM). The mRNA expression of BDNF and its receptors decreased in the hippocampus in the border zone ipsilateral to the injury while there was an increase in mRNA expression at the contralateral side. The increase in BDNF mRNA expression in the hippocampus was sustained for 2 weeks following injury, with the highest expression noted in the CA3 cell layer. Furthermore, the protein analysis by RPPM showed increased levels of BDNF in the frontal cortex and the hippocampus up to 2 weeks after TBI. At 8 weeks following injury there was an intense labeling of the truncated TrkB receptor and the p75NTR in the area surrounding the cavity. Our study is the first report on the expression of BDNF and its receptors following penetrating TBI and suggests that their expression is altered long after the acute phase of injury. Further studies are needed to investigate if the late expressions of these receptors are beneficial or deleterious. In either case it indicates the possibility to influence the recovery after brain injury during the chronic phase and the development of treatments that may improve the outcome of TBI patients. (C) 2013 Elsevier B.V. All rights reserved.	[Rostami, Elham; Plantman, Stefan; Risling, Marten] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden; [Rostami, Elham] Univ Uppsala Hosp, Dept Neurosci & Neurosurg, Uppsala, Sweden; [Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Davidsson, Johan] Chalmers, Div Vehicle Safety, S-41296 Gothenburg, Sweden; [Agoston, Denes] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Grafman, Jordan] Rehabil Inst Chicago, Cognit Neurosci Lab, Chicago, IL USA		Rostami, E (corresponding author), Karolinska Inst, Dept Neurosci, Retzius Vag 8, SE-17177 Stockholm, Sweden.	Elham.rostami@ki.se	Davidsson, Johan/A-3229-2016	Davidsson, Johan/0000-0002-1717-1514; Grafman, Jordan H./0000-0001-8645-4457			BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Bentley CA, 2000, J NEUROSCI, V20, P7706; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen Y, 2009, J INT MED RES, V37, P281, DOI 10.1177/147323000903700201; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Ding Q, 2011, NEUROSCIENCE, V192, P773, DOI 10.1016/j.neuroscience.2011.06.032; Drake CT, 1999, J NEUROSCI, V19, P8009; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Eide FF, 1996, J NEUROSCI, V16, P3123; EMFORS P, 1989, NEURON, V2, P1605; Emfors P., 1990, P NATL ACAD SCI USA, V87, P5454; Frade JM, 1996, NATURE, V383, P166; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; FRISEN J, 1992, P NATL ACAD SCI USA, V89, P11282, DOI 10.1073/pnas.89.23.11282; Giehl KM, 2001, J NEUROSCI, V21, P3492, DOI 10.1523/JNEUROSCI.21-10-03492.2001; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Haapasalo A, 1999, ONCOGENE, V18, P1285, DOI 10.1038/sj.onc.1202401; Haapasalo A, 2001, BIOCHEM BIOPH RES CO, V280, P1352, DOI 10.1006/bbrc.2001.4296; Hartmann M, 2004, J CELL SCI, V117, P5803, DOI 10.1242/jcs.01511; HAYES RC, 1992, MOL BRAIN RES, V15, P291, DOI 10.1016/0169-328X(92)90120-Z; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; Keyvani K, 2004, J NEUROPATH EXP NEUR, V63, P598, DOI 10.1093/jnen/63.6.598; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Lipsky RH, 2007, ANN NY ACAD SCI, V1122, P130, DOI 10.1196/annals.1403.009; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; Michaelsen K, 2010, EUR J NEUROSCI, V32, P1854, DOI 10.1111/j.1460-9568.2010.07460.x; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MUDO G, 1993, NEUROSCIENCE, V57, P901, DOI 10.1016/0306-4522(93)90036-F; Naumann T, 2002, J NEUROSCI, V22, P2409, DOI 10.1523/JNEUROSCI.22-07-02409.2002; Oderfeld-Nowak B, 2003, NEUROSCIENCE, V120, P31, DOI 10.1016/S0306-4522(03)00289-6; Plantman S, 2012, J NEUROTRAUM, V29, P1219, DOI 10.1089/neu.2011.2182; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; RISLING M, 1992, J NEUROCYTOL, V21, P79, DOI 10.1007/BF01189007; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Schallert T, 2000, J CEREBR BLOOD F MET, V20, P1513, DOI 10.1097/00004647-200011000-00001; Shulga A, 2012, J NEUROSCI, V32, P1757, DOI 10.1523/JNEUROSCI.3282-11.2012; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; TANIUCHI M, 1988, J NEUROSCI, V8, P664; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Yacoubian TA, 2000, NAT NEUROSCI, V3, P342, DOI 10.1038/73911; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zaccaro MC, 2001, J BIOL CHEM, V276, P31023, DOI 10.1074/jbc.M104630200	62	44	47	0	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 13	2014	1542						195	205		10.1016/j.brainres.2013.10.047			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	299UF	WOS:000330420500019	24192075				2022-02-06	
J	Chen, YC; Mao, HJ; Yang, KH; Abel, T; Meaney, DF				Chen, Yung Chia; Mao, Haojie; Yang, King H.; Abel, Ted; Meaney, David F.			A modified controlled cortical impact technique to model mild traumatic brain injury mechanics in mice	FRONTIERS IN NEUROLOGY			English	Article						controlled cortical impact; mild traumatic brain injury; biomechanics; strain rate; glia reactivity	CLOSED-HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; FLUID PERCUSSION MODEL; FINITE-ELEMENT MODEL; AXONAL INJURY; PROFESSIONAL FOOTBALL; ANIMAL-MODEL; CONCUSSION; STRETCH; STRAIN	For the past 25 years, controlled cortical impact (CCI) has been a useful tool in traumatic brain injury (TBI) research, creating injury patterns that includes primary contusion, neuronal loss, and traumatic axonal damage. However, when CCI was first developed, very little was known on the underlying biomechanics of mild TBI. This paper uses information generated from recent computational models of mild TBI in humans to alter CCI and better reflect the biomechanical conditions of mild TBI. Using a finite element model of CCI in the mouse, we adjusted three primary features of CCI: the speed of the impact to achieve strain rates within the range associated with mild TBI, the shape, and material of the impounder to minimize strain concentrations in the brain, and the impact depth to control the peak deformation that occurred in the cortex and hippocampus. For these modified cortical impact conditions, we observed peak strains and strain rates throughout the brain were significantly reduced and consistent with estimated strains and strain rates observed in human mild TBI. We saw breakdown of the blood brain barrier but no primary hemorrhage. Moreover, neuronal degeneration, axonal injury, and both astrocytic and microglia reactivity were observed up to 8 days after injury. Significant deficits in rotarod performance appeared early after injury, but we observed no impairment in spatial object recognition or contextual fear conditioning response 5 and 8 days after injury, respectively. Together, these data show that simulating the biomechanical conditions of mild TBI with a modified cortical impact technique produces regions of cellular reactivity and neuronal loss that coincide with only a transient behavioral impairment.	[Chen, Yung Chia; Meaney, David F.] Univ Penn, Dept Bioengn, 2105 33rd St,240 Skirkanich Hall, Philadelphia, PA 19104 USA; [Mao, Haojie; Yang, King H.] Wayne State Univ, Bioengn Ctr, Detroit, MI USA; [Abel, Ted] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 2105 33rd St,240 Skirkanich Hall, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Abel, Ted/AAX-2825-2021; Mao, Haojie/Q-7514-2018	Abel, Ted/0000-0003-2423-4592; Mao, Haojie/0000-0002-7563-9234; Meaney, David/0000-0002-0954-4122	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; New Jersey Commission for Brain Injury Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088176] Funding Source: NIH RePORTER	We thank Mr. Nikhil Mone for his help in part of meshing and modeling work. Funding was provided by grants from the National Institutes of Health and the New Jersey Commission for Brain Injury Research.	Albert-WeiSSenberger Christiane, 2012, Exp Transl Stroke Med, V4, P1, DOI 10.1186/2040-7378-4-1; Anderson KJ, 2003, J NEUROTRAUM, V20, P1223, DOI 10.1089/089771503770802899; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 1999, THRESHOLDS MECH INJU; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dokko Y, 2003, 18 INT TECHN C ENH S, P19; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Ellingson Benjamin M., 2005, V41, P86; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Fijalkowski RJ, 2009, STAPP CAR CRASH JO, V53, P193; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Hamilton NA, 2010, SEMIN PEDIATR SURG, V19, P271, DOI 10.1053/j.sempedsurg.2010.06.005; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lee Bruce, 2005, NeuroRx, V2, P372; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; Meaney D.F., 1990, P 1990 INT IRCOBI C, P215; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Miller R., 1998, FINITE ELEMENT MODEL; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Oliveira AMM, 2011, LEARN MEMORY, V18, P161, DOI 10.1101/lm.1939811; Oliveira AMM, 2010, LEARN MEMORY, V17, P155, DOI 10.1101/lm.1625310; Patel TP, 2014, J NEUROSCI, V34, P4200, DOI 10.1523/JNEUROSCI.4172-13.2014; Pena A, 2005, ACT NEUR S, V95, P333; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Rashid B, 2014, J MECH BEHAV BIOMED, V33, P43, DOI 10.1016/j.jmbbm.2012.07.015; Ruan J. S., 1993, FINITE ELEMENT MODEL; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Shreiber DI, 1997, IN VIVO THRESHOLDS M; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Singh Anita, 2006, Stapp Car Crash J, V50, P601; Singh P, 2012, J BIOL CHEM, V287, P4348, DOI 10.1074/jbc.M111.253740; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; TEASDALE G, 1974, LANCET, V2, P81; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Ward C. C., 1975, DEV DETAILED FINITE; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang L., 2003, P 2003 SUMM BIOENG C, P137; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	90	44	46	1	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								100	10.3389/fneur.2014.00100			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QW	WOS:000209629300097	24994996	Green Published, gold			2022-02-06	
J	Cifu, DX; Hart, BB; West, SL; Walker, W; Carne, W				Cifu, David X.; Hart, Brett B.; West, Steven L.; Walker, William; Carne, William			The Effect of Hyperbaric Oxygen on Persistent Postconcussion Symptoms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; hyperbaric oxygen therapy; postconcussion syndrome	POST-CONCUSSION SYNDROME; TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSION; PLACEBO-RESPONSE; THERAPY; CHECKLIST; MILITARY; DISORDER; PAIN	Background: The high incidence of persistent postconcussion symptoms in service members with combat-related mild traumatic brain injury has prompted research in the use of hyperbaric oxygen (HBO2) for management. Objective: The effects of HBO2 on persistent postconcussion symptoms in 60 military service members with at least 1 combat-related mild traumatic brain injury were examined in a single-center, double-blind, randomized, sham-controlled, prospective trial at the Naval Medicine Operational Training Center at Naval Air Station Pensacola. Methods: Over a 10-week period, subjects received a series of 40, once-daily, hyperbaric chamber compressions at 2.0 atmospheres absolute (ATA). During each session, subjects breathed 1 of 3 preassigned oxygen fractions (10.5%, 75%, or 100%) for 60 minutes, resulting in an oxygen exposure equivalent to breathing surface air, 100% oxygen at 1.5 ATA, or 100% oxygen at 2.0 ATA, respectively. Individual, subscale and total item responses on the Rivermead Postconcussion Symptom Questionnaire and individual and total Posttraumatic Disorder Checklist-Military Version were measured just prior to intervention and immediately postintervention. Results: Between-group testing of pre- and postintervention means revealed no significant differences on individual or total scores on the Posttraumatic Disorder Checklist-Military Version or Rivermead Postconcussion Symptom Questionnaire, demonstrating a successful randomization and no significant main effect for HBO2 at 1.5 or 2.0 ATA equivalent compared with the sham compression. Within-group testing of pre- and postintervention means revealed significant differences on several individual items for each group and difference in the Posttraumatic Disorder Checklist-Military Version total score for the 2.0 ATA HBO2 group. Discussion: The primary analyses of between group differences found no evidence of efficacy for HBO2. The scattered within group differences are threatened by Type 2 errors and could be explained by nonspecific effects. Conclusion: This study demonstrated that HBO2 at either 1.5 or 2.0 ATA equivalent had no effect on postconcussion symptoms after mild traumatic brain injury when compared with sham compression.	[Cifu, David X.] Dept Vet Affairs, Phys Med & Rehabil Program Off, Washington, DC USA; [Cifu, David X.; West, Steven L.; Walker, William; Carne, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Cifu, David X.; Walker, William; Carne, William] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Hart, Brett B.] Naval Med Operat Training Ctr, Pensacola, FL USA; [Walker, William; Carne, William] Richmond Def & Vet Brain Injury Ctr, Richmond, VA USA		Cifu, DX (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 1223 E Marshall St, Richmond, VA 23298 USA.	dcifu@vcu.edu		Cifu, David/0000-0003-1600-9387	Defense Advanced Research Projects Agency grant [N66001-09-2-206]; US Navy Bureau of Medicine and Surgery; US Army Medical Materiel Development Activity; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	Funding was provided for the primary study by a Defense Advanced Research Projects Agency grant (N66001-09-2-206), US Navy Bureau of Medicine and Surgery for contract funding temporary duty requirements, and the US Army Medical Materiel Development Activity for end-of-study contract funding. Dr Carne's and Dr Walker's efforts were additionally supported through a contract from the Defense and Veterans Brain Injury Center. The funding sources had no role in the study design, analysis, interpretation of the data, the writing of the paper, or the decision to submit the paper for publication.	BENNETT MH, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD004609.PUB3; Bennett MH, 2012, EXTREME PHYSIOL MED, V1, DOI 10.1186/2046-7648-1-14; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Cifu D, 2011, OVERCOMING POSTDEPLO; Cifu DX, J REHABIL R IN PRESS; Clarke D, 2009, UNDERSEA HYPERBAR M, V36, P13; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Gesell L.B., 2008, HYPERBARIC OXYGEN TH; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Harch PG, 2012, P 2 INT S HYP OXYG C, P31; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; McDonagh M, 2004, ARCH PHYS MED REHAB, V85, P1198, DOI 10.1016/j.apmr.2003.12.026; Peng Y, 2010, PROG NEURO-PSYCHOPH, V34, P1018, DOI 10.1016/j.pnpbp.2010.05.016; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stein DJ, 2006, J CLIN PSYCHIAT, V67, P1741, DOI 10.4088/JCP.v67n1111; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Walker RL, 2010, PSYCHOL SERV, V7, P136, DOI 10.1037/a0019684; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; Weaver LK, 2012, UNDERSEA HYPERBAR M, V39, P807; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549	26	44	45	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					11	20		10.1097/HTR.0b013e3182a6aaf0			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400004	24052094				2022-02-06	
J	Clark, AL; Amick, MM; Fortier, C; Milberg, WP; McGlinchey, RE				Clark, Alexandra L.; Amick, Melissa M.; Fortier, Catherine; Milberg, William P.; McGlinchey, Regina E.			Poor Performance Validity Predicts Clinical Characteristics and Cognitive Test Performance of OEF/OIF/OND Veterans in a Research Setting	CLINICAL NEUROPSYCHOLOGIST			English	Article						Symptom validity; Effort testing; Symptom exaggeration; Deployment	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; POSTTRAUMATIC-STRESS-DISORDER; WORD MEMORY TEST; SYMPTOM VALIDITY; HEAD-INJURY; DIGIT SPAN; POSTCONCUSSION SYNDROME; COMBAT VETERANS	This study examined the performance of 198 Veteran research participants deployed during Operation Enduring Freedom, Operation Iraqi Freedom, and/or Operation New Dawn (OEF/OIF/OND) on four measures of performance validity: the Medical Symptom Validity Test (MSVT), California Verbal Learning Test: Forced Choice Recognition (FCR), Reliable Digit Span (RDS), and TOVA Symptom Exaggeration Index (SEI). Failure on these performance validity tests (PVTs) ranged from 4% to 9%. The overall base rate of poor performance validity, as measured by failure of the MSVT in conjunction with an embedded PVT (FCR, RDS, SEI), was 5.6%. Regression analyses revealed that poor performance validity predicted cognitive test performance and self-reported psychological symptom severity. Furthermore, a greater prevalence of traumatic brain injury (TBI), Post-Traumatic Stress Disorder (PTSD), co-morbid TBI/PTSD, and other Axis I diagnoses, was observed among participants with poor effort. Although poor performance validity is relatively uncommon in a research setting, these findings demonstrate that clinicians should be cautious when interpreting psychological symptoms and neuropsychological test performance of Veteran participants who fail effort measures.	[Clark, Alexandra L.; Amick, Melissa M.; Fortier, Catherine; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA 02130 USA; [Clark, Alexandra L.; Amick, Melissa M.; Fortier, Catherine; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, GRECC, Boston, MA 02130 USA; [Fortier, Catherine; Milberg, William P.; McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Amick, Melissa M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA		Amick, MM (corresponding author), VA Boston Healthcare Syst, 150 South Huntington Ave, Boston, MA 02130 USA.	Melissa.Amick@va.gov	Fortier, Catherine/AAS-2163-2021; McGlinchey, Regina E/R-1971-2016	Fortier, Catherine/0000-0002-8953-9904; 	Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Center Grant [B6796-C]	This work was supported by the Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Center Grant [B6796-C] awarded to Dr. Regina McGlinchey.	Anil AE, 2003, CLIN NEUROPSYCHOL, V17, P159, DOI 10.1076/clin.17.2.159.16510; [Anonymous], 2010, IBM SPSS STAT WIND V; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Calhoun PS, 2000, J PERS ASSESS, V75, P338, DOI 10.1207/S15327752JPA7502_11; Carone Dominic A, 2009, Appl Neuropsychol, V16, P309, DOI 10.1080/09084280903297883; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Crowson JJ, 1998, J ANXIETY DISORD, V12, P605, DOI 10.1016/S0887-6185(98)00037-1; Delis D., 2001, D KEFS EXAMINERS TEC; Delis D.C., 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Drane DL, 2006, EPILEPSIA, V47, P1879, DOI 10.1111/j.1528-1167.2006.00611.x; Elhai JD, 2012, PTSD MILD TRAUMATIC, P174; Fortier C. B., J HEAD TRAU IN PRESS, V22; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; Frueh BC, 2005, BRIT J PSYCHIAT, V186, P467, DOI 10.1192/bjp.186.6.467; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gfeller JD, 2013, BEHAV SCI LAW, V31, P833, DOI 10.1002/bsl.2084; Grafton KV, 2005, CLIN J PAIN, V21, P73, DOI 10.1097/00002508-200501000-00009; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS MED SYMPTOM V; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; GREENBERG LM, 1993, J CHILD PSYCHOL PSYC, V34, P1019, DOI 10.1111/j.1469-7610.1993.tb01105.x; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; Greiffenstein MF, 2006, LEGAL CRIMINOL PSYCH, V11, P131, DOI 10.1348/135532505X49828; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Haggerty KA, 2007, CLIN NEUROPSYCHOL, V21, P917, DOI 10.1080/13854040600899724; Henry GK, 2009, CLIN NEUROPSYCHOL, V23, P153, DOI 10.1080/13854040801969524; Henry GK, 2005, CLIN NEUROPSYCHOL, V19, P121, DOI 10.1080/13854040490516604; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Lange RT, 2010, PSYCHIAT RES, V176, P229, DOI 10.1016/j.psychres.2009.03.004; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lanyon RI, 2001, J PERS ASSESS, V76, P169, DOI 10.1207/S15327752JPA7601_10; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larson EB, 2013, J INT NEUROPSYCH SOC, V19, P88, DOI 10.1017/S1355617712000999; Leark RA, 2002, ARCH CLIN NEUROPSYCH, V17, P335, DOI 10.1016/S0887-6177(01)00118-4; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Roth R. S., 2013, J PALLIATIVE CARE ME, V1, P2; Ruocco AC, 2008, CLIN NEUROPSYCHOL, V22, P547, DOI 10.1080/13854040701336444; Russo AC, 2012, ARCH CLIN NEUROPSYCH, V27, P840, DOI 10.1093/arclin/acs090; Silver JM, 2012, J NEUROL NEUROSUR PS, V83, P836, DOI 10.1136/jnnp-2011-302078; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tiffen J., 1968, PURDUE PEGBOARD EXAM; Tolin DF, 2010, PSYCHOL ASSESSMENT, V22, P729, DOI 10.1037/a0020973; Van Dyke S. A., 2013, CLIN NEUROPSYCHOL, P1; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weathers FW, 1991, PCL C DSM 4; Weschler D., 2008, WESCHLER ADULT INTEL; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Whiteside DM, 2009, CLIN NEUROPSYCHOL, V23, P523, DOI 10.1080/13854040802389169; Whitley, 1998, STOLEN VALOR VIETNAM; Whitney KA, 2010, APPL NEUROPSYCHOL, V17, P196, DOI 10.1080/09084282.2010.499787; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Wisdom N. M., 2013, CLIN NEUROPSYCHOL, V27, P1; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Young J. C., 2011, AM AC CLIN NEUR M WA; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083; Zakzanis KK, 2012, APPL NEUROPSYCH-ADUL, V19, P98, DOI 10.1080/09084282.2011.644099	99	44	44	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2014	28	5					802	825		10.1080/13854046.2014.904928			24	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AP4MM	WOS:000342051100008	24766521				2022-02-06	
J	Hanak, BW; Walcott, BP; Nahed, BV; Muzikansky, A; Mian, MK; Kimberly, WT; Curry, WT				Hanak, Brian W.; Walcott, Brian P.; Nahed, Brian V.; Muzikansky, Alona; Mian, Matthew K.; Kimberly, William T.; Curry, William T.			Postoperative Intensive Care Unit Requirements After Elective Craniotomy	WORLD NEUROSURGERY			English	Article						Craniotomy; Elective; ICU; Postoperative care	TRAUMATIC BRAIN-INJURY; RESOURCE USE; TUMOR SURGERY; ICU CARE; COST; EXPERIENCE	OBJECTIVE: Commonly, patients undergoing craniotomy are admitted to an intensive care setting postoperatively to allow for close monitoring. We aim to determine the frequency with which patients who have undergone elective craniotomies require intensive care unit (ICU) elevel interventions or experience significant complications during the postoperative period to identify a subset of patients for whom an alternative to ICU-level care may be appropriate. METHODS: Following Institutional Review Board approval, a prospective, consecutive cohort of adult patients undergoing elective craniotomy was established at the Massachusetts General Hospital between the dates of April 2010 and March 2011. Inclusion criteria were intradural operations requiring craniotomy performed on adults (18 years of age or older). Exclusion criteria were cases of an urgent or emergent nature, patients who remained intubated postoperatively, and patients who had a ventriculostomy drain in place at the conclusion of the case. RESULTS: Four hundred patients were analyzed. Univariate analysis revealed that patients with diabetes (P = 0.00047), those who required intraoperative blood product administration (P = 0.032), older patients (P < 0.0001), those with higher intraoperative blood losses (P = 0.041), and those who underwent longer surgical procedures (P = 0.021) were more likely to require ICU-level interventions or experience significant postoperative complications. Multivariate analysis only found diabetes (P = 0.0005) and age (P = 0.0091) to be predictive of a patient's need for postoperative ICU admission. CONCLUSIONS: Diabetes and older age predict the need for ICU-level intervention after elective craniotomy. Properly selected patients may not require postcraniotomy ICU monitoring. Further study of resource utilization is necessary to validate these preliminary findings, particularly in different hospital types.	[Hanak, Brian W.] Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurosurg, Seattle, WA 98104 USA; [Walcott, Brian P.; Nahed, Brian V.; Mian, Matthew K.; Curry, William T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA; [Muzikansky, Alona] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Biostat Unit, Boston, MA USA; [Kimberly, William T.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA		Walcott, BP (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA.	walcott.brian@mgh.harvard.edu	; Nahed, Brian/E-4239-2014	Hanak, Brian/0000-0002-3155-7413; Nahed, Brian/0000-0001-8537-106X	Harvard Catalyst; Harvard Clinical and Translational Science Center (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 RR 025758]; Harvard University; Council of State Neurosurgical Societiese-Congress of Neurological Surgeons (Medical Student Summer Fellowship in Socioeconomic Research); Council of State Neurological Societies Socioeconomic fellowship; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS076597] Funding Source: NIH RePORTER	This work was conducted with support from Harvard Catalyst, The Harvard Clinical and Translational Science Center (NIH Award UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centers). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, the National Center for Research Resources, or the National Institutes of Health. Funding was also provided by the Council of State Neurosurgical Societiese-Congress of Neurological Surgeons (Medical Student Summer Fellowship in Socioeconomic Research). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. Walcott is supported by the Council of State Neurological Societies Socioeconomic fellowship (2012-2013).	Basali A, 2000, ANESTHESIOLOGY, V93, P48, DOI 10.1097/00000542-200007000-00012; Beauregard CL, 2003, SURG NEUROL, V60, P483, DOI 10.1016/S0090-3019(03)00517-2; Bernstein M, 2001, CAN J NEUROL SCI, V28, P120, DOI 10.1017/S0317167100052781; Boulton M, 2008, J NEUROSURG, V108, P649, DOI 10.3171/JNS/2008/108/4/0649; Bui JQH, 2011, J NEUROSURG, V115, P1236, DOI 10.3171/2011.8.JNS11105; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Grundy PL, 2008, BRIT J NEUROSURG, V22, P360, DOI 10.1080/02688690801961858; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; Hartman M, 2010, HLTH CARE EXPENDITUR; Iapichino G, 2005, HEALTH POLICY, V73, P228, DOI 10.1016/j.healthpol.2004.11.015; Iwashyna TJ, 2009, CRIT CARE MED, V37, P1545, DOI 10.1097/CCM.0b013e31819fe8f8; Khaldi A, 2010, J NEUROSURG, V113, P1021, DOI 10.3171/2009.11.JNS081048; Lattimore SU, 2003, STROKE, V34, pE55, DOI 10.1161/01.STR.0000073789.12120.F3; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Milbrandt EB, 2008, CRIT CARE MED, V36, P2504, DOI 10.1097/CCM.0b013e318183ef84; Moerer O, 2007, CRIT CARE, V11, DOI 10.1186/cc5952; Morasch MD, 1996, J AM COLL SURGEONS, V183, P387; Nitahara J A, 1998, Neurosurg Focus, V5, pe4; Rhondali O, 2011, J NEUROSURG ANESTH, V23, P118, DOI 10.1097/ANA.0b013e318206d5f8; Shorr Andrew F, 2002, Curr Opin Crit Care, V8, P337, DOI 10.1097/00075198-200208000-00011; TAYLOR WAS, 1995, J NEUROSURG, V82, P48, DOI 10.3171/jns.1995.82.1.0048; Varelas PN, 2008, NEUROCRIT CARE, V9, P293, DOI 10.1007/s12028-008-9050-6; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; Ward NS, 2008, CRIT CARE MED, V36, P471, DOI 10.1097/CCM.0B013E3181629511; Ziai WC, 2003, CRIT CARE MED, V31, P2782, DOI 10.1097/01.CCM.0000098860.52812.24	26	44	45	2	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2014	81	1					165	172		10.1016/j.wneu.2012.11.068			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AC2DV	WOS:000332309200048	23182731	Green Published, Green Accepted			2022-02-06	
J	Shohami, E; Biegon, A				Shohami, Esther; Biegon, Anat			Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Cognitive enhancer; D-cycloserine; glutamate receptors; stroke	LONG-TERM POTENTIATION; AGONIST D-CYCLOSERINE; CLOSED-HEAD INJURY; COUPLED GLYCINE RECEPTOR; FLUID PERCUSSION INJURY; EXCITATORY AMINO-ACIDS; D-ASPARTATE RECEPTORS; ACUTE ISCHEMIC-STROKE; CLINICAL-TRIALS; NEUROTROPHIC FACTOR	For more than two decades the intensive research effort on the role of NMDA receptors (NMDAR) in traumatic brain injury (TBI) and cerebral ischemia (stroke) was led by the observations that extracellular concentrations of glutamate and aspartate are elevated after the insult and play a major role in brain pathologies. Indeed, NMDAR antagonists were shown to improve post-injury recovery in animal models and subsequently, large scale placebo-controlled clinical trials in TBI and stroke were performed with NMDAR antagonists. However, all these trials have demonstrated either no benefit or even deleterious effects. The discrepancy between the animal and human studies prompted us to investigate the temporal changes of the NMDAR after brain insult in TBI and stroke mouse models. We found that the early hyperactivation of the NMDAR is followed by loss of functional NMDAR which persists for weeks. Such dynamic changes could well explain the discrepancies between the preclinical and clinical experience as well as suggest alternative modes of treatment, namely, activation, rather than blockade of the NMDAR in the sub-acute period after TBI and stroke. Stimulation of the glycine modulatory site of the glycine/NMDAR by the partial agonist D-cycloserine (DCS) when given at least 24 hrs after TBI or stroke was shown to improve recovery of neurobehavioral and cognitive functions. It was also shown to restore impaired hippocampal Long-Term potentiation (LTP) and induce expression of Brain Derived-Neurotrophic Factor (BDNF) in a TBI model and to improve somatosensory and cognitive function in a stroke model. Experiments to optimize the DCS treatment paradigm showed that similar benefits were demonstrated in TBI mice whether the drug was given as a single injection at 24 or 72 hrs post injury, or as double (24 and 48 hrs) or triple (24, 48 and 72 hrs) doses. Interestingly, beneficial effects of DCS were reported in a range of animal models of human diseases as well as in several clinical indications thought to involve disruptions in NMDAR function, such as drug addiction, post-traumatic stress disorder, Parkinson's disease, aging and psychiatric disorders. As DCS has a good safety profile, and is already in use in humans in several different indications, and based on studies with DCS in the mouse TBI model, a multi-center prospective randomized controlled clinical trial, aiming to assess the effect of a single dose of DCS on cognitive outcome in patients with moderate TBI has recently begun.	[Shohami, Esther] Hebrew Univ Jerusalem, Inst Drug Res, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Biegon, Anat] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA; [Biegon, Anat] SUNY Stony Brook, Sch Med, Dept Neurol, Stony Brook, NY USA		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Inst Drug Res, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il			BSFUS-Israel Binational Science Foundation [2005-021-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS050285]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050285] Funding Source: NIH RePORTER	Supported by grants from the BSF# 2005-021-01 and from the NIH 1R01NS050285.	Adeleye A, 2010, EUR J PHARMACOL, V629, P25, DOI 10.1016/j.ejphar.2009.11.066; Albensi BC, 2007, CURR PHARM DESIGN, V13, P3185, DOI 10.2174/138161207782341321; Alessandri B, 1996, ACT NEUR S, V67, P6; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARAN H, 1994, BRAIN RES, V652, P195, DOI 10.1016/0006-8993(94)90227-5; BARON H, 1955, Antibiot Annu, V3, P136; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Billard JM, 2007, EUR J NEUROSCI, V25, P2260, DOI 10.1111/j.1460-9568.2007.05488.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOWERY NG, 1987, NATURE, V326, P338, DOI 10.1038/326338a0; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Chasson GS, 2010, BEHAV RES THER, V48, P675, DOI 10.1016/j.brat.2010.03.007; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Christensen D, 1999, PAIN, V83, P433, DOI 10.1016/S0304-3959(99)00126-8; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Danysz W, 1998, PHARMACOL REV, V50, P597; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Davis SM, 2000, STROKE, V31, P347, DOI 10.1161/01.STR.31.2.347; Dhawan J, 2011, FUTUR NEUROL, V6, P823, DOI 10.2217/FNL.11.55; Dhawan J, 2010, NEUROIMAGE, V51, P599, DOI 10.1016/j.neuroimage.2010.02.073; Dhonnchadha BAN, 2010, NEUROPSYCHOPHARMACOL, V35, P357, DOI 10.1038/npp.2009.139; Dravid SM, 2010, J NEUROSCI, V30, P2741, DOI 10.1523/JNEUROSCI.5390-09.2010; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fujihira T, 2007, NEUROCHEM INT, V51, P233, DOI 10.1016/j.neuint.2007.06.003; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Gottlieb JD, 2011, SCHIZOPHR RES, V131, P69, DOI 10.1016/j.schres.2011.05.029; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Hewitt DJ, 2000, CLIN J PAIN, V16, pS73, DOI 10.1097/00002508-200006001-00013; Hofmann SG, 2006, ARCH GEN PSYCHIAT, V63, P298, DOI 10.1001/archpsyc.63.3.298; HOOD WF, 1989, NEUROSCI LETT, V98, P91, DOI 10.1016/0304-3940(89)90379-0; Hoyte L, 2004, CURR MOL MED, V4, P131, DOI 10.2174/1566524043479248; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kalia LV, 2008, LANCET NEUROL, V7, P742, DOI 10.1016/S1474-4422(08)70165-0; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; LANTHORN TH, 1994, AMINO ACIDS, V6, P247, DOI 10.1007/BF00813745; Ledgerwood L, 2004, BEHAV NEUROSCI, V118, P505, DOI 10.1037/0735-7044.118.3.505; Ledgerwood L, 2003, BEHAV NEUROSCI, V117, P341, DOI 10.1037/0735-7044.117.2.341; Lees KR, 1997, NEUROLOGY, V49, pS66, DOI 10.1212/WNL.49.5_Suppl_4.S66; Levin ED, 2011, PHARMACOL BIOCHEM BE, V98, P210, DOI 10.1016/j.pbb.2010.12.023; Liraz-Zaltsman S, 2011, J MOL NEUROSCI, V45, pS75; Liraz-Zaltsman S, 2011, SYNAPSE, V65, P634, DOI 10.1002/syn.20889; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Matsumoto Y, 2001, EUR J PHARMACOL, V430, P283, DOI 10.1016/S0014-2999(01)01374-7; Millecamps M, 2007, PAIN, V132, P108, DOI 10.1016/j.pain.2007.03.003; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Morton RF, 1956, ANTIBIOT ANNU, V31, P169; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Norberg MM, 2008, BIOL PSYCHIAT, V63, P1118, DOI 10.1016/j.biopsych.2008.01.012; Obviagle B, 2003, CURR NEUROL NEUROSCI, V3, P9; OGAWA N, 1991, NEUROCHEM RES, V16, P519, DOI 10.1007/BF00974869; PITKANEN M, 1994, EUR J PHARMACOL, V253, P125, DOI 10.1016/0014-2999(94)90766-8; QUARTERMAIN D, 1994, EUR J PHARMACOL, V257, P7, DOI 10.1016/0014-2999(94)90687-4; Ressler KJ, 2004, ARCH GEN PSYCHIAT, V61, P1136, DOI 10.1001/archpsyc.61.11.1136; Richardson R, 2004, LEARN MEMORY, V11, P510, DOI 10.1101/lm.78204; Rivas Salalzar JL, 1970, SCAND J RESP DIS S, V71, P314; Rothbaum BO, 2008, AM J PSYCHIAT, V165, P293, DOI 10.1176/appi.ajp.2007.07121871; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Schneider JS, 2000, BRAIN RES, V860, P190, DOI 10.1016/S0006-8993(00)02036-9; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Shohami E., 2011, TRAUMATIC BRAIN SPIN; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; Tan-No K, 2007, J PHARMACOL SCI, V104, P39, DOI 10.1254/jphs.FP0070203; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Thanos PK, 2011, SYNAPSE, V65, P938, DOI 10.1002/syn.20922; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; vanBerckel BNM, 1997, NEUROPSYCHOPHARMACOL, V16, P317, DOI 10.1016/S0893-133X(96)00196-0; WALKER W C, 1957, Tubercle, V38, P297, DOI 10.1016/S0041-3879(57)80097-X; Wang AL, 2010, BEHAV BRAIN RES, V208, P38, DOI 10.1016/j.bbr.2009.11.006; WATSON GB, 1990, BRAIN RES, V510, P158, DOI 10.1016/0006-8993(90)90745-W; Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Zhu M, 2001, PHARMACOTHERAPY, V21, P891, DOI 10.1592/phco.21.11.891.34524	83	44	44	0	13	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2014	13	4					567	573		10.2174/18715273113126660196			7	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	AN8EO	WOS:000340836200005	24168367				2022-02-06	
J	Stone, MC; Albertson, RM; Chen, L; Rolls, MM				Stone, Michelle C.; Albertson, Richard M.; Chen, Li; Rolls, Melissa M.			Dendrite Injury Triggers DLK-Independent Regeneration	CELL REPORTS			English	Article							WALLERIAN DEGENERATION; CAENORHABDITIS-ELEGANS; AXON REGENERATION; DROSOPHILA; NEURONS; KINASE; ORIENTATION; MECHANISMS; POLARITY; MICROTUBULES	Axon injury triggers regeneration through activation of a conserved kinase cascade, which includes the dual leucine zipper kinase (DLK). Although dendrites are damaged during stroke, traumatic brain injury, and seizure, it is not known whether mature neurons monitor dendrite injury and initiate regeneration. We probed the response to dendrite damage using model Drosophila neurons. Two larval neuron types regrew dendrites in distinct ways after all dendrites were removed. Dendrite regeneration was also triggered by injury in adults. Next, we tested whether dendrite injury was initiated with the same machinery as axon injury. Surprisingly, DLK, JNK, and fos were dispensable for dendrite regeneration. Moreover, this MAP kinase pathway was not activated by injury to dendrites. Thus, neurons respond to dendrite damage and initiate regeneration without using the conserved DLK cascade that triggers axon regeneration.	[Stone, Michelle C.; Albertson, Richard M.; Chen, Li; Rolls, Melissa M.] Penn State Univ, University Pk, PA 16802 USA		Rolls, MM (corresponding author), Penn State Univ, University Pk, PA 16802 USA.	mur22@psu.edu	Rolls, Melissa/G-6402-2014	Rolls, Melissa/0000-0002-5021-4360; Stone, Michelle/0000-0001-6215-7933	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 GM085115]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM085115] Funding Source: NIH RePORTER	We are very grateful to the Bloomington Drosophila Stock Center, the Vienna Drosophila RNAi Center, and FlyTrap; all are invaluable resources. Catherine Collins, Wesley Grueber, and Dirk Bohmann generously provided us with Drosophila stocks. Tadashi Uemura provided helpful information for imaging da neurons in adults. Michelle Nguyen kindly helped collect flies and embryos. This work was funded by the NIH (R01 GM085115), and M.M.R. was a Pew Scholar in the Biomedical Sciences.	Abe N, 2008, CURR OPIN NEUROBIOL, V18, P276, DOI 10.1016/j.conb.2008.06.005; Baas PW, 2011, DEV NEUROBIOL, V71, P403, DOI 10.1002/dneu.20818; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; Caunt CJ, 2013, FEBS J, V280, P489, DOI 10.1111/j.1742-4658.2012.08716.x; Cho Y, 2012, EMBO J, V31, P3063, DOI 10.1038/emboj.2012.160; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Collins CA, 2006, NEURON, V51, P57, DOI 10.1016/j.neuron.2006.05.026; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Ghosh-Roy A, 2010, J NEUROSCI, V30, P3175, DOI 10.1523/JNEUROSCI.5464-09.2010; Gomis-Ruth S, 2008, CURR BIOL, V18, P992, DOI 10.1016/j.cub.2008.06.026; Goodwin PR, 2012, J NEUROSCI, V32, P8158, DOI 10.1523/JNEUROSCI.0251-12.2012; Greenwood SM, 2007, NEUROPHARMACOLOGY, V53, P891, DOI 10.1016/j.neuropharm.2007.10.003; Grueber WB, 2002, DEVELOPMENT, V129, P2867; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; Hughes CL, 2007, MOL CELL NEUROSCI, V35, P383, DOI 10.1016/j.mcn.2007.04.001; Hwang RY, 2007, CURR BIOL, V17, P2105, DOI 10.1016/j.cub.2007.11.029; Kim ME, 2012, NEURON, V73, P79, DOI 10.1016/j.neuron.2011.10.033; Liu K, 2011, ANNU REV NEUROSCI, V34, P131, DOI 10.1146/annurev-neuro-061010-113723; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Murphy TH, 2008, J NEUROSCI, V28, P1756, DOI 10.1523/JNEUROSCI.5128-07.2008; Nix P, 2011, P NATL ACAD SCI USA, V108, P10738, DOI 10.1073/pnas.1104830108; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; O'Brien GS, 2009, CURR BIOL, V19, P2086, DOI 10.1016/j.cub.2009.10.051; Rishal I, 2010, EXP NEUROL, V223, P5, DOI 10.1016/j.expneurol.2009.08.010; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Rolls MM, 2007, NEURAL DEV, V2, DOI 10.1186/1749-8104-2-7; Rolls MM, 2011, DEV NEUROBIOL, V71, P419, DOI 10.1002/dneu.20836; Satoh D, 2008, NAT CELL BIOL, V10, P1164, DOI 10.1038/ncb1776; Shimono K, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-37; Shin JE, 2012, NEURON, V74, P1015, DOI 10.1016/j.neuron.2012.04.028; Song YQ, 2012, GENE DEV, V26, P1612, DOI 10.1101/gad.193243.112; Stone MC, 2008, MOL BIOL CELL, V19, P4122, DOI 10.1091/mbc.E07-10-1079; Stone MC, 2010, MOL BIOL CELL, V21, P767, DOI 10.1091/mbc.E09-11-0967; Sugimura K, 2003, J NEUROSCI, V23, P3752; Taniguchi K, 2007, DEV BIOL, V311, P251, DOI 10.1016/j.ydbio.2007.08.048; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; Xiong X, 2010, J CELL BIOL, V191, P211, DOI 10.1083/jcb.201006039; Yan D, 2009, CELL, V138, P1005, DOI 10.1016/j.cell.2009.06.023; Zeng LH, 2007, J NEUROSCI, V27, P11604, DOI 10.1523/JNEUROSCI.0983-07.2007; Zheng Y, 2008, NAT CELL BIOL, V10, P1172, DOI 10.1038/ncb1777	41	44	43	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	JAN	2014	6	2					247	253		10.1016/j.celrep.2013.12.022			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	AA5VD	WOS:000331166800002	24412365	Green Accepted, gold			2022-02-06	
J	Taylor, PA; Ludwigsen, JS; Ford, CC				Taylor, Paul A.; Ludwigsen, John S.; Ford, Corey C.			Investigation of blast-induced traumatic brain injury	BRAIN INJURY			English	Article						Blast; mild traumatic brain injury; modelling; simulation	WHITE-MATTER	Objective: Many troops deployed in Iraq and Afghanistan have sustained blast-related, closed-head injuries from being within non-lethal distance of detonated explosive devices. Little is known, however, about the mechanisms associated with blast exposure that give rise to traumatic brain injury (TBI). This study attempts to identify the precise conditions of focused stress wave energy within the brain, resulting from blast exposure, which will correlate with a threshold for persistent brain injury. Methods: This study developed and validated a set of modelling tools to simulate blast loading to the human head. Using these tools, the blast-induced, early-time intracranial wave motions that lead to focal brain damage were simulated. Results: The simulations predict the deposition of three distinct wave energy components, two of which can be related to injury-inducing mechanisms, namely cavitation and shear. Furthermore, the results suggest that the spatial distributions of these damaging energy components are independent of blast direction. Conclusions: The predictions reported herein will simplify efforts to correlate simulation predictions with clinical measures of TBI and aid in the development of protective headwear.	[Taylor, Paul A.; Ludwigsen, John S.] Sandia Natl Labs, Terminal Ballist Technol, Albuquerque, NM 87185 USA; [Ford, Corey C.] Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA		Taylor, PA (corresponding author), Sandia Natl Labs, Terminal Ballist Technol, POB 5800, Albuquerque, NM 87185 USA.	pataylo@sandia.gov					Bayly PV, 2013, APPL IMAGING TECHNIQ, V4, P117; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Brennen CE, 2003, P 5 INT S CAV OS JAP; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; Carter DR, 1984, APPLETON LANGE; Centers for Disease Control and Prevention, 2007, TRAUM BRAIN INJ US; Defense and Veteran Brain Injury Center, DOD WORLDW NUMB TBI; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fischer H., 1991, US MILITARY CASUALTY, P1; Grujicic M, 2010, MULTIDISCIP MODEL MA, V6, P335, DOI 10.1108/15736101011080097; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Gruss E, 2006, J TRAUMA, V60, P1284, DOI 10.1097/01.ta.0000220015.21948.ec; Hertel E. S., 1993, P 19 INT S SHOCK WAV, P377, DOI DOI 10.1007/978-3-642-78829-1_61; Hertel ES, 1998, CTH REFERENCE MANUAL; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nahum A., 1977, 21 STAPP CAR CRASH C, DOI DOI 10.4271/770922; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; SIERRA Solid Mechanics Team, 2011, SIERR SOLIDMECHANICS; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	31	44	45	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	7					879	895		10.3109/02699052.2014.888478			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH9XL	WOS:000336498600001	24766453	Green Published, hybrid			2022-02-06	
J	Sommerauer, M; Valko, PO; Werth, E; Baumann, CR				Sommerauer, Michael; Valko, Philipp O.; Werth, Esther; Baumann, Christian R.			Excessive sleep need following traumatic brain injury: a case-control study of 36 patients	JOURNAL OF SLEEP RESEARCH			English	Article						excessive daytime sleepiness; hypersomnia; raumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; CLOSED HEAD INJURY; PRACTICE PARAMETERS; DAYTIME SLEEPINESS; LESIONS; SCALE; RECOVERY; RAT	Increased sleep need following traumatic brain injury, referred to in this study as post-traumatic pleiosomnia, is common, but so far its clinical impact and therapeutic implications have not been characterized. We present a case-control study of 36 patients with post-traumatic pleiosomnia, defined by an increased sleep need of at least 2h per 24h after traumatic brain injury, compared to 36 controls. We assessed detailed history, sleep-activity patterns with sleep logs and actigraphy, nocturnal sleep with polysomnography and daytime sleep propensity with multiple sleep latency tests. Actigraphy recordings revealed that traumatic brain injury (TBI) patients had longer estimated sleep durations than controls (10.8h per 24h, compared to 7.3h). When using sleep logs, TBI patients underestimated their sleep need. During nocturnal sleep, patients had higher amounts of slow-wave sleep than controls (20 versus 13.8%). Multiple sleep latency tests revealed excessive daytime sleepiness in 15 patients (42%), and 10 of them had signs of chronic sleep deprivation. We conclude that post-traumatic pleiosomnia may be even more frequent than reported previously, because affected patients often underestimate their actual sleep need. Furthermore, these patients exhibit an increase in slow-wave sleep which may reflect recovery mechanisms, intrinsic consequences of diffuse brain damage or relative sleep deprivation.	[Sommerauer, Michael; Valko, Philipp O.; Werth, Esther; Baumann, Christian R.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland		Sommerauer, M (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklinikstr 26, CH-8091 Zurich, Switzerland.	michael.sommerauer@rwth-aachen.de	Werth, E/AAN-7955-2021	Werth, Esther/0000-0002-5099-3122; Baumann, Christian/0000-0003-3417-1978	Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF) [32003B-125504]; Schweizerischer Versicherungs-verband (SVV)	This work was supported by the Swiss National Science Foundation (SNF; 32003B-125504 to C. B.; www.snf.ch) and an unrestricted grant of the Schweizerischer Versicherungs-verband (SVV). The SNF is an independent national non-profit funding organization. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Academy of Sleep Medicine, 2005, ICSD 2 INT CLASS SLE; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Bloch KE, 1999, RESPIRATION, V66, P440, DOI 10.1159/000029408; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; CROMPTON MR, 1971, LANCET, V1, P669; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Dijk Derk-Jan, 2009, J Clin Sleep Med, V5, pS6; Fronczek R, 2007, BRAIN, V130, P1577, DOI 10.1093/brain/awm090; Gao B, 2008, CEREBROVASC DIS, V26, P413, DOI 10.1159/000151683; Gao B, 2010, SLEEP, V33, P879, DOI 10.1093/sleep/33.7.879; Gerashchenko D, 2003, EXP NEUROL, V184, P1010, DOI 10.1016/S0014-4886(03)00388-1; Iber C., 2007, AASM MANUAL SCORING, P7; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; Morgenthaler T, 2007, SLEEP, V30, P519, DOI 10.1093/sleep/30.4.519; Pizza F, 2013, J SLEEP RES, V22, P32, DOI 10.1111/j.1365-2869.2012.01032.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	28	44	46	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1105	1365-2869		J SLEEP RES	J. Sleep Res.	DEC	2013	22	6					634	639		10.1111/jsr.12068			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	250VI	WOS:000326884000005	23837871	Bronze			2022-02-06	
J	Tan, ZJ; Turner, RC; Leon, RL; Li, XL; Hongpaisan, J; Zheng, W; Logsdon, AF; Naser, ZJ; Alkon, DL; Rosen, CL; Huber, JD				Tan, Zhenjun; Turner, Ryan C.; Leon, Rachel L.; Li, Xinlan; Hongpaisan, Jarin; Zheng, Wen; Logsdon, Aric F.; Naser, Zachary J.; Alkon, Daniel L.; Rosen, Charles L.; Huber, Jason D.			Bryostatin Improves Survival and Reduces Ischemic Brain Injury in Aged Rats After Acute Ischemic Stroke	STROKE			English	Article						aging; blood-brain barrier; infarction; protein kinase C; tissue plasminogen activator	PROTEIN-KINASE-C; DISEASE TRANSGENIC MICE; ALZHEIMERS-DISEASE; POSTHYPOXIC REOXYGENATION; FUNCTIONAL RECOVERY; REPERFUSION INJURY; CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; PKC; ACTIVATION	Background and Purpose Bryostatin, a potent protein kinase C (PKC) activator, has demonstrated therapeutic efficacy in preclinical models of associative memory, Alzheimer disease, global ischemia, and traumatic brain injury. In this study, we tested the hypothesis that administration of bryostatin provides a therapeutic benefit in reducing brain injury and improving stroke outcome using a clinically relevant model of cerebral ischemia with tissue plasminogen activator reperfusion in aged rats. Methods Acute cerebral ischemia was produced by reversible occlusion of the right middle cerebral artery (MCAO) in 18- to 20-month-old female Sprague-Dawley rats using an autologous blood clot with tissue plasminogen activator-mediated reperfusion. Bryostatin was administered at 6 hours post-MCAO, then at 3, 6, 9, 12, 15, and 18 days after MCAO. Functional assessment was conducted at 2, 7, 14, and 21 days after MCAO. Lesion volume and hemispheric swelling/atrophy were performed at 2, 7, and 21 days post-MCAO. Histological assessment of PKC isozymes was performed at 24 hours post-MCAO. Results Bryostatin-treated rats showed improved survival post-MCAO, especially during the first 4 days. Repeated administration of bryostatin post-MCAO resulted in reduced infarct volume, hemispheric swelling/atrophy, and improved neurological function at 21 days post-MCAO. Changes in PKC expression and epsilon PKC expression in neurons were noted in bryostatin-treated rats at 24 hours post-MCAO. Conclusions Repeated bryostatin administration post-MCAO protected the brain from severe neurological injury post-MCAO. Bryostatin treatment improved survival rate, reduced lesion volume, salvaged tissue in infarcted hemisphere by reducing necrosis and peri-infarct astrogliosis, and improved functional outcome after MCAO.	[Tan, Zhenjun; Turner, Ryan C.; Leon, Rachel L.; Li, Xinlan; Naser, Zachary J.; Rosen, Charles L.] W Virginia Univ, Hlth Sci Ctr, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA; [Hongpaisan, Jarin; Zheng, Wen; Alkon, Daniel L.] W Virginia Univ, Hlth Sci Ctr, Blanchette Rockefeller Neurosci Inst, Morgantown, WV 26506 USA; [Logsdon, Aric F.; Huber, Jason D.] W Virginia Univ, Hlth Sci Ctr, Dept Basic Pharmaceut Sci, Sch Pharm, Morgantown, WV 26506 USA		Huber, JD (corresponding author), W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA.	jdhuber@hsc.wvu.edu	Leon, Rachel/AAJ-2673-2021	Turner, Ryan/0000-0001-5523-0645	National Institutes of Health's National Institute of Neurological Disorders and Stroke [RO1 NS061954]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061954] Funding Source: NIH RePORTER	This study was supported by a grant from National Institutes of Health's National Institute of Neurological Disorders and Stroke (RO1 NS061954 to J.D.H.).	Alkon DL, 2007, TRENDS PHARMACOL SCI, V28, P51, DOI 10.1016/j.tips.2006.12.002; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; Bright R, 2005, STROKE, V36, P2781, DOI 10.1161/01.STR.0000189996.71237.f7; Bright R, 2008, NEUROSCI LETT, V441, P120, DOI 10.1016/j.neulet.2008.05.080; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; DiNapoli VA, 2010, NEUROSCIENCE, V170, P633, DOI 10.1016/j.neuroscience.2010.07.011; DiNapoli VA, 2008, NEUROBIOL AGING, V29, P753, DOI 10.1016/j.neurobiolaging.2006.12.007; DiNapoli VA, 2006, J NEUROSCI METH, V154, P233, DOI 10.1016/j.jneumeth.2005.12.026; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; Etcheberrigaray R, 2004, P NATL ACAD SCI USA, V101, P11141, DOI 10.1073/pnas.0403921101; Fleegal MA, 2005, AM J PHYSIOL-HEART C, V289, pH2012, DOI 10.1152/ajpheart.00495.2005; Hongpaisan J, 2007, P NATL ACAD SCI USA, V104, P19571, DOI 10.1073/pnas.0709311104; Hongpaisan J, 2011, J NEUROSCI, V31, P630, DOI 10.1523/JNEUROSCI.5209-10.2011; Joseph C, 2012, J CEREBR BLOOD F MET, V32, P1632, DOI 10.1038/jcbfm.2012.65; Katzan IL, 2004, ARCH NEUROL-CHICAGO, V61, P346, DOI 10.1001/archneur.61.3.346; KRIZBAI I, 1995, J NEUROCHEM, V65, P459; Matsumoto S, 2004, J CEREBR BLOOD F MET, V24, P54, DOI 10.1097/01.WCB.0000095920.70924.F5; Popa-Wagner A, 2011, AGEING RES REV, V10, P71, DOI 10.1016/j.arr.2009.10.008; Quattrone A, 2001, P NATL ACAD SCI USA, V98, P11668, DOI 10.1073/pnas.191388398; Reshef A, 1997, NEUROSCI LETT, V238, P37, DOI 10.1016/S0304-3940(97)00841-0; Rosen CL, 2005, J NEUROSURG, V103, P687, DOI 10.3171/jns.2005.103.4.0687; Selvatici R, 2003, J NEUROSCI RES, V71, P64, DOI 10.1002/jnr.10464; Shirai Y, 2008, FEBS J, V275, P3988, DOI 10.1111/j.1742-4658.2008.06556.x; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Skaper SD, 2001, ANN NY ACAD SCI, V939, P11; Sonobe Y, 2009, J BIOL CHEM, V284, P31834, DOI 10.1074/jbc.M109.025940; Sun MK, 2008, P NATL ACAD SCI USA, V105, P13620, DOI 10.1073/pnas.0805952105; Sun MK, 2009, P NATL ACAD SCI USA, V106, P14676, DOI 10.1073/pnas.0907842106; Willis CL, 2010, J CEREBR BLOOD F MET, V30, P1847, DOI 10.1038/jcbfm.2010.119; Zhao CT, 2009, P NATL ACAD SCI USA, V106, P21353, DOI 10.1073/pnas.0812872106; Zohar O, 2011, NEUROBIOL DIS, V41, P329, DOI 10.1016/j.nbd.2010.10.001	31	44	47	1	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499	1524-4628		STROKE	Stroke	DEC	2013	44	12					3490	3497		10.1161/STROKEAHA.113.002411			8	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	257LR	WOS:000327386300323	24172582	Bronze, Green Accepted			2022-02-06	
J	Foebel, AD; Hirdes, JP; Heckman, GA; Kergoat, MJ; Patten, S; Marrie, RA				Foebel, Andrea D.; Hirdes, John P.; Heckman, George A.; Kergoat, Marie-Jeanne; Patten, Scott; Marrie, Ruth Ann		Ideas PNC Res Team	Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study	BMC HEALTH SERVICES RESEARCH			English	Article						Diagnostic validity; Nursing homes; Home care; Psychiatry; interRAI	MINIMUM DATA SET; RESIDENT ASSESSMENT INSTRUMENT; QUALITY INDICATORS; HEART-FAILURE; OLDER-PEOPLE; RELIABILITY; INFORMATION; ADJUSTMENT; SERVICES; EUROPE	Background: The interRAI suite of assessment instruments can provide valuable information to support person-specific care planning across the continuum of care. Comprehensive clinical information is collected with these instruments, including disease diagnoses. In Canada, interRAI data holdings represent some of the largest repositories of clinical information in the country for persons with neurological conditions. This study examined the accuracy of the diagnostic information captured by interRAI instruments designed for use in the home care, long-term care and mental health care settings as compared with national administrative databases. Methods: The interRAI assessments were matched with an inpatient hospital record and emergency department (ED) visit record in the preceding 90 days. Diagnoses captured on the interRAI instruments were compared to those recorded in either administrative record for each individual. Diagnostic validity was examined through sensitivity, specificity and positive predictive value analysis for the following conditions: multiple sclerosis, epilepsy, Alzheimer's disease and other dementias, Parkinson's disease, traumatic brain injury, stroke, diabetes mellitus, heart failure and reactive airway disease. Results: In the three large study samples (home care: n = 128,448; long-term care: n = 26,644; mental health: n = 13,812), interRAI diagnoses demonstrated high specificity when compared to administrative records, for both neurological conditions (range 0.80 - 1.00) and comparative chronic diseases (range 0.83 - 1.00). Sensitivity and positive predictive values (PPV) were more varied by specific diagnosis, with sensitivities and PPV for neurological conditions ranging from 0.23 to 0.94 and 0.14 to 0.77, respectively. The interRAI assessments routinely captured more cases of the diagnoses of interest than the administrative records. Conclusions: The interRAI assessment collected accurate information about disease diagnoses when compared to administrative records within three months. Such information is likely relevant to day-to-day care in these three environments and can be used to inform care planning and resource allocation decisions.	[Foebel, Andrea D.; Hirdes, John P.; Heckman, George A.] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON N2L 3G1, Canada; [Kergoat, Marie-Jeanne] Inst Univ Geriatrie Montreal, Montreal, PQ, Canada; [Patten, Scott] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Marrie, Ruth Ann] Univ Manitoba, Dept Med, Winnipeg, MB, Canada; [Marrie, Ruth Ann] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada		Foebel, AD (corresponding author), Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON N2L 3G1, Canada.	adfoebel@uwaterloo.ca	Patten, Scott/B-4434-2011	Patten, Scott/0000-0001-9871-4041; Marrie, Ruth Ann/0000-0002-1855-5595; Heckman, George/0000-0003-3847-3287	Public Health Agency of Canada; Ontario Home Care Research and Knowledge Exchange Chair; Ontario Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario; Don Paty Career Development Award from the MS Society of Canada	This study is part of the National Population Health Study of Neurological Conditions. We wish to acknowledge the membership of Neurological Health Charities Canada and the Public Health Agency of Canada for their contribution to the success of this initiative. Funding for the study was provided by the Public Health Agency of Canada. In addition, Dr. Hirdes' participation is supported through the Ontario Home Care Research and Knowledge Exchange Chair funded by the Ontario Ministry of Health and Long Term Care. Dr. Marrie is supported, in part, by a Don Paty Career Development Award from the MS Society of Canada. The opinions expressed in this publication are those of the authors/researchers, and do not necessarily reflect the official views of the Public Health Agency of Canada or the Ontario Ministry of Health and Long Term Care.	Berg K, 2002, HEALTH CARE FINANC R, V23, P19; Bernabei R, 2009, HAZZARDS GERIATRIC M, P69; Brand CA, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-281; Canadian Home Care Association, 1877, PORTR HOM CAR CAN EX; Canadian Institute for Health Information (CIHI), ICD 10 CA CCI IMPL S; Canadian Institute for Health Information (CIHI), ONT MENT HLTH REP SY; Canadian Institute for Health Information (CIHI), CONT CAR REP SYST CC; Canadian Institute for Health Information (CIHI),, DISCH ABSTR DAT DAD; Canadian Institute for Health Information (CIHI), INT STAT CLASS DIS R; Canadian Institute for Health Information (CIHI), HOM CAR REP SYST HCR; Canadian Institute for Health Information (CIHI), 2005, DAT QUAL DISCH ABSTR; Canadian Institute for Health Information-CIHI, 2010, RAI MDS 2 0 CAN VERS; Canadian Institute for Health Information-CIHI, 2010, RAI HC MAN CAN VERS; Carpenter GI, 2006, AGE AGEING, V35, P327, DOI 10.1093/ageing/afl038; Carpenter I, 2004, AGING CLIN EXP RES, V16, P259; *CIHI, 2002, DISCH ABSTR DAT DAT; Daamen MAMJ, 2010, SCAND J CARING SCI, V24, P202, DOI 10.1111/j.1471-6712.2009.00708.x; Dalby DM, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-7; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Foebel AD, 2011, CHRONIC DIS CAN, V31, P49; FRIES BE, 1994, MED CARE, V32, P668, DOI 10.1097/00005650-199407000-00002; Fries BE, 1997, AGE AGEING, V26, P13, DOI 10.1093/ageing/26.suppl_2.13; Gambassi G, 1998, MED CARE, V36, P167, DOI 10.1097/00005650-199802000-00006; Gray LC, 2008, J AM GERIATR SOC, V56, P536, DOI 10.1111/j.1532-5415.2007.01590.x; Gray LC, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-71; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; Hirdes J P, 2000, Hosp Q, V4, P44; Hirdes J P, 1999, Healthc Manage Forum, V12, P30; Hirdes JP, 2011, CAN J AGING, V30, P371, DOI 10.1017/S0714980811000304; Hirdes JP, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-277; Hirdes JP, 2004, GERONTOLOGIST, V44, P665, DOI 10.1093/geront/44.5.665; Hirdes JP, 2002, J BEHAV HEALTH SER R, V29, P419, DOI 10.1007/BF02287348; Hirdes JP., 2010, INTERRAI INTERRAI ME; Jones RN, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-96; Juurlink D, I CLIN EVALUATIVE SC; Landi F, 2000, MED CARE, V38, P1184, DOI 10.1097/00005650-200012000-00005; Martin L, 2009, J PSYCHIATR MENT HLT, V16, P646, DOI 10.1111/j.1365-2850.2009.01429.x; Martin L., 2007, J POLICY PRACT INTEL, V4, P23, DOI DOI 10.1111/J.1741-1130.2006.00094.X; Martin L, 2011, J INTELLECT DISABILI, V15, P131, DOI 10.1177/1744629511413506; Mor V, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-20; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; Morris JN, 2000, CAN J AGING, V19, P87, DOI 10.1017/S071498080001391X; Morris JN, 1997, J AM GERIATR SOC, V45, P1017, DOI 10.1111/j.1532-5415.1997.tb02975.x; Onder G, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-5; Poss J W, 2008, Healthc Manage Forum, V21, P33; Poss JW, 2008, MED CARE, V46, P380, DOI 10.1097/MLR.0b013e31815c3b6c; Public Health Agency of Canada (PHAC), NAT POP HLTH STUD NE; Wodchis WP, 2008, MED CARE, V46, P882, DOI 10.1097/MLR.0b013e3181789471	48	44	44	0	21	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1472-6963		BMC HEALTH SERV RES	BMC Health Serv. Res.	NOV 1	2013	13								457	10.1186/1472-6963-13-457			11	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services	AC0YW	WOS:000332222400001	24176093	Green Published, gold			2022-02-06	
J	Jenkins, DD; Lee, T; Chiuzan, C; Perkel, JK; Rollins, LG; Wagner, CL; Katikaneni, LP; Bass, WT; Kaufman, DA; Horgan, MJ; Laungani, S; Givelichian, LM; Sankaran, K; Yager, JY; Martin, R				Jenkins, Dorothea D.; Lee, Timothy; Chiuzan, Cody; Perkel, Jessica K.; Rollins, Laura Grace; Wagner, Carol L.; Katikaneni, Lakshmi P.; Bass, W. Thomas; Kaufman, David A.; Horgan, Michael J.; Laungani, Sheela; Givelichian, Laurence M.; Sankaran, Koravangatta; Yager, Jerome Y.; Martin, Renee			Altered Circulating Leukocytes and Their Chemokines in a Clinical Trial of Therapeutic Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						chemokines; hypoxic ischemic brain injury; induced hypothermia; leukocytes	MONOCYTE CHEMOATTRACTANT PROTEIN-1; STROKE-INDUCED IMMUNODEPRESSION; TRAUMATIC BRAIN-INJURY; WHOLE-BODY HYPOTHERMIA; CENTRAL-NERVOUS-SYSTEM; MODERATE HYPOTHERMIA; BONE-MARROW; INFLAMMATORY RESPONSE; PROGENITOR CELLS; MICE LACKING	Objectives: To determine systemic hypothermia's effect on circulating immune cells and their corresponding chemokines after hypoxic ischemic encephalopathy in neonates. Design: In our randomized, controlled, multicenter trial of systemic hypothermia in neonatal hypoxic ischemic encephalopathy, we measured total and leukocyte subset and serum chemokine levels over time in both hypothermia and normothermia groups, as primary outcomes for safety. Setting: Neonatal ICUs participating in a Neurological Disorders and Stroke sponsored clinical trial of therapeutic hypothermia. Patients: Sixty-five neonates with moderate to severe hypoxic ischemic encephalopathy within 6 hours after birth. Interventions: Patients were randomized to normothermia of 37 degrees C or systemic hypothermia of 33 degrees C for 48 hours. Measurements and Main Results: Complete and differential leukocyte counts and serum chemokines were measured every 12 hours for 72 hours. The hypothermia group had significantly lower median circulating total WBC and leukocyte subclasses than the normothermia group before rewarming, with a nadir at 36 hours. Only the absolute neutrophil count rebounded after rewarming in the hypothermia group. Chemokines, monocyte chemotactic protein-1 and interleukin-8, which mediate leukocyte chemotaxis as well as bone marrow suppression, were negatively correlated with their target leukocytes in the hypothermia group, suggesting active chemokine and leukocyte modulation by hypothermia. Relative leukopenia at 60-72 hours correlated with an adverse outcome in the hypothermia group. Conclusions: Our data are consistent with chemokine-associated systemic immunosuppression with hypothermia treatment. In hypothermic neonates, persistence of lower leukocyte counts after rewarming is observed in infants with more severe CNS injury.	[Jenkins, Dorothea D.; Perkel, Jessica K.; Wagner, Carol L.; Katikaneni, Lakshmi P.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Lee, Timothy] Akron Childrens Hosp, Dept Pediat Emergency Med, Akron, OH USA; [Chiuzan, Cody; Martin, Renee] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA; [Rollins, Laura Grace] Univ Massachusetts, Dept Clin Psychol, Boston, MA 02125 USA; [Bass, W. Thomas] Eastern Virginia Med Sch, Dept Pediat, Norfolk, VA 23501 USA; [Kaufman, David A.] Univ Virginia, Dept Pediat, Charlottesville, VA USA; [Horgan, Michael J.] Albany Med Ctr, Dept Pediat, Albany, NY USA; [Laungani, Sheela] Brooklyn Hosp Ctr, Dept Pediat, Brooklyn, NY USA; [Givelichian, Laurence M.; Sankaran, Koravangatta] Univ Saskatchewan, Dept Pediat, Saskatoon, SK, Canada; [Yager, Jerome Y.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada		Jenkins, DD (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	jenkd@musc.edu	Chiuzan, Cody/M-9379-2019; Ward, LG/AAX-3500-2020; Chiuzan, Cody/K-8770-2019	Ward, LG/0000-0002-4792-5954; horgan, michael/0000-0003-0991-6464; Chiuzan, Cody/0000-0001-8169-5032	National Institutes of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38602]; Saskatchewan Health Research foundation; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Supported by R01 NS38602 from National Institutes of Neurologic Disorders and Stroke. The study sponsor had no input into the collection, analysis, and interpretation of data and the writing or submission of the manuscript for publication.; Dr. Givelichian's work on this project was supported by the Saskatchewan Health Research foundation. No form of payment was received for this manuscript. Dr. Jenkins received grant support from NINDS, is employed by the Medical University of SC and University Medical Associates, provided expert testimony for various legal firms, received grant support from the National Institutes of Health (NIH), other: NIH scientific review groups, and received support for article research from NIH. Drs. Rollins, Wagner, Katikaneni, Bass, Kaufman, Horgan, Laungani, and Sankaran received funding from NIH. Dr. Givelichian received funding from funding from NIH and the Saskatchewan Health Research Foundation. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; BALAJI S, 1991, BRIT HEART J, V66, P221; BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; Broxmeyer HE, 1996, J EXP MED, V184, P1825, DOI 10.1084/jem.184.5.1825; Buck BH, 2008, STROKE, V39, P355, DOI 10.1161/STROKEAHA.107.490128; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; Chapman KZ, 2009, J CEREBR BLOOD F MET, V29, P1764, DOI 10.1038/jcbfm.2009.113; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Colditz IG, 2007, THROMB HAEMOSTASIS, V97, P688, DOI 10.1160/TH07-02-0105; Denes A, 2011, J CEREBR BLOOD F MET, V31, P1036, DOI 10.1038/jcbfm.2010.198; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Eicher DJ, 2005, PEDIATR NEUROL, V32, P18, DOI 10.1016/j.pediatrneurol.2004.06.015; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; GARCIA JH, 1993, AM J PATHOL, V142, P623; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Grau AJ, 2001, J NEUROL SCI, V192, P41, DOI 10.1016/S0022-510X(01)00590-1; Hug A, 2009, STROKE, V40, P3226, DOI 10.1161/STROKEAHA.109.557967; Hughes PM, 2002, J CEREBR BLOOD F MET, V22, P308, DOI 10.1097/00004647-200203000-00008; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Jenkins DD, 2012, J CEREBR BLOOD F MET, V32, P1888, DOI 10.1038/jcbfm.2012.83; Jin YX, 2009, STROKE, V40, P3107, DOI 10.1161/STROKEAHA.109.549691; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Klehmet J, 2009, NEUROSCIENCE, V158, P1184, DOI 10.1016/j.neuroscience.2008.07.044; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Liesz A, 2009, STROKE, V40, P2849, DOI 10.1161/STROKEAHA.109.549618; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; MANROE BL, 1979, J PEDIATR-US, V95, P89, DOI 10.1016/S0022-3476(79)80096-7; MATTHYS D, 1995, PEDIATR CARDIOL, V16, P294, DOI 10.1007/BF00798065; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Newman TB, 2010, PEDIATRICS, V126, P903, DOI 10.1542/peds.2010-0935; Offner H, 2009, NEUROSCIENCE, V158, P1098, DOI 10.1016/j.neuroscience.2008.05.033; Ormstad H, 2011, J NEUROL, V258, P677, DOI 10.1007/s00415-011-6006-0; Oto J, 2008, J ANESTH, V22, P207, DOI 10.1007/s00540-008-0639-x; Pitchford SC, 2009, CELL STEM CELL, V4, P62, DOI 10.1016/j.stem.2008.10.017; Pruenster M, 2009, NAT IMMUNOL, V10, P101, DOI 10.1038/ni.1675; Reid S, 1999, BLOOD, V93, P1524, DOI 10.1182/blood.V93.5.1524.405k07_1524_1533; Shankaran S, 2008, PEDIATRICS, V122, pE791, DOI 10.1542/peds.2008-0456; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006; VANOSS CJ, 1980, J RETICULOENDOTH SOC, V27, P561; Vogelgesang A, 2008, STROKE, V39, P237, DOI 10.1161/STROKEAHA.107.493635; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wengner AM, 2008, BLOOD, V111, P42, DOI 10.1182/blood-2007-07-099648; Weston RM, 2007, J CEREBR BLOOD F MET, V27, P100, DOI 10.1038/sj.jcbfm.9600324; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030; Zozulya AL, 2007, J IMMUNOL, V178, P520, DOI 10.4049/jimmunol.178.1.520	52	44	44	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	OCT	2013	14	8					786	795		10.1097/PCC.0b013e3182975cc9			10	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	AI0EF	WOS:000336518300012	23897243				2022-02-06	
J	Classen, S; Wang, YN; Crizzle, AM; Winter, SM; Lanford, DN				Classen, Sherrilene; Wang, Yanning; Crizzle, Alexander M.; Winter, Sandra M.; Lanford, Desiree N.			Predicting Older Driver On-Road Performance by Means of the Useful Field of View and Trail Making Test Part B	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						aging; automobile driving; cognition; ROC curve; vision tests	TRAUMATIC BRAIN-INJURY; DRIVING PERFORMANCE; PARKINSONS-DISEASE; VEHICLE CRASHES; VISUAL-SEARCH; ADULTS; IMPAIRMENT; CURVES; STROKE; RISK	The Useful Field of View(R) (UFOV) and Trail Making Test Part B (Trails B) are measures of divided attention. We determined which measure was more accurate in predicting on-road outcomes among drivers (N = 198, mean age = 73.86, standard deviation = 6.05). Receiver operating characteristic curves for the UFOV (Risk Index [RI] and Subtests 1-3) and Trails B significantly predicted on-road outcomes. Contrasting Trails B with the UFOV RI and subtests, the only difference was found between the UFOV RI and Trails B, indicating the UFOV RI was the best predictor of on-road outcomes. Misclassifications of drivers totaled 28 for the UFOV RI, 62 for Trails B, and 58 for UFOV Subtest 2. The UFOV RI is a superior test in predicting on-road outcomes, but the Trails B has acceptable accuracy and is comparable to the other UFOV subtests.	[Classen, Sherrilene] Univ Western Ontario, Sch Occupat Therapy, Elborn Coll, London, ON N6A 5B9, Canada; [Classen, Sherrilene; Crizzle, Alexander M.; Winter, Sandra M.; Lanford, Desiree N.] Univ Florida, Coll Publ Hlth & Hlth Profess, Inst Mobil Act & Participat, Gainesville, FL USA; [Classen, Sherrilene; Crizzle, Alexander M.; Winter, Sandra M.; Lanford, Desiree N.] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Occupat Therapy, Gainesville, FL USA; [Wang, Yanning] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Epidemiol, Gainesville, FL USA		Classen, S (corresponding author), Univ Western Ontario, Sch Occupat Therapy, Elborn Coll, London, ON N6A 5B9, Canada.	sclassen@uwo.ca		Tilahin, Shimelis/0000-0001-8975-8026; Crizzle, Alexander/0000-0002-5289-7257			BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; Bedard M, 2010, AM J OCCUP THER, V64, P336, DOI 10.5014/ajot.64.2.336; Classen S, 2011, AM J OCCUP THER, V65, P579, DOI 10.5014/ajot.2011.001073; Classen S, 2008, TRAFFIC INJ PREV, V9, P456, DOI 10.1080/15389580802260026; Clay OJ, 2005, OPTOMETRY VISION SCI, V82, P724, DOI 10.1097/01.opx.0000175009.08626.65; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Duchek JM, 1998, J GERONTOL B-PSYCHOL, V53, pP130, DOI 10.1093/geronb/53B.2.P130; Edwards JD, 2006, ARCH CLIN NEUROPSYCH, V21, P275, DOI 10.1016/j.acn.2006.03.001; Fisk GD, 2002, J HEAD TRAUMA REHAB, V17, P16, DOI 10.1097/00001199-200202000-00004; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goode KT, 1998, J CLIN PSYCHOL MED S, V5, P425, DOI 10.1023/A:1026206927686; Hunt LA, 2010, AM J OCCUP THER, V64, P105, DOI 10.5014/ajot.64.1.105; Justiss MD, 2006, TOP GERIATR REHABIL, V22, P121; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mackworth N. H., 1965, PSYCHON SCI, V3, P67, DOI [10.3758/BF03343023, DOI 10.3758/BF03343023]; Marcotte TD, 2004, NEUROLOGY, V63, P1417, DOI 10.1212/01.WNL.0000141920.33580.5D; Marshall SC, 2007, TOP STROKE REHABIL, V14, P98, DOI 10.1310/tsr1401-98; Mazer BL, 2003, ARCH PHYS MED REHAB, V84, P541, DOI 10.1053/apmr.2003.50085; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Mullen NW, 2010, AM J OCCUP THER, V64, P288, DOI 10.5014/ajot.64.2.288; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; Posse S, 2006, TOP GERIATR REHABIL, V22, P113; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Rubin GS, 2007, INVEST OPHTH VIS SCI, V48, P1483, DOI 10.1167/iovs.06-0474; Stav WB, 2008, J SAFETY RES, V39, P1, DOI 10.1016/j.jsr.2007.10.004; Streiner DL, 2007, CAN J PSYCHIAT, V52, P121, DOI 10.1177/070674370705200210; Uc EY, 2006, ANN NEUROL, V60, P407, DOI 10.1002/ana.20958	32	44	45	0	20	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2013	67	5					574	582		10.5014/ajot.2013.008136			9	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	220EQ	WOS:000324565400011	23597697	Green Published			2022-02-06	
J	Coole, C; Radford, K; Grant, M; Terry, J				Coole, Carol; Radford, Kathryn; Grant, Mary; Terry, Jane			Returning to Work After Stroke: Perspectives of Employer Stakeholders, a Qualitative Study	JOURNAL OF OCCUPATIONAL REHABILITATION			English	Article						Stroke; Qualitative research; Employers; Work; Vocational rehabilitation; Return to work	TRAUMATIC BRAIN-INJURY; VOCATIONAL-REHABILITATION; LINE MANAGERS; SUPERVISORS; BARRIERS; FACILITATORS; ADULTS; BACK	Purpose More than 40 % of working age adults with stroke fail to return to work. The work context is a key factor in return to work, but little is known about the experiences of employers in supporting employees with stroke. The aim of this study was to explore return to work after stroke from the employer perspective, to identify key features associated with success and to seek participants' views regarding the role of healthcare in return to work. Methods Data was gathered through 18 semi-structured interviews with employer stakeholders and included small business owners, line managers, human resources and occupational health staff. Data was analysed thematically. Results The main themes identified were: the impact of stroke on the employer, characteristics of the employee, communication, knowledge and information, experience of other stakeholders, integrating healthcare in return to work. Conclusion Employers face complex emotional and practical issues when helping an employee return to work after stroke, for which many lack knowledge and experience. The range and quality of support networks that they access is variable and advice and support from clinicians is welcomed. Further research is necessary to investigate how such support could be funded and integrated within existing service provision.	[Coole, Carol] Univ Nottingham, Fac Med & Hlth Sci, Queens Med Ctr, Nottingham NG7 2HA, England; [Radford, Kathryn; Grant, Mary] Univ Nottingham, Div Rehabil & Ageing, Queens Med Ctr, Nottingham NG7 2UH, England; [Terry, Jane] Community Stroke Team, Nottingham NG7 5LR, England		Coole, C (corresponding author), Univ Nottingham, Fac Med & Hlth Sci, Queens Med Ctr, A Floor,South Block Link, Nottingham NG7 2HA, England.	Carolyn.coole@nottingham.ac.uk	Radford, Kate A/F-8571-2013	Radford, Kate A/0000-0001-6246-3180			Alaszewski A, 2007, DISABIL REHABIL, V29, P1858, DOI 10.1080/09638280601143356; Amir Z, 2010, J OCCUP REHABIL, V20, P435, DOI 10.1007/s10926-009-9197-9; [Anonymous], 2008, GOV RESP DC BLACKS R; Bond GR, 2008, PSYCHIATR REHABIL J, V31, P280, DOI 10.2975/31.4.2008.280.290; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Carbonneau H., 2010, DEMENTIA, V9, P327, DOI [10.1177/1471301210375316, DOI 10.1177/1471301210375316]; Care Quality Commission, 2011, SUPP LIF STROK REV S; Cohen CA, 2002, INT J GERIATR PSYCH, V17, P184, DOI 10.1002/gps.561; Culler KH, 2011, TOP STROKE REHABIL, V18, P325, DOI 10.1310/tsr1804-325; Cunningham I, 2004, BRIT J MANAGE, V15, P273, DOI 10.1111/j.1467-8551.2004.00419.x; Daniel K, 2009, STROKE, V40, pE431, DOI [10.1161/STROKEAHA.108.534487, 10.1161/STROKEAHA.108.535088]; de Vries G, 2012, J AFFECT DISORDERS, V136, P1017, DOI 10.1016/j.jad.2011.06.035; *DEP WORK PENS, 2004, BUILD CAP WORK UK FR; Department for Work and Pensions Department of Health Health & Safety Executive, 2008, HLTH WORK WELL BEING; Department of Health, 2007, NAT STROK STRAT; Department of Health, 2010, NHS OUTC FRAM 2011 1; Deshpande P, 2004, VOCATIONAL ASSESSMEN; Doucet T., 2012, Annals of Physical and Rehabilitation Medicine, V55, P112, DOI 10.1016/j.rehab.2012.01.007; Fadyl JK, 2009, J HEAD TRAUMA REHAB, V24, P195, DOI 10.1097/HTR.0b013e3181a0d458; Frank AO, 2006, INT J THER REHABIL, V13, P126, DOI 10.12968/ijtr.2006.13.3.21364; Frost D., 2011, HLTH WORK INDEPENDEN; Fylan B, 2011, 780 DEP WORK PENS; Gard Gunvor, 2006, Work, V26, P191; Glozier N, 2008, STROKE, V39, P1526, DOI 10.1161/STROKEAHA.107.503219; Haafkens JA, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-104; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P467, DOI 10.1097/00001199-200611000-00002; Holmgren K, 2007, J OCCUP REHABIL, V17, P93, DOI 10.1007/s10926-006-9041-4; Hussey L, 2010, OCCUP MED-OXFORD, V60, P294, DOI 10.1093/occmed/kqq022; Intercollegiate Stroke Working Party, 2008, NAT CLIN GUID STROK; Lambeek LC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1035; Lemieux P, 2011, J OCCUP REHABIL, V21, P293, DOI 10.1007/s10926-011-9316-2; Lindstrom B, 2009, J REHABIL MED, V41, P714, DOI 10.2340/16501977-0423; Lock S, 2005, DISABIL SOC, V20, P33, DOI 10.1080/0968759042000283629; Munir F, 2012, J OCCUP REHABIL, V22, P196, DOI 10.1007/s10926-011-9331-3; Park CH, 2012, PSYCHO-ONCOLOGY, V21, P282, DOI 10.1002/pon.1893; Playford ED, 2011, MAPPING VOCATIONAL R; Radford KA, 2011, INT J STROKE S2, V6, P49; Saeki S, 2010, J REHABIL MED, V42, P254, DOI 10.2340/16501977-0503; Saka O, 2009, AGE AGEING, V38, P27, DOI 10.1093/ageing/afn281; Sawney P, 2003, OCCUP MED-OXFORD, V53, P246, DOI 10.1093/occmed/kqg065; Sinclair A, 2012, 793 DEP WORK PENS; Soklaridis S, 2010, SOC SCI MED, V71, P1557, DOI 10.1016/j.socscimed.2010.08.017; Treger I, 2007, DISABIL REHABIL, V29, P1397, DOI 10.1080/09638280701314923; Tyerman A, 2004, VOCATIONAL ASSESSMEN; Vestling M, 2003, J REHABIL MED, V35, P127, DOI 10.1080/16501970310010475; Vocational Rehabilitation Society, 2007, STAND PRACT; Waddell G, 2008, VOCATIONAL REHABILIT; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WILL MC, 1984, EXCEPT CHILDREN, V51, P11, DOI 10.1177/001440298405100102; Wolfenden B, 2009, INT J REHABIL RES, V32, P93, DOI 10.1097/MRR.0b013e328325a358	50	44	45	0	20	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1053-0487	1573-3688		J OCCUP REHABIL	J. Occup. Rehabil.	SEP	2013	23	3					406	418		10.1007/s10926-012-9401-1			13	Rehabilitation; Social Issues	Social Science Citation Index (SSCI)	Rehabilitation; Social Issues	197VS	WOS:000322880900011	23212240	Green Published, Green Submitted, Green Accepted, hybrid			2022-02-06	
J	Mihalik, JP; Lengas, E; Register-Mihalik, JK; Oyama, S; Begalle, RL; Guskiewicz, KM				Mihalik, Jason P.; Lengas, Eric; Register-Mihalik, Johna K.; Oyama, Sakiko; Begalle, Rebecca L.; Guskiewicz, Kevin M.			The Effects of Sleep Quality and Sleep Quantity on Concussion Baseline Assessment	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						assessment; baseline; college; concussion; student-athlete; traumatic brain injury	COGNITIVE PERFORMANCE; COLLEGE-STUDENTS; RECURRENT CONCUSSION; POSTURAL CONTROL; DEPRIVATION; PATTERNS; MOOD; ASSOCIATION; INJURY; HEALTH	Objective: Proper concussion assessment is imperative for properly caring for athletes who sustain traumatic brain injuries. Decreased sleep quality and sleep quantity affect cognition and may threaten the validity of clinical measures often used as a part of the concussion assessment. The purpose of this study was to determine if sleep quality or sleep quantity affects performance on clinical measures of concussion. Design: Prospective cohort design. Setting: Clinical research center. Participants: One hundred fifty-five college student-athletes (57 females, 98 males; age = 18.8 +/- 0.8 years; mass = 78.4 +/- 19.6 kg; height = 177.4 +/- 12.3 cm). Interventions: We performed preseason baseline testing by using a well-accepted and multifaceted protocol inclusive of neurocognition, balance performance, and symptom reporting. Information related to sleep quality and sleep quantity was also collected during preseason baseline testing. Main Outcome Measures: The CNS Vital Signs battery (computerized neurocognitive test), Sensory Organization Test (computerized dynamic posturography), and a Graded Symptom Checklist (symptom evaluation) were used. Results: Subjects with a low sleep quantity the night before baseline reported both a greater number of symptoms and higher total symptom severity score. No clinically significant effects for sleep quality were observed. Conclusions: Sleep-deprived athletes reporting for baseline testing should be rescheduled for testing after a normal night's sleep.	[Mihalik, Jason P.; Lengas, Eric; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Begalle, Rebecca L.; Guskiewicz, Kevin M.] Univ N Carolina, Sch Med, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Begalle, Rebecca L.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Allied Hlth Sci, Sch Med, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, Raleigh, NC USA; [Oyama, Sakiko] Univ Texas San Antonio, Dept Hlth & Kinesiol, San Antonio, TX USA		Mihalik, JP (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, 313 Woollen Gymnasium,Campus Box 8605, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322; Register-Mihalik, Johna/0000-0002-4229-4743; Oyama, Sakiko/0000-0001-8263-9251			Bougard C, 2011, EXP BRAIN RES, V209, P109, DOI 10.1007/s00221-010-2524-8; Buboltz WC, 2001, J AM COLL HEALTH, V50, P131, DOI 10.1080/07448480109596017; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Clanton NR, 2011, CANCER-AM CANCER SOC, V117, P2559, DOI 10.1002/cncr.25797; DEARY IJ, 1987, BRIT MED J, V295, P1513, DOI 10.1136/bmj.295.6612.1513; Fabbri M, 2006, NEUROPSYCHOLOGIA, V44, P2520, DOI 10.1016/j.neuropsychologia.2006.03.033; FITZPATRICK MF, 1991, THORAX, V46, P569, DOI 10.1136/thx.46.8.569; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gribble PA, 2004, PERCEPT MOTOR SKILL, V99, P1035, DOI 10.2466/pms.99.3.1035-1045; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; JACQUES CHM, 1990, J FAM PRACTICE, V30, P223; Kelly WE, 2004, COLL STUD J, V35, P84; Kelman L, 2005, HEADACHE, V45, P904, DOI 10.1111/j.1526-4610.2005.05159.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lieberman HR, 2005, AVIAT SPACE ENVIR MD, V76, pC7; Lieberman HR, 2002, PSYCHOPHARMACOLOGY, V164, P250, DOI 10.1007/s00213-002-1217-9; Pilcher JJ, 1997, J PSYCHOSOM RES, V42, P583, DOI 10.1016/S0022-3999(97)00004-4; ROBBINS J, 1990, WESTERN J MED, V152, P82; Robillard R, 2011, CLIN NEUROPHYSIOL, V122, P1771, DOI 10.1016/j.clinph.2011.02.010; Trockel MT, 2000, J AM COLL HEALTH, V49, P125, DOI 10.1080/07448480009596294; Tsai LL, 2004, J PSYCHOSOM RES, V56, P231, DOI 10.1016/S0022-3999(03)00507-5; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Williamson AM, 2000, OCCUP ENVIRON MED, V57, P649, DOI 10.1136/oem.57.10.649	28	44	45	2	41	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2013	23	5					343	348		10.1097/JSM.0b013e318295a834			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	212YD	WOS:000324017900004	23917732				2022-02-06	
J	Campolo, M; Ahmad, A; Crupi, R; Impellizzeri, D; Morabito, R; Esposito, E; Cuzzocrea, S				Campolo, Michela; Ahmad, Akbar; Crupi, Rosalia; Impellizzeri, Daniela; Morabito, Rossana; Esposito, Emanuela; Cuzzocrea, Salvatore			Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury	JOURNAL OF ENDOCRINOLOGY			English	Article						melatonin; dexamethasone; TBI; inflammation; cell death; motor function	REDUCES SECONDARY INJURY; NITRIC-OXIDE SYNTHASE; KAPPA-B ACTIVITY; OXIDATIVE STRESS; ANTIINFLAMMATORY ACTIVITY; NEUROVASCULAR UNIT; MICE MODEL; RAT MODEL; NEUROPROTECTION; RECOVERY	Traumatic brain injury (TBI) is a major cause of preventable death and morbidity in young adults. This complex condition is characterized by a significant blood-brain barrier leakage that stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain. Recovery of function after TBI is partly through neuronal plasticity. In order to test whether combination therapy with melatonin and dexamethasone (DEX) might improve functional recovery, a controlled cortical impact (CCI) was performed in adult mice, acting as a model of TBI. Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. The therapy with melatonin (10 mg/kg) and DEX (0.025 mg/kg) is able to reduce edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazoliumchloride staining across the brain sections. Melatonin- and DEX-mediated improvements in tissue histology shown by the reduction in lesion size and an improvement in apoptosis level further support the efficacy of combination therapy. The combination therapy also blocked the infiltration of astrocytes and reduced CCI-mediated oxidative stress. In addition, we have also clearly demonstrated that the combination therapy significantly ameliorated neurological scores. Taken together, our results clearly indicate that combination therapy with melatonin and DEX presents beneficial synergistic effects, and we consider it an avenue for further development of novel combination therapeutic agents in the treatment of TBI that are more effective than a single effector molecule.	[Campolo, Michela; Ahmad, Akbar; Crupi, Rosalia; Impellizzeri, Daniela; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Dept Biol & Environm Sci, I-98100 Messina, Italy; [Morabito, Rossana] Univ Messina, Dept Human & Social Sci, I-98100 Messina, Italy; [Cuzzocrea, Salvatore] Univ Manchester, Manchester Royal Infirm, Manchester Biomed Res Ctr, Sch Med, Manchester M13 9WL, Lancs, England		Cuzzocrea, S (corresponding author), Univ Messina, Dept Biol & Environm Sci, Policlin Univ Via C Valeria, I-98100 Messina, Italy.	salvator@unime.it	Crupi, Rosalia/U-4364-2019; Campolo, Michela/K-6432-2016	Ahmad, Akbar/0000-0003-1841-9670; MORABITO, Rossana/0000-0003-4904-4963; Crupi, Rosalia/0000-0002-7629-3132; Cuzzocrea, Salvatore/0000-0001-6131-3690; Impellizzeri, Daniela/0000-0001-9492-3161			Afanas'ev IB, 2007, MOL BIOTECHNOL, V37, P2, DOI 10.1007/s12033-007-0056-7; Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Antunes F, 1999, FREE RADICAL BIO MED, V26, P117, DOI 10.1016/S0891-5849(98)00168-3; Bethea JR, 1998, J NEUROSCI, V18, P3251; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Cevc G, 2004, BBA-BIOMEMBRANES, V1663, P61, DOI 10.1016/j.bbamem.2004.01.006; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crisafulli C, 2006, J PINEAL RES, V41, P228, DOI 10.1111/j.1600-079X.2006.00358.x; Cuzzocrea S, 2005, ARTHRITIS RHEUM-US, V52, P1929, DOI 10.1002/art.21044; Cuzzocrea S, 2008, MOL PHARMACOL, V73, P323, DOI 10.1124/mol.107.041475; Di Bella L, 2006, NEUROENDOCRINOL LETT, V27, P425; Dundar K, 2005, CLIN EXP PHARMACOL P, V32, P926, DOI 10.1111/j.1440-1681.2005.04286.x; Esposito E, 2008, J PINEAL RES, V45, P149, DOI 10.1111/j.1600-079X.2008.00569.x; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Fowler G, 2003, FREE RADICAL BIO MED, V34, P77, DOI 10.1016/S0891-5849(02)01186-3; Genovese T, 2005, J PINEAL RES, V38, P198, DOI 10.1111/j.1600-079X.2004.00194.x; Genovese T, 2007, NEUROSCIENCE, V150, P168, DOI 10.1016/j.neuroscience.2007.06.059; Genovese T, 2007, J PINEAL RES, V43, P140, DOI 10.1111/j.1600-079X.2007.00454.x; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ismailoglu O, 2012, TURK NEUROSURG, V22, P740, DOI 10.5137/1019-5149.JTN.6197-12.1; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jeanneteau F, 2008, P NATL ACAD SCI USA, V105, P4862, DOI 10.1073/pnas.0709102105; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11; Li ZQ, 2009, BRAIN RES, V1264, P98, DOI 10.1016/j.brainres.2009.01.055; Livrea MA, 1997, FREE RADICAL BIO MED, V23, P706, DOI 10.1016/S0891-5849(97)00018-X; MCEWEN BS, 1987, ENVIRON HEALTH PERSP, V74, P177, DOI 10.2307/3430447; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Nichols NR, 2005, BRAIN RES REV, V48, P287, DOI 10.1016/j.brainresrev.2004.12.019; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Ozawa Hitoshi, 2005, Journal of Nippon Medical School, V72, P316, DOI 10.1272/jnms.72.316; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Venegas C, 2012, J PINEAL RES, V52, P217, DOI 10.1111/j.1600-079X.2011.00931.x; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	53	44	45	1	10	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0022-0795	1479-6805		J ENDOCRINOL	J. Endocrinol.	JUN	2013	217	3					291	301		10.1530/JOE-13-0022			11	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	151JU	WOS:000319457600009	23532863	Bronze			2022-02-06	
J	Torbic, H; Forni, AA; Anger, KE; Degrado, JR; Greenwood, BC				Torbic, Heather; Forni, Allison A.; Anger, Kevin E.; Degrado, Jeremy R.; Greenwood, Bonnie C.			Use of antiepileptics for seizure prophylaxis after traumatic brain injury	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article							PROPHYLACTICALLY ADMINISTERED PHENYTOIN; INTRAVENOUS LEVETIRACETAM; POSTTRAUMATIC EPILEPSY; RISK-FACTORS; PREVENTION; VALPROATE; FAILURE	Purpose. Antiepileptics used for seizure prophylaxis after traumatic brain injury (TBI) are reviewed. Summary. Of the 275,000 people who are hospitalized with TBI each year, approximately 5-7% experience a posttraumatic seizure (PIS). According to the latest guidelines issued by the Brain Trauma Foundation and the American Academy of Neurology (AAN) for the management of severe TBI, PTS prophylaxis is recommended only during the first seven days after TBI. Of the available antiepileptic drugs, phenytoin has been the most extensively studied for the prophylaxis of PTS. Phenobarbital, valproate, and carbamazepine have not been as extensively researched, and, given their adverse-effect profiles and pharmacodynamic properties, there is no advantage to using these agents over phenytoin. Levetiracetam has demonstrated comparable efficacy to phenytoin for PTS prophylaxis and is associated with fewer adverse effects and monitoring considerations; it may be a reasonable alternative to phenytoin. However, levetiracetam has been associated with an increased seizure tendency. The Brain Trauma Foundation recommends using phenytoin for early PTS prophylaxis. The guidelines also state that valproate has demonstrated similar efficacy to phenytoin but warn that its use may be associated with increased mortality. Conclusion. The available literature supports the use of antiepileptics for early PTS prophylaxis during the first week after a TBI. Phenytoin has been extensively studied for this indication and is recommended by the AAN and Brain Trauma Foundation guidelines for early PTS prophylaxis. Levetiracetam has demonstrated comparable efficacy to phenytoin for early PTS prophylaxis and may be a reasonable alternative to consider in this patient population.	[Torbic, Heather; Anger, Kevin E.; Degrado, Jeremy R.; Greenwood, Bonnie C.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Forni, Allison A.] UMass Mem Med Ctr, Worcester, MA USA		Torbic, H (corresponding author), Brigham & Womens Hosp, Dept Pharm, 75 Francis St, Boston, MA 02115 USA.	htorbic@partners.org	Anger, Kevin/AAW-8108-2020; DeGrado, Jeremy/AAF-3482-2021	Anger, Kevin/0000-0002-3202-3421; DeGrado, Jeremy/0000-0002-0141-7137; Greenwood, Bonnie/0000-0002-7472-9043			[Anonymous], 2009, KEPPR LEV PACK INS; [Anonymous], 2011, DIL PHEN PACK INS; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Dennis KC, CURRENT PERSPECTIVES; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Frend V, 2007, CLIN NEUROPHARMACOL, V30, P362, DOI 10.1097/WNF.0b013e318059ae1c; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Jensen FE, 2009, EPILEPSIA S2, V50, P1; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Kraus J, 2000, HEAD INJURY, P1; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Patsalos PN, 2004, CLIN PHARMACOKINET, V43, P707, DOI 10.2165/00003088-200443110-00002; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; Ruegg S, 2008, EPILEPSY BEHAV, V12, P477, DOI 10.1016/j.yebeh.2008.01.004; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TEASDALE G, 1974, LANCET, V2, P81; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; von Winckelmann SL, 2008, PHARMACOTHERAPY, V28, P1391, DOI 10.1592/phco.28.11.1391; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231	33	44	46	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	MAY 1	2013	70	9					759	766		10.2146/ajhp120203			8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	137WQ	WOS:000318469300008	23592358				2022-02-06	
J	Mondello, S; Buki, A; Italiano, D; Jeromin, A				Mondello, Stefania; Buki, Andras; Italiano, Domenico; Jeromin, Andreas			alpha-Synuclein in CSF of patients with severe traumatic brain injury	NEUROLOGY			English	Article							LEWY BODIES; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; HEAD-INJURY; DEMENTIA; TRAJECTORIES; BIOMARKERS; DIAGNOSIS; MECHANISMS; EXOCYTOSIS	Objective: The study aims to examine alpha-synuclein in the CSF of patients with severe traumatic brain injury (TBI) and its relationship with clinical characteristics and long-term outcomes. Methods: This prospective case-control study enrolled patients with severe TBI (Glasgow Coma Score <= 8) who underwent ventriculostomy. CSF samples were taken from each TBI patient at admission and daily for up to 8 days after injury and successively assessed by ELISA. Control CSF was collected for analysis from subjects receiving lumbar puncture for other medical reasons. We used trajectory analysis to identify distinct temporal profiles of CSF alpha-synuclein that were compared with clinical outcomes. Results: CSF alpha-synuclein was elevated in TBI patients after injury as compared to controls (p = 0.0008). Overall, patients who died had higher concentrations (area under the curve) over 8 days of observation compared to those who survived at 6 months postinjury (p = 0.002). Two distinct temporal alpha-synuclein profiles were recognized over time. Subjects who died had consistently elevated alpha-synuclein levels compared to those who survived with alpha-synuclein levels near controls. High-risk trajectory was a strong and accurate predictor of death with 100% specificity and a very high sensitivity (83%). Conclusions: Taken together, these data support the hypothesis that in severe TBI patients, substantial increase of CSF alpha-synuclein may indicate widespread neurodegeneration and reflect secondary neuropathologic events occurring after injury. The determination of CSF alpha-synuclein may be a valuable prognostic marker, adding to the clinical assessment and creating opportunities for medical intervention.	[Mondello, Stefania; Jeromin, Andreas] Banyan Biomarkers Inc, Clin Dept, Alachua, FL USA; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; Hungarian Acad Sci, Clin Neurosci Image Ctr, Pecs, Hungary; [Italiano, Domenico] Univ Messina, Dept Clin & Expt Med & Pharmacol, Messina, Italy		Mondello, S (corresponding author), Banyan Biomarkers Inc, Clin Dept, Alachua, FL USA.	stm_mondello@hotmail.com	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614	Department of DefenseUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03- 1-0066]; Banyan Biomarkers, Inc.	Supported by the Department of Defense (DAMD17-03-1-0772 and DAMD17-03- 1-0066).; S. Mondello is an employee and receives salaries from Banyan Biomarkers, Inc. A. Buki is a consultant for Banyan Biomarkers, Inc. D. Italiano reports no disclosures. A. Jeromin was an employee and received salaries from Banyan Biomarkers, Inc. Go to Neurology.org for full disclosures.	Adou K, 2009, ANAL CHEM, V81, P10186, DOI 10.1021/ac902275h; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Clough RL, 2011, J NEUROCHEM, V117, P275, DOI 10.1111/j.1471-4159.2011.07199.x; Danzer KM, 2011, FASEB J, V25, P326, DOI 10.1096/fj.10-164624; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Foulds PG, 2012, NEUROBIOL DIS, V45, P188, DOI 10.1016/j.nbd.2011.08.003; Gure TR, 2010, J GERONTOL A-BIOL, V65, P434, DOI 10.1093/gerona/glp197; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Jones DJ, 2010, J CLIN CHILD ADOLESC, V39, P667, DOI 10.1080/15374416.2010.501286; Kasuga K, 2010, J NEUROL NEUROSUR PS, V81, P608, DOI 10.1136/jnnp.2009.197483; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kramer ML, 2007, J NEUROSCI, V27, P1405, DOI 10.1523/JNEUROSCI.4564-06.2007; Larsen KE, 2006, J NEUROSCI, V26, P11915, DOI 10.1523/JNEUROSCI.3821-06.2006; Lee EJ, 2010, J IMMUNOL, V185, P615, DOI 10.4049/jimmunol.0903480; Lee HJ, 2005, J NEUROSCI, V25, P6016, DOI 10.1523/JNEUROSCI.0692-05.2005; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lee VMY, 2006, NEURON, V52, P33, DOI 10.1016/j.neuron.2006.09.026; Lovell MA, 2008, NEUROLOGY, V70, P2212, DOI 10.1212/01.wnl.0000312383.39973.88; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mollenhauer B, 2011, LANCET NEUROL, V10, P230, DOI 10.1016/S1474-4422(11)70014-X; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Nagin D, 1999, CHILD DEV, V70, P1181, DOI 10.1111/1467-8624.00086; Reesink FE, 2010, J ALZHEIMERS DIS, V22, P87, DOI 10.3233/JAD-2010-100186; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Tokuda T, 2010, NEUROLOGY, V75, P1766, DOI 10.1212/WNL.0b013e3181fd613b; Vekrellis K, 2012, EXPERT OPIN THER TAR, V16, P421, DOI 10.1517/14728222.2012.674111; Vekrellis K, 2011, LANCET NEUROL, V10, P1015, DOI 10.1016/S1474-4422(11)70213-7; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	37	44	44	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	APR	2013	80	18					1662	1668		10.1212/WNL.0b013e3182904d43			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	141AC	WOS:000318696600014	23553480				2022-02-06	
J	Kirov, II; Tal, A; Babb, JS; Lui, YW; Grossman, RI; Gonen, O				Kirov, Ivan I.; Tal, Assaf; Babb, James S.; Lui, Yvonne W.; Grossman, Robert I.; Gonen, Oded			Diffuse axonal injury in mild traumatic brain injury: a 3D multivoxel proton MR spectroscopy study	JOURNAL OF NEUROLOGY			English	Article						Brain injury; Diffuse axonal injury; Magnetic resonance spectroscopy	MAGNETIC-RESONANCE-SPECTROSCOPY; HEAD-INJURY; RELAXATION-TIMES; ADULT BRAIN; MATTER; DAMAGE; PREVALENCE; RECOVERY; TESLA	Since mild traumatic brain injury (mTBI) often leads to neurological symptoms even without clinical MRI findings, our goal was to test whether diffuse axonal injury is quantifiable with multivoxel proton MR spectroscopic imaging (H-1-MRSI). T1- and T2-weighted MRI images and three-dimensional H-1-MRSI (480 voxels over 360 cm(3), about 30 % of the brain) were acquired at 3 T from 26 mTBI patients (mean Glasgow Coma Scale score 14.7, 18-56 years old, 3-55 days after injury) and 13 healthy matched contemporaries as controls. The N-acetylaspartate (NAA), choline (Cho), creatine (Cr) and myo-inositol (mI) concentrations and gray-matter/white-matter (GM/WM) and cerebrospinal fluid fractions were obtained in each voxel. Global GM and WM absolute metabolic concentrations were estimated using linear regression, and patients were compared with controls using two-way analysis of variance. In patients, mean NAA, Cr, Cho and mI concentrations in GM (8.4 +/- A 0.7, 6.9 +/- A 0.6, 1.3 +/- A 0.2, 5.5 +/- A 0.6 mM) and Cr, Cho and mI in WM (4.8 +/- A 0.5, 1.4 +/- A 0.2, 4.6 +/- A 0.7 mM) were not different from the values in controls. The NAA concentrations in WM, however, were significantly lower in patients than in controls (7.2 +/- A 0.8 vs. 7.7 +/- A 0.6 mM, p = 0.0125). The Cho and Cr levels in WM of patients were positively correlated with time since mTBI. This H-1-MRSI approach allowed us to ascertain that early mTBI sequelae are (1) diffuse (not merely local), (2) neuronal (not glial), and (3) in the global WM (not GM). These findings support the hypothesis that, similar to more severe head trauma, mTBI also results in diffuse axonal injury, but that dysfunction rather than cell death dominates shortly after injury.	[Kirov, Ivan I.; Tal, Assaf; Babb, James S.; Lui, Yvonne W.; Grossman, Robert I.; Gonen, Oded] NYU, Dept Radiol, Sch Med, New York, NY 10016 USA		Gonen, O (corresponding author), NYU, Dept Radiol, Sch Med, 660 1st Ave,4th Floor, New York, NY 10016 USA.	oded.gonen@med.nyu.edu	Kirov, Ivan/I-2792-2019	Kirov, Ivan/0000-0001-5641-8578; Babb, James/0000-0003-1798-1186; Gonen, Oded/0000-0002-3148-2028; Tal, Assaf/0000-0001-6718-6522	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EB01015, NS39135, NS29029, NS050520]; Human Frontiers Science Project; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS050520, R01NS029029, R37NS029029, R01NS050520, R01NS039135] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants EB01015, NS39135, NS29029 and NS050520. Assaf Tal is also supported by the Human Frontiers Science Project. We thank Ms. Nissa Perry and Mr. Joseph Reaume for subject recruitment.	Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Baker EH, 2008, J MAGN RESON IMAGING, V27, P489, DOI 10.1002/jmri.21285; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bigler ED, 2010, PSYCHOL INJ LAW, V3, P36, DOI 10.1007/s12207-010-9064-1; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M, 2010, TRAUMATIC BRAIN INJU; Frahm J., 1997, MAGNETIC RESONANCE S, P329; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Ge YL, 2002, AM J NEURORADIOL, V23, P1327; Goelman G, 2006, MAGN RESON MED, V56, P34, DOI 10.1002/mrm.20942; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HU J, 1995, J MAGN RESON SER B, V108, P213, DOI 10.1006/jmrb.1995.1126; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JOHNSON VE, 2012, EXP NEUROL IN PRESS; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kirov II, 2008, MAGN RESON MED, V60, P790, DOI 10.1002/mrm.21715; Kirov II, 2012, MAGN RESON MED, V67, P27, DOI 10.1002/mrm.23001; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kreis R, 2005, MAGN RESON MED, V54, P761, DOI 10.1002/mrm.20673; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Nakabayashi M, 2007, J NEUROSURG, V106, P370, DOI 10.3171/jns.2007.106.3.370; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Posse S, 2007, MAGN RESON MED, V58, P236, DOI 10.1002/mrm.21287; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100107-01, 10.3928/02793695-20100108-02]; Soher BJ, 1998, MAGNET RESON MED, V40, P822, DOI 10.1002/mrm.1910400607; Son BC, 2000, ACT NEUR S, V76, P13; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Tal A, 2012, NMR BIOMED, V25, P1392, DOI 10.1002/nbm.2812; Tanelian T., 2008, INVISIBLE WOUNDS WAR, P305; TEASDALE G, 1974, LANCET, V2, P81; Traber F, 2004, J MAGN RESON IMAGING, V19, P537, DOI 10.1002/jmri.20053; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	49	44	46	0	25	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	JAN	2013	260	1					242	252		10.1007/s00415-012-6626-z			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	063NV	WOS:000313007600034	22886061	Green Accepted			2022-02-06	
J	Chamard, E; Theoret, H; Skopelja, EN; Forwell, LA; Johnson, AM; Echlin, PS				Chamard, Emilie; Theoret, Hugo; Skopelja, Elaine N.; Forwell, Lorie A.; Johnson, Andrew M.; Echlin, Paul S.			A prospective study of physician-observed concussion during a varsity university hockey season: metabolic changes in ice hockey players. Part 4 of 4	NEUROSURGICAL FOCUS			English	Article						concussion; ice hockey; magnetic resonance imaging; magnetic resonance spectroscopy; sex; Canada	TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; INTERNATIONAL-CONFERENCE; FUNCTIONAL CONNECTIVITY; SPORTS CONCUSSION; CORPUS-CALLOSUM; EPIDEMIOLOGY; MILD; ASSOCIATION; STATEMENT	Object. Despite negative neuroimaging findings using traditional neuroimaging methods such as MRI and CT, sports-related concussions have been shown to cause neurometabolic changes in both the acute and subacute phases of head injury. However, no prospective clinical study has used an independent physician-observer design in the monitoring of these changes. The objective of this study was to evaluate the effects of repetitive concussive and subconcussive head impacts on neurometabolic concentrations in a prospective study of two Canadian Interuniversity Sports (CIS) ice hockey teams using MR spectroscopy (MRS). Methods. Forty-five ice hockey players (25 men and 20 women) participated in this study. All participants underwent pre- and postseason MRI, including spectroscopy imaging, using a 3-T MRI machine. The linear combination model was used to quantify the following ratios: glutamate/creatine-phosphocreatine (Cr), myoinositol/Cr, and N-acetylaspartate (NAA)/Cr. Individuals sustaining a medically diagnosed concussion were sent for MRI at 72 hours, 2 weeks, and 2 months after injury. Results. No statistically significant differences were observed between athletes who were diagnosed with a concussion and athletes who were not clinically diagnosed as sustaining a concussion. Although no statistically significant longitudinal metabolic changes were observed among athletes who were diagnosed with a concussion, the results demonstrated a predictable pattern of initial impairment, followed by a gradual return to ratios that were similar to, but lower than, baseline ratios. No significant pre- to postseason changes were demonstrated among men who were not observed to sustain a concussion. However, a substantively significant decrease in the NAA/Cr ratio was noted among the female hockey players (t((13)) = 2.58, p = 0.02, eta(2) = 0.34). Conclusions. A key finding in this study, from the standpoint of future research design, is the demonstration of substantively significant metabolic changes among the players who were not diagnosed with a concussion. In addition, it may explain why there are few statistically significant differences demonstrated between players who were diagnosed with a concussion and players who were not diagnosed with a concussion (that is, the potency of the independent variable was diminished by the fact that the group of players not diagnosed with a concussion might be better described as a subgroup of the players who may have sustained a concussion but were not observed and diagnosed with a concussion). This result suggests that definitions of concussion may need to be revisited within sports with high levels of repetitive subconcussive head impacts. Future analysis of these data will examine the relationships between the modes of MRI (diffusion tensor imaging, MRS, and susceptibility-weighted MR imaging) used in this study, along with other more sensitive evaluative techniques. This type of intermodal comparison may improve the identification of concussions that were previously dependent on the unreliable self-reporting of recognized concussion symptomatology by the athlete or on poorly validated neuropsychological tests. (http://thejns.org/doi/abs/10.3171/2012.10.FOCUS12305)	[Echlin, Paul S.] Elliott Sports Med Clin, Burlington, ON L7N 2G3, Canada; [Chamard, Emilie; Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Chamard, Emilie; Theoret, Hugo] CHU St Justine, Montreal, PQ, Canada; [Skopelja, Elaine N.] Indiana Univ, Sch Med Lib, Indianapolis, IN 46204 USA; [Forwell, Lorie A.] Univ Western Ontario, Fowler Kennedy Sport Med Clin, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Sch Phys Therapy, London, ON, Canada; [Johnson, Andrew M.] Univ Western Ontario, Sch Hlth Studies, London, ON, Canada		Echlin, PS (corresponding author), Elliott Sports Med Clin, 1100 Walkers Line,Suite 2, Burlington, ON L7N 2G3, Canada.	psechlin@gmail.com	Johnson, Andrew M/B-2048-2012	Skopelja, Elaine/0000-0002-2847-8909; Theoret, Hugo/0000-0002-7458-8797; Johnson, Andrew M./0000-0002-7269-3016	Ontario Trillium Foundation; Dave Irwin Foundation for Brain Injury; Ontario Neurotrauma Foundation; Air Canada	Funding for this work was provided to the HCEP and Dr. Echlin by the Ontario Trillium Foundation, the Dave Irwin Foundation for Brain Injury, the Ontario Neurotrauma Foundation, and Air Canada.	Agel J, 2007, J ATHL TRAINING, V42, P249; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Braun CMJ, 2002, LATERALITY, V7, P97, DOI 10.1080/13576500143000212; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Toga A.W., 2002, BRAIN MAPPING METHOD, Vsecond; Tremblay S, 2012, CEREB CORTEX; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	32	44	45	0	25	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E4	10.3171/2012.10.FOCUS12305			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500005	23199427	Bronze			2022-02-06	
J	Dobrunz, D; Toma, AC; Tanner, P; Pfohl, T; Palivan, CG				Dobrunz, Dominik; Toma, Adriana C.; Tanner, Pascal; Pfohl, Thomas; Palivan, Cornelia G.			Polymer Nanoreactors with Dual Functionality: Simultaneous Detoxification of Peroxynitrite and Oxygen Transport	LANGMUIR			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; LIPOSOME-ENCAPSULATED HEMOGLOBIN; RESONANCE RAMAN-SPECTROSCOPY; TRIBLOCK COPOLYMER VESICLES; TRAUMATIC BRAIN-INJURY; RED-BLOOD-CELLS; NITRIC-OXIDE; CREATINE-KINASE; METHEMOGLOBIN; OXYHEMOGLOBIN	The design of multifunctional systems is in focus today:is a key. strategy for coping with complex challenges in various domains that include chemistry, medicine, environmental sciences, and technology. Herein, we introduce protein-containing polymer nanoreactors with dual functionality: peroxynitrite degradation and oxygen transport. Vesicles made of poly-(2-methyloxazoline)-poly(dimethylsiloxane)-poly(2-methyloxazoline) successfully encapsulated hemoglobin (Hb), which serves as a model protein because of its dual function in oxygen transport and peroxynitrite degradation. By inserting channel proteins, the polymer membranes of vesicles permitted passage of various compounds that served for the assessment of in situ Hb activity. The requisite conformational changes. in the protein. structure and the. change in oxidation states that took place within the confined space of the vesicle cavity demonstrated that Hb preserved its dual functionality: peroxynitrite degradation and oxygen transport The functionality of our nanoreactor, combined With its simple procedure of production and extensive stability over several months, supports it as a promising system for further medical applications.	[Dobrunz, Dominik; Toma, Adriana C.; Tanner, Pascal; Pfohl, Thomas; Palivan, Cornelia G.] Univ Basel, Dept Chem, CH-4056 Basel, Switzerland		Palivan, CG (corresponding author), Univ Basel, Dept Chem, Klingelbergstr 80, CH-4056 Basel, Switzerland.		Pfohl, Thomas/D-7296-2016	Pfohl, Thomas/0000-0002-7879-5216	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; NCCR Nanoscale ScienceSwiss National Science Foundation (SNSF)European Commission; Forschungsfonds der Universitat Basel	This work was supported by the Swiss National Science Foundation and by NCCR Nanoscale Science, and this is gratefully acknowledged. The authors thank Prof. W. Meier of the University of Basel for providing the block copolymer and for useful discussions. The authors acknowledge Prof. C. Schonenberger from the University of Basel for access to the Raman spectrometer. A.C.T. thanks the "Forschungsfonds der Universitat Basel" for funding and T. Frohlich for support with Raman measurements. D.D. thanks Dr. Ozana Fischer-Onaca for useful discussions. The authors acknowledge Mark Inglin for reading the manuscript.	ABE K, 1979, EUR J BIOCHEM, V101, P423, DOI 10.1111/j.1432-1033.1979.tb19735.x; Arifin DR, 2005, BIOMACROMOLECULES, V6, P2172, DOI 10.1021/bm0501454; Arifin DR, 2005, ARTIF CELL BLOOD SUB, V33, P113, DOI 10.1081/BIO-200055874; Arosio D, 2002, BIOPOLYMERS, V63, P1, DOI 10.1002/bip.1057; Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; Ascenzi P, 2009, BIOCHEM BIOPH RES CO, V390, P27, DOI 10.1016/j.bbrc.2009.09.050; Axthelm F, 2008, J PHYS CHEM B, V112, P8211, DOI 10.1021/jp803032w; Balasubramanian V, 2010, EXPERT OPIN DRUG DEL, V7, P63, DOI 10.1517/17425240903394520; Barenholz Y, 2001, CURR OPIN COLLOID IN, V6, P66, DOI 10.1016/S1359-0294(00)00090-X; Bermudez H, 2002, MACROMOLECULES, V35, P8203, DOI 10.1021/ma020669l; Bouloumie A, 1997, HYPERTENSION, V30, P934, DOI 10.1161/01.HYP.30.4.934; Broz P, 2005, J CONTROL RELEASE, V102, P475, DOI 10.1016/j.jconrel.2004.10.014; Centis V, 2011, BIOCHEM ENG J, V55, P162, DOI 10.1016/j.bej.2011.04.001; Chang TMS, 2010, WIRES NANOMED NANOBI, V2, P418, DOI 10.1002/wnan.95; Chang TMS, 2003, ARTIF CELL BLOOD SUB, V31, P231, DOI 10.1081/BIO-120023155; Chen DF, 2007, BIOMED MATER, V2, pS126, DOI 10.1088/1748-6041/2/3/S08; Cohn SM, 1997, ANN MED, V29, P371, DOI 10.3109/07853899708999364; Dairou J, 2004, J BIOL CHEM, V279, P7708, DOI 10.1074/jbc.M311469200; Dhont J. K. G., 1996, INTRO DYNAMICS COLLO, P147; Droege W., 2006, DISEASE AND CANCER, P885; Exner M, 2000, CHEM RES TOXICOL, V13, P287, DOI 10.1021/tx990201k; Faivre B, 1998, ARTIF CELL BLOOD SUB, V26, P17, DOI 10.3109/10731199809118943; Gaoshan Shen, 2008, 2008 2nd International Conference on Bioinformatics and Biomedical Engineering (ICBBE '08), P1476; Graff A, 2002, P NATL ACAD SCI USA, V99, P5064, DOI 10.1073/pnas.062654499; Graff A, 2010, MACROMOL CHEM PHYS, V211, P229, DOI 10.1002/macp.200900517; Grzelakowski M, 2009, SMALL, V5, P2545, DOI 10.1002/smll.200900603; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; Hunt JA, 1997, CHEM BIOL, V4, P845, DOI 10.1016/S1074-5521(97)90117-4; Kumar M, 2007, P NATL ACAD SCI USA, V104, P20719, DOI 10.1073/pnas.0708762104; Li DJ, 2004, ACTA BIOCH BIOPH SIN, V36, P87, DOI 10.1093/abbs/36.2.87; Li JF, 2003, NEUROSCI LETT, V350, P173, DOI 10.1016/S0304-3940(03)00881-4; Li SL, 2005, BIOMATERIALS, V26, P3759, DOI 10.1016/j.biomaterials.2004.09.015; Matsui M, 2006, IEICE T ELECTRON, VE89C, P1741, DOI 10.1093/ietele/e89-c.12.1741; McCool BA, 2004, J NON-CRYST SOLIDS, V333, P143, DOI 10.1016/j.jnoncrysol.2003.09.061; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mihm MJ, 2002, BIOCHIMIE, V84, P1013, DOI 10.1016/S0300-9084(02)00005-6; Nagatomo S, 2011, J AM CHEM SOC, V133, P10101, DOI 10.1021/ja111370f; Nardin C, 2000, CHEM COMMUN, P1433, DOI 10.1039/b004280n; Nardin C, 2000, LANGMUIR, V16, P1035, DOI 10.1021/la990951u; Nauser T, 2002, J PHYS CHEM A, V106, P4084, DOI 10.1021/jp025518z; Onaca O, 2010, MACROMOL BIOSCI, V10, P531, DOI 10.1002/mabi.200900379; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Phillips WT, 1999, J PHARMACOL EXP THER, V288, P665; Prilipov A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1016/S0378-1097(98)00151-7; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Rameez S, 2008, BIOCONJUGATE CHEM, V19, P1025, DOI 10.1021/bc700465v; Rameez S, 2012, BIOTECHNOL PROGR, V28, P636, DOI 10.1002/btpr.1532; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Rigler P, 2006, J AM CHEM SOC, V128, P367, DOI 10.1021/ja056719u; Romero N, 2003, J BIOL CHEM, V278, P44049, DOI 10.1074/jbc.M305895200; Romero N, 2006, IUBMB LIFE, V58, P572, DOI 10.1080/15216540600936549; Sakai H, 2000, BIOCONJUGATE CHEM, V11, P425, DOI 10.1021/bc990173h; Sakai H, 2008, J BIOL CHEM, V283, P1508, DOI 10.1074/jbc.M707660200; Sanders KE, 2002, BLOOD, V100, P299, DOI 10.1182/blood.V100.1.299; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; SPIRO TG, 1972, P NATL ACAD SCI USA, V69, P2622, DOI 10.1073/pnas.69.9.2622; SPIRO TG, 1975, P ROY SOC LOND A MAT, V345, P89, DOI 10.1098/rspa.1975.0127; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Sun J, 2009, LANGMUIR, V25, P13726, DOI 10.1021/la901194k; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; Tanner P, 2011, FEBS LETT, V585, P1699, DOI 10.1016/j.febslet.2011.05.003; Tanner P, 2011, CHEM-EUR J, V17, P4552, DOI 10.1002/chem.201002782; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; Torres IP, 2008, J APPL PHYSIOL, V104, P1809, DOI 10.1152/japplphysiol.00025.2008; Tsuruga M, 1998, J BIOL CHEM, V273, P8607, DOI 10.1074/jbc.273.15.8607; Uppu RM, 1996, ANAL BIOCHEM, V236, P242, DOI 10.1006/abio.1996.0162; van Dongen SFM, 2009, CHEM-EUR J, V15, P1107, DOI 10.1002/chem.200802114; Wohland T, 2001, BIOPHYS J, V80, P2987, DOI 10.1016/S0006-3495(01)76264-9; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Xu HX, 1999, PHYS REV LETT, V83, P4357, DOI 10.1103/PhysRevLett.83.4357; YAMAMOTO T, 1973, J BIOL CHEM, V248, P5211; Zhang XL, 2008, J BIOMED MATER RES B, V87B, P354, DOI 10.1002/jbm.b.31110; Zhao J, 2007, BIOMATERIALS, V28, P1414, DOI 10.1016/j.biomaterials.2006.10.012	74	44	44	0	49	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0743-7463			LANGMUIR	Langmuir	NOV 13	2012	28	45					15889	15899		10.1021/la302724m			11	Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Materials Science	038RH	WOS:000311191300016	23083075				2022-02-06	
J	Honeybul, S; Ho, KM				Honeybul, Stephen; Ho, Kwok M.			How "Successful" Is Calvarial Reconstruction Using Frozen Autologous Bone?	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							NEUROSURGICAL SITE INFECTIONS; TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; HYDROXYAPATITE CEMENT; SURGICAL DECOMPRESSION; TITANIUM CRANIOPLASTY; CRANIAL DEFECTS; RISK-FACTORS; COMPLICATIONS; CRANIOTOMY	Background: The authors investigated the long-term outcome of frozen autologous bone cranioplasty in patients who had undergone decompressive craniectomy for severe traumatic brain injury. Methods: A retrospective analysis was undertaken of all patients who had undergone decompressive craniectomy at the two major trauma hospitals in Western Australia between 2004 and 2010. A specific note was made regarding "failure" of frozen autologous bone because of either infection or bone flap resorption. Results: A total of 194 patients required either unilateral or bilateral decompressive craniectomy for severe traumatic brain injury during the study period. Of these patients, 156 had had an autologous cranioplasty. Among these patients, the cranioplasty was judged a failure in 45 (29 percent). Thirteen (8.5 percent; 95 percent confidence interval, 5.0 to 14.0 percent) developed an infection requiring removal of the cranioplasty. Thirty-two (21 percent; 95 percent confidence interval, 15 to 28 percent) developed clinical symptoms or signs relating to resorption of the cranioplasty. Fourteen (9 percent) required secondary titanium cranioplasty, two were offered surgical augmentation but declined, and 16 (10 percent) developed significant bone resorption through both the inner and outer tables of the skull. Conclusions: This study has demonstrated that the use of frozen autologous bone is associated with a high long-term failure rate; however, this does not necessarily imply that alternative materials should be routinely used. Although a number are available, their efficacy over and above frozen autologous bone remains to be established and perhaps this will only be demonstrated in the setting of a formal clinical trial. (Plast. Reconstr. Surg. 130: 1110, 2012.)	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; Royal Perth Hosp, Dept Intens Care, Perth, WA, Australia; Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Adamo MA, 2008, J NEUROSURG, V108, P174, DOI 10.3171/JNS/2008/108/01/0174; Arnaud E, 2000, CHILD NERV SYST, V16, P659, DOI 10.1007/s003810000321; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bhaskar IP, 2011, J CLIN NEUROSCI, V18, P1690, DOI 10.1016/j.jocn.2011.02.046; Blum KS, 1997, PEDIATR NEUROSURG, V26, P33, DOI 10.1159/000121158; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Costantino PD, 2000, OTOLARYNG HEAD NECK, V123, P409, DOI 10.1067/mhn.2000.107679; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; FOSTER R.D., 2000, SCHMIDEK SWEET OPERA, P29; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hieu L C, 2002, Technol Health Care, V10, P413; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2009, J CLIN NEUROSCI, V16, P727, DOI 10.1016/j.jocn.2008.06.015; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Joffe J, 1999, BRIT J NEUROSURG, V13, P576, DOI 10.1080/02688699943088; JOFFE JM, 1992, BRIT J NEUROSURG, V6, P343, DOI 10.3109/02688699209023793; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Korinek AM, 2005, BRIT J NEUROSURG, V19, P155, DOI 10.1080/02688690500145639; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Lu LC, 2001, J BONE JOINT SURG AM, V83A, pS82; MAAS CS, 1990, ARCH OTOLARYNGOL, V116, P551; Marchac D, 2008, J PLAST RECONSTR AES, V61, P744, DOI 10.1016/j.bjps.2007.10.055; Matic D, 2002, PLAST RECONSTR SURG, V110, P1, DOI 10.1097/00006534-200207000-00001; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Neovius E, 2010, J PLAST RECONSTR AES, V63, P1615, DOI 10.1016/j.bjps.2009.06.003; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Phemister D.B., 1914, SURG GYNECOL OBSTET, V19, P303; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PROLO D.J, 1996, NEUROSURGERY, V2nd, P2783; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Saringer W, 2002, ACTA NEUROCHIR, V144, P1193, DOI 10.1007/s00701-002-0995-5; Schaffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006-0589; Scolozzi P, 2007, J CRANIOFAC SURG, V18, P224, DOI 10.1097/01.scs.0000249359.56417.7e; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Sultan SM, 2011, PLAST RECONSTR SURG, V127, P1855, DOI 10.1097/PRS.0b013e31820e89a5; Thesleff T, 2011, NEUROSURGERY, V68, P1535, DOI 10.1227/NEU.0b013e31820ee24e; Verheggen R, 2001, ACTA NEUROCHIR, V143, P919, DOI 10.1007/s007010170022; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Wong RK, 2011, J CRANIOFAC SURG, V22, P247, DOI 10.1097/SCS.0b013e3181f7b7db; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	57	44	46	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	NOV	2012	130	5					1110	1117		10.1097/PRS.0b013e318267d4de			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	030LL	WOS:000310572100059	23096611				2022-02-06	
J	Gross, T; Schuepp, M; Attenberger, C; Pargger, H; Amsler, F				Gross, T.; Schueepp, M.; Attenberger, C.; Pargger, H.; Amsler, F.			Outcome in polytraumatized patients with and without brain injury	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							QUALITY-OF-LIFE; SF-36 HEALTH SURVEY; MULTIPLE TRAUMA; BASIC ISSUES; HEAD-INJURY; RECOMMENDATIONS; SCALE; SCORE; CARE; PREDICTORS	Background To investigate the long-term outcome in polytrauma victims with traumatic brain injury (TBI) and without traumatic brain injury (NTBI). Methods Cohort study based on prospectively collected data. Evaluation of functional outcome and quality of life at least 2 years (median 2.5) following trauma in 111 survivors [39.5?+/-?20.9 years; injury severity score (ISS) 27.9?+/-?8.2; TBI: n?=?45; NTBI: n?=?66] out of a total of 211 consecutive multiply-injured patients with an ISS >?16, all primarily admitted to the intensive care unit. Results Significantly fewer TBI patients lived independently compared with NTBI patients (71% vs. 95%; P?<?0.001). TBI patients showed a higher decrease in their capacity to work compared with NTBI patients (P?<?0.002). Both study groups experienced a significantly reduced long-term outcome in comparison with pre-injury level in all dimensions of the short form (SF)-36. Following stepwise logistic regression, the mental sum component of the SF-36 and the Nottingham Health Profile discriminated independently between TBI and NTBI patients (R 2?=?0.219; P?<?0.001). Conclusion More than 2 years after injury, polytraumatized patients with and without TBI suffer from a reduction in functional outcome and quality of life, but TBI patients are doing importantly worse. Any comparison of trauma patient cohorts should consider these differences between TBI and NTBI patients. Given their discriminatory potential, the sensitivity of self-reported measures needs further affirmation with neuropsychological assessments.	[Gross, T.] Kantonsspital, Dept Surg, Trauma Unit, CH-5001 Aarau, Switzerland; [Gross, T.; Schueepp, M.; Attenberger, C.; Amsler, F.] Univ Basel Hosp, Comp Assisted Radiol & Surg Switzerland CARCAS, Basel, Switzerland; [Schueepp, M.; Pargger, H.] Univ Basel Hosp, Dept Anesthesia & Intens Care Med, CH-4031 Basel, Switzerland; [Attenberger, C.] Klinikum Augsburg, Augsburg, Germany; [Amsler, F.] Http Www Amslerconsulting Ch, Basel, Switzerland		Gross, T (corresponding author), Kantonsspital, Dept Surg, Trauma Unit, Tellstr, CH-5001 Aarau, Switzerland.	thomas.gross@ksa.ch		Amsler, Felix/0000-0003-4259-7004	Scientific Foundation of the Swiss Accident Insurance Fund (SUVA); Voluntary Academic Society (FAG) Basel, Swiss Intervention; Swiss National Information Center for Accident Prevention (BFU)	This investigation was financially supported by the Scientific Foundation of the Swiss Accident Insurance Fund (SUVA), the Voluntary Academic Society (FAG) Basel, Swiss Intervention, and the Swiss National Information Center for Accident Prevention (BFU). There are no conflicts of interest, especially not with the organizations involved.	Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Attenberger C, 2012, INJURY, V43, P1566, DOI 10.1016/j.injury.2011.01.002; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; Bouillon B, 1998, LANGENBECK ARCH SURG, V383, P228, DOI 10.1007/s004230050123; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brasel KJ, 2010, J TRAUMA, V68, P263, DOI 10.1097/TA.0b013e3181caa58f; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; Butcher N, 2009, INJURY, V40, pS12, DOI 10.1016/j.injury.2009.10.032; Committee on Trauma American College of Surgeons, 1997, ADV TRAUM LIF SUPP P; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Dimopoulou I, 2004, AM J PHYS MED REHAB, V83, P171, DOI 10.1097/01.PHM.0000107497.77487.C1; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Fuglistaler-Montali I, 2009, WORLD J SURG, V33, P2477, DOI 10.1007/s00268-009-0193-1; Gennarelli T, 1990, ABBREVIATED INJURY S; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Grote S, 2011, J NEUROTRAUM, V28, P527, DOI 10.1089/neu.2010.1433; Harris I, 2008, J TRAUMA, V64, P696; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JENNETT B, 1975, LANCET, V1, P480; Klein M, 2009, J TRAUMA, V67, P890; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lehmann U, 1999, EUR J SURG, V165, P1116, DOI 10.1080/110241599750007603; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Livingston DH, 2009, J TRAUMA, V67, P341, DOI 10.1097/TA.0b013e3181a5cc34; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MacKenzie EJ, 2006, J TRAUMA, V61, P688, DOI 10.1097/01.ta.0000195985.56153.68; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Moore L, 2006, J TRAUMA, V61, P718, DOI 10.1097/01.ta.0000197906.28846.87; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P87; Neugebauer E, 2006, EUR J TRAUMA, V32, P44, DOI 10.1007/s00068-006-0150-8; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Orwelius L, 2011, INTENS CARE MED, V37, P831, DOI 10.1007/s00134-011-2137-0; Redmill DA, 2006, INJURY, V37, P243, DOI 10.1016/j.injury.2005.11.014; Ringdal M, 2009, J TRAUMA, V66, P1226, DOI 10.1097/TA.0b013e318181b8e3; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Soberg HL, 2007, J TRAUMA, V62, P471, DOI 10.1097/TA.0b013e31802e95f4; Sumann Gunther, 2002, Curr Opin Crit Care, V8, P587, DOI 10.1097/00075198-200212000-00017; Szende A, 2004, MEASURING SELF REPOR; TEASDALE G, 1974, LANCET, V2, P81; THIAGARAJAN J, 1994, ANAESTHESIA, V49, P211; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Van Beeck EF, 2007, J TRAUMA, V62, P534, DOI 10.1097/TA.0b013e31802e70c7; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilde EA, 2010, J NEUROTRAUM, V27, P975, DOI 10.1089/neu.2009.1193	56	44	44	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2012	56	9					1163	1174		10.1111/j.1399-6576.2012.02724.x			12	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	003TW	WOS:000308635200013	22735047				2022-02-06	
J	Patel, MB; McKenna, JW; Alvarez, JM; Sugiura, A; Jenkins, JM; Guillamondegui, OD; Pandharipande, PP				Patel, Mayur B.; McKenna, John W.; Alvarez, JoAnn M.; Sugiura, Ayaka; Jenkins, Judith M.; Guillamondegui, Oscar D.; Pandharipande, Pratik P.			Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial	TRIALS			English	Article						Traumatic brain injury; Sympathetic hyperactivity; Sympathetic storm; Autonomic dysfunction; Adrenergic blockade; Beta-blocker; Alpha(2)-agonist; Propranolol; Clonidine; Agitation	BETA-BLOCKER EXPOSURE; COMMON DATA ELEMENTS; CEREBRAL PERFUSION; TARGETED THERAPY; HEAD-INJURY; CATECHOLAMINES; DEXMEDETOMIDINE; RECOMMENDATIONS; PRINCIPLES; AGITATION	Background: Severe TBI, defined as a Glasgow Coma Scale <= 8, increases intracranial pressure and activates the sympathetic nervous system. Sympathetic hyperactivity after TBI manifests as catecholamine excess, hypertension, abnormal heart rate variability, and agitation, and is associated with poor neuropsychological outcome. Propranolol and clonidine are centrally acting drugs that may decrease sympathetic outflow, brain edema, and agitation. However, there is no prospective randomized evidence available demonstrating the feasibility, outcome benefits, and safety for adrenergic blockade after TBI. Methods/Design: The DASH after TBI study is an actively accruing, single-center, randomized, double-blinded, placebo-controlled, two-arm trial, where one group receives centrally acting sympatholytic drugs, propranolol (1 mg intravenously every 6 h for 7 days) and clonidine (0.1 mg per tube every 12 h for 7 days), and the other group, double placebo, within 48 h of severe TBI. The study uses a weighted adaptive minimization randomization with categories of age and Marshall head CT classification. Feasibility will be assessed by ability to provide a neuroradiology read for randomization, by treatment contamination, and by treatment compliance. The primary endpoint is reduction in plasma norepinephrine level as measured on day 8. Secondary endpoints include comprehensive plasma and urine catecholamine levels, heart rate variability, arrhythmia occurrence, infections, agitation measures using the Richmond Agitation-Sedation Scale and Agitated Behavior scale, medication use (antihypertensive, sedative, analgesic, and antipsychotic), coma-free days, ventilator-free days, length of stay, and mortality. Neuropsychological outcomes will be measured at hospital discharge and at 3 and 12 months. The domains tested will include global executive function, memory, processing speed, visual-spatial, and behavior. Other assessments include the Extended Glasgow Outcome Scale and Quality of Life after Brain Injury scale. Safety parameters evaluated will include cardiac complications. Discussion: The DASH After TBI Study is the first randomized, double-blinded, placebo-controlled trial powered to determine feasibility and investigate safety and outcomes associated with adrenergic blockade in patients with severe TBI. If the study results in positive trends, this could provide pilot evidence for a larger multicenter randomized clinical trial. If there is no effect of therapy, this trial would still provide a robust prospective description of sympathetic hyperactivity after TBI.	[Patel, Mayur B.; Pandharipande, Pratik P.] Nashville VA Med Ctr, Vet Affairs VA Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; [Patel, Mayur B.; McKenna, John W.; Sugiura, Ayaka; Jenkins, Judith M.; Guillamondegui, Oscar D.] Vanderbilt Univ, Med Ctr, Div Trauma & Surg Crit Care, Dept Surg, Nashville, TN 37212 USA; [Alvarez, JoAnn M.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Pandharipande, Pratik P.] Vanderbilt Univ, Med Ctr, Div Crit Care, Dept Anesthesia, Nashville, TN 37212 USA		Patel, MB (corresponding author), Nashville VA Med Ctr, Vet Affairs VA Tennessee Valley Healthcare Syst, 1310 24th Ave S, Nashville, TN 37212 USA.	mayur.b.patel@Vanderbilt.edu	Patel, Mayur/K-2363-2013	Sugiura, Ayaka/0000-0001-5326-5019; Pandharipande, Pratik/0000-0002-1389-8580	Vanderbilt Institute for Clinical and Translational Research via National Center for Advancing Translational Sciences [UL1TR000445]; AHRQ Health Services [5T32HS013833-08]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32HS013833] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000445] Funding Source: NIH RePORTER	The DASH After TBI Study is an investigator-initiated trial supported by Vanderbilt Institute for Clinical and Translational Research award to MBP via CTSA award number UL1TR000445 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. This CTSA grant also supports the Vanderbilt REDCap infrastructure, the Clinical Research Center used in this trial for catecholamine endpoints, and provides biostatistical support. AHRQ Health Services 5T32HS013833-08 and the Division of Trauma also supported MBP.	Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P917; Chan AKM, 2010, EXPERT OPIN PHARMACO, V11, P2849, DOI 10.1517/14656566.2010.511613; Choi Y, 2006, COGN BEHAV NEUROL, V19, P204, DOI 10.1097/01.wnn.0000213919.95266.0d; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Dizdarevic K, 2012, CLIN NEUROL NEUROSUR, V114, P142, DOI 10.1016/j.clineuro.2011.10.005; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; GREENDYKE RM, 1986, J NERV MENT DIS, V174, P290, DOI 10.1097/00005053-198605000-00005; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HE HB, 1992, J CHROMATOGR-BIOMED, V574, P213, DOI 10.1016/0378-4347(92)80032-L; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Hinson HE, 2012, CURR OPIN CRIT CARE, V18, P139, DOI 10.1097/MCC.0b013e3283513290; HOFFMAN WE, 1991, ANESTH ANALG, V73, P460; Horner J, 2012, RAPACHE WEB APPL DEV; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kroes MCW, 2010, J NEUROSCI, V30, P3959, DOI 10.1523/JNEUROSCI.5469-09.2010; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Mowery NT, 2008, J TRAUMA, V65, P621, DOI 10.1097/TA.0b013e3181837980; Nordstrom CH, 2005, NEUROCRIT CARE, V2, P83, DOI 10.1385/NCC:2:1:083; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; Nott MT, 2010, BRAIN INJURY, V24, P1214, DOI 10.3109/02699052.2010.506858; Oei NYL, 2010, NEUROBIOL LEARN MEM, V93, P388, DOI 10.1016/j.nlm.2009.12.005; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; PAYEN D, 1990, CRIT CARE MED, V18, P392, DOI 10.1097/00003246-199004000-00008; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; R Development Core Team, 2011, R LANG ENV STAT COMP; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Schneider JS, 2010, BEHAV BRAIN RES, V211, P236, DOI 10.1016/j.bbr.2010.03.040; Schulz KF, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-18; Tran TY, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E8; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1988, AM J PHYSIOL, V254, pE287, DOI 10.1152/ajpendo.1988.254.3.E287; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899	51	44	45	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-6215			TRIALS	Trials	SEP 26	2012	13								177	10.1186/1745-6215-13-177			9	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	053HQ	WOS:000312262500001	23013802	Green Published, gold			2022-02-06	
J	Mayer, AR; Yang, Z; Yeo, RA; Pena, A; Ling, JM; Mannell, MV; Stippler, M; Mojtahed, K				Mayer, Andrew R.; Yang, Zhen; Yeo, Ronald A.; Pena, Amanda; Ling, Josef M.; Mannell, Maggie V.; Stippler, Martina; Mojtahed, Kasra			A functional MRI study of multimodal selective attention following mild traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Attention; fMRI; Multimodal	ANTERIOR CINGULATE CORTEX; TASK-INDUCED DEACTIVATION; CROSS-MODAL DISTRACTION; EVENT-RELATED FMRI; WORKING-MEMORY; COGNITIVE CONTROL; RESTING-STATE; DEFAULT-MODE; NEURAL MECHANISMS; CONCUSSION	Previous work suggests that the ability to selectively attend to and resolve conflicting information may be the most enduring cognitive deficit following mild traumatic brain injury (mTBI). The current study used fMRI to evaluate potential differences in hemodynamic activation in 22 mTBI patients and 22 carefully matched healthy controls (HC) during a multimodal selective attention task (numeric Stroop). Behavioral data indicated faster reaction times for congruent versus incongruent trials and for stimuli presented at 0.66 compared to 0.33 Hz across both groups, with minimal differences in behavioral performance across the groups. Similarly, there were no group-wise differences in functional activation within lateral and medial prefrontal cortex during the execution of cognitive control (incongruent versus congruent trials). In contrast, within-group comparisons indicated robust patterns of attention-related modulations (ARM) within the bilateral dorsolateral prefrontal cortex and bilateral visual streams for HC but not mTBI patients. In addition, mTBI patients failed to exhibit task-induced deactivation within the default-mode network (DMN) under conditions of higher attentional load. In summary, in spite of near normal behavioral performance, current results suggest within-group abnormalities during both the top-down allocation of visual attention and in regulating the DMN during the semi-acute stage of mTBI.	[Mayer, Andrew R.; Yang, Zhen; Yeo, Ronald A.; Pena, Amanda; Ling, Josef M.; Mannell, Maggie V.; Mojtahed, Kasra] Lovelace Biomed & Environm Res, Mind Res Network, Albuquerque, NM 87106 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Neurol, Sch Med, Albuquerque, NM 87131 USA; [Mayer, Andrew R.; Yeo, Ronald A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Stippler, Martina] Univ New Mexico, Neurosurg Dept, Sch Med, Albuquerque, NM 87131 USA		Mayer, AR (corresponding author), Lovelace Biomed & Environm Res, Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE,MSC, Albuquerque, NM 87106 USA.	amayer@mrn.org	He, Robert/L-9441-2013; He, Hongbo/H-1815-2013		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24-HD050836, R21-NS064464-01A1, 3 R21 NS064464-01 S1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health [R24-HD050836, R21-NS064464-01A1 and 3 R21 NS064464-01 S1 to A.M.].	Baier B, 2006, J NEUROSCI, V26, P12260, DOI 10.1523/JNEUROSCI.1457-06.2006; Banich MT, 2000, COGNITIVE BRAIN RES, V10, P1, DOI 10.1016/S0926-6410(00)00015-X; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder JR, 1999, J COGNITIVE NEUROSCI, V11, P80, DOI 10.1162/089892999563265; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Degerman A, 2007, NEUROIMAGE, V34, P1683, DOI 10.1016/j.neuroimage.2006.11.019; Dhamala M, 2007, NEUROIMAGE, V34, P764, DOI 10.1016/j.neuroimage.2006.07.044; Eichele T, 2008, P NATL ACAD SCI USA, V105, P6173, DOI 10.1073/pnas.0708965105; Eimer M, 2002, J COGNITIVE NEUROSCI, V14, P254, DOI 10.1162/089892902317236885; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Giza CC, 2001, J ATHL TRAINING, V36, P228; Greicius MD, 2004, J COGNITIVE NEUROSCI, V16, P1484, DOI 10.1162/0898929042568532; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hester R, 2004, CEREB CORTEX, V14, P986, DOI 10.1093/cercor/bhh059; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hutchison M, 2011, AM J SPORT MED, V39, P2331, DOI 10.1177/0363546511413375; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson JA, 2005, CEREB CORTEX, V15, P1609, DOI 10.1093/cercor/bhi039; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Liu TS, 2003, CEREB CORTEX, V13, P1334, DOI 10.1093/cercor/bhg080; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mannell MV, 2010, HUM BRAIN MAPP, V31, P424, DOI 10.1002/hbm.20876; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2009, CEREB CORTEX, V19, P993, DOI 10.1093/cercor/bhn148; Mayer A. R., 2011, HUMAN BRAIN MAPPING; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Roberts KL, 2008, J COGNITIVE NEUROSCI, V20, P1063, DOI 10.1162/jocn.2008.20074; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shulman GL, 1997, CEREB CORTEX, V7, P193, DOI 10.1093/cercor/7.3.193; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Spence C, 2004, COGN AFFECT BEHAV NE, V4, P148, DOI 10.3758/CABN.4.2.148; Talairach J., 1988, COPLANAR STERIOTAXIC; Talsma D, 2006, INT J PSYCHOPHYSIOL, V62, P249, DOI 10.1016/j.ijpsycho.2006.04.006; van Veen V, 2001, NEUROIMAGE, V14, P1302, DOI 10.1006/nimg.2001.0923; Weissman DH, 2004, J NEUROSCI, V24, P10941, DOI 10.1523/JNEUROSCI.3669-04.2004; Woodruff PWR, 1996, NEUROREPORT, V7, P1909, DOI 10.1097/00001756-199608120-00007; Yang Z., 2012, J NEUROTRAUMA	67	44	44	0	29	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557			BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		343	354		10.1007/s11682-012-9178-z			12	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	967LI	WOS:000305908900013	22673802				2022-02-06	
J	Patel, SP; Sullivan, PG; Lyttle, TS; Magnuson, DSK; Rabchevsky, AG				Patel, S. P.; Sullivan, P. G.; Lyttle, T. S.; Magnuson, D. S. K.; Rabchevsky, A. G.			ACETYL-L-CARNITINE TREATMENT FOLLOWING SPINAL CORD INJURY IMPROVES MITOCHONDRIAL FUNCTION CORRELATED WITH REMARKABLE TISSUE SPARING AND FUNCTIONAL RECOVERY	NEUROSCIENCE			English	Article						mitochondrial bioenergetics; L1/L2 SCI; locomotor function; locomotor neuronal circuitry; central pattern generator; neuroprotection	PYRUVATE-DEHYDROGENASE COMPLEX; CENTRAL PATTERN GENERATOR; TRAUMATIC BRAIN-INJURY; LIPID-PEROXIDATION; L-ACETYLCARNITINE; OXIDATIVE STRESS; NEONATAL-RAT; PROPRIOSPINAL NEURONS; HINDLIMB LOCOMOTION; ALZHEIMERS-DISEASE	We have recently documented that treatment with the alternative biofuel, acetyl-L-carnitine (ALC, 300 mg/kg), as late as 1 h after T10 contusion spinal cord injury (SCI), significantly maintained mitochondrial function 24 h after injury. Here we report that after more severe contusion SCI centered on the L1/L2 segments that are postulated to contain lamina X neurons critical for locomotion (the "central pattern generator"), ALC treatment resulted in significant improvements in acute mitochondrial bioenergetics and long-term hind limb function. Although control-injured rats were only able to achieve slight movements of hind limb joints, ALC-treated animals produced consistent weight-supported plantar steps 1 month after injury. Such landmark behavioral improvements were significantly correlated with increased tissue sparing of both gray and white matter proximal to the injury, as well as preservation of choline acetyltransferase (ChAT)-positive neurons in lamina X rostral to the injury site. These findings signify that functional improvements with ALC treatment are mediated, in part, by preserved locomotor circuitry rostral to upper lumbar contusion SCI. Based on beneficial effects of ALC on mitochondrial bioenergetics after injury, our collective evidence demonstrate that preventing mitochondrial dysfunction acutely "promotes" neuroprotection that may be associated with the milestone recovery of plantar, weight-supported stepping. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Patel, S. P.; Sullivan, P. G.; Lyttle, T. S.; Rabchevsky, A. G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Patel, S. P.; Lyttle, T. S.; Rabchevsky, A. G.] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; [Sullivan, P. G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Magnuson, D. S. K.] Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA; [Magnuson, D. S. K.] Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA		Rabchevsky, AG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B471,Biomed & Biolog Sci Res Bldg,741 S Limestone, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915; Magnuson, David/0000-0003-3816-3676	KSCHIRT [8-13]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS051220, R01NS069633]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069633, P30NS051220] Funding Source: NIH RePORTER	The authors are thankful for the expert technical assistance of Chris R. O'Dell and Khalid C. Eldhan. This study was supported by KSCHIRT #8-13 (A. G. R.), NIH/NINDS R01NS069633 (A. G. R. and P. G. S.), NIH/NINDS P30 NS051220, and a generous donation from the Michael and Helen Schaffer Foundation, Boston, MA, USA.	AKDEMIR H, 1993, RES EXP MED, V193, P297, DOI 10.1007/BF02576237; Arafa HMM, 2009, BASIC CLIN PHARMACOL, V105, P30, DOI 10.1111/j.1742-7843.2009.00399.x; Aureli T, 2000, NEUROCHEM RES, V25, P395, DOI 10.1023/A:1007501306623; Aureli T, 1999, EUR J BIOCHEM, V263, P287, DOI 10.1046/j.1432-1327.1999.00524.x; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; Bertrand S, 2002, EUR J NEUROSCI, V16, P1741, DOI 10.1046/j.1460-9568.2002.02233.x; Blass J P, 1978, Adv Neurol, V21, P181; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BONAVITA E, 1986, INT J CLIN PHARM TH, V24, P511; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.1984.03340250025015; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; Bracken MB, 2001, SPINE, V26, pS47, DOI 10.1097/00007632-200112151-00010; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; CAZALETS JR, 1995, J NEUROSCI, V15, P4943; Cazalets JR, 1996, J NEUROSCI, V16, P298; Chikawa T, 2001, J NEUROTRAUM, V18, P93, DOI 10.1089/089771501750055802; Cowley KC, 1997, J NEUROPHYSIOL, V77, P247, DOI 10.1152/jn.1997.77.1.247; DEMEIRLEIR L, 1993, PEDIATR NEUROL, V9, P216, DOI 10.1016/0887-8994(93)90088-T; Dhitavat S, 2002, NEUROCHEM RES, V27, P501, DOI 10.1023/A:1019800703683; Diaz-Ruiz A, 2000, NEUROREPORT, V11, P1765, DOI 10.1097/00001756-200006050-00033; El-Awady EE, 2011, EUR J PHARMACOL, V650, P335, DOI 10.1016/j.ejphar.2010.09.085; Elanchezhian R, 2009, MOL VIS, V15, P1485; FARRELL S, 1986, BIOCHIM BIOPHYS ACTA, V876, P175, DOI 10.1016/0005-2760(86)90332-2; Finkel E, 2001, SCIENCE, V292, P624, DOI 10.1126/science.292.5517.624; Hadi B, 2000, J NEUROSURG, V93, P266, DOI 10.3171/spi.2000.93.2.0266; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hao J., 2011, BR J NUTR, V22, P1; Hota KB, 2012, HIPPOCAMPUS, V22, P723, DOI 10.1002/hipo.20934; Hou SP, 2008, J COMP NEUROL, V509, P382, DOI 10.1002/cne.21771; Hunot S, 2001, SCIENCE, V292, P865, DOI 10.1126/science.1060885; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kido Y, 2001, J NEUROCHEM, V79, P959, DOI 10.1046/j.1471-4159.2001.00621.x; Kjaerulff O, 1996, J NEUROSCI, V16, P5777; Koc RK, 1999, SPINAL CORD, V37, P29, DOI 10.1038/sj.sc.3100732; Kremer E, 1997, J NEUROPHYSIOL, V77, P1155, DOI 10.1152/jn.1997.77.3.1155; KSIEZAKREDING H, 1984, MECH AGEING DEV, V26, P67, DOI 10.1016/0047-6374(84)90165-9; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; LOWITT S, 1995, METABOLISM, V44, P677, DOI 10.1016/0026-0495(95)90128-0; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Magnuson DSK, 2005, J NEUROTRAUM, V22, P529, DOI 10.1089/neu.2005.22.529; Magnuson DSK, 1998, ANN NY ACAD SCI, V860, P436, DOI 10.1111/j.1749-6632.1998.tb09069.x; Mannelli LDC, 2007, EUR J NEUROSCI, V26, P820, DOI 10.1111/j.1460-9568.2007.05722.x; Mannelli LDC, 2009, J NEUROSCI RES, V87, P200, DOI 10.1002/jnr.21815; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; McEwen ML, 2011, NEUROTHERAPEUTICS, V8, P168, DOI 10.1007/s13311-011-0031-7; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Musicco C, 2011, J PROTEOMICS, V74, P2536, DOI 10.1016/j.jprot.2011.05.041; Ohashi R, 1999, J PHARMACOL EXP THER, V291, P778; ONOFRJ M, 1995, INT J CLIN PHARM RES, V15, P9; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; PARADIES G, 1992, BIOCHIM BIOPHYS ACTA, V1103, P324, DOI 10.1016/0005-2736(92)90103-S; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Pettegrew JW, 2000, MOL PSYCHIATR, V5, P616, DOI 10.1038/sj.mp.4000805; Pocernich CB, 2003, NEUROTOX RES, V5, P515, DOI 10.1007/BF03033161; Rabchevsky AG, 1999, J NEUROTRAUM, V16, P817, DOI 10.1089/neu.1999.16.817; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; Rabchevsky AG, 2011, PHARMACOL THERAPEUT, V132, P15, DOI 10.1016/j.pharmthera.2011.05.001; RAI G, 1990, CURR MED RES OPIN, V11, P638, DOI 10.1185/03007999009112690; Ravikumar R, 2007, J NEUROTRAUM, V24, P1618, DOI 10.1089/neu.2007.0329; Rebouche CJ, 2004, ANN NY ACAD SCI, V1033, P30, DOI 10.1196/annals.1320.003; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; ROSS IB, 1993, NEUROSURGERY, V33, P470; ROSS IB, 1993, SURG NEUROL, V40, P461, DOI 10.1016/0090-3019(93)90048-6; SANO M, 1992, ARCH NEUROL-CHICAGO, V49, P1137, DOI 10.1001/archneur.1992.00530350051019; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scafidi S, 2010, J NEUROCHEM, V114, P820, DOI 10.1111/j.1471-4159.2010.06807.x; SHEU KFR, 1985, ANN NEUROL, V17, P444; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; SORBI S, 1983, ANN NEUROL, V13, P72, DOI 10.1002/ana.410130116; SPAGNOLI A, 1991, NEUROLOGY, V41, P1726, DOI 10.1212/WNL.41.11.1726; Springer JE, 2010, J NEUROTRAUM, V27, P139, DOI 10.1089/neu.2009.0952; Steencken ACC, 2010, NEUROSCIENCE, V170, P971, DOI 10.1016/j.neuroscience.2010.06.064; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Swamy-Mruthinti S, 1999, EXP EYE RES, V69, P109, DOI 10.1006/exer.1999.0680; TEMPESTA E, 1987, DRUG EXP CLIN RES, V13, P417; Tufekci O, 2009, CHEMOTHERAPY, V55, P451, DOI 10.1159/000240020; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Virmani Ashraf, 2004, Molecular Aspects of Medicine, V25, P533, DOI 10.1016/j.mam.2004.06.003; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Xiong YQ, 2009, FREE RADICAL RES, V43, P604, DOI 10.1080/10715760902977432; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Yu WR, 2009, EUR J NEUROSCI, V29, P114, DOI 10.1111/j.1460-9568.2008.06555.x; Zaidan E, 1998, J NEUROCHEM, V70, P233	106	44	46	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 17	2012	210						296	307		10.1016/j.neuroscience.2012.03.006			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	951ON	WOS:000304730000029	22445934	Green Accepted			2022-02-06	
J	Driver, S; Ede, A; Dodd, Z; Stevens, L; Warren, AM				Driver, Simon; Ede, Alison; Dodd, Zane; Stevens, Laurel; Warren, Anne Marie			What barriers to physical activity do individuals with a recent brain injury face?	DISABILITY AND HEALTH JOURNAL			English	Article						Rehabilitation; Physical activity; Health; Barriers; Intention	PEOPLE; EXERCISE; HEALTH; DISABILITIES; EXPERIENCE; AQUATICS; OUTCOMES; FITNESS; ACCESS; ADULTS	Background and Objective: Traumatic brain injury (TBI) is a serious public health issue that challenges professionals to develop effective health promotion strategies to meet individual's diverse and unique needs. One effective health promotion strategy is physical activity (PA), although barriers to activity frequently prevent participation. Thus, there is a need to identify the barriers to participation, amount of weekly PA completed, and readiness to be active if effective health promotion programs are to be implemented. Methods: A convenience sample of 28 outpatients with a TBI completed a questionnaire before discharge from a comprehensive outpatient program and descriptive statistics were reported. In addition independent t tests and effect sizes were calculated between amount of PA and stage of change. Results: Our results indicated that participants only faced an average of 2.25 barriers (range 0-9), completed a mean of 46 minutes of PA each week, and reported being in the "action" stage of PA participation. Individuals in the action and maintenance stage completed significantly more PA (21.67; t [25] = -15.43; p < .001; Cohen's D effect size = 4.39) than precontemplators or contemplators. Conclusions: Individuals with a TBI face many different barriers that prevent them from being active, placing them at further risk of experiencing secondary and chronic conditions. Practitioners should acknowledge that each individual faces a unique set of barriers emphasizing the importance of individualized health promotion programs. (C) 2012 Elsevier Inc. All rights reserved.	[Driver, Simon] Oregon State Univ, Sch Biol & Populat Hlth, Corvallis, OR 97331 USA; [Ede, Alison] Michigan State Univ, E Lansing, MI 48824 USA; [Dodd, Zane] Univ N Texas, Denton, TX 76203 USA; [Stevens, Laurel] Baylor Inst Rehabil, Dallas, TX 75204 USA; [Warren, Anne Marie] Baylor Med Ctr, Dallas, TX 75246 USA		Driver, S (corresponding author), Oregon State Univ, Sch Biol & Populat Hlth, 206 Womens Bldg, Corvallis, OR 97331 USA.	simon.driver@oregonstate.edu		driver, simon/0000-0003-2356-432X; Warren, Ann Marie/0000-0002-3753-5573			[Anonymous], 1998, NIH Consens Statement, V16, P1; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; COHEN J, 1990, AM PSYCHOL, V45, P1304, DOI 10.1037/0003-066X.45.12.1304; COHEN J, 1994, AM PSYCHOL, V49, P997, DOI 10.1037/0003-066X.49.12.997; Cohen J., 1988, STAT ANAL BEHAV SCI; [Division of Nutrition and physical activity National Center for chronic disease Prevention and Health Promotion Centers for Disease Control and Prevention Public Health Service U. S. Department of Health and Human Services], 1999, PROM PHYS ACT GUID C; Driver S, 2006, BRAIN INJURY, V20, P133, DOI 10.1080/02699050500443822; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; Driver S, 2003, J COGNITIVE REHABILI, V21, P26; Dunton GF, 2007, PSYCHOL HEALTH, V22, P929, DOI 10.1080/14768320601124915; Gemmell C, 2006, BRAIN INJURY, V20, P151, DOI 10.1080/02699050500442998; Glenn M, 2005, APATHY EVALUATION SC; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Heath G W, 1997, Exerc Sport Sci Rev, V25, P195; Heller T., 2001, EXERCISE NUTR HLTH E; Jackson AW, 2007, RES Q EXERCISE SPORT, V78, P24; Kahn EB, 2002, AM J PREV MED, V22, P73, DOI 10.1016/S0749-3797(02)00434-8; Kirchner CE, 2008, AM J PREV MED, V34, P349, DOI 10.1016/j.amepre.2008.01.005; Kosma M, 2006, ADAPT PHYS ACT Q, V23, P49, DOI 10.1123/apaq.23.1.49; Lee YS, 2005, J WOMEN AGING, V17, P55, DOI 10.1300/J074v17n01_05; Lox CL., 2003, PSYCHOL EXERCISE INT; Malec J., 2005, MAYO PORTLAND ADAPTA; MARCUS BH, 1992, RES Q EXERCISE SPORT, V63, P60, DOI 10.1080/02701367.1992.10607557; National Data and Statistical Center, 2010 TBIMS NAT DAT U; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437; Rimmer JH, 2008, J REHABIL RES DEV, V45, P315, DOI 10.1682/JRRD.2007.02.0042; Rimmer JH, 2008, AM J LIFESTYLE MED, V2, P409, DOI 10.1177/1559827608317397; Rimmer JH, 2005, AM J PUBLIC HEALTH, V95, P2022, DOI 10.2105/AJPH.2004.051870; Rimmer JH, 2000, ARCH PHYS MED REHAB, V81, P182; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Sherer M, 2004, AWARENESS QUESTIONNA; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sorensen M, 2008, SCAND J MED SCI SPOR, V18, P651, DOI 10.1111/j.1600-0838.2007.00686.x; U.S. Department of Health and Human Services, 2005, 209911 NCJ US DEP JU, P1; *US DEP HHS, 2001, SURG GEN CALL ACT PR; US Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; Wolfson, 1993, HALSTEAD REITAN NEUR; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; [No title captured]	44	44	44	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1936-6574	1876-7583		DISABIL HEALTH J	Disabil. Health J.	APR	2012	5	2					117	125		10.1016/j.dhjo.2011.11.002			9	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation	913HT	WOS:000301868700007	22429546				2022-02-06	
J	Zhang, W; Huguenard, JR; Buckmaster, PS				Zhang, Wei; Huguenard, John R.; Buckmaster, Paul S.			Increased Excitatory Synaptic Input to Granule Cells from Hilar and CA3 Regions in a Rat Model of Temporal Lobe Epilepsy	JOURNAL OF NEUROSCIENCE			English	Article							PILOCARPINE-TREATED RATS; V PYRAMIDAL NEURONS; INJURED EPILEPTOGENIC NEOCORTEX; SEIZURE-INDUCED NEUROGENESIS; MOSSY FIBER REORGANIZATION; INDUCED STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; DENTATE GYRUS; FASCIA-DENTATA; HIPPOCAMPAL SLICES	One potential mechanism of temporal lobe epilepsy is recurrent excitation of dentate granule cells through aberrant sprouting of their axons (mossy fibers), which is found in many patients and animal models. However, correlations between the extent of mossy fiber sprouting and seizure frequency are weak. Additional potential sources of granule cell recurrent excitation that would not have been detected by markers of mossy fiber sprouting in previous studies include surviving mossy cells and proximal CA3 pyramidal cells. To test those possibilities in hippocampal slices from epileptic pilocarpine-treated rats, laser-scanning glutamate uncaging was used to randomly and focally activate neurons in the granule cell layer, hilus, and proximal CA3 pyramidal cell layer while measuring evoked EPSCs in normotopic granule cells. Consistent with mossy fiber sprouting, a higher proportion of glutamate-uncaging spots in the granule cell layer evoked EPSCs in epileptic rats compared with controls. In addition, stimulation spots in the hilus and proximal CA3 pyramidal cell layer were more likely to evoke EPSCs in epileptic rats, despite significant neuron loss in those regions. Furthermore, synaptic strength of recurrent excitatory inputs to granule cells from CA3 pyramidal cells and other granule cells was increased in epileptic rats. These findings reveal substantial levels of excessive, recurrent, excitatory synaptic input to granule cells from neurons in the hilus and proximal CA3 field. The aberrant development of these additional positive-feedback circuits might contribute to epileptogenesis in temporal lobe epilepsy.	[Zhang, Wei; Buckmaster, Paul S.] Stanford Univ, Dept Comparat Med, Stanford, CA 94305 USA; [Huguenard, John R.; Buckmaster, Paul S.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA		Buckmaster, PS (corresponding author), Stanford Univ, Dept Comparat Med, 300 Pasteur Dr,R321 Edwards Bldg, Stanford, CA 94305 USA.	psb@stanford.edu	Huguenard, John/K-6429-2019; Huguenard, John/I-5016-2012	Huguenard, John/0000-0002-6950-1191; Huguenard, John/0000-0002-6950-1191	National Institute of Neurological Disorders and Stroke-National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034774, R01NS040276, P50NS012151, P01NS012151] Funding Source: NIH RePORTER	This work was supported by National Institute of Neurological Disorders and Stroke-National Institutes of Health. We are grateful to Dr. David Prince for providing access to equipment.	Babb TL, 1996, EPILEPSY RES, V26, P193, DOI 10.1016/S0920-1211(96)00053-8; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Blumcke I, 2000, EPILEPSIA, V41, pS174, DOI 10.1111/j.1528-1157.2000.tb01577.x; Brill J, 2009, J NEUROSCI, V29, P7413, DOI 10.1523/JNEUROSCI.6098-08.2009; Buckmaster PS, 2011, J NEUROSCI, V31, P2337, DOI 10.1523/JNEUROSCI.4852-10.2011; Buckmaster PS, 2004, COMPARATIVE MED, V54, P473; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Buckmaster PS, 1996, J COMP NEUROL, V366, P271; Cameron MC, 2011, J COMP NEUROL, V519, P2175, DOI 10.1002/cne.22623; Cavazos JE, 2004, NEUROSCIENCE, V126, P677, DOI 10.1016/j.neuroscience.2004.04.014; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; Del Turco D, 2003, HIPPOCAMPUS, V13, P685, DOI 10.1002/hipo.10118; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Esclapez M, 1999, J COMP NEUROL, V408, P449, DOI 10.1002/(SICI)1096-9861(19990614)408:4<449::AID-CNE1>3.0.CO;2-R; Fino E, 2009, FRONT NEURAL CIRCUIT, V3, DOI 10.3389/neuro.04.002.2009; FRANCK JE, 1995, EPILEPSIA, V36, P543, DOI 10.1111/j.1528-1157.1995.tb02566.x; Gabriel S, 2004, J NEUROSCI, V24, P10416, DOI 10.1523/JNEUROSCI.2074-04.2004; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Gorter JA, 2001, EUR J NEUROSCI, V13, P657, DOI 10.1046/j.1460-9568.2001.01428.x; Harvey BD, 2005, J COMP NEUROL, V488, P442, DOI 10.1002/cne.20594; HOUSER CR, 1990, J NEUROSCI, V10, P267; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; Jiao YQ, 2007, EXP NEUROL, V205, P569, DOI 10.1016/j.expneurol.2007.03.025; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; Jung KH, 2004, EUR J NEUROSCI, V19, P3219, DOI 10.1111/j.0953-816X.2004.03412.x; Kadam SD, 2007, J COMP NEUROL, V505, P716, DOI 10.1002/cne.21533; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; KNEISLER TB, 1995, J PHYSIOL-LONDON, V487, P125, DOI 10.1113/jphysiol.1995.sp020866; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Kron MM, 2010, J NEUROSCI, V30, P2051, DOI 10.1523/JNEUROSCI.5655-09.2010; Kumar SS, 2007, J NEUROSCI, V27, P1239, DOI 10.1523/JNEUROSCI.3182-06.2007; Larimer P, 2008, J NEUROSCI, V28, P12212, DOI 10.1523/JNEUROSCI.3612-08.2008; Lehmann TN, 2001, EUR J NEUROSCI, V14, P83, DOI 10.1046/j.0953-816x.2001.01632.x; LEMOS T, 1995, EXP BRAIN RES, V102, P423; LI XG, 1994, J COMP NEUROL, V339, P181, DOI 10.1002/cne.903390204; Lynch M, 2000, J NEUROPHYSIOL, V83, P693, DOI 10.1152/jn.2000.83.2.693; Lynd-Balta E, 2004, NEUROSCIENCE, V126, P105, DOI 10.1016/j.neuroscience.2004.03.004; MASUKAWA LM, 1992, BRAIN RES, V579, P119, DOI 10.1016/0006-8993(92)90750-4; Mathern GW, 1998, J NEUROSCI RES, V54, P734, DOI 10.1002/(SICI)1097-4547(19981215)54:6<734::AID-JNR2>3.0.CO;2-P; Mathern GW, 1997, NEUROSCIENCE, V77, P1003, DOI 10.1016/S0306-4522(96)00516-7; MATHERN GW, 1993, ELECTROEN CLIN NEURO, V87, P326, DOI 10.1016/0013-4694(93)90186-Y; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; MODY I, 1987, NATURE, V326, P701, DOI 10.1038/326701a0; Molnar P, 1999, J NEUROPHYSIOL, V82, P1883, DOI 10.1152/jn.1999.82.4.1883; Morgan RJ, 2008, P NATL ACAD SCI USA, V105, P6179, DOI 10.1073/pnas.0801372105; NADLER JV, 1980, BRAIN RES, V182, P1; Namgung U, 1997, P NATL ACAD SCI USA, V94, P11675, DOI 10.1073/pnas.94.21.11675; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Parent JM, 2006, ANN NEUROL, V59, P81, DOI 10.1002/ana.20699; Parent JM, 1997, J NEUROSCI, V17, P3727; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418, DOI 10.1152/jn.1998.79.1.418; Perez Y, 1996, EUR J NEUROSCI, V8, P736, DOI 10.1111/j.1460-9568.1996.tb01259.x; Pierce JP, 2007, NEUROSCI LETT, V422, P136, DOI 10.1016/j.neulet.2007.06.016; Pierce JP, 2011, J COMP NEUROL, V519, P1196, DOI 10.1002/cne.22568; Pierce JP, 2005, EXP NEUROL, V196, P316, DOI 10.1016/j.expneurol.2005.08.007; Pitkanen A, 2005, EPILEPSY RES, V63, P27, DOI 10.1016/j.eplepsyres.2004.10.003; Pitkanen A, 2000, EPILEPSIA, V41, pS24, DOI 10.1111/j.1528-1157.2000.tb01552.x; Prang P, 2003, BRAIN RES, V978, P205, DOI 10.1016/S0006-8993(03)02836-1; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rao MS, 2006, J NEUROSCI RES, V83, P1088, DOI 10.1002/jnr.20802; Raol YSH, 2003, ANN NEUROL, V53, P503, DOI 10.1002/ana.10490; REPRESA A, 1993, HIPPOCAMPUS, V3, P257, DOI 10.1002/hipo.450030303; Salin P, 1995, J NEUROSCI, V15, P8234; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scharfman HE, 2003, J NEUROPHYSIOL, V90, P2536, DOI 10.1152/jn.00251.2003; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; SCHARFMAN HE, 1990, NEUROSCIENCE, V37, P693, DOI 10.1016/0306-4522(90)90100-I; SCHARFMAN HE, 1995, J NEUROPHYSIOL, V74, P179, DOI 10.1152/jn.1995.74.1.179; SCHARFMAN HE, 1994, J NEUROPHYSIOL, V72, P2167, DOI 10.1152/jn.1994.72.5.2167; Scharfman HE, 2007, PROG BRAIN RES, V163, P627, DOI 10.1016/S0079-6123(07)63034-9; Seress L, 2009, J NEUROSURG, V111, P1237, DOI 10.3171/2008.11.JNS08779; Shepherd GMG, 2003, NEURON, V38, P277, DOI 10.1016/S0896-6273(03)00152-1; Shetty AK, 2005, J NEUROSCI, V25, P8391, DOI 10.1523/JNEUROSCI.1538-05.2005; Siddiqui AH, 2005, BRAIN RES, V1066, P129, DOI 10.1016/j.brainres.2005.10.066; Sik A, 2006, J COMP NEUROL, V496, P229, DOI 10.1002/cne.20921; Simmons ML, 1997, J NEUROPHYSIOL, V78, P1860, DOI 10.1152/jn.1997.78.4.1860; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; Smith BN, 2002, J NEUROPHYSIOL, V87, P1655, DOI 10.1152/jn.00581.2001; Spencer SS, 1999, EPILEPSIA, V40, P708, DOI 10.1111/j.1528-1157.1999.tb00767.x; Spigelman I, 1998, NEUROSCIENCE, V86, P109, DOI 10.1016/S0306-4522(98)00028-1; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Thind KK, 2008, J COMP NEUROL, V509, P190, DOI 10.1002/cne.21745; Thind KK, 2010, J COMP NEUROL, V518, P647, DOI 10.1002/cne.22235; Timofeeva OA, 1999, EPILEPSY RES, V33, P99, DOI 10.1016/S0920-1211(98)00078-3; vonCampe G, 1997, HIPPOCAMPUS, V7, P472; Wenzel HJ, 2000, EPILEPSIA, V41, pS70, DOI 10.1111/j.1528-1157.2000.tb01560.x; Wenzel HJ, 2000, HIPPOCAMPUS, V10, P244, DOI 10.1002/1098-1063(2000)10:3<244::AID-HIPO5>3.0.CO;2-7; Williams PA, 2004, EPILEPSIA, V45, P1210, DOI 10.1111/j.0013-9580.2004.60403.x; Winokur RS, 2004, EPILEPSY RES, V58, P93, DOI 10.1016/j.eplepsyres.2004.01.002; Wong R K, 1986, Adv Neurol, V44, P583; Wuarin JP, 1996, J NEUROSCI, V16, P4438; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067, DOI 10.1152/jn.2001.85.3.1067; Zhan RZ, 2010, J NEUROPHYSIOL, V104, P3293, DOI 10.1152/jn.00663.2010; Zhang NH, 1999, J COMP NEUROL, V405, P472; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009; Zhang X, 2002, J NEUROSCI, V22, P6052	104	44	44	0	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 25	2012	32	4					1183	1196		10.1523/JNEUROSCI.5342-11.2012			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	885SM	WOS:000299801100005	22279204	Bronze, Green Accepted, Green Published			2022-02-06	
J	Saltzherr, TP; Bakker, FC; Beenen, LFM; Dijkgraaf, MGW; Reitsma, JB; Goslings, JC				Saltzherr, T. P.; Bakker, F. C.; Beenen, L. F. M.; Dijkgraaf, M. G. W.; Reitsma, J. B.; Goslings, J. C.		REACT Study Grp	Randomized clinical trial comparing the effect of computed tomography in the trauma room versus the radiology department on injury outcomes	BRITISH JOURNAL OF SURGERY			English	Article; Proceedings Paper	11th European Congress of Trauma and Emergency Surgery of the European-Society-for-Trauma-and-Emergency-Surgery (ESTES)	MAY 15-18, 2010	Brussels, BELGIUM	European Soc Trauma & Emergency Surg (ESTES)			INTRAHOSPITAL TRANSPORT; MANAGEMENT	Background: Computed tomography (CT) of injured patients in the radiology department requires potentially dangerous and time-consuming patient transports and transfers. It was hypothesized that CT in the trauma room would improve patient outcome and workflow. Methods: A randomized trial compared the effect of locating a CT scanner in the trauma room versus the radiology department in two Dutch trauma hospitals. Injured patients aged at least 16 years were assigned randomly to one of these hospitals at the time of transport. The primary outcome measure was the number of non-institutionalized days within the first year after randomization. Subgroup analyses were performed in patients with multiple trauma or severe traumatic brain injury (TBI). Results: Some 1124 patients were included, of whom 1045 were available for analysis. The median number of non-institutionalized days was 360 days in the intervention group versus 362 days for the control group (P = 0.068). The time from arrival to the first CT imaging was 13 min shorter in the intervention group (36 versus 49 min; P < 0.001). Patient transfers and transports were reduced by more than half in the intervention group. For both multiple trauma (265 patients) and TBI (121) subgroups, differences in mortality and out-of-hospital days favoured the intervention group, but were not statistically significant. Conclusion: A CT scanner located in the trauma room reduces the time to acquire CT images and improves workflow, but does not lead to substantial improvements in clinical outcomes in a general trauma population. Observed beneficial effects on outcomes in patients with multiple trauma or severe TBI were not statistically significant. Registration number: ISRCTN55332315 (http://www.controlled-trials.com).	[Saltzherr, T. P.; Goslings, J. C.] Vrije Univ Amsterdam Med Ctr, Acad Med Ctr, Dept Surg, Trauma Unit, NL-1005 AZ Amsterdam, Netherlands; [Beenen, L. F. M.] Vrije Univ Amsterdam Med Ctr, Acad Med Ctr, Dept Radiol, NL-1005 AZ Amsterdam, Netherlands; [Dijkgraaf, M. G. W.; Reitsma, J. B.] Vrije Univ Amsterdam Med Ctr, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, NL-1005 AZ Amsterdam, Netherlands; [Bakker, F. C.] Vrije Univ Amsterdam Med Ctr, Dept Traumatol, NL-1005 AZ Amsterdam, Netherlands		Goslings, JC (corresponding author), Vrije Univ Amsterdam Med Ctr, Acad Med Ctr, Dept Surg, Trauma Unit, Meibergdreef 9, NL-1005 AZ Amsterdam, Netherlands.	j.c.goslings@amc.nl	Beenen, Ludo F/AAA-3114-2021; Bossuyt, Patrick M./B-4557-2016; Dijkgraaf, Marcel GW/G-6663-2011	Beenen, Ludo F/0000-0001-9204-1026; Bossuyt, Patrick M./0000-0003-4427-0128; 			Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Committee on Trauma American College of Surgeons, 2009, ADV TRAUM LIF SUPP A; CONSORT, CONSORT 2010 STAT; Exadaktylos AK, 2001, J TRAUMA, V51, P1173, DOI 10.1097/00005373-200112000-00025; Gaarder C, 2009, J TRAUMA, V67, P323, DOI 10.1097/TA.0b013e3181a4ed27; Gross T, 2010, BRIT J SURG, V97, P118, DOI 10.1002/bjs.6842; Hilbert P, 2007, INJURY, V38, P552, DOI 10.1016/j.injury.2006.12.023; Hoeymans N, 2005, QUAL LIFE RES, V14, P655, DOI 10.1007/s11136-004-1214-z; Holmes JF, 2005, J TRAUMA, V58, P902, DOI 10.1097/01.TA.0000162138.36519.2A; Jin PHPFK, 2008, J TRAUMA, V64, P1320, DOI 10.1097/TA.0b013e318059b9ae; Koerner M, 2008, RADIOGRAPHICS, V28, P225, DOI 10.1148/rg.281075047; Lee KL, 2009, INJURY, V40, P873, DOI 10.1016/j.injury.2008.12.001; Papson JPN, 2007, ACAD EMERG MED, V14, P574, DOI 10.1197/j.aem.2007.02.034; Saltzherr TP, 2008, INJURY, V39, P809, DOI 10.1016/j.injury.2008.01.010; Saltzherr TP, 2008, BMC EMERG MED, V8, DOI 10.1186/1471-227X-8-10; Waydhas C, 1999, CRIT CARE, V3, pR83, DOI 10.1186/cc362; Weninger P, 2007, J TRAUMA, V62, P584, DOI 10.1097/01.ta.0000221797.46249.ee	18	44	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1323	1365-2168		BRIT J SURG	Br. J. Surg.	JAN	2012	99			1			105	113		10.1002/bjs.7705			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	930PG	WOS:000303151000017	22441863				2022-02-06	
J	Thompson, HJ; Dikmen, S; Temkin, N				Thompson, Hilaire J.; Dikmen, Sureyya; Temkin, Nancy			Prevalence of Comorbidity and its Association with Traumatic Brain Injury and Outcomes in Older Adults	RESEARCH IN GERONTOLOGICAL NURSING			English	Article							SEVERITY SCORE; EARLY HYPERGLYCEMIA; HEALTH-CARE; MORTALITY; AGE; INDEX; RISK; TBI	The study aims were to examine the association between age, comorbidity, and cause of injury in older adults with traumatic brain injury (TBI); and to determine which comorbidities relate to mortality, length of stay, and functional outcome at hospital discharge, controlling for initial injury severity, age, and sex. A retrospective cohort study design was used; clinical and outcome trauma registry data were obtained for 196 adults 55 and older with TBI. The majority had at least one comorbid condition (e.g., hypertension, alcohol abuse). In-hospital mortality was 31%. Among the oldest-old, motor vehicle collisions and falls were significantly associated with specific chronic diseases. Prior myocardial infarction was significantly associated with an increased risk of in-hospital death. Injury Severity Score and Glasgow Coma Scale score were predictive of discharge function, but comorbidity did not add significantly to the model. Primary TBI prevention efforts in older adults must consider the impact of comorbidity and cause of injury, particularly in the oldest-old. Alcohol abuse is common in older adults with TBI; screening should be conducted and interventions developed to prevent future injury. Future study is warranted to understand the interplay between pathophysiology of comorbid disease and injury and how to best manage rehabilitation within the context of aging.	[Thompson, Hilaire J.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Neurosurg, Seattle, WA 98195 USA; [Thompson, Hilaire J.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA		Thompson, HJ (corresponding author), Univ Washington, Sch Nursing, Box 357266, Seattle, WA 98195 USA.	hilairet@uw.edu			John A. Hartford Foundation [06-202]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [KL2RR025015]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR025015] Funding Source: NIH RePORTER	The authors disclose that they have no significant :financial interests in any product or class of products discussed directly or indirectly in this activity. This work was supported in part by the John A. Hartford Foundation (grant 06-202) and the National Institutes of Health (grant KL2RR025015) to Dr. Thompson. Dr. Thompson acknowledges the mentorship of Dr. Sarah H. Kagan during her Claire M. Fagin Fellowship at which time this work was completed.	Alban RF, 2010, AM SURGEON, V76, P1108; Andelic Nada, 2010, J Trauma Manag Outcomes, V4, P6, DOI 10.1186/1752-2897-4-6; [Anonymous], 2005, INJ PREV CONTR DAT S; [Anonymous], 2010, OLD AM 2010 KEY IND; Ashman TA, 2004, BRAIN INJURY, V18, P191, DOI 10.1080/0269905031000149506; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bergstrom MF, 2011, INJURY PREV, V17, P108, DOI 10.1136/ip.2010.028951; Bolorunduro OB, 2011, J SURG RES, V166, P40, DOI 10.1016/j.jss.2010.04.012; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; BULL JP, 1975, ACCIDENT ANAL PREV, V7, P249, DOI 10.1016/0001-4575(75)90026-3; Centers for Disease Control and Prevention, 2003, MORBIDITY MORTALITY, V52; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Donohue JT, 2007, J TRAUMA, V62, P419, DOI 10.1097/01.ta.0000219286.88179.18; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Faul M, 2010, TRAUMATIC BRAIN INJU; Gabbe BJ, 2005, ACAD EMERG MED, V12, P318, DOI 10.1197/j.aem.2004.12.002; Gale SC, 2007, AM SURGEON, V73, P454; Grimby A, 1997, AGING CLIN EXP RES, V9, P356, DOI 10.1007/BF03339614; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kennedy RL, 2002, J TRAUMA, V52, P660, DOI 10.1097/00005373-200204000-00008; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LeMier M, 2001, Inj Prev, V7, P334, DOI 10.1136/ip.7.4.334; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; McKenzie K, 2009, INJURY PREV, V15, P188, DOI 10.1136/ip.2008.020479; Meredith JW, 2002, J TRAUMA, V53, P621, DOI 10.1097/00005373-200210000-00001; Michael Y.L., 2010, PRIMARY CARE RELEVAN; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Norris SL, 2008, J AM GERIATR SOC, V56, P149, DOI 10.1111/j.1532-5415.2007.01530.x; Sperry JL, 2007, J TRAUMA, V63, P487, DOI 10.1097/TA.0b013e31812e51fc; Sperry JL, 2009, J TRAUMA, V66, P1076, DOI 10.1097/TA.0b013e31817db0de; STEVENS JA, 2008, PREVENTING FALLS WHA; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; TEASDALE G, 1974, LANCET, V2, P81; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2010, ANN SURG, V252, P370, DOI 10.1097/SLA.0b013e3181df03d6	42	44	45	0	8	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	1940-4921			RES GERONTOL NURS	Res. Gerontol. Nurs.	JAN	2012	5	1			SI		17	24		10.3928/19404921-20111206-02			8	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	879TE	WOS:000299354300004	22165997	Green Accepted			2022-02-06	
S	Uteshev, VV		Islam, MS		Uteshev, Victor V.			alpha 7 Nicotinic ACh Receptors as a Ligand-Gated Source of Ca2+ Ions: The Search for a Ca2+ Optimum	CALCIUM SIGNALING	Advances in Experimental Medicine and Biology		English	Article; Book Chapter						alpha 7 nAChR; NMDA; Ca2+; Permeability; Ion channel; Receptor; ACh; Choline; Nicotinic; Positive allosteric modulator; PNU-120596; Neuroprotection; Cognitive; Cognition; Dementia; Neurotoxicity; Synaptic; Extrasynaptic; Alzheimer; Schizophrenia; Trauma; Auditory; Gating	METHYL-D-ASPARTATE; BETA-AMYLOID PEPTIDE; ALPHA-7-NICOTINIC ACETYLCHOLINE-RECEPTOR; POSITIVE ALLOSTERIC MODULATION; CULTURED CORTICAL-NEURONS; SEVERE ALZHEIMERS-DISEASE; RAT HIPPOCAMPAL-NEURONS; LONG-TERM POTENTIATION; SINGLE-CHANNEL PROPERTIES; TRAUMATIC BRAIN-INJURY	The spatiotemporal distribution of cytosolic Ca2+ ions is a key determinant of neuronal behavior and survival. Distinct sources of Ca2+ ions including ligand-and voltage-gated Ca2+ channels contribute to intracellular Ca2+ homeostasis. Many normal physiological and therapeutic neuronal functions are Ca2+-dependent, however an excess of cytosolic Ca2+ or a lack of the appropriate balance between Ca2+ entry and clearance may destroy cellular integrity and cause cellular death. Therefore, the existence of optimal spatiotemporal patterns of cytosolic Ca2+ elevations and thus, optimal activation of ligand-and voltage-gated Ca2+ ion channels are postulated to benefit neuronal function and survival. Alpha7 nicotinic acetylcholine receptors (nAChRs) are highly permeable to Ca2+ ions and play an important role in modulation of neurotransmitter release, gene expression and neuroprotection in a variety of neuronal and non-neuronal cells. In this review, the focus is placed on a 7 nAChR-mediated currents and Ca2+ influx and how this source of Ca2+ entry compares to NMDA receptors in supporting cytosolic Ca2+ homeostasis, neuronal function and survival.	Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA		Uteshev, VV (corresponding author), Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	Victor.Uteshev@unthsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK082625] Funding Source: NIH RePORTER; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK082625] Funding Source: Medline		Aarsland D, 2009, LANCET NEUROL, V8, P613, DOI 10.1016/S1474-4422(09)70146-2; Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; AKAIKE A, 1994, BRAIN RES, V644, P181, DOI 10.1016/0006-8993(94)91678-0; Albuquerque EX, 2000, BEHAV BRAIN RES, V113, P131, DOI 10.1016/S0166-4328(00)00208-4; ALKONDON M, 1994, J PHARMACOL EXP THER, V271, P494; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; Alva Gustavo, 2008, Psychiatry (Edgmont), V5, P27; ARENDASH GW, 1995, BRAIN RES, V674, P252, DOI 10.1016/0006-8993(94)01449-R; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; Asomugha CO, 2010, J NEUROCHEM, V112, P214, DOI 10.1111/j.1471-4159.2009.06447.x; Asztely F, 1997, NEURON, V18, P281, DOI 10.1016/S0896-6273(00)80268-8; Atri A, 2008, ALZ DIS ASSOC DIS, V22, P209, DOI 10.1097/WAD.0b013e31816653bc; Banerjee C, 2000, NEUROBIOL DIS, V7, P666, DOI 10.1006/nbdi.2000.0317; Barron SC, 2009, MOL PHARMACOL, V76, P253, DOI 10.1124/mol.109.056226; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; Bertrand D, 2008, MOL PHARMACOL, V74, P1407, DOI 10.1124/mol.107.042820; Bertrand N, 1996, NEUROCHEM INT, V28, P293, DOI 10.1016/0197-0186(95)00086-0; Bezprozvanny I, 2008, TRENDS NEUROSCI, V31, P454, DOI 10.1016/j.tins.2008.06.005; Bitner RS, 2010, J PHARMACOL EXP THER, V334, P875, DOI 10.1124/jpet.110.167213; Bitner RS, 2007, J NEUROSCI, V27, P10578, DOI 10.1523/JNEUROSCI.2444-07.2007; Blair LAC, 1999, J NEUROSCI, V19, P1940; Boess FG, 2007, J PHARMACOL EXP THER, V321, P716, DOI 10.1124/jpet.106.118976; Bok J, 2007, MOL CELL NEUROSCI, V36, P13, DOI 10.1016/j.mcn.2007.05.008; Borgdorff AJ, 2002, NATURE, V417, P649, DOI 10.1038/nature00780; Brandt SK, 2011, NEUROSCIENCE, V172, P387, DOI 10.1016/j.neuroscience.2010.10.071; Briggs CA, 1997, PHARMACOL BIOCHEM BE, V57, P231, DOI 10.1016/S0091-3057(96)00354-1; Briggs CA, 2009, BRIT J PHARMACOL, V158, P1486, DOI 10.1111/j.1476-5381.2009.00426.x; Brown KL, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00166; Buccafusco JJ, 2007, BIOCHEM PHARMACOL, V74, P1202, DOI 10.1016/j.bcp.2007.07.010; Buccafusco JJ, 2005, TRENDS PHARMACOL SCI, V26, P352, DOI 10.1016/j.tips.2005.05.007; Buccafusco JJ, 2004, J ALZHEIMERS DIS, V6, pS85; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; Catassi A, 2008, MUTAT RES-REV MUTAT, V659, P221, DOI 10.1016/j.mrrev.2008.04.002; Catassi A, 2008, EUR J CANCER, V44, P2296, DOI 10.1016/j.ejca.2008.06.045; CHEN HSV, 1992, J NEUROSCI, V12, P4427; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Clifford PM, 2008, BRAIN RES, V1234, P158, DOI 10.1016/j.brainres.2008.07.092; COLLINS F, 1991, J NEUROSCI, V11, P2582; Conroy WG, 2003, NEURON, V38, P759, DOI 10.1016/S0896-6273(03)00324-6; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Creeley CE, 2008, NEUROBIOL AGING, V29, P153, DOI 10.1016/j.neurobiolaging.2006.10.020; D'Andrea MR, 2006, CURR PHARM DESIGN, V12, P677, DOI 10.2174/138161206775474224; Dajas-Bailador F, 2004, TRENDS PHARMACOL SCI, V25, P317, DOI 10.1016/j.tips.2004.04.006; Davare MA, 2003, P NATL ACAD SCI USA, V100, P16018, DOI 10.1073/pnas.2236970100; Davis R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007524; Dineley KT, 2007, FRONT BIOSCI-LANDMRK, V12, P5030, DOI 10.2741/2445; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Dineley KT, 2002, J BIOL CHEM, V277, P25056, DOI 10.1074/jbc.M200066200; Dinklo T, 2011, J PHARMACOL EXP THER, V336, P560, DOI 10.1124/jpet.110.173245; Disterhoft JF, 2007, AGING CELL, V6, P327, DOI 10.1111/j.1474-9726.2007.00297.x; Dunbar GC, 2011, J PSYCHOPHARMACOL, V25, P1020, DOI 10.1177/0269881110367727; Dziewczapolski G, 2009, J NEUROSCI, V29, P8805, DOI 10.1523/JNEUROSCI.6159-08.2009; Egea J, 2007, NEUROSCIENCE, V145, P866, DOI 10.1016/j.neuroscience.2006.12.036; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; Ehlers MD, 2007, NEURON, V54, P447, DOI 10.1016/j.neuron.2007.04.010; El-Hajj RA, 2007, LIFE SCI, V81, P1317, DOI 10.1016/j.lfs.2007.08.039; Ellis JR, 2006, INT J NEUROPSYCHOPH, V9, P175, DOI 10.1017/S1461145705005407; Faghih Ramin, 2007, Recent Pat CNS Drug Discov, V2, P99; Farlow MR, 2010, CLIN THER, V32, P1234, DOI 10.1016/j.clinthera.2010.06.019; Felix R, 1997, NEUROSCIENCE, V81, P1009, DOI 10.1016/S0306-4522(97)00224-8; Ferchmin PA, 2003, J PHARMACOL EXP THER, V305, P1071, DOI 10.1124/jpet.102.048173; Fernandes CC, 2010, J NEUROSCI, V30, P8841, DOI 10.1523/JNEUROSCI.6236-09.2010; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; Franklin JL, 1998, J CELL BIOL, V142, P1313, DOI 10.1083/jcb.142.5.1313; Frazier CJ, 1998, J NEUROSCI, V18, P8228; FREEDMAN R, 1995, BIOL PSYCHIAT, V38, P22, DOI 10.1016/0006-3223(94)00252-X; Freedman R, 2000, J CHEM NEUROANAT, V20, P299, DOI 10.1016/S0891-0618(00)00109-5; Freir DB, 2003, BRAIN RES, V967, P27, DOI 10.1016/S0006-8993(02)04190-2; Fu HJ, 2006, J NEUROCHEM, V98, P1400, DOI 10.1111/j.1471-4159.2006.03960.x; Fucile S, 2004, NEUROSCIENCE, V127, P53, DOI 10.1016/j.neuroscience.2004.04.017; Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006; Fucile S, 2003, CELL CALCIUM, V34, P205, DOI 10.1016/S0143-4160(03)00071-X; Fucile S, 2002, P NATL ACAD SCI USA, V99, P3956, DOI 10.1073/pnas.052699599; Fujii S, 2000, NEUROSCI LETT, V286, P134, DOI 10.1016/S0304-3940(00)01076-4; Furey ML, 1997, P NATL ACAD SCI USA, V94, P6512, DOI 10.1073/pnas.94.12.6512; Gilbert D, 2009, CELL CALCIUM, V45, P198, DOI 10.1016/j.ceca.2008.10.003; Green A, 2005, PHARMACOL BIOCHEM BE, V81, P575, DOI 10.1016/j.pbb.2005.04.010; Groc L, 2009, NEUROSCIENCE, V158, P4, DOI 10.1016/j.neuroscience.2008.05.029; Groc L, 2006, P NATL ACAD SCI USA, V103, P18769, DOI 10.1073/pnas.0605238103; Gronlien JH, 2007, MOL PHARMACOL, V72, P715, DOI 10.1124/mol.107.035410; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Gusev AG, 2010, J PHARMACOL EXP THER, V332, P588, DOI 10.1124/jpet.109.162099; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Hao JW, 2011, EXP NEUROL, V227, P110, DOI 10.1016/j.expneurol.2010.09.020; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Harkany T, 2000, EUR J NEUROSCI, V12, P2735, DOI 10.1046/j.1460-9568.2000.00164.x; Hatton GI, 2002, J NEUROSCI, V22, P29, DOI 10.1523/JNEUROSCI.22-01-00029.2002; Hefft S, 1999, J PHYSIOL-LONDON, V515, P769, DOI 10.1111/j.1469-7793.1999.769ab.x; Herman MA, 2007, J NEUROSCI, V27, P9736, DOI 10.1523/JNEUROSCI.3009-07.2007; Hernandez CM, 2010, J NEUROSCI, V30, P2442, DOI 10.1523/JNEUROSCI.5038-09.2010; Hogg RC, 2003, REV PHYSIOL BIOCH P, V147, P1, DOI 10.1007/s10254-003-0005-1; Hu M, 2007, BRAIN RES, V1151, P227, DOI 10.1016/j.brainres.2007.03.051; Hu M, 2009, BRIT J PHARMACOL, V158, P1857, DOI 10.1111/j.1476-5381.2009.00474.x; Hurst RS, 2005, J NEUROSCI, V25, P4396, DOI 10.1523/JNEUROSCI.5269-04.2005; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; JAHR CE, 1993, P NATL ACAD SCI USA, V90, P11573, DOI 10.1073/pnas.90.24.11573; Jenden DJ, 1996, LIFE SCI, V58, P2003, DOI 10.1016/0024-3205(96)00191-9; Jonnala RR, 2001, J NEUROSCI RES, V66, P565, DOI 10.1002/jnr.10022; De Rosa MJ, 2009, LIFE SCI, V85, P444, DOI 10.1016/j.lfs.2009.07.010; Kaczorowski CC, 2009, LEARN MEMORY, V16, P362, DOI 10.1101/lm.1365609; Kalappa BI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013964; Kaneko S, 1997, BRAIN RES, V765, P135, DOI 10.1016/S0006-8993(97)00556-8; Kawashima K, 2003, LIFE SCI, V74, P675, DOI 10.1016/j.lfs.2003.09.037; Kem WR, 2000, BEHAV BRAIN RES, V113, P169, DOI 10.1016/S0166-4328(00)00211-4; Khiroug SS, 2002, J PHYSIOL-LONDON, V540, P425, DOI 10.1113/jphysiol.2001.013847; Kihara T, 1997, ANN NEUROL, V42, P159, DOI 10.1002/ana.410420205; Kirrane RM, 2001, SCHIZOPHR RES, V48, P1, DOI 10.1016/S0920-9964(00)00059-1; Kitagawa H, 2003, NEUROPSYCHOPHARMACOL, V28, P542, DOI 10.1038/sj.npp.1300028; Klein J, 1998, NEUROCHEM INT, V32, P479, DOI 10.1016/S0197-0186(97)00127-7; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; Koller G, 2003, NEUROPSYCHOBIOLOGY, V48, P87, DOI 10.1159/000072883; Kotermanski SE, 2009, J NEUROSCI, V29, P2774, DOI 10.1523/JNEUROSCI.3703-08.2009; Koval L, 2011, INT J BIOCHEM CELL B, V43, P516, DOI 10.1016/j.biocel.2010.12.003; Kullmann DM, 2000, PROG BRAIN RES, V125, P339; Leiser SC, 2009, PHARMACOL THERAPEUT, V122, P302, DOI 10.1016/j.pharmthera.2009.03.009; Leonard S, 2000, EUR J PHARMACOL, V393, P237, DOI 10.1016/S0014-2999(00)00035-2; LeonS FE, 1997, J CLIN NEUROPHYSIOL, V14, P144, DOI 10.1097/00004691-199703000-00007; Leroi I, 2009, MOVEMENT DISORD, V24, P1217, DOI 10.1002/mds.22495; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; LESTER RAJ, 1992, J NEUROSCI, V12, P635; Levin ED, 2002, J NEUROBIOL, V53, P633, DOI 10.1002/neu.10151; Levin O S, 2009, Neurosci Behav Physiol, V39, P597, DOI 10.1007/s11055-009-9167-x; Li YX, 2002, J NEUROCHEM, V81, P853, DOI 10.1046/j.1471-4159.2002.00891.x; Li YX, 1999, BRAIN RES, V830, P218, DOI 10.1016/S0006-8993(99)01372-4; Lipton SA, 2007, NAT REV NEUROSCI, V8, P803, DOI 10.1038/nrn2229; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; LONDON ED, 1989, NEUROCHEM RES, V14, P745, DOI 10.1007/BF00964952; Lopez JR, 2008, J NEUROCHEM, V105, P262, DOI 10.1111/j.1471-4159.2007.05135.x; Lopez-Hernandez GY, 2009, NEUROPHARMACOLOGY, V56, P821, DOI 10.1016/j.neuropharm.2009.01.011; Loughead J, 2010, BIOL PSYCHIAT, V67, P715, DOI 10.1016/j.biopsych.2010.01.016; Lyford LK, 2002, BBA-BIOMEMBRANES, V1559, P69, DOI 10.1016/S0005-2736(01)00437-0; Lynch G, 2011, PHARMACOL BIOCHEM BE, V99, P116, DOI 10.1016/j.pbb.2010.12.024; Malysz J, 2009, J PHARMACOL EXP THER, V330, P257, DOI 10.1124/jpet.109.151886; Marini AM, 1998, J BIOL CHEM, V273, P29394, DOI 10.1074/jbc.273.45.29394; MARTIN EJ, 1994, DRUG DEVELOP RES, V31, P135, DOI 10.1002/ddr.430310208; Martin LF, 2007, INT REV NEUROBIOL, V78, P225, DOI 10.1016/S0074-7742(06)78008-4; Martin SE, 2004, BRAIN RES, V1022, P254, DOI 10.1016/j.brainres.2004.07.016; Mashkina AP, 2007, NEUROCHEM INT, V51, P356, DOI 10.1016/j.neuint.2007.04.009; Mashkina AP, 2010, CELL MOL NEUROBIOL, V30, P901, DOI 10.1007/s10571-010-9519-7; Maskell PD, 2003, BRIT J PHARMACOL, V140, P1313, DOI 10.1038/sj.bjp.0705559; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; Mennerick S, 2000, MOL NEUROBIOL, V22, P41; Meyer EM, 1997, BRAIN RES, V768, P49, DOI 10.1016/S0006-8993(97)00536-2; Meyer EM, 1998, J PHARMACOL EXP THER, V284, P1026; Meyer EM, 1998, BRAIN RES, V786, P252, DOI 10.1016/S0006-8993(97)00300-4; Mielke JG, 2009, NEUROSCI RES, V65, P296, DOI 10.1016/j.neures.2009.08.003; Mike A, 2000, BRAIN RES, V882, P155, DOI 10.1016/S0006-8993(00)02863-8; Nagele RG, 2002, NEUROSCIENCE, V110, P199, DOI 10.1016/S0306-4522(01)00460-2; Nakazawa H, 1999, J NEUROCHEM, V73, P1075, DOI 10.1046/j.1471-4159.1999.0731075.x; Nimmrich V, 2008, J NEUROSCI, V28, P788, DOI 10.1523/JNEUROSCI.4771-07.2008; Nizri E, 2006, NEUROPHARMACOLOGY, V50, P540, DOI 10.1016/j.neuropharm.2005.10.013; Nizri E, 2009, J IMMUNOL, V183, P6681, DOI 10.4049/jimmunol.0902212; Nordberg A, 2001, BIOL PSYCHIAT, V49, P200, DOI 10.1016/S0006-3223(00)01125-2; NORDBERG A, 1986, NEUROSCI LETT, V72, P115, DOI 10.1016/0304-3940(86)90629-4; North WG, 2010, BREAST CANCER RES TR, V122, P307, DOI 10.1007/s10549-009-0556-1; NUTTER TJ, 1995, J GEN PHYSIOL, V105, P701, DOI 10.1085/jgp.105.6.701; Ogita K, 2003, J NEUROCHEM, V85, P1336, DOI 10.1046/j.1471-4159.2003.01778.x; Oh MM, 2006, NEUROSCIENCE, V137, P113, DOI 10.1016/j.neuroscience.2005.08.063; Okubo Y, 2010, P NATL ACAD SCI USA, V107, P6526, DOI 10.1073/pnas.0913154107; Olincy A, 2006, ARCH GEN PSYCHIAT, V63, P630, DOI 10.1001/archpsyc.63.6.630; Paleari L, 2008, CELL PROLIFERAT, V41, P936, DOI 10.1111/j.1365-2184.2008.00566.x; Palma E, 1999, J BIOL CHEM, V274, P18335, DOI 10.1074/jbc.274.26.18335; Papadia S, 2007, NEUROSCIENTIST, V13, P572, DOI 10.1177/1073858407305833; Papke RL, 1996, NEUROSCI LETT, V213, P201; Papke RL, 2002, BRIT J PHARMACOL, V137, P49, DOI 10.1038/sj.bjp.0704833; Parikh V, 2006, J NEUROCHEM, V97, P488, DOI 10.1111/j.1471-4159.2006.03766.x; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; PATRICK J, 1993, PROG BRAIN RES, V98, P113; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; Pichat P, 2007, NEUROPSYCHOPHARMACOL, V32, P17, DOI 10.1038/sj.npp.1301188; Pierrot N, 2004, J NEUROCHEM, V88, P1140, DOI 10.1046/j.1471-4159.2003.02227.x; Plosker GL, 2005, PHARMACOECONOMICS, V23, P193, DOI 10.2165/00019053-200523020-00010; Pokorska A, 2003, J NEUROCHEM, V84, P447, DOI 10.1046/j.1471-4159.2003.01504.x; Qi XL, 2007, NEUROCHEM INT, V51, P377, DOI 10.1016/j.neuint.2007.04.002; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Ren K, 2007, NEUROSCIENCE, V148, P230, DOI 10.1016/j.neuroscience.2007.05.013; Ren K, 2007, NEUROSCIENCE, V145, P314, DOI 10.1016/j.neuroscience.2006.11.023; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; Roncarati R, 2008, ASSAY DRUG DEV TECHN, V6, P181, DOI 10.1089/adt.2007.120; Rosa AO, 2006, J MOL NEUROSCI, V30, P61, DOI 10.1385/JMN:30:1:61; Ross RG, 2010, J CHILD PSYCHOL PSYC, V51, P535, DOI 10.1111/j.1469-7610.2009.02187.x; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rusakov DA, 2004, CEREB CORTEX, V14, P748, DOI 10.1093/cercor/bhh035; SANDS SB, 1993, BIOPHYS J, V65, P2614, DOI 10.1016/S0006-3495(93)81296-7; Sarkar SN, 2008, P NATL ACAD SCI USA, V105, P15148, DOI 10.1073/pnas.0802379105; Sarter M, 2005, NAT REV NEUROSCI, V6, P48, DOI 10.1038/nrn1588; Schneider LS, 2011, ARCH NEUROL-CHICAGO, V68, P58, DOI 10.1001/archneurol.2010.343; Schugens MM, 1997, NEUROSCI LETT, V224, P57, DOI 10.1016/S0304-3940(97)13452-8; Scragg JL, 2004, FASEB J, V18, P150, DOI 10.1096/fj.04-2659fje; SCREMIN OU, 1991, STROKE, V22, P643, DOI 10.1161/01.STR.22.5.643; SEGUELA P, 1993, J NEUROSCI, V13, P596; Shao ZY, 2000, J PHYSIOL-LONDON, V527, P507, DOI 10.1111/j.1469-7793.2000.00507.x; Sharma G, 2002, J NEUROBIOL, V53, P524, DOI 10.1002/neu.10114; Shimohama S, 1998, BRAIN RES, V779, P359, DOI 10.1016/S0006-8993(97)00194-7; SHIMOHAMA S, 1986, J NEUROCHEM, V46, P288, DOI 10.1111/j.1471-4159.1986.tb12960.x; Shimohama S, 2001, BIOL PSYCHIAT, V49, P233, DOI 10.1016/S0006-3223(00)01100-8; Skok MV, 2007, LIFE SCI, V80, P2334, DOI 10.1016/j.lfs.2007.02.005; Smith CC, 2006, J NEUROSCI, V26, P8517, DOI 10.1523/JNEUROSCI.5279-05.2006; Soderman A, 2008, BRAIN RES, V1227, P240, DOI 10.1016/j.brainres.2008.06.062; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Stevens KE, 1996, NEUROPSYCHOPHARMACOL, V15, P152, DOI 10.1016/0893-133X(95)00178-G; Sudweeks SN, 2000, J PHYSIOL-LONDON, V527, P515, DOI 10.1111/j.1469-7793.2000.00515.x; Swerdlow NR, 2009, NEUROPSYCHOPHARMACOL, V34, P1854, DOI 10.1038/npp.2009.7; Tachibana N, 2010, INTERNAL MED, V49, P2167, DOI 10.2169/internalmedicine.49.4069; Takeuchi H, 2009, J NEUROSCI RES, V87, P576, DOI 10.1002/jnr.21869; Tatsumi R, 2006, J MED CHEM, V49, P4374, DOI 10.1021/jm060249c; Thibault O, 1996, SCIENCE, V272, P1017, DOI 10.1126/science.272.5264.1017; Thibault O, 2001, J NEUROSCI, V21, P9744, DOI 10.1523/JNEUROSCI.21-24-09744.2001; Thomsen MS, 2010, CURR PHARM DESIGN, V16, P323, DOI 10.2174/138161210790170094; Timmermann DB, 2007, J PHARMACOL EXP THER, V323, P294, DOI 10.1124/jpet.107.120436; Tovar KR, 2002, NEURON, V34, P253; Traynelis SF, 2010, PHARMACOL REV, V62, P405, DOI 10.1124/pr.109.002451; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Ueda K, 1997, J NEUROCHEM, V68, P265; Uteshev VV, 2010, ACTA BIOCH BIOPH SIN, V42, P8, DOI 10.1093/abbs/gmp101; Uteshev VV, 1997, BIOPHYS J, V72, P1127, DOI 10.1016/S0006-3495(97)78761-7; Uteshev VV, 1996, PFLUG ARCH EUR J PHY, V432, P607, DOI 10.1007/s004240050176; Uteshev VV, 2005, NEUROSCIENCE, V134, P133, DOI 10.1016/j.neuroscience.2005.03.013; Uteshev VV, 1996, BIOPHYS J, V71, P1256, DOI 10.1016/S0006-3495(96)79325-6; Uteshev VV, 2003, J NEUROPHYSIOL, V89, P1797, DOI 10.1152/jn.00943.2002; Uteshev VV, 2002, BRAIN RES, V948, P33, DOI 10.1016/S0006-8993(02)02946-3; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; Valera E, 2008, NEUROCHEM INT, V53, P148, DOI 10.1016/j.neuint.2008.07.007; van Kampen M, 2004, PSYCHOPHARMACOLOGY, V172, P375, DOI 10.1007/s00213-003-1668-7; Verbois SL, 2003, NEUROPHARMACOLOGY, V44, P224, DOI 10.1016/S0028-3908(02)00366-0; Vercelletto M, 2011, J ALZHEIMERS DIS, V23, P749, DOI 10.3233/JAD-2010-101632; Virginio C, 2002, EUR J PHARMACOL, V445, P153, DOI 10.1016/S0014-2999(02)01750-8; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang HY, 2009, J NEUROSCI, V29, P10961, DOI 10.1523/JNEUROSCI.6088-08.2009; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang HY, 2003, J BIOL CHEM, V278, P31547, DOI 10.1074/jbc.M212532200; WEISS JH, 1994, J NEUROCHEM, V62, P372; Wishka DG, 2006, J MED CHEM, V49, P4425, DOI 10.1021/jm0602413; Woodruff-Pak DS, 2000, EXP AGING RES, V26, P323, DOI 10.1080/036107300750015723; Woodruff-Pak DS, 2003, BEHAV BRAIN RES, V143, P159, DOI 10.1016/S0166-4328(03)00039-1; WOODRUFFPAK DS, 1994, BRAIN RES, V645, P309, DOI 10.1016/0006-8993(94)91665-9; Yawata I, 2008, LIFE SCI, V82, P1111, DOI 10.1016/j.lfs.2008.03.010; Young GT, 2008, P NATL ACAD SCI USA, V105, P14686, DOI 10.1073/pnas.0804372105; Yu CR, 1998, J PHYSIOL-LONDON, V509, P651, DOI 10.1111/j.1469-7793.1998.651bm.x; Yu CR, 1998, J PHYSIOL-LONDON, V509, P667, DOI 10.1111/j.1469-7793.1998.667bm.x; Zhang ZW, 1996, NEURON, V17, P1231, DOI 10.1016/S0896-6273(00)80253-6; Zheng KY, 2008, BIOPHYS J, V95, P4584, DOI 10.1529/biophysj.108.129874	251	44	44	0	5	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0065-2598	2214-8019	978-94-007-2887-5; 978-94-007-2888-2	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2012	740						603	638		10.1007/978-94-007-2888-2_27	10.1007/978-94-007-2888-2		36	Medicine, Research & Experimental; Neurosciences	Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Neurosciences & Neurology	BA3EQ	WOS:000334165700028	22453962	Green Accepted			2022-02-06	
J	Chen, SH; Chen, Y; Fang, WK; Huang, DW; Huang, KC; Tseng, SH				Chen, Shih-Han; Chen, Yun; Fang, Wen-Kuei; Huang, Da-Wei; Huang, Kuo-Chang; Tseng, Sheng-Hong			Comparison of Craniotomy and Decompressive Craniectomy in Severely Head-Injured Patients With Acute Subdural Hematoma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Acute subdural hematoma; Complication; Craniotomy; Decompressive craniectomy; Outcome	TRAUMATIC BRAIN-INJURY; PROGNOSTIC-FACTORS; MANAGEMENT; MULTICENTER; LESIONS; COMA	Background: Decompressive craniectomy (DC) is helpful in lowering the intracranial pressure in patients with severe head injuries. However, it is still unclear which surgical approach (DC or craniotomy) is the optimal treatment strategy for severely head-injured patients with acute subdural hematoma (SDH). To clarify this point, we compared the outcomes and complications of the patients with acute SDH and low Glasgow Coma Scale (GCS) score treated with craniotomy or DC. Methods: We analyzed 102 patients with acute SDH and GCS scores of 4 to 8. Of them, 42 patients (41.2%) were treated with craniotomy and 60 (58.8%) treated with DC for evacuation of hematoma. The demographic and clinical data were analyzed including patient age, sex, injury mechanism, GCS score, pupil size and light reflex, time interval from injury to operation, types of surgical procedures, intracranial findings in pre- and postoperative computed tomography scan, intracranial pressure, complications, requirement of permanent cerebrospinal fluid diversion, and Glasgow Outcome Scale score after at least 1 year of follow-up. Results: The craniotomy and DC groups showed no difference in the demographic and clinical data. There was no difference in the outcomes and complication rates between these two groups except that the DC group had higher mortality than the craniotomy group (23.3% vs. 7.1%, p = 0.04). Conclusion: Both craniotomy and DC were feasible treatment strategies for acute SDH. The patients with acute SDH and low GCS score treated with craniotomy or DC showed no difference in the outcomes and complications.	[Tseng, Sheng-Hong] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Taipei, Taiwan; [Chen, Shih-Han; Fang, Wen-Kuei; Huang, Da-Wei; Huang, Kuo-Chang] Chiayi Christian Hosp, Dept Surg, Chiayi, Taiwan; [Chen, Yun] Far Eastern Mem Hosp, Dept Surg, Taipei, Taiwan; [Chen, Yun] Yuan Ze Univ, Dept Chem Engn & Mat Sci, Tao Yuan, Taiwan		Tseng, SH (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, 7 Chung Shan S Rd, Taipei 100, Taiwan.	tsh5110@ntu.edu.tw					Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock MR, 2006, NEUROSURGERY, V58, psi; Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Hutchinson P J, 2004, Curr Opin Crit Care, V10, P101, DOI 10.1097/00075198-200404000-00004; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Meier U, 2008, ACTA NEUROCHIR SUPPL, V102, P29, DOI 10.1007/978-3-211-85578-2_6; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Paci GM, 2009, J TRAUMA, V67, P531, DOI 10.1097/TA.0b013e3181b840e8; Potts MB, 2008, ACTA NEUROCHIR SUPPL, V102, P109, DOI 10.1007/978-3-211-85578-2_22; Salvatore C, 2008, J NEUROSURG, V108, P74, DOI 10.3171/JNS/2008/108/01/0074; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; TEASDALE G, 1974, LANCET, V2, P81; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Wong GKC, 2010, ACTA NEUROCHIR SUPPL, V106, P235, DOI 10.1007/978-3-211-98811-4_44	25	44	48	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2011	71	6					1632	1636		10.1097/TA.0b013e3182367b3c			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	869RT	WOS:000298616400034	22027888				2022-02-06	
J	Ma, YH; Liu, WB; Wang, Y; Chao, XD; Qu, Y; Wang, K; Fei, Z				Ma, Yihui; Liu, Wenbo; Wang, Yuan; Chao, Xiaodong; Qu, Yan; Wang, Kai; Fei, Zhou			VEGF protects rat cortical neurons from mechanical trauma injury induced apoptosis via the MEK/ERK pathway	BRAIN RESEARCH BULLETIN			English	Article						VEGF; Neuroprotection; ERK; Neuron; Traumatic brain injury	ENDOTHELIAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE; FOCAL CEREBRAL-ISCHEMIA; BRAIN-INJURY; IN-VITRO; HIPPOCAMPAL-NEURONS; FACTOR RECEPTOR; CELL-DEATH; INHIBITION; NEUROGENESIS	Traumatic brain injury (TBI) is a serious insult that frequently leads to neurological dysfunction or death. Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis and vascular permeability. Recently, VEGF has been identified as a neurotrophic factor and has been implicated in the pathogenic mechanisms of TBI. However, the possible mechanisms of VEGF in primary or secondary injuries after TBI are largely unknown. The present study attempted to determine whether VEGF has a protective effect on primary cortical neurons against mechanical trauma injury, which is an in vitro insult mimicking traumatic brain injury. We found that pretreatment of primary cortical neurons in culture with VEGF decreased neuronal death in a concentration-dependent manner, and VEGF counteracted the mechanical trauma mediated apoptotic death of cultured cortical neurons. VEGF up-regulates the activity of ERK (extracellular signal-regulated kinase) in cultured cortical neurons and U0126 (a mitogen activated protein kinase kinase (MEK) inhibitor) suppressed VEGF induced activity of ERK. Furthermore, incubation of cells with U0126 attenuated the ability of VEGF to protect neurons against mechanical trauma-induced apoptosis. Therefore, the present study supports the notion that MEK/ERK pathway is involved in VEGF mediated neuroprotection against mechanical trauma injury. (C) 2011 Elsevier Inc. All rights reserved.	[Ma, Yihui; Liu, Wenbo; Wang, Yuan; Chao, Xiaodong; Qu, Yan; Wang, Kai; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China		Fei, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China.	zhoufeifmmu@gmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930093, 81070951, 30700255]	The National Natural Science Foundation of China (No. 30930093, No. 81070951 and No. 30700255) supported this research.	Carey RG, 2002, J NEUROSCI, V22, P1583, DOI 10.1523/JNEUROSCI.22-05-01583.2002; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; Jiang Q, 2000, BRAIN RES, V857, P71, DOI 10.1016/S0006-8993(99)02364-1; Jin K, 2001, NEUROSCIENCE, V108, P351, DOI 10.1016/S0306-4522(01)00154-3; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Lee HT, 2010, J NEUROCHEM, V113, P79, DOI 10.1111/j.1471-4159.2010.06584.x; Lin JR, 2010, BRAIN RES BULL, V83, P284, DOI 10.1016/j.brainresbull.2010.08.002; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; LU KT, 2011, J NEUROTRAUMA; Lu YP, 2010, BRAIN RES, V1360, P40, DOI 10.1016/j.brainres.2010.09.016; Ma YH, 2011, J NEUROSCI RES, V89, P969, DOI 10.1002/jnr.22628; Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Park EM, 2004, NEUROSCIENCE, V123, P147, DOI 10.1016/j.neuroscience.2003.08.023; Park EM, 2006, NEUROSCI LETT, V402, P190, DOI 10.1016/j.neulet.2006.04.004; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Payette DJ, 2008, INT J CLIN EXP PATHO, V1, P44; Shiote M, 2005, NEUROSCIENCE, V132, P175, DOI 10.1016/j.neuroscience.2004.12.031; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Sundberg LM, 2011, J NEUROTRAUM, V28, P565, DOI 10.1089/neu.2010.1533; Svensson B, 2002, J CEREBR BLOOD F MET, V22, P1170, DOI 10.1097/01.wcb.0000037988.07114.98; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tolosa L, 2009, NEUROSCIENCE, V158, P1348, DOI 10.1016/j.neuroscience.2008.10.060; Tolosa L, 2008, J NEUROCHEM, V105, P1080, DOI 10.1111/j.1471-4159.2007.05206.x; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Xia Y, 2010, NEUROPHARMACOLOGY, V58, P330, DOI 10.1016/j.neuropharm.2009.10.009; Zheng XR, 2010, BRAIN RES BULL, V81, P372, DOI 10.1016/j.brainresbull.2009.11.012	38	44	47	2	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	NOV 25	2011	86	5-6					441	446		10.1016/j.brainresbull.2011.07.007			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	871AZ	WOS:000298711300022	21801813				2022-02-06	
J	Wallace, DM; Shafazand, S; Ramos, AR; Carvalho, DZ; Gardener, H; Lorenzo, D; Wohlgemuth, WK				Wallace, D. M.; Shafazand, S.; Ramos, A. R.; Carvalho, D. Z.; Gardener, H.; Lorenzo, D.; Wohlgemuth, W. K.			Insomnia characteristics and clinical correlates in Operation Enduring Freedom/Operation Iraqi Freedom veterans with post-traumatic stress disorder and mild traumatic brain injury: An exploratory study	SLEEP MEDICINE			English	Article						Veterans; Traumatic brain injury; Insomnia; Post-traumatic stress disorder; Actigraphy; Sleep disturbances	SHORT-SLEEP DURATION; COMBAT-RELATED PTSD; MINOR HEAD-INJURY; QUALITY-OF-LIFE; DISTURBANCE; ACTIGRAPHY; SYMPTOMS; MILITARY; VALIDITY; CONSEQUENCES	Background: There is limited data on chronic insomnia in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans, in whom post-traumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) often co-exist. Our aim was to compare sleep characteristics of three groups of OEF/OIF veterans: (1) healthy sleepers (HS), (2) those with insomnia associated with PTSD and mTBI (PTSD-mTBI), and (3) those with insomnia associated with PTSD alone. Methods: Consecutive veterans with insomnia complaints (>6 months) were recruited over 6 months from the Miami VA Post Deployment clinic. Participants completed a sleep disorders clinical interview, medical history, and questionnaires about insomnia, sleepiness, pain, fatigue, depression, PTSD, and health-related quality of life. They underwent polysomnography (PSG) with 2 weeks of actigraphy (ACT) and sleep diaries. Results: There were no differences in demographics or most questionnaire responses between PTSD and PTSD-mTBI groups. Subjective daytime sleepiness was significantly greater in PTSD-mTBI subjects compared with HS and PTSD participants. Significant co-morbid sleep disorders were noted in insomnia patients. PSG and ACT wake after sleep onset was significantly shorter in PTSD-mTBI subjects as compared with PTSD participants. Conclusion: Insomnia patients with PTSD-mTBI were subjectively sleepier despite spending less time awake during the night than PTSD subjects, possibly as a consequence of head trauma. Published by Elsevier B.V.	[Wallace, D. M.; Ramos, A. R.; Lorenzo, D.; Wohlgemuth, W. K.] Vet Affairs Med Ctr, Bruce W Carter Dept, Dept Neurol, Miami, FL 33125 USA; [Wallace, D. M.; Gardener, H.; Lorenzo, D.; Wohlgemuth, W. K.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Shafazand, S.] Univ Miami, Dept Med, Div Pulm Crit Care & Sleep Med, Miami, FL USA; [Carvalho, D. Z.] Univ Fed Rio Grande do Sul, Neurol Serv, Hosp Clin Porto Alegre, Sch Med, Porto Alegre, RS, Brazil		Wallace, DM (corresponding author), Vet Affairs Med Ctr, Bruce W Carter Dept, Dept Neurol, 1201 NW 16th St, Miami, FL 33125 USA.	dwallace@med.miami.edu	Ramos, Alberto/X-4249-2019; Wallace, Douglas/AAL-3719-2020	Wallace, Douglas/0000-0002-8982-1088; Carvalho, Diego/0000-0002-8822-1638; Ramos, Alberto/0000-0002-9861-6609			American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Breslau N, 2004, ARCH GEN PSYCHIAT, V61, P508, DOI 10.1001/archpsyc.61.5.508; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Ledesma RD, 2009, TUTOR QUANT METHODS, V5, P25, DOI 10.20982/tqmp.05.1.p025; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iber C., 2007, AASM MANUAL SCORING, P7; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; Katz DA, 2002, J FAM PRACTICE, V51, P229; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kaynak H, 2006, EUR J NEUROL, V13, P1333, DOI 10.1111/j.1468-1331.2006.01499.x; Keane T.M., 1991, PCL M DSM 4; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kobayashi I, 2007, PSYCHOPHYSIOLOGY, V44, P660, DOI 10.1111/j.1469-8986.2007.537.x; Krakow B, 2004, J TRAUMA STRESS, V17, P257, DOI 10.1023/B:JOTS.0000029269.29098.67; Lam SP, 2008, J CLIN PSYCHIAT, V69, P1374, DOI 10.4088/JCP.v69n0904; Leger D, 2001, PSYCHOSOM MED, V63, P49, DOI 10.1097/00006842-200101000-00006; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lichstein KL, 2006, SLEEP, V29, P232; Littner M, 2003, SLEEP, V26, P337, DOI 10.1093/sleep/26.3.337; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Meissel K., 2010, ACSPRI SOC SCI METH; MELLMAN TA, 1995, BIOL PSYCHIAT, V38, P174, DOI 10.1016/0006-3223(94)00238-X; Mellman TA, 2002, AM J PSYCHIAT, V159, P1696, DOI 10.1176/appi.ajp.159.10.1696; Mellman TA, 1997, SLEEP, V20, P46, DOI 10.1093/sleep/20.1.46; Sanchez-Ortuno MM, 2010, J CLIN SLEEP MED, V6, P21; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Romano J., 2006, ANN M FLOR ASS I RES, P1, DOI DOI 10.1017/CBO9781107415324.004; ROSS RJ, 1994, SLEEP, V17, P723, DOI 10.1093/sleep/17.8.723; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Storch EA, 2004, DEPRESS ANXIETY, V19, P187, DOI 10.1002/da.20002; Thase ME, 2005, GEN HOSP PSYCHIAT, V27, P100, DOI 10.1016/j.genhosppsych.2004.09.006; Ulmer CS, 2011, J CLIN SLEEP MED, V7, P57; Vallieres A, 2003, SLEEP, V26, P902, DOI 10.1093/sleep/26.7.902; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vgontzas AN, 2010, SLEEP, V33, P1159, DOI 10.1093/sleep/33.9.1159; Vgontzas AN, 2009, DIABETES CARE, V32, P1980, DOI 10.2337/dc09-0284; Vgontzas AN, 2009, SLEEP, V32, P491, DOI 10.1093/sleep/32.4.491; Westermeyer J, 2007, J ANXIETY DISORD, V21, P966, DOI 10.1016/j.janxdis.2006.11.009; Wilson S, 2005, DRUGS, V65, P927, DOI 10.2165/00003495-200565070-00003; Wohlgemuth WK, 1999, PSYCHOPHYSIOLOGY, V36, P233, DOI 10.1017/S0048577299971214; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	55	44	44	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	OCT	2011	12	9					850	859		10.1016/j.sleep.2011.06.004			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	858FG	WOS:000297780700008	21925943	Green Submitted			2022-02-06	
J	Logi, F; Pasqualetti, P; Tomaiuolo, F				Logi, Fiammetta; Pasqualetti, Patrizio; Tomaiuolo, Francesco			Predict recovery of consciousness in post-acute severe brain injury: The role of EEG reactivity	BRAIN INJURY			English	Article						Coma; vegetative state; prognosis	SEVERE HEAD-INJURY; CEREBRAL ANOXIA; COMA; PROGNOSIS; PROGNOSTICATION; ARREST; SCALE	Objective: This study tested the hypothesis of electroencephalographic reactivity (EEG-R) as a reliable tool for the prognostic evaluation of consciousness recovery in post-acute brain injury. Methods: EEG was recorded in 50 unconscious patients. All patients had a GCS <= 8 and LCF score <= 2. They suffered from traumatic brain injury, cerebrovascular disease or anoxia. EEG was classified according to Synek classification (1988) as benign, malignant and 'uncertain significance'. EEG-R to painful stimuli was tested. Results: Twenty per cent of patients fulfilled the criteria for benign prognosis, 38% for malignant prognosis, while 42% of them were included in the 'uncertain' category, preventing them from stating a prognosis. EEG-R was detected in 48% of patients classified 'uncertain' and 92% of them recovered consciousness within 5 months from EEG recording. Multivariable analysis indicates that an unconscious patient admitted to the Rehabilitation Unit within 2 months from brain injury, with a LCF score equal to 2 and the presence of EEG-R has a probability of recovery of consciousness higher than 97%. Conclusion: EEG-R is a good positive factor for the prognosis of recovery of consciousness in the post-acute phase of brain injury, with a high specificity (88.9%). Nevertheless, its absence is not invariably associated with a poor prognosis.	[Logi, Fiammetta; Tomaiuolo, Francesco] Multispecialist Rehabil Ctr, Severe Acquired Brain Injury Unit, Auxilium Vitae Volterra, Italy; [Pasqualetti, Patrizio] Fatebenefratelli Assoc Res AFaR, Dept Neurosci, Rome, Italy		Logi, F (corresponding author), Auxilium Vitae Volterra SpA, Unita Gravi Cerebrolesioni Acquisite, Borgo S Lazzaro 5, I-56048 Volterra, Italy.	fiammettal@hotmail.com	Tomaiuolo, Francesco/AAC-1534-2019; Pasqualetti, Patrizio/D-4496-2013	Pasqualetti, Patrizio/0000-0001-5560-1979; Tomaiuolo, Fancesco/0000-0003-1230-2770			Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; BRICOLO A, 1979, REV EEG NEUROPHYSIOL, V9, P116, DOI 10.1016/S0370-4475(79)80066-0; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; Fischer C., 2002, Annales de Readaptation et de Medecine Physique, V45, P448, DOI 10.1016/S0168-6054(02)00295-7; GUERIT JM, 1999, ELECTROENCEPHALOGR S, V52, P117; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; Hagen C., 1979, COGNITIVE ASSESSMENT; HOCKADAY JM, 1965, ELECTROEN CLIN NEURO, V18, P575, DOI 10.1016/0013-4694(65)90075-1; Kaplan PW, 2006, SEMIN NEUROL, V26, P403, DOI 10.1055/s-2006-948321; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Pfurtscheller G, 1999, CLIN NEUROPHYSIOL, V110, P1842, DOI 10.1016/S1388-2457(99)00141-8; RamachandranNair R, 2005, PEDIATR NEUROL, V33, P345, DOI 10.1016/j.pediatrneurol.2005.05.007; SYNEK VM, 1988, CLIN ELECTROENCEPHAL, V19, P160, DOI 10.1177/155005948801900310; SYNEK VM, 1990, CLIN ELECTROENCEPHAL, V21, P25, DOI 10.1177/155005949002100111; TEASDALE G, 1974, LANCET, V2, P81; Thenayan EAL, 2010, J CRIT CARE, V25, P300, DOI 10.1016/j.jcrc.2009.06.049; Young GB, 1997, CAN J NEUROL SCI, V24, P320, DOI 10.1017/S0317167100032996; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	21	44	51	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2011	25	10					972	979		10.3109/02699052.2011.589795			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	801TZ	WOS:000293464800007	21745174				2022-02-06	
J	Poljac, E; Montagne, B; de Haan, EHF				Poljac, Ervin; Montagne, Barbara; de Haan, Edward H. F.			Reduced recognition of fear and sadness in post-traumatic stress disorder	CORTEX			English	Article						Post-traumatic stress disorder, PTSD; Facial expression; Emotion recognition; Face perception	EVENT-RELATED POTENTIALS; FACIAL EXPRESSIONS; IMPAIRED RECOGNITION; HIPPOCAMPAL VOLUME; SEXUAL-ABUSE; BRAIN-INJURY; EMOTION; PERCEPTION; PTSD; DEPRESSION	Post-traumatic stress disorder (PTSD) is associated with impairments in emotional experience and expression. The current study examined the recognition of emotional facial expressions in PTSD patients and matched healthy controls, both in terms of accuracy and sensitivity. The task involved short video clips of a neutral face changing (morphing) into one of the six basic emotions (happiness, anger, fear, surprise, disgust and sadness). Clips differed in length, with short clips terminating at 20% of maximum emotional intensity, and the longest ones ending with a full-blown expression. We observed a specific impairment in the PTSD group for recognizing the emotions fear and sadness. This result was observed via a reduced accuracy and a decreased sensitivity for these emotions. We discuss the observed altered affective processing and its possible clinical implications. (C) 2010 Elsevier Srl. All rights reserved.	[Poljac, Ervin] Univ Leuven, Expt Psychol Lab, Louvain, Belgium; [Poljac, Ervin] Int Univ Sarajevo, Dept Psychol, Sarajevo, Bosnia & Herceg; [Montagne, Barbara] Radboud Univ Nijmegen, Med Ctr, Dept Psychiat, NL-6525 ED Nijmegen, Netherlands; [de Haan, Edward H. F.] Univ Amsterdam, Dept Psychol, NL-1012 WX Amsterdam, Netherlands		Poljac, E (corresponding author), Univ Leuven, Expt Psychol Lab, Tiensestr 102, Louvain, Belgium.	Ervin.Poljac@psy.kuleuven.be		de Haan, Edward/0000-0003-0312-3674			ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; [Anonymous], 2000, DIAGNOSTIC STAT MANU; Avdibegovic E, 2008, PSYCHIAT DANUB, V20, P474; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BENSON PJ, 1991, IMAGE VISION COMPUT, V9, P123, DOI 10.1016/0262-8856(91)90022-H; Benton A., 1994, CONTRIBUTIONS NEUROP; Bowler RM, 1998, ARCH CLIN NEUROPSYCH, V13, P455, DOI 10.1016/S0887-6177(97)00092-9; Bremner JD, 2004, J NERV MENT DIS, V192, P643, DOI 10.1097/01.nmd.0000142027.52893.c8; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Brewin CR, 2003, CLIN PSYCHOL REV, V23, P339, DOI 10.1016/S0272-7358(03)00033-3; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Calder AJ, 1996, VIS COGN, V3, P81, DOI 10.1080/713756735; Dalgleish T, 2004, PSYCHOL BULL, V130, P228, DOI 10.1037/0033-2909.130.2.228; DEHAAN EHF, 2002, ENCY HUMAN BRAIN, P67; DOLAN R, 2009, NEW OXFORD TXB PSYCH, P257; Ekman P., 1999, HDB COGNITION EMOTIO; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; FEINBERG TE, 1986, ARCH GEN PSYCHIAT, V43, P276; Felmingham KL, 2003, NEUROREPORT, V14, P777, DOI 10.1097/00001756-200304150-00024; Frewen PA, 2008, J TRAUMA STRESS, V21, P243, DOI 10.1002/jts.20320; Frewen PA, 2006, ANN NY ACAD SCI, V1071, P110, DOI 10.1196/annals.1364.010; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hargrave R, 2002, J NEUROPSYCH CLIN N, V14, P64, DOI 10.1176/appi.neuropsych.14.1.64; Kemp AH, 2007, PSYCHIAT RES-NEUROIM, V155, P265, DOI 10.1016/j.pscychresns.2007.01.010; Kemp AH, 2008, CNS SPECTRUMS, V13, P1066, DOI 10.1017/S1092852900017120; Lembke A, 2002, AM J PSYCHIAT, V159, P302, DOI 10.1176/appi.ajp.159.2.302; Liberzon I, 2006, ANN NY ACAD SCI, V1071, P87, DOI 10.1196/annals.1364.009; Mathersul D, 2009, J CLIN EXP NEUROPSYC, V31, P278, DOI 10.1080/13803390802043619; McClure EB, 2003, AM J PSYCHIAT, V160, P1172, DOI 10.1176/appi.ajp.160.6.1172; Montagne B, 2005, PERS INDIV DIFFER, V38, P5, DOI 10.1016/j.paid.2004.02.008; MONTAGNE B, 2005, J INT NEUROPSYCHO S2, V11; Montagne B, 2007, PERCEPT MOTOR SKILL, V104, P589, DOI 10.2466/PMS.104.2.589-598; Montagne Barbara, 2006, Cogn Neuropsychiatry, V11, P389, DOI 10.1080/13546800444000254; Montagne Barbara, 2005, Cogn Process, V6, P136, DOI 10.1007/s10339-005-0050-6; Montagne B, 2006, CORTEX, V42, P705, DOI 10.1016/S0010-9452(08)70408-8; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Phillips ML, 1999, PSYCHIAT RES-NEUROIM, V92, P11, DOI 10.1016/S0925-4927(99)00031-1; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2003, NEUROREPORT, V14, P913, DOI 10.1097/01.wnr.0000071767.24455.10; Reynolds M, 1999, BEHAV RES THER, V37, P201, DOI 10.1016/S0005-7967(98)00132-6; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; SIFNEOS PE, 1973, PSYCHOTHER PSYCHOSOM, V22, P255, DOI 10.1159/000286529; SPEEDIE LJ, 1990, J NEUROL NEUROSUR PS, V53, P607, DOI 10.1136/jnnp.53.7.607; Stanford MS, 2001, PSYCHIAT RES, V102, P125, DOI 10.1016/S0165-1781(01)00236-0; Stephan BCM, 2006, J INT NEUROPSYCH SOC, V12, P884, DOI 10.1017/S1355617706061066; Taylor GJ, 2004, PSYCHOTHER PSYCHOSOM, V73, P68, DOI 10.1159/000075537; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Venn HR, 2006, INT J NEUROPSYCHOPH, V9, P229, DOI 10.1017/S1461145705006012; Venn HR, 2004, BIPOLAR DISORD, V6, P286, DOI 10.1111/j.1399-5618.2004.00121.x; Villarreal G, 2002, BIOL PSYCHIAT, V52, P119, DOI 10.1016/S0006-3223(02)01359-8; Williams LM, 2006, NEUROIMAGE, V29, P347, DOI 10.1016/j.neuroimage.2005.03.047; Woodward SH, 2006, BIOL PSYCHIAT, V59, P582, DOI 10.1016/j.biopsych.2005.07.033; Yehuda R, 2004, BIOL PSYCHIAT, V55, P291, DOI 10.1016/S0006-3223(03)00641-3	55	44	44	1	28	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452			CORTEX	Cortex	SEP	2011	47	8					974	980		10.1016/j.cortex.2010.10.002			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	797UJ	WOS:000293155300007	21075363				2022-02-06	
J	Cohen-Yeshurun, A; Trembovler, V; Alexandrovich, A; Ryberg, E; Greasley, PJ; Mechoulam, R; Shohami, E; Leker, RR				Cohen-Yeshurun, Ayelet; Trembovler, Victoria; Alexandrovich, Alexander; Ryberg, Erik; Greasley, Peter J.; Mechoulam, Raphael; Shohami, Esther; Leker, Ronen R.			N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; endocannabinoids; N-arachidonoyl-L-serine; neuroprotection; traumatic brain injury	CB2 RECEPTOR ACTIVATION; CANNABINOID RECEPTOR; K+ CHANNELS; RAT-BRAIN; IN-VIVO; CONSTITUENT; BAD; PHOSPHORYLATION; IDENTIFICATION; CANNABIDIOL	N-arachidonoyl-L-serine (AraS) is a brain component structurally related to the endocannabinoid family. We investigated the neuroprotective effects of AraS following closed head injury induced by weight drop onto the exposed fronto-parietal skull and the mechanisms involved. A single injection of AraS following injury led to a significant improvement in functional outcome, and to reduced edema and lesion volume compared with vehicle. Specific antagonists to CB2 receptors, transient receptor potential vanilloid 1 (TRPV1) or large conductance calcium-activated potassium (BK) channels reversed these effects. Specific binding assays did not indicate binding of AraS to the GPR55 cannabinoid receptor. N-arachidonoyl-L-serine blocked the attenuation in phosphorylated extracellular-signal-regulated kinase 1/2 (ERK) levels and led to an increase in pAkt in both the ipsilateral and contralateral cortices. Increased levels of the prosurvival factor Bcl-xL were evident 24 hours after injury in AraS-treated mice, followed by a 30% reduction in caspase-3 activity, measured 3 days after injury. Treatment with a CB2 antagonist, but not with a CB1 antagonist, reversed this effect. Our results suggest that administration of AraS leads to neuroprotection via ERK and Akt phosphorylation and induction of their downstream antiapoptotic pathways. These protective effects are related mostly to indirect signaling via the CB2R and TRPV1 channels but not through CB1 or GPR55 receptors. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1768-1777; doi:10.1038/jcbfm.2011.53; published online 20 April 2011	[Cohen-Yeshurun, Ayelet; Trembovler, Victoria; Alexandrovich, Alexander; Mechoulam, Raphael; Shohami, Esther] Hebrew Univ Jerusalem, Dept Pharmacol, Inst Drug Res, Fac Med, IL-91120 Jerusalem, Israel; [Cohen-Yeshurun, Ayelet; Leker, Ronen R.] Hadassah Hebrew Univ, Med Ctr, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Dept Neurol, IL-91120 Jerusalem, Israel; [Ryberg, Erik; Greasley, Peter J.] AstraZeneca R&D, Molndal, Sweden		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Dept Pharmacol, Inst Drug Res, Fac Med, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il; leker@hadassah.org.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA-9789]; Brettler Center for Research in Molecular Pharmacology and Therapeutics; HU School of Pharmacy; Peritz and Chantal Scheinberg Cerebrovascular Research Fund; Sol Irwin Juni Trust; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA009789] Funding Source: NIH RePORTER	This study was supported by NIH Grant No. DA-9789, a grant from the Brettler Center for Research in Molecular Pharmacology and Therapeutics, the HU School of Pharmacy, The Peritz and Chantal Scheinberg Cerebrovascular Research Fund, and the Sol Irwin Juni Trust Fund. ES is the incumbent of the Dr Leon and Mina Deutch Chair in Psychopharmacology at the Hebrew University.	Barna I, 2009, EUR NEUROPSYCHOPHARM, V19, P533, DOI 10.1016/j.euroneuro.2009.02.001; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen XQ, 2005, J NEUROSCI RES, V79, P798, DOI 10.1002/jnr.20396; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Cudaback E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008702; Dasari VR, 2008, NEUROBIOL DIS, V32, P486, DOI 10.1016/j.nbd.2008.09.005; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Fride E, 2005, NEUROPHARMACOLOGY, V48, P1117, DOI 10.1016/j.neuropharm.2005.01.023; Godlewski G, 2009, J PHARMACOL EXP THER, V328, P351, DOI 10.1124/jpet.108.144717; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; GOMEZ DP, 2000, BIOCHEM J, V347, P369; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Hayakawa K, 2007, J NEUROCHEM, V102, P1488, DOI 10.1111/j.1471-4159.2007.04565.x; Imlach WL, 2008, J PHARMACOL EXP THER, V327, P657, DOI 10.1124/jpet.108.143933; Leker RR, 2003, STROKE, V34, P2000, DOI 10.1161/01.STR.0000079817.68944.1E; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Moranta D, 2007, J NEUROSCI RES, V85, P656, DOI 10.1002/jnr.21140; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Ozaita A, 2007, J NEUROCHEM, V102, P1105, DOI 10.1111/j.1471-4159.2007.04642.x; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pignataro G, 2008, J CEREBR BLOOD F MET, V28, P232, DOI 10.1038/sj.jcbfm.9600559; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Zhang M, 2008, NEUROSCIENCE, V152, P753, DOI 10.1016/j.neuroscience.2008.01.022; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447; Zhang X, 2010, BRIT J PHARMACOL, V160, P1583, DOI 10.1111/j.1476-5381.2010.00841.x; Zhuang ZY, 2004, J NEUROSCI, V24, P8300, DOI 10.1523/JNEUROSCI.2893-04.2004	42	44	47	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2011	31	8					1768	1777		10.1038/jcbfm.2011.53			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	800EH	WOS:000293342100014	21505478	Green Published, Bronze			2022-02-06	
J	Shum, D; Levin, H; Chan, RCK				Shum, David; Levin, Harvey; Chan, Raymond C. K.			Prospective memory in patients with closed head injury: A review	NEUROPSYCHOLOGIA			English	Article						Traumatic brain injury; Closed head injury; Prospective memory	TRAUMATIC BRAIN-INJURY; SELF-AWARENESS; PERFORMANCE; MODERATE; ADULTS; EVENT; CHILDREN; COMPONENTS; RECOVERY; TASKS	This paper aimed to review the limited, but growing literature on prospective memory (PM) following closed head injury (CHI). Search of two commonly used databases yielded studies that could be classified as: self- or other-report of PM deficits; behavioral PM measures in adults with CHI, behavioral PM measures in children and adolescents with CHI, and treatment of PM in adults with CHI. The methodology and findings of these studies were critically reviewed and discussed. Because of the small number of studies, meta-analysis was only conducted for studies that used behavioral PM measures in adults to integrate findings. PM deficits were found to be commonly reported by patients with CHI and their significant others and they could be identified using behavioral measures in adults, children and adolescents with CHI. However, more work is needed to clarify the nature and mechanisms of these deficits. Although some promising results have been reported by studies that evaluated PM treatment, most studies lack tight experimental control and used only a small number of participants. The paper concluded with some suggestions for future research. (C) 2011 Elsevier Ltd. All rights reserved.	[Shum, David] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; [Shum, David] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4111, Australia; [Levin, Harvey] Univ Texas Houston Med Sch, Houston, TX USA; [Levin, Harvey] Baylor Coll Med, Houston, TX 77030 USA; [Chan, Raymond C. K.] Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China		Shum, D (corresponding author), Griffith Univ, Sch Psychol, Mt Gravatt Campus,176 Messines Ridge Rd, Mt Gravatt, Qld 4122, Australia.	d.shum@griffith.edu.au; rckchan@psych.ac.cn	Shum, David/A-3914-2008; Chan, Raymond CK/B-6717-2009	Shum, David/0000-0002-4810-9262; Chan, Raymond CK/0000-0002-3414-450X	Australian Academy of Science; Department of Veteran AffairsUS Department of Veterans Affairs; National Institute of Neurological Disorders And StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202]; Griffith UniversityGriffith University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	Preparation of this manuscript was supported by an Australian Academy of Science, Scientific Visits to China Grant to David Shum, PhD; a Griffith Health Institute Distinguished Visiting Researcher Award, a Merit Review and Center of Excellence for Traumatic Brain Injury grants from the Department of Veteran Affairs, and Award Number P01NS056202 from the National Institute of Neurological Disorders And Stroke to Harvey Levin, PhD; and a Griffith University Allan Sewell Visiting Fellowship to Raymond Chan, PhD. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding bodies.	Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; Cohen J., 2013, STAT POWER ANAL BEHA; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Faul M, 2010, TRAUMATIC BRAIN INJU; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Fleming JM, 1996, BRAIN INJURY, V10, P1; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Higgins, 2005, COMPREHENSIVE META A; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kinsella GJ, 2009, BRAIN IMPAIR, V10, P45, DOI 10.1375/brim.10.1.45; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Kliegel M., 2008, PROSPECTIVE MEMORY C; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Knight RG, 2009, BRAIN IMPAIR, V10, P3, DOI 10.1375/brim.10.1.3; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin H., 2002, HDB MEMORY DISORDERS, P381; Levin HS., 1982, NEUROBEHAVIORAL CONS; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McCauley SR, 2010, J INT NEUROPSYCH SOC, V16, P335, DOI 10.1017/S135561770999138X; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; McKerracher G, 2005, NEUROPSYCHOL REHABIL, V15, P115, DOI 10.1080/09602010443000056; McQueen, 2003, BRAIN IMPAIR, V4, P135, DOI [10.1375/brim.4.2.135.270, DOI 10.1375/BRIM.4.2.135.27024]; Neulinger K., 2002, BRAIN IMPAIR, V3, P1, DOI [10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Raskin SA, 2009, BRAIN IMPAIR, V10, P76, DOI 10.1375/brim.10.1.76; Reynolds JR, 2009, CEREB CORTEX, V19, P1208, DOI 10.1093/cercor/bhn164; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Simons JS, 2006, NEUROPSYCHOLOGIA, V44, P1388, DOI 10.1016/j.neuropsychologia.2006.01.005; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wang Y, 2009, SCHIZOPHR RES, V114, P64, DOI 10.1016/j.schres.2009.07.009; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; WILSON BA, 2002, HDB MEMORY DISORDERS	54	44	45	0	23	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	JUL	2011	49	8			SI		2156	2165		10.1016/j.neuropsychologia.2011.02.006			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	793FL	WOS:000292805700003	21315750				2022-02-06	
J	Li, N; Zhao, WG; Zhang, WF				Li, Ning; Zhao, Wei-Guo; Zhang, Wei-Feng			Acute Kidney Injury in Patients with Severe Traumatic Brain Injury: Implementation of the Acute Kidney Injury Network Stage System	NEUROCRITICAL CARE			English	Article						Acute kidney injury; Renal dysfunction; Traumatic brain injury; Outcome; Acute kidney injury network (AKIN)	ORGAN DYSFUNCTION; RENAL DYSFUNCTION; FLUID THERAPY; HEAD-INJURY; OUTCOMES; FAILURE; COMPLICATIONS; SCORE	Background There is limited information on the incidence and effect of acute kidney injury (AKI) in patients with severe traumatic brain injury (TBI), although AKI may affect outcome. Recently, acute kidney injury network (AKIN) classification has been widely accepted as a consensus definition for AKI. The aim of this study is to estimate the frequency and level of severity of AKI in patients with severe TBI by using AKIN criteria and to study whether AKI affects outcome. Methods The authors retrospectively identified a total of 136 patients with severe TBI admitted to the neurosurgical center during a 3-year period ending May 2010. Demographic data, severity of TBI, serum creatinine, urine output, outcome at 6 month, and death were collected. Renal function was assessed by using AKIN criteria. Results Thirty-one patients (23%) were classified as having AKI by using AKIN criteria during their hospitalization. Of them, 21 patients (68%) were stratified as stage 1, 7 patients (22%) as stage 2, and 3 patients (10%) as stage 3. Patients who developed AKI were older, had lower Glasgow coma scale at admission, and had higher level of admission serum creatinine and blood urea nitrogen. Patients with AKI had higher mortality and worse outcome when compared with patients with normal renal function. Furthermore, patients with mild renal dysfunction (stage 1 AKI) are also found having increased mortality and worse long-term outcome, compared with patients without renal dysfunction. Conclusion It is demonstrated using the newly defined AKIN criteria for renal dysfunction that AKI is a relatively common feature in patients with severe TBI, and even seemingly insignificant decrease in renal function may be associated with worse outcome. This study highlights the importance of close surveillance of renal function and stresses the value of renal hygiene in the severe TBI population.	[Li, Ning; Zhao, Wei-Guo; Zhang, Wei-Feng] Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Neurosurg, Shanghai 200025, Peoples R China		Zhao, WG (corresponding author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Neurosurg, Shanghai 200025, Peoples R China.	lining930@yahoo.com; rjneurosurgery@yahoo.com.cn; zhangwf198@163.com					Ali T, 2007, J AM SOC NEPHROL, V18, P1292, DOI 10.1681/ASN.2006070756; Barrantes F, 2008, CRIT CARE MED, V36, P1397, DOI 10.1097/CCM.0b013e318168fbe0; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Chen YC, 2009, SHOCK, V31, P139, DOI 10.1097/SHK.0b013e31817d419e; Coca SG, 2007, AM J KIDNEY DIS, V50, P712, DOI 10.1053/j.ajkd.2007.07.018; Costantini TW, 2009, J TRAUMA, V67, P283, DOI 10.1097/TA.0b013e3181a51a51; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Levy MM, 2005, CRIT CARE MED, V33, P2194, DOI 10.1097/01.CCM.0000182798.39709.84; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Molitoris BA, 2007, NAT CLIN PRACT NEPHR, V3, P439, DOI 10.1038/ncpneph0551; Moore EM, 2010, RENAL FAILURE, V32, P1060, DOI 10.3109/0886022X.2010.510234; Nijboer WN, 2010, CRIT CARE MED, V38, P1155, DOI 10.1097/CCM.0b013e3181cf6e78; Ponte B, 2008, NEPHROL DIAL TRANSPL, V23, P3859, DOI 10.1093/ndt/gfn398; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wahlstrom MR, 2009, ACTA ANAESTH SCAND, V53, P18, DOI 10.1111/j.1399-6576.2008.01798.x; Zacharia BE, 2009, STROKE, V40, P2375, DOI 10.1161/STROKEAHA.108.545210; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2003, J CRIT CARE, V18, P238, DOI 10.1016/j.jcrc.2003.10.007	22	44	45	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2011	14	3					377	381		10.1007/s12028-011-9511-1			5	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	759FT	WOS:000290226800008	21298359				2022-02-06	
J	Ryan, ML; Ogilvie, MP; Pereira, BMT; Gomez-Rodriguez, JC; Manning, RJ; Vargas, PA; Duncan, RC; Proctor, KG				Ryan, Mark L.; Ogilvie, Michael P.; Pereira, Bruno M. T.; Gomez-Rodriguez, Juan Carlos; Manning, Ronald J.; Vargas, Paola A.; Duncan, Robert C.; Proctor, Kenneth G.			Heart Rate Variability Is an Independent Predictor of Morbidity and Mortality in Hemodynamically Stable Trauma Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma		ECG; Traumatic brain injury; Computed axial tomography; Heart rate variability	ACUTE MYOCARDIAL-INFARCTION; BRAIN-INJURY; COMPUTED-TOMOGRAPHY; PERIOD VARIABILITY; INTRACRANIAL HYPERTENSION; SYSTEMS; TRIAGE; DEATH; CT; PRESSURE	Background: Reduced heart rate variability (HRV) reflects autonomic dysfunction and can triage patients better than routine trauma criteria or vital signs. However, there is questionable specificity and no consensus measurement technique. The purpose of this study was to analyze whether factors that alter autonomic function affect the specificity of HRV for assessing traumatic injury. Methods: We evaluated 216 hemodynamically stable adults (3:1 M: F; 97:3 blunt: penetrating; age 49 years +/- 1 year, mean +/- standard error) undergoing computed axial tomography (CT) scan to rule out traumatic brain injury (TBI). All were prospectively instrumented with a Mars Holter system (GE Healthcare, Milwaukee, WI). HRV was determined offline using time domain (standard deviation of normal-normal intervals, root-mean-square successive difference) and frequency domain (very low frequency [VLF], LF, wideband frequency, high frequency [HF], low to HF index ratio) calculations from 15-minute electrocardiogram and correlated with routine vital signs, mortality, TBI, morbidity, length of stay (LOS), and comorbidities. Significance (p <= 0.05) was determined using nonparametric analysis, Student's t test, analysis of variance, or multiple logistic regression. Results: VLF alone predicted survival, severity of TBI, intensive care unit LOS, and hospital LOS (all p < 0.05). Beta-blockers or diabetes had no effect, whereas age, sedation, mechanical ventilation, spinal cord injury, and intoxication influenced one or more of the variables with age being the most powerful confounder (all p < 0.05). Except for the Glasgow Coma Scale, no other routine trauma or hemodynamic criteria correlated with any of these outcomes. Conclusions: Decreased VLF is an independent predictor of mortality and morbidity in hemodynamically stable trauma patients. Other time and other frequency domain variables correlated with some, but not all, outcomes. All were heavily influenced by factors that alter autonomic function, especially patient age.	[Proctor, Kenneth G.] Univ Miami, Miller Sch Med, Div Trauma, Dewitt Daughtry Family Dept Surg,Ryder Trauma Ctr, Miami, FL 33136 USA; [Duncan, Robert C.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA		Proctor, KG (corresponding author), Univ Miami, Miller Sch Med, Div Trauma, Dewitt Daughtry Family Dept Surg,Ryder Trauma Ctr, 1800 NW 10th Ave, Miami, FL 33136 USA.	kproctor@miami.edu	Proctor, Kenneth/AAA-2199-2022; Pereira, Bruno M/D-4542-2015	Proctor, Kenneth/0000-0003-1326-6628; Pereira, Bruno M/0000-0003-3763-1749; Vargas Gaitan, Paola Andrea/0000-0002-8038-6665; Gomez-Rodriguez, Juan Carlos/0000-0002-3617-1763			Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Batchinsky AI, 2007, CRIT CARE MED, V35, P519, DOI 10.1097/01.CCM.0000254065.44990.77; Batchinsky AI, 2010, J TRAUMA, V68, P1178, DOI 10.1097/TA.0b013e3181bb98a6; Batchinsky AI, 2009, SHOCK, V32, P565, DOI 10.1097/SHK.0b013e3181a993dc; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; BIGGER JT, 1993, CIRCULATION, V88, P927, DOI 10.1161/01.CIR.88.3.927; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Conci F, 2001, J NEUROL NEUROSUR PS, V71, P621, DOI 10.1136/jnnp.71.5.621; Cooke WH, 2006, AVIAT SPACE ENVIR MD, V77, P1107; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Fathizadeh P, 2004, CRIT CARE MED, V32, P1300, DOI 10.1097/01.CCM.0000127776.78490.E4; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Grogan EL, 2005, J TRAUMA, V58, P7, DOI 10.1097/01.TA.0000151179.74839.98; Haji-Michael PG, 2000, CRIT CARE MED, V28, P2578, DOI 10.1097/00003246-200007000-00066; Hon E. H., 1965, AM J OBSTET GYNECOL, V87, P814; Huikuri HV, 2009, EUR HEART J, V30, P689, DOI 10.1093/eurheartj/ehn537; Kahraman S, 2010, J NEUROSURG ANESTH, V22, P296, DOI 10.1097/ANA.0b013e3181e25fc3; Kasaoka S, 2010, J CRIT CARE, V25, P313, DOI 10.1016/j.jcrc.2009.06.047; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; King DR, 2009, J TRAUMA, V67, P436, DOI 10.1097/TA.0b013e3181ad67de; LOWENSOHN RI, 1977, LANCET, V1, P626; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Morris JA, 2007, J AM COLL SURGEONS, V204, P885, DOI 10.1016/j.jamcollsurg.2007.01.019; Morris JA, 2006, J TRAUMA, V60, P1165, DOI 10.1097/01.ta.0000220384.04978.3b; Mowery NT, 2008, J TRAUMA, V65, P621, DOI 10.1097/TA.0b013e3181837980; Norris PR, 2005, J SURG RES, V129, P122, DOI 10.1016/j.jss.2005.04.024; Novak V, 1997, CIRCULATION, V96, P1056; Perkiomaki JS, 2010, ANN NONINVAS ELECTRO, V15, P250, DOI 10.1111/j.1542-474X.2010.00372.x; Proctor KG, 2007, J TRAUMA, V63, P33, DOI 10.1097/01.ta.0000251593.32396.df; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; Rickards CA, 2010, CRIT CARE MED, V38, P1666, DOI 10.1097/CCM.0b013e3181e74cab; Ryan KL, 2010, SHOCK, V33, P583, DOI 10.1097/SHK.0b013e3181cd8cbe; Seely AJE, 2004, CRIT CARE, V8, pR367, DOI 10.1186/cc2948; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Signorini M G, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P3431; Sing RF, 2006, J TRAUMA, V60, P499; Takabatake N, 2001, AM J RESP CRIT CARE, V163, P1314, DOI 10.1164/ajrccm.163.6.2004175; Taylor JA, 1998, CIRCULATION, V98, P547, DOI 10.1161/01.CIR.98.6.547; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Vinik AI, 2003, DIABETES CARE, V26, P1553, DOI 10.2337/diacare.26.5.1553; Werdan K, 2009, CAN J PHYSIOL PHARM, V87, P266, DOI 10.1139/Y09-012; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	44	44	47	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2011	70	6					1371	1380		10.1097/TA.0b013e31821858e6			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	775QR	WOS:000291478500019	21817974				2022-02-06	
J	Knerlich-Lukoschus, F; Noack, M; von der Ropp-Brenner, B; Lucius, R; Mehdorn, HM; Held-Feindt, J				Knerlich-Lukoschus, Friederike; Noack, Malte; von der Ropp-Brenner, Beata; Lucius, Ralph; Mehdorn, Hubertus Maximilian; Held-Feindt, Janka			Spinal Cord Injuries Induce Changes in CB1 Cannabinoid Receptor and C-C Chemokine Expression in Brain Areas Underlying Circuitry of Chronic Pain Conditions	JOURNAL OF NEUROTRAUMA			English	Article						cannabinoid receptor-1; chemokines; central pain; spinal cord injury; transient receptor potential vanilloid receptor 1	CENTRAL NEUROPATHIC PAIN; ACID AMIDE HYDROLASE; IMMUNOHISTOCHEMICAL LOCALIZATION; OPIOID RECEPTORS; RAT-BRAIN; HETEROLOGOUS DESENSITIZATION; ENDOCANNABINOID LEVELS; NEURONAL EXPRESSION; CONTUSION INJURIES; IN-VIVO	Due to their involvement in neuro-modulatory processes, the endogenous cannabinoid system and chemokine network, which were shown to interact which each other, are potential key elements in the cascades underlying central neuropathic pain development after spinal cord injury (SCI). Expression profiles of cannabinoid receptor type-1 (CB1), and of the chemokines chemokine ligand 2 (C-C motif) (CCL2), chemokine ligand 3 (C-C motif) (CCL3), plus their main receptors CCR2 and CCR1, were investigated in brain regions related to pain, emotion, learning, and memory in a rat SCI paradigm of post-traumatic neuropathic pain. Immunoreactivity (IR) was investigated 7 days and 42 days after sham operation, and moderate (100-kdyn), and severe (200-kdyn) thoracic spinal cord contusion lesions. Hippocampal (HC) subregions, amygdaloid complex, anterior cingulate cortex (ACC), periaqueductal gray (PAG), and thalamic nuclei were analyzed. Seven days after lesioning, CB1 IR was induced in thalamic nuclei and HC subregions (CA3 and dentate gyrus), and downregulated in amygdaloid nuclei, ACC, and PAG. On day 42, CB1 IR remained elevated in the HC and thalamic areas, and was induced in ACC after 100-kdyn, but downregulated after 200-kdyn lesions. It remained reduced in the PAG of severely lesioned animals, paralleling their prolonged neuropathic pain-related behavior. Double-labeling revealed partial co-expression of CB1 with the pain-related vanilloid receptor transient receptor potential vanilloid receptor 1 (TRPV1), and chemokines (CCL2 and CCL3). These chemokines were induced in the PAG, thalamus, and HC, especially in the chronic time course after severe SCI. Thus interactions of CB1, C-C chemokines, and TRPV1 likely play a role in SCI-induced plastic changes in the brain, underlying emotional-affective pain responses and central pain development after spinal cord lesions.	[Knerlich-Lukoschus, Friederike; Noack, Malte; von der Ropp-Brenner, Beata; Mehdorn, Hubertus Maximilian; Held-Feindt, Janka] Univ Schleswig Holstein, Med Ctr, Dept Neurosurg, D-24105 Kiel, Germany; [Knerlich-Lukoschus, Friederike; Lucius, Ralph] Univ Kiel, Dept Anat, Kiel, Germany		Held-Feindt, J (corresponding author), Univ Schleswig Holstein, Med Ctr, Dept Neurosurg, Campus Kiel,Arnold Heller Str 3 Geb 41, D-24105 Kiel, Germany.	held-feindtj@nch.uni-kiel.de	Knerlich-Lukoschus, Friederike F/J-2895-2016; Held-Feindt, Janka/E-4690-2010; Lucius, Ralph/B-1614-2010	Knerlich-Lukoschus, Friederike F/0000-0002-6284-0449; Knerlich-Lukoschus, Friederike/0000-0003-4907-015X	Stiftung Neurochirurgische Forschung; Ministry for Science, Commerce, and Transportation of Schleswig-Holstein	We thank Professor Maurice R. Elphick (School of Biological Sciences, Queen Mary, University of London, London, U.K.) who kindly provided the C-terminal CB<INF>1</INF> antibody used in this study. We also greatly appreciate Brigitte Rehmke's, Ute Malcus-Coskun's, and Jorg Krause's excellent technical assistance. This work was funded by Stiftung Neurochirurgische Forschung (F. K. L.), and the Ministry for Science, Commerce, and Transportation of Schleswig-Holstein [Gefordert mit den Mitteln der Fakultatsubergreifenden Forschungsforderung des Medizin-Ausschusses beider Medizinischer Fakultaten in Kiel und Lubeck] (R.L. and J.H.-F.).	Adler MW, 2005, AAPS J, V7, pE865, DOI 10.1208/aapsj070484; Ahmed MM, 2010, SPINE J, V10, P1049, DOI 10.1016/j.spinee.2010.08.015; Baastrup C, 2008, CNS DRUGS, V22, P455, DOI 10.2165/00023210-200822060-00002; Banisadr G, 2005, J COMP NEUROL, V492, P178, DOI 10.1002/cne.20729; Banisadr G, 2005, J COMP NEUROL, V489, P275, DOI 10.1002/cne.20598; Benamar K, 2008, J PHARMACOL EXP THER, V325, P641, DOI 10.1124/jpet.107.135053; Chen XH, 2007, DRUG ALCOHOL DEPEN, V88, P36, DOI 10.1016/j.drugalcdep.2006.09.010; Corasaniti M T, 2006, Cell Death Differ, V13, P534, DOI 10.1038/sj.cdd.4401848; Cristino L, 2006, NEUROSCIENCE, V139, P1405, DOI 10.1016/j.neuroscience.2006.02.074; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; De Wied D, 1991, Methods Achiev Exp Pathol, V15, P167; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Egertova M, 2000, J COMP NEUROL, V422, P159, DOI 10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1; Egertova M, 2003, NEUROSCIENCE, V119, P481, DOI 10.1016/S0306-4522(03)00145-3; Farquhar-Smith WP, 2000, MOL CELL NEUROSCI, V15, P510, DOI 10.1006/mcne.2000.0844; Fernandez-Ruiz J, 2000, TRENDS NEUROSCI, V23, P14, DOI 10.1016/S0166-2236(99)01491-5; Finnerup NB, 2004, EUR J NEUROL, V11, P73, DOI 10.1046/j.1351-5101.2003.00725.x; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Grimsey NL, 2008, J NEUROSCI METH, V171, P78, DOI 10.1016/j.jneumeth.2008.02.014; Hubscher CH, 2006, EXP NEUROL, V197, P177, DOI 10.1016/j.expneurol.2005.09.007; Hulsebosch CE, 2005, CURR PHARM DESIGN, V11, P1411, DOI 10.2174/1381612053507864; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Jalalvand E, 2008, NEUROSCIENCE, V157, P446, DOI 10.1016/j.neuroscience.2008.08.052; Jensen MP, 2007, ARCH PHYS MED REHAB, V88, P638, DOI 10.1016/j.apmr.2007.02.002; Katona I, 2001, J NEUROSCI, V21, P9506, DOI 10.1523/JNEUROSCI.21-23-09506.2001; Katona I, 1999, J NEUROSCI, V19, P4544; KAUER JA, 2008, TINS, V32, P215; Kim SR, 2005, J NEUROSCI, V25, P662, DOI 10.1523/JNEUROSCI.4166-04.2005; Knerlich-Lukoschus F, 2008, J NEUROTRAUM, V25, P427, DOI 10.1089/neu.2007.0431; Knerlich-Lukoschus F, 2010, GLIA, V58, P916, DOI 10.1002/glia.20974; KNERLICHLUKOSCH.F, 2010, J NEUROTRAUMA, V27; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Maione S, 2006, J PHARMACOL EXP THER, V316, P969, DOI 10.1124/jpet.105.093286; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Miller RJ, 2008, J NEUROSCI, V28, P11792, DOI 10.1523/JNEUROSCI.3588-08.2008; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Neugebauer V, 2004, NEUROSCIENTIST, V10, P221, DOI 10.1177/1073858403261077; ONAIVI ES, 1990, J PHARMACOL EXP THER, V253, P1002; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Pernia-Andrade AJ, 2009, SCIENCE, V325, P760, DOI 10.1126/science.1171870; Pertwee RG, 2001, PROG NEUROBIOL, V63, P569, DOI 10.1016/S0301-0082(00)00031-9; Petrosino S, 2007, NEUROPHARMACOLOGY, V52, P415, DOI 10.1016/j.neuropharm.2006.08.011; Pettit DAD, 1998, J NEUROSCI RES, V51, P391; Roberts JC, 2004, BRAIN RES, V995, P176, DOI 10.1016/j.brainres.2003.10.001; Ross RA, 2003, BRIT J PHARMACOL, V140, P790, DOI 10.1038/sj.bjp.0705467; Rostene W, 2007, NAT REV NEUROSCI, V8, P895, DOI 10.1038/nrn2255; Sagar DR, 2004, EUR J NEUROSCI, V20, P175, DOI 10.1111/j.1460-9568.2004.03481.x; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Szabo I, 2002, P NATL ACAD SCI USA, V99, P10276, DOI 10.1073/pnas.102327699; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; WATANABE Y, 1992, BRAIN RES, V588, P341, DOI 10.1016/0006-8993(92)91597-8; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545; Wolf SA, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-12; Zhang HJ, 2005, BRAIN RES, V1055, P103, DOI 10.1016/j.brainres.2005.06.072; Zhang N, 2004, J IMMUNOL, V173, P594, DOI 10.4049/jimmunol.173.1.594; Zhang N, 2005, P NATL ACAD SCI USA, V102, P4536, DOI 10.1073/pnas.0406030102; Zhao P, 2007, J NEUROSCI, V27, P8893, DOI 10.1523/JNEUROSCI.2209-07.2007; Zhu CZ, 2009, BRIT J PHARMACOL, V157, P645, DOI 10.1111/j.1476-5381.2009.00184.x	60	44	45	2	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2011	28	4					619	634		10.1089/neu.2010.1652			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	746IW	WOS:000289240200011	21265596				2022-02-06	
J	Tokuda, S; Mahaffey, CL; Monks, B; Faulkner, CR; Birnbaum, MJ; Danzer, SC; Frankel, WN				Tokuda, Satoko; Mahaffey, Connie L.; Monks, Bobby; Faulkner, Christian R.; Birnbaum, Morris J.; Danzer, Steve C.; Frankel, Wayne N.			A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice	HUMAN MOLECULAR GENETICS			English	Article							TRAUMATIC BRAIN-INJURY; LHERMITTE-DUCLOS-DISEASE; INBRED MOUSE STRAINS; GLUCOSE-HOMEOSTASIS; SOMA SIZE; B-GAMMA; EPILEPSY; MODEL; PHOSPHORYLATION; GENE	In a phenotype-driven mutagenesis screen, a novel, dominant mouse mutation, Nmf350, caused low seizure threshold, sporadic tonic-clonic seizures, brain enlargement and ectopic neurons in the dentate hilus and molecular layer of the hippocampus. Genetic mapping implicated Akt3, one of four candidates within the critical interval. Sequencing analysis revealed that mutants have a missense mutation in Akt3 (encoding one of three AKT/protein kinase B molecules), leading to a non-synonymous amino acid substitution in the highly conserved protein kinase domain. Previous knockout studies showed that Akt3 is pivotal in postnatal brain development, including a smaller brain, although seizures were not observed. In contrast to Akt3(Nmf350), we find that Akt3 null mice exhibit an elevated seizure threshold. An in vitro kinase assay revealed that Akt3(Nmf350) confers higher enzymatic activity, suggesting that Akt3(Nmf350) might enhance AKT signaling in the brain. In the dentate gyrus of Akt3(Nmf350) homozygotes, we also observed a modest increase in immunoreactivity of phosphorylated ribosomal protein S6, an AKT pathway downstream target. Together these findings suggest that Akt3(Nmf350) confers an increase of AKT3 activity in specific neuronal populations in the brain, and a unique dominant phenotype. Akt3(Nmf350) mice provide a new tool for studying physiological roles of AKT signaling in the brain, and potentially novel mechanisms for epilepsy.	[Tokuda, Satoko; Mahaffey, Connie L.; Frankel, Wayne N.] Jackson Lab, Bar Harbor, ME 04609 USA; [Monks, Bobby; Birnbaum, Morris J.] Univ Penn, Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA; [Faulkner, Christian R.; Danzer, Steve C.] Cincinnati Childrens Hosp, Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA		Frankel, WN (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	wayne.frankel@jax.org		Birnbaum, Morris/0000-0001-9972-8680	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA034196]; The Jackson Laboratory Neuroscience Mutagenesis Facility (NMF) [U01 NS41215]; Epilepsy Foundation; Jackson Laboratory Postdoctoral Fellowship; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS031348, NS041215, DK56886, NS-065020]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK056886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065020, U01NS041215, R01NS031348] Funding Source: NIH RePORTER	This work was subsidized by a cancer core center grant from the National Cancer Institute (grant CA034196). The initial part of this work was funded as part of The Jackson Laboratory Neuroscience Mutagenesis Facility (NMF), cooperative agreement U01 NS41215. S.T. was supported in part by an Epilepsy Foundation of America Fellowship and in part by a Jackson Laboratory Postdoctoral Fellowship. W.N.F. was funded by grants from the National Institutes of Health (grant numbers NS031348, NS041215). M.J.B. was funded by a grant from the National Institutes of Health (grant number DK56886). S.C.D. was funded by a grant from the National Institutes of Health (grant number NS-065020).	Aoki K, 1998, J BIOL CHEM, V273, P26698, DOI 10.1074/jbc.273.41.26698; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Boumil RM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001046; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Buchner DA, 2004, MAMM GENOME, V15, P344, DOI 10.1007/s00335-004-2332-1; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Ferraro TN, 2004, MAMM GENOME, V15, P239, DOI 10.1007/s00335-003-2270-3; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Frankel WN, 2001, GENOMICS, V74, P306, DOI 10.1006/geno.2001.6564; FRANKEL WN, 1994, GENETICS, V138, P481; Gardiner RM, 2000, J NEUROL, V247, P327, DOI 10.1007/s004150050598; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Heckman KL, 2007, NAT PROTOC, V2, P924, DOI 10.1038/nprot.2007.132; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Jablonski MM, 2005, MOL VIS, V11, P569; Keays DA, 2007, CELL, V128, P45, DOI 10.1016/j.cell.2006.12.017; Kenedy AA, 2003, GENE, V303, P35, DOI 10.1016/S0378-1119(02)01141-1; Kermany MH, 2006, HEARING RES, V220, P76, DOI 10.1016/j.heares.2006.07.011; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Kwon CH, 2003, P NATL ACAD SCI USA, V100, P12923, DOI 10.1073/pnas.2132711100; Ljungberg MC, 2009, DIS MODEL MECH, V2, P389, DOI 10.1242/dmm.002386; Lucarini N, 2007, PEDIATR NEUROL, V37, P157, DOI 10.1016/j.pediatrneurol.2007.06.001; Meikle L, 2007, J NEUROSCI, V27, P5546, DOI 10.1523/JNEUROSCI.5540-06.2007; Neufeld TP, 2003, MECH DEVELOP, V120, P1283, DOI 10.1016/j.mod.2003.07.003; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Okado H, 2009, DEV BIOL, V331, P140, DOI 10.1016/j.ydbio.2009.04.030; Piermartiri TCB, 2009, NEUROTOX RES, V16, P106, DOI 10.1007/s12640-009-9057-6; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Wang QH, 2003, NEURON, V38, P915, DOI 10.1016/S0896-6273(03)00356-8; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yang Y, 2003, HUM MOL GENET, V12, P975, DOI 10.1093/hmg/ddg118; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200; Zeng Ling-Hui, 2009, Mol Cell Pharmacol, V1, P124; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238	41	44	49	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0964-6906	1460-2083		HUM MOL GENET	Hum. Mol. Genet.	MAR 1	2011	20	5					988	999		10.1093/hmg/ddq544			12	Biochemistry & Molecular Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Genetics & Heredity	716SJ	WOS:000286993500012	21159799	Bronze, Green Published			2022-02-06	
J	Meehan, WP; Taylor, AM; Proctor, M				Meehan, William P., III; Taylor, Alex M.; Proctor, Mark			The Pediatric Athlete: Younger Athletes with Sport-Related Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Mild traumatic brain injury; Head injury; Trauma; Injury; Sports	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; HIGH-SCHOOL; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL PERFORMANCE; CEREBRAL CONCUSSION; CONTACT-SPORTS; 2ND IMPACT; RECOVERY	Although much of the lay media attention surrounding sport-related concussion (SRC) focuses on professional athletes, SRC is a common injury in pediatric sports. The anatomy, biomechanics, and response to injury of the developing pediatric brain differ from those of the adult. Similarly, the neurocognitive abilities of the child are developing more rapidly than in an adult. The effects of concussive brain injury on the life of a child are different from those of an adult. This article focuses on the aspects of SRC that are specific to the younger athletes.	[Meehan, William P., III; Taylor, Alex M.] Childrens Hosp Boston, Div Sports Med, Sports Concuss Clin, Dept Orthoped, Boston, MA 02115 USA; [Meehan, William P., III] Childrens Hosp Boston, Dept Med, Div Emergency Med, Boston, MA 02115 USA; [Taylor, Alex M.] Childrens Hosp Boston, Dept Neurol, Boston, MA 02115 USA; [Proctor, Mark] Childrens Hosp Boston, Dept Neurosurg, Boston, MA 02115 USA		Meehan, WP (corresponding author), Childrens Hosp Boston, Div Sports Med, Sports Concuss Clin, Dept Orthoped, 319 Longwood Ave, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	This article was supported by the NIH through a T32 Award to Dr Meehan (T32 HD040128-06A1).	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barth JT, 1989, MILD HEAD INJURY, P257; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BERNEY J, 1994, CHILD NERV SYST, V10, P509, DOI 10.1007/BF00335073; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Bruce D A, 1982, Clin Sports Med, V1, P495; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; COLLINS M, 2004, CURR OPIN ORTHOP, V15, P100; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; GRONWALL D, 1975, LANCET, V2, P995; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Holbourn AHS, 1943, LANCET, V2, P438; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2008, J INT NEUROPSYCHO S1, V14, pi; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 1999, SPORTS-RELATED CONCUSSION, P3; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; PELLMAN EJ, 2004, NEUROSURGERY, V55, P1303; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Russo S, 2006, CURR OPIN PEDIATR, V18, P376; Sakas DE, 1997, NEUROSURGERY, V41, P661, DOI 10.1097/00006123-199709000-00031; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHNITKER MT, 1949, J PEDIATR-US, V35, P557, DOI 10.1016/S0022-3476(49)80138-7; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Theye Fred, 2004, Clin Med Res, V2, P165; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; VAGNOZZI R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Washington RL, 2001, PEDIATRICS, V107, P1205; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	94	44	44	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					133	+		10.1016/j.csm.2010.08.004			13	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	691XR	WOS:000285114800013	21074088	Green Accepted			2022-02-06	
J	Maric, NP; Doknic, M; Pavlovic, D; Pekic, S; Stojanovic, M; Jasovic-Gasic, M; Popovic, V				Maric, N. P.; Doknic, M.; Pavlovic, D.; Pekic, S.; Stojanovic, M.; Jasovic-Gasic, M.; Popovic, V.			Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION			English	Article						Traumatic brain injury; GH deficiency; GH therapy; psychiatric symptoms; depression	ADULTS; SUBSTITUTION; REPLACEMENT; OUTCOMES; MEMORY	Objective: Traumatic brain injury (TBI) has been recently recognized as a risk factor for cognitive impairment and hypopituitarism, presented most frequently with GH deficiency (GHD). GHD is associated not only with changes in body composition, but also with impaired quality of life, cognitive dysfunctions and some psychiatric sequelae, usually classified as "depression" or "atypical depression". The impact of GH therapy on mental status in TBI patients is still unknown. Design: Psychiatric and cognitive functions were tested in 6 GHD patients at baseline (minimum 3 yr after TBI), reassessed after 6 months of GH therapy as well as 12 months after discontinuation of GH therapy. Psychiatric and cognitive examinations included semi-structured interviews and 3 instruments: Symptom-checklist (SCL-90-R), Zung Depression Inventory, and standard composite neuropsychological battery. Results: Six months of GH therapy in GHD TBI patients improved cognitive abilities (particularly verbal and non-verbal memory) and significantly improved psychiatric functioning. Severity of depression decreased, as well as intensity of interpersonal sensitivity, hostility, paranoid ideation, anxiety, and psychoticism. Somatization, obsessive-compulsive symptoms and phobic anxiety decreased in all except in one patient. In 3 GHD patients who stopped GH therapy for 12 months we registered worsening of the verbal and non-verbal memory, as well symptoms in 3 SCL dimensions: inter-personal sensitivity, anxiety, and paranoid ideation. Conclusion: GH-deficient TBI patients are depressed and have cognitive impairment. GH therapy induced reduction of depression, social dysfunction, and certain cognitive domains. Our preliminary data support the necessity of conducting randomized placebo-controlled trials on the effects of GH therapy on neuropsychological and psychiatric status in GHD TBI patients. (J. Endocrinol. Invest. 33: 770-775, 2010) (C) 2010, Editrice Kurtis	[Maric, N. P.; Jasovic-Gasic, M.] Univ Clin Ctr Belgrade, Inst Psychiat, Belgrade, Serbia; [Maric, N. P.; Doknic, M.; Pavlovic, D.; Pekic, S.; Jasovic-Gasic, M.; Popovic, V.] Univ Belgrade, Sch Med, Belgrade, Serbia; [Doknic, M.; Pekic, S.; Stojanovic, M.; Popovic, V.] Inst Endocrinol Diabet & Metab Dis, Belgrade, Serbia; [Pavlovic, D.] Univ Clin Ctr Belgrade, Inst Neurol, Belgrade, Serbia		Maric, NP (corresponding author), UCC, Inst Psychiat, Pasterova 2, Belgrade 11000, Serbia.	nadjamaric@yahoo.com	Pekic, Sandra/S-7175-2016; Maric, Nadja/AAP-2722-2020	Maric, Nadja/0000-0002-7051-853X	Ministry of Science of Republic of SerbiaMinistry of Education, Science & Technological Development, Serbia [145019]	This study was supported by a grant from the Ministry of Science of Republic of Serbia (Project 145019).	ADEM A, 1989, BRAIN RES, V503, P299, DOI 10.1016/0006-8993(89)91678-8; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P47, DOI 10.1016/j.ghir.2004.11.004; Bonne O, 2008, J CLIN PSYCHIAT, V69, P1087, DOI 10.4088/JCP.v69n0707; Clayton P, 2007, GROWTH HORM IGF RES, V17, P369, DOI 10.1016/j.ghir.2007.04.010; Creyghton Wouter M, 2004, Semin Vasc Med, V4, P167, DOI 10.1055/s-2004-835375; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Heaton RK, 1981, MANUAL WISCONSIN CAR; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Hoofien D, 2005, APPL NEUROPSYCHOL, V12, P30, DOI 10.1207/s15324826an1201_6; Huisman J, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-25; JOHANSSON JO, 1995, NEUROENDOCRINOLOGY, V61, P57, DOI 10.1159/000126813; Kaplan E.F., 1978, BOSTON NAMING TEST; Lasaite Lina, 2004, Medicina (Kaunas), V40, P740; Newcomer JW, 2001, HIPPOCAMPUS, V11, P529, DOI 10.1002/hipo.1069.abs; Nilsson AG, 2007, GROWTH HORM IGF RES, V17, P441, DOI 10.1016/j.ghir.2007.05.005; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Ranganath C, 2005, HIPPOCAMPUS, V15, P997, DOI 10.1002/hipo.20141; Rey A., 1964, EXAMEN CLIN PSYCHOL; Schneider HJ, 2003, EUR J ENDOCRINOL, V149, P377, DOI 10.1530/eje.0.1490377; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Wolfson, 1993, HALSTEAD REITAN NEUR; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	29	44	46	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0391-4097	1720-8386		J ENDOCRINOL INVEST	J. Endocrinol. Invest.	DEC	2010	33	11					770	775		10.1007/BF03350340			6	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	727HD	WOS:000287787900001	20479569				2022-02-06	
J	Berry, C; Salim, A; Alban, R; Mirocha, J; Margulies, DR; Ley, EJ				Berry, Chersse; Salim, Ali; Alban, Rodrigo; Mirocha, James; Margulies, Daniel R.; Ley, Eric J.			Serum Ethanol Levels in Patients with Moderate to Severe Traumatic Brain Injury Influence Outcomes: A Surprising Finding	AMERICAN SURGEON			English	Article							ALCOHOL-INTOXICATION; HEAD-INJURY; MORTALITY; DEFICITS	Animal studies routinely demonstrate an alcohol (ETOH) -mediated increase in survival after experimental traumatic brain injury (TB!). Recent clinical studies also suggest ETOH plays a neuroprotective role in moderate to severe TBI. We sought to investigate the relationship between ETOH and outcomes in patients with moderate to severe TBI using a countywide database. The Los Angeles County Trauma System database was queried for all adult (older than 14 years) patients with isolated moderate to severe TBI trauma (head Abbreviated Injury Score [AIS] 3 or greater, all other AIS 3 or less) who had ETOH levels measured on admission between 1998 and 2005. A total of 7304 patients were evaluated with 3219 (44.1%) patients testing positive for serum ETOH. ETOH-positive patients with TBI had a significantly lower mortality rate compared with ETOH negative patients (8.5 vs 10.5%, P = 0.005). Even after logistic regression analysis, a positive ETOH was associated with reduced mortality (adjusted OR 0.82, 95% CI: 0.69-0.99, P = 0.035). Therefore, a positive serum ETOH level was independently associated with significantly improved survival in patients with isolated moderate to severe TBI. The neuroprotective role ETOH plays in TBI is in contrast to previous findings and deserves further attention as a potential therapeutic.	[Berry, Chersse; Salim, Ali; Alban, Rodrigo; Mirocha, James; Margulies, Daniel R.; Ley, Eric J.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA		Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Berry, Cherisse/AAO-5701-2020				Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; WALTER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x	16	44	46	0	3	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	OCT	2010	76	10					1067	1070					4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	663AO	WOS:000282855600009	21105611				2022-02-06	
J	Lustenberger, T; Talving, P; Barmparas, G; Schnuriger, B; Lam, L; Inaba, K; Demetriades, D				Lustenberger, Thomas; Talving, Peep; Barmparas, Galinos; Schnueriger, Beat; Lam, Lydia; Inaba, Kenji; Demetriades, Demetrios			Skateboard-Related Injuries: Not to be Taken Lightly. A National Trauma Databank Analysis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Skateboard injuries; Head injuries; Extremity fractures; Outcomes; Prevention		Background: With the increasing popularity of skateboarding, trauma centers are experiencing increased number of skateboard injuries. The incidence and type of injuries and the effect of age on these variables are poorly described in the literature. Methods: Data from National Trauma Databank during a 5-year period was used for this study. Injury Severity Score (ISS), injured body area, specific injuries, and outcomes were calculated according to age groups (younger than 10 years, 10-16 years, and older than 16 years). Results: During the study period, there were 2,270 admissions due to skateboard-related injuries (0.1% of all trauma admissions). There were 187 patients (8%) younger than 10 years, 1,314 patients (58%) 10 years to 16 years, and 769 patients (34%) older than 16 years. The overall mortality was 1.1% and ranged from 0% in the age group younger than 10 years to 0.3% in the group 10 years to 16 years and 2.6% in the group older than 16 years (p < 0.001). The incidence of severe trauma (Injury Severity Score >= 16) in the three age groups was 5.4%, 13.5%, and 23.7%, respectively (p < 0.001). The incidence of traumatic brain injury in the three age groups was 24.1%, 32.6%, and 45.5%, respectively (p < 0.001). The younger age group (younger than 10 years) was significantly more likely to suffer femur fractures and less likely to suffer tibia fractures than the older age groups. Helmets and use of a skateboard park were significant factors protecting against head injury. Conclusion: Skateboard-related injuries are associated with a high incidence of traumatic brain injury and long bone fractures. Age plays an important role in the anatomic distribution of injuries, injury severity, and outcomes. Our findings demonstrate that helmet utilization and designated skateboard areas significantly reduce the incidence of serious head injuries.	[Lustenberger, Thomas; Talving, Peep; Barmparas, Galinos; Schnueriger, Beat; Lam, Lydia; Inaba, Kenji; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA 90033 USA		Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Los Angeles Cty Gen Hosp LAC USC,Dept Surg, Div Acute Care Surg Trauma Emergency Surg & Surg, 1200 N State St, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013; Barmparas, Galinos/L-6530-2019; INABA, KENJI/AAC-8532-2020	Talving, Peep/0000-0002-9741-2073; 			Bull MJ, 2002, PEDIATRICS, V109, P542; CASS DT, 1990, MED J AUSTRALIA, V153, P140, DOI 10.5694/j.1326-5377.1990.tb136832.x; Forsman L, 2001, BRIT J SPORT MED, V35, P325, DOI 10.1136/bjsm.35.5.325; KRUSE P, 1990, Ugeskrift for Laeger, V152, P681; Kyle SB, 2002, J TRAUMA, V53, P686, DOI 10.1097/00005373-200210000-00011; Osberg JS, 1998, ARCH PEDIAT ADOL MED, V152, P985; Rethnam Ulfin, 2008, BMC Res Notes, V1, P59, DOI 10.1186/1756-0500-1-59; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; SCHMID A, 1993, UNFALLCHIRURG, V96, P641; Skateboard injuries, 1995, PEDIATRICS, V95, P611; Zalavras C, 2005, AM J SPORT MED, V33, P568, DOI 10.1177/0363546504269256	11	44	44	6	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2010	69	4					924	927		10.1097/TA.0b013e3181b9a05a			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	664KP	WOS:000282959100052	20065875				2022-02-06	
J	Fernandez-Espejo, D; Junque, C; Cruse, D; Bernabeu, M; Roig-Rovira, T; Fabregas, N; Rivas, E; Mercader, JM				Fernandez-Espejo, Davinia; Junque, Carme; Cruse, Damian; Bernabeu, Montserrat; Roig-Rovira, Teresa; Fabregas, Neus; Rivas, Eva; Mercader, Jose M.			Combination of diffusion tensor and functional magnetic resonance imaging during recovery from the vegetative state	BMC NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; MINIMALLY CONSCIOUS STATES; COLLEGE-OF-PHYSICIANS; CEREBRAL BLOOD-FLOW; DEFAULT NETWORK; AXONAL INJURY; RESTING STATE; HEAD-INJURY; BASE-LINE	Background: The rate of recovery from the vegetative state (VS) is low. Currently, little is known of the mechanisms and cerebral changes that accompany those relatively rare cases of good recovery. Here, we combined functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI) to study the evolution of one VS patient at one month post-ictus and again twelve months later when he had recovered consciousness. Methods: fMRI was used to investigate cortical responses to passive language stimulation as well as task-induced deactivations related to the default-mode network. DTI was used to assess the integrity of the global white matter and the arcuate fasciculus. We also performed a neuropsychological assessment at the time of the second MRI examination in order to characterize the profile of cognitive deficits. Results: fMRI analysis revealed anatomically appropriate activation to speech in both the first and the second scans but a reduced pattern of task-induced deactivations in the first scan. In the second scan, following the recovery of consciousness, this pattern became more similar to that classically described for the default-mode network. DTI analysis revealed relative preservation of the arcuate fasciculus and of the global normal-appearing white matter at both time points. The neuropsychological assessment revealed recovery of receptive linguistic functioning by 12-months post-ictus. Conclusions: These results suggest that the combination of different structural and functional imaging modalities may provide a powerful means for assessing the mechanisms involved in the recovery from the VS.	[Fernandez-Espejo, Davinia; Junque, Carme] Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain; [Fernandez-Espejo, Davinia; Junque, Carme] Inst Biomed Res August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Cruse, Damian] MRC Cognit & Brain Sci Unit, Cambridge, England; [Bernabeu, Montserrat] Inst Univ Neurorehabil Guttmann, Head Injury Unit, Badalona, Spain; [Roig-Rovira, Teresa] Inst Univ Neurorehabil Guttmann, Dept Neuropsychol, Badalona, Spain; [Fabregas, Neus; Rivas, Eva] Univ Barcelona, Dept Anesthesiol, Hosp Clin, Barcelona, Spain; [Mercader, Jose M.] Hosp Clin Barcelona, Ctr Diagnost Imatge Hosp Clin Barcelona CDIC, Barcelona, Spain		Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain.	cjunque@ub.edu	Cruse, Damian/ABA-6346-2021; Junque, Carme/B-4400-2011; Fernandez-Espejo, Davinia/AAT-5481-2021	Cruse, Damian/0000-0003-4363-5981; Junque, Carme/0000-0002-6381-3063; Fernandez-Espejo, Davinia/0000-0001-5941-7546; Rivas, Eva/0000-0002-5816-998X	Spanish Ministry of Science and InnovationSpanish Government [SAF2007-66077]; Generalitat de CatalunyaGeneralitat de CatalunyaGeneral Electric [2009SGR0941]; Spanish Ministry for EducationSpanish Government [AP2006-00862]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [U.1055.01.002.00007.01]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_U105559847] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105559847] Funding Source: researchfish	This work was supported by grants SAF2007-66077 from the Spanish Ministry of Science and Innovation and 2009SGR0941 from the Generalitat de Catalunya to the Neuropsychology Research Group. D. Fernandez-Espejo was supported by a fellowship from the Spanish Ministry for Education (AP2006-00862). D. Cruse was supported by a Medical Research Council Translational Grant (U.1055.01.002.00007.01).	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bassetti C, 2000, LANCET, V356, P484, DOI 10.1016/S0140-6736(00)02561-7; Bates D, 2003, CLIN MED, V3, P249; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bekinschtein T, 2005, NEUROPSYCHOL REHABIL, V15, P307, DOI 10.1080/09602010443000443; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Brett M., 2002, 8 INT C FUNCT MAPP H, V16; Canavero S, 2009, J NEUROL, V256, P834, DOI 10.1007/s00415-009-5019-4; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Dehaene-Lambertz G, 2002, SCIENCE, V298, P2013, DOI 10.1126/science.1077066; deJong BM, 1997, CLIN NEUROL NEUROSUR, V99, P213, DOI 10.1016/S0303-8467(97)00024-3; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Di HB, 2008, CLIN MED, V8, P502, DOI 10.7861/clinmedicine.8-5-502; Fair DA, 2007, NEUROIMAGE, V35, P396, DOI 10.1016/j.neuroimage.2006.11.051; Fernandez-Espejo D, 2008, BRAIN INJURY, V22, P882, DOI 10.1080/02699050802403573; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GOODGLASS H, 1986, EVALUACION AFASIA TR, P2; GRAVES WW, CEREB CORTEX; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hagen C, 1979, REHABILITATION HEAD; Harrison BJ, 2008, P NATL ACAD SCI USA, V105, P9781, DOI 10.1073/pnas.0711791105; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kaisti KK, 2002, ANESTHESIOLOGY, V96, P1358, DOI 10.1097/00000542-200206000-00015; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Lezak MD, 2004, NEUROPSYCHOLOGICAL A; Maquet P, 2000, J SLEEP RES, V9, P207; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; Moritz CH, 2001, MAGN RESON IMAGING, V19, P1129, DOI 10.1016/S0730-725X(01)00432-5; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Owen AM, 2008, NAT REV NEUROSCI, V9, P235, DOI 10.1038/nrn2330; Owen AM, 2002, NEUROCASE, V8, P394, DOI 10.1076/neur.8.4.394.16184; Pardee R. E, 1999, MANUAL NORMAS PROCED; Pena-Casanova J., 1991, PROGRAMA INTEGRADO E; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Salek-Haddadi A, 2003, ANN NEUROL, V53, P663, DOI 10.1002/ana.10586; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Staffen W, 2006, J NEUROL NEUROSUR PS, V77, P1383, DOI 10.1136/jnnp.2006.095166; Steriade M, 2001, ARCH ITAL BIOL, V139, P37; Stoeckel C, 2009, CORTEX, V45, P1091, DOI 10.1016/j.cortex.2008.12.004; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Vigneau M, 2006, NEUROIMAGE, V30, P1414, DOI 10.1016/j.neuroimage.2005.11.002; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wechsler D., 1999, ESCALA INTELIGENCIA; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; [No title captured]	64	44	48	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	SEP 3	2010	10								77	10.1186/1471-2377-10-77			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	667ZY	WOS:000283239200001	20815871	Green Published, gold			2022-02-06	
J	Jarlestedt, K; Rousset, CI; Faiz, M; Wilhelmsson, U; Stahlberg, A; Sourkova, H; Pekna, M; Mallard, C; Hagberg, H; Pekny, M				Jarlestedt, Katarina; Rousset, Catherine I.; Faiz, Maryam; Wilhelmsson, Ulrika; Stahlberg, Anders; Sourkova, Hana; Pekna, Marcela; Mallard, Carina; Hagberg, Henrik; Pekny, Milos			Attenuation of Reactive Gliosis Does Not Affect Infarct Volume in Neonatal Hypoxic-Ischemic Brain Injury in Mice	PLOS ONE			English	Article							FIBRILLARY ACIDIC PROTEIN; INTERMEDIATE-FILAMENTS; HYPOTONIC STRESS; ASTROCYTES; VIMENTIN; GFAP; REGENERATION; DEFICIENT; PCR; NEUROGENESIS	Background: Astroglial cells are activated following injury and up-regulate the expression of the intermediate filament proteins glial fibrillary acidic protein (GFAP) and vimentin. Adult mice lacking the intermediate filament proteins GFAP and vimentin (GFAP(-/-) Vim(-/-)) show attenuated reactive gliosis, reduced glial scar formation and improved regeneration of neuronal synapses after neurotrauma. GFAP(-/-) Vim(-/-) mice exhibit larger brain infarcts after middle cerebral artery occlusion suggesting protective role of reactive gliosis after adult focal brain ischemia. However, the role of astrocyte activation and reactive gliosis in the injured developing brain is unknown. Methodology/Principal Findings: We subjected GFAP(-/-) Vim(-/-) and wild-type mice to unilateral hypoxia-ischemia (HI) at postnatal day 9 (P9). Bromodeoxyuridine (BrdU; 25 mg/kg) was injected intraperitoneally twice daily from P9 to P12. On P12 and P31, the animals were perfused intracardially. Immunohistochemistry with MAP-2, BrdU, NeuN, and S100 antibodies was performed on coronal sections. We found no difference in the hemisphere or infarct volume between GFAP(-/-) Vim(-/-) and wild-type mice at P12 and P31, i.e. 3 and 22 days after HI. At P31, the number of NeuN(+) neurons in the ischemic and contralateral hemisphere was comparable between GFAP(-/-) Vim(-/-) and wild-type mice. In wild-type mice, the number of S100(+) astrocytes was lower in the ipsilateral compared to contralateral hemisphere (65.0 +/- 50.1 vs. 85.6 +/- 34.0, p<0.05). In the GFAP(-/-) Vim(-/-) mice, the number of S100(+) astrocytes did not differ between the ischemic and contralateral hemisphere at P31. At P31, GFAP(-/-) Vim(-/-) mice showed an increase in NeuN(+)BrdU(+) (surviving newly born) neurons in the ischemic cortex compared to wild-type mice (6.7 +/- 7.7; n = 29 versus 2.9 +/- 3.6; n = 28, respectively, p<0.05), but a comparable number of S100(+)BrdU(+) (surviving newly born) astrocytes. Conclusions/Significance: Our results suggest that attenuation of reactive gliosis in the developing brain does not affect the hemisphere or infarct volume after HI, but increases the number of surviving newborn neurons.	[Jarlestedt, Katarina; Mallard, Carina; Hagberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Perinatal Ctr, Gothenburg, Sweden; [Rousset, Catherine I.; Hagberg, Henrik] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London, England; [Hagberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Dept Obstet & Gynecol, Gothenburg, Sweden; [Pekna, Marcela] Univ Gothenburg, Sahlgrenska Acad, Dept Med Chem & Cell Biol, Inst Biomed, Gothenburg, Sweden; [Faiz, Maryam; Wilhelmsson, Ulrika; Stahlberg, Anders; Sourkova, Hana; Pekny, Milos] Univ Gothenburg, Ctr Brain Repair & Rehabil, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil,Sahlgrenska Acad, Gothenburg, Sweden		Jarlestedt, K (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Perinatal Ctr, Gothenburg, Sweden.	Milos.Pekny@neuro.gu.se	Pekna, Marcela/AAM-3249-2021; Pekna, Marcela/AAM-3261-2021	Pekna, Marcela/0000-0003-2734-8237; Pekna, Marcela/0000-0003-2734-8237; Hagberg, Henrik/0000-0003-3962-1448; Stahlberg, Anders/0000-0003-4243-0191; Mallard, Carina/0000-0001-8953-919X; Wilhelmsson, Ulrika/0000-0003-3227-2687	Swedish Research CouncilSwedish Research CouncilEuropean Commission [11548, 20116, 09455, 14185]; Medical Research Council (United Kingdom)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [P19381]; LUA/ALF Gothenburg; Region of Vastra Gotaland; Ragnar and Torsten Soderberg's Foundations; Hjarnfonden; Edith Jacobsson's Foundation; John and Brit Wennerstrom's Foundation; W. and M. Lundgren's Foundation; A. and U. Amlov's Foundation; Free Mason Foundation; Swedish Stroke Foundation;  [ALFGBG7592];  [ALFGBG11267];  [ALFGBG2863]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802853] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802853] Funding Source: researchfish; Action Medical Research [1764] Funding Source: researchfish	This study was supported by the Swedish Research Council, 11548 ( M. P.), 20116 ( M. P.), 09455 ( H. H.), 14185 ( C. M.), Medical Research Council (United Kingdom) contract: P19381 ( H. H.), LUA/ALF Gothenburg, ALFGBG7592 ( M. P.), ALFGBG11267 ( M. P.), ALFGBG2863 ( H. H.), The Region of Vastra Gotaland ( RUN), Ragnar and Torsten Soderberg's Foundations, Hjarnfonden, Edith Jacobsson's Foundation, John and Brit Wennerstrom's Foundation for Neurological Research, W. and M. Lundgren's Foundation, A. and U. Amlov's Foundation, The Free Mason Foundation and the Swedish Stroke Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderova M, 2001, GLIA, V35, P189, DOI 10.1002/glia.1084; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Chen YM, 2001, J NEUROCHEM, V77, P1601, DOI 10.1046/j.1471-4159.2001.00374.x; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Ding M, 1998, MOL BRAIN RES, V62, P77, DOI 10.1016/S0169-328X(98)00240-X; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; Iwata-Ichikawa E, 1999, J NEUROCHEM, V72, P2334, DOI 10.1046/j.1471-4159.1999.0722334.x; Jing RF, 2007, J CELL SCI, V120, P1267, DOI 10.1242/jcs.03423; Johnston MV, 2005, BRAIN PATHOL, V15, P234; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Larsson A, 2004, NEUROCHEM RES, V29, P2069, DOI 10.1007/s11064-004-6880-2; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; MCRAE A, 1995, DEV BRAIN RES, V84, P245, DOI 10.1016/0165-3806(94)00177-2; Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 2001, Prog Brain Res, V132, P23; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Sent E, 2006, MENT RETARD DEV D R, V12, P97, DOI 10.1002/mrdd.20106; Sheldon RA, 1998, BRAIN RES, V810, P114, DOI 10.1016/S0006-8993(98)00892-0; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Stahlberg A, 2005, EXPERT REV MOL DIAGN, V5, P221, DOI 10.1586/14737159.5.2.221; Sullivan SM, 2010, GLIA, V58, P181, DOI 10.1002/glia.20911; Vexler ZS, 2009, DEV NEUROSCI-BASEL, V31, P378, DOI 10.1159/000232556; Widestrand A, 2007, STEM CELLS, V25, P2619, DOI 10.1634/stemcells.2007-0122; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	32	44	44	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2010	5	4							e10397	10.1371/journal.pone.0010397			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	589MV	WOS:000277154200029	20442854	Green Published, Green Submitted, gold			2022-02-06	
J	McKinlay, A; Kyonka, EGE; Grace, RC; Horwood, LJ; Fergusson, DM; MacFarlane, MR				McKinlay, A.; Kyonka, E. G. E.; Grace, R. C.; Horwood, L. J.; Fergusson, D. M.; MacFarlane, M. R.			An investigation of the pre-injury risk factors associated with children who experience traumatic brain injury	INJURY PREVENTION			English	Article							MILD HEAD-INJURY; NEUROPSYCHOLOGICAL FUNCTION; PSYCHOSOCIAL OUTCOMES; MATERNAL DEPRESSION; BEHAVIOR PROBLEMS; ADOLESCENTS; FAMILY; CHILDHOOD; PREDICTORS; ACCIDENTS	Background and Objective Traumatic brain injury (TBI) is a frequently occurring event in childhood that may have significant ongoing effects. Little is known about the child and family characteristics that predispose children to these injuries. A greater understanding of the risk factors associated with childhood TBI may provide an opportunity to prevent their occurrence. Methods Information provided by a large birth cohort study (n = 1265) was used to determine the child and family risk factors of TBI in children aged 0-15 years (n = 187). All information regarding child, family, and injury events were collected prospectively and unrelated to the injury event itself. Child variables included in the analysis were sex and the level of behavioural problems. Parental variables included were family socioeconomic status, mother's age, education level, depressive symptoms, number of adverse life events experienced by the family, and parenting style. Results The most important risk factors were sex, adverse life events, and parenting style. The results suggest evidence of modest increases in the rate of TBI for those in the highest risk categories (male, >= 4 life events per annum, high maternal punitiveness) compared to the lowest risk categories, with hazard ratios in the region of 1.4-1.6. Conclusions Overall characteristics of both the family and child predicted a TBI event. An increased understanding of risks associated with TBI in childhood will provide an avenue to prevent these injuries by targeting at-risk families and aiding the development of appropriate intervention strategies.	[McKinlay, A.; Kyonka, E. G. E.; Grace, R. C.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; [Kyonka, E. G. E.] W Virginia Univ, Morgantown, WV 26506 USA; [Horwood, L. J.; Fergusson, D. M.] Univ Otago, Christchurch Hlth & Dev Study, Christchurch, New Zealand; [MacFarlane, M. R.] Christchurch Hosp, Dept Neurosurg, Christchurch, New Zealand		McKinlay, A (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	audrey.mckinlay@canterbury.ac.nz		Kyonka, Elizabeth/0000-0001-7974-6080; McKinlay, Audrey/0000-0001-9846-8514; Horwood, L./0000-0003-4881-1956; Fergusson, David/0000-0002-8117-017X; Grace, Randolph/0000-0003-1115-6089	Health Research Council of New ZealandHealth Research Council of New Zealand; National Child Health Research Foundation; Canterbury Medical Research Foundation; New Zealand Lottery Grants Board	The Christchurch Health and Development Study has been funded by grants from the Health Research Council of New Zealand, the National Child Health Research Foundation, the Canterbury Medical Research Foundation, and the New Zealand Lottery Grants Board. This research was funded by grants from the Canterbury Medical Research Foundation and the New Zealand Lottery Grants Board. The research was conducted during tenure of an ACC Post-Doctoral Research Career Development Award from the Health Research Council of New Zealand and the Accident Compensation Corporation.	BIJUR PE, 1990, PEDIATRICS, V86, P337; BRADLEY RH, 1977, AM J MENT DEF, V81, P417; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CASEY R, 1987, PEDIATRICS, V80, P159; CHESS S, 1966, J AMER ACAD CHILD PS, V5, P226, DOI 10.1016/S0002-7138(09)62054-9; Damashek A, 2009, J PEDIATR PSYCHOL, V34, P344, DOI 10.1093/jpepsy/jsn097; DAVIDSON LL, 1988, PEDIATRICS, V82, P644; Demellweek Colin, 2002, Pediatr Rehabil, V5, P81, DOI 10.1080/136384902320807194; EATON WO, 1986, PSYCHOL BULL, V100, P19, DOI 10.1037/0033-2909.100.1.19; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; Fergusson DM, 1998, J EMOT BEHAV DISORD, V6, P2, DOI 10.1177/106342669800600101; FERGUSSON DM, 1985, PEDIATRICS, V75, P30; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Horwood LJ, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.1.e9; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LANGLEY J, 1980, AUST PAEDIATR J, V16, P244; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1998, BRAIN INJURY, V12, P41; McGraw MB, 1941, CHILD DEV, V12, P255; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MCKINLAY A, CHILD HLTH CARE DEV, DOI DOI 10.1111/J.1365-2214.2009.00947.X; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Morrongiello BA, 2004, INJURY PREV, V10, P114, DOI 10.1136/ip.2003.003459; O'Connor TG, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.5.e68; PILOWSKY I, 1969, BRIT J PSYCHIAT, V115, P937, DOI 10.1192/bjp.115.525.937; PLESS IB, 1989, AM J PUBLIC HEALTH, V79, P995, DOI 10.2105/AJPH.79.8.995; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schwebel DC, 2008, J PEDIATR PSYCHOL, V33, P1108, DOI 10.1093/jpepsy/jsn046; SILVA PA, 1996, DUNEDIN MULTIDISCIPL; Stratton G, 2007, OBESITY, V15, P1513, DOI 10.1038/oby.2007.179; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Uno D, 1998, J YOUTH ADOLESCENCE, V27, P585, DOI 10.1023/A:1022883023725	48	44	44	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	FEB	2010	16	1					31	35		10.1136/ip.2009.022483			5	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	569GQ	WOS:000275585000008	20179033				2022-02-06	
J	Arun, P; Ariyannur, PS; Moffett, JR; Xing, GQ; Hamilton, K; Grunberg, NE; Ives, JA; Namboodiri, AMA				Arun, Peethambaran; Ariyannur, Prasanth S.; Moffett, John R.; Xing, Guoqiang; Hamilton, Kristen; Grunberg, Neil E.; Ives, John A.; Namboodiri, Aryan M. A.			Metabolic Acetate Therapy for the Treatment of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						ATP; glyceryltriacetate; myelin synthesis; N-acetylaspartate	CONTROLLED CORTICAL IMPACT; N-ACETYLASPARTATE; MITOCHONDRIAL DYSFUNCTION; KETOGENIC DIET; RATS; SYNTHETASE; OXIDATION; SEVERITY; PROTEINS; JUVENILE	Patients suffering from traumatic brain injury (TBI) have decreased markers of energy metabolism, including N-acetylaspartate (NAA) and ATP. In the nervous system, NAA-derived acetate provides acetyl-CoA required for myelin lipid synthesis. Acetate can also be oxidized in mitochondria for the derivation of metabolic energy. In the current study, using the controlled cortical impact model of TBI in rats, we investigated the effects of the hydrophobic acetate precursor, glyceryltriacetate (GTA), as a method of delivering metabolizable acetate to the injured brain. We found that GTA administration significantly increased the levels of both NAA and ATP in the injured hemisphere 4 and 6 days after injury, and also resulted in significantly improved motor performance in rats 3 days after injury.	[Arun, Peethambaran; Ariyannur, Prasanth S.; Moffett, John R.; Namboodiri, Aryan M. A.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Neurosci Program, Bethesda, MD 20814 USA; [Arun, Peethambaran; Ariyannur, Prasanth S.; Moffett, John R.; Namboodiri, Aryan M. A.] Uniformed Serv Univ Hlth Sci, Mol & Cell Biol Program, Bethesda, MD 20814 USA; [Xing, Guoqiang] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Hamilton, Kristen; Grunberg, Neil E.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA; [Ives, John A.] Samueli Inst, Alexandria, VA USA		Namboodiri, AMA (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Neurosci Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	anamboodiri@usuhs.mil	Messier, Claude/A-2322-2008; Xing, Guoqiang/ABA-8450-2020; Hamilton, Kristen/B-8116-2015; Ariyannur, Prasanth S./C-1280-2008	Messier, Claude/0000-0002-4791-1763; Ariyannur, Prasanth S./0000-0003-0888-8094	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS RO1/R56, 039387]; Samueli Institute; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-06-2-0009]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039387] Funding Source: NIH RePORTER	This work was supported by grants from the NIH (NS RO1/R56; 039387) and the Samueli Institute (G170VR-under Award No. W81XWH-06-2-0009 from the U.S. Army Medical Research and Materiel Command).	Adibhatla RM, 2006, AAPS J, V8, pE314; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Arun P, 2008, J NEUROCHEM, V106, P1669, DOI 10.1111/j.1471-4159.2008.05524.x; BAILEY JW, 1991, JPEN-PARENTER ENTER, V15, P32, DOI 10.1177/014860719101500132; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Dash RR, 2009, J HAZARD MATER, V163, P1, DOI 10.1016/j.jhazmat.2008.06.051; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Madhavarao CN, 2009, J INHERIT METAB DIS, V32, P640, DOI 10.1007/s10545-009-1155-3; Madhavarao CN, 2005, P NATL ACAD SCI USA, V102, P5221, DOI 10.1073/pnas.0409184102; Mathew R, 2005, J PHARMACOL EXP THER, V315, P297, DOI 10.1124/jpet.105.087536; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Nikolau BJ, 2000, BIOCHEM SOC T, V28, P591, DOI 10.1042/BST0280591; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073	29	44	44	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					293	298		10.1089/neu.2009.0994			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200026	19803785	Green Published			2022-02-06	
J	James, ML; Wang, HC; Venkatraman, T; Song, PP; Lascola, CD; Laskowitz, DT				James, Michael L.; Wang, Haichen; Venkatraman, Talaignair; Song, Pingping; Lascola, Christopher D.; Laskowitz, Daniel T.			Brain Natriuretic Peptide Improves Long-Term Functional Recovery after Acute CNS Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						brain natriuretic peptide; cerebral blood flow; intracerebral hemorrhage; nesiritide; neuroinflammation; neuroprotection; traumatic brain injury	CEREBRAL-BLOOD-FLOW; NITRIC-OXIDE SYNTHASE; INTRACEREBRAL HEMORRHAGE; ANGIOTENSIN-II; PLASMA-CONCENTRATIONS; ISCHEMIC-STROKE; HEART-FAILURE; L-ARGININE; INFLAMMATION; ATRIAL	There is emerging evidence to suggest that brain natriuretic peptide (BNP) is elevated after acute brain injury, and that it may play an adaptive role in recovery through augmentation of cerebral blood flow (CBF). Through a series of experiments, we tested the hypothesis that the administration of BNP after different acute mechanisms of central nervous system (CNS) injury could improve functional recovery by improving CBF. C57 wild-type mice were exposed to either pneumatic-induced closed traumatic brain injury (TBI) or collagenase-induced intracerebral hemorrhage (ICH). After injury, either nesiritide (hBNP) (8 mu g/kg) or normal saline were administered via tail vein injection at 30 min and 4 h. The mice then underwent functional neurological testing via rotorod latency over the following 5 days and neurocognitive testing via Morris water maze testing on days 24-28. Cerebral blood flow (CBF) was assessed by laser Doppler from 25 to 90 min after injury. After ICH, mRNA polymerase chain reaction (PCR) and histochemical staining were performed during the acute injury phase (<24 h) to determine the effects on inflammation. Following TBI and ICH, administration of hBNP was associated with improved functional performance as assessed by rotorod and Morris water maze latencies (p < 0.01). CBF was increased (p < 0.05), and inflammatory markers (TNF-alpha and IL-6; p < 0.05), activated microglial (F4/80; p < 0.05), and neuronal degeneration (Fluoro-Jade B; p < 0.05) were reduced in mice receiving hBNP. hBNP improves neurological function in murine models of TBI and ICH, and was associated with enhanced CBF and downregulation of neuroinflammatory responses. hBNP may represent a novel therapeutic strategy after acute CNS injury.	[James, Michael L.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [James, Michael L.; Wang, Haichen; Song, Pingping; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; [Venkatraman, Talaignair; Lascola, Christopher D.] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; [Song, Pingping; Lascola, Christopher D.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA		James, ML (corresponding author), Duke Univ, Med Ctr 3094, Durham, NC 27710 USA.	james040@mc.duke.edu	Lascola, Christopher D/B-9126-2017; James, Michael L./AAJ-5592-2020	Lascola, Christopher D/0000-0002-8031-782X; James, Michael L./0000-0002-8715-5210	FAER Mentored Research	This study was made possible through funding from the FAER Mentored Research Training Grant (M.L.J.).	Brosnan MJ, 1999, HYPERTENSION, V33, P290, DOI 10.1161/01.HYP.33.1.290; Burger AJ, 2002, AM HEART J, V144, P1102, DOI 10.1067/mhj.2002.125620; CLARKSON PBM, 1995, CLIN SCI, V88, P159, DOI 10.1042/cs0880159; Di Angelantonlo E, 2007, J NEUROL SCI, V260, P139, DOI 10.1016/j.jns.2007.04.018; Fainardi E, 2008, NEURORADIOLOGY, V50, P729, DOI 10.1007/s00234-008-0402-x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Holscher C, 1999, BEHAV BRAIN RES, V100, P225, DOI 10.1016/S0166-4328(98)00134-X; Ito T, 2001, J RENIN-ANGIO-ALDO S, V2, P174, DOI 10.3317/jraas.2001.024; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; James ML, 2008, NEUROCRIT CARE, V9, P139, DOI 10.1007/s12028-007-9030-2; Jensen JK, 2006, CEREBROVASC DIS, V22, P439, DOI 10.1159/000094997; Kasama S, 2004, J NUCL MED, V45, P1108; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; Konig D, 2007, EXERC IMMUNOL REV, V13, P15; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laskowitz DT, 2009, STROKE, V40, P77, DOI 10.1161/STROKEAHA.108.516377; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu DC, 2008, SURG NEUROL, V69, P226, DOI 10.1016/j.surneu.2007.02.051; Luchner A, 2004, CARDIOVASC RES, V63, P443, DOI 10.1016/j.cardiores.2004.05.004; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Ma KK, 2004, J MOL CELL CARDIOL, V36, P505, DOI 10.1016/j.yjmcc.2004.01.001; McGirt MJ, 2004, NEUROSURGERY, V54, P1369, DOI 10.1227/01.NEU.0000125016.37332.50; McGrath MF, 2005, TRENDS ENDOCRIN MET, V16, P469, DOI 10.1016/j.tem.2005.10.007; Meirovich YF, 2008, J HEART LUNG TRANSPL, V27, P31, DOI 10.1016/j.healun.2007.09.025; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Modrego Pedro J, 2008, Int J Med Sci, V5, P18; Montaner J, 2008, STROKE, V39, P2280, DOI 10.1161/STROKEAHA.107.505354; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; Mun-Bryce S, 2006, BRAIN RES, V1073, P481, DOI 10.1016/j.brainres.2005.12.071; Mun-Bryce S, 2004, BRAIN RES, V1026, P218, DOI 10.1016/j.brainres.2004.08.023; Nakagawa K, 2005, CEREBROVASC DIS, V19, P157, DOI 10.1159/000083249; Nguyen AP, 2008, CURR NEUROVASC RES, V5, P171, DOI 10.2174/156720208785425710; Orakcioglu B, 2008, NEUROCRIT CARE, V8, P448, DOI 10.1007/s12028-007-9047-6; Powner DJ, 2007, NEUROCRIT CARE, V7, P119, DOI 10.1007/s12028-007-0079-8; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; ROSENBERG GA, 1990, ACT NEUR S, V51, P280; Rubattu S, 2008, AM J HYPERTENS, V21, P733, DOI 10.1038/ajh.2008.174; Saavedra JM, 2005, CELL MOL NEUROBIOL, V25, P485, DOI 10.1007/s10571-005-4011-5; Sakata Y, 2001, J HYPERTENS, V19, P1905, DOI 10.1097/00004872-200110000-00027; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; Sviri GE, 2006, ACTA NEUROCHIR, V148, P529, DOI 10.1007/s00701-005-0666-4; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Tsuchiya D, 2003, BRAIN RES, V970, P131, DOI 10.1016/S0006-8993(03)02300-X; Vesely DL, 2009, J INVEST MED, V57, P29, DOI 10.2310/JIM.0b013e3181948b37; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Yamada M, 2000, J CEREBR BLOOD F MET, V20, P709, DOI 10.1097/00004647-200004000-00008; Yancy CW, 2004, AM J CARDIOL, V94, P595, DOI 10.1016/j.amjcard.2004.05.022; Yemisci M, 2008, CEREBROVASC DIS, V26, P190, DOI 10.1159/000145327; Young JB, 2002, JAMA-J AM MED ASSOC, V287, P1531, DOI 10.1001/jama.287.12.1531; Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082	62	44	46	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					217	228		10.1089/neu.2009.1022			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200019	19803787	Green Submitted			2022-02-06	
J	Moreira, MS; Velasco, IT; Ferreira, LS; Ariga, SKK; Barbeiro, DF; Meneguzzo, DT; Abatepaulo, F; Marques, MM				Moreira, Maria Stella; Velasco, Irineu Tadeu; Ferreira, Leila Soares; Kubo Ariga, Suely Kunimi; Barbeiro, Denise Frediani; Meneguzzo, Daiane Thais; Abatepaulo, Fatima; Marques, Marcia Martins			Effect of phototherapy with low intensity laser on local and systemic immunomodulation following focal brain damage in rat	JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY			English	Article						IL-1 beta; IL-6; IL-10; TNF-alpha; Low power laser; Cryogenic brain injury	PRO-INFLAMMATORY CYTOKINES; NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; TERM NEUROLOGICAL DEFICITS; HUMAN ORAL-MUCOSA; TNF-ALPHA; RECEPTOR ANTAGONIST; INTERLEUKIN-1 RECEPTOR; PERIPHERAL-NERVE; THERAPY	Brain injury is responsible for significant morbidity and mortality in trauma patients, but controversy still exists over therapeutic management for these patients. The objective of this study was to analyze the effect of phototherapy with low intensity lasers on local and systemic immunomodulation following cryogenic brain injury. Laser phototherapy was applied (or not-controls) immediately after cryogenic brain injury performed in 51 adult male Wistar rats. The animals were irradiated twice (3 h interval), with continuous diode laser (gallium-aluminum-arsenide (GaAlAs), 780 nm, or indium-gallium-aluminum-phosphide (InGaAlP), 660 nm) in two points and contact mode, 40 mW, spot size 0.042 cm(2), 3 J/cm(2) and 5 J/cm(2) (3 s and 5 s, respectively). The experimental groups were: Control (non-irradiated), RL3 (visible red laser/ 3 J/cm(2)), RL5 (visible red laser/5 J/cm(2)), IRL3 (infrared laser/ 3 J/cm(2)), IRL5 (infrared laser/5 J/cm(2)). The production of interleukin-1IL-1 beta (IL-1 beta), interleukin6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-alpha) was analyzed by enzyme immunoassay technique (ELISA) test in brain and blood samples. The IL-1 beta concentration in brain of the control group ;was significantly reduced in 24 h (p < 0.01). This reduction was also observed in the RL5 and IRL3 groups. The TNF-alpha and IL-6 concentrations increased significantly (p < 0.01 and p < 0.05, respectively) in the blood of all groups, except by the IRL3 group. The IL-6 levels in RL3 group were significantly smaller than in control group in both experimental times. IL-10 concentration was maintained stable in all groups in brain and blood. Under the conditions of this study, it is possible to conclude that the laser phototherapy can affect TNF-alpha, IL-1 beta and IL-6 levels in the brain and in circulation in the first 24 h following cryogenic brain injury. (C) 2009 Elsevier B.V. All rights reserved.	[Marques, Marcia Martins] Univ Sao Paulo, Fac Odontol, Dept Dent, BR-05508000 Sao Paulo, Brazil; [Moreira, Maria Stella; Velasco, Irineu Tadeu; Kubo Ariga, Suely Kunimi; Barbeiro, Denise Frediani; Abatepaulo, Fatima] Univ Sao Paulo, Fac Med, LIM 51, BR-05508000 Sao Paulo, Brazil		Marques, MM (corresponding author), Univ Sao Paulo, Fac Odontol, Dept Dent, Av Prof Lineu Prestes,2227,Cidade Univ, BR-05508000 Sao Paulo, Brazil.	mmmarques@usp.br	Marques, Marcia M/F-3780-2012; Meneguzzo, Daiane T./ABD-8253-2020; Moreira, Maria Stella N A/F-8054-2014	Marques, Marcia M/0000-0002-9398-1252; Meneguzzo, Daiane T./0000-0002-8821-3734; Moreira, Maria Stella N A/0000-0002-4533-4544	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brasilia, DF, BrazilCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	We thank the staffs of the Labs: LIM51 at the Medicine School and LELO (Special Laboratory of Lasers in Dentistry) at the School of Dentistry, University of Sao Paulo, Brazil. We are also grateful to ours Grants sponsors Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Sao Paulo, Brazil and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brasilia, DF, Brazil.	Aimbire F, 2006, PHOTOMED LASER SURG, V24, P33, DOI 10.1089/pho.2006.24.33; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; Boschi ES, 2008, LASER SURG MED, V40, P500, DOI 10.1002/lsm.20658; Campana V, 2003, J CLIN LASER MED SUR, V21, P99, DOI 10.1089/104454703765035529; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Damante CA, 2004, LASER SURG MED, V35, P377, DOI 10.1002/lsm.20111; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; GebickeHaerter PJ, 1996, NEUROCHEM INT, V29, P1; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; JOYCE DA, 1994, EUR J IMMUNOL, V24, P2699, DOI 10.1002/eji.1830241119; Kandolf-Sekulovic L, 2003, PHOTODERMATOL PHOTO, V19, P203, DOI 10.1034/j.1600-0781.2003.00040.x; KARU T, 1989, Journal of Photochemistry and Photobiology B Biology, V3, P638, DOI 10.1016/1011-1344(89)80088-0; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Kujawa J, 2004, J CLIN LASER MED SUR, V22, P111, DOI 10.1089/104454704774076163; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MENEGUZZO DT, 2008, P SPIE, V6846; MENEGUZZO DT, 2007, P SPIE, V6428; Mirsky N, 2002, ANTIOXID REDOX SIGN, V4, P785, DOI 10.1089/152308602760598936; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Moriyama Y, 2009, LASER SURG MED, V41, P227, DOI 10.1002/lsm.20745; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Penkowa M, 1999, GLIA, V25, P343; Quintana A, 2008, DEV NEUROBIOL, V68, P195, DOI 10.1002/dneu.20584; Rochkind S, 2007, PHOTOMED LASER SURG, V25, P436, DOI 10.1089/pho.2007.2093; Sawasaki I, 2009, LASER MED SCI, V24, P113, DOI 10.1007/s10103-007-0531-1; Shefer G, 2001, J CELL PHYSIOL, V187, P73, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1053>3.0.CO;2-9; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; Sousa LR, 2009, PHOTOMED LASER SURG, V27, P37, DOI 10.1089/pho.2007.2220; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; TAKAO T, 1993, ENDOCRINOLOGY, V132, P1497, DOI 10.1210/en.132.4.1497; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Unsicker K, 1992, Curr Opin Neurobiol, V2, P671, DOI 10.1016/0959-4388(92)90037-L; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	58	44	45	1	8	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	1011-1344			J PHOTOCH PHOTOBIO B	J. Photochem. Photobiol. B-Biol.	DEC 2	2009	97	3					145	151		10.1016/j.jphotobiol.2009.09.002			7	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	526TI	WOS:000272316600005	19800810				2022-02-06	
J	Dobkin, BH				Dobkin, Bruce H.			Motor rehabilitation after stroke, traumatic brain, and spinal cord injury: common denominators within recent clinical trials	CURRENT OPINION IN NEUROLOGY			English	Article						functional electrical stimulation; gait training; robotics; spinal cord injury; stroke rehabilitation	CONSTRAINT-INDUCED MOVEMENT; TRANSCRANIAL MAGNETIC STIMULATION; UPPER EXTREMITY FUNCTION; MULTIPLE-SCLEROSIS; RANDOMIZED-TRIAL; CORTICAL STIMULATION; EXERCISE PROGRAM; AEROBIC CAPACITY; RECOVERY; THERAPY	Purpose of review Experimental studies and clinical trials that aim to improve motor function for use of the upper extremity and walking are traditionally separated by the category of neurological disease. This boundary may deter investigators from finding common denominators in the conceptual basis and deployment of rehabilitation interventions, especially across nonprogressive diseases in adults, such as stroke, brain trauma, and spinal cord injury. Recent findings The results of recent randomized clinical trials for walking by treadmill training and robotic devices and for the upper extremity by constraint-induced therapy, robotics, and brain stimulation suggest that more efficient strategies are needed to devise and prove the value of new therapies. Summary Investigators should consider working across disease platforms to develop and test the most optimal methods for training patients, the most practical trial designs, the best dose-response characteristics of interventions, the most meaningful outcome measures, and the likelihood of transfer of trained performance to real-world settings. Clinicians in the community may be more likely to adopt evidence-based practices drawn from positive trial results if these treatment strategies focus on key motor impairments and related disabilities, rather than on diseases.	Univ Calif Los Angeles, Geffen UCLA Sch Med, Dept Neurol, Los Angeles, CA 90095 USA		Dobkin, BH (corresponding author), Univ Calif Los Angeles, Geffen UCLA Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	bdobkin@mednet.ucla.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD037439] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013642] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41 RR013642] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD037439] Funding Source: Medline		Alaverdashvili M, 2008, BEHAV BRAIN RES, V188, P281, DOI 10.1016/j.bbr.2007.11.007; Alon G, 2007, NEUROREHAB NEURAL RE, V21, P207, DOI 10.1177/1545968306297871; Angevaren M., 2008, COCHRANE DATABASE SY; Askim T, 2009, NEUROREHAB NEURAL RE, V23, P295, DOI 10.1177/1545968308322840; Beer S, 2008, MULT SCLER J, V14, P231, DOI 10.1177/1352458507082358; Bestmann S, 2008, CEREB CORTEX, V18, P1281, DOI 10.1093/cercor/bhm159; Blesch A, 2009, TRENDS NEUROSCI, V32, P41, DOI 10.1016/j.tins.2008.09.008; Boake C, 2007, NEUROREHAB NEURAL RE, V21, P14, DOI 10.1177/1545968306291858; Byl NN, 2008, NEUROREHAB NEURAL RE, V22, P494, DOI 10.1177/1545968308317431; Carmichael ST, 2008, STROKE, V39, P1380, DOI 10.1161/STROKEAHA.107.499962; Cheeran B, 2009, NEUROREHAB NEURAL RE, V23, P97, DOI 10.1177/1545968308326636; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; Criscimagna-Hemminger SE, 2008, J NEUROSCI, V28, P9610, DOI 10.1523/JNEUROSCI.3071-08.2008; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Dobkin BH, 2003, NEUROREHAB NEURAL RE, V17, P153, DOI 10.1177/0888439003255508; Dobkin BH, 2008, NEUROREHAB NEURAL RE, V22, P105, DOI 10.1177/1545968308315046; Dobkin BH, 2008, NAT CLIN PRACT NEURO, V4, P76, DOI 10.1038/ncpneuro0709; Dobkin BH, 2007, DEV NEUROBIOL, V67, P1133, DOI 10.1002/dneu.20514; Dobkin BH, 2009, NEUROREHAB NEURAL RE, V23, P197, DOI 10.1177/1545968309331863; Dobkin BH, 2009, NEUROREHAB NEURAL RE, V23, P633, DOI 10.1177/1545968309338290; Dobkin BH, 2007, NEUROREHAB NEURAL RE, V21, P3, DOI 10.1177/1545968306297329; Donaldson C, 2009, NEUROREHAB NEURAL RE, V23, P389, DOI 10.1177/1545968308326635; Dromerick AW, 2009, NEUROLOGY, V73, P195, DOI 10.1212/WNL.0b013e3181ab2b27; Duncan PW, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-39; Enzinger C, 2009, STROKE, V40, P2460, DOI 10.1161/STROKEAHA.109.550053; Fawcett JW, 2009, BRAIN, V132, P1417, DOI 10.1093/brain/awp121; Franceschini M, 2009, STROKE, V40, P3079, DOI 10.1161/STROKEAHA.109.555540; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; Fujiwara T, 2009, NEUROREHAB NEURAL RE, V23, P125, DOI 10.1177/1545968308321777; Furkiewicz MT, 2007, NEUROREHAB NEURAL RE, V21, P527, DOI 10.1177/1545968307301872; Goodman AD, 2009, LANCET, V373, P732, DOI 10.1016/S0140-6736(09)60442-6; Gueugneau N, 2009, NEUROREHAB NEURAL RE, V23, P237, DOI 10.1177/1545968308321775; Harvey RL, 2009, NEUROREHAB NEURAL RE, V23, P32, DOI 10.1177/1545968308317532; Hassett LM, 2009, J REHABIL MED, V41, P247, DOI 10.2340/16501977-0316; Hesse S, 2008, AM J PHYS MED REHAB, V87, P779, DOI 10.1097/PHM.0b013e318186b4bc; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Hiscock A, 2008, NEUROREHAB NEURAL RE, V22, P228, DOI 10.1177/1545968307307115; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Hornby TG, 2008, STROKE, V39, P1786, DOI 10.1161/STROKEAHA.107.504779; Housman SJ, 2009, NEUROREHAB NEURAL RE, V23, P505, DOI 10.1177/1545968308331148; KERKOVICH D, 2009, NEUROREHABIL NEURAL; Kloosterman MGM, 2009, SPINAL CORD, V47, P196, DOI 10.1038/sc.2008.113; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P160, DOI 10.1177/1545968308320642; Lo AC, 2008, NEUROREHAB NEURAL RE, V22, P661, DOI 10.1177/1545968308318473; Lo AC, 2009, NEUROREHAB NEURAL RE, V23, P775, DOI 10.1177/1545968309338195; Luft AR, 2008, STROKE, V39, P3341, DOI 10.1161/STROKEAHA.108.527531; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Mehrholz J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub2; Morris ME, 2006, NEUROREHAB NEURAL RE, V20, P424, DOI 10.1177/1545968305285092; Pang MYC, 2006, CLIN REHABIL, V20, P97, DOI 10.1191/0269215506cr926oa; Plow EB, 2009, STROKE, V40, P1926, DOI 10.1161/STROKEAHA.108.540823; Pollock A, 2008, STROKE, V39, P519, DOI 10.1161/STROKEAHA.107.492710; Pomeroy VM, 2007, NEUROREHAB NEURAL RE, V21, P509, DOI 10.1177/1545968307300418; Quaney BM, 2009, NEUROREHAB NEURAL RE, V23, P879, DOI 10.1177/1545968309338193; Ridgel AL, 2009, NEUROREHAB NEURAL RE, V23, P600, DOI 10.1177/1545968308328726; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sawaki L, 2008, NEUROREHAB NEURAL RE, V22, P505, DOI 10.1177/1545968308317531; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Simmons L, 2008, NEUROREHAB NEURAL RE, V22, P458, DOI 10.1177/1545968308315597; Snaphaan L, 2009, BRAIN, V132, P1882, DOI 10.1093/brain/awp133; Snook EM, 2009, NEUROREHAB NEURAL RE, V23, P108, DOI 10.1177/1545968308320641; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Tang A, 2009, NEUROREHAB NEURAL RE, V23, P398, DOI 10.1177/1545968308326426; Thrasher TA, 2008, NEUROREHAB NEURAL RE, V22, P706, DOI 10.1177/1545968308317436; van Praag H, 2009, TRENDS NEUROSCI, V32, P283, DOI 10.1016/j.tins.2008.12.007; Verma P, 2008, NEUROREHAB NEURAL RE, V22, P429, DOI 10.1177/1545968307313500; Volpe BT, 2008, NEUROREHAB NEURAL RE, V22, P305, DOI 10.1177/1545968307311102; Ward NS, 2008, CURR OPIN NEUROL, V21, P625, DOI 10.1097/WCO.0b013e32831997af; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Winchester P, 2005, NEUROREHAB NEURAL RE, V19, P313, DOI 10.1177/1545968305281515; Winstein CJ, 2003, NEUROREHAB NEURAL RE, V17, P137, DOI 10.1177/0888439003255511; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	74	44	44	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2009	22	6					563	569		10.1097/WCO.0b013e3283314b11			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	529UK	WOS:000272544100001	19724226	Green Accepted			2022-02-06	
J	Hu, ZG; Wang, HD; Jin, W; Yin, HX				Hu, Zhi Gang; Wang, Han Dong; Jin, Wei; Yin, Hong Xia			Ketogenic Diet Reduces Cytochrome c Release and Cellular Apoptosis Following Traumatic Brain Injury in Juvenile Rats	ANNALS OF CLINICAL AND LABORATORY SCIENCE			English	Article						traumatic brain injury; ketogenic diet; cytochrome c release; apoptosis; brain edema	FOCAL CEREBRAL-ISCHEMIA; D-BETA-HYDROXYBUTYRATE; KETONE-BODIES; CORTICAL CONTUSION; CASPASE ACTIVATION; DNA FRAGMENTATION; EXPRESSION; MITOCHONDRIAL; BCL-2; DEATH	Ketone bodies have been shown to be favorable alternative metabolic substrates and are protective under neuropathologies. At the same time, cytochrome c release has been reported following traumatic brain injury (TBI) and precipitates apoptosis via the mitochondrial pathway. The present study investigated the effects of a ketogenic diet (KD) on TBI. TBI was produced using the Feeney weight-drop model and the animals were fed either normal diet (ND) or KD. Brain edema was estimated by wet/dry weight ratio; cytochrome c was detected by Western blotting; cellular apoptosis in the penumbra area was examined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and active caspase-3 immunohistochemical staining. The results show that brain edema, cytochrome c release, and cellular apoptosis were induced after TBI and that KD reduced these changes dramatically. These findings suggest that KD has potential therapeutic benefit in TBI.	[Hu, Zhi Gang; Wang, Han Dong; Jin, Wei; Yin, Hong Xia] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hdwang_nj@yahoo.com.cn	Yin, Hong/AAC-5784-2020				Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; Babu PP, 2000, NEUROSCI LETT, V291, P196, DOI 10.1016/S0304-3940(00)01404-X; Buki A, 2000, J NEUROSCI, V20, P2825; Cheng BH, 2007, AUTON NEUROSCI-BASIC, V134, P38, DOI 10.1016/j.autneu.2007.02.002; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Eun SH, 2006, BRAIN DEV-JPN, V28, P566, DOI 10.1016/j.braindev.2006.03.011; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; HAWKINS RA, 1979, SCIENCE, V205, P325, DOI 10.1126/science.451608; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keene DL, 2006, PEDIATR NEUROL, V35, P1, DOI 10.1016/j.pediatrneurol.2006.01.005; Kossoff EH, 2006, EPILEPSIA, V47, P421, DOI 10.1111/j.1528-1167.2006.00438.x; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li JY, 2006, NEUROSCIENCE, V142, P789, DOI 10.1016/j.neuroscience.2006.06.064; Li PA, 2001, BRAIN RES, V896, P69, DOI 10.1016/S0006-8993(01)01997-7; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Masuda R, 2005, J NEUROSCI RES, V80, P501, DOI 10.1002/jnr.20464; Matz PG, 2001, STROKE, V32, P506, DOI 10.1161/01.STR.32.2.506; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Papandreou D, 2006, BRIT J NUTR, V95, P5, DOI 10.1079/BJN20051591; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reger MA, 2004, NEUROBIOL AGING, V25, P311, DOI 10.1016/S0197-4580(03)00087-3; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; RINK A, 1995, AM J PATHOL, V147, P1575; Sugawara T, 1999, J NEUROSCI, V19, part. no.; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VanItallie TB, 2005, NEUROLOGY, V64, P728, DOI 10.1212/01.WNL.0000152046.11390.45; Veech RL, 2001, IUBMB LIFE, V51, P241; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wang XD, 2001, GENE DEV, V15, P2922; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Ziegler DR, 2003, NEUROCHEM RES, V28, P1793, DOI 10.1023/A:1026107405399	54	44	45	0	8	ASSOC CLINICAL SCIENTISTS	MIDDLEBURY	PO BOX 1287, MIDDLEBURY, VT 05753 USA	0091-7370	1550-8080		ANN CLIN LAB SCI	Ann. Clin. Lab. Sci.	WIN	2009	39	1					76	83					8	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	405TP	WOS:000263247400012	19201746				2022-02-06	
J	Harris, NG; Carmichael, ST; Hovda, DA; Sutton, RL				Harris, N. G.; Carmichael, S. T.; Hovda, D. A.; Sutton, R. L.			Traumatic Brain Injury Results in Disparate Regions of Chondroitin Sulfate Proteoglycan Expression That Are Temporally Limited	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						chondroitin sulfate proteoglycans; cortex; immunohistochemistry; mRNA; RT-PCR; traumatic brain injury; controlled cortical impact injury; perineuronal nets	SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; EXTRACELLULAR-MATRIX; FUNCTIONAL RECOVERY; CORTICAL CONTUSION; GLIAL SCAR; REACTIVE ASTROCYTES; AXON REGENERATION; PERINEURONAL NETS	Axonal injury is a major hallmark of traumatic brain injury (TBI), and it seems likely that therapies directed toward enhancing axon repair could potentially improve functional outcomes. One potential target is chondroitin sulfate proteoglycans (CSPGs), which are major axon growth inhibitory molecules that are generally, but not always, up-regulated after central nervous system injury. The current study was designed to determine temporal changes in cerebral cortical mRNA or protein expression levels of CSPGs and to determine their regional localization and cellular association by using immunohistochemistry in a controlled cortical impact model of TBI. The results showed significant increases in versican mRNA at 4 and 14 days after TBI but no change in neurocan, aggrecan, or phosphacan. Semiquantitative Western blot (WB) analysis of cortical CSPG protein expression revealed a significant ipsilateral decrease of all CSPGs at 1 day after TBI. Lower CSPG protein levels were sustained until at least 14 days, after which the levels began to normalize. Immunohistochemistry data confirm previous reports of regional increases in CSPG proteins after CNS injury, seen primarily within the developing glial scar after TBI, but also corroborate the WB data by revealing wide areas of pericontusional tissue that are deficient in both extracellular and perineuronal net-associated CSPGs. Given the evidence that CSPGs are largely inhibitory to axonal growth, we interpret these data to indicate a potential for regional spontaneous plasticity after TBI. If this were the case, the gradual normalization of CSPG proteins over time postinjury would suggest that this may be temporally as well as regionally limited. (C) 2009 Wiley-Liss, Inc.	[Harris, N. G.; Hovda, D. A.; Sutton, R. L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Harris, N. G.; Hovda, D. A.; Sutton, R. L.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Carmichael, S. T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA		Harris, NG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu		Harris, Neil/0000-0002-1965-6750; Carmichael, S Thomas/0000-0002-1169-9203	NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055910]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055910] Funding Source: NIH RePORTER	UCLA Brain Injury Research Center; NIH NINDS	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Asher RA, 2000, J NEUROSCI, V20, P2427; Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; ASHER RA, 1995, GLIA, V13, P294, DOI 10.1002/glia.440130406; Aya-ay J, 2005, EXP NEUROL, V193, P149, DOI 10.1016/j.expneurol.2004.11.021; Barritt AW, 2006, J NEUROSCI, V26, P10856, DOI 10.1523/JNEUROSCI.2980-06.2006; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Celio MR, 1998, TRENDS NEUROSCI, V21, P510, DOI 10.1016/S0166-2236(98)01298-3; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Deepa SS, 2006, J BIOL CHEM, V281, P17789, DOI 10.1074/jbc.M600544200; Dityatev A, 2007, DEV NEUROBIOL, V67, P570, DOI 10.1002/dneu.20361; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dobbertin A, 2003, MOL CELL NEUROSCI, V24, P951, DOI 10.1016/S1044-7431(03)00257-4; DOMOWICZ M, 1995, DEV BIOL, V171, P655, DOI 10.1006/dbio.1995.1312; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Emery DL, 2000, J COMP NEUROL, V424, P521; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Garwood J, 2003, J BIOL CHEM, V278, P24164, DOI 10.1074/jbc.M211721200; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; HORNIK K, 2008, R PROJECT STAT COMPU; Houle JD, 2006, J NEUROSCI, V26, P7405, DOI 10.1523/JNEUROSCI.1166-06.2006; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Jain A, 2004, J NEUROSCI RES, V77, P299, DOI 10.1002/jnr.20161; Jaworski DM, 1999, EXP NEUROL, V157, P327, DOI 10.1006/exnr.1999.7062; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Lander C, 1998, J NEUROSCI, V18, P174; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Lemons ML, 2001, J NEUROSCI, V21, P4772, DOI 10.1523/JNEUROSCI.21-13-04772.2001; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Maeda N, 1996, DEVELOPMENT, V122, P647; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Matsui F, 2005, J NEUROSCI RES, V81, P837, DOI 10.1002/jnr.20603; Matsui F, 2002, NEUROSCIENCE, V112, P773, DOI 10.1016/S0306-4522(02)00136-7; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; Miyata S, 2004, BRAIN RES, V1017, P163, DOI 10.1016/j.brainres.2004.05.034; Moon LDF, 2002, NEUROSCIENCE, V109, P101, DOI 10.1016/S0306-4522(01)00457-2; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Okamoto M, 2003, EXP NEUROL, V184, P179, DOI 10.1016/S0014-4886(03)00251-6; Ong WY, 1999, NEUROSCIENCE, V92, P83, DOI 10.1016/S0306-4522(98)00751-9; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Properzi F, 2003, BIOCHEM SOC T, V31, P335, DOI 10.1042/BST0310335; Rasband W. S, 2008, IMAGEJ; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Reeves TM, 2003, J NEUROSCI, V23, P10182; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Seidenbecher CI, 2002, J NEUROCHEM, V83, P738, DOI 10.1046/j.1471-4159.2002.01183.x; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Soares S, 2007, EUR J NEUROSCI, V26, P1446, DOI 10.1111/j.1460-9568.2007.05794.x; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; Yick LW, 2003, EXP NEUROL, V182, P160, DOI 10.1016/S0014-4886(02)00052-3	73	44	46	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	OCT	2009	87	13					2937	2950		10.1002/jnr.22115			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	492SB	WOS:000269678600013	19437549	Green Accepted			2022-02-06	
J	Wu, Z; Hao, SY; Zhang, JT; Zhang, LW; Jia, GJ; Tang, J; Mao, XR; Wang, L; Wang, ZC				Wu, Zhen; Hao, Shuyu; Zhang, Junting; Zhang, Liwei; Jia, Guijun; Tang, Jie; Mao, Xinru; Wang, Liang; Wang, Zhongcheng			Foramen magnum meningiomas: experiences in 114 patients at a single institute over 15 years	SURGICAL NEUROLOGY			English	Article						Foramen magnum; Meningioma; Surgical approach; Microsurgery	TRAUMATIC BRAIN-INJURY; FAR-LATERAL APPROACH; INTRADURAL LESIONS; CERVICAL-SPINE; BENIGN-TUMORS; ANTERIOR; HYPOPITUITARISM; RESECTION; MIDLINE	Background: Although there has been great development in the anatomical understanding and operative techniques for skull base tumors, controversy still exists regarding the optimal surgical strategies for the FMMs. We report clinical and radiologic features as well as the surgical findings and outcome for patients with FMM treated at our institution over the last 15 years. Methods: We reviewed 114 consecutive cases of FMM operated between May 1993 and June 2008 in the neurosurgery department at Beijing Tiantan Hospital. Results: There were 68 female and 46 male patients (mean age, 52.3 years; range, 28-76 years). Foramen magnum meningiomas were classified as anterior (80 cases), anterolateral (24 cases), and posterolateral (10 cases). Mean duration of symptoms was 11.7 months (ranging from 1.5 to 240 months). Cervico-occipital pain (80.7%) and headache and dizziness (42.1%) were the most common presenting symptoms. The preoperative KPS was 72.5 +/- 8.3. Mean maximum diameter of the tumors on MRI was 3.35 cm (range, 1.5-4.7 cm). Posterior midline approach was performed in 10 cases, far-lateral retrocondylar approach in 97 cases, and extended far-lateral approach in 7 cases. Gross total resection was achieved in 86.0% of patients and subtotal resection in 14.0%. Surgical mortality was 1.8%. Follow-up data were available for 93 patients, with a mean follow-up of 90.3 months (range, 1-180 months), of which 59 (63.4%) lived a normal life (KPS, 80-100). Conclusion: Our experience suggests that most anterior and anterolateral FMMs can be completely resected by a far-lateral retrocondylar approach without resection of the occipital condyle. Complete resection of the tumor should be attempted at the first operation. Postoperative management of FMM is important for the prognosis. Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.	[Wu, Zhen; Zhang, Junting; Zhang, Liwei; Jia, Guijun; Tang, Jie; Mao, Xinru; Wang, Liang] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Hao, Shuyu; Wang, Zhongcheng] Capital Med Univ, Beijing Neurosurg Inst, Beijing 100050, Peoples R China		Zhang, JT (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China.	zhangjunting2003@yahoo.com.cn			Capital Medical Development Foundation	We gratefully acknowledge grant No. 2007-2064 from the Capital Medical Development Foundation.	ABE H, 1983, SHINKEI GEKA, V11, P353; Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Arnaldo E, 2002, NEUROL MED-CHIR, V42, P472, DOI 10.2176/nmc.42.472; Arnautovic KI, 2000, J NEUROSURG, V92, P71, DOI 10.3171/spi.2000.92.1.0071; Bassiouni H, 2006, NEUROSURGERY, V59, P1177, DOI 10.1227/01.NEU.0000245629.77968.37; Bertalanffy H, 1996, Acta Neurochir Suppl, V65, P82; Boulton Melfort R, 2003, Neurosurg Focus, V14, pe10; Bruneau M, 2008, NEUROSURG REV, V31, P19, DOI 10.1007/s10143-007-0097-1; CHONO Y, 1985, Neurological Surgery, V13, P109; David C A, 1997, Clin Neurosurg, V44, P467; de Tella OI, 2006, ARQ NEURO-PSIQUIAT, V64, P437, DOI 10.1590/S0004-282X2006000300016; George B, 1997, SURG NEUROL, V47, P371, DOI 10.1016/S0090-3019(96)00204-2; GEORGE B, 1988, SURG NEUROL, V29, P484, DOI 10.1016/0090-3019(88)90145-0; Goel A, 2001, NEUROSURGERY, V49, P102, DOI 10.1097/00006123-200107000-00016; Gupta SK, 2004, BRIT J NEUROSURG, V18, P164, DOI 10.1080/02688690410001681028; HUSAG L, 1983, COMPUTERTOM SONOGRAP, V3, P149; KENNING TJ, 2008, J NEUROONCOL; KIM KS, 1982, SURG NEUROL, V17, P287, DOI 10.1016/0090-3019(82)90124-0; KRATIMENOS GP, 1993, BRIT J NEUROSURG, V7, P129, DOI 10.3109/02688699309103469; Menezes AH, 2008, CHILD NERV SYST, V24, P1203, DOI 10.1007/s00381-008-0597-5; MEYER FB, 1984, J NEUROSURG, V61, P136, DOI 10.3171/jns.1984.61.1.0136; Muthukumar N, 1999, SURG NEUROL, V51, P268, DOI 10.1016/S0090-3019(98)00099-8; Nanda A, 2002, J NEUROSURG, V96, P302, DOI 10.3171/jns.2002.96.2.0302; Pamir MN, 2004, J CLIN NEUROSCI, V11, P863, DOI 10.1016/j.jocn.2004.02.007; Rhoton A L Jr, 1994, Neurosurg Clin N Am, V5, P349; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Schneider HJ, 2006, ACTA NEUROCHIR, V148, P449, DOI 10.1007/s00701-005-0724-y; Sekhar LN, 1996, J NEURO-ONCOL, V29, P249, DOI 10.1007/BF00165655; SEN CN, 1990, NEUROSURGERY, V27, P197, DOI 10.1227/00006123-199008000-00004; Sharma BS, 1999, NEUROL INDIA, V47, P268; Tsao GJ, 2008, J GEN INTERN MED, V23, P206, DOI 10.1007/s11606-007-0474-z; Wang Zhen-yu, 2004, Beijing Da Xue Xue Bao Yi Xue Ban, V36, P634	32	44	48	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	OCT	2009	72	4					376	382		10.1016/j.surneu.2009.05.006			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	498YW	WOS:000270183900012	19608233				2022-02-06	
J	Tsaousides, T; Warshowsky, A; Ashman, TA; Cantor, JB; Spielman, L; Gordon, WA				Tsaousides, Theodore; Warshowsky, Adam; Ashman, Teresa A.; Cantor, Joshua B.; Spielman, Lisa; Gordon, Wayne A.			The Relationship Between Employment-Related Self-Efficacy and Quality of Life Following Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article; Proceedings Paper	84th Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	OCT 03-07, 2007	Washington, DC	Amer Congress Rehabil Med		traumatic brain injury; employment; self-efficacy; quality of life	WORK; RETURN; SATISFACTION; INDIVIDUALS; DISABILITY; COMMUNITY; STABILITY; MODEL	Objectives: This study examines the relative contribution of employment-related and general self-efficacy to perceptions of quality of life (QoL) for individuals with traumatic brain injury. Design: Correlational. Setting: Community-based research and training center. Participants: 427 individuals with self-reported TBI under the age of 65 were included in analysis. Main Outcome Measure: Employment-related self-efficacy, general self-efficacy, perceived quality of life (PQoL), unmet important needs (UIN). Results: Significant correlations were found between income, injury severity, age at injury, and employment and the QoL variables. In addition, employment-related and general self-efficacy correlated positively with both PQoL and UIN. Employment-related and general self-efficacy accounted for 16% of the variance in PQoL and 9.5% of the variance in UIN, over and above other variables traditionally associated with QoL. Conclusions: These findings highlight the importance of including subjective appraisals of employment, such as perceived self-efficacy at the workplace, in assessing QoL and successful return to work following TBI.	[Tsaousides, Theodore; Warshowsky, Adam; Ashman, Teresa A.; Cantor, Joshua B.; Spielman, Lisa; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA		Tsaousides, T (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.	theodore.tsaousides@mssm.edu	Ashman, Teresa/B-1621-2013				Andrews F. M., 1976, SOCIAL INDICATORS WE; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BIGELOW DA, 1991, COMMUNITY MENT HLT J, V27, P125, DOI 10.1007/BF00752815; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dumont C, 2004, J HEAD TRAUMA REHAB, V19, P431, DOI 10.1097/00001199-200411000-00002; FLANAGAN T, 1982, QUEENS QUART, V89, P596; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Oppermann JD, 2004, BRAIN INJURY, V18, P941, DOI 10.1080/02699050410001671919; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Tsaousides T, 2008, REHABIL PSYCHOL, V53, P456, DOI 10.1037/a0012579; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	34	44	45	0	5	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2009	54	3					299	305		10.1037/a0016807			7	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology; Rehabilitation	488SW	WOS:000269371100007	19702428				2022-02-06	
J	Topjian, AA; Lin, R; Morris, MC; Ichord, R; Drott, H; Bayer, CR; Helfaer, MA; Nadkarni, V				Topjian, Alexis A.; Lin, Richard; Morris, Marilyn C.; Ichord, Rebecca; Drott, Henry; Bayer, Carey R.; Helfaer, Mark A.; Nadkarni, Vinay			Neuron-specific enolase and S-100B are associated with neurologic outcome after pediatric cardiac arrest	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						neuron-specific enolase; nerve tissue protein S-100; prognosis; heart arrest; biological markers; children	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; PLASMINOGEN-ACTIVATOR INHIBITOR-1; EUROPEAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; CARDIOPULMONARY-RESUSCITATION; SERUM-LEVELS; REGAINING CONSCIOUSNESS; CEREBROSPINAL-FLUID	Objective: To characterize the pattern of serum biochemical markers of central nervous system injury (neuron-specific enolase [NSE], S-100B, plasminogen activator inhibitor-1 [PAI-1]) after pediatric cardiac arrest and determine whether there is an association between biomarker concentrations and neurologic outcome. Design: Prospective, observational study. Setting: Urban, tertiary care children's hospital. Patients: Cardiac arrest survivors, n = 35. Interventions: Serial blood sampling, pediatric cerebral performance category, and standardized neurologic examination. Measurements and Main Results: Serial serum NSE and S-100B concentrations over 96 hrs and PAI-1 at 24 hrs were measured in children (age < 18 yrs) who had return of spontaneous circulation following cardiac arrest. Neurologic outcome was prospectively categorized as poor if the change in pre- to postarrest pediatric cerebral performance category was >= 2. Biomarker concentrations were compared between outcome groups and between survival groups using longitudinal analysis correcting for multiple comparisons. Median levels (25th, 75th percentiles) are reported. Receiver operating characteristic analyses were performed at all time points. Biomarker concentrations showed statistically significant differences. Of the 35 patients, neurologic outcomes were poor in 19, with 15 deaths. Median NSE concentrations differed by outcome when measured at >= 48 hrs, and by survival at >= 24 hrs. S-100B concentrations were not significantly associated with neurologic outcome. S-100B levels were associated with survival outcome at >= 48 hrs. PAI-1 levels were not significantly associated with either neurologic or survival outcomes. Conclusions: The timing, intensity, and duration of serum NSE and S-100B biomarker concentration patterns are associated with neurologic and survival outcomes following pediatric cardiac arrest. Serum NSE concentrations at >= 48 hrs are associated with neurologic outcome, whereas serum S-100B levels at >= 48 hrs are associated with survival. Prospective analysis of these markers may help to predict outcomes and guide postresuscitative therapies. (Pediatr Crit Care Med 2009; 10:479-490)	[Topjian, Alexis A.; Lin, Richard; Helfaer, Mark A.; Nadkarni, Vinay] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Ichord, Rebecca] Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; [Morris, Marilyn C.] Childrens Hosp New York Presbyterian, Dept Pediat, New York, NY USA; [Drott, Henry] Childrens Hosp Philadelphia, Clin Lab, Philadelphia, PA 19104 USA; [Bayer, Carey R.] Morehouse Sch Med, Dept Pediat, Ctr Excellence Sexual Hlth, Atlanta, GA 30310 USA		Topjian, AA (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA.	topjian@email.chop.edu			Endowed Chair of Pediatric Critical Care Medicine; CTRC [M01-RR00240]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000240] Funding Source: NIH RePORTER	Supported, in part, by Endowed Chair of Pediatric Critical Care Medicine and CTRC grant M01-RR00240.	Akcan-Arikan A, 2007, KIDNEY INT, V71, P1028, DOI 10.1038/sj.ki.5002231; Balasa VV, 1999, THROMB HAEMOSTASIS, V81, P739, DOI 10.1055/s-0037-1614564; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bottiger BW, 2001, CIRCULATION, V103, P2694; DALESSANDRO M, 1992, TUMOR BIOL, V13, P352, DOI 10.1159/000217786; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; Estelles A, 2001, THROMB HAEMOSTASIS, V86, P647; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; GANDO S, 1995, CRIT CARE MED, V23, P1835, DOI 10.1097/00003246-199511000-00009; Gando S, 1997, THROMB HAEMOSTASIS, V77, P278; Geppert A, 2001, CRIT CARE MED, V29, P1670, DOI 10.1097/00003246-200109000-00003; Hachimi-Idrissi S, 2002, RESUSCITATION, V53, P251, DOI 10.1016/S0300-9572(02)00027-8; Hajnal BL, 1999, PEDIATR NEUROL, V21, P788, DOI 10.1016/S0887-8994(99)00101-0; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hu JR, 1997, J NEUROCHEM, V69, P2294; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Lindberg L, 1998, J THORAC CARDIOV SUR, V116, P281, DOI 10.1016/S0022-5223(98)70128-X; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Meaney PA, 2006, PEDIATRICS, V118, P2424, DOI 10.1542/peds.2006-1724; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; MULLIE A, 1988, LANCET, V1, P137; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Nagdyman N, 2003, PEDIATR RES, V54, P270, DOI 10.1203/01.PDR.0000072518.98189.A0; Nsiri B, 1996, HEMATOL CELL THER, V38, P279, DOI 10.1007/s00282-996-0279-2; Palmio J, 2001, J NEUROL SCI, V183, P27, DOI 10.1016/S0022-510X(00)00478-0; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; Prohl J, 2007, CRIT CARE MED, V35, P1230, DOI 10.1097/01.CCM.0000261892.10559.85; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Reisinger J, 2007, EUR HEART J, V28, P52, DOI 10.1093/eurheartj/ehl316; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Samson RA, 2006, NEW ENGL J MED, V354, P2328, DOI 10.1056/NEJMoa052917; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Schindler MB, 1996, NEW ENGL J MED, V335, P1473, DOI 10.1056/NEJM199611143352001; SCHMECHEL D, 1978, SCIENCE, V199, P313, DOI 10.1126/science.339349; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Shevell MI, 1999, PEDIATR NEUROL, V21, P776, DOI 10.1016/S0887-8994(99)00102-2; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Slonim AD, 1997, CRIT CARE MED, V25, P1951, DOI 10.1097/00003246-199712000-00008; Snyder-Ramos SA, 2004, ANAESTHESIA, V59, P344, DOI 10.1111/j.1365-2044.2004.03663.x; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Spinella Philip C, 2004, Pediatr Crit Care Med, V5, P53, DOI 10.1097/01.PCC.0000102221.98378.7D; Suzuki Y, 1999, NEUROLOGY, V53, P1761, DOI 10.1212/WNL.53.8.1761; Tekgul H, 2004, PEDIATR NEUROL, V31, P326, DOI 10.1016/j.pediatrneurol.2004.05.004; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88; ZARITSKY A, 1995, PEDIATRICS, V96, P765; ZELTZER PM, 1986, CANCER, V57, P1230, DOI 10.1002/1097-0142(19860315)57:6<1230::AID-CNCR2820570628>3.0.CO;2-#; ZELTZER PM, 1983, LANCET, V2, P361; Zingler VC, 2003, EUR NEUROL, V49, P79, DOI 10.1159/000068503	66	44	45	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUL	2009	10	4					479	490		10.1097/PCC.0b013e318198bdb5			12	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	468SI	WOS:000267840500008	19307814				2022-02-06	
J	Agoston, DV; Gyorgy, A; Eidelman, O; Pollard, HB				Agoston, Denes V.; Gyorgy, Andrea; Eidelman, Ofer; Pollard, Harvey B.			Proteomic Biomarkers for Blast Neurotrauma: Targeting Cerebral Edema, Inflammation, and Neuronal Death Cascades	JOURNAL OF NEUROTRAUMA			English	Article						antibody microarray; bioinformatics; blast; mass spectrometry; protein microarray; reverse-capture; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HUMAN CEREBROSPINAL-FLUID; CENTRAL-NERVOUS-SYSTEM; PROTEIN MICROARRAYS; GLIAL ACTIVATION; EXPRESSION; CYTOKINES; DISCOVERY; ASTROCYTE; HISTORY	Proteomics for blast traumatic brain injury (bTBI) research represents an exciting new approach that can greatly help to address the complex pathology of this condition. Antibody-based platforms, antibody microarrays (AbMA), and reverse capture protein microarrays (RCPM) can complement the classical methods based on 2D gel electrophoresis and mass spectrometry (2DGE/MS). These new technologies can address problematic issues, such as sample complexity, sensitivity, quantitation, reproducibility, and analysis time, which are typically associated with 2DGE/MS. Combined with bioinformatics analysis and interpretation of primary microarray data, these methods will generate a new level of understanding about bTBI at the level of systems biology. As biological and clinical knowledge and the availability of these systems become more widely established, we expect that AbMA and RCPM will be used routinely in clinical diagnostics, and also for following therapeutic progress. At the technical level, we anticipate that these platforms will evolve to accommodate comprehensive, high-speed, label-free analysis on a human proteome-wide scale.	[Agoston, Denes V.; Gyorgy, Andrea] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Eidelman, Ofer; Pollard, Harvey B.] Uniformed Serv Univ Hlth Sci, Ctr Med Prote, Bethesda, MD 20814 USA		Agoston, DV (corresponding author), Uniformed Serv Univ Sch Med, Dept Anat Physiol & Genet, Neurosurg Program Natl Capital Consortium, Program Neurosci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.mil					Alaiya AA, 2000, INT J CANCER, V86, P731, DOI 10.1002/(SICI)1097-0215(20000601)86:5<731::AID-IJC20>3.0.CO;2-A; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Baranzini SE, 2006, AUTOIMMUNITY, V39, P651, DOI 10.1080/08916930601061686; Breitling R, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-100; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Cahill DJ, 2001, J IMMUNOL METHODS, V250, P81, DOI 10.1016/S0022-1759(01)00325-8; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Davson H, 1966, Sci Basis Med Annu Rev, P238; Doherty NS, 1998, ELECTROPHORESIS, V19, P355, DOI 10.1002/elps.1150190234; EKINS RP, 1991, CLIN CHEM, V37, P1955; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Guy R J, 2000, J R Nav Med Serv, V86, P27; HARRIS EK, 1975, CLIN CHEM, V21, P1457; HARRIS EK, 1974, CLIN CHEM, V20, P1535; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; KAUR C, 1997, ANN ACAD MED SINGAP, V29, P27; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Knezevic V, 2001, PROTEOMICS, V1, P1271, DOI 10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.3.CO;2-Y; Levison SW, 2000, GLIA, V32, P328, DOI 10.1002/1098-1136(200012)32:3<328::AID-GLIA110>3.0.CO;2-7; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 2002, NAT GENET, V32, P526, DOI 10.1038/ng1037; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Mircean C, 2005, BIOINFORMATICS, V21, P1935, DOI 10.1093/bioinformatics/bti258; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Oltvai ZN, 2002, SCIENCE, V298, P763, DOI 10.1126/science.1078563; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Pieroni E, 2008, PROTEOMICS, V8, P799, DOI 10.1002/pmic.200700767; Pollard HB, 2007, PROTEOM CLIN APPL, V1, P934, DOI 10.1002/prca.200700154; Pollard HB, 2006, MOL CELL PROTEOMICS, V5, P1628, DOI 10.1074/mcp.M600091-MCP200; Pollard HB, 2005, PROTEOMICS, V5, P2210, DOI 10.1002/pmic.200401120; Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21; Ramaswamy Anitha, 2005, Proteome Sci, V3, P9, DOI 10.1186/1477-5956-3-9; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Redell JB, 2007, J NEUROSCI RES, V85, P1980, DOI 10.1002/jnr.21324; Redell JB, 2007, NEUROSCI LETT, V413, P36, DOI 10.1016/j.neulet.2006.11.060; Rifai N, 2006, NAT BIOTECHNOL, V24, P971, DOI 10.1038/nbt1235; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schweitzer B, 2002, CURR OPIN BIOTECH, V13, P14, DOI 10.1016/S0958-1669(02)00278-1; Soen Y, 2003, PLOS BIOL, V1, P429, DOI 10.1371/journal.pbio.0000065; Srivastava M, 2006, MOL GENET METAB, V87, P303, DOI 10.1016/j.ymgme.2005.10.021; Srivastava M, 2004, CLIN CANCER RES, V10, P2344, DOI 10.1158/1078-0432.CCR-03-0278; Srivastava M, 2007, INT J CANCER, V121, P2628, DOI 10.1002/ijc.23008; Stoll G, 2000, J NEURAL TRANSM-SUPP, P81; Sylvia FR, 2001, MIL MED, V166, P918, DOI 10.1093/milmed/166.10.918; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Wang J, 2002, CURR TOP MICROBIOL, V265, P23; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, NEW ENGL J MED, V353, P633; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	66	44	45	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2009	26	6					901	911		10.1089/neu.2008.0724			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	455OV	WOS:000266773600008	19397421				2022-02-06	
J	Kenning, TJ; Gandhi, RH; German, JW				Kenning, Tyler J.; Gandhi, Ravi H.; German, John W.			A comparison of hinge craniotomy and decompressive craniectomy for the treatment of malignant intracranial hypertension: early clinical and radiographic analysis	NEUROSURGICAL FOCUS			English	Article						decompressive craniectomy; hinge craniotomy; cerebral decompression; intracranial hypertension	TRAUMATIC BRAIN-INJURY; CEREBRAL-ARTERY INFARCTION; HEMICRANIECTOMY; CHILDREN; EXPANSION	Object. Hinge craniotomy (HC) has recently been described as an alternative to decompressive craniectomy (DC). Although HC may obviate the need for cranial reconstruction, an analysis comparing HC to DC has not yet been published. Methods. A retrospective review was conducted of 50 patients who underwent cranial decompression (20 with HC, 30 with DC). Baseline demographics, neurological examination results, and underlying pathology were reviewed. Clinical outcome was assessed by length of ventilatory support, length of intensive care unit stay, and survival at discharge. Control of intracranial hypertension was assessed by average daily intracranial pressure (ICP) for the duration of ICP monitoring and an ICP therapeutic intensity index. Radiographic outcomes were assessed by comparing preoperative and postoperative CT scans for: 1) Rotterdam score; 2) postoperative volume of cerebral expansion; 3) presence of uncal herniation; 4) intracerebral hemorrhage; and 5) extraaxial hematoma. Postoperative CT scans were analyzed for the size of the craniotomy/craniectomy and magnitude of extracranial herniation. Results. No significant differences were identified in baseline demographics, neurological examination results, or Rotterdam score between the HC and DC groups. Both HC and DC resulted in adequate control of ICP, as reflected in the average ICP for each group of patients (HC = 12.0 +/- 5.6 mm Hg, DC = 12.7 +/- 4.4 mm Hg; p > 0.05) at the same average therapeutic intensity index (HC = 1.2 +/- 0.3, DC = 1.2 +/- 0.4; p > 0.05). The need for reoperation (3 [15%] of 20 patients in the HC group, 3 [10%] of 30 patients in the DC group; p > 0.05), hospital survival (15 [75%] of 20 in the HC group, 21 [70%] of 30 in the DC group; p > 0.05), and mean duration of both mechanical ventilation (9.0 +/- 7.2 days in the HC group, 11.7 +/- 12.0 days in the DC group; p > 0.05) and intensive care unit stay (11.6 +/- 7.7 days in the HC group, 15.6 +/- 15.3 days in the DC group; p > 0.05) were similar. The difference in operative time for the two procedures was not statistically significant (130.4 +/- 71.9 minutes in the HC group, 124.9 +/- 63.3 minutes in the DC group; p > 0.05). The size of the cranial defect was comparable between the 2 groups. Postoperative imaging characteristics, including Rotterdam score, also did not differ significantly. Although a smaller volume of cerebral expansion was associated with HC (77.5 +/- 54.1 ml) than DC (105.1 +/- 65.1 ml), this difference was not statistically significant. Conclusions. Hinge craniotomy appears to be at least as good as DC in providing postoperative ICP control and results in equivalent early clinical outcomes. (DOI: 10.3171/2009.4.FOCUS0960)	[Kenning, Tyler J.; Gandhi, Ravi H.; German, John W.] Albany Med Ctr, Div Neurosurg, Albany, NY 12208 USA		Kenning, TJ (corresponding author), Albany Med Ctr, Div Neurosurg, 47 New Scotland Ave,MC-10, Albany, NY 12208 USA.	kennint@mail.amc.edu					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Chen CC, 2007, J CLIN NEUROSCI, V14, P317, DOI 10.1016/j.jocn.2005.05.024; Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Goettler CE, 2007, J TRAUMA, V62, P777, DOI 10.1097/TA.0b013e31802ee55e; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018; KO K, 2007, NEUROSURGERY S2, V60; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Pillai A, 2007, J NEUROSURG, V106, P59, DOI 10.3171/jns.2007.106.1.59; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	20	44	46	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	JUN	2009	26	6							E6	10.3171/2009.4.FOCUS0960			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	451WK	WOS:000266501400006	19485719	Bronze			2022-02-06	
J	Almaguel, FG; Liu, JW; Pacheco, FJ; Casiano, CA; De Leon, M				Almaguel, Frankis G.; Liu, Jo-Wen; Pacheco, Fabio J.; Casiano, Carlos A.; De Leon, Marino			Activation and Reversal of Lipotoxicity in PC12 and Rat Cortical Cells Following Exposure to Palmitic Acid	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						ASCOS; DHA; hypoxia/ischemia; lipotoxicity; neurotoxicity; traumatic brain injury	POLYUNSATURATED FATTY-ACIDS; FOCAL CEREBRAL-ISCHEMIA; PERCUSSION BRAIN-INJURY; DOCOSAHEXAENOIC ACID; GENE-EXPRESSION; HUMAN-ALBUMIN; NEUROTROPHIC FACTOR; LIPID-PEROXIDATION; OXIDATIVE STRESS; PRIMARY CULTURE	Lipotoxicity involves a series of pathological cellular responses after exposure to elevated levels of fatty acids. This process may be detrimental to normal cellular homeostasis and cell viability. The present study shows that nerve growth factor-differentiated PC12 cells (NGFDPC12) and rat cortical cells (RCC) exposed to high levels of palmitic acid (PA) exhibit significant lipotoxicity and death linked to an "augmented state of cellular oxidative stress" (ASCOS). The ASCOS response includes generation of reactive oxygen species (ROS), alterations in the mitochondrial transmembrane potential, and increase in the mRNA levels of key cell death/survival regulatory genes. The observed cell death was apoptotic based on nuclear morphology, caspase-3 activation, and cleavage of lamin B and PARR Quantitative real-time PCR measurements showed that cells undergoing lipotoxicity exhibited an increase in the expression of the mRNAs encoding the cell death-associated proteins BNIP3 and FAS receptor. Cotreatment of NGFDPC12 and RCC cells undergoing lipotoxicity with docosahexaenoic acid (DHA) and bovine serum albumin (BSA) significantly reduced cell death within the first 2 hr following the initial exposure to PA. The data suggest that lipotoxicity in NGFDPC12 and cortical neurons triggers a strong cell death apoptotic response. Results with NGFDPC12 cells suggest a linkage between induction of ASCOS and the apoptotic process and exhibit a temporal window that is sensitive to DHA and BSA interventions. (C) 2008 Wiley-Liss, Inc.	[Almaguel, Frankis G.; Liu, Jo-Wen; Pacheco, Fabio J.; Casiano, Carlos A.; De Leon, Marino] Loma Linda Univ, Ctr Hlth Disparties & Mol Med, Sch Med, Loma Linda, CA 92350 USA; [Almaguel, Frankis G.; Liu, Jo-Wen; Pacheco, Fabio J.; Casiano, Carlos A.; De Leon, Marino] Loma Linda Univ, Dept Basic Sci, Sch Med, Loma Linda, CA 92350 USA; [Pacheco, Fabio J.] Ctr Univ Adventista Sao Paulo, Dept Biol Sci, Sao Paulo, Brazil		De Leon, M (corresponding author), Loma Linda Univ, Ctr Hlth Disparties & Mol Med, Sch Med, Loma Linda, CA 92350 USA.	madeleon@llu.edu	De Leon, Marino/A-6922-2009	De Leon, Marino/0000-0001-6576-785X	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25 GM060507, R25 GM060507-08, R25 GM060507-01A1, R25 GM060507-07, R25 GM060507-02] Funding Source: Medline; NIMHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [P20 MD006988, P20 MD001632-04, P20 MD001632, P20 MD001632-03] Funding Source: Medline; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [P20MD001632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM060507] Funding Source: NIH RePORTER; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [P20MD006988] Funding Source: NIH RePORTER		ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; Aid S, 2003, J LIPID RES, V44, P1545, DOI 10.1194/jlr.M300079-JLR200; Arab K, 2006, BRIT J NUTR, V95, P18, DOI 10.1079/BJN20051626; AUESTAD N, 1991, J NEUROCHEM, V56, P1376, DOI 10.1111/j.1471-4159.1991.tb11435.x; Bazan NG, 2005, ANN NY ACAD SCI, V1053, P137, DOI 10.1196/annals.1344.011; Bazan NG, 2005, BRAIN PATHOL, V15, P159; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; Bazan NG, 2006, CELL MOL NEUROBIOL, V26, P901, DOI 10.1007/s10571-006-9064-6; Belayev L, 2005, STROKE, V36, P118, DOI 10.1161/01.STR.0000149620.74770.2e; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Belayev L, 2002, STROKE, V33, P1077, DOI 10.1161/hs0402.105555; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Belayev L, 2004, BRAIN RES, V998, P243, DOI 10.1016/j.brainres.2003.11.015; Belayev L, 1997, J NEUROSURG, V87, P595, DOI 10.3171/jns.1997.87.4.0595; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; CAVANAGH ME, 1985, ANAT EMBRYOL, V172, P345, DOI 10.1007/BF00318983; de Turco EBR, 2002, J NEUROCHEM, V83, P515, DOI 10.1046/j.1471-4159.2002.01121.x; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; DYKENS JA, 1994, J NEUROCHEM, V63, P584; EDMOND J, 1987, J NEUROSCI RES, V18, P551, DOI 10.1002/jnr.490180407; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Garcia MC, 1998, J NEUROCHEM, V70, P24; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; Guajardo MH, 2002, BBA-MOL CELL BIOL L, V1581, P65, DOI 10.1016/S1388-1981(02)00121-X; HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Homayoun P, 1997, J NEUROCHEM, V69, P199; Horrocks LA, 2004, PROSTAG LEUKOTR ESS, V70, P361, DOI 10.1016/j.plefa.2003.12.011; Hulbert AJ, 2003, J EXP BIOL, V206, P2303, DOI 10.1242/jeb.00399; JESBERGER JA, 1991, INT J NEUROSCI, V57, P1, DOI 10.3109/00207459109150342; Kilkus JP, 2008, J NEUROCHEM, V106, P1745, DOI 10.1111/j.1471-4159.2008.05490.x; Kim HY, 2004, BIOCHEMISTRY-US, V43, P1030, DOI 10.1021/bi035197x; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003-MCP200; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; Remmers M, 1999, BRAIN RES, V827, P237, DOI 10.1016/S0006-8993(99)01304-9; Rokyta R, 1996, Cesk Fysiol, V45, P4; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Singh SK, 2007, GROWTH FACTORS, V25, P363, DOI 10.1080/08977190801886905; SODERBERG M, 1991, LIPIDS, V26, P421, DOI 10.1007/BF02536067; Stillwell W, 2005, REPROD NUTR DEV, V45, P559, DOI 10.1051/rnd:2005046; SUN DD, 1994, J NEUROCHEM, V62, P1921; Tabernero A, 2002, J BIOL CHEM, V277, P4240, DOI 10.1074/jbc.M108760200; Ulloth JE, 2003, J NEUROCHEM, V84, P655, DOI 10.1046/j.1471-4159.2003.01571.x; Unger RH, 2003, TRENDS ENDOCRIN MET, V14, P398, DOI 10.1016/j.tem.2003.09.008; Unger RH, 2000, INT J OBESITY, V24, pS28, DOI 10.1038/sj.ijo.0801498; Valentine RC, 2004, PROG LIPID RES, V43, P383, DOI 10.1016/j.plipres.2004.05.004; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Yehuda S, 2002, NEUROBIOL AGING, V23, P843, DOI 10.1016/S0197-4580(02)00074-X; Yu-Poth S, 2005, J NUTR, V135, P2541, DOI 10.1093/jn/135.11.2541; Yu-Poth S, 2004, J NUTR, V134, P68, DOI 10.1093/jn/134.1.68	61	44	44	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2009	87	5					1207	1218		10.1002/jnr.21918			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	416DF	WOS:000263984700017	18951473	Green Accepted			2022-02-06	
J	Lagares, A; Ramos, A; Perez-Nunez, A; Ballenilla, F; Alday, R; Gomez, PA; Kaen, A; Lobato, RD				Lagares, Alfonso; Ramos, Ana; Perez-Nunez, Angel; Ballenilla, Federico; Alday, Rafael; Gomez, Pedro A.; Kaen, Ariel; Lobato, Ramiro D.			The role of MR imaging in assessing prognosis after severe and moderate head injury	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Head trauma; MRI; CT; Diffuse axonal injury; Prognosis	DIFFUSE AXONAL INJURY; TRAUMATIC BRAIN-INJURY; COMA-DATA-BANK; MAGNETIC-RESONANCE; COMPUTERIZED-TOMOGRAPHY; VEGETATIVE STATE; SCALE SCORE; STEM INJURY; CT FINDINGS; FIELD MR	The objective of this work is two-fold: to determine the role of MRI findings in establishing the prognosis of patients with moderate and severe traumatic brain injury (TBI) admitted to our centre, measured with different outcome scales; and to determine in which patients the information given by MR findings adds prognostic information to that from traditional prognostic factors. One hundred patients suffering moderate or severe head injury in whom MRI had been performed in the first 30 days after trauma were included. The MRI was evaluated by two neuroradiologists who were not aware of the initial CT results or the clinical situation of the patients. Outcome was determined 6 months after head injury by means of the extended version of the Glasgow Outcome Scale. The prognostic capacity of the different factors related to outcome was compared by the analysis of receiver operating characteristic (ROC) curves and the area under the curve (AUC) for each factor. There exists a clear relation between the depth of the traumatic lesions shown on MRI, and their classification by the proposed scale, and the outcome of patients suffering traumatic brain injury determined by different scales 6 months after injury. The anatomical substrate of TBI depicted by MRI could be a useful prognostic tool in patients suffering moderate and severe head injury. Patients with a score of 4 or less on the motor subscale of the GCS scale are those who could benefit most from the prognostic information provided by MRI.	[Lagares, Alfonso; Perez-Nunez, Angel; Alday, Rafael; Gomez, Pedro A.; Kaen, Ariel; Lobato, Ramiro D.] Hosp 12 Octubre, Dept Neurosurg, Madrid 28041, Spain; [Ramos, Ana; Ballenilla, Federico] Hosp 12 Octubre, Dept Neuroradiol, Madrid 28041, Spain		Lagares, A (corresponding author), Hosp 12 Octubre, Dept Neurosurg, Crta Andalucia Km 5 4, Madrid 28041, Spain.	algadoc@yahoo.com	Gomez, Pedro/N-5051-2019; kaen, ariel/G-3786-2015; Perez-Nunez, Angel/AAG-4422-2020; Lagares, Alfonso/B-2969-2011; KAEN, ARIEL/F-1338-2015	Gomez, Pedro/0000-0002-4185-5238; Perez-Nunez, Angel/0000-0002-2391-6586; Lagares, Alfonso/0000-0003-3996-0554; KAEN, ARIEL/0000-0002-0595-9515	Fundacion Mutua MadrilenaInstituto de Salud Carlos III	This study was supported by a grant from Fundacion Mutua Madrilena.	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Aguas J, 2005, NEUROCIRUGIA, V16, P14; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Boto GR, 2004, NEUROCIRUGIA, V15, P233; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; CORDOBES F, 1983, J NEUROSURG, V58, P217, DOI 10.3171/jns.1983.58.2.0217; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Hoelper BM, 2000, ACT NEUR S, V76, P265; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kesler SR, 2000, BRAIN INJURY, V14, P851; Lagares A, 2006, NEUROCIRUGIA, V17, P105; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Marshall LF, 1991, J NEUROSURG S, V75, P14; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sahuquillo J, 2002, ADV TECH STAND NEUR, V27, P23; SAHUQUILLO J, 1989, ACTA NEUROCHIR WIEN, V101, P762; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P37; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; Toschlog EA, 2003, AM SURGEON, V69, P491; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; VILALTA J, 1984, REV NEUROLOGIA, V57, P133; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	62	44	48	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	APR	2009	151	4					341	356		10.1007/s00701-009-0194-8			16	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	437OS	WOS:000265497400008	19224121				2022-02-06	
J	DiLeonardi, AM; Huh, JW; Rahupathi, R				DiLeonardi, Ann Mae; Huh, Jimmy W.; Rahupathi, Ramesh			Impaired axonal transport and neurofilament compaction occur in separate populations of injured axons following diffuse brain injury in the immature rat	BRAIN RESEARCH			English	Article						Traumatic axonal injury; Children; Mild traumatic brain injury; Closed head injury; NMDA; AMPA; White matter	LATERAL FLUID PERCUSSION; CLOSED-HEAD INJURY; AXOLEMMAL PERMEABILITY; COGNITIVE DEFICITS; NEONATAL PIG; PHOSPHORYLATION; ACCUMULATION; NEURODEGENERATION; PROTEOLYSIS; ANTAGONISTS	Diffuse brain injury is a leading cause of mortality in infants and children under 4 years of age and results in cognitive deficits in survivors. The anatomic basis for these behavioral deficits maybe traumatic axonal injury (TAI), which manifests as impaired axonal transport (IAT) and neurofilament compaction (NFC), and may occur as a result of glutamate receptor activation. The extent of IAT and NFC was evaluated at 6, 24 and 72 h following non-contusive brain trauma in the 17 day-old rat to examine the causal relationship between these two pathologic entities; in addition, the effect of antagonists to the ionotropic glutamate receptors on TAI was evaluated. At 6 h post-injury, NFC was observed primarily in the cingulum, and appeared as swollen axons and terminal bulbs. By 24 h, swollen axons were additionally present in the corpus callosum and lateral white matter tracts, and appeared to increase in diameter. At 72 h, the extent of axonal swellings exhibiting compacted neurofilaments appeared to decrease, and was accompanied by punctate immunoreactivity within axon tracts suggestive of axonal degeneration. Although NFC was present in the same anatomical locations where axonal accumulation of amyloid precursor protein (APP) has been observed, double-label immunohistochemistry revealed no evidence of colocalization of compacted neurofilament and APP. Pre-injury treatment with either the NMDA receptor antagonist, ifenprodil, or the AMPA receptor antagonist, NBQX, had no significant effect on the extent of TAI, suggesting that excitotoxicity may not be a primary mechanism underlying TAL Importantly, these data are indicative of the heterogeneity of mechanisms underlying TAI in the traumatically-injured immature brain. (C) 2009 Elsevier B.V. All rights reserved.	[Rahupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; [DiLeonardi, Ann Mae; Rahupathi, Ramesh] Drexel Univ, Coll Med, Program Neurosci, Philadelphia, PA 19129 USA; [Huh, Jimmy W.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA		Rahupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.	rramesh@drexelmed.edu		DiLeonardi, Ann Mae/0000-0002-1476-7726	University of Pennsylvania; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08-NS053651, R01-NS41561]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS053651, R01NS041561] Funding Source: NIH RePORTER	The authors acknowledge expert technical assistance from Ashley Widing (animal surgery), Ami Oristaglio-Wilson (blinded quantification) and Louise Bertrand (confocal microscopy). We are also grateful to Dr. John Q. Trojanowski (Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia PA) for the gift of the RM014 antibody. These studies were supported, in part, by The Endowed Chair of Critical Care Medicine, the Florence RC Murray grant from the Children's Hospital of Philadelphia (JWH, RR), a Research Foundation grant from the University of Pennsylvania (JWH, RR), and NINDS grants K08-NS053651 (JWH) and R01-NS41561 (RR).	Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Lariviere RC, 2004, J NEUROBIOL, V58, P131, DOI 10.1002/neu.10270; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Rosen CJ, 1999, J CLIN DENSITOM, V2, P3, DOI 10.1385/JCD:2:1:3; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHEETZ AJ, 1994, FASEB J, V8, P745, DOI 10.1096/fasebj.8.10.8050674; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818	41	44	48	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 31	2009	1263						174	182		10.1016/j.brainres.2009.01.021			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	431CV	WOS:000265039800019	19368848	Green Accepted			2022-02-06	
J	Tashlykov, V; Katz, Y; Volkov, A; Gazit, V; Schreiber, S; Zohar, O; Pick, CG				Tashlykov, V.; Katz, Y.; Volkov, A.; Gazit, V.; Schreiber, S.; Zohar, O.; Pick, C. G.			Minimal Traumatic Brain Injury Induce Apoptotic Cell Death in Mice	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Apoptosis; H&E; C-jun; p53; Bcl-2; Minimal TBI; Mice	MINOR HEAD-INJURY; COGNITIVE DEFICITS; NERVOUS-SYSTEM; NEURONS; JUN; HIPPOCAMPUS; MODELS; MOUSE; BCL-2; RATS	In the United States, 1.4 million people suffer from traumatic brain injury (TBI) each year because of traffic, sports, or war-related injuries. The majority of TBI victims suffer mild to minimal TBI (mTBI), but most are released undiagnosed. Detailed pathologies are poorly understood. We characterized the microscopic changes of neurons of closed-head mTBI mice after increased unilateral trauma using hematoxylin and eosin (H&E) stain, and correlated it with the expression of the apoptotic proteins c-jun, p53, and BCL-2. Minimal damage to the brain increases the number of pyknotic appearing neurons and activates the apoptotic proteins in both hemispheres. Although minimal, increased impact was positively correlated with the increased number of damaged neurons. These results may explain the wide variety of behavioral and cognitive deficits closed-head mTBI causes in mice. Our cumulative results point to the pathological origin of post-concussion syndrome and may aid in the development of future neuroprotective strategies for the disease.	[Pick, C. G.] Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Schreiber, S.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel; [Zohar, O.] Johns Hopkins Univ Montgomery Cty Campus, Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA; [Volkov, A.] Chaim Sheba Med Ctr, Dept Pathol, Ramat Gan, Israel; [Katz, Y.] Rambam Med Ctr, Dept Anesthesiol, Haifa, Israel; [Tashlykov, V.] Chaim Sheba Med Ctr, Dept Neurol, Ramat Gan, Israel; [Tashlykov, V.; Katz, Y.; Gazit, V.] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Lab Anesthesia Pain & Neural Res, IL-31096 Haifa, Israel		Pick, CG (corresponding author), Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il	Pick, Chaim/D-4789-2009; Schreiber, Shaul/E-5821-2010; Volkov, Alex/P-5220-2018	Schreiber, Shaul/0000-0002-2189-0693; Volkov, Alex/0000-0002-3157-7422			Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bogolepov N N, 2004, Neurosci Behav Physiol, V34, P611, DOI 10.1023/B:NEAB.0000028293.62205.5f; Bonny C, 2005, REV NEUROSCIENCE, V16, P57; BROWN AW, 1972, J NEUROL SCI, V16, P59, DOI 10.1016/0022-510X(72)90102-5; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Ooigawa H, 2006, ACTA NEUROPATHOL, V112, P471, DOI 10.1007/s00401-006-0108-2; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Ozaki T, 1998, NEUROSCIENCE, V84, P1187, DOI 10.1016/S0306-4522(97)00536-8; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; RINK A, 1995, AM J PATHOL, V147, P1575; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Ward NL, 2000, EUR J NEUROSCI, V12, P1867, DOI 10.1046/j.1460-9568.2000.00070.x; Zohar O, 2006, NEUROSCI LETT, V394, P239, DOI 10.1016/j.neulet.2005.10.099; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	30	44	44	2	14	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	JAN	2009	37	1					16	24		10.1007/s12031-008-9094-2			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	387SE	WOS:000261971100003	18651249				2022-02-06	
J	Cheng, JP; Hoffman, AN; Zafonte, RD; Kline, AE				Cheng, Jeffrey P.; Hoffman, Ann N.; Zafonte, Ross D.; Kline, Anthony E.			A delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learning	BEHAVIOURAL BRAIN RESEARCH			English	Article						beam-walking; controlled cortical impact; functional recovery; learning and memory; morris water maze; neurobehavior; traumatic brain injury	TRAUMATIC BRAIN-INJURY; BAY X 3702; WATER MAZE PERFORMANCE; COGNITIVE DEFICITS; METHYLPHENIDATE TREATMENT; NEUROBEHAVIORAL BENEFIT; HALOPERIDOL; MEMORY; WAY-100635; IMPAIRMENT	An early (i.e., 15 min) single systemic administration of the 5-HT1A receptor agonist 8-OH-DPAT enhances behavioral recovery after experimental traumatic brain injury (TBI). However, acute administration of pharmacotherapies after TBI may be clinically challenging and thus the present Study sought to investigate the potential efficacy of a delayed and chronic 8-OH-DPAT treatment regimen. Forty-eight isoflurane-anesthetized adult male rats received either a controlled cortical impact or sham injury and beginning 24 h later were administered 8-OH-DPAT (0.1 or 0.5 mg/kg) or saline vehicle (1.0 mL/kg) intraperitoneally once daily until all behavioral assessments were completed. Neurobehavior was assessed by motor and cognitive tests on post-operative days 1-5 and 14-19, respectively. The lower dose of 8-OH-DPAT (0.1 mg/kg) enhanced motor performance, acquisition of spatial learning, and memory retention vs. both the higher dose (0.5 mg/kg) and vehicle treatment (p < 0.05). These data replicate previous findings from our laboratory showing that 8-OH-DPAT improves neurobehavior after TBI, and extend those results by demonstrating that the benefits can be achieved even when treatment is withheld for 24 h. A delayed and chronic treatment regimen may be more clinically feasible. (C) 2008 Elsevier B.V. All rights reserved.	[Kline, Anthony E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Cheng, Jeffrey P.; Hoffman, Ann N.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA		Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD043851, HD046700]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851, R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by National Institutes of Health grants HD043851 and HD046700 awarded to AEK.	Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; CARLI M, 1995, BEHAV BRAIN RES, V67, P67, DOI 10.1016/0166-4328(94)00105-O; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; Galeotti N, 2000, JPN J PHARMACOL, V84, P418, DOI 10.1254/jjp.84.418; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harkany T, 2001, NEUROSCIENCE, V108, P629, DOI 10.1016/S0306-4522(01)00444-4; Helsley S, 1998, PROG NEURO-PSYCHOPH, V22, P1179, DOI 10.1016/S0278-5846(98)00068-2; HOFFMAN AN, LIFE SCI IN PRESS; Kant GJ, 1996, PHARMACOL BIOCHEM BE, V53, P385, DOI 10.1016/0091-3057(95)02038-1; Kant GJ, 1998, PHARMACOL BIOCHEM BE, V59, P729, DOI 10.1016/S0091-3057(97)00553-4; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; KREISS DS, 1992, NEUROPHARMACOLOGY, V31, P1073, DOI 10.1016/0028-3908(92)90110-B; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Luttgen M, 2005, NEUROPHARMACOLOGY, V48, P830, DOI 10.1016/j.neuropharm.2005.01.007; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; Meneses A, 2007, BEHAV BRAIN RES, V184, P81, DOI 10.1016/j.bbr.2007.06.026; Misane I, 2003, NEUROPSYCHOPHARMACOL, V28, P253, DOI 10.1038/sj.npp.1300024; Ohman J, 2001, J NEUROTRAUM, V18, P1313, DOI 10.1089/08977150152725614; Pitsikas N, 2003, BRAIN RES, V983, P215, DOI 10.1016/S0006-8993(03)03091-9; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Sakaue M, 2000, BRIT J PHARMACOL, V129, P1028, DOI 10.1038/sj.bjp.0703139; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schneider AM, 2003, LEARN MEMORY, V10, P394, DOI 10.1101/lm.54903; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Torup L, 2000, EUR J PHARMACOL, V395, P137, DOI 10.1016/S0014-2999(00)00175-8; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Wilson MS, 2002, AM J PHYS MED REHAB, V81, P364, DOI 10.1097/00002060-200205000-00009; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	65	44	44	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	DEC 1	2008	194	1					79	85		10.1016/j.bbr.2008.06.025			7	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	355MM	WOS:000259713000011	18638506	Green Accepted			2022-02-06	
J	Heskestad, B; Baardsen, R; Helseth, E; Ingebrigtsen, T				Heskestad, Ben; Baardsen, Roald; Helseth, Eirik; Ingebrigtsen, Tor			Guideline Compliance in Management of Minimal, Mild, and Moderate Head Injury: High Frequency of Noncompliance Among Individual Physicians Despite Strong Guideline Support From Clinical Leaders	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injury; Guidelines; Physicians-compliance	TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; IMPLEMENTATION; HOSPITALS; IMPACT; RULE	Background. The evidence-based Scandinavian Guidelines for the Initial Management of Minimal, Mild, and Moderate Head Injuries were developed to provide safe and cost-effective assessment of patients. A survey based on a questionnaire directed to clinical managers in all Norwegian hospitals indicated that the guidelines had influenced management practice significantly. However, implementation of guidelines and compliance from clinical leaders does not necessarily influence individual physicians decisions making. Methods: To evaluate physicians-compliance with the Scandinavian Guidelines in individual patients, we conducted a study (January 2003 to January 2004) that included all patients with minimal, mild, and moderate head injury who presented to the emergency department in a Norwegian university hospital. Guideline compliance was evaluated in the assessment and treatment of 508 patients. The management of each single patient was classified as compliant with the guidelines or not. Classification as compliant required correct use of computed tomography (CT) and hospital admission in accordance with the guideline. Results: The overall physicians-compliance with the Scandinavian Guidelines was 51%. A substantial overtriage with unnecessary CT examinations and hospital admissions was seen in patients with minimal and mild head injuries. Among patients with minimal head injury, 69% underwent overtriage, 18% with unnecessary hospital admission, 27% with unnecessary CT, and 24% with both. Among patients with mild head injury, 37% were subject to overtriage, all with admission for observation after a negative CT. All patients with moderate head injury were treated in accordance with the guideline. Conclusions Guidelines for assessment and treatment of minimal and mild head injuries may not have the intended degree of influence on clinical practice. Even in departments where clinical managers report that the practice is evidence based, physicians may not act in accordance with this in their daily practice. This causes significant unnecessary costs, estimated as USD 2,167.000 annually in Norway.	[Heskestad, Ben; Helseth, Eirik] Ullevaal Univ Hosp, Dept Neurosurg, N-0407 Oslo, Norway; [Ingebrigtsen, Tor] Univ Tromso, Inst Clin Med, Tromso, Norway; [Ingebrigtsen, Tor] Univ Hosp N Norway, Dept Neurosurg, Tromso, Norway; [Baardsen, Roald] Stavanger Univ Hosp, Dept Neurosurg, Stavanger, Norway		Heskestad, B (corresponding author), Ullevaal Univ Hosp, Dept Neurosurg, N-0407 Oslo, Norway.	ben.heskestad@ulleval.no	Helseth, Eirik/AAH-2466-2020	Ingebrigtsen, Tor/0000-0001-5966-9786			Bellner J, 1999, ACTA NEUROL SCAND, V100, P355; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; *CENTR BANK NORW N, EXCH RAT 2007; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 2000, Tidsskr Nor Laegeforen, V120, P1985; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X	15	44	44	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2008	65	6					1309	1313		10.1097/TA.0b013e31815e40cd			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	383WV	WOS:000261706000022	19077619				2022-02-06	
J	Coats, B; Margulies, SS				Coats, Brittany; Margulies, Susan S.			Potential for head injuries in infants from low-height falls	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						anthropomorphic surrogate; biomechanical study; child abuse; head impact; low-height fall; pediatric head injury	SHAKEN BABY SYNDROME; TRAUMATIC AXONAL INJURY; PROFESSIONAL FOOTBALL; SKULL FRACTURES; CHILDREN; IMPACTS; CONCUSSION; BRAIN	Object. Falls are the most common accident scenario in young children as well as the most common history provided in child abuse cases. Understanding the biomechanics of falls provides clinicians with objective data to aid in their diagnosis of accidental or inflicted trauma. The objective of this study was to determine impact forces and angular accelerations associated with low-height falls in infants. Methods. An instrumented anthropomorphic infant surrogate was created to measure the forces and 3D angular accelerations associated with falls from low heights (0.3-0.9 m) onto a mattress, carpet pad, or concrete. Results. Although height significantly increased peak angular acceleration (alpha(p)), change in peak-to-peak angular velocity, time duration associated with the change in velocity, and peak impact force (F-p) for head-first drops onto a carpet pad or concrete, none of these variables were significantly affected by height when dropped onto a mattress. The ap was not significantly different for drops onto a carpet pad and concrete from 0.6 or 0.9 m due to compression of the carpet pad. Surprisingly, sagittal alpha(p) was equaled or surpassed by axial alpha(p). Conclusions. These are the first 3D angular acceleration and impact force data available for head impact in infants from low-height falls. A future study involving a computational model of the infant head will use the loads measured in this study to predict the probability of occipital skull fracture on impact from head-first low-height falls. Together, these studies will provide data that will aid clinicians in the evaluation of accidental and inflicted head injuries, and will contribute to the design of safer environments for children. (DOI: 10.3171/PED.2008.2.11.321)	[Coats, Brittany; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 210 S 33rd St,Suite 240, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Coats, Brittany/A-4523-2009		NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001445, R49CE000411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039679, R01 NS39679] Funding Source: Medline; NCIPC CDC HHS [R01 CE001445, R49/CE000411-01] Funding Source: Medline		BRETON F, 1990, BIOL PSYCHOL, V31, P57, DOI 10.1016/0301-0511(90)90078-B; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; Coats B., 2007, THESIS U PENNSYLVANI; Coats B, 2007, STAPP CAR CRASH JO, V51, P1; Coats B, 2006, J NEUROTRAUM, V23, P1222, DOI 10.1089/neu.2006.23.1222; Cory CZ, 2003, MED SCI LAW, V43, P317, DOI 10.1258/rsmmsl.43.4.317; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; GENNARELLI T, 1972, STRAPP CAR CRASH C D; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HALL JR, 1989, J TRAUMA, V29, P1273, DOI 10.1097/00005373-198909000-00015; HELFER RE, 1977, PEDIATRICS, V60, P533; MARGULIES SS, 1999, COMP DIFFUSE BRAIN I; Meaney DF, 1991, THESIS U PENNSYLVANI; Ohman Anna Maria, 2008, Pediatr Phys Ther, V20, P53, DOI 10.1097/PEP.0b013e31815ebb27; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PRANGE M, 2002, THESIS U PENNSYLVANI; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Society of Automotive Engineers (SAE), 1995, SURF VEH REC PRACT J; Tarantino CA, 1999, PEDIATR EMERG CARE, V15, P5, DOI 10.1097/00006565-199902000-00002; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; WEBER W, 1985, Z RECHTSMED, V94, P93; WEBER W, 1984, Z RECHTSMED, V92, P87, DOI 10.1007/BF02116216; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; Wolfson DR, 2005, P I MECH ENG H, V219, P63, DOI 10.1243/095441105X9237; Zar J.H., 2013, BIOSTATISTICAL ANAL BIOSTATISTICAL ANAL	30	44	44	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	NOV	2008	2	5					321	330		10.3171/PED.2008.2.11.321			10	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	364UX	WOS:000260362000009	18976102				2022-02-06	
J	Siman, R; Roberts, VL; McNeil, E; Dang, A; Bavaria, JE; Ramchandren, S; McGarvey, M				Siman, Robert; Roberts, Victoria L.; McNeil, Elizabeth; Dang, Antony; Bavaria, Joseph E.; Ramchandren, Sindhu; McGarvey, Michael			Biomarker evidence for mild central nervous system injury after surgically-induced circulation arrest	BRAIN RESEARCH			English	Article						ischemia; acute CNS damage; surrogate marker; calpain; circulation arrest	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; TISSUE-PLASMINOGEN ACTIVATOR; ARTERY-BYPASS-SURGERY; ACUTE ISCHEMIC-STROKE; CEREBROSPINAL-FLUID; SURROGATE MARKERS; CARDIAC-ARREST; RAT-BRAIN; CALPAIN-I	Previously, we identified 14-3-3 beta and zeta isoforms and proteolytic fragments of alpha-spectrin as proteins released from degenerating neurons that also rise markedly in cerebrospinal fluid (CSF) following experimental brain injury or ischemia. in rodents, but these proteins have not been studied before as potential biomarkers for ischemic central nervous system injury in humans. Here we describe longitudinal analysis of these proteins along with the neuron-enriched hypophosphorylated neurofilament H (pNFH) and the deubiquitinating enzyme UCH-L1 in lumbar CSF samples from 19 surgical cases of aortic aneurysm repair, 7 involving cardiopulmonary bypass with deep hypothermic circulatory arrest (DHCA). CSF levels of the proteins were near the lower limit of detection by Western blot or enzyme-linked fluorescence immunoassay at the onset of surgical procedures, but increased substantially in a subset of cases, typically within 12-24 h. All cases involving DHCA were characterized by > 3-fold elevations in CSF levels of the two 14-3-3 isoforms, UCH-L1, and pNFH. Six of 7 also exhibited marked increases in alpha-spectrin fragments generated by calpain, a protease known to trigger necrotic neurodegeneration. Among cases involving aortic cross-clamping but not DHCA, the proteins rose in CSF preferentially in the subset experiencing acute neurological complications. Our results suggest the neuron-enriched 14-3-3 beta, 14-3-3 zeta, pNFH, UCH-L1, and calpain-cleaved a-spectrin may serve as a panel of biomarkers with clinical potential for the detection and management of ischemic central nervous system injury, including for mild damage associated with surgically-induced circulation arrest. (c) 2008 Elsevier B.V. All rights reserved.	[Siman, Robert; Roberts, Victoria L.; McNeil, Elizabeth; Dang, Antony] Univ Penn, Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Bavaria, Joseph E.] Univ Penn, Sch Med, Div Cardiovasc Surg, Philadelphia, PA 19104 USA; [Ramchandren, Sindhu; McGarvey, Michael] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Ramchandren, Sindhu] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI 48109 USA		Siman, R (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	siman@mail.med.upenn.edu	Ramchandren, Sindhu/D-6942-2012	Ramchandren, Sindhu/0000-0002-5201-9200	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048234] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS048234, R01 NS048234-01A2, R01 NS048234] Funding Source: Medline		AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Anand N, 2005, CEREBROVASC DIS, V20, P213, DOI 10.1159/000087701; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arrowsmith JE, 2000, BRIT J ANAESTH, V84, P378, DOI 10.1093/oxfordjournals.bja.a013444; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; BETZ D, 1998, CEREBROVASC DIS, P358; Boston P, 1980, BIOCHEM SOC T, V8, P617, DOI 10.1042/bst0080617; Cheung AT, 2005, ANN THORAC SURG, V80, P1280, DOI 10.1016/j.athoracsur.2005.04.027; Cheung AT, 2002, ANN THORAC SURG, V74, P413, DOI 10.1016/S0003-4975(02)03714-1; del Zoppo GJ, 2000, THROMB RES, V98, pV73; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; Ergin MA, 1999, ANN THORAC SURG, V67, P1887, DOI 10.1016/S0003-4975(99)00432-4; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; Gao L, 2005, CHEST, V128, P3664, DOI 10.1378/chest.128.5.3664; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Jauch EC, 2006, STROKE, V37, P2508, DOI 10.1161/01.STR.0000242290.01174.9e; Jung C, 2000, CELL MOTIL CYTOSKEL, V47, P120, DOI 10.1002/1097-0169(200010)47:2<120::AID-CM3>3.0.CO;2-6; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; LASEK RJ, 1985, ANN NY ACAD SCI, V455, P462, DOI 10.1111/j.1749-6632.1985.tb50429.x; Lawrence EJ, 2005, RESUSCITATION, V64, P383, DOI 10.1016/j.resuscitation.2004.07.016; LUNDAR T, 1983, SCAND J THORAC CARD, V17, P237, DOI 10.3109/14017438309099358; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; MARTIN H, 1994, J NEUROCHEM, V63, P2259; McGorvey ML, 2007, NEUROCRIT CARE, V6, P35, DOI 10.1385/Neurocrit.Care2007;06:35-39; McKeating EG, 1998, ACT NEUR S, V71, P117; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Newman SP, 2002, LANCET NEUROL, V1, P119, DOI 10.1016/S1474-4422(02)00043-1; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2005, J NEUROTRAUM, V22, P407, DOI 10.1089/neu.2005.22.407; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROCHE GW, 1996, NEW ENGL J MED, V335, P1857; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Selnes OA, 2005, ANN NEUROL, V57, P615, DOI 10.1002/ana.20481; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shiiya N, 2004, ANN THORAC SURG, V77, P2034, DOI 10.1016/j.athoracsur.2003.12.057; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; STERNBERGER LA, 1982, P NATL ACAD SCI-BIOL, V79, P1326, DOI 10.1073/pnas.79.4.1326; Tanaka Y, 2007, BRAIN RES, V1154, P194, DOI 10.1016/j.brainres.2007.03.085; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	58	44	45	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 5	2008	1213						1	11		10.1016/j.brainres.2008.03.034			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	319TD	WOS:000257186000001	18456245	Green Accepted			2022-02-06	
J	Jamieson, LM; Harrison, JE; Berry, JG				Jamieson, Lisa M.; Harrison, James E.; Berry, Jesia G.			Hospitalisation for head injury due to assault among Indigenous and non-Indigenous Australians, July 1999 to June 2005	MEDICAL JOURNAL OF AUSTRALIA			English	Article							TRAUMATIC BRAIN-INJURY; UNITED-STATES; CHILDREN	Objective: To describe rates of hospitalisation for head injury due to assault among Indigenous and non-Indigenous Australians. Design, setting and participants: Secondary analysis of routinely collected hospital morbidity. data for 42 874 inpatients at public and private hospitals in Queensland, Western Australia, South Australia and the Northern Territory for the 6-year period 1 July 1999 - 30 June 2005. Main outcome measures: Rates per 100000 population of head injury due to assault by Indigenous status, age, sex and location of residence. Results: The overall rate of head injury due to assault was 60.4 per 100000 population (95% CI, 59.8-60.9). The rate among the Indigenous population was 854.8 per 100000 (95% CI, 841.0-868.9), 21 times that among the non-Indigenous population (40.7 per 100000; 95% CI, 40.2-41.2). Most Indigenous (88%) and non-Indigenous (83%) victims of head injury due to assault were aged between 15 and 44 years. The peak incidence among the Indigenous population was in the 30-34-year age group, whereas that among the non-Indigenous population was in the 20-24-year age group. Indigenous females experienced 69 times the injury rate experienced by non-Indigenous females. Conclusions: Indigenous people, particularly women, were disproportionately represented among those hospitalised for head injury due to assault. Head injury imposes a substantial burden of care on individuals and communities. Along with the costs of treating head injury, these are good reasons to strengthen efforts to prevent head injury generally, with special attention to high-risk population segments.	[Harrison, James E.; Berry, Jesia G.] Flinders Univ S Australia, Res Ctr Injury Studies, Adelaide, SA, Australia; [Jamieson, Lisa M.] Univ Adelaide, Sch Dent, Adelaide, SA, Australia			lisa.jamieson@adelaide.edu.au	Jamieson, Lisa M/M-5914-2014; Harrison, James/B-8958-2009	Harrison, James/0000-0001-9893-8491; Berry, Jesia/0000-0002-4446-7927			*AUSTR I HLTH WELF, 2005, 101 AIHW HSE; *AUSTR I HLTH WELF, 2004, 53 AIHW PHE; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Cunningham J, 1996, MED J AUSTRALIA, V165, P309, DOI 10.5694/j.1326-5377.1996.tb124987.x; Davey TM, 2005, J PAEDIATR CHILD H, V41, P278, DOI 10.1111/j.1440-1754.2005.00611.x; Gruen RL, 2006, LANCET, V368, P130, DOI 10.1016/S0140-6736(06)68812-0; Helps YLM, 2006, INJURY TECHNICAL PAP; Kiely JM, 2006, J TRAUMA, V61, P791, DOI 10.1097/01.ta.0000239360.29852.1d; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEHOCZKY S, 2002, 47110 AUSTR BUR STAT; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; McIntyre PB, 2005, MED J AUSTRALIA, V182, P207, DOI 10.5694/j.1326-5377.2005.tb06667.x; Memmott Paul, 2001, VIOLENCE INDIGENOUS; Moncrieff NJ, 2004, J CRANIOFAC SURG, V15, P686, DOI 10.1097/00001665-200407000-00030; National Public Health Partnership, 2004, NAT AB TORR STRAIT I; National Public Health Partnership, 2004, NAT INJ PREV SAF PRO; Peden M, 2000, INJURY LEADING CAUSE; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Ryb GE, 2006, J TRAUMA, V61, P799, DOI 10.1097/01.ta.0000196763.14289.4e; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Thurman DJ., 1995, GUIDELINES SURVEILLA; Turner-Stokes L, 2005, J NEUROL NEUROSUR PS, V76, P901, DOI 10.1136/jnnp.2005.066472; WILD R, 2007, NO TERR BOARD INQ PR	23	44	44	0	0	AUSTRALASIAN MED PUBL CO LTD	PYRMONT	LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA	0025-729X			MED J AUSTRALIA	Med. J. Aust.	MAY 19	2008	188	10					576	579		10.5694/j.1326-5377.2008.tb01793.x			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	319GA	WOS:000257150900007	18484929	Green Submitted			2022-02-06	
J	Hawley, CA; Joseph, S				Hawley, Carol A.; Joseph, Stephen			Predictors of positive growth after traumatic brain injury: A longitudinal study	BRAIN INJURY			English	Article						brain injury; outcome; follow-up; post-traumatic growth; trauma	SEVERE HEAD-INJURY; POSTTRAUMATIC GROWTH; FOLLOW-UP; PRACTICAL SCALE; ADJUSTMENT; ADVERSITY; OUTCOMES	Primary objective: To investigate long-term positive psychological growth in individuals with traumatic brain injury (TBI) and to relate growth to injury characteristics and early outcomes. Research design: Longitudinal study. Method and procedure: Long-term follow-up of a group of TBI survivors recruited between 1991-1995. In 2004, 240 of the 563 original participants were invited to take part in a follow-up study. At follow-up, survivors completed the Positive Changes in Outlook Questionnaire (CiOP) along with a structured interview/questionnaire which permitted a Glasgow Outcome Scale (GOSE) score to be assigned. Results: One hundred and sixty-five TBI survivors completed both questionnaire and CiOP. One hundred and three (62%) participants had suffered severe TBI, 24 (15%) moderate and 38 (23%) mild. Mean length of follow-up was 11.5 years post-injury (range 9-25 years). On the GOSE at follow-up, 43 (26%) had severe disability; 72 (44%) moderate disability; and 50 (30%) good recovery. Scores on the CiOP indicated positive psychological growth in over half of the sample, as evidenced by agreement with items such as 'I don't take life for granted anymore' and 'I value my relationships much more now'. CiOP total scores did not correlate with any injury or early outcome variables. However, at long-term follow-up there was a negative correlation between positive growth and anxiety and depression. Conclusion: Survivors of mild, moderate and severe TBI showed evidence of long-term positive changes in outlook.	[Hawley, Carol A.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England; [Joseph, Stephen] Univ Nottingham, CTRG, Sch Sociol & Social Policy, Ctr Social Work, Nottingham NG7 2RD, England		Hawley, CA (corresponding author), Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019	joseph, stephen/0000-0001-7171-3356			ADAMS N, 1996, AUSTR NZ J FAMILY TH, V17, P75; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HAWLEY CA, 2000, BRIT J THERAPY REHAB, V7, P116; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOSEPH S, 1993, J TRAUMA STRESS, V6, P271, DOI 10.1002/jts.2490060209; Joseph S, 2005, PSYCHOL ASSESSMENT, V17, P70, DOI 10.1037/1040-3590.17.1.70; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McGrath J, 2004, CLIN REHABIL, V18, P767, DOI 10.1191/0269215504cr802oa; MCGRATH JC, TRAUMA RECOVERY GROW, P259; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Powell T, 2007, BRAIN INJURY, V21, P31, DOI 10.1080/02699050601106245; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; STEGER MF, IN PRESS J PERSONALI; Stilwell P, 1999, NEUROPSYCHOL REHABIL, V9, P277, DOI 10.1080/096020199389374; TEASDALE G, 1974, LANCET, V2, P81; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1007/BF02103658; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; WHIMALL L, 2006, J NEUROL NEUROSUR PS, V77, P640; *WHO, 1980, INT CLASS IMP DIS HA, P42; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	44	45	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2008	22	5					427	435		10.1080/02699050802064607			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	302RH	WOS:000255986500008	18415723	Green Submitted			2022-02-06	
J	Ayer, RE; Sugawara, T; Chen, W; Tong, W; Zhang, JH				Ayer, Robert E.; Sugawara, Takashi; Chen, Wanqiu; Tong, Wenni; Zhang, John H.			Melatonin decreases mortality following severe subarachnoid hemorrhage	JOURNAL OF PINEAL RESEARCH			English	Article						acute brain injury; lipid peroxidation; melatonin; mortality; oxidative stress; subarachnoid hemorrhage	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; HYDROXYL RADICAL SCAVENGER; VEHICLE-CONTROLLED TRIAL; DOSE TIRILAZAD MESYLATE; DOUBLE-BLIND; INDUCED NEUROPROTECTION; REDUCES VOLUME; RAT; ISCHEMIA	Aneurysmal subarachnoid hemorrhage (SAH) is a devastating disease that is associated with significant morbidity and mortality. There is substantial evidence to suggest that oxidative stress is significant in the development of acute brain injury following SAH. Melatonin is a strong antioxidant that has low toxicity and easily passes through the blood-brain barrier. Previous studies have shown that melatonin provides neuroprotection in animal models of ischemic stroke. This study hypothesizes that melatonin will provide neuroprotection when administered 2 hr after SAH. The filament perforation model of SAH was performed in male Sprague-Dawley rats weighing between 300 and 380 g. Melatonin (15 or 150 mg/kg), or vehicle was given via intraperitoneal injection 2 hr after SAH. Mortality and neurologic deficits were assessed 24 hr after SAH. A significant reduction in 24-hr mortality was seen following treatment with high dose melatonin. There was no improvement in neurologic scores with treatment. Brain water content and lipid peroxidation were measured following the administration of high dose melatonin to identify a mechanism for the increased survival. High dose melatonin tended to reduce brain water content following SAH, but had no effect on the lipid peroxidation of brain samples. Large doses of melatonin significantly reduces mortality and brain water content in rats following SAH through a mechanism unrelated to oxidative stress.	[Zhang, John H.] Loma Linda Univ, Med Ctr, Dept Neurosurg, Loma Linda, CA 92350 USA; [Ayer, Robert E.; Sugawara, Takashi; Chen, Wanqiu; Tong, Wenni; Zhang, John H.] Loma Linda Univ, Dept Physiol & Pharmacol, Loma Linda, CA 92350 USA; [Zhang, John H.] Loma Linda Univ, Dept Anesthesiol, Loma Linda, CA 92350 USA		Zhang, JH (corresponding author), Loma Linda Univ, Med Ctr, Dept Neurosurg, 11234 Anderson St, Loma Linda, CA 92350 USA.	johnzhang3910@yahoo.com	Sugawara, Takashi/ABI-3295-2020	Zhang, John H./0000-0002-4319-4285	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043338, R01NS045694, R01NS053407] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS43338, NS45694, NS53407] Funding Source: Medline		Asano T, 1999, CRIT REV NEUROSURG, V9, P303, DOI 10.1007/s003290050147; Asano T, 1996, J NEUROSURG, V84, P792, DOI 10.3171/jns.1996.84.5.0792; Aydin MV, 2005, NEUROL RES, V27, P77, DOI 10.1179/016164105X18331; Badaut J, 2003, ACTA NEUROCHIR SUPPL, V86, P495; BAENA RRY, 1988, ACTA NEUROCHIR S, V43, P177; BARCHAS J, 1967, NATURE, V214, P919, DOI 10.1038/214919a0; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Biros MH, 1999, ACAD EMERG MED, V6, P1088, DOI 10.1111/j.1553-2712.1999.tb00109.x; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Busch E, 1998, STROKE, V29, P2155, DOI 10.1161/01.STR.29.10.2155; Cahill J, 2007, NEUROSURGERY, V60, P531, DOI 10.1227/01.NEU.0000249287.99878.9B; Cheung RTF, 2006, J PINEAL RES, V41, P337, DOI 10.1111/j.1600-079X.2006.00372.x; Cheung RTF, 2003, J PINEAL RES, V34, P153, DOI 10.1034/j.1600-079X.2003.00034.x; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; DOCZI T, 1985, ACTA NEUROCHIR, V77, P110, DOI 10.1007/BF01476215; Gaetani P, 1992, J Neurosurg Sci, V36, P1; Gaetani P, 1998, J NEUROSURG, V89, P748, DOI 10.3171/jns.1998.89.5.0748; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Germano A, 1998, J NEUROSURG, V88, P1075, DOI 10.3171/jns.1998.88.6.1075; Gorgulu AK, 2001, NEUROSURGERY, V49, P1434; Gul S, 2005, SURG NEUROL, V64, P355, DOI 10.1016/j.surneu.2005.03.036; Haley EC, 1997, J NEUROSURG, V86, P467, DOI 10.3171/jns.1997.86.3.0467; Handa Y, 2000, SURG NEUROL, V53, P323, DOI 10.1016/S0090-3019(00)00168-3; Imperatore C, 2000, LIFE SCI, V66, P779, DOI 10.1016/S0024-3205(99)00651-7; Josko J, 2001, FOLIA NEUROPATHOL, V39, P243; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kaynar MY, 2005, NEUROL RES, V27, P562, DOI 10.1179/016164105X17288; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Kondoh T, 2002, LIFE SCI, V72, P583, DOI 10.1016/S0024-3205(02)02256-7; Kusaka G, 2004, J CEREBR BLOOD F MET, V24, P916, DOI 10.1097/01.WCB.0000125886.48838.7E; Kusaka I, 2004, AM J PHYSIOL-HEART C, V286, pH2442, DOI 10.1152/ajpheart.01169.2003; Lanzino G, 1999, J NEUROSURG, V90, P1011, DOI 10.3171/jns.1999.90.6.1011; Lanzino G, 1999, J NEUROSURG, V90, P1018, DOI 10.3171/jns.1999.90.6.1018; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Lima ACP, 2003, NEUROTOX RES, V5, P323, DOI 10.1007/BF03033152; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Martinez-Cruz F, 2002, NEUROSCI LETT, V331, P208, DOI 10.1016/S0304-3940(02)00884-4; Mayberg MR, 1998, NEUROSURG CLIN N AM, V9, P615; Mayhan WG, 1999, AM J PHYSIOL-CELL PH, V276, pC1148, DOI 10.1152/ajpcell.1999.276.5.C1148; MCCORMICK WF, 1965, J NEUROSURG, V22, P155, DOI 10.3171/jns.1965.22.2.0155; Orakcioglu B, 2005, EXP NEUROL, V193, P369, DOI 10.1016/j.expneurol.2005.01.017; Ostrowski RP, 2006, NEUROL RES, V28, P399, DOI 10.1179/016164106X115008; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Pei Z, 2002, J PINEAL RES, V32, P168, DOI 10.1034/j.1600-079x.2002.1o847.x; Pei Z, 2003, J PINEAL RES, V34, P110, DOI 10.1034/j.1600-079X.2003.00014.x; Pei Z, 2002, NEUROSCI LETT, V318, P141, DOI 10.1016/S0304-3940(01)02503-4; Rosen J, 2006, J PINEAL RES, V41, P374, DOI 10.1111/j.1600-079X.2006.00379.x; Sack RL, 1997, SLEEP, V20, P908, DOI 10.1093/sleep/20.10.908; Schievink WI, 2004, NEUROEPIDEMIOLOGY, V23, P299, DOI 10.1159/000080096; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Schwartz AY, 2000, J NEUROSCI METH, V96, P161, DOI 10.1016/S0165-0270(00)00156-4; Sehba FA, 2006, NEUROL RES, V28, P381, DOI 10.1179/016164106X114991; Sibon I, 2004, EUR J NEUROL, V11, P497, DOI 10.1111/j.1468-1331.2004.00847.x; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Titova E, 2007, CLIN EXP PHARMACOL P, V34, P845, DOI 10.1111/j.1440-1681.2007.04664.x; Torii K, 2004, J PINEAL RES, V36, P18, DOI 10.1046/j.1600-079X.2003.00097.x; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Watanabe T, 1997, NEUROL RES, V19, P563, DOI 10.1080/01616412.1997.11740859; Yamamoto S, 2000, J NEUROSURG, V92, P1009, DOI 10.3171/jns.2000.92.6.1009; Yatsushige H, 2007, J NEUROSCI RES, V85, P1436, DOI 10.1002/jnr.21281; Yon JH, 2006, NEUROBIOL DIS, V21, P522, DOI 10.1016/j.nbd.2005.08.011	65	44	45	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	MAR	2008	44	2					197	204		10.1111/j.1600-079X.2007.00508.x			8	Endocrinology & Metabolism; Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	264AK	WOS:000253257400012	18289172				2022-02-06	
J	Genovese, T; Rossi, A; Mazzon, E; Di Paola, R; Muia, C; Caminiti, R; Bramanti, P; Sautebin, L; Cuzzocrea, S				Genovese, T.; Rossi, A.; Mazzon, E.; Di Paola, R.; Muia, C.; Caminiti, R.; Bramanti, P.; Sautebin, L.; Cuzzocrea, S.			Effects of zileuton and montelukast in mouse experimental spinal cord injury	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						zileuton; montelukast; spinal cord injury; 5-lipoxygenase; cysteinyl-leukotrienes	NECROSIS-FACTOR-ALPHA; LEUKOTRIENE-B4 PRODUCES HYPERALGESIA; POLYMORPHONUCLEAR LEUKOCYTES; CELLULAR-LOCALIZATION; INFLAMMATORY RESPONSE; TRANSPLANTS SUPPORT; RECEPTOR ANTAGONIST; GM-1 GANGLIOSIDE; CONTROLLED TRIAL; MOTOR FUNCTION	Background and purpose: 5-lipoxygenase (5-LO) is the key enzyme in leukotriene (LT) biosynthesis from arachidonic acid (AA). Here, we examined the role of the 5-LO-product, cysteinyl-LT (Cys-LT), with a 5-LO inhibitor (zileuton) and a Cys-LT, receptor antagonist (montelukast), in the inflammatory response and tissue injury associated with spinal cord injury (SCI). Experimental approach: SCI was induced in mice by the application of vascular clips to the dura via a two-level T6 to T7 laminectomy for 1 min. Cord inflammation was assessed histologically and by measuring inflammatory mediators (ELISA) and apoptosis by annexin V, TUNEL, Fas ligand staining and Bax and Bcl-2 expression (immunohistochemistry and western blots). Motor function in hindlimbs was assessed by a locomotor rating scale, for 10 days after cord injury. Key results: SCI in mice resulted in tissue damage, oedema, neutrophil infiltration, apoptosis, tumour necrosis-alpha (TNF-alpha) and cyclooxygenase-2 (COX-2) expression, prostaglandin E-2 (PGE(2)) and leukotriene B-4 (LTB4) production, and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in injured tissue. Treatment of the mice with zileuton or montelukast reduced the spinal cord inflammation and tissue injury, neutrophil infiltration, TNF-alpha, COX-2 and pERK1/2 expression, PGE2 and LTB4 production, and apoptosis. In separate experiments, zileuton or montelukast significantly improved the recovery of limb function over 10 days. Conclusions and implications: Zileuton and montelukast produced a substantial reduction of inflammatory events associated with experimental SCI. Our data underline the important role of 5-LO and Cys-LT in neurotrauma.	Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, I-98125 Messina 5, Italy; [Genovese, T.; Rossi, A.; Mazzon, E.; Di Paola, R.; Bramanti, P.; Cuzzocrea, S.] IRCCS, Ctr Neurolesi Bonino Pulejo, Messina, Italy; [Rossi, A.; Sautebin, L.] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; [Caminiti, R.] Univ Messina, Sch Med, Dept Human Pathol, Messina, Italy		Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Via C Valeria, I-98125 Messina 5, Italy.	salvator@unime.it	Bramanti, Placido/K-5117-2016; Mazzon, Emanuela/AAL-4334-2020; di paola, rosanna/U-4356-2019	Antonietta, Rossi/0000-0002-3237-2584; mazzon, emanuela/0000-0002-5073-717X; di paola, rosanna/0000-0001-6725-8581; GENOVESE, Tiziana/0000-0002-3335-7327			Adachi K, 2005, NEUROSCI RES, V51, P73, DOI 10.1016/j.neures.2004.10.007; Anderson Aileen J, 2002, J Spinal Cord Med, V25, P70; Bao F, 2004, J NEUROCHEM, V90, P1194, DOI 10.1111/j.1471-4159.2004.02580.x; Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bertolini A, 2002, CURR MED CHEM, V9, P1033, DOI 10.2174/0929867024606650; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; BISGAARD H, 1985, PROSTAGLANDINS, V30, P791, DOI 10.1016/0090-6980(85)90007-3; Blain JF, 2000, PROSTAG LEUKOTR ESS, V62, P361, DOI 10.1054/plef.2000.0167; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bregman B S, 1997, Adv Neurol, V72, P257; Bregman BS, 1998, EXP NEUROL, V149, P13, DOI 10.1006/exnr.1997.6669; Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Cuzzocrea S, 2005, LAB INVEST, V85, P808, DOI 10.1038/labinvest.3700276; DEMOPOULOS HB, 1978, SCAN ELECTRON MICROS, V2, P677; Diener PS, 1998, J NEUROSCI, V18, P779; Diener PS, 1998, J NEUROSCI, V18, P763; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Failla M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-137; FORDHUTCHINSON AW, 1980, AGENTS ACTIONS, V10, P548, DOI 10.1007/BF02024162; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GEISLER FH, 1992, J NEUROTRAUM, V9, pS517; Genovese T, 2005, J NEUROIMMUNOL, V166, P55, DOI 10.1016/j.jneuroim.2005.05.009; Greene KA, 1996, J SPINAL DISORD, V9, P355; GREENE KA, 1994, CRIT REV NEUROSURG, V4, P254; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hensley K, 2006, ANTIOXID REDOX SIGN, V8, P2075, DOI 10.1089/ars.2006.8.2075; Ichiyama T, 2007, CLIN EXP ALLERGY, V37, P608, DOI 10.1111/j.1365-2222.2007.02692.x; Jacobs T P, 1987, Cent Nerv Syst Trauma, V4, P95; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; Joshi M, 2002, J NEUROTRAUM, V19, P191, DOI 10.1089/08977150252806956; Jung SB, 2005, J CLIN IMMUNOL, V25, P482, DOI 10.1007/s10875-005-5431-1; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Lee KS, 2007, J ALLERGY CLIN IMMUN, V119, P141, DOI 10.1016/j.jaci.2006.09.001; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; LEVINE JD, 1984, SCIENCE, V225, P743, DOI 10.1126/science.6087456; Marusic S, 2005, J EXP MED, V202, P841, DOI 10.1084/jem.20050665; Mazzon E, 2006, SHOCK, V25, P377, DOI 10.1097/01.shk.0000209530.30564.22; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; MITSUHASHI T, 1994, PARAPLEGIA, V32, P524, DOI 10.1038/sc.1994.84; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; Nishisho T, 1996, NEUROSURGERY, V39, P950, DOI 10.1097/00006123-199611000-00014; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Rossi A, 2005, J LEUKOCYTE BIOL, V78, P985, DOI 10.1189/jlb.1004619; Saito H, 2004, IMMUNOLOGY, V113, P246, DOI 10.1111/j.1365-2567.2004.01944.x; Schutte B, 1998, J NEUROSCI METH, V86, P63, DOI 10.1016/S0165-0270(98)00147-2; SHEA TB, 1994, BIOTECHNIQUES, V16, P1126; SHOHAMI E, 1987, PROSTAG LEUKOTR ESS, V28, P169, DOI 10.1016/0262-1746(87)90161-2; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Sugaya K, 2000, JPN J PHARMACOL, V82, P85, DOI 10.1254/jjp.82.85; SUTTORP N, 1987, INFECT IMMUN, V55, P104, DOI 10.1128/IAI.55.1.104-110.1987; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tugtepe H, 2007, EUR J PHARMACOL, V557, P69, DOI 10.1016/j.ejphar.2006.11.009; Virchow JC, 2001, CLIN EXP ALLERGY, V31, P836, DOI 10.1046/j.1365-2222.2001.01051.x; Wada K, 2006, FASEB J, V20, P1785, DOI 10.1096/fj.06-5809com; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Xu W, 2005, SPINAL CORD, V43, P204, DOI 10.1038/sj.sc.3101674; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004	72	44	47	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	FEB	2008	153	3					568	582		10.1038/sj.bjp.0707577			15	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	258QW	WOS:000252884000019	18059327	Green Published			2022-02-06	
J	Grados, MA; Vasa, RA; Riddle, MA; Slomine, BS; Salorio, C; Christensen, J; Gerring, J				Grados, Marco A.; Vasa, Roma A.; Riddle, Mark A.; Slomine, Beth S.; Salorio, Cynthia; Christensen, James; Gerring, Joan			New onset obsessive-compulsive symptoms in children and adolescents with severe traumatic brain injury	DEPRESSION AND ANXIETY			English	Article						obsessive-compulsive disorder; traumatic brain injury; pediatric; anterior cingulate cortex; temporal lobe	TEMPORAL-LOBE EPILEPSY; CLOSED-HEAD INJURY; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL GLUCOSE-METABOLISM; ANTERIOR CINGULATE CORTEX; PSYCHIATRIC-DISORDERS; UNMEDICATED PATIENTS; PROVOCATION; COMORBIDITY; PERSONALITY	Traumatic brain injury (TBI) constitutes a major source of psychiatric morbidity and disability. This study examines new onset of obsessions and compulsions (OCS) within 1 year of severe pediatric TBI Eighty children and adolescents ages 6-18 years with severe TBI were interviewed by a child psychiatrist using the Diagnostic Interview for Children and Adolescents-Revised to diagnose OCS and comorbidities A brain magnetic resonance imaging used a 1.5 T scanner 3 months after injury with a T1-weighted spoiled gradient-recalled-echo sequence to provide high spatial resolution and T1- and T2*-contrast sensitivity. Race, sex, socioeconomic status, psychosocial adversity, and injury severity were used to predict new onset OCS. Psychiatric comorbidities and brain lesion volumes in orbitofrontal, mesial prefrontal, temporal lobe, basal ganglia, and thalamus were examined in relation to new onset OCS. Twenty-one children (21/72, 29.2%) had OCS after TBI. Most common were worries about disease, cleanliness, and inappropriate actions as well as excessive cleaning, doing things a certain way and ordering. Anxiety disorders, mania, dysthymia, depressive symptoms, and posttraumatic stress disorder were significantly associated with new onset OCS. Injury severity was not associated with new onset OCS. Greater psychosocial adversity (P = 0.009), and being female (P = 0.005) were associated with OCS while mesial prefrontal and temporal lobe lesions were associated with new onset obsessions (P<0.05). OCS are common after severe pediatric TBI and are associated with greater comorbidities. New onset obsessions are associated with female sex, psychosocial adversity, and mesial prefrontal and temporal lesions.	[Grados, Marco A.; Vasa, Roma A.; Riddle, Mark A.; Gerring, Joan] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA; [Vasa, Roma A.; Slomine, Beth S.; Salorio, Cynthia; Christensen, James; Gerring, Joan] Johns Hopkins Univ, Sch Med, Kennedy Krieger Res Inst, Baltimore, MD USA		Grados, MA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, 600 N Wolfe St,CMSC 346, Baltimore, MD 21287 USA.	mjgrados@jhmi.edu		Grados, Marco/0000-0002-6189-6264	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066284] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066284] Funding Source: Medline		Adler CM, 2000, J PSYCHIATR RES, V34, P317, DOI 10.1016/S0022-3956(00)00022-4; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Barbieri V, 2005, EPILEPSY BEHAV, V6, P617, DOI 10.1016/j.yebeh.2005.02.010; BAXTER LR, 1987, ARCH GEN PSYCHIAT, V44, P211; BAXTER LR, 1990, J CLIN PSYCHIAT, V51, P22; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; BIRD HR, 1992, J AM ACAD CHILD PSY, V31, P78, DOI 10.1097/00004583-199201000-00012; Bogetto F, 1999, EUR PSYCHIAT, V14, P434, DOI 10.1016/S0924-9338(99)00224-2; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Breiter HC, 1996, NEUROIMAGE, V4, pS127, DOI 10.1006/nimg.1996.0063; Busatto GF, 2001, J AM ACAD CHILD PSY, V40, P347, DOI 10.1097/00004583-200103000-00015; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Childers MK, 1998, BRAIN INJURY, V12, P613; Damasio H, 1995, HUMAN BRAIN ANATOMY; DRUMMOND LM, 1988, BRIT J PSYCHIAT, V153, P839, DOI 10.1192/bjp.153.6.839; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; INSEL TR, 1992, PSYCHIAT CLIN N AM, V15, P813; *ISG TECHN, 1995, ALL SOFTW; JENIKE M, 1984, J AFFECT DISORDERS, V2, P359; KANNER AM, 1993, NEUROPSY NEUROPSY BE, V6, P126; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; KROLL L, 1993, J NERV MENT DIS, V181, P457, DOI 10.1097/00005053-199307000-00011; Lensi P, 1996, BRIT J PSYCHIAT, V169, P101, DOI 10.1192/bjp.169.1.101; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; Monaco F, 2005, EPILEPSY BEHAV, V7, P491, DOI 10.1016/j.yebeh.2005.07.003; Nestadt G, 2000, AM J HUM GENET, V67, P1611, DOI 10.1086/316898; Neumeister A, 2004, ARCH GEN PSYCHIAT, V61, P765, DOI 10.1001/archpsyc.61.8.765; NOSHIRVANI HF, 1991, BRIT J PSYCHIAT, V158, P260, DOI 10.1192/bjp.158.2.260; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Procyk E, 2000, NAT NEUROSCI, V3, P502, DOI 10.1038/74880; Pujol J, 2002, NEUROIMAGE, V15, P847, DOI 10.1006/nimg.2001.1004; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rauch SL, 1997, J NEUROPSYCH CLIN N, V9, P568; RAUCH SL, 1994, ARCH GEN PSYCHIAT, V51, P62; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; ROBINSON D, 1995, ARCH GEN PSYCHIAT, V52, P393; Rushworth MFS, 2004, TRENDS COGN SCI, V8, P410, DOI 10.1016/j.tics.2004.07.009; Sachdev PS, 2005, AUST NZ J PSYCHIAT, V39, P757, DOI 10.1080/j.1440-1614.2005.01680.x; Saxena S, 2004, AM J PSYCHIAT, V161, P1038, DOI 10.1176/appi.ajp.161.6.1038; Stein DJ, 2006, METAB BRAIN DIS, V21, P267, DOI 10.1007/s11011-006-9021-6; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P690; Szeszko PR, 1999, ARCH GEN PSYCHIAT, V56, P913, DOI 10.1001/archpsyc.56.10.913; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; ValleniBasile LA, 1996, J AM ACAD CHILD PSY, V35, P898, DOI 10.1097/00004583-199607000-00015; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726	55	44	48	0	9	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1091-4269			DEPRESS ANXIETY	Depress. Anxiety		2008	25	5					398	407		10.1002/da.20398			10	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	304UH	WOS:000256134100004	17957806				2022-02-06	
J	Iverson, GL; Kaarto, ML; Koehle, MS				Iverson, Grant L.; Kaarto, Michelle L.; Koehle, Michael S.			Normative data for the balance error scoring system: Implications for brain injury evaluations	BRAIN INJURY			English	Article						balance; postural stability; concussion; traumatic brain injury; military	POSTURAL STABILITY; MOTOR-PERFORMANCE; CONCUSSION; DEFICITS; INSTABILITY	Primary objective: Patients who sustain traumatic brain injuries can experience temporary or permanent deficits in static or dynamic balance. The Balance Error Scoring System (BESS) is a brief, easily-administered test of static balance that recently has been recommended for use with military personnel who do not recover rapidly from a mild traumatic brain injury. However, the test lacks normative reference values for healthy adults, which greatly limits its clinical usefulness. The purpose of this study is to provide normative data for healthy men and women across the lifespan. Methods: Community-dwelling adults (n = 589) between the ages of 20-69 (M = 49.75, SD = 10.81) were administered the BESS. They did not have significant medical, neurological or lower extremity problems that might have an adverse effect on balance. Results: There was no relation between BESS and height and a very small correlation between BESS and weight. There was a small correlation between BESS and waist girth and body mass index. BESS performance was similar in men and women. BESS scores were consistent across the age groups until the 50s, when they worsened. Normative reference values stratified by age groups are presented. Conclusions: These normative data provide a frame of reference for interpreting BESS performance in civilians and military personnel who sustain traumatic brain injuries and adults with diverse neurological problems.	[Iverson, Grant L.; Koehle, Michael S.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Iverson, Grant L.] Copeman Neurosci Ctr, Vancouver, BC, Canada; [Kaarto, Michelle L.; Koehle, Michael S.] Copeman Healthcare Ctr, Vancouver, BC, Canada		Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca	Koehle, Michael S/C-7850-2013	Koehle, Michael S/0000-0001-7026-8422; Iverson, Grant/0000-0001-7348-9570			Bressel E, 2007, J ATHL TRAINING, V42, P42; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Choy NL, 2003, J GERONTOL A-BIOL, V58, P525; Collins M. W., 2007, BRAIN INJURY MED PRI, P407; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; *DVBIC, 2006, DEF VET BRAIN INJ CT; Era P, 2006, GERONTOLOGY, V52, P204, DOI 10.1159/000093652; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Gidlow C., 2006, HLTH ED J, V65, P338, DOI DOI 10.1177/0017896906069378; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hopman WM, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-150; Iverson G.L., 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Patel AV, 2007, J ATHL TRAINING, V42, P66; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Susco TM, 2004, J ATHL TRAINING, V39, P241; Valovich TC, 2003, J ATHL TRAINING, V38, P51; VALOVICH TC, 2004, J ATHL TRAINING, V14, P287; Wardle J, 2002, AM J PUBLIC HEALTH, V92, P1299, DOI 10.2105/AJPH.92.8.1299; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	28	44	44	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					147	152		10.1080/02699050701867407			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600005	18240043				2022-02-06	
J	Kwok, FY; Lee, TMC; Leung, CHS; Poon, WS				Kwok, Florence Y.; Lee, Tatia M. C.; Leung, Clarence H. S.; Poon, Wai S.			Changes of cognitive functioning following mild traumatic brain injury over a 3-month period	BRAIN INJURY			English	Article						traumatic brain injury; attention; cognitive functions; mild TBI; neuropsychology	POSITRON-EMISSION-TOMOGRAPHY; MINOR HEAD-INJURY; ATTENTION; SYMPTOMS; DEFICITS; CONCUSSION; CHINESE; ADULTS	Primary objective: To examine the cognitive functioning in patients with complicated mild traumatic brain injury immediately post-injury and at 1 and 3 months post-injury. Research design, methods, and procedures: Between-group comparisons were adopted for this study. Specifically, both patients and healthy controls were administered neuropsychological assessments measuring attention, memory and executive functions at three time points. Results: Findings indicate that patients performed significantly more poorly in information processing and divided attention, sustained attention, verbal recognition and verbal fluency immediately post-injury. While the information processing and divided attention of mild TBI patients improved at 1 month and returned to normal at 3 months post-injury, their sustained attention remained significantly poorer over the 3-month period. Conclusions: Findings suggest that attention dysfunction is noticeable immediately following a mild TBI. Different attention functions appear to recover at a different pace over time, suggesting that the condition may have a differential impact on the different sub-types of attention.	[Kwok, Florence Y.; Lee, Tatia M. C.] Univ Hong Kong, Neuropsychol Lab, Hong Kong, Hong Kong, Peoples R China; [Lee, Tatia M. C.] MacLehose Med Rehabil Ctr, Inst Clin Neuropsychol, Hong Kong, Hong Kong, Peoples R China; [Leung, Clarence H. S.; Poon, Wai S.] Chinese Univ Hong Kong, Prince Wales Hosp, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China		Lee, TMC (corresponding author), Univ Hong Kong, Neuropsychol Lab, K610,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	tmclee@hkusua.hku.hk	Poon, Wai Sang/F-1558-2011; Lee, Tatia Mei Chun/D-4922-2009		The University of Hong KongUniversity of Hong Kong; Wai Lun Education Foundation Limited; S. K. Yee Medical Foundation	The project was supported by the University Development Fund and the Research Output Prize of The University of Hong Kong, the Wai Lun Education Foundation Limited and the S. K. Yee Medical Foundation.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Benton AL, 1974, REVISED VISUAL RETEN; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Brown L., 1997, TEST NONVERBAL INTEL, V3rd; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fernandez-Duque D, 2001, J CLIN EXP NEUROPSYC, V23, P74, DOI 10.1076/jcen.23.1.74.1217; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gunstad J, 2006, ARCH CLIN NEUROPSYCH, V21, P645, DOI 10.1016/j.acn.2006.05.009; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lee TMC, 2002, J CLIN EXP NEUROPSYC, V24, P615, DOI 10.1076/jcen.24.5.615.1001; Lee TMC, 2000, J CLIN EXP NEUROPSYC, V22, P465, DOI 10.1076/1380-3395(200008)22:4;1-0;FT465; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEWIS RF, 1992, DIG VIG TEST PROF US; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff R. M., 1989, MILD HEAD INJURY, P176; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smith A., 1982, SYMBOL DIGIT MODALIT; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; ZAKZANIS KK, 1999, MILD TRAUMATIC BRAIN	43	44	44	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	10					740	751		10.1080/02699050802336989			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	347MJ	WOS:000259145400003	18787983				2022-02-06	
J	Ownsworth, T; Shum, D				Ownsworth, Tamara; Shum, David			Relationship between executive functions and productivity outcomes following stroke	DISABILITY AND REHABILITATION			English	Article						stroke; executive functions; employment; productivity	TRAUMATIC BRAIN-INJURY; COGNITIVE IMPAIRMENT; SELF-AWARENESS; REHABILITATION; CONSEQUENCES; SENSITIVITY; MANAGEMENT; FREQUENCY; DEFICITS; FLUENCY	Purpose. Stroke occurs in many individuals of working age and can considerably disrupt their capacity for employment and other productive activities. Few studies have examined the relationship between loss of productivity and cognitive impairment, particularly deficits in executive function. The present study examined whether performance on tests of executive function is related to employment and productivity at 12-months follow-up. Method. Twenty-seven individuals (mean age = 47.3 years, SD = 10.7) on average 2.1 years (SD = 1.6) post-stroke were recruited from hospital and community rehabilitation services and administered a theory-driven battery of executive function tests (i.e. Health and Safety sub-test, FAS Test, Five-Point test, Key Search Test and Tinkertoy Test). A 12-month follow-up assessment of employment outcome ('employed' or 'unemployed') and productivity (measured by the Sydney Psychosocial Reintegration Scale) was conducted. Results. A series of between-group comparisons identified that a measure of purposive behaviour and self-regulation (i.e. the Tinkertoy Test) best distinguished between the employed and unemployed groups (p < 0.01) irrespective of time since injury and neglect. Level of post-stroke productivity was significantly correlated with measures of planning (p < 0.05), self-monitoring (p < 0.01) and self-regulation (p < 0.05), as well as time since injury (p < 0.05) and functional status (p < 0.01). Conclusions. These findings highlight the importance of routinely assessing executive functions to guide cognitive rehabilitation interventions following stroke.	[Ownsworth, Tamara; Shum, David] Griffith Univ, Sch Psychol, Nathan, Qld 4111, Australia; [Ownsworth, Tamara; Shum, David] Griffith Univ, Appl Cognitive Neurosci Res Ctr, Nathan, Qld 4111, Australia		Ownsworth, T (corresponding author), Griffith Univ, Sch Psychol, Nathan, Qld 4111, Australia.	t.ownsworth@griffith.edu.au	Shum, David/A-3914-2008; Ownsworth, Tamara/ABB-6961-2021	Shum, David/0000-0002-4810-9262; Ownsworth, Tamara/0000-0003-1835-7094			Ashburn A, 2006, DISABIL REHABIL, V28, P809, DOI 10.1080/09638280500534689; Australian Institute of Health and Welfare, 2003, DIS PREV TRENDS; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; BOGOUSSLAVSKY J, 1994, EUR NEUROL, V34, P306, DOI 10.1159/000117068; Burgess P, 1996, BEHAV ASSESSMENT DYS; Cartoni A, 2005, NEUROPSYCHOL REHABIL, V15, P55, DOI 10.1080/09602010443000029; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Delis DC., 2001, DELIS KAPLAN EXECUTI; Golding E., 1989, MIDDLESEX ELDERLY AS; Hartman-Maeir A, 2002, J REHABIL MED, V34, P158, DOI 10.1080/16501970213236; Jones F, 2006, DISABIL REHABIL, V28, P841, DOI 10.1080/09638280500534952; Kaplan E., 1988, CLIN NEUROPSYCHOLOGY, P125; Lee GP, 1997, CLIN NEUROPSYCHOL, V11, P59, DOI 10.1080/13854049708407030; Leeds L, 2001, AGE AGEING, V30, P251, DOI 10.1093/ageing/30.3.251; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lezak MD., 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Loeb, 1996, INDEPENDENT LIVING S; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Ownsworth T, 2006, REHABIL PSYCHOL, V51, P50, DOI 10.1037/0090-5550.51.1.50; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Pedersen PM, 1996, J NEUROL REHABIL, V10, P243; Pohjasvaara T, 2002, EUR J NEUROL, V9, P269, DOI 10.1046/j.1468-1331.2002.00396.x; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stemmer B, 2000, BRAIN COGNITION, V44, P25; Stephens S, 2004, INT J GERIATR PSYCH, V19, P1053, DOI 10.1002/gps.1209; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D.T., 1996, FRONTAL LOBES; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; Teasdale TW, 2005, BRAIN INJURY, V19, P1049, DOI 10.1080/02699050500110421; TUPPER DE, 1989, ANN M NAT AC NEUR NO; VONCRAMON DY, 1992, NEUROPSYCHOL REHABIL, V2, P207; Wozniak MA, 2002, NEUROEPIDEMIOLOGY, V21, P159, DOI 10.1159/000059516	42	44	45	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2008	30	7					531	540		10.1080/09638280701355694			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	279IL	WOS:000254348800007	17852299				2022-02-06	
J	Safaz, I; Alaca, R; Yasar, E; Tok, F; Yilmaz, B				Safaz, Ismail; Alaca, Ridvan; Yasar, Evren; Tok, Fatih; Yilmaz, Bilge			Medical complications, physical function and communication skills in patients with traumatic brain injury: A single centre 5-year experience	BRAIN INJURY			English	Article						traumatic brain injury; complication; epilepsy; pressure ulcer; incontinence	HETEROTOPIC OSSIFICATION; VENOUS THROMBOEMBOLISM; RISK-FACTORS; SWALLOWING DISORDERS; VERBAL IMPAIRMENT; REHABILITATION; HEAD; INCONTINENCE; SEIZURES; OUTCOMES	Objective: The aim of this retrospective study was to review the medical complications of patients with traumatic brain injury (TBI) who were followed in 2000-2006. Methods and procedures: The demographic data, functional and cognitive status of 116 persons with TBI were noted. The presence of communication problems, swallowing disturbances, urinary and faecal incontinence, pressure ulcer, deep venous thrombosis (DVT), post-traumatic seizure (PTS) and heterotopic ossification (HO) were recorded at first admission and follow-up. Main outcome and results: This study detected aphasia in 19.0%, dysarthria in 30.2%, dysphagia in 17.2%, pressure ulcers in 6.9% and DVT in 2.6% the our patients with TBI. Urinary and faecal incontinence on admission were 32.7% and 26.7%, respectively. Patients with incontinence had poorer cognitive function than those with normal continence. HO rate was 18.1% and the ambulation levels of patients with HO were worse than those without HO. PTS was seen in 13.8% of the patients on admission and this ratio increased to 21.6% during the follow-up. In these patients, the aetiological risk factors for PTS were gunshot and fall injuries. Conclusions: Considering the wide spectrum of complications, this study advocates that these persons with TBI should be followed promptly by a multidisciplinary team.	[Safaz, Ismail; Alaca, Ridvan; Yasar, Evren; Tok, Fatih; Yilmaz, Bilge] Turkish Armed Force Rehabil Ctr, Dept Phys Med & Rehabil, Gulhane Mil Med Acad, Ankara, Turkey		Safaz, I (corresponding author), TSK Rehabil Merkezi Bilkent Ankara, TR-06530 Ankara, Turkey.	safazi@yahoo.com	YILMAZ, Bilge/W-6481-2019; YILMAZ, Bilge/A-7428-2013	YILMAZ, Bilge/0000-0003-1173-9399; YILMAZ, Bilge/0000-0003-1173-9399			Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Aras MD, 2004, INT J REHABIL RES, V27, P257, DOI 10.1097/00004356-200412000-00001; Boake C, 2000, PHYS MED REHABILITAT, P1073; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; Connolly JF, 1999, ARCH PHYS MED REHAB, V80, P1309, DOI 10.1016/S0003-9993(99)90035-7; Cullen N, 2007, BRAIN INJURY, V21, P215, DOI 10.1080/02699050701202027; Demir SO, 2006, J REHABIL MED, V38, P68, DOI 10.1080/16501970510041262; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Elhan AH, 2005, J REHABIL MED, V37, P306, DOI 10.1080/16501970510037573; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Foxx-Orenstein A, 2003, ARCH PHYS MED REHAB, V84, P231, DOI 10.1053/apmr.2003.50095; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Gil M, 1996, BRAIN INJURY, V10, P39, DOI 10.1080/026990596124700; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Johns JS, 1999, J HEAD TRAUMA REHAB, V14, P269, DOI 10.1097/00001199-199906000-00007; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Lai JM, 1997, BRAIN INJURY, V11, P331, DOI 10.1080/026990597123485; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Mazaux JM, 2001, J REHABIL MED, V33, P99; Morgan AS, 1999, J HEAD TRAUMA REHAB, V14, P454, DOI 10.1097/00001199-199910000-00006; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Safaz I, 2008, J NEUROSURG, V108, P370, DOI 10.3171/JNS/2008/108/2/0370; Safaz I, 2008, AM J PHYS MED REHAB, V87, P65, DOI 10.1097/PHM.0b013e31815b5b4d; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Teasell R, 2007, BRAIN INJURY, V21, P201, DOI 10.1080/02699050701201854; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; VARGHESE G, 1992, PHYS MED REH CLIN N, V3, P407; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; Wang YT, 2005, J COMMUN DISORD, V38, P231, DOI 10.1016/j.jcomdis.2004.12.001; WATANABE TK, 2001, PHYS MED REHABILITAT, V15, P283	35	44	45	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	10					733	739		10.1080/02699050802304714			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	347MJ	WOS:000259145400002	18720099				2022-02-06	
J	Sterr, A; Herron, K; Dijk, DJ; Ellis, J				Sterr, Annette; Herron, Katherine; Dijk, Derk-Jan; Ellis, Jason			Time to wake-up: Sleep problems and daytime sleepiness in long-term stroke survivors	BRAIN INJURY			English	Article						sleepiness; sleep disturbance; chronic illness; stroke; well-being	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; DEPRESSION SCALE; HOSPITAL ANXIETY; INDEX; APNEA; RELIABILITY; INSOMNIA; VALIDITY	Background and purpose: In work with chronic stroke patients the authors observed that patients frequently appear sleepy and often comment on their poor sleep. Sleep difficulties are frequently reported and indeed clinically recognized in the acute phase post-stroke, but little is known about the sleep and daytime sleepiness of chronic stroke patients with sustained disabilities. The latter, however, deserves clarification because sleep is a critical modulator of health, daytime performance and wellbeing. The present study therefore explored the sleep and sleepiness in a chronic stroke population with sustained physical deficits. Methods: An opportunity sample of 20 patients with chronic low-functioning hemiplegia (12 months) completed the Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Medical Outcome Study Short Form 36 and Hospital Anxiety and Depression Scale. Results: Compared to a normative healthy population, long-term stroke survivors reported poorer sleep and greater daytime sleepiness. Increased levels of sleepiness were associated with longer chronicity, whereas nocturnal sleep parameters were not. Conclusions: In line with clinical observations, stroke survivors with sustained physical disabilities report poorer sleep and experience greater levels of sleepiness. Further research in a larger cohort and including objective sleep measures is necessary to investigate the nature and scale of sleep difficulties and daytime sleepiness in more detail so that care and treatment strategies can be developed in due course.	[Sterr, Annette; Herron, Katherine] Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England; [Dijk, Derk-Jan] Univ Surrey, Surrey Sleep Res Ctr, Guildford GU2 7XH, Surrey, England; [Ellis, Jason] Univ Glasgow, Div Psychol Med, Glasgow G12 8QQ, Lanark, Scotland		Sterr, A (corresponding author), Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England.	a.sterr@surrey.ac.uk	Dijk, Derk-Jan/D-8387-2011; Ellis, Jason/E-7783-2013	Sterr, Annette/0000-0003-4490-985X; Ellis, Jason/0000-0002-8496-520X	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0200128] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0200128] Funding Source: Medline		Adamson Joy, 2004, J Stroke Cerebrovasc Dis, V13, P171, DOI 10.1016/j.jstrokecerebrovasdis.2004.06.003; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Bassetti C, 1999, SLEEP, V22, P217, DOI 10.1093/sleep/22.2.217; Bassetti CL, 2005, SEMIN NEUROL, V25, P19, DOI 10.1055/s-2005-867073; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Broadley SA, 2007, J CLIN NEUROSCI, V14, P328, DOI 10.1016/j.jocn.2006.01.017; Buck D, 2000, STROKE, V31, P2004, DOI 10.1161/01.STR.31.8.2004; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cadilhac DA, 2005, J CLIN NEUROSCI, V12, P632, DOI 10.1016/j.jocn.2004.08.014; Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5; Catalano T., 2003, AUSTR J PRIMARY HLTH, V9, P80; Chervin RD, 1997, J PSYCHOSOM RES, V42, P145, DOI 10.1016/S0022-3999(96)00239-5; Dyken ME, 1996, STROKE, V27, P401, DOI 10.1161/01.STR.27.3.401; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; *FRAM HEART STUD N, 1996, HEART STROK STAT UPD; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; Leppavuori A, 2002, CEREBROVASC DIS, V14, P90, DOI 10.1159/000064737; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Manocchia M, 2001, QUAL LIFE RES, V10, P331, DOI 10.1023/A:1012299519637; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; PALOMAKI H, 1989, STROKE, V20, P1311, DOI 10.1161/01.STR.20.10.1311; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Siengsuhon CF, 2008, TOP STROKE REHABIL, V15, P1, DOI 10.1310/tsr1501-1; Vock J, 2002, J SLEEP RES, V11, P331, DOI 10.1046/j.1365-2869.2002.00316.x; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	44	46	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	7-8					575	579		10.1080/02699050802189727			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	318MG	WOS:000257095300008	18568710				2022-02-06	
J	Anderson, V; Catroppa, C				Anderson, Vicic; Catroppa, Cathy			Memory outcome at 5 years post-childhood traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; children memory	CLOSED-HEAD-INJURY; WORKING-MEMORY; CHILDREN; RECOVERY; SEVERITY; MILD	Primary objective: This study seeks to extend previous findings by documenting memory performance in a sample of 70 children at 5 years post-injury. It was anticipated that increasing injury severity would be associated with decreased performance on working and complex memory tasks. It was also expected that injury severity would significantly predict memory, but that the time from insult to subsequent testing would be associated with an increased relationship to non-injury factors. Research design: Participants were assessed at 5 years post-injury, aged between 6-14 years, using measures of immediate, working and complex memory. Methods and procedures: The sample comprised 18 children who had sustained a severe TBI, 24 with a moderate TBI, 11 with a mild TBI and 17 healthy controls, matched for age, gender and socio-economic-status. Results: Results indicated that severe TBI was associated with decreased complex auditory-verbal memory performance, although children with TBI did not display impairment on immediate, working or complex visual-spatial memory. While injury severity significantly predicted complex memory outcome, non-injury factors failed to significantly predict either working or complex memory performance. Conclusions: Future research should be engineered towards further clarifying what influences recovery from childhood TBI in the elongated post-injury period.	[Anderson, Vicic; Catroppa, Cathy] Royal Childrens Hosp, Melbourne, Vic, Australia; [Anderson, Vicic; Catroppa, Cathy] Univ Melbourne, Parkville, Vic 3052, Australia; [Anderson, Vicic; Catroppa, Cathy] Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			AMACHER AL, 1988, PEDIAT HEAD INJURY; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, BRAIN DAM B, P125; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2000, BRAIN INJURY, V14, P679; ANDERSON VA, 1997, NEUROPSYCHOLOGICAL A; Andrewes D., 2001, NEUROPSYCHOLOGY THEO; Baddeley, 1990, HUMAN MEMORY THEORY; BADDELEY A, 2000, HUMAN MEMMORY THEORY; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Ciccetti D., 1984, VINELAND ADAPTIVE BE; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; DANIEL A, 1983, POWER PRIVILEDGE PRE; Dennis M, 2004, DEV NEUROPSYCHOL, V25, P1, DOI 10.1207/s15326942dn2501&2_1; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Fidell L.S., 2000, USING MULTIVARIATE S; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GONZALEZ LM, IN PRESS J INT NEURO; Harris JR, 1996, J COMMUN DISORD, V29, P79, DOI 10.1016/0021-9924(94)00035-2; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Lehnung M, 2003, BRAIN INJURY, V17, P855, DOI 10.1080/0269905031000089369; LENNENBURG EH, 1967, BIOL FDN LANGUAGE; LEVIN H, 1988, NEUROPSYCHOLOGY, V8, P171; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Ong LC, 1998, J PAEDIATR CHILD H, V34, P363, DOI 10.1046/j.1440-1754.1998.00239.x; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Strang J.D., 1983, CHILD NEUROPSYCHOLOG; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Tranel D., 2002, HDB MEMORY DISORDERS; Vakil E, 2004, CHILD NEUROPSYCHOL, V10, P57, DOI 10.1080/09297040490911078; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; WECHSLER D, 1991, MAN WECHSLER INTELLI; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	47	44	44	1	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1399	1409		10.1080/02699050701785070			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200008	18066942				2022-02-06	
J	Chau, RMC; Teo, PML; Kam, MKM; Leung, SF; Cheung, KY; Chan, ATC				Chau, Ricky M. C.; Teo, Peter M. L.; Kam, Michael K. M.; Leung, S. F.; Cheung, K. Y.; Chan, Anthony T. C.			Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-STAGE nasopharyngeal carcinoma: To treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord	MEDICAL DOSIMETRY			English	Article						NPC; 2DRT; advanced T-stage; IMRT; DVH; TCP; NTCP	TUMOR-CONTROL PROBABILITY; HONG-KONG EXPERIENCE; NECK CANCERS; RADIOTHERAPY; HEAD; IRRADIATION; MODEL; PLANS	The aim of this study is to evaluate the deficiencies in target coverage and organ protection of 2-dimensional radiation therapy (2DRT) in the treatment of advanced T-stage T3-4) nasopharyngeal carcinoma (NPC), and assess the extent of improvement that could be achieved with intensity modulated radiation therapy IMRT), with special reference to of the dose to the planning organ-at-risk volume (PRV) of the brainstem and spinal cord. A dosimetric study was performed on 10 patients with advanced T-stage (T3-4 and N0-2) NPC. Computer tomography (CT) images of 2.5-mm slice thickness of the head and neck were acquired with the patient immobilized in semi-extended-head position. A 2D plan based on Ho's technique, and an IMRT plan based on a 7-coplanar portals arrangement, were established for each patient. 2DRT was planned with the field borders and shielding drawn on the simulator radiograph with reference to bony landmarks, digitized, and entered into a planning computer for reconstruction of the 3D dose distribution. The 2DRT and IMRT treatment plans were evaluated and compared with respect to the dose-volume histograms (DVHs) of the targets and the organs-at-risk (OARs), tumor control probability (TCP), and normal tissue complication probabilities (NTCPs). With IMRT, the dose coverage of the target was superior to that of 2DRT. The mean minimum dose of the GTV and PTV were increased from 33.7 Gy (2DRT) to 62.6 Gy (IMRT), and 11.9 Gy (2DRT) to 47.8 Gy (IMRT), respectively. The D-95 of the GTV and PTV were also increased from 57.1 Gy (2DRT) to 67 Gy (IMRT), and 45 Gy (2DRT) to 63.6 Gy (IMRT), respectively. The TCP was substantially increased to 78.5% in IMRT. Better protection of the critical normal organs was also achieved with IMRT. The mean maximum dose delivered to the brainstem and spinal cord were reduced significantly from 61.8 Gy (2DRT) to 52.8 Gy IMRT) and 56 Gy (2DRT) to 43.6 Gy IMRT), respectively, which were within the conventional dose limits of 54 Gy for brainstem and of 45 Gy for spinal cord. The mean maximum doses deposited on the PRV of the brainstem and spinal cord were 60.7 Gy and 51.6 Gy respectively, which were above the conventional dose limits. For the chiasm, the mean dose maximum and the dose to 5% of its volume were reduced from 64.3 Gy (2DRT) to 53.7 Gy (IMRT) and from 62.8 Gy (2DRT) to 48.7 Gy IMRT), respectively, and the corresponding NTCP was reduced from 18.4% to 2.1%. For the temporal lobes, the mean dose to 10 % of its volume (about 4.6 cc) was reduced from 63.8 Gy (2DRT) to 55.4 Gy (IMRT) and the NTCP was decreased from 11.7% to 3.4%. The therapeutic ratio for T3-4 NPC tumors can be significantly improved with IMRT treatment technique due to improvement both in target coverage and the sparing of the critical normal organ. Although the maximum doses delivered to the brainstem, and spinal cord in IMRT can be kept at or below their conventional dose limits, the maximum doses deposited on the PRV often exceed these limits due to the close proximity between the target and OARs. In other words, ideal dosimetric considerations cannot be fulfilled in IMRT planning for T34 NPC tumors. A compromise of the maximal dose limit to the PRV of the brainstem and spinal cord would need be accepted if dose coverage to the targets is not to be unacceptably compromised. Dosimetric comparison with 2DRT plans show that these dose limits to PRV were also frequently exceeded in 2DRT plans for locally advanced NPC. A dedicated retrospective study on the incidence of clinical injury to neurological organs in a large seriesof patients with T3-4 NPC treated by 2DRT may provide useful reference data in exploring how far the PRV dose constraints may be relaxed, to maximize the target coverage without compromising the normal organ function. (C) 2007 American Association of Medical Dosimetrists.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China; Sanatorium Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China		Chau, RMC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China.	S033928@mailserv.cuhk.edu.hk	Chan, Anthony Tak Cheung/R-3940-2018; Cheung, Kin/ABB-1335-2021	Chan, Anthony Tak Cheung/0000-0002-6912-8091; 			BURMAN C, 1991, INT J RADIAT ONCOL, V21, P123, DOI 10.1016/0360-3016(91)90172-Z; Chao KSC, 2000, INT J CANCER, V90, P92, DOI 10.1002/(SICI)1097-0215(20000420)90:2<92::AID-IJC5>3.0.CO;2-9; Chao KSC, 2001, INT J RADIAT ONCOL, V49, P907, DOI 10.1016/S0360-3016(00)01441-3; Chau RMC, 2001, RADIOTHER ONCOL, V58, P143, DOI 10.1016/S0167-8140(00)00336-4; Cheng JCH, 2001, INT J CANCER, V96, P126, DOI 10.1002/ijc.1004; Eisbruch A, 1999, INT J RADIAT ONCOL, V45, P577, DOI 10.1016/S0360-3016(99)00247-3; EMAMI B, 1991, INT J RADIOL ONCOL B, V16, P1623; Ho JH, 1978, INT J RADIAT ONCOL, V4, P183; HO JHC, 1982, TREATMENT CANC, P24; HONORE HB, 2002, INT J RADICOL ONCOL, V53, P638; Hunt MA, 2001, INT J RADIAT ONCOL, V49, P623, DOI 10.1016/S0360-3016(00)01389-4; ICRU, 1999, 50 ICRU; *INT UN AG CANC UI, 1997, TNM CLASS MAL TUM; Kam MKM, 2003, INT J RADIAT ONCOL, V56, P145, DOI 10.1016/S0360-3016(03)00075-0; Kam MKM, 2004, INT J RADIAT ONCOL, V60, P1440, DOI 10.1016/j.ijrobp.2004.05.022; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Lee AWM, 2005, INT J RADIAT ONCOL, V61, P1107, DOI 10.1016/j.ijrobp.2004.07.702; Lee N, 2002, INT J RADIAT ONCOL, V53, P12, DOI 10.1016/S0360-3016(02)02724-4; LYMAN JT, 1987, INT J RADIAT ONCOL, V13, P103, DOI 10.1016/0360-3016(87)90266-5; NIEMIERKO A, 1993, RADIOTHER ONCOL, V29, P140, DOI 10.1016/0167-8140(93)90239-5; Purdy JA, 2002, SEMIN RADIAT ONCOL, V12, P199, DOI 10.1053/srao.2002.32432; Raaijmakers E, 2002, RADIOTHER ONCOL, V65, P1, DOI 10.1016/S0167-8140(02)00211-6; Sanchez-Nieto B, 1999, INT J RADIAT ONCOL, V44, P369, DOI 10.1016/S0360-3016(99)00029-2; Sultanem K, 2000, INT J RADIAT ONCOL, V48, P711, DOI 10.1016/S0360-3016(00)00702-1; TEO P, 1989, INT J RADIAT ONCOL, V17, P515, DOI 10.1016/0360-3016(89)90102-8; Teo P, 1996, INT J RADIAT ONCOL, V36, P291, DOI 10.1016/S0360-3016(96)00323-9; WEBB S, 1993, PHYS MED BIOL, V38, P653, DOI 10.1088/0031-9155/38/6/001; WONG SM, 2003, J HK COLL RADIOL S, V6, P127; Xia P, 2000, INT J RADIAT ONCOL, V48, P329, DOI 10.1016/S0360-3016(00)00585-X; Zhou JN, 2003, INT J RADIAT ONCOL, V57, P673, DOI 10.1016/S0360-3016(03)00626-6	30	44	59	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0958-3947	1873-4022		MED DOSIM	Med. Dosim.	WIN	2007	32	4					263	270		10.1016/j.meddos.2007.02.006			8	Oncology; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Radiology, Nuclear Medicine & Medical Imaging	233FG	WOS:000251075200005	17980826				2022-02-06	
J	Schmittner, MD; Vajkoczy, SL; Horn, P; Bertsch, T; Ouintel, M; Vajkoczy, P; Muench, E				Schmittner, Marc D.; Vajkoczy, Susanne L.; Horn, Peter; Bertsch, Thomas; Ouintel, Michael; Vajkoczy, Peter; Muench, Elke			Effects of fentanyl and S(+)-ketamine on cerebral hemodynamics, gastrointestinal motility, and need of vasopressors in patients with intracranial pathologies - A pilot study	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						intracranial pressure; ketamine; fentanyl; bispectral index; gastrointestinal motility	BISPECTRAL INDEX; BLOOD-FLOW; KETAMINE ANESTHESIA; DRUG ABSORPTION; PRESSURE; SEDATION; PHARMACOLOGY; INHIBITION; SUFENTANIL; ALFENTANIL	In neurosurgical patients, opioids are administered to prevent secondary cerebral damage. Complications often related to the administration of opioids are a decrease in blood pressure affording the use of vasopressors and intestinal atonia. One alternative approach to opioids is the application of S(+)ketamine. However, owing to a suspected elevation of intracranial pressure (ICP), the administration of S(+)-ketamine has questioned for a long time. The aim of the present study was to evaluate ICP, gastrointestinal motility, and catecholamine consumption in neurosurgical patients undergoing 2 different protocols of anesthesia using fentanyl or S(+)-ketamine. Twenty-four patients sustaining traumatic brain injury or aneurysmal subarachnoid hemorrhage received methohexitone plus either fentanyl or S(+)-ketamine to establish a comparable level of sedation. To reach an adequate cerebral perfusion pressure (CPP), the norepinephrine dosage was adapted successively. Enteral nutrition and gastrointestinal stimulation were started directly after admission on the critical care unit. ICP, CPP, and norepinephrine dosage were recorded over 5 days and also the time intervals to full enteral nutrition and first defecation. There was no difference regarding ICP, CPP, and the time period until full enteral nutrition or first defecation between both groups. Patients who underwent analgesia with S(+)ketamine showed a trend to a lower demand of norepinephrine compared with the fentanyl group. Our results indicate that S(+)-ketamine does not increase ICP and that its use in neurosurgical patients should not be discouraged on the basis of ICP-related concerns.	Heidelberg Univ, Univ Hosp Mannheim, Dept Anesthesiol & Crit Care Med, D-6900 Heidelberg, Germany; Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, D-6900 Heidelberg, Germany; Univ Gottingen, Dept Anesthesiol & Crit Care Med, D-3400 Gottingen, Germany		Muench, E (corresponding author), Heidelberg Univ, Fac Med Mannheim, Dept Anesthesiol & Crit Care Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	elke.muench@t-online.de					Adams HA, 1997, ANAESTHESIST, V46, P1081, DOI 10.1007/s001010050510; Adams HA, 2001, ANASTH INTENSIV NOTF, V36, P417, DOI 10.1055/s-2001-15435; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Banki N, 2006, J NEUROSURG, V105, P15, DOI 10.3171/jns.2006.105.1.15; BENNETT MWR, 1994, ANAESTHESIA, V49, P155, DOI 10.1111/j.1365-2044.1994.tb03376.x; Botero CA, 2000, J CARDIOTHOR VASC AN, V14, P409, DOI 10.1053/jcan.2000.7933; Bourgoin A, 2005, CRIT CARE MED, V33, P1109, DOI 10.1097/01.CCM.0000162491.26292.98; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; Brain Trauma Foundation, 2003, UPD NOT GUID MAN SEV; CHI OZ, 1994, ANESTH ANALG, V79, P860; Christ G, 1997, ANAESTH INTENS CARE, V25, P255, DOI 10.1177/0310057X9702500308; Citerio G, 2001, CRIT CARE MED, V29, P1466, DOI 10.1097/00003246-200107000-00027; De Schepper HU, 2004, NEUROGASTROENT MOTIL, V16, P383, DOI 10.1111/j.1365-2982.2004.00513.x; Deeren DH, 2005, INTENS CARE MED, V31, P1577, DOI 10.1007/s00134-005-2802-2; DeLuca A, 1996, PHARMACOL THERAPEUT, V69, P103, DOI 10.1016/0163-7258(95)02053-5; DOMINO EF, 1965, CLIN PHARMACOL THER, V6, P279; FREYE E, 1994, ANAESTHESIST, V43, P87, DOI 10.1007/s001010050036; FRIESEN R, 1987, ANESTH ANALG, V66, P431, DOI 10.1213/00000539-198705000-00011; GARDNER AE, 1972, ANESTH ANAL CURR RES, V51, P741; GOODING JM, 1977, ANESTH ANALG, V56, P813; Hans P, 2005, BRIT J ANAESTH, V94, P336, DOI 10.1093/bja/aei047; JENNETT B, 1975, LANCET, V1, P480; Kolbel CB, 2000, INTENS CARE MED, V26, P1421, DOI 10.1007/s001340000630; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; Langsjo JW, 2003, ANESTHESIOLOGY, V99, P614, DOI 10.1097/00000542-200309000-00016; MAYBERG TS, 1993, ANESTHESIOLOGY, V79, pA204; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; MCARTHUR CJ, 1995, INTENS CARE MED, V21, P573, DOI 10.1007/BF01700162; McDermott NB, 2003, ANESTH ANALG, V97, P39, DOI 10.1213/01.ANE.0000067402.02136.A2; NIMMO WS, 1975, BRIT J CLIN PHARMACO, V2, P509, DOI 10.1111/j.1365-2125.1975.tb00568.x; NIMMO WS, 1984, BRIT J ANAESTH, V56, P29, DOI 10.1093/bja/56.1.29; PAPAZIAN L, 1993, BRIT J ANAESTH, V71, P267, DOI 10.1093/bja/71.2.267; PFENNINGER E, 1985, ACTA NEUROCHIR, V78, P113, DOI 10.1007/BF01808689; Proescholdt M, 2001, BRAIN RES, V904, P245, DOI 10.1016/S0006-8993(01)02465-9; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Reeker W, 2000, CAN J ANAESTH, V47, P572, DOI 10.1007/BF03018950; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; SCHWEDLER M, 1982, CAN ANAESTH SOC J, V29, P222, DOI 10.1007/BF03007120; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; TAKESHITA H, 1972, ANESTHESIOLOGY, V36, P69, DOI 10.1097/00000542-197201000-00013; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P537; TODD JG, 1983, BRIT J ANAESTH, V55, P1189, DOI 10.1093/bja/55.12.1189; Vereecke HEM, 2003, ANAESTHESIA, V58, P957, DOI 10.1046/j.1365-2044.2003.03403.x; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007	46	44	48	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2007	19	4					257	262		10.1097/ANA.0b013e31811f3feb			6	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	213ZL	WOS:000249705700008	17893578				2022-02-06	
J	Venneti, S; Wagner, AK; Wang, G; Slagel, SL; Chen, X; Lopresti, BJ; Mathis, CA; Wiley, CA				Venneti, Sriram; Wagner, Amy K.; Wang, Guoji; Slagel, Susan L.; Chen, Xiangbal; Lopresti, Brian J.; Mathis, Chester A.; Wiley, Clayton A.			The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: Implications for PET imaging	EXPERIMENTAL NEUROLOGY			English	Article						peripheral benzodiazepine receptor; microglia; PET imaging; traumatic brain injury; DAA1106; PK11195	POSITRON-EMISSION-TOMOGRAPHY; CONTROLLED CORTICAL IMPACT; MILD COGNITIVE IMPAIRMENT; IN-VIVO; ISCHEMIC-STROKE; ACTIVATED MICROGLIA; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; PK11195 BINDING; MOUSE-BRAIN	Traumatic brain injury (TBI) is a significant cause of mortality, morbidity, and disability. Microglial activation is commonly observed in response to neuronal injury which, when prolonged, is thought to be detrimental to neuronal survival. Activated microglia can be labeled using PK11195, a ligand that binds the peripheral benzodiazepine receptor (PBR), receptors which are increased in activated microglia and sparse in the resting brain. We compared the binding properties of two PBR ligands PK11195 and DAA1106 in rats using the controlled cortical impact (CCI) model of experimental TBI. While both ligands showed relative increases with specific binding in the cortex ipsitateral to injury compared to the contralateral side, [H-3]DAA1106 showed higher binding affinity compared with [H-3](R)-PK11195. Combined immunohistochemistry and autoradiography in brain tissues near the injury site showed that [H-3]DAA1106 binding co-registered with activated microglia more than astrocytes. Further, increased [H-3]DAA1106-specific binding positively correlated with the degree of microglial activation, and to a lesser degree with reactive astrocytosis. Finally, in vivo administration of each ligand in rats with TBI showed greater retention of [C-11]DAA1106 compared to [C-11](R)-PK11195 at the site of the contusion as assessed by ex vivo autoradiography. These results in a rat model of TBI indicate that [C-11] DAA1106 binds with higher affinity to microglia when compared with PK11195, suggesting that [C-11]DAA1106 may represent a better ligand than [C-11](R)-PK11195 for in vivo PET imaging of activated microglia in TBI. (c) 2007 Elsevier Inc. All rights reserved.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA 15213 USA		Wiley, CA (corresponding author), Presbyterian Univ Hosp, Div Neuropathol, 200 Lothrop St A515, Pittsburgh, PA 15213 USA.	wiley1@pitt.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833, K08 HD040833] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24 MH001717-08, K24 MH01717, R01 MH071151-03, R01 MH071151, R01 MH64921, K24 MH001717, R01 MH064921] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH071151, K24MH001717, R01MH064921] Funding Source: NIH RePORTER		Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Banati RB, 2000, BRAIN, V123, P2321, DOI 10.1093/brain/123.11.2321; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bontke CF, 1996, PHYS MED REHABILITAT, P1027; Cagnin A, 2002, EUR NEUROPSYCHOPHARM, V12, P581, DOI 10.1016/S0924-977X(02)00107-4; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Chaki S, 1999, EUR J PHARMACOL, V371, P197, DOI 10.1016/S0014-2999(99)00118-1; Chen MK, 2004, BRAIN, V127, P1379, DOI 10.1093/brain/awh161; Culty M, 2001, DRUG DEVELOP RES, V52, P475, DOI 10.1002/ddr.1149; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Debruyne JC, 2003, EUR J NEUROL, V10, P257, DOI 10.1046/j.1468-1331.2003.00571.x; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Fetler L, 2005, SCIENCE, V309, P392, DOI 10.1126/science.1114852; Gerhard A, 2000, NEUROREPORT, V11, P2957, DOI 10.1097/00001756-200009110-00025; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; GIORDANA MT, 1994, NEUROPATH APPL NEURO, V20, P163, DOI 10.1111/j.1365-2990.1994.tb01175.x; GROOM GN, 1995, J NUCL MED, V36, P2207; Hammoud DA, 2005, J NEUROVIROL, V11, P346, DOI 10.1080/13550280500187351; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Ikoma Y, 2007, J CEREBR BLOOD F MET, V27, P173, DOI 10.1038/sj.jcbfm.9600325; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Maeda J, 2004, SYNAPSE, V52, P283, DOI 10.1002/syn.20027; Mankowski JL, 2003, J NEUROVIROL, V9, P94, DOI 10.1080/13550280390173283; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; MYERS R, 1991, J CEREBR BLOOD F MET, V11, P314, DOI 10.1038/jcbfm.1991.64; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Okuyama S, 1999, LIFE SCI, V64, P1455, DOI 10.1016/S0024-3205(99)00079-X; Ouchi Y, 2005, ANN NEUROL, V57, P168, DOI 10.1002/ana.20338; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; Park LCH, 2001, MECH AGEING DEV, V123, P21, DOI 10.1016/S0047-6374(01)00336-0; Pavese N, 2006, NEUROLOGY, V66, P1638, DOI 10.1212/01.wnl.0000222734.56412.17; Pedersen MD, 2006, EUR J NEUROSCI, V24, P991, DOI 10.1111/j.1460-9568.2006.04975.x; PETITTABOUE MC, 1991, EUR J PHARMACOL, V200, P347, DOI 10.1016/0014-2999(91)90594-G; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; RAMSAY SC, 1992, LANCET, V339, P1054, DOI 10.1016/0140-6736(92)90576-O; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Schuitemaker A, 2004, NEUROBIOL AGING, V25, pS286, DOI 10.1016/S0197-4580(04)80947-3; Schuitemaker A, 2006, NEUROIMAGE, V31, pT159, DOI 10.1016/j.neuroimage.2006.04.142; SHAH SP, 1995, ADV CEM BASED MATER, V2, P1, DOI 10.1016/1065-7355(95)90032-2; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 1996, NEUROTOXICOLOGY, V17, P671; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner MR, 2004, NEUROBIOL DIS, V15, P601, DOI 10.1016/j.nbd.2003.12.012; Venneti S, 2004, J CLIN INVEST, V113, P981, DOI 10.1172/JCI200420227; Versijpt J, 2005, MULT SCLER J, V11, P127, DOI 10.1191/1352458505ms1140oa; Vowinckel E, 1997, J NEUROSCI RES, V50, P345, DOI 10.1002/(SICI)1097-4547(19971015)50:2<345::AID-JNR22>3.0.CO;2-5; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wiley CA, 2006, J NEUROVIROL, V12, P262, DOI 10.1080/13550280600873868; Zhang MR, 2003, NUCL MED BIOL, V30, P513, DOI 10.1016/S0969-8051(03)00016-7	62	44	46	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2007	207	1					118	127		10.1016/j.expneurol.2007.06.003			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	210TB	WOS:000249477400013	17658516	Green Accepted			2022-02-06	
J	Marcol, W; Kotulska, K; Larysz-Brysz, M; Kowalik, JL				Marcol, Wieslaw; Kotulska, Katarzyna; Larysz-Brysz, Magdalena; Kowalik, Joanna Lewin			BDNF contributes to animal model neuropathic pain after peripheral nerve transection	NEUROSURGICAL REVIEW			English	Article						autotomy behavior; neuropathic pain; BDNF; neuroma; regeneration	RAT SPINAL-CORD; NEUROTROPHIC FACTOR; SCIATIC-NERVES; MESSENGER-RNA; BRAIN; REGENERATION; INJURY; NEURONS; NGF; INHIBITION	The outcome of peripheral nerve injury is often impaired by neuropathic pain, which is resistant to most analgesics and presents a serious clinical problem. The mechanisms underlying post-traumatic neuropathic pain remain unclear, but they are likely associated with the regeneration processes. Brain-derived neurotrophic factor (BDNF) is known to enhance peripheral nerve regeneration and is also considered to be an endogenous modulator of nociceptive responses following spinal cord lesion. The aim of this work was to examine the local effect of BDNF in a neuropathic pain model. Sciatic nerves of adult male rats were transected and supplied with connective tissue chambers filled with (1) fibrin only, (2) fibrin with BDNF, or (3) fibrin with antibodies against BDNF. In control animals the nerve was transected and no chamber was applied. During follow-up, autotomy behavior was assessed. Seven weeks after the operation, the number of surviving and regenerating neurons in dorsal root ganglia was counted and the neuroma incidence was examined. We found that local inactivation of BDNF decreased the incidence as well as severity of autotomy and neuroma formation, but did not influence neuron regeneration into the chambers. These results indicate that BDNF plays a locally crucial role in neuropathic pain development after peripheral nerve injury.	L Warynski Silesian Med Acad, Dept Physiol, PL-40752 Katowice, Poland; Childrens Mem Hlth Inst, Dept Neurol, Warsaw, Poland		Marcol, W (corresponding author), L Warynski Silesian Med Acad, Dept Physiol, 18 Medykow St, PL-40752 Katowice, Poland.	Vie@alpha.net.pl		Lewin-Kowalik, Joanna/0000-0002-7971-449X; Kotulska-Jozwiak, Katarzyna/0000-0002-5015-250X			Al-Qattan MM, 1999, J HAND SURG-BRIT EUR, V24B, P547, DOI 10.1054/jhsb.1999.0222; Apfel SC, 1996, MOL CELL NEUROSCI, V7, P134, DOI 10.1006/mcne.1996.0010; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Bennett DLH, 2001, NEUROSCIENTIST, V7, P13, DOI 10.1177/107385840100700105; Bowsher D, 2002, PAIN, V95, P187, DOI 10.1016/S0304-3959(01)00389-X; Boyd JG, 2002, EUR J NEUROSCI, V15, P613, DOI 10.1046/j.1460-9568.2002.01891.x; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Eaton MJ, 2002, GENE THER, V9, P1387, DOI 10.1038/sj.gt.3301814; Fukuoka T, 2001, J NEUROSCI, V21, P4891, DOI 10.1523/JNEUROSCI.21-13-04891.2001; Kennedy JM, 2004, NEUROREPORT, V15, P807, DOI 10.1097/00001756-200404090-00013; Kerr BJ, 1999, J NEUROSCI, V19, P5138; Kryger GS, 2001, J HAND SURG-AM, V26A, P635, DOI 10.1053/jhsu.2001.26035; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lewin-Kowalik Joanna, 2002, Med Sci Monit, V8, pBR414; Ljungberg C, 1999, NEUROSCI LETT, V262, P29, DOI 10.1016/S0304-3940(99)00040-3; Marcol W, 2003, J NEUROSCI RES, V72, P417, DOI 10.1002/jnr.10560; MARCOL W, 2002, J PHYSIOL PHARM S1, V53, P22; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Michael GJ, 1997, J NEUROSCI, V17, P8476; Midha R, 2003, J NEUROSURG, V99, P555, DOI 10.3171/jns.2003.99.3.0555; Miki K, 2000, NEUROSCI LETT, V278, P85, DOI 10.1016/S0304-3940(99)00908-8; Obata K, 2006, NEUROSCI RES, V55, P1, DOI 10.1016/j.neures.2006.01.005; Petersen A, 2001, BRAIN RES BULL, V56, P331, DOI 10.1016/S0361-9230(01)00580-9; Ro LS, 1996, NEUROSCI LETT, V218, P87; Sakai Y, 2005, J BIOMED MATER RES B, V73B, P355, DOI 10.1002/jbm.b.30219; Shu XQ, 1999, P NATL ACAD SCI USA, V96, P7693, DOI 10.1073/pnas.96.14.7693; SIUCIAK JA, 1995, EUR J NEUROSCI, V7, P663, DOI 10.1111/j.1460-9568.1995.tb00670.x; Stoll G, 1999, BRAIN PATHOL, V9, P313; Thompson SWN, 1999, P NATL ACAD SCI USA, V96, P7714, DOI 10.1073/pnas.96.14.7714; WALL PD, 1979, PAIN, V7, P103, DOI 10.1016/0304-3959(79)90002-2; WILLENBRING S, 1994, PAIN, V58, P135, DOI 10.1016/0304-3959(94)90194-5; Zhang JY, 2000, EUR J NEUROSCI, V12, P4171, DOI 10.1111/j.1460-9568.2000.01312.x; Zhou XF, 2000, EUR J NEUROSCI, V12, P100, DOI 10.1046/j.1460-9568.2000.00884.x; Zimmermann M, 2001, EUR J PHARMACOL, V429, P23, DOI 10.1016/S0014-2999(01)01303-6	34	44	49	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JUL	2007	30	3					235	243		10.1007/s10143-007-0085-5			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	177XF	WOS:000247185100019	17530308				2022-02-06	
J	Swaine, BR; Tremblay, C; Platt, RW; Grimard, G; Zhang, X; Pless, IB				Swaine, Bonnie R.; Tremblay, Camille; Platt, Robert W.; Grimard, Guy; Zhang, Xun; Pless, I. Barry			Previous head injury is a risk factor for subsequent head injury in children: A longitudinal cohort study	PEDIATRICS			English	Article; Proceedings Paper	6th World Congress on Brain Injury	MAY 06-08, 2005	Melbourne, AUSTRALIA			children; recurrence; injury; head trauma; rehabilitation	TRAUMATIC BRAIN-INJURY; CONCUSSION MANAGEMENT; ACCIDENT-PRONENESS; 2ND IMPACT; MILD; EPIDEMIOLOGY; CHILDHOOD; SEQUELAE; SPORTS; TRENDS	OBJECTIVE. The objective of this study was to determine whether children who sought care for a head injury were at greater risk of having a subsequent head injury within the following 6 and 12 months compared with children who sought care for an injury other than to the head. DESIGN/SETTING. This was a longitudinal cohort study conducted in the emergency departments of 2 Montreal (Quebec, Canada) pediatric hospitals. PARTICIPANTS. The parents of 11 867 injured children aged 1 to 18 years were interviewed by telephone at 6 (n = 10 315) and 12 (n = 9486) months after their child's injury to ascertain outcome (ie, subsequent head injury) and to provide information on potential risk factors (age, gender, chronic medical condition, activity level, and socioeconomic status). MAIN OUTCOME MEASURE. The outcome of interest was a head injury requiring medical attention within the following year ascertained by parental recall or physician claims data. RESULTS. A total of 245 and 386 previously head-injured children sustained a subsequent head injury within 6 and 12 months, respectively. Children who sought care for an initial head injury (n = 3599) were at higher risk of having a subsequent head injury within 6 months than children who sought care for an injury not to the head (n = 6716). The adjusted odds ratio suggested weak confounding by age, gender, and history of previous head injury. Results were consistent on the basis of physician claims data and 12-month follow-up interview data. CONCLUSIONS. These results provide evidence that having a head injury increases a child's risk of having a subsequent head injury. Although age, gender, and history of previous head injury confound the relationship, the effect remains substantial.	Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Sch Rehabil, Montreal, PQ H3C 3J7, Canada; Inst Readaptat Montreal, Montreal Metropolitain, Ctr Rech Interdisciplinaire Readaptat, Montreal, PQ, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Montreal Childrens Hosp, Res Inst, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; Hop St Justine, Montreal, PQ H3T 1C5, Canada		Swaine, BR (corresponding author), Univ Montreal, Fac Med, Ecole Readaptat, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	bonnie.swaine@umontreal.ca		Platt, Robert/0000-0002-5981-8443			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BIJUR PE, 1990, PEDIATRICS, V86, P337; BIJUR PE, 1988, PEDIATRICS, V82, P707; Breslow N, 1987, DESIGN ANAL COHORT S, V2; Brudvik C, 2000, INJURY, V31, P761, DOI 10.1016/S0020-1383(00)00093-0; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CASEY R, 1986, PEDIATRICS, V78, P497; CERNAN J, 1996, HEAD INJURY POSTCONC, P441; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; COX DR, 1972, J R STAT SOC B, V34, P187; Dowd MD, 1996, AM J PUBLIC HEALTH, V86, P929, DOI 10.2105/AJPH.86.7.929; EMINSON CJ, 1986, J EPIDEMIOL COMMUN H, V40, P170, DOI 10.1136/jech.40.2.170; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Kostylova A, 2005, INJURY PREV, V11, P186, DOI 10.1136/ip.2004.006585; LANDIS JR, 1977, BIOMETRICS, V33, P174; Mackenzie S G, 1999, Inj Prev, V5, P208; MANTEL N, 1959, J NATL CANCER I, V22, P719; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; PARTINGTON MW, 1960, ARCH DIS CHILD, V35, P215, DOI 10.1136/adc.35.181.215; PICKETT W, 2003, PEDIATRICS 1, V111; PLESS IB, 2000, UNINTENTIONAL INJURI; RIVARA FP, 1982, AM J DIS CHILD, V136, P399, DOI 10.1001/archpedi.1982.03970410017003; RIVARA FP, 1994, PEDIATR ANN, V23, P12, DOI 10.3928/0090-4481-19940101-06; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHEIDT PC, 1995, AM J PUBLIC HEALTH, V85, P932, DOI 10.2105/AJPH.85.7.932; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; SWAINE B, 2002, 6 WORLD C INJ PREV C; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Swaine BR, 2000, AM J PHYS MED REHAB, V79, P412, DOI 10.1097/00002060-200009000-00002; SWAINE BR, 1999, 3 WORLD C BRAIN INJ; WARREN D, 1989, Pediatric Emergency Care, V5, P83, DOI 10.1097/00006565-198906000-00003; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	46	44	44	1	17	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	APR	2007	119	4					749	758		10.1542/peds.2006-1186			10	Pediatrics	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	153BH	WOS:000245406200037	17403846				2022-02-06	
J	Smith, MP; Cass, WA				Smith, Michael P.; Cass, Wayne A.			GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease	NEUROSCIENCE LETTERS			English	Article						GDNF; reactive oxygen species; protein carbonyls; 4-hydroxynonenal; striatum; Sabstantia nigra; dopamine	TRAUMATIC BRAIN-INJURY; RAT SUBSTANTIA-NIGRA; NEUROTROPHIC FACTOR; CELL-LINE; DOPAMINE NEURONS; TIME-COURSE; INTRASTRIATAL 6-HYDROXYDOPAMINE; DISTINCT MECHANISMS; LIPID-PEROXIDATION; SINGLE INJECTION	Many current theories of Parkinson's disease (PD) suggest that oxidative stress is involved in the neurodegenerative process. Potential neuroprotective agents could protect neurons through inherent antioxidant properties or through the Upregulation of the brain's antioxidant defenses. Glial cell line-derived neurotrophic factor (GDNF) has been shown to protect and restore dopamine neurons in experimental models of PD and to improve motor function in human patients. This study was designed to investigate GDNF's effect on oxidative stress in a model of PD. GDNF or vehicle was injected into the right striatum of male Fischer-344 rats. Three days later 6-OHDA or saline was injected into the same striatum. The striatum and substantia nigra from both sides of the brain were removed 24 h after 6-OHDA or saline injection and analyzed for the oxidative stress markers protein carbonyls and 4-hydroxynonenal. Both markers were significantly reduced in GDNF+6-OHDA treated animals compared to vehicle+6-OHDA treated animals. In addition, in animals allowed to recover for 3.5-4 weeks after the 6-OHDA administration, the GDNF led to significant protection against loss of striatal and nigral tissue levels of dopamine. These results suggest that the protective effects of GDNF against 6-OHDA involve a reduction in oxidative stress. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Chandler Med Ctr, Lexington, KY 40536 USA		Cass, WA (corresponding author), Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Chandler Med Ctr, MN-225, Lexington, KY 40536 USA.	wacass1@uky.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG000242, R01 AG017963, R01 AG017963-05, AG17963, T32 AG000242-12, AG00242] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000242, R01AG017963] Funding Source: NIH RePORTER		Aksenov MY, 2001, NEUROSCI LETT, V305, P5, DOI 10.1016/S0304-3940(01)01786-4; Aoi M, 2000, NEUROSCI RES, V36, P319, DOI 10.1016/S0168-0102(00)00097-3; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Betarbet R, 2005, EXP NEUROL, V191, pS17, DOI 10.1016/j.expneurol.2004.08.021; Candelario-Jalil E, 2001, NEUROSCI RES, V41, P233, DOI 10.1016/S0168-0102(01)00282-6; Cass WA, 2004, EXP NEUROL, V187, P205; Cass WA, 2003, BRAIN RES, V984, P133, DOI 10.1016/S0006-8993(03)03122-6; Cass WA, 1996, J NEUROSCI, V16, P8132; Chao CC, 1999, NEUROPHARMACOLOGY, V38, P913, DOI 10.1016/S0028-3908(99)00030-1; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.3.CO;2-5; Ding YM, 2004, J NEUROCHEM, V89, P776, DOI 10.1111/j.1471-4159.2004.02415.x; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Gong YS, 1999, J ASIAN NAT PROD RES, V1, P153, DOI 10.1080/10286029908039859; Grondin R, 2003, J NEUROSCI, V23, P1974; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HUDSON J, 1995, BRAIN RES BULL, V36, P425, DOI 10.1016/0361-9230(94)00224-O; Iannotti C, 2004, EXP NEUROL, V189, P317, DOI 10.1016/j.expneurol.2004.05.033; Ilic TV, 1999, FUNCT NEUROL, V14, P141; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; JEON BS, 1995, NEURODEGENERATION, V4, P131, DOI 10.1006/neur.1995.0016; Kearns CM, 1997, J NEUROSCI, V17, P7111; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; Kikuchi A, 2002, NEUROBIOL DIS, V9, P244, DOI 10.1006/nbdi.2002.0466; Kirik D, 2000, EUR J NEUROSCI, V12, P3871, DOI 10.1046/j.1460-9568.2000.00274.x; Kirik D, 1998, EXP NEUROL, V152, P259, DOI 10.1006/exnr.1998.6848; Klein SM, 2005, HUM GENE THER, V16, P509, DOI 10.1089/hum.2005.16.509; Kramer BC, 2004, J NEUROCYTOL, V33, P213, DOI 10.1023/B:NEUR.0000030696.62829.ec; Lotharius J, 1999, J NEUROSCI, V19, P1284; Maguire-Zeiss KA, 2005, MOL BRAIN RES, V134, P18, DOI 10.1016/j.molbrainres.2004.09.014; Mattson MP, 1999, J NEUROSCI RES, V58, P152, DOI 10.1002/(SICI)1097-4547(19991001)58:1<152::AID-JNR15>3.3.CO;2-M; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McGrath LT, 2001, QJM-MON J ASSOC PHYS, V94, P485, DOI 10.1093/qjmed/94.9.485; Patel NK, 2005, ANN NEUROL, V57, P298, DOI 10.1002/ana.20374; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Poon HF, 2004, BRAIN RES, V1018, P86, DOI 10.1016/j.brainres.2004.05.048; Przedborski S, 2005, ANTIOXID REDOX SIGN, V7, P685, DOI 10.1089/ars.2005.7.685; Serra JA, 2001, J NEURAL TRANSM, V108, P1135, DOI 10.1007/s007020170003; Shastry BS, 2001, NEUROSCI RES, V41, P5, DOI 10.1016/S0168-0102(01)00254-1; Slevin JT, 2005, J NEUROSURG, V102, P216, DOI 10.3171/jns.2005.102.2.0216; Smith MP, 2007, NEUROSCIENCE, V144, P1057, DOI 10.1016/j.neuroscience.2006.10.004; Stadtman ER, 2002, FREE RADICAL BIO MED, V33, P597, DOI 10.1016/S0891-5849(02)00904-8; Theodore S, 2006, NEUROSCIENCE, V137, P925, DOI 10.1016/j.neuroscience.2005.10.056; TOMAC A, 1995, P NATL ACAD SCI USA, V92, P8274, DOI 10.1073/pnas.92.18.8274; Toth G, 2002, J NEUROSCI RES, V69, P622, DOI 10.1002/jnr.10358; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Ugarte SD, 2003, J NEUROSCI RES, V73, P105, DOI 10.1002/jnr.10632; Venero JL, 1997, J NEUROCHEM, V68, P2458; Wang Y, 1997, J NEUROSCI, V17, P4341; Zuch CL, 2000, J COMP NEUROL, V427, P440, DOI 10.1002/1096-9861(20001120)427:3<440::AID-CNE10>3.0.CO;2-7	49	44	46	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 2	2007	412	3					259	263		10.1016/j.neulet.2006.11.017			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138WC	WOS:000244393000015	17125923	Green Accepted			2022-02-06	
J	Neese, SL; Sherill, LK; Tan, AA; Roosevelt, RW; Browning, RA; Smith, DC; Duke, A; Clough, RW				Neese, Steven L.; Sherill, Luke K.; Tan, Arlene A.; Roosevelt, Rodney W.; Browning, Ronald A.; Smith, Douglas C.; Duke, Andrea; Clough, Rich W.			Vagus nerve stimulation may protect GABAergic neurons following traumatic brain injury in rats: An immunocytochemical study	BRAIN RESEARCH			English	Article						GABA; fluid percussion injury; epilepsy; GAD; cerebral cortex; hippocampus; neuroprotection	FLUID PERCUSSION INJURY; LOCUS-COERULEUS LESIONS; POSTTRAUMATIC EPILEPSY; RECOVERY; SEIZURE; HIPPOCAMPUS; PENTYLENETETRAZOL; ELECTROSHOCK; FOS	Seizures and subclinical seizures occur following experimental brain injury in rats and may result from inhibitory neuron loss. This study numerically compares cortical and hippocampal glutamic acid decarboxylase (GAD) positive neurons between sham fluid percussion injury (FPI), FPI with sham Vagus Nerve Simulation (VNS), and FPI with chronic intermittent VNS initiated at 24 h post FPI in rats. Rats (n=8/group) were prepared for immunocytochemistry of GAD at 15 days post FPI. Serial sections were collected and GAD immunoreactive neurons were counted in the hippocampal hilus and two levels of the cerebral cortex. Numbers of quantifiable GAD cells in the rostral cerebral cortices were different between groups, both ipsilateral and contralateral to the FPI. Post hoc analysis of cell counts rostral to the ipsilateral epicenter, revealed a significant 26% reduction in the number of GAD cells/unit area of cerebral cortex following FPI. In the FPI-VNS group, this percentage loss was attenuated to only an 8.5% reduction, a value not significantly different from the sham group. In the contralateral side of the rostral cerebral cortex, FPI induced a significant 24% reduction in GAD cells/unit area; whereas, the VNS-treated rats showed no appreciable diminution of GAD cells rostral to the contralateral epicenter. Hippocampal analysis revealed a similar reduction of GAD cells in the FPI group; however, unlike the cortex this was not statistically significant. In the FPI-VNS group, a trend towards increased numbers of hilar GAD cells was observed, even over and above that of the sham FPI group; however, this was also not statistically significant. Together, these data suggest that VNS protects cortical GAD cells from death subsequent to FPI and may increase GAD cell counts in the hippocampal hilus of the injured brain. (c) 2006 Elsevier B.V. All rights reserved.	So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; So Illinois Univ, Dept Psychol, Brain & Cognit Sci Program, Carbondale, IL 62901 USA; So Illinois Univ, SIU Ctr Integrated Res Cognit & Neural Sci, Carbondale, IL 62901 USA		Clough, RW (corresponding author), So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA.	rclough@siumed.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041551] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS041551-04, R01 NS041551, NS041551] Funding Source: Medline		Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BENMENACHEM E, 1995, EPILEPSY RES, V20, P221, DOI 10.1016/0920-1211(94)00083-9; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BROWNING RA, 1987, NEUROTRANSMITTERS EP, P277; BUTERBAUGH GG, 1977, NEUROPHARMACOLOGY, V16, P617, DOI 10.1016/0028-3908(77)90032-6; CLOUGH RW, 1994, J NEURAL TRANSP PLAS, V5, P65, DOI 10.1155/NP.1994.65; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Eells JB, 1997, NEUROSCI LETT, V233, P21, DOI 10.1016/S0304-3940(97)00611-3; ELIAS H, 1980, AM J ANAT, V159, P411, DOI 10.1002/aja.1001590407; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Goldstein LB, 1997, RESTOR NEUROL NEUROS, V11, P55, DOI 10.3233/RNN-1997-111206; JOBE PC, 1986, J PHARMACOL EXP THER, V222, P662; KILIAN M, 1973, NEUROPHARMACOLOGY, V12, P681, DOI 10.1016/0028-3908(73)90121-4; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Krahl SE, 1998, EPILEPSIA, V39, P709, DOI 10.1111/j.1528-1157.1998.tb01155.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marrosu F, 2003, EPILEPSY RES, V55, P59, DOI 10.1016/S0920-1211(03)00107-4; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Maynert E W, 1975, Adv Neurol, V13, P79; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTYRE DC, 1980, EXP NEUROL, V69, P395, DOI 10.1016/0014-4886(80)90222-8; NARITOKU DK, 1995, EPILEPSY RES, V22, P53, DOI 10.1016/0920-1211(95)00035-9; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; ROOSEVELT RW, IN PRESS BRAIN RES; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schachter SC, 2002, NEUROLOGY, V59, pS1, DOI 10.1212/WNL.59.6_suppl_4.S1; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; Soghomonian JJ, 1998, TRENDS PHARMACOL SCI, V19, P500, DOI 10.1016/S0165-6147(98)01270-X; Toth Z, 1997, J NEUROSCI, V17, P8106; Weinshenker D, 2002, PHARMACOL THERAPEUT, V94, P213, DOI 10.1016/S0163-7258(02)00218-8	36	44	52	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 12	2007	1128	1					157	163		10.1016/j.brainres.2006.09.073			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	135CC	WOS:000244130400018	17125748	Green Accepted			2022-02-06	
J	Mainio, A; Kyllonen, T; Viilo, K; Hakko, H; Sarkioja, T; Rasanen, P				Mainio, Arja; Kyllonen, Tiina; Viilo, Kaisa; Hakko, Helina; Sarkioja, Terttu; Rasanen, Pirkko			Traumatic brain injury, psychiatric disorders and suicide: A population-based study of suicide victims during the years 1988-2004 in Northern Finland	BRAIN INJURY			English	Article						traumatic brain injury; suicide; depression; alcohol abuse	RISK-FACTORS; HEAD-INJURY; AXIS-I; DEPRESSION; PREVENTION; MORTALITY; BEHAVIOR	Background: Depression and substance abuse are common among patients with traumatic brain injury (TBI). However, previous studies have not examined the temporal association between psychiatric disorders, TBI and suicide. Objective: To study the prevalence of TBI injury among suicide victims; to determine the association of suicide, psychiatric disorders and TBI severity; and to examine the effect of pre- and post-traumatic psychiatric disorders on their remaining life-time. Methods: This study examined all suicides (n = 1877) committed during a 16-year period in the province of Oulu, Finland. The information of suicide victims was extracted from the official death certificates and the National Hospital Discharge Registers. Results: TBI was found in 5.5% (n = 103) of the victims. Compared to the victims without TBI, those with TBI had significantly more hospital-treated psychiatric and alcohol disorders. If TBI subjects had comorbid psychiatric disorders, the time period between TBI and suicide was under 3 years in similar to 90% of victims in this suicide population. Conclusions: Seriousness of injury, male gender, older age, being unemployed and presence of psychiatric and alcohol disorders are important to identify as possible predictors for suicidal behaviour in TBI patients. Further studies are required to shed light on interventions aimed at better life management.	Univ Oulu, Dept Psychiat, Oulu, Finland; Univ Oulu, Dept Forens Med, Oulu, Finland		Mainio, A (corresponding author), Oulu Univ Hosp, Dept Psychiat, POB 26, FIN-90029 OYS, Finland.	arja.mainio@oulu.fi					ACHTE KA, 1971, ACTA PSYCHIAT SCAN S, V225, P1; Borges G, 2006, PSYCHOL MED, V36, P1747, DOI 10.1017/S0033291706008786; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Keskimaki I, 1991, INT J HLTH SCI, V2, P15; Kishi Y, 2001, J NERV MENT DIS, V189, P623, DOI 10.1097/00005053-200109000-00009; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Preti A, 1997, J AFFECT DISORDERS, V44, P123, DOI 10.1016/S0165-0327(97)00035-9; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2003, J HEAD TRAUMA REHAB, V18, P445, DOI 10.1097/00001199-200309000-00006; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Suokas J, 2001, ACTA PSYCHIAT SCAND, V104, P117, DOI 10.1034/j.1600-0447.2001.00243.x; Suominen K, 2004, SOC PSYCH PSYCH EPID, V39, P720, DOI 10.1007/s00127-004-0796-7; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tiihonen J, 2006, ARCH GEN PSYCHIAT, V63, P1358, DOI 10.1001/archpsyc.63.12.1358	22	44	44	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	8					851	855		10.1080/02699050701504265			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	202YZ	WOS:000248942400006	17676442				2022-02-06	
J	Pang, BC; Kuralmani, V; Joshi, R; Yin, HL; Lee, KK; Ang, BT; Li, JY; Leong, TY; Ng, I				Pang, Boon Chuan; Kuralmani, Vellaisamy; Joshi, Rohit; Yin Hongli; Lee, Kah Keow; Ang, Beng Ti; Li, Jinyan; Leong, Tze Yun; Ng, Ivan			Hybrid outcome prediction model for severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; assessment tools; Bayesian network; decision tree; discriminant analysis; human studies; logistic regression; neural network; outcome measures; traumatic brain injuries	SEVERE HEAD-INJURY; VARIABLES; PROGNOSIS; CLASSIFICATION; TREE	Numerous studies addressing different methods of head injury prognostication have been published. Unfortunately, these studies often incorporate different head injury prognostication models and study populations, thus making direct comparison difficult, if not impossible. Furthermore, newer artiricial intelligence tools such as machine learning methods have evolved in the field of data analysis, alongside more traditional methods of analysis. This study targets the development of a set of integrated prognostication model combining different classes of outcome and prognostic factors. Methodologies such as discriminant analysis, logistic regression, decision tree, Bayesian network, and neural network were employed in the study. Several prognostication models were developed using prospectively collected data from 513 severe closed head-injured patients admitted to the Neurocritical Unit at National Neuroscience Institute of Singapore, from April 1999 to February 2003. The correlation between prognostic factors at admission and outcome at 6 months following injury was studied. Overritting error, which may falsely distinguish different outcomes, was compared graphically. Tenfold cross-validation technique, which reduces overfitting error, was used to validate outcome prediction accuracy. The overall prediction accuracy achieved ranged from 49.79% to 81.49%. Consistently high outcome prediction accuracy was seen with logistic regression and decision tree. Combining both logistic regression and decision tree models, a hybrid prediction model was then developed. This hybrid model would more accurately predict the 6-month post-severe head injury outcome using baseline admission parameters.	Natl Inst Neurosci, Dept Neurosurg, Acute Brain Injury Res Lab, Singapore 308433, Singapore; Inst Infocomm Res, Knowledge Discovery Dept, Data Mining Lab, Singapore, Singapore; Natl Univ Singapore, Sch Comp, Dept Comp Sci, Singapore 117548, Singapore		Ng, I (corresponding author), Natl Inst Neurosci, Dept Neurosurg, Acute Brain Injury Res Lab, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	ivan_ng@nni.com.sg	Yin, Hong/AAC-5784-2020; LEONG, Tze Yun/H-1142-2015	Leong, Tze Yun/0000-0002-1139-803X; Li, Jinyan/0000-0003-1833-7413			ABDELMONEN A, 2004, DISCRIMINANT ANAL CO; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; *BRAIN TRAUM FDN, 2002, MAN PROGN SEV TRAUM; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; CHENG J, 1997, P 6 ACM INT C INF KN; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CHOI SC, 1996, NEUROTRAUMA, V53, P779; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1999, TRAUMATIC BRAIN INJU, P67; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Morrison D.F., 1990, MULTIVARIATE STAT ME; Mukherjee K, 2000, NEUROL INDIA, V48, P43; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; OVERGAARD J, 1973, LANCET, V2, P631; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Pillai SV, 2003, NEUROL INDIA, V51, P345; Quinlan J. R., 1986, Machine Learning, V1, P81, DOI 10.1023/A:1022643204877; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; *SAS I INC, 2006, ENT MIN 9 1; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; *SPSS INC, 2006, SPSS 12 0 WIND; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Steinberg D., 1995, CART TREE STRUCTURED; STEINBERG D, 1997, CART CLASSIFICATION; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wilson WJ, 2002, J NEUROSURG, V97, P1062, DOI 10.3171/jns.2002.97.5.1062; YONO J, 2001, J CLIN NUEUROSCI, V8, P120; [No title captured]	41	44	45	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					136	146		10.1089/neu.2006.0113			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100013	17263677				2022-02-06	
J	Gnagey, L; Clayton, HM; Lanovaz, JL				Gnagey, L.; Clayton, H. M.; Lanovaz, J. L.			Effect of standing tarsal angle on joint kinematics and kinetics	EQUINE VETERINARY JOURNAL			English	Article						horse; conformation; kinematics; kinetics; tarsal joint; hock joint	RISK-FACTORS; CONFORMATION; HORSES	Reasons for performing study: The tarsal joint is a frequent site of lameness, but little objective information is available regarding the effects of tarsal conformation on joint movements or forces. Objective: To compare tarsal kinematics and kinetics in horses with large, intermediate and small tarsal angles. Methods: Sagittal plane standing angle of the right tarsal joint was measured in 16 horses as they stood squarely with the hind hooves vertically beneath the hip joint. Tarsal angles were classified as small (< 155.5 degrees), intermediate (155.5-165.5 degrees) or large (> 165.5 degrees). Reflective markers, attached over the centres of joint rotation, were tracked during stance as the horses trotted across a force plate at a standardised speed. Joint angles and ground reaction forces were combined with morphometric data to calculate net joint moments and net joint powers across the tarsus using inverse dynamics. Results: In all horses, the tarsus flexed during the impact phase and extended in late. stance. Tarsal angles were stratified according to standing tarsal angle throughout stance. Horses with large standing angles showed less flexion and less energy absorption at the tarsus during the impact phase than those with intermediate or small angles and generated less vertical impulse than horses with small standing angles. Net extensor moment at the tarsus during stance was lower for horses with large standing angles. Conclusions: In horses with large tarsal angles, less concussion was absorbed during the impact phase, which may be a factor in the development of degenerative joint disease; and the smaller vertical impulse and extensor moment later in stance may limit propulsive ability. However, the smaller net joint moment may reduce the risk of plantar ligament desmitis. Clinical significance: The effects of conformation on kinematics and kinetics of the tarsal joint may influence both performance and soundness.	Michigan State Univ, Coll Vet Med, Mary Anne McPhail Equine Performance Ctr, Dept Large Anim Clin Sci, E Lansing, MI 48824 USA		Clayton, HM (corresponding author), Michigan State Univ, Vet Med Ctr D202, Coll Vet Med, E Lansing, MI 48854 USA.			Lanovaz, Joel/0000-0001-7070-6648			Anderson TM, 2004, EQUINE VET J, V36, P571, DOI 10.2746/0425164044864462; Axelsson M, 2001, EQUINE VET J, V33, P84, DOI 10.2746/042516401776767502; BACK W, 1994, VET QUART, V16, pS91; BACK W, 1995, EQUINE VET J, V27, P39, DOI 10.1111/j.2042-3306.1995.tb03030.x; Back W, 1996, PFERDEHEILKUNDE, V12, P647; BLACK JB, 1992, P AM ASS EQUINE PRAC, V37, P393; Dolvik NI, 1999, ACTA AGR SCAND A-AN, V49, P156, DOI 10.1080/090647099424060; DREVEMO S, 1980, EQUINE VET J, V12, P60, DOI 10.1111/j.2042-3306.1980.tb02310.x; Dyson S. J., 2000, P 46 ANN AAEP CONV, V46, P137, DOI [10.3920/978-90-8686-577-2, DOI 10.3920/978-90-8686-577-2]; Eksell P, 1998, ACTA VET SCAND, V39, P339; HOLMSTROM M, 1995, EQUINE VET J, V27, P281, DOI 10.1111/j.2042-3306.1995.tb03078.x; HOLMSTROM M, 1990, EQUINE VET J, V22, P186, DOI 10.1111/j.2042-3306.1990.tb04245.x; HOLMSTROM M, 1993, LIVEST PROD SCI, V33, P293, DOI 10.1016/0301-6226(93)90009-7; HOLMSTROM M, 2000, P C EQ SPORT MED SCI, P45; Khumsap S, 2001, Equine Vet J Suppl, P21; MAGNUSSON LE, 1985, STUDIES CONFORMATION, P194; MARKS D, 2000, P AM ASS EQUINE PRAC, V46, P39; MCILWRAITH CW, 2003, P AM ASS EQUINE PRAC, V49, P59; MULLER J, 1976, ZUCHTERISCHE WEITERE, P105; RADIN EL, 1972, LANCET, V1, P519; STASHAK TS, 1987, ADAMS LAMENESS HORSE, P695	21	44	48	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0425-1644	2042-3306		EQUINE VET J	Equine Vet. J.	NOV	2006	38	7					628	633		10.2746/042516406X159043			6	Veterinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Veterinary Sciences	128YT	WOS:000243696300008	17402467				2022-02-06	
J	Svendsen, HA; Teasdale, TW				Svendsen, Henriette Aaby; Teasdale, Thomas William			The influence of neuropsychological rehabilitation on symptomatology and quality of life following brain injury: A controlled long-term follow-up	BRAIN INJURY			English	Article						brain-injury; rehabilitation; follow-up	CLOSED HEAD-INJURY; COGNITIVE REHABILITATION; SUBJECTIVE EXPERIENCE; POPULATION; ADJUSTMENT; RELATIVES; TBI; NEUROREHABILITATION; OUTCOMES; TRAUMA	Primary objective: To establish whether, following acquired brain injury, intensive post-acute neuropsychological rehabilitation could have long-term beneficial effects. Methods and procedures: A group of 37 adults who had suffered cerebrovascular accidents or traumatic brain injuries and who had undergone a rehabilitation programme were followed up 12-22 years post-injury, together with a non-rehabilitated control group of 13 adults, matched for brain-injury and demographics characteristics. Both groups completed a set of questionnaires concerning broad aspects of psychological well-being. Significant others completed similar questionnaires. Main outcomes and results: The rehabilitation group showed significantly lower levels of brain injury symptoms and higher levels of competency at follow-up. They also rated internal locus of control and general self-efficacy as significantly higher than the control group. Anxiety and depression levels were significantly lower and quality of life significantly higher in the rehabilitation group for both the subjects themselves and for their significant others. Conclusions: Within methodological limitations this study suggests that post-acute neuropsychological rehabilitation can have long-term beneficial effects.	Univ Copenhagen, Ctr Rehabil Brain Injury, Dept Psychol, DK-2300 Copenhagen S, Denmark		Svendsen, HA (corresponding author), Univ Copenhagen, Ctr Rehabil Brain Injury, Dept Psychol, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	henriette.svendsen@psy.ku.dk					Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; CHRISTENSEN AL, 1988, NEUROPSYCHOL REHABIL, P115; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Diller L, 2003, NEURO S B C, P293; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Field A., 2009, DISCOVERING STAT USI, V3rd ed; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; HART T, 2000, PATIENT COMPETENCY R; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOHANSEN LE, 2004, FOLLOW UP UNDERSOGEL; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Magnusson A, 2000, AM J PSYCHIAT, V157, P234, DOI 10.1176/appi.ajp.157.2.234; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Noerholm V, 2004, QUAL LIFE RES, V13, P531, DOI 10.1023/B:QURE.0000018485.05372.d6; Norholm V, 2001, NORD J PSYCHIAT, V55, P229; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schwarzer R., 1995, MEASURES HLTH PSYCHO, P35, DOI DOI 10.1037/T00393-000; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Teasdale T W, 1995, Appl Neuropsychol, V2, P116; Teasdale TW, 2005, BRAIN INJURY, V19, P1049, DOI 10.1080/02699050500110421; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; TEASDALE TW, 1993, BRAIN INJURY, V7, P535, DOI 10.3109/02699059309008181; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TREXLER LE, 2000, INT HDB NEUROPSYCHOL, P137; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 2003, NEURO S B C, P329; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	53	44	44	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2006	20	12					1295	1306		10.1080/02699050601082123			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	110DF	WOS:000242357800008	17132552				2022-02-06	
J	da Rocha, AB; Schneider, RF; de Freitas, GR; Andre, C; Grivicich, I; Zanoni, C; Fossa, A; Gehrke, JT; Jotz, GP; Kaufmann, M; Simon, D; Regner, A				da Rocha, Adriana Brondani; Schneider, Rogerio Fett; de Freitas, Gabriel R.; Andre, Charles; Grivicich, Ivana; Zanoni, Caroline; Fossa, Aline; Gehrke, Junia T.; Jotz, Geraldo Pereira; Kaufmann, Mauro; Simon, Daniel; Regner, Andrea			Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males	CLINICAL CHEMISTRY AND LABORATORY MEDICINE			English	Article						biomarkers; humans; multitrauma; outcome; S100B protein; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; PROTEIN S-100B; CARDIAC-ARREST; DAMAGE; RELEASE; DEATH; ASTROCYTES; S100-BETA; SURGERY	Background: Severe traumatic brain injury (-TBI) is associated with a 30% - 70% mortality rate. S100B has been proposed as a biomarker for indicating outcome after TBI. Nevertheless, controversy has arisen concerning the predictive value of S100B for severe TBI in the context of multitrauma. Therefore, our aim was to determine whether S100B serum levels correlate with primary outcome following isolated severe TBI or multitrauma in males. Methods: Twenty- three consecutive male patients (-age 18 - 65 years), victims of severe TBI [Glasgow Coma Scale (-GCS) 3 - 8x (-10 isolated TBI and 13 multitrauma with TBI) and a control group consisting of eight healthy volunteers were enrolled in this prospective study. Clinical outcome variables of severe TBI comprised: survival, time to intensive care unit (-ICU) discharge, and neurological assessment [Glasgow Outcome Scale (-GOS) at ICU discharge]. Venous blood samples were taken at admission in the ICU (-study entry), 24 h later, and 7 days later. Serum S100B concentration was measured by an immunoluminometric assay. Results: At study entry (mean time 10.9 h after injury), mean S100B concentrations were significantly increased in the patient with TBI (1.448 mu g/ L) compared with the control group (0.037 mu g/L) and patients with fatal outcome had higher mean S100B (2.10 mg/ L) concentrations when compared with survivors (0.85 mg/ L). In fact, there was a significant correlation between higher initial S100B concentrations and fatal outcome (Spearman's =0.485, p=0.019). However, there was no correlation between higher S100B concentrations and the presence of multitrauma. The specificity of S100B in predicting mortality according to the cut- off of 0.79 mg/ L was 73% at study entry. Conclusions: Increased serum S100B levels constitute a valid predictor of unfavourable outcome in severe TBI, regardless of the presence of associated multitrauma.	Univ Luterana Brasil, Lab Marcadores Estresse Celular, Ctr Pesquisa Ciencias Med, BR-92425900 Canoas, RS, Brazil; Univ Luterana Brasil, Programa Posgrad Diagnost Genet & Mol, BR-92425900 Canoas, RS, Brazil; Univ Luterana Brasil, Programa Posgrad Genet & Toxicol Aplicada, BR-92425900 Canoas, RS, Brazil; Univ Luterana Brasil, Curso Med, BR-92425900 Canoas, RS, Brazil; Univ Fed Rio de Janeiro, Dept Neurol, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil; Univ Terapia Intens, Hosp Cristo Redentor, Porto Alegre, RS, Brazil; SAMU, Hosp Municipal Pronto Socorro, Porto Alegre, RS, Brazil		Regner, A (corresponding author), Univ Luterana Brasil, Lab Marcadores Estresse Celular, Ctr Pesquisa Ciencias Med, Ave Farroupilha 8001,Pred 22,5 Andar, BR-92425900 Canoas, RS, Brazil.	regner@uol.com.br	Regner, Andrea/M-2596-2014; JOTZ, GERALDO P/G-2664-2014; Grivicich, Ivana/A-6777-2013; de Freitas, Gabriel R/B-1298-2013; Simon, Daniel/A-9087-2011	Regner, Andrea/0000-0002-6657-7991; JOTZ, GERALDO P/0000-0001-6289-7827; Grivicich, Ivana/0000-0001-9820-5730; Simon, Daniel/0000-0003-1122-8468			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; DAROCHA AB, 2005, J NEUROTRAUM, V15, P385; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; DUFF D, 2003, AXONE, V23, P18; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hu JR, 1997, J NEUROCHEM, V69, P2294; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015, DOI 10.1152/ajpheart.2000.279.3.H1015; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Jonsson H, 2003, RESTOR NEUROL NEUROS, V21, P151; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kraus J, 1996, NEUROTRAUMA, P13; Lai Y. C., 1998, Annals Academy of Medicine Singapore, V27, P326; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Neuwelt EA, 2004, NEUROSURGERY, V54, P131, DOI 10.1227/01.NEU.0000097715.11966.8E; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; PELINKA LE, 2003, EUR J TRAUMA, V5, P316; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Snyder-Ramos SA, 2003, RESTOR NEUROL NEUROS, V21, P123; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; ZAGARA G, 1992, J NEUROSURG SCI, V35, P77	44	44	48	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1434-6621	1437-4331		CLIN CHEM LAB MED	Clin. Chem. Lab. Med.	OCT	2006	44	10					1234	1242		10.1515/CCLM.2006.218			9	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	093TU	WOS:000241193900011	17032136				2022-02-06	
J	Stiefel, MF; Udoetuk, JD; Storm, PB; Sutton, LN; Kim, H; Dominguez, TE; Helfaer, MA; Huh, JW				Stiefel, Michael F.; Udoetuk, Joshua D.; Storm, Phillip B.; Sutton, Leslie N.; Kim, Heakyung; Dominguez, Troy E.; Helfaer, Mark A.; Huh, Jimmy W.			Brain tissue oxygen monitoring in pediatric patients with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; brain tissue oxygen monitoring; intracranial pressure; cerebral perfusion pressure; pediatric neurosurgery	SEVERE HEAD-INJURY; ELEVATED INTRACRANIAL-PRESSURE; CHILDREN; EXPERIENCE; MANAGEMENT; HYPOXIA; DAMAGE; CARE; HYPOTENSION; METABOLISM	Object. Intracranial pressure (ICP) and cerebral perfusion pressure (CPP) monitoring are fundamental to the management of severe traumatic brain injury (TBI). In adults, brain tissue oxygen monitoring (specifically PO2) and treatment have been shown to be safe additions to conventional neurocritical care and are associated with improved outcome. Brain tissue oxygen monitoring, however, has not been described in pediatric patients with TBI. In this report, the authors present preliminary experience with the use of ICP and PO2 monitoring in this population. Methods. Pediatric patients (age < 18 years) with severe TBI (Glasgow Coma Scale score < 8) admitted to a Level I trauma center who underwent ICP and PO, monitoring were evaluated. Therapy was directed at maintaining ICP below 20 mm Hg and age-appropriate CPP (>= 40 min Hg). Data obtained in six patients (two girls and four boys ranging in age from 6-16 years) were analyzed. Brain tissue oxygen levels were significantly higher (p < 0.01) at an ICP of less than 20 mm, Hg (PO, 29.29 +/- 7.17 mm Hg) than at an ICP of greater than or equal to 20 mm Hg (PO2 22.83 +/- 13.85 mm Hg). Significant differences (p < 0.01) were also measured when CPP was less than 40 mm Hg (PO2 2.53 +/- 7.98 mm Hg) and greater than or equal to 40 min Hg (PO2 28.97 +/- 7.85 mm Hg). Conclusions. Brain tissue oxygen monitoring may be a safe and useful addition to ICP monitoring in the treatment of pediatric patients with severe TBI.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Anesthesiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Crit Care, Philadelphia, PA 19104 USA		Stiefel, MF (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3 Silverstein Pavil,3400 Spruce St, Philadelphia, PA 19104 USA.	stiefelm@uphs.upenn.edu					ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Bardt TF, 1998, ACT NEUR S, V71, P153; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GOTSCHALL CS, 1995, J NEUROTRAUM, V12, P611, DOI 10.1089/neu.1995.12.611; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Langlois JH, 2003, CHILD DEV, V74, P969, DOI 10.1111/1467-8624.00581; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Littlejohns Linda R, 2003, Crit Care Nurse, V23, P17; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MAYER TA, 1985, ANN EMERG MED, V14, P1178, DOI 10.1016/S0196-0644(85)81025-8; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003	47	44	46	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2006	105	4		S			281	286		10.3171/ped.2006.105.4.281			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	093WO	WOS:000241201200009	17328278				2022-02-06	
J	Wilde, EA; Bigler, ED; Haider, JM; Chu, ZL; Levin, HS; Li, XQ; Hunter, JV				Wilde, Elisabeth A.; Bigler, Erin D.; Haider, Janelle M.; Chu, Zili; Levin, Harvey S.; Li, Xiaoqi; Hunter, Jill V.			Vulnerability of the anterior commissure in moderate to severe pediatric traumatic brain injury	JOURNAL OF CHILD NEUROLOGY			English	Article							CORPUS-CALLOSUM; FIBER TRACKING; HEAD-INJURY; TEMPORAL-LOBE; NUCLEUS; NEURONS; SIZE; PROJECTIONS; MORPHOLOGY; CORTEX	In relation to the adult brain, the immature brain might be more vulnerable to damage during and following traumatic brain iujury, particularly in white-matter tracts. Given well-established evidence of corpus callosum atrophy, we hypothesized that anterior commissure volume (using quantitative magnetic resonance imaging [MRI]) in this structure would be decreased in children with moderate to severe traumatic brain injury relative to typically developing children. Second, given the purported role of the anterior commissure in interhemispheric axon conveyance between temporal lobes, we hypothesized that temporal lobe white matter, temporal lesion volume, and injury severity (Glasgow Coma Scale score) would be predictive of decreased anterior commissure cross-sectional volume in patients with traumatic brain injury. Finally, we wished to establish the relationship between the anterior commissure and the temporal stem, a major white-matter tract into the temporal lobes, using diffusion tensor imaging fiber-tracking maps for each patient. We also hypothesized that children with traumatic brain injury would exhibit decreased fractional anisotropy in relation to typically developing children in a fiber system including the anterior commissure and the temporal lobes. Decreased anterior commissure cross-sectional volume was observed in patients with traumatic brain injury, and, as predicted, anterior commissure and temporal white-matter volumes were positively related to each other and to higher Glasgow Coma Scale scores. Lesion volume was not independently predictive of anterior commissure volume in the overall model. Diffusion tensor imaging fractional anisotropy values differed between the groups for the temporal stem-anterior commissure system, with the traumatic brain injury group exhibiting decreased fractional anisotropy. The anterior commissure, like the corpus callosum, appears to be highly vulnerable to white-matter degenerative changes resulting from mechanisms such as the direct impact of trauma, progressive axonal injury as tissue in other brain regions atrophies, or myelin degeneration. This is the first systematic examination of anterior commissure atrophy following traumatic brain injury using in vivo quantitative MRI and diffusion tensor imaging fiber tracking in pediatric subjects.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA; Texas Childrens Hosp, Dept Diagnost Imaging, Houston, TX 77030 USA		Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	ewilde@bcm.tmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19 HD 035476] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19HD035476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ALLEN LS, 1992, P NATL ACAD SCI USA, V89, P7199, DOI 10.1073/pnas.89.15.7199; Basser PJ, 2000, MAGNET RESON MED, V44, P41, DOI 10.1002/1522-2594(200007)44:1<41::AID-MRM8>3.0.CO;2-O; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; BIGLER ED, 2005, NEUROPSYCHIATRY TRAU, P79; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Condes-Lara M, 2003, BRAIN RES, V982, P288, DOI 10.1016/S0006-8993(03)03054-3; DEMETER S, 1988, HUM NEUROBIOL, V6, P219; DEMETER S, 1990, J COMP NEUROL, V302, P29, DOI 10.1002/cne.903020104; Di Virgilio G, 1999, EXP BRAIN RES, V124, P1, DOI 10.1007/s002210050593; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hoogenraad F., 2002, MULTICENTER EVALUATI; Jones HE, 1997, BRAIN RES BULL, V42, P341, DOI 10.1016/S0361-9230(96)00293-6; KLINGLER J, 1960, J COMP NEUROL, V115, P333, DOI 10.1002/cne.901150305; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; LAMANTIA AS, 1994, J COMP NEUROL, V340, P328, DOI 10.1002/cne.903400304; Larriva-Sahd J, 1998, NEUROSCI LETT, V241, P119, DOI 10.1016/S0304-3940(98)00043-3; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Livy DJ, 2001, TERATOLOGY, V63, P15, DOI 10.1002/1096-9926(200101)63:1<15::AID-TERA1003>3.3.CO;2-H; Martinez-Lorenzana G, 2004, NEUROSCI LETT, V366, P154, DOI 10.1016/j.neulet.2004.05.026; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Netsch T, 2001, EIGHTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOL I, PROCEEDINGS, P718, DOI 10.1109/ICCV.2001.937595; Otake K, 2003, NEUROSCIENCE, V119, P623, DOI 10.1016/S0306-4522(03)00216-1; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Sandell JH, 2003, J COMP NEUROL, V466, P14, DOI 10.1002/cne.10859; Stieltjes B, 2001, NEUROIMAGE, V14, P723, DOI 10.1006/nimg.2001.0861; STURROCK RR, 1976, J ANAT, V122, P447; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092	41	44	44	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	SEP	2006	21	9					769	776		10.1177/08830738060210090201			8	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	102KV	WOS:000241810800010	16970884				2022-02-06	
J	Diaz-Arrastia, R; Baxter, VK				Diaz-Arrastia, Ramon; Baxter, Victoria K.			Genetic factors in outcome after traumatic brain injury - What the human genome project can teach us about brain trauma	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						apolipoprotein E4; genetics; Human Genome Project; outcomes; traumatic brain injury	INTERLEUKIN-1 RECEPTOR ANTAGONIST; APOLIPOPROTEIN-E EPSILON-4; GLOBAL CEREBRAL-ISCHEMIA; HEAD-INJURY; ALZHEIMERS-DISEASE; RISK-FACTOR; APOE GENOTYPE; NEURONAL DAMAGE; E POLYMORPHISM; ANIMAL-MODELS	It is becoming increasingly clear that genetic factors modify outcome after traumatic brain injury (TBI). The best known example of this is the association between the apolipoprotein E4 allele (APOE 84) and poorer outcomes. However, our knowledge of the many other genes that might influence outcome is still in its infancy. This article will review the basic principles underlying recent advances in genetics, and then describe the current state of knowledge regarding the impact of genetic factors on TBI outcome. We conclude that although genetic advances have implications for prognosis, their biggest contribution will be to elucidate the pathophysiology of TBI,,potentially leading to new treatments.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA		Diaz-Arrastia, R (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ramon.Diaz-Arrastia@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652] Funding Source: Medline		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; BLAKEMORE AIF, 1994, ARTHRITIS RHEUM, V37, P1380, DOI 10.1002/art.1780370917; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Buttini M, 1999, J NEUROSCI, V19, P4867; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; CLEMENS JA, 1991, STROKE, V22, P1048, DOI 10.1161/01.STR.22.8.1048; Corder EH, 1998, NAT MED, V4, P1182, DOI 10.1038/2677; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; CRUSIUS JBA, 1995, LANCET, V346, P979, DOI 10.1016/S0140-6736(95)91607-5; delaConcha EG, 1997, J NEUROIMMUNOL, V80, P172, DOI 10.1016/S0165-5728(97)00153-7; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Du Y, 2000, NEUROLOGY, V55, P480, DOI 10.1212/WNL.55.4.480; Emahazion T, 1999, GENE, V238, P315, DOI 10.1016/S0378-1119(99)00330-3; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Goldstein DB, 2001, NAT GENET, V29, P109, DOI 10.1038/ng1001-109; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hartman RE, 2002, J NEUROSCI, V22, P10083; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Huang D, 1998, J NEUROIMMUNOL, V81, P76, DOI 10.1016/S0165-5728(97)00161-6; INMAN D, 1997, SOC NEUR ABSTR, V25, P899; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; Krzywkowski P, 1999, NEUROSCIENCE, V92, P1273, DOI 10.1016/S0306-4522(99)00061-5; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lanterna LA, 2005, NEUROLOGY, V64, P1238, DOI 10.1212/01.WNL.0000156523.77347.B4; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANSFIELD JC, 1994, GASTROENTEROLOGY, V106, P637, DOI 10.1016/0016-5085(94)90696-3; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; MCDOWELL TL, 1995, ARTHRITIS RHEUM, V38, P221, DOI 10.1002/art.1780380210; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Overmyer M, 1999, DEMENT GERIATR COGN, V10, P252, DOI 10.1159/000017128; PALMER GC, 1995, J PHARMACOL EXP THER, V274, P991; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Perrier S, 1998, CLIN IMMUNOL IMMUNOP, V87, P309, DOI 10.1006/clin.1998.4520; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PLOMIN R, 1994, BEHAV GENET, V24, P107, DOI 10.1007/BF01067815; POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Stroemer RP, 1997, J CEREBR BLOOD F MET, V17, P597; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Tamaoka A, 2000, NEUROLOGY, V54, P2319, DOI 10.1212/WNL.54.12.2319; TARLOW JK, 1993, HUM GENET, V91, P403; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Zhang Z., 1997, Society for Neuroscience Abstracts, V23, P899; [No title captured]	90	44	46	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2006	21	4					361	374		10.1097/00001199-200607000-00007			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	064SJ	WOS:000239109100007	16915011				2022-02-06	
J	Paparrigopoulos, T; Melissaki, A; Tsekou, H; Efthymiou, A; Kribeni, G; Baziotis, N; Geronikola, X				Paparrigopoulos, Thomas; Melissaki, Antigoni; Tsekou, Hara; Efthymiou, Anna; Kribeni, Georgia; Baziotis, Nikos; Geronikola, Xenia			Melatonin secretion after head injury: A pilot study	BRAIN INJURY			English	Article						melatonin; traumatic brain injury; intensive care unit	INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; CRITICALLY ILL PATIENTS; CIRCADIAN-RHYTHM; SLEEP QUALITY; PATTERNS; SURGERY; INSOMNIA; ICU	Primary objective: To investigate the circadian rhythm of serum melatonin in patients with traumatic brain injury (TBI) during Intensive Care Unit (ICU) stay and its relationship with core body temperature fluctuations and measures of severity of their condition. Methods and procedures: The pilot study was conducted in the ICU of a general hospital in Athens, Greece. Blood melatonin was determined in eight patients consecutively admitted at the ICU following severe head injury, eight times per day during the first and second day following admission. Core body temperature was recorded at hourly intervals. Patients were also assessed with the Glasgow Coma Score (GCS) and the APACHE II score. Results: Melatonin concentrations were lower than the normally reported values. Mean night-time melatonin levels were higher than mean daytime levels both on the first and second days, although not statistically significant. Diurnal variation of melatonin was associated with the GCS. Thus, patients with low GCS (n=4) did not exhibit a consistent diurnal variation of melatonin, whereas those with high GCS (n = 4) retained the normally expected fluctuations. Conclusions: ICU-treated TBI patients exhibit reduced melatonin levels and a circadian secretion profile which is related to the severity of the injury. Patients with more severe head trauma exhibit a clearly disrupted pattern of melatonin secretion, whereas those with less severe trauma preserve a relatively intact diurnal rhythm. Furthermore, the diurnal secretion pattern of melatonin appeared to be dissociated from the circadian rhythm of core body temperature. These preliminary findings may have implications for the management of TBI patients.	Univ Athens, Eginit Hosp, Sch Med, Sleep Res Unit,Dept Psychiat, GR-11528 Athens, Greece; Agios Savvas Gen Hosp, ICU, Athens, Greece; Agios Savvas Gen Hosp, Dept Nucl Med, Athens, Greece		Paparrigopoulos, T (corresponding author), Univ Athens, Eginit Hosp, Sch Med, Sleep Res Unit,Dept Psychiat, 74 Vas Sofias Ave, GR-11528 Athens, Greece.	tompaparrigopoulos@teledomenet.gr					AURELL J, 1985, BRIT MED J, V290, P1029, DOI 10.1136/bmj.290.6474.1029; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; BENTLEY S, 1977, BRIT MED J, V2, P1503, DOI 10.1136/bmj.2.6101.1503; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; BREZINSKI A, 1997, NEW ENGL J MED, V336, P186, DOI DOI 10.1056/NEJM199701163360306; BURNS AM, 1992, DRUGS, V43, P507, DOI 10.2165/00003495-199243040-00007; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Cronin AJ, 2000, LANCET, V356, P1244, DOI 10.1016/S0140-6736(00)02795-1; Dagan Y, 2002, SLEEP MED REV, V6, P45, DOI 10.1053/smrv.2001.0190; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Frisk U, 2004, CLIN SCI, V107, P47, DOI 10.1042/CS20030374; Gabor J Y, 2001, Curr Opin Crit Care, V7, P21, DOI 10.1097/00075198-200102000-00004; Geoffriau M, 1998, HORM RES, V49, P136, DOI 10.1159/000023160; Goscinski I, 2001, Neurol Neurochir Pol, V35, P63; Herdegen JJ, 2002, CRIT CARE MED, V30, P709, DOI 10.1097/00003246-200203000-00040; Hilton B A, 1976, J Adv Nurs, V1, P453, DOI 10.1111/j.1365-2648.1976.tb00932.x; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Karkela J, 2002, ACTA ANAESTH SCAND, V46, P30, DOI 10.1034/j.1399-6576.2002.460106.x; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; KRACHMAN SL, 1995, CHEST, V107, P1713, DOI 10.1378/chest.107.6.1713; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; MEYER TJ, 1994, CHEST, V105, P1211, DOI 10.1378/chest.105.4.1211; Miyazaki T, 2003, SURGERY, V133, P662, DOI 10.1067/msy.2003.149; Moskala Marek, 2004, Neurol Neurochir Pol, V38, P401; Mundigler G, 2002, CRIT CARE MED, V30, P536, DOI 10.1097/00003246-200203000-00007; Nishimura S, 1998, J PINEAL RES, V25, P73, DOI 10.1111/j.1600-079X.1998.tb00542.x; Olofsson K, 2004, ACTA ANAESTH SCAND, V48, P679, DOI 10.1111/j.0001-5172.2004.00401.x; PARSONS LC, 1982, NURS RES, V31, P260; RICHARDS KC, 1988, HEART LUNG, V17, P35; ROSENTHAL NE, 1991, J CLIN ENDOCR METAB, V73, P227; Shilo L, 1999, AM J MED SCI, V317, P278, DOI 10.1097/00000441-199905000-00002; THORPY MJ, 1990, ICSD INT CLASSIFICAT; TreggiariVenzi M, 1996, INTENS CARE MED, V22, P1186, DOI 10.1007/BF01709334; WEITZMAN ED, 1978, J NEUROL TRANSM    S, V13, P325	38	44	44	0	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					873	878		10.1080/02699050600832114			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300010	17060154				2022-02-06	
J	Vos, PE; van Gils, M; Beems, T; Zimmerman, C; Verbeek, MM				Vos, P. E.; van Gils, M.; Beems, T.; Zimmerman, C.; Verbeek, M. M.			Increased GFAP and S100 beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						GFAP; NSE; coma; S100 beta; subarachnoid haemorrhage	NEURON-SPECIFIC ENOLASE; FIBRILLARY ACIDIC PROTEIN; CEREBROSPINAL-FLUID CSF; TRAUMATIC BRAIN-INJURY; S-100 PROTEIN; CEREBRAL VASOSPASM; BLOOD; S100B; RELEASE; DAMAGE	Assessment of initial disease severity after subarachnoid haemorrhage (SAH) remains difficult. The objective of the study is to identify biochemical markers of brain damage in peripheral blood after SAH. Hospital admission S100 beta, glial fibrillary acidic protein (GFAP) and neuron-specific enolase (NSE) serum levels were analysed in 67 patients with SAH. Disease severity was determined by using the World Federation of Neurological Surgeons (WFNS) scale and the Fisher CT (computerized tomography) grading scale. Mean astroglial serum concentrations taken at hospital admission were increased (S100 beta 2.8-fold and GFAP 1.8-fold) compared with the upper limit of normal laboratory reference values (P95). The mean NSE concentration was within normal limits. S100 beta (P < 0.001) and GFAP (P =0.011) but not NSE levels were higher in patients who were in coma at the time of hospital admission compared with patients who were not. Similarly S100 beta and GFAP but not NSE serum levels increased with higher WFNS scores, raised intracranial pressure and higher CT Fisher grade scores. Concerning the location of the aneurysm, S100 beta and GFAP serum levels were within normal limits after a perimesencephalic type of haemorrhage and significantly increased after aneurysmal type SAH. Increased glial (S100 beta and GFAP) but not neuronal (NSE) protein serum concentrations are found after SAH, associated to the clinical severity of the initial injury.	Radboud Univ Nigmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nigmegen, Med Ctr, Dept Neurosurg, Nijmegen, Netherlands; Radboud Univ Nigmegen, Med Ctr, Dept Intens Care, Nijmegen, Netherlands; Radboud Univ Nigmegen, Med Ctr, Lab Pediat & Neurol, Nijmegen, Netherlands		Vos, PE (corresponding author), Radboud Univ Nigmegen, Med Ctr, Dept Neurol, Hp 935,POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012; Verbeek, Marcel M/D-1971-2010	Verbeek, Marcel M/0000-0003-4635-7876			Anderson RE, 1999, ANN THORAC SURG, V67, P1721, DOI 10.1016/S0003-4975(99)00318-5; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Beems T, 2003, ACTA NEUROCHIR, V145, P37, DOI 10.1007/s00701-002-1019-1; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Borel CO, 2003, STROKE, V34, P427, DOI 10.1161/01.STR.0000053848.06436.AB; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Gruber A, 2000, J NEUROSURG ANESTH, V12, P297, DOI 10.1097/00008506-200010000-00001; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P105; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kay A, 2003, STROKE, V34, pE240, DOI 10.1161/01.STR.0000100157.88508.2F; Kay A, 2003, STROKE, V34, P637, DOI 10.1161/01.STR.0000057579.25430.16; KRUSE A, 1991, ACTA NEUROCHIR, V110, P106, DOI 10.1007/BF01400675; Lagares A, 2001, ACTA NEUROCHIR, V143, P665, DOI 10.1007/s007010170044; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; MABE H, 1991, SURG NEUROL, V36, P170, DOI 10.1016/0090-3019(91)90108-L; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Mees SMD, 2003, NEUROLOGY, V61, P1132, DOI 10.1212/01.WNL.0000090466.68866.02; Mussack T, 2003, EUR J MED RES, V8, P457; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Nina P, 2001, SURG NEUROL, V55, P197, DOI 10.1016/S0090-3019(01)00402-5; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Sarrafzadeh A, 2003, STROKE, V34, P1382, DOI 10.1161/01.STR.0000074036.97859.02; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Shore PM, 2004, J NEUROTRAUM, V21, P1113; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wallin A, 1996, DEMENTIA, V7, P267, DOI 10.1159/000106891; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Woertgen C, 2004, NEUROSURG REV, V27, P178, DOI 10.1007/s10143-004-0341-x; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	41	44	53	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	JUN	2006	13	6					632	638		10.1111/j.1468-1331.2006.01332.x			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	050CY	WOS:000238066300010	16796588				2022-02-06	
J	Hamanaka, S; Asukai, N; Kamijo, Y; Hatta, K; Kishimoto, J; Miyaoka, H				Hamanaka, S; Asukai, N; Kamijo, Y; Hatta, K; Kishimoto, J; Miyaoka, H			Acute stress disorder and posttraumatic stress disorder symptoms among patients severely injured in motor vehicle accidents in Japan	GENERAL HOSPITAL PSYCHIATRY			English	Article						motor vehicle accident; acute stress disorder; posttraumatic stress disorder; physical injury severity; physical disability	2-YEAR PROSPECTIVE EVALUATION; TRAUMATIC BRAIN-INJURY; FOLLOW-UP; VICTIMS; SURVIVORS; PREDICTION; PTSD; DEPRESSION; THERAPY; SCALE	Objective: The prevalence of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) in seriously injured survivors of motor vehicle accidents (MVAs) in Japan was investigated. Furthermore, predictive factors in the early stage for development of PTSD were evaluated. Method: Subjects were consecutive samples (N = 100) of patients hospitalized with severe MVA injuries surveyed at two time points: within I month after the MVA and then 6 months later. In the first survey, we conducted the Acute Stress Disorder Interview and compiled results of a self-rating questionnaire; in the second survey, we conducted a structured clinical interview via telephone. Results: The prevalence of ASD and PTSD were 9.0% and 8.5%, respectively. The shift from ASD to PTSD was more pronounced when we included partial diagnoses of ASD and PTSD. Three predictive factors for PTSD were identified through multiple logistic analysis: ASD-positive, presence of persistent physical disability and physical injury severity. Conclusions: Even among severely injured MVA survivors, most acute stress symptoms subside over time. However, having ASD or partial ASD in the early stage, and the presence of physical disability as an aftereffect are strong predictive factors for PTSD. These findings validate the importance of evidence-based intervention for ASD to forestall PTSD. (c) 2006 Elsevier Inc. All rights reserved.	Kitasato Univ, Dept Psychiat, Sch Med, Sagamihara, Kanagawa 2288520, Japan; Tokyo Inst Psychiat, Div Social Psychiat, Tokyo 1568585, Japan; Kitasato Univ, Sch Med, Dept Emergency & Crit Care Med, Sagamihara, Kanagawa 2288520, Japan; Juntendo Univ, Sch Med, Dept Psychiat, Tokyo 1138421, Japan; Univ Tokyo, Sch Med, Dept Clin Bioinformat, Grad Sch Med, Tokyo 1138655, Japan		Hamanaka, S (corresponding author), Kitasato Univ, Dept Psychiat, Sch Med, Sagamihara, Kanagawa 2288520, Japan.	satokohamanaka@ybb.ne.jp	Hatta, Kotaro/AAN-4791-2020				Asukai N, 2002, J NERV MENT DIS, V190, P175, DOI 10.1097/00005053-200203000-00006; ASUKAI N, 1998, PSYCHIAT CLIN NEUR S, V52, pS75; Asukai N., 2003, JAP J TRAUM STRESS, V1, P47; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Bisson JI, 2004, BRIT J PSYCHIAT, V184, P63, DOI 10.1192/bjp.184.1.63; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; Blanchard EB, 2002, J TRAUMA STRESS, V15, P199, DOI 10.1023/A:1015299126858; Blanchard EB, 1997, J TRAUMA STRESS, V10, P215, DOI 10.1002/jts.2490100205; BLANCHARD EB, 1994, BEHAB RES THER, V11, P369; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 2003, AUST NZ J PSYCHIAT, V37, P226, DOI 10.1046/j.1440-1614.2003.01130.x; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA., 2000, ACUTE STRESS DISORDE; Buckley B, 2004, J TRAUMA STRESS, V17, P317, DOI 10.1023/B:JOTS.0000038480.87290.4a; Creamer M, 2004, BEHAV RES THER, V42, P315, DOI 10.1016/S0005-7967(03)00141-4; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; First M., 1997, STRUCTURED CLIN INTE; Fuglsang AK, 2004, NORD J PSYCHIAT, V58, P223, DOI 10.1080/08039480410006278; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1999, J TRAUMA STRESS, V12, P519, DOI 10.1023/A:1024723205259; HIROHATA S, 2002, SEISHINKEISHI, V104, P549; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Holeva V, 2001, J PSYCHOSOM RES, V51, P687, DOI 10.1016/S0022-3999(01)00256-2; ISHII T, 2005, SEISHINKA CHIRYOUGAK, V20, P183; Jeavons S, 2000, BEHAV RES THER, V38, P499, DOI 10.1016/S0005-7967(99)00073-X; KATO H, 2000, B KOBE U FAC MED, V60, P1; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KNAUS WA, 1985, CRITICAL CARE MED, V13, P10; Koren D, 1999, AM J PSYCHIAT, V156, P367; Kuch K, 1996, CAN J PSYCHIAT, V41, P429, DOI 10.1177/070674379604100707; MAES M, 2001, PSYCHIAT RES, V15, P1; Marmar C., 2004, ASSESSING PSYCHOL TR; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou R, 2001, AM J PSYCHIAT, V158, P1231, DOI 10.1176/appi.ajp.158.8.1231; Mayou RA, 2002, BEHAV RES THER, V40, P665, DOI 10.1016/S0005-7967(01)00069-9; MEZZICH JE, 1996, CULTURE PSYCHIAT DIA; Michaels AJ, 1999, J TRAUMA, V47, P867, DOI 10.1097/00005373-199911000-00009; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Veazey CH, 2004, APPL PSYCHOPHYS BIOF, V29, P51, DOI 10.1023/B:APBI.0000017863.35714.a1; Weiss D.S., 2004, ASSESSING PSYCHOL TR, V2, P168, DOI DOI 10.1007/978-0-387-70990-1_10; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941	49	44	45	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0163-8343			GEN HOSP PSYCHIAT	Gen. Hosp. Psych.	MAY-JUN	2006	28	3					234	241		10.1016/j.genhosppsych.2006.02.007			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	045SE	WOS:000237761700008	16675367				2022-02-06	
J	Zhang, Z; Artelt, M; Burnet, M; Trautmann, K; Schluesener, HJ				Zhang, Z.; Artelt, M.; Burnet, M.; Trautmann, K.; Schluesener, H. J.			Early infiltration of CD8(+) macrophages/microglia to lesions of rat traumatic brain injury	NEUROSCIENCE			English	Article						traumatic brain injury; microglia; macrophages; weight-drop model; endothelial monocyte-activating polypeptide II	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HEMATOGENOUS MACROPHAGES; P2X(4) RECEPTOR; EMAP-II; EXPRESSION; MICROGLIA; MONOCYTES; ACTIVATION; ACCUMULATION; RECRUITMENT	Local inflammatory responses play an important role in mediating secondary tissue damage in traumatic brain injury. Characterization of leukocytic subpopulations contributing to the early infiltration of the damaged tissue might aid in further understanding of lesion development and contribute to definition of cellular targets for selective immunotherapy. In a rat traumatic brain injury model, significant CD8(+) cell accumulation was observed 3 days post-injury. The CD8(+) cells were strictly distributed to the pannecrotic areas and around the pannecrotic perimeter. The morphology, time course of accumulation and distribution of CD8(+) cells were similar to that of reactive ED1(+) and enclothelial monocyteactivating polypepticle II+ microglia/macrophages, but different from W3/13(+) T cells. Further double-labeling experiments confirmed that the major cellular sources of CD8 were reactive macrophages/microglia. Both the location of these CD8(+) macrophages/microglia to the border of the pannecrosis and their co-expression of endothelial monocyte-activating polypeptide II and P2X(4) receptor suggest they might have a central role in lesion development and might thus be candidates fordevelopment of immunotherapeutic, anti-inflammatory strategies. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Synovo GmbH, D-72076 Tubingen, Germany		Zhang, Z (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	zhangzhiren@yahoo.com	Zhang, Zhiren/O-1012-2019; zhang, zhiren/I-1046-2014; Burnet, Michael/AAB-2958-2019	Zhang, Zhiren/0000-0002-5238-2835; zhang, zhiren/0000-0002-5238-2835; 			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Brabeck C, 2002, EXP NEUROL, V177, P341, DOI 10.1006/exnr.2002.7985; Cavaliere F, 2003, NEUROSCIENCE, V120, P85, DOI 10.1016/S0306-4522(03)00228-8; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Guo LH, 2005, NEUROSCIENCE, V134, P199, DOI 10.1016/j.neuroscience.2005.04.026; Hirji N, 1997, J IMMUNOL, V158, P1833; Hirji N, 1998, J IMMUNOL, V160, P6004; Hirji NS, 1999, INT ARCH ALLERGY IMM, V118, P180, DOI 10.1159/000024060; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Jander S, 2001, BRAIN PATHOL, V11, P27; KAFFENBERGER W, 1987, J LEUKOCYTE BIOL, V42, P181, DOI 10.1002/jlb.42.3.181; Kato H, 2000, BRAIN PATHOL, V10, P137; Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864; Kostulas N, 2002, STROKE, V33, P1129, DOI 10.1161/hs0402.105379; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kubes P, 2000, BRAIN PATHOL, V10, P127; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Ladeby R, 2005, GLIA, V50, P121, DOI 10.1002/glia.20159; Lehrmann E, 1997, J COMP NEUROL, V386, P461; Lin TJ, 2000, J IMMUNOL, V164, P1783, DOI 10.4049/jimmunol.164.4.1783; MCCALL MN, 1992, IMMUNOLOGY, V76, P310; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mueller CA, 2003, J NEUROTRAUM, V20, P1007, DOI 10.1089/089771503770195858; Mueller CA, 2003, J NEUROIMMUNOL, V135, P1, DOI 10.1016/S0165-5728(02)00427-7; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schroeter M, 2003, AM J PATHOL, V163, P1517, DOI 10.1016/S0002-9440(10)63508-0; Schroeter M, 2001, ACTA NEUROPATHOL, V101, P440; Schwab JM, 2005, J NEUROIMMUNOL, V163, P185, DOI 10.1016/j.jneuroim.2005.02.016; Scriba A, 1997, J LEUKOCYTE BIOL, V62, P741, DOI 10.1002/jlb.62.6.741; Scriba A, 1998, SCAND J IMMUNOL, V47, P332; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Tam FWK, 1999, NEPHROL DIAL TRANSPL, V14, P1658, DOI 10.1093/ndt/14.7.1658; TORRESNAGEL N, 1992, EUR J IMMUNOL, V22, P2841, DOI 10.1002/eji.1830221113; Walker DG., 1998, CONTEMP NEUROSCI, P61, DOI 10.1007/978-1-59259-473-3_2; Weissenbock H, 2000, BRAIN PATHOL, V10, P260, DOI 10.1111/j.1750-3639.2000.tb00259.x; Wu YP, 2001, J NEUROPATH EXP NEUR, V60, P1062, DOI 10.1093/jnen/60.11.1062; Zhang ZR, 2006, EXP NEUROL, V197, P252, DOI 10.1016/j.expneurol.2005.09.015	47	44	45	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2006	141	2					637	644		10.1016/j.neuroscience.2006.04.027			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	072JA	WOS:000239668500008	16725271				2022-02-06	
J	Longhi, L; Zanier, ER; Royo, N; Stocchetti, N; McIntosh, TK				Longhi, L; Zanier, ER; Royo, N; Stocchetti, N; McIntosh, TK			Stem cell transplantation as a therapeutic strategy for traumatic brain injury	TRANSPLANT IMMUNOLOGY			English	Article						traumatic brain injury; neuroprotection; transplantation; stem cell	MARROW STROMAL CELLS; BONE-MARROW; PROGENITOR CELLS; COGNITIVE FUNCTION; NEURONAL CELLS; RAT MODEL; SURVIVAL; MIGRATION; RECOVERY; DIFFERENTIATION	Stem cell transplantation has enormous potential to be a viable therapeutic approach to replace the lost tissue/cells following traumatic brain injury (TBI). Several types of cell lines such as immortalized progenitors cells, embryonic rodent and human stem cells and bone marrow-derived cells have been successfully transplanted in experimental models of TBI, resulting in reduced neurobehavioral deficits and attenuation of histological damage. To date, it remains unclear whether stem cell are effective following transplantation into the injured brain via either cell replacement, trophic support, or manipulation of the local environment to stimulate endogenous neuroprotection/regeneration. This paper will review the most current and exciting pre-clinical data regarding the utility of cellular transplantation in experimental models of TBI. We believe that further work must continue to better understand the interaction between the host and the transplanted cells as well as the mechanisms regulating their differentiation into mature and functionally active neurons/glia. (C) 2005 Elsevier B.V. All rights reserved.	Univ Milan, Osped Maggiore Policlin, Fdn IRCCS, Dept Anesthesia & Crit Care Med,Neurosurg Intens, I-20100 Milan, Italy; Univ Penn, Dept Neurosurg, Head Injury Lab, Philadelphia, PA 19104 USA		Longhi, L (corresponding author), Univ Milan, Osped Maggiore Policlin, Fdn IRCCS, Dept Anesthesia & Crit Care Med,Neurosurg Intens, Via Sforza 35, I-20100 Milan, Italy.	lucalonghi@policlinico.mi.it	Stocchetti, Nino/O-7444-2017; Zanier, Elisa/AAA-8095-2020; Longhi, Luca/AAF-9903-2021	Stocchetti, Nino/0000-0003-3250-6834; Zanier, Elisa/0000-0002-3011-8718; Longhi, Luca/0000-0001-9894-8788			Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; EMSLEY JG, 2005, PROG NEUROBIOL; Englund U, 2002, DEV BRAIN RES, V134, P123, DOI 10.1016/S0165-3806(01)00330-3; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Jennett B., 1997, HEAD INJURY, P439; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; LE J, 2002, BIODRUGS, V16, P389; Lenzlinger PM, 2002, EXP NEUROL, V175, P421; Lindvall O, 2004, STROKE, V35, P2691, DOI 10.1161/01.STR.0000143323.84008.f4; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/neu.2004.21.1723; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lundberg C, 1996, BRAIN RES, V737, P295, DOI 10.1016/0006-8993(96)00923-7; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Seaberg RM, 2003, TRENDS NEUROSCI, V26, P125, DOI 10.1016/S0166-2236(03)00031-6; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Sinden JD, 1997, NEUROSCIENCE, V81, P599, DOI 10.1016/S0306-4522(97)00330-8; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Sortwell CE, 2003, FRONT BIOSCI, V8, pS522, DOI 10.2741/1096; Svendsen CN, 2004, NAT MED, V10, P224, DOI 10.1038/nm0304-224; Tate MC, 2002, CELL TRANSPLANT, V11, P283; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P457; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; ZHANG C, 2005, J NEUROTRAUMA	48	44	50	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0966-3274	2210-3384		TRANSPL IMMUNOL	Transpl. Immunol.	DEC	2005	15	2					143	148		10.1016/j.trim.2005.09.003			6	Immunology; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Transplantation	007GM	WOS:000234956800007	16412958				2022-02-06	
J	Beers, SR; Skold, A; Dixon, CE; Adelson, PD				Beers, SR; Skold, A; Dixon, CE; Adelson, PD			Neurobehavioral effects of amantadine after pediatric traumatic brain injury - A preliminary report	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						amantadine hydrochloride; behavior; Behavior Rating Inventory of Executive Function; executive function; neuropsychological tests; traumatic brain injury	DORSOLATERAL PREFRONTAL CORTEX; BEHAVIOR RATING INVENTORY; EXECUTIVE FUNCTION BRIEF; WATER MAZE PERFORMANCE; WORKING-MEMORY TASK; CLOSED-HEAD-INJURY; MILD HEAD; METHYLPHENIDATE TREATMENT; FUNCTIONAL-DEVELOPMENT; WORD FLUENCY	Objective: To investigate the safety and efficacy of a dopamine agonist, amantadine hydrochloride (AMH), in the treatment of neurobehavioral sequelae of pediatric TBI. Procedures: Age- and severity-matched traumatic brain injury groups, randomized to AMH (n = 17) or usual care (n = 10), completed behavior scales and neuropsychological tests. Effect sizes measured the treatment effect within subjects and between groups. Side effects were tracked over the 12-week study course. Results: Behavior improved in the AMH group, but only those 2 years or fewer postinjury showed a treatment effect on cognitive tests. Conclusions: After traumatic brain injury, a 12-week course of AMH was safe and, according to parent report, improved behavior. AMH may have the potential to improve cognition in more recently injured children.	Western Psychiat Inst & Clin, Traumat Brain Injury Program, Pittsburgh, PA 15213 USA; Pediat Neurotrauma Ctr, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA		Beers, SR (corresponding author), Western Psychiat Inst & Clin, Traumat Brain Injury Program, 3811 OHara St, Pittsburgh, PA 15213 USA.	beerssr@upmc.edu	Adelson, David/W-2083-2019		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD047976] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ALEXANDER GE, 1978, BRAIN RES, V143, P233, DOI 10.1016/0006-8993(78)90566-8; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Andersson Stein, 1992, Tidsskrift for den Norske Laegeforening, V112, P2070; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BEERS SR, 2004, P INT NEUR SOC 32 AN; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; BUTTERS N, 1987, J CLIN EXP NEUROPSYC, V9, P479, DOI 10.1080/01688638708410764; Carter CS, 1998, AM J PSYCHIAT, V155, P1285, DOI 10.1176/ajp.155.9.1285; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; *CHOIC MED INC, 2001, AM HYDR; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Denckla M B, 1994, FRAMES REFERENCE ASS, P117; DESONNEVILLE LMJ, 1991, J CHILD PSYCHOL PSYC, V32, P285; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; EDBY K, 1995, CHILD NERV SYST, V11, P607, DOI 10.1007/BF00301001; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; Fuster JM., 1980, PREFRONTAL CORTEX AN; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA IP, 2000, BEHAV RATING INVENTO; Golden CJ, 1978, STROOP COLOR WORD TE; GOLDMAN PS, 1970, EXP NEUROL, V27, P291, DOI 10.1016/0014-4886(70)90222-0; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAYDEN FG, 1983, ANTIMICROB AGENTS CH, V23, P458, DOI 10.1128/AAC.23.3.458; Heaton R., 1993, WISCONSIN CART SORTI; HERRMANN EC, 1960, P SOC EXP BIOL MED, V103, P625, DOI 10.3181/00379727-103-25617; Hooper SR, 2002, J LEARN DISABIL-US, V35, P57, DOI 10.1177/002221940203500105; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; HUTTENLOCHER PR, 1990, NEUROPSYCHOLOGIA, V28, P517, DOI 10.1016/0028-3932(90)90031-I; Isoardi RA, 1999, NEUROIMAGE, V9, P145, DOI 10.1006/nimg.1998.0392; King BH, 2001, J AM ACAD CHILD PSY, V40, P654, DOI 10.1097/00004583-200106000-00009; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Langlois JA, 2001, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Margo KL, 1998, AM FAM PHYSICIAN, V57, P1073; Masters KJ, 1997, J AM ACAD CHILD PSY, V36, P301, DOI 10.1097/00004583-199703000-00001; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mattes J, 1980, Psychopharmacol Bull, V16, P67; McEvoy LK, 1998, CEREB CORTEX, V8, P563, DOI 10.1093/cercor/8.7.563; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PORTER GE, 1993, PEDIATR INFECT DIS J, V12, P106; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Reitan R. M., 1992, NEUROPSYCHOLOGICAL E; Romine CB, 2004, NEUROPSYCHOL REV, V14, P43, DOI 10.1023/B:NERV.0000026648.94811.32; Sailer M, 2000, PHARMACOPSYCHIATRY, V33, P28, DOI 10.1055/s-2000-7966; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Semel E., 1995, CLIN EVALUATION LANG, VThird; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Thurman DJ, 2001, HEAD TRAUMA, P327; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilkinson R, 1999, BRAIN INJURY, V13, P1025; Zafonte RD, 1998, BRAIN INJURY, V12, P617	87	44	47	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2005	20	5					450	463		10.1097/00001199-200509000-00006			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	965NO	WOS:000231957600007	16170253				2022-02-06	
J	Ottens, AK; Kobeissy, FH; Wolper, RA; Haskins, WE; Hayes, RL; Denslow, ND; Wang, KKW				Ottens, AK; Kobeissy, FH; Wolper, RA; Haskins, WE; Hayes, RL; Denslow, ND; Wang, KKW			A multidimensional differential proteomic platform using dual-phase ion-exchange chromatography-polyacrylamide gel electrophoresis/reversed-phase liquid chromatography tandem mass spectrometry	ANALYTICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; SEPARATION METHOD; MESSENGER-RNA; BREAST-CANCER; PROTEINS; IDENTIFICATION; EXPRESSION; TECHNOLOGIES; PEPTIDES	Differential proteomic analysis has arisen as a large-scale means to discern proteome-wide changes upon treatment, injury, or disease. Tandem protein separation methods are required for large-scale differential proteomic analysis. Here, a novel multidimensional platform for resolving and differentially analyzing complex biological samples is presented. The platform, collectively termed CAX-PAGE/ RPLC-MSMS, combines biphasic ion-exchange chromatography with polyacrylamide gel electrophoresis for protein separation, quantification, and differential band targeting, followed by capillary reversed-phase liquid chromatography and data-dependent tandem mass spectrometry for quantitative and qualitative peptide analysis. CAX-PAGE provides high protein resolving power with a theoretical peak capacity of 3570, extendable to 7600, a wide protein mass range verified from 16 to 273 kDa, and reproducible differential sample comparison without the added expense of fluorescent dyes and imaging equipment. Demonstrated using a neuroproteomic model, CAX-PAGE revealed an increased number of differential proteins, 137, compared with 82 found by 2D difference gel electrophoresis. When combined with RPLC-MSMS for protein identification, an additional quantification step is performed for internal validation, confirming a 2-fold or greater change in 89% of identified differential targets.	Univ Florida, Ctr Neuroproteom & Biomarker Res, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA; Univ Florida, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32610 USA		Ottens, AK (corresponding author), Univ Florida, Ctr Neuroproteom & Biomarker Res, Gainesville, FL 32610 USA.	aottens@mbi.ufl.edu	Kobeissy, Firas/E-7042-2017; Ottens, Andrew/K-3352-2012	Kobeissy, Firas/0000-0002-5008-6944; Ottens, Andrew/0000-0002-2118-3796; Wang, Kevin/0000-0002-9343-6473			Aebersold R, 2001, CHEM REV, V101, P269, DOI 10.1021/cr990076h; Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Ahmed N, 2005, J CHROMATOGR B, V815, P39, DOI 10.1016/j.jchromb.2004.10.070; Alban A, 2003, PROTEOMICS, V3, P36, DOI 10.1002/pmic.200390006; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; BERGH GVD, 2003, ELECTROPHORESIS, V24, P1471; Chong BE, 2001, RAPID COMMUN MASS SP, V15, P291, DOI 10.1002/rcm.227; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; ELRASSI Z, 1986, J CHROMATOGR, V359, P255, DOI 10.1016/0021-9673(86)80079-6; Feng BB, 2001, RAPID COMMUN MASS SP, V15, P821, DOI 10.1002/rcm.276; Figeys D, 2003, ANAL CHEM, V75, P2891, DOI 10.1021/ac030142m; Fountoulakis M, 2004, MASS SPECTROM REV, V23, P231, DOI 10.1002/mas.10075; Fountoulakis M, 2001, AMINO ACIDS, V21, P363, DOI 10.1007/s007260170002; Freeman WM, 2004, NEUROCHEM RES, V29, P1065, DOI 10.1023/B:NERE.0000023594.21352.17; Gade D, 2003, J MOL MICROB BIOTECH, V5, P240, DOI 10.1159/000071076; GIDDINGS JC, 1991, UNIFIED SEPARATION S, P112; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; Griffin TJ, 2001, J BIOL CHEM, V276, P45497, DOI 10.1074/jbc.R100014200; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hamler RL, 2004, PROTEOMICS, V4, P562, DOI 10.1002/pmic.200300606; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Haskins WE, 2001, ANAL CHEM, V73, P5005, DOI 10.1021/ac010774d; Hennessy TP, 2005, J CHROMATOGR B, V817, P127, DOI 10.1016/j.jchromb.2004.10.043; Herr AE, 2003, ANAL CHEM, V75, P1180, DOI 10.1021/ac026239a; Hoffmann P, 2001, PROTEOMICS, V1, P807, DOI 10.1002/1615-9861(200107)1:7<807::AID-PROT807>3.0.CO;2-6; Hu S, 2004, ANAL CHEM, V76, P4044, DOI 10.1021/ac0498314; Issaq HJ, 2002, ELECTROPHORESIS, V23, P3048, DOI 10.1002/1522-2683(200209)23:17<3048::AID-ELPS3048>3.0.CO;2-L; Janini GM, 2003, J CHROMATOGR B, V787, P43, DOI 10.1016/S1570-0232(02)00616-5; Kim SI, 2004, NEUROCHEM RES, V29, P1317, DOI 10.1023/B:NERE.0000023618.35579.7c; Krapfenbauer K, 2003, ELECTROPHORESIS, V24, P1847, DOI 10.1002/elps.200305401; Krishnan Srinivasan, 2001, P575; LARMANN JP, 1993, ELECTROPHORESIS, V14, P439, DOI 10.1002/elps.1150140169; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Lubman DM, 2002, J CHROMATOGR B, V782, P183, DOI 10.1016/S1570-0232(02)00551-2; McDonald WH, 2002, DIS MARKERS, V18, P99, DOI 10.1155/2002/505397; Meng FY, 2004, ANAL CHEM, V76, P2852, DOI 10.1021/ac0354903; Moritz RL, 2004, ANAL CHEM, V76, P4811, DOI 10.1021/ac049717l; Morrison RS, 2002, MOL CELL PROTEOMICS, V1, P553, DOI 10.1074/mcp.R200004-MCP200; Nishihara JC, 2002, ELECTROPHORESIS, V23, P2203, DOI 10.1002/1522-2683(200207)23:14<2203::AID-ELPS2203>3.0.CO;2-H; Opiteck GJ, 1998, ANAL BIOCHEM, V258, P349, DOI 10.1006/abio.1998.2588; Patton WF, 2002, J CHROMATOGR B, V771, P3, DOI 10.1016/S1570-0232(02)00043-0; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Rabilloud T, 2000, ANAL CHEM, V72, p48A, DOI 10.1021/ac002709u; REGNIER FE, 1987, SCIENCE, V238, P319, DOI 10.1126/science.3310233; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Shaw J, 2003, PROTEOMICS, V3, P1181, DOI 10.1002/pmic.200300439; Skold K, 2002, PROTEOMICS, V2, P447, DOI 10.1002/1615-9861(200204)2:4<447::AID-PROT447>3.0.CO;2-A; Steel LF, 2005, J CHROMATOGR B, V815, P275, DOI 10.1016/j.jchromb.2004.10.072; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Tonge R, 2001, PROTEOMICS, V1, P377; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Voss T, 2000, ELECTROPHORESIS, V21, P3345, DOI 10.1002/1522-2683(20001001)21:16<3345::AID-ELPS3345>3.0.CO;2-Z; Wall DB, 2000, ANAL CHEM, V72, P1099, DOI 10.1021/ac991332t; Wang HX, 2004, PROTEOMICS, V4, P2476, DOI 10.1002/pmic.200300763; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wells DA, 2003, LC GC N AM, V21, P522; Zhang ZL, 2001, PROTEOMICS, V1, P1001, DOI 10.1002/1615-9861(200108)1:8<1001::AID-PROT1001>3.3.CO;2-8; Zheng SP, 2003, BIOTECHNIQUES, V35, P1202, DOI 10.2144/03356rr02; ZHU BY, 1992, J CHROMATOGR, V594, P75, DOI 10.1016/0021-9673(92)80314-K; Zhu K, 2004, J CHROMATOGR A, V1053, P133, DOI 10.1016/j.chroma.2004.08.080	67	44	48	0	4	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	AUG 1	2005	77	15					4836	4845		10.1021/ac050478r			10	Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry	951HQ	WOS:000230920600030	16053296				2022-02-06	
J	Vlodavsky, E; Palzur, E; Feinsod, M; Soustiel, JF				Vlodavsky, E; Palzur, E; Feinsod, M; Soustiel, JF			Evaluation of the apoptosis-related proteins of the BCL-2 family in the traumatic penumbra area of the rat model of cerebral contusion, treated by hyperbaric oxygen therapy: a quantitative immunohistochemical study	ACTA NEUROPATHOLOGICA			English	Article						apoptosis; Bcl-2; hyperbaric oxygen; traumatic brain injury	BRAIN-INJURY; CELL-DEATH; NEURONAL DEATH; HEAD-INJURY; MECHANISMS; ISCHEMIA; BAX; EXPRESSION; PATHWAYS	The growth and progression of traumatic brain injury (TBI) lesions depend significantly on developments in the traumatic penumbra area, perilesional region, where delayed neuronal death occurs. Recent data supports the important role of apoptosis in delayed cell death in TBI. Previously we demonstrated a significant reduction of apoptosis in traumatic penumbra in animals treated by hyperbaric oxygen (HBO). In this study we evaluate the expression of apoptosis-related proteins of the Bcl-2 family (Bcl-2, Bax and Bcl-xL) in the traumatic penumbra area in correlation with the extent of apoptosis in the rat model of focal cerebral contusion, treated by HBO. Sprague-Dawley rats underwent cortical dynamic deformation, some with subsequent hypoxemia. A group of both hypoxemic and non-hypoxemic animals was treated by HBO. The pathological study was based on immunohistochemical staining of the brain sections for Bcl-2, Bax and Bcl-xL with quantitative evaluation of staining by image analysis. The expression of Bcl-2 in hypoxemic animals was lower than in non-hypoxemic animals, but a significant increase in Bcl-2 expression was seen in both groups after HBO treatment. Bcl-xL also demonstrated an increase after HBO treatment but less significant. Staining for Bax protein did not demonstrate significant change after treatment. These data correlate well with the reduction of TUNEL-positive cells in traumatic penumbra after HBO treatment. We concluded that the apoptotic mechanisms are important in delayed cell death in TBI and that post-traumatic hypoxemia increases the intensity of apoptosis, probably through a decrease in Bcl-2 and BclxL expression which normally repress apoptosis. The beneficial effect of HBO treatment in our model of brain contusion correlates well with the increased expression of anti-apoptotic proteins (Bcl-2 and Bcl-xL) following treatment and the appropriate decrease in the extent of apoptosis. In light of these results, the usage of HBO is justified as neuroprotective treament in TBI.	Rambam Med Ctr, Inst Pathol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, IL-31096 Haifa, Israel; Rambam Med Ctr, Dept Neurosurg, Haifa, Israel; Rambam Med Ctr, Acute Brain Res Lab, Haifa, Israel		Vlodavsky, E (corresponding author), Rambam Med Ctr, Inst Pathol, POB 9602, IL-31096 Haifa, Israel.	vlodavsky@rambam.health.gov.il		Palzur, Eilam/0000-0003-2032-2974			Barth M, 2000, ACTA NEUROCHIR SUPPL, V76, P121; Chen L, 2000, Fa Yi Xue Za Zhi, V16, P211; Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; Cregan SP, 1999, J NEUROSCI, V19, P7860; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kondo A, 1996, NEUROPATH APPL NEURO, V22, P350, DOI 10.1111/j.1365-2990.1996.tb01114.x; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Luo Chun, 2002, Chin J Traumatol, V5, P299; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Rosenthal RE, 2003, STROKE, V34, P1311, DOI 10.1161/01.STR.0000066868.95807.91; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Wada S, 2000, MAR BIOTECHNOL, V2, P285, DOI 10.1007/s101260000006; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55	25	44	60	0	4	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	AUG	2005	110	2					120	126		10.1007/s00401-004-0946-8			7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	956VG	WOS:000231327400003	16001273				2022-02-06	
J	Maegele, M; Lippert-Gruener, M; Ester-Bode, T; Sauerland, S; Schafer, U; Molcany, M; Lefering, R; Bouillon, B; Neiss, WF; Angelov, DN; Klug, N; McIntosh, TK; Neugebauer, EAM				Maegele, M; Lippert-Gruener, M; Ester-Bode, T; Sauerland, S; Schafer, U; Molcany, M; Lefering, R; Bouillon, B; Neiss, WF; Angelov, DN; Klug, N; McIntosh, TK; Neugebauer, EAM			Reversal of neuromotor and cognitive dysfunction in an enriched environment combined with multimodal early onset stimulation after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cognitive; enriched environment; neuromotor; rat; recovery; stimulation; traumatic brain injury	FLUID-PERCUSSION INJURY; FACTOR MESSENGER-RNA; CEREBRAL-CORTEX; SPATIAL MEMORY; FUNCTIONAL RECOVERY; UNITED-STATES; YOUNG-RATS; HIPPOCAMPAL; INCREASES; LESIONS	This study was designed to investigate the additional benefits of a multimodal early onset stimulation (MEOS) paradigm when combined with enriched environment (EE) versus EE only and standard housing (SH) on the recovery after experimental traumatic brain injury (TBI). Male Sprague-Dawley rats were subjected to moderate lateral fluid percussion (LFP) brain injury (n = 40) or sham operation (n = 6). Thereafter, the injured and sham/EE + MEOS and EE only groups were placed into a complex EE consisting of tunnel-connected wide-bodied cages with various beddings, inclining platforms, and toys. Along with group living and environmental complexity, injured and sham/EE + MEOS animals were additionally exposed to a standardized paradigm of multimodal stimulation including auditory, visual, olfactory, and motor stimuli. In contrast, injured and sham/SH groups were housed individually without stimulation. A standardized composite neuroscore (NS) test was used to assess acute post-traumatic neuromotor deficits (24 h after injury) and recovery on days 7 and 15; recovery of cognitive function was assessed on days 11-15 using the Barnes maze. Neuromotor impairment was comparable in all injured animals at 24 h post-injury, but brain-injured EE + MEOS rats performed significantly better than both brain-injured SH and EE groups when tested on post-injury days 7 and 15 (p = 0.004). Similarly, latencies to locate the hidden box under the Barnes maze platform were significantly shortened in EE + MEOS animals at day 15 (p = 0.003). These results indicate that the reversal of neuromotor and cognitive dysfunction after TBI can be substantially enhanced when MEOS is added to EE.	Univ Cologne, Fac Med, Biochem & Expt Abt, D-51109 Cologne, Germany; Univ Cologne, Neurochirurg Klin, D-5000 Cologne, Germany; Klinikum Koln Merheim, Neurol Klin, Cologne, Germany; Univ Cologne, Inst Anat 1, D-5000 Cologne, Germany; Univ Penn, Traumat Brain Injury Lab, Dept Neurosurg, Philadelphia, PA 19104 USA		Maegele, M (corresponding author), Univ Cologne, Fac Med, Biochem & Expt Div, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de		Sauerland, Stefan/0000-0003-1048-796X			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Belayev A, 2003, BRAIN RES, V964, P121, DOI 10.1016/S0006-8993(02)04089-1; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRENNER E, 1983, NEUROSCI LETT, V42, P13, DOI 10.1016/0304-3940(83)90414-7; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Czeh B, 1998, HIPPOCAMPUS, V8, P647, DOI 10.1002/(SICI)1098-1063(1998)8:6<647::AID-HIPO7>3.0.CO;2-L; DIAMOND MC, 1967, J COMP NEUROL, V131, P357, DOI 10.1002/cne.901310305; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EINON DF, 1980, Q J EXP PSYCHOL, V32, P137, DOI 10.1080/00335558008248239; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; FERCHMIN PA, 1970, BRAIN RES, V20, P49, DOI 10.1016/0006-8993(70)90153-8; FERCHMIN PA, 1986, DEV PSYCHOBIOL, V19, P511, DOI 10.1002/dev.420190604; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Galani R, 1997, NEUROBIOL LEARN MEM, V67, P43, DOI 10.1006/nlme.1996.3745; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GONZALEZLIMA F, 1994, DEV PSYCHOBIOL, V27, P343, DOI 10.1002/dev.420270603; Greenough W. T., 1992, Brain Dysfunction, V5, P129; Gruner ML, 2000, BRAIN INJURY, V14, P585; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; INGLIS FM, 1995, NEUROSCIENCE, V66, P81, DOI 10.1016/0306-4522(94)00578-S; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LILJEQUIST R, 1993, BEHAV BRAIN RES, V56, P107, DOI 10.1016/0166-4328(93)90027-N; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; Lippert-Gruner M, 2002, ACT NEUR S, V79, P21; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAEGELE M, 2002, LANGENBECK ARCH SURG, V387, P266; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MOHAMMED AK, 1986, BRAIN RES, V398, P6, DOI 10.1016/0006-8993(86)91243-6; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; PAYLOR R, 1992, BEHAV BRAIN RES, V52, P49, DOI 10.1016/S0166-4328(05)80324-9; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1996, J NEUROSCI, V16, P1083; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; ROSENZWEIG M R, 1969, Developmental Psychobiology, V2, P87, DOI 10.1002/dev.420020208; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SINSON G, 1995, J NEUROCHEM, V65, P2209; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Sosin DM, 1996, BRAIN INJURY, V10, P47; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; WHISHAW IQ, 1984, BEHAV NEURAL BIOL, V42, P183, DOI 10.1016/S0163-1047(84)91046-X; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449	91	44	46	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2005	22	7					772	782		10.1089/neu.2005.22.772			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	945VQ	WOS:000230530800005	16004580				2022-02-06	
J	Makoroff, KL; Cecil, LM; Care, M; Ball, WS				Makoroff, KL; Cecil, LM; Care, M; Ball, WS			Elevated lactate as an early marker of brain injury in inflicted traumatic brain injury	PEDIATRIC RADIOLOGY			English	Article						inflicted traumatic brain injury; magnetic resonance spectroscopy; lactate; outcomes	MAGNETIC-RESONANCE SPECTROSCOPY; HEAD; INFANTS; DAMAGE	Background: Traumatic brain injury is a major cause of disability and death in the pediatric population. The metabolic and neurochemical abnormalities that underlie traumatic brain injury remain poorly understood, but hypoxia-ischemic injury might play an important role. Objective: This study evaluated children with inflicted traumatic brain injury using magnetic resonance spectroscopy (MRS). We postulated that children with hypoxic-ischemic injury indicated by elevated lactate in the acute phase of injury will have worse early neurological status and short-term clinical outcomes than those without lactate upon MRS. Materials and methods: This prospective study employed proton MRS to sample bilaterally the frontal lobes and the parasagittal cortex within the parietal and occipital lobes of 11 patients with inflicted traumatic brain injury who were undergoing a clinical MRI examination. Patients' measured clinical course while hospitalized included initial neurological evaluation, presence of seizure activity, need for admission to the pediatric intensive care unit (PICU), number of days hospitalized, presence of retinal hemorrhages and presence of bone fractures. Measurement of outcome was determined using the Pediatric Overall Performance Category Scale (POPCS; 1=good performance; 6=death). Results: Four children demonstrated elevated lactate and diminished N-acetyl aspartate (a neuronal marker) within several regions, indicating global ischemic injury (lactate-positive global group). These four children all had seizure activity and abnormal initial neurological examinations and required admission to the PICU. The mean POPCS for this group was 3.25. In four other children, lactate was detected within at least one region, indicating a focal ischemic injury (lactate-positive focal group); two of these children had seizure activity, and two had an abnormal initial neurological examination. The mean POPCS score was 1.5 for this group. The remaining three children had no evidence of lactate upon MRS (lactate-negative group). These children did not have seizure activity, did not require admission to the PICU, nor did they have initial abnormal neurological examinations. The mean POPCS score was 1.3 for this group. Summary: Patients with inflicted traumatic brain injury and evidence of hypoxic-ischemic injury as indicated by elevated lactate on MRS tend to have worse early neurological status and early outcome scores. Lactate levels as sampled by MRS might predict early clinical outcome in inflicted traumatic brain injury.	Univ Cincinnati, Coll Med, Dept Pediat,Cincinnati Childrens Hosp, Mayerson Ctr Safe & Healthy Children, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Radiol, Imaging Res Ctr,Cincinnati Childrens Hosp Med Ct, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Imaging Res Ctr,Cincinnati Childrens Hosp Med Ct, Cincinnati, OH 45229 USA		Makoroff, KL (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat,Cincinnati Childrens Hosp, Mayerson Ctr Safe & Healthy Children, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Kathi.Makoroff@cchmc.org		Cecil, Kim/0000-0001-8233-5485			Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Cecil K M, 2001, Top Magn Reson Imaging, V12, P435, DOI 10.1097/00002142-200112000-00005; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kadri Munaf, 2003, J Perinatol, V23, P181, DOI 10.1038/sj.jp.7210913; LANFERMANN H, 1995, RADIOLOGY, V196, P203, DOI 10.1148/radiology.196.1.7784568; LESCOHIER I, 1993, PEDIATRICS, V91, P721; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; WEBB PG, 1994, MAGNET RESON MED, V31, P365, DOI 10.1002/mrm.1910310404	15	44	46	0	5	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	JUL	2005	35	7					668	676		10.1007/s00247-005-1441-7			9	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	935SA	WOS:000229802500003	15830194				2022-02-06	
J	McEwen, ML; Springer, JE				McEwen, ML; Springer, JE			A mapping study of caspase-3 activation following acute spinal cord contusion in rats	JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY			English	Article						apoptosis; contusion; myelin; secondary injury; spinal cord injury; central nervous system trauma	TRAUMATIC BRAIN-INJURY; CELL-DEATH; OLIGODENDROCYTE PROGENITORS; INFLAMMATORY RESPONSE; MORPHOLOGICAL-CHANGES; APOPTOTIC CELLS; ENDONUCLEASE-G; EXPRESSION; SURVIVAL; PROTEIN	Spinal cord injury (SCI) initiates a cascade of biochemical changes that results in necrotic and apoptotic cell death. There is evidence that caspase-3 activation and apoptotic cell death occur within hours after SCI. However, the time course and cellular localization of activated caspase-3 has not been examined. Such information is essential because caspase-3-independent apoptotic pathways do exist. In this experiment, we describe the distribution of and cell types containing activated caspase-3 at 4 hr, 1 day, 2 days, 4 days, and 8 days following SCI in rats. Numerous caspase-3-positive cells were observed at 4 hr and 1 day postinjury and colocalized most often with CC1, a marker for oligodendroglia. Both markers disappeared near the injury epicenter over the next several days. Activated caspase-3 was again present in the injured spinal cord on postoperative day 8, which coincided with a reemergence of CC1-positive cells. Many of these CC1-positive cells again colocalized activated caspase-3. NeuN-positive neurons of the dorsal horn were occasionally immunopositive for activated caspase-3 at early time points. OX42-positive microglia/macrophages rarely contained activated caspase-3. The results indicate a biphasic pattern of caspase-3 activation during the first 8 days postinjury, suggesting that at least two mechanisms activate caspase-3 following SCI. This time-course study provides a framework for investigating and understanding the different signaling events contributing to this biphasic pattern of caspase-3 activation.	Univ Kentucky, Med Ctr, Dept Phys Med & Rehabil, Cardinal Hill Rehabil Hosp, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Phys Med & Rehabil, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		McEwen, ML (corresponding author), Univ Kentucky, Med Ctr, Dept Phys Med & Rehabil, Cardinal Hill Rehabil Hosp, 800 Rose St,MN 225, Lexington, KY 40536 USA.	mlmcew2@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040015, R01NS046380] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 00242] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40015, NS 46380] Funding Source: Medline		Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bhat RV, 1996, GLIA, V17, P169; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; BUNGE RP, 1993, ADV NEUROL, V59, P75; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; DUVALL E, 1985, IMMUNOLOGY, V56, P351; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Frei E, 2000, EXP NEUROL, V163, P373, DOI 10.1006/exnr.2000.7379; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Hentze H, 2001, BIOCHEM BIOPH RES CO, V283, P1111, DOI 10.1006/bbrc.2001.4918; Ishii K, 2001, J NEUROSCI RES, V65, P500, DOI 10.1002/jnr.1180; Jones LL, 2002, J NEUROSCI, V22, P4611, DOI 10.1523/JNEUROSCI.22-11-04611.2002; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XZ, 1997, J NEUROSCI, V17, P5395; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Nicotera P, 2000, BRAIN PATHOL, V10, P276, DOI 10.1111/j.1750-3639.2000.tb00261.x; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; Noyan-Ashraf MH, 2005, GLIA, V49, P588, DOI 10.1002/glia.20140; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Racke MM, 2002, J NEUROCHEM, V80, P1039, DOI 10.1046/j.0022-3042.2002.00787.x; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	46	44	45	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0022-1554	1551-5044		J HISTOCHEM CYTOCHEM	J. Histochem. Cytochem.	JUL	2005	53	7					809	819		10.1369/jhc.4A6467.2005			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	940OW	WOS:000230154800002	15995139	Bronze			2022-02-06	
J	Wahlstrom, MR; Olivecrona, M; Koskinen, LOD; Rydenhag, B; Naredi, S				Wahlstrom, MR; Olivecrona, M; Koskinen, LOD; Rydenhag, B; Naredi, S			Severe traumatic brain injury in pediatric patients: treatment and outcome using an intracranial pressure targeted therapy - the Lund concept	INTENSIVE CARE MEDICINE			English	Article						severe traumatic brain injury; children; intracranial pressure; outcome; intracranial pressure targeted therapy	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; CHILDREN; MANAGEMENT; SURVIVAL; SCALE; PERMEABILITY; PRINCIPLES; MUSCLE; LEVEL	Objective: This study evaluated the outcome of treatment according to the Lund concept in children with severe traumatic brain injury and investigated whether the preset goals of the protocol were achieved. Design and setting: A two-center retrospective study in neurointensive care units at university hospitals. Patients: Forty-one children with severe traumatic brain injury from blunt trauma and arriving at hospital within 24 h after injury. Median age was 8.8 years ( range 3 months - 14.2 years), Glasgow Coma Scale 7 ( 3 - 8), and Injury Severity Score 25 ( 16 - 75). All children had pathological findings on initial computed tomography. All developed intracranial hypertension, and survivors required intensive care longer than 72 h. Interventions: Treatment according to the principles of the Lund concept. Measurements and results: Neurosurgery was required in 46% of the children. Survival rate was 93% and favorable outcome ( Glasgow Outcome Score 4 or 5) was 80% at long-term follow-up ( median 12 months postinjury, range 2.5 - 26). The preset physiological and biochemical goals were achieved in over 90% of observations. Conclusions: Treating pediatric patients with severe traumatic brain injury, according to the Lund concept, results in a favorable outcome when the protocol is followed.	Umea Univ Hosp, Dept Anesthesia & Intens Care, S-90185 Umea, Sweden; Univ Umea Hosp, Dept Neurosurg, S-90185 Umea, Sweden; Sahlgrens Univ Hosp, Dept Neurosurg, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Anesthesia & Intens Care, S-41345 Gothenburg, Sweden		Wahlstrom, MR (corresponding author), Umea Univ Hosp, Dept Anesthesia & Intens Care, S-90185 Umea, Sweden.	marie.rodling@anestesi.umu.se	Koskinen, Lars-Owe/AAQ-8957-2020	Naredi, Silvana/0000-0002-4409-6089; Koskinen, Lars-Owe/0000-0003-3528-8502; Olivecrona, Magnus/0000-0001-8457-4711			ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P567, DOI 10.1007/BF01705723; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carney NA, 2003, CRIT CARE MED, V31, pS417, DOI 10.1097/00003246-200306006-00001; Cassidy LD, 2003, J PEDIATR SURG, V38, P482, DOI 10.1053/jpsu.2003.50084; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kongstad L, 1999, ACTA PHYSIOL SCAND, V165, P369; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; Moller AD, 1997, AM J PHYSIOL-HEART C, V273, pH200, DOI 10.1152/ajpheart.1997.273.1.H200; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P916, DOI 10.1111/j.1399-6576.1995.tb04198.x; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Ott R, 2000, J TRAUMA, V49, P729, DOI 10.1097/00005373-200010000-00023; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Potoka DA, 2001, J TRAUMA, V51, P824, DOI 10.1097/00005373-200111000-00002; REILLY PL, 1988, CHILD NERV SYST, V4, P30; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; Steven JM, 1996, SMITHS ANESTHESIA IN, P229; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; TODD NV, 1990, ACTA NEUROCHIR WIEN, V51, pS296; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011	41	44	47	0	5	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2005	31	6					832	839		10.1007/s00134-005-2632-2			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	932UC	WOS:000229578000013	15838678	Green Submitted			2022-02-06	
J	Urban, RJ; Harris, P; Masel, B				Urban, RJ; Harris, P; Masel, B			Anterior hypopituitarism following traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; head trauma; hypopituitarism; growth hormone deficiency	NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; POSTTRAUMATIC HYPOPITUITARISM; PITUITARY APOPLEXY; GH; INSUFFICIENCY; REPLACEMENT; DIAGNOSIS; SECONDARY; ANEURYSM	Primary objectives. To review evidence that there exists a substantial sub-population of patients with endocrine disorders as a result of traumatic brain injury (TBI) and to underscore the importance of screening patients with TBI considered most at risk for hypopituitarism with the goal of attaining beneficial effects in terms of morbidity and quality of life. Design and methods. Reviewed recent literature regarding the frequency of TBI-induced hypopituitarism. Main outcomes and results. Studies by Kelly DF, Gaw Gonzalo IT, Cohan P, et al. Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: A preliminary report. Journal of Neurosurgery 2000; 93: 743-751, Lieberman SA, Oberoi AL, Gilkison CR, et al. Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. Journal of Clinical Endocrinology and Metabolism 2001; 86: 2752-2756 and Aimaretti G, Ambrosio MR, Di Somma C, et al. Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism. Screening study at 3 months after the brain injury, In press., found that about one-half to one-third of patients with TBI had anterior pituitary hormone deficiencies, including growth hormone (GH) deficiency in 15-21%, and subtle deficiencies in thyroid, adrenal and gonadal axes. One or more hormonal deficiencies produce diverse physical and psychological symptoms that may mimic symptoms attributed to brain trauma and may impair rehabilitation. A more general concern is the fact that hypopituitarism increases the risk of significant morbidity (e.g. ischaemic heart disease) and mortality (shortened life span). Conclusions. To attain maximal improvement in mental and physical functioning as well as in quality of life for victims of TBI, it is crucial that anterior pituitary hormonal function be assessed. Appropriate hormone replacement therapy for those patients with both TBI and TBI-induced pituitary function impairment could, for the first time, allow treatment and correction of underlying causes of TBI sequelae rather than merely symptomatic treatment.	Transit Learning Ctr Galveston, Galveston, TX 77550 USA; Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol, Galveston, TX 77550 USA; Pfizer Ltd, Sandwich Labs, Clin Dev, Sandwich CT13 9NJ, Kent, England		Masel, B (corresponding author), Transit Learning Ctr Galveston, 1528 PO St, Galveston, TX 77550 USA.	bmasel@tlc-galveston.org					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; AIMARETTI G, IN PRES TRAUMATIC BR; ALTMAN R, 1961, ANN INTERN MED, V55, P149, DOI 10.7326/0003-4819-55-1-149; ARGYROPOULOU M, 1992, J PEDIATR-US, V120, P886, DOI 10.1016/S0022-3476(05)81955-9; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Barbeau C, 1998, ARCH PEDIATRIE, V5, P274, DOI 10.1016/S0929-693X(97)89368-2; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bontha S, 2000, ENDOCRINOLOGIST, V10, P277, DOI 10.1097/00019616-200010040-00010; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; *CDCP NAT CTR INJ, 2002, TRAUM BRAIN INJ FACT; Ceballos R, 1966, Ala J Med Sci, V3, P185; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; CYTOWIC RE, 1986, NEW ENGL J MED, V314, P715; DANGELICA M, 1995, J TRAUMA, V39, P768, DOI 10.1097/00005373-199510000-00031; DANIEL PM, 1959, LANCET, V2, P927; EDWARDS OM, 1986, MEDICINE, V65, P281; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; Fellner F, 1998, Rontgenpraxis, V51, P243; FERNANDEZREAL JM, 1994, CLIN INVESTIGATOR, V72, P302; FUJITA K, 1992, EUR J PEDIATR, V151, P266, DOI 10.1007/BF02072226; Gibney J, 1999, J CLIN ENDOCR METAB, V84, P2596, DOI 10.1210/jc.84.8.2596; GUPTA N, 2000, NEUROREVIEW; Hernandez A, 1998, EUR J NEUROL, V5, P499, DOI 10.1046/j.1468-1331.1998.550499.x; Hernberg-Stahl E, 2001, J CLIN ENDOCR METAB, V86, P5277, DOI 10.1210/jc.86.11.5277; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; JORGENSEN JOL, 1994, EUR J ENDOCRINOL, V130, P224, DOI 10.1530/eje.0.1300224; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KLEIN MJ, 2002, EMED J          0415; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kusanagi Hiroaki, 2000, Journal of Nippon Medical School, V67, P130, DOI 10.1272/jnms.67.130; LEE SC, 1994, BRAIN INJURY, V8, P571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LINDENBERG R, 1973, MEDICOLEGAL INVESTIG, P420; Mitchell A, 1997, Crit Care Nurse, V17, P34; MITCHELL A, 1997, CRITICAL CARE NURSE, V17, P53; MITCHELL A, 1997, CRITICAL CARE NURSE, V17, P46; MITCHELL A, 1997, CRITICAL CARE NURSE, V17, P40; Newman CB, 1998, ENDOCRINOLOGIST, V8, P178, DOI 10.1097/00019616-199805000-00009; OLIVER RM, 1991, BRIT J CLIN PRACT, V45, P150; PIERUCCI G, 1971, Pathologica (Genoa), V63, P71; Simmonds M, 1914, DEUT MED WOCHENSCHR, V40, P322, DOI 10.1055/s-0029-1190185; SOULES MR, 1979, SOUTHERN MED J, V72, P1592, DOI 10.1097/00007611-197912000-00029; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Wettstein M, 1996, Conn Med, V60, P583; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	48	44	51	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2005	19	5					349	358		10.1080/02699050400004807			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	932JH	WOS:000229549500005	16094782				2022-02-06	
J	Nilsson, AL; Sunnerhagen, KS; Grimby, G				Nilsson, AL; Sunnerhagen, KS; Grimby, G			Scoring alternatives for FIM in neurological disorders applying Rasch analysis	ACTA NEUROLOGICA SCANDINAVICA			English	Article						stroke; traumatic brain injury; spinal cord injury; ordinal scale; latent trait analysis; Functional Independence Measure; Scandinavia	FUNCTIONAL INDEPENDENCE MEASURE; CROSS-CULTURAL VALIDITY; REHABILITATION; DISABILITY; STROKE; IMPAIRMENT; SCALES; MODEL	Objective - The Functional Independence Measure (FIMTM) is an internationally widely used outcome measure. The aim of this study was to evaluate the structural properties of FIMTM using the Rasch model, with regard to scoring within rehabilitation centres in Scandinavia. Materials and methods - FIMTM data from 1660 patients with stroke, traumatic brain injury and spinal cord injury were analysed. The best models with respect to person separation were determined, together with person reliability, item separation, disordered categories, distance of more than 1.4 logits between categories and item fit to the model. Results - Analysis showed disordering using seven categories in all three diagnoses. After collapsing of categories a four-category scale was the best solution. Conclusions - Decreasing the categories from seven to four may be one way of dealing with problems of disordered thresholds. Further studies are also needed in order to try the suggested scale in clinical settings and to compare it with the original FIMTM scale.	Gothenburg Univ, Inst Clin Neuro Sci, Gothenburg, Sweden		Nilsson, AL (corresponding author), Sahlgrens Univ Hosp, Inst Clin Neuro Sci, Guldhedsgatan 19, S-41345 Gothenburg, Sweden.	asa.lundgren-nilsson@rehab.gu.se	Grimby, Gunnar/AAB-3178-2019; Sunnerhagen, Katharina Stibrant/AAE-2405-2020	Sunnerhagen, Katharina Stibrant/0000-0002-5940-4400			Andrich D., 1988, RASCH MODELS MEASURE; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Catz A, 1997, SPINAL CORD, V35, P850, DOI 10.1038/sj.sc.3100504; Claesson L, 2001, J REHABIL MED, V33, P137; Cohen ME, 2000, ARCH PHYS MED REHAB, V81, pS21, DOI 10.1053/apmr.2000.20620; Deutsch A, 1996, CRITICAL REV PHYS ME, V8, P267; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; FISHER AG, 1992, AM J OCCUP THER, V46, P183, DOI 10.5014/ajot.46.2.183; FISHER AG, 1992, AM J OCCUP THER, V46, P278, DOI 10.5014/ajot.46.3.278; FISHER WP, 1993, AM J OCCUP THER, V47, P331, DOI 10.5014/ajot.47.4.331; Gosman-Hedstrom G, 2000, DISABIL REHABIL, V22, P702, DOI 10.1080/09638280050191972; Gosman-Hedstrom G, 2004, DISABIL REHABIL, V26, P410, DOI 10.1080/09638280410001662978; Grimby G, 1996, SCAND J REHABIL MED, V28, P51; Grimby G, 1996, ARCH PHYS MED REHAB, V77, P1109, DOI 10.1016/S0003-9993(96)90131-8; Haigh R, 2001, J REHABIL MED, V33, P273; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEINEMANN AW, 2001, 1 WORLD C INT SOC PH; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kucukdeveci AA, 2001, CLIN REHABIL, V15, P311, DOI 10.1191/026921501676877265; Linacre, 1992, RASCH MEASUREMENT T, V6, P233; Linacre J M, 1999, J Outcome Meas, V3, P103; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Linacre JM., 1995, RASCH MEASUREMENT T, V9, P450; LINACRE JM, 2002, WINSTEPS COMPUTER PR; Lundgren-Nilsson A, 2005, J REHABIL MED, V37, P23, DOI 10.1080/16501970410032696; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; Rasch Georg, 1980, PROBABILISTIC MODELS; Svensson E, 2001, J REHABIL MED, V33, P47, DOI 10.1080/165019701300006542; Tennant A, 2004, MED CARE, V42, P37, DOI 10.1097/01.mlr.0000103529.63132.77; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Wright B, 1979, BEST TEST DESIGN; Wright B, 1994, MEASUREMENT T, V8, P370; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857; Wright BD., 1982, RATING SCALE ANAL	35	44	45	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	APR	2005	111	4					264	273		10.1111/j.1600-0404.2005.00404.x			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	902HT	WOS:000227346200010	15740579				2022-02-06	
J	Hopkins, RO; Tate, DF; Bigler, ED				Hopkins, RO; Tate, DF; Bigler, ED			Anoxic versus traumatic brain injury: Amount of tissue loss, not etiology, alters cognitive and emotional function	NEUROPSYCHOLOGY			English	Article						anoxic brain injury (ABI); traumatic brain injury (TBI); brain imaging; cognitive function	DIFFUSE AXONAL INJURY; TEMPORAL-LOBE; HEAD-INJURY; MEMORY; VOLUME; DAMAGE; MR; PERFORMANCE; APOPTOSIS; ISCHEMIA	Research in neuropsychology suggests that the etiology of a neurologic injury determines the neuropathological and neuropsychological changes. This study compared neuropsychological outcome in subjects who had traumatic brain injury (TBI) with subjects who had anoxic brain injury (ABI), who were matched for age, gender, and ventricle-to-brain ratio. There were no group differences for morphologic or neuropsychological measures. Both groups exhibited impaired memory, attention, and executive function, as well as slowed mental processing speed. Intelligence Correlated with whole brain volume, and measures of memory correlated with hippocampal atrophy. There was no unique contribution of hippocampal atrophy on neuropsychological outcome between the groups. In the absence of localized lesions, the amount of neural tissue loss, rather than etiology, may be the critical factor in neuropsychological outcome.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Univ Utah, Salt Lake City, UT 84112 USA		Hopkins, RO (corresponding author), Brigham Young Univ, Dept Psychol, 1122 Spence W Kimball Tower, Provo, UT 84602 USA.	mona_hopkins@byu.edu	Tate, David/G-5166-2011	Tate, David/0000-0003-0213-1920			Ackerly SS, 1964, FRONTAL GRANULAR COR, P192; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; BANDAK FA, 1996, TRAUMATIC BRAIN INJU; BARAT M, 1989, Annales de Readaptation et de Medecine Physique, V32, P657; Beck AT, 1993, BECK ANXIETY INVENTO; Beck AT, 1987, BECK DEPRESSION INVE; Biagas Katherine, 1999, Current Opinion in Pediatrics, V11, P223, DOI 10.1097/00008480-199906000-00009; Bigler E D, 1988, Arch Clin Neuropsychol, V3, P383, DOI 10.1016/0887-6177(88)90052-2; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P442, DOI 10.1017/S1355617704103111; Bigler ED, 2003, AM J NEURORADIOL, V24, P2066; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BIGLER ED, IN PRESS NEUROREHABI; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Clarke E, 1996, ILLUSTRATED HIST BRA; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Conti AC, 1998, J NEUROSCI, V18, P5663; Crawford JR, 2003, J INT NEUROPSYCH SOC, V9, P989, DOI 10.1017/S1355617703970032; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; FINGER S., 1994, ORIGINS NEUROSCIENCE; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; Gale SD, 1999, BRAIN INJURY, V13, P229, DOI 10.1080/026990599121601; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; Gale SD, 2004, J INT NEUROPSYCH SOC, V10, P60; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; Gilland E, 1998, J CEREBR BLOOD F MET, V18, P297, DOI 10.1097/00004647-199803000-00008; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GRAFMAN J, 1986, J NEUROSCI, V6, P301; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V2, P823; GROSS CG, 1964, FRONTAL GRANULAR COR, P74; Groswasser Z, 2002, BRAIN INJURY, V16, P681, DOI 10.1080/02699050110119835; Hay PJ, 2002, J PSYCHOSOM RES, V53, P699, DOI 10.1016/S0022-3999(02)00424-5; HELFFENSTEIN D, 2000, CARBVON MONOXIDE TOX, P439; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN PAM, 2002, NEUROPSYCHIATRY CLIN, V14, P176; Hopkins R O, 1995, J Int Neuropsychol Soc, V1, P501; HOPKINS RO, TXB CLIN NEUROPSYCHO; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; IRLE E, 1987, BRAIN RES REV, V12, P307, DOI 10.1016/0165-0173(87)90003-8; Ives B, 2003, J LEARN DISABIL-US, V36, P490, DOI 10.1177/00222194030360060101; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KASS IS, 1986, J PHYSIOL-LONDON, V378, P313, DOI 10.1113/jphysiol.1986.sp016221; Kesner RP, 2001, NEUROPSYCHOLOGY, V15, P58, DOI 10.1037/0894-4105.15.1.58; LASHLEY K, 1950, SOC EXPT BIOL S NO R, P478; Lezak MD, 1976, NEUROPSYCHOLOGICAL A; LEZAK MD, 1995, NEUROPSYCHOLOGICALA; LURIA AR, 1966, HIGHERS CORTICAL FUN; LUTZ PL, 1994, BRAIN WITHOUT OXYGEN; Manns JR, 2003, NEURON, V38, P127, DOI 10.1016/S0896-6273(03)00146-6; Manns JR, 2003, NEURON, V37, P171, DOI 10.1016/S0896-6273(02)01147-9; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MIN SK, 1986, ACTA PSYCHIAT SCAND, V73, P80, DOI 10.1111/j.1600-0447.1986.tb02671.x; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; PARKER RS, 1990, TAUMATIC BRAIN INJUR; PARKIN AJ, 1987, CORTEX, V23, P655, DOI 10.1016/S0010-9452(87)80055-2; Raz N, 2003, BEHAV NEUROSCI, V117, P1169, DOI 10.1037/0735-7044.117.6.1169; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Reynolds CR, 1999, ARCH CLIN NEUROPSYCH, V14, P235, DOI 10.1016/S0887-6177(98)00018-3; ROBB R, 1995, ANALYZE 3 DIMENSIONA; Rosen AC, 2003, BEHAV NEUROSCI, V117, P1150, DOI 10.1037/0735-7044.117.6.1150; Russell E. W., 1970, ASSESSMENT BRAIN DAM; SCHURR A, 1992, HIPPOCAMPUS, V2, P221, DOI 10.1002/hipo.450020303; SIESJO BK, 1989, ANN NY ACAD SCI, V568, P234; Smith A., 1981, HDB CLIN NEUROPSYCHO, P175; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Spreen O, 1998, COMPRENDIUM NEUROPSY; Stevens JP., 1996, APPL MULTIVARIATE ST; SWIERCINSKY DP, 1977, J CONSULT CLIN PSYCH, V45, P808, DOI 10.1037/0022-006X.45.5.808; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; VICK NA, 1949, GRINKLERS NEUROLOGY; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wichern D.W., 2002, APPL MULTIVARIATE ST; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767	82	44	44	0	6	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2005	19	2					233	242		10.1037/0894-4105.19.2.233			10	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	906DE	WOS:000227619900010	15769207				2022-02-06	
J	Pietrapiana, P; Tamietto, M; Torrini, G; Mezzanato, T; Rago, R; Perino, C				Pietrapiana, P; Tamietto, M; Torrini, G; Mezzanato, T; Rago, R; Perino, C			Role of premorbid factors in predicting safe return to driving after severe TBI	BRAIN INJURY			English	Article						TBI; brain injury; driving safety; premorbid factors	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; FUNCTIONAL INDEPENDENCE MEASURE; SPINAL-CORD-INJURY; ACCIDENT INVOLVEMENT; ALZHEIMERS-DISEASE; CEREBRAL-DAMAGE; RELATIVES VIEW; SELF-AWARENESS; REHABILITATION	Primary objective: The present study explored the possibility of predicting post- injury fitness to safe driving in patients with severe traumatic brain injury ( TBI) ( n = 66). Methods and procedure: Sixteen different measures, derived from four domains ( demo/ biographic, medico- functional, neuropsychological, and psychosocial) were used as predictor variables, whereas driving outcomes were assessed in terms of driving status ( post- TBI drivers versus non- drivers) and driving safety ( number of post- TBI car accidents and violations). Main outcomes and results: About 50% of the patients resumed driving after TBI. Compared to post- TBI non- drivers, post- injury drivers had shorter coma duration. With regard to driving safety, the final multiple regression model combined four predictors ( years post- injury, accidents and violations before TBI, pre- TBI- risky- personality- index, and pre- TBI- risky- driving- style- index) and explained 72.5% of variance in the outcome measure. Conclusions: Since the best three predictors of post- injury driving safety addressed patients' premorbid factors, the results suggest that in order to evaluate the actual possibility of safe driving after TBI, it would be advisable to consider carefully patients' pre- TBI histories.	Univ Turin, Dipartimento Psicol, I-10123 Turin, Italy; Ausiliatrice Hosp, Turin, Italy; Univ Turin, Ctr Cognit Sci, I-10124 Turin, Italy		Tamietto, M (corresponding author), Univ Turin, Dipartimento Psicol, Via Po 14, I-10123 Turin, Italy.	tamietto@psych.unito.it		Tamietto, Marco/0000-0002-8815-8499			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; BALL K, 1991, HUM FACTORS, V33, P583, DOI 10.1177/001872089103300509; Bieliauskas LA, 1998, CLIN NEUROPSYCHOL, V12, P206, DOI 10.1076/clin.12.2.206.1994; Boake C., 1998, J INT NEUROPSYCH SOC, V4, P75; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROWER W, 1992, 2 INT C OBJ EV REH M; COLEMAN RD, 2002, ARCH PHYS MED REHAB, P83; CROFT D, 1987, BRIT J OCCUPATIONAL, V50, P357; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; DEBELLEIX X, 2001, EUROPA MEDICOPHYSICA, V37, P201; Dimarco F, 2001, EURA MEDICOPHYS, V37, P215; DITUNNO JF, 1995, SPINAL CORD INJURY C; ENGUM ES, 1989, COGNITIVE REHABILITA, V7, P22; Evans L., 1991, TRAFFIC SAFETY DRIVE; FARMER J, 2000, BRAIN INJURY, P14; Finset A, 2000, BRAIN INJURY, V14, P887; Fisk GD, 1998, BRAIN INJURY, V12, P683; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FORMISANO R, 2001, EUROPA MEDICOPHYSICA, V37, P257; FOX G, 1993, ASTB C SEPT TOK, P1; Fox G K, 1992, Disabil Rehabil, V14, P140; FOX GK, 1998, ARCH PHYS MED REHAB, P79; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; Hal KM, 1997, J REHABILITATION OUT, V1, P63; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 1999, ARCH PHYS MED REHAB, V80, P1471, DOI 10.1016/S0003-9993(99)90260-5; Hartje W, 1991, NEUROPSYCHOL REHABIL, V3, P161; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; HELLAWELL DJ, 1999, BRAIN INJURY, P13; HILLIER SL, 1997, BRAIN INJURY, P11; HOFMEIJER AMJ, 2002, EUROPA MEDICOPHYSICA, V38, P29; HUNT L, 1993, J AM GERIATR SOC, V71, P177; JONES MH, 1978, 783 U SO CAL; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; Kapust L R, 1992, J Geriatr Psychiatry Neurol, V5, P210; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KORTELING JE, 1990, HUM FACTORS, V32, P95, DOI 10.1177/001872089003200107; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Lincoln N., 1992, CLIN REHABIL, V6, P275, DOI DOI 10.1177/026921559200600402; Lishman W. A., 1987, ORGANIC PSYCHIAT; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Lundqvist A, 2001, BRAIN INJURY, V15, P981, DOI 10.1080/02699050110065637; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Meyers J E, 1999, Appl Neuropsychol, V6, P154, DOI 10.1207/s15324826an0603_3; MICHON JA, 1989, ACCIDENT ANAL PREV, V21, P341, DOI 10.1016/0001-4575(89)90025-0; MIHAL WL, 1976, J APPL PSYCHOL, V61, P229, DOI 10.1037/0021-9010.61.2.229; Nouri F M, 1987, Int Disabil Stud, V9, P110; Novack TA, 2000, BRAIN INJURY, V14, P987; O'Shanick G J, 1989, Psychiatr Med, V7, P1; ODENHEIMER GL, 1994, J GERONTOL, V49, P153, DOI DOI 10.1093/GERONJ/49.4.M153; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ott BR, 2000, DEMENT GERIATR COGN, V11, P153, DOI 10.1159/000017229; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.3.CO;2-1; PERINO C, 1997, GIORNALE ITALIANO RI, V1, P53; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; QUIGLEY FL, 1983, AM J OCCUP THER, V37, P474, DOI 10.5014/ajot.37.7.474; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; RAPPORT LJ, 1998, M AM PSYCH ASS SAN F; ROTHKE S, 1989, INT J CLIN NEUROPSYC, V11, P134; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; SCHWEITZER JR, 1994, ERGONOMICS REHABILIT, P85; SHORE D, 1980, ARCH PHYS MED REHAB, V61, P81; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; SPINNLER H, 1987, ITAL J NEUROL SCI S, P6; STORKX LC, 1986, J CLIN EXPT NEUROPSY, V8, P421; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Trobe JD, 1996, ARCH NEUROL-CHICAGO, V53, P411, DOI 10.1001/archneur.1996.00550050033021; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; VANWOLFFELAAR P, 1988, ROAD USER BEHAVIOUR, P302; VANZOMEREN A, 1987, ARCH PHYS MED REHAB, V68, P607; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; WALLER PF, 1988, TRANSPORTATION AGING, V2, P72; Wechsler D., 1997, WAIS R WECHSLER ADUL; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; Wilson T, 1983, Int Rehabil Med, V5, P170; [No title captured]	94	44	46	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2005	19	3					197	211		10.1080/02699050400017197			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	906WJ	WOS:000227675000006	15832894	Green Submitted			2022-02-06	
J	Himanen, L; Portin, R; Isoniemi, H; Helenius, H; Kurki, T; Tenovuo, O				Himanen, L; Portin, R; Isoniemi, H; Helenius, H; Kurki, T; Tenovuo, O			Cognitive functions in relation to MRI findings 30 years after traumatic brain injury	BRAIN INJURY			English	Article							ALZHEIMERS-DISEASE; TEMPORAL-LOBE; HIPPOCAMPAL VOLUMES; FRONTAL-LOBE; MEMORY SCALE; HEAD-INJURY; PERFORMANCE; RISK; DIAGNOSIS; EDUCATION	Objective: The aim of the study was to relate cognitive effects of a remote traumatic brain injury (TBI) to MRI findings and severity of injury. Method: Sixty-one patients were assessed on average 30 years after a TBI of variable severity. A comprehensive cognitive test battery was used to evaluate memory, executive functions and cognitive overall impairment. Multiple regression analyses were used to examine the relationships between cognitive variables and MRI volumetric findings (the volumes of the hippocampus and the lateral ventricles) and local contusions on MRI. Also, the effect of injury severity on cognitive outcome was evaluated. Results: Reductions in hippocampal volumes and lateral ventricular enlargement were significantly associated with impaired memory functions, memory complaints and executive functions. Of the MRI parameters used, the best predictor for cognitive outcome was the volume of the lateral ventricle. There was only a modest relationship between severity of injury and cognitive performance, Conclusions: The results show that long-term memory impairments after TBI are associated with MRI volumetric measures. This suggests that the degree of diffuse injury leading to atrophic changes is prognostically more important than the initial severity of TBI.	Turku Univ, Cent Hosp, Dept Neurol, FIN-20521 Turku, Finland; Turku Univ, Dept Biostat, FIN-20520 Turku, Finland; Turku Univ, Cent Hosp, Dept Radiol, FIN-20521 Turku, Finland		Himanen, L (corresponding author), Turku Univ, Cent Hosp, Dept Neurol, PL 52, FIN-20521 Turku, Finland.	ls.himanen@kolumbus.fi		Himanen, Leena/0000-0001-7261-8027; Kurki, Timo/0000-0001-5532-3534			Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; Benton AL, 1963, REVISED VISUAL RETEN; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Coffey CE, 2001, J NEUROPSYCH CLIN N, V13, P471, DOI 10.1176/appi.neuropsych.13.4.471; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Hackert VH, 2002, NEUROIMAGE, V17, P1365, DOI 10.1006/nimg.2002.1248; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; ICHISE M, 1994, J NUCL MED, V35, P217; JACK CR, 1992, NEUROLOGY, V42, P183, DOI 10.1212/WNL.42.1.183; Kesler SR, 2000, BRAIN INJURY, V14, P851; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Killiany RJ, 2002, NEUROLOGY, V58, P1188, DOI 10.1212/WNL.58.8.1188; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LAAKSO MP, 1995, J NEURAL TRANSM-PARK, V9, P73, DOI 10.1007/BF02252964; Laakso MP, 1996, NEUROLOGY, V46, P678, DOI 10.1212/WNL.46.3.678; LEHTOVIRTA M, 1995, NEUROSCIENCE, V67, P65, DOI 10.1016/0306-4522(95)00014-A; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Novack TA, 2000, BRAIN INJURY, V14, P987; Pihlajamaki M, 2000, ANN NEUROL, V47, P470, DOI 10.1002/1531-8249(200004)47:4<470::AID-ANA10>3.0.CO;2-M; PORTIN R, 1995, PSYCHOL MED, V25, P1295, DOI 10.1017/S0033291700033262; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; Reider-Groswasser II, 2002, BRAIN INJURY, V16, P517, DOI 10.1080/02699050110119141; Reiman EM, 1998, ANN NEUROL, V44, P288, DOI 10.1002/ana.410440226; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Smith RJ, 1998, HUMAN BRAIN FUNCT, P135; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Ylikoski R, 2000, ACTA NEUROL SCAND, V101, P273, DOI 10.1034/j.1600-0404.2000.101004273.x	45	44	46	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2005	19	2					93	100		10.1080/02699050410001720031			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	990JR	WOS:000233739600003	15841753				2022-02-06	
J	Bonny, C; Borsello, T; Zine, A				Bonny, C; Borsello, T; Zine, A			Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases	REVIEWS IN THE NEUROSCIENCES			English	Article						c-Jun N-terminal kinase (JNK); apoptosis; signaling pathways; ischemic damage; hearing loss; JNK inhibition; D-JNKI-1 peptide	N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; STRESS-INDUCED APOPTOSIS; PEPTIDE INHIBITOR; SIGNALING PATHWAY; INDUCED COCHLEAR; CEP-1347 KT7515; NOISE EXPOSURE; NEURONAL DEATH; HAIR-CELLS	The c-Jun N-terminal kinases (JNKs) are members of the family of mitogen activated protein kinases (MAPKs). While the functions of the JNKs under physiological conditions are diverse and not completely understood, there is increasing evidence that JNKs are potent effectors of apoptosis in both the brain and the mammalian inner ear following a variety of injuries. The activation of the inducible transcription factor c-Jun by N-terminal phosphorylation is a central event in JNK-mediated neural and inner ear hair cell death. A cell permeable peptide designed specifically to inhibit JNK signaling has proven successful in in vivo models of both neuronal degeneration following cerebral ischemia and auditory hair cell degeneration following exposure to either acoustic trauma or a toxic level of an aminoglycoside antibiotic. Here we discuss the evidence supporting the application of JNK inhibitors to prevent cellular degeneration in several central nervous system (CNS) and peripheral nervous system (PNS) diseases with an emphasis on traumatic ischemic damage to the CNS and acquired deafness in the PNS receptors.	Univ Montpellier I, INSERM, U583, Inst Neurosci Montpellier, F-34091 Montpellier, France; Univ Lausanne, DBCM, Lausanne, Switzerland; Ist Ric Farmacol Mario Negri, Biol Neurodegenerat Disorders Lab, Milan, Italy; Univ Lausanne, Div Med Genet, Lausanne, Switzerland		Zine, A (corresponding author), Univ Montpellier I, INSERM, U583, Inst Neurosci Montpellier, BP 74103, F-34091 Montpellier, France.	zine@montp.inserm.fr	Bonny, Christophe/AAV-7214-2021; Borsello, Tiziana/ABG-7759-2020; Borsello, Tiziana/J-8232-2016	Borsello, Tiziana/0000-0002-9729-7642			Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Bodmer D, 2002, LARYNGOSCOPE, V112, P2057, DOI 10.1097/00005537-200211000-00028; Borsello T, 2004, TRENDS MOL MED, V10, P239, DOI 10.1016/j.molmed.2004.03.008; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x; Carboni S, 2004, J PHARMACOL EXP THER, V310, P25, DOI 10.1124/jpet.103.064246; Conlon BJ, 1999, HEARING RES, V128, P40, DOI 10.1016/S0378-5955(98)00195-6; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FORGE A, 1985, HEARING RES, V19, P171, DOI 10.1016/0378-5955(85)90121-2; Forge A, 2000, HEARING RES, V139, P97, DOI 10.1016/S0378-5955(99)00177-X; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALAZONETIS D, 1998, CELL, V55, P917; Harris CA, 2002, J NEUROSCI, V22, P103, DOI 10.1523/JNEUROSCI.22-01-00103.2002; Hu BH, 2002, HEARING RES, V166, P62, DOI 10.1016/S0378-5955(02)00286-1; Huang T, 2000, INT J DEV NEUROSCI, V18, P259, DOI 10.1016/S0736-5748(99)00094-5; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacono AA, 1998, HEARING RES, V117, P31, DOI 10.1016/S0378-5955(97)00214-1; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508; Ko HW, 1998, J NEUROCHEM, V71, P1390; Kopke R, 1999, ANN NY ACAD SCI, V884, P171, DOI 10.1111/j.1749-6632.1999.tb08641.x; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lefebvre PP, 2002, AUDIOL NEURO-OTOL, V7, P165, DOI 10.1159/000058304; Legos JJ, 2002, EXPERT OPIN INV DRUG, V11, P603; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Lynch ED, 2004, LARYNGOSCOPE, V114, P333, DOI 10.1097/00005537-200402000-00029; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Maroney AC, 1998, J NEUROSCI, V18, P104; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Ogita K, 2000, NEUROREPORT, V11, P859, DOI 10.1097/00001756-200003200-00040; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; Pirvola U, 2000, J NEUROSCI, V20, P43, DOI 10.1523/JNEUROSCI.20-01-00043.2000; Priuska EM, 1995, BIOCHEM PHARMACOL, V50, P1749, DOI 10.1016/0006-2952(95)02160-4; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; Scarpidis U, 2003, OTOL NEUROTOL, V24, P409, DOI 10.1097/00129492-200305000-00011; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; Shizuki K, 2002, NEUROSCI LETT, V320, P73, DOI 10.1016/S0304-3940(02)00059-9; STEINBERG GK, 1995, NEUROBIOL DIS, V2, P109, DOI 10.1006/nbdi.1995.0011; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Vago P, 1998, NEUROREPORT, V9, P431, DOI 10.1097/00001756-199802160-00014; Wang J, 2003, J NEUROSCI, V23, P8596; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu DC, 2000, J CEREBR BLOOD F MET, V20, P1320, DOI 10.1097/00004647-200009000-00007; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yamasoba T, 1998, BRAIN RES, V784, P82, DOI 10.1016/S0006-8993(97)01156-6; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Ylikoski J, 2002, HEARING RES, V163, P71, DOI 10.1016/S0378-5955(01)00380-X; Yoshizumi M, 2004, EXP CELL RES, V292, P1, DOI 10.1016/j.yexcr.2003.08.003; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; Zivin JA, 1998, MG CLIN NEUROSC, V16, P128	59	44	47	0	4	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.		2005	16	1					57	67					11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	911SO	WOS:000228025200004	15810654				2022-02-06	
J	Davis, DP; Heister, R; Poste, JC; Hoyt, DB; Ochs, M; Dunford, JV				Davis, DP; Heister, R; Poste, JC; Hoyt, DB; Ochs, M; Dunford, JV			Ventilation patterns in patients with severe traumatic brain injury following paramedic rapid sequence intubation	NEUROCRITICAL CARE			English	Article						paramedic; rapid sequence intubation; ventilation; hyperventilation; traumatic brain injury; intubation; head injury; airway management	TIDAL CARBON-DIOXIDE; CEREBRAL-BLOOD-FLOW; INDUCED LUNG INJURY; SEVERE HEAD-INJURY; MECHANICAL VENTILATION; INTRAHOSPITAL TRANSPORT; TISSUE PO2; HYPERVENTILATION; ARTERIAL; CYTOKINES	Introduction: Inadvertent hyperventilation has been documented during aeromedical transports but has not been studied following paramedic rapid sequence intubation (RSI). The San Diego Paramedic RST Trial was designed to study the impact of paramedic RSI on outcome inpatients with severe head injury. This analysis explores ventilation patterns in a cohort of trial patients undergoing end-tidal CO2 (ETCO2) monitoring. Methods: Adult patients with severe head injury (Glasgow Coma Score: 3-8) unable to be intubated without RSI were prospectively enrolled in the trial. Midazolam and succinylcholine were used for RSI; rocuronium was administered following tube confirmation. Standardized ventilation protocols were used by most paramedics; however, one agency instituted ETCO2 monitoring during the second trial year, with paramedics instructed to target ETCO, values of 30 to 35 mmHg. The incidence and duration of inadvertent hyperventilation (ETCO2: < 30 mmHg) and severe hyperventilation (ETCO2: < 25 mmHg) were explored for patients undergoing ETCO2 monitoring. The initial, final, minimum, and maximum values for ETCO2 and the maximum and minimum ventilatory rate values were also calculated using descriptive statistics (95% confidence interval). The pattern of ETCO2 values over time and distribution of recorded ventilatory rate values were explored graphically. Results: A total of 76 trial patients had adequate ETCO, data for this analysis. The mean values for initial, final, maximum, and minimum ETCO2 were 40.8 (range: 37.5-44.2),28.4 (range: 25.4-31.4),45.1 (range: 41.4-48.8), and 23.5 mmHg (range: 21.4-25.5), respectively. The mean maximum and minimum ventilatory rate values were 36.0/minute (range: 33.5-38.5) and 12.8/minute (range: 11.9-13.7), respectively. ETCO2 values less than 30 and 25 mmHg were documented in 79% and 59% of patients, respectively, with mean durations of 485 (range: 378-592) and 390 seconds (range: 285-494). Conclusion: Inadvertent hyperventilation is common following paramedic RSI, despite ETCO2 monitoring and target parameters.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Div Trauma, San Diego, CA 92103 USA; San Diego Cty EMS, San Diego, CA USA		Davis, DP (corresponding author), UCSD Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					Ali SS, 2002, MED PRIN PRACT, V11, P35, DOI 10.1159/000048658; Ausina A, 1998, ACT NEUR S, V71, P1; Bao Yinghui, 2000, Chin J Traumatol, V3, P210; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BUXTON RL, 1970, LANCET, V2, P498; Casati A, 1997, Minerva Anestesiol, V63, P177; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; GERVAIS HW, 1987, CRIT CARE MED, V15, P761, DOI 10.1097/00003246-198708000-00010; Grenier B, 1999, ANESTH ANALG, V88, P43, DOI 10.1097/00000539-199901000-00009; Hardman JG, 2003, ANESTH ANALG, V97, P1846, DOI 10.1213/01.ANE.0000090316.46604.89; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; HURST JM, 1989, J TRAUMA, V29, P1637, DOI 10.1097/00005373-198912000-00008; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; PEPE PE, 2002, EMERGENCY VENTILATOR, P80; ROSSANDA M, 1968, SCAND J CLIN LAB I S, V102; RUSSELL GB, 1994, J TRAUMA, V36, P317, DOI 10.1097/00005373-199403000-00006; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Schneider GH, 1998, ACT NEUR S, V71, P62; Sitzwohl C, 1998, ANESTH ANALG, V86, P1131, DOI 10.1097/00000539-199805000-00043; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Slutsky A S, 2000, Respir Res, V1, P73, DOI 10.1186/rr15; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P563, DOI 10.1089/neu.2000.17.563; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Tobias JD, 1996, PEDIATR EMERG CARE, V12, P249, DOI 10.1097/00006565-199608000-00003; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/00003246-200208000-00003; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Weinger M B, 1987, J Clin Monit, V3, P73, DOI 10.1007/BF00858353; WHITWAM JG, 1966, BRIT J ANAESTH, V38, P846, DOI 10.1093/bja/38.11.846; Wilson MR, 2003, J APPL PHYSIOL, V95, P1385, DOI 10.1152/japplphysiol.00213.2003; Zhang HB, 2002, ANESTHESIOLOGY, V97, P1426, DOI 10.1097/00000542-200212000-00014; Zornow MH, 2002, CRIT CARE MED, V30, P2774, DOI 10.1097/00003246-200212000-00026	48	44	44	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2005	2	2					165	171		10.1385/NCC:2:2:165			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	947JI	WOS:000230639100009	16159059				2022-02-06	
J	Hostetler, SG; Xiang, HY; Smith, GA				Hostetler, SG; Xiang, HY; Smith, GA			Characteristics of ice hockey-related injuries treated in US emergency departments, 2001-2002	PEDIATRICS			English	Article						ice hockey; athletic injuries; National Electronic Injury Surveillance System; United States	SPINAL-INJURIES; FACIAL INJURIES; NECK INJURIES; FACE MASKS; HEAD; JUNIOR; CONCUSSIONS; SPORTS; HELMETS; PLAYERS	Objective. Ice hockey, a popular sport in some regions, has potential for injury due to the velocities of players, pucks, and sticks. Previous studies conducted worldwide have shown that the rate of injury increases as the size and the speed of players increase, as well as when checking is allowed. However, national data about the annual number and types of injuries among ice hockey players are lacking. Data from previous studies were collected from regional tournaments, collegiate teams, local emergency departments (EDs), and different countries. The purpose of this article is to examine ice hockey injuries using a national US database to determine the age distribution of total injuries, injury types, and body regions injured, with a particular focus on ice hockey players <18 years old. Methods. Data regarding ice hockey-related injuries treated in US EDs between January 1, 2001, and December 31, 2002, were extracted from the National Electronic Injury Surveillance System (NEISS). Data considered included age, gender, race, injury diagnosis, and body region injured. Ice hockey-related injury cases were identified using the consumer product code for ice hockey and the narrative description of the incident in NEISS. Results. An estimated 32 750 individuals with ice hockey-related injuries were treated in US EDs in 2001 2002, including >18000 youths <18 years old. The number of injuries peak through adolescence (ages 12-17; 47% of all injuries). Males experienced 90% of all injuries. A very small percentage of individuals were hospitalized after injury (1.2% of individuals <18 years old; 0.5% of individuals greater than or equal to18 years old). The incidence of head injuries increased as age decreased, although the trend was not statistically significant. The upper extremity (44%) accounted for the highest total percentages of body regions injured for youths <18 years old, and trunk (14%) and facial injuries (10%) represented the smallest total percentages. Players >= 18 years old had significantly more lacerations than younger players (38% of injuries for 18- to 24-year-olds; 25% for 25- to 34-year-olds; 50% for 35- to 44-year-olds compared with 19% for 6- to 11-year-olds and 14% for 12- to 17-year-olds). Conclusions. Adolescents had the greatest number of ice hockey-related injuries treated in NEISS hospital EDs in 2001-2002; thus, ongoing efforts to develop injury prevention strategies should focus on this age group. Players <= 17 years old had a lower percentage of lacerations compared with all older players and a higher percentage of upper extremity injuries. The percentage of individuals hospitalized after injury was very low, yet youths <18 years old had twice the percentage of hospitalization after injury compared with individuals greater than or equal to18 years old. Males experienced the vast majority of all ice hockey-related injuries, with females representing a higher percentage of injuries among youths than among adults. Children and adults alike can reap the physical fitness and social benefits from ice hockey, when they are able to avoid predictable and preventable injuries.	Ohio State Univ, Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA		Xiang, HY (corresponding author), Ohio State Univ, Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	xiangh@pediatrics.ohiostate.edu	Xiang, Huiyun/E-4335-2011				Anderson AJ, 2000, PEDIATRICS, V105, P657, DOI 10.1542/peds.105.3.640; Baugh DK, 1998, HEALTH CARE FINANC R, V19, P129; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CASTALDI C R, 1991, Dental Clinics of North America, V35, P647; *CDCP, FACTS AD INJ; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Juhn MS, 2002, CLIN J SPORT MED, V12, P46, DOI 10.1097/00042752-200201000-00014; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; Lee MA, 2003, J HEALTH CARE POOR U, V14, P436, DOI 10.1177/1049208903255801; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MCFAULL S, 2001, CHIRPP NEWS, V19, P1; Miller TR, 2000, FUTURE CHILD, V10, P137, DOI 10.2307/1602828; Molsa J, 2000, AM J SPORT MED, V28, P322; Molsa J, 2003, AM J SPORT MED, V31, P751; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; MURRAY TM, 1995, PEDIATRICS, V95, P419; PASHBY T, 1987, CAN J OPHTHALMOL, V22, P293; PASHBY TJ, 1988, INT OPHTHALMOL CLIN, V28, P228, DOI 10.1097/00004397-198802830-00013; Patel Dilip R, 2002, Adolesc Med, V13, P569; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; Pinto M, 1999, CLIN J SPORT MED, V9, P70, DOI 10.1097/00042752-199904000-00005; Rampton J, 1997, CLIN J SPORT MED, V7, P162, DOI 10.1097/00042752-199707000-00002; Reid SR, 1999, PEDIATR EMERG CARE, V15, P310, DOI 10.1097/00006565-199910000-00002; REYNEN PD, 1994, AM J SPORT MED, V22, P167, DOI 10.1177/036354659402200203; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; SCHWARTZ ML, 1998, OXFORD TXB SPORTS ME, P319; Sim F H, 1978, Am J Sports Med, V6, P378, DOI 10.1177/036354657800600612; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; STUART MJ, PREVENTION ICE HOCKE; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; TATOR CH, 1984, CAN MED ASSOC J, V130, P875; Tator CH, 1998, CLIN SPORT MED, V17, P183, DOI 10.1016/S0278-5919(05)70072-7; Tegner Y, 1991, Br J Sports Med, V25, P87; TOWNER EML, 1994, BRIT MED J, V308, P449, DOI 10.1136/bmj.308.6926.449; U. S. Consumer Product Safety Commission, 2000, NAT EL INJ SURV SYST; *US HOCK INC, 2003, 2002 2003 OFF RUL IC; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596	49	44	45	0	13	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2004	114	6					E661	E666		10.1542/peds.2004-1565			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	875WN	WOS:000225453000052	15574599				2022-02-06	
J	Bruce, JM; Echemendia, RJ				Bruce, JM; Echemendia, RJ			Concussion history predicts self-reported symptoms before and following a concussive event	NEUROLOGY			English	Article; Proceedings Paper	50th Annual Meeting of the American-College-of-Sports-Medicine	MAY 28-31, 2003	San Francisco, CA	Amer Coll Sports Med				The authors evaluated how history of concussion affects symptom reporting prior to and after sustaining a concussion. At baseline, athletes with a positive concussion history reported more current symptomatology than athletes who had never been concussed. At 2 hours postinjury, concussed athletes with a history of previous concussion (PC) reported fewer symptoms than concussed athletes with no previous concussion history (NPC). By 1 week postinjury, however, PC athletes reported more symptoms than NPC athletes.	Penn State Univ, Coll Liberal Arts, Dept Psychol, University Pk, PA 16802 USA; Psychol & Neurobehav Associates, University Pk, PA USA		Bruce, JM (corresponding author), Penn State Univ, Coll Liberal Arts, Dept Psychol, 314 Bruce V Moore Bldg, University Pk, PA 16802 USA.	jmb518@psu.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Echemendia RJ, 2004, STUD NEUROPSYCHOL DE, P479; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Kelly JP, 1997, NEUROLOGY, V48, P581; ROSENBAUM AM, 2003, THESIS PENNSYLVANIA	6	44	44	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 26	2004	63	8					1516	1518					3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	865VN	WOS:000224732400037	15505180				2022-02-06	
J	Kadyan, V; Mysiw, WJ; Bogner, JA; Corrigan, JD; Fugate, LP; Clinchot, DM				Kadyan, V; Mysiw, WJ; Bogner, JA; Corrigan, JD; Fugate, LP; Clinchot, DM			Gender differences in agitation after traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						agitation; traumatic brain injury; gender difference; outcome	NURSING-HOME RESIDENTS; ESTROGEN; PATIENT	Objective: To determine sex differences in extent and type of posttraumatic agitation during acute rehabilitation. Design: This prospective, observational study was performed at a Midwest, regional, university-based acute rehabilitation center. Results: In a total of 158 subjects, comprising 120 men (76%) and 38 women (24%), there were no significant differences between male and female subjects for age, Glasgow Coma Scale score, Rancho Los Amigos Level of Cognitive Functioning Scale, Mini Mental State Exam, days in acute hospital, and days in rehabilitation. No difference in incidence was observed between sexes based on the criterion of agitation as three or more abnormal total Agitated Behavior Scale scores in 48 hrs (P = 0.890). Also, no difference in posttraumatic agitation between the two sexes (P = 0.396) was observed with the criterion of agitation as two or more abnormal total Agitated Behavior Scale scores in 2 days. There were no differences observed between the sexes for peak intensity and average intensity for the total score or each of the factor scores of the Agitated Behavior Scale. Conclusion: Posttraumatic agitation is seen in approximately 50% of patients after traumatic brain injury and usually lasts for <10 days. There are no significant sex differences in the frequency, duration, presentation, or extent of posttraurnatic agitation. These data imply that both sexes, despite any predetermined notions, should be treated equally with respect to posttraurnatic agitation management.	Ohio State Univ, Coll Med, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Kadyan, V (corresponding author), 480 W 9th Ave, Columbus, OH 43210 USA.		Mysiw, Walter/E-3724-2011; Corrigan, John D./E-2921-2011	Clinchot, Daniel/0000-0002-2810-7227			Bogner JA, 1999, J HEAD TRAUMA REHAB, V14, P91, DOI 10.1097/00001199-199902000-00012; Bogner JA, 2000, J HEAD TRAUMA REHAB, V15, P656, DOI 10.1097/00001199-200002000-00005; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Burgio LD, 2000, INT PSYCHOGERIATR, V12, P495, DOI 10.1017/S104161020000661X; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, pS8, DOI 10.1053/apmr.2003.50046; Centers for Disease Control and Prevention, 2001, TRAUM BRAIN INJ US R; COHEN D, 1993, J AM GERIATR SOC, V41, P229, DOI 10.1111/j.1532-5415.1993.tb06697.x; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Kadyan V, 2003, BRAIN INJURY, V17, P631, DOI 10.1080/0269905031000070224; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Schreiner AS, 2001, INT J GERIATR PSYCH, V16, P209, DOI 10.1002/1099-1166(200102)16:2<209::AID-GPS314>3.0.CO;2-9	21	44	45	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	OCT	2004	83	10					747	752		10.1097/01.PHM.0000140790.30468.F4			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	857ST	WOS:000224139300001	15385782				2022-02-06	
J	Kleindienst, A; Harvey, HB; Rice, AC; Muller, C; Hamm, RJ; Gaab, MR; Bullock, MR				Kleindienst, A; Harvey, HB; Rice, AC; Muller, C; Hamm, RJ; Gaab, MR; Bullock, MR			Intraventricular infusion of the neurotrophic protein S100B improves cognitive recovery after fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; NSE; rat; S100B protein; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; CORTICAL IMPACT INJURY; CEREBROSPINAL-FLUID; S-100 PROTEIN; NEURITE EXTENSION; GROWTH-FACTOR; SERUM-LEVELS; HEAD-INJURY; RELEASE	Elevated serum S100B levels have been shown to be a predictor of poor outcome after traumatic brain injury (TBI). Experimental data, on the other hand, demonstrate a neuroprotective and neurotrophic effect of this calcium-binding protein. The purpose of this study was to examine the role of increased S100B levels on functional outcome after TBI. Following lateral fluid percussion or sham injury in male Sprague Dawley rats (n = 56), we infused S100B (50 ng/h) or vehicle into the cerebrospinal fluid of the ipsilateral ventricle for 7 days using an osmotic mini-pump. Assessment of cognitive performance by the Morris water maze on days 30-34 after injury revealed an improved performance of injured animals after S100B infusion (P < 0.05), when compared to vehicle infusion. Blood samples for analysis of clinical markers of brain damage, S100B and neuron specific enolase, taken at 30 min, 3 h, 4 h, 2 days, or 5 days showed a typical peak 3 h after injury (P < 0.01), and higher serum levels correlated significantly with an impaired cognitive recovery (p < 0.01). The correlation of higher serum S100B levels with poor water maze performance may result from injury induced opening of the blood-brain barrier, allowing the passage of S100B into serum. Thus while higher serum levels of S100B seem to reflect the degree of blood-brain barrier opening and severity of injury, a beneficial effect of intraventricular S100B administration on long-term functional recovery after TBI has been demonstrated for the first time. The exact mechanism by which S100B exerts its neuroprotective or neurotrophic influence remains unknown and needs to be elucidated by further investigation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Humboldt Univ, Charite, Inst Lab Med & Pathobiochem, Berlin, Germany; Univ Greifswald, Dept Neurosurg, Greifswald, Germany		Kleindienst, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, 1101 E Marshall St,Box 980508, Richmond, VA 23298 USA.	akleindienst@vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587-26] Funding Source: Medline		Agelink MW, 2001, J NEUROL NEUROSUR PS, V71, P394, DOI 10.1136/jnnp.71.3.394; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DONATO R, 1976, J NEUROCHEM, V27, P439, DOI 10.1111/j.1471-4159.1976.tb12266.x; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, P86; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KRAGH J, 1993, BIOL PSYCHIAT, V33, P794, DOI 10.1016/0006-3223(93)90020-E; Li YK, 1998, J NEUROCHEM, V71, P1421; MATSUTANI T, 1985, NEUROCHEM RES, V10, P1155, DOI 10.1007/BF00965889; Peskind ER, 2001, NEUROCHEM INT, V39, P409, DOI 10.1016/S0197-0186(01)00048-1; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; RICKMANN M, 1995, BRAIN RES, V688, P8, DOI 10.1016/0006-8993(95)00495-C; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wilder PT, 1998, PROTEIN SCI, V7, P794, DOI 10.1002/pro.5560070330; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	39	44	47	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					541	547		10.1089/089771504774129874			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900005	15165362				2022-02-06	
J	Aitken, ME; Mele, N; Barrett, KW				Aitken, ME; Mele, N; Barrett, KW			Recovery of injured children: Parent perspectives on family needs	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the Pediatric-Academic-Society	MAY   05, 2003	Seattle, WA	Pediat Acad Soc		family; injuries; pediatrics; rehabilitation; support groups	TRAUMATIC BRAIN INJURY; PEDIATRIC TRAFFIC INJURY; STRESS-DISORDER; ADOLESCENTS; MORBIDITY; SUPPORT; QUALITY; LIFE	Objective: To study the broader impact of emotional and financial burdens of injury in children on their families, along with solutions to these problems. Design: Focus groups were conducted to reveal the needs of parents and children after injury. Audiotaped semistructured interviews were conducted by a team of qualitative researchers. Setting: Tertiary care children's hospital. Participants: Mothers of children who had sustained traumatic injury. Interventions: Not applicable. Main Outcome Measures: Summary of reported themes of experience and suggested interventions. Data were analyzed by using content analysis software. Results: Overall satisfaction with care was high. Parents expressed concerns with communication, access to care, and the transition both within the phases of medical care and from medical care into the community. Consistent financial and social stressors were voiced, along with the need for peer support during all phases of care. Conclusions: Parents provided valuable insight into their needs after their child's injury. Attention to constructive communication, clarification of the system of care, continued family-centered care, and development of peer support programs may meet the needs of caregivers and therefore facilitate improvement in pediatric injury recovery.	Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Pediat, Fayetteville, AR 72701 USA; Univ Memphis, Loewenberg Sch Nursing, Memphis, TN 38152 USA		Aitken, ME (corresponding author), Arkansas Childrens Hosp, Dept Pediat, 800 Marshall St,Slot 512-26, Little Rock, AR 72202 USA.	AitkenMaryE@uams.edu	Aitken, Mary/ABG-6119-2021	Aitken, Mary/0000-0002-8318-9755	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCH054003-01-0] Funding Source: Medline		Ainbinder JG, 1998, J PEDIATR PSYCHOL, V23, P99, DOI 10.1093/jpepsy/23.2.99; Aitken ME, 2002, PEDIATRICS, V110, P337, DOI 10.1542/peds.110.2.337; Aitken ME, 1999, ARCH PHYS MED REHAB, V80, P889, DOI 10.1016/S0003-9993(99)90079-5; Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Brooks BM, 2003, DISABIL REHABIL, V25, P51, DOI 10.1080/09638280210151987; Crabtree B. F., 1999, DOING QUALITATIVE RE; de Vries APJ, 1999, PEDIATRICS, V104, P1293, DOI 10.1542/peds.104.6.1293; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; JAFFE KM, 1992, PEDIATR ANN, V21, P438, DOI 10.3928/0090-4481-19920701-09; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Montgomery V, 2002, J TRAUMA, V52, P1121, DOI 10.1097/00005373-200206000-00016; Morgan DL., 1998, FOCUS GROUP KIT; Osberg JS, 1997, BRAIN INJURY, V11, P11; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Strauss A., 1990, BASICS QUALITATIVE R; Taylor S, 1995, CLIN PSYCHOL REV, V15, P721, DOI 10.1016/0272-7358(95)00043-7; WALAND P, 1988, J HEAD TRAUMA REHAB, V3, P51; WELLS N, 2000, WHAT DO FAMILIES SAY; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008; Winston FK, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e90; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393	25	44	44	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4					567	573		10.1016/j.apmr.2003.06.018			7	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	810MM	WOS:000220708400006	15083431				2022-02-06	
J	McNally, HA; Ben Borgens, R				McNally, HA; Ben Borgens, R			Three-dimensional imaging of living and dying neurons with atomic force microscopy	JOURNAL OF NEUROCYTOLOGY			English	Article							MAMMALIAN SPINAL-CORD; POLYETHYLENE-GLYCOL; GROWTH; REPAIR; MEMBRANES; RECOVERY; INJURY; CELLS	Atomic Force Microscopy (AFM) has been used to image the morphology of developing neurons and their processes. Additionally, AFM can physically interact with the cell under investigation in numerous ways. Here we use the AFM to both three-dimensionally image the neuron and to inflict a nano/micro-puncture to its membrane. Thus, the same instrument used as a tool to precisely penetrate/cut the membrane at the nanoscale level is employed to image the morphological responses to damage. These first high resolution AFM images of living chick dorsal root ganglion cells and cells of sympathetic ganglion and their growing processes provide confirmation of familiar morphologies. The increased resolution of the AFM revealed these structures to be significantly more complex and variable than anticipated. Moreover we describe novel, dynamic, and unreported architectures, particularly large dorsally projecting ridges, spines, and ribbons of cytoplasm that appear and disappear on the order of minutes. In addition, minute (ca. 100 nm) hair-like extensions of membrane along the walls of nerve processes that also shift in shape and density, appearing and disappearing over periods of minutes were seen. We also provide "real time'' images of the death of the neuron cell body after nano/micro scale damage to its membrane. These somas excreted their degraded cytoplasm, revealed as an enlarging pool beneath and around the cell. Conversely, identical injury, even repeated perforations and nanoslices, to the neurite's membrane do not lead to demise of the process. This experimental study not only provides unreported neurobiology and neurotrauma, but also emphasizes the unique versatility of AFM as an instrument that can ( 1) physically manipulate cells, ( 2) provide precise quantitative measurements of distance, surface area and volume at the nanoscale if required, ( 3) derive physiologically significant data such as membrane pressure and compliance, and ( 4) during the same period of study-provide unexcelled imaging of living samples.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Purdue Univ, Sch Engn, W Lafayette, IN 47907 USA		McNally, HA (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	mcnallyh@purdue.edu					BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; BORGENS RB, 2003, RESTORING FUNCTION I; Bray D, 1992, CELL MOVEMENTS; Colton RJ, 1997, CURR OPIN CHEM BIOL, V1, P370, DOI 10.1016/S1367-5931(97)80076-2; DeFelipe J., 1988, CAJAL CEREBRAL CORTE; DIMITROV DS, 1984, BIOCHIM BIOPHYS ACTA, V779, P437, DOI 10.1016/0304-4157(84)90020-0; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Engel A, 1999, TRENDS CELL BIOL, V9, P77, DOI 10.1016/S0962-8924(98)01415-9; HARRIS WA, 1986, NATURE, V320, P266, DOI 10.1038/320266a0; Jena BP, 1997, CELL BIOL INT, V21, P683, DOI 10.1006/cbir.1997.0212; LAL R, 1995, AM J PHYSIOL-CELL PH, V269, pC275, DOI 10.1152/ajpcell.1995.269.1.C275; Lee T, 2000, J NANOPART RES, V2, P345, DOI 10.1023/A:1010053303142; LEMMON V, 1992, J NEUROSCI, V12, P818; MEYER G, 1988, APPL PHYS LETT, V53, P2400, DOI 10.1063/1.100425; Morris V.J., 1999, ATOMIC FORCE MICROSC; Peasley MA, 2002, AM J PHYSIOL-CELL PH, V283, pC980, DOI 10.1152/ajpcell.00591.2001; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; Ricci D., 2004, GROWTH CONES LIVING, P125; SCHWISTER K, 1985, BIOCHIM BIOPHYS ACTA, V816, P332, DOI 10.1016/0005-2736(85)90501-2; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; SNYDER SR, 1992, ANAL CHEM, V64, pR116; Stoeckli ET, 1996, DEV BIOL, V177, P15, DOI 10.1006/dbio.1996.0141; Suter DM, 2000, J NEUROBIOL, V44, P97, DOI 10.1002/1097-4695(200008)44:2<97::AID-NEU2>3.0.CO;2-U; VALE RD, 1992, INTRO MOL NEUROBIOLO, P263; VENTIMIGLIA R, 1998, CULTURING NERVE CELL, P391	29	44	46	0	17	KLUWER ACADEMIC PUBL	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-4864			J NEUROCYTOL	J. Neurocytol.	MAR	2004	33	2					251	258		10.1023/B:NEUR.0000030700.48612.0b			8	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	827DO	WOS:000221879200008	15322383	Green Submitted			2022-02-06	
J	Macciocchi, SN; Bowman, B; Coker, J; Apple, D; Leslie, D				Macciocchi, SN; Bowman, B; Coker, J; Apple, D; Leslie, D			Effect of co-morbid traumatic brain injury on functional outcome of persons with spinal cord injuries	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						spinal cord injury; brain injury; functional outcomes; rehabilitation	CLOSED HEAD-INJURY; COGNITIVE DYSFUNCTION	Objective: This study was undertaken to determine if persons who sustain a spinal cord injury (SCI) and co-morbid brain injury (dual diagnosis [DDS]) evidence smaller functional gains and experience significantly longer rehabilitation lengths of stay than persons with only an SCI. Design: This retrospective comparison study was performed at a 100-bed rehabilitation hospital specializing in acute SCI and traumatic brain injury rehabilitation. Summary scale outcome data of persons who sustained an SCI were compared with outcome data of a group of persons with a DIDS. Comparisons were established by matching groups principally on level of SCI and admission Motor FIM(TM) score and secondarily on education, sex, and age. Outcome measures included admission Motor and Cognitive FIM score, discharge Motor and Cognitive FIM score, Motor and Cognitive FIM change, length of stay, and rehabilitation charges. Results: Persons with a DDS evidenced a significantly more impaired Cognitive FIM score at admission and discharge from rehabilitation. Persons with a DDS also achieved a significantly lower Motor FIM change than persons with SCI. There were no significant differences between DIDS and SCI groups regarding Cognitive FIM change, length of stay, or rehabilitation charges. Injury severity as defined by the Glasgow Coma Scale or intracranial lesions did not predict response to treatment in the DIDS group. Conclusion: Persons with a DIDS achieved smaller functional gains during rehabilitation than peers with SCI. Brain injuries seem to limit functional gains, although the relationship between brain injury severity and functional change is not linear. Prospective studies are needed to identify factors limiting functional gains in rehabilitation and assist in developing specific treatment programs for persons with SCI and brain injury.	Shepherd Ctr, Neuropsychol Div, Atlanta, GA 30309 USA; Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA		Macciocchi, SN (corresponding author), Shepherd Ctr, Neuropsychol Div, 2020 Peachtree Rd,NW, Atlanta, GA 30309 USA.						BLACK K, 1999, TOP SPINAL CORD INJ, V5, P47; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; PAGNI CA, 1991, ACTA NEUROCHIR, V111, P1, DOI 10.1007/BF01402506; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; *STAT U NEW YORK B, 1993, GUID UN DAT SET MED; Strubreither W, 1997, SPINAL CORD, V35, P487, DOI 10.1038/sj.sc.3100495; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0	16	44	46	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JAN	2004	83	1					22	26		10.1097/01.PHM.0000104661.86307.91			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	758FM	WOS:000187623100004	14709971				2022-02-06	
J	Bush, BA; Novack, TA; Malec, JF; Stringer, AY; Millis, SR; Madan, A				Bush, BA; Novack, TA; Malec, JF; Stringer, AY; Millis, SR; Madan, A			Validation of a model for evaluating outcome after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; outcome assessment (health care); rehabilitation; validation studies [publication type]	HEAD-INJURY; DISABILITY	Objective: To validate a model that examines the contribution of premorbid variables, injury severity, and functional and cognitive status to outcome 1 year after traumatic brain injury (TBI). Design: Cross-validation study using a larger, national, prospective, longitudinal sample. Setting: Acute inpatient rehabilitation hospitals at Traumatic Brain Injury Model Systems centers. Participants: Two sample populations followed through acute rehabilitation to 1 year after TBI. The original sample included 107 patients, and the cross-validation sample included 294 patients. Participants were predominately young men who had experienced moderate to severe TBI in motor vehicle crashes. Interventions: Acute medical and rehabilitation care. Main Outcome Measures: Disability Rating Scale, Community Integration Questionnaire, and return to employment. Results: Structural equation modeling was used to compare the fit of the data to a path analysis developed through clinical use and previous research. Both samples provided adequate goodness of fit, supporting the model's validity. Injury severity affected cognitive and functional status, and cognitive and functional status significantly influenced 1-year outcome. Premorbid factors and injury severity did not directly influence outcome. Conclusions: Both samples supported the proposed model, which was cross-validated. Injury severity indirectly influences outcome through its effects on cognitive and functional status. Although treatment to decrease injury severity is obviously important, concentrated rehabilitation interventions aimed at improving patients' cognitive and functional status may have a more significant impact on 1-year outcome and should be the focus of future research.	Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; Mayo Med Ctr, Dept Phys Med & Rehabil, Rochester, MN USA; Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA; Kessler Med Rehabil Res & Educ Corp, Res Dept, W Orange, NJ USA		Bush, BA (corresponding author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1530 3rd Ave S,CPM253, Birmingham, AL 35294 USA.	babush@uobmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 07420] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A 980010] Funding Source: Medline; ODCDC CDC HHS [R49/CCR 40364] Funding Source: Medline		BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bollen K.A., 1993, TESTING STRUCTURAL E, V154; BOLLEN KA, 1989, SOCIOL METHOD RES, V17, P303, DOI 10.1177/0049124189017003004; BOLLEN KA, 1986, PSYCHOMETRIKA, V51, P375, DOI 10.1007/BF02294061; Browne, 1993, TESTING STRUCTURAL E, DOI [10.1177/0049124192021002005, DOI 10.1177/0049124192021002005]; Byrne B. M., 1989, PRIMER LISREL BASIC; Carmines E.G., 1981, SOCIAL MEASUREMENT C, P65, DOI DOI 10.1207/S15327965PLI0404_1; Delis DC, 1987, CALIFORNIA VERBAL LE; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hamster K., 1983, MULTILINGUAL APHASIA; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 1981, MANAGEMENT HEAD INJU; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Lezak MD, 1976, NEUROPSYCHOLOGICAL A; Long J.S., 1983, CONFIRMATORY FACTOR; MARSH HW, 1988, PSYCHOL BULL, V103, P391, DOI 10.1037/0033-2909.103.3.391; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Wechsler, 1997, WECHSLER ADULT INTEL	22	44	44	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2003	84	12					1803	1807		10.1016/S0003-9993(03)00367-8			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	751JY	WOS:000187064400012	14669187				2022-02-06	
J	Queen, RM; Weinhold, PS; Kirkendall, DT; Yu, B				Queen, RM; Weinhold, PS; Kirkendall, DT; Yu, B			Theoretical study of the effect of ball properties on impact force in soccer heading	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						children; inflation pressure; ball size; mathematical modeling	TRAUMATIC BRAIN-INJURY; PLAYERS; CONCUSSION; PERFORMANCE; PROPORTIONS; STIFFNESS; FOOTBALL; MASS	Purpose: The objective of this study was to theoretically model, based on the Hertz contact theory, the impact force and contact time, as well as the linear and angular head accelerations during heading in children using two neck stiffness conditions (infinite and negligible stiffness). Methods: The following mathematical model inputs were obtained: elastic modulus and mass of size three, four, and five balls at inflation pressures of 10, 12, and 14 psi, head modulus, head mass, head length, head and trunk moment of inertia, and the precontact ball velocity. The model outputs consisted of linear and angular head acceleration, impact force, contact time between the ball and head, and head impact criteria (HIC) all at the point of impact. Head mass and length were obtained as a percentage of body weight and height, respectively, based on age, Results: With an increase in head mass, there is a decrease in the linear and angular head acceleration. With an increase in ball size, for the same head mass, there is an increase in the contact time between the head and the ball. Changing ball inflation pressure has little effect on the impact characteristics. Infinite neck stiffness decreased linear and angular head acceleration and HIC. Conclusion: Head mass and ball size have an effect on linear and angular head acceleration and contact time, respectively, whereas ball inflation pressure has a minimal effect on the impact characteristics. These results indicate that children should be restricted to using the appropriate ball for their age. Smaller head size within an age group is an underemphasized though important identifier of a player's injury risk.	Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Human Movement Sci, Div Phys Therapy, Chapel Hill, NC 27599 USA		Queen, RM (corresponding author), Univ N Carolina, Dept Biomed Engn, CB 7575,152 Macnider Bldg, Chapel Hill, NC 27599 USA.			Weinhold, Paul/0000-0002-7307-3580			ARMSTRONG CW, 1987, SCI FOOTBALL, P394; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; CHOU S, 1974, 740082 SAE, P197; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Crisco JJ, 1997, MED SCI SPORT EXER, V29, P26, DOI 10.1097/00005768-199701000-00005; Ekblom B., 1994, FOOTBALL; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GRESZCZUK LB, 1992, IMPACT DYNAMICS, P55; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; JENSEN RK, 1989, J BIOMECH, V22, P529, DOI 10.1016/0021-9290(89)90004-3; JENSEN RK, 1986, J BIOMECH, V19, P359, DOI 10.1016/0021-9290(86)90012-6; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; KHALIL TB, 1993, BIOMECHANICS IMPACT, P1107; LEVENDUSKY TA, 1987, SCI FOOTBALL, P385; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATSER JT, 1999, JAMA-J AM MED ASSOC, V28, P971; MCNAIR PJ, 1992, CLIN BIOMECH, V7, P131, DOI 10.1016/0268-0033(92)90027-2; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; PHEASANT S, 2001, BODYSPACE, P174; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; TIMOSHENKO S, 1951, THEORY ELASTICITY, P372; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; WILSON GJ, 1991, INT J SPORTS MED, V12, P403, DOI 10.1055/s-2007-1024702	27	44	45	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2003	35	12					2069	2076		10.1249/01.MSS.0000099081.20125.A5			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	753QJ	WOS:000187241800018	14652504				2022-02-06	
J	Kay, AD; Day, SP; Kerr, M; Nicoll, JAR; Packard, CJ; Caslake, MJ				Kay, AD; Day, SP; Kerr, M; Nicoll, JAR; Packard, CJ; Caslake, MJ			Remodeling of cerebrospinal fluid lipoprotein particles after human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						APOE epsilon 4; cerebrospinal fluid; cholesterol; traumatic brain injury	APOLIPOPROTEIN-E POLYMORPHISM; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; HEAD-INJURY; E GENOTYPE; CEREBRAL-ISCHEMIA; HUMAN HIPPOCAMPUS; NEURONAL DAMAGE; GLOBAL-ISCHEMIA; ANIMAL-MODELS	The association between possession of the APOE epsilon4 allele and unfavourable outcome after traumatic brain injury (TBI) suggests that the apolipoprotein E protein (apoE) plays a key role in the response of the human brain to injury. ApoE is known to regulate cholesterol metabolism in the periphery through its action as a ligand for receptor mediated uptake of lipoprotein particles (Lps). Greater understanding of cholesterol metabolism in the human central nervous system may identify novel treatment strategies applicable to acute brain injury. We report findings from the analysis of lipoproteins in the cerebrospinal fluid (CSF) of patients with TBI and non-injured controls, testing the hypothesis that remodeling of CSF lipoproteins reflects the response of the brain to TBI. CSF Lps were isolated from the CSF of controls and patients with severe TBI by size exclusion chromatography, and the lipoprotein fractions analysed for cholesterol, phospholipid, apoAI, and apoE. There was a marked decrease in apoE containing Lps in the TBI CSF compared to controls (P = 0.002). After TBI there was no significant decrease in apoI containing CSF Lps (CSF LpAI), but the apoAI resided on smaller sized particles than in control CSF. There was a population of very small sized Lps in TBI CSF, which were associated with the increased cholesterol (P = 0.0001) and phospholipid (p = 0.040) seen after TBI. The dramatic loss of apoE containing Lps from the CSF, and the substantial increase in CSF cholesterol, support the concept that apoE and cholesterol metabolism are intimately linked in the context of acute brain injury. Treatment strategies targeting CNS lipid transport, required for neuronal sprouting and synaptogenesis, may be applicable to traumatic brain injury.	Univ Glasgow, Dept Neurosurg, Inst Neurol Sci, So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland; Univ Glasgow, Dept Pathol Biochem, Glasgow, Lanark, Scotland; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Nursing Res, Pittsburgh, PA 15260 USA; Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton SO9 5NH, Hants, England		Kay, AD (corresponding author), Univ Glasgow, Dept Neurosurg, Inst Neurol Sci, So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland.		Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246; Day, Stephen/0000-0003-4923-9373			Baskin F, 1997, J NEUROL SCI, V148, P15, DOI 10.1016/S0022-510X(96)05335-X; Carlin C, 2000, J NEUROPATH EXP NEUR, V59, P361, DOI 10.1093/jnen/59.5.361; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; Demeester N, 2000, J LIPID RES, V41, P963; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fagan AM, 2000, ANN NEUROL, V48, P201, DOI 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.3.CO;2-O; Guyton JR, 1998, J NEUROCHEM, V70, P1235; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Jurevics HA, 1997, J LIPID RES, V38, P723; Koch S, 2001, J LIPID RES, V42, P1143; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; McColl BW, 2003, AM J PATHOL, V162, P273, DOI 10.1016/S0002-9440(10)63818-7; Montine KS, 1998, J LIPID RES, V39, P2443; Montine TJ, 1997, AM J PATHOL, V151, P1571; Nicoll JAR, 2001, NEUROREPORT, V12, P695, DOI 10.1097/00001756-200103260-00016; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Rebeck GW, 1998, EXP NEUROL, V149, P175, DOI 10.1006/exnr.1997.6710; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Starck M, 2000, CELL BIOCHEM FUNCT, V18, P9, DOI 10.1002/(SICI)1099-0844(200001/03)18:1<9::AID-CBF841>3.0.CO;2-X; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655	38	44	44	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2003	20	8					717	723		10.1089/089771503767869953			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	712BU	WOS:000184777000003	12965051				2022-02-06	
J	Van Damme, P; Callewaert, G; Eggermont, J; Robberecht, W; Van Den Bosch, L				Van Damme, P; Callewaert, G; Eggermont, J; Robberecht, W; Van Den Bosch, L			Chloride influx aggravates Ca2+-dependent AMPA receptor-mediated motoneuron death	JOURNAL OF NEUROSCIENCE			English	Article						AMPA receptor; calcium; motoneuron; chloride; excitotoxicity; amyotrophic lateral sclerosis	RAT SPINAL-CORD; AMINO-ACID NEUROTRANSMITTERS; ARTERY ENDOTHELIAL-CELLS; PATCH-CLAMP TECHNIQUE; MOTOR-NEURON DEATH; CEREBRAL-ISCHEMIA; SELECTIVE VULNERABILITY; INTRACELLULAR CHLORIDE; CL; EXCITOTOXICITY	AMPA receptor-mediated excitotoxicity has been implicated in the pathogenesis of stroke, neurotrauma, epilepsy, and many neurodegenerative diseases such as motoneuron disease. We studied the role of Cl- in AMPA receptor-mediated Ca2+-dependent excitotoxicity in cultured rat spinal motoneurons. Using the gramicidin perforated patch-clamp technique, the intracellular Cl- concentration could be calculated from the reversal potential of the GABA-induced current. The membrane depolarization caused by AMPA receptor stimulation resulted in Cl- influx through 5-nitro-2(3-phenylpropyl-amino) benzoic acid- and niflumic acid-sensitive Cl- channels. Cl- influx during AMPA receptor stimulation aggravated excitotoxic motoneuron death by two mechanisms: an increase of AMPA receptor conductance and an elevation of the Ca2+ driving force through a partial repolarization. The Cl- influx during AMPA receptor stimulation was enhanced by coadministration of GABA. This resulted in an increased Ca2+ influx and an enhanced cell death, suggesting that concomitant GABAergic stimulation may aggravate excitotoxic motoneuron death.	Catholic Univ Louvain, Dept Neurobiol, B-3000 Louvain, Belgium; Catholic Univ Louvain, Dept Physiol, B-3000 Louvain, Belgium		Robberecht, W (corresponding author), Dept Neurol, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Van Damme, Philip/A-6464-2009; Van Den Bosch, Ludo/B-7258-2012	Van Damme, Philip/0000-0002-4010-2357; Van Den Bosch, Ludo/0000-0003-0104-4067; Eggermont, Jan/0000-0002-8497-1159			ABE Y, 1994, J NEUROPHYSIOL, V72, P1530, DOI 10.1152/jn.1994.72.4.1530; AKAIKE N, 1994, JPN J PHYSIOL, V44, pS113; Al-Noori S, 2000, NEUROSCIENCE, V101, P337, DOI 10.1016/S0306-4522(00)00384-5; BOSLEY TM, 1983, J NEUROCHEM, V40, P189, DOI 10.1111/j.1471-4159.1983.tb12670.x; Canton T, 2001, J PHARMACOL EXP THER, V299, P314; CARLTON SM, 1990, J COMP NEUROL, V300, P162, DOI 10.1002/cne.903000203; Carriedo SG, 1996, J NEUROSCI, V16, P4069; CHOI DW, 1987, J NEUROSCI, V7, P369; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Ehrlich I, 1999, J PHYSIOL-LONDON, V520, P121, DOI 10.1111/j.1469-7793.1999.00121.x; Farooque M, 1999, ACTA NEUROPATHOL, V98, P22, DOI 10.1007/s004010051047; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; GRAHAM SH, 1990, NEUROSCI LETT, V110, P124, DOI 10.1016/0304-3940(90)90799-F; Gulyas AI, 2001, EUR J NEUROSCI, V13, P2205, DOI 10.1046/j.0953-816x.2001.01600.x; Hasbani MJ, 2001, J NEUROSCI, V21, P2393, DOI 10.1523/JNEUROSCI.21-07-02393.2001; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P3597; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; Inglefield JR, 1998, J NEUROCHEM, V71, P1396; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kakazu Y, 1999, J NEUROSCI, V19, P2843; KYROZIS A, 1995, J NEUROSCI METH, V57, P27, DOI 10.1016/0165-0270(94)00116-X; LANIUS RA, 1993, MOL BRAIN RES, V20, P192, DOI 10.1016/0169-328X(93)90041-M; Lapchak PA, 2000, STROKE, V31, P1953, DOI 10.1161/01.STR.31.8.1953; LERMA J, 1992, MOL PHARMACOL, V41, P217; Li YX, 1998, J PHYSIOL-LONDON, V509, P847, DOI 10.1111/j.1469-7793.1998.847bm.x; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MADDEN KP, 1994, STROKE, V25, P2271, DOI 10.1161/01.STR.25.11.2271; MAGOUL R, 1987, NEUROSCIENCE, V20, P1001, DOI 10.1016/0306-4522(87)90258-2; MRSULJA BB, 1978, J NEURAL TRANSM    S, V14, P23; Muimo R, 1998, AM J RESP CELL MOL, V18, P270, DOI 10.1165/ajrcmb.18.2.2850; Nilius B, 1997, J PHYSIOL-LONDON, V498, P381, DOI 10.1113/jphysiol.1997.sp021865; OWEN DG, 1986, J NEUROPHYSIOL, V55, P1115, DOI 10.1152/jn.1986.55.6.1115; OWEN DG, 1984, NATURE, V311, P567, DOI 10.1038/311567a0; PLAITAKIS A, 1991, ADV NEUROL, V56, P319; PRICE DL, 1976, J CELL BIOL, V68, P389, DOI 10.1083/jcb.68.2.389; RHEE JS, 1994, J NEUROPHYSIOL, V72, P1103, DOI 10.1152/jn.1994.72.3.1103; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; Schwartz-Bloom RD, 2001, J NEUROCHEM, V77, P353, DOI 10.1046/j.1471-4159.2001.00274.x; Singer JH, 1998, J NEUROPHYSIOL, V80, P2608, DOI 10.1152/jn.1998.80.5.2608; TERHARNE KJ, 1994, AM J PHYSIOL, V267, pL592; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Van Damme P, 2003, NEUROSCI LETT, V343, P81, DOI 10.1016/S0304-3940(03)00314-8; Van Damme P, 2002, J NEUROPHYSIOL, V88, P1279, DOI 10.1152/jn.2002.88.3.1279; Van Damme P, 2002, J NEUROPHYSIOL, V88, P965, DOI 10.1152/jn.2002.88.2.965; Van Den Bosch L, 2000, J NEUROL SCI, V180, P29, DOI 10.1016/S0022-510X(00)00414-7; Van den Bosch L, 2000, BRAIN RES BULL, V53, P383, DOI 10.1016/S0361-9230(00)00371-3; Van den Bosch L, 2002, NEUROPHARMACOLOGY, V42, P706, DOI 10.1016/S0028-3908(02)00010-2; Vandenberghe W, 1998, BRAIN RES, V807, P1, DOI 10.1016/S0006-8993(98)00569-1; Voets T, 1996, J PHYSIOL-LONDON, V497, P95, DOI 10.1113/jphysiol.1996.sp021752; Yamada KA, 1998, NEUROBIOL DIS, V5, P67, DOI 10.1006/nbdi.1998.0190; ZORUMSKI CF, 1990, NEURON, V5, P61, DOI 10.1016/0896-6273(90)90033-C	55	44	44	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 15	2003	23	12					4942	4950					9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	696MY	WOS:000183891700019	12832516				2022-02-06	
J	Langeluddecke, PM; Lucas, SK				Langeluddecke, PM; Lucas, SK			Quantitative measures of memory malingering on the Wechsler Memory Scale - Third edition in mild head injury litigants	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingered neurocognitive dysfunction; traumatic brain injury; neuropsychological assessment	PERFORMANCE; INCENTIVES; DEFICITS; SUBTEST	Wechsler Memory Scale-Third edition (WMS-III) performance in 25 mild traumatic brain injury (TBI) litigants who met the criteria for probable malingered neurocognitive dysfunction (MND) was compared with 50 nonmalingering subjects. The base rate for probable MND in the population studied was 27%. Overall, malingerers showed globally depressed memory function. They returned significantly poorer scores than nonmalingerers on all WMS-III indexes and subtests, and on selected WMS-III index difference scores and intelligence-memory difference scores. Using the minimum score returned in the nonmalingerers as the cut-off for malingering, the delayed auditory recognition memory tasks were highly effective in detecting malingering. Raw scores below 43 on the auditory recognition-delayed (AR-D) subtest or below 18 on word list II-recognition, identified around 80% of the malingerers. In a group of 50 severe TBI litigants, only a very small proportion (i.e., <10%) returned scores below the cut-offs for malingering for the mild TBI subjects. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	Westmead Hosp, Dept Med Psychol, Westmead, NSW 2145, Australia		Langeluddecke, PM (corresponding author), Suite 1003,37 Bligh St, Sydney, NSW 2000, Australia.	langeluddecke@bigpond.com					ALLEN LM, 1999, CARB 97 COMPUTERIZED; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; BERNARD LC, 1993, ARCH CLIN NEUROPSYCH, V8, P539, DOI 10.1016/0887-6177(93)90054-5; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Gouvier WD, 1998, CRIT ISS NE, P55; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Haines ME, 1995, NEUROPSYCHOL REV, V5, P125, DOI 10.1007/BF02208438; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Killgore WDS, 2000, PSYCHOL REP, V86, P851, DOI 10.2466/PR0.86.3.851-857; Lee G. P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI DOI 10.1037/1040-3590.4.1.43; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; Millis SR, 1996, NEUROREHABILITATION, V7, P55, DOI 10.3233/NRE-1996-7106; NELSON HD, 1991, REVISED NAWTL ADULT; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Reitan RM, 1998, CRIT ISS NE, P163; Rey A., 1964, EXAMEN CLIN PSYCHOL, P121; Reynolds CR, 1998, CRIT ISS NE, P261; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; Schwartz SM, 1998, INT J LAW PSYCHIAT, V21, P261, DOI 10.1016/S0160-2527(98)00004-1; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Suchy Y, 2000, CLIN NEUROPSYCHOL, V14, P56, DOI 10.1076/1385-4046(200002)14:1;1-8;FT056; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Williams JM, 1998, CRIT ISS NE, P105; Wynkoop T.F., 2001, J FORENSIC NEUROPSYC, V2, P71; [No title captured]	44	44	45	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2003	18	2					181	197	PII S0887-6177(01)00195-0	10.1016/S0887-6177(01)00195-0			17	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	648LC	WOS:000181152000008	14591470	Bronze			2022-02-06	
J	Hilton, GD; Nunez, JL; McCarthy, MM				Hilton, GD; Nunez, JL; McCarthy, MM			Sex differences in response to kainic acid and estradiol in the hippocampus of newborn rats	NEUROSCIENCE			English	Article						excitotoxicity; developmental; sex differentiation; estradiol	DENDRITIC SPINE DENSITY; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; METHYL-D-ASPARTATE; ADULT FEMALE RATS; NEUROTROPHIC FACTOR; BINDING-SITES; KAINATE RECEPTORS; PYRAMIDAL CELLS; GLUTAMATE NEUROTOXICITY	Premature and full-term human infants are at considerable risk of excitotoxic-mediated brain damage due to hypoxia-ischemia, infection or other trauma. Glutamate receptor activation is a major source of excitoxicity in the adult and developing brain, and the hippocampus is particularly vulnerable to damage. The seven-day-old rat is a widely used model of pediatric brain damage, in large part due to the relative insensitivity of the brain to exogenous glutamate treatment prior to this age. We have reexamined the possible role of glutamate in pediatric brain damage in the newborn rat using kainic acid treatment and attending to the sex of the animal as well as the effects of pretreatment with the gonadal steroid estradiol. Consistent with previous studies, we found no evidence of damage 7 days posttreatment in the CA1 region of the hippocampus in males or females. There was also little to no damage in the CA2/3 or dentate gyrus of males. In females, however, kainic-acid treatment induced substantial damage in the dentate gyrus and moderate damage in CA2/3, as assessed by neuron number and regional volume. Pretreatment with estradiol was protective against kainic acid-induced damage in females but was permissive for damage in the dentate gyrus of males. Estradiol treatment in the absence of kainic acid treatment was also neuroprotective in females in that it increased neuron number and volume throughout the hippocampal formation, suggesting that the basis of the sex difference observed in hippocampal volume was hormonally mediated. There was no effect of exogenous estradiol given to males in the absence of kainic acid. We conclude that the newborn female rat brain, but not the male, is sensitive to glutamate-mediated toxicity and that gonadal steroids play a complex role in both naturally occurring sex differences in hippocampal volume and response to injury. (C) 2003 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA		Hilton, GD (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.		McCarthy, Margaret/O-2059-2017	McCarthy, Margaret/0000-0003-2243-4726			ADAMS JA, 1997, PEDIATR RES, V41, P563; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Azcoitia I, 1998, NEUROREPORT, V9, P3075, DOI 10.1097/00001756-199809140-00029; Azcoitia I, 1999, J NEUROCYTOL, V28, P699, DOI 10.1023/A:1007025219044; BAHN S, 1994, J NEUROSCI, V14, P5525; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; BENARI Y, 1984, DEV BRAIN RES, V14, P284, DOI 10.1016/0165-3806(84)90314-6; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Brake WG, 2001, ENDOCRINOLOGY, V142, P1284, DOI 10.1210/en.142.3.1284; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; CAMPOCHIARO P, 1978, P NATL ACAD SCI USA, V75, P2025, DOI 10.1073/pnas.75.4.2025; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; COOK TM, 1986, NEUROSCIENCE, V18, P79, DOI 10.1016/0306-4522(86)90180-6; Cossart R, 1998, NAT NEUROSCI, V1, P470, DOI 10.1038/2185; Dammann O, 1997, PEDIATR RES, V42, P1, DOI 10.1203/00006450-199707000-00001; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davis EC, 1996, BRAIN RES, V734, P10, DOI 10.1016/0006-8993(96)00298-3; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; Edwards AD, 1997, PEDIATR RES, V42, P684, DOI 10.1203/00006450-199711000-00022; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FERKANY JW, 1983, J PHARMACOL EXP THER, V225, P399; Foy MR, 1999, J NEUROPHYSIOL, V81, P925, DOI 10.1152/jn.1999.81.2.925; Frerking M, 1998, NAT NEUROSCI, V1, P479, DOI 10.1038/2194; Ganguly K, 2001, CELL, V105, P521, DOI 10.1016/S0092-8674(01)00341-5; GARCIALADONA FJ, 1993, NEUROSCI LETT, V151, P209, DOI 10.1016/0304-3940(93)90022-D; GERALL AA, 1992, HDB BEHAV NEUROBIOLO; GHO M, 1986, BRAIN RES, V385, P411, DOI 10.1016/0006-8993(86)91093-0; GOULD E, 1990, J NEUROSCI, V10, P1286; Gratacos E, 2001, J NEUROCHEM, V78, P1287, DOI 10.1046/j.1471-4159.2001.00538.x; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Gu Q, 1996, J NEUROSCI, V16, P3620; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Harukuni I, 2001, BRAIN RES, V900, P137, DOI 10.1016/S0006-8993(01)02278-8; He Z, 2002, J NEUROL SCI, V193, P79, DOI 10.1016/S0022-510X(01)00648-7; Ivanova T, 2001, J NEUROSCI RES, V66, P221, DOI 10.1002/jnr.1214; Katoh-Semba R, 1999, NEUROSCI RES, V35, P19, DOI 10.1016/S0168-0102(99)00059-0; Klau M, 2001, J NEUROSCI RES, V66, P327, DOI 10.1002/jnr.10007; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Lauterbach MD, 2001, NEUROPSYCHOLOGY, V15, P411, DOI 10.1037/0894-4105.15.3.411; Liu Z, 1996, DEV BRAIN RES, V97, P178, DOI 10.1016/S0165-3806(96)00141-1; Matsumoto A, 2000, SEXUAL DIFFERENTIATION OF THE BRAIN, P203; Mattson MP, 1997, NEUROREPORT, V8, P3817, DOI 10.1097/00001756-199712010-00031; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; McGeer E G, 1981, Int Rev Neurobiol, V22, P173, DOI 10.1016/S0074-7742(08)60293-7; MILLER LP, 1990, NEUROSCIENCE, V35, P45, DOI 10.1016/0306-4522(90)90118-N; MILNER TA, 1982, BRAIN RES, V243, P180, DOI 10.1016/0006-8993(82)91136-2; Mong JA, 1999, J NEUROBIOL, V40, P602, DOI 10.1002/(SICI)1097-4695(19990915)40:4<602::AID-NEU14>3.0.CO;2-O; Moss RL, 1999, STEROIDS, V64, P14, DOI 10.1016/S0039-128X(98)00092-0; NUNEZ JL, 2001, SOC NEUR ABS, V27; OKEEFE JA, 1990, DEV BRAIN RES, V57, P119, DOI 10.1016/0165-3806(90)90191-Z; PAXINOS J, 1986, RAT BRAIN STEREOTAXI; Petersen A, 2001, BRAIN RES BULL, V56, P331, DOI 10.1016/S0361-9230(01)00580-9; RHODA J, 1984, ENDOCRINOLOGY, V114, P1754, DOI 10.1210/endo-114-5-1754; RodriguezMoreno A, 1997, NEURON, V19, P893, DOI 10.1016/S0896-6273(00)80970-8; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sampei K, 2000, STROKE, V31, P738, DOI 10.1161/01.STR.31.3.738; Schmitz D, 2001, P NATL ACAD SCI USA, V98, P11003, DOI 10.1073/pnas.191351498; Shughrue PJ, 2000, NEUROSCIENCE, V99, P605, DOI 10.1016/S0306-4522(00)00242-6; Sie LTL, 2000, NEUROPEDIATRICS, V31, P128, DOI 10.1055/s-2000-7496; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Singh M, 1999, J NEUROSCI, V19, P1179; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Solum DT, 2002, J NEUROSCI, V22, P2650, DOI 10.1523/JNEUROSCI.22-07-02650.2002; Solum DT, 2001, DEV BRAIN RES, V128, P165, DOI 10.1016/S0165-3806(01)00171-7; SPERK G, 1985, BRAIN RES, V338, P289, DOI 10.1016/0006-8993(85)90159-3; Tandon P, 1999, NEUROSCIENCE, V91, P293, DOI 10.1016/S0306-4522(98)00609-5; ToranAllerand CD, 1996, J STEROID BIOCHEM, V56, P169, DOI 10.1016/0960-0760(95)00234-0; VANNUCCI RC, 1990, PEDIATR RES, V27, P317, DOI 10.1203/00006450-199004000-00001; Veliskova J, 2000, EPILEPSIA, V41, pS30, DOI 10.1111/j.1528-1157.2000.tb01553.x; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; WEILAND NG, 1992, ENDOCRINOLOGY, V131, P662, DOI 10.1210/en.131.2.662; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; WOLF G, 1984, DEV BRAIN RES, V14, P15, DOI 10.1016/0165-3806(84)90004-X; WONG M, 1992, J NEUROSCI, V12, P3217, DOI 10.1523/JNEUROSCI.12-08-03217.1992; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; Woolley CS, 1996, J COMP NEUROL, V373, P108; Woolley CS, 2000, EPILEPSIA, V41, P510, DOI 10.1111/j.1528-1157.2000.tb00203.x; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yang SH, 2002, J APPL PHYSIOL, V92, P195, DOI 10.1152/jappl.2002.92.1.195; Zaidi AU, 2001, J NEUROSCI, V21, P169, DOI 10.1523/JNEUROSCI.21-01-00169.2001	89	44	46	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2003	116	2					383	391		10.1016/S0306-4522(02)00716-9			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	643MJ	WOS:000180864800008	12559094				2022-02-06	
J	Litvan, I				Litvan, I			Update on epidemiological aspects of progressive supranuclear palsy	MOVEMENT DISORDERS			English	Article; Proceedings Paper	Workshop on Parkinsonism and Dementia	MAY 09-11, 2002	ISTANBUL, TURKEY	Movement Disorder Soc, European Sect		parkinsonism; tau; genetic factors; epidemiology	RICHARDSON-OLSZEWSKI-SYNDROME; MULTIPLE SYSTEM ATROPHY; NINDS NEUROPATHOLOGIC CRITERIA; PARKINSONISM-DEMENTIA COMPLEX; ALZHEIMERS-DISEASE; CORTICOBASAL DEGENERATION; NATURAL-HISTORY; FRONTOTEMPORAL DEMENTIA; ENDOGENOUS AMINE; RISK-FACTORS	The cause of progressive supranuclear palsy (PSP), the most common form of the atypical parkinsonian disorders, is unknown. PSP is characterized by four-repeat tau aggregates in neurons (neurofibrillary tangles) and glia in specific basal ganglia and brainstem areas. A thorough literature review led us to hypothesize that genetic and/or environmental factors contribute to its development. It is likely that inheritance of the H1/H1 tau genotype represents a predisposition to develop PSP requiring other environmental or genetic factors. Less likely, a relatively rare mutation with low penetrance could contribute to the abnormal tau aggregation present in this disorder. The possible role of chemicals in the diet or occupation, hypertension, traumatic brain injury, coffee, and inflammation or oxidative injury are reviewed. (C) 2003 Movement Disorder Society.	Univ Louisville, Sch Med, Dept Neurol, Movement Disorder Program, Louisville, KY 40202 USA		Litvan, I (corresponding author), Univ Louisville, Sch Med, Dept Neurol, Movement Disorder Program, A Bldg,Room 113,500 S Preston, Louisville, KY 40202 USA.	i.litvan@louisville.edu	Litvan, Irene/X-9319-2018	Litvan, Irene/0000-0002-3485-3445			Baker M, 1999, HUM MOL GENET, V8, P711, DOI 10.1093/hmg/8.4.711; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bhatt M, 2000, MOVEMENT DISORD, V15, P313, DOI 10.1002/1531-8257(200003)15:2<313::AID-MDS1017>3.0.CO;2-P; Bird TD, 1999, BRAIN, V122, P741, DOI 10.1093/brain/122.4.741; Boeve BF, 2003, ANN NEUROL, V54, pS15, DOI 10.1002/ana.10570; Bower JH, 1999, NEUROLOGY, V52, P1214, DOI 10.1212/WNL.52.6.1214; Bower JH, 1997, NEUROLOGY, V49, P1284, DOI 10.1212/WNL.49.5.1284; Bugiani O, 1999, J NEUROPATH EXP NEUR, V58, P667, DOI 10.1097/00005072-199906000-00011; Caparros-Lefebvre D, 1999, LANCET, V354, P281, DOI 10.1016/S0140-6736(98)10166-6; Caparros-Lefebvre D., 2001, MOVEMENT DISORD, V16, P394; Chambers CB, 1999, ANN NEUROL, V46, P325, DOI 10.1002/1531-8249(199909)46:3<325::AID-ANA8>3.0.CO;2-V; COBUZZI RJ, 1994, J NEUROCHEM, V62, P1503; COLLINS MA, 1992, ANN NY ACAD SCI, V648, P263, DOI 10.1111/j.1749-6632.1992.tb24551.x; COLLINS SJ, 1995, J NEUROL NEUROSUR PS, V58, P167, DOI 10.1136/jnnp.58.2.167; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; DAVIS PH, 1988, NEUROLOGY, V38, P1546, DOI 10.1212/WNL.38.10.1546; Di Maria E, 2000, ANN NEUROL, V47, P374, DOI 10.1002/1531-8249(200003)47:3<374::AID-ANA15>3.3.CO;2-#; Diamond M. C., 1988, ENRICHING HEREDITY I; Dickson DW, 2002, J NEUROPATH EXP NEUR, V61, P935, DOI 10.1093/jnen/61.11.935; Dickson DW, 1999, J NEUROL, V246, P6; Drache B, 1997, J NEUROSCI RES, V47, P98; DRUCKER G, 1990, BRAIN RES, V509, P125, DOI 10.1016/0006-8993(90)90318-6; DUBINSKY RM, 1987, NEUROLOGY, V37, P570, DOI 10.1212/WNL.37.4.570; Fabbrini G, 1998, ARCH NEUROL-CHICAGO, V55, P1153, DOI 10.1001/archneur.55.8.1153; Friedrich MR, 1999, JAMA-J AM MED ASSOC, V282, P2200, DOI 10.1001/jama.282.23.2200; GEARING M, 1994, NEUROLOGY, V44, P1015, DOI 10.1212/WNL.44.6.1015; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gerhard A, 2001, NEUROLOGY, V56, pA270; Ghika J, 1997, ARCH NEUROL-CHICAGO, V54, P1104, DOI 10.1001/archneur.1997.00550210038010; GOETZ CG, 1992, NEUROL CLIN, V10, P907, DOI 10.1016/S0733-8619(18)30187-7; Golbe LI, 1996, NEUROLOGY, V47, P148, DOI 10.1212/WNL.47.1.148; Golbe LI, 2000, LANCET, V356, P870, DOI 10.1016/S0140-6736(00)02672-6; GOLBE LI, 1988, NEUROLOGY, V38, P1031, DOI 10.1212/WNL.38.7.1031; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hallett M, 2000, MOVEMENT DISORD, V15, P436, DOI 10.1002/1531-8257(200005)15:3<436::AID-MDS1003>3.0.CO;2-L; Halliday G, 2000, CLIN EXP PHARMACOL P, V27, P1, DOI 10.1046/j.1440-1681.2000.03200.x; Halliday GM, 2000, ARCH NEUROL-CHICAGO, V57, P831, DOI 10.1001/archneur.57.6.831; HAUW JJ, 1994, NEUROLOGY, V44, P2015, DOI 10.1212/WNL.44.11.2015; Houlden H, 2001, NEUROLOGY, V56, P1702, DOI 10.1212/WNL.56.12.1702; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Iijima M, 1999, NEUROREPORT, V10, P497, DOI 10.1097/00001756-199902250-00010; Ishizawa K, 2001, J NEUROPATH EXP NEUR, V60, P647, DOI 10.1093/jnen/60.6.647; Kawai H, 1998, J NEUROCHEM, V70, P745; Kawas CH, 1999, ALZ DIS ASSOC DIS, V13, P124, DOI 10.1097/00002093-199907000-00002; KIKUCHI K, 1991, DRUG METAB DISPOS, V19, P257; KOTAKE Y, 1995, J NEUROCHEM, V65, P2633; Kotake Y, 1996, NEUROSCI LETT, V217, P69; Kuhn W, 1996, J NEURAL TRANSM, V103, P1435, DOI 10.1007/BF01271257; Lannuzel A., 2000, MOV DISORD S3, V13, P28; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Letenneur L, 2000, AM J EPIDEMIOL, V151, P1064, DOI 10.1093/oxfordjournals.aje.a010149; LI G, 1992, NEUROLOGY, V42, P1481, DOI 10.1212/WNL.42.8.1481; Lippa CF, 1995, NEURODEGENERATION, V4, P425, DOI 10.1006/neur.1995.0051; Lippa CF, 1998, NEUROBIOL AGING, V19, P527, DOI 10.1016/S0197-4580(98)00089-X; Litvan I, 1997, NEUROLOGY, V48, P119, DOI 10.1212/WNL.48.1.119; Litvan I, 1996, J NEUROL NEUROSUR PS, V60, P615, DOI 10.1136/jnnp.60.6.615; Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010; Litvan I, 1996, NEUROLOGY, V47, P1, DOI 10.1212/WNL.47.1.1; Litvan I, 1996, NEUROLOGY, V46, P922, DOI 10.1212/WNL.46.4.922; Litvan I, 2001, SEMIN NEUROL, V21, P41, DOI 10.1055/s-2001-13118; Litvan I, 2001, NEUROLOGY, V57, P138, DOI 10.1212/WNL.57.1.138; Lopez OL, 1999, NEUROLOGY, V53, P1292, DOI 10.1212/WNL.53.6.1292; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Mackenzie IRA, 2000, NEUROLOGY, V54, P732, DOI 10.1212/WNL.54.3.732; MAHER ER, 1986, NEUROLOGY, V36, P1005, DOI 10.1212/WNL.36.7.1005; MAKINO Y, 1990, J NEUROCHEM, V55, P963, DOI 10.1111/j.1471-4159.1990.tb04585.x; MAKINO Y, 1988, LIFE SCI, V43, P373, DOI 10.1016/0024-3205(88)90115-4; MASTAGLIA F L, 1973, Proceedings of the Australian Association of Neurologists, V10, P35; Matsubara K, 1998, EUR J PHARMACOL, V348, P77, DOI 10.1016/S0014-2999(98)00131-9; MCCRANK E, 1989, CAN J PSYCHIAT, V34, P934, DOI 10.1177/070674378903400916; MCCRANK E, 1990, NEUROLOGY, V40, P1637, DOI 10.1212/WNL.40.10.1637-a; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; Mortiner J.A., 1988, ET DEM ALZH TYP DAHL, P39; Muller J, 2001, ARCH NEUROL-CHICAGO, V58, P259, DOI 10.1001/archneur.58.2.259; NAGATSU T, 1988, NEUROSCI LETT, V87, P178, DOI 10.1016/0304-3940(88)90166-8; Nath U, 2003, NEUROLOGY, V60, P910, DOI 10.1212/01.WNL.0000052991.70149.68; Nath U, 2001, BRAIN, V124, P1438, DOI 10.1093/brain/124.7.1438; NEAFSEY EJ, 1989, NEUROSCI LETT, V105, P344, DOI 10.1016/0304-3940(89)90645-9; Nee L E, 1991, Clin Auton Res, V1, P9, DOI 10.1007/BF01826052; NEFZGER MD, 1968, AM J EPIDEMIOL, V88, P149, DOI 10.1093/oxfordjournals.aje.a120874; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; NIWA T, 1989, J CHROMATOGR-BIOMED, V491, P397, DOI 10.1016/S0378-4347(00)82857-1; NIWA T, 1988, J CHROMATOGR, V452, P85, DOI 10.1016/S0021-9673(01)81439-4; NIWA T, 1989, J CHROMATOGR-BIOMED, V493, P347, DOI 10.1016/S0378-4347(00)82740-1; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PEZZOLI G, 1989, LANCET, V2, P874, DOI 10.1016/S0140-6736(89)93050-X; PEZZOLI G, 1990, BRAIN RES, V531, P355, DOI 10.1016/0006-8993(90)90801-H; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Santacruz P, 1998, NEUROLOGY, V50, P1637, DOI 10.1212/WNL.50.6.1637; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; Schrag A, 1999, LANCET, V354, P1771, DOI 10.1016/S0140-6736(99)04137-9; Sergeant N, 1999, J NEUROCHEM, V72, P1243, DOI 10.1046/j.1471-4159.1999.0721243.x; Soto-Otero R, 2001, NEUROSCI LETT, V298, P187, DOI 10.1016/S0304-3940(00)01746-8; SPENCER PS, 1991, NEUROLOGY, V41, P62, DOI 10.1212/WNL.41.5_Suppl_2.62; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; STEELE JC, 1964, ARCH NEUROL-CHICAGO, V10, P333, DOI 10.1001/archneur.1964.00460160003001; TASAKI Y, 1991, J NEUROCHEM, V57, P1940, DOI 10.1111/j.1471-4159.1991.tb06407.x; TETRUD JW, 1994, NEUROLOGY, V44, P1051, DOI 10.1212/WNL.44.6.1051; van Swieten JC, 1999, ANN NEUROL, V46, P617, DOI 10.1002/1531-8249(199910)46:4<617::AID-ANA10>3.0.CO;2-I; Vanacore N, 2000, NEUROLOGY, V54, P114, DOI 10.1212/WNL.54.1.114; Wenning GK, 1998, J NEUROL NEUROSUR PS, V64, P184, DOI 10.1136/jnnp.64.2.184; WINIKATES J, 1994, J NEURAL TRANSM-SUPP, P189; YAMADA T, 1994, ACTA NEUROL SCAND, V89, P42; YOSHIDA M, 1990, NEUROSCI LETT, V119, P109, DOI 10.1016/0304-3940(90)90768-5; ZHANG ZX, 1990, ARCH NEUROL-CHICAGO, V47, P1019, DOI 10.1001/archneur.1990.00530090097019; ZHANG ZX, 1990, ARCH NEUROL-CHICAGO, V47, P1069, DOI 10.1001/archneur.1990.00530100031010	112	44	46	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-3185	1531-8257		MOVEMENT DISORD	Mov. Disord.		2003	18			6			S43	S50		10.1002/mds.10562			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	724XW	WOS:000185514400007	14502655				2022-02-06	
J	Ke, CS; Poon, WS; Ng, HK; Lai, FMM; Tang, NLS; Pang, JCS				Ke, CS; Poon, WS; Ng, HK; Lai, FMM; Tang, NLS; Pang, JCS			Impact of experimental acute hyponatremia on severe traumatic brain injury in rats: Influences on injuries, permeability of blood-brain barrier, ultrastructural features, and aquaporin-4 expression	EXPERIMENTAL NEUROLOGY			English	Article						head injury; hyponatremia; aquaporin-4; ultrastructure	AXONAL INJURY; MEMBRANE DOMAINS; WATER TRANSPORT; HEAD-INJURY; MODEL; CELLS; EDEMA; IMMUNOREACTIVITY; ENCEPHALOPATHY; DISEASE	The effects of acute hyponatremia on severe traumatic brain injury (TBI) in 35 adult male Sprague-Dawley rats were studied in a replicated focal and diffuse injury rat model. Such effects were assessed by the cerebral contusion volume and axonal injury (AI) densities, determined by quantitative immunoreactivity of beta-amyloid precursor protein, by blood-brain barrier (BBB) permeability based on endogenous IgG immunostaining, and by ultrastructural features. Significant increase of contusion volume (P < 0.05) and of AI in the segment of corpus callosum. beneath the contusion (P < 0.05) and ipsilateral thalamus (P < 0.05) were observed at 4 h postinjury during the hyponatremic phase. No change in BBB permeability was observed in the hyponatremia + TBI (HT) groups. Significant swelling of perivascular astrocytic foot processes in the HT groups was seen at 4 h (P < 0.01) and I day postinjury (P < 0.01) by quantitative image analysis of ultrastructures. However, attenuated swelling of perivascular astrocytic foot processes in severely edematous medulla oblongata with simultaneous swelling of perikaryal astrocytic processes was observed in the HT 1-day group. The ultrastructural features were also correlated with the down-regulation of aquaporin-4 (AQP4) mRNA expression (P < 0.05). Results suggest that acute hyponatremia acts as one of the secondary insults following severe TBI. Such exacerbation may not be attributable to further disruption of BBB permeability, but rather to the ischemia resulting from the swelling of perivascular astrocytic foot processes impeding microcirculation. Down-regulated AQP4 mRNA expression may be one of the molecular mechanisms maintaining water homeostasis in diffusely injured brain exposed to acute hyponatremia. (C) 2002 Elsevier Science (USA).	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China		Ke, CS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin, Hong Kong, Peoples R China.		Ng, Ho Keung/I-3952-2015; Poon, Wai Sang/F-1558-2011; Tang, Nelson L/P-5018-2017	Tang, Nelson L/0000-0002-3607-5819			AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADLER S, 1993, NMR BIOMED, V6, P119, DOI 10.1002/nbm.1940060203; ADLER S, 1989, AM J PHYSIOL, V256, pF113, DOI 10.1152/ajprenal.1989.256.1.F113; Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; Arieff A I, 1987, Adv Intern Med, V32, P325; ARUOMA OI, 1988, BIOCHEM J, V256, P251, DOI 10.1042/bj2560251; Atchison James W., 1993, Brain Injury, V7, P347, DOI 10.3109/02699059309034961; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; BOURKE RS, 1980, BIOL GLIAL SWELLING, V28, P98; Bussmann C, 2001, CHILD NERV SYST, V17, P58; Clark EC, 1996, KIDNEY INT, V49, P470, DOI 10.1038/ki.1996.66; CLUITMANS FHM, 1990, AM J MED, V88, P161, DOI 10.1016/0002-9343(90)90467-R; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; Dohanics J, 1996, J NEUROSCI, V16, P2373; FOX JL, 1971, J NEUROSURG, V34, P506, DOI 10.3171/jns.1971.34.4.0506; HALLIWELL B, 1989, FREE RADICAL BIO MED, V2, P86; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Ke C, 2000, ACT NEUR S, V76, P405; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KROLL M, 1992, J INTERN MED, V232, P291; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MELTON JE, 1983, AM J PHYSIOL, V244, pR724, DOI 10.1152/ajpregu.1983.244.5.R724; Mitrofanis J, 1999, J COMP NEUROL, V412, P173; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nagelhus EA, 1996, NEUROSCIENCE, V72, P743, DOI 10.1016/0306-4522(96)00003-6; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Nielsen S, 1997, J NEUROSCI, V17, P171; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Pierce JES, 1996, J NEUROSCI, V16, P1083; ROJIANI AM, 1994, ACTA NEUROPATHOL, V88, P287; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; Schuh-Hofer S, 2001, NEUROSCI LETT, V306, P61, DOI 10.1016/S0304-3940(01)01878-X; Soupart A, 1997, J LAB CLIN MED, V130, P226, DOI 10.1016/S0022-2143(97)90100-1; STERNS RH, 1989, KIDNEY INT, V35, P69, DOI 10.1038/ki.1989.9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; VEXLER ZS, 1994, J CLIN INVEST, V93, P256, DOI 10.1172/JCI116953	46	44	50	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2002	178	2					194	206		10.1006/exnr.2002.8037			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	628HX	WOS:000179988500005	12504879				2022-02-06	
J	van Geel, WJA; de Reus, HPM; Nijzing, H; Verbeek, MM; Vos, PE; Lamers, KJB				van Geel, WJA; de Reus, HPM; Nijzing, H; Verbeek, MM; Vos, PE; Lamers, KJB			Measurement of glial fibrillary acidic protein in blood: an analytical method	CLINICA CHIMICA ACTA			English	Article						glial fibrillary acidic protein; severe traumatic brain injury; blood values	CEREBROSPINAL-FLUID; ACUTE STROKE; S-100	Background: In the present study, a new assay for the measurement of glial fibrillary acidic protein (GFAP) in human blood is described. The aim of the study was to present the characteristics of a new GFAP assay for blood analysis. Methods: The method, a newly developed enzyme-linked immunosorbent assay (ELISA), was validated using blood samples from healthy blood donors and from patients with severe traumatic brain injury (TBI). Results: 22 out of 72 healthy blood donors had a detectable GFAP level. The reference values (percentiles) are as follows: P50 = 0.15 mug/l and P95 = 0.49 mug/l; range 0.15-0.76 mug/l. Conclusions: GFAP in blood might be a promising new marker for astrocyte involvement after acute brain damage. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Nijmegen, Ctr Med, Lab Pediat & Neurol, NL-6525 GC Nijmegen, Netherlands; Byk Nederland BV, Zwanenburg, Netherlands; Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands		van Geel, WJA (corresponding author), Univ Nijmegen, Ctr Med, Lab Pediat & Neurol, Reinier Postlaan 4, NL-6525 GC Nijmegen, Netherlands.		Vos, Pieter/A-6043-2012; Verbeek, Marcel M/D-1971-2010	Verbeek, Marcel M/0000-0003-4635-7876			Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Duchen L. W, 1984, GREENFIELDS NEUROPAT, P1; ENDO T, 1981, J BIOL CHEM, V256, P2485; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Missler U, 1999, CLIN CHEM, V45, P138; NOPPE M, 1986, CLIN CHIM ACTA, V155, P143, DOI 10.1016/0009-8981(86)90275-5; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6	10	44	45	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981			CLIN CHIM ACTA	Clin. Chim. Acta	DEC	2002	326	1-2					151	154	PII S0009-8981(02)00330-3	10.1016/S0009-8981(02)00330-3			4	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	618TW	WOS:000179434200014	12417106				2022-02-06	
J	Verbois, SL; Scheff, SW; Pauly, JR				Verbois, SL; Scheff, SW; Pauly, JR			Time-dependent changes in rat brain cholinergic receptor expression after experimental brain injury	JOURNAL OF NEUROTRAUMA			English	Article						alpha 7*nicotinic receptor; autoradiography; bungarotoxin; epibatidine; MK-801; neurotrauma; QNB	CENTRAL-NERVOUS-SYSTEM; NICOTINIC RECEPTORS; ACETYLCHOLINE-RECEPTORS; SELECTIVE AGONIST; BINDING; CALCIUM; MICE; INHIBITION; DISORDERS; SUBTYPES	Alterations in neurotransmitter receptor expression in the central nervous system may contribute to physiological and behavioral deficits that follow traumatic brain injury (TBI). Previous studies from our laboratory have demonstrated significant and widespread deficits in alpha7* nicotinic cholinergic receptor (alpha7* nAChr) expression 2 days following cortical contusion brain injury. The purpose of this study was to evaluate changes in alpha7* nAChr expression over a wider range of post-TBI recovery intervals. Animals were anesthetized and subjected to a moderate cortical contusion brain injury (2 mm cortical compression). Animals were euthanatized at various post-TBI time intervals, ranging from I h to 21 days, and quantitative autoradiography was used to evaluate cholinergic receptor subtype expression in the cerebral cortex and hippocampus. As previously reported, the alpha7* nAChr was the most sensitive target of TBI-induced plasticity. Significant decreases in alpha-[I-125]-bungarotoxin (BTX) binding occurred as early as I h post-TBI, and persisted in some brain regions for up to 21 days. A kinetic analysis of changes in BTX binding, performed 2 days following brain injury, indicated that the binding deficits are not due to significant changes in receptor affinity. TBI-induced changes in alpha3*/alpha4* nACh receptors, muscarinic cholinergic receptors, and NMDA-type glutamate receptor expression were lower in magnitude, restricted to fewer brain regions and more transient in nature. Persistent deficits in alpha7* nAChr expression following TBI may contribute to impaired functional outcome following brain injury.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA; Univ Kentucky, Coll Pharm, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Pauly, JR (corresponding author), Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, 800 Rose St, Lexington, KY 40536 USA.	jpauly@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042196, R01NS039828] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828, NS42196] Funding Source: Medline		Adams CE, 2001, BRAIN RES, V922, P180, DOI 10.1016/S0006-8993(01)03115-8; Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320; Albuquerque EX, 1998, J PHYSIOLOGY-PARIS, V92, P309, DOI 10.1016/S0928-4257(98)80039-9; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Burnashev N, 1998, CELL CALCIUM, V24, P325, DOI 10.1016/S0143-4160(98)90056-2; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Collins AC, 1996, DRUG DEVELOP RES, V38, P231, DOI 10.1002/(SICI)1098-2299(199607/08)38:3/4<231::AID-DDR12>3.0.CO;2-1; Dani JA, 2001, BIOL PSYCHIAT, V49, P166, DOI 10.1016/S0006-3223(00)01011-8; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Delbono O, 1997, J PHARMACOL EXP THER, V280, P428; Eglen RM, 2001, TRENDS PHARMACOL SCI, V22, P409, DOI 10.1016/S0165-6147(00)01737-5; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hilmas C, 2001, J NEUROSCI, V21, P7463, DOI 10.1523/JNEUROSCI.21-19-07463.2001; Hoofien D, 2001, BRAIN INJURY, V15, P189; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hurley Robin A., 2002, Curr Treat Options Neurol, V4, P59, DOI 10.1007/s11940-002-0005-5; Lavine N, 1997, J COMP NEUROL, V380, P175, DOI 10.1002/(SICI)1096-9861(19970407)380:2<175::AID-CNE3>3.0.CO;2-0; Levin ED, 2000, EUR J PHARMACOL, V393, P141, DOI 10.1016/S0014-2999(99)00885-7; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; Liu QS, 2001, P NATL ACAD SCI USA, V98, P4734, DOI 10.1073/pnas.081553598; Lukas RJ, 1999, PHARMACOL REV, V51, P397; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; PAULY JR, 1990, PSYCHOPHARMACOLOGY, V101, P310, DOI 10.1007/BF02244047; Paxinos G, 1997, RAT BRAIN STEREOTAXI; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; Perry E, 2000, EUR J PHARMACOL, V393, P215, DOI 10.1016/S0014-2999(00)00064-9; Perry EK, 2001, ALCOHOL, V24, P63, DOI 10.1016/S0741-8329(01)00130-6; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rusted JM, 2000, BEHAV BRAIN RES, V113, P121, DOI 10.1016/S0166-4328(00)00207-2; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHRODER W, 1998, ALZHEIMER DIS REV, V2, P61; SEGUELA P, 1993, J NEUROSCI, V13, P596; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Simosky JK, 2001, BIOL PSYCHIAT, V50, P493, DOI 10.1016/S0006-3223(01)01093-9; Sparks JA, 1999, PSYCHOPHARMACOLOGY, V141, P145, DOI 10.1007/s002130050818; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Waldo MC, 2000, BIOL PSYCHIAT, V47, P231, DOI 10.1016/S0006-3223(99)00272-3; Whiteaker P, 2000, EUR J PHARMACOL, V393, P123, DOI 10.1016/S0014-2999(00)00052-2; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; Woodruff-Pak DS, 2001, P NATL ACAD SCI USA, V98, P2089, DOI 10.1073/pnas.031584398	46	44	45	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2002	19	12					1569	1585		10.1089/089771502762300238			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	629UY	WOS:000180070700005	12542858				2022-02-06	
J	Knoblach, SM; Faden, AI				Knoblach, SM; Faden, AI			Administration of either anti-intercellular adhesion molecule-1 or a nonspecific control antibody improves recovery after traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						antibody; anti-ICAM-1; CNS; expression; function; head injury; IgG	CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; ISCHEMIC CELL-DAMAGE; SPINAL-CORD-INJURY; NEUTROPHIL ACCUMULATION; MONOCLONAL-ANTIBODY; MICE DEFICIENT; UP-REGULATION; P-SELECTIN; ANTI-ICAM-1 ANTIBODY	Intercellular adhesion molecule-1 (ICAM-1) is an endothelial protein that facilitates invasion of leukocytes into the CNS in response to injury or inflammation. ICAM-1 expression correlates with the severity of clinical head injuries, but its importance in secondary injury events is not fully understood. Therefore, we evaluated ICAM-1 expression and the effect of anti-ICAM-1 treatment on motor recovery and neutrophil invasion after traumatic brain injury induced via the lateral fluid-percussion method in the rat. ICAM-1 was expressed in large and small blood vessels within the injured cortex at 10 and 24 h after injury. Repeated administration of anti-ICAM-1 antibody (clone 1A29) at 1, 10, and again at 24 h after injury significantly improved performance in two of three motor tests, compared to saline controls. Equal doses of nonspecific control antibody (IgG) also significantly improved motor test scores, compared to saline controls. Cortical myeloperoxidase activity, an indicator of neutrophil invasion, was significantly reduced 26 h after injury in animals treated with anti-ICAM-1. Animals treated with IgG showed a trend toward reduction that did not reach significance. These data suggest that ICAM-1 may be involved in neutrophil invasion and neurological dysfunction after TBI, but also implicate a role for a nonspecific antibody effect in improved functional outcome.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA		Knoblach, SM (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW, Washington, DC 20007 USA.	knoblachs@giccs.georgetown.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007459] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32HD07459] Funding Source: Medline; ODCDC CDC HHS [R49CCR306634-07] Funding Source: Medline		BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; BIRDSALL HH, 1991, AM J PATHOL, V139, P1341; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; BOWES MP, 1995, NEUROLOGY, V45, P815, DOI 10.1212/WNL.45.4.815; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; Cole DJ, 1996, ANESTH ANALG, V83, P342, DOI 10.1097/00000539-199608000-00024; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; DeGraba TJ, 1998, NEUROLOGY, V51, pS62, DOI 10.1212/WNL.51.3_Suppl_3.S62; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; Etienne S, 1998, J IMMUNOL, V161, P5755; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Furuya K, 2001, STROKE, V32, P2665, DOI 10.1161/hs3211.098535; Ginsberg MD, 2001, J NEUROSURG, V94, P499, DOI 10.3171/jns.2001.94.3.0499; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HERY C, 1995, J NEUROIMMUNOL, V57, P101, DOI 10.1016/0165-5728(94)00168-N; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; Isaksson J, 2000, J NEUROTRAUM, V17, P333, DOI 10.1089/neu.2000.17.333; Jaeschke H, 1996, TOXICOL APPL PHARM, V139, P213, DOI 10.1006/taap.1996.0160; Jean WC, 1998, NEUROSURGERY, V43, P1382, DOI 10.1097/00006123-199812000-00076; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P108, DOI 10.1016/0167-4781(92)90107-B; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165-5728(99)00084-3; Lewczuk P, 1998, J NEUROIMMUNOL, V87, P156, DOI 10.1016/S0165-5728(98)00084-8; LUNDBLAD JL, 1986, REV INFECT DIS, V8, pS382; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Mazzoni MC, 1996, CARDIOVASC RES, V32, P709, DOI 10.1016/0008-6363(96)00146-0; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKeating EG, 1998, BRIT J ANAESTH, V80, P77, DOI 10.1093/bja/80.1.77; McKeating EG, 1998, ACT NEUR S, V71, P200; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; PALMER C, 1995, CLIN PERINATOL, V22, P481; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Schneider D, 1998, EUR NEUROL, V40, P78, DOI 10.1159/000007962; Seilhean D, 1997, NEUROPATH APPL NEURO, V23, P83, DOI 10.1111/j.1365-2990.1997.tb01190.x; SHRIKANT P, 1995, J IMMUNOL, V155, P1489; Shrikant P, 1996, J IMMUNOL, V157, P1819; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Soares HD, 1995, J NEUROSCI, V15, P8223; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAMATANI T, 1993, INT IMMUNOL, V2, P166; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Vuorte J, 1999, J IMMUNOL, V162, P2353; WANG XK, 1994, MOL BRAIN RES, V26, P61, DOI 10.1016/0169-328X(94)90074-4; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Worthington V, 1993, WORTHINGTON ENZYME M; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; ZIELASEK J, 1993, NEUROSCI LETT, V153, P136, DOI 10.1016/0304-3940(93)90306-6	66	44	54	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2002	19	9					1039	1050		10.1089/089771502760341956			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	598KW	WOS:000178275900005	12482117				2022-02-06	
J	McCullers, DL; Sullivan, PG; Scheff, SW; Herman, JP				McCullers, DL; Sullivan, PG; Scheff, SW; Herman, JP			Traumatic brain injury regulates adrenocorticosteroid receptor mRNA levels in rat hippocampus	BRAIN RESEARCH			English	Article						glucocorticoid; mineralocorticoid; cortical impact; spironolactone; RU486	GLUCOCORTICOID-RECEPTOR; GENE-TRANSCRIPTION; CORTICOSTERONE; TOXICITY; FACILITATION; EXPRESSION; BLOCKADE; CORTISOL; FEEDBACK; RHYTHM	Glucocorticoid activation of two types of adrenocorticosteroid receptors (ACRs), the mineralocorticoid receptor (MR) and glucocorticoid receptor (GR), influences the vulnerability of hippocampal neurons to insult. To examine the potential impact of ACR activation following traumatic brain injury (TBI), the current study assesses regulation of MR and GR expression and glucocorticoid levels following controlled cortical impact (CCI). Male Sprague-Dawley rats were pretreated for 48 h with vehicle, the MR antagonist spironolactone, or the GR antagonist mifepristone (RU486). On day three, subjects were sham-operated or injured by unilateral CCI. In situ hybridization analysis determined that pretreatment with either MR antagonist spironolactone or GR antagonist RU486 increased 24-h hippocampal GR mRNA levels in sham-operated animals only, suggesting that MR and GR regulation of GR mRNA is suppressed following TBI. Injury decreased GR mRNA levels in the ipsilateral dentate gyrus of all pretreatment groups and bilaterally increased MR mRNA levels in CA3 of antagonist-pretreated animals. One day post-injury, plasma corticosterone levels were comparable in sham and injured animals pretreated with vehicle. A separate group of animals that did not receive pretreatment injections prior to sham operation or injury were included for a 24-h time course analysis of plasma ACTH and corticosterone levels. Injury increased hypothalamic-pituitary-adrenal (HPA) activation for approximately 6 h following injury. These results indicate that hippocampal ACR mRNA levels and HPA activation are altered by TBI. Regulation of MR and GR expression following TBI may influence hippocampal neuron viability by modulating glucocorticoid signaling after injury. (C) 2002 Published by Elsevier Science B.V.	Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45267 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Herman, JP (corresponding author), Univ Cincinnati, Dept Psychiat, POB 670559,231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jpherman@psychiatry.uc.edu	Herman, James P/D-4960-2015	Herman, James P/0000-0003-3571-2406	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010836] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12965, AG10836, AG00242] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline		Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Cabral ALB, 2001, MOL CELL ENDOCRINOL, V175, P67, DOI 10.1016/S0303-7207(01)00396-3; CHABERT PR, 1984, J STEROID BIOCHEM, V20, P1253, DOI 10.1016/0022-4731(84)90154-7; Chao HM, 1998, ENDOCRINOLOGY, V139, P1810, DOI 10.1210/en.139.4.1810; DAGOSTINO J, 1982, ACTA ENDOCRINOL-COP, V100, P85, DOI 10.1530/acta.0.1000085; DALLMAN MF, 1992, J NEUROENDOCRINOL, V4, P517, DOI 10.1111/j.1365-2826.1992.tb00200.x; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Herman JP, 1998, J NEUROSCI, V18, P7462; HERMAN JP, 1989, MOL ENDOCRINOL, V3, P1886, DOI 10.1210/mend-3-11-1886; HERMAN JP, 1989, J NEUROSCI, V9, P3072; HERMAN JP, 1993, MOL CELL NEUROSCI, V4, P181, DOI 10.1006/mcne.1993.1022; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; KWAK SP, 1992, NEUROENDOCRINOLOGY, V55, P74, DOI 10.1159/000126099; LEVINE RL, 1980, HORM RES, V13, P385, DOI 10.1159/000179306; Liu Z, 1997, NEUROREPORT, V8, P2019, DOI 10.1097/00001756-199705260-00043; LOWY MT, 1990, BRAIN RES, V533, P348, DOI 10.1016/0006-8993(90)91362-K; LOWY MT, 1992, J NEUROCHEM, V58, P1561, DOI 10.1111/j.1471-4159.1992.tb11379.x; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCullers DL, 2001, J NEUROSCI RES, V64, P277; McIntosh LJ, 1996, NEUROTOXICOLOGY, V17, P873; MCINTOSH TK, 1981, J CLIN ENDOCR METAB, V53, P117, DOI 10.1210/jcem-53-1-117; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; RATKA A, 1989, NEUROENDOCRINOLOGY, V50, P117, DOI 10.1159/000125210; REUL JMHM, 1989, MOL ENDOCRINOL, V3, P1674, DOI 10.1210/mend-3-10-1674; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Ruhmann-Wennhold A, 1977, Ann N Y Acad Sci, V297, P498, DOI 10.1111/j.1749-6632.1977.tb41877.x; SAPOLSKY RM, 1988, BRAIN RES, V453, P367, DOI 10.1016/0006-8993(88)90180-1; SAPOLSKY RM, 1986, NEUROENDOCRINOLOGY, V43, P440, DOI 10.1159/000124561; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1228; Sarrieau A, 1996, NEUROSCI LETT, V206, P207, DOI 10.1016/S0304-3940(96)12454-X; SECKL JR, 1990, J NEUROENDOCRINOL, V2, P911, DOI 10.1111/j.1365-2826.1990.tb00659.x; SEROOGY KB, 1996, NEUROCHEMISTRY PRACT, P121; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; SPENCER RL, 1990, BRAIN RES, V514, P37, DOI 10.1016/0006-8993(90)90433-C; Spencer RL, 1998, ENDOCRINOLOGY, V139, P2718, DOI 10.1210/en.139.6.2718; vanHaarst AD, 1997, NEUROCHEM RES, V22, P1323, DOI 10.1023/A:1022010904600; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.ge.19.120185.001233; Yau JLW, 1999, NEUROSCI LETT, V277, P45, DOI 10.1016/S0304-3940(99)00858-7	43	44	45	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 23	2002	947	1					41	49	PII S0006-8993(02)02904-9	10.1016/S0006-8993(02)02904-9			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	589PR	WOS:000177769400006	12144851				2022-02-06	
J	Yang, JY; Tsai, FC; Chana, JS; Chuang, SS; Chang, SY; Huang, WC				Yang, JY; Tsai, FC; Chana, JS; Chuang, SS; Chang, SY; Huang, WC			Use of free thin anterolateral thigh flaps combined with cervicoplasty for reconstruction of postburn anterior cervical contractures	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							NECK DEFECTS; HEAD	Free thin anterolateral thigh flaps combined with cervicoplasty were used in a series of seven patients undergoing reconstruction for previous burn injury from September of 2000 to May of 2001 at Chang Gung Memorial Hospital. This method uses a suprafascial dissection technique to provide a thin flap to improve cervical contour. Neck contractures had resulted from flame burns in six patients and from a chemical burn in one patient. The mean age was 32.7 years (range, 22 to 45 years). The size of excised scar ranged from 10 x 2 cm to 26 x 5 cm (mean, 19.7 x 3.3 cm). The size of flaps ranged from 11 x 5 cm to 26 x 8 cm (mean, 21.3 xd 6.5 cm). Average operative time was 6 hours. Average hospital stay was 10 days. All flaps survived, with one flap sustaining partial marginal loss. The donor site was closed primarily in five cases and by using a split-thickness skin graft in two cases. At a mean follow-up time of 5 months, the functional improvement was measured as follows; a mean increase in extension of 30 degrees (preoperatively, 95 degrees; postoperatively, 125 degrees), a mean increase in rotation of 18 degrees (preoperatively, 59 degrees; postoperatively, 77 degrees), and a mean increase in lateral flexion of 12.5 degrees (preoperatively, 26.5 degrees; postoperatively, 39 degrees). The average cervicomandibular angle was improved by 25 degrees (preoperatively, 145 degrees; postoperatively, 120 degrees). This series demonstrates that the use of free thin anterolateral thigh flaps combined with cervicoplasty provides a one-stage reconstruction with a thin, pliable flap that achieves good cervical contour with low donor-site morbidity.	Chang Gung Mem Hosp, Dept Plast Surg, LinKou Burn Ctr, Tao Yuan, Taiwan		Yang, JY (corresponding author), Chang Gung Mem Hosp, Dept Plast Surg, LinKou Burn Ctr, Taipei 5,Fu Hsin St, Tao Yuan, Taiwan.						BAKER TJ, 1977, PLAST RECONSTR SURG, V59, P24, DOI 10.1097/00006534-197701000-00004; BALAKRISHNAN C, 1991, PLAST RECONSTR SURG, V88, P171, DOI 10.1097/00006534-199107000-00040; DECASTRO CC, 1980, ANN PLAST SURG, V4, P370; EDLICH RF, 1984, OTOLARYNG CLIN N AM, V17, P361; ELLENBOGEN R, 1980, PLAST RECONSTR SURG, V66, P826, DOI 10.1097/00006534-198012000-00003; FELDMAN JJ, 1990, PLAST RECONSTR SURG, V85, P333, DOI 10.1097/00006534-199003000-00001; FELDMAN JJ, 1984, PEDIAT PLASTIC SURG, V1; Guerrero-Santos J, 1978, Clin Plast Surg, V5, P29; HYAKUSOKU H, 1994, BRIT J PLAST SURG, V47, P465, DOI 10.1016/0007-1226(94)90028-0; Iwuagwu FC, 1999, PLAST RECONSTR SURG, V103, P1198, DOI 10.1097/00006534-199904040-00015; KENNEY J G, 1990, Journal of Burn Care and Rehabilitation, V11, P443, DOI 10.1097/00004630-199009000-00012; Kimata Y, 1997, ARCH OTOLARYNGOL, V123, P1325; Kimata Y, 1998, PLAST RECONSTR SURG, V102, P1517, DOI 10.1097/00006534-199810000-00026; Knipper P, 1997, ANN PLAS SURG, V39, P566, DOI 10.1097/00000637-199712000-00002; KOBUS K, 1985, ANN PLAS SURG, V15, P14, DOI 10.1097/00000637-198507000-00003; Kobus K, 1988, EUR J PLAST SURG, V11, P126; KOSHIMA I, 1993, PLAST RECONSTR SURG, V92, P411, DOI 10.1097/00006534-199309000-00004; KOSHIMA I, 1993, PLAST RECONSTR SURG, V92, P421, DOI 10.1097/00006534-199309000-00005; LAITUNG JKG, 1990, ANN PLAS SURG, V25, P205, DOI 10.1097/00000637-199009000-00010; MARINO H, 1963, Plast Reconstr Surg, V31, P45, DOI 10.1097/00006534-196301000-00005; MASSALSKI TB, 1990, BINARY ALLOY PHASE D, V1, P295; MILLARD DR, 1968, PLAST RECONSTR SURG, V41, P513, DOI 10.1097/00006534-196806000-00001; NEALE HW, 1993, PLAST RECONSTR SURG, V91, P624, DOI 10.1097/00006534-199304000-00009; PETERSON R, 1978, S SURGERY AGING FACE, P115; SONG YG, 1984, BRIT J PLAST SURG, V37, P149, DOI 10.1016/0007-1226(84)90002-X; Vistnes L M, 1979, Ann Plast Surg, V2, P381, DOI 10.1097/00000637-197905000-00004; VOINCHET V, 1995, BURNS, V21, P143, DOI 10.1016/0305-4179(95)92141-X	27	44	46	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0032-1052			PLAST RECONSTR SURG	Plast. Reconstr. Surg.	JUL	2002	110	1					39	46		10.1097/00006534-200207000-00009			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	565YW	WOS:000176399000009	12087229				2022-02-06	
J	Brawanski, A; Faltermeier, R; Rothoerl, RD; Woertgen, C				Brawanski, A; Faltermeier, R; Rothoerl, RD; Woertgen, C			Comparison of near-infrared spectroscopy and tissue Po-2 time series in patients after severe head injury and aneurysmal subarachnoid hemorrhage	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						near-infrared spectroscopy (NIRS); rSo(2); tissue Po-2 (tipo(2)); frequency analysis; multitaper analysis; modeling	CEREBRAL OXYGENATION; OXIMETRY; BULB	Monitoring of local oxygen pressure in brain white matter (tipo(2)) and of local hemoglobin oxygen saturation (rSo(2)) with near-infrared spectroscopy (NIRS) are increasingly employed techniques in neurosurgical intensive care units. Using frequency-based mathematical method,,, the authors sought to ascertain whether both techniques contained similar information. Twelve patient,,; treated in the intensive care unit were included (subarachnoid hemorrhage, n = 3 traumatic brain injury, n = 9). A tipo(2) probe and an NIRS sensor were positioned over the frontal lobe with the most pathologic changes on initial computed tomography scan. The authors calculated coherence of tipo(2) and rSo(2). its overall density distribution, its distribution per data set, and its time evolution. The authors identified a band of significantly correlated frequencies (from 0 to 1.3 x 10(3) Hz) in more than 90% of the data sets for coherence and overall density distribution. Time evolution showed slow but marked changes of significant coherence, By means of spectral analysis the authors show that tipo(2) and rSo(2) signals contain similar information. albeit using completely different registration methodologies.	Univ Regensburg, Dept Neurosurg, D-93053 Regensburg, Germany		Brawanski, A (corresponding author), Univ Regensburg, Dept Neurosurg, Germany Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	alexander.brawanski@klinik.uni-regensburg.de					BRILLINGER BR, 1981, TIME SERIES DATA ANA; Buchner K, 2000, ZBL NEUROCHIR, V61, P69, DOI 10.1055/s-2000-8262; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; GHIL M, 1996, DECADAL CLIMATE VARI, P445; Henson LC, 1998, ANESTHESIOLOGY, V88, P58, DOI 10.1097/00000542-199801000-00011; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KIRKPATRICK PJ, 1995, J NEUROSURG, V83, P963, DOI 10.3171/jns.1995.83.6.0963; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Meixensberger J, 1998, ACT NEUR S, V71, P260; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; PARK J, 1987, J GEOPHYS RES-SOLID, V92, P12675, DOI 10.1029/JB092iB12p12675; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; Schreiber T., 1997, NONLINEAR TIME SERIE; Schwarz G, 1996, J NEUROSURG ANESTH, V8, P189, DOI 10.1097/00008506-199607000-00001; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Vinas FC, 1998, CRIT REV NEUROSURG, V8, P31, DOI 10.1007/s003290050058; [No title captured]	18	44	49	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2002	22	5					605	611		10.1097/00004647-200205000-00012			7	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	548CN	WOS:000175371200012	11973433	Bronze			2022-02-06	
J	Loop, T; Liu, ZH; Humar, M; Hoetzel, A; Benzing, A; Pahl, HL; Geiger, KK; Pannen, BHJ				Loop, T; Liu, ZH; Humar, M; Hoetzel, A; Benzing, A; Pahl, HL; Geiger, KK; Pannen, BHJ			Thiopental inhibits the activation of nuclear factor kappa B	ANESTHESIOLOGY			English	Article; Proceedings Paper	48th Annual Meeting of the German-Society-of-Anesthesiology-and-Intensive-Care-Medicine	JUN 13-16, 2001	NEURNBERG, GERMANY	German Soc Anesthesiol & Intens Care Med			TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURIES; IN-VITRO; TRANSCRIPTION FACTOR; UNITED-STATES; KINASE; RESPONSES; ALPHA; COMPLEX; PHOSPHORYLATION	Background: Thiopental is frequently used for the treatment of intracranial hypertension after severe head injury. Its longterm administration increases the incidence of nosocomial infections, which contributes to the high mortality rate of these patients. However, the mechanism of its immunosuppressing effect remains unknown. Methods: The effect of thiopental (200-1000 mug/ml) on the activation of the nuclear transcription factor kappaB (NF-kappaB; electrophoretic mobility shift assays), on NF-kappaB-driven reporter gene activity (transient transfection assays), on the expression of NF-kappaB target genes (enzyme-linked immunoassays), on T-cell activation (How cytometric analyses of CD69 expression), and on the content of the NF-kappaB inhibitor IkappaB-alpha (Western blotting) was studied in human T lymphocytes in vitro. Results: Thiopental inhibited the activation of the transcription factor NF-kappaB but did not alter the activity of the cyclic adenosine monophosphate response element binding protein. Other barbiturates (methohexital), anesthetics (etomidate, propofol, ketamine), or opioids (fentanyl, morphine) did not affect NF-kappaB activation. Thiopental-mediated suppression of NF-kappaB could be observed in Jurkat cells and in primary CD3(+) lymphocytes from healthy volunteers, was time- and concentration-dependent, occurred at concentrations that are clinically achieved, and persisted for hours after the incubation. It was associated with an inhibition of NF-kappaB-driven reporter gene activity, of the expression of interleukin-2, -6, and -8, and interferon gamma, and of the activation of CD3(+) lymphocytes. Suppression of NY-kappaB appeared to involve reduced degradation of IkappaB-1alpha. Conclusion: The results demonstrate that thiopental inhibits the activation of NF-kappaB and may thus provide a molecular mechanism for some of the immunosuppressing effects associated with thiopental therapy.	Univ Hosp Freiburg, Dept Anesthesiol, Freiburg, Germany; Univ Hosp Freiburg, Dept Anesthesiol & Crit Care Med, Freiburg, Germany; Univ Hosp Freiburg, Dept Expt Anesthesiol, Freiburg, Germany		Pannen, BHJ (corresponding author), Univ Freiburg, Anasthesiol Klin, Hugstetter Str 55, D-79106 Freiburg, Germany.	pannen@nz.ukl.uni-freiburg.de		Benzing, Albert/0000-0003-3979-6467			Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Ben-Eliyahu S, 1999, ANESTHESIOLOGY, V91, P732, DOI 10.1097/00000542-199909000-00026; CorreaSales C, 1997, INT J IMMUNOPHARMACO, V19, P117, DOI 10.1016/S0192-0561(97)00003-9; De Deyne C, 2000, EUR J ANAESTH, V17, P3; DONEGAN JH, 1985, AM J PHYSIOL, V249, pH421, DOI 10.1152/ajpheart.1985.249.2.H421; EBERHARDT KEW, 1992, INFECTION, V20, P12, DOI 10.1007/BF01704886; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Heine J, 1996, BRIT J ANAESTH, V77, P387, DOI 10.1093/bja/77.3.387; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hofbauer R, 1998, INTENS CARE MED, V24, P973, DOI 10.1007/s001340050698; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; Ishikawa K, 1999, J TRAUMA, V46, P999, DOI 10.1097/00005373-199906000-00004; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KRESS HG, 1989, ACTA ANAESTH SCAND, V33, P122, DOI 10.1111/j.1399-6576.1989.tb02873.x; KRUMHOLZ W, 1995, EUR J ANAESTH, V12, P141; Larsen B, 1998, ANESTHESIOLOGY, V89, P1218, DOI 10.1097/00000542-199811000-00023; Manna SK, 1999, J IMMUNOL, V163, P6800; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOHLER H, 1988, EUR J ANAESTH, P15; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Nadal P, 1995, Eur J Emerg Med, V2, P14, DOI 10.1097/00063110-199503000-00004; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; Nishina K, 1998, ANESTH ANALG, V86, P159, DOI 10.1097/00000539-199801000-00032; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pannen B H, 1995, New Horiz, V3, P183; ROBERTS I, 2001, BARBITURATES ACUTE T; Salman H, 1998, LIFE SCI, V63, P2221, DOI 10.1016/S0024-3205(98)00506-2; Salo M, 1997, ANAESTHESIA, V52, P341, DOI 10.1111/j.1365-2044.1997.95-pz0084.x; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tian J, 1999, J NEUROIMMUNOL, V96, P21, DOI 10.1016/S0165-5728(98)00264-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YASUDA T, 1993, INT J LEGAL MED, V105, P239, DOI 10.1007/BF01642801; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	45	44	52	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2002	96	5					1202	1213		10.1097/00000542-200205000-00025			12	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Anesthesiology	547EU	WOS:000175320700024	11981162				2022-02-06	
J	Brouwer, WH; Withaar, FK; Tant, MLM; van Zomeren, AH				Brouwer, WH; Withaar, FK; Tant, MLM; van Zomeren, AH			Attention and driving in traumatic brain injury: A question of coping with time-pressure	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive dysfunction; divided attention; driving skill; information processing; motor dysfunction; perceptual dysfunction; procedural knowledge	CLOSED-HEAD INJURY; FITNESS; DAMAGE	Background: Diffuse and focal traumatic brain injury (TBI) can result in perceptual, cognitive, and motor dysfunction possibly leading to activity limitations in driving. Characteristic dysfunctions for severe diffuse TBI are confronted with function requirements derived from the hierarchical task analysis of driving skill. Objective. Specifically, we focus on slow information processing, divided attention, and the development of procedural knowledge. Also the effects of a combination of diffuse and focal dysfunctions, specifically homonymous hemianopia and the dysexecutive syndrome, are discussed. Finally, we turn to problems and challenges with regard to assessment and rehabilitation methods in the areas of driving and fitness to drive.	Univ Groningen, Dept Psychol, NL-9712 TS Groningen, Netherlands; Acad Hosp, Dept Neurol, Groningen, Netherlands		Brouwer, WH (corresponding author), Univ Groningen, Acad Hosp, Neuropsychol & Gerontol Unit, Dept Psychol, Poortweg 4,POB 30001, NL-9700 RB Groningen, Netherlands.			Tant, Mark/0000-0002-5347-0095			Barer D. H., 1989, CLIN REHABIL, V3, P179; Brouwer W, 2001, BRAIN COGNITION, V46, P54, DOI 10.1016/S0278-2626(01)80033-6; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BRUN A, 1999, SCI PRACT NEUROPSYCH, P349; Damasio A., 1994, DESCARTES ERROR EMOT; Evans L., 1991, TRAFFIC SAFETY DRIVE; FITTS PM, 1964, CATEGORIES HUMAN LEA, P253; Groeger J.A., 2000, UNDERSTANDING DRIVIN; HOPEWELL CA, 1985, J CLIN EXP NEUROPSYC, V7, P148; KINSBOURNE M, 1978, ATTENTION PERFORM, V7, P81; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; MICHON JA, 1971, PSYCHONOMIE ONDERWEG; Pincus J. H., 1998, SCI PRACT NEUROPSYCH, P547; RICHARDSON JTE, 1999, CLIN NEUROPSYCHOLOGI; SHORE D, 1980, ARCH PHYS MED REHAB, V65, P163; STRICH SJ, 1961, LANCET, V2, P443; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANBALEN HGG, 1990, P 5 EUR REG C REH; VANWOLFFELAAR PC, 1990, DRIVING BEHAV SOCIAL, P564; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VUILLEUMIER P, 1995, CLIN NEUROL NEUROSUR, V97, P39, DOI 10.1016/0303-8467(94)00056-C; WICKENS C. D., 1984, VARIETIES ATTENTION, P63; WITHAAR FK, 2000, THESIS U GRONINGEN; 1995, REGELING EISEN RIJGE	28	44	46	3	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2002	17	1					1	15		10.1097/00001199-200202000-00003			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	519MM	WOS:000173730100004	11860325				2022-02-06	
J	Choi, SC; Clifton, GL; Marmarou, A; Miller, ER				Choi, SC; Clifton, GL; Marmarou, A; Miller, ER			Misclassification and treatment effect on primary outcome measures in clinical trials of severe neurotrauma	JOURNAL OF NEUROTRAUMA			English	Article						clinical trials; interobserver variability; misclassifications; number of outcome categories; power; primary outcome measures	DISABILITY RATING-SCALE; HEAD; RECOVERY	The power of clinical trials depends mainly on the choice of the primary outcome measure, the statistical test, and the sample size. The most widely used outcome measure has been the five-category Glasgow Outcome Scale (GOS). Contrary to intuition, we show that more categories do not necessarily increase the power of a trial and actually can decrease power. This is so for two reasons. The more categories of outcome measure used, the more the likelihood for misclassifications. The effect of 0 %, 10 %, and 20 % misclassification rate upon power is illustrated. Misclassification rates in two completed trials are examined based on comparative overlap in GOS and Disability Rating Scale (DRS) categories. The outcome results of the "National Acute Brain Injury Study: Hypothermia" indicate that the ideal number of categories also depends upon the effect of study treatment. In the recently completed hypothermia trial, the use of a dichotomized GOS (good recovery/moderate disability versus severe disability/vegetative/dead) is shown to be more sensitive than use of three or more categories of the GOS. The results point to the importance of training study investigators who will collect the outcome data. The results also indicate that the number of categories should be carefully determined using the pilot data or the data from phase II trials.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA 23298 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		Choi, SC (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Box 980032, Richmond, VA 23298 USA.	choi@hsc.vcu.edu					Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; JENNETT B, 1975, LANCET, V1, P480; LEHMAN EL, 1976, NONPARAMETRICS STAT; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Marmarou A, 2001, HEAD TRAUMA, P371; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	13	44	44	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2002	19	1					17	22		10.1089/089771502753460204			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	517LD	WOS:000173611300002	11852975				2022-02-06	
J	Satoh, K; Ikeda, Y; Shioda, S; Tobe, T; Yoshikawa, T				Satoh, K; Ikeda, Y; Shioda, S; Tobe, T; Yoshikawa, T			Edarabone scavenges nitric oxide	REDOX REPORT			English	Article							PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; RADICALS; SYNTHASE; MIGRAINE; NO	Oxygen free radicals have been proposed to be major causative agents in secondary brain damage in traumatic and ischemic brain injury. Edarabone (3-methyl-1-phenyl-2-pyrazolin-5-one), a powerful antioxidative radical scavenger, is the only drug currently available in clinical practice for the treatment of cerebral infarction. There has been increasing interest in the role of nitric oxide (NO*) as a causative agent in brain injury. In the present study, we investigated the scavenging effect of Edarabone on nitric oxide (NO*), using an electron spin resonance (ESR) method. NO* was generated from 1-hydroxy-2-oxo-3-(N-3-methyl-3-aminopropyl)-3-methyl-1-triazene (NOC-7), and analyzed by 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxy (carboxy-PTI) produced from the reaction between 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxy-3-oxide (carboxy-PTIO) and NO*. Edarabone directly scavenged NO* in a dose-dependent manner. These ESR studies indicate that Edarabone has a direct NO* scavenging activity and the additional possibility of novel neuroprotective activities against brain injury and focal cerebral ischemia.	Showa Univ, Sch Pharmaceut Sci, Dept Med Informat, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Sch Med, Dept Neurosurg, Tokyo 1428555, Japan; Showa Univ, Sch Med, Dept Anat 1, Tokyo 1428555, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kyoto, Japan; Kyoto Prefectural Univ Med, Dept Med 1, Kyoto, Japan		Satoh, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Med Informat, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	ksugar@pharm.showa-u.ac.jp					Akaike T, 1996, METHOD ENZYMOL, V268, P211; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; Asanuma M, 2001, J NEUROCHEM, V76, P1895, DOI 10.1046/j.1471-4159.2001.00205.x; Beal MF, 1998, ANN NEUROL, V44, pS110; DORHEIM MA, 1994, BIOCHEM BIOPH RES CO, V205, P659, DOI 10.1006/bbrc.1994.2716; Gatto EM, 2000, NITRIC OXIDE-BIOL CH, V4, P534, DOI 10.1006/niox.2000.0288; HOGG N, 1995, FREE RADICAL RES, V22, P47, DOI 10.3109/10715769509147527; IKEDA Y, 2001, J CLIN EXP MED, V199, P471; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; KIMURA E, 1996, AM J PHYSIOL, V270, pC748; KOSAKA H, 1989, CARCINOGENESIS, V10, P563, DOI 10.1093/carcin/10.3.563; Law A, 2001, BRAIN RES REV, V35, P73, DOI 10.1016/S0165-0173(00)00051-5; MITSUTA K, 1990, B CHEM SOC JPN, V63, P187, DOI 10.1246/bcsj.63.187; Nishibayashi S, 1996, J NEUROCHEM, V67, P2208; Noda Y, 1997, RES COMMUN MOL PATH, V96, P115; Olesen J, 2000, PATHOL BIOL, V48, P648; OLESEN J, 1994, TRENDS PHARMACOL SCI, V15, P149, DOI 10.1016/0165-6147(94)90075-2; OURESHI GA, 1995, NEUROREPORT, V6, P1642, DOI 10.1097/00001756-199508000-00013; WATANABE K, 1997, JPN PHARMACOL THER, V25, pS1691; WATANABE K, 1997, JPN PHARMACOL THER, V25, pS1699; Yamamoto Y, 1996, REDOX REP, V2, P333, DOI 10.1080/13510002.1996.11747069	21	44	57	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1351-0002	1743-2928		REDOX REP	Redox Rep.		2002	7	4					219	222		10.1179/135100002125000587			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605PZ	WOS:000178687400005	12396667	Bronze			2022-02-06	
J	Piot-Grosjean, O; Wahl, F; Gobbo, O; Stutzmann, JM				Piot-Grosjean, O; Wahl, F; Gobbo, O; Stutzmann, JM			Assessment of sensorimotor and cognitive deficits induced by a moderate traumatic injury in the right parietal cortex of the rat	NEUROBIOLOGY OF DISEASE			English	Article						traumatic brain injury; rat; sensorimotor function; cognitive function; functional recovery	CONTROLLED CORTICAL IMPACT; EXPERIMENTAL BRAIN INJURY; CLOSED-HEAD-INJURY; FLUID-PERCUSSION MODEL; LONG-TERM; HIPPOCAMPAL DAMAGE; CEREBRAL EDEMA; SPATIAL MEMORY; TIME-COURSE; MAZE	The purpose of this study was to set-up a battery of behavioral tests to assess sensorimotor and cognitive deficits following a moderate traumatic brain injury (TBI) in rats. Coordinated walking ability was evaluated in an accelerated rotarod test. Vestibulomotor function and fine motor coordination were assessed by using a beam-walking task. Rotarod and beam-walking performances were both altered in injured rats compared to sham-operated and control rats. A more pronounced and longer-lasting deficit was measured in the beam-walking test. Cognitive function was studied by using the Lashley maze paradigm. A spatial localization deficit was significant for 4 weeks posttrauma in TBI rats. The beam-walking task and the Lashley maze are robust and sensitive methods in detecting sensorimotor and cognitive impairment after TBI in rats, respectively. These tests are proposed for evaluating the ability of new pharmacological agents to improve the functional recovery after a TBI in rats. (C) 2001 Elsevier Science.	Aventis Pharma, Neurodegenerat Dis Grp, CRVA, F-94403 Vitry Sur Seine, France		Piot-Grosjean, O (corresponding author), Aventis Pharma, Neurodegenerat Dis Grp, CRVA, 13 Quai Jules Guesde, F-94403 Vitry Sur Seine, France.		Gobbo, Oliviero L/R-1763-2016; Gobbo, Oliviero/S-2043-2019	Gobbo, Oliviero L/0000-0003-4629-9485; Gobbo, Oliviero/0000-0003-4629-9485			Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Cervos-Navarro J., 1991, J NEUROL SCI, V103, P3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DENENBERG VH, 1991, PHYSIOL BEHAV, V50, P857, DOI 10.1016/0031-9384(91)90031-I; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; JUCKER M, 1990, PHYSIOL BEHAV, V47, P207, DOI 10.1016/0031-9384(90)90062-9; Lashley KS, 1933, PHYSIOL REV, V13, P0001, DOI 10.1152/physrev.1933.13.1.1; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAIER NRF, 1934, J COMP NEUROL, V61, P395; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCDANIEL WF, 1995, BEHAV BRAIN RES, V70, P165, DOI 10.1016/0166-4328(95)80006-9; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; Newton R, 1989, Brain Inj, V3, P335, DOI 10.3109/02699058909004558; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OKEEFE J, 1979, BEHAV BRAIN SCI, V2, P487, DOI 10.1017/S0140525X00063949; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; SCHROTT LM, 1992, PHYSIOL BEHAV, V52, P1085, DOI 10.1016/0031-9384(92)90463-C; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267	56	44	47	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	DEC	2001	8	6					1082	1093		10.1006/nbdi.2001.0450			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	505BV	WOS:000172892100016	11741403				2022-02-06	
J	Suehiro, E; Singleton, RH; Stone, JR; Povlishock, JT				Suehiro, E; Singleton, RH; Stone, JR; Povlishock, JT			The immunophilin ligand FK506 attenuates the axonal damage associated with rapid rewarming following posttraumatic hypothermia	EXPERIMENTAL NEUROLOGY			English	Article						traumatic axonal injury; hypothermia; rewarming; FK506; beta-amyloid precursor protein (APP); RMO-14	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; CYCLOSPORINE-A; AXOLEMMAL PERMEABILITY; HEAD-INJURY; PHOSPHORYLATION; MODEL; RATS; PROTEOLYSIS; CALCINEURIN	Our laboratory has shown that traumatically induced axonal injury (TAI) is significantly reduced by posttraumatic hypothermia followed by slow rewarming. Further, TAI can be exacerbated by rapid rewarming, and the damaging consequences of rapid rewarming can be reversed by cyclosporin A, which is believed to protect via blunting mitochondrial permeability transition (MPT). In this communication, we continue investigating the damaging consequences of rapid posthypothermic rewarming and the protective role of immunophilin ligands using another member of the immunophilin family, FK506, which does not affect MPT but rather inhibits calcineurin. Rats were subjected to impact-acceleration brain injury followed by the induction of hypothermia with subsequent rapid or slow posthypothermic rewarming. During rewarming, animals received either FK506 or its vehicle. Three hours postinjury, animals were prepared for the visualization of TAI via antibodies targeting impaired axoplasmic transport (APP) and/or overt neurofilament alteration (RMO-14). Rapid rewarming exacerbated TAI, which was attenuated by FK506. This protection was statistically significant for the APP-immunoreactive fibers but not for the RMO-14-positive fibers. Combined labeling, using one chromagen to visualize both axonal changes, suggested that these two immunoreactive profiles revealed two distinct pathologies not occurring along the same axon. Collectively, these studies confirmed previous observations identifying the adverse consequences of rapid rewarming while also showing the complexity of the pathobiology of TAL Additionally, the demonstration that FK506 is protective suggests that calcineurin may be a major target for neuroprotection. (C) 2001 Academic Press.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi 7558505, Japan		Suehiro, E (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Box 980709, Richmond, VA 23298 USA.		Suehiro, Eiichi/I-5852-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kaplan B, 1996, TRANSPLANTATION, V62, P1174, DOI 10.1097/00007890-199610270-00025; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOIZUMI H, 2001, IN PRESS BRAIN RES; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; Lee RKK, 1999, J NEUROSCI, V19, P940; LEE VMY, 1987, J NEUROSCI, V7, P3474; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lote CJ, 2000, CLIN SCI, V99, P285, DOI 10.1042/CS20000076; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin R, 1999, NEUROSCIENCE, V88, P327, DOI 10.1016/S0306-4522(98)00244-9; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; MATA M, 1992, J NEUROCYTOL, V21, P199, DOI 10.1007/BF01194978; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pijak DS, 1996, J COMP NEUROL, V368, P569; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; POVLISHOCK JT, 2001, HEAD TRAUMA BASIC PR; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197	38	44	45	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	NOV	2001	172	1					199	210		10.1006/exnr.2001.7765			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	491BH	WOS:000172087800017	11681852				2022-02-06	
J	Mueller, FO				Mueller, FO			Catastrophic head injuries in high school and collegiate sports	JOURNAL OF ATHLETIC TRAINING			English	Article						fatality; brain injury	FOOTBALL PLAYERS; CONCUSSION	Objective: To describe the incidence of catastrophic head injuries in a variety of high school and college sports. Design and Setting: Data on catastrophic head injuries were compiled in a national surveillance system maintained by the National Center for Catastrophic Sports Injury Research. The data were compiled with the assistance of coaches, athletic trainers, athletic directors, executive officers of state and national athletic organizations, a national newspaper clipping service, professional associates of the researchers, and national sport organizations. Subjects: Data included all high school and college athletic programs in the United States. Measurements: Background information on the athlete (age, height, weight, experience, previous injury, etc), accident information, immediate and postaccident medical care, type of injury, and equipment involved. Autopsy reports were used when available. Results: A football-related fatality has occurred every year from 1945 through 1999, except for 1990. Head-related deaths accounted for 69% of football fatalities, cervical spinal injuries for 16.3%, and other injuries for 14.7%. High school football produced the greatest number of football head-related deaths. From 1984 through 1999, 69 football head-related injuries resulted in permanent disability. Sixty-three of the injuries were associated with high school football and 6 with college football. Although football has received the most attention, other sports have also been associated with head-related deaths and permanent disability injuries. From 1982 through 1999, 20 deaths and 19 permanent disability injuries occurred in a variety of sports. Track and field, baseball, and cheerleading had the highest incidence of these catastrophic injuries. Three deaths and 3 injuries resulting in permanent disability have occurred in female participants. Conclusions/Recommendations: Reliable data collection systems and continual analysis of the data can help us to reduce the number of catastrophic head-related injuries. I include additional recommendations for injury prevention.	Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA		Mueller, FO (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, CB 8700,204 Fetzer Gymnasium, Chapel Hill, NC 27599 USA.						Cantu R., 1992, PHYSICIAN SPORTSMED, V20, P14; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; JANE JA, 1981, ART SCI SPORTS MED; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; MUELLER FO, 2000, ANN SURVEY FOOTBALL, P1; NELSON WE, 1981, PHYSICIAN SPORTSMED, V9, P886; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider RC., 1973, HEAD NECK INJURIES F	11	44	45	0	16	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					312	315					4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	557NC	WOS:000175913800016	12937502				2022-02-06	
J	Schaefer, PW				Schaefer, PW			Applications of DWI in clinical neurology	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	4th Advanced Course on Magnetic Resonance Techniques in Multiple Sclerosis	MAY 18-20, 2000	MILIAN, ITALY			EP DWI; magnetic resonance; neurologic deficit	DIFFUSION-WEIGHTED MR; CREUTZFELDT-JAKOB-DISEASE; ACUTE CEREBRAL-ISCHEMIA; HIGH-RESOLUTION MEASUREMENT; TRAUMATIC BRAIN INJURY; TRACER BOLUS PASSAGES; MAGNETIC-RESONANCE; ACUTE STROKE; APPARENT DIFFUSION; SIGNAL INTENSITY	Echo planar diffusion-weighted imaging (EP DWI) provides information about the physiologic state of the brain that is not available on conventional magnetic resonance (MR) images. Specifically, it provides signal proportional to the molecular diffusion of water molecules. It has proven highly sensitive in the detection of acute infarction and it is reliable in differentiating acute stroke from other diseases that mimic acute stroke clinically and on conventional MR images. With perfusion imaging, diffusion-weighted imaging is useful in predicting final infarct size and patient outcome. Diffusion MR is also becoming increasingly useful in the evaluation of a wide variety of other disease processes including neoplasms, intracranial infections and traumatic brain injury. Because acute stroke is common in the differential diagnosis of the majority of patients who present with acute neurologic deficits, diffusion-weighted imaging has become an essential sequence. (C) 2001 Elsevier Science B.V. All rights reserved.	Massachusetts Gen Hosp, Div Neuroradiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Div Neuroradiol, Boston, MA 02115 USA		Schaefer, PW (corresponding author), Massachusetts Gen Hosp, Div Neuroradiol, Fruit St,GRB 285, Boston, MA 02114 USA.		Schaefer, Pamela/AAA-1323-2019				Ay H, 1999, NEUROLOGY, V52, P1784, DOI 10.1212/WNL.52.9.1784; AY H, 1999, 24 AM HEART ASS INT; Bahn MM, 1997, ARCH NEUROL-CHICAGO, V54, P1411, DOI 10.1001/archneur.1997.00550230078021; Baird AE, 1997, ANN NEUROL, V41, P581, DOI 10.1002/ana.410410506; Barber PA, 1998, NEUROLOGY, V51, P418, DOI 10.1212/WNL.51.2.418; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaulieu C, 1999, ANN NEUROL, V46, P568, DOI 10.1002/1531-8249(199910)46:4<568::AID-ANA4>3.0.CO;2-R; BEAULIEU CF, 1993, MAGNET RESON MED, V30, P201, DOI 10.1002/mrm.1910300208; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; BRUNBERG JA, 1995, AM J NEURORADIOL, V16, P361; BRYAN RN, 1991, AM J NEURORADIOL, V12, P611; CHABRIAT H, 1999, REVERSIBLE DECREASE; Chenevert TL, 2000, JNCI-J NATL CANCER I, V92, P2029, DOI 10.1093/jnci/92.24.2029; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; Connelly A, 1997, ARCH DIS CHILD, V77, P38, DOI 10.1136/adc.77.1.38; Corvol JC, 1998, STROKE, V29, P2649, DOI 10.1161/01.STR.29.12.2649; COWAN EM, 1994, NEUROPEDIATRICS, V25, P172, DOI 10.1055/s-2008-1073018; DARDZINSKI BJ, 1993, MAGNET RESON MED, V30, P318, DOI 10.1002/mrm.1910300307; Demaerel P, 1999, NEUROLOGY, V52, P205, DOI 10.1212/WNL.52.1.205; Duong TQ, 1998, MAGN RESON MED, V40, P1, DOI 10.1002/mrm.1910400102; Ebisu T, 1996, MAGN RESON IMAGING, V14, P1113, DOI 10.1016/S0730-725X(96)00237-8; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; Everdingen KJ, 1998, STROKE, V29, P1783; Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; GRANT P, 2001, IN PRESS RADIOLOGY; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HASEGAWA Y, 1994, NEUROLOGY, V44, P1484, DOI 10.1212/WNL.44.8.1484; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; KARONEN J, 2000, RADIOLOGY, V217, P668; Karonen JO, 1999, STROKE, V30, P1583, DOI 10.1161/01.STR.30.8.1583; KIDWELL C, 1999, 24 AM HEART ASS INT; Kim YJ, 1998, AM J ROENTGENOL, V171, P1487, DOI 10.2214/ajr.171.6.9843275; Kotsenas AL, 1999, PEDIATR RADIOL, V29, P524, DOI 10.1007/s002470050636; Krishnamoorthy KS, 2000, J CHILD NEUROL, V15, P592, DOI 10.1177/088307380001500905; KUCHARCZYK J, 1991, MAGNET RESON MED, V19, P311, DOI 10.1002/mrm.1910190220; KUCHARCZYK J, 1993, RADIOLOGY, V188, P711, DOI 10.1148/radiology.188.3.8351338; Lansberg MG, 1999, NEUROLOGY, V52, P1021, DOI 10.1212/WNL.52.5.1021; Lecouvet FE, 1999, NEUROLOGY, V52, P1085, DOI 10.1212/WNL.52.5.1085; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lovblad KO, 1997, ANN NEUROL, V42, P164; Lovblad KO, 1998, AM J NEURORADIOL, V19, P1061; Lutsep HL, 1997, ANN NEUROL, V41, P574, DOI 10.1002/ana.410410505; MAEDA M, 1992, J COMPUT ASSIST TOMO, V16, P514, DOI 10.1097/00004728-199207000-00003; MARKS M, 1999, 24 AM HEART ASS INT; Marks MP, 1996, RADIOLOGY, V199, P403, DOI 10.1148/radiology.199.2.8668785; MATSUMOTO K, 1995, AM J NEURORADIOL, V16, P1107; MINEMATSU K, 1993, NEUROLOGY, V43, P397, DOI 10.1212/WNL.43.2.397; MINEMATSU K, 1992, STROKE, V23, P1304, DOI 10.1161/01.STR.23.9.1304; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MINTOROVITCH J, 1994, J CEREBR BLOOD F MET, V14, P332, DOI 10.1038/jcbfm.1994.40; MOHR JP, 1995, STROKE, V26, P807, DOI 10.1161/01.STR.26.5.807; MOONEN CTW, 1991, MAGNET RESON MED, V19, P327, DOI 10.1002/mrm.1910190223; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; MULLER TB, 1995, STROKE, V26, P451, DOI 10.1161/01.STR.26.3.451; Nagesh V, 1998, STROKE, V29, P1778, DOI 10.1161/01.STR.29.9.1778; Niendorf T, 1996, MAGN RESON MED, V36, P847, DOI 10.1002/mrm.1910360607; Ostergaard L, 1996, MAGNET RESON MED, V36, P726, DOI 10.1002/mrm.1910360511; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Phillips MD, 1999, NEUROIMAG CLIN N AM, V9, P41; QUAST MJ, 1993, MAGN RESON IMAGING, V11, P465, DOI 10.1016/0730-725X(93)90465-P; Rordorf G, 1998, STROKE, V29, P939, DOI 10.1161/01.STR.29.5.939; ROSEN BR, 1991, MAGNET RESON MED, V19, P285, DOI 10.1002/mrm.1910190216; ROSEN BR, 1991, MAGNET RESON MED, V22, P293, DOI 10.1002/mrm.1910220227; ROSEN BR, 1990, MAGNET RESON MED, V14, P249, DOI 10.1002/mrm.1910140211; Schaefer P, 1998, P 36 ANN M AM SOC NE; SCHAEFER P, 1999, P 37 ANN M AM SOC NE; SCHAEFER P, 1997, P 35 ANN M AM SOC NE; Schaper S, 1997, PROTEINS, V28, P1; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; SCHUIER G, 1995, 3 SCI M SOC MAGN RES; Schwamm LH, 1998, STROKE, V29, P2268, DOI 10.1161/01.STR.29.11.2268; Schwartz RB, 1998, AM J NEURORADIOL, V19, P859; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; SINGER M, 1998, P 36 ANN M AM SOC NE; Singer MB, 1998, STROKE, V29, P133, DOI 10.1161/01.STR.29.1.133; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; Strupp M, 1998, ANN NEUROL, V43, P164, DOI 10.1002/ana.410430206; SYKOVA E, 1994, J CEREBR BLOOD F MET, V14, P301, DOI 10.1038/jcbfm.1994.37; Tatlisumak T, 1998, STROKE, V29, P850, DOI 10.1161/01.STR.29.4.850; TIEN RD, 1994, AM J ROENTGENOL, V162, P671, DOI 10.2214/ajr.162.3.8109520; Tong DC, 1998, NEUROLOGY, V50, P864, DOI 10.1212/WNL.50.4.864; TSURUDA JS, 1990, AM J NEURORADIOL, V11, P925; Tuor UI, 1998, EXP NEUROL, V150, P321, DOI 10.1006/exnr.1997.6766; Ueda T, 1999, AM J NEURORADIOL, V20, P983; vanderToorn A, 1996, MAGN RESON MED, V36, P914, DOI 10.1002/mrm.1910360614; VILLRINGER A, 1988, MAGNET RESON MED, V6, P164, DOI 10.1002/mrm.1910060205; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; WEISHMANN UC, 1997, LANCET, V350, P493; WICK M, 1995, STROKE, V26, P1930, DOI 10.1161/01.STR.26.10.1930	92	44	48	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	MAY 1	2001	186			1			S25	S35		10.1016/S0022-510X(01)00488-9			11	Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	450FJ	WOS:000169730600005	11334987				2022-02-06	
J	Maurino, J; Saposnik, G; Lepera, S; Rey, RC; Sica, RE				Maurino, J; Saposnik, G; Lepera, S; Rey, RC; Sica, RE			Multiple simultaneous intracerebral hemorrhages - Clinical features and outcome	ARCHIVES OF NEUROLOGY			English	Article							HEMATOMAS; MR	Background: The simultaneous occurrence of intracerebral hemorrhages in different arterial territories is an uncommon clinical event. Its predisposing factors and pathophysiological mechanisms are not clearly defined. Objective: To analyze the frequency, risk factors, clinical features, neuroimaging findings, and outcome of multiple simultaneous intracerebral hemorrhages (SIHs). Patients and Methods: We studied all patients with acute stroke admitted to our hospital from July 18, 1997, through December 18, 1999. Multiple SIHs were defined as the presence of 2 or more intracerebral hemorrhages affecting different arterial territories with identical computed tomographic density profiles. Patients with a history of traumatic brain injury were excluded from this study. Diagnostic investigation included routine blood and urine tests, coagulation studies, a chest radiograph, electrocardiogram, 2-dimensional transthoracic echocardiography, and computed tomography of the head without contrast medium. Disability was assessed using the National Institutes of Health Stroke Scale and Modified Rankin Scale. Results: Among 142 patients with hemorrhagic stroke, we found 4 (2.8%) with SIHs. All 4 patients had a history of uncontrolled arterial hypertension. We excluded other potential causes of multiple SIHs by using appropriate diagnostic tests. The most common clinical manifestations were headache and weakness. Localization of hematomas was supratentorial, except for one patient who had both infratentorial and supratentorial hemorrhages. The mean National Institutes of Health score an admission was 15 and the Modified Rankin Scale score was higher than 4 at 3 months. Conclusions: In our study, all patients with multiple SIHs had arterial hypertension and a poor outcome. Additional analytic studies, including new imaging techniques, can help to elucidate the association between arterial hypertension and multiple SIHs, rick factors, and underlying mechanisms of this clinical condition.	Univ Buenos Aires, Hosp JM Ramos Mejia, Dept Neurol, Stroke Serv, RA-1425 Buenos Aires, DF, Argentina		Maurino, J (corresponding author), Univ Buenos Aires, Hosp JM Ramos Mejia, Dept Neurol, Stroke Serv, Soler 4019,Sexto Piso, RA-1425 Buenos Aires, DF, Argentina.		Saposnik, Gustavo/M-3937-2017	Saposnik, Gustavo/0000-0002-5950-9886			BRODERICK JP, 1990, J NEUROSURG, V72, P195, DOI 10.3171/jns.1990.72.2.0195; Chan S, 1996, AM J NEURORADIOL, V17, P1821; DAMASIO H, 1983, ARCH NEUROL-CHICAGO, V40, P138, DOI 10.1001/archneur.1983.04050030032005; FREYTAG E, 1968, J NEUROL NEUROSUR PS, V31, P616, DOI 10.1136/jnnp.31.6.616; GILLES C, 1984, NEUROLOGY, V34, P730, DOI 10.1212/WNL.34.6.730; Guerrero A L, 1997, Neurologia, V12, P320; HICKEY WF, 1983, ARCH NEUROL-CHICAGO, V40, P519, DOI 10.1001/archneur.1983.04210070059016; KOMIYAMA M, 1995, NEURORADIOLOGY, V37, P129; Kwa VIH, 1998, ANN NEUROL, V44, P372, DOI 10.1002/ana.410440313; MCCORMICK WF, 1973, STROKE, V4, P946, DOI 10.1161/01.STR.4.6.946; Offenbacher H, 1996, AM J NEURORADIOL, V17, P573; Seijo M, 1996, Rev Neurol, V24, P549; Tanikake T, 1983, No Shinkei Geka, V11, P1085; TANNO H, 1989, Neurological Surgery, V17, P223; UNO M, 1991, Neurological Surgery, V19, P933; VERSTICHEL P, 1991, REV NEUROL, V147, P671; WEISBERG L, 1981, NEUROLOGY, V31, P897, DOI 10.1212/WNL.31.7.897	17	44	51	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	APR	2001	58	4					629	632		10.1001/archneur.58.4.629			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	419EG	WOS:000167935900013	11295994	Bronze			2022-02-06	
J	Rovlias, A; Kotsou, S				Rovlias, A; Kotsou, S			The blood leukocyte count and its prognostic significance in severe head injury	SURGICAL NEUROLOGY			English	Article						head injury; leukocytosis; neurological outcome; severity of injury	TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN INJURY; SUBARACHNOID HEMORRHAGE; CEREBRAL-ISCHEMIA; REPERFUSION INJURY; MYOCARDIAL INJURY; SKELETAL-MUSCLE; PLASMA; CATECHOLAMINES; INTERLEUKIN-1	BACKGROUND Head injury is associated with increased blood levels of catecholamines and cortisol. Catecholamines release neutrophil stores, and corticosteroids cause a decrease in the egress of neutrophils from the circulation. The acute-phase response is also characterized by a leukocytosis upon admission. Therefore, it is possible that an increase in the white blood cell (WBC) count might serve as an additional diagnostic and prognostic indicator in head injury. METHODS We prospectively studied 624 patients with severe, moderate, or minor head injury who were admitted to the neurosurgical department of Asclepeion Hospital in Athens between December 1997 and March 1999. In all cases, WBC count was obtained on admission to the emergency department. Factors that might influence WBC were excluded from this study. RESULTS Patients with severe head injury had significantly higher white blood cell counts than did those with moderate or minor injury (p < 0.001). Among the patients with severe head injury, a significant relationship was found between WBC counts and Glasgow Coma Scale score, pupillary reaction, and presence of subarachnoid hemorrhage (p < 0.001). In the same group of patients, WBC counts were significantly higher in those with an unfavorable outcome (p < 0.001). Multivariate analysis also showed that WBC counts were an independent predictor of outcome. CONCLUSIONS WBC counts on admission could serve as a significant parameter of severity of injury and as an additional predictor of neurological outcome in patients with severe head injury. (C) 2001 by Elsevier Science Inc.	Asclepeion Gen Hosp, Dept Neurosurg, Athens, Greece		Rovlias, A (corresponding author), 55 Erasinidou Str, Athens 17237, Greece.						Bednar MM, 1997, NEUROL RES, V19, P588; BOGGS DANE R., 1967, SEMINAR HEMATOL, V4, P359; Bouzarth NF, 1986, SURG GYNECOL OBSTET, V126, P995; CAPPS JA, 1896, AM J MED SCI, V3, P650; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COCHRANE CG, 1966, J EXP MED, V124, P733, DOI 10.1084/jem.124.4.733; CRUICKSHANK J M, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P634; CRUICKSHANK JM, 1972, J OBSTET GYN BR COMM, V79, P450; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; Dale DC, 1991, PRINCIPLES INTERNAL, P359; DEKABAN A, 1952, AMA ARCH NEUROL PSY, V67, P641, DOI 10.1001/archneurpsyc.1952.02320170059008; DINARELLO CA, 1985, J CLIN IMMUNOL, V5, P287, DOI 10.1007/BF00918247; DUTKA AJ, 1989, STROKE, V20, P390, DOI 10.1161/01.STR.20.3.390; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ENGLER RL, 1983, AM J PATHOL, V111, P98; FANTONE JC, 1982, AM J PATHOL, V107, P397; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HARLAN JM, 1985, BLOOD, V65, P513; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, P699; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; HUGHES WL, 1963, ARCH INTERN MED, V111, P338, DOI 10.1001/archinte.1963.03620270064010; JACKSON IJ, 1949, ARCH NEURO PSYCHIATR, V62, P572, DOI 10.1001/archneurpsyc.1949.02310170047004; JANOFF A, 1965, J EXP MED, V122, P841, DOI 10.1084/jem.122.5.841; JENNETT B, 1975, LANCET, V1, P480; JOLLY SR, 1983, CIRCULATION, V68, P185; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; KAKARIEKA A, 1995, CEREBROVASC DIS, V5, P403, DOI 10.1159/000107892; KESKIL S, 1994, ACTA NEUROCHIR, V131, P211, DOI 10.1007/BF01808615; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; KORTHUIS RJ, 1988, AM J PHYSIOL, V254, pH823, DOI 10.1152/ajpheart.1988.254.5.H823; KSIEZYCKA E, 1983, CIRCULATION, V68, P185; LUCCHESI BR, 1986, ANNU REV PHARMACOL, V26, P201, DOI 10.1146/annurev.pa.26.040186.001221; MARCUS AJ, 1983, STROKE, V14, P475, DOI 10.1161/01.STR.14.4.475; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McLaurin RL, 1974, HDB CLIN NEUROLOGY, V23, P109; Metchnikoff E., 1887, ANN I PASTEUR PARIS, V1, P321; MISSORI P, 1997, CLIN NEUROLOGY NEU S, V99, pS79; MOUFARRIJ NA, 1984, J NEUROSURG, V61, P1107, DOI 10.3171/jns.1984.61.6.1107; NEILDWYER G, 1974, BRAIN, V97, P79, DOI 10.1093/brain/97.1.79; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PARKINSON D, 1984, SURG NEUROL, V21, P132, DOI 10.1016/0090-3019(84)90330-6; Pentelenyi T, 1992, Acta Neurochir Suppl (Wien), V55, P21; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; POZZILLI C, 1985, ACTA NEUROL SCAND, V71, P396; RAO PS, 1983, CIRCULATION, V68, P185; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SCHMIDSCHONBEIN GW, 1987, FASEB J, V46, P2397; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Smith RR, 1988, CEREBRAL VASOSPASM; SPALLONE A, 1987, SURG NEUROL, V27, P253, DOI 10.1016/0090-3019(87)90038-3; SUVAL WD, 1987, AM J SURG, V154, P211, DOI 10.1016/0002-9610(87)90181-4; TEASDALE G, 1974, LANCET, V2, P81; VASTHARE US, 1990, SURG NEUROL, V33, P261, DOI 10.1016/0090-3019(90)90046-R; VONHOLST H, 1982, ACTA NEUROCHIR, V62, P177, DOI 10.1007/BF01403622; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YAMAKAWA T, 1987, CIRC SHOCK, V22, P323	64	44	57	0	5	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0090-3019			SURG NEUROL	Surg. Neurol.	APR	2001	55	4					190	196		10.1016/S0090-3019(01)00414-1			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	433WQ	WOS:000168784000001	11358584				2022-02-06	
J	Balabanov, R; Goldman, H; Murphy, S; Pellizon, G; Owen, C; Rafols, J; Dore-Duffy, P				Balabanov, R; Goldman, H; Murphy, S; Pellizon, G; Owen, C; Rafols, J; Dore-Duffy, P			Endothelial cell activation following moderate traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						adhesion molecules; E-selectin; endothelial cell activation; glucose transporter; ICAM-1; transferrin receptor; traumatic brain injury	INTERCELLULAR-ADHESION MOLECULE-1; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; HYDROGEN-PEROXIDE; MULTIPLE-SCLEROSIS; ICAM-1 EXPRESSION; HYPOBARIC HYPOXIA; GENE-EXPRESSION; RAT-BRAIN; TRANSFERRIN	Traumatic brain injury (TBI) initiates a cascade of acute and chronic injury responses which include disturbances in the cerebrovasculature that may result in the activation of the microvascular endothelial development of a dysfunction endothelium. The present study examines endothelial cell (EC) activation in a percussion model of moderate TBI. The criteria for endothelial activation used in these studies was surface expression of a number of markers collectively termed endothelial activation antigens. Temporal induction of the major histocompatibility (MHC) class II molecules, E-selectin (CD62E), vascular cell adhesion molecule (VACM-1) (CD106) as well as altered expression of constitutively expressed intercellular adhesion molecule-1 (ICAM-1) (CD54), the glucose transporter protein (glut-1), the transferrin receptor (tfR) (CD71), and MHC class I molecules was examined at various times following impact Induction of E-selectin and increased expression of ICAM-1 was seen by 2 h post-impact (PI) and was sustained through 24 h PI. Decreased expression of immunologically reactive glut-1 and tfR was observed by 2-4 h PI and remained low up to 24 h PI. No induction of VCAM-1, MHC class II molecules or altered constitutive expression or MHC class I molecules was seen. Changes in EC activation were observed predominantly at the site of impact and were diminished temporarily. These results indicate that mild concussive injury to the brain results in activation of the endothelium.	Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Anat, Detroit, MI 48201 USA		Dore-Duffy, P (corresponding author), Wayne State Univ, Sch Med, Dept Neurol, 421 E Canfield Ave 3206 Elliman Bldg, Detroit, MI 48201 USA.						Betz A. Lorris, 1993, P303; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; BRIELAND JK, 1992, ARCH BIOCHEM BIOPHYS, V294, P205; CABRE F, 1993, AGENTS ACTIONS, V38, P212, DOI 10.1007/BF01976213; CHIHARA J, 1992, J LIPID MEDIATOR, V5, P159; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; CORTRAN R, 1988, ENDOTHELIAL CELL BIO, P335; DeWitt D S, 1988, Brain Inj, V2, P291, DOI 10.3109/02699058809150899; Dore-Duffy P, 1999, MICROVASC RES, V57, P75, DOI 10.1006/mvre.1998.2112; DOREDUFFY P, 1994, J CEREBR BLOOD F MET, V14, P837, DOI 10.1038/jcbfm.1994.105; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GASIC AC, 1991, CIRCULATION, V84, P2154, DOI 10.1161/01.CIR.84.5.2154; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GUILIAN D, 1985, SCIENCE, V228, P497; HARIK SI, 1994, J APPL PHYSIOL, V77, P896, DOI 10.1152/jappl.1994.77.2.896; HARKER LA, 1988, ENDOTHELIAL CELLS, V1, P167; HARTUNG HP, 1994, NEUROLOGY, V44, P1153, DOI 10.1212/WNL.44.6.1153; HURWITZ AA, 1994, ADV NEUROIMMUNOL, V4, P249, DOI 10.1016/S0960-5428(06)80263-9; ISHIZUKA T, 1994, EUR J PHARMACOL, V262, P113, DOI 10.1016/0014-2999(94)90034-5; JANDER S, 1995, J CEREBR BLOOD F MET, V15, P42, DOI 10.1038/jcbfm.1995.5; KIM JS, 1995, J NEUROL SCI, V128, P45, DOI 10.1016/0022-510X(94)00203-Z; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; LACASSE C, 1991, J LEUKOCYTE BIOL, V49, P245, DOI 10.1002/jlb.49.3.245; LAFRENIE RM, 1993, CELL BIOPHYS, V23, P83; LAMANNA JC, 1992, J APPL PHYSIOL, V72, P2238, DOI 10.1152/jappl.1992.72.6.2238; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MILHOAN KA, 1992, AM J PHYSIOL, pH965; MORGANTIKOSSMAN MC, 1991, TRENDS PHARMACOL SCI, V13, P286; MORRIS CM, 1992, J NEUROCHEM, V59, P300, DOI 10.1111/j.1471-4159.1992.tb08904.x; MUNRO JM, 1989, AM J PATHOL, V135, P121; NOBLE E, 1991, AM J CARDIOL, V68, pC6; Noble KE, 1996, EUR J IMMUNOL, V26, P2944, DOI 10.1002/eji.1830261221; ORFEO T, 1994, J TRAUMA, V37, P347, DOI 10.1097/00005373-199409000-00003; ORUNDI PD, 1994, J NEUROTRAUM, V11, P105; PANEGYRES PK, 1992, J NEUROL NEUROSUR PS, V55, P4, DOI 10.1136/jnnp.55.1.4; POBER JS, 1988, AM J PATHOL, V133, P426; POBER JS, 1988, ENDOTHELIAL CELLS, V2, P259; Povlishock J T, 1992, Hum Cell, V5, P345; REHNCRONA S, 1989, J CEREBR BLOOD F MET, V9, P65, DOI 10.1038/jcbfm.1989.9; SASSEVILLE VG, 1992, AM J PATHOL, V141, P1021; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SUZUKI Y, 1992, BIOCHEM BIOPH RES CO, V184, P1339, DOI 10.1016/S0006-291X(05)80029-4; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TAYLOR EM, 1991, J NEUROCHEM, V57, P1584, DOI 10.1111/j.1471-4159.1991.tb06355.x; THEIL EC, 1990, J BIOL CHEM, V265, P4771; WAKEFIELD AJ, 1994, J CLIN PATHOL, V47, P129, DOI 10.1136/jcp.47.2.129; WARD PA, 1991, MOL ASPECTS MED, V12, P169, DOI 10.1016/0098-2997(91)90012-B; WASHINGTON R, 1994, ANN NEUROL, V35, P89, DOI 10.1002/ana.410350114; WILSON J, 1990, BLOOD, V76, P2578; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	55	44	47	1	7	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	MAR-APR	2001	23	2-3					175	182		10.1179/016164101101198514			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	422DX	WOS:000168104200009	11320596				2022-02-06	
J	Wheeler, MA; McMillan, CT				Wheeler, Mark A.; McMillan, Corey T.			Focal retrograde amnesia and the episodic-semantic distinction	COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE			English	Article							TEMPORAL-LOBE PATHOLOGY; CLOSED-HEAD INJURY; AUTOBIOGRAPHICAL EVENTS; MEMORY-DEFICIT; RETRIEVAL; PATIENT; RECOVERY; SELF; CONSOLIDATION; DISSOCIATION	This article reports a review of focal retrograde amnesia (FRA), or the phenomenon of organically based severe memory loss restricted to retrograde, or pretraumatic, memory. Cases of FRA are classified according to the type of memory loss: episodic, semantic, or both. A few different clusters of the disorder were identified. Lesions to either the anterior temporal lobes or the posterior/visual cortex can result in an FRA that devastates retrograde episodic memory, while having smaller effects on semantic memory. A number of left-hemisphere patients have FRA confined to semantic memory. There are several additional examples of FRA following minor cerebral trauma that disrupts either episodic memory alone or both episodic and semantic memory that are not accompanied by evidence of structural brain lesions. We discuss these different profiles of FRA and their implications for the understanding of memory retrieval.	[Wheeler, Mark A.; McMillan, Corey T.] Temple Univ, Philadelphia, PA 19122 USA		Wheeler, MA (corresponding author), Temple Univ, Dept Psychol, Weiss Hall, Philadelphia, PA 19122 USA.	mwheeler@nimbus.temple.edu	McMillan, Corey/M-3228-2013	McMillan, Corey/0000-0002-7581-6405			Baddeley A. D., 1990, AUTOBIOGRAPHICAL MEM; BROWN JW, 1995, APHASIOLOGY, V9, P163, DOI 10.1080/02687039508248703; Calabrese P, 1996, J NEUROL NEUROSUR PS, V61, P304, DOI 10.1136/jnnp.61.3.304; Carlesimo GA, 1998, CORTEX, V34, P449, DOI 10.1016/S0010-9452(08)70767-6; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; CROVITZ HF, 1976, B PSYCHONOMIC SOC, V7, P61, DOI 10.3758/BF03337122; CROVITZ HF, 1974, B PSYCHONOMIC SOC, V4, P517; Dalla Barba G, 1998, CORTEX, V34, P547; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P252, DOI 10.1001/archneur.1985.04060030070012; DERENZI E, 1987, CORTEX, V23, P575, DOI 10.1016/S0010-9452(87)80050-3; DeRenzi E, 1997, NEUROPSYCHOLOGIA, V35, P781, DOI 10.1016/S0028-3932(97)00018-3; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; DERENZI E, 1995, CORTEX, V31, P531, DOI 10.1016/S0010-9452(13)80064-0; Evans JJ, 1996, NEUROCASE, V2, P1; Fink GR, 1996, J NEUROSCI, V16, P4275; Fujii T, 1999, CORTEX, V35, P599, DOI 10.1016/S0010-9452(08)70822-0; Galton F., 1879, BRAIN, V2, P148, DOI DOI 10.1093/BRAIN/2.2.149; Glenberg AM, 1997, BEHAV BRAIN SCI, V20, P1, DOI 10.1017/S0140525X97470012; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; GROSSI D, 1988, CORTEX, V24, P457, DOI 10.1016/S0010-9452(88)80009-1; HODGES JR, 1993, BRAIN, V116, P921, DOI 10.1093/brain/116.4.921; HOKKANEN L, 1995, PSYCHOL MED, V25, P203, DOI 10.1017/S0033291700028245; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; KAPUR N, 1994, NEUROPSYCHOLOGIA, V32, P23, DOI 10.1016/0028-3932(94)90066-3; KAPUR N, 1989, CORTEX, V25, P387, DOI 10.1016/S0010-9452(89)80053-X; Kapur N, 1996, J COGNITIVE NEUROSCI, V8, P416, DOI 10.1162/jocn.1996.8.5.416; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; Kapur N, 1999, PSYCHOL BULL, V125, P800, DOI 10.1037/0033-2909.125.6.800; KIHLSTROM JF, 1995, HDB MEMORY DISORDERS, P337; Klein SB, 1996, J EXP PSYCHOL GEN, V125, P250, DOI 10.1037/0096-3445.125.3.250; Kopelman MD, 1999, NEUROPSYCHOLOGIA, V37, P939, DOI 10.1016/S0028-3932(98)00143-2; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; Kroll NEA, 1997, BRAIN, V120, P1377, DOI 10.1093/brain/120.8.1377; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; LUCCHELLI F, 1995, BRAIN, V118, P167, DOI 10.1093/brain/118.1.167; Maguire EA, 1999, HIPPOCAMPUS, V9, P54, DOI 10.1002/(SICI)1098-1063(1999)9:1<54::AID-HIPO6>3.0.CO;2-O; Maravita A, 1995, CORTEX, V31, P653, DOI 10.1016/S0010-9452(13)80018-4; Markowitsch HJ, 1999, CORTEX, V35, P243, DOI 10.1016/S0010-9452(08)70797-4; MARKOWITSCH HJ, 1985, J COMP NEUROL, V242, P425, DOI 10.1002/cne.902420310; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P947, DOI 10.1080/01688639308402610; Mattioli F, 1996, CORTEX, V32, P121, DOI 10.1016/S0010-9452(96)80021-9; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; Nyberg L, 1995, NEUROREPORT, V7, P249, DOI 10.1097/00001756-199512290-00060; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; OGDEN JA, 1993, NEUROPSYCHOLOGIA, V31, P571, DOI 10.1016/0028-3932(93)90053-3; PANDYA DN, 1987, FRONTAL LOBES REVISI, P159; Reinvang I, 1998, NEUROPSYCHOLOGIA, V36, P1335, DOI 10.1016/S0028-3932(98)00021-9; ROMANCAMPOS G, 1980, CORTEX, V16, P509, DOI 10.1016/S0010-9452(80)80053-0; Rubin DC, 1998, P NATL ACAD SCI USA, V95, P5413, DOI 10.1073/pnas.95.9.5413; SCHACTER DL, 1984, J VERB LEARN VERB BE, V23, P593, DOI 10.1016/S0022-5371(84)90373-6; SNOWDEN JS, 1996, FRONTOTEMPORAL LOBAR; STRACCIARI A, 1994, CORTEX, V30, P459, DOI 10.1016/S0010-9452(13)80341-3; STUSS DT, 1988, BRAIN COGNITION, V8, P21, DOI 10.1016/0278-2626(88)90036-X; Tanaka Y, 1999, NEUROLOGY, V53, P344, DOI 10.1212/WNL.53.2.344; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; TULVING E, 1984, BEHAV BRAIN SCI, V7, P223, DOI 10.1017/S0140525X0004440X; Tulving E., 1983, ELEMENTS EPISODIC ME; Viskontas IV, 2000, J NEUROSCI, V20, P5853, DOI 10.1523/JNEUROSCI.20-15-05853.2000; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331; WILLIAMS M, 1954, J NEUROL NEUROSUR PS, V17, P173, DOI 10.1136/jnnp.17.3.173; Yasuda K, 1997, CORTEX, V33, P623, DOI 10.1016/S0010-9452(08)70721-4; YONEDA Y, 1992, EUR NEUROL, V32, P340, DOI 10.1159/000116857	66	44	46	0	7	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1530-7026	1531-135X		COGN AFFECT BEHAV NE	Cogn. Affect. Behav. Neurosci.	MAR	2001	1	1					22	36		10.3758/CABN.1.1.22			15	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	V32LU	WOS:000208953500004	12467101	Bronze			2022-02-06	
J	Bradshaw, DRS; Ivarsson, J; Morfey, CL; Viano, DC				Bradshaw, DRS; Ivarsson, J; Morfey, CL; Viano, DC			Simulation of acute subdural hematoma and diffuse axonal injury in coronal head impact	JOURNAL OF BIOMECHANICS			English	Article						brain injury; head impact; subdural hematoma; diffuse axonal injury; physical model	PRIMATE	Coronal head impacts were simulated in a physical model, based on the hypothesis that acute subdural hematoma (ASDH) is related to cerebral vertex displacement and diffuse axonal injury (DAI) to local Green-Lagrange strain. The geometry of the 2D model was based on anatomical measurements taken from the MRI scans of 10 adult males. Silicone gel modelled the cerebrum, paraffin the CSF and elastic membranes the trabeculae of the sulci. Pendulum impacts gave peak angular acceleration of 7800 rad s (- 2) in models with and without sulci. The motion of the gel and Green-Lagrange strain were calculated from tracked coordinates of Patrick markers. Worst-case bridging vein strains are produced on the contrecoup side and are approximately doubled by adding sulci. Given that axons in the corpus callosum are highly oriented, Green-Lagrange strain was resolved in the fibre direction. It is found to be close to the minimum principal strain, indicating a degree of natural, teleological protection for the axons. The data support the use of Delta (0) over dot (peak) as a suitable descriptor for the risk of DAT but not for ASDH. (C) 2000 Elsevier Science Ltd. All rights reserved.	Univ Southampton, Inst Sound & Vibrat Res, Fluid Dynam & Acoust Grp, Highfield SO17 1BJ, England; First Technol Safety Syst, Plymouth, MI 48170 USA; Chalmers Univ Technol, Dept Machine & Vehicle Design, SE-41296 Gothenburg, Sweden		Bradshaw, DRS (corresponding author), Univ Southampton, Inst Sound & Vibrat Res, Fluid Dynam & Acoust Grp, Highfield SO17 1BJ, England.						ALDMAN B, 1981, P HEAD NECK INJ CONS; BAIN AC, 1999, P 43 STAPP CAR CRASH; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Holbourn AHS, 1943, LANCET, V2, P438; Ivarsson J, 2000, J BIOMECH, V33, P181, DOI 10.1016/S0021-9290(99)00144-X; IVARSSON J, 1999, THESIS CHALMERS U TE; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LOWENHIELM P, 1978, J BIOENG, V2, P501; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARGULIES SS, 1987, THESIS U PENNSYLVANI; MEANEY DF, 1990, P INT IRCOBI C BIOM; Meaney DF, 1991, THESIS U PENNSYLVANI; Miller RT, 1998, P 42 STAPP CAR CRASH; SAUREN AAH, 1993, P INT IRCOBI C BIOM; Viano D., 1997, INT J CRASHWORTHINES, V2, P191; Viano D. C., 1999, J CRASH PREVENTION I, V1, P35; Zarkovic K, 1991, Neurol Croat, V40, P129	20	44	50	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	JAN	2001	34	1					85	94		10.1016/S0021-9290(00)00135-4			10	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	392UV	WOS:000166431700010	11425084				2022-02-06	
J	Marklund, N; Clausen, F; Lewen, A; Hovda, DA; Olsson, Y; Hillered, L				Marklund, N; Clausen, F; Lewen, A; Hovda, DA; Olsson, Y; Hillered, L			alpha-Phenyl-tert-N-butyl nitrone (PBN) improves functional and morphological outcome after cortical contusion injury in the rat	ACTA NEUROCHIRURGICA			English	Article						MAP-2; Morris Water Maze; PBN; radical; rat; scavenger; TBI	TRAUMATIC BRAIN INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; SPATIAL MEMORY PERFORMANCE; EXPERIMENTAL HEAD-INJURY; SPIN-TRAPPING AGENT; CEREBRAL BLOOD-FLOW; FLUID-PERCUSSION; SUPEROXIDE-DISMUTASE; FREE-RADICALS; LIPID-PEROXIDATION	alpha -Phenyl-tert-N-butyl nitrone (BBN), a potent reactive oxygen species (ROS) scavenger, has shown robust neuroprotective properties in several models of acute brain injury, although not previously evaluated in traumatic brain injury (TBI). In this study, we assessed the potential efficacy of PEN in a weight drop model producing a controlled cortical contusion. Sham operation, mild or severe injury was induced in intubated and ventilated rats and functional and morphological outcome was used as end-points at two weeks postinjury. In the trauma groups, saline or PEN (30 mg/kg) was injected as an intravenous bolus 30 minutes prior to injury. At day 11-15 post-injury, cognitive disturbance was assessed using the Morris Water Maze (MWM) and estimation of lesion volume and hemispheric loss of tissue was made. No change in MWM performance were found in either of the mildly traumatized groups as compared to uninjured controls. In contrast, a significant decrease in total mean latency and increase in path length in the severely traumatized rats were found. PEN-treatment significantly improved MWM performance as compared to saline treatment at the severe injury level (p < 0.05). The mild injury level caused a discrete atrophy of the ipsilateral cortex with no effect of PEN treatment. The severe injury caused a substantial loss of ipsilateral hemispheric tissue and a large cortical cavitation. PEN pre-treatment significantly reduced the lesion volume and reduced hemispheric loss of tissue at this injury level (p < 0.05). Our results support the involvement of ROS in the injury process contributing to the tissue loss and cognitive disturbance after TBI. The potential clinical utility of PEN will have to be assessed using a post-injury dosing regime.	Univ Uppsala Hosp, Dept Neurosurg, Uppsala, Sweden; Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Dept Surg, Los Angeles, CA USA; Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA USA; Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden		Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Div Neurosurg, S-75185 Uppsala, Sweden.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626			AU AM, 1985, J CELL BIOCHEM, V27, P449, DOI 10.1002/jcb.240270413; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; CHEN GM, 1990, FREE RADICAL RES COM, V9, P317, DOI 10.3109/10715769009145690; CHEN GM, 1990, FREE RADICAL BIO MED, V9, P93, DOI 10.1016/0891-5849(90)90110-5; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CLAUSEN F, 1999, SOC NEUR ABSTR, V29, P822; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; Conti AC, 1998, J NEUROSCI, V18, P5663; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Farooque M, 1997, J NEUROTRAUM, V14, P469, DOI 10.1089/neu.1997.14.469; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferger B, 1998, J NEUROCHEM, V70, P276; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hensley K, 1998, J NEUROCHEM, V71, P2549; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; INANAMI O, 1995, FREE RADICAL RES, V23, P33, DOI 10.3109/10715769509064017; Kawamata T, 1997, ACT NEUR S, V70, P191; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marshall L F, 1995, New Horiz, V3, P573; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Paxinos G, 1997, RAT BRAIN STEREOTAXI; Peeling J, 1998, BRAIN RES, V795, P63, DOI 10.1016/S0006-8993(98)00253-4; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Sack CA, 1996, NEUROSCI LETT, V205, P181, DOI 10.1016/0304-3940(96)12417-4; SANADA T, 1993, J NEUROTRAUM, V10, P65, DOI 10.1089/neu.1993.10.65; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; VALTYSSON J, 1994, ACTA NEUROCHIR, V129, P58, DOI 10.1007/BF01400874; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	68	44	44	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2001	143	1					73	81		10.1007/s007010170141			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	402CA	WOS:000166967400031	11345721				2022-02-06	
J	Possl, O; Jurgensmeyer, S; Karlbauer, F; Wenz, C; Goldenberg, G				Possl, O; Jurgensmeyer, S; Karlbauer, F; Wenz, C; Goldenberg, G			Stability of employment after brain injury: a 7-year follow-up study	BRAIN INJURY			English	Article							HEAD-INJURY; WORK; RETURN; REHABILITATION	Forty-three patients with severe traumatic brain injury (n = 24), cerebrovascular diseases (n = 15), or other acquired brain damage (n = 4) were followed-up 7-8 years after neuropsychological rehabilitation including a vocational re-entry programme. Current vocational status and work history since rehabilitation were investigated by means of a structured interview. Before interview, the patients were classified on the basis of medical records into four groups: (A) patients with minor residual neuropsychological impairments, (B) patients with minor impairments but psychopathological symptoms, (C) patients with persistent neuropsychological impairments showing no psychopathological symptoms, and (D) patients with persistent impairments and psychopathological symptoms. For patients in group A, a good, and for those in group D, a poor long-term employment outcome was predicted, while no predictions were made for the intermediate groups. Of the 43 interviewed subjects, 16 (37%) reported a stable return to work at pre-morbid level and seven (16%) at a lower level. In eight patients (19%), persisting difficulties in maintaining work were documented. Twelve subjects (28%) had retired within a period of 2 years after work trial. The relationship between patient classification and longterm employment outcome was only weak. Four out of 11 patients with a good prognosis (group A) experienced vocational adjustment problems or had retired. Three out of 10 patients with a poor prognosis (group D) were able to continue successfully with their previous jobs. These cases are described in detail. The employment outcome of the intermediate groups was very heterogeneous. The results suggest that particular attention should be paid to the long-term consequences of a reduced capacity for work, even if minor in degree. The success of patients despite a poor prognosis illustrate unsolved problems in relation to the ecological validity of neuropsychological measures of executive dysfunctions.	Stadt Krankenhaus Munchen Bogenhausen, Abt Neuropsychol, D-81925 Munich, Germany		Possl, O (corresponding author), Stadt Krankenhaus Munchen Bogenhausen, Abt Neuropsychol, Englschalkinger Str 77, D-81925 Munich, Germany.						ASHELY MJ, 1997, BRAIN INJURY, V11, P677; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HAFFEY WJ, 1989, REHABIL PSYCHOL, V34, P147, DOI 10.1037//0090-5550.34.2.147; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; JOHNSTONE B, 1995, NEUROREHABILITATION, V5, P75, DOI 10.3233/NRE-1995-5107; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P195; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Sherron P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, https://doi.org/10.1097/00001199-199109000-00004]; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEHMAN P, 1990, VOCATIONAL REHABILIT; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047	23	44	44	0	6	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2001	15	1					15	27					13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	384UF	WOS:000165963600002	11201311				2022-02-06	
J	Irazuzta, JE; Pretzlaff, R; Rowin, M; Milam, K; Zemlan, FP; Zingarelli, B				Irazuzta, JE; Pretzlaff, R; Rowin, M; Milam, K; Zemlan, FP; Zingarelli, B			Hypothermia as an adjunctive treatment for severe bacterial meningitis	BRAIN RESEARCH			English	Article						meningitis; hypothermia; intracranial pressure; cerebral perfusion pressure; inflammation; cleaved tau protein	TRAUMATIC BRAIN INJURY; NITRIC-OXIDE SYNTHASE; CEREBRAL PERFUSION-PRESSURE; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; CEREBROSPINAL-FLUID; RAT-BRAIN; MYELOPEROXIDASE ACTIVITY; NEUTROPHIL ACCUMULATION; HEAD-INJURY	Brain injury due to bacterial meningitis results in a high mortality rate and significant neurologic sequelae in survivors. The objective of this study was to determine if the application of moderate hypothermia shortly after the administration of antibiotics would attenuate the inflammatory response and increase in intracranial pressure that occurs in meningitis. For this study we used a rabbit model of severe Group B streptococcal meningitis. The first component of this study evaluated the effects of hypothermia on blood-brain barrier function and markers of inflammation in meningitic animals. The second part of the study evaluated the effects of hypothermia on intracranial pressure, cerebral perfusion pressure and brain edema. This study demonstrates that the use of hypothermia preserves CSF/serum glucose ratio, decreases CSF protein and nitric oxide and attenuates myeloperoxidase activity in brain tissue. In the second part of this study we show a decrease in intracranial pressure, an improvement in cerebral perfusion pressure and a decrease in cerebral edema in hypothermic meningitic animals. We conclude that in the treatment of severe bacterial meningitis, the application of moderate hypothermia initiated shortly after antibiotic therapy improves short-term physiologic measures associated with brain injury. (C) 2000 Elsevier Science B.V. All rights reserved.	Childrens Hosp, Med Ctr, Div Crit Care, Cincinnati, OH 45229 USA; Marshall Univ, Huntington, WV USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA		Irazuzta, JE (corresponding author), Div Crit Care, 1 Childrens Plaza, Dayton, OH 45404 USA.	irazuzta@aol.com	, Basilia/AAV-7582-2021				AMAEE FR, 1995, ACTA OTO-LARYNGOL, V115, P386, DOI 10.3109/00016489509139334; Angstwurm K, 2000, J CEREBR BLOOD F MET, V20, P834, DOI 10.1097/00004647-200005000-00010; ARDITI M, 1989, J INFECT DIS, V160, P1005, DOI 10.1093/infdis/160.6.1005; Arditi M, 1998, PEDIATRICS, V102, P1087, DOI 10.1542/peds.102.5.1087; BARAFF LJ, 1993, PEDIATR INFECT DIS J, V12, P389, DOI 10.1097/00006454-199305000-00008; BARONE FC, 1995, MOL CHEM NEUROPATHOL, V24, P13, DOI 10.1007/BF03160109; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BERING EA, 1961, AM J PHYSIOL, V200, P417; Black SM, 1995, NEUROBIOL DIS, V2, P145, DOI 10.1006/nbdi.1995.0016; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; Boje KMK, 1996, BRAIN RES, V720, P75, DOI 10.1016/0006-8993(96)00142-4; BURYAKOVA AV, 1975, ARCH NEUROL-CHICAGO, V32, P28, DOI 10.1001/archneur.1975.00490430050007; BUSTER BL, 1995, INFECT IMMUN, V63, P3835, DOI 10.1128/IAI.63.10.3835-3839.1995; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CANEVARY L, 1999, BRAIN RES, V817, P341; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; Darakchiev BJ, 1997, ACT NEUR S, V70, P98; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hansbrough JF, 1996, J SURG RES, V61, P17, DOI 10.1006/jsre.1996.0074; HOROWITZ L, 1997, AM J PHYSIOL, V272, pH614; HORWITZ SJ, 1980, ANN NEUROL, V7, P524, DOI 10.1002/ana.410070605; Irazuzta JE, 2000, LIFE SCI, V67, P365, DOI 10.1016/S0024-3205(00)00637-8; Irazuzta JE, 1999, BRAIN RES, V847, P143, DOI 10.1016/S0006-8993(99)02120-4; KELLY BJ, 1993, CHEST, V103, P1246, DOI 10.1378/chest.103.4.1246; KILPI T, 1993, PEDIATR INFECT DIS J, V12, P184, DOI 10.1097/00006454-199303000-00002; Kim YS, 1996, INFECT IMMUN, V64, P3148, DOI 10.1128/IAI.64.8.3148-3153.1996; KIM YS, 1995, J NEUROPATH EXP NEUR, V54, P531, DOI 10.1097/00005072-199507000-00007; Koedel U, 1999, BRAIN PATHOL, V9, P57; Kornelisse RF, 1996, J INFECT DIS, V174, P120, DOI 10.1093/infdis/174.1.120; Lahrtz F, 1998, J NEUROIMMUNOL, V85, P33, DOI 10.1016/S0165-5728(97)00267-1; LEBEL MH, 1989, PEDIATRICS, V83, P161; Marion DW, 1997, J INTENSIVE CARE MED, V12, P239, DOI 10.1177/088506669701200504; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; Moller K, 2000, CRIT CARE MED, V28, P1027, DOI 10.1097/00003246-200004000-00019; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUSTAFA MM, 1989, J CLIN INVEST, V84, P1253, DOI 10.1172/JCI114292; Nemoto EM, 1996, J NEUROSURG ANESTH, V8, P52, DOI 10.1097/00008506-199601000-00012; RENNICK G, 1993, BRIT MED J, V306, P953, DOI 10.1136/bmj.306.6883.953; RISCHBIETH R. H., 1960, MED JOUR AUSTRALIA I, V47, P578; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSOMOFF HL, 1959, J NEUROSURG, V16, P177, DOI 10.3171/jns.1959.16.2.0177; Rowin ME, 1999, PEDIATR RES, V45, p173A, DOI 10.1203/00006450-199904020-01028; ROWIN ME, 2000, INFLAMMATION, V23, P23; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SWARTZ MN, 1984, NEW ENGL J MED, V14, P912; TAUBER MG, 1987, J INFECT DIS, V156, P456, DOI 10.1093/infdis/156.3.456; Tucci S, 1998, CLIN BIOCHEM, V31, P143, DOI 10.1016/S0009-9120(98)00003-4; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Whalen MJ, 1997, ACT NEUR S, V70, P260; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; ZEMLAN FP, 1997, NEUR ABSTR, V23, P2220; ZEMLAN FP, 2000, IN PRESS CHARACTERIZ; Zingarelli B, 1996, J IMMUNOL, V156, P350	66	44	48	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 20	2000	881	1					88	97		10.1016/S0006-8993(00)02894-8			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	366ZQ	WOS:000090036500012	11033098				2022-02-06	
J	Minnes, P; Graffi, S; Nolte, ML; Carlson, P; Harrick, L				Minnes, P; Graffi, S; Nolte, ML; Carlson, P; Harrick, L			Coping and stress in Canadian family caregivers of persons with traumatic brain injuries	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; RELATIVES VIEW	The purpose of this study was to document the stresses reported by Canadian caregivers of persons with brain injuries and to consider the factors which serve to mediate or moderate such stress. Highest stress scores on the Holroyd Questionnaire on Resources and Stress-Short Form (QRS) were associated with Lifespan Care and Personal Burden. Although overall burden as reported on the QRS by parents and spouses did not differ from other studies, it did differ somewhat for specific types of burden. Social Support and Spiritual Support, as measured by the F-COPES, fell within the medium use category, and scores for Reframing, Mobilizing and Passive Appraisal fell within the high use category. In multiple regression analyses, client competency as measured by the Patient Competency Rating Scale emerged as a major predictor of stress associated with Cognitive Impairment, Physical Limitations, Lifespan Care, Terminal Illness Stress, Limits on Family Opportunities, and Personal Burden. In contrast, other client characteristics (e.g. Time Since Injury) accounted for relatively little variance. The results also indicate that both Reframing and Seeking Spiritual Support as coping strategies can make an important contribution to stress reduction.	Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada; Reg Community Brain Injury Serv, Kingston, ON, Canada		Minnes, P (corresponding author), Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada.						ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; BOND N, 1984, CLOSED HEAD INJURY P, P123; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; DEPOMOEI R, 1991, HEAD INJURY FAMILY M, P100; FOLKMAN S, 1988, J PERS SOC PSYCHOL, V54, P466, DOI 10.1037/0022-3514.54.3.466; FRANK R G, 1990, Brain Injury, V4, P289, DOI 10.3109/02699059009026179; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; HOLROYD J, 1979, J CLIN PSYCHOL, V325, P743; HOLROYD J, 1982, MANUAL QUESTIONNAIRE; Jackson A, 1991, COUNS PSYCHOL, V4, P355; KAY T, 1991, HEAD INJURY FAMILY M, P121; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Larsen, 1987, FAMILY CRISIS ORIENT; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCCOLL MA, IN PRESS DISABILITY; MCCUBBIN HI, 1982, FAMILY STRESS COPING, P00026, DOI DOI 10.1177/0730888412446710; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MINNES P, 1998, HDB MENTAL RETARDATI, P693; MINNES PM, 1988, AM J MENT RETARD, V93, P184; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; TAYLOR SE, 1983, AM PSYCHOL, V38, P1161, DOI 10.1037/0003-066X.38.11.1161; Willer B., 1990, CANADIAN J REHABILIT, V3, P167; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WILTON K, 1986, J MENT DEFIC RES, V30, P163	35	44	47	0	3	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2000	14	8					737	748					12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	342XT	WOS:000088672000007	10969892				2022-02-06	
J	Shields, DC; Schaecher, KE; Hogan, EL; Banik, NL				Shields, DC; Schaecher, KE; Hogan, EL; Banik, NL			Calpain activity and expression increased in activated glial and inflammatory cells in penumbra of spinal cord injury lesion	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						calpain; calpastatin; spinal cord injury; calcium; neutral proteinase	PROTEOLYTIC-ENZYME; DEGRADATION; BRAIN; PROTEINS; DEMYELINATION; INHIBITOR; NEURONS; DISEASE	Following traumatic injury of the spinal cord, cells adjacent to the lesion are subject to ischemic cell death as a result of vascular disruption and secondary inflammatory responses. Proteases such as calcium-activated neutral proteinase (calpain) have been implicated in axon and myelin destruction following injury since they degrade structural proteins in the axon-myelin unit. To examine the role of calpain in cell death following spinal cord injury (SCI), calpain activity and translational expression were evaluated using Western blotting techniques. Calpain activity (as measured by specific substrate degradation) was significantly increased in and around the lesion site as early as 4 hr following injury with continued elevation at 48 hr compared to sham controls. Likewise, calpain expression was significantly increased in both the lesion site and penumbra at 4 and 48 hr after injury. Using double immunofluorescent labeling for calpain and cell-specific markers, this increase in calpain expression was found to be due in part to activated glial/inflammatory cells such as astrocytes, microglia, and infiltrating macrophages in these areas. Thus, since calpain degrades many myelin and axonal structural proteins, the increased activity and expression of this enzyme may be responsible for destruction of myelinated axons adjacent to the lesion site following SCI. (C) 2000 Wiley-Liss, Inc.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA		Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol, 171 Ashley Ave, Charleston, SC 29425 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31622, NS38146] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038146, R01NS031622] Funding Source: NIH RePORTER		Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; BALENTINE JD, 1985, TRAUMA CENTRAL NERVO, P285; BANAYSCHWARTZ M, 1994, NEUROCHEM RES, V19, P563, DOI 10.1007/BF00971331; Banik N.L, 1999, CALPAIN PHARM TOXICO, P211; Banik Naren L., 1992, P571; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002; BANIK NL, 1986, J NEUROL SCI, V73, P245, DOI 10.1016/0022-510X(86)90149-8; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P92; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DESHPANDE RV, 1995, J NEUROSCI RES, V42, P259, DOI 10.1002/jnr.490420214; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HOGAN EL, 1985, HDB NEUROCHEMISTRY, V10, P285; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MouattPrigent A, 1996, NEUROSCIENCE, V73, P979, DOI 10.1016/0306-4522(96)00100-5; NIXON RA, 1986, J NEUROSCI, V6, P1264; Perot P L Jr, 1987, Cent Nerv Syst Trauma, V4, P149; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Shields DC, 1998, BRAIN RES, V794, P68, DOI 10.1016/S0006-8993(98)00193-0; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Smith ME, 1998, J NEUROSCI RES, V54, P68, DOI 10.1002/(SICI)1097-4547(19981001)54:1<68::AID-JNR8>3.0.CO;2-F; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1	35	44	45	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUL 15	2000	61	2					146	150					5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	331AJ	WOS:000087994500005	10878587				2022-02-06	
J	Palmese, CA; Raskin, SA				Palmese, CA; Raskin, SA			The rehabilitation of attention in individuals with mild traumatic brain injury, using the APT-II programme	BRAIN INJURY			English	Article							HEAD-INJURY	Traumatic brain injury (TBI) is a prevalent cause of cognitive impairments and dysfunctions and affects over 2 million individuals each year. Mild traumatic brain injury (MTBI) is generally defined by a brief loss of consciousness, and post-traumatic amnesia that lasts for less than 24 hours. One region of the brain that is likely affected in patients with MTBI is the pre-frontal cortex. This region mediates several functions, including those required for adequate attention. Three individuals, diagnosed with MTBI and difficulties with attention, volunteered to participate in the study. Individuals were presented with 10 weeks of cognitive retraining with the Attention Process Training-II (APT-II) programme, followed by 6 or 7 weeks of educational and applicational programmes. Cognitive tests were administered both pre- and post-training to assess the effectiveness of the programme. Analysis of the results showed that the APT-II programme improved attention and performance speed in each of the three individuals. In addition, any rehabilitated cognitive skills remained stable in each individual in the absence of the rehabilitation programme for at least 6 weeks.	Trinity Coll, Program Neurosci, Hartford, CT 06106 USA; Trinity Coll, Dept Psychol, Hartford, CT 06106 USA; CUNY Queens Coll, Neuropsychol Program, Flushing, NY 11367 USA		Palmese, CA (corresponding author), CUNY Coll Staten Isl, PSAS Dept, Bldg 4S,Rm223,2800 Victory Blvd, Staten Isl, NY 10314 USA.		Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			Anderson SD, 1996, B AM ACAD PSYCH LAW, V24, P493; BRUCKNER P, 1996, AUSTR FAMILY PHYSICI, V25, P1445; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Diamond M. C., 1988, ENRICHING HEREDITY I; FARMER JE, 1988, BRAIN INJURY, V4, P323; GIARDI PA, 1994, FINAL REPORT FINDING; GRONWALL DM, 1977, PERCEPT MOTOR SKILL, V55, P367; JOHNSTONE B, 1998, RECOVERY TRAUMATIC B, P115; KAY T, 1986, MINOR HEAD INJURY IN; KOLB B, 1996, FUNDAMENTALS HUMAN N; LEWINE JD, 1998, RECOVERY TRAUMATIC B, P1; LEWIS R, 1996, MANUAL REPEATABLE CO; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Raskin S., 1992, NEUROREHABILITATION, V2, P38; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Raskin SA, 1994, HDB NEUROREHABILITAT, P243; SINDEN JD, 1992, ADV EXPT MED BIOL RE, P35; Smith A., 1993, SYMBOL DIGIT MODALIT; SOHLBERG M, 1989, ATTENTION PROCESS TE; SOHLBERG M, ATTENTION PROCESS TR, V2; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TSUBOKAWA T, 1998, RECOVERY TRAUMATIC B, P83; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY	29	44	44	1	8	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2000	14	6					535	548					14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	325WN	WOS:000087699600004	10887887				2022-02-06	
J	O'Dell, DM; Gibson, CJ; Wilson, MS; DeFord, SM; Hamm, RJ				O'Dell, DM; Gibson, CJ; Wilson, MS; DeFord, SM; Hamm, RJ			Positive and negative modulation of the GABA(A) receptor and outcome after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						traumatic brain injury; diazepam; bicuculline; cognition; (gamma)-aminobutyric acid; rat	GAMMA-AMINOBUTYRIC-ACID; EXCITATORY AMINO-ACIDS; CEREBRAL BLOOD-FLOW; CLOSED HEAD-INJURY; GLUTAMATE NEUROTOXICITY; POSTISCHEMIC DIAZEPAM; CEREBROSPINAL-FLUID; GERBIL HIPPOCAMPUS; NEURONAL INJURY; NERVOUS-SYSTEM	Glutamate-mediated excitotoxicity has been shown to contribute to cellular dysfunction following traumatic brain injury (TBI). Increasing inhibitory function through stimulation of gamma-aminobutyric acid (GABA(A)) receptors may attenuate excitotoxic effects and improve outcome. The present experiment examined the effects of diazepam, a positive modulator at the GABA(A) receptor, on survival and cognitive performance in traumatically brain-injured animals. In experiment 1, 15 min prior to central fluid percussion brain injury, rats (n = 8 per group) were injected (i.p.) with saline or diazepam (5 mg/kg or 10 mg/kg). Additional rats (n = 8) were surgically prepared but not injured (sham-injury). Rats pre-treated with the 5 mg/kg dose of diazepam had significantly lower mortality (0%) than injured, saline-treated rats (53%). Also, diazepam-treated (5 mg/kg) rats had significantly shorter latencies to reach the goal platform in the Morris water maze test performed 11-15 days post-injury. In experiment 2, at 15 min post-injury, rats were given either saline (n = 5) or 5 mg/kg diazepam (n = 6). Rats treated with diazepam did not differ in mortality from injured rats treated with vehicle. However, rats treated with diazepam at 15 min post-injury had significantly shorter latencies to reach the goal platform in the Morris water maze than injured, vehicle-treated rats. In experiment 3, the post-injury administration of bicuculline (1.5 mg/kg, n = 8), a GABA, antagonist, increased Morris water maze goal latencies compared to injured animals treated with saline (n = 8). These results suggest that enhancing inhibitory function during the acute: post-injury period produces beneficial effects on both survival and outcome following experimental TBI. (C) 2000 Elsevier Science B.V. All rights reserved.	Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA		Hamm, RJ (corresponding author), Virginia Commonwealth Univ, Dept Psychol, POB 842018, Richmond, VA 23284 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; FOSTER NL, 1987, J CEREBR BLOOD F MET, V7, P415, DOI 10.1038/jcbfm.1987.84; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P1; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HOVDA DA, 1990, ACT NEUR S, V51, P331; Inglefield JR, 1995, HIPPOCAMPUS, V5, P460, DOI 10.1002/hipo.450050508; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JOHANSEN FF, 1991, ACTA NEUROL SCAND, V84, P1; JOHANSEN J, 1985, P NATL ACAD SCI USA, V82, P3935, DOI 10.1073/pnas.82.11.3935; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; Kanthasamy AG, 1995, BRAIN RES, V705, P97, DOI 10.1016/0006-8993(95)01147-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LOSCHER W, 1987, J NEUROCHEM, V49, P152, DOI 10.1111/j.1471-4159.1987.tb03407.x; LYDEN PD, 1994, STROKE, V25, P189, DOI 10.1161/01.STR.25.1.189; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MACDONALD RL, 1993, EPILIPSIA, V34, P1; MARK RJ, 1995, NEUROBIOL AGING, V16, P187, DOI 10.1016/0197-4580(94)00150-2; MATHEW RJ, 1985, BIOL PSYCHIAT, V20, P1109, DOI 10.1016/0006-3223(85)90010-1; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; ROALD OK, 1986, ACTA ANAESTH SCAND, V30, P341, DOI 10.1111/j.1399-6576.1986.tb02427.x; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHWARTZ RD, 1994, BRAIN RES, V647, P153, DOI 10.1016/0006-8993(94)91411-7; SCHWARTZ RD, 1995, J NEUROSCI, V15, P529; SHUAIB A, 1993, EXP NEUROL, V123, P284, DOI 10.1006/exnr.1993.1160; Smith DH, 1997, NEUROSCI LETT, V231, P135, DOI 10.1016/S0304-3940(97)00551-X; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; STERNAU LL, 1989, STROKE, V20, P281, DOI 10.1161/01.STR.20.2.281; STUDY RE, 1982, JAMA-J AM MED ASSOC, V247, P2147, DOI 10.1001/jama.247.15.2147; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; VOLL CL, 1991, NEUROLOGY, V41, P423, DOI 10.1212/WNL.41.3.423; Wallis RA, 1995, EUR J PHARMACOL, V294, P475, DOI 10.1016/0014-2999(95)00568-4; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YLINEN A, 1991, NEUROPEPTIDES, V19, P205, DOI 10.1016/0143-4179(91)90120-8; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	54	44	46	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 10	2000	861	2					325	332		10.1016/S0006-8993(00)02055-2			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	303GL	WOS:000086414100013	10760494				2022-02-06	
J	Cheung, NS; Beart, PM; Pascoe, CJ; John, CA; Bernard, O				Cheung, NS; Beart, PM; Pascoe, CJ; John, CA; Bernard, O			Human Bcl-2 protects against AMPA receptor-mediated apoptosis	JOURNAL OF NEUROCHEMISTRY			English	Article						(S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate; Bcl-2; apoptosis; necrosis; glutamate; excitotoxicity	PROGRAMMED CELL-DEATH; INDUCED NEURONAL APOPTOSIS; PROTOONCOGENE BCL-2; HIPPOCAMPAL-NEURONS; GLUTAMATE RECEPTORS; CORTICAL-NEURONS; KAINIC ACID; NEUROTOXICITY; SCHIZOPHRENIA; ACTIVATION	Dysfunctions of the (S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) subtype of ionotropic receptor for the brain's major excitatory neurotransmitter, L-glutamate, occur in various neurological conditions. We have previously demonstrated that AMPA receptor-mediated excitotoxicity occurs by apoptosis and here examined the influence of the expression of cell death repressor gene Bcl-2 on this excitotoxic insult. Using neuronal cortical cultures prepared from transgenic mice expressing the human Bcl-2 gene, the influence of Bcl-2 on AMPA receptor-mediated neuronal death was compared with that seen with staurosporine and H2O2. At day 6 cultures were exposed to AMPA (0.1-100 mu M), and cellular injury was analyzed 48 h after insult using phase-contrast microscopy, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide viability assay, and DNA staining with 4,6-diamidino-2-phenylindole and Sytox Green. AMPA produced a concentration-dependent increase in cell death that was significantly attenuated by human Bcl-2. AMPA (3 mu M) increased the number of apoptotic nuclei to 60% of control in wild-type cultures, and human Bcl-2 significantly decreased the number of apoptotic nuclei to 30% of AMPA-treated cultures. Human Bcl-2 only provided significant neuroprotection against neuronal injury induced by tow concentrations of staurosporine (1-10 nM) and H2O2 (0.1-30 mu M) and where neuronal death was by apoptosis, but not against H2O2-induced necrosis. Our findings indicate that overexpression of Bcl-2 in primary cultured neurons protects in an insult-dependent manner against AMPA receptor-mediated apoptosis, whereas protection was not seen against more traumatic insults. This study provides new insights into the molecular therapeutics of neurodegenerative conditions.	Monash Univ, Dept Pharmacol, Clayton, Vic 3168, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia		Beart, PM (corresponding author), Monash Univ, Dept Pharmacol, Clayton, Vic 3168, Australia.	Phil.beart@med.monash.edu.au					AKBARIAN S, 1995, BRAIN RES, V699, P297, DOI 10.1016/0006-8993(95)00922-D; ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BEHL C, 1993, BIOCHEM BIOPH RES CO, V197, P949, DOI 10.1006/bbrc.1993.2571; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Cheung NS, 1998, NEUROPHARMACOLOGY, V37, P1419, DOI 10.1016/S0028-3908(98)00123-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COYLE JT, 1983, J NEUROCHEM, V41, P1; Eastwood SL, 1997, BIOL PSYCHIAT, V41, P636, DOI 10.1016/S0006-3223(96)00220-X; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; Gill R, 1997, INT REV NEUROBIOL, V40, P197; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Haugland R. P., 1996, HDB FLUORESCENT PROB, P149; Heaton MB, 1999, BRAIN RES, V817, P13, DOI 10.1016/S0006-8993(98)01173-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jacobson MD, 1998, CURR BIOL, V8, pR418, DOI 10.1016/S0960-9822(98)70267-2; Jia WWG, 1996, MOL BRAIN RES, V42, P350, DOI 10.1016/S0169-328X(96)00223-9; John CA, 1999, NEUROSCI LETT, V268, P9, DOI 10.1016/S0304-3940(99)00342-0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kerr JFR, 1991, APOPTOSIS MOL BASIS, P5; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Nath R, 1998, J NEUROCHEM, V71, P186; Nicotera P, 1997, Adv Neurol, V72, P95; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; Olney J, 1978, KAINIC ACID TOOL NEU, P95; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Simonian NA, 1996, NEUROSCIENCE, V75, P1047, DOI 10.1016/0306-4522(96)00326-0; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Williams TL, 1997, ANN NEUROL, V42, P200, DOI 10.1002/ana.410420211; WONG EHF, 1991, ANNU REV PHARMACOL, V31, P401; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; ZHONG LT, 1993, MOL BRAIN RES, V19, P353, DOI 10.1016/0169-328X(93)90139-G	52	44	45	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2000	74	4					1613	1620		10.1046/j.1471-4159.2000.0741613.x			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	295DL	WOS:000085951400032	10737619				2022-02-06	
J	Matsushita, Y; Shima, K; Nawashiro, H; Wada, K				Matsushita, Y; Shima, K; Nawashiro, H; Wada, K			Real-time monitoring of glutamate following fluid percussion brain injury with hypoxia in the rat	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; biosensor; dialysis electrode; glutamate; lateral fluid percussion; TBI; TTC	APOPTOTIC CELL-DEATH; CLOSED-HEAD INJURY; BLOOD-FLOW; DIALYSIS ELECTRODE; CEREBRAL-ISCHEMIA; CYTOCHROME-C; RELEASE; NEURONS; CHLORIDE; STAIN	In the present study, extracellular glutamate (Glu) was monitored in real time using an enzyme electrode biosensor following traumatic brain injury (TBI) either with or without inducing hypoxia in the rat. We also measured the cortical contusion volume at 3 days after insult by staining with 2,3,5-triphenyltetrazolium chloride (TTC). Male Sprague-Dawley rats (300-400g) were anesthetized and then subjected to lateral fluid percussion (FP) brain injury of moderate severity (3.5-4.0 atm), using the Dragonfly device model (no. HPD-1700). The experimental animals mere divided into four groups. Group 1 (n = 10) was subjected to TBI only, group 2 (n = 10) to TBI followed by 20 min of moderate hypoxia (FiO2: 10%), group 3 (n = 4) to 20 min of moderate hypoxia without TBI, and group 4 (n = 4) to sham. Seventy-two hours after the insults, the animals were sacrificed, their brains were stained with TTC, and the lesion volumes were calculated. A surge in the extracellular Glu concentration occurred immediately after TBI in groups 1 and 2. There was no significant difference between the two groups. Group 2 showed a prolonged efflux of Glu during hypoxia (p < 0.05). In group 3, Glu continued to show a mild increase. The cortical contusion volume in group 2 was significantly larger than that in group 1. To evaluate the possible involvement of apoptosis in groups 1 and 2, separate rats were sacrificed under the same procedures after 1, 6, 24, and 72 h after insult (n = 2/group). Immunohistochemical analysis demonstrated an increased number of both the cysteine protease caspase-3-positive cells at 24 h and TUNEL-positive cells at 72 h in group 2. These results suggest that TBI with moderate hypoxia induced the prolonged efflux of Glu, which thus resulted in more cortical damage due to necrosis and apoptosis.	Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan		Shima, K (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	shima@ndmc.jp					Asai S, 1996, NEUROREPORT, V7, P1092, DOI 10.1097/00001756-199604100-00028; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; COLE DJ, 1990, ACTA NEUROPATHOL, V80, P152, DOI 10.1007/BF00308918; Conti AC, 1998, J NEUROSCI, V18, P5663; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Harada J, 1997, BRAIN RES, V753, P251, DOI 10.1016/S0006-8993(97)00011-5; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kharlamov A, 1996, BRAIN RES, V734, P1; KITA H, 1994, ACTA NEUROCHIR, P452; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LISZCZAK TM, 1984, ACTA NEUROPATHOL, V65, P150, DOI 10.1007/BF00690469; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu Z, 1997, NEUROREPORT, V8, P2019, DOI 10.1097/00001756-199705260-00043; Long JB, 1996, J NEUROTRAUM, V13, P149, DOI 10.1089/neu.1996.13.149; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MINEMATSU K, 1992, NEUROLOGY, V42, P235, DOI 10.1212/WNL.42.1.235; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; RINK A, 1995, AM J PATHOL, V147, P1575; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tenneti L, 1998, J NEUROCHEM, V71, P946; WALKER MC, 1995, J NEUROCHEM, V65, P725; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; Zhao H, 1997, NEUROREPORT, V8, P2389, DOI 10.1097/00001756-199707070-00057	50	44	50	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2000	17	2					143	153		10.1089/neu.2000.17.143			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	286MB	WOS:000085448800004	10709872				2022-02-06	
J	Tate, RL; Pfaff, A; Jurjevic, L				Tate, RL; Pfaff, A; Jurjevic, L			Resolution of disorientation and amnesia during post-traumatic amnesia	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						brain injuries; post-traumatic amnesia; confusion; cognition disorders	CLOSED-HEAD INJURY; POSTTRAUMATIC AMNESIA; PRACTICAL SCALE; ORIENTATION; RECOVERY; MEMORY	Objectives-Despite the growing number of instruments for the prospective measurement of post-traumatic amnesia (PTA) after traumatic brain injury, fundamental issues about the natural history of its resolution and methods of examination remain unresolved. The aims of the present study were to: (1) examine the sequence of resolution of disorientation and amnesia, and (2) determine if the method of measuring the memory component affected the duration of PTA. Methods-The sample comprised 31 severely injured patients admitted to a brain injury rehabilitation unit who were examined daily until they emerged from PTA. They were administered a composite PTA scale, covering orientation and memory items from standard PTA scales. Patients were consecutively allocated to one of two groups according to the method of measuring the memory component. Each group was administered identical materials with a different procedure. Results-The most common sequence for resolution of disorientation in both groups was person, followed by place, then time. Overall, amnesia resolved before disorientation in 94% of cases. Correlation coefficients between return of components of orientation and memory were all highly significant, ranging from r=0.81 to 0.93. Significant variability occurred in the number of days to emerge from PTX according to the scale used. There was evidence that the method of measuring memory influenced the patient's capacity to consistently sustain criterion scores on the scale. Conclusions-These results are contrary to findings in mildly injured patients, in whom orientation usually returns before memory They also demonstrate that the duration of PTA will be dictated by the method used. These findings raise validity issues with respect to the prospective measurement of PTA, and in particular determining when an individual patient has emerged from PTA, which require further investigation.	Royal Rehabil Ctr, Dept Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Univ Sydney, Dept Med, Rehabil Studies Unit, Sydney, NSW, Australia; Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia		Tate, RL (corresponding author), Royal Rehabil Ctr, Dept Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	rtate@med.usyd.edu.au					ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1984, ARCH PHYS MED REHAB, V65, P652; DANIEL WF, 1987, CORTEX, V23, P169, DOI 10.1016/S0010-9452(87)80030-8; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; FORRESTER G, 1995, J FARR SERVICES POST; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; HORN S, 1991, J CLIN EXP NEUROPSYC, V13, P19; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Jennett B, 1981, MANAGEMENT HEAD INJU; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SISLER G, 1975, CAN PSYCHIAT ASSOC J, V20, P333, DOI 10.1177/070674377502000502; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TEASDALE G, 1974, LANCET, V2, P81; Wilson BA., 1992, NEUROPSYCHOL REHABIL, V2, P231, DOI [DOI 10.1080/09602019208401410, 10.1080/09602019208401410]; [No title captured]	28	44	45	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2000	68	2					178	185		10.1136/jnnp.68.2.178			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	279DM	WOS:000085029000012	10644784	Green Published, Bronze			2022-02-06	
J	Murphy, LS; Teasdale, GM; Murray, GD; Miller, DJ; Pickard, JD; Shaw, MDM				Murphy, LS; Teasdale, GM; Murray, GD; Miller, DJ; Pickard, JD; Shaw, MDM			Head injuries in four British neurosurgical centres	BRITISH JOURNAL OF NEUROSURGERY			English	Article						case mix; clinical trials; head injury; intensive care; intracranial pressure monitoring	INTENSIVE-CARE; MANAGEMENT; SCALE	An issue in the design of trials in traumatic brain injury is whether variation amongst centres in 'conventional' management could mask the impact of a powerful new pharmacological agent. We report the results of an observational study of 988 patients admitted to one of four British neurosurgical units between 1986 and 1988 within 3 days of a severe head injury. The centres fell into two pairs on the basis of the 'intensity' of management. In Edinburgh and Southampton, more frequent use of intracranial pressure monitoring, ventilation and osmotic diuretics was made than in Glasgow and Liverpool. The odds ratio for an independent outcome at 6 months in Edinburgh or Southampton, relative to Glasgow or Liverpool, controlling for case mix, was 1.43 (95% CI, 1.03-1.98, p = 0.033). Thus, there is weak evidence of an association between the approach to management and clinical outcome at 6 months.	Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Glasgow, Dept Med & Therapeut, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Neurosurg, Glasgow G12 8QQ, Lanark, Scotland; Univ Cambridge, Dept Neurosurg, Cambridge CB2 1TN, England; Walton Ctr Neurol & Neurosurg NHS Trust, Liverpool, Merseyside, England		Murray, GD (corresponding author), Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.			Murray, Gordon/0000-0001-9866-4734			Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bullock MR, 1996, J NEUROTRAUM, V13, P643; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; HARARI RJ, 1992, J NEUROSURG, V76, pA397; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1980, J NEUROL NEUROSUR PS, V43, P289, DOI 10.1136/jnnp.43.4.289; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; MASS AIR, 1983, J NEUROSURG, V58, P321; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	14	44	44	0	0	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	DEC	1999	13	6					564	569		10.1080/02688699943060			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	272YR	WOS:000084679500004	10715724				2022-02-06	
J	Hill-Felberg, SJ; McIntosh, TK; Oliver, DL; Raghupathi, R; Barbarese, E				Hill-Felberg, SJ; McIntosh, TK; Oliver, DL; Raghupathi, R; Barbarese, E			Concurrent loss and proliferation of astrocytes following lateral fluid percussion brain injury in the adult rat	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						proliferating cell nuclear antigen; Cajal's gold sublimate; glial fibrillary acidic protein; blood brain barrier; inflammation; macrophages	CELL NUCLEAR ANTIGEN; REACTIVE ASTROCYTES; EXPRESSION; IMMUNOHISTOCHEMISTRY; APOPTOSIS; PROTEIN; MOUSE	Astrocyte populations were analyzed over a period of 1 month in the hippocampus following lateral fluid percussion (FP) brain injury. Rats (n = 23) were subjected either to a brain injury of moderate severity, or to anesthesia and surgery without injury (n = 7), At 3 days, 1, 2, or 4 weeks postinjury, subgroups of animals were sacrificed and the brains removed and sectioned for histochemical analysis, The density of astrocytes, identified with gold sublimate staining, decreased significantly in the ipsilateral hippocampus of injured rats 3 days following injury, eventually falling to 64% of the total astrocyte population present in uninjured animals by 1 week postinjury, One month postinjury, the density of hippocampal astrocytes had returned to 85% of the total number of astrocytes observed in the hippocampus of uninjured animals. In order to characterize the post-traumatic formation of new astrocytes, immunohistochemistry was performed using antibodies to proliferating cell nuclear antigen (PCNA) and to glial fibriallary acidic protein (GFAP), Positive immunolabeling for both PCNA and GFAP was most abundant at 3 days following FP brain injury in regions where the blood brain barrier was compromised, and was not detectable by 1 month postinjury, These results indicate that astrocyte proliferation after injury may be evoked by mitogens released from vascular sources, and may be an attempt to compensate for some of the astrocytic cell loss observed after injury. J, Neurosci, Res, 57:271-279, 1999, (C) 1999 Wiley-Liss, Inc.	Univ Connecticut, Ctr Hlth, Dept Neurol, Farmington, CT USA; Univ Connecticut, Ctr Hlth, Dept Anat, Farmington, CT USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Hill-Felberg, SJ (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Suite 944, Houston, TX 77030 USA.		Oliver, Douglas L./AAZ-2011-2020	Oliver, Douglas L./0000-0002-1176-4001	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019943, P01NS008803, R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, R01-NS19943, P01-NS08803] Funding Source: Medline		ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; CAVANAGH JB, 1970, J ANAT, V106, P471; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GUILIAN D, 1988, J NEUROSCI, V8, P2485; GUILIAN D, 1985, SCIENCE, V228, P497; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HATTON JD, 1993, GLIA, V9, P18, DOI 10.1002/glia.440090104; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; JANECZKO K, 1994, INT J DEV NEUROSCI, V12, P431, DOI 10.1016/0736-5748(94)90027-2; JANECZKO K, 1989, BRAIN RES, V485, P236, DOI 10.1016/0006-8993(89)90566-0; KORR H, 1994, CELL TISSUE RES, V278, P85, DOI 10.1007/BF00305780; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LIU HM, 1994, J NEUROPATH EXP NEUR, V53, P118, DOI 10.1097/00005072-199403000-00002; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYACHI K, 1978, J IMMUNOL, V121, P2228; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; MIYAKE T, 1992, BRAIN RES, V590, P300, DOI 10.1016/0006-8993(92)91109-R; POLVISHOCK JT, 1992, J NEUROTRAUMA S, V9, pS189; RINK A, 1995, AM J PATHOL, V147, P1575; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vaughn J E, 1971, UCLA Forum Med Sci, V14, P103; VAUGHN JE, 1969, J COMP NEUROL, V131, P143; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	37	44	46	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUL 15	1999	57	2					271	279		10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	211JM	WOS:000081157500013	10398305				2022-02-06	
J	Reinert, MM; Bullock, R				Reinert, MM; Bullock, R			Clinical trials in head injury	NEUROLOGICAL RESEARCH			English	Article						head injury; neuroprotection; trials; therapy; pathomechanism; secondary injury	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; SUBARACHNOID HEMORRHAGE; ARTERY OCCLUSION; FOCAL ISCHEMIA; FREE-RADICALS; AXONAL CHANGE; CALCIUM; NIMODIPINE; DAMAGE	Secondary brain damage, following severe head injury is considered to be a major cause for Dad outcome. Impressive reductions of the extent of brain damage in experimental studies have raised high expectations for cerebral neuroprotective treatment, in the clinic. Therefore multiple compounds were and are being evaluated in trials. In this review we discuss the pathomechanisms of traumatic brain damage, based upon their clinical importance. The role of hypothermia, mannitol, barbiturates, steroids, free radical scavengers, arachidonic acid inhibitors, calcium channel blockers, N-methyl-D-aspartate (NMDA) antagonists, and potassium channel blockers, will be discussed. The importance of a uniform strategic approach for evaluation of potentially interesting new compounds in clinical trials, to ameliorate outcome in patients with severe head injury, is proposed. To achieve this goal, two nonprofit organizations were founded: the European Brain injury Consortium (EBIC) and the American Brain Injury Consortium (ABIC). Their aim lies in conducting better clinical trials, which incorporate lessons learned from previous trials, such that the succession of negative, or incomplete studies, as performed in previous years, will cease.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		Reinert, MM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631, Richmond, VA 23298 USA.		Reinert, Michael/AAA-3929-2019	Reinert, Michael/0000-0002-0971-9543	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ALBERS GW, 1995, STROKE, V26, P254, DOI 10.1161/01.STR.26.2.254; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; ANDINE P, 1992, J CEREBR BLOOD F MET, V12, P773, DOI 10.1038/jcbfm.1992.108; BAER P, 1993, CELL, V14, P293; BIESTRO AA, 1995, J NEUROSURG, V83, P627, DOI 10.3171/jns.1995.83.4.0627; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BULLOCK J, 1993, GLUTAMATE TRANSMITTE, P113; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; COLD GE, 1990, NEUROSURGERY, V27, P660; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; FAGG GE, 1988, EXCITATORY AMINO ACI, P63; Faupel G, 1976, DYNAMICS BRAIN EDEMA, P337; FISHER M, 1994, CEREBROVASC DIS, V4, P20, DOI 10.1159/000108547; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; GERMANO IM, 1987, J NEUROSURG, V67, P81, DOI 10.3171/jns.1987.67.1.0081; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; GREENAMYRE JT, 1994, NEUROLOGY, V44, P7; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P89, DOI 10.1038/jcbfm.1990.11; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENSEN K, 1991, ACTA NEUROCHIR, V108, P116, DOI 10.1007/BF01418518; JOHNSON J, 1988, EXCITATORY AMINO ACI, P109; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P153; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAZDA S, 1982, ARZNEIMITTEL-FORSCH, V32-1, P331; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lazorthes G, 1964, Clin Neurosurg, V12, P293; LEE MHK, 1993, BRAIN RES, V613, P156; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCLELLAN DR, 1986, COMA TRAMATIQUE, P165; Mendelow A D, 1984, Neurol Res, V6, P189; MOHAMED AA, 1985, ANN NEUROL, V18, P705, DOI 10.1002/ana.410180613; Muir KW, 1997, CLIN NEUROPHARMACOL, V20, P311, DOI 10.1097/00002826-199708000-00003; MUIZELAAR JP, 1993, ANN EMERG MED, V22, P1014, DOI 10.1016/S0196-0644(05)82744-1; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; NOZAKI K, 1992, J CEREBR BLOOD F MET, V12, P400, DOI 10.1038/jcbfm.1992.57; OKONKWO D, 1998, J NEUROTRAUM, V15, P889; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PULSINELLI W, 1992, LANCET, V339, P533, DOI 10.1016/0140-6736(92)90347-6; ROBINSON MJ, 1990, CEREBROVAS BRAIN MET, V2, P205; Santos A. L. M., 1995, Journal of Neurotrauma, V12, P389; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; STEWART L, 1996, UNPUB 1 OBSERVATIONS; SYMON L, 1974, STROKE, V5, P355, DOI 10.1161/01.STR.5.3.355; TOWART R, 1981, CIRC RES, V48, P650, DOI 10.1161/01.RES.48.5.650; VERITY MA, 1992, NEUROTOXICOLOGY, V13, P139; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	77	44	44	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	1999	21	4					330	338		10.1080/01616412.1999.11740940			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	219FE	WOS:000081596600001	10406003	Green Submitted			2022-02-06	
J	Vigue, B; Ract, C; Benayed, M; Zlotine, N; Leblanc, PE; Samii, K; Bissonnette, B				Vigue, B; Ract, C; Benayed, M; Zlotine, N; Leblanc, PE; Samii, K; Bissonnette, B			Early SjvO(2) monitoring in patients with severe brain trauma	INTENSIVE CARE MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Societe-Francaise-d-Anesthesie-Reanimation	SEP, 1997	PARIS, FRANCE	Soc Francaise Anesthes Reanimat		SjvO(2); cerebral perfusion pressure; intracranial pressure	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; MANAGEMENT; DESATURATION; HYPOTENSION	Objective: To investigate early cerebral variables after minimal resuscitation and to compare the adequacy of a cerebral perfusion pressure (CPP) guideline above 70 mmHg, with jugular bulb venous oxygen saturation (SjvO(2)) monitoring in a patient with traumatic brain injury (TBI). Design: Prospective, observational study. Setting: Anesthesiological intensive care unit. Patients: 27 TBI patients with a postresuscitation Glasgow Coma Scale score less than 8. Intervention: After initial resuscitation, cerebral monitoring was performed and CPP increased to 70 mmHg by an increase in mean arterial pressure (MAP) with volume expansion and vasopressors as needed. Measurements and results: MAP, in tracranial pressure (ICP), CPP, and simultaneous arterial and venous blood gases were measured at baseline and after treatment. Before treatment, 37 % of patients had an SjvO(2) below 55 %, and SjvO(2) was significantly correlated with CPP (r = 0.73, p < 0.0001). After treatment, we observed a significant increase (p < 0,0001) in CPP (78 +/- 10 vs 53 +/- 15 mmHg), MAP (103 +/- 10 vs 79 +/- 9 mmHg) and SvjO(2) (72 +/- 7 vs 56 +/- 12), without a significant change in ICP (25 +/- 14 vs 25 +/- 11 mmHg). Conclusion: The present study shows that early cerebral monitoring with SjvO(2) is critical to assess cerebral ischemic risk and that MAP monitoring alone is not sensitive enough to determine the state of oxygenation of the brain. SjvO(2) monitoring permits the early identification of patients with low CPP and high risk of cerebral ischemia. In emergency situations it can be used alone when ICP monitoring is contraindicated or not readily available. However, ICP monitoring gives complementary information necessary to adapt treatment.	Hop Bicetre, Dept Anesthesiol, F-94275 Le Kremlin Bicetre, France; Univ Toronto, Dept Anesthesiol, Toronto, ON, Canada		Vigue, B (corresponding author), Hop Bicetre, Dept Anesthesiol, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.						ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; Chesnut R M, 1995, New Horiz, V3, P366; Chesnut RM, 1997, CRIT CARE MED, V25, P1275, DOI 10.1097/00003246-199708000-00011; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gopinath SP, 1996, ANESTH ANALG, V83, P1014, DOI 10.1097/00000539-199611000-00020; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MYBURGH JA, 1996, YB INTENSIVE CARE EM, P716; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Shapiro H, 1994, ANESTHESIA, P1897; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; WISNER DH, 1993, J TRAUMA, V35, P271, DOI 10.1097/00005373-199308000-00017	20	44	50	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	MAY	1999	25	5					445	451		10.1007/s001340050878			7	Critical Care Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200JZ	WOS:000080537600005	10401936				2022-02-06	
J	Willer, B; Button, J; Rempel, R				Willer, B; Button, J; Rempel, R			Residential and home-based postacute rehabilitation of individuals with traumatic brain injury: A case control study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	74th Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	SEP 12-14, 1997	BOSTON, MASSACHUSETTS	Amer Congress Rehabil Med			COMMUNITY INTEGRATION QUESTIONNAIRE	Objectives: To compare the outcomes of severely brain-injured individuals treated in a postacute residential rehabilitation program with a matched sample of individuals receiving limited services in their homes or on an outpatient basis. Design: Controlled study using a matched design in a before-and-after trial and a 1-year follow-up trial. Setting: A postacute community-based residential rehabilitation program or in the homes of patients. Patients and Other Participants: The treatment group included all persons admitted consecutively for rehabilitation to the postacute residential program over a 3-year period (n = 23). All subjects had severe traumatic brain injury, The comparison group was selected from the roster of a support group on the basis of a systematic matching procedure. Matching variables included gender, age, length of coma, time since injury, and level of disability. Subjects of the two groups were matched on an individual basis. Main Outcome Measures: A functional assessment instrument (modified Health and Activity Limitations Survey [HALS]) and the Community Integration Questionnaire (CIQ). Results: Individuals with traumatic brain injury who received residential-based postacute rehabilitation displayed a statistically significant increase in functional abilities when compared with a traditional (home-based) service group. More specifically, treatment subjects showed significantly greater improvement in motor skills and cognitive abilities, Treatment subjects also showed greater improvement in community integration, although this may have been accounted for by initial,group differences. Conclusions: Postacute rehabilitation appears to be effective in improving function for individuals with severe brain injury. Residential-based services appear to produce greater functional improvement, whereas home-based services are more effective at maintaining community integration. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	SUNY Buffalo, Buffalo, NY 14214 USA; Ontario Brain Injury Assoc, St Catharines, ON, Canada; Anagram Rehabil Community, Niagara On The Lake, ON, Canada		Willer, B (corresponding author), SUNY Buffalo, 114 Farber Hall, Buffalo, NY 14214 USA.						Allen K, 1996, JAMA-J AM MED ASSOC, V275, P1001, DOI 10.1001/jama.275.13.1001; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Evans R W, 1991, J Insur Med, V23, P192; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; FREDERICKSON M, 1995, ARCH PHYS MED REHAB, V76, pSC5; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; FURRIE AD, 1995, DISABIL REHABIL, V17, P344, DOI 10.3109/09638289509166720; HARRICK L, 1994, BRAIN INJURY, V8, P631; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; MCDOWELL I, 1988, DISABILITY SCORE HLT; MCMAHON BT, 1994, SHORTEST DISTANCE PU; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; *STAT CAN, 1989, HLTH ACT LIM SURV HA; Switzer S F, 1991, J Insur Med, V23, P239; Walker WC, 1996, BRAIN INJURY, V10, P65; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1994, BRAIN INJURY REHABIL, P355; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Wood R. L., 1987, BRAIN INJURY REHABIL; 1988, DISABILITY DATABASE	27	44	44	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1999	80	4					399	406		10.1016/S0003-9993(99)90276-9			8	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	184TG	WOS:000079629100007	10206601				2022-02-06	
J	Krishnappa, IK; Contant, CF; Robertson, CS				Krishnappa, IK; Contant, CF; Robertson, CS			Regional changes in cerebral extracellular glucose and lactate concentrations following severe cortical impact injury and secondary ischemia in rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebral ischemia; glucose; lactate; microdialysis; traumatic brain injury	TRAUMATIC BRAIN INJURY; COMPRESSION CONTUSION TRAUMA; ENERGY PHOSPHATE-METABOLISM; FLUID-PERCUSSION INJURY; BLOOD-FLOW; HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; CEREBROSPINAL-FLUID; LACTIC-ACIDOSIS; OXYGEN DELIVERY	Traumatic brain injury (TBI) causes the brain to be more susceptible to secondary insults, and the occurrence of a secondary insult after trauma increases the damage that develops in the brain. To study the synergistic effect of trauma and ischemia on brain energy metabolites, regional changes in the extracellular concentrations of glucose and lactate following a severe cortical impact injury were measured employing a microdialysis technique. Three microdialysis probes were placed in center of the impact site, in an area adjacent to the impact site, and in the contralateral parietal cortex, and perfused with artificial cerebrospinal fluid (CSF) at 2 mu l/min. Rats were assigned to one of the following experimental groups (n = 7 per group): (1) combined impact injury and secondary insult, (2) impact injury with sham secondary insult, (3) sham impact with secondary insult, or (4) sham impact and sham secondary insult. The impact injury was produced with a pneumatic impactor (5 m/sec, 3-mm deformation). One hour following the impact injury, a secondary insult was produced by bilateral carotid occclusion for 1 h. The impact injury resulted in a three- to fivefold global increase in dialysate lactate concentrations, with a corresponding fall in dialysate glucose concentration by 50% compared to no change in lactate or glucose concentrations in sham-injured animals (p < .0001 for both lactate and glucose). The secondary insult resulted in a second increase in dialysate lactate and decrease in dialysate glucose concentration that was significantly greater in the animals that had suffered the impact injury than in the sham-injured animals. Ischemia and traumatic injury have synergistic effects on lactate accumulation and on glucose depletion in the brain that probably reflects persisting ischemia, but may also indicate mitochondrial abnormalities and inhibition of oxidative metabolism.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Krishnappa, IK (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	Indrak@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Goodman J. C., 1995, Journal of Neurotrauma, V12, P371; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Scremin OU, 1997, J NEUROTRAUM, V14, P573, DOI 10.1089/neu.1997.14.573; SUTTON LN, 1995, PEDIATR NEUROSURG, V22, P81, DOI 10.1159/000120881; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; Valtysson J, 1998, ACTA NEUROCHIR, V140, P387, DOI 10.1007/s007010050113; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; Zauner A, 1996, ACT NEUR S, V67, P40	43	44	49	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1999	16	3					213	224		10.1089/neu.1999.16.213			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	178QQ	WOS:000079277800003	10195469				2022-02-06	
J	Light, R; Asarnow, R; Satz, P; Zaucha, K; McCleary, C; Lewis, R				Light, R; Asarnow, R; Satz, P; Zaucha, K; McCleary, C; Lewis, R			Mild closed-head injury in children and adolescents: Behavior problems and academic outcomes	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article							FOLLOW-UP; SEQUELAE; TRAUMA	The issue of whether mild head injuries (HIs) in children cause behavior problems and poor scholastic performance is controversial. This study included 119 children (range = 8-16 years old) with HI, 114 with other injuries, and 106 with no injury (NI). Behavioral functioning was assessed with the Child Behavior Checklist; academic functioning, with school grades and standardized testing. Higher T scores were found for both injury groups versus NI participants on preinjury behavioral status. All 3 groups' behavioral scores decreased relative to baseline at 1 year. HI and NI groups did not differ in school grades or achievement testing either pre- or postinjury. These results are consistent with the conclusion that head injury of the mildest type does not increase the probability of new overt behavioral or academic problems.	Daniel Freeman Mem Hosp, Rehabil Serv, Inglewood, CA 90301 USA; Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; Univ So Calif, Sch Med, Dept Neurol, Los Angeles, CA 90089 USA; Pomona Coll, Dept Psychol, Claremont, CA 91711 USA		Light, R (corresponding author), Daniel Freeman Mem Hosp, Rehabil Serv, 333 N Prairie Ave, Inglewood, CA 90301 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS026801] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS26801-04, P50 NS30308-02] Funding Source: Medline		Achenbach T, 1983, MANUAL CHILD BEHAV C; ARSARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BIJUR PE, 1990, PEDIATRICS, V86, P337; BLACK P, 1971, HEAD INJURIES, P131; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BUTTERBAUGH G, 1993, J CLIN EXP NEUROPSYC, V15, P84; CASEY R, 1986, PEDIATRICS, V78, P497; Cohen J., 2013, STAT POWER ANAL BEHA; DENCKLA MB, 1995, TRAUMATIC HEAD INJUR, pR6; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Horowitz I, 1983, Int Rehabil Med, V5, P32; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; KEWMAN DG, 1992, J CLIN EXPT NEUROPSY, V14, P100; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1994, J HEAD TRAUMA REHAB, V9, P106; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEAHY LF, 1987, J CLIN EXP NEUROPSYC, V9, P55; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Light R, 1987, J HEAD TRAUMA REHAB, V2, P11, DOI DOI 10.1097/00001199-198703000-00005; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; LYONS MJ, 1984, J PEDIATR PSYCHOL, V9, P485, DOI 10.1093/jpepsy/9.4.485; OGLES BM, 1996, ASSESSING OUTCOME CL; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SHAFFER D, 1995, TRAUMATIC HEAD INJUR, P117; Slater E.J., 1989, J ADOLESCENT RES, V4, P371; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; Winogron H W, 1984, J Clin Neuropsychol, V6, P267	34	44	44	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X			J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	DEC	1998	66	6					1023	1029					7	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	151DU	WOS:000077706100016	9874916				2022-02-06	
J	Spain, DA; McIlvoy, LH; Fix, SE; Carrillo, EH; Boaz, PW; Harpring, JE; Raque, GH; Miller, FB				Spain, DA; McIlvoy, LH; Fix, SE; Carrillo, EH; Boaz, PW; Harpring, JE; Raque, GH; Miller, FB			Effect of a clinical pathway for severe traumatic brain injury on resource utilization	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	57th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 24-27, 1997	WAIKOLOA, HAWAII	Amer Assoc Surg Trauma		traumatic brain injury; multiple injuries; clinical pathway	HEAD-INJURY; TRACHEOSTOMY; MANAGEMENT; ARTHROPLASTY; GASTROSTOMY; MORBIDITY; KNEE; CARE; RISK; HIP	Background: The usefulness of clinical pathways for the complex trauma patient is unclear. We analyzed the effect of a clinical pathway for severe traumatic brain injury (TBI) on resource utilization. Methods: A clinical pathway for severe TBI (Glasgow Coma Scale (GCS) score less than or equal to 8 at 24 hours) was developed by a multidisciplinary team and used for all patients with severe TBI, Data were gathered prospectively for 15 months and compared with data from historical controls from the previous year. Patients who survived < 48 hours were excluded. Results: The clinical pathway was used for 84 patients with severe TBI and compared with 49 historical controls. No differences in Injury Severity Scores (27 vs. 27) or GCS scores at 24 hours (6.2 vs. 6.5) existed between control or pathway patients. There was an overall increase in the mortality rate of pathway patients (from 12.2 to 21.4%), but this was entirely attributable to withdrawal of care that was initiated by family members in patients with an average age of 71 years, an average GCS score of 4.7, and an average Injury Severity Score of 29, Among survivors, pathway patients had a significant decrease in ventilator days (11.5 +/- 0.9 vs. 14.6 +/- 1.2; p < 0.05), intensive care unit days (16.7 +/- 1.0 vs. 21.2 +/- 1.4; p < 0.05), and hospital days (23.4 +/- 1.2 vs. 31.0 +/- 3.0; p < 0.05). There were no differences in the incidence of complications or functional outcomes. Conclusion: The use of a clinical pathway for severe TBI resulted in a significant reduction in resource utilization. This study suggests that clinical pathways may be a useful component of patient care after blunt trauma. Key Words: Traumatic brain injury, Multiple injuries, Clinical pathway.	Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville Hosp, Trauma Inst, Louisville, KY USA; Univ Louisville Hosp, Dept Nursing, Louisville, KY USA; Vet Adm Med Ctr, Louisville, KY 40202 USA		Spain, DA (corresponding author), Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA.						*AM ASS NEUR SURG, 1996, GUID MAN SEV HEAD IN; Amadio PC, 1996, MAYO CLIN PROC, V71, P127, DOI 10.4065/71.2.127; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Brothers TE, 1997, AM SURGEON, V63, P213; Calligaro KD, 1995, J VASC SURG, V22, P649, DOI 10.1016/S0741-5214(95)70055-2; CARRILLO EH, 1997, SURG ENDOSC-ULTRAS, V11, P210; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/BF01709556; DAMELIO LF, 1994, AM SURGEON, V60, P180; DAVIS JT, 1995, ANN THORAC SURG, V59, P1074, DOI 10.1016/0003-4975(95)00001-2; FORKNER DJ, 1996, NURSING MANAGEMENT, V27, P35; Gadacz TR, 1997, AM SURGEON, V63, P107; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; GIBBS BF, 1995, ANN VASC SURG, V9, P423, DOI 10.1007/BF02143853; GRANGER CV, 1994, GUIDE USE UNIFORM DA; Gregor C, 1996, JOINT COMM J QUAL IM, V22, P617, DOI 10.1016/S1070-3241(16)30269-3; Griffen F D, 1997, Bull Am Coll Surg, V82, P29; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; Katterhagen G, 1996, Oncology (Williston Park), V10, P113; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Korpiel Michael R., 1995, Journal of Burn Care and Rehabilitation, V16, P191, DOI 10.1097/00004630-199503001-00003; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Millaire A, 1996, CARDIOVASC DRUG THER, V10, P11, DOI 10.1007/BF00051125; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; Morton J R, 1995, Bull Am Coll Surg, V80, P30; Muluk SC, 1997, J VASC SURG, V25, P84, DOI 10.1016/S0741-5214(97)70324-0; Nikas DJ, 1996, SOUTHERN MED J, V89, P1074, DOI 10.1097/00007611-199611000-00009; QUIGLEY MR, 1997, J TRAUMA, V41, P7; RHODES M, 1996, AM J SURG, V173, P35; RODRIGUEZ JL, 1990, SURGERY, V108, P655; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015	33	44	44	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	1998	45	1					101	104		10.1097/00005373-199807000-00022			4	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	101TA	WOS:000074883200025	9680020				2022-02-06	
J	Rinker, CF; McMurry, FG; Groeneweg, VR; Bahnson, FF; Banks, KL; Gannon, DM				Rinker, CF; McMurry, FG; Groeneweg, VR; Bahnson, FF; Banks, KL; Gannon, DM			Emergency craniotomy in a rural Level III trauma center	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	57th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 24-27, 1997	WAIKOLOA, HAWAII	Amer Assoc Surg Trauma			ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; EPIDURAL HEMATOMA; TENTORIAL HERNIATION; EXTRADURAL HEMATOMA; COMATOSE PATIENTS; MANAGEMENT; MORTALITY; SURGERY; CARE	Patients with closed head injury and expanding epidural (EDH) or subdural (SDH) hematoma require urgent craniotomy for decompression and control of hemorrhage. In remote areas where neurosurgeons are not available, trauma surgeons may occasionally need to intervene to avert progressive neurologic injury and death. In 1990, a young man with rapidly deteriorating neurologic signs underwent emergency burr hole decompression of a combined EDH/SDH at our hospital, with complete recovery. In anticipation of future need, five surgeons at our rural, American College of Surgeons-verified Level III trauma center participated in a neurosurgeon-directed course in emergency craniotomy, Since January 1, 1991, 792 patients have been entered into the trauma registry, including 60 with closed head injury and Glasgow Coma Scale (GCS) score of 13 or less. All but seven were transferred to a regional Level II trauma center, which is a minimum flight time of 1 hour each way. All patients with EDH (5) and 2 of 14 with SDH were deemed too unstable for transport and underwent burr hole decompression followed by immediate transfer. All craniotomies were approved by the consulting neurosurgeon and were done for computed tomography-confirmed lesions combined with neurologic deterioration as demonstrated by (1) GCS score of 8 or less, (2) lateralizing signs (dilated pupil, hemiparesis), or (3) development of combined bradycardia and hypertension. One patient with a GCS score of 3 on arrival died. Seven survivors (mean follow-up, 3.9 years; range, 1-6.5 years), including the index case, function independently, although one survivor has moderate cognitive and motor impairment. We conclude that early craniotomy for expanding epidural and subdural hematomas by properly trained surgeons may save lives and reduce morbidity in properly selected cases when timely access to a neurosurgeon is not possible.	Montana State Univ, Bozeman, MT 59717 USA; Bozeman Deaconess Hosp, Bozeman, MT USA		Rinker, CF (corresponding author), Amer Coll Surg, 925 Highland Blvd, Bozeman, MT 59715 USA.						*AM COLL SURG, 1993, ADV TRAUM LIF SUPP P, P181; *AM COLL SURG, 1993, ADV TRAUM LIF SUPP P, P295; ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; BATTERSBY RDE, 1990, BRIT J HOSP MED, V44, P276; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Becker DP, 1989, TXB HEAD INJURY, P1; BULLOCK R, 1995, GUIDELINES MANAGEMEN, P12; Burton C, 1965, J Trauma, V5, P643, DOI 10.1097/00005373-196509000-00008; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; Gudeman S. K., 1989, TXB HEAD INJURY, P138; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; HOFF JT, 1978, WESTERN J MED, V128, P112; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; LOWE JG, 1996, NEUROLOGY TRAUMA, P140; MAHONEY BD, 1981, NEUROSURGERY, V8, P551, DOI 10.1227/00006123-198105000-00006; ORTLER M, 1993, UNFALLCHIRURG, V96, P628; OSULLIVAN MGJ, 1990, BRIT J SURG, V77, P1391, DOI 10.1002/bjs.1800771223; POON WS, 1991, INJURY, V22, P323, DOI 10.1016/0020-1383(91)90016-8; Reale F, 1984, J Neurosurg Sci, V28, P9; SCHECTER WP, 1985, ARCH SURG-CHICAGO, V120, P1163; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHARAR SR, 1988, J TRAUMA, V28, P794, DOI 10.1097/00005373-198806000-00012; SPRINGER MFB, 1988, AM J EMERG MED, V6, P640, DOI 10.1016/0735-6757(88)90110-6; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212	27	44	44	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1998	44	6					984	989		10.1097/00005373-199806000-00009			6	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	ZU123	WOS:000074164600009	9637153				2022-02-06	
J	Koller, H; Allert, N; Oel, D; Stoll, G; Siebler, M				Koller, H; Allert, N; Oel, D; Stoll, G; Siebler, M			TNF alpha induces a protein kinase C-dependent reduction in astroglial K+ conductance	NEUROREPORT			English	Article						astrocytes; cell culture; cytokine; electrophysiology; inflammatory brain diseases; neuroimmunology; TNF alpha	TUMOR-NECROSIS-FACTOR; PRIMARY CULTURES; GLUTAMATE UPTAKE; RAT-BRAIN; ASTROCYTES; MEMBRANE; EXPRESSION; DEMENTIA; CELLS	INCUBATION of cultured cortical astrocytes with tumor necrosis factor alpha (TNF alpha) led to a marked reduction of membrane potential. Here we report that this depolarization depends on activation of protein kinase C (PKC), since it could be blocked by the PKC antagonists staurosporine and H7 and it could be mimicked by direct activation of PKC using the phorbol ester phorbol 12-myristate 13 acetate (PMA). Analyses of whole cell currents revealed a reduction of inwardly rectifying K+ currents whereas K+ outward currents were not affected. We conclude that TNF alpha induces changes of basic electrophysiological properties of astrocytes which are similar to those induced by proliferation or an in vitro model of traumatic injury. (C) 1998 Rapid Science Ltd.	Heinrich Heine Univ, Dept Neurol, D-40001 Dusseldorf, Germany		Koller, H (corresponding author), Heinrich Heine Univ, Dept Neurol, POB 101007, D-40001 Dusseldorf, Germany.						AKERMAN KEO, 1988, NEUROSCI LETT, V92, P265, DOI 10.1016/0304-3940(88)90600-3; BALLANYI K, 1987, J PHYSIOL-LONDON, V382, P159, DOI 10.1113/jphysiol.1987.sp016361; BALLESTAS ME, 1995, GLIA, V14, P267, DOI 10.1002/glia.440140404; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; FLOTT B, 1991, GLIA, V4, P293, DOI 10.1002/glia.440040307; Francke M, 1997, GLIA, V20, P210, DOI 10.1002/(SICI)1098-1136(199707)20:3<210::AID-GLIA5>3.0.CO;2-B; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pa.32.040192.002113; Janigro D, 1997, J NEUROSCI, V17, P2813; Koller H, 1997, J NEUROIMMUNOL, V76, P185, DOI 10.1016/S0165-5728(97)00056-8; Koller H, 1996, BRAIN, V119, P2021, DOI 10.1093/brain/119.6.2021; Koller H, 1997, PROG NEUROBIOL, V52, P1, DOI 10.1016/S0301-0082(96)00065-2; Largo C, 1996, J NEUROSCI, V16, P1219; MacFarlane SN, 1997, J NEUROSCI, V17, P7316; MACVICAR BA, 1987, NATURE, V329, P242, DOI 10.1038/329242a0; MURPHY HS, 1994, AM J PHYSIOL, V267, pL145, DOI 10.1152/ajplung.1994.267.2.L145; NORRIS JG, 1994, J IMMUNOL, V152, P841; RANSOM CB, 1995, J NEUROPHYSIOL, V73, P333, DOI 10.1152/jn.1995.73.1.333; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SHARIEF MK, 1992, J INFECT DIS, V166, P350, DOI 10.1093/infdis/166.2.350; WALZ W, 1984, BRAIN RES, V292, P367, DOI 10.1016/0006-8993(84)90772-8; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; Ye ZC, 1996, NEUROREPORT, V7, P2181, DOI 10.1097/00001756-199609020-00025	24	44	49	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0959-4965			NEUROREPORT	Neuroreport	MAY 11	1998	9	7					1375	1378					4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZR650	WOS:000074000000025	9631432				2022-02-06	
J	Katz, DI; Alexander, MP; Klein, RB				Katz, DI; Alexander, MP; Klein, RB			Recovery of arm function in patients with paresis after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; MOTOR RECOVERY; BASAL GANGLIA; FOLLOW-UP; STROKE; REHABILITATION; HEMORRHAGE; COMA	Objective: To characterize the frequency of recovery of arm paresis in patients with traumatic brain injury (TBI) admitted to rehabilitation. Design: Retrospective review identifying a cohort of patients with moderate or severe arm paresis after TBI followed at least 6 months postinjury. Setting: Freestanding acute rehabilitation hospital TBI unit. Patients and Methods: Forty-four patients with moderate to severe arm paresis were selected from 264 consecutive admissions and characterized by injury pathology subtype, injury severity (duration of unconsciousness [loss of consciousness, LOG] and posttraumatic amnesia [PTA]), age, and level of paresis according to Brunnstrom Stages of Recovery (BS 1 to 6). Patient groups with and without arm paresis were compared according to these variables (t tests and chi(2)). Main Outcome Measures: Recovery of arm paresis to isolated motor function (BS 5 or 6) and time to achieve recovery. Recovered and nonrecovered patients were compared (Mann-Whitney, t tests, and chi(2)) on injury severity, initial level of paresis, age, time to rehabilitation admission, and pathology subtype. Time to recovery was compared for patients at different levels of initial paresis, ranges of LOC, and pathology subtypes (Mann-Whitney and Kruskal-Wallis tests). Results: Forty-four patients (17%) had moderate (BS 3 to 4) or severe (BS 1 to 2) paresis at rehabilitation admission. They were more severely injured than nonparetic patients based on longer LOC (p < .002) and PTA (p < .009). Thirty-six patients (82%) recovered by 6 months; 72% of these recovered by 2 months. If still paretic at 2 months, only 56% recovered. Mean recovery time was 6.9 weeks (SD, 6.1) from injury. Time to recovery was best predicted by initial level of paresis and injury severity (r(2) = .48), but not age. Patients with diffuse injury tended towards a more protracted recovery (7.9 weeks, SD 6.5) than patients with focal injury (4.2 weeks, SD 3.9) (p = .08) and only those with diffuse injury showed further recovery after 3 months. Conclusions: Arm paresis after TBI is relatively infrequent. Most patients recover by 2 months but later recovery is possible, especially in patients with primarily diffuse brain damage. Recovery is highly related to initial impairment, injury severity, and distribution of brain injury. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Healths Braintree Hosp Rehabil Network, TBI Program, Braintree, MA 02185 USA; Healths Braintree Hosp Rehabil Network, Dept Neurol, Braintree, MA 02185 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA		Katz, DI (corresponding author), Healths Braintree Hosp Rehabil Network, TBI Program, 250 Pond St, Braintree, MA 02185 USA.			Katz, Douglas/0000-0002-7502-8505			ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BONITA R, 1988, STROKE, V19, P497; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BRUNNSTROM S, 1966, MOVEMENT THERAPY HEM, P34; Damasio H., 1989, LESION ANAL NEUROPSY; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P1; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; FAHY TJ, 1967, LANCET, V2, P475; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAY CS, 1990, AGE AGEING, V19, P179, DOI 10.1093/ageing/19.3.179; JORGENSEN HS, 1995, ANN NEUROL, V38, P45, DOI 10.1002/ana.410380110; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1983, ARCH NEUROL-CHICAGO, V40, P601, DOI 10.1001/archneur.1983.04050090037004; Levin HS., 1982, NEUROBEHAVIORAL CONS; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MacPherson Valerie, 1992, Brain Injury, V6, P489, DOI 10.3109/02699059209008146; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OLSEN TS, 1990, STROKE, V21, P247, DOI 10.1161/01.STR.21.2.247; Parker V M, 1986, Int Rehabil Med, V8, P69; Posner JB., 1980, DIAGNOSIS STUPOR COM, V3; REDDING MJ, 1988, STROKE, V19, P1354; SUNDERLAND A, 1989, J NEUROL NEUROSUR PS, V52, P1267, DOI 10.1136/jnnp.52.11.1267; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; TALMAGE EW, 1983, PHYS THER, V12, P2010; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521	33	44	45	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	1998	79	5					488	493		10.1016/S0003-9993(98)90060-0			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	ZM198	WOS:000073514500002	9596386				2022-02-06	
J	Xiong, Y; Peterson, PL; Muizelaar, JP; Lee, CP				Xiong, Y; Peterson, PL; Muizelaar, JP; Lee, CP			Amelioration of mitochondrial function by a novel antioxidant U-101033E following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						antioxidants; brain mitochondria; calcium; oxidative phosphorylation; rats; traumatic brain injury	SEVERE HEAD-INJURY; NERVOUS-SYSTEM TRAUMA; FACIAL MOTOR-NEURONS; LIPID-PEROXIDATION; FOREBRAIN MITOCHONDRIA; ISCHEMIA; TRIAL; MULTICENTER; INHIBITION; AXOTOMY	In the present study, a severe traumatic brain injury (TBI) was produced over the right parietal cortex of rats using the controlled cortical impact injury (CCII) model, TBI perturbed calcium homeostasis and impaired electron transfer and energy coupling activities of forebrain mitochondria isolated from injured hemispheres with a maximal injury at 12-72 h, Efficacy of the blood-brain barrier penetrating antioxidant U-101033E on TBI-induced mitochondrial impairment was evaluated, In the dose-response experiment, two i.v. boluses (vehicle or 1-10 mg/kg of U-101033E) were administered at 5 min and 2h post-TBI, Forebrain mitochondria from each hemisphere were examined at 12 h post-injury, With respect to forebrain mitochondrial dysfunction, the drug showed a bell-shaped dose-response curve with an optimal dose of 3 mg/kg (n = 5, p < 0.05 vs, vehicle), In the time-course experiment, two i.v. boluses of 3 mg U-101033E/kg (the optimal dose) were given at 5 min and 2 h post-injury and forebrain mitochondria were examined at 6 h-14 days post-injury, U-101033E significantly restored electron transfer, energy coupling capacity, and Ca2(+) transport capacity during 6 h to 14 days post-injury, Our data indicate that the antioxidant U-101033E administered post-injury at proper dosage can effectively restore TBI-induced mitochondrial dysfunction and support the contention that oxidative stress plays an important role in the pathogenesis of TBI.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA		Lee, CP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.			Xiong, Ye/0000-0001-9770-6031			CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; ERNSTER L, 1993, ACTIVE OXYGENS, LIPID PEROXIDES, AND ANTIOXIDANTS, P1; ForsmarkAndree P, 1997, FREE RADICAL BIO MED, V22, P391, DOI 10.1016/S0891-5849(96)00330-9; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall ED, 1996, ACT NEUR S, V66, P107; Hall ED, 1996, J NEUROSCI RES, V44, P293, DOI 10.1002/(SICI)1097-4547(19960501)44:3<293::AID-JNR10>3.0.CO;2-6; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1994, ACTA NEUROCHIR, P521; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lee C. P., 1993, V2, P41; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINN F, 1987, EXP NEUROL, V96, P321, DOI 10.1016/0014-4886(87)90050-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1995, J HEAD TRAUMA REHAB, V10, P1; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; PETERSON PL, 1997, 65 ANN M AM ASS NEUR, P260; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SCIAMANNA MA, 1993, ARCH BIOCHEM BIOPHYS, V305, P215, DOI 10.1006/abbi.1993.1414; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Smith SL, 1996, EXP NEUROL, V141, P304, DOI 10.1006/exnr.1996.0165; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WITTING PK, 1995, FEBS LETT, V375, P45, DOI 10.1016/0014-5793(95)01172-B; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 1997, FASEB J, V11, pA955; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	46	44	45	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1997	14	12					907	917		10.1089/neu.1997.14.907			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	YU127	WOS:000071685000003	9475372				2022-02-06	
J	Prigatano, GP; Ogano, M; Amakusa, B				Prigatano, GP; Ogano, M; Amakusa, B			A cross-cultural study on impaired self-awareness in Japanese patients with brain dysfunction	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						brain dysfunction; cerebrovascular accident; Japanese; traumatic brain injury; self-awareness	BEHAVIORAL LIMITATIONS; HEAD-INJURY; ANOSOGNOSIA	Japanese patients with brain dysfunction (21 with severe traumatic brain injury [TBI], 21 with right, and 21 with left cerebral vascular accidents [CVA]) were asked to make behavioral ratings regarding their competencies in several areas, Relatives of patients and physical therapists who treated them also rated each patient's behavioral competency. Japanese patients with TBI overestimated their behavioral competencies compared with therapists' ratings, but not relatives' ratings. Japanese patients with TBI overestimated self-care skills but not their ability to interact in socioemotional situations. Patients who had right and left CVA did not differ in their mean ratings of behavioral competency. Among all patient groups, there was no correlation between self-reported competencies and performance on a neuropsychological test. Family ratings of patients' behavioral competencies correlated with the patients' neuropsychological test performance. Post hoc analyses of patients with TBI suggest that speed of finger tapping related to an impaired self-awareness. Whereas cultural factors may influence self reports of behavioral competency, patients across cultures with brain dysfunction seem to have reduced insight into their actual level of neuropsychological functioning.	ST JOSEPHS HOSP,BARROW NEUROL INST,DIV NEUROL,PHOENIX,AZ								CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; GAINOTTI G, 1975, PSYCHIAT CLIN, V8, P99, DOI 10.1159/000283622; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HANDA T, 1983, PHYS THER C NAT HOSP; JOHNSON MK, 1951, J BONE JOINT SURG AM, V33, P623; LEBRUN Y, 1987, CORTEX, V23, P251, DOI 10.1016/S0010-9452(87)80035-7; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MIZUNO M, 1991, Keio Journal of Medicine, V40, P221; MORIYAMA S, 1987, P JOINT JAP CHIN STR; OTA T, 1974, NEUROSURGERY, V2, P623; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; PRIGATANO GP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P381; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P342; Prigatano GP, 1995, PSYCHOL ASSESSMENT, V7, P396; PRIGATANO GP, 1997, IN PRESS CLIN NEUROP; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Rosenstein LD., 1995, ADM SCORING MANUAL B; STARKSTEIN SE, 1993, NEUROPSY NEUROPSY BE, V6, P43; Walker A E, 1972, Scand J Rehabil Med, V4, P5; WEILLER C, 1993, ANN NEUROL, V33, P181; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO	28	44	45	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	APR	1997	10	2					135	143					9	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	WY139	WOS:A1997WY13900009	9150515				2022-02-06	
J	Reitan, RM; Wolfson, D				Reitan, RM; Wolfson, D			Emotional disturbances and their interaction with neuropsychological deficits	NEUROPSYCHOLOGY REVIEW			English	Article						emotional disturbance; neuropsychological deficits; neuropsychological tests; tests of personality and emotional status; brain damage	FRONTAL-SUBCORTICAL CIRCUITS; CLOSED-HEAD-INJURY; TEST-PERFORMANCE; BASE RATES; MOOD DISORDERS; DEPRESSION; MMPI; SYMPTOMS; OUTPATIENTS; VARIABLES	The interaction and relationships between neuropsychological tests (which are principally oriented to intellectual and cognitive abilities) and tests of personality and emotional status are complex, but nevertheless important in the clinical assessment of brain-damaged persons. Are indications of emotional disturbances to be expected as a direct consequence of brain damage? If so, how can the indications of emotional disturbances be differentiated from results obtained with psychiatrically disturbed (non-brain-damaged) subjects? Some authors have presumed that emotional disturbances, such as depression, acute anxiety, etc., in their own right cause impaired performances on neuropsychological tests, whereas other authors have proposed that brain damage predisposes the individual to demonstrate evidence of emotional disturbances. If emotional disturbances cause impairment on neuropsychological tests, why is it that so many emotionally disturbed persons without brain damage tend to perform normally on neuropsychological tests? This review of relevant publications considers (1) different general approaches to these questions and their implications for neuropsychology, (2) evidence of differential sensitivity to brain damage of neuropsychological and emotional instruments, (3) the sensitivity and specificity of self-assessments and complaints of head-injured subjects, (4) MMPI findings among head-injured subjects and in interaction with neuropsychological measurements, and (5) principles and guidelines that may be of value in clinical application of findings reported in the literature.			Reitan, RM (corresponding author), REITAN NEUROPSYCHOL LAB,2920 S 4TH AVE,TUCSON,AZ 85713, USA.						Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Alfano Dennis P, 1992, Clin Neuropsychol, V6, P134, DOI 10.1080/13854049208401850; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P111; ALVAREZ RR, 1962, PERCEPT MOTOR SKILL, V14, P91; ALVES WM, 1985, CENTRAL NERVOUS SYST, P255; Beck AT, 1987, BECK DEPRESSION INVE; BIELIAUSKAS LA, 1993, J CLIN EXP NEUROPSYC, V15, P119, DOI 10.1080/01688639308407223; BIELIAUSKAS LA, 1991, J CLIN EXP NEUROPSYC, V13, P433; BIELIAUSKAS LA, 1991, J CLIN EXP NEUROPSYC, V13, P101; BIELIAUSKAS LA, 1991, CLIN NEUROPSYCHOL, V5, P252; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Butcher J.N., 1989, MANUAL RESTANDARDIZE; BYRNE DG, 1977, J PSYCHIAT RES, V13, P185, DOI 10.1016/0022-3956(77)90008-5; CAINE ED, 1986, NEUROPSYCHOLOGICAL A, P221; CASSILETH BR, 1987, CANCER, V60, P547, DOI 10.1002/1097-0142(19870801)60:3+<547::AID-CNCR2820601518>3.0.CO;2-W; COHEN RM, 1982, ARCH GEN PSYCHIAT, V39, P593; CULLUM CM, 1988, J NERV MENT DIS, V176, P332, DOI 10.1097/00005053-198806000-00002; CUMMINGS JL, 1993, J CLIN PSYCHIAT, V54, P14; CUMMINGS JL, 1994, PSYCHIAT ANN, V24, P525, DOI 10.3928/0048-5713-19941001-10; CUMMINGS JL, 1992, AM J PSYCHIAT, V149, P443; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1974, PERCEPT MOTOR SKILL, V39, P831, DOI 10.2466/pms.1974.39.2.831; DIKMEN S, 1977, J NERV MENT DIS, V165, P247, DOI 10.1097/00005053-197710000-00004; Dikmen S, 1976, Trans Am Neurol Assoc, V101, P72; DIKMEN S, 1974, J ABNORM PSYCHOL, V83, P675, DOI 10.1037/h0037473; DOEHRING DG, 1960, J CLIN PSYCHOL, V16, P307; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; FOX DD, 1993, ANN M NAT AC NEUR PH; GASS CS, 1990, PSYCHOL REP, V67, P435, DOI 10.2466/PR0.67.6.435-438; GASS CS, 1992, ARCH CLIN NEUROPSYCH, V7, P17, DOI 10.1016/0887-6177(92)90015-F; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GASS CS, 1992, J CLIN PSYCHOL, V48, P493, DOI 10.1002/1097-4679(199207)48:4<493::AID-JCLP2270480409>3.0.CO;2-P; GASS CS, 1991, J CLIN PSYCHOL, V47, P100, DOI 10.1002/1097-4679(199101)47:1<100::AID-JCLP2270470116>3.0.CO;2-H; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P628; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; HENRY GM, 1973, AM J PSYCHIAT, V130, P966, DOI 10.1176/ajp.130.9.966; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; KAUFMAN AS, 1994, J PSYCHOEDUC ASSESS, V12, P112, DOI 10.1177/073428299401200201; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; MALEC JF, 1990, J CLIN PSYCHOL, V46, P551, DOI 10.1002/1097-4679(199009)46:5<551::AID-JCLP2270460502>3.0.CO;2-M; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MAYBERG HS, 1988, AM J PSYCHIAT, V145, P937; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; MEYERINK LH, 1988, J CLIN PSYCHOL, V44, P764, DOI 10.1002/1097-4679(198809)44:5<764::AID-JCLP2270440517>3.0.CO;2-Y; NEWMAN B, 1992, NEW YORK U MED CTR R, V4, P3; PAOLO AM, 1991, J CLIN PSYCHOL, V47, P529, DOI 10.1002/1097-4679(199107)47:4<529::AID-JCLP2270470409>3.0.CO;2-I; POPE KS, 1993, MMPI MMPI2 MMPIA COU; REIFLER BV, 1982, AM J PSYCHIAT, V139, P623; Reiker P., 1985, J CLIN ONCOL, V3, P1117; REITAN R M, 1955, AMA Arch Neurol Psychiatry, V73, P28; REITAN RM, 1955, ARCH NEURO PSYCHIATR, V73, P530, DOI 10.1001/archneurpsyc.1955.02330110046005; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; Ruff R. M., 1989, MILD HEAD INJURY, P176; Spielberger CD, 1970, MANUAL STATE TRAIT A; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STOUDEMIRE A, 1995, PSYCHOL FACTORS AFFE; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; VINGERHOETS G, 1995, CLIN NEUROPSYCHOL, V9, P198, DOI 10.1080/13854049508401603; WILSON SR, 1990, J CLIN PSYCHOL, V46, P565, DOI 10.1002/1097-4679(199009)46:5<565::AID-JCLP2270460504>3.0.CO;2-3; Wolfson, 1993, HALSTEAD REITAN NEUR	67	44	44	0	8	PLENUM PUBL CORP	NEW YORK	CONSULTANTS BUREAU, 233 SPRING ST, NEW YORK, NY 10013	1040-7308			NEUROPSYCHOL REV	Neuropsychol. Rev.	MAR	1997	7	1					3	19		10.1007/BF02876970			17	Psychology, Clinical; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	XK494	WOS:A1997XK49400001	9243528				2022-02-06	
J	Childers, MK; Stacy, M; Cooke, DL; Stonnington, HH				Childers, MK; Stacy, M; Cooke, DL; Stonnington, HH			Comparison of two injection techniques using botulinum toxin in spastic hemiplegia	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						botulinum toxin; spasticity; hemiplegia; gait	CEREBRAL-PALSY; A TOXIN	This study sought to test the hypothesis that injections of botulinum toxin type A (BTX-A) at the mid belly of the gastrocnemius muscle in spastic hemiplegic adults produce superior clinical results to proximal injections directed toward the muscular origin. We designed a randomized, double-blind, placebo-controlled intervention study at a university tertiary care setting. Seventeen subjects with chronic spastic hemiplegic gait were enrolled from a volunteer community sample; time range from acute neurologic insult was 0.75 to 31 yr; age range was 19 to 71 yr; gender consisted of 11 men and 4 women; diagnoses were 12 patients with stroke, 2 with traumatic brain injuries, and 1 with a brain tumor, Two subjects were withdrawn from the study because of (1) acute vascular occlusion before intervention and (2) noncompliance with follow-up visits. After baseline measurements, subjects were injected with 50 units of BTX-A (volume, 0.5 cc) into the medial or lateral gastrocnemius: (1) proximally at one site near the muscular origin; (2) distally at three sites along the mid belly. We measured outcome using the Fugl-Meyer score, Ashworth scale, ankle range of motion, and a timed 50-ft fastest walk. No outcome measures showed a significant effect attributable to site of injections. Confounding variables included physical therapy and varying duration of illness in the study cohort. We conclude that the results failed to support the hypothesis that BTX-A injections at the mid belly of the gastrocnemius produced superior functional improvements to injections located near the muscular origin using localization techniques described. Additional research comparing more precise localization methods for BTX-A injections might Further establish the importance of electromyographic guidance using BTX-A in management of spasticity.	ST JOSEPHS HOSP,BARROW NEUROL INST,PHOENIX,AZ; MEM MED CTR,DEPT PHYS MED & REHABIL,SAVANNAH,GA		Childers, MK (corresponding author), UNIV MISSOURI,DEPT PHYS MED & REHABIL,501 RUSK REHABIL CTR,COLUMBIA,MO 65212, USA.			Childers, Martin/0000-0003-4754-0883	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133P10011] Funding Source: Medline		AGANA BT, 1994, ARCH PHYS MED REHAB, V75, P1063; ASHWORTH B, 1964, PRACTITIONER, V192, P540; AWAD EA, 1993, INJECTION TECHNIQUES; BORGSTEIN J, 1993, AM J PHYS MED REHAB, V72, P364; BORODIC GE, 1994, MOVEMENT DISORD, V9, P31, DOI 10.1002/mds.870090106; Coers C, 1959, INNERVATION MUSCLE; COERS C, 1958, AM J PHYS MED REHABI, V38, P166; Daniel W. W., 1990, APPLIED NONPARAMETRI; DAS TK, 1989, BRIT J CLIN PRACT, V43, P401; DAS TK, 1989, POSTGRAD MED J, V65, P208, DOI 10.1136/pgmj.65.762.208; DENGLER R, 1992, J NEUROL, V239, P375; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; DYKSTRA DD, 1990, ARCH PHYS MED REHAB, V71, P24; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; GRAZKO MA, 1995, NEUROLOGY, V45, P712, DOI 10.1212/WNL.45.4.712; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1321, DOI 10.1136/jnnp.57.11.1321; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; KOMAN LA, 1993, J PEDIATR ORTHOPED, V13, P489, DOI 10.1097/01241398-199307000-00013; KONSTANZER A, 1992, MOV DISORD, V7, P416; MEMIN B, 1992, REV NEUROL, V148, P212; NOORT S, 1990, NEUROLOGY, V40, P1332; NORKIN CC, 1994, MEASUREMENT JOINT MO; OBRIEN CF, 1996, NEUROLOGY, V46, P1306; PIERSON SH, 1994, NEUROLOGY, V44, P15; PRIORI A, 1995, BRAIN, V118, P801, DOI 10.1093/brain/118.3.801; SHAARI CM, 1993, MUSCLE NERVE, V16, P964, DOI 10.1002/mus.880160913; SINGH B, 1994, ANN NEUROL, V36, P513; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; WIEGAND H, 1976, N-S ARCH PHARMACOL, V292, P161, DOI 10.1007/BF00498587	29	44	44	0	11	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV-DEC	1996	75	6					462	469		10.1097/00002060-199611000-00013			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	WA783	WOS:A1996WA78300010	8985111				2022-02-06	
J	Cifu, DX; Kaelin, DL; Wall, BE				Cifu, DX; Kaelin, DL; Wall, BE			Deep venous thrombosis: Incidence on admission to a brain injury rehabilitation program	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							VEIN THROMBOSIS; INTRACEREBRAL HEMORRHAGE; PULMONARY-EMBOLISM; THROMBOEMBOLISM; STROKE; PROPHYLAXIS; COMPRESSION	Objective: To determine the incidence of deep venous thrombosis (DVT) in brain injured individuals at time of admission to a brain injury (BI) rehabilitation program. Design: Prospective study, sequential case series. Setting: University tertiary care BI rehabilitation center. Data Set: Eighty-two traumatic brain injury (TBI) and 71 atraumatic brain injury (ABI) patients were consecutively admitted to our BI unit over a 12-month period and screened within 24 hours of admission for a lower extremity DVT with color flow duplex Doppler ultrasonography. All patients had been prophylaxed with either subcutaneous heparin anticoagulation therapy or intermittent compression devices, and all patients were within 2 months of the original BI. Main Outcome Measure: Evidence of intrinsic venous occlusion by duplex Doppler. Results: DVTs were detected and treated prior to rehabilitation admission in three patients (2%), and these persisted at rehabilitation admission. New DVTs were detected at time of rehabilitation admission in 17 patients (11%). All were occult DVTs; none of the 17 patients had clinical findings indicative of acute DVT. No significant differences were noted in the TBI group when age, highest 24-hour Glasgow Coma Scale score, length of acute hospitalization, type of DVT prophylaxis, or presence of an extremity fracture were compared for individuals with and without DVT. No significant differences were noted in the ABI group when age, length of acute hospitalization, and type of DVT prophylaxis were compared for individuals with and without DVT. Conclusion: The overall incidence of DVTs was 13% and the incidence of occult DVT was 11%. Individuals with TBI had an overall incidence of DVTs of 20% and an occult DVT incidence of 18%. Individuals with ABI had an overall incidence of DVT's of 6% and an occult DVT incidence of 4%. These findings indicate the importance of baseline screening for DVT in this patient population. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,RICHMOND,VA 23298; INDIANA UNIV,DEPT PHYS MED & REHABIL,BLOOMINGTON,IN 47405					Cifu, David/0000-0003-1600-9387			BLACK PM, 1986, NEUROSURGERY, V18, P25, DOI 10.1227/00006123-198601000-00005; BRANDSTATER ME, 1992, ARCH PHYS MED REHAB, V73, pS379; COPE C, 1973, RADIOLOGY, V109, P581, DOI 10.1148/109.3.581; DESMUKH M, 1991, AM J PHYS MED REHAB, V70, P313; DICKMANN U, 1988, KLIN WOCHENSCHR, V66, P1182, DOI 10.1007/BF01727666; FOGELHOLM R, 1992, J NEUROL NEUROSUR PS, V55, P1121, DOI 10.1136/jnnp.55.12.1121; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P1121; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; HAEGER K, 1969, ANGIOLOGY, V20, P219, DOI 10.1177/000331976902000406; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; HIRSH J, 1982, HEMOSTASIS THROMBOSI, P831; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL R, 1982, HAEMOSTASIS THROMBOS, P844; KAUFMAN HH, 1983, ANGIOLOGY, V34, P627, DOI 10.1177/000331978303401001; LACHMANN EA, 1992, ARCH PHYS MED REHAB, V73, P482; LANDI G, 1992, ARCH NEUROL-CHICAGO, V49, P279, DOI 10.1001/archneur.1992.00530270093024; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P1, DOI 10.1016/S0003-9993(96)90210-5; MIYAMOTO AT, 1980, ARCH PHYS MED REHAB, V61, P584; *OFF MED APPL RES, 1986, JAMA-J AM MED ASSOC, V256, P744; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; RENTSCH HP, 1987, SCHWEIZ MED WSCHR, V117, P1853; SIOSON ER, 1988, ARCH PHYS MED REHAB, V69, P183; SKILLMAN JJ, 1978, SURGERY, V83, P554; STEINBURG DP, 1993, ARCH PHYS MED REHAB, V74, P1243; Subbarao J, 1984, IMJ Ill Med J, V165, P328; TEASDALE G, 1974, LANCET, V2, P81; WARLOW C, 1976, BRIT MED J, V1, P1178, DOI 10.1136/bmj.1.6019.1178; WEINMANN EE, 1994, NEW ENGL J MED, V331, P1630, DOI 10.1056/NEJM199412153312407; WHEELER HB, 1986, CHEST, V89, pS407, DOI 10.1378/chest.89.5.407S; WHEELER HB, 1994, ARCH INTERN MED, V154, P1921, DOI 10.1001/archinte.154.17.1921	30	44	44	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1996	77	11					1182	1185		10.1016/S0003-9993(96)90145-8			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	VR820	WOS:A1996VR82000017	8931533				2022-02-06	
J	HAMM, RJ; PIKE, BR; TEMPLE, MD; ODELL, DM; LYETH, BG				HAMM, RJ; PIKE, BR; TEMPLE, MD; ODELL, DM; LYETH, BG			THE EFFECT OF POSTINJURY KINDLED SEIZURES ON COGNITIVE PERFORMANCE OF TRAUMATICALLY BRAIN-INJURED RATS	EXPERIMENTAL NEUROLOGY			English	Article							PROPHYLACTICALLY ADMINISTERED PHENYTOIN; CLOSED HEAD-INJURY; POSTTRAUMATIC SEIZURES; PENTYLENETETRAZOL; MK-801; IMPAIRMENT; RECOVERY; DEFICITS; FAILURE; ACID	The purpose of this experiment was to examine the consequences of postinjury seizures on cognitive performance after experimental traumatic brain injury (TBI). Rats either were injured at a moderate (2.1 atm) level of central fluid percussion TBI (n = 16) or were surgically prepared but did not receive a fluid pulse (sham-injured control, n = 16). Beginning 24 h after TBI, injured animals were injected (ip) once daily (Days 1-24 postinjury) with either saline (n = 8) or 25 mg/kg pentylenetetrazol (PTZ) (n = 8). Sham-injured rats were injected with an equal volume of saline (n = 8) or PTZ (n = 8). In both injured and sham injured animals, daily injections of PTZ resulted in an increase in the severity of behavioral seizures over days. On Days 25-29 after injury or sham injury, all animals were tested in the Morris water maze (MWM). Analysis of maze performance indicated that in sham injured animals PTZ-produced seizures had a detrimental effect on performance. In injured animals, however, PTZ-treated animals exhibited significantly faster acquisition and better terminal performance in the MWM than did untreated injured animals. These results show that posttraumatic kindled seizures do not exacerbate behavioral deficits after TBI and may, in fact, improve recovery following injury. The findings of this experiment are consistent with the hypothesis that post-TBI neuronal depression may contribute to behavioral morbidity following injury. (C) 1995 Academic Press, Inc.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,RICHMOND,VA 23284		HAMM, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23284, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BARKAI E, 1994, J NEUROPHYSIOL, V72, P72, DOI 10.1152/jn.1994.72.1.72; BARTH TM, 1990, STROKE, V21, P153; BECKER A, 1992, BEHAV NEURAL BIOL, V57, P37, DOI 10.1016/0163-1047(92)90735-M; BRAILOWSKY S, 1986, BRAIN RES, V362, P322, DOI 10.1016/0006-8993(86)90457-9; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; CORDA MG, 1992, J PHARMACOL EXP THER, V262, P792; CORDA MG, 1991, PHARMACOL BIOCHEM BE, V40, P329, DOI 10.1016/0091-3057(91)90562-G; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DIETRICH WD, 1994, J NEUROTRAUM, V6, P629; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dugan Ellen M., 1994, Emergency Medicine Clinics of North America, V12, P1081; Feeney D M, 1987, Brain Inj, V1, P27, DOI 10.3109/02699058709034441; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FOY PM, 1992, J NEUROL NEUROSUR PS, V77, P753; GIORGI O, 1991, EUR J PHARMACOL, V193, P363, DOI 10.1016/0014-2999(91)90152-G; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; GRECKSCH G, 1991, PHARMACOL BIOCHEM BE, V39, P825, DOI 10.1016/0091-3057(91)90174-Z; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HERNANDEZ TD, 1988, EXP NEUROL, V103, P318; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HUMPEL C, 1993, NEUROSCIENCE, V53, P909, DOI 10.1016/0306-4522(93)90476-V; KENNEDY CR, 1986, J HEAD TRAUMA REHAB, V1, P66; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KULKARNI SK, 1994, METHOD FIND EXP CLIN, V16, P735; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; OHNO K, 1993, J NEUROL NEUROSUR PS, V56, P1231, DOI 10.1136/jnnp.56.11.1231; PAZDERNIK TL, 1985, NEUROSCIENCE, V14, P823, DOI 10.1016/0306-4522(85)90146-0; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SMITH DB, 1991, ADV NEUROLOGY, V55; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITH KR, 1994, ARCH NEUROL-CHICAGO, V51, P653, DOI 10.1001/archneur.1994.00540190029012; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; VOIGT JP, 1990, BIOMED BIOCHIM ACTA, V49, P143; WATSON CW, 1945, J NEUROPHYSIOL, V8, P221; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231	50	44	44	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	1995	136	2					143	148		10.1006/exnr.1995.1091			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TK258	WOS:A1995TK25800006	7498404				2022-02-06	
J	Soares, HD; Sinson, GP; McIntosh, TK				Soares, HD; Sinson, GP; McIntosh, TK			Fetal hippocampal transplants attenuate CA3 pyramidal cell death resulting from fluid percussion brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; fetal neural transplants; hippocampus	NERVE GROWTH-FACTOR; INTRACEREBRAL NEURAL IMPLANTS; NEUROTROPHIC FACTOR PREVENTS; MOTOR NEURONS; NEOCORTICAL TRANSPLANTS; CORTICAL TRANSPLANTS; MEMORY DEFICITS; GRAFTS; CORTEX; DEGENERATION	Transplantation of fetal neural tissue has been demonstrated to prevent neuronal loss in a number of CNS injury models including spinal cord contusion, However, no studies have examined the neuroprotective role of fetal transplants in models of traumatic brain injury, The present study examined the ability of fetal neural grafts to attenuate neuronal loss resulting from lateral fluid percussion (FP) brain injury in the rat, Lateral FP in the rat elicits a focal contusion within the parietal/temporal cortex and induces cell death in a subset of hippocampal CA3 pyramidal neurons, To examine potential neuroprotective effects of fetal neural grafts, either E16 fetal hippocampus, E16 fetal cortex, or sterile lactated Ringers was stereotaxically transplanted directly into contused cortex 2 days after FP brain injury, The effects of fetal transplants upon adjacent injured hippocampal CA3 regions were then assessed at 4 weeks after grafting utilizing quantitative image analysis, Both fetal cortex and hippocampal grafts survived within contused cortex, Fetal hippocampal grafts significantly attenuated CA3 cell death resulting from lateral fluid percussion, while fetal cortical transplants induced a small, but nonsignificant, amelioration of CA3 pyramidal loss, Thus, neuroprotection by fetal grafts appeared to be tissue specific with hippocampal, but not cortical, fetal transplants significantly reducing posttraumatic CA3 loss, In summary, fetal neural transplantation can ameliorate hippocampal cell death following experimental brain injury.	ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110; UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803, R55NS026818, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline		ARENDT T, 1988, NATURE, V332, P448, DOI 10.1038/332448a0; BARTH TM, 1994, CEREB CORTEX, V4, P271, DOI 10.1093/cercor/4.3.271; BJORKLUND A, 1987, TRENDS NEUROSCI, V10, P509, DOI 10.1016/0166-2236(87)90131-7; BJORKLUND A, 1984, ANNU REV NEUROSCI, V7, P279, DOI 10.1146/annurev.ne.07.030184.001431; BRAUGHLER JM, 1991, J NEUROTRAUM, V8, P51; BREGMAN BS, 1986, J COMP NEUROL, V244, P86, DOI 10.1002/cne.902440107; CIRCIRATA F, 1992, ARCH ITAL BIOL, V130, P101; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAS GD, 1980, AM J ANAT, V158, P135, DOI 10.1002/aja.1001580204; DUNNETT S, 1991, TRENDS NEUROSCI, V14, P371, DOI 10.1016/0166-2236(91)90166-R; Dunnett SB, 1992, NEURAL TRANSPLANTATI, P1; ESCOBAR M, 1989, BRAIN RES, V478, P368, DOI 10.1016/0006-8993(89)91519-9; FLOETER MK, 1984, J NEUROSCI, V4, P141; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; GAGE FH, 1988, J COMP NEUROL, V269, P147, DOI 10.1002/cne.902690112; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; GONZALEZ MF, 1988, EXP NEUROL, V99, P154, DOI 10.1016/0014-4886(88)90135-5; GRAHAM DI, 1993, HEAD INJURY, P91; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAUN F, 1984, DEV BRAIN RES, V15, P290, DOI 10.1016/0165-3806(84)90108-1; HAUN F, 1987, J COMP NEUROL, V256, P561, DOI 10.1002/cne.902560408; HEFTI F, 1986, J NEUROSCI, V6, P2155; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HUDSON JL, 1994, J NEUROSCI, V14, P283; JAEGER CB, 1979, BRAIN RES, V165, P338, DOI 10.1016/0006-8993(79)90566-3; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LABBE R, 1983, SCIENCE, V221, P470, DOI 10.1126/science.6683427; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; LU SY, 1993, J NEURAL TRANSP PLAS, V4, P279, DOI 10.1155/NP.1993.279; LYETH GS, 1972, BRAIN RES, V42, P311; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; PAULABARBOSA MM, 1991, ALCOHOL ALCOHOLISM, V26, P177, DOI 10.1093/oxfordjournals.alcalc.a045099; PERRI BR, 1995, UNPUB J CEREB BLOOD; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; RIDLEY RM, 1993, ANN NY ACAD SCI, V695, P274, DOI 10.1111/j.1749-6632.1993.tb23066.x; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SHARRARD WJW, 1986, REV CHIR ORTHOP, V72, P247; SIEVERS J, 1989, J COMP NEUROL, V281, P267; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; SORENSEN JC, 1992, EXP BRAIN RES, V92, P299; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; Witter M. P., 1989, HIPPOCAMPUS NEW VIST, P53; WOODRUFF ML, 1993, PHYSIOL BEHAV, V54, P579, DOI 10.1016/0031-9384(93)90253-C; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YOUNG W, 1992, J NEUROTRAUMA S, V1, pS9	51	44	45	1	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1995	12	6					1059	1067		10.1089/neu.1995.12.1059			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	TU518	WOS:A1995TU51800006	8742134				2022-02-06	
J	SUN, FY; FADEN, AI				SUN, FY; FADEN, AI			PRETREATMENT WITH ANTISENSE OLIGODEOXYNUCLEOTIDES DIRECTED AGAINST THE NMDA-R1 RECEPTOR ENHANCES SURVIVAL AND BEHAVIORAL RECOVERY FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	BRAIN RESEARCH			English	Article						N-METHYL-D-ASPARTATE; ANTISENSE OLIGODEOXYNUCLEOTIDE; NEUROPROTECTION; TRAUMATIC BRAIN INJURY; MORTALITY; BEHAVIORAL RECOVERY; ASTROCYTIC REACTION	EXCITATORY AMINO-ACIDS; D-ASPARTATE RECEPTORS; CEREBRAL-ISCHEMIA; MOLECULAR DIVERSITY; TRANSPORT SITES; GLUTAMATE; ANTAGONISTS; CHANNEL; NEURONS; HIPPOCAMPUS	Treatment with N-methyl-D-aspartate (NMDA) receptor antagonists limits tissue damage following CNS ischemia or trauma, supporting the hypothesis that NMDA receptors participate in the pathophysiology of such injuries. An alternative approach for evaluating this hypothesis is to examine the effects of selective inhibition of NMDA receptor synthesis, using antisense oligodeoxynucleotides. In the present studies, the effects of antisense oligodeoxynucleotides directed at NMDA-R1 receptor subunit, administered intracerebroventricularly (i.c.v.) prior to injury, were evaluated in a well-defined traumatic brain injury model in rats. Outcome measures included survival, motor recovery, and histological changes. Administration of antisense oligodeoxynucleotides (15 nmol/ml twice daily X 2 days) did not alter physiological variables or motor function prior to trauma. However, such treatment significantly decreased mortality and improved behavioral recovery at 2 weeks after trauma as compared to animals treated with the corresponding sense oligodeoxynucleotides. Although cell counts in hippocampus did not differ between treatment groups, astrocyte activation as reflected by glial fibrillary astrocytic protein (GFAP) immunocytochemistry was significantly reduced in antisense treated animals. These findings provide additional evidence that NMDA receptors contribute to secondary injury after brain trauma and may suggest an alternative treatment approach.	GEORGETOWN UNIV,MED CTR,SCH MED,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,SCH MED,DEPT PHARMACOL,WASHINGTON,DC 20007						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 306634] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER		ALBERS GW, 1990, CLIN NEUROPHARMACOL, V13, P177, DOI 10.1097/00002826-199006000-00001; ANDERSON KJ, 1991, BRAIN RES, V562, P285, DOI 10.1016/0006-8993(91)90633-7; ANDERSON KJ, 1993, BRAIN RES, V622, P93, DOI 10.1016/0006-8993(93)90806-X; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BUCHAN AM, 1990, CEREBROVAS BRAIN MET, V2, P1; BULLER AL, 1994, J NEUROSCI, V14, P5471; FADDIS BT, 1988, AM J ANAT, V183, P316, DOI 10.1002/aja.1001830405; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; ISHII T, 1993, J BIOL CHEM, V268, P2836; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, CEREBROVAS BRAIN MET, V2, P25; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; Paxinos G, 1986, RAT BRAIN STEREOTAXI; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; SHANK RP, 1981, LIFE SCI, V28, P837, DOI 10.1016/0024-3205(81)90044-8; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SHARPIR AY, 1990, J NEUROTRAUM, V7, P131; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P779, DOI 10.1016/0306-4522(89)90298-4; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0	41	44	47	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 25	1995	693	1-2					163	168		10.1016/0006-8993(95)00731-5			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	RX133	WOS:A1995RX13300019	8653404				2022-02-06	
J	BERRYHILL, P; LILLY, MA; LEVIN, HS; HILLMAN, GR; MENDELSOHN, D; BRUNDER, DG; FLETCHER, JM; KUFERA, J; KENT, TA; YEAKLEY, J; BRUCE, D; EISENBERG, HM				BERRYHILL, P; LILLY, MA; LEVIN, HS; HILLMAN, GR; MENDELSOHN, D; BRUNDER, DG; FLETCHER, JM; KUFERA, J; KENT, TA; YEAKLEY, J; BRUCE, D; EISENBERG, HM			FRONTAL-LOBE CHANGES AFTER SEVERE DIFFUSE CLOSED-HEAD INJURY IN CHILDREN - A VOLUMETRIC STUDY OF MAGNETIC-RESONANCE-IMAGING	NEUROSURGERY			English	Article						CHILDREN; CLOSED HEAD INJURY; MAGNETIC RESONANCE IMAGING	COMA DATA-BANK; BRAIN MORPHOLOGY; ADOLESCENTS; SEQUELAE; MRI; SPECT; CT	IN VIEW OF the pathophysiology and biomechanics of severe closed head injury (CHI) in children, we postulated that the frontal lobes sustain diffuse injury, even in the absence of focal brain lesions detected by magnetic resonance imaging (MRI). This study quantitated the morphological effects of CHI on the frontal lobes in children who sustained head trauma of varying severity. The MRI findings of 14 children who had sustained severe CHIs (Glasgow Coma Scale score of less than or equal to 8) were compared with the findings in a matched group of 14 children having sustained mild head injuries (Glasgow Coma Scale score of 13-15). The patients ranged in age from 5 to 15 years at the time of their MRIs, which were acquired at least 3 months postinjury. MRI findings revealed no focal areas of abnormal signal in the frontal lobes. Volumetric analysis disclosed that the total prefrontal cerebrospinal fluid increased and the gray matter volume decreased in the patients with severe CHI, relative to the mildly injured comparison group. Gray matter volume was also reduced in the orbitofrontal and dorsolateral regions of the brains of children with severe CHI, relative to the children who sustained mild head trauma. These volumetric findings indicate that prefrontal tissue loss occurs after severe CHI in children, even in the absence of focal brain lesions in this area. Nearly two-thirds of the children who sustained severe CHIs were moderately disabled after an average postinjury interval of 3 years or more, whereas 12 of the 14 patients with mild CHIs attained a good recovery (2 were moderately disabled) by the time of study. Although this initial study of brain morphometry after CHI in children was not designed to isolate the contribution of frontal lobe damage to residual disability, further research involving a larger sample is in progress to address this issue.	UNIV MARYLAND MED SYST,DIV NEUROSURG,BALTIMORE,MD 21201; UNIV TEXAS,MED BRANCH,DEPT PHARMACOL,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT COMP SCI,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550; UNIV TEXAS,SW MED CTR,ALGUR H MEADOWS DIAGNOST IMAGING CTR,DALLAS,TX 75230; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DIV RADIOL,HOUSTON,TX 77225; PEDIAT ASSOCIATES,NEUROSURGEONS CHILDRENS,DALLAS,TX				fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020	Kent, Thomas/0000-0002-9877-7584	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BERGER MS, 1980, J NEUROSURG, V62, P194; BERNARDI B, 1993, TOP MAGN RESON IMAG, V5, P161; BIJUR PE, 1990, PEDIATRICS, V86, P337; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Filipek Pauline A., 1992, V6, P301; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; HILLMAN GR, 1991, J COMPUT ASSIST TOMO, V15, P640, DOI 10.1097/00004728-199107000-00021; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; JENNETT B, 1975, LANCET, V1, P480; JERNIGAN T L, 1989, Neurology, V39, P138; JERNIGAN TL, 1990, DEV MED CHILD NEUROL, V32, P379; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; PRAYER L, 1993, ACTA RADIOL, V34, P593; REISS AL, 1993, ANN NEUROL, V34, P228; Schnitzlein H.N., 1990, IMAGING ANATOMY HEAD; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TEASDALE G, 1974, LANCET, V2, P81	33	44	44	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1995	37	3					392	399		10.1227/00006123-199509000-00004			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	RU161	WOS:A1995RU16100009	7501101				2022-02-06	
J	FULTON, RL; VOIGT, WJ; HILAKOS, AS				FULTON, RL; VOIGT, WJ; HILAKOS, AS			CONFUSION SURROUNDING THE TREATMENT OF TRAUMATIC CARDIAC-ARREST	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							THORACOTOMY; RESUSCITATION; HEMORRHAGE	BACKGROUND: To delineate the most reasonable approach to patients with traumatic cardiac arrest we studied the experience at our level 1 trauma center. STUDY DESIGN: Patients with life-threatening trauma admitted during a 41-month period were screened to identify 245 patients who suffered cardiac arrest. Mechanisms of injury, location of arrest, length of arrest, transport methods, treatment rendered, neurologic state, outcomes, and cost of treatment were determined. RESULTS: Six (2.4 percent) patients survived. Mechanism of injury, location of arrest, and age did not correlate with survival. Arrest time longer than ten minutes and loss of neurologic function were associated with mortality. Cost of care was not excessive. CONCLUSIONS: Patients with traumatic cardiac arrest with intact neurologic function should receive treatment. Resuscitation should not be attempted in patients who also have severe brain injury or prolonged time of cardiac arrest.	UNIV LOUISVILLE HOSP,INST TRAUMA,LOUISVILLE,KY		FULTON, RL (corresponding author), UNIV LOUISVILLE,SCH MED,DEPT SURG,LOUISVILLE,KY 40292, USA.						[Anonymous], 1993, ADV TRAUMA LIFE SUPP; APRAHAMIAN C, 1985, ANN EMERG MED, V14, P95; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; BOYD M, 1992, J TRAUMA, V33, P714, DOI 10.1097/00005373-199211000-00021; BUCKBERG GD, 1979, J THORAC CARDIOV SUR, V77, P803; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; COPASS MK, 1984, AM J SURG, V148, P20, DOI 10.1016/0002-9610(84)90284-8; CUE JI, 1990, J TRAUMA, V30, P1007, DOI 10.1097/00005373-199008000-00010; DURHAM LA, 1992, J TRAUMA, V32, P775, DOI 10.1097/00005373-199206000-00019; ESPOSITO TJ, 1991, J TRAUMA, V31, P881, DOI 10.1097/00005373-199107000-00001; EVANS J, 1979, ANN SURG, V189, P777, DOI 10.1097/00000658-197906000-00015; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; FULTON RL, 1993, SURG GYNECOL OBSTET, V176, P327; LORENZ HP, 1992, J TRAUMA, V32, P780, DOI 10.1097/00005373-199206000-00020; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; Richardson J D, 1985, Curr Surg, V42, P361; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; SHIMAZU S, 1983, J TRAUMA, V23, P213, DOI 10.1097/00005373-198303000-00006; WALPOLE RE, 1989, PROBABILITY STATISTI; WEIDLER DJ, 1974, STROKE, V5, P759, DOI 10.1161/01.STR.5.6.759; WRIGHT SW, 1989, ANN EMERG MED, V18, P721, DOI 10.1016/S0196-0644(89)80003-4; 1994, TXB ADV CARDIAC LIFE	22	44	44	0	0	AMER COLL SURGEONS	CHICAGO	54 EAST ERIE ST, CHICAGO, IL 60611	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	SEP	1995	181	3					A209	A214					6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	RT205	WOS:A1995RT20500003	7670679				2022-02-06	
J	DUNN, JT; LEESHALEY, PR; BROWN, RS; WILLIAMS, CW; ENGLISH, LT				DUNN, JT; LEESHALEY, PR; BROWN, RS; WILLIAMS, CW; ENGLISH, LT			NEUROTOXIC COMPLAINT BASE RATES OF PERSONAL-INJURY CLAIMANTS - IMPLICATIONS FOR NEUROPSYCHOLOGICAL ASSESSMENT	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; IMPAIRMENT	This study reports base rate data for 113 family practice patients with no history of head trauma or toxic exposure, 68 family practice patients with a history of head trauma or toxic exposure, and 156 personal injury claimants with no history of toxic exposure or head trauma who presented for a psychological evaluation due to emotional distress. Personal injury claimants reported suffering from significantly more neurotoxic and neuropsychologic symptoms than subjects with a reported history of head trauma and/or toxic exposure. The authors urge that evaluating psychologists consider the base rate of these symptoms in litigating populations and use caution in relying on self-reported symptoms as evidence of injury when patients are in litigation.	LEES HALEY PSYCHOL CORP, ENCINO, CA USA								Anger W.K., 1985, NEUROTOXICITY IND CO, P51; ANGER WK, 1990, BEHAVIORAL MEASURES, P69; BAKER EL, 1988, ANNU REV PUBL HEALTH, V9, P223; BEAUMONT JG, 1990, BEHAVIORAL MEASURES, P86; COOK PB, 1989, OCCUPATIONAL HLTH HA; COTTROL C, 1993, HOSP COMMUNITY PSYCH, V44, P715; ELWOOD RW, 1993, CLIN PSYCHOL REV, V13, P409, DOI 10.1016/0272-7358(93)90012-B; Fischman M. L., 1988, CHEM HAZARDS WORKPLA; FOX DD, 1994, ARCH CLIN NEUROPSYCH, V9, P211, DOI 10.1016/0887-6177(94)90026-4; GASS CS, 1991, J CLIN PSYCHOL, V47, P100, DOI 10.1002/1097-4679(199101)47:1<100::AID-JCLP2270470116>3.0.CO;2-H; Gibbs MS, 1986, ADV ENVIRON PSYCHOL, V6, P47; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; HARTMAN DE, 1988, NEUROPSYCHOLOGICAL T; JAMES RC, 1985, IND TOXICOLOGY, P123; Johnson BL, 1990, ADV NEUROBEHAVIORAL; LAVE LB, 1987, CHEM HLTH ENV; Lees-Haley P. R., 1992, FORENSIC REPORTS, V5, P385; Lees-Haley Paul R., 1989, DEFENSE COUNSEL J, V56, P110; LEESHALEY P, 1990, FORENSIC REPORTS, V3, P421; LEESHALEY PR, 1990, PERCEPT MOTOR SKILL, V70, P1379, DOI 10.2466/PMS.70.4.1379-1382; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; MARKOWITZ JS, 1986, ADV ENVIRON PSYCHOL, V6, P89; MARQUIS JK, 1989, GUIDE GENERAL TOXICO; Matarazzo J.D., 1989, PSYCHOL ASSESSMENT, V1, P186, DOI [https://doi.org/10.1037/1040-3590.1.3.186, DOI 10.1037/1040-3590.1.3.186]; Matarazzo J. D., 1987, CLIN NEUROPSYCHOL, V1, P307; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; MATARAZZO JD, 1988, J CLIN PSYCHOL, V44, P940, DOI 10.1002/1097-4679(198811)44:6<940::AID-JCLP2270440615>3.0.CO;2-A; MEEHL PE, 1960, AM PSYCHOL, V15, P19, DOI 10.1037/h0041744; MEEHL PE, 1955, PSYCHOL ASSESSMENT, V4, P190; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODONNELL WE, 1993, J CLIN PSYCHOL, V49, P372, DOI 10.1002/1097-4679(199305)49:3<372::AID-JCLP2270490311>3.0.CO;2-K; REITAN RM, 1992, CLIN NEUROPSYCHOLOGY; RUSSELL RW, 1990, BEHAVIORAL MEASURES, P359; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1977, LANCET, V1, P1; VANDERKILK BA, 1987, PSYCHOL TRAUMA; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; Weissman H. N., 1990, BEHAVIORAL SCI LAW, V8, P67; WILLIAMSON AM, 1990, BEHAVIORAL MEASURES, P56; ZISKIN J, 1988, COPING PSYCHIATRIC P; 1991, INT CLASS DIS	43	44	44	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9762	1097-4679		J CLIN PSYCHOL	J. Clin. Psychol.	JUL	1995	51	4					577	584		10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E			8	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	RQ994	WOS:A1995RQ99400017	7593681				2022-02-06	
J	GOLDSTEIN, LB				GOLDSTEIN, LB			PRESCRIBING OF POTENTIALLY HARMFUL DRUGS TO PATIENTS ADMITTED TO HOSPITAL AFTER HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						HEAD TRAUMA; RECOVERY	VISUAL-CORTEX ABLATION; AMPHETAMINE-INDUCED RECOVERY; BINOCULAR DEPTH-PERCEPTION; CORTICAL HEMIPLEGIA; LOCOMOTOR FUNCTION; BRAIN INJURY; BEAM-WALKING; HALOPERIDOL; EXPERIENCE; PHENYTOIN	Fundamental studies in laboratory animals show that certain drugs influence behavioural recovery after brain injury. Although some drugs have the potential to enhance recovery, others may be detrimental. The purpose of the present study was to determine how often these potentially detrimental drugs are used in the management of patients with traumatic brain injury. The medical records of 100 patients with head trauma admitted to a university hospital during one year were reviewed and the frequencies of medication prescriptions during the stay in hospital were recorded. Only 14% of patients with head injury were taking medications at the time of injury. All of the patients were prescribed medications during their stay in hospital. Seventy two per cent of the patients received one or a combination of the drugs (neuroleptics and other central dopamine receptor antagonists, benzodiazepines, and the anticonvulsants phenytoin and phenobarbitone) that animal studies suggest may impair recovery. Until the true impact of these classes of drugs on the recovery process is better understood, care should be exercised in their use.	DUKE UNIV,CTR HLTH POLICY RES & EDUC,DURHAM,NC 27710; VET AFFAIRS MED CTR,DURHAM,NC 27705		GOLDSTEIN, LB (corresponding author), DUKE UNIV,MED CTR,DEPT MED NEUROL,BOX 3651,DURHAM,NC 27710, USA.						Barbay S., 1993, Society for Neuroscience Abstracts, V19, P1012; BARTH TM, 1990, STROKE, V21, P153; BRAILOWSKY S, 1986, BRAIN RES, V362, P322, DOI 10.1016/0006-8993(86)90457-9; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; CHWEH AY, 1986, PHARMACOL BIOCHEM BE, V24, P1301, DOI 10.1016/0091-3057(86)90188-7; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DERYCK M, 1990, STROKE, V21, P158; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; GOLDSTEIN LB, 1990, STROKE, V21, P139; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GOLDSTEIN LB, 1988, NEUROLOGY, V38, P1806, DOI 10.1212/WNL.38.11.1806; GOLDSTEIN LB, 1989, ANN NEUROL, V26, P157; GOLDSTEIN LB, 1990, J NEURO REHAB, V4, P137; GOLDSTEIN LB, 1995, IN PRESS NEUROLOGY; GOLDSTEIN LB, 1989, CEREBROVASC DIS, P303; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HAYES RL, 1985, J CEREB BLOOD FLO S1, V5, pS395; HERNANDEZ TD, 1994, BRAIN RES, V635, P300, DOI 10.1016/0006-8993(94)91451-6; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; HOVDA DA, 1985, P W PHARMACOL SOC, V28, P209; JENNETT B, 1975, LANCET, V1, P480; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; Marshall L. F., 1985, CENTRAL NERVOUS SYST, P45; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; PORCH EE, 1986, CLIN APHASIOLOGY, V16, P309; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Saponjic R. M., 1993, Society for Neuroscience Abstracts, V19, P1012; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHALLERT T, 1992, PHYS MED REHABIL, V6, P375; SMITH KR, 1994, ARCH NEUROL-CHICAGO, V51, P653, DOI 10.1001/archneur.1994.00540190029012; STEPHENS J, 1986, ARCH PHYS MED REHAB, V67, P666; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; WALKERBATSON D, 1992, RESTOR NEUROL NEUROS, V4, P47, DOI 10.3233/RNN-1992-4106	45	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	1995	58	6					753	755		10.1136/jnnp.58.6.753			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	RC686	WOS:A1995RC68600026	7608684	Green Published, Bronze			2022-02-06	
J	MOREHEAD, M; BARTUS, RT; DEAN, RL; MIOTKE, JA; MURPHY, S; SALL, J; GOLDMAN, H				MOREHEAD, M; BARTUS, RT; DEAN, RL; MIOTKE, JA; MURPHY, S; SALL, J; GOLDMAN, H			HISTOPATHOLOGIC CONSEQUENCES OF MODERATE CONCUSSION IN AN ANIMAL-MODEL - CORRELATIONS WITH DURATION OF UNCONSCIOUSNESS	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD-INJURY; LESIONS; RATS; MEMORY; VULNERABILITY; HIPPOCAMPUS; ANTERIOR; THALAMUS; DEFICIT	Although duration of unconsciousness is commonly used as a prognostic index following traumatic brain injury (TBI), few controlled studies have statistically evaluated the relationship between unconsciousness and histologic pathology, particularly after moderate head injury, Using a pendulum-striker concussive device, a reproducible model of TBI in rats was developed. This model is uncomplicated by skull fractures, contusions, or experimenter-induced craniotomies. In the present study, the severity of the histopathology observed in this model of moderate closed-head injury at 48 h posttrauma is linearly related to the duration of unconsciousness (p < 0.0001), The pathology, assessed with a silver stain for neurodegeneration, is particularly striking if unconsciousness persists for 4 minutes or more, These data suggest that the initial period of unconsciousness may be a useful predictor of clinical brain histopathology associated with moderate closed-head injury, predicting either the degree of pathology and/or the rate it progresses if left untreated.	WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201; TUFTS UNIV,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BOSTON,MA 02111; UNIV CALIF IRVINE,DEPT DEV & CELL BIOL,IRVINE,CA 92717		MOREHEAD, M (corresponding author), ALKERMES INC,NEUROBIOL,64 SIDNEY ST,4TH FLOOR,CAMBRIDGE,MA 02139, USA.						AGGLETON JP, 1991, BEHAV BRAIN RES, V44, P151, DOI 10.1016/S0166-4328(05)80020-8; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BERACOCHEA DJ, 1989, BEHAV NEURAL BIOL, V51, P364, DOI 10.1016/S0163-1047(89)91000-5; CHASON JL, 1966, J TRAUM, V6, P767, DOI 10.1097/00005373-196611000-00008; GALLYAS F, 1980, STAIN TECHNOL, V55, P299, DOI 10.3109/10520298009067258; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDMAN H, 1993, ANN EMERG MED, V22, P1035, DOI 10.1016/S0196-0644(05)82747-7; GOLDMAN H, 1993, J NEUROTRAUM, V10, P385, DOI 10.1089/neu.1993.10.385; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAROON JC, 1992, PHYSICIAN SPORTSMED, V20, P37, DOI 10.1080/00913847.1992.11710269; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOREHEAD M, 1991, ALCOHOL POTENTIATES; MOREHEAD M, 1993, APR AM NEUR M; NADLER JV, 1983, METHOD ENZYMOL, V103, P393; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; Paxinos G, 1986, RAT BRAIN STEREOTAXI; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SQUIRE LR, 1981, J NEUROSCI, V1, P635; STOKES KA, 1990, BEHAV NEURAL BIOL, V53, P334, DOI 10.1016/0163-1047(90)90198-F; TEASDALE G, 1984, LANCET, V2, P81; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; WINOCUR G, 1985, BEHAV BRAIN RES, V16, P135, DOI 10.1016/0166-4328(85)90088-9; [No title captured]	33	44	44	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1994	11	6					657	667		10.1089/neu.1994.11.657			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	QD215	WOS:A1994QD21500003	7723065				2022-02-06	
J	CHIAVIELLO, CT; CHRISTOPH, RA; BOND, GR				CHIAVIELLO, CT; CHRISTOPH, RA; BOND, GR			STAIRWAY-RELATED INJURIES IN CHILDREN	PEDIATRICS			English	Article						STAIRS; STAIRWAY; CHILDREN; INJURY CONTROL; CHILDHOOD INJURIES; HEAD INJURIES	TRAUMA	Objective. To identify the pattern and severity of injury associated with stairway-related falls in children. Methods. During a 2-year period, all children less than 5 years of age presenting to the University of Virginia Pediatric Emergency Department with a stairway-related injury were prospectively studied. At the time of the emergency department visit, demographic and epidemiologic information was obtained. Injuries were assigned E codes and N codes. A Modified Injury Severity Scale (MISS) score was calculated for each child. Excluded from the study were children with suspected intentional trauma and children with walker-related stairway injuries. Results. Sixty-nine children were enrolled in the study. The median age was 2 years. Head and neck injuries occurred in 90% of the patients, extremity injuries in 6%, and truncal injuries in 4%. Injury to more than one body region did not occur. The majority of injuries were minor. Ninety-six percent had a total MISS score less than or equal to 2. Fifteen patients (22%) suffered significant injuries, including concussion in 11 (16%), skull fracture in 5 (7%), cerebral contusion in 2 (3%), subdural hematoma in 1 (1%), and a C-2 fracture in 1 (1%). Conclusions. The majority of stairway-related injuries are minor. Injuries to the head and neck region predominate. Injuries to multiple body regions are rare. However, significant stairway-related injuries may be more common than previously reported.			CHIAVIELLO, CT (corresponding author), UNIV VIRGINIA,DEPT PEDIAT,DIV EMERGENCY MED,CHARLOTTESVILLE,VA 22908, USA.						Baker SP, 1992, THE INJURY FACT BOOK, VSecond; BARLOW B, 1983, J PEDIATR SURG, V18, P509, DOI 10.1016/S0022-3468(83)80210-3; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; JOFFE M, 1988, PEDIATRICS, V82, P457; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; 1964, CLIN NEUROSURG, V12, P386; 1980, INT CLASSIFICATION D, V1	9	44	47	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics	NOV	1994	94	5					679	681					3	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	PN912	WOS:A1994PN91200005	7936895				2022-02-06	
J	HALLETT, JD; ZASLER, ND; MAURER, P; CASH, S				HALLETT, JD; ZASLER, ND; MAURER, P; CASH, S			ROLE CHANGE AFTER TRAUMATIC BRAIN INJURY IN ADULTS	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						DISABILITY EVALUATION; SOCIAL ADJUSTMENT	SEVERE HEAD-INJURY; SOCIAL RECOVERY; COMMUNITY; SCALE; COMA	Objectives. The purpose of this study was to gather information regarding changes in adult life roles following severe traumatic brain injury. Method. The Role Checklist and a semistructured interview were administered to 28 adults with traumatic brain injury who bad been in the community for at least 8 months prior to the study. All 28 subjects reported role changes in their lives Results. The majority of the role changes were losses (71%). More than 64% percent of the subjects reported three or four role losses. The losses were in major organizing roles such as worker, hobbyist, and friend. Most role gains were seen in the roles of home maintainer, family member, and religious participant. Almost 40% of all roles were reported as changed (loss or gain), while more than 60% of roles were reported as unchanged (continuous or absent). The participants' subjective impressions concerning the role changes and why they occurred were elicited. Conclusion. With a better understanding of possible role change after traumatic brain injury, rehabilitation professionals can target the development of specific skills necessary for the continuation of valued roles.	NATL NEUROREHABIL CONSORTIUM INC,RICHMOND,VA; VIRGINIA COMMONWEALTH UNIV,DEPT OCCUPAT THERAPY,RICHMOND,VA 23284		HALLETT, JD (corresponding author), PUNXSUTAWNEY AREA HOSP,DEPT OCCUPAT THERAPY,PUNXSUTAWNEY,PA 15767, USA.						BERMANN D, 1988, HEAD INJURY GUIDE FU, P35; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; GLOAG D, 1985, BRIT MED J, V290, P913, DOI 10.1136/bmj.290.6472.913; HEARD C, 1977, AM J OCCUP THER, V31, P243; JENNETT B, 1984, CLOSED HEAD INJURY P, P37; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MOORHEAD L, 1969, AM J OCCUP THER, V23, P329; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; OAKLEY F, 1982, THESIS VIRGINIA COMM; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PEZZULI TW, 1988, THESIS VIRGINIA COMM; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; TEASDALE G, 1974, LANCET, V2, P81; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; World Health Organization, 1991, WORLD HLTH STAT ANN	21	44	45	0	6	AMER OCCUPATION THERAPY ASSN	ROCKVILLE	1383 PICCARD DRIVE PO BOX ROCKVILLE, MD 20850-4375	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	MAR	1994	48	3					241	246		10.5014/ajot.48.3.241			6	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	MW828	WOS:A1994MW82800007	8178918				2022-02-06	
J	YANG, KY; TAFT, WC; DIXON, CE; TODARO, CA; YU, RK; HAYES, RL				YANG, KY; TAFT, WC; DIXON, CE; TODARO, CA; YU, RK; HAYES, RL			ALTERATIONS OF PROTEIN-KINASE-C IN RAT HIPPOCAMPUS FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL-ISCHEMIA; REDISTRIBUTION; DISSOCIATION; ACTIVATION	Calcium-dependent excitotoxic processes contribute significantly to pathologic responses to traumatic brain injury (TBI). TBI causes neuronal depolarization and excessive excitatory neurotransmitter release, which may lead to increases in intracellular calcium levels. However, responses of calcium-dependent enzymes such as protein kinase C (PKC) following TBI are poorly understood. Since PKC plays an important role in signal transduction and maintenance of normal neuronal function, we investigated changes in PKC activity and protein levels following fluid percussion brain injury in rats. We observed a 23.1% increase in PKC activity 1 h postinjury and 80.7% increase in PKC activity 3 h postinjury. There was no statistically significant change in PKC activity 5 min and 24 h after injury. PKC immunolabelling studies detected a significant increase in PKC levels in membrane fractions 3 h but not 1 h after injury. Thus PKC activation is transiently increased following TBI and may play an important role in pathophysiologic responses to TBI.	UNIV MESSINA,NEUROCHIRURG CLIN,I-98100 MESSINA,ITALY; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOCHEM,RICHMOND,VA 23298; UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458] Funding Source: Medline		CARDELL M, 1990, NEUROSCI LETT, V119, P228, DOI 10.1016/0304-3940(90)90840-6; CRUMRINE RC, 1990, J NEUROCHEM, V55, P2001, DOI 10.1111/j.1471-4159.1990.tb05788.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MASLIAH E, 1991, J NEUROSCI, V11, P2759; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLAH Z, 1990, NEUROCHEM RES, V15, P515, DOI 10.1007/BF00966209; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Prasad M. R., 1992, Society for Neuroscience Abstracts, V18, P174; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; SHAPIRA Y, 1989, Neurological Research, V11, P169; SMITH M, 1990, 8TH P ANN M SOC NEUR; Taft W. C., 1992, Society for Neuroscience Abstracts, V18, P174; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; WIELOCH T, 1991, J NEUROCHEM, V56, P1227, DOI 10.1111/j.1471-4159.1991.tb11415.x; Yang K., 1992, Society for Neuroscience Abstracts, V18, P173; YU RK, 1990, TROPHIC FACTORS NERV, P175	25	44	44	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FAL	1993	10	3					287	295		10.1089/neu.1993.10.287			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	MC021	WOS:A1993MC02100005	8258841				2022-02-06	
J	MICHAUD, LJ; DUHAIME, AC; BATSHAW, ML				MICHAUD, LJ; DUHAIME, AC; BATSHAW, ML			TRAUMATIC BRAIN INJURY IN CHILDREN	PEDIATRIC CLINICS OF NORTH AMERICA			English	Article							SEVERE HEAD-INJURIES; YOUNG-ADULTS; CHILDHOOD; MOTOR; ADOLESCENTS; SEQUELAE; COMA		UNIV PENN,SCH MED,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV CHILD DEV,PHILADELPHIA,PA; CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV REHABIL MED,PHILADELPHIA,PA; CHILDRENS HOSP PHILADELPHIA,DEPT REHABIL MED,PHILADELPHIA,PA; CHILDRENS HOSP PHILADELPHIA,DEPT NEUROSURG,PHILADELPHIA,PA		MICHAUD, LJ (corresponding author), CHILDRENS SEASHORE HOUSE,3405 CIV CTR BLVD,PHILADELPHIA,PA, USA.						AGRAN P, 1990, AM J DIS CHILD, V144, P653, DOI 10.1001/archpedi.1990.02150300051017; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; Bragg RM, 1992, J HEAD TRAUMA REHAB, V7, P94; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; CARNEY J, 1990, Pediatrician, V17, P222; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHRISTOFFEL KK, 1992, PEDIATR ANN, V21, P430, DOI 10.3928/0090-4481-19920701-08; Comninos S C, 1979, Acta Neurochir Suppl (Wien), V28, P144; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DEPOMPEI R, 1991, NEUROREHABILITATION, V1, P29; DILLON H, 1961, JAMA-J AM MED ASSOC, V175, P86, DOI 10.1001/jama.1961.03040020012003; DUHAIME AC, 1992, PEDIATRICS, V90, P179; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; GENNARELLI TA, 1985, NEUROSURGERY, P1531; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GHAJAR J, 1992, PEDIATR CLIN N AM, V39, P1093; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KAUFMAN HH, 1985, NEUROSURGERY, V16, P754, DOI 10.1227/00006123-198506000-00002; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARGOLIS LH, 1988, AM J DIS CHILD, V142, P1099, DOI 10.1001/archpedi.1988.02150100093035; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; OLDS DL, 1986, PEDIATRICS, V78, P65; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RIVARA FP, 1990, AM J DIS CHILD, V144, P692, DOI 10.1001/archpedi.1990.02150300090023; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WALKER M L, 1985, P84; YLVISAKER M, 1989, J HEAD TRAUMA REHAB, V4, P51; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48; 1992, PEDIATRICS, V89, P512; 1990, AM J DIS CHILD, V144, P627	45	44	44	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0031-3955			PEDIATR CLIN N AM	Pediatr. Clin. N. Am.	JUN	1993	40	3					553	565					13	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	LD173	WOS:A1993LD17300008	8493065				2022-02-06	
J	MENDELSOHN, DB; LEVIN, HS; HARWARD, H; BRUCE, D				MENDELSOHN, DB; LEVIN, HS; HARWARD, H; BRUCE, D			CORPUS-CALLOSUM LESIONS AFTER CLOSED HEAD-INJURY IN CHILDREN - MRI, CLINICAL-FEATURES AND OUTCOME	NEURORADIOLOGY			English	Article						BRAIN; MAGNETIC RESONANCE IMAGING; TRAUMA; CORPUS CALLOSUM	DIFFUSE AXONAL INJURY; BRAIN-DAMAGE; TRAUMA	Thirty-four children who sustained moderate to severe closed head injury underwent magnetic resonance imaging (MRI). Eight (24%) had MRI evidence of corpus callosum injury, most commonly within the posterior body and splenium. In contradistinction to reports in adults, there was no definite relationship between callosal injury and lower initial Glasgow Coma Scale scores, nor was there a significantly higher incidence of primary brain-stem lesions, diffuse axonal shear injury or intraventricular hemorrhage. In none of these 8 children did the initial admission computed tomography show evidence of callosal injury. Callosal injuries on MRI are not necessarily a poor prognostic finding, the majority of the 8 children showing good functional recovery.	UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75230; GREENERY REHABIL CTR,DALLAS,TX; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75230; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; GENNARELLI TA, 1982, ANN NEUROL, V12, P546; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; JENNETT B, 1975, LANCET, V1, P480; LINDENBERG R, 1955, AM J PATHOL, V31, P297; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862	11	44	44	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0028-3940			NEURORADIOLOGY	Neuroradiology	OCT	1992	34	5					384	388		10.1007/BF00596495			5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	JQ585	WOS:A1992JQ58500004	1407515				2022-02-06	
J	SABATES, NR; GONCE, MA; FARRIS, BK				SABATES, NR; GONCE, MA; FARRIS, BK			NEUROOPHTHALMOLOGICAL FINDINGS IN CLOSED HEAD TRAUMA	JOURNAL OF CLINICAL NEURO-OPHTHALMOLOGY			English	Article						CLOSED HEAD TRAUMA; TUNNEL VISUAL FIELDS; CRANIAL NERVE PALSY; BASILAR SKULL FRACTURE	INJURY; NERVE; DISABILITY; COUNTY	Visual abnormalities following closed head trauma are common and can affect any part of the visual pathway. We reviewed 181 consecutive patients referred with visual complaints following closed head trauma. A motor vehicle accident was the most common etiology of trauma in 57% of cases, direct trauma to the head in 15%, and injuries sustained from a fall in 13%. Sixty-three percent of patients lost consciousness and 26% suffered a skull fracture. Thirty-five percent of all patients had visual field defects with functional (tunnel) fields the most common. Over 88% of eyes had 20/20 or better visual acuity. Thirty-three percent of patients suffered a cranial nerve palsy, with 75% resolving without intervention. The severity of head injury was directly related to the lack of proper seat belt and helmet use. Most visual complaints were improved with a simple refraction. Most binocular diplopia cleared with time, with only 15 cases requiring surgical correction.	UNIV OKLAHOMA,HLTH SCI CTR,DEAN A MCGEE EYE INST,DEPT OPHTHALMOL,608 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73104; MASSACHUSETTS EYE & EAR HOSP,BOSTON,MA 02114; TULANE UNIV,NEW ORLEANS,LA 70118; RETINA ASSOCIATES,BOSTON,MA		FARRIS, BK (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEAN A MCGEE EYE INST,DEPT OPHTHALMOL,608 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73104, USA.						ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BURGER LJ, 1970, BRAIN, V93, P567, DOI 10.1093/brain/93.3.567; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; ELISEVICH KV, 1984, SURG NEUROL, V22, P565, DOI 10.1016/0090-3019(84)90433-6; Evans R W, 1987, Tex Med, V83, P49; HARLEY RD, 1980, OPHTHALMOLOGY, V87, P24; HUGHES B, 1962, B JOHNS HOPKINS HOSP, V111, P98; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KEANE JR, 1989, ARCH NEUROL-CHICAGO, V46, P761, DOI 10.1001/archneur.1989.00520430055017; KHAWAM E, 1967, ARCH OPHTHALMOL-CHIC, V77, P761, DOI 10.1001/archopht.1967.00980020763009; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KLINE LB, 1984, NEUROSURGERY, V14, P756, DOI 10.1227/00006123-198406000-00021; LAMBERT WG, 1985, BR J CLIN PRAC, V10, P41; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUCKER CW, 1958, AM J OPHTHALMOL, V46, P787, DOI 10.1016/0002-9394(58)90989-9; RUCKER CW, 1966, AM J OPHTHALMOL, V61, P1293, DOI 10.1016/0002-9394(66)90258-3; RUSH JA, 1981, ARCH OPHTHALMOL-CHIC, V99, P76, DOI 10.1001/archopht.1981.03930010078006; SARINO PJ, 1980, NEUROLOGY, V30, P963; SCHIEMANN DA, 1987, FEMS MICROBIOL LETT, V41, P19; SMACHI J, 1970, JPN J OPHTHALMOL, V12, P70; SOSIN DM, 1990, JAMA-J AM MED ASSOC, P2395; Turner JWA, 1943, BRAIN, V66, P140; WALSH FB, 1969, CLIN NEUROOPHTHALMOL, P2381; WALSH FRANK B., 1966, INVEST OPHTHALMOL, V5, P433; ZETTAS FP, 1979, J TRAUMA, V19, P833	27	44	44	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0272-846X			J CLIN NEURO-OPHTHAL		DEC	1991	11	4					273	277					5	Neurosciences; Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Ophthalmology	GU126	WOS:A1991GU12600011	1838548				2022-02-06	
J	VINK, R; PORTOGHESE, PS; FADEN, AI				VINK, R; PORTOGHESE, PS; FADEN, AI			KAPPA-OPIOID ANTAGONIST IMPROVES CELLULAR BIOENERGETICS AND RECOVERY AFTER TRAUMATIC BRAIN INJURY	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article						NUCLEAR MAGNETIC RESONANCE; ENERGY METABOLISM; MAGNESIUM	MAGNETIC-RESONANCE SPECTROSCOPY; INTRACELLULAR FREE MG-2+; P-31 NMR-SPECTROSCOPY; SPINAL-CORD INJURY; NOR-BINALTORPHIMINE; FREE MAGNESIUM; RAT; NALOXONE; PH; ISCHEMIA	Treatment with opioid receptor antagonists improves outcome after experimental brain trauma, although the mechanisms underlying the protective actions of these compounds remain speculative. We have proposed that endogenous opioids contribute to the pathophysiology of traumatic brain injury through actions at kappa-opioid receptors, possibly by affecting cellular bioenergetic state. In the present study, the effects of the kappa-selective opioid-receptor antagonist nor-binaltorphimine (nor-BNI) were examined after fluid percussion brain injury in rats. Metabolic changes were evaluated by P-31 magnetic resonance spectroscopy; the same animals were subsequently followed over 2 wk to evaluate neurological recovery. Nor-BNI, administered intravenously as a 10 or 20 mg/kg bolus at 30 min after injury, significantly improved neurological outcome at 2 wk posttrauma compared with controls. Animals treated with nor-BNI showed significantly greater recovery of intracellular free magnesium concentrations and cytosolic phosphorylation potentials during the first 4 h after injury compared with saline-treated controls. The improvement in cytosolic phosphorylation potential was significantly correlated to neurological outcome. These data support the hypothesis that kappa-opioid receptors mediate pathophysiological changes after traumatic brain injury and that the beneficial effects of opioid-receptor antagonists may result from improvement of posttraumatic cellular bioenergetics.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; VET ADM MED CTR, CTR NEURAL INJURY, SAN FRANCISCO, CA 94121 USA; UNIV MINNESOTA, COLL PHARM, DEPT MED CHEM, MINNEAPOLIS, MN 55455 USA		VINK, R (corresponding author), JAMES COOK UNIV N QUEENSLAND, DEPT CHEM & BIOCHEM, TOWNSVILLE, QLD 4811, AUSTRALIA.		Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P451; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1988, PHYSL BASIS FUNCTION, P531; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NICOLETTI F, 1987, J NEUROCHEM, V48, P967, DOI 10.1111/j.1471-4159.1987.tb05611.x; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; STOKES BT, 1984, BRAIN RES, V290, P187, DOI 10.1016/0006-8993(84)90753-4; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1989, BIOCHEM BIOPH RES CO, V165, P913, DOI 10.1016/S0006-291X(89)80053-1; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	31	44	46	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0002-9513			AM J PHYSIOL	Am. J. Physiol.	DEC	1991	261	6	2				R1527	R1532		10.1152/ajpregu.1991.261.6.R1527			6	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	GX687	WOS:A1991GX68700087					2022-02-06	
J	SAAL, JA				SAAL, JA			COMMON AMERICAN FOOTBALL INJURIES	SPORTS MEDICINE			English	Article								As many as 1.5 million young men participate in American football in the United States. An estimated 1.2 million football-related injuries are sustained annually. Since the 1970s epidemiological studies have shown that the risk of injury is higher in older athletes and lower in teams with more experienced coaches and more assistant coaches. 51% of injuries occurred at training; contact sessions were 4.7 times more likely to produce injuries than controlled sessions. Injury rates were reduced by wearing shorter cleats and preseason conditioning. Overall, lower extremity injuries accounted for 50% of all injuries (with knee injuries accounting for up to 36%). Upper extremity injuries accounted for 30%. In general, sprains and strains account for 40% of injuries, contusions 25%, fractures 10%, concussions 5% and dislocations 15%. Cervical spine injuries have the potential to be catastrophic, but they declined dramatically in the decade 1975 to 1984, due to the impact of rule changes modifying tackling and blocking techniques and improved fitness, equipment and coaching. Appropriate diagnostic evaluation of cervical injuries is mandatory. The evidence supporting prophylactic knee bracing is not compelling and does not mandate compulsory or routine use. Return to play criteria include: full range of motion; normal strength; normal neurological evaluation; no joint swelling or instability; ability to run and sustain contact without pain; no intake of pain medication; player education about preventive measures and future risks. These criteria should be strictly observed. In addition to ankle and knee rehabilitation, lumbar spine injuries present a challenge for the physician. Repetitive flexion, extension and torsional stresses predispose the lumbar spine to injury. Rehabilitation consists of pain control and training. The training phase aims to eliminate repetitive injuries by minimising stress at the intervertebral joint. Football is a high risk sport. Coaches, players, trainers and physicians must all become aware of the proper means to prevent injuries.			SAAL, JA (corresponding author), SETON MED CTR,SAN FRANCISCO SPINE INST,1850 SULLIVAN AVE,SUITE 140,DALY CITY,CA 94015, USA.							0	44	44	1	19	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0112-1642			SPORTS MED	Sports Med.	AUG	1991	12	2					132	147		10.2165/00007256-199112020-00005			16	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	FZ359	WOS:A1991FZ35900005	1947533				2022-02-06	
J	WOLF, G; FISCHER, S; HASS, P; ABICHT, K; KEILHOFF, G				WOLF, G; FISCHER, S; HASS, P; ABICHT, K; KEILHOFF, G			MAGNESIUM-SULFATE SUBCUTANEOUSLY INJECTED PROTECTS AGAINST KAINATE-INDUCED CONVULSIONS AND NEURODEGENERATION - INVIVO STUDY ON THE RAT HIPPOCAMPUS	NEUROSCIENCE			English	Article							EXCITATORY AMINO-ACIDS; GLUTAMATE NEUROTOXICITY; CALCIUM-CONCENTRATION; NERVOUS-SYSTEM; BRAIN INJURY; ASPARTATE; INVITRO; NEURONS; RECEPTOR; DEPENDENCE	Kainate, an agonist of a unique subclass of glutamate receptors (kainate receptor), was injected intracerebroventricularly in rats to induce convulsive reactions and hippocampal damage in order to model glutamate-mediated brain injury. Rats treated with magnesium sulfate (subcutaneously injected, up to 600 mg/kg) were found to be protected from kainate neurotoxicity depending on the dose and time of application. Results were largely consistent with those obtained previously by using quinolinate as an excitotoxic N-methyl-D-asparate-receptor agonist. Magnesium is discussed as being a natural and relatively safe therapeutic in cases of glutamate-induced (hypoxic, ischemic, traumatic, or convulsive) disorders of the brain.	MED ACAD MAGDEBURG,INST CLIN CHEM,O-3034 MAGDEBURG,GERMANY; MED ACAD MAGDEBURG,DIAGNOST LAB,O-3034 MAGDEBURG,GERMANY		WOLF, G (corresponding author), MED ACAD MAGDEBURG,INST BIOL,ERICH WEINERT STR 3,O-3034 MAGDEBURG,GERMANY.		Hass, Peter/AAP-8768-2021	Hass, Peter/0000-0003-0164-5284			ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; ASHTON D, 1989, BRAIN RES, V487, P402, DOI 10.1016/0006-8993(89)90850-0; BERDICHEVSKY E, 1987, BRAIN RES, V423, P213, DOI 10.1016/0006-8993(87)90842-0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; GARTHWAITE G, 1986, NEUROSCI LETT, V66, P193, DOI 10.1016/0304-3940(86)90189-8; GOLDMAN RS, 1988, NEW ENGL J MED, V319, P1224; HONORE T, 1989, MED RES REV, V9, P1, DOI 10.1002/med.2610090102; KASS IS, 1982, J PHYSIOL-LONDON, V332, P459, DOI 10.1113/jphysiol.1982.sp014424; KEILHOFF G, 1990, NEUROSCIENCE, V34, P235, DOI 10.1016/0306-4522(90)90317-W; LEHMANN A, 1990, NEUROSCI RES COMMUN, V76, P27; MCCASLIN PP, 1988, EUR J PHARMACOL, V152, P341, DOI 10.1016/0014-2999(88)90729-7; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MELDRUM B, 1989, CEREBROVASC DIS, P47; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; PRITCHARD JA, 1975, AM J OBSTET GYNECOL, V123, P543, DOI 10.1016/0002-9378(75)90042-3; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; SCHMIDT W, 1990, METAB BRAIN DIS, V5, P19, DOI 10.1007/BF00996975; Schwarcz R., 1987, P19; STONE TW, 1985, NEUROSCIENCE, V15, P597, DOI 10.1016/0306-4522(85)90063-6; WATKINS JC, 1989, NMDA RECEPTOR; WOLF G, 1984, DEV BRAIN RES, V14, P15, DOI 10.1016/0165-3806(84)90004-X; WOLF G, 1990, NEUROSCI LETT, V117, P207, DOI 10.1016/0304-3940(90)90145-Y	26	44	44	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0306-4522			NEUROSCIENCE	Neuroscience		1991	43	1					31	34		10.1016/0306-4522(91)90413-I			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FV809	WOS:A1991FV80900004	1833668				2022-02-06	
J	FISHER, RG; ORIA, RA; MATTOX, KL; WHIGHAM, CJ; PICKARD, LR				FISHER, RG; ORIA, RA; MATTOX, KL; WHIGHAM, CJ; PICKARD, LR			CONSERVATIVE MANAGEMENT OF AORTIC LACERATIONS DUE TO BLUNT TRAUMA	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							ARTERIAL INJURIES; AORTOGRAPHY	Three patients with angiographically documented thoracic aortic lacerations were managed conservatively over 8 years due to the nonthreatening appearance of the injuries in two and the presence of an associated major closed head injury in a third. The lesion(s) resolved in one, diminished in another, and remained unchanged in the third. At least ten other cases managed similarly are recorded in the literature. In certain selected circumstances this approach may represent a viable alternative to the current standard of immediate surgical correction of aortic injuries.	BAYLOR UNIV,DEPT SURG,HOUSTON,TX 77030		FISHER, RG (corresponding author), BAYLOR UNIV,DEPT RADIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.						AKINS CW, 1981, ANN THORAC SURG, V31, P305, DOI 10.1016/S0003-4975(10)60955-1; CONN JH, 1971, J TRAUM, V11, P167, DOI 10.1097/00005373-197102000-00007; COWLEY RA, 1989, 69TH M AM ASS THOR S; FLECKENSTEIN JL, 1987, CARDIOVASC INTER RAD, V10, P194, DOI 10.1007/BF02593868; FRYKBERG ER, 1989, J TRAUMA, V29, P577, DOI 10.1097/00005373-198905000-00006; KOURY WC, 1975, RADIOLOGY, V116, P23, DOI 10.1148/116.1.23; KUBOTA RT, 1985, CT-J COMPUT TOMOGR, V9, P237, DOI 10.1016/0149-936X(85)90068-2; MATTOX JL, 1987, VASCULAR SURGICAL EM, P341; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; PEZZELLA AT, 1978, AM SURGEON, V44, P699; STAIN SC, 1989, ARCH SURG-CHICAGO, V124, P1136; Wheat M W Jr, 1980, World J Surg, V4, P563	12	44	44	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1990	30	12					1562	1566		10.1097/00005373-199012000-00022			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	EP971	WOS:A1990EP97100022	2258973				2022-02-06	
J	VINK, R; MCINTOSH, TK; YAMAKAMI, I; FADEN, AI				VINK, R; MCINTOSH, TK; YAMAKAMI, I; FADEN, AI			P-31 NMR CHARACTERIZATION OF GRADED TRAUMATIC BRAIN INJURY IN RATS	MAGNETIC RESONANCE IN MEDICINE			English	Article									VET ADM MED CTR,SAN FRANCISCO,CA 94121		VINK, R (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,CTR NEURAL INJURY,SAN FRANCISCO,CA 94143, USA.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ALBIN MS, 1969, J TRAUM, V9, P1000, DOI 10.1097/00005373-196912000-00004; BOTTOMLEY PA, 1984, RADIOLOGY, V150, P441, DOI 10.1148/radiology.150.2.6691099; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; CHANCE B, 1978, P NATL ACAD SCI USA, V75, P4925, DOI 10.1073/pnas.75.10.4925; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; COURTEN-MYERS G M, 1985, Stroke, V16, P1016; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EVELHOCH JL, 1985, MAGNET RESON MED, V2, P410, DOI 10.1002/mrm.1910020409; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GONZALEZMENDEZ R, 1985, J CEREBR BLOOD F MET, V5, P512, DOI 10.1038/jcbfm.1985.77; GONZALEZMENDEZ R, 1984, J MAGN RESON, V57, P526, DOI 10.1016/0022-2364(84)90270-1; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; GYULAI L, 1985, J BIOL CHEM, V260, P3947; HILBERMAN M, 1984, J CEREBR BLOOD F MET, V4, P334, DOI 10.1038/jcbfm.1984.50; KIM SH, 1985, J CEREB BLOOD FLOW M, V5, P423; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LITT L, 1985, J CEREBR BLOOD F MET, V5, P537, DOI 10.1038/jcbfm.1985.81; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, IN PRESS NEUROSCIENC; MOON RB, 1973, J BIOL CHEM, V248, P7276; MYERS RE, 1977, ARCH NEUROL-CHICAGO, V34, P65, DOI 10.1001/archneur.1977.00500140019003; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; PETROFF OAC, 1984, ANN NEUROL, V16, P169, DOI 10.1002/ana.410160203; PRICHARD JW, 1986, ANNU REV NEUROSCI, V9, P61; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; SATO M, 1984, J CEREBR BLOOD F MET, V4, P173, DOI 10.1038/jcbfm.1984.25; SHOUBRIDGE EA, 1982, FEBS LETT, V140, P288, DOI 10.1016/0014-5793(82)80916-2; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SWANSON PD, 1969, ARCH NEUROL-CHICAGO, V20, P653, DOI 10.1001/archneur.1969.00480120099010; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHIDA S, 1985, J CEREBR BLOOD F MET, V5, P490, DOI 10.1038/jcbfm.1985.75; [No title captured]	34	44	44	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0740-3194			MAGNET RESON MED	Magn.Reson.Med.	JAN	1988	6	1					37	48		10.1002/mrm.1910060105			12	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	L8880	WOS:A1988L888000004	3352504				2022-02-06	
J	DAVIDOFF, G; MORRIS, J; ROTH, E; BLEIBERG, J				DAVIDOFF, G; MORRIS, J; ROTH, E; BLEIBERG, J			CLOSED HEAD-INJURY IN SPINAL-CORD INJURED PATIENTS - RETROSPECTIVE STUDY OF LOSS OF CONSCIOUSNESS AND POST-TRAUMATIC AMNESIA	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT PHYS MED & REHABIL,CHICAGO,IL 60611								BLEIBERG J, 1983, ARCH PHYS MED REHAB, V64, P448; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DUBO H, 1983, P AM SPINAL INJURY A, P35; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GUTTMANN L, 1963, SPINAL INJURIES, P81; Harris P, 1968, Paraplegia, V5, P215; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Meinecke F W, 1968, Paraplegia, V5, P196; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SCHUENEMAN A, 1982, SCI DIG, V4, P35; Schueneman AL, 1982, SCI DIG, V4, P64; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; STRANG I, 1978, INJURY, V10, P154; WAGNER KA, 1983, P AM SPINAL INJURY A, P96; WILMOTT CB, 1983, P AM SPINAL INJURY A, P105; YOUNG JS, 1982, SPINAL CORD INJURY S, P34; 1980, 9 NW U MCG MED CTR M; [No title captured]	27	44	45	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.		1985	66	1					41	43					3	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	AAF50	WOS:A1985AAF5000012	3966867				2022-02-06	
J	TORNHEIM, PA; MCLAURIN, RL				TORNHEIM, PA; MCLAURIN, RL			ACUTE CHANGES IN REGIONAL BRAIN WATER-CONTENT FOLLOWING EXPERIMENTAL CLOSED HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article									UNIV CINCINNATI,COLL MED,DIV NEUROSURG,CINCINNATI,OH 45267		TORNHEIM, PA (corresponding author), UNIV CINCINNATI,COLL MED,DEPT ANAT,CINCINNATI,OH 45267, USA.						BRUCE DA, 1979, NEURAL TRAUMA, P155; CANCILLA PA, 1972, LAB INVEST, V26, P376; CLASEN RA, 1957, SURG GYNECOL OBSTET, V104, P591; CLASEN RA, 1962, J NEUROPATH EXP NEUR, V21, P579, DOI 10.1097/00005072-196210000-00006; CLASEN RA, 1953, SURG GYNECOL OBSTET, V96, P605; CORALES RL, 1980, INTRACRANIAL PRESSUR, V4, P280; DICK AR, 1976, J NEUROSURG, V45, P141, DOI 10.3171/jns.1976.45.2.0141; FUJIMOTO T, 1976, DYNAMICS BRAIN EDEMA, P171; GAZENDAM J, 1979, J NEUROSURG, V51, P70, DOI 10.3171/jns.1979.51.1.0070; GENNARELLI TA, 1980, INTRACRANIAL PRESSUR, V4, P28; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hossman K, 1976, DYNAMICS BRAIN EDEMA, P219; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; Klatzo I, 1965, Prog Brain Res, V15, P73; KOBRINE AI, 1977, J NEUROSURG, V46, P256, DOI 10.3171/jns.1977.46.2.0256; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LEE JC, 1966, ARCH NEUROL-CHICAGO, V14, P36, DOI 10.1001/archneur.1966.00470070040005; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; NELSON SR, 1974, J NEUROSURG, V41, P193, DOI 10.3171/jns.1974.41.2.0193; PAPPIUS HM, 1969, ARCH NEUROL-CHICAGO, V20, P207, DOI 10.1001/archneur.1969.00480080107013; RAPOPORT SI, 1979, NEURAL TRAUMA, P51; Tornheim P A, 1976, Surg Neurol, V5, P171; WAGA S, 1979, SURG NEUROL, V11, P191	24	44	44	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1981	55	3					407	413		10.3171/jns.1981.55.3.0407			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	MC924	WOS:A1981MC92400010	7264732				2022-02-06	
J	Feigin, VL; Vos, T; Alahdab, F; Amit, AML; Barnighausen, TW; Beghi, E; Beheshti, M; Chavan, PP; Criqui, MH; Desai, R; Dharmaratne, SD; Dorsey, ER; Eagan, AW; Elgendy, IY; Filip, I; Giampaoli, S; Giussani, G; Hafezi-Nejad, N; Hole, MK; Ikeda, T; Johnson, CO; Kalani, R; Khatab, K; Khubchandani, J; Kim, D; Koroshetz, WJ; Krishnamoorthy, V; Krishnamurthi, RV; Liu, XF; Lo, WD; Logroscino, G; Mensah, GA; Miller, TR; Mohammed, S; Mokdad, AH; Moradi-Lakeh, M; Morrison, SD; Shivamurthy, VKN; Naghavi, M; Nichols, E; Norrving, B; Odell, CM; Pupillo, E; Radfar, A; Roth, GA; Shafieesabet, A; Sheikh, A; Sheikhbahaei, S; Shin, JI; Singh, JA; Steiner, TJ; Stovner, LJ; Wallin, MT; Weiss, J; Wu, CK; Zunt, JR; Adelson, JD; Murray, CJL				Feigin, Valery L.; Vos, Theo; Alahdab, Fares; Amit, Arianna Maever L.; Barnighausen, Till Winfried; Beghi, Ettore; Beheshti, Mahya; Chavan, Prachi P.; Criqui, Michael H.; Desai, Rupak; Dhamminda Dharmaratne, Samath; Dorsey, E. Ray; Wilder Eagan, Arielle; Elgendy, Islam Y.; Filip, Irina; Giampaoli, Simona; Giussani, Giorgia; Hafezi-Nejad, Nima; Hole, Michael K.; Ikeda, Takayoshi; Owens Johnson, Catherine; Kalani, Rizwan; Khatab, Khaled; Khubchandani, Jagdish; Kim, Daniel; Koroshetz, Walter J.; Krishnamoorthy, Vijay; Krishnamurthi, Rita V.; Liu, Xuefeng; Lo, Warren David; Logroscino, Giancarlo; Mensah, George A.; Miller, Ted R.; Mohammed, Salahuddin; Mokdad, Ali H.; Moradi-Lakeh, Maziar; Morrison, Shane Douglas; Shivamurthy, Veeresh Kumar N.; Naghavi, Mohsen; Nichols, Emma; Norrving, Bo; Odell, Christopher M.; Pupillo, Elisabetta; Radfar, Amir; Roth, Gregory A.; Shafieesabet, Azadeh; Sheikh, Aziz; Sheikhbahaei, Sara; Shin, Jae Il; Singh, Jasvinder A.; Steiner, Timothy J.; Stovner, Lars Jacob; Wallin, Mitchell Taylor; Weiss, Jordan; Wu, Chenkai; Zunt, Joseph Raymond; Adelson, Jaimie D.; Murray, Christopher J. L.		GBD 2017 US Neurological Disorder	Burden of Neurological Disorders Across the US From 1990-2017 A Global Burden of Disease Study	JAMA NEUROLOGY			English	Article							SYSTEMATIC ANALYSIS; NATIONAL BURDEN; STROKE; PREVALENCE; DISABILITY; MORTALITY; REGION	This analysis of the Global Burden of Disease 2017 study presents burden estimates of major neurological disorders in the US states by age and sex from 1990 to 2017. Question What is the current burden of neurological disorders in the US by states, and what are the temporal trends (from 1990 to 2017)? Findings Systematic analysis of the Global Burden of Disease study shows that, in 2017, the 3 most burdensome neurological disorders in the US were stroke, Alzheimer disease and other dementias, and migraine. The burden of individual neurological disorders varied moderately to widely by states (a 1.2-fold to 7.5-fold difference), and the absolute numbers of incident, prevalent, and fatal cases and disability-adjusted life-years of neurological disorders (except for traumatic brain injury incidence; spinal cord injury prevalence; meningitis prevalence, deaths, and disability-adjusted life-years; and encephalitis disability-adjusted life-years) across all US states increased from 1990 to 2017. Meaning A large and increasing number of people have various neurological disorders in the US, with significant variation in the burden of and trends in neurological disorders across the US states, and the reasons for these geographic variations need to be explored further. Importance Accurate and up-to-date estimates on incidence, prevalence, mortality, and disability-adjusted life-years (burden) of neurological disorders are the backbone of evidence-based health care planning and resource allocation for these disorders. It appears that no such estimates have been reported at the state level for the US. Objective To present burden estimates of major neurological disorders in the US states by age and sex from 1990 to 2017. Design, Setting, and Participants This is a systematic analysis of the Global Burden of Disease (GBD) 2017 study. Data on incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) of major neurological disorders were derived from the GBD 2017 study of the 48 contiguous US states, Alaska, and Hawaii. Fourteen major neurological disorders were analyzed: stroke, Alzheimer disease and other dementias, Parkinson disease, epilepsy, multiple sclerosis, motor neuron disease, migraine, tension-type headache, traumatic brain injury, spinal cord injuries, brain and other nervous system cancers, meningitis, encephalitis, and tetanus. Exposures Any of the 14 listed neurological diseases. Main Outcome and Measure Absolute numbers in detail by age and sex and age-standardized rates (with 95% uncertainty intervals) were calculated. Results The 3 most burdensome neurological disorders in the US in terms of absolute number of DALYs were stroke (3.58 [95% uncertainty interval [UI], 3.25-3.92] million DALYs), Alzheimer disease and other dementias (2.55 [95% UI, 2.43-2.68] million DALYs), and migraine (2.40 [95% UI, 1.53-3.44] million DALYs). The burden of almost all neurological disorders (in terms of absolute number of incident, prevalent, and fatal cases, as well as DALYs) increased from 1990 to 2017, largely because of the aging of the population. Exceptions for this trend included traumatic brain injury incidence (-29.1% [95% UI, -32.4% to -25.8%]); spinal cord injury prevalence (-38.5% [95% UI, -43.1% to -34.0%]); meningitis prevalence (-44.8% [95% UI, -47.3% to -42.3%]), deaths (-64.4% [95% UI, -67.7% to -50.3%]), and DALYs (-66.9% [95% UI, -70.1% to -55.9%]); and encephalitis DALYs (-25.8% [95% UI, -30.7% to -5.8%]). The different metrics of age-standardized rates varied between the US states from a 1.2-fold difference for tension-type headache to 7.5-fold for tetanus; southeastern states and Arkansas had a relatively higher burden for stroke, while northern states had a relatively higher burden of multiple sclerosis and eastern states had higher rates of Parkinson disease, idiopathic epilepsy, migraine and tension-type headache, and meningitis, encephalitis, and tetanus. Conclusions and Relevance There is a large and increasing burden of noncommunicable neurological disorders in the US, with up to a 5-fold variation in the burden of and trends in particular neurological disorders across the US states. The information reported in this article can be used by health care professionals and policy makers at the national and state levels to advance their health care planning and resource allocation to prevent and reduce the burden of neurological disorders.	[Feigin, Valery L.; Vos, Theo; Dhamminda Dharmaratne, Samath; Owens Johnson, Catherine; Mokdad, Ali H.; Naghavi, Mohsen; Nichols, Emma; Odell, Christopher M.; Roth, Gregory A.; Adelson, Jaimie D.; Murray, Christopher J. L.] Univ Washington, Inst Hlth Metr & Evaluat, Population Hlth Bldg,3980 15th Ave NE, Seattle, WA 98195 USA; [Feigin, Valery L.; Krishnamurthi, Rita V.] Auckland Univ Technol, Fac Hlth & Environm Sci, Sch Publ Hlth & Psychosocial Studies, Auckland, New Zealand; [Feigin, Valery L.] Res Ctr Neurol, Moscow, Russia; [Vos, Theo; Dhamminda Dharmaratne, Samath; Mokdad, Ali H.; Naghavi, Mohsen; Roth, Gregory A.; Murray, Christopher J. L.] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA USA; [Alahdab, Fares] Mayo Clin Fdn Med Educ & Res, Mayo Evidence Based Practice Ctr, Rochester, MN USA; [Amit, Arianna Maever L.] Univ Philippines Manila, Dept Epidemiol & Biostat, Manila, Philippines; [Amit, Arianna Maever L.] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA; [Barnighausen, Till Winfried] Heidelberg Univ, Heidelberg Inst Global Hlth, Heidelberg, Germany; [Barnighausen, Till Winfried] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Beghi, Ettore; Pupillo, Elisabetta] Mario Negri Inst Pharmacol Res, Dept Neurosci, Milan, Italy; [Beheshti, Mahya] NYU, Dept Phys Med & Rehabil, New York, NY USA; [Chavan, Prachi P.] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Buffalo, NY USA; [Criqui, Michael H.] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; [Desai, Rupak] Atlanta Vet Affairs Med Ctr, Div Cardiol, Decatur, GA USA; [Dhamminda Dharmaratne, Samath] Univ Peradeniya, Dept Community Med, Peradeniya, Sri Lanka; [Dorsey, E. Ray] Univ Rochester, Rochester, NY USA; [Wilder Eagan, Arielle] Harvard Univ, Dept Global Hlth & Social Med, Boston, MA 02115 USA; [Wilder Eagan, Arielle] Tufts Med Ctr, Dept Social Serv, Boston, MA 02111 USA; [Elgendy, Islam Y.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; [Elgendy, Islam Y.] Harvard Univ, Div Cardiol, Boston, MA 02115 USA; [Filip, Irina] Kaiser Permanente, Dept Psychiat, Fontana, CA USA; [Filip, Irina] AT Still Univ, Sch Osteopath Med Arizona, Arizona Sch Hlth Sci, Mesa, AZ 85206 USA; [Giampaoli, Simona] Italian Natl Inst Hlth, Dept Cardiovasc Endocrine Metab Dis & Aging, Ist Super Sanita, Rome, Italy; [Giussani, Giorgia] Mario Negri Inst Pharmacol Res, Lab Neurol Disorders, Milan, Italy; [Hafezi-Nejad, Nima; Sheikhbahaei, Sara] Johns Hopkins Univ, Dept Radiol & Radiol Sci, Baltimore, MD USA; [Hafezi-Nejad, Nima] Univ Tehran Med Sci, Sch Med, Tehran, Iran; [Hole, Michael K.] Univ Texas Austin, Dept Pediat, Austin, TX 78712 USA; [Ikeda, Takayoshi] Auckland Univ Technol, Dept Biostat & Epidemiol, Auckland, New Zealand; [Kalani, Rizwan; Zunt, Joseph Raymond] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Khatab, Khaled] Sheffield Hallam Univ, Fac Hlth & Wellbeing, Sheffield, S Yorkshire, England; [Khatab, Khaled] Ohio Univ, Coll Arts & Sci, Zanesville, OH USA; [Khubchandani, Jagdish] Ball State Univ, Dept Nutr & Hlth Sci, Muncie, IN 47306 USA; [Kim, Daniel] Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USA; [Koroshetz, Walter J.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Krishnamoorthy, Vijay] Duke Univ, Dept Anesthesiol, Durham, NC USA; [Krishnamoorthy, Vijay] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Liu, Xuefeng] Univ Michigan, Dept Syst Populat & Leadership, Ann Arbor, MI 48109 USA; [Lo, Warren David] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Lo, Warren David] Nationwide Childrens Hosp, Dept Pediat Neurol, Columbus, OH USA; [Logroscino, Giancarlo] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy; [Logroscino, Giancarlo] Fdn Cardinale Giovanni Panico Hosp, Dept Clin Res Neurol, Tricase, Italy; [Mensah, George A.] NIH, Ctr Translat Res & Implementat Sci, Bldg 10, Bethesda, MD 20892 USA; [Mensah, George A.] Univ Cape Town, Dept Med, Cape Town, South Africa; [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA; [Miller, Ted R.] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia; [Mohammed, Salahuddin] Univ Mississippi, Dept Biomol Sci, Oxford, MS USA; [Mohammed, Salahuddin] Mizan Tepi Univ, Dept Pharm, Mizan, Ethiopia; [Moradi-Lakeh, Maziar] Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, Iran; [Morrison, Shane Douglas] Univ Michigan, Sect Plast Surg, Ann Arbor, MI 48109 USA; [Shivamurthy, Veeresh Kumar N.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; [Norrving, Bo] Lund Univ, Dept Clin Sci, Lund, Sweden; [Radfar, Amir] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA; [Roth, Gregory A.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA; [Shafieesabet, Azadeh] Charite Med Univ Berlin, Dept Cardiol, Berlin, Germany; [Shafieesabet, Azadeh] Ctr Stroke Res Berlin, Berlin, Germany; [Sheikh, Aziz] Univ Edinburgh, Ctr Med Informat, Edinburgh, Midlothian, Scotland; [Sheikh, Aziz] Harvard Univ, Div Gen Internal Med, Boston, MA 02115 USA; [Shin, Jae Il] Yonsei Univ, Coll Med, Seoul, South Korea; [Singh, Jasvinder A.] Univ Alabama Birmingham, Med Sch Birmingham, Birmingham, AL USA; [Singh, Jasvinder A.] US Dept Vet Affairs, Med Serv, Birmingham, AL USA; [Steiner, Timothy J.; Stovner, Lars Jacob] Norwegian Univ Sci & Technol, Dept Neuromed & Movement Sci, Trondheim, Norway; [Steiner, Timothy J.] Imperial Coll London, Div Brain Sci, London, England; [Stovner, Lars Jacob] St Olavs Hosp, Dept Neurol & Clin Neurophysiol, Trondheim, Norway; [Wallin, Mitchell Taylor] George Washington Univ, Dept Neurol, Washington, DC USA; [Wallin, Mitchell Taylor] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Weiss, Jordan] Univ Calif Berkeley, Dept Demog, Berkeley, CA 94720 USA; [Wu, Chenkai] Duke Kunshan Univ, Global Hlth Res Ctr, Kunshan, Peoples R China; [Wu, Chenkai] Duke Univ, Duke Global Hlth Inst, Durham, NC USA		Feigin, VL (corresponding author), Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Fac Hlth & Environm Sci, Sch Publ Hlth & Psychosocial Studies, 90 Akoranga Dr, Auckland 0627, New Zealand.; Vos, T (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Population Hlth Bldg,3980 15th Ave NE, Seattle, WA 98195 USA.	valery.feigin@aut.ac.nz; tvos@uw.edu	Alahdab, Fares/N-6680-2013; Mokdad, Ali H./AAD-1232-2022; Radfar, Amir/I-8057-2019; Moradi-Lakeh, Maziar/ABC-9793-2021; Desai, Rupak/K-9846-2019; Shivamurthy, Veeresh Kumar N./AAF-8891-2020; Zunt, Joseph/ABD-2886-2021; Giussani, Giorgia/AAA-8029-2020; Krishnamurthi, Rita/AAU-7841-2021; Khubchandani, Jagdish/D-1831-2014; Elgendy, Islam Y/C-3900-2017; SHIN, JAE IL/ABD-9660-2021; Chavan, Prachi/AAG-1103-2019; Amit, Arianna Maever L/E-4482-2017; SHIN, JAE IL/J-6922-2017; Eagan, Arielle/AAN-3673-2020	Alahdab, Fares/0000-0001-5481-696X; Mokdad, Ali H./0000-0002-4994-3339; Radfar, Amir/0000-0001-6177-3048; Moradi-Lakeh, Maziar/0000-0001-7381-5305; Desai, Rupak/0000-0002-5315-6426; Shivamurthy, Veeresh Kumar N./0000-0001-7171-755X; Giussani, Giorgia/0000-0003-2460-3095; Krishnamurthi, Rita/0000-0003-0869-2083; Khubchandani, Jagdish/0000-0002-9058-4278; Elgendy, Islam Y/0000-0001-9853-7591; SHIN, JAE IL/0000-0003-2326-1820; Chavan, Prachi/0000-0003-4022-6605; Amit, Arianna Maever L/0000-0003-4571-400X; SHIN, JAE IL/0000-0003-2326-1820; Eagan, Arielle/0000-0002-6973-9052; Miller, Ted/0000-0002-0958-2639; Beghi, Ettore/0000-0003-2542-0469; Steinmetz, Jaimie/0000-0003-2397-4070; Weiss, Jordan/0000-0002-0392-3535	Bill AMP; Melinda Gates FoundationCGIAR; Health Data Research UK; Alexander von Humboldt Foundation through the Alexander von Humboldt Professor Award - German Federal Ministry of Education and Research	This study was supported by the Bill & Melinda Gates Foundation. Dr Sheikh acknowledges support from Health Data Research UK. Dr Barnighausen acknowledges support from the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor Award, funded by the German Federal Ministry of Education and Research.	Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Borlongan CV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078490; Dorsey ER, 2018, LANCET NEUROL, V17, P939, DOI 10.1016/S1474-4422(18)30295-3; Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI 10.1016/S1474-4422(18)30499-X; Feigin VL, 2019, NEUROEPIDEMIOLOGY, V52, P1, DOI 10.1159/000495197; Fereshtehnejad SM, 2019, EUR J NEUROL, V26, P1252, DOI 10.1111/ene.13972; Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1; GBD 2016 Stroke Collaborators, 2019, LANCET NEUROL, V18, P439, DOI [10.1016/S1474-4422(19)30034-1, DOI 10.1016/S1474-4422(19)30034-1]; GBD 2017 Causes of Death Collaborators, 2018, LANCET, V392, P1736, DOI [DOI 10.1016/S0140-6736(18)32203-7, 10.1016/S0140-6736(18)32203-7]; Global Health Data Exchange, GBD RES TOOL; Gooch CL, 2017, ANN NEUROL, V81, P479, DOI 10.1002/ana.24897; Hachinski V, 2019, ALZHEIMERS DEMENT, V15, P961, DOI 10.1016/j.jalz.2019.06.001; Howard G, 1997, STROKE, V28, P936, DOI 10.1161/01.STR.28.5.936; Institute for Health Metrics and Evaluation (IHME), 2019, GBD COMP DAT VIS; James SL, 2019, LANCET NEUROL, V18, P56, DOI 10.1016/S1474-4422(18)30415-0; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Johnson CO, 2019, LANCET NEUROL, V18, P439, DOI 10.1016/S1474-4422(19)30034-1; Karp DN, 2016, STROKE, V47, P1939, DOI 10.1161/STROKEAHA.116.012997; Liao YL, 2009, STROKE, V40, P3336, DOI 10.1161/STROKEAHA.109.561688; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Logroscino G, 2018, LANCET NEUROL, V17, P1083, DOI 10.1016/S1474-4422(18)30404-6; MARTINEZ R, 2019, REV PANAM SALUD PUBL, V43, pNIL_0042, DOI DOI 10.1093/ije/dyy254; Mokdad AH, 2018, JAMA-J AM MED ASSOC, V319, P1444, DOI 10.1001/jama.2018.0158; Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; Nichols E, 2019, LANCET NEUROL, V18, P88, DOI 10.1016/S1474-4422(18)30403-4; Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8; Simpson S, 2011, J NEUROL NEUROSUR PS, V82, P1132, DOI 10.1136/jnnp.2011.240432; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI 10.1016/S1474-4422(18)30322-3; Stovner LJ, 2019, SOCIETAL IMPACT HEAD, P112, DOI 10.1007/978-3-030-24728-7_9; Vos T, 2015, INTEGRATIVE METAREGR; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; Vosoughi K, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-0990-3; Wang WZ, 2017, CIRCULATION, V135, P759, DOI 10.1161/CIRCULATIONAHA.116.025250; Zunt JR, 2018, LANCET NEUROL, V17, P1061, DOI 10.1016/S1474-4422(18)30387-9	34	43	43	7	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	FEB	2021	78	2					165	176		10.1001/jamaneurol.2020.4152		NOV 2020	12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QG9TR	WOS:000590787900003	33136137	Green Published, hybrid, Green Accepted			2022-02-06	
J	Ge, XT; Guo, MT; Hu, TP; Li, WZ; Huang, S; Yin, ZY; Li, Y; Chen, FL; Zhu, LY; Kang, CS; Jiang, RC; Lei, P; Zhang, JN				Ge, Xintong; Guo, Mengtian; Hu, Tianpeng; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Li, Ying; Chen, Fanglian; Zhu, Luoyun; Kang, Chunsheng; Jiang, Rongcai; Lei, Ping; Zhang, Jianning			Increased Microglial Exosomal miR-124-3p Alleviates Neurodegeneration and Improves Cognitive Outcome after rmTBI	MOLECULAR THERAPY			English	Article							TRAUMATIC BRAIN-INJURY; AMYLOID-BETA; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; EXTRACELLULAR VESICLES; STROMAL CELLS; NEUROGRANIN; MICROVESICLES; EPIDEMIOLOGY	Repetitive mild traumatic brain injury (rmTBI) is considered to be an important risk factor for long-term neurodegenerative disorders such as Alzheimer's disease, which is characterized by beta-amyloid abnormalities and impaired cognitive function. Microglial exosomes have been reported to be involved in the transportation, distribution, and clearance of beta-amyloid in Alzheimer's disease. However, their impacts on the development of neurodegeneration after rmTBI are not yet known. The role of miRNAs in microglial exosomes on regulating post-traumatic neurodegeneration was investigated in the present study. We demonstrated that miR-124-3p level in microglial exosomes from injured brain was significantly altered in the acute, sub-acute, and chronic phases after rmTBI. In in vitro experiments, microglial exosomes with upregulated miR-124-3p (EXO-124) alleviated neurodegeneration in repetitive scratch-injured neurons. The effects were exerted by miR-124-3p targeting Rela, an inhibitory transcription factor of ApoE that promotes the beta-amyloid proteolytic breakdown, thereby inhibiting beta-amyloid abnormalities. In mice with rmTBI, the intravenously injected microglial exosomes were taken up by neurons in injured brain. Besides, miR-124-3p in the exosomes was transferred into hippocampal neurons and alleviated neurodegeneration by targeting the Rela/ApoE signaling pathway. Consequently, EXO-124 treatments improved the cognitive outcome after rmTBI, suggesting a promising therapeutic strategy for future clinical translation.	[Ge, Xintong; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Ge, Xintong; Li, Ying; Chen, Fanglian; Kang, Chunsheng; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin 300052, Peoples R China; [Ge, Xintong; Li, Ying; Chen, Fanglian; Kang, Chunsheng; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Guo, Mengtian; Hu, Tianpeng; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Lei, Ping] Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorder, Tianjin 300052, Peoples R China; [Guo, Mengtian; Hu, Tianpeng; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Lei, Ping] Tianjin Med Univ Gen Hosp, Dept Geriatr, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Zhu, Luoyun] Tianjin Med Univ Gen Hosp, Dept Med Examinat, Tianjin 300052, Peoples R China		Jiang, RC; Zhang, JN (corresponding author), Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ Gen Hosp, Dept Geriatr, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jiang116216@163.com; leiping1974@163.com; jnzhang@tmu.edu.cn	Kang, Chunsheng/AAM-5979-2021	Kang, Chunsheng/0000-0002-3255-3369; Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501055, 81772060, 81720108015, 81671221]; Tianjin Municipal Science and Technology Commission Natural Fund Project [18JCQNJC81100]	This research was supported by grants from the National Natural Science Foundation of China (grants 81501055, 81772060, 81720108015, and 81671221) and the Tianjin Municipal Science and Technology Commission Natural Fund Project (grant 18JCQNJC81100). The authors appreciate Changzheng Du from Peking University Cancer Hospital and Shu Zhang, Lei Han, Yunfei Wang, Li Liu, Weiyun Cui, and Lei Zhou from the Tianjin Neurological Institute for their technical support.	Agosta F, 2014, ANN NEUROL, V76, P813, DOI 10.1002/ana.24235; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028; Bradley-Whitman MA, 2018, BRAIN INJURY, V32, P363, DOI 10.1080/02699052.2017.1418907; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Chen S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.135; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cirrito JR, 2011, P NATL ACAD SCI USA, V108, P14968, DOI 10.1073/pnas.1107411108; Cunha C, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6986175; Dabrowska S, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1571-8; Edwards G, 2017, BIOCHEM BIOPH RES CO, V483, P1137, DOI 10.1016/j.bbrc.2016.07.123; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2018, J NEUROSCI METH, V308, P162, DOI 10.1016/j.jneumeth.2018.07.021; Ge XT, 2019, J NEUROTRAUM, V36, P1291, DOI 10.1089/neu.2018.5728; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Glebov K, 2015, GLIA, V63, P626, DOI 10.1002/glia.22772; Goetzl EJ, 2018, ANN NEUROL, V83, P544, DOI 10.1002/ana.25172; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gouwens LK, 2018, ACS CHEM NEUROSCI, V9, P1416, DOI 10.1021/acschemneuro.8b00029; Guadagno J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.151; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Hooper C, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-144; Huang S, 2018, FASEB J, V32, P512, DOI 10.1096/fj.201700673R; Jamal M, 2018, J MOL NEUROSCI, V65, P84, DOI 10.1007/s12031-018-1074-6; Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Joshi P, 2014, CELL DEATH DIFFER, V21, P582, DOI 10.1038/cdd.2013.180; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kvartsberg H, 2015, ALZHEIMERS DEMENT, V11, P1180, DOI 10.1016/j.jalz.2014.10.009; Laskowitz DT, 2017, SCI REP-UK, V7, DOI 10.1038/srep46461; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Leger M, 2013, NAT PROTOC, V8, P2531, DOI 10.1038/nprot.2013.155; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Li L, 2008, BRAIN RES, V1226, P234, DOI 10.1016/j.brainres.2008.06.037; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Peacock WF, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00641; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Porro C, 2015, J NEUROIMMUNOL, V288, P70, DOI 10.1016/j.jneuroim.2015.09.006; Qin Z, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00406; Ramos-Cejudo J, 2018, EBIOMEDICINE, V28, P21, DOI 10.1016/j.ebiom.2018.01.021; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Song YY, 2019, THERANOSTICS, V9, P2910, DOI 10.7150/thno.30879; Stejskal D, 2011, BIOMED PAP, V155, P263, DOI 10.5507/bp.2011.049; Tarawneh R, 2015, JAMA NEUROL, V72, P656, DOI 10.1001/jamaneurol.2015.0202; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Trotta T, 2018, BIOCHEM PHARMACOL, V148, P184, DOI 10.1016/j.bcp.2017.12.020; Venkat P, 2019, STROKE, V50, P2865, DOI 10.1161/STROKEAHA.119.025371; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Wellington H, 2016, NEUROLOGY, V86, P829, DOI 10.1212/WNL.0000000000002423; Yu AY, 2017, IMMUNOL LETT, V182, P1, DOI 10.1016/j.imlet.2016.12.003; Yuyama K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00229; Zhang YL, 2017, NATURE, V548, P52, DOI 10.1038/nature23282; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang Y, 2017, MOL NEUROBIOL, V54, P2659, DOI 10.1007/s12035-016-9851-0	67	43	45	7	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1525-0016	1525-0024		MOL THER	Mol. Ther.	FEB 5	2020	28	2					503	522		10.1016/j.ymthe.2019.11.017			20	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	KK6YH	WOS:000512884900018	31843449	hybrid, Green Published			2022-02-06	
J	Beqiri, E; Smielewski, P; Robba, C; Czosnyka, M; Cabeleira, MT; Tas, J; Donnelly, J; Outtrim, JG; Hutchinson, P; Menon, D; Meyfroidt, G; Depreitere, B; Aries, MJ; Ercole, A				Beqiri, Erta; Smielewski, Peter; Robba, Chiara; Czosnyka, Marek; Cabeleira, Manuel Teixeira; Tas, Jeanette; Donnelly, Joseph; Outtrim, Joanne G.; Hutchinson, Peter; Menon, David; Meyfroidt, Geert; Depreitere, Bart; Aries, Marcel J.; Ercole, Ari			Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure: the COGiTATE phase II study protocol	BMJ OPEN			English	Article						autoregulation; Optimal CPP; COGiTATE; precision medicine; individualised TBI management; intensive care	REACTIVITY INDEX; AUTOREGULATION; BEDSIDE; CARE	Introduction Individualising therapy is an important challenge for intensive care of patients with severe traumatic brain injury (TBI). Targeting a cerebral perfusion pressure (CPP) tailored to optimise cerebrovascular autoregulation has been suggested as an attractive strategy on the basis of a large body of retrospective observational data. The objective of this study is to prospectively assess the feasibility and safety of such a strategy compared with fixed thresholds which is the current standard of care from international consensus guidelines. Methods and analysis CPPOpt Guided Therapy: Assessment of Target Effectiveness (COGiTATE) is a prospective, multicentre, non-blinded randomised, controlled trial coordinated from Maastricht University Medical Center, Maastricht (The Netherlands). The other original participating centres are Cambridge University NHS Foundation Trust, Cambridge (UK), and University Hospitals Leuven, Leuven (Belgium). Adult severe TBI patients requiring intracranial pressure monitoring are randomised within the first 24 hours of admission in neurocritical care unit. For the control arm, the CPP target is the Brain Trauma Foundation guidelines target (60-70 mm Hg); for the intervention group an automated CPP target is provided as the CPP at which the patient's cerebrovascular reactivity is best preserved (CPPopt). For a maximum of 5 days, attending clinicians review the CPP target 4-hourly. The main hypothesis of COGiTATE are: (1) in the intervention group the percentage of the monitored time with measured CPP within a range of 5 mm Hg above or below CPPopt will reach 36%; (2) the difference in between groups in daily therapy intensity level score will be lower or equal to 3. Ethics and dissemination Ethical approval has been obtained for each participating centre. The results will be presented at international scientific conferences and in peer-reviewed journals.	[Beqiri, Erta; Smielewski, Peter; Czosnyka, Marek; Cabeleira, Manuel Teixeira; Donnelly, Joseph; Hutchinson, Peter] Univ Cambridge, Clin Neurosci, Cambridge, England; [Beqiri, Erta] Univ Milan, Physiol & Transplantat, Milan, Italy; [Robba, Chiara] Univ Genoa, Anaesthesia & Intens Care, Policlin San Martino, IRCCS Oncol & Neurosci, Genoa, Italy; [Tas, Jeanette; Aries, Marcel J.] Maastricht Univ, Med Ctr, Intens Care, Maastricht, Netherlands; [Outtrim, Joanne G.; Menon, David; Ercole, Ari] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Meyfroidt, Geert; Depreitere, Bart] Univ Ziekenhuizen Leuven, Intens Geneeskunde, Leuven, Belgium		Beqiri, E (corresponding author), Univ Cambridge, Clin Neurosci, Cambridge, England.; Beqiri, E (corresponding author), Univ Milan, Physiol & Transplantat, Milan, Italy.	erta.beqiri@gmail.com	Robba, Chiara/AAS-7421-2020; Depreitere, Bart/AAA-9846-2020; Ercole, Ari/B-6288-2009	Depreitere, Bart/0000-0002-7458-0648; Ercole, Ari/0000-0001-8350-8093; beqiri, erta/0000-0002-8108-0000	European Society of Intensive Care Medicine small investigator award	This study was supported by European Society of Intensive Care Medicine small investigator award (N/A: awarded to MJA).	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dias C, 2015, NEUROCRIT CARE, V23, P92, DOI 10.1007/s12028-014-0103-8; Donnelly J, 2015, EXPERT REV NEUROTHER, V15, P169, DOI 10.1586/14737175.2015.996552; Ercole A, 2018, ACTA NEUROCHIR SUPPL, V126, P55, DOI 10.1007/978-3-319-65798-1_12; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Kelly S, 2018, ACTA NEUROCHIR SUPPL, V126, P317, DOI 10.1007/978-3-319-65798-1_62; Liu XY, 2017, J NEUROTRAUM, V34, P3081, DOI 10.1089/neu.2017.5003; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Menon DK, 2017, HAND CLINIC, V140, P239, DOI 10.1016/B978-0-444-63600-3.00014-3; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; R Development Core Team, 2012, R LANG ENV STAT COMP; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7; Zuercher P, 2016, J NEUROTRAUM, V33, P1768, DOI 10.1089/neu.2015.4266; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	19	43	43	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open	SEP	2019	9	9							e030727	10.1136/bmjopen-2019-030727			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JO7XE	WOS:000497787600311	31542757	gold, Green Published			2022-02-06	
J	Gall, LS; Vulliamy, P; Gillespie, S; Jones, TE; Pierre, RSJ; Breukers, SE; Gaarder, C; Juffermans, NP; Maegele, M; Stensballe, J; Johansson, PI; Davenport, RA; Brohi, K; Kolstadbraaten, KM; Baksaas-Aasen, K; Naess, PA; Ostrowski, SR; Vrangbaek, K; Bergmann, R; Hansen, SK; Rourke, C; Goerlinger, K; Hochleitner, M; Dias, J; Stanworth, SJ; Curry, N; Sturmer, EK; Schafer, N; Driessen, A; Balvers, K; van Dieren, S; Harrison, M; Soyel, H				Gall, Lewis S.; Vulliamy, Paul; Gillespie, Scarlett; Jones, Timothy E.; Pierre, Rochelle S. J.; Breukers, Sabine E.; Gaarder, Christine; Juffermans, Nicole P.; Maegele, Marc; Stensballe, Jakob; Johansson, Par, I; Davenport, Ross A.; Brohi, Karim; Kolstadbraaten, K. M.; Baksaas-Aasen, K.; Naess, P. A.; Ostrowski, S. R.; Vrangbaek, K.; Bergmann, R.; Hansen, S. K.; Rourke, C.; Goerlinger, K.; Hochleitner, M.; Dias, J.; Stanworth, S. J.; Curry, N.; Stuermer, E. K.; Schaefer, N.; Driessen, A.; Balvers, K.; van Dieren, S.; Harrison, M.; Soyel, H.		Targeted Action Curing Trauma-Indu	The S100A10 Pathway Mediates an Occult Hyperfibrinolytic Subtype in Trauma Patients	ANNALS OF SURGERY			English	Article						coagulopathy; fibrinolysis; S100A10; trauma	ANNEXIN II TETRAMER; TRANEXAMIC ACID; FIBRINOLYSIS SHUTDOWN; EARLY COAGULOPATHY; PLASMINOGEN; INJURY; HETEROTETRAMER; ACTIVATION; RECEPTORS; MORTALITY	Objective: To determine the characteristics of trauma patients with low levels of fibrinolysis as detected by viscoelastic hemostatic assay (VHA) and explore the underlying mechanisms of this subtype. Background: Hyperfibrinolysis is a central component of acute traumatic coagulopathy but a group of patients present with low levels of VHA-detected fibrinolysis. There is concern that these patients may be at risk of thrombosis if empirically administered an antifibrinolytic agent. Methods: A prospective multicenter observational cohort study was conducted at 5 European major trauma centers. Blood was drawn on arrival, within 2 hours of injury, for VHA (rotation thromboelastometry [ROTEM]) and fibrinolysis plasma protein analysis including the fibrinolytic mediator S100A10. An outcomes-based threshold for ROTEM hypofibrinolysis was determined and patients grouped by this and by D-dimer (DD) levels. Results: Nine hundred fourteen patients were included in the study. The VHA maximum lysis (ML) lower threshold was determined to be <5%. Heterogeneity existed among patients with low ML, with survivors sharing similar clinical and injury characteristics to patients with normal ML values (5-15%). Those who died were critically injured with a preponderance of traumatic brain injury and had a 7-fold higher DD level (died vs. survived: 103,170 vs. 13,672 ng/mL, P < 0.001). Patients with low ML and high DD demonstrated a hyperfibrinolytic biomarker profile, low tissue plasminogen activator levels but high plasma levels of S100A10. S100A10 was negatively correlated with % ML (r = -0.26, P < 0.001) and caused a significant reduction in % ML when added to whole blood ex-vivo. Conclusions: Patients presenting with low ML and low DD levels have low injury severity and normal outcomes. Conversely, patients with low ML but high DD levels are severely injured, functionally coagulopathic and have poor clinical outcomes. These patients have low tissue plasminogen activator levels and are not detectable by ROTEM. S100A10 is a cell surface plasminogen receptor which may drive the hyperfibrinolysis in these patients and which when shed artificially lowers % ML ex-vivo.	[Gall, Lewis S.; Vulliamy, Paul; Gillespie, Scarlett; Jones, Timothy E.; Pierre, Rochelle S. J.; Breukers, Sabine E.; Davenport, Ross A.; Brohi, Karim; Rourke, C.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Trauma Sci, Blizard Inst, London E1 2AT, England; [Gaarder, Christine; Kolstadbraaten, K. M.; Baksaas-Aasen, K.; Naess, P. A.; Ostrowski, S. R.; Vrangbaek, K.; Bergmann, R.; Hansen, S. K.] Oslo Univ Hosp, Dept Traumatol, Oslo, Norway; [Juffermans, Nicole P.] Acad Med Ctr, Dept Intens Care Med, Amsterdam, Netherlands; [Maegele, Marc; Stuermer, E. K.; Schaefer, N.; Driessen, A.] Univ Witten Herdecke, Cologne Merhe Med Ctr, Dept Traumatol & Orthopaed Surg, Cologne, Germany; [Stensballe, Jakob; Johansson, Par, I] Univ Copenhagen, Dept Anaesthesia, Ctr Head & Orthopaed, Rigshosp, Copenhagen, Denmark; [Stensballe, Jakob; Johansson, Par, I] Copenhagen Univ Hosp, Capital Reg Blood Bank, Rigshosp, Dept Anaesthesia,Ctr Head & Orthopaed, Copenhagen, Denmark; [Stensballe, Jakob; Johansson, Par, I] Univ Copenhagen, Rigshosp, Trauma Ctr, Ctr Head & Orthopaed, Copenhagen, Denmark; [Goerlinger, K.] Univ Duisburg Essen, Univ Hosp Essen, Dept Anaesthesiol & Intens Care Med, Duisburg, Germany; [Goerlinger, K.; Hochleitner, M.] Tem Int, Munich, Germany; [Dias, J.] Haemonet SA, Dept Clin Mkt, Signy, Switzerland; [Stanworth, S. J.; Curry, N.] Oxford Univ Hosp NHS Fdn Trust, Dept Haematol, Oxford, England; [Stanworth, S. J.] NHS Blood & Transplant, Oxford, England; [Curry, N.] NIHR BRC Oxford Haematol Theme, Oxford, England; [Balvers, K.; van Dieren, S.; Harrison, M.; Soyel, H.] Queen Mary Univ London, Sch Elect Engn & Comp Sci, London, England; [Harrison, M.] Newcastle Univ, Sch Comp, Newcastle, NSW, Australia		Brohi, K (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Trauma Sci, Blizard Inst, London E1 2AT, England.	k.brohi@qmul.ac.uk	Ostrowski, Sisse R/E-7423-2011; Baksaas-Aasen, Kjersti/AAP-4957-2021	Ostrowski, Sisse R/0000-0001-5288-3851; Baksaas-Aasen, Kjersti/0000-0002-1140-8939	European Commission under the FP7 HEALTH-Contract [F3-2013-602771]; Royal College of Surgeons of England; Barts Charity (UK)	The research leading to these results has received funding from the European Commission under the FP7 HEALTH-Contract No. F3-2013-602771. PVis the recipient of a research fellowship from the Royal College of Surgeons of England. Additional financial support was provided by Barts Charity (UK). Reagents and materials were provided on an unrestricted basis by Haemonetics (USA) and TEM international (Germany).	[Anonymous], 2013, PREHOSPITAL TRANEXAM; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Choi KS, 2001, J BIOL CHEM, V276, P25212, DOI 10.1074/jbc.M101426200; Cole E, 2015, ANN SURG, V261, P390, DOI 10.1097/SLA.0000000000000717; Davenport RA, 2017, ANESTHESIOLOGY, V126, P115, DOI 10.1097/ALN.0000000000001428; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Egeland M, 2011, NEUROPHARMACOLOGY, V61, P442, DOI 10.1016/j.neuropharm.2011.01.046; Gall LS, 2017, SEMIN THROMB HEMOST, V43, P224, DOI 10.1055/s-0036-1598001; Ganter MT, 2008, ANESTH ANALG, V106, P1366, DOI 10.1213/ane.0b013e318168b367; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kwaan HC, 2004, J THROMB HAEMOST, V2, P306, DOI 10.1111/j.1538-7933.2004.00593.x; Luo M, 2013, SEMIN THROMB HEMOST, V39, P338, DOI 10.1055/s-0033-1334143; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; MacLeod TJ, 2003, J BIOL CHEM, V278, P25577, DOI 10.1074/jbc.M301017200; Madureira PA, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/353687; Madureira PA, 2011, BLOOD, V118, P4789, DOI 10.1182/blood-2011-06-334672; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Moore EE, 2016, TRANSFUSION, V56, pS110, DOI 10.1111/trf.13486; Moore HB, 2016, J AM COLL SURGEONS, V222, P347, DOI 10.1016/j.jamcollsurg.2016.01.006; Moore HB, 2014, J TRAUMA ACUTE CARE, V77, P811, DOI 10.1097/TA.0000000000000341; Morrison JJ, 2013, JAMA SURG, V148, P218, DOI 10.1001/jamasurg.2013.764; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; O'Connell PA, 2011, BLOOD, V117, P4095, DOI 10.1182/blood-2010-07-298851; Raza I, 2013, J THROMB HAEMOST, V11, P307, DOI 10.1111/jth.12078; Roberts I, 2016, TRANSFUSION, V56, pS115, DOI 10.1111/trf.13490; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5	28	43	44	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	JUN	2019	269	6					1184	1191		10.1097/SLA.0000000000002733			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	IQ4OM	WOS:000480730100035	31082919	Green Accepted			2022-02-06	
J	Carlson, AP; Abbas, M; Alunday, RL; Qeadan, F; Shuttleworth, CW				Carlson, Andrew P.; Abbas, Mohammad; Alunday, Robert L.; Qeadan, Fares; Shuttleworth, C. William			Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; vasospasm; spreading depression; spreading depolarization; delayed cerebral ischemia; vascular disorders; traumatic brain injury	SUBARACHNOID HEMORRHAGE; NMDA RECEPTOR; DEPRESSION; ISCHEMIA; CLUSTERS; SEDATION	OBJECTIVE Retrospective clinical data and case studies support a therapeutic effect of ketamine in suppression of spreading depolarization (SD) following brain injury. Preclinical data strongly support efficacy in terms of frequency of SD as well as recovery from electrocorticography (ECoG) depression. The authors present the results of the first prospective controlled clinical trial testing the role of ketamine used for clinical sedation on occurrence of SD. METHODS Ten patients with severe traumatic brain injury (TBI) or aneurysmal subarachnoid hemorrhage (SAH) were recruited for this pilot trial. A standard ECoG strip was placed at the time of craniotomy, and the patients were then placed on an alternating every-6-hour schedule of ketamine or other sedation agent. The order of treatment was randomized. The ketamine dose was adjusted to clinical effect or maintained at a subanesthetic basal dose (0.1 mg/kg/hr) if no sedation was required. SD was scored using standard criteria, blinded to ketamine dosing. Occurrence of SD was compared with the hourly dose of ketamine to determine the effect of ketamine on SD occurrence. RESULTS Successful ECoG recordings were obtained in all 10 patients: 8 with SAH and 2 with TBI. There were a total of 1642 hours of observations with adequate ECoG: 833 hours off ketamine and 809 hours on ketamine. Analysis revealed a strong dose-dependent effect such that hours off ketamine or on doses of less than 1.15 mg/kg/hr were associated with an increased risk of SD compared with hours on doses of 1.15 mg/kg/hr or more (OR 13.838, 95% CI 1.99-1000). This odds ratio decreased with lower doses of 1.0 mg/kg/hr (OR 4.924, 95% CI 1.337-43.516), 0.85 mg/kg/ hr (OR 3.323, 95% CI 1.139-16.074), and 0.70 mg/kg/hr (OR 2.725, 95% CI 1.068-9.898) to a threshold of no effect at 0.55 mg/kg/hr (OR 1.043, 95% CI 0.565-2.135). When all ketamine data were pooled (i.e., on ketamine at any dose vs off ketamine), a nonsignificant overall trend toward less SD during hours on ketamine (chi(2) = 3.86, p = 0.42) was observed. CONCLUSIONS Ketamine effectively inhibits SD over a wide range of doses commonly used for sedation, even in nonintubated patients. These data also provide the first prospective evidence that the occurrence of SD can be influenced by clinical intervention and does not simply represent an unavoidable epiphenomenon after injury. These data provide the basis for future studies assessing clinical improvement with SD-directed therapy.	[Carlson, Andrew P.; Abbas, Mohammad; Alunday, Robert L.] Univ New Mexico, Sch Med, Dept Neurosurg, Albuquerque, NM 87131 USA; [Qeadan, Fares] Univ New Mexico, Sch Med, Dept Internal Med, Albuquerque, NM 87131 USA; [Shuttleworth, C. William] Univ New Mexico, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA		Carlson, AP (corresponding author), Univ New Mexico, Albuquerque, NM 87131 USA.	andrewcarlson@salud.unm.edu	Carlson, Andrew P/B-4369-2012; Qeadan, Fares/ABD-3131-2020; Qeadan, Fares/B-9482-2014	Carlson, Andrew P/0000-0003-2189-3699; Qeadan, Fares/0000-0002-3376-220X	National Center for Advancing Translational Sciences pilot grant [1UL1TR001449-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS106901, GM109089]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM109089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS106901, R01NS051288] Funding Source: NIH RePORTER	Support was provided by the National Center for Advancing Translational Sciences pilot grant no. 1UL1TR001449-01 to the Clinical Translational Science Center (to A.P.C.) and NIH grants nos. NS106901 and GM109089 (to C.W.S.).	Agresti A, 2011, INT ENCY STAT SCI, DOI DOI 10.1007/978-3-642-04898-2_161; Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; Carlson AP, 2012, NEUROL RES, V34, P223, DOI 10.1179/1743132811Y.0000000077; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; De Pinto Mario, 2008, J Opioid Manag, V4, P54; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2017, J CEREBR BLOOD F MET, V37, P1595, DOI 10.1177/0271678X16654496; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010; Duque JC, 2008, J VET PHARMACOL THER, V31, P344, DOI 10.1111/j.1365-2885.2008.00965.x; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; GORELOVA NA, 1987, ELECTROEN CLIN NEURO, V66, P440, DOI 10.1016/0013-4694(87)90213-6; Hartings JA, 2017, J CEREBR BLOOD F MET, V37, P1571, DOI 10.1177/0271678X16654495; Hartings JA, 2014, ANN NEUROL, V76, P681, DOI 10.1002/ana.24256; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; Reinhart KM, 2018, EXP NEUROL, V305, P121, DOI 10.1016/j.expneurol.2018.04.007; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303; Sanchez-Porras R, 2014, NEUROPHARMACOLOGY, V84, P52, DOI 10.1016/j.neuropharm.2014.04.018; Schiefecker AJ, 2015, NEUROCRIT CARE, V22, P293, DOI 10.1007/s12028-014-0050-4; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Strayer RJ, 2009, AM J EMERG MED, V27, P512, DOI 10.1016/j.ajem.2009.01.020; Vollenweider FX, 1997, EUR NEUROPSYCHOPHARM, V7, P25, DOI 10.1016/S0924-977X(96)00042-9; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; 2015, ANN EMERG MED, V65, P43, DOI DOI 10.1016/J.ANNEMERGMED.2014.06.018	36	43	43	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2019	130	5					1513	1519		10.3171/2017.12.JNS171665			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	HW0VW	WOS:000466401100013	29799344	Green Accepted, Bronze			2022-02-06	
J	Krukowski, K; Chou, A; Feng, X; Tiret, B; Paladini, MS; Riparip, LK; Chaumeil, MM; Lemere, C; Rosi, S				Krukowski, Karen; Chou, Austin; Feng, Xi; Tiret, Brice; Paladini, Maria-Serena; Riparip, Lara-Kirstie; Chaumeil, Myriam M.; Lemere, Cynthia; Rosi, Susanna			Traumatic Brain Injury in Aged Mice Induces Chronic Microglia Activation, Synapse Loss, and Complement-Dependent Memory Deficits	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						traumatic brain injury; complement; C1q; microglia; synapse	COGNITIVE FUNCTION; CNS; DYSFUNCTION; INHIBITION; DRIVES; IMPACT	Traumatic brain injury (TBI) is of particular concern for the aging community since there is both increased incidence of TBI and decreased functional recovery in this population. In addition, TBI is the strongest environmental risk factor for development of Alzheimer's disease and other dementia-related neurodegenerative disorders. Critical changes that affect cognition take place over time following the initial insult. Our previous work identified immune system activation as a key contributor to cognitive deficits observed in aged animals. Using a focal contusion model in the current study, we demonstrate a brain lesion and cavitation formation, as well as prolonged blood-brain barrier breakdown. These changes were associated with a prolonged inflammatory response, characterized by increased microglial cell number and phagocytic activity 30 days post injury, corresponding to significant memory deficits. We next aimed to identify the injury-induced cellular and molecular changes that lead to chronic cognitive deficits in aged animals, and measured increases in complement initiation components C1q, C3, and CR3, which are known to regulate microglial-synapse interactions. Specifically, we found significant accumulation of C1q on synapses within the hippocampus, which was paralleled by synapse loss 30 days post injury. We used genetic and pharmacological approaches to determine the mechanistic role of complement initiation on cognitive loss in aging animals after TBI. Notably, both genetic and pharmacological blockade of the complement pathway prevented memory deficits in aged injured animals. Thus, therapeutically targeting early components of the complement cascade represents a significant avenue for possible clinical intervention following TBI in the aging population.	[Krukowski, Karen; Chou, Austin; Feng, Xi; Tiret, Brice; Paladini, Maria-Serena; Riparip, Lara-Kirstie; Chaumeil, Myriam M.; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA; [Krukowski, Karen; Chou, Austin; Feng, Xi; Paladini, Maria-Serena; Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Tiret, Brice; Chaumeil, Myriam M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Surbeck Lab Adv Imaging, San Francisco, CA 94143 USA; [Lemere, Cynthia] Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, 75 Francis St, Boston, MA 02115 USA; [Lemere, Cynthia] Harvard Med Sch, Boston, MA 02115 USA; [Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Rosi, Susanna] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Rosi, Susanna] Univ Calif San Francisco, Kavli Inst Fundamental Neurosci, San Francisco, CA 94143 USA		Rosi, S (corresponding author), Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Kavli Inst Fundamental Neurosci, San Francisco, CA 94143 USA.	karen.krukowski@ucsf.edu; austinc06@gmail.com; xi.feng@ucsf.edu; brice.tiret@ucsf.edu; paladini.mariaserena@gmail.com; lriparip@gmail.com; myriam.chaumeil@ucsf.edu; clemere@bwh.harvard.edu; susanna.rosi@ucsf.edu	; Feng, Xi/N-7160-2016	PALADINI, MARIA SERENA/0000-0001-7320-6622; Feng, Xi/0000-0002-6920-1519; Chaumeil, Myriam/0000-0002-2110-4613; Chou, Austin/0000-0003-4328-5811	NIH NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG056770, R21NS096718, AG042016, AG044713, R01AG060057]; NRSA post-doctoral fellowship from the NIA [F32AG054126]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AI027763]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA213441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG056770] Funding Source: NIH RePORTER	This work was supported by NIH NIA grants R01AG056770 (SR), R21NS096718 (SR, MC), AG042016 (SR), AG044713 (CL), and R01AG060057 (CL). K.K. is supported by an NRSA post-doctoral fellowship from the NIA F32AG054126. The San Francisco General Hospital Flow Core Facility was supported by the National Institutes of Health (P30 AI027763).	Alawieh A, 2018, J NEUROSCI, V38, P2519, DOI 10.1523/JNEUROSCI.2197-17.2018; Chou A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061616; Chou A, 2017, P NATL ACAD SCI USA, V114, pE6420, DOI 10.1073/pnas.1707661114; Feng X, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0671-y; Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004; Guglielmetti C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17758-4; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008; Krukowski K, 2018, BRAIN BEHAV IMMUN, V74, P106, DOI 10.1016/j.bbi.2018.08.008; Krukowski K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26039-7; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lee JY, 2019, METHODS MOL BIOL, V2045, P299, DOI 10.1007/7651_2018_121; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Norris GT, 2018, J EXP MED, V215, P1789, DOI 10.1084/jem.20172244; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Patel NA, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1240-3; Prieto GA, 2015, P NATL ACAD SCI USA, V112, pE5078, DOI 10.1073/pnas.1514486112; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Shi QQ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf6295; Shi QQ, 2015, J NEUROSCI, V35, P13029, DOI 10.1523/JNEUROSCI.1698-15.2015; Snigdha S, 2016, J NEUROSCI, V36, P3611, DOI 10.1523/JNEUROSCI.2693-15.2016; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stephan AH, 2013, J NEUROSCI, V33, P13460, DOI 10.1523/JNEUROSCI.1333-13.2013; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Vasek MJ, 2016, NATURE, V534, P538, DOI 10.1038/nature18283	39	43	43	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1422-0067		INT J MOL SCI	Int. J. Mol. Sci.	DEC	2018	19	12							3753	10.3390/ijms19123753			17	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	HG9JM	WOS:000455323500055	30486287	gold, Green Published, Green Submitted			2022-02-06	
J	Russo, EB				Russo, Ethan B.			Cannabis Therapeutics and the Future of Neurology	FRONTIERS IN INTEGRATIVE NEUROSCIENCE			English	Article						cannabis; pain; brain tumor; epilepsy; Alzheimer disease; Parkinson disease; traumatic brain injury; microbiome	ACTIVATED-RECEPTOR-GAMMA; IRRITABLE-BOWEL-SYNDROME; DOUBLE-BLIND; PARKINSONS-DISEASE; MEDICAL MARIJUANA; CONTROLLED-TRIAL; GUT MICROBIOTA; PAIN; SYMPTOMS; MIGRAINE	Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of neurodegenerative disorders into the realm of actual palliation, arrest or reversal of the attendant pathological processes. While cannabis-based medicines have demonstrated safety, efficacy and consistency sufficient for regulatory approval in spasticity in multiple sclerosis (MS), and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges remain. This review will examine the intriguing promise that recent discoveries regarding cannabis-based medicines offer to neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), and cannabis terpenoids in the putative treatment of five syndromes, currently labeled recalcitrant to therapeutic success, and wherein improved pharmacological intervention is required: intractable epilepsy, brain tumors, Parkinson disease (PD), Alzheimer disease (AD) and traumatic brain injury (TBI)/chronic traumatic encephalopathy (CTE). Current basic science and clinical investigations support the safety and efficacy of such interventions in treatment of these currently intractable conditions, that in some cases share pathological processes, and the plausibility of interventions that harness endocannabinoid mechanisms, whether mediated via direct activity on CB1 and CB2 (tetrahydrocannabinol, THC, caryophyllene), peroxisome proliferator-activated receptor-gamma (PPAR gamma; THCA), 5-HT1A (CBD, CBDA) or even nutritional approaches utilizing prebiotics and probiotics. The inherent polypharmaceutical properties of cannabis botanicals offer distinct advantages over the current single-target pharmaceutical model and portend to revolutionize neurological treatment into a new reality of effective interventional and even preventative treatment.	[Russo, Ethan B.] Int Cannabis & Cannabinoids Inst, Prague, Czech Republic		Russo, EB (corresponding author), Int Cannabis & Cannabinoids Inst, Prague, Czech Republic.	ethan.russo@icci.science	Russo, Ethan B/D-9933-2015	Russo, Ethan B/0000-0003-4715-515X			Ahmed AIA, 2015, CLIN PHARMACOL THER, V97, P597, DOI 10.1002/cpt.117; Aso E, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00037; Babson KA, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0775-9; Bagdy G, 2007, J NEUROCHEM, V100, P857, DOI 10.1111/j.1471-4159.2006.04277.x; Baker D, 2003, LANCET NEUROL, V2, P291, DOI 10.1016/S1474-4422(03)00381-8; Bergamaschi MM, 2011, NEUROPSYCHOPHARMACOL, V36, P1219, DOI 10.1038/npp.2011.6; Bisogno T, 2001, BRIT J PHARMACOL, V134, P845, DOI 10.1038/sj.bjp.0704327; Bolognini D, 2013, BRIT J PHARMACOL, V168, P1456, DOI 10.1111/bph.12043; Bowe WP, 2011, GUT PATHOG, V3, DOI 10.1186/1757-4749-3-1; Brady CM, 2004, MULT SCLER J, V10, P425, DOI 10.1191/1352458504ms1063oa; Brodie JS, 2015, TRENDS PHARMACOL SCI, V36, P802, DOI 10.1016/j.tips.2015.08.010; Calame W, 2008, BRIT J NUTR, V100, P1269, DOI 10.1017/S0007114508981447; Carroll CB, 2004, NEUROLOGY, V63, P1245, DOI 10.1212/01.WNL.0000140288.48796.8E; Casarejos MJ, 2013, J ALZHEIMERS DIS, V35, P525, DOI 10.3233/JAD-130050; Cascio MG, 2014, HDB OF CANNABIS, P137; Chagas MHN, 2014, J CLIN PHARM THER, V39, P564, DOI 10.1111/jcpt.12179; Chagas MHN, 2014, J PSYCHOPHARMACOL, V28, P1088, DOI 10.1177/0269881114550355; Chao DHM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29094; Cherry JD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185541; Clarke G, 2012, ALIMENT PHARM THER, V35, P403, DOI 10.1111/j.1365-2036.2011.04965.x; Clendinning J, 1843, Med Chir Trans, V26, P188; Cluny NL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144270; Colle R, 2017, PHARMACOPSYCHIATRY, V50, P49, DOI 10.1055/s-0042-120120; Colle R, 2017, NEUROPSYCH DIS TREAT, V13, P9, DOI 10.2147/NDT.S121149; Cordain L, 2002, ARCH DERMATOL, V138, P1584, DOI 10.1001/archderm.138.12.1584; Devinsky O, 2018, NEUROLOGY, V90, pE1204, DOI 10.1212/WNL.0000000000005254; Devinsky O, 2017, NEW ENGL J MED, V376, P2011, DOI 10.1056/NEJMoa1611618; Devinsky O, 2016, LANCET NEUROL, V15, P270, DOI 10.1016/S1474-4422(15)00379-8; Donovan M, 1845, DUBLIN J MED SCI, V26, P368, DOI DOI 10.1007/BF02971741; Dumitru CA, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00159; Elrod HA, 2008, PPAR RES, V2008, DOI 10.1155/2008/704165; Emery DC, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00195; Esposito G, 2006, NEUROSCI LETT, V399, P91, DOI 10.1016/j.neulet.2006.01.047; Esposito G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028668; Eubanks LM, 2006, MOL PHARMACEUT, V3, P773, DOI 10.1021/mp060066m; Fallon S, 1999, NOURISHING TRADITION; Fife Terry D, 2015, Neurol Clin Pract, V5, P344; Finseth TA, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/874849; Foroughi M, 2011, CHILD NERV SYST, V27, P671, DOI 10.1007/s00381-011-1410-4; Gehring S, 2011, J NEURO-ONCOL, V102, P383, DOI 10.1007/s11060-010-0351-1; Gottschling S., 2011, ANGEW SCHMERZTHERAPI, P55, DOI DOI 10.1007/BF03359593; Gowers W.R., 1888, MANUAL DIS NERVOUS S; Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; He MQ, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0183-1; Hergenrather, 2017, CANNABIS DEMENTIA; Hill MN, 2013, PSYCHONEUROENDOCRINO, V38, P2952, DOI 10.1016/j.psyneuen.2013.08.004; Iuvone T, 2004, J NEUROCHEM, V89, P134, DOI 10.1111/j.1471-4159.2003.02327.x; Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008; Jones NA, 2010, J PHARMACOL EXP THER, V332, P569, DOI 10.1124/jpet.109.159145; Kales HC, 2007, AM J PSYCHIAT, V164, P1568, DOI 10.1176/appi.ajp.2007.06101710; Karler R., 1979, MARIHUANA BIOL EFFEC, P619, DOI [DOI 10.1016/B978-0-08-023759-6.50052-4, 10.1016/b978-0-08-023759-6.50052-4]; Kavia RBC, 2010, MULT SCLER J, V16, P1349, DOI 10.1177/1352458510378020; Keshavarzian A, 2015, MOVEMENT DISORD, V30, P1351, DOI 10.1002/mds.26307; Kim SS, 2008, BIOSCI BIOTECH BIOCH, V72, P2507, DOI 10.1271/bbb.70388; Latorre JGS, 2015, CURR CARDIOL REP, V17, DOI 10.1007/s11886-015-0627-3; Lei P, 2010, INT J BIOCHEM CELL B, V42, P1775, DOI 10.1016/j.biocel.2010.07.016; Leweke FM, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.15; Lewis MA, 2018, PLANTA MED, V84, P225, DOI 10.1055/s-0043-122240; Ligresti A, 2006, J PHARMACOL EXP THER, V318, P1375, DOI 10.1124/jpet.106.105247; Lorenz R, 2004, NEUROENDOCRINOL LETT, V25, P40; Lotan I, 2014, CLIN NEUROPHARMACOL, V37, P41, DOI 10.1097/WNF.0000000000000016; Maa E, 2014, EPILEPSIA, V55, P783, DOI 10.1111/epi.12610; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MacCallum CA, 2018, EUR J INTERN MED, V49, P12, DOI 10.1016/j.ejim.2018.01.004; Maccarrone M, 2017, EXPERT REV CLIN PHAR, V10, P443, DOI 10.1080/17512433.2017.1292849; Massi P, 2004, J PHARMACOL EXP THER, V308, P838, DOI 10.1124/jpet.103.061002; Mayeux R, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006239; McGuire P, 2018, AM J PSYCHIAT, V175, P225, DOI 10.1176/appi.ajp.2017.17030325; McPartland JM, 2017, CANNABIS CANNABINOID, V2, P87, DOI 10.1089/can.2016.0032; MERRITT JC, 1980, OPHTHALMOLOGY, V87, P222; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mitchell S. W., 1874, MED SURG REP, V31, P67; Muller-Vahl K. R., 2002, Journal of Cannabis Therapeutics, V2, P145, DOI 10.1300/J175v02n03_10; Muller-Vahl KR, 2003, J CLIN PSYCHIAT, V64, P459, DOI 10.4088/JCP.v64n0417; MUNSON AE, 1975, J NATL CANCER I, V55, P597, DOI 10.1093/jnci/55.3.597; Musso G, 2010, CURR OPIN LIPIDOL, V21, P76, DOI 10.1097/MOL.0b013e3283347ebb; Nadal X, 2017, BRIT J PHARMACOL, V174, P4263, DOI 10.1111/bph.14019; National Academies of Sciences Engineering and Medicine, 2017, HLTH EFF CAN CANN CU; Novotna A, 2011, EUR J NEUROL, V18, P1122, DOI 10.1111/j.1468-1331.2010.03328.x; Nozaki C, 2015, EUR NEUROPSYCHOPHARM, V25, P1388, DOI 10.1016/j.euroneuro.2015.04.001; Nurmikko TJ, 2007, PAIN, V133, P210, DOI 10.1016/j.pain.2007.08.028; O'Shaughnessy W. B., 1838, T MED PHYS SOC BENGA, V71-102, P421; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; Olah A, 2014, J CLIN INVEST, V124, P3713, DOI 10.1172/JCI64628; Omalu B, 2018, NEUROSURGERY, V82, P237, DOI 10.1093/neuros/nyx536; Osler W, 1915, PRINCIPLES PRACTICE; Pacher P, 2018, NAT REV CARDIOL, V15, P151, DOI 10.1038/nrcardio.2017.130; Pamplona FA, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00759; Perlmutter F., 2015, BRAIN MAKER POWER GU; Pertwee R.G., 2014, HDB CANNABIS; Pisani A, 2005, ANN NEUROL, V57, P777, DOI 10.1002/ana.20462; Porter BE, 2013, EPILEPSY BEHAV, V29, P574, DOI 10.1016/j.yebeh.2013.08.037; Press CA, 2015, EPILEPSY BEHAV, V45, P49, DOI 10.1016/j.yebeh.2015.02.043; Raichlen DA, 2012, J EXP BIOL, V215, P1331, DOI 10.1242/jeb.063677; RAMAN A, 1995, LETT APPL MICROBIOL, V21, P242, DOI 10.1111/j.1472-765X.1995.tb01051.x; Rekand T, 2014, EUR NEUROL, V71, P4, DOI 10.1159/000357742; Reymond E. A. E. E., 1976, CONTENTS LIBRARIES 1; Rhyne DN, 2016, PHARMACOTHERAPY, V36, P505, DOI 10.1002/phar.1673; Rog DJ, 2005, NEUROLOGY, V65, P812, DOI 10.1212/01.wnl.0000176753.45410.8b; Rousseaux C, 2007, NAT MED, V13, P35, DOI 10.1038/nm1521; Rudroff T, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00299; Russo E., 2001, Journal of Cannabis Therapeutics, V1, P21, DOI 10.1300/J175v01n02_04; Russo E. B., 2015, BR J CARDIOL, V22, P7; Russo E.B., 2017, CANNABIS SATIVA L BO, DOI 10.1007/978-3-319-54564-6_2; Russo E.B., 2013, COMPREHENSIVE TREATM, P181, DOI [10.1007/978-1-4614-1560-2_18, DOI 10.1007/978-1-4614-1560-2_18]; Russo E. B., 2015, CLIN RES, P58, DOI [10.14524/CR-15-0004, DOI 10.14524/CR-15-0004]; Russo EB, 2005, NEUROCHEM RES, V30, P1037, DOI 10.1007/s11064-005-6978-1; Russo EB, 2004, NEUROENDOCRINOL LETT, V25, P31; Russo EB, 2007, CHEM BIODIVERS, V4, P1614, DOI 10.1002/cbdv.200790144; Russo EB, 2007, CHEM BIODIVERS, V4, P1729, DOI 10.1002/cbdv.200790150; Russo EB, 2017, ADV PHARMACOL, V80, P67, DOI 10.1016/bs.apha.2017.03.004; Russo EB, 2017, EPILEPSY BEHAV, V70, P292, DOI 10.1016/j.yebeh.2016.09.040; Russo EB, 2016, CANNABIS CANNABINOID, V1, P154, DOI 10.1089/can.2016.0009; Russo EB, 2016, TRENDS PHARMACOL SCI, V37, P594, DOI 10.1016/j.tips.2016.04.005; Russo EB, 2011, BRIT J PHARMACOL, V163, P1344, DOI 10.1111/j.1476-5381.2011.01238.x; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sarchielli P, 2007, NEUROPSYCHOPHARMACOL, V32, P1384, DOI 10.1038/sj.npp.1301246; Schenkman M, 2018, JAMA NEUROL, V75, P219, DOI 10.1001/jamaneurol.2017.3517; Seguin E., 1877, MED REC, V12, P774; Serpell M, 2014, EUR J PAIN, V18, P999, DOI 10.1002/j.1532-2149.2013.00445.x; Shen Y, 2016, CURR STEM CELL RES T, V11, P208, DOI 10.2174/1574888X10666150728122034; Slavin J, 2013, NUTRIENTS, V5, P1417, DOI 10.3390/nu5041417; Soni D, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0499-0; Subramenium GA, 2015, J MED MICROBIOL, V64, P879, DOI 10.1099/jmm.0.000105; Sulak D, 2017, EPILEPSY BEHAV, V70, P328, DOI 10.1016/j.yebeh.2016.12.032; Sun H, 2008, INT J DEV NEUROSCI, V26, P505, DOI 10.1016/j.ijdevneu.2008.01.009; Tepper BJ, 2014, NUTRIENTS, V6, P3363, DOI 10.3390/nu6093363; Thiele EA, 2018, LANCET, V391, P1085, DOI 10.1016/S0140-6736(18)30136-3; Torres S, 2011, MOL CANCER THER, V10, P90, DOI 10.1158/1535-7163.MCT-10-0688; van den Elsen GAH, 2015, NEUROLOGY, V84, P2338, DOI 10.1212/WNL.0000000000001675; Venderova K, 2004, MOVEMENT DISORD, V19, P1102, DOI 10.1002/mds.20111; Volicer L, 1997, INT J GERIATR PSYCH, V12, P913, DOI 10.1002/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.3.CO;2-4; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920; Walther S, 2006, PSYCHOPHARMACOLOGY, V185, P524, DOI 10.1007/s00213-006-0343-1; Zhang LQ, 2013, BRIT J PHARMACOL, V170, P661, DOI 10.1111/bph.12315; Zuardi AW, 2009, J PSYCHOPHARMACOL, V23, P979, DOI 10.1177/0269881108096519	138	43	43	10	52	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5145			FRONT INTEGR NEUROSC	Front. Integr. Neurosci.	OCT 18	2018	12								51	10.3389/fnint.2018.00051			11	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	GX3GY	WOS:000447611400002	30405366	gold, Green Published			2022-02-06	
J	Gabler, LF; Crandall, JR; Panzer, MB				Gabler, Lee F.; Crandall, Jeff R.; Panzer, Matthew B.			Development of a Metric for Predicting Brain Strain Responses Using Head Kinematics	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Brain deformation; Finite element modeling; Rotational; Second-order system	INJURY; CONCUSSION; DIRECTION	Diffuse brain injuries are caused by excessive brain deformation generated primarily by rapid rotational head motion. Metrics that describe the severity of brain injury based on head motion often do not represent the governing physics of brain deformation, rendering them ineffective over a broad range of head impact conditions. This study develops a brain injury metric based on the response of a second-order mechanical system, and relates rotational head kinematics to strain-based brain injury metrics: maximum principal strain (MPS) and cumulative strain damage measure (CSDM). This new metric, universal brain injury criterion (UBrIC), is applicable over a broad range of kinematics encountered in automotive crash and sports. Efficacy of UBrIC was demonstrated by comparing it to MPS and CSDM predicted in 1600 head impacts using two different finite element (FE) brain models. Relative to existing metrics, UBrIC had the highest correlation with the FE models, and performed better in most impact conditions. While UBrIC provides a reliable measurement for brain injury assessment in a broad range of head impact conditions, and can inform helmet and countermeasure design, an injury risk function was not incorporated into its current formulation until validated strain-based risk functions can be developed and verified against human injury data.	[Gabler, Lee F.; Crandall, Jeff R.; Panzer, Matthew B.] Univ Virginia, Ctr Appl Biomech, Dept Mech & Aerosp Engn, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA		Panzer, MB (corresponding author), Univ Virginia, Ctr Appl Biomech, Dept Mech & Aerosp Engn, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA.	mbp2q@virginia.edu			Partnership for Dummy Technology and Biomechanics (PDB)	The authors thank the Partnership for Dummy Technology and Biomechanics (PDB) for support and funding for this research.	Alshareef A, 2018, J NEUROTRAUM, V35, P780, DOI 10.1089/neu.2017.5362; [Anonymous], J2111 SAE INT; Baldwin G, 2015, C TRAUM BRAIN INJ US; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Forman Jason, 2008, Ann Adv Automot Med, V52, P141; Gabler LF, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4038357; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; Gadd C., 1966, SAE TECHNICAL PAPER; Gennarelli T, 1971, P 15 STAPP CAR CRASH; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Holbourn AHS, 1943, LANCET, V2, P438; Ji SB, 2015, ANN BIOMED ENG, V43, P1877, DOI 10.1007/s10439-014-1193-3; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; King AI, 2003, IRCOBI C LISB PORT S; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Laituri K, 2015, SAE TECHNICAL PAPER; Lobo B, 2015, LECT NOTES COMPUT SC, V9502, P114, DOI 10.1007/978-3-319-27293-1_11; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Milton S. J., 2002, INTRO PROBABILITY ST, V4th; Mueller B., 2015, P 24 INT TECHN C ENH; National Operating Committee on the Standards for Athletic Equipment (NOCSAE), 2012, STAND TEST METH EQ U; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman J.A, 1986, P 1986 INT IRCOBI C; NHTSA NVS | Vehicle Crash Test Database, VEH CRASH TEST DAT; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Panzer MB, 2016, INT J AUTOMOT ENG, V7, P37, DOI 10.20485/jsaeijae.7.1_37; Patrick L. M, 1963, P 7 STAPP CAR CRASH; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Sanchez EJ, 2017, J NEUROTRAUM, V34, P2410, DOI 10.1089/neu.2016.4681; Santiago LA, 2012, BRAIN INJURY, V26, P107, DOI 10.3109/02699052.2011.635363; Saunders J, 2015, 24 INT TECHN C ENH S; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takahashi, 2015, SAE TECHNICAL PAPER; Takhounts E. G, 2011, 11026 BRIC; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Thibault L. E, 1985, SAE TECHNICAL PAPER; Versace J, 1971, REV SEVERITY INDEX; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; von Gierke H. E, 1964, BIOASTRONAUTICS, P61	46	43	43	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JUL	2018	46	7					972	985		10.1007/s10439-018-2015-9			14	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	GH8GR	WOS:000433906500005	29594689				2022-02-06	
J	Wen, L; You, WD; Wang, H; Meng, YY; Feng, JF; Yang, XF				Wen, Liang; You, Wendong; Wang, Hao; Meng, Yuanyuan; Feng, Junfeng; Yang, Xiaofeng			Polarization of Microglia to the M2 Phenotype in a Peroxisome Proliferator-Activated Receptor Gamma-Dependent Manner Attenuates Axonal Injury Induced by Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; microglia; neuroinflammation; peroxisome proliferator-activated receptor gamma (PPAR-gamma); polarization	PPAR-GAMMA; MACROPHAGE ACTIVATION; TNF-ALPHA; INFLAMMATION; ROSIGLITAZONE; AGONIST; DISEASE; DAMAGE; MODEL; NEURODEGENERATION	Increasing evidence indicates that activated microglia play an important role in the inflammatory response following traumatic brain injury (TBI). Inhibiting M1 and stimulating M2 activated microglia have demonstrated protective effects in several animal models of central nervous system diseases. However, it is not clear whether the polarization of microglia to M2 attenuates axonal injury following TBI. In this study, we used a lateral fluid percussion injury device to induce axonal injury in mice. Mice were randomly assigned to the sham, TBI, TBI + rosiglitazone (peroxisome proliferator-activated receptor gamma [PPAR-gamma] agonist), and TBI + GW9662 (PPAR-gamma antagonist) groups. Axonal injury was assessed using immunohistochemical staining for beta amyloid precursor protein. The inflammatory response was assessed by enzyme-linked immunosorbent assay, microglia polarization was assessed using specific markers of M1 and M2 microglia, and neurological function was assessed using the neurological severity score. Following TBI, microglia of the M1 phenotype increased significantly, while those of the M2 phenotype decreased. Rosiglitazone-induced PPAR-gamma activation promoted microglia polarization to the M2 phenotype, which reduced the inflammatory response, attenuated axonal injury in the cerebral cortex, and improved neurological function. Conversely, GW9662 inhibited the polarization of microglia to M2 and aggravated inflammation and axonal injury. Our in vitro findings in lipopolysaccharide-induced microglia were consistent with those of our in vivo experiments. In conclusion, the polarization of microglia to the M2 phenotype via PPAR-gamma activation attenuated axonal injury following TBI in mice, which may be a potential therapeutic approach for TBI-induced axonal injury.	[Wen, Liang; You, Wendong; Wang, Hao; Meng, Yuanyuan; Yang, Xiaofeng] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Neurosurg, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China; [Feng, Junfeng] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China		Yang, XF (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Neurosurg, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.	zjcswk@zju.edu.cn			Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LY15H090005]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81200955, 31371406, 81771317]; SMC-Star Award for Young Scholars	The authors sincerely thank the laboratory staff of the First Affiliated Hospital College of Medicine at Zhejiang University for their technical assistance. Our study was supported by the Natural Science Foundation of Zhejiang Province (No. LY15H090005) and the National Natural Science Foundation of China (No. 81200955, No. 31371406 and No. 81771317). JFF is also supported by SMC-Star Award for Young Scholars (B).	Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Vieira RDA, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00178; Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Byrav DSP, 2013, PHARMACOL REP, V65, P951; Carta AR, 2011, NEUROSCIENCE, V194, P250, DOI 10.1016/j.neuroscience.2011.07.046; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kita T, 2000, INT J LEGAL MED, V113, P221, DOI 10.1007/s004149900095; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Liu H, 2016, BIOCHEM BIOPH RES CO, V472, P648, DOI 10.1016/j.bbrc.2016.03.003; Liu M, 2017, J NEUROTRAUM, V34, P414, DOI 10.1089/neu.2015.4361; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Mandrekar-Colucci S, 2013, ASN NEURO, V5, DOI 10.1042/AN20130030; Mandrekar-Colucci S, 2012, J NEUROSCI, V32, P10117, DOI 10.1523/JNEUROSCI.5268-11.2012; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moein P, 2013, BRAIN INJURY, V27, P1454, DOI 10.3109/02699052.2013.825009; Pan J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0270-3; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Pilipovic K, 2015, PROG NEURO-PSYCHOPH, V59, P8, DOI 10.1016/j.pnpbp.2015.01.003; Ramanan S, 2009, INT J RADIAT ONCOL, V75, P870, DOI 10.1016/j.ijrobp.2009.06.059; Ranganathan PV, 2013, AM J PHYSIOL-RENAL, V304, pF948, DOI 10.1152/ajprenal.00580.2012; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wang B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4479; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Xiao YC, 2010, GLIA, V58, P932, DOI 10.1002/glia.20975; Ya JC, 2015, MOL MED REP, V12, P6591, DOI 10.3892/mmr.2015.4292; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhang B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0440-3	51	43	44	5	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2018	35	19					2330	2340		10.1089/neu.2017.5540		JUN 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GV3OA	WOS:000434867400001	29649924				2022-02-06	
J	Zhang, JN; Zhang, FY; Dong, JF				Zhang, Jianning; Zhang, Fangyi; Dong, Jing-fei			Coagulopathy induced by traumatic brain injury: systemic manifestation of a localized injury	BLOOD			English	Article							PLATELET-ACTIVATING-FACTOR; PLASMINOGEN-BINDING SITES; ADENOSINE-DIPHOSPHATE; INTRAVASCULAR COAGULATION; ENDOTHELIAL JUNCTIONS; PROCOAGULANT ACTIVITY; TIME-COURSE; MORTALITY; DYSFUNCTION; BLOOD	Traumatic brain injury (TBI)-induced coagulopathy is a common and well-recognized risk for poor clinical outcomes, but its pathogenesis remains poorly understood, and treatment options are limited and ineffective. We discuss the recent progress and knowledge gaps in understanding this lethal complication of TBI. We focus on (1) the disruption of the brain-blood barrier to disseminate brain injury systemically by releasing brain-derived molecules into the circulation and (2) TBI-induced hypercoagulable and hyperfibrinolytic states that result in persistent and delayed intracranial hemorrhage and systemic bleeding.	[Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China; [Zhang, Jianning] Tianjin Inst Neurol, Tianjin, Peoples R China; [Zhang, Fangyi] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; [Dong, Jing-fei] Bloodworks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA; [Dong, Jing-fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA		Zhang, JN (corresponding author), Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China.; Dong, JF (corresponding author), Bloodworks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA.	jianningzhang@hotmail.com; jfdong@psbc.org			National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS087296]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL119391]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029];  [81271361];  [81271359]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087296] Funding Source: NIH RePORTER	This study is supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke grant NS087296 and National Heart, Lung, and Blood Institute grant HL119391 (J.-f.D.), Natural Science Foundation of China State Key Program Grant 81330029, and Research grants 81271361 and 81271359 (J.Z.).	Abdelmalik PA, 2016, NEUROCRIT CARE, V24, P361, DOI 10.1007/s12028-015-0191-0; Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Bartels AN, 2016, SURGERY, V160, P954, DOI 10.1016/j.surg.2016.07.012; Batchelor JS, 2013, BRIT J NEUROSURG, V27, P12, DOI 10.3109/02688697.2012.705361; Batchelor JS, 2012, BRIT J NEUROSURG, V26, P525, DOI 10.3109/02688697.2011.650736; BROMMER EJP, 1984, THROMB RES, V34, P109, DOI 10.1016/0049-3848(84)90067-7; Brown SB, 2000, J BIOL CHEM, V275, P5987, DOI 10.1074/jbc.275.8.5987; Cardenas JC, 2014, SHOCK, V41, P514, DOI 10.1097/SHK.0000000000000161; Castellino FJ, 2014, J TRAUMA ACUTE CARE, V76, P1169, DOI 10.1097/TA.0000000000000216; Chang R, 2016, BLOOD, V128, P1043, DOI 10.1182/blood-2016-01-636423; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; Chapman MP, 2016, J TRAUMA ACUTE CARE, V80, P16, DOI 10.1097/TA.0000000000000885; Cristante E, 2013, P NATL ACAD SCI USA, V110, P832, DOI 10.1073/pnas.1209362110; Daley MJ, 2017, EUR J TRAUMA EMERG S, V43, P105, DOI 10.1007/s00068-016-0643-z; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Donahue DL, 2014, J NEUROTRAUM, V31, P404, DOI 10.1089/neu.2013.3089; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; EMEIS JJ, 1992, ANN NY ACAD SCI, V667, P249, DOI 10.1111/j.1749-6632.1992.tb51622.x; Fabbri A, 2013, CRIT CARE, V17, DOI 10.1186/cc12575; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Folkerson LE, 2018, AM J EMERG MED, V36, P38, DOI 10.1016/j.ajem.2017.06.057; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Haltmeier T, 2018, INJURY, V49, P62, DOI 10.1016/j.injury.2017.07.035; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Haseloff RF, 2015, SEMIN CELL DEV BIOL, V38, P16, DOI 10.1016/j.semcdb.2014.11.004; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Hijazi N, 2015, BLOOD, V125, P2558, DOI 10.1182/blood-2014-08-588442; Horng S, 2017, J CLIN INVEST, V127, P3136, DOI 10.1172/JCI91301; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P817, DOI 10.1097/TA.0b013e3182aafcf0; Karri J, 2017, SHOCK, V48, P644, DOI 10.1097/SHK.0000000000000912; Kim DY, 2015, J NEUROTRAUM, V32, P1815, DOI 10.1089/neu.2014.3728; Komarova YA, 2017, CIRC RES, V120, P179, DOI 10.1161/CIRCRESAHA.116.306534; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/neu.2004.21.1756; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Maani CV, 2009, CURR OPIN ANESTHESIO, V22, P255, DOI 10.1097/ACO.0b013e32832922be; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maeda T, 1997, ACT NEUR S, V70, P102; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Medved L, 2003, THROMB HAEMOSTASIS, V89, P409; Mitra B, 2012, INJURY, V43, P22, DOI 10.1016/j.injury.2010.10.015; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Nakae R, 2016, J NEUROTRAUM, V33, P688, DOI 10.1089/neu.2015.4039; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Ploplis VA, 2014, J NEUROTRAUM, V31, P1672, DOI 10.1089/neu.2013.3302; Prodan CI, 2016, J NEUROTRAUM, V33, P818, DOI 10.1089/neu.2014.3846; Reddy GD, 2015, CURR TREAT OPTION NE, V17, DOI 10.1007/s11940-015-0379-9; Roberts I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI [10.3310/HTA17100, 10.3310/hta17100]; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; SATOH K, 1992, ACTA NEUROL SCAND, V85, P122, DOI 10.1111/j.1600-0404.1992.tb04010.x; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231; Siljander P, 2001, ARTERIOSCL THROM VAS, V21, P618, DOI 10.1161/01.ATV.21.4.618; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; Tsukita S, 2000, ANN NY ACAD SCI, V915, P129, DOI 10.1111/j.1749-6632.2000.tb05235.x; Tsurupa G, 2001, BIOCHEMISTRY-US, V40, P801, DOI 10.1021/bi001789t; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; VARADI A, 1983, BIOCHEMISTRY-US, V22, P2440, DOI 10.1021/bi00279a021; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wu XW, 2016, AM J PHYSIOL-REG I, V310, pR323, DOI 10.1152/ajpregu.00401.2015; Wutzler S, 2009, J AM COLL SURGEONS, V209, P75, DOI 10.1016/j.jamcollsurg.2009.03.015; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Zhao ZL, 2016, BLOOD, V127, P2763, DOI [10.1182/blood-2015-12688838, 10.1182/blood-2015-12-688838]; Zhou Y, 2018, BLOOD, V131, P563, DOI 10.1182/blood-2017-08-801738	76	43	46	1	7	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	MAY 3	2018	131	18					2001	2006		10.1182/blood-2017-11-784108			6	Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Hematology	GE6ZC	WOS:000431378700004	29507078	Green Published, Bronze			2022-02-06	
J	Archer, DB; Vaillancourt, DE; Coombes, SA				Archer, Derek B.; Vaillancourt, David E.; Coombes, Stephen A.			A Template and Probabilistic Atlas of the Human Sensorimotor Tracts using Diffusion MRI	CEREBRAL CORTEX			English	Article						diffusion; movement; sensorimotor; tractography; white matter template	PREDICTS MOTOR IMPAIRMENT; TRAUMATIC BRAIN-INJURY; CORTICOSPINAL TRACT; DESCENDING PATHWAYS; FRONTAL-LOBE; SPINAL-CORD; TOPOGRAPHIC ORGANIZATION; LATERAL SURFACE; STROKE; AREAS	The purpose of this study was to develop a high-resolution sensorimotor area tract template (SMATT) which segments corticofugal tracts based on 6 cortical regions in primary motor cortex, dorsal premotor cortex, ventral premotor cortex, supplementary motor area (SMA), pre-supplementary motor area (preSMA), and primary somatosensory cortex using diffusion tensor imaging. Individual probabilistic tractography analyses were conducted in 100 subjects using the highest resolution data currently available. Tractography results were refined using a novel algorithm to objectively determine slice level thresholds that best minimized overlap between tracts while preserving tract volume. Consistent with tracing studies in monkey and rodent, our observations show that cortical topography is generally preserved through the internal capsule, with the preSMA tract remaining most anterior and the primary somatosensory tract remaining most posterior. We combine our results into a freely available white matter template named the SMATT. We also provide a probabilistic SMATT that quantifies the extent of overlap between tracts. Finally, we assess how the SMATT operates at the individual subject level in another independent data set, and in an individual after stroke. The SMATT and probabilistic SMATT provide new tools that segment and label sensorimotor tracts at a spatial resolution not previously available.	[Archer, Derek B.; Vaillancourt, David E.; Coombes, Stephen A.] Univ Florida, Dept Appl Physiol & Kinesiol, Lab Rehabil Neurosci, POB 118206, Gainesville, FL 32611 USA; [Vaillancourt, David E.] Univ Florida, Dept Neurol, Coll Med, Gainesville, FL 32611 USA; [Vaillancourt, David E.] Univ Florida, Dept Biomed Engn, Gainesville, FL 32611 USA		Coombes, SA (corresponding author), Univ Florida, Dept Appl Physiol & Kinesiol, Lab Rehabil Neurosci, POB 118206, Gainesville, FL 32611 USA.	scoombes@ufl.edu			American Heart AssociationAmerican Heart Association [15GRNT25700431]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS058487]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U54MH091657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG047266] Funding Source: NIH RePORTER	The American Heart Association (contract grant number 15GRNT25700431) and the National Institutes of Health (contract grant number R01 NS058487).	Andersson JLR, 2016, NEUROIMAGE, V125, P1063, DOI 10.1016/j.neuroimage.2015.10.019; Andersson JLR, 2015, NEUROIMAGE, V122, P166, DOI 10.1016/j.neuroimage.2015.07.067; Archer DB, 2016, HUM BRAIN MAPP, V37, P2039, DOI 10.1002/hbm.23155; BARNARD JW, 1956, J COMP NEUROL, V105, P25, DOI 10.1002/cne.901050103; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2006, NEUROIMAGE, V30, P220, DOI 10.1016/j.neuroimage.2005.09.036; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Clatworthy PL, 2010, NEUROIMAGE, V49, P2001, DOI 10.1016/j.neuroimage.2009.10.083; Coleman KA, 1997, J COMP NEUROL, V381, P143, DOI 10.1002/(SICI)1096-9861(19970505)381:2<143::AID-CNE3>3.0.CO;2-3; Coombes SA, 2012, CEREB CORTEX, V22, P616, DOI 10.1093/cercor/bhr141; Coombes SA, 2011, NEUROIMAGE, V54, P2226, DOI 10.1016/j.neuroimage.2010.10.003; Coombes SA, 2010, J NEUROPHYSIOL, V103, P2114, DOI 10.1152/jn.00920.2009; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; DUM RP, 1991, J NEUROSCI, V11, P667; Dum RP, 2005, J NEUROSCI, V25, P1375, DOI 10.1523/JNEUROSCI.3902-04.2005; Feinberg DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015710; Frazier JA, 2005, AM J PSYCHIAT, V162, P1256, DOI 10.1176/appi.ajp.162.7.1256; FRIES W, 1993, BRAIN, V116, P369, DOI 10.1093/brain/116.2.369; GALEA MP, 1994, CEREB CORTEX, V4, P166, DOI 10.1093/cercor/4.2.166; Goldstein JM, 2007, BIOL PSYCHIAT, V61, P935, DOI 10.1016/j.biopsych.2006.06.027; Groisser BN, 2014, NEUROREHAB NEURAL RE, V28, P751, DOI 10.1177/1545968314521896; HE SQ, 1995, J NEUROSCI, V15, P3284; HE SQ, 1993, J NEUROSCI, V13, P952; HEFFNER RS, 1983, BRAIN BEHAV EVOLUT, V23, P165, DOI 10.1159/000121494; Hou JM, 2016, HUM BRAIN MAPP, V37, P2195, DOI 10.1002/hbm.23163; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jang SH, 2016, J NEUROTRAUM, V33, P1790, DOI 10.1089/neu.2015.4298; Jang SH, 2015, NEUROSCI LETT, V585, P77, DOI 10.1016/j.neulet.2014.11.030; Jang SH, 2009, NEUROREHABILITATION, V24, P285, DOI 10.3233/NRE-2009-0480; Jaspers E, 2016, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00112; Jbabdi S, 2015, NAT NEUROSCI, V18, P1546, DOI 10.1038/nn.4134; Jbabdi S, 2012, MAGN RESON MED, V68, P1846, DOI 10.1002/mrm.24204; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; KEIZER K, 1989, EXP BRAIN RES, V74, P311; Lehericy S, 2004, ANN NEUROL, V55, P522, DOI 10.1002/ana.20030; Lehericy S, 2004, CEREB CORTEX, V14, P1302, DOI 10.1093/cercor/bhh091; Lemon RN, 2005, MUSCLE NERVE, V32, P261, DOI 10.1002/mus.20333; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; Lindenberg R, 2010, NEUROLOGY, V74, P280, DOI 10.1212/WNL.0b013e3181ccc6d9; Lindenberg R, 2012, HUM BRAIN MAPP, V33, P1040, DOI 10.1002/hbm.21266; LUPPINO G, 1994, NEUROREPORT, V5, P2545, DOI 10.1097/00001756-199412000-00035; Maier MA, 2002, CEREB CORTEX, V12, P281, DOI 10.1093/cercor/12.3.281; Makris N, 2006, SCHIZOPHR RES, V83, P155, DOI 10.1016/j.schres.2005.11.020; Mayka MA, 2006, NEUROIMAGE, V31, P1453, DOI 10.1016/j.neuroimage.2006.02.004; Misra G., 2016, CEREB CORTEX; Misra G, 2015, CEREB CORTEX, V25, P1906, DOI 10.1093/cercor/bhu001; Moeller S, 2010, MAGN RESON MED, V63, P1144, DOI 10.1002/mrm.22361; Morecraft RJ, 2015, J COMP NEUROL, V523, P669, DOI 10.1002/cne.23703; Muggeo VMR, 2003, STAT MED, V22, P3055, DOI 10.1002/sim.1545; Newton JM, 2006, BRAIN, V129, P1844, DOI 10.1093/brain/awl106; NUDO RJ, 1990, J COMP NEUROL, V296, P559, DOI 10.1002/cne.902960405; NUDO RJ, 1990, J COMP NEUROL, V296, P584, DOI 10.1002/cne.902960406; Park CH, 2013, NEUROIMAGE-CLIN, V2, P521, DOI 10.1016/j.nicl.2013.04.002; Park JK, 2008, KOREAN J RADIOL, V9, P191, DOI 10.3348/kjr.2008.9.3.191; Plow EB, 2015, NEUROSCIENTIST, V21, P225, DOI 10.1177/1073858414537381; Potter-Baker KA, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00079; Rouiller EM, 1998, EUR J NEUROSCI, V10, P729, DOI 10.1046/j.1460-9568.1998.00075.x; Sach M, 2004, BRAIN, V127, P340, DOI 10.1093/brain/awh041; Schaechter JD, 2008, NEUROIMAGE, V39, P1370, DOI 10.1016/j.neuroimage.2007.09.071; Schaechter JD, 2009, HUM BRAIN MAPP, V30, P3461, DOI 10.1002/hbm.20770; Schulz R, 2012, STROKE, V43, P2248, DOI 10.1161/STROKEAHA.112.662619; Setsompop K, 2012, MAGN RESON MED, V67, P1210, DOI 10.1002/mrm.23097; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Sotiropoulos SN, 2013, MAGN RESON MED, V70, P1682, DOI 10.1002/mrm.24623; Sotiropoulos SN, 2013, NEUROIMAGE, V80, P125, DOI 10.1016/j.neuroimage.2013.05.057; Stinear CM, 2007, BRAIN, V130, P170, DOI 10.1093/brain/awl333; Stinear CM, 2012, BRAIN, V135, P2527, DOI 10.1093/brain/aws146; Tovar-Moll F, 2015, J NEUROIMAGING, V25, P200, DOI 10.1111/jon.12171; TRAVIS AM, 1955, BRAIN, V78, P155, DOI 10.1093/brain/78.2.155; van Baarsen KM, 2016, NEUROIMAGE, V124, P724, DOI 10.1016/j.neuroimage.2015.09.014; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Zhu LL, 2010, STROKE, V41, P910, DOI 10.1161/STROKEAHA.109.577023	82	43	43	1	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	MAY	2018	28	5					1685	1699		10.1093/cercor/bhx066			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GF3XH	WOS:000431890800010	28334314	Bronze, Green Published			2022-02-06	
J	Schaffert, J; Lobue, C; White, CL; Chiang, HS; Didehbani, N; Lacritz, L; Rossetti, H; Dieppa, M; Hart, J; Cullum, CM				Schaffert, Jeff; Lobue, Christian; White, Charles L., III; Chiang, Hsueh-Sheng; Didehbani, Nyaz; Lacritz, Laura; Rossetti, Heidi; Dieppa, Marisara; Hart, John, Jr.; Cullum, C. Munro			Traumatic Brain Injury History Is Associated With an Earlier Age of Dementia Onset in Autopsy-Confirmed Alzheimer's Disease	NEUROPSYCHOLOGY			English	Article						National Alzheimer's Coordinating Center (NACC); traumatic brain injury (TBI); Alzheimer's disease (AD); age of onset; autopsy	MILD COGNITIVE IMPAIRMENT; SEVERE HEAD-INJURY; DIAGNOSTIC-CRITERIA; CLINICAL-DIAGNOSIS; NATIONAL INSTITUTE; INCREASED RISK; OF-ONSET; PATHOLOGY; RECOMMENDATIONS; DEGENERATION	Objective: To evaluate whether a history of traumatic brain injury (TBI) with reported loss of consciousness (LOC) is a risk factor for earlier onset of Alzheimer's disease (AD) in an autopsy-confirmed sample. Method: Data from 2,133 participants with autopsy-confirmed AD (i.e., at least Braak neurofibrillary tangle stages III to VI and CERAD neuritic plaque score moderate to frequent) were obtained from the National Alzheimer's Coordinating Center (NACC). Participants were categorized by presence/absence of self-reported remote (i.e., > 1 year prior to their first Alzheimer's Disease Center visit) history of TBI with LOC (TBI+ vs. TBI-). Analyses of Covariance (ANCOVA) controlling for sex, education, and race compared groups on clinician-estimated age of symptom onset and age of diagnosis. Results: Average age of onset was 2.34 years earlier (p = .01) for the TBI+ group (n = 194) versus the TBI+ group (n = 1900). Dementia was diagnosed on average 2.83 years earlier (p = .002) in the TBI+ group (n = 197) versus the TBI+ group (n = 1936). Using more stringent neuropathological criteria (i.e., Braak stages V-VI and CERAD frequent), both age of AD onset and diagnosis were 3.6 years earlier in the TBI+ group (both p's < .001). Conclusions: History of TBI with reported LOC appears to be a risk factor for earlier AD onset. This is the first study to use autopsy-confirmed cases, supporting previous investigations that used clinical criteria for the diagnosis of AD. Further investigation as to possible underlying mechanisms of association is needed.	[Schaffert, Jeff; Lobue, Christian; Didehbani, Nyaz; Lacritz, Laura; Rossetti, Heidi] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [White, Charles L., III] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Chiang, Hsueh-Sheng; Hart, John, Jr.] Univ Texas Dallas, Sch Behav & Brain Sci, Richardson, TX 75083 USA; [Chiang, Hsueh-Sheng; Dieppa, Marisara] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Hart, John, Jr.; Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Cullum, C. Munro] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA		Cullum, CM (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	munro.cullum@utsouthwestern.edu	White, Charles L/AAJ-1858-2021; Cullum, C. Munro/AAC-2496-2019	White, Charles L/0000-0002-3870-2804; Cullum, C. Munro/0000-0001-9706-5465; Dieppa, Marisara/0000-0002-4532-0601; Didehbani, Nyaz/0000-0001-6121-5759; Chiang, Hsueh-Sheng/0000-0003-2211-6007; Schaffert, Jeff/0000-0002-8842-980X	University of Texas Southwestern Alzheimer's disease Center (NIH/NIA) [P3012300-19]; Texas Alzheimer's Research and Care Consortium (TARCC); NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574];  [P50 AG005138];  [P30 AG008051];  [P30 AG013854];  [P30 AG008017];  [P30 AG010161];  [P50 AG047366];  [P30 AG010129];  [P50 AG016573];  [P50 AG005131];  [P50 AG023501];  [P30 AG035982];  [P30 AG028383];  [P30 AG053760];  [P30 AG010124];  [P50 AG005133];  [P50 AG005142];  [P30 AG012300];  [P30 AG049638];  [P50 AG005136];  [P50 AG033514];  [P50 AG005681];  [P50 AG047270]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG016573, P30AG013854, U01AG016976, P50AG005142, P50AG023501, P30AG008017, P30AG012300, P50AG047266, P30AG028383, P50AG005131, P50AG047270, P50AG047366, P50AG008702, P50AG005138, P50AG005134, P50AG025688, P30AG035982, P50AG005146, P50AG005136, P30AG010129, P50AG016574, P30AG013846, P50AG005681, P30AG019610, P30AG010124, P30AG010161, P30AG053760, P50AG005133, P30AG010133, P30AG049638, P50AG033514, P30AG008051] Funding Source: NIH RePORTER	This work was supported in part by the University of Texas Southwestern Alzheimer's disease Center (NIH/NIA grant P3012300-19) and the Texas Alzheimer's Research and Care Consortium (TARCC). The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA funded ADCs: P30 AG019610 (PI Eric Reiman), P30 AG013846 (PI Neil Kowall), P50 AG008702 (PI Scott Small), P50 AG025688 (PI Allan Levey), P50 AG047266 (PI Todd Golde), P30 AG010133 (PI Andrew Saykin), P50 AG005146 (PI Marilyn Albert), P50 AG005134 (PI Bradley Hyman), P50 AG016574 (PI Ronald Petersen), P50 AG005138 (PI Mary Sano), P30 AG008051 (PI Thomas Wisniewski), P30 AG013854 (PI M. Marsel Mesulam), P30 AG008017 (PI Jeffrey Kaye), P30 AG010161 (PI David Bennett), P50 AG047366 (PI Victor Henderson), P30 AG010129 (PI Charles DeCarli), P50 AG016573 (PI Frank LaFerla), P50 AG005131 (PI James Brewer), P50 AG023501 (PI Bruce Miller), P30 AG035982 (PI Russell Swerdlow), P30 AG028383 (PI Linda Van Eldik), P30 AG053760 (PI Henry Paulson), P30 AG010124 (PI John Trojanowski), P50 AG005133 (PI Oscar Lopez), P50 AG005142 (PI Helena Chui), P30 AG012300 (PI Roger Rosenberg), P30 AG049638 (PI Suzanne Craft), P50 AG005136 (PI Thomas Grabowski), P50 AG033514 (PI Sanjay Asthana), P50 AG005681 (PI John Morris), P50 AG047270 (PI Stephen Strittmatter).	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b; Bigler Erin D, 2015, Handb Clin Neurol, V128, P691, DOI 10.1016/B978-0-444-63521-1.00043-1; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Deutsch MB, 2015, DEMENT GERIATR COGN, V39, P143, DOI 10.1159/000369787; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Li W, 2016, J NEUROL, V263, P1280, DOI 10.1007/s00415-016-8093-4; LoBue C., J NEUROPSYCHIATRY CL; LoBue C, 2017, CLIN NEUROPSYCHOL, V31, P85, DOI 10.1080/13854046.2016.1257069; Lobue C, 2016, J ALZHEIMERS DIS, V51, P727, DOI 10.3233/JAD-150895; LoBue C, 2016, J NEUROL NEUROSUR PS, V87, P817, DOI 10.1136/jnnp-2015-311438; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MIRRA SS, 1993, ARCH PATHOL LAB MED, V117, P132; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Serrano-Pozo A, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006189; Silbert LC, 2012, NEUROLOGY, V79, P741, DOI 10.1212/WNL.0b013e3182661f2b; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Sundman MH, 2014, J ALZHEIMERS PARKINS, V4, P137; Tomaiuolo F, 2012, BRAIN RES BULL, V87, P373, DOI 10.1016/j.brainresbull.2012.01.008; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633	41	43	45	2	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2018	32	4					410	416		10.1037/neu0000423			7	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	GH1GU	WOS:000433151900004	29389151	Bronze, Green Accepted			2022-02-06	
J	Zeiler, FA; Donnelly, J; Smielewski, P; Menon, DK; Hutchinson, PJ; Czosnyka, M				Zeiler, Frederick A.; Donnelly, Joseph; Smielewski, Peter; Menon, David K.; Hutchinson, Peter J.; Czosnyka, Marek			Critical Thresholds of Intracranial Pressure-Derived Continuous Cerebrovascular Reactivity Indices for Outcome Prediction in Noncraniectomized Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; ICP index; outcome; thresholds	CEREBRAL PERFUSION-PRESSURE; BLOOD-FLOW; AUTOREGULATION	The aim of the study was to compare intracranial pressure (ICP)-derived cerebrovascular reactivity indices in their ability to predict six-month outcome, and to determine/compare critical thresholds related to outcome for each index in adult noncraniectomized traumatic brain injury (TBI). Using a retrospective cohort of nondecompressive craniectomy (non-DC) patients with TBI, we performed univariate and multi-variate binary logistic regression outcome analysis of: pressure reactivity index (PRx), pulse amplitude index (PAx), and a newly described index (RAC) calculated as the regression coefficient between ICP waveform amplitude and cerebral perfusion pressure (CPP). Finally, we performed sequential chi-square threshold analysis for each index as it related to six-month binary outcomes. Outcome was assessed via dichotomized Glasgow Outcome Scores (GOS): (A) favorable (GOS 4 or 5) versus unfavorable (GOS 3 or less), (B) alive versus dead. There were 358 non-DC patients with TBI included in all aspects of the analysis. In an analysis of the entire recording period for all patients using univariate binary logistic regression, the areas under the curves (AUCs) for favorable versus unfavorable outcome were: PRx (0.573, p<0.0001), PAx (0.606, p<0.0001), and RAC (0.655, p<0.0001). Similarly, the AUCs for alive versus dead outcome were: PRx (0.651, p<0.0001), PAx (0.705, p<0.0001), and RAC (0.722, p<0.0001). RAC displayed superior AUC statistics compared with PRx and PAx, using both univariate and multi-variate regression. RAC displayed more stable critical thresholds related to six-month outcomes. Thresholds for both favorable versus unfavorable and alive versus dead outcomes for PRx, PAx, and RAC across the entire recording period were: +0.35 and +0.35, 0 and +0.25, -0.10 and -0.05, respectively. In non-DC patients with TBI, RAC appears to be superior to PRx and PAx in six-month outcome prediction, using both univariate and multi-variate logistic regression. Further, RAC displayed more stable critical thresholds associated with binary outcomes at six months. Further analysis of RAC in TBI is required.	[Zeiler, Frederick A.; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Zeiler, Frederick A.] Univ Manitoba, Dept Surg, Rady Fac Hlth Sci, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada; [Donnelly, Joseph; Smielewski, Peter; Hutchinson, Peter J.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci,Brain Phys Lab, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland		Zeiler, FA (corresponding author), Univ Manitoba, Dept Surg, Rady Fac Hlth Sci, Winnipeg, MB, Canada.	umzeiler@myumanitoba.ca	Donnelly, Joseph/N-6803-2019; Donnelly, Joseph/E-9235-2018	Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Zeiler, Frederick/0000-0003-1737-0510; czosnyka, marek/0000-0003-2446-8006	Cambridge Commonwealth Trust Scholarship; Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery; University of Manitoba Clinician Investigator Program; R. Samuel McLaughlin Research and Education Award; Manitoba Medical Service Foundation; University of Manitoba Faculty of Medicine Dean's Fellowship Fund; Woolf Fisher Scholarship (New Zealand); National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre; NIHRNational Institute for Health Research (NIHR); European Union Framework Program 7 grant (CENTER-TBI) [602150]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1002277] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013] Funding Source: researchfish	This work was made possible through salary support through the Cambridge Commonwealth Trust Scholarship, the Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery, the University of Manitoba Clinician Investigator Program, R. Samuel McLaughlin Research and Education Award, the Manitoba Medical Service Foundation, and the University of Manitoba Faculty of Medicine Dean's Fellowship Fund.; JD is supported by a Woolf Fisher Scholarship (New Zealand).; These studies were supported by National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award to DKM, and an NIHR Research Professorship to PJAH. Authors were also supported by a European Union Framework Program 7 grant (CENTER-TBI; Grant Agreement No. 602150)	Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2014, NEUROCRIT CARE, V21, P95, DOI 10.1007/s12028-014-0046-0; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; Le Roux P, 2014, NEUROCRIT CARE, V21, P1, DOI 10.1007/s12028-014-0041-5; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Zeiler F.A., 2017, J NEUROTRAUM, DOI DOI 10.1089/neu.2017.5364; Zeiler FA, 2017, J NEUROTRAUM, V34, P3070, DOI 10.1089/neu.2017.5129; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	14	43	43	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2018	35	10					1107	1115		10.1089/neu.2017.5472			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GF8DL	WOS:000432198500001	29241396	Green Submitted			2022-02-06	
J	Ziogas, NK; Koliatsos, VE				Ziogas, Nikolaos K.; Koliatsos, Vassilis E.			Primary Traumatic Axonopathy in Mice Subjected to Impact Acceleration: A Reappraisal of Pathology and Mechanisms with High-Resolution Anatomical Methods	JOURNAL OF NEUROSCIENCE			English	Article						axonopathy; NMNAT2-SARM1; CLARITY; corticospinal tract; traumatic brain injury; 2-photon microscopy	AMYLOID PRECURSOR PROTEIN; BRAIN-INJURY; AXONAL INJURY; WALLERIAN DEGENERATION; ACTIVATION; SARM1; HEAD; MICROGLIA; CLEAVAGE; DAMAGE	Traumatic axonal injury (TAI) is a common neuropathology in traumatic brain injury and is featured by primary injury to axons. Here, wegenerated TAI with impact acceleration of the head in male Thy1-eYFP-H transgenic mice in which specific populations of neurons and their axons are labeled with yellow fluorescent protein. This model results in axonal lesions in multiple axonal tracts along with bloodbrain barrier disruption and neuroinflammation. The corticospinal tract, a prototypical long tract, is severely affected and is the focus of this study. Using optimized CLARITY at single-axon resolution, we visualized the entire corticospinal tract volume from the pons to the cervical spinal cord in 3D and counted the total number of axonal lesions and their progression over time. Our results divulged the presence of progressive traumatic axonopathy that was maximal at the pyramidal decussation. The perikarya of injured corticospinal neurons atrophied, but there was no evidence of neuronal cell death. We also used CLARITY at single-axon resolution to explore the role of the NMNAT2-SARM1 axonal self-destruction pathway in traumatic axonopathy. When we interfered with this pathway by genetically ablating SARM1 or by pharmacological strategies designed to increase levels of Nicotinamide (Nam), a feedback inhibitor of SARM1, we found a significant reduction in the number of axonal lesions early after injury. Our findings show that high-resolution neuroanatomical strategies reveal important features of TAI with biological implications, especially the progressive axonopathic nature of TAI and the role of the NMNAT2-SARM1 pathway in the early stages of axonopathy.	[Ziogas, Nikolaos K.; Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA		Ziogas, NK; Koliatsos, VE (corresponding author), Johns Hopkins Univ, Sch Med, 720 Rutland Ave,Ross Res Bldg,Room 558, Baltimore, MD 21205 USA.	nziogas1@jhmi.edu; koliat@jhmi.edu			Department of DefenseUnited States Department of Defense [W81XWH-14-0396]; State of Maryland TEDCO [2015-MSCRFI-1718]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1EY028039]; Sidran Family Foundation; Spyros N. Lemos Memorial Fund; Johns Hopkins-LIBRA fellowship program; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY028039] Funding Source: NIH RePORTER	This work was supported by Department of Defense W81XWH-14-0396, State of Maryland TEDCO 2015-MSCRFI-1718, National Institutes of Health RO1EY028039, the Sidran Family Foundation, and the Spyros N. Lemos Memorial Fund. N.K.Z. was supported by the Johns Hopkins-LIBRA fellowship program. We thank J. Boyd for advice and invaluable assistance with 2-photon microscopy; J. Ryu and W. Gilliam for breeding of Thy1-eYFP-H/SARM1<SUP>-/-</SUP> mice; T. Omer for assistance with axon counts; K.T. Ramesh and F. Madouh for technical assistance with the impact acceleration device; A. Hoke for supplying SARM1<SUP>-/-</SUP> founders; A. Popratiloff and C. Brantner of the Nanofabrication and Imaging Center of George Washington University for help with 2-photon imaging resources; and all members of the V.E.K. laboratory for feedback and support.	Blackstad TW, 1981, NEUROANATOMICAL TRAC, P1; Bruzzone S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007897; Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267; Capurso SA, 1997, J NEUROSCI, V17, P7372; Carter LM, 2008, J NEUROSCI, V28, P14107, DOI 10.1523/JNEUROSCI.2217-08.2008; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Clatterbuck RE, 1998, NEUROBIOL DIS, V5, P17, DOI 10.1006/nbdi.1998.0181; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248; Essuman K, 2017, NEURON, V93, P1334, DOI 10.1016/j.neuron.2017.02.022; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Finn JT, 2000, J NEUROSCI, V20, P1333; Gerdts J, 2016, NEURON, V89, P449, DOI 10.1016/j.neuron.2015.12.023; Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Gu YZ, 2017, J CELL BIOL, V216, P2179, DOI 10.1083/jcb.201606065; Hanell A, 2015, ACTA NEUROPATHOL, V129, P317, DOI 10.1007/s00401-014-1376-x; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Kobayashi K, 2008, J NEUROSCI, V28, P2892, DOI 10.1523/JNEUROSCI.5589-07.2008; Kobeissy F. H, 2015, BRAIN NEUROTRAUMA MO; Li JR, 2007, BIOMED SCI INSTRUM, V43, P24; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Nahimana A, 2009, BLOOD, V113, P3276, DOI 10.1182/blood-2008-08-173369; National Academy Press, 2011, GUID CAR US LAB AN; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Paxinos G., 2012, PAXINOS FRANKLINS MO; Porrero C, 2010, BRAIN RES, V1345, P59, DOI 10.1016/j.brainres.2010.05.061; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Sasaki Y, 2016, ELIFE, V5, DOI 10.7554/eLife.19749; Sasaki Y, 2009, J NEUROSCI, V29, P6526, DOI 10.1523/JNEUROSCI.1429-09.2009; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Summers DW, 2016, P NATL ACAD SCI USA, V113, pE6271, DOI 10.1073/pnas.1601506113; Szretter KJ, 2009, J VIROL, V83, P9329, DOI 10.1128/JVI.00836-09; Tomer R, 2014, NAT PROTOC, V9, P1682, DOI 10.1038/nprot.2014.123; Van Gool F, 2009, NAT MED, V15, P206, DOI 10.1038/nm.1906; Walker LJ, 2017, ELIFE, V6, DOI 10.7554/eLife.22540; Waller, 1850, PHILOS T R SOC LOND, VI, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021]; Wang JT, 2015, P NATL ACAD SCI USA, V112, P10093, DOI 10.1073/pnas.1508337112; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Weil A, 2013, TXB NEUROPATHOLOGY, P45; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yamada J, 2013, J COMP NEUROL, V521, P1184, DOI 10.1002/cne.23228; Yu FS, 2017, J NEUROTRAUM, V34, P1364, DOI 10.1089/neu.2016.4569; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501	56	43	43	3	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 18	2018	38	16					4031	4047		10.1523/JNEUROSCI.2343-17.2018			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GD5NU	WOS:000430554500014	29567804	Green Published, Bronze			2022-02-06	
J	Chen, XR; Wang, HD; Zhou, ML; Li, X; Fang, ZN; Gao, HZ; Li, YS; Hu, WP				Chen, Xiangrong; Wang, Handong; Zhou, Mengliang; Li, Xiang; Fang, Zhongning; Gao, Hongzhi; Li, Yasong; Hu, Weipeng			Valproic Acid Attenuates Traumatic Brain Injury-Induced Inflammation in Vivo: Involvement of Autophagy and the Nrf2/ARE Signaling Pathway	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						traumatic brain injury; valproic acid; HDAC3; microglia; inflammatory; autophagy; Nrf2/ARE pathway	HEMORRHAGIC-SHOCK; RATS; APOPTOSIS; CELLS; NEUROPROTECTION; NEUROGENESIS; SUPPRESSION; ACTIVATION; INHIBITION; EXPRESSION	Microglial activation and the inflammatory response in the central nervous system (CNS) play important roles in secondary damage after traumatic brain injury (TBI). Transcriptional activation of genes that limit secondary damage to the CNS are mediated by a cis-acting element called the antioxidant responsive element (ARE). ARE is known to associate with the transcription factor NF-E2-related factor 2 (Nrf2), a transcription factor that is associated with histone deacetylases (HDACs). This pathway, known as the Nrf2/ARE pathway, is a critical antioxidative factor pathway that regulates the balance of oxygen free radicals and the inflammatory response, and is also related to autophagic activities. Although valproic acid (VPA) is known to inhibit HDACs, it is unclear whether VPA plays a role in the microglia-mediated neuroinflammatory response after TBI via regulating oxidative stress and autophagy induced by the Nrf2/ARE signaling pathway. In this study, we demonstrate that microglial activation, oxidative stress, autophagy, and the Nrf2/ARE signaling pathway play essential roles in secondary injury following TBI. Treatment with VPA alleviated TBI-induced secondary brain injury, including neurological deficits, cerebral edema, and neuronal apoptosis. Moreover, VPA treatment upregulated the occurrence of autophagy and Nrf2/ARE pathway activity after TBI, and there was an increase in H3, H4 histone acetylation levels, accompanied by decreased transcriptional activity of the HDAC3 promoter in cortical lesions. These results suggest that VPA-mediated up-regulation of autophagy and antioxidative responses are likely due to increased activation of Nrf2/ARE pathway, through direct inhibition of HDAC3. This inhibition further reduces TBI-induced microglial activation and the subsequent inflammatory response, ultimately leading to neuroprotection.	[Chen, Xiangrong; Wang, Handong; Zhou, Mengliang; Li, Xiang] Southern Med Univ, Jinling Hosp, Nanjing Sch Clin Med, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China; [Chen, Xiangrong; Fang, Zhongning; Gao, Hongzhi; Li, Yasong; Hu, Weipeng] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou, Peoples R China		Wang, HD (corresponding author), Southern Med Univ, Jinling Hosp, Nanjing Sch Clin Med, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.	njhdwang@hotmail.com	zhang, chuengji/AAD-4591-2020	Zhou, Meng-liang/0000-0002-1165-5489	Natural Science Foundation of Fujian ProvinceNatural Science Foundation of Fujian Province [2015J01443]; Key Medical Subjects of Jiangsu Province [ZDXKB2016023]	This work was supported by grants from the Natural Science Foundation of Fujian Province (Grant No. 2015J01443) for XC and the Key Medical Subjects of Jiangsu Province (Grant No. ZDXKB2016023).	Bai Y, 2017, EXP BIOL MED, V242, P527, DOI 10.1177/1535370216685433; Bonay M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.256; Cha HY, 2016, CANCER LETT, V372, P65, DOI 10.1016/j.canlet.2015.12.016; Chen S, 2014, NEUROCHEM RES, V39, P1621, DOI 10.1007/s11064-014-1241-2; Chen X., 2017, RNA BIOL, P1, DOI DOI 10.1155/2017/5196958; Chen XR, 2017, J NEUROINFLAMM, V14, DOI [10.1186/s12974-017-0917-3, 10.1186/s12974-018-1151-3]; Chhor V, 2017, BRAIN BEHAV IMMUN, V63, P197, DOI 10.1016/j.bbi.2016.11.001; Chu TC, 2015, REGEN MED, V10, P193, DOI [10.2217/RME.14.86, 10.2217/rme.14.86]; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012; Gao YY, 2017, AM J TRANSL RES, V9, P887; Genet GF, 2017, J NEUROTRAUM, V34, P1054, DOI 10.1089/neu.2016.4574; Guadagno J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.151; He RN, 2015, AUTOPHAGY, V11, P740, DOI 10.1080/15548627.2015.1034404; Hopp S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0815-8; Jang J, 2016, CELL, V165, P410, DOI 10.1016/j.cell.2016.02.014; Ji MM, 2015, AUTOPHAGY, V11, P2160, DOI 10.1080/15548627.2015.1082024; Jin YC, 2016, WORLD NEUROSURG, V88, P433, DOI 10.1016/j.wneu.2015.10.055; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Lastres-Becker I, 2014, BRAIN, V137, P78, DOI 10.1093/brain/awt323; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Nikolian VC, 2018, J TRAUMA ACUTE CARE, V84, P459, DOI 10.1097/TA.0000000000001765; Nikolian VC, 2017, J TRAUMA ACUTE CARE, V83, P1066, DOI 10.1097/TA.0000000000001612; Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889; Penas C, 2011, NEUROSCIENCE, V178, P33, DOI 10.1016/j.neuroscience.2011.01.012; Rajendran P, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0132-y; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Sillesen M, 2016, J TRAUMA ACUTE CARE, V80, P26, DOI 10.1097/TA.0000000000000896; Sinha SP, 2017, BRAIN BEHAV IMMUN, V61, P353, DOI 10.1016/j.bbi.2017.01.006; Suda S, 2015, BRAIN RES, V1606, P1, DOI 10.1016/j.brainres.2015.02.013; Sun Z, 2009, MOL CELL BIOL, V29, P2658, DOI 10.1128/MCB.01639-08; Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133; Tang CH, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/2923182; Vlahakis A, 2017, AUTOPHAGY, V13, P1256, DOI 10.1080/15548627.2017.1299314; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wasik U, 2017, SCI REP-UK, V7, DOI 10.1038/srep44769; Wilson CB, 2014, BEHAV BRAIN RES, V268, P72, DOI 10.1016/j.bbr.2014.03.029; Xue F, 2016, BEHAV BRAIN RES, V309, P1, DOI 10.1016/j.bbr.2016.04.045; Yan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084116; Yang XY, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00131; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46763; Zhang RR, 2017, MOL NEUROBIOL, V54, P6006, DOI 10.1007/s12035-016-0111-0; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.292; Zou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087915	49	43	46	1	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	APR 17	2018	11								117	10.3389/fnmol.2018.00117			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GD0WQ	WOS:000430222100001	29719500	gold, Green Published			2022-02-06	
J	Lee, SW; Gajavelli, S; Spurlock, MS; Andreoni, C; Vaccari, JPD; Bullock, MR; Keane, RW; Dietrich, WD				Lee, Stephanie W.; Gajavelli, Shyam; Spurlock, Markus S.; Andreoni, Cody; Vaccari, Juan Pablo de Rivero; Bullock, M. Ross; Keane, Robert W.; Dietrich, W. Dalton			Microglial Inflammasome Activation in Penetrating Ballistic-Like Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						inflammasome; microglia; penetrating ballistic-like brain injury; penetrating traumatic brain injury	INNATE IMMUNE-RESPONSE; NLRP3 INFLAMMASOME; CELL-DEATH; LOADING CONTROL; TOTAL PROTEIN; CEREBROSPINAL-FLUID; GUNSHOT WOUNDS; UNITED-STATES; GASDERMIN D; BETA-ACTIN	Penetrating traumatic brain injury (PTBI) is a significant cause of death and disability in the United States. Inflammasomes are one of the key regulators of the interleukin (IL)-1 beta mediated inflammatory responses after traumatic brain injury. However, the contribution of inflammasome signaling after PTBI has not been determined. In this study, adult male Sprague-Dawley rats were subjected to sham procedures or penetrating ballistic-like brain injury (PBBI) and sacrificed at various time-points. Tissues were assessed by immunoblot analysis for expression of IL-1 beta, IL-18, and components of the inflammasome: apoptosis-associated speck-like protein containing a caspase-activation and recruitment domain (ASC), caspase-1, X-linked inhibitor of apoptosis protein (XIAP), nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3), and gasdermin-D (GSDMD). Specific cell types expressing inflammasome proteins also were evaluated immunohistochemically and assessed quantitatively. After PBBI, expression of IL-1 beta, IL-18, caspase-1, ASC, XIAP, and NLRP3 peaked around 48 h. Brain protein lysates from PTBI animals showed pyroptosome formation evidenced by ASC laddering, and also contained increased expression of GSDMD at 48 h after injury. ASC-positive immunoreactive neurons within the perilesional cortex were observed at 24 h. At 48 h, ASC expression was concentrated in morphologically activated cortical microglia. This expression of ASC in activated microglia persisted until 12 weeks following PBBI. This is the first report of inflammasome activation after PBBI. Our results demonstrate cell-specific patterns of inflammasome activation and pyroptosis predominantly in microglia, suggesting a sustained pro-inflammatory state following PBBI, thus offering a therapeutic target for this type of brain injury.	[Lee, Stephanie W.; Gajavelli, Shyam; Spurlock, Markus S.; Andreoni, Cody; Vaccari, Juan Pablo de Rivero; Bullock, M. Ross; Keane, Robert W.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace,LPLC 2-30, Miami, FL 33136 USA.	ddietrich@med.miami.edu	de Rivero Vaccari, Juan Pablo/ABE-3248-2020; de Rivero Vaccari, Juan Pablo/H-5718-2019; Gajavelli, Shyam/AAI-1374-2019	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; Gajavelli, Shyam/0000-0002-5947-6973	NIH NINDS awardsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS089443, RO1 NS042133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, R01NS089443] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD023579] Funding Source: NIH RePORTER	NIH NINDS awards R01 NS089443 and RO1 NS042133. The authors wish to thank Deborah Shear and Walter Reed Army Research Institute for providing the PBBI apparatus; Melissa Carballosa-Gautam and Pantelis Tsoulfas for confocal microscopy training, and Karla N. Rivera and Michael Kaplan for immunohistochemistry and immunoblotting support for this study.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Beaman V, 2000, ANN EMERG MED, V35, P258, DOI 10.1016/S0196-0644(00)70077-1; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bruns J., 2003, EPILEPSIA, V44, pS2; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Cartagena CM, 2013, NEUROMOL MED, V15, P504, DOI 10.1007/s12017-013-8236-z; Cartagena CM, 2013, J MOL NEUROSCI, V49, P301, DOI 10.1007/s12031-012-9828-z; Chen W, 2015, ELECTROPHORESIS, V36, P2046, DOI 10.1002/elps.201500138; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Davis A E, 2000, Crit Care Nurs Q, V23, P1; de Lanerolle NC, 2015, SEMIN NEUROL, V35, P12, DOI 10.1055/s-0035-1544240; de Rivero Vaccari J.P., 2015, J NEUROCHEM, V136, pS39; Djukic M, 2006, BRAIN, V129, P2394, DOI 10.1093/brain/awl206; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Du L, 2017, MOL NEUROBIOL, V54, P7567, DOI 10.1007/s12035-016-0245-0; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Fann DYW, 2013, AGEING RES REV, V12, P941, DOI 10.1016/j.arr.2013.09.004; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Gajavelli S, 2015, J CEREBR BLOOD F MET, V35, P773, DOI 10.1038/jcbfm.2014.243; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Gilda JE, 2015, METHODS MOL BIOL, V1295, P381, DOI 10.1007/978-1-4939-2550-6_27; Gilda JE, 2013, ANAL BIOCHEM, V440, P186, DOI 10.1016/j.ab.2013.05.027; Gressot LV, 2014, J NEUROSURG, V121, P645, DOI 10.3171/2014.5.JNS131872; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hanisch UK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00065; He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139; Hellwig S, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00071; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Ji KA, 2007, GLIA, V55, P1577, DOI 10.1002/glia.20571; Joseph B, 2014, J AM COLL SURGEONS, V218, P58, DOI 10.1016/j.jamcollsurg.2013.08.018; Kabba J. A., 2017, CELL MOL NEUROBIOL, P1; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Khan MB, 2014, WORLD NEUROSURG, V82, P14, DOI 10.1016/j.wneu.2013.01.026; Lin DJ., 2012, SURG NEUROL INT, V3, P98, DOI [DOI 10.4103/2152-7806, 10.4103/2152-7806.100187, DOI 10.4103/2152-7806.100187]; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Oehmichen Manfred, 2009, Leg Med (Tokyo), V11 Suppl 1, pS50, DOI 10.1016/j.legalmed.2009.01.113; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; Pruitt BA, 2001, J TRAUMA, V51, pS1, DOI 10.1097/00005373-200108001-00001; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Sarkar S, 2017, NPJ PARKINSON DIS, V3, DOI 10.1038/s41531-017-0032-2; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Taabazuing CY, 2017, CELL CHEM BIOL, V24, P507, DOI 10.1016/j.chembiol.2017.03.009; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Thacker JS, 2016, ANAL BIOCHEM, V496, P76, DOI 10.1016/j.ab.2015.11.022; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Torres-Platas SG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-12; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Venegas C, 2017, NATURE, V552, P355, DOI 10.1038/nature25158; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang S.J., 2017, CELL MOL NEUROBIOL, V265, P22; Yao CP, 2008, BRAIN INJURY, V22, P723, DOI 10.1080/02699050802304706; Zhou Y, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0094-3	81	43	45	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1681	1693		10.1089/neu.2017.5530		APR 2018	13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000428879200001	29439605	Green Published			2022-02-06	
J	Maki, T; Morancho, A; Segundo, PMS; Hayakawa, K; Takase, H; Liang, AC; Gabriel-Salazar, M; Medina-Gutierrez, E; Washida, K; Montaner, J; Lok, J; Lo, EH; Arai, K; Rosell, A				Maki, Takakuni; Morancho, Anna; Martinez-San Segundo, Pablo; Hayakawa, Kazuhide; Takase, Hajime; Liang, Anna C.; Gabriel-Salazar, Marina; Medina-Gutierrez, Esperanza; Washida, Kazuo; Montaner, Joan; Lok, Josephine; Lo, Eng H.; Arai, Ken; Rosell, Anna			Endothelial Progenitor Cell Secretome and Oligovascular Repair in a Mouse Model of Prolonged Cerebral Hypoperfusion	STROKE			English	Article						angiogenin; carotid stenosis; endothelial progenitor cell; repair; white matter	TRAUMATIC BRAIN-INJURY; WHITE-MATTER LESIONS; ISCHEMIC-STROKE; ANGIOGENIN; STEM; GROWTH; TRANSPLANTATION; CANCER; MICE; OLIGODENDROCYTE	Background and Purpose-Endothelial progenitor cells (EPCs) have been extensively investigated as a therapeutic approach for repairing the vascular system in cerebrovascular diseases. Beyond vascular regeneration per se, EPCs may also release factors that affect the entire neurovascular unit. Here, we aim to study the effects of the EPC secretome on oligovascular remodeling in a mouse model of white matter injury after prolonged cerebral hypoperfusion. Methods-The secretome of mouse EPCs was analyzed with a proteome array. In vitro, the effects of the EPC secretome and its factor angiogenin were assessed on primary oligodendrocyte precursor cells and mature human cerebral microvascular endothelial cells (hCMED/D3). In vivo, mice were subjected to permanent bilateral common carotid artery stenosis, then treated with EPC secretome at 24 hours and at 1 week, and cognitive outcome was evaluated with the Y maze test together with oligodendrocyte precursor cell proliferation/differentiation and vascular density in white matter at 4 weeks. Results-Multiple growth factors, cytokines, and proteases were identified in the EPC secretome, including angiogenin. In vitro, the EPC secretome significantly enhanced endothelial and oligodendrocyte precursor cell proliferation and potentiated oligodendrocyte precursor cell maturation. Angiogenin was proved to be a key factor since pharmacological blockade of angiogenin signaling negated the positive effects of the EPC secretome. In vivo, treatment with the EPC secretome increased vascular density, myelin, and mature oligodendrocytes in white matter and rescued cognitive function in the mouse hypoperfusion model. Conclusions-Factors secreted by EPCs may ameliorate white matter damage in the brain by boosting oligovascular remodeling.	[Maki, Takakuni; Hayakawa, Kazuhide; Takase, Hajime; Liang, Anna C.; Washida, Kazuo; Lok, Josephine; Lo, Eng H.; Arai, Ken] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, 149 13th St, Charlestown, MA 02129 USA; [Maki, Takakuni; Hayakawa, Kazuhide; Takase, Hajime; Liang, Anna C.; Washida, Kazuo; Lok, Josephine; Lo, Eng H.; Arai, Ken] Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, 149 13th St, Charlestown, MA 02129 USA; [Maki, Takakuni; Hayakawa, Kazuhide; Takase, Hajime; Liang, Anna C.; Washida, Kazuo; Lok, Josephine; Lo, Eng H.; Arai, Ken] Harvard Med Sch, 149 13th St, Charlestown, MA 02129 USA; [Morancho, Anna; Martinez-San Segundo, Pablo; Gabriel-Salazar, Marina; Medina-Gutierrez, Esperanza; Montaner, Joan; Rosell, Anna] Univ Autonoma Barcelona, Neurovasc Res Lab, Vall dHebron Res Inst, Barcelona, Spain		Arai, K (corresponding author), Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, 149 13th St, Charlestown, MA 02129 USA.; Arai, K (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, 149 13th St, Charlestown, MA 02129 USA.; Arai, K (corresponding author), Harvard Med Sch, 149 13th St, Charlestown, MA 02129 USA.; Rosell, A (corresponding author), Vall dHebron Res Inst, Neurovasc Res Lab, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.	karai@partners.org; anna.rosell@vhir.org	Montaner, Joan/D-3063-2015; 眞木, 崇州/AAO-1160-2020; Retana, Anna Morancho/K-8804-2014	Montaner, Joan/0000-0003-4845-2279; Retana, Anna Morancho/0000-0001-9059-3206; Rosell Novel, Anna/0000-0003-1082-3599	Miguel Servet program [CPII15/00003]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission; European Regional Development FundsEuropean Commission [PI13/01094, PI16/00981, RD12/0014/0005]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS065089, P201-NS055104]; Uehara Memorial FoundationUehara Memorial Foundation; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS093415, R01NS065089, P01NS055104] Funding Source: NIH RePORTER	This work has been supported by the Miguel Servet program to Dr Rosell (CPII15/00003), by research grants from Instituto de Salud Carlos III with European Regional Development Funds (PI13/01094, PI16/00981, and RD12/0014/0005), by the National Institutes of Health (NIH; R01-NS065089, P201-NS055104), by the Uehara Memorial Foundation, and by the Japan Society for the Promotion of Science.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bai L, 2012, NAT NEUROSCI, V15, P862, DOI 10.1038/nn.3109; Bai YY, 2015, STROKE, V46, P1938, DOI 10.1161/STROKEAHA.114.008495; Bain JM, 2013, TRANSL STROKE RES, V4, P158, DOI 10.1007/s12975-012-0213-6; Barcena C, 2015, SCI REP-UK, V5, DOI 10.1038/srep07916; Carenza E, 2014, ACTA BIOMATER, V10, P3775, DOI 10.1016/j.actbio.2014.04.010; Cho GW, 2010, MOL CELL BIOCHEM, V340, P133, DOI 10.1007/s11010-010-0410-0; Di Santo S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095731; Di Santo S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005643; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Friedrich EB, 2006, CIRC RES, V98, pE20, DOI 10.1161/01.RES.0000205765.28940.93; Gao XW, 2008, ACTA BIOCH BIOPH SIN, V40, P619, DOI 10.1111/j.1745-7270.2008.00442.x; Garbuzova-Davis S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031254; Goncalves KA, 2016, CELL, V166, P894, DOI 10.1016/j.cell.2016.06.042; Gordon D, 2010, J NEUROPATH EXP NEUR, V69, P1087, DOI 10.1097/NEN.0b013e3181f97392; Hayakawa K, 2011, J NEUROSCI, V31, P10666, DOI 10.1523/JNEUROSCI.1944-11.2011; He TR, 2005, AM J PHYSIOL-HEART C, V289, pH968, DOI 10.1152/ajpheart.01166.2004; Horie N, 2011, STEM CELLS, V29, P274, DOI 10.1002/stem.584; Hu GF, 1998, P NATL ACAD SCI USA, V95, P9791, DOI 10.1073/pnas.95.17.9791; Ibaragi S, 2009, CLIN CANCER RES, V15, P1981, DOI 10.1158/1078-0432.CCR-08-2593; Ihara M, 2014, METHODS MOL BIOL, V1135, P95, DOI 10.1007/978-1-4939-0320-7_8; Jadasz JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071814; Kim SU, 2009, J NEUROSCI RES, V87, P2183, DOI 10.1002/jnr.22054; Le Bras B, 2006, NAT NEUROSCI, V9, P340, DOI 10.1038/nn1646; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Maki T, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00275; Maki T, 2011, STROKE, V42, P1122, DOI 10.1161/STROKEAHA.110.603399; McQueen J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087227; Miyamoto N, 2015, J NEUROSCI, V35, P14002, DOI 10.1523/JNEUROSCI.1592-15.2015; Miyamoto N, 2014, CELL MOL LIFE SCI, V71, P1055, DOI 10.1007/s00018-013-1488-9; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Morancho A, 2015, J CEREBR BLOOD F MET, V35, P1547, DOI 10.1038/jcbfm.2015.180; Morancho A, 2013, J CELL MOL MED, V17, P1543, DOI 10.1111/jcmm.12116; Moubarik C, 2011, STEM CELL REV REP, V7, P208, DOI 10.1007/s12015-010-9157-y; Napoli E, 2016, TRANSL STROKE RES, V7, P452, DOI 10.1007/s12975-016-0490-6; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Park KJ, 2014, J CEREBR BLOOD F MET, V34, P357, DOI 10.1038/jcbfm.2013.216; Reimer MM, 2011, J NEUROSCI, V31, P18185, DOI 10.1523/JNEUROSCI.4936-11.2011; Rosell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073244; Sebastia J, 2009, CELL DEATH DIFFER, V16, P1238, DOI 10.1038/cdd.2009.52; Shibata M, 2004, STROKE, V35, P2598, DOI 10.1161/01.STR.0000143725.19053.60; Shibata M, 2007, STROKE, V38, P2826, DOI 10.1161/STROKEAHA.107.490151; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tajiri N, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00116; Thiyagarajan N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2126; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Yang ZJ, 2010, ATHEROSCLEROSIS, V211, P103, DOI 10.1016/j.atherosclerosis.2010.02.022; Yoshioka N, 2006, P NATL ACAD SCI USA, V103, P14519, DOI 10.1073/pnas.0606708103; Zhang J, 2013, EXPERT OPIN BIOL TH, V13, P1229, DOI 10.1517/14712598.2013.804507; Zhang RL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00201; Zhang YQ, 2013, J SURG RES, V185, P441, DOI 10.1016/j.jss.2013.05.073	51	43	43	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	2018	49	4					1003	+		10.1161/STROKEAHA.117.019346			21	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	GB6BW	WOS:000429153900042	29511131	Green Accepted, Bronze			2022-02-06	
J	Beker, MC; Caglayan, B; Yalcin, E; Caglayan, AB; Turkseven, S; Gurel, B; Kelestemur, T; Sertel, E; Sahin, Z; Kutlu, S; Kilic, U; Baykal, AT; Kilic, E				Beker, Mustafa Caglar; Caglayan, Berrak; Yalcin, Esra; Caglayan, Ahmet Burak; Turkseven, Seyma; Gurel, Busra; Kelestemur, Taha; Sertel, Elif; Sahin, Zafer; Kutlu, Selim; Kilic, Ulkan; Baykal, Ahmet Tarik; Kilic, Ertugrul			Time-of-Day Dependent Neuronal Injury After Ischemic Stroke: Implication of Circadian Clock Transcriptional Factor Bmal1 and Survival Kinase AKT	MOLECULAR NEUROBIOLOGY			English	Article						Circadian rhythm; Cerebral ischemia; Proteomics; Akt signaling; PI3K; Bmal1	FOCAL CEREBRAL-ISCHEMIA; HYPOXIA-INDUCIBLE FACTOR; TRAUMATIC BRAIN-INJURY; PROTEIN BMAL1; MECHANISMS; EXPRESSION; PATHWAY; GROWTH; RAT; METABOLISM	Occurrence of stroke cases displays a time-of-day variation in human. However, the mechanism linking circadian rhythm to the internal response mechanisms against pathophysiological events after ischemic stroke remained largely unknown. To this end, temporal changes in the susceptibility to ischemia/reperfusion (I/R) injury were investigated in mice in which the ischemic stroke induced at four different Zeitgeber time points with 6-h intervals (ZT0, ZT6, ZT12, and ZT18). Besides infarct volume and brain swelling, neuronal survival, apoptosis, ischemia, and circadian rhythm related proteins were examined using immunohistochemistry, Western blot, planar surface immune assay, and liquid chromatography-mass spectrometry tools. Here, we present evidence that midnight (ZT18; 24:00) I/R injury in mice resulted in significantly improved infarct volume, brain swelling, neurological deficit score, neuronal survival, and decreased apoptotic cell death compared with ischemia induced at other time points, which were associated with increased expressions of circadian proteins Bmal1, PerI, and Clock proteins and survival kinases AKT and Erk-1/2. Moreover, ribosomal protein S6, mTOR, and Bad were also significantly increased, while the levels of PRAS40, negative regulator of AKT and mTOR, and phosphorylated p53 were decreased at this time point compared to ZT0 (06:00). Furthermore, detailed proteomic analysis revealed significantly decreased CSKP, HBB-1/2, and HBA levels, while increased GNAZ, NEGR1, IMPCT, and PDE1B at midnight as compared with early morning. Our results indicate that nighttime I/R injury results in less severe neuronal damage, with increased neuronal survival, increased levels of survival kinases and circadian clock proteins, and also alters the circadian-related proteins.	[Beker, Mustafa Caglar; Caglayan, Berrak; Yalcin, Esra; Caglayan, Ahmet Burak; Turkseven, Seyma; Gurel, Busra; Kelestemur, Taha; Sertel, Elif; Kilic, Ulkan; Kilic, Ertugrul] Istanbul Medipol Univ, Regenerat & Restorat Med Res Ctr, Ekinciler Cad 19, TR-34810 Istanbul, Turkey; [Beker, Mustafa Caglar; Caglayan, Berrak; Yalcin, Esra; Caglayan, Ahmet Burak; Kelestemur, Taha; Sertel, Elif; Kilic, Ertugrul] Istanbul Medipol Univ, Dept Physiol, TR-34810 Istanbul, Turkey; [Beker, Mustafa Caglar; Caglayan, Ahmet Burak; Kelestemur, Taha; Kutlu, Selim] Necmettin Erbakan Univ, Dept Physiol, TR-42060 Konya, Turkey; [Gurel, Busra; Baykal, Ahmet Tarik] Acibadem Univ, Sch Med, Dept Med Biochem, TR-34752 Istanbul, Turkey; [Sahin, Zafer] Necmettin Erbakan Univ, Dept Physiotherapy & Rehabil, TR-42060 Konya, Turkey		Kilic, E (corresponding author), Istanbul Medipol Univ, Regenerat & Restorat Med Res Ctr, Ekinciler Cad 19, TR-34810 Istanbul, Turkey.; Kilic, E (corresponding author), Istanbul Medipol Univ, Dept Physiol, TR-34810 Istanbul, Turkey.	ekilic@medipol.edu.tr	Sahin, Zafer/ABD-5367-2020; Kilic, Ertugrul/W-4563-2018; Beker, Mustafa Caglar/ABH-2222-2020; Gurel, Busra/AAD-6244-2020; Baykal, Ahmet T/C-3948-2013; Kutlu, Selim/AAQ-5501-2021; Beker, Mustafa/AAR-8731-2021	Sahin, Zafer/0000-0001-7982-7155; Kilic, Ertugrul/0000-0001-6494-8923; Baykal, Ahmet T/0000-0002-8814-7351; Kutlu, Selim/0000-0001-9257-4797; Beker, Mustafa/0000-0002-9476-8488; Yalcin, Esra/0000-0002-1064-7989; Kelestemur, Taha/0000-0003-3616-1204; Gurel, Busra/0000-0001-9779-1467; caglayan, ahmet burak/0000-0002-6242-3709; Caglayan, Berrak/0000-0002-5072-132X	Necmettin Erbakan UniversityNecmettin Erbakan University [161330001]; Turkish Academy of Sciences (TUBA)Turkish Academy of Sciences	This study was supported by The Turkish Academy of Sciences (TUBA) and Necmettin Erbakan University (Scientific Research Project: 161330001).	Abe M, 2002, J NEUROSCI, V22, P350, DOI 10.1523/JNEUROSCI.22-01-00350.2002; Acioglu C, 2016, BRAIN BEHAV IMMUN, V56, P310, DOI 10.1016/j.bbi.2016.03.027; Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Beker MC, 2015, ONCOTARGET, V6, P30604, DOI 10.18632/oncotarget.5773; Bele T, 2016, J NEUROCHEM, V138, P587, DOI 10.1111/jnc.13680; Boone DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046204; Chang AM, 2012, J PHYSIOL-LONDON, V590, P3103, DOI 10.1113/jphysiol.2011.226555; Dlaboga D, 2008, NEUROPHARMACOLOGY, V54, P745, DOI 10.1016/j.neuropharm.2007.12.002; Elliott WJ, 1998, STROKE, V29, P992, DOI 10.1161/01.STR.29.5.992; Fahrenkrug J, 2008, J NEUROENDOCRINOL, V20, P323, DOI 10.1111/j.1365-2826.2008.01651.x; Fodor Dana Marieta, 2014, Clujul Med, V87, P242, DOI 10.15386/cjmed-328; Hacariz O, 2014, PROTEOMICS, V14, P1519, DOI 10.1002/pmic.201400012; Hata Y, 1996, J NEUROSCI, V16, P2488; He YD, 2010, TRANSL STROKE RES, V1, P48, DOI 10.1007/s12975-009-0004-x; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Ho MKC, 2001, ONCOGENE, V20, P1615, DOI 10.1038/sj.onc.1204190; Hultman R, 2014, MOL CELL NEUROSCI, V58, P53, DOI 10.1016/j.mcn.2013.12.004; Karatsoreos IN, 2011, P NATL ACAD SCI USA, V108, P1657, DOI 10.1073/pnas.1018375108; Khapre RV, 2011, CELL CYCLE, V10, P4162, DOI 10.4161/cc.10.23.18381; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kilic E, 2010, J CEREBR BLOOD F MET, V30, P969, DOI 10.1038/jcbfm.2009.268; Kim H, 2017, BIOCHEM BIOPH RES CO, V482, P1367, DOI 10.1016/j.bbrc.2016.12.043; Ko ML, 2009, J NEUROCHEM, V108, P1607, DOI 10.1111/j.1471-4159.2009.05931.x; Koh PO, 2012, NEUROSCI LETT, V507, P156, DOI 10.1016/j.neulet.2011.12.012; Kohsaka A, 2007, TRENDS ENDOCRIN MET, V18, P4, DOI 10.1016/j.tem.2006.11.005; Kondratov RV, 2009, AGING-US, V1, P979, DOI 10.18632/aging.100113; KUBOTA K, 1987, STROKE, V18, P812, DOI 10.1161/str.18.4.812b; Kunz A, 2010, BEST PRACT RES-CLIN, V24, P495, DOI 10.1016/j.bpa.2010.10.001; Mander BA, 2015, NAT NEUROSCI, V18, P1051, DOI 10.1038/nn.4035; Manev H, 1998, J Stroke Cerebrovasc Dis, V7, P165, DOI 10.1016/S1052-3057(98)80002-5; Meng He, 2008, J Circadian Rhythms, V6, P9, DOI 10.1186/1740-3391-6-9; Nafzger S, 2017, CELL CALCIUM, V61, P10, DOI 10.1016/j.ceca.2016.10.001; Okamura H, 2002, CELL TISSUE RES, V309, P47, DOI 10.1007/s00441-002-0572-5; Paranjpe Dhanashree A, 2005, J Circadian Rhythms, V3, P7, DOI 10.1186/1740-3391-3-7; Pardiwalla F K, 1993, J Assoc Physicians India, V41, P203; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Razorenova OV, 2012, CELL CYCLE, V11, P213, DOI 10.4161/cc.11.2.18786; Roenneberg T, 2002, CELL TISSUE RES, V309, P3, DOI 10.1007/s00441-002-0568-1; Roffe M, 2013, J BIOL CHEM, V288, P10860, DOI 10.1074/jbc.M113.461970; Sattlegger E, 2011, J BIOL CHEM, V286, P10341, DOI 10.1074/jbc.M110.171587; Serhatli M, 2014, J PROTEOME RES, V13, P5071, DOI 10.1021/pr5006586; Sharp FR, 2001, ADV EXP MED BIOL, V502, P273; Soddu A, 2017, NEUROLOGY, V88, P226, DOI 10.1212/WNL.0000000000003529; Spudich A, 2006, NAT NEUROSCI, V9, P487, DOI 10.1038/nn1676; Srivastava S, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0295-6; Tischkau SA, 2007, EXP NEUROL, V208, P314, DOI 10.1016/j.expneurol.2007.09.003; Turin TC, 2012, ACTA NEUROL SCAND, V125, P206, DOI 10.1111/j.1600-0404.2011.01522.x; Vinall PE, 2000, J NEUROSURG, V93, P82, DOI 10.3171/jns.2000.93.1.0082; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yamamoto T, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-18; Yan J, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000193; Zheng XZ, 2010, CURR BIOL, V20, P1203, DOI 10.1016/j.cub.2010.05.027; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	55	43	44	1	14	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAR	2018	55	3					2565	2576		10.1007/s12035-017-0524-4			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FY5TG	WOS:000426897800060	28421530				2022-02-06	
J	Cole, JH; Jolly, A; de Simoni, S; Bourke, N; Patel, MC; Scott, G; Sharp, DJ				Cole, James H.; Jolly, Amy; de Simoni, Sara; Bourke, Niall; Patel, Maneesh C.; Scott, Gregory; Sharp, David J.			Spatial patterns of progressive brain volume loss after moderate-severe traumatic brain injury	BRAIN			English	Article						traumatic brain injury; voxel-based morphometry; longitudinal; neurodegeneration; brain atrophy	TENSOR-BASED MORPHOMETRY; WHITE-MATTER INJURY; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; LONGITUDINAL CHANGES; DIFFUSION-TENSOR; ATROPHY RATES; FOLLOW-UP; TAU-PET; MILD	Traumatic brain injury leads to significant loss of brain volume, which continues into the chronic stage. This can be sensitively measured using volumetric analysis of MRI. Here we: (i) investigated longitudinal patterns of brain atrophy; (ii) tested whether atrophy is greatest in sulcal cortical regions; and (iii) showed how atrophy could be used to power intervention trials aimed at slowing neurodegeneration. In 61 patients with moderate-severe traumatic brain injury (mean age = 41.55 years +/- 12.77) and 32 healthy controls (mean age = 34.22 years +/- 10.29), cross-sectional and longitudinal (1-year follow-up) brain structure was assessed using voxel-based morphometry on T1-weighted scans. Longitudinal brain volume changes were characterized using a novel neuroimaging analysis pipeline that generates a Jacobian determinant metric, reflecting spatial warping between baseline and follow-up scans. Jacobian determinant values were summarized regionally and compared with clinical and neuropsychological measures. Patients with traumatic brain injury showed lower grey and white matter volume in multiple brain regions compared to controls at baseline. Atrophy over 1 year was pronounced following traumatic brain injury. Patients with traumatic brain injury lost a mean (+/- standard deviation) of 1.55% +/- 2.19 of grey matter volume per year, 1.49% +/- 2.20 of white matter volume or 1.51% +/- 1.60 of whole brain volume. Healthy controls lost 0.55% +/- 1.13 of grey matter volume and gained 0.26% +/- 1.11 of white matter volume; equating to a 0.22% +/- 0.83 reduction in whole brain volume. Atrophy was greatest in white matter, where the majority (84%) of regions were affected. This effect was independent of and substantially greater than that of ageing. Increased atrophy was also seen in cortical sulci compared to gyri. There was no relationship between atrophy and time since injury or age at baseline. Atrophy rates were related to memory performance at the end of the follow-up period, as well as to changes in memory performance, prior to multiple comparison correction. In conclusion, traumatic brain injury results in progressive loss of brain tissue volume, which continues for many years postinjury. Atrophy is most prominent in the white matter, but is also more pronounced in cortical sulci compared to gyri. These findings suggest the Jacobian determinant provides a method of quantifying brain atrophy following a traumatic brain injury and is informative in determining the long-term neurodegenerative effects after injury. Power calculations indicate that Jacobian determinant images are an efficient surrogate marker in clinical trials of neuroprotective therapeutics.	[Cole, James H.; Jolly, Amy; de Simoni, Sara; Bourke, Niall; Patel, Maneesh C.; Scott, Gregory; Sharp, David J.] Imperial Coll London, Computat Cognit & Clin Neuroimaging Lab, Div Brain Sci, Hammersmith Hosp, London, England		Cole, JH (corresponding author), Imperial Coll London, Computat Cognit & Clin Neuroimaging Lab, Hammersmith Hosp, 3rd Floor Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	james.cole@imperial.ac.uk	Sharp, David J/A-2119-2013; Cole, James H/I-5197-2019	Cole, James H/0000-0003-1908-5588; Scott, Gregory/0000-0001-8063-5871; Jolly, Amy/0000-0002-7413-9772	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/L022141/1]; Imperial College London National Institute of Health (NIHR) Biomedical Research Centre; National Institute of Health Research Professorship [RP-011-048]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [1769568, MR/L022141/1] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1769568] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	J.H.C. is funded by a research grant to Imperial College London from the Medical Research Council (MR/L022141/1). D.J.S. has a National Institute of Health Research Professorship: RP-011-048. The work was also supported by the Imperial College London National Institute of Health (NIHR) Biomedical Research Centre.	Ashburner J., 2000, NEUROIMAGE, V11, pS465, DOI [10.1016/S1053-8119(00)91396-X, DOI 10.1016/S1053-8119(00)91396-X]; Ashburner J, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00197; Beckett LA, 2000, STAT MED, V19, P1469, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1469::AID-SIM439>3.0.CO;2-J; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bonner-Jackson A, 2013, J INT NEUROPSYCH SOC, V19, P739, DOI 10.1017/S1355617713000507; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Brezova V, 2014, NEUROIMAGE-CLIN, V5, P128, DOI 10.1016/j.nicl.2014.03.012; Cash DM, 2015, NEUROIMAGE, V123, P149, DOI 10.1016/j.neuroimage.2015.07.087; Cash David M, 1800, Alzheimers Res Ther, V6, P87, DOI 10.1186/s13195-014-0087-9; CHEVAN A, 1991, AM STAT, V45, P90, DOI 10.2307/2684366; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Green REA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00067; Gutman BA, 2015, NEUROBIOL AGING, V36, pS69, DOI 10.1016/j.neurobiolaging.2014.05.038; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Holmes HE, 2016, NEUROBIOL AGING, V39, P184, DOI 10.1016/j.neurobiolaging.2015.12.001; Hua X, 2016, NEUROBIOL AGING, V37, P26, DOI 10.1016/j.neurobiolaging.2015.09.018; Hua X, 2010, NEUROIMAGE, V51, P63, DOI 10.1016/j.neuroimage.2010.01.104; Hua X, 2009, NEUROIMAGE, V48, P668, DOI 10.1016/j.neuroimage.2009.07.011; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kim J, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00052; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Landman BA, 2011, NEUROIMAGE, V54, P2854, DOI 10.1016/j.neuroimage.2010.11.047; LaPoint MR, 2017, NEUROIMAGE, V157, P612, DOI 10.1016/j.neuroimage.2017.05.049; Leow AD, 2009, NEUROIMAGE, V45, P645, DOI 10.1016/j.neuroimage.2009.01.004; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Maass A, 2017, NEUROIMAGE, V157, P448, DOI 10.1016/j.neuroimage.2017.05.058; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Rohrer JD, 2011, BRAIN, V134, P2565, DOI 10.1093/brain/awr198; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Sarro L, 2016, BRAIN, V139, P2740, DOI 10.1093/brain/aww193; Scahill RI, 2002, P NATL ACAD SCI USA, V99, P4703, DOI 10.1073/pnas.052587399; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sluimer JD, 2008, NEUROLOGY, V70, P1836, DOI 10.1212/01.wnl.0000311446.61861.e3; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Tomaiuolo F, 2012, BRAIN RES BULL, V87, P373, DOI 10.1016/j.brainresbull.2012.01.008; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Vannorsdall TD, 2010, J NEUROPSYCH CLIN N, V22, P173, DOI 10.1176/appi.neuropsych.22.2.173; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	72	43	44	3	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2018	141		3				822	836		10.1093/brain/awx354			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FY4RP	WOS:000426813600026	29309542	hybrid, Green Published			2022-02-06	
J	Bree, D; Levy, D				Bree, Dara; Levy, Dan			Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: Implications for mechanisms of post-traumatic headache	CEPHALALGIA			English	Article						Cephalic allodynia; conditioned place preference; sumatriptan; Anti-CGRP monoclonal antibody	TRAUMATIC BRAIN-INJURY; DOUBLE-BLIND; PREVENTIVE TREATMENT; EPISODIC MIGRAINE; DURAL AFFERENTS; UP-REGULATION; SUMATRIPTAN; EFFICACY; SAFETY; PATHOPHYSIOLOGY	Background and objective Posttraumatic headache (PTH) is one of the most common, debilitating and difficult symptoms to manage after a mild traumatic brain injury, or concussion. However, the mechanisms underlying PTH remain elusive, in part due to the lack of a clinically relevant animal model. Here, we characterized for the first time, headache and pain-related behaviours in a rat model of concussion evoked by a mild closed head injury (mCHI) - the major type of military and civilian related trauma associated with PTH - and tested responses to current and novel headache therapies. Methods Concussion was induced in adult male rats using a weight-drop device. Characterization of headache and pain related behaviours included assessment of cutaneous tactile pain sensitivity, using von Frey monofilaments, and ongoing pain using the conditioned place preference or aversion (CPP/CPA) paradigms. Sensitivity to headache/migraine triggers was tested by exposing rats to low-dose glyceryl trinitrate (GTN). Treatments included acute systemic administration of sumatriptan and chronic systemic administration of a mouse anti-CGRP monoclonal antibody. Results Concussed rats developed cephalic tactile pain hypersensitivity that was resolved by two weeks post-injury and was ameliorated by treatment with sumatriptan or anti-CGRP monoclonal antibody. Sumatriptan also produced CPP seven days post mCHI, but not in sham animals. Following the resolution of the concussion-evoked cephalic hypersensitivity, administration of GTN produced a renewed and pronounced cephalic pain hypersensitivity that was inhibited by sumatriptan or anti-CGRP antibody treatment as well as a CGRP-dependent CPA. GTN had no effect in sham animals. Conclusions Concussion leads to the development of headache and pain-related behaviours, in particular sustained enhanced responses to GTN, that are mediated through a CGRP-dependent mechanism. Treatment with anti-CGRP antibodies may be a useful approach to treat PTH.	[Bree, Dara; Levy, Dan] Beth Israel Deaconess Med Ctr, Dept Anesthesia, Boston, MA 02215 USA; [Bree, Dara; Levy, Dan] Beth Israel Deaconess Med Ctr, Dept Crit Care, Boston, MA 02215 USA; [Bree, Dara; Levy, Dan] Beth Israel Deaconess Med Ctr, Dept Pain Med, Boston, MA 02215 USA; [Bree, Dara; Levy, Dan] Harvard Med Sch, Boston, MA USA		Levy, D (corresponding author), Dept Anesthesia Crit Care & Pain Med, 330 Brookline Ave DA 717, Boston, MA 02215 USA.	dlevy1@bidmc.harvard.edu	Levy, Dan/AAF-1871-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078263, R21NS077882, R01NS086830] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS077882, R01 NS078263, R01 NS086830] Funding Source: Medline		Abend NS, 2008, J CHILD NEUROL, V23, P438, DOI 10.1177/0883073807309772; Ashina M, 2000, BRAIN, V123, P1830, DOI 10.1093/brain/123.9.1830; Ashina M, 2004, CEPHALALGIA, V24, P967, DOI 10.1111/j.1468-2982.2004.00780.x; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Benromano T, 2015, EUR J PAIN, V19, P621, DOI 10.1002/ejp.583; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Bigal ME, 2015, LANCET NEUROL, V14, P1081, DOI 10.1016/S1474-4422(15)00249-5; Bigal ME, 2015, LANCET NEUROL, V14, P1091, DOI 10.1016/S1474-4422(15)00245-8; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Bree D, 2015, J PAIN, V16, P421, DOI 10.1016/j.jpain.2015.01.010; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N; Burstein R, 2004, ANN NEUROL, V55, P19, DOI 10.1002/ana.10786; Burstein R, 2004, ANN NEUROL, V55, P27, DOI 10.1002/ana.10785; Burstein R, 2001, PAIN, V89, P107, DOI 10.1016/S0304-3959(00)00478-4; DeFelice M, 2013, ANN NEUROL, V74, P257, DOI 10.1002/ana.23922; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; Edelmayer RM, 2012, PAIN, V153, P1949, DOI 10.1016/j.pain.2012.06.012; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Feliciano DP, 2014, NEUROSCI LETT, V583, P55, DOI 10.1016/j.neulet.2014.09.030; Ferrari LF, 2016, NEUROSCIENCE, V317, P121, DOI 10.1016/j.neuroscience.2016.01.005; Griggs RB, 2015, NEUROREPORT, V26, P522, DOI 10.1097/WNR.0000000000000382; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; IVERSEN HK, 1989, PAIN, V38, P17, DOI 10.1016/0304-3959(89)90067-5; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010; King MV, 2004, NEUROPHARMACOLOGY, V47, P195, DOI 10.1016/j.neuropharm.2004.03.012; Kopruszinski CM, 2017, CEPHALALGIA, V37, P560, DOI 10.1177/0333102416650702; Levy D, 2016, CEPHALALGIA, V36, P915, DOI 10.1177/0333102415617412; Levy D, 2012, BRAIN BEHAV IMMUN, V26, P311, DOI 10.1016/j.bbi.2011.09.016; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lucas S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0520-1; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Macolino CM, 2014, J NEUROSCI METH, V226, P139, DOI 10.1016/j.jneumeth.2014.01.008; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mitsikostas DD, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0522-1; Moriarty O, 2016, BEHAV BRAIN RES, V303, P61, DOI 10.1016/j.bbr.2016.01.027; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Navratilova E, 2012, P NATL ACAD SCI USA, V109, P20709, DOI 10.1073/pnas.1214605109; OLESEN J, 1993, NEUROREPORT, V4, P1027, DOI 10.1097/00001756-199308000-00008; Oshinsky ML, 2007, HEADACHE, V47, P1026, DOI 10.1111/j.1526-4610.2007.00871.x; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Perry CJ, 2016, ANN NEUROL, V79, P1000, DOI 10.1002/ana.24665; Pietrobon D, 2013, ANNU REV PHYSIOL, V75, P365, DOI 10.1146/annurev-physiol-030212-183717; Pradhan AA, 2014, PAIN, V155, P269, DOI 10.1016/j.pain.2013.10.004; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Russo AF, 2015, ANNU REV PHARMACOL, V55, P533, DOI 10.1146/annurev-pharmtox-010814-124701; Sun H, 2016, LANCET NEUROL, V15, P382, DOI 10.1016/S1474-4422(16)00019-3; Tfelt-Hansen P, 1998, HEADACHE, V38, P748, DOI 10.1046/j.1526-4610.1998.3810748.x; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Vargas BB, 2012, CURR OPIN NEUROL, V25, P284, DOI 10.1097/WCO.0b013e3283535bf5; Visser WH, 1996, HEADACHE, V36, P471, DOI 10.1046/j.1526-4610.1996.3608471.x; VOS BP, 1994, J NEUROSCI, V14, P2708; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Winner P, 2003, MAYO CLIN PROC, V78, P1214, DOI 10.4065/78.10.1214; Yan J, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-6; Zhao J, 2014, PAIN, V155, P1392, DOI 10.1016/j.pain.2014.04.019	58	43	43	0	8	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	FEB	2018	38	2					246	258		10.1177/0333102416681571			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FW2QY	WOS:000425150600004	27899434	Green Accepted			2022-02-06	
J	Baniqued, PL; Gallen, CL; Voss, MW; Burzynska, AZ; Wong, CN; Cooke, GE; Duffy, K; Fanning, J; Ehlers, DK; Salerno, EA; Aguinaga, S; McAuley, E; Kramer, AF; D'Esposito, M				Baniqued, Pauline L.; Gallen, Courtney L.; Voss, Michelle W.; Burzynska, Agnieszka Z.; Wong, Chelsea N.; Cooke, Gillian E.; Duffy, Kristin; Fanning, Jason; Ehlers, Diane K.; Salerno, Elizabeth A.; Aguinaga, Susan; McAuley, Edward; Kramer, Arthur F.; D'Esposito, Mark			Brain Network Modularity Predicts Exercise-Related Executive Function Gains in Older Adults	FRONTIERS IN AGING NEUROSCIENCE			English	Article						executive function; cognitive control; functional connectivity; exercise; brain network modularity	WORKING-MEMORY CAPACITY; WHITE-MATTER INTEGRITY; RESTING-STATE NETWORKS; AGE-RELATED-CHANGES; INDIVIDUAL-DIFFERENCES; AEROBIC FITNESS; CARDIORESPIRATORY FITNESS; COMMUNITY STRUCTURE; COGNITIVE DECLINE; OXYGEN-CONSUMPTION	Recent work suggests that the brain can be conceptualized as a network comprised of groups of sub-networks or modules. The extent of segregation between modules can be quantified with a modularity metric, where networks with high modularity have dense connections within modules and sparser connections between modules. Previous work has shown that higher modularity predicts greater improvements after cognitive training in patients with traumatic brain injury and in healthy older and young adults. It is not known, however, whether modularity can also predict cognitive gains after a physical exercise intervention. Here, we quantified modularity in older adults (N = 128, mean age = 64.74) who underwent one of the following interventions for 6 months (NCT01472744 on ClinicalTrials.gov): (1) aerobic exercise in the form of brisk walking (Walk), (2) aerobic exercise in the form of brisk walking plus nutritional supplement (Walk), (3) stretching, strengthening and stability (SSS), or (4) dance instruction. After the intervention, the Walk, Walk+ and SSS groups showed gains in cardiorespiratory fitness (CRF), with larger effects in both walking groups compared to the SSS and Dance groups. The Walk, Walk+ and SSS groups also improved in executive function (EF) as measured by reasoning, working memory, and task-switching tests. In the Walk, Walk+, and SSS groups that improved in EF, higher baseline modularity was positively related to EF gains, even after controlling for age, in-scanner motion and baseline EF. No relationship between modularity and EF gains was observed in the Dance group, which did not show training-related gains in CRF or EF control. These results are consistent with previous studies demonstrating that individuals with a more modular brain network organization are more responsive to cognitive training. These findings suggest that the predictive power of modularity may be generalizable across interventions aimed to enhance aspects of cognition and that, especially in low-performing individuals, global network properties can capture individual differences in neuroplasticity.	[Baniqued, Pauline L.; Gallen, Courtney L.; D'Esposito, Mark] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Baniqued, Pauline L.; Wong, Chelsea N.; Cooke, Gillian E.; Duffy, Kristin; McAuley, Edward; Kramer, Arthur F.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; [Voss, Michelle W.] Univ Iowa, Dept Psychol & Brain Sci, Iowa City, IA USA; [Burzynska, Agnieszka Z.] Colorado State Univ, Dept Human Dev & Family Studies, Ft Collins, CO 80523 USA; [Cooke, Gillian E.] Univ Illinois, Interdisciplinary Hlth Sci Inst, Urbana, IL USA; [Fanning, Jason; Ehlers, Diane K.; Salerno, Elizabeth A.; Aguinaga, Susan; McAuley, Edward] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL USA; [Fanning, Jason] Wake Forest Sch Med, Dept Internal Med Gerontol, Winston Salem, NC USA; [Kramer, Arthur F.] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA; [Kramer, Arthur F.] Northeastern Univ, Mech & Ind Engn Dept, Boston, MA 02115 USA		Baniqued, PL (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.; Baniqued, PL (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA.	paulineb@berkeley.edu	Kramer, Arthur/AAB-2937-2019; Ehlers, Diane/AAK-4945-2021; Salerno, Elizabeth/N-1317-2019; Ehlers, Diane/I-4052-2018	Salerno, Elizabeth/0000-0001-5152-3168; Ehlers, Diane/0000-0002-9545-9556; Kramer, Arthur/0000-0001-5870-2724	National Science Foundation (IGERT)National Science Foundation (NSF) [0903622]; Beckman Institute for Advanced Science and Technology; Department of Defense (NDSEG)United States Department of Defense; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R37 AG025667, NS079698]; Center for Nutrition Learning and Memory, UIUC [2012-04673]; American Cancer SocietyAmerican Cancer Society [PF-16-021-01-CPPB]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R37AG025667, R01AG025667] Funding Source: NIH RePORTER	This work was supported by the National Science Foundation (IGERT Grant 0903622 to PB), Beckman Institute for Advanced Science and Technology (Graduate Fellowship to PB), Department of Defense (NDSEG to CG), National Institutes of Health (Grant R37 AG025667 to AK and EM, Grant NS079698 to MD), Center for Nutrition Learning and Memory, UIUC (Grant 2012-04673 to AK and EM), and the American Cancer Society (Postdoctoral Fellowship Grant PF-16-021-01-CPPB to DE). We thank Anya Knecht and Susan Houseworth for coordinating the intervention, Nancy Dodge and Holly Tracy for assistance in MRI data collection, Kathleen Kramer and Kishan Patel for assistance with Freesurfer processing, and members of the Lifelong Brain and Cognition Laboratory and Exercise Psychology Laboratory for assistance in data collection.	Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Arnemann KL, 2015, NEUROLOGY, V84, P1568, DOI 10.1212/WNL.0000000000001476; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Avants BB, 2010, NEUROIMAGE, V49, P2457, DOI 10.1016/j.neuroimage.2009.09.062; Awick EA, 2015, QUAL LIFE RES, V24, P455, DOI 10.1007/s11136-014-0762-0; Balke B., 1959, PRESENT STATUS PHYS; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Baniqued P. L., 2015, SOC NEUR ANN M CHIC; Basak C, 2011, BRAIN COGNITION, V76, P407, DOI 10.1016/j.bandc.2011.03.017; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Bennett G. K., 1997, DIFFERENTIAL APTITUD; Berchtold NC, 2010, NEUROSCIENCE, V167, P588, DOI 10.1016/j.neuroscience.2010.02.050; Bertolero MA, 2015, P NATL ACAD SCI USA, V112, pE6798, DOI 10.1073/pnas.1510619112; Betzel RF, 2014, NEUROIMAGE, V102, P345, DOI 10.1016/j.neuroimage.2014.07.067; Bherer Louis, 2013, J Aging Res, V2013, P657508, DOI [10.1155/2013/197326, 10.1155/2013/657508]; Birn RM, 2013, NEUROIMAGE, V83, P550, DOI 10.1016/j.neuroimage.2013.05.099; Bouchard C, 2001, MED SCI SPORT EXER, V33, pS446, DOI 10.1097/00005768-200106001-00013; Brown AD, 2010, NEUROBIOL AGING, V31, P2047, DOI 10.1016/j.neurobiolaging.2008.11.002; Buckley RF, 2017, NEUROLOGY, V89, P29, DOI 10.1212/WNL.0000000000004059; Buckner RL, 2004, NEUROIMAGE, V23, P724, DOI 10.1016/j.neuroimage.2004.06.018; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Burzynska AZ, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00059; Burzynska AZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120315; Cao H, 2014, NEUROIMAGE, V84, P888, DOI 10.1016/j.neuroimage.2013.09.013; Chaddock L, 2010, BRAIN RES, V1358, P172, DOI 10.1016/j.brainres.2010.08.049; Chadick JZ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5223; Chan MY, 2014, P NATL ACAD SCI USA, V111, pE4997, DOI 10.1073/pnas.1415122111; Chen ZJ, 2008, CEREB CORTEX, V18, P2374, DOI 10.1093/cercor/bhn003; Chen ZJ, 2011, NEUROIMAGE, V56, P235, DOI 10.1016/j.neuroimage.2011.01.010; Clune J, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2863; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; D'Esposito M, 2003, NAT REV NEUROSCI, V4, P863, DOI 10.1038/nrn1246; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Draheim C, 2016, PERSPECT PSYCHOL SCI, V11, P133, DOI 10.1177/1745691615596990; Duncan ES, 2016, BRAIN CONNECT, V6, P524, DOI 10.1089/brain.2016.0437; DUSTMAN RE, 1984, NEUROBIOL AGING, V5, P35, DOI 10.1016/0197-4580(84)90083-6; Ehlers DK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00110; Ehlers DK, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8570960; Ehlers DK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164246; Ekstrom RB., 1976, MANUAL KIT FACTOR RE; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Erickson KI, 2010, CEREB CORTEX, V20, P2522, DOI 10.1093/cercor/bhp293; Ericsson A, 2008, I S BIOMED IMAGING, P480, DOI 10.1109/ISBI.2008.4541037; Etnier JL, 2006, BRAIN RES REV, V52, P119, DOI 10.1016/j.brainresrev.2006.01.002; Fabiani M, 2012, PSYCHOPHYSIOLOGY, V49, P283, DOI 10.1111/j.1469-8986.2011.01331.x; Fanning J, 2017, J BEHAV MED, V40, P332, DOI 10.1007/s10865-016-9788-9; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fonov V., 2009, NEUROIMAGE, V47, pS102; Fornito A, 2015, NAT REV NEUROSCI, V16, P159, DOI 10.1038/nrn3901; Fortunato S, 2010, PHYS REP, V486, P75, DOI 10.1016/j.physrep.2009.11.002; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; FROELICHER VF, 1975, CHEST, V68, P331, DOI 10.1378/chest.68.3.331; Gabrieli JDE, 2015, NEURON, V85, P11, DOI 10.1016/j.neuron.2014.10.047; Gallen CL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169015; Geerligs L, 2015, CEREB CORTEX, V25, P1987, DOI 10.1093/cercor/bhu012; Giavasis S., 2015, C PAC CPAC VERSION 0; Gordon EM, 2017, NEURON, V95, P791, DOI 10.1016/j.neuron.2017.07.011; Grady C, 2012, NAT REV NEUROSCI, V13, P491, DOI 10.1038/nrn3256; Gratton C, 2012, J COGNITIVE NEUROSCI, V24, P1275, DOI 10.1162/jocn_a_00222; Guiney H, 2013, PSYCHON B REV, V20, P73, DOI 10.3758/s13423-012-0345-4; Hagberg A. A., 2008, PROC 7 PYTHON SCI C, P11; HAWKINS HL, 1992, PSYCHOL AGING, V7, P643, DOI 10.1037/0882-7974.7.4.643; Heckemann R. A., 2003, P 2 UK E SCI ALL HAN; Hedden T, 2012, J NEUROSCI, V32, P16233, DOI 10.1523/JNEUROSCI.2462-12.2012; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; HUBERTY CJ, 1989, PSYCHOL BULL, V105, P302, DOI 10.1037/0033-2909.105.2.302; JACK CR, 1989, RADIOLOGY, V172, P549, DOI 10.1148/radiology.172.2.2748838; Jain V, 2010, J CEREBR BLOOD F MET, V30, P1598, DOI 10.1038/jcbfm.2010.49; Johnson M.B., 1989, WOODCOCK JOHNSON PSY; Kane MJ, 2005, PSYCHOL BULL, V131, P66, DOI 10.1037/0033-2909.131.1.66; Kashtan N, 2005, P NATL ACAD SCI USA, V102, P13773, DOI 10.1073/pnas.0503610102; Kawagoe T, 2017, SCI REP-UK, V7, DOI 10.1038/srep40107; Kelly ME, 2014, AGEING RES REV, V16, P12, DOI 10.1016/j.arr.2014.05.002; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32; Kitzbichler MG, 2011, J NEUROSCI, V31, P8259, DOI 10.1523/JNEUROSCI.0440-11.2011; Kramer AF, 1999, ACTA PSYCHOL, V101, P339, DOI 10.1016/S0001-6918(99)00011-6; Kramer AF, 2001, HUMAN FACTORS INTERVENTIONS FOR THE HEALTH CARE OF OLDER ADULTS, P91; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; Landman BA, 2011, NEUROIMAGE, V54, P2854, DOI 10.1016/j.neuroimage.2010.11.047; Laumann TO, 2015, NEURON, V87, P657, DOI 10.1016/j.neuron.2015.06.037; Leckie RL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00985; Liu-Ambrose T, 2012, NEUROBIOL AGING, V33, P1690, DOI 10.1016/j.neurobiolaging.2011.05.010; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; Lustig C, 2009, NEUROPSYCHOL REV, V19, P504, DOI 10.1007/s11065-009-9119-9; Madden DJ, 2012, BBA-MOL BASIS DIS, V1822, P386, DOI 10.1016/j.bbadis.2011.08.003; Madden DJ, 2009, NEUROPSYCHOL REV, V19, P415, DOI 10.1007/s11065-009-9113-2; Mathewson KE, 2012, PSYCHOPHYSIOLOGY, V49, P1558, DOI 10.1111/j.1469-8986.2012.01474.x; Meunier D, 2014, NEUROBIOL AGING, V35, P42, DOI 10.1016/j.neurobiolaging.2013.07.003; Meunier D, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00200; Meunier D, 2009, NEUROIMAGE, V44, P715, DOI 10.1016/j.neuroimage.2008.09.062; Monti JM, 2012, HIPPOCAMPUS, V22, P1876, DOI 10.1002/hipo.22023; Muschelli J, 2014, NEUROIMAGE, V96, P22, DOI 10.1016/j.neuroimage.2014.03.028; Newman MEJ, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.036104; Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103; Newman MEJ, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.026113; Nomura EM, 2010, P NATL ACAD SCI USA, V107, P12017, DOI 10.1073/pnas.1002431107; O'Bryant SE, 2008, ARCH NEUROL-CHICAGO, V65, P963, DOI 10.1001/archneur.65.7.963; Onoda K, 2013, NEUROSCI LETT, V556, P104, DOI 10.1016/j.neulet.2013.10.023; Persson J, 2006, CEREB CORTEX, V16, P907, DOI 10.1093/cercor/bhj036; Power JD, 2013, CURR OPIN NEUROBIOL, V23, P223, DOI 10.1016/j.conb.2012.12.009; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Pudas S, 2018, CEREB CORTEX, V28, P936, DOI 10.1093/cercor/bhw418; Ravens J, 1962, ADV PROGR MATRICES; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; Ross R, 2016, CIRCULATION, V134, pE653, DOI 10.1161/CIR.0000000000000461; Rosvall M, 2008, P NATL ACAD SCI USA, V105, P1118, DOI 10.1073/pnas.0706851105; Sadaghiani S, 2015, P NATL ACAD SCI USA, V112, P8463, DOI 10.1073/pnas.1420687112; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Salthouse TA, 2005, NEUROPSYCHOLOGY, V19, P532, DOI 10.1037/0894-4105.19.4.532; Salthouse TA, 2004, INTELLIGENCE, V32, P541, DOI 10.1016/j.intell.2004.07.003; Salthouse TA, 1996, NEUROPSYCHOLOGY, V10, P272, DOI 10.1037/0894-4105.10.2.272; Salthouse TA, 2003, PSYCHOL AGING, V18, P91, DOI 10.1037/0882-7974.18.1.91; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; SALTHOUSE TA, 1993, J GERONTOL, V48, pP29, DOI 10.1093/geronj/48.1.P29; Salthouse TA, 2017, J GERONTOL B-PSYCHOL, V72, P7, DOI 10.1093/geronb/gbw069; Salthouse TA, 2010, NEUROPSYCHOLOGY, V24, P563, DOI 10.1037/a0019026; Samanez-Larkin GR, 2008, SOC COGN AFFECT NEUR, V3, P290, DOI 10.1093/scan/nsn029; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Schultz DH, 2016, J NEUROSCI, V36, P8551, DOI 10.1523/JNEUROSCI.0358-16.2016; Siegel JS, 2017, CEREB CORTEX, V27, P4492, DOI 10.1093/cercor/bhw253; Soman S, 2016, HUM BRAIN MAPP, V37, P2185, DOI 10.1002/hbm.23166; Song J, 2014, BRAIN CONNECT, V4, P662, DOI 10.1089/brain.2014.0286; Stanley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00954; Stevens AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030468; Stroth S, 2009, NEUROPSYCHOL REHABIL, V19, P223, DOI 10.1080/09602010802091183; Tosh CR, 2015, P BIOL SCI, V282, DOI DOI 10.1098/RSPB.2014.2568; TUKEY JW, 1962, ANN MATH STAT, V33, P1, DOI 10.1214/aoms/1177704711; Vo LTK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016093; Voss MW, 2016, NEUROIMAGE, V131, P113, DOI 10.1016/j.neuroimage.2015.10.044; Voss MW, 2013, HUM BRAIN MAPP, V34, P2972, DOI 10.1002/hbm.22119; Voss MW, 2013, TRENDS COGN SCI, V17, P525, DOI 10.1016/j.tics.2013.08.001; Voss MW, 2013, BRAIN BEHAV IMMUN, V28, P90, DOI 10.1016/j.bbi.2012.10.021; Voss MW, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00032; Voss MW, 2010, NEUROPSYCHOLOGIA, V48, P1394, DOI 10.1016/j.neuropsychologia.2010.01.005; Warren DE, 2014, P NATL ACAD SCI USA, V111, P14247, DOI 10.1073/pnas.1322173111; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WENGER HA, 1986, SPORTS MED, V3, P346, DOI 10.2165/00007256-198603050-00004; Wilcox R. R., 2005, OUTLIER DETECTION; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Wilson RS, 2002, PSYCHOL AGING, V17, P179, DOI 10.1037/0882-7974.17.2.179; Zachary R. A., 1986, SHIPLEY I LIVING SCA; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; Zimmerman B, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00059	152	43	43	1	24	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	JAN 4	2018	9								426	10.3389/fnagi.2017.00426			17	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Geriatrics & Gerontology; Neurosciences & Neurology	FR8WO	WOS:000419355600001	29354050	gold, Green Published			2022-02-06	
J	Wang, HJ; Song, GB; Chuang, HY; Chiu, CD; Abdelmaksoud, A; Ye, YF; Zhao, L				Wang, Haijun; Song, Guobin; Chuang, Haoyu; Chiu, Chengdi; Abdelmaksoud, Ahmed; Ye, Youfan; Zhao, Lei			Portrait of glial scar in neurological diseases	INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY			English	Article						fibrosis; glial scar; inflammation; neurological diseases	ASTROCYTES; PROTEINS; MATRIX; CELLS	Fibrosis is formed after injury in most of the organs as a common and complex response that profoundly affects regeneration of damaged tissue. In central nervous system (CNS), glial scar grows as a major physical and chemical barrier against regeneration of neurons as it forms dense isolation and creates an inhibitory environment, resulting in limitation of optimal neural function and permanent deficits of human body. In neurological damages, glial scar is mainly attributed to the activation of resident astrocytes which surrounds the lesion core and walls off intact neurons. Glial cells induce the infiltration of immune cells, resulting in transient increase in extracellular matrix deposition and inflammatory factors which inhibit axonal regeneration, impede functional recovery, and may contribute to the occurrence of neurological complications. However, recent studies have underscored the importance of glial scar in neural protection and functional improvement depending on the specific insults which involves various pivotal molecules and signaling. Thus, to uncover the veil of scar formation in CNS may provide rewarding therapeutic targets to CNS diseases such as chronic neuroinflammation, brain stroke, spinal cord injury (SCI), traumatic brain injury (TBI), brain tumor, and epileptogenesis. In this article, we try to describe the new portrait of glial scar and trending of research in neurological diseases to readers.	[Wang, Haijun; Song, Guobin; Abdelmaksoud, Ahmed] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China; [Chuang, Haoyu] China Med Univ, Tainan Municipal An Nan Hosp, Dept Neurosurg, Tainan, Taiwan; [Chuang, Haoyu] China Med Univ, Beigang Hosp, Dept Neurosurg, Beigang, Taiwan; [Chuang, Haoyu; Chiu, Chengdi] China Med Univ, Sch Med, Taichung, Taiwan; [Chiu, Chengdi] China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan; [Ye, Youfan] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Ophthalmol, Wuhan 430022, Hubei, Peoples R China; [Zhao, Lei] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Infect Dis, Wuhan 430022, Hubei, Peoples R China		Ye, YF (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Ophthalmol, Wuhan 430022, Hubei, Peoples R China.; Zhao, L (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Infect Dis, Wuhan 430022, Hubei, Peoples R China.	yeyoufan@sina.com; leizhao@hust.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371840, 81600373, 81201026]; Hubei Province Health and Family Planning Scientific Research Project [WJ2017Q021, WJ2017Z015]; Hubei Provincial Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [2017CFB471, 2016CFB643]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [2017KFYXJJ238]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a grant from the National Natural Science Foundation of China (81371840, 81600373, and 81201026), Hubei Province Health and Family Planning Scientific Research Project (WJ2017Q021 and WJ2017Z015), Hubei Provincial Natural Science Foundation of China (2017CFB471 and 2016CFB643), and the Fundamental Research Funds for the Central Universities (2017KFYXJJ238).	Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Duan CL, 2015, GLIA, V63, P1660, DOI 10.1002/glia.22837; Faiz M, 2015, CELL STEM CELL, V17, P624, DOI 10.1016/j.stem.2015.08.002; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Koulakoff A, 2008, GLIA, V56, P1299, DOI 10.1002/glia.20698; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Schattin A, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00161; Susarla BTS, 2011, J NEUROCHEM, V119, P868, DOI 10.1111/j.1471-4159.2011.07470.x; Yang G, 2009, NATURE, V462, P920, DOI 10.1038/nature08577; Zhang JM, 2017, J CELL SCI, V130, P2447, DOI 10.1242/jcs.196154	15	43	45	4	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2058-7384			INT J IMMUNOPATH PH	Int. J. Immunopathol. Pharmacol.	JAN-FEB	2018	31									10.1177/2058738418801406			6	Immunology; Pathology; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Pathology; Pharmacology & Pharmacy	HL5GD	WOS:000458753700001	30309271	gold, Green Published, Green Submitted			2022-02-06	
J	Wu, Q; Gao, C; Wang, HC; Zhang, XM; Li, QQ; Gu, ZY; Shi, XY; Cui, YC; Wang, T; Chen, XP; Wang, X; Luo, CL; Tao, LY				Wu, Qiong; Gao, Cheng; Wang, Haochen; Zhang, Xinmu; Li, Qianqian; Gu, Zhiya; Shi, Xiuyu; Cui, Yongchun; Wang, Tao; Chen, Xiping; Wang, Xin; Luo, Chengliang; Tao, Luyang			Mdivi-1 alleviates blood-brain barrier disruption and cell death in experimental traumatic brain injury by mitigating autophagy dysfunction and mitophagy activation	INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY			English	Article						Dynamin-related protein 1; Traumatic brain injury; Autophagy; Mitophagy; Blood-brain barrier	INTRACEREBRAL HEMORRHAGE MODEL; MITOCHONDRIAL FISSION; IN-VITRO; MEMBRANE PERMEABILIZATION; PROTECTS MITOCHONDRIA; CORTICAL-NEURONS; DAMAGE; PATHWAY; MICE; DRP1	Dynamin-related protein 1 (Drp1) is a key regulator of mitochondrial fission. Our previous studies proved that the inhibition of Drpl may help attenuate traumatic brain injury (TBI)-induced functional outcome and cell death through maintaining normal mitochondrial morphology and inhibiting activation of apoptosis. However, the molecular mechanisms of Drpl after TBI remain poorly understood. In this study, we investigated the role of mitochondrial division inhibitor 1 (Mdivi-1), a small molecule inhibitor of Drpl, in underlying mechanisms of general autophagy and mitochondria autophagy (mitophagy) after experimental TBI. In vivo, we found that autophagosomes accumulated in cortical neurons at 24 h after TBI, owing to the enhanced autophagy indicated by the accumulation of LC3 and the decrease of p62; but Mdivi-1 reversed the enhancement. Mdivi-1 also alleviated the number of LC3 puncta and TUNEL-positive structures in cells, indicating that autophagy maybe involved in Mdivi-l's anti-apoptosis effects. Then, the expression level of mitochondrial dynamics related and mitophagy related proteins was assessed using the isolated mitochondria. The results showed that TBI-induced mitochondrial fission (represented by Drpl), mtDNA concentration down-regulation and PTEN induced putative kinase 1 (PINK1)-Parkin mediated mitophagy activation were all inhibited by Mdivi-1. In addition, TBI-induced blood-brain barrier (BBB) disruption and matrix metalloproteinases (MMP)-9 expression up-regulation were inhibited following Mdivi-1 treatment. In vitro, Mdivi-1 significantly alleviated the scratch injury-induced cell death, loss of mitochondrial membrane potential, reactive oxygen species (ROS) production and ATP reduction in primary cortical neurons (PCNs). Additionally, the lysosome inhibitor chloroquine (CQ) abrogated the Mdivi1-induced decrease in autophagosomes accumulation and cell death at 24 h both in the basal state and under the conditions of scratch cell injury. Together, these data demonstrate that Mdivi-1 mitigates TBI-induced BBB disruption and cell death at least in part by a mechanism involving inhibiting autophagy dysfunction and mitophagy activation.	[Wu, Qiong; Gao, Cheng; Wang, Haochen; Gu, Zhiya; Wang, Tao; Chen, Xiping; Luo, Chengliang; Tao, Luyang] Soochow Univ, Coll Med, Dept Forens Med, 178 Ganjiang East St, Suzhou 215123, Peoples R China; [Zhang, Xinmu; Wang, Xin; Luo, Chengliang] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Li, Qianqian] Wannan Med Coll, Dept Forens Med, Wuhu 241002, Peoples R China; [Shi, Xiuyu] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Cui, Yongchun] Chinese Acad Med Sci, Fu Wai Hosp, State Key Lab Cardiovasc Dis, Beijing 100037, Peoples R China; [Cui, Yongchun] Chinese Acad Med Sci, Fu Wai Hosp,Natl Ctr Cardiovasc Dis, Beijing Key Lab Preclin Res & Evaluat Cardiovasc, Ctr Cardiovasc Expt Study & Evaluat, Beijing 100037, Peoples R China; [Cui, Yongchun] Peking Union Med Coll, Beijing 100037, Peoples R China		Luo, CL; Tao, LY (corresponding author), Soochow Univ, Coll Med, Dept Forens Med, 178 Ganjiang East St, Suzhou 215123, Peoples R China.	clluo@suda.edu.cn; taoluyang@suda.edu.cn	Cui, Yong/AAF-9300-2020; Zhang, Xinmu/G-8128-2018		National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81530062, 81400999, 81373251, 81601643]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014M551660]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Beijing Natural Science FoundationBeijing Natural Science Foundation [7172181]	This work was supported by the National Science Foundation of China (Nos. 81530062, 81400999, 81373251, and 81601643), China Postdoctoral Science Foundation (No. 2014M551660), a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and Beijing Natural Science Foundation (7172181).	Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Chang CR, 2010, ANN NY ACAD SCI, V1201, P34, DOI 10.1111/j.1749-6632.2010.05629.x; Chang LK, 2002, J CELL BIOL, V157, P771, DOI 10.1083/jcb.200112130; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985; Fukui K, 2012, FREE RADICAL RES, V46, P184, DOI 10.3109/10715762.2011.647689; Gao Y, 2017, MOL NEUROBIOL, V54, P3879, DOI 10.1007/s12035-016-9947-6; Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Herrmann JM, 2012, ADV EXP MED BIOL, V748, P41, DOI 10.1007/978-1-4614-3573-0_3; Iwai-Kanai E, 2008, AUTOPHAGY, V4, P322, DOI 10.4161/auto.5603; Ji J, 2012, J NEUROTRAUM, V29, P776, DOI 10.1089/neu.2010.1602; Jin YC, 2015, WORLD NEUROSURG, V84, P420, DOI 10.1016/j.wneu.2015.03.039; Kang JW, 2016, J PINEAL RES, V60, P383, DOI 10.1111/jpi.12319; Kim T, 2016, J NEUROSCI, V36, P7055, DOI 10.1523/JNEUROSCI.1241-16.2016; Knott AB, 2008, ANN NY ACAD SCI, V1147, P283, DOI 10.1196/annals.1427.030; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2013, J NEUROTRAUM, V30, P597, DOI 10.1089/neu.2012.2425; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Luo CL, 2015, J MOL NEUROSCI, V56, P988, DOI 10.1007/s12031-015-0568-8; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Purnell PR, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-86; Qiu X, 2013, NEUROSCIENCE, V245, P157, DOI 10.1016/j.neuroscience.2013.04.019; Rambold AS, 2011, AUTOPHAGY, V7, P1568, DOI 10.4161/auto.7.12.17992; Saito T, 2015, CIRC RES, V116, P1477, DOI 10.1161/CIRCRESAHA.116.303790; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Song JX, 2012, CHIN MED-UK, V7, DOI 10.1186/1749-8546-7-1; Song Y, 2015, NEUROSCI J, V2015; Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wang DB, 2013, J NEUROSCI, V33, P1357, DOI 10.1523/JNEUROSCI.3365-12.2013; Wang T, 2015, J MOL NEUROSCI, V55, P240, DOI 10.1007/s12031-014-0313-8; Wu Q, 2017, HISTOL HISTOPATHOL, V32, P551, DOI 10.14670/HH-11-841; Wu Q, 2016, BRAIN RES, V1630, P134, DOI 10.1016/j.brainres.2015.11.016; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Yuan F, 2016, J NEUROCHEM, V136, P581, DOI 10.1111/jnc.13423; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087241; Zhang WH, 2008, STROKE, V39, P455, DOI 10.1161/STROKEAHA.107.496810; Zuo W, 2016, BRIT J PHARMACOL, V173, P1665, DOI 10.1111/bph.13468; Zuo W, 2014, NEUROPHARMACOLOGY, V86, P103, DOI 10.1016/j.neuropharm.2014.07.002	45	43	45	3	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1357-2725	1878-5875		INT J BIOCHEM CELL B	Int. J. Biochem. Cell Biol.	JAN	2018	94						44	55		10.1016/j.biocel.2017.11.007			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU5JJ	WOS:000423888700007	29174311				2022-02-06	
J	Mac Donald, CL; Johnson, AM; Wierzechowski, L; Kassner, E; Stewart, T; Nelson, EC; Werner, NJ; Adam, OR; Rivet, DJ; Flaherty, SF; Oh, JS; Zonies, D; Fang, R; Brody, DL				Mac Donald, Christine L.; Johnson, Ann M.; Wierzechowski, Linda; Kassner, Elizabeth; Stewart, Theresa; Nelson, Elliot C.; Werner, Nicole J.; Adam, Octavian R.; Rivet, Dennis J.; Flaherty, Stephen F.; Oh, John S.; Zonies, David; Fang, Raymond; Brody, David L.			Outcome Trends after US Military Concussive Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast TBI; clinical outcomes; concussive TBI; PTSD	POSTTRAUMATIC-STRESS-DISORDER; NEUROBEHAVIORAL RATING-SCALE; MENTAL-HEALTH PROBLEMS; HEAD-INJURY; STRUCTURED INTERVIEWS; COMBAT VETERANS; BLAST; SYMPTOMS; IRAQ; PERSONNEL	Care for US military personnel with combat-related concussive traumatic brain injury (TBI) has substantially changed in recent years, yet trends in clinical outcomes remain largely unknown. Our prospective longitudinal studies of US military personnel with concussive TBI from 2008-2013 at Landstuhl Regional Medical Center in Germany and twp sites in Afghanistan provided an opportunity to assess for changes in outcomes over time and analyze correlates of overall disability. We enrolled 321 active-duty US military personnel who sustained concussive TBI in theater and 254 military controls. We prospectively assessed clinical outcomes 6-12 months later in 199 with concussive TBI and 148 controls. Global disability, neurobehavioral impairment, depression severity, and post-traumatic stress disorder (PTSD) severity were worse in concussive TBI groups in comparison with controls in all cohorts. Global disability primarily reflected a combination of work-related and nonwork-related disability. There was a modest but statistically significant trend toward less PTSD in later cohorts. Specifically, there was a decrease of 5.9 points of 136 possible on the Clinician Administered PTSD Scale (-4.3%) per year (95% confidence interval, 2.8-9.0 points, p=0.0037 linear regression, p=0.03 including covariates in generalized linear model). No other significant trends in outcomes were found. Global disability was more common in those with TBI, those evacuated from theater, and those with more severe depression and PTSD. Disability was not significantly related to neuropsychological performance, age, education, self-reported sleep deprivation, injury mechanism, or date of enrollment. Thus, across multiple cohorts of US military personnel with combat-related concussion, 6-12 month outcomes have improved only modestly and are often poor. Future focus on early depression and PTSD after concussive TBI appears warranted. Adverse outcomes are incompletely explained, however, and additional studies with prospective collection of data on acute injury severity and polytrauma, as well as reduced attrition before follow-up will be required to fully address the root causes of persistent disability after wartime injury.	[Mac Donald, Christine L.; Johnson, Ann M.; Nelson, Elliot C.; Werner, Nicole J.; Brody, David L.] Washington Univ, Sch Med, St Louis, MO USA; [Mac Donald, Christine L.] Univ Washington, Dept Neurol Surg, 325 9th Ave,Box 359924, Seattle, WA 98104 USA; [Wierzechowski, Linda; Kassner, Elizabeth; Stewart, Theresa; Flaherty, Stephen F.; Oh, John S.; Zonies, David; Fang, Raymond] Landstuhl Reg Med Ctr, Landstuhl, Germany; [Adam, Octavian R.; Rivet, Dennis J.] Naval Med Ctr Portsmouth, Portsmouth, VA USA; [Adam, Octavian R.] Berkshire Med Ctr, Med Ctr, Pittsfield, MA USA; [Rivet, Dennis J.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Flaherty, Stephen F.] Acute Surg Care Specialists, El Paso, TX USA; [Oh, John S.] Walter Reed Natl Mil Med Ctr, Crit Care & Acute Care Surg, Bethesda, MD USA; [Zonies, David] Oregon Hlth & Sci Univ, Trauma & Crit Care, Portland, OR 97201 USA; [Fang, Raymond] Univ Maryland, R Adams Cowley Shock Trauma Ctr, US Air Force Ctr Sustainment Trauma & Readiness S, Baltimore, MD 21201 USA		Mac Donald, CL (corresponding author), Univ Washington, Dept Neurol Surg, 325 9th Ave,Box 359924, Seattle, WA 98104 USA.; Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	cmacd@uw.edu; brodyd@neuro.wustl.edu	Oh, John/AAS-9557-2020; Zonies, David/B-6497-2011	Oh, John/0000-0001-9010-0627; 	Congressionally Directed Medical Research ProgramUnited States Department of Defense; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Funded by grants from the Congressionally Directed Medical Research Program and Defense Advanced Research Projects Agency (DLB) with additional support from NIH fellowships to CLM and DLB. The funding agencies played no role in the acquisition, analysis, or interpretation of the data.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; [Anonymous], 1999, J Clin Psychiatry, V60 Suppl 16, P3; Attari A, 2014, J RES MED SCI, V19, P592; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Castro CA, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.24713; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Conners C. K., 2000, CONNERS CONTINUOUS P; Delis D.C., 2000, CALIFORNIA VERBAL LE; Dempsey Kenneth E, 2009, J Trauma Nurs, V16, P6, DOI 10.1097/01.JTN.0000348063.41099.a7; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Galea S, 2012, TREATMENT POSTTRAUMA; Hamster K., 1983, MULTILINGUAL APHASIA; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Jeffreys M., 2014, CLIN GUIDE MEDICATIO; Karlin BE, 2010, J TRAUMA STRESS, V23, P663, DOI 10.1002/jts.20588; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Lynn W. J., 2010, POLICY GUIDANCE MANA; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; Matthews CG., 1964, INSTRUCTION MANUAL A; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Raskind MA, 2003, AM J PSYCHIAT, V160, P371, DOI 10.1176/appi.ajp.160.2.371; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Reitan RM, 1992, TRAIL MAKING TEST MA; Rutherford G., 2009, IOM I MED LONG TERM, V7; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shalev AY, 2012, ARCH GEN PSYCHIAT, V69, P166, DOI 10.1001/archgenpsychiatry.2011.127; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Warner CH, 2011, ARCH GEN PSYCHIAT, V68, P1065, DOI 10.1001/archgenpsychiatry.2011.112; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WechslerD, 2001, WECHSLER TEST ADULT; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498	56	43	43	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2017	34	14					2206	2219		10.1089/neu.2016.4434			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	EZ8RQ	WOS:000404995000003	27198861	Green Published			2022-02-06	
J	Neukomm, LJ; Burdett, TC; Seeds, AM; Hampel, S; Coutinho-Budd, JC; Farley, JE; Wong, J; Karadeniz, YB; Osterloh, JM; Sheehan, AE; Freeman, MR				Neukomm, Lukas J.; Burdett, Thomas C.; Seeds, Andrew M.; Hampel, Stefanie; Coutinho-Budd, Jaeda C.; Farley, Jonathan E.; Wong, Jack; Karadeniz, Yonca B.; Osterloh, Jeannette M.; Sheehan, Amy E.; Freeman, Marc R.			Axon Death Pathways Converge on Axundead to Promote Functional and Structural Axon Disassembly	NEURON			English	Article							TRAUMATIC BRAIN-INJURY; UBIQUITIN-LIGASE; WALLERIAN DEGENERATION; NEUROPROTECTIVE EFFICACY; DROSOPHILA-MELANOGASTER; SELF-DESTRUCTION; MOSAIC ANALYSIS; CELL-DEATH; SARM1; RECEPTOR	Axon degeneration is a hallmark of neurodegenerative disease and neural injury. Axotomy activates an intrinsic pro-degenerative axon death signaling cascade involving loss of the NAD(+) biosynthetic enzyme Nmnat/Nmnat2 in axons, activation of dSarm/Sarm1, and subsequent Sarm-dependent depletion of NAD(+). Here we identify Axundead (Axed) as a mediator of axon death. axed mutants suppress axon death in several types of axons for the lifespan of the fly and block the pro-degenerative effects of activated dSarm in vivo. Neurodegeneration induced by loss of the sole fly Nmnat ortholog is also fully blocked by axed, but not dsarm, mutants. Thus, pro-degenerative pathwaysactivatedby dSarm signaling or Nmnat elimination ultimately converge on Axed. Remarkably, severed axons morphologically preserved by axon death pathway mutations remain integrated in circuits and able to elicit complex behaviors after stimulation, indicating that blockade of axon death signaling results in long-term functional preservation of axons.	[Neukomm, Lukas J.; Burdett, Thomas C.; Coutinho-Budd, Jaeda C.; Farley, Jonathan E.; Wong, Jack; Karadeniz, Yonca B.; Osterloh, Jeannette M.; Sheehan, Amy E.; Freeman, Marc R.] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA USA; [Seeds, Andrew M.; Hampel, Stefanie] Howard Hughes Med Inst, Janelia Res Campus, Ashburn, VA USA; [Burdett, Thomas C.; Freeman, Marc R.] Oregon Hlth & Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA; [Seeds, Andrew M.; Hampel, Stefanie] Univ Puerto Rico, Inst Neurobiol, Med Sci Campus, San Juan, PR 00936 USA; [Osterloh, Jeannette M.] Gladstone Inst, San Francisco, CA USA		Neukomm, LJ; Freeman, MR (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA USA.; Freeman, MR (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.	lukas.neukomm@gmail.com; freemmar@ohsu.edu	Neukomm, Lukas/I-8636-2019	Neukomm, Lukas/0000-0002-5007-3959; Hampel, Stefanie/0000-0001-8287-549X; Freeman, Marc/0000-0003-3481-3715; Seeds, Andrew/0000-0002-4932-6496	Charles A. King Trust Postdoctoral Fellowship by Harold Whitworth Pierce Charitable Trust; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS053538]	The authors wish to thank Freeman laboratory members and colleagues in the field for feedback, comments, and suggestions. This work was supported by the Charles A. King Trust Postdoctoral Fellowship supported by the Harold Whitworth Pierce Charitable Trust (to L.J.N.) and by NINDS grant R01 NS053538 (to M.R.F.). During the period of this study, M.R.F. was an Investigator with the Howard Hughes Medical Institute.	Babetto E, 2013, CELL REP, V3, P1422, DOI 10.1016/j.celrep.2013.04.013; Backhaus B., 1984, DROS INFORM SERV, V60, P210; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Cambronne XA, 2016, SCIENCE, V352, P1474, DOI 10.1126/science.aad5168; Chuang CF, 2005, GENE DEV, V19, P270, DOI 10.1101/gad.1276505; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Coutinho-Budd J, 2013, CURR OPIN NEUROBIOL, V23, P1073, DOI 10.1016/j.conb.2013.07.002; De Jesus-Cortes H., 2015, NPJ PARKINSONS DIS, V1, P889; Essuman K, 2017, NEURON, V93, P1334, DOI 10.1016/j.neuron.2017.02.022; Fang YS, 2012, CURR BIOL, V22, P590, DOI 10.1016/j.cub.2012.01.065; Geisler S, 2016, BRAIN, V139, P3092, DOI 10.1093/brain/aww251; Gerdts J, 2016, NEURON, V89, P449, DOI 10.1016/j.neuron.2015.12.023; Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366; Gerdts J, 2013, J NEUROSCI, V33, P13569, DOI 10.1523/JNEUROSCI.1197-13.2013; Gilley J, 2015, CELL REP, V10, P1974, DOI 10.1016/j.celrep.2015.02.060; Gilley J, 2013, J NEUROSCI, V33, P13410, DOI 10.1523/JNEUROSCI.1534-13.2013; Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300; Hampel S, 2015, ELIFE, V4, DOI 10.7554/eLife.08758; Henninger N, 2016, BRAIN, V139, P1094, DOI 10.1093/brain/aww001; Hoopfer ED, 2006, NEURON, V50, P883, DOI 10.1016/j.neuron.2006.05.013; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lee T, 2000, NEURON, V28, P807, DOI 10.1016/S0896-6273(00)00155-0; Li N, 2015, GENE DEV, V29, P157, DOI 10.1101/gad.251785.114; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Metaxakis A, 2005, GENETICS, V171, P571, DOI 10.1534/genetics.105.041848; Milde S, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001539; Muthukumar AK, 2014, NAT NEUROSCI, V17, P1340, DOI 10.1038/nn.3791; Neukomm LJ, 2014, P NATL ACAD SCI USA, V111, P9965, DOI 10.1073/pnas.1406230111; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Potter CJ, 2010, CELL, V141, P536, DOI 10.1016/j.cell.2010.02.025; Rongvaux A, 2003, BIOESSAYS, V25, P683, DOI 10.1002/bies.10297; Sasaki Y, 2016, ELIFE, V5, DOI 10.7554/eLife.19749; Sebo ZL, 2014, FLY, V8, P52, DOI 10.4161/fly.26828; Seeds AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02951; Simonin Y, 2007, EUR J NEUROSCI, V25, P2269, DOI 10.1111/j.1460-9568.2007.05501.x; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Stogios PJ, 2004, TRENDS BIOCHEM SCI, V29, P634, DOI 10.1016/j.tibs.2004.10.003; Stork T, 2014, NEURON, V83, P388, DOI 10.1016/j.neuron.2014.06.026; Summers DW, 2014, J NEUROSCI, V34, P9338, DOI 10.1523/JNEUROSCI.0877-14.2014; Tasdemir-Yilmaz OE, 2014, GENE DEV, V28, P20, DOI 10.1101/gad.229518.113; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Venken KJT, 2011, NAT METHODS, V8, P737, DOI 10.1038/nmeth.1662; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Walker LJ, 2017, ELIFE, V6, DOI 10.7554/eLife.22540; Wang AL, 2006, J NEUROSCI RES, V84, P1799, DOI 10.1002/jnr.21075; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Xiong X, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001440; Xu DB, 2005, DEVELOPMENT, V132, P2125, DOI 10.1242/dev.01790; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Zhai RG, 2006, PLOS BIOL, V4, P2336, DOI 10.1371/journal.pbio.0040416	59	43	45	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	JUL 5	2017	95	1					78	+		10.1016/j.neuron.2017.06.031			19	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EZ7CB	WOS:000404876500012	28683272	Bronze			2022-02-06	
J	Namjoshi, DR; Cheng, WH; Bashir, A; Wilkinson, A; Stukas, S; Martens, KM; Whyte, T; Abebe, ZA; McInnes, KA; Cripton, PA; Wellington, CL				Namjoshi, Dhananjay R.; Cheng, Wai Hang; Bashir, Asma; Wilkinson, Anna; Stukas, Sophie; Martens, Kris M.; Whyte, Tom; Abebe, Zelalem A.; McInnes, Kurt A.; Cripton, Peter A.; Wellington, Cheryl L.			Defining the biomechanical and biological threshold of murine mild traumatic brain injury using CHIMERA (Closed Head Impact Model of Engineered Rotational Acceleration)	EXPERIMENTAL NEUROLOGY			English	Article						CHIMERA; Traumatic brain injury; Closed head injury; Animal model of traumatic brain injury; Biomechanics; Behavior; Neuropathology	CLINICAL MANAGEMENT; CONCUSSION; FOOTBALL; MECHANISMS; DIAGNOSIS	CHIMERA (Closed Head Impact Model of Engineered Rotational Acceleration) is a recently described animal model of traumatic brain injury (TBI) that primarily produces diffuse axonal injury (DAI) characterized by white matter inflammation and axonal damage. CHIMERA was specifically designed to reliably generate a variety of TBI severities using precise and quantifiable biomechanical inputs in a nonsurgical user-friendly platform. The objective of this study was to define the lower limit of single impact mild TBI (mTBI) using CHIMERA by characterizing the dose-response relationship between biomechanical input and neurological, behavioral, neuropathological and biochemical outcomes. Wild-type male mice were subjected to a single CHIMERA TBI using six impact energies ranging from 0.1 to 0.7 J, and post-TBI outcomes were assessed over an acute period of 14 days. Here we report that single TBI using CHIMERA induces injury dose- and time-dependent changes in behavioral and neurological deficits, axonal damage, white matter tract microgliosis and astrogliosis. Impact energies of 0.41 or below produced no significant phenotype (subthreshold), 0.5 J led to significant changes for one or more phenotypes (threshold), and 0.6 and 0.7 J resulted in significant changes in all outcomes assessed (mTBI). We further show that linear head kinematics are the most robust predictors of duration of unconsciousness, severity of neurological deficits, white matter injury, and microgliosis following single TBI. Our data extend the validation of CHIMERA as a biofidelic animal model of DAI and establish working parameters to guide future investigations of the mechanisms underlying axonal pathology and inflammation induced by mechanical trauma. Crown Copyright (C) 2017 Published by Elsevier Inc.	[Namjoshi, Dhananjay R.; Cheng, Wai Hang; Bashir, Asma; Wilkinson, Anna; Stukas, Sophie; Martens, Kris M.; Wellington, Cheryl L.] Univ British Columbia, Dept Pathol & Lab Med, Djavad Mowafaghian Ctr Brain Hlth, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada; [Whyte, Tom; Abebe, Zelalem A.; McInnes, Kurt A.; Cripton, Peter A.] Univ British Columbia, Dept Mech Engn, Vancouver, BC, Canada; [Whyte, Tom; Abebe, Zelalem A.; McInnes, Kurt A.; Cripton, Peter A.; Wellington, Cheryl L.] Univ British Columbia, Int Collaborat Repair Discoveries, Vancouver, BC, Canada		Wellington, CL (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Djavad Mowafaghian Ctr Brain Hlth, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	dnamjoshi@gmail.com; chengwh@mail.ubc.ca; asmab@mail.ubc.ca; wanna@mail.ubc.ca; stukas@mail.ubc.ca; krismmartens@gmail.com; tom@mech.ubc.ca; cripton@mech.ubc.ca; wcheryl@mail.ubc.ca	Cripton, Peter Alec/AAC-8268-2020	Cripton, Peter Alec/0000-0002-5067-0833; Stukas, Sophie/0000-0001-8819-8821; McInnes, Kurt/0000-0001-5931-2963; Cheng, Wai Hang/0000-0002-3408-9184; Whyte, Tom/0000-0002-3562-3844; Bashir, Asma/0000-0002-3616-9436; Namjoshi, Dhananjay/0000-0003-1753-5581	Alzheimer Society Research Program Doctoral Award; Comissao Technica de Atribuicao de Bolsas para Estudos Pos Graduados Macao; Canadian Institutes for Health Research Graduate Fellowship; University of British Columbia Doctoral Fellowship; Weston Brain Institute	Operating funding for this project was supplied by a Transformational Grant from the Weston Brain Institute to C.L.W. W H.C. is supported by Alzheimer Society Research Program Doctoral Award and Comissao Technica de Atribuicao de Bolsas para Estudos Pos Graduados Macao. A.B. is supported by Canadian Institutes for Health Research Graduate Fellowship and University of British Columbia Doctoral Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bogoslovsky T, 2016, DIAGNOSTICS, V6, DOI 10.3390/diagnostics6040037; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Coats B, 2017, J NEUROTRAUM, V34, P235, DOI 10.1089/neu.2015.4352; Courtney A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00221; Cullen DK, 2016, METHODS MOL BIOL, V1462, P289, DOI 10.1007/978-1-4939-3816-2_17; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hodgson V.R., 1971, COMPARISON HEAD ACCE; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kamins J, 2016, NEUROSURG CLIN N AM, V27, P441, DOI 10.1016/j.nec.2016.05.005; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Ommaya A.K., 1967, SCALING EXPT DATA CE; Oresic M, 2016, EBIOMEDICINE, V12, P118, DOI 10.1016/j.ebiom.2016.07.015; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; SINHA JN, 1968, JPN J PHARMACOL, V18, P519, DOI 10.1254/jjp.18.519; Szabo T.J., 1996, HUMAN SUBJECT KINEMA; Te Ao B, 2014, NEUROLOGY, V83, P1645, DOI 10.1212/WNL.0000000000000933; TEASDALE G, 1974, LANCET, V2, P81; United Sates Departments of Defense and Veterans Affairs, 2008, COMM DEF TBI; Warner, 1991, FORCE DEFLECTION FRA; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	37	43	43	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2017	292						80	91		10.1016/j.expneurol.2017.03.003			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ET5FR	WOS:000400310100008	28274861	hybrid			2022-02-06	
J	Eskreis-Winkler, S; Zhang, Y; Zhang, JW; Liu, Z; Dimov, A; Gupta, A; Wang, Y				Eskreis-Winkler, Sarah; Zhang, Yan; Zhang, Jingwei; Liu, Zhe; Dimov, Alexey; Gupta, Ajay; Wang, Yi			The clinical utility of QSM: disease diagnosis, medical management, and surgical planning	NMR IN BIOMEDICINE			English	Article; Proceedings Paper	4th International Workshop on MRI Phase Contrast and Quantitative Susceptibility Mapping (QSM)	SEP 26-28, 2016	Univ Graz, Graz, AUSTRIA		Univ Graz	QSM; quantitative susceptibility mapping; susceptibility-weighted imaging; iron; neurological; neurodegenerative diseases	SUSCEPTIBILITY MAPPING QSM; MULTIPLE-SCLEROSIS LESIONS; BACKGROUND FIELD REMOVAL; OXYGEN EXTRACTION FRACTION; ENABLED DIPOLE INVERSION; IMAGING FILTERED PHASE; GRADIENT-ECHO MRI; MAGNETIC-SUSCEPTIBILITY; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA	Quantitative susceptibility mapping (QSM) is an MR technique that depicts and quantifies magnetic susceptibility sources. Mapping iron, the dominant susceptibility source in the brain, has many important clinical applications. Herein, we review QSM applications in the diagnosis, medical management, and surgical treatment of disease. To assist in early disease diagnosis, QSM can identify elevated iron levels in the motor cortex of amyotrophic lateral sclerosis patients, in the substantia nigra of Parkinson's disease (PD) patients, in the globus pallidus, putamen, and caudate of Huntington's disease patients, and in the basal ganglia of Wilson's disease patients. Additionally, QSM can distinguish between hemorrhage and calcification, which could prove useful in tumor subclassification, and can measure microbleeds in traumatic brain injury patients. In guiding medical management, QSM can be used to monitor iron chelation therapy in PD patients, to monitor smoldering inflammation of multiple sclerosis (MS) lesions after the blood-brain barrier (BBB) seals, to monitor active inflammation of MS lesions before the BBB seals without using gadolinium, and to monitor hematoma volume in intracerebral hemorrhage. QSM can also guide neurosurgical treatment. Neurosurgeons require accurate depiction of the subthalamic nucleus, a tiny deep gray matter nucleus, prior to inserting deep brain stimulation electrodes into the brains of PD patients. QSM is arguably the best imaging tool for depiction of the subthalamic nucleus. Finally, we discuss future directions, including bone QSM, cardiac QSM, and using QSM to map cerebral metabolic rate of oxygen. Copyright (C) 2016 John Wiley & Sons, Ltd.	[Eskreis-Winkler, Sarah; Zhang, Yan; Zhang, Jingwei; Liu, Zhe; Dimov, Alexey; Gupta, Ajay; Wang, Yi] Weill Cornell Med, Dept Radiol, New York, NY 10065 USA		Wang, Y (corresponding author), Weill Cornell Med, Dept Radiol, New York, NY 10065 USA.	yiwang@med.cornell.edu	Dimov, Alexey V./AAC-4157-2019	Dimov, Alexey V./0000-0003-0460-6635	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA178007]; National Institute of Biomedical Imaging and EngineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB013443]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS095562, R01 NS090464, R01 NS072370]	Sponsors: National Cancer Institute, R01 CA178007; National Institute of Biomedical Imaging and Engineering, R01 EB013443; National Institute of Neurological Disorders and Stroke, R01 NS095562, R01 NS090464, R01 NS072370.	Acosta-Cabronero J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081093; Atasoy HT, 2004, NEUROL INDIA, V52, P332; Ayton S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7760; Azuma M, 2016, AM J NEURORADIOL, V37, P782, DOI 10.3174/ajnr.A4645; Beard JL, 2003, ANNU REV NUTR, V23, P41, DOI 10.1146/annurev.nutr.23.020102.075739; Bian W, 2016, AM J NEURORADIOL, V37, P1808, DOI 10.3174/ajnr.A4830; Bilgic B, 2014, MAGN RESON MED, V72, P1444, DOI 10.1002/mrm.25029; Blazejewska AI, 2015, J MAGN RESON IMAGING, V41, P1065, DOI 10.1002/jmri.24644; Blystad I, 2016, AM J NEURORADIOL, V37, P94, DOI 10.3174/ajnr.A4501; Brar S, 2009, ARCH NEUROL-CHICAGO, V66, P371, DOI 10.1001/archneurol.2008.586; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Bulte DP, 2012, NEUROIMAGE, V60, P582, DOI 10.1016/j.neuroimage.2011.12.017; Cellura E, 2012, CLIN NEUROL NEUROSUR, V114, P550, DOI 10.1016/j.clineuro.2011.11.026; Chandran AS, 2016, J NEUROSURG, V124, P96, DOI 10.3171/2015.1.JNS142066; Chawla S, 2016, AM J NEURORADIOL, V37, P1223, DOI 10.3174/ajnr.A4729; Chen WW, 2014, RADIOLOGY, V271, P183, DOI 10.1148/radiol.13130353; Chen WW, 2014, RADIOLOGY, V270, P496, DOI 10.1148/radiol.13122640; Crichton RR, 2011, J NEURAL TRANSM, V118, P301, DOI 10.1007/s00702-010-0470-z; de Hollander G, 2014, HUM BRAIN MAPP, V35, P4440, DOI 10.1002/hbm.22485; de Rochefort L, 2008, MAGN RESON MED, V60, P1003, DOI 10.1002/mrm.21710; de Rochefort L, 2010, MAGN RESON MED, V63, P194, DOI 10.1002/mrm.22187; Deh K, 2015, J MAGN RESON IMAGING, V42, P1592, DOI 10.1002/jmri.24943; Deistung A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057924; Devos D, 2014, ANTIOXID REDOX SIGN, V21, P195, DOI 10.1089/ars.2013.5593; DEXTER DT, 1987, LANCET, V2, P1219; DEXTER DT, 1992, ANN NEUROL, V32, pS94, DOI 10.1002/ana.410320716; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; Dominguez DJ, 2015, J NEUROL NEUROSURG P; Du GW, 2016, MOVEMENT DISORD, V31, P317, DOI 10.1002/mds.26417; Du GW, 2011, MOVEMENT DISORD, V26, P1627, DOI 10.1002/mds.23643; Dwyer MG, 2015, J NEUROIMMUNOL, V281, P44, DOI 10.1016/j.jneuroim.2015.03.002; Eskreis-Winkler S, 2015, J MAGN RESON IMAGING, V42, P224, DOI 10.1002/jmri.24745; Fan AP, 2015, NEUROIMAGE, V104, P146, DOI 10.1016/j.neuroimage.2014.09.068; Fan AP, 2014, MAGN RESON MED, V72, P149, DOI 10.1002/mrm.24918; Fine JM, 2015, NEUROSCI LETT, V584, P362, DOI 10.1016/j.neulet.2014.11.013; Fritzsch D, 2014, INVEST RADIOL, V49, P299, DOI 10.1097/RLI.0000000000000010; Gauthier CJ, 2012, NEUROIMAGE, V60, P1212, DOI 10.1016/j.neuroimage.2011.12.056; Gross RE, 2006, MOVEMENT DISORD, V21, pS259, DOI 10.1002/mds.20960; Guan XJ, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3489; Guo C, 2013, NEUROBIOL AGING, V34, P562, DOI 10.1016/j.neurobiolaging.2012.05.009; Gupta A, 2014, AM J NEURORADIOL, V35, P250, DOI 10.3174/ajnr.A3668; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 2015, MAGN RESON IMAGING, V33, P1, DOI 10.1016/j.mri.2014.09.004; Haacke EM, 2009, J MAGN RESON IMAGING, V29, P537, DOI 10.1002/jmri.21676; HALLGREN B, 1958, J NEUROCHEM, V3, P41, DOI 10.1111/j.1471-4159.1958.tb12607.x; Hametner S, 2013, ANN NEUROL, V74, P848, DOI 10.1002/ana.23974; Harrison DM, 2016, AM J NEURORADIOL, V37, P1447, DOI 10.3174/ajnr.A4726; Harrison TR, 2010, HARRISONS NEUROLOGY; Hinoda T, 2015, INVEST RADIOL, V50, P522, DOI 10.1097/RLI.0000000000000159; Ide S, 2015, EUR RADIOL, V25, P710, DOI 10.1007/s00330-014-3472-7; Kanda T, 2015, RADIOLOGY, V275, P803, DOI 10.1148/radiol.14140364; Kansagara D., 2013, COMPLICATIONS MILD T; Khabipova D, 2015, NEUROIMAGE, V107, P163, DOI 10.1016/j.neuroimage.2014.11.038; Klohs J, 2011, J CEREBR BLOOD F MET, V31, P2282, DOI 10.1038/jcbfm.2011.118; Kressler B, 2010, IEEE T MED IMAGING, V29, P273, DOI 10.1109/TMI.2009.2023787; Kudo K, 2016, J CEREBR BLOOD F MET, V36, P1424, DOI 10.1177/0271678X15606713; Kutzelnigg A, 2014, HAND CLINIC, V122, P15, DOI 10.1016/B978-0-444-52001-2.00002-9; Kwan JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035241; Langkammer C, 2015, NEUROIMAGE, V111, P622, DOI 10.1016/j.neuroimage.2015.02.041; Langkammer C, 2013, RADIOLOGY, V267, P551, DOI 10.1148/radiol.12120707; Langkammer C, 2012, NEUROIMAGE, V62, P1593, DOI 10.1016/j.neuroimage.2012.05.049; Lassmann H, 2011, J NEUROL SCI, V306, P167, DOI 10.1016/j.jns.2010.07.023; Li JQ, 2012, MAGN RESON MED, V68, P1563, DOI 10.1002/mrm.24135; Li W, 2016, NMR BIOMED; Li W, 2015, NEUROIMAGE, V108, P111, DOI 10.1016/j.neuroimage.2014.12.043; Li W, 2014, NMR BIOMED, V27, P219, DOI 10.1002/nbm.3056; Li W, 2011, NEUROIMAGE, V55, P1645, DOI 10.1016/j.neuroimage.2010.11.088; Li X, 2016, J MAGN RESON IMAGING, V43, P463, DOI 10.1002/jmri.24976; Li X, 2012, NEUROIMAGE, V62, P314, DOI 10.1016/j.neuroimage.2012.04.042; Lin PY, 2015, AM J NEURORADIOL, V36, P467, DOI 10.3174/ajnr.A4137; Liu CL, 2011, NEUROIMAGE, V56, P930, DOI 10.1016/j.neuroimage.2011.02.024; Liu CL, 2010, MAGN RESON MED, V63, P1471, DOI 10.1002/mrm.22482; Liu J, 2012, NEUROIMAGE, V59, P2560, DOI 10.1016/j.neuroimage.2011.08.082; Liu T, 2013, RADIOLOGY, V269, P216, DOI 10.1148/radiol.13121991; Liu T, 2013, MAGN RESON MED, V69, P467, DOI 10.1002/mrm.24272; Liu T, 2012, IEEE T MED IMAGING, V31, P816, DOI 10.1109/TMI.2011.2182523; Liu T, 2012, RADIOLOGY, V262, P269, DOI 10.1148/radiol.11110251; Liu T, 2011, MAGN RESON MED, V66, P777, DOI 10.1002/mrm.22816; Liu TA, 2010, MAGN RESON IMAGING, V28, P1383, DOI 10.1016/j.mri.2010.06.011; Liu T, 2009, MAGN RESON MED, V61, P196, DOI 10.1002/mrm.21828; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Lo CP, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-100; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Macellari F, 2014, STROKE, V45, P903, DOI 10.1161/STROKEAHA.113.003701; Makdissi M, 2014, AUST FAM PHYSICIAN, V43, P94; Mehta V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057573; Mikati AG, 2014, STROKE, V45, P598, DOI 10.1161/STROKEAHA.113.003548; Moon Y, 2016, J ALZHEIMERS DIS, V51, P737, DOI 10.3233/JAD-151037; Murakami Y, 2015, AM J NEURORADIOL, V36, P1102, DOI 10.3174/ajnr.A4260; Nijeholt GJLA, 1998, BRAIN, V121, P687, DOI 10.1093/brain/121.4.687; Ogasawara A, 2015, EUR RADIOL; Barbosa JHO, 2015, MAGN RESON IMAGING, V33, P559, DOI 10.1016/j.mri.2015.02.021; Planting BR, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00876; Press D, 2016, CHOLINESTERASE INHIB; Radbruch A, 2015, RADIOLOGY, V275, P783, DOI 10.1148/radiol.2015150337; Raven EP, 2013, J ALZHEIMERS DIS, V37, P127, DOI 10.3233/JAD-130209; Richter EO, 2004, J NEUROSURG, V100, P541, DOI 10.3171/jns.2004.100.3.0541; Roccatagliata L, 2009, RADIOLOGY, V251, P503, DOI 10.1148/radiol.2511081269; Rouault TA, 2013, NAT REV NEUROSCI, V14, P551, DOI 10.1038/nrn3453; Rudko DA, 2014, RADIOLOGY, V272, P851, DOI 10.1148/radiol.14132475; Santin MD, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3491; Schafer A, 2012, HUM BRAIN MAPP, V33, P2831, DOI 10.1002/hbm.21404; Schenck J, 2015, ISMRM 23 ANN M EXH C; Schenck John F, 2006, Top Magn Reson Imaging, V17, P41, DOI 10.1097/01.rmr.0000245455.59912.40; Schmalbrock P, 2016, AM J NEURORADIOL, V37, P439, DOI 10.3174/ajnr.A4599; Schweitzer AD, 2015, AM J ROENTGENOL, V204, P1086, DOI 10.2214/AJR.14.13459; Schweser F, 2011, NEUROIMAGE, V54, P2789, DOI 10.1016/j.neuroimage.2010.10.070; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Shinohara RT, 2012, AM J NEURORADIOL, V33, P1586, DOI 10.3174/ajnr.A2997; Shmueli K, 2009, MAGN RESON MED, V62, P1510, DOI 10.1002/mrm.22135; Stuber C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010100; Sun HF, 2015, NEUROIMAGE, V105, P486, DOI 10.1016/j.neuroimage.2014.11.010; Sun HF, 2014, MAGN RESON MED, V71, P1151, DOI 10.1002/mrm.24765; Tan H, 2016, AM J NEURORADIOL, V37, P1209, DOI 10.3174/ajnr.A4724; Tan H, 2014, INVEST RADIOL, V49, P498, DOI 10.1097/RLI.0000000000000043; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; Treaba CA, 2014, DIAGN INTERV RADIOL, V20, P178, DOI 10.5152/dir.2013.13313; van Bergen JMG, 2016, AM J NEURORADIOL, V37, P789, DOI 10.3174/ajnr.A4617; Vega RA, 2014, NEUROSURG CLIN N AM, V25, P159, DOI 10.1016/j.nec.2013.08.008; WALSHE JM, 1993, Q J MED, V86, P197; Wang S, 2013, IEEE T BIO-MED ENG, V60, P3441, DOI 10.1109/TBME.2013.2266795; Wang S, 2013, STROKE, V44, P2315, DOI 10.1161/STROKEAHA.113.001638; Wang Y, 2015, MAGN RESON MED, V73, P82, DOI 10.1002/mrm.25358; Wang Y, 2009, IEEE ENG MED BIO, P53, DOI 10.1109/IEMBS.2009.5335128; Ward R, 2014, LANCET NEUROL, V13, P1045, DOI 10.1016/S1474-4422(14)70117-6; Wehrli FW, 2016, AM J NEURORADIOL; Wen Y, 2016, MAGN RESON MED, V75, P823, DOI 10.1002/mrm.25652; Wen Y, 2014, MAGN RESON MED, V72, P1065, DOI 10.1002/mrm.24998; Wharton S, 2010, MAGN RESON MED, V63, P1292, DOI 10.1002/mrm.22334; Wisnieff C, 2014, ANN M INT SOC MAGN R, P3403; Wisnieff C, 2016, MAGN RESON IMAGING, V34, P682, DOI 10.1016/j.mri.2015.12.003; Wisnieff C, 2015, MAGN RESON MED, V74, P564, DOI 10.1002/mrm.25420; Wisnieff C, 2013, NEUROIMAGE, V70, P363, DOI 10.1016/j.neuroimage.2012.12.050; Xie LK, 2016, AM J PHYSIOL-RENAL, V310, pF174, DOI 10.1152/ajprenal.00351.2015; Xu B, 2014, MAGN RESON MED, V72, P438, DOI 10.1002/mrm.24937; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537; Zhang JW, 2015, MAGN RESON MED, V74, P945, DOI 10.1002/mrm.25463; Zhang Y, 2016, AM J NEURORADIOL, V37, P1794, DOI 10.3174/ajnr.A4856; Zhang Y, 2016, AM J NEURORADIOL, V37, P1629, DOI 10.3174/ajnr.A4825; Zhang Y, 2015, 31 C ECTRIMS BARC SP, P986; Zhang Y, 2016, J MAGN RESON IMAGING, V44, P426, DOI 10.1002/jmri.25144; Zhou D, 2014, NMR BIOMED, V27, P312, DOI 10.1002/nbm.3064; Zivadinov R, 2012, NEUROIMAGE, V59, P331, DOI 10.1016/j.neuroimage.2011.07.045	143	43	45	2	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	APR	2017	30	4			SI				e3668	10.1002/nbm.3668			11	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	EQ5CY	WOS:000398100400008	27906525				2022-02-06	
J	Moore, RD; Lepine, J; Ellemberg, D				Moore, R. Davis; Lepine, Julien; Ellemberg, Dave			The independent influence of concussive and sub-concussive impacts on soccer players' neurophysiological and neuropsychological function	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Sub-concussion; Concussion; Neurophysiology; ERPs; Neuropsychology	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; DEFAULT MODE NETWORK; HEAD IMPACTS; NEUROCOGNITIVE PERFORMANCE; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; COGNITIVE CONTROL; SPORT HELD; FEMALE	Accumulating research demonstrates that repetitive sub-concussive impacts can alter the structure, function and connectivity of the brain. However, the functional significance of these alterations as well as the independent contribution of concussive and sub-concussive impacts to neurophysiological and neuropsychological health are unclear. Accordingly, we compared the neurophysiological and neuropsychological function of contact athletes with (concussion group) and without (sub-concussion group) a history of concussion, to non-contact athletes. We evaluated event-related brain potentials (ERPs) elicited during an oddball task and performance on a targeted battery of neuropsychological tasks. Athletes in the sub-concussion and concussion groups exhibited similar amplitude reductions in the ERP indices of attentional resource allocation (P3b) and attentional orienting (P3a) relative to non-contact athletes. However, only athletes in the concussion group exhibited reduced amplitude in the ERP index of perceptual attention (N1). Athletes in the sub-concussion and concussion groups also exhibited deficits in memory recall relative to non-contact athletes, but athletes in the concussion group also exhibited significantly more recall errors than athletes in the sub-concussion group. Additionally, only athletes in the concussion group exhibited response delays during the oddball task. The current findings suggest that sub concussive impacts are associated with alterations in the neurophysiological and neuropsychological indices of essential cognitive functions, albeit to a lesser degree than the combination of sub-concussive and concussive impacts. (C) 2016 Elsevier B.V. All rights reserved.	[Moore, R. Davis] Univ South Carolina, Arnold Sch Publ Hlth, 921 Assembly St, Columbia, SC 29201 USA; [Lepine, Julien; Ellemberg, Dave] Univ Montreal, Dept Kinesiol, 100 Boul Edouard Montpetit, Montreal, PQ H3T 1J4, Canada		Moore, RD (corresponding author), Univ South Carolina, Arnold Sch Publ Hlth, 921 Assembly St, Columbia, SC 29201 USA.	moorerd3@mailbox.sc.edu; julien.lepine@umontreal.ca; dave.ellemberg@umontreal.ca			CIHRCanadian Institutes of Health Research (CIHR) [R0017986] Funding Source: Medline		Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHL TRAIN SPORTS HL, V6, P1; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Buckner RL, 2012, NEUROIMAGE, V62, P1137, DOI 10.1016/j.neuroimage.2011.10.035; Castelli D. M., 2012, DEV COGNITIVE NEU S1, V2, P590; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Culbertson WC, 1998, ASSESSMENT, V5, P215, DOI 10.1177/107319119800500302; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; DONCHIN E, 1981, PSYCHOPHYSIOLOGY, V18, P493, DOI 10.1111/j.1469-8986.1981.tb01815.x; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; HILLYARD SA, 1984, PERCEPT PSYCHOPHYS, V36, P185, DOI 10.3758/BF03202679; Hillyard SA, 1998, P NATL ACAD SCI USA, V95, P781, DOI 10.1073/pnas.95.3.781; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Koerte IK, 2015, J NEUROTRAUMA; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Luck S. J., 2005, EVENT RELATED POTENT; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moore R. D., 2015, BIOL PSYCHOL; Moore RD, 2014, J ATHL TRAINING, V49, P24, DOI 10.4085/1062-6050-49.1.01; Munte T.F., 2000, HDB NEUROPSYCHOLOGY, P139; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Nieuwenhuis S, 2005, PSYCHOL BULL, V131, P510, DOI 10.1037/0033-2909.131.4.510; Oostenveld R, 2001, CLIN NEUROPHYSIOL, V112, P713, DOI 10.1016/S1388-2457(00)00527-7; Polich J., 2003, THEORETICAL OVERVIEW; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Slobounov S, 2012, CLIN NEUROPHYSIOL, V123, P1755, DOI 10.1016/j.clinph.2011.12.022; Smith A., 1982, PSYCHOL SERVICES; Stephens R., 2010, J NEUROPSYCHIATRY CL; Straume-Naesheim TM, 2009, NEUROSURGERY, V64, P719, DOI 10.1227/01.NEU.0000340681.12949.6D; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; TUCKER DM, 1993, ELECTROEN CLIN NEURO, V87, P154, DOI 10.1016/0013-4694(93)90121-B; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zillmer E.A., 2001, TOWER LONDON DX TOLD	65	43	43	1	31	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	FEB	2017	112						22	30		10.1016/j.ijpsycho.2016.11.011			9	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	EJ5GK	WOS:000393245600003	27867100				2022-02-06	
J	Storey, EP; Master, SR; Lockyer, JE; Podolak, OE; Grady, MF; Master, CL				Storey, Eileen P.; Master, Stephen R.; Lockyer, Julia E.; Podolak, Olivia E.; Grady, Matthew F.; Master, Christina L.			Near Point of Convergence after Concussion in Children	OPTOMETRY AND VISION SCIENCE			English	Article						concussion; mild traumatic brain injury; near point of convergence; Brock string; pencil pushups; vision therapy	SPORT-RELATED CONCUSSION; VISUAL FUNCTION; HIGH-SCHOOL; RECOVERY; NEARPOINT	Purpose. To determine the incidence of abnormal near point of convergence (NPC) after acute concussion in pediatric patients and to describe the clinical course of such patients. Methods. A retrospective cohort study of 275 pediatric patients 5 to 18 years of age presenting to a tertiary care children's hospital subspecialty concussion program with a new concussion between July 1, 2014 and June 30, 2015 was conducted. Results. Sixty-seven out of 275 pediatric patients presenting to a subspecialty concussion referral program were found to have abnormal NPC on physical examination as measured by an accommodative rule. Twenty-six (46%) patients recovered with standard clinical care over a median time frame of 4.5 weeks (range 1-18), including a brief period of cognitive and physical rest followed by gradual return to school and physical activities without any formal interventions. An additional 23 (41%) patients recovered a median of 11 weeks post-injury after referral for formal vestibular therapy, including interventions for abnormal convergence, such as Brock string and pencil pushups. Seven (13%) patients with persistent abnormal NPC and concomitant symptoms that necessitated referral for formal office-based vision therapy with developmental optometry recovered a median of 23 weeks post-injury and a median of 16 weeks after referral to vision therapy. Conclusions. Assessment for NPC is a diagnostic entity that warrants consideration in children with concussion. Concussion questionnaires may not be sensitive to detect vision symptoms in children, making an accurate assessment for convergence important in the evaluation of concussion. Some children with abnormal NPC will recover without any formal intervention after concussion; however, a subset of patients with persistent abnormal NPC after concussion may benefit from interventions including vestibular and/or vision therapy.	[Storey, Eileen P.; Lockyer, Julia E.; Podolak, Olivia E.; Grady, Matthew F.; Master, Christina L.] Childrens Hosp Philadelphia, Div Orthoped Surg, Philadelphia, PA 19104 USA; [Master, Stephen R.] Weill Cornell Med Sch, New York, NY USA; [Grady, Matthew F.; Master, Christina L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA		Master, CL (corresponding author), Childrens Hosp Philadelphia, Div Orthoped, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	masterc@email.chop.edu		Master, Christina/0000-0002-6717-4270			Baker JG, 2014, INT J CLIN PRACT, V68, P1286, DOI 10.1111/ijcp.12517; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Faul M, 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hayes GJ, 1998, OPTOMETRY VISION SCI, V75, P506, DOI 10.1097/00006324-199807000-00019; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Pardini D, 2004, BRIT J SPORT MED, V38, P654; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Scheiman M, 2005, ARCH OPHTHALMOL-CHIC, V123, P14, DOI 10.1001/archopht.123.1.14; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Thiagarajan P, 2013, J REHABIL RES DEV, V50, P1223, DOI 10.1682/JRRD.2012.12.0235; Zuckerman SL, 2012, NEUROSURGERY, V71, pE558, DOI 10.1227/01.neu.0000417735.94052.d6	26	43	43	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	JAN	2017	94	1					96	100		10.1097/OPX.0000000000000910			5	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Ophthalmology	EM5ZZ	WOS:000395393900013	27391530				2022-02-06	
J	Wang, ZC; Nong, J; Shultz, RB; Zhang, ZL; Kim, T; Tom, VJ; Ponnappan, RK; Zhong, YH				Wang, Zhicheng; Nong, Jia; Shultz, Robert B.; Zhang, Zhiling; Kim, Taegyo; Tom, Veronica J.; Ponnappan, Ravi K.; Zhong, Yinghui			Local delivery of minocycline from metal ion-assisted self-assembled complexes promotes neuroprotection and functional recovery after spinal cord injury	BIOMATERIALS			English	Article						Spinal cord injury; Minocycline; Drug delivery; Neuroprotection; Inflammation; Secondary injury	INTRACEREBRAL-HEMORRHAGE; PROVIDES NEUROPROTECTION; CELL-DEATH; APOPTOSIS; OLIGODENDROCYTES; CONTUSION; MICROGLIA; BRAIN; PROLIFERATION; NEUROTOXICITY	Many mechanisms contribute to the secondary injury cascades following traumatic spinal cord injury (SCI). However, most current treatment strategies only target one or a few elements in the injury cascades, and have been largely unsuccessful in clinical trials. Minocycline hydrochloride (MH) is a clinically available antibiotic and anti-inflammatory drug that has been shown to target a broad range of secondary injury mechanisms via its anti-inflammatory, anti-oxidant, and anti-apoptotic properties. However, MH is only neuroprotective at high concentrations. The inability to translate the high doses of MH used in experimental animals to tolerable doses in human patients limits its clinical efficacy. In addition, the duration of MH treatment is limited because long-term systemic administration of high doses of MH has been shown to cause liver toxicity and even death. We have developed a drug delivery system in the form of hydrogel loaded with polysaccharide-MH complexes self-assembled by metal ions for controlled release of MH. This drug delivery system can be injected into the intrathecal space for local delivery of MH with sufficient dose and duration, without causing any additional tissue damage. We show that local delivery of MH at a dose that is lower than the standard human dose (3 mg/kg) was more effective in reducing secondary injury and promoting locomotor functional recovery than systemic injection of MH with the highest dose and duration reported in experimental animal SCI (90-135 mg/kg). (C) 2016 Elsevier Ltd. All rights reserved.	[Wang, Zhicheng; Nong, Jia; Shultz, Robert B.; Zhang, Zhiling; Zhong, Yinghui] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA; [Kim, Taegyo; Tom, Veronica J.] Drexel Univ, Spinal Cord Res Ctr, Dept Neurobiol & Anat, Coll Med, Philadelphia, PA 19129 USA; [Ponnappan, Ravi K.] Drexel Univ, Coll Med, Dept Orthopaed Surg, Philadelphia, PA 19102 USA		Zhong, YH (corresponding author), Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA.	yz348@drexel.edu		Nong, Jia/0000-0002-9210-7707	National Institute of Neurological Disorders And Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS084379]; Drexel-Coulter Translational Research Partnership; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS084379] Funding Source: NIH RePORTER	We thank Dr. Narayan Avadhani (Department of Animal Biology, University of Pennsylvania) for kindly providing RAW264.7 macrophages. This work was supported by the National Institute of Neurological Disorders And Stroke of the National Institutes of Health under Award Number R21NS084379 and the Drexel-Coulter Translational Research Partnership.	Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Anderberg L, 2007, UPSALA J MED SCI, V112, P259, DOI 10.3109/2000-1967-200; Audet JN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034932; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Ek CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012021; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139; Ghica MV, 2011, PHARMAZIE, V66, P853, DOI 10.1691/ph.2011.1061; Goulden V, 1996, BRIT J DERMATOL, V134, P693, DOI 10.1111/j.1365-2133.1996.tb06972.x; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Iannotti CA, 2011, EXP NEUROL, V230, P3, DOI 10.1016/j.expneurol.2010.03.010; JOSHI YM, 1981, BIOPHYS CHEM, V13, P65, DOI 10.1016/0301-4622(81)80026-9; Kashi TSJ, 2012, INT J NANOMED, V7, P221, DOI 10.2147/IJN.S27709; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Koda M, 2002, J NEUROTRAUM, V19, P777, DOI 10.1089/08977150260139147; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; Kwon BK, 2011, J NEUROTRAUM, V28, P1545, DOI 10.1089/neu.2009.1149; LAMBS L, 1984, AGENTS ACTIONS, V14, P743, DOI 10.1007/BF01978919; Leal EC, 2015, AM J PATHOL, V185, P1638, DOI 10.1016/j.ajpath.2015.02.011; Lee JHT, 2010, SPINE, V35, P2041, DOI 10.1097/BRS.0b013e3181d2d6c5; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Garcia-Martinez EM, 2010, BIOCHEM PHARMACOL, V79, P239, DOI 10.1016/j.bcp.2009.07.028; Milane A, 2007, CHROMATOGRAPHIA, V65, P277, DOI 10.1365/s10337-006-0167-5; Nobunaga AI, 1999, ARCH PHYS MED REHAB, V80, P1372, DOI 10.1016/S0003-9993(99)90247-2; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Papa S, 2016, BIOMATERIALS, V75, P13, DOI 10.1016/j.biomaterials.2015.10.015; Papa S, 2013, ACS NANO, V7, P9881, DOI 10.1021/nn4036014; Paquette David W, 2002, Compend Contin Educ Dent, V23, P15; Pi RB, 2004, J NEUROCHEM, V91, P1219, DOI 10.1111/j.1471-4159.2004.02796.x; Pinney SP, 2003, J CARDIOVASC PHARM, V42, P469, DOI 10.1097/00005344-200310000-00003; Sandrow HR, 2008, EXP NEUROL, V210, P489, DOI 10.1016/j.expneurol.2007.11.029; Shoichet MS, 2007, PROG BRAIN RES, V161, P385, DOI 10.1016/S0079-6123(06)61027-3; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Singh A, 2014, J NEUROSCI METH, V226, P124, DOI 10.1016/j.jneumeth.2014.01.001; Soliman GM, 2010, MACROMOL BIOSCI, V10, P278, DOI 10.1002/mabi.200900259; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Sung JH, 2010, INT J PHARMACEUT, V392, P232, DOI 10.1016/j.ijpharm.2010.03.024; Takeda M, 2011, SPINE, V36, P1919, DOI 10.1097/BRS.0b013e3181ffda29; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka T. M., 2001, J NEUROCHEM, V91, P568; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Xue MZ, 2010, AM J PATHOL, V176, P1193, DOI 10.2353/ajpath.2010.090361; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zhang ZL, 2015, BIOFABRICATION, V7, DOI 10.1088/1758-5090/7/1/015006	57	43	45	4	67	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	JAN	2017	112						62	71		10.1016/j.biomaterials.2016.10.002			10	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	ED9CB	WOS:000389166700006	27744221	Green Accepted			2022-02-06	
J	Iverson, GL				Iverson, Grant L.			Suicide and Chronic Traumatic Encephalopathy	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MILD COGNITIVE IMPAIRMENT; STRESSFUL LIFE EVENTS; MAJOR DEPRESSION; BRAIN-INJURY; CHRONIC PAIN; ALZHEIMERS-DISEASE; RISK-FACTORS; PSYCHIATRIC-DISORDERS; COMPLETED SUICIDE; ADULT DEPRESSION	For nearly 80 years, suicidality was not considered to be a core clinical feature of chronic traumatic encephalopathy (CTE). In recent years, suicide has been widely cited as being associated with CTE, and now depression has been proposed to be one of three core diagnostic features alongside cognitive impairment and anger control problems. This evolution of the clinical features has been reinforced by thousands of media stories reporting a connection between mental health problems in former athletes and military veterans, repetitive neurotrauma, and CTE. At present, the science underlying the causal assumption between repetitive neurotrauma, depression, suicide, and the neuropathology believed to be unique to CTE is inconclusive. Epidemiological evidence indicates that former National Football League players, for example, are at lower, not greater, risk for suicide than men in the general population. This article aims to discuss the critical issues and literature relating to these possible relationships.	[Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGen Hosp Children Sports Concuss Program, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA		Iverson, GL (corresponding author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.; Iverson, GL (corresponding author), Spaulding Rehabil Hosp, Boston, MA USA.; Iverson, GL (corresponding author), MassGen Hosp Children Sports Concuss Program, Boston, MA USA.; Iverson, GL (corresponding author), Red Sox Fdn, Boston, MA USA.; Iverson, GL (corresponding author), Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA.	giverson@mgh.harvard.edu		Iverson, Grant/0000-0001-7348-9570			Almeida OP, 2014, J PSYCHIATR NEUROSCI, V39, P200, DOI 10.1503/jpn.130158; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anderson RJ, 2001, DIABETES CARE, V24, P1069, DOI 10.2337/diacare.24.6.1069; Arsenault-Lapierre G, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-37; ATKINSON JH, 1991, PAIN, V45, P111, DOI 10.1016/0304-3959(91)90175-W; Ayerbe L, 2013, BRIT J PSYCHIAT, V202, P14, DOI 10.1192/bjp.bp.111.107664; Banks SM, 1996, PSYCHOL BULL, V119, P95, DOI 10.1037/0033-2909.119.1.95; Barnes DE, 2006, ARCH GEN PSYCHIAT, V63, P273, DOI 10.1001/archpsyc.63.3.273; Baron SL, 2012, AM J CARDIOL, V109, P889, DOI 10.1016/j.amjcard.2011.10.050; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; BECK AT, 1990, AM J PSYCHIAT, V147, P190; BECK AT, 1985, AM J PSYCHIAT, V142, P559; Binder EB, 2010, MOL PSYCHIATR, V15, P574, DOI 10.1038/mp.2009.141; Blosnich J, 2013, ARCH SUICIDE RES, V17, P52, DOI 10.1080/13811118.2013.748415; Bodenmann G, 2013, CURR OPIN PSYCHIATR, V26, P464, DOI 10.1097/YCO.0b013e3283642de7; Bradley RG, 2008, ARCH GEN PSYCHIAT, V65, P190, DOI 10.1001/archgenpsychiatry.2007.26; Breslau N, 2000, NEUROLOGY, V54, P308, DOI 10.1212/WNL.54.2.308; Breslau N, 2003, NEUROLOGY, V60, P1308, DOI 10.1212/01.WNL.0000058907.41080.54; BRESLAU N, 1994, HEADACHE, V34, P387, DOI 10.1111/j.1526-4610.1994.hed3407387.x; Brown GK, 2014, CONCISE GUIDE TO UNDERSTANDING SUICIDE: EPIDEMIOLOGY, PATHOPHYSIOLOGY, AND PREVENTION, P42; Bruce JM, 2008, J GERIATR PSYCH NEUR, V21, P34, DOI 10.1177/0891988707311032; Bruffaerts R, 2010, BRIT J PSYCHIAT, V197, P20, DOI 10.1192/bjp.bp.109.074716; Bulloch A, 2012, DEPRESS ANXIETY, V29, P1058, DOI 10.1002/da.22001; Bulloch AG, 2009, DEPRESS ANXIETY, V26, P1172, DOI 10.1002/da.20618; Busch F.N., 2009, ADV PSYCHIAT TREATME, V15, P271, DOI [10.1192/apt.bp.107.004937, DOI 10.1192/APT.BP.107.004937]; Campbell LC, 2003, BIOL PSYCHIAT, V54, P399, DOI 10.1016/S0006-3223(03)00545-6; Castellani RJ, 2015, J NEUROPATH EXP NEUR, V74, P493, DOI 10.1097/NEN.0000000000000193; Cheng QJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108724; Conner KR, 2012, DRUG ALCOHOL DEPEN, V120, P155, DOI 10.1016/j.drugalcdep.2011.07.013; Conner KR, 2004, AM J GERIAT PSYCHIAT, V12, P37, DOI 10.1176/appi.ajgp.12.1.37; Conner KR, 2001, SUICIDE LIFE-THREAT, V31, P367, DOI 10.1521/suli.31.4.367.22048; Conwell Y, 2010, INT J GERIATR PSYCH, V25, P371, DOI 10.1002/gps.2348; Cottler LB, 2011, DRUG ALCOHOL DEPEN, V116, P188, DOI 10.1016/j.drugalcdep.2010.12.003; Critchley M, 1949, PUNCH DRUNK SYNDROME; Davis DS, 2014, J MED ETHICS, V40, P543, DOI 10.1136/medethics-2012-101022; Davis GA, 2015, NEUROSURGERY, V76, P643, DOI 10.1227/NEU.0000000000000722; DIAMOND J, 2005, IRRITABLE MALE SYNDR; Djamshidian A, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0285-6; Draper B, 2010, ALZHEIMERS DEMENT, V6, P75, DOI 10.1016/j.jalz.2009.04.1229; Farmer AE, 2003, PSYCHOL MED, V33, P1169, DOI 10.1017/S0033291703008419; Fassberg MM, 2012, INT J ENV RES PUB HE, V9, P722, DOI 10.3390/ijerph9030722; Fava M, 2010, MOL PSYCHIATR, V15, P856, DOI 10.1038/mp.2009.20; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Fishbain DA, 1997, CLIN J PAIN, V13, P116, DOI 10.1097/00002508-199706000-00006; Foster T, 2011, ARCH SUICIDE RES, V15, P1, DOI 10.1080/13811118.2011.540213; Friis RH, 2002, EUR PSYCHIAT, V17, P241, DOI 10.1016/S0924-9338(02)00682-X; Gatt JM, 2009, MOL PSYCHIATR, V14, P681, DOI 10.1038/mp.2008.143; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gonzalez HM, 2010, J PSYCHIATR RES, V44, P1043, DOI 10.1016/j.jpsychires.2010.03.017; Gothe F, 2012, PANMINERVA MED, V54, P161; Gvion Y, 2011, ARCH SUICIDE RES, V15, P93, DOI 10.1080/13811118.2011.565265; Halpin M, 2012, OMEGA-J DEATH DYING, V65, P317, DOI 10.2190/OM.65.4.e; Hassett AL, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0436-1; Hauger RL, 2009, ANN NY ACAD SCI, V1179, P120, DOI 10.1111/j.1749-6632.2009.05011.x; Heim C, 2008, PSYCHONEUROENDOCRINO, V33, P693, DOI 10.1016/j.psyneuen.2008.03.008; Heim C, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.041.2009; Hooley JM, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0435-2; Hung CI, 2006, CEPHALALGIA, V26, P26, DOI 10.1111/j.1468-2982.2005.00985.x; Ilgen MA, 2008, GEN HOSP PSYCHIAT, V30, P521, DOI 10.1016/j.genhosppsych.2008.09.003; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Iverson GL, 2014, BRIT J SPORT MED, V48, P162, DOI 10.1136/bjsports-2013-092935; Jaremka LM, 2013, DEPRESS ANXIETY, V30, P288, DOI 10.1002/da.22078; Ji NJ, 2014, J AFFECT DISORDERS, V156, P56, DOI 10.1016/j.jad.2013.11.015; Jopson NM, 2003, J PSYCHOSOM RES, V54, P503, DOI 10.1016/S0022-3999(02)00455-5; Kendler KS, 2000, AM J PSYCHIAT, V157, P1243, DOI 10.1176/appi.ajp.157.8.1243; Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P789, DOI 10.1001/archpsyc.60.8.789; Kendler KS, 2001, AM J PSYCHIAT, V158, P582, DOI 10.1176/appi.ajp.158.4.582; Kendler KS, 1999, AM J PSYCHIAT, V156, P837, DOI 10.1176/ajp.156.6.837; Khera M, 2013, ARCH ESP UROL, V66, P729; Kosteniuk JG, 2014, DEMENT GER COGN D EX, V4, P209, DOI 10.1159/000363226; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lee AR, 2014, PSYCHIAT RES, V219, P518, DOI 10.1016/j.psychres.2014.06.037; Lee GJ, 2012, BIOL PSYCHIAT, V71, P814, DOI 10.1016/j.biopsych.2011.12.024; Leung YW, 2012, PSYCHOSOM MED, V74, P786, DOI 10.1097/PSY.0b013e31826ddbed; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lin EHB, 2010, DIABETES CARE, V33, P264, DOI 10.2337/dc09-1068; Luppino FS, 2010, ARCH GEN PSYCHIAT, V67, P220, DOI 10.1001/archgenpsychiatry.2010.2; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, pE100, DOI 10.2105/AJPH.2013.301794; Mackin RS, 2012, INT J GERIATR PSYCH, V27, P355, DOI 10.1002/gps.2713; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martin LA, 2013, JAMA PSYCHIAT, V70, P1100, DOI 10.1001/jamapsychiatry.2013.1985; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McAuliffe C, 2002, BEHAV COGN PSYCHOTH, V30, P385, DOI 10.1017/S1352465802004010; McCarthy TC, 2015, NEWSDAY; McGirr Alexander, 2007, Curr Psychiatry Rep, V9, P460, DOI 10.1007/s11920-007-0062-2; McGuffin P, 2005, HUM MOL GENET, V14, P3337, DOI 10.1093/hmg/ddi363; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McWilliams LA, 2003, PAIN, V106, P127, DOI 10.1016/S0304-3959(03)00301-4; Medici M, 2014, J CLIN ENDOCR METAB, V99, P1213, DOI 10.1210/jc.2013-3589; Meng L, 2012, J HYPERTENS, V30, P842, DOI 10.1097/HJH.0b013e32835080b7; Millspaugh JA, 1937, US NAVAL MED B, V35, P297; Modrego PJ, 2004, ARCH NEUROL-CHICAGO, V61, P1290, DOI 10.1001/archneur.61.8.1290; Monroe SM, 2005, PSYCHOL REV, V112, P417, DOI 10.1037/0033-295X.112.2.417; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Mormont E, 2014, J GERIATR PSYCH NEUR, V27, P231, DOI 10.1177/0891988714532021; Naarding P, 2011, EXPERT REV NEUROTHER, V11, P77, DOI [10.1586/ern.10.92, 10.1586/ERN.10.92]; Naranjo DM, 2011, ANN FAM MED, V9, P115, DOI 10.1370/afm.1212; National Institute of Neurological Disorders and Stroke, 2015, 1 NIH CONS C DEF NEU; Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI 10.1038/mp.2009.29; Ohayon MM, 2004, ENCEPHALE, V30, P222; Olin JT, 2002, AM J GERIAT PSYCHIAT, V10, P125; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Palmer K, 2010, J ALZHEIMERS DIS, V20, P175, DOI 10.3233/JAD-2010-1352; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Perlis RH, 2009, ACTA PSYCHIAT SCAND, V119, P282, DOI 10.1111/j.1600-0447.2008.01298.x; Pollack W.S., 1998, NEW PSYCHOTHERAPY ME; Raskind MA, 2008, AM J MED, V121, P28, DOI 10.1016/j.amjmed.2008.09.011; Ravven S, 2013, HARVARD REV PSYCHIAT, V21, P59, DOI 10.1097/HRP.0b013e31828a3612; Richard E, 2013, JAMA NEUROL, V70, P383, DOI 10.1001/jamaneurol.2013.603; Richardson T, 2013, CLIN PSYCHOL REV, V33, P1148, DOI 10.1016/j.cpr.2013.08.009; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Scott KM, 2010, PSYCHOSOM MED, V72, P712, DOI 10.1097/PSY.0b013e3181e3333d; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sheftell FD, 2002, HEADACHE, V42, P934, DOI 10.1046/j.1526-4610.2002.02217.x; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simmons RD, 2010, NAT REV NEUROL, V6, P603, DOI 10.1038/nrneurol.2010.143; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Sisask M, 2012, INT J ENV RES PUB HE, V9, P123, DOI 10.3390/ijerph9010123; Steinberg M, 2008, INT J GERIATR PSYCH, V23, P170, DOI 10.1002/gps.1858; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Sullivan PF, 2000, AM J PSYCHIAT, V157, P1552, DOI 10.1176/appi.ajp.157.10.1552; Tang NKY, 2006, PSYCHOL MED, V36, P575, DOI 10.1017/S0033291705006859; Van der Mussele S, 2014, J ALZHEIMERS DIS, V42, P1239, DOI 10.3233/JAD-140405; Van Orden KA, 2005, CURR PSYCHIATRY REV, V1, P187, DOI 10.2174/1573400054065541; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Weir DR., 2009, NATL FOOTBALL LEAGUE; Wilcox HC, 2004, DRUG ALCOHOL DEPEN, V76, pS11, DOI 10.1016/j.drugalcdep.2004.08.003; Wilson KG, 2002, CLIN J PAIN, V18, P77, DOI 10.1097/00002508-200203000-00002; Winkler D, 2005, PSYCHOTHER PSYCHOSOM, V74, P303, DOI 10.1159/000086321; Wortzel HS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/424280; Yang AC, 2013, SOC PSYCH PSYCH EPID, V48, P427, DOI 10.1007/s00127-012-0562-1; Yeap BB, 2014, MATURITAS, V79, P227, DOI 10.1016/j.maturitas.2014.05.015; Zarrour FA, 2009, J PSYCHIATR PRACT, V15, P289, DOI 10.1097/01.pra.0000358315.88931.fc	140	43	44	3	298	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2016	28	1					9	16		10.1176/appi.neuropsych.15070172			8	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	DM0PB	WOS:000376046800013	26449269	Bronze			2022-02-06	
J	Feather-Schussler, DN; Ferguson, TS				Feather-Schussler, Danielle N.; Ferguson, Tanya S.			A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Medicine; Issue 117; Behavior; neonatal mouse; motor deficits; cerebral palsy; hypoxia; ischemia; inflammation; neonatal motor tests	SPINAL-CORD; ADULT; INJURY; BEHAVIOR; BRAIN; RATS	As the sheer number of transgenic mice strains grow and rodent models of pediatric disease increase, there is an expanding need for a comprehensive, standardized battery of neonatal mouse motor tests. These tests can validate injury or disease models, determine treatment efficacy and/or assess motor behaviors in new transgenic strains. This paper presents a series of neonatal motor tests to evaluate general motor function, including ambulation, hindlimb foot angle, surface righting, negative geotaxis, front-and hindlimb suspension, grasping reflex, four limb grip strength and cliff aversion. Mice between the ages of post-natal day 2 to 14 can be used. In addition, these tests can be used for a wide range of neurological and neuromuscular pathologies, including cerebral palsy, hypoxic-ischemic encephalopathy, traumatic brain injury, spinal cord injury, neurodegenerative diseases, and neuromuscular disorders. These tests can also be used to determine the effects of pharmacological agents, as well as other types of therapeutic interventions. In this paper, motor deficits were evaluated in a novel neonatal mouse model of cerebral palsy that combines hypoxia, ischemia and inflammation. Forty-eight hours after injury, five tests out of the nine showed significant motor deficits: ambulation, hindlimb angle, hindlimb suspension, four limb grip strength, and grasping reflex. These tests revealed weakness in the hindlimbs, as well as fine motor skills such as grasping, which are similar to the motor deficits seen in human cerebral palsy patients.	[Feather-Schussler, Danielle N.; Ferguson, Tanya S.] Temple Univ, Lewiz Katz Sch Med, Dept Med Genet & Mol Biochem, Philadelphia, PA 19122 USA; [Feather-Schussler, Danielle N.; Ferguson, Tanya S.] Shriners Hosp Pediat Res Ctr, Philadelphia, PA 19140 USA		Ferguson, TS (corresponding author), Temple Univ, Lewiz Katz Sch Med, Dept Med Genet & Mol Biochem, Philadelphia, PA 19122 USA.; Ferguson, TS (corresponding author), Shriners Hosp Pediat Res Ctr, Philadelphia, PA 19140 USA.	tanyaf@temple.edu			Shriners Hospitals	We would like to thank everyone at Shriners Hospital Pediatric Research Center, in particular Dr. Mickey Seltzer, of whom without his support, this work would not have been funded. In addition, we would like to thank Isha Srivastava, who contributed to early data collection and Amy He, who helped with the figures. This study was funded by Shriners Hospitals for Children. No funding source played a role in experimental design or decision to submit the paper for publication.	Balasubramaniam J., 2005, J CEREBR BLOOD F MET; BARRETT CP, 1984, EXP NEUROL, V84, P374, DOI 10.1016/0014-4886(84)90234-6; Carlson G., 2011, EXPT PROTOCOLS SMA A; Corti S., 2014, TREAT NMD EXPT PROTO; Corti S, 2008, J CLIN INVEST, V118, P3316, DOI 10.1172/JCI35432; Craig A, 2003, EXP NEUROL, V181, P231, DOI 10.1016/S0014-4886(03)00032-3; Cusick CG, 1996, PROG BRAIN RES, V108, P379, DOI 10.1016/S0079-6123(08)62553-4; El-Khodor B. F., 2011, EXPT PROTOCOLS SMA A; El-Khodor BF, 2008, EXP NEUROL, V212, P29, DOI 10.1016/j.expneurol.2008.02.025; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; FOX WM, 1965, ANIM BEHAV, V13, P234, DOI 10.1016/0003-3472(65)90041-2; Futagi Y, 2012, INT J PEDIAT, V2012, DOI 10.1155/2012/191562; Gordon AM, 1999, DEV MED CHILD NEUROL, V41, P586, DOI 10.1017/S0012162299001231; Grondard C, 2005, J NEUROSCI, V25, P7615, DOI 10.1523/JNEUROSCI.1245-05.2005; Heyser Charles J, 2004, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0818s25; Hill JM, 2008, PROCEEDINGS OF THE 3RD FRONTIERS IN BIOMEDICAL DEVICES CONFERENCE - 2008, P39; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Shen Y., 2010, J VIS EXP; Shen Y, 2012, J NEUROSCI RES, V90, P105, DOI 10.1002/jnr.22722; Tremml P, 1998, BEHAV BRAIN RES, V95, P65, DOI 10.1016/S0166-4328(97)00211-8; Venerosi A, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-12; Villapol S, 2008, NEUROSCIENTIST, V14, P339, DOI 10.1177/1073858408316003; WAHLSTEN D, 1974, BRAIN RES, V72, P251, DOI 10.1016/0006-8993(74)90863-4; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; WILLIAMS E, 1953, BEHAVIOUR, V6, P35, DOI 10.1163/156853954X00031; Yu Y., 2016, COMB SECT M IN PRESS	26	43	43	1	5	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	NOV	2016		117							e53569	10.3791/53569			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ1QX	WOS:000397845800005	27842358	Green Published, Bronze			2022-02-06	
J	Tirabassi, J; Brou, L; Khodaee, M; Lefort, R; Fields, SK; Comstock, RD				Tirabassi, Jill; Brou, Lina; Khodaee, Morteza; Lefort, Roxanna; Fields, Sarah K.; Comstock, R. Dawn			Epidemiology of High School Sports-Related Injuries Resulting in Medical Disqualification 2005-2006 Through 2013-2014 Academic Years	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						adolescent; fracture; concussion; ligaments	REHABILITATION; PREVENTION; PATTERNS; ATHLETE	Background: Although rare, season-or career-ending injuries in young athletes are concerning because they can result in time lost from sport participation and school, social costs, and economic costs of medical care. Purpose: To describe rates and patterns of medically disqualifying (MDQ) injuries among United States high school athletes overall and by sport, sex, type of athletic activity, and mechanism. Study Design: Descriptive epidemiological study. Methods: Sports-related injury data on high school athletes were collected during the 2005-2006 through 2013-2014 academic years from a large national sample of United States high schools via High School Reporting Information Online (RIO). MDQ injuries were defined as season-or career-ending injuries. Results: From 2005-2006 through 2013-2014, High School RIO captured 59,862 total injuries including 3599 MDQ injuries (6.0% of all injuries). Most MDQ injuries (60.4%) occurred in competition. Football had the highest injury rate (26.5 per 100,000 athlete-exposures), followed by gymnastics (18.6) and wrestling (17.9). MDQ injury rates were higher among girls in the sex-comparable sports of basketball (rate ratio [RR], 1.6; 95% CI, 1.3-2.0), cross-country (RR, 2.6; 95% CI, 1.0-7.5), soccer (RR, 1.6; 95% CI, 1.3-1.9), and track and field (RR, 2.6; 95% CI, 1.7-4.0). Player-player contact (48.2%) was the most common MDQ injury mechanism. The most commonly injured body site was the knee (33.7%). The most common MDQ injury diagnosis was sprains/strains (35.9%); the most common specific MDQ injury was knee sprains/strains (25.4%), with the anterior cruciate ligament being the most commonly injured knee structure. Among boys, fracture was the most common diagnosis in 3 sports, and sprain/strain was the most common in 6 sports. Among girls, sprain/strain was the most common diagnosis in 9 sports, and fracture was the most common only in softball. Conclusion: MDQ injuries vary by sport, sex, and type of athletic activity and occur most frequently as a result of player-player contact. These findings should prompt additional research into the development, implementation, and evaluation of targeted injury prevention efforts.	[Tirabassi, Jill; Brou, Lina; Khodaee, Morteza; Lefort, Roxanna; Fields, Sarah K.; Comstock, R. Dawn] Univ Colorado, Sch Med, Dept Family Med, 3055 Roslyn St,Suite 100, Denver, CO 80238 USA; [Brou, Lina; Lefort, Roxanna; Comstock, R. Dawn] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Fields, Sarah K.] Univ Colorado, Dept Commun, Denver, CO 80202 USA; [Comstock, R. Dawn] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA		Tirabassi, J (corresponding author), Univ Colorado, Sch Med, Dept Family Med, 3055 Roslyn St,Suite 100, Denver, CO 80238 USA.	jill.tirabassi@gmail.com		Lefort, Roxanna/0000-0002-5631-1233	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations; National Operating Committee on Standards for Athletic Equipment; DonJoy Orthotics; EyeBlack; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674, R49CE001172] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: The content of this report provided by the High School Reporting Information Online (RIO) surveillance system was funded in part by the Centers for Disease Control and Prevention (grant No. R49/CE000674-01 and R49/CE001172-01). The author responsible for High School RIO, R.D.C., also acknowledges the generous research funding contributions of the National Federation of State High School Associations, National Operating Committee on Standards for Athletic Equipment, DonJoy Orthotics, and EyeBlack.	Agel J, 2007, J ATHL TRAINING, V42, P270; Arvinen-Barrow M, 2014, J ATHL TRAINING, V49, P764, DOI 10.4085/1062-6050-49.3.44; Badgeley MA, 2013, J PHYS ACT HEALTH, V10, P160, DOI 10.1123/jpah.10.2.160; Carter CW, 2011, CLIN SPORT MED, V30, P679, DOI 10.1016/j.csm.2011.06.004; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Covassin T, 2015, CLIN SPORT MED, V34, P199, DOI 10.1016/j.csm.2014.12.004; Crossman J, 1997, SPORTS MED, V23, P333, DOI 10.2165/00007256-199723050-00005; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Feeley BT, 2008, AM J SPORT MED, V36, P1597, DOI 10.1177/0363546508316021; Fields SK, 2005, SPORT SOC-SERIES, P1; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2011, CLIN PEDIATR, V50, P594, DOI 10.1177/0009922810390513; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Mansell J, 2005, J ATHL TRAINING, V40, P310; Mitchell J, 2015, AM J SPORT MED, V43, P1676, DOI 10.1177/0363546515577786; National Federation of State High School Associations, 2014, 2013 2014 HIGH SCH A; Powell JW, 1999, J ATHL TRAINING, V34, P277; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Ross MJ, 1996, J CONSULT CLIN PSYCH, V64, P406, DOI 10.1037/0022-006X.64.2.406; Swenson DM, 2012, AM J SPORT MED, V40, P2078, DOI 10.1177/0363546512453304; United States Census Bureau, CENS REG DIV US; vanMechelen W, 1997, SPORTS MED, V24, P176, DOI 10.2165/00007256-199724030-00006; Vertinsky P., 1994, ETERNALLY WOUNDED WO; Washington RL, 2001, PEDIATRICS, V107, P1459	26	43	44	0	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2016	44	11					2925	2932		10.1177/0363546516644604			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	EB4RE	WOS:000387359900005	27166289				2022-02-06	
J	Impellizzeri, D; Campolo, M; Bruschetta, G; Crupi, R; Cordaro, M; Paterniti, I; Cuzzocrea, S; Esposito, E				Impellizzeri, Daniela; Campolo, Michela; Bruschetta, Giuseppe; Crupi, Rosalia; Cordaro, Marika; Paterniti, Irene; Cuzzocrea, Salvatore; Esposito, Emanuela			Traumatic Brain Injury Leads to Development of Parkinson's Disease Related Pathology in Mice	FRONTIERS IN NEUROSCIENCE			English	Article						chronic traumatic brain injury; Parkinson's disease; e-synuclein; nuclear factor-kappa B; microglia; astrocytes; neurotrophic factors; non-motor symptoms	NF-KAPPA-B; ALPHA-SYNUCLEIN; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; TREATMENT STRATEGIES; ANXIETY; RATS; PATHOGENESIS; ASTROCYTES; EXPRESSION	Traumatic brain injury (TBI) is a major health and socio-economic problem that affects all societies. This condition results from the application of external physical strength to the brain that leads to transitory or permanent structural and functional impairments. Moreover, TBI is a risk factor for neurodegeneration and can e.g., increase the risk for Parkinson's disease (PD), a late-onset neurodegenerative disorder with loss of dopaminergic neurons in substantia nigra. In this study, we wanted to explore the possible development of PD-related pathology within the context of an experimental model of TBI. Traumatic brain injury was induced in mice by controlled cortical impact. At different time points behavioral tests (open field, elevated plus maze tests, and Barnes maze) were performed: The animals were sacrificed 30 days after the impact and the brains were processed for Western blot and immunohistochemical analyses. Following TBI there was a significant decrease in expression of tyrosine hydroxylase and dopamine transporter in the substantia nigra as well as significant behavioral alterations. In addition, a strong increase in neuroinflammation was evident, as shown by increased levels of cyclooxygenase-2 and inducible nitric oxide synthase as well as I kappa B-alpha degradation and nuclear-KB translocation. Moreover, neurotrophic factors such as brain-derived neurotrophic factor, neurotrophin-3, nerve growth factor, and glial cell line-derived neurotrophic factor were decreased 30 days post-TBI. Interestingly, we observed a significant accumulation of alpha-synuclein in microglia compared to astrocytes. This study suggests that PD-related molecular events can be triggered upon TBI. The biological mechanisms linking brain trauma and neurodegenerative diseases need to be further investigated.	[Impellizzeri, Daniela; Campolo, Michela; Bruschetta, Giuseppe; Crupi, Rosalia; Cordaro, Marika; Paterniti, Irene; Cuzzocrea, Salvatore; Esposito, Emanuela] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Messina, Italy; [Cuzzocrea, Salvatore] St Louis Univ, Dept Physiol & Pharmacol, St Louis, MO 63103 USA		Esposito, E (corresponding author), Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Messina, Italy.	eesposito@unime.it	Cordaro, Marika/K-7329-2016; Campolo, Michela/K-6432-2016; Crupi, Rosalia/U-4364-2019	Cordaro, Marika/0000-0002-3980-0043; Impellizzeri, Daniela/0000-0001-9492-3161; Crupi, Rosalia/0000-0002-7629-3132; Cuzzocrea, Salvatore/0000-0001-6131-3690			Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baquet ZC, 2005, J NEUROSCI, V25, P6251, DOI 10.1523/JNEUROSCI.4601-04.2005; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bonito-Oliva A, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00290; Bourque MJ, 2000, EUR J NEUROSCI, V12, P3172, DOI 10.1046/j.1460-9568.2000.00219.x; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brandt I, 2008, PEPTIDES, V29, P1472, DOI 10.1016/j.peptides.2008.05.005; Burke RE, 1998, J NEUROCHEM, V71, P517; Campolo M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0196-1; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Davis A E, 2000, Crit Care Nurs Q, V23, P1; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Ding W, 2012, ANIM REPROD SCI, V131, P172, DOI 10.1016/j.anireprosci.2012.02.013; Engler H, 2009, BRAIN BEHAV IMMUN, V23, P518, DOI 10.1016/j.bbi.2009.01.018; Esposito E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-66; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Grandoso L, 2007, INT J PHARMACEUT, V343, P69, DOI 10.1016/j.ijpharm.2007.05.027; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hoyer W, 2002, J MOL BIOL, V322, P383, DOI 10.1016/S0022-2836(02)00775-1; Jomova K, 2010, MOL CELL BIOCHEM, V345, P91, DOI 10.1007/s11010-010-0563-x; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kirkwood M, 2013, MILD TRAUMATIC BRAIN; Li XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071341; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mallajosyula JK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001616; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MENZA MA, 1993, BIOL PSYCHIAT, V34, P465, DOI 10.1016/0006-3223(93)90237-8; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Oueslati A, 2010, PROG BRAIN RES, V183, P115, DOI 10.1016/S0079-6123(10)83007-9; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Peterson AL, 2008, NEUROTHERAPEUTICS, V5, P270, DOI 10.1016/j.nurt.2008.02.003; Phani Sudarshan, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS207, DOI 10.1016/S1353-8020(11)70064-5; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Przedborski Serge, 2007, Handb Clin Neurol, V83, P535, DOI 10.1016/S0072-9752(07)83026-0; Rappold PM, 2010, NEUROTHERAPEUTICS, V7, P413, DOI 10.1016/j.nurt.2010.07.001; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Shahaduzzaman M, 2013, MED HYPOTHESES, V81, P675, DOI 10.1016/j.mehy.2013.07.025; SIMON P, 1994, BEHAV BRAIN RES, V61, P59, DOI 10.1016/0166-4328(94)90008-6; Stahl K, 2011, BRAIN RES, V1378, P105, DOI 10.1016/j.brainres.2010.12.090; Tajiri N, 2014, BRAIN RES, V1559, P65, DOI 10.1016/j.brainres.2014.02.041; Ulusoy A, 2013, MOL NEUROBIOL, V47, P484, DOI 10.1007/s12035-012-8329-y; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; von Bohlen und Halbach O, 2005, FASEB J, V19, P1740, DOI 10.1096/fj.05-3845fje; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhao S, 2016, MOL NEUROBIOL, V53, P1884, DOI 10.1007/s12035-015-9128-z; Zhou DJ, 2011, J INFECT DIS, V203, P1647, DOI 10.1093/infdis/jir163	58	43	45	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	OCT 13	2016	10								458	10.3389/fnins.2016.00458			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DY7GD	WOS:000385296700001	27790086	gold, Green Published			2022-02-06	
J	Hawryluk, GWJ; Bullock, MR				Hawryluk, Gregory W. J.; Bullock, M. Ross			Past, Present, and Future of Traumatic Brain Injury Research	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury (TBI); Research; Secondary injury; Clinical trials; Trends; History; Big data	SEVERE HEAD-INJURY; MITOCHONDRIAL PERMEABILITY TRANSITION; CELLULAR INFLAMMATORY RESPONSE; RANDOMIZED CONTROLLED-TRIALS; DISABILITY RATING-SCALE; EXCITATORY AMINO-ACIDS; SPINAL-CORD CONTUSION; GLASGOW-OUTCOME-SCALE; CLINICAL-TRIALS; CYCLOSPORINE-A	Traumatic brain injury (TBI) is the greatest cause of death and severe disability in young adults; its incidence is increasing in the elderly and in the developing world. Outcome from severe TBI has improved dramatically as a result of advancements in trauma systems and supportive critical care, however we remain without a therapeutic which acts directly to attenuate brain injury. Recognition of secondary injury and its molecular mediators has raised hopes for such targeted treatments. Unfortunately, over 30 late-phase clinical trials investigating promising agents have failed to translate a therapeutic for clinical use. Numerous explanations for this failure have been postulated and are reviewed here. With this historical context we review ongoing research and anticipated future trends which are armed with lessons from past trials, new scientific advances, and improved research infrastructure and funding. There is great hope that these new efforts will finally lead to an effective therapeutic for TBI as well as better clinical management strategies.	[Hawryluk, Gregory W. J.] Univ Utah, Dept Neurosurg, 175 North Med Dr East, Salt Lake City, UT 84132 USA; [Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Lois Pope LIFE Ctr,Neurotrauma, 1095 NW 14th Terrace, Miami, FL 33136 USA		Bullock, MR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurosurg, Lois Pope LIFE Ctr,Neurotrauma, 1095 NW 14th Terrace, Miami, FL 33136 USA.	rbullock@med.miami.edu					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; American College of Surgeons, 2015, BEST PRACT MAN TRAUM; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; [Anonymous], 2001, J Trauma, V51, pS3; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P561; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS91; Brain Trauma Foundation, 2005, GUID FIELD MAN COMB; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Bullock R., 1997, TRAUMA CARE, V7, P16; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Choi SC, 2001, NEUROL RES, V23, P190, DOI 10.1179/016164101101198325; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Committee N.G., 2015, NCS GUID; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Craton N, 2014, CLIN J SPORT MED, V24, P93, DOI 10.1097/JSM.0000000000000023; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; D'Onofrio G, 2010, ANN EMERG MED, V56, P551, DOI 10.1016/j.annemergmed.2010.06.562; Daoud H, 2014, NEUROCRIT CARE, V20, P427, DOI 10.1007/s12028-013-9879-1; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Edwards P, 2005, LANCET, V365, P1957; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fawcett WJ, 1999, BRIT J ANAESTH, V83, P302, DOI 10.1093/bja/83.2.302; Fehlings MG, 2001, SPINE, V26, pS55, DOI 10.1097/00007632-200112151-00011; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Finkelstein E., 2006, INCIDENCE EC BURDEN; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Georgoff P, 2010, WORLD NEUROSURG, V74, P331, DOI 10.1016/j.wneu.2010.03.025; Ghajar J, 2004, LANCET NEUROL, V3, P708, DOI 10.1016/S1474-4422(04)00932-9; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Harrington M, 2000, LANCET, V355, P2147, DOI 10.1016/S0140-6736(00)02388-6; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Hawryluk GWJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E14; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Kwon BK, 2011, J NEUROTRAUM, V28, P1525, DOI 10.1089/neu.2010.1296; Laine C, 2007, ANN INTERN MED, V146, P450, DOI 10.7326/0003-4819-146-6-200703200-00154; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Lu J, 2008, J NEUROTRAUM, V25, P641, DOI 10.1089/neu.2007.0510; Lu Li-quan, 2003, Chin J Traumatol, V6, P302; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas Andrew I R, 2015, Handb Clin Neurol, V128, P455, DOI 10.1016/B978-0-444-63521-1.00029-7; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; May MT, 2006, LANCET, V368, P451, DOI 10.1016/S0140-6736(06)69152-6; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neher MD, 2014, SOUTH MED J, V107, P248, DOI 10.1097/SMJ.0000000000000086; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Ropper AH, 2012, NEW ENGL J MED, V367, P2539, DOI 10.1056/NEJMe1212289; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Snapinn Steven M, 2000, Curr Control Trials Cardiovasc Med, V1, P19, DOI 10.1186/CVM-1-1-019; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Tanasescu Radu, 2014, Biomed J, V37, P41, DOI 10.4103/2319-4170.130440; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; [The American Association of Neurological Surgeons The Brain Trauma Foundation], 2000, J NEUROTRAUM, V17, P463; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Tymianski M, 2011, NAT NEUROSCI, V14, P1369, DOI 10.1038/nn.2951; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 2010, NEUROTHERAPEUTICS, V7, P1, DOI 10.1016/j.nurt.2009.12.001; Wilson JTL, 2007, NEUROSURGERY, V61, P123, DOI 10.1227/01.neu.0000279732.21145.9e; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Wong GKC, 2013, J CLIN NEUROSCI, V20, P1693, DOI 10.1016/j.jocn.2012.12.032; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zetterberg H, 2015, MOL CELL NEUROSCI, V66, P99, DOI 10.1016/j.mcn.2015.02.003; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599	189	43	46	3	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	2016	27	4					375	+		10.1016/j.nec.2016.05.002			23	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DY9SQ	WOS:000385475800003	27637391				2022-02-06	
J	McQuistion, K; Zens, T; Jung, HS; Beems, M; Leverson, G; Liepert, A; Scarborough, J; Agarwal, S				McQuistion, Kaitlyn; Zens, Tiffany; Jung, Hee Soo; Beems, Megan; Leverson, Glen; Liepert, Amy; Scarborough, John; Agarwal, Suresh			Insurance status and race affect treatment and outcome of traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Insurance status; Race; Ethnicity; Outcomes; Rehabilitation	END-OF-LIFE; RACIAL DISPARITIES; ETHNIC DISPARITIES; REHABILITATION PLACEMENT; MECHANICAL VENTILATION; DISCHARGE DISPOSITION; SOCIOECONOMIC-STATUS; FUNCTIONAL OUTCOMES; CARE; MORTALITY	Background: There is increasing evidence that race and socioeconomic factors affect patient outcomes after traumatic brain injury (TBI). Our goal was to assess the effect of race, ethnicity and insurance status on hospital length of stay, procedures performed, mortality, and discharge disposition after TBI. Methods: This was a retrospective cohort study using the National Trauma Data Bank (2002-2012) to analyze patients aged 14-89 y with one of five closed head injuries. Univariate regressions identified demographic and injury characteristics that were significant predictors of outcomes. These variables were then included in multivariate regression models. Results: We analyzed 187,354 TBI patients. The sample was 78% white, 9% black, 9% Hispanic, 3% Asian, and 1% native American, and included 42% Medicare, 30% private insurance, 12% uninsured, 8% other insurance, and 8% Medicaid. Compared with white patients, black and Hispanic patients were more likely to have a TBI procedure (blacks odds ratio [OR] = 1.19, P < 0.001; Hispanics OR = 1.33, P < 0.001), had longer hospital stays (blacks coeff = 1.02, P < 0.001; Hispanics coeff = 0.61, P < 0.001), were less likely to die in the hospital (blacks OR = 0.90, P = 0.006; Hispanics OR = 0.90, P = 0.007), and more (black OR = 1.09, P = 0.001) or less likely (Hispanic OR = 0.76, P < 0.001) to be discharged to rehabilitation. Compared with the privately insured, the uninsured were less likely to have a TBI procedure (OR = 0.90, P = 0.001), had longer hospital stays (coeff = 0.24, P < 0.001), were more likely to die in the hospital (OR = 1.37, P < 0.001), and less likely to be discharged to rehabilitation (OR = 0.53, P < 0.001). Conclusions: Race/ethnicity and insurance status significantly affect TBI patient outcomes, even after controlling for demographic and injury characteristics. (C) 2016 Elsevier Inc. All rights reserved.	[McQuistion, Kaitlyn; Zens, Tiffany; Jung, Hee Soo; Beems, Megan; Leverson, Glen; Liepert, Amy; Scarborough, John; Agarwal, Suresh] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Div Trauma & Acute Care Surg, Madison, WI USA		Agarwal, S (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Sect Trauma Acute Care Surg Burn & Surg Crit Care, 600 Highland Ave G5-335, Madison, WI 53792 USA.; Agarwal, S (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Trauma, 600 Highland Ave G5-335, Madison, WI 53792 USA.	agarwal@surgery.wisc.edu		Liepert, Amy/0000-0002-9333-9905; Beems, Megan/0000-0002-2767-5994	University of Wisconsin Shapiro Summer Research Program; University of Wisconsin School of Medicine and Public Health Department of Surgery	The authors thank the University of Wisconsin Shapiro Summer Research Program and the University of Wisconsin School of Medicine and Public Health Department of Surgery for supporting this research.	Alban RF, 2010, AM SURGEON, V76, P1108; [Anonymous], 1998, NIH CONSENS STATEMEN, V16, P1; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Asemota AO, 2013, J NEUROTRAUM, V30, P2057, DOI 10.1089/neu.2013.3091; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Bradbury R C, 2001, Health Serv Manage Res, V14, P203, DOI 10.1258/0951484011912708; Brasel KJ, 2002, J SURG RES, V107, P223, DOI 10.1006/jsre.2002.6512; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cohen R. A., 2015, HLTH INSURANCE COVER; Cooper Z, 2012, J HEALTH CARE POOR U, V23, P857, DOI 10.1353/hpu.2012.0064; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; Dunlay SM, 1995, ARCH INTERN MED, V155, P2056; Egede LE, 2012, AM J PUBLIC HEALTH, V102, pS266, DOI 10.2105/AJPH.2011.300176; Englum BR, 2011, J AM COLL SURGEONS, V213, P699, DOI 10.1016/j.jamcollsurg.2011.08.017; Faul M, 2010, TRAUMATIC BRAIN INJU, P13, DOI DOI 10.3171/2009.10.JNS091500; Gerszten PC, 2001, AM J MED QUAL, V16, P212, DOI 10.1177/106286060101600605; Grace Sherry L, 2005, J Cardiopulm Rehabil, V25, P24, DOI 10.1097/00008483-200501000-00006; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; Hwabejire JO, 2013, JAMA SURG, V148, P956, DOI 10.1001/jamasurg.2013.2148; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kane WG, 2014, J HEAD TRAUMA REHAB, V29, pE10, DOI 10.1097/HTR.0000000000000028; Khaliq Amir A, 2003, J Health Hum Serv Adm, V25, P471; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Kwak J, 2005, GERONTOLOGIST, V45, P634, DOI 10.1093/geront/45.5.634; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, P1986, DOI 10.2105/AJPH.2014.302087; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, pE100, DOI 10.2105/AJPH.2013.301794; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCutcheon BA, 2015, J NEUROSURG, V123, P406, DOI 10.3171/2015.3.JNS131356; Meagher AD, 2015, J NEUROSURG, V122, P595, DOI 10.3171/2014.10.JNS14187; Missios S, 2016, INJURY, V47, P154, DOI 10.1016/j.injury.2015.06.037; Muni S, 2011, CHEST, V139, P1025, DOI 10.1378/chest.10-3011; MURPHY L D, 1990, Brain Injury, V4, P95, DOI 10.3109/02699059009026153; Nandi A, 2014, EPIDEMIOLOGY, V25, P170, DOI 10.1097/EDE.0000000000000038; Nirula R, 2009, J TRAUMA, V66, P255, DOI 10.1097/TA.0b013e31815ede46; Pentland B, 1988, Br J Neurosurg, V2, P61, DOI 10.3109/02688698808999660; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rosen H, 2009, ARCH SURG-CHICAGO, V144, P1006, DOI 10.1001/archsurg.2009.195; Rubin MA, 2014, J CRIT CARE, V29, P49, DOI 10.1016/j.jcrc.2013.08.023; Sacks GD, 2011, J TRAUMA, V71, P1011, DOI 10.1097/TA.0b013e3182092c27; Selassie AW, 2014, J HEAD TRAUMA REHAB, V29, pE8, DOI 10.1097/HTR.0b013e3182976ad3; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Sorani MD, 2009, J TRAUMA, V67, P75, DOI 10.1097/TA.0b013e31818234e8; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; WILLIAMS RJL, 1994, J ROY SOC MED, V87, P83	53	43	43	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2016	205	2					261	271		10.1016/j.jss.2016.06.087			11	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Surgery	EC2VG	WOS:000387981700001	27664871				2022-02-06	
J	Zhong, JJ; Jiang, L; Cheng, CJ; Huang, ZJ; Zhang, HR; Liu, H; He, JC; Cao, F; Peng, JH; Jiang, Y; Sun, XC				Zhong, Jianjun; Jiang, Li; Cheng, Chongjie; Huang, Zhijian; Zhang, Hongrong; Liu, Han; He, Junchi; Cao, Fang; Peng, Jianhua; Jiang, Yong; Sun, Xiaochuan			Altered expression of long non-coding RNA and mRNA in mouse cortex after traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Long noncoding RNA	PROMOTES CELL-PROLIFERATION; RAT CEREBRAL-CORTEX; GENE-EXPRESSION; POOR-PROGNOSIS; GASTRIC-CANCER; DISEASE; PROFILE; IDENTIFICATION; ACTIVATION; MALAT1	Background and objective: The present study aims to detect the altered lncRNA expression in the mouse cortex after traumatic brain injury (TBI). We also simultaneously detected the altered mRNA profile to further analyze the possible function of lncRNA. Method: C57BL/6 mice (n=18) were used to construct a controlled cortical impact model. At 24 h post-TBI, the cortex around injury site was collected and the total RNA was extracted to construct the cDNA library. RNA sequencing (RNA-seq) was carried out followed by RT-PCR for confirmation. Bioinformatic analysis (including GO analysis, KEGG pathway and co-expression analysis) also were performed. Results: A total of 64,530 transcripts were detected in the current sequencing study, in which 27,457 transcripts were identified as mRNA and 37,073 transcripts as lncRNA. A total of 1580 mRNAs (1430 up regulated and 150 down-regulated) and 823 lncRNAs (667 up-regulated and 156 down-regulated) were significantly changed according to the criteria ((l)log(2)((fold change))vertical bar > 1 and P < 0.05). These altered mRNAs were mainly related to inflammatory and immunological activity, metabolism, neuronal and vascular network. The expression of single lncRNA may be related with several mRNAs, and so was the mRNA. Also, a total of 360 new mRNAs and 8041 new lncRNAs were identified. The good reproducibility and reliability of RNA-seq were confirmed by RT-PCR. Conclusion: Numerous lncRNAs and mRNAs were significantly altered in mouse cortex around the injury site 24 h after TBI. Our present data may provide a promising approach for further study about TBI. (C) 2016 Elsevier B.V. All rights reserved.	[Zhong, Jianjun; Jiang, Li; Cheng, Chongjie; Huang, Zhijian; Zhang, Hongrong; Liu, Han; He, Junchi; Sun, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Cao, Fang] Zunyi Med Coll, Affiliated Hosp 1, Dept Cerebrovasc, Zunyi 653000, Guizhou, Peoples R China; [Peng, Jianhua; Jiang, Yong] Southwest Med Univ, Affiliated Hosp, Dept Neurosurg, Luzhou 646000, Sichaun, Peoples R China		Sun, XC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.		He, Junchi/AAD-8482-2019	sun, xiao chuan/0000-0001-6992-332X; Huang, Zhijian/0000-0002-8241-0761; Peng, Jianhua/0000-0003-3348-9538	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571159, 81371319]; Chongqing Graduate Innovation Project [40010200100417]	This work was supported by grants from the National Natural Science Foundation of China (Grant No.: 81571159, 81371319) and the Chongqing Graduate Innovation Project (grant No.: 40010200100417). We express special acknowledgement to "Chongqing Key Labrotory of Biochemistry and Molecular Pharmacology" for providing experimental platform.	Bali KK, 2014, TRENDS MOL MED, V20, P437, DOI 10.1016/j.molmed.2014.05.006; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bernard D, 2010, EMBO J, V29, P3082, DOI 10.1038/emboj.2010.199; Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Carpenter S, 2013, SCIENCE, V341, P789, DOI 10.1126/science.1240925; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784; Francelle L, 2015, NEUROBIOL AGING, V36, DOI 10.1016/j.neurobiolaging.2014.11.014; Goh CS, 2000, J MOL BIOL, V299, P283, DOI 10.1006/jmbi.2000.3732; Gomez JA, 2013, CELL, V152, P743, DOI 10.1016/j.cell.2013.01.015; Hannon MJ, 2013, J CLIN ENDOCR METAB, V98, P3229, DOI 10.1210/jc.2013-1555; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Jiang BC, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0047-9; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Johnson R, 2012, NEUROBIOL DIS, V46, P245, DOI 10.1016/j.nbd.2011.12.006; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Li ZH, 2014, P NATL ACAD SCI USA, V111, P1002, DOI 10.1073/pnas.1313768111; Liu JY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.466; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lucafo M, 2015, CURR MOL MED, V15, P94, DOI 10.2174/1566524015666150114122354; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mercer TR, 2008, P NATL ACAD SCI USA, V105, P716, DOI 10.1073/pnas.0706729105; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Michalik KM, 2014, CIRC RES, V114, P1389, DOI 10.1161/CIRCRESAHA.114.303265; Nagano T, 2011, CELL, V145, P178, DOI 10.1016/j.cell.2011.03.014; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Ng SY, 2013, MOL CELL, V51, P349, DOI 10.1016/j.molcel.2013.07.017; Ng SY, 2012, EMBO J, V31, P522, DOI 10.1038/emboj.2011.459; Puthanveetil P, 2015, J CELL MOL MED, V19, P1418, DOI 10.1111/jcmm.12576; Qureshi IA, 2012, NAT REV NEUROSCI, V13, P528, DOI 10.1038/nrn3234; Ramos AD, 2013, CELL STEM CELL, V12, P616, DOI 10.1016/j.stem.2013.03.003; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Ruan YL, 1997, J NEUROSCI RES, V50, P383, DOI 10.1002/(SICI)1097-4547(19971101)50:3<383::AID-JNR4>3.0.CO;2-E; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Shi ZH, 2015, CELL PHYSIOL BIOCHEM, V36, P542, DOI 10.1159/000430119; Sun M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-319; Sun M, 2014, TUMOR BIOL, V35, P1065, DOI 10.1007/s13277-013-1142-z; Thum T, 2014, CIRC RES, V114, P1366, DOI 10.1161/CIRCRESAHA.114.303896; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilhelm BT, 2008, NATURE, V453, P1239, DOI 10.1038/nature07002; Yan K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010132; Yoshioka N, 2010, J COMP NEUROL, V518, P3867, DOI 10.1002/cne.22431; Yu B, 2013, NEUROSCI LETT, V534, P117, DOI 10.1016/j.neulet.2012.12.014; Zangrando J, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-460; Zhong J., 2016, NEUROSCIENCE; Zhu JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101707; Zhu L, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0157-3	55	43	49	2	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 1	2016	1646						589	600		10.1016/j.brainres.2016.07.002			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT9TH	WOS:000381844700066	27380725				2022-02-06	
J	Meulenbroek, P; Turkstra, LS				Meulenbroek, Peter; Turkstra, Lyn S.			Job stability in skilled work and communication ability after moderate-severe traumatic brain injury	DISABILITY AND REHABILITATION			English	Article							LONG-TERM OUTCOMES; HEAD-INJURY; ACUTE PREDICTORS; NEUROPSYCHOLOGICAL STATUS; PROGNOSTIC-FACTORS; FOLLOW-UP; RETURN; EMPLOYMENT; REHABILITATION; RECOVERY		[Meulenbroek, Peter] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Meulenbroek, Peter] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Turkstra, Lyn S.] Univ Wisconsin, Dept Commun Sci & Disorders, Madison, WI USA		Meulenbroek, P (corresponding author), Northwestern Univ, Rehabil Inst Chicago, Dept Phys Med & Rehabil, 345 E Super St,Rm 1328, Chicago, IL 60611 USA.	peter.meulenbroek@northwestern.edu	Turkstra, Lyn/ABC-5831-2021	Meulenbroek, Peter/0000-0003-4233-9910; Turkstra, Lyn/0000-0002-6948-6921	National Institutes of Health (NIH): National Institute for Deafness and other Communication Disorders (NIDCD) [1F31DC011462-01A1]; Walker Foundation Grant; Mary E. Switzer Merit Research Fellowship [H133F140026]; National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services; Advanced Rehabilitation Research Training Award: Interventions for Neurologic Communication Disorders [H133P120013]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F31DC011462] Funding Source: NIH RePORTER	Research for this study was supported by a pre-doctoral fellowship award granted by the National Institutes of Health (NIH): National Institute for Deafness and other Communication Disorders (NIDCD) #1F31DC011462-01A1 (to Dr. Peter Meulenbroek) and funding from The Walker Foundation Grant (to Dr. Lyn S. Turkstra). Preparation of this manuscript was supported by an Advanced Rehabilitation Research Training Award: Interventions for Neurologic Communication Disorders #H133P120013 (to Dr. Leora R. Cherney), and from a Mary E. Switzer Merit Research Fellowship #H133F140026 (to Dr. Peter Meulenbroek) from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR). The authors have no conflicts of interest to report.	BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Bjorkdahl A, 2010, BRAIN INJURY, V24, P1061, DOI 10.3109/02699052.2010.494588; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown J, 1993, NELSON DENNY READING; Bureau of Labor Statistics, 2013, EMPL MAJ IND SECT; Burgess P, 1996, BEHAV ASSESSMENT DYS; BURTON LF, 1987, J REHABIL, V53, P71; BUTLER RW, 1989, CLIN NEUROPSYCHOL, V3, P235; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Conrad C., 1998, STRATEGIC ORG COMMUN; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Crosling G, 2002, ENGL SPECIF PURP, V21, P41, DOI 10.1016/S0889-4906(00)00031-4; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Delis D.C., 2000, CVLT 2 CALIFORNIA VE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Gale HF, 2002, IND RELAT, V41, P48; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Gunnarsson B.-L., 2009, CONTINUUM DISCOURSE; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hanlon RE, 2005, BRAIN INJURY, V19, P257, DOI 10.1080/02699050400004955; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hartley L. L, 1995, COGNITIVE COMMUNICAT; Hux K, 2009, BRAIN INJURY, V23, P8, DOI 10.1080/02699050802590353; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Isaki E, 2000, BRAIN INJURY, V14, P441; Johnson R, 1987, Int Disabil Stud, V9, P49; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; MacDonald S., 2005, FAVRES FUNCTIONAL AS; MacDonald S, 2010, BRAIN INJURY, V24, P486, DOI 10.3109/02699050903518118; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Mather N., 2001, WOODCOCK JOHNSON 3 T; Mayo NE, 2009, J REHABIL MED, V41, P209, DOI 10.2340/16501977-0343; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; Meulenbroek P, 2013, CLIN APH C; Meulenbroek P, 2015, J VOCAT REH IN PRESS, V43; National Center for O* NET Development, 2010, O NET DESCR JOB ZON; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Penn C, 2000, NEUROGENIC COMMUNICA, P103; Possl O, 2001, BRAIN INJURY, V15, P15; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Rietdijk R, 2013, BRAIN INJURY, V27, P812, DOI 10.3109/02699052.2013.775491; Roberts CB, 2004, INT J REHABIL RES, V27, P145, DOI 10.1097/01.mrr.0000127142.43208.3b; Robles MM, 2012, BUS PROF COMMUN Q, V75, P453, DOI 10.1177/1080569912460400; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; SALZBERG CL, 1986, APPL RES MENT RETARD, V7, P299, DOI 10.1016/S0270-3092(86)80003-0; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Schnurr S., 2013, EXPLORING PROFESSION; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherron P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, https://doi.org/10.1097/00001199-199109000-00004]; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Soeker MS, 2012, WORK, V42, P589, DOI 10.3233/WOR-2012-1414; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Stubbe M., 2003, POWER POLITENESS WOR; Stubbs Michael, 1983, DISCOURSE ANAL SOCIO; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; THORNBORROW Joanna, 2002, POWER TALK LANGUAGE; Thurman D. J, 2007, BRAIN INJURY MED PRI, P44; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 2011, HANDBOOK OF PSYCHOLINGUISTIC AND COGNITIVE PROCESSES: PERSPECTIVES IN COMMUNICATION DISORDERS, P603; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Tyerman A., 2008, PSYCHOL APPROACHES R, P376; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Watanabe S, 2013, WORK, V45, P273, DOI 10.3233/WOR-131594; Wechsler D., 2008, WAIS 4 WECHSLER ADUL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR, V3rd edn; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Williams MW, 2013, CLIN NEUROPSYCHOL, V27, P356, DOI 10.1080/13854046.2013.765507; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	90	43	43	1	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	FEB 27	2016	38	5					452	461		10.3109/09638288.2015.1044621			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	DA5HS	WOS:000367834600006	25958999	Green Accepted			2022-02-06	
J	Gioia, GA				Gioia, Gerard A.			Medical-School Partnership in Guiding Return to School Following Mild Traumatic Brain Injury in Youth	JOURNAL OF CHILD NEUROLOGY			English	Article						mild traumatic brain injury; TBI; youth; pediatric; concussion	CONCUSSION; EXERCISE; SPORT; RECOMMENDATIONS; REST	Mild traumatic brain injury is recognized as a prevalent and significant risk concern for youth. Appropriate school return is particularly challenging. The medical and school systems must be prepared partners to support the school return of the student with mild traumatic brain injury. Medical providers must be trained in assessment and management skills with a focused understanding of school demands. Schools must develop policies and procedures to prepare staff to support a gradual return process with the necessary academic accommodations. Ongoing communication between the family, student, school, and medical provider is essential to supporting recovery. A systematic gradual return to school process is proposed including levels of recommended activity and criteria for advancement. Targets for intervention are described with associated strategies for supporting recovery. A 10-element Progressive Activities of Controlled Exertion (PACE) model for activity-exertion management is introduced to manage symptom exacerbation. A strong medical-school partnership will maximize outcomes for students with mild traumatic brain injury.	[Gioia, Gerard A.] George Washington Univ, Sch Med, Childrens Natl Hlth Syst, Div Pediat Neuropsychol, Rockville, MD USA		Gioia, GA (corresponding author), Childrens Natl Hlth Syst, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA.	ggioia@childrensnational.org			CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/ CCU323352, U49CE001385]; NIH from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [M01RR020359]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30/HDO40677-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE001385] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This paper was supported in part by CDC Awards U17/ CCU323352 and U49CE001385, and NIH Grants M01RR020359 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH P30/HDO40677-07.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Aylward B., 2009, HDB PEDIAT PSYCHOL, V4th, P3; (CDC). National Center for Injury Prevention and Control, 2007, HEADS BRAIN INJ YOUR; Centers for Disease Control and Prevention, HELP STUD REC CONC C; Centers for Disease Control and Prevention, HEADS SCH KNOW YOUR; Centers for Disease Control and Prevention, RET SCH CONC FACT SH; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2012, PEDIATR ANN, V41, P198, DOI 10.3928/00904481-20120426-10; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Institute of Medicine's Committee on Sports-Related Concussions in Youth, 2013, SPORTS REL CONC YOUT; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McAvoy K., 2011, REAP BENEFITS GOOD C; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCrory P, 2005, BRIT J SPORT MED, V37, P141; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Oregon Center for Applied Science, 2007, BRAIN 101 CONC PLAYB; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Zuckerbraun NS, 2014, PEDIATRICS, V133, P635, DOI 10.1542/peds.2013-2600	28	43	43	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	JAN	2016	31	1			SI		93	108		10.1177/0883073814555604			16	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	CY8HW	WOS:000366650400010	25535055	Green Accepted			2022-02-06	
J	Li, W; Wang, T; Xiao, SF				Li, Wei; Wang, Tao; Xiao, Shifu			Type 2 diabetes mellitus might be a risk factor for mild cognitive impairment progressing to Alzheimer's disease	NEUROPSYCHIATRIC DISEASE AND TREATMENT			English	Article						T2DM; AD; MCI; risk factor	MENTAL-STATE-EXAMINATION; FOLLOW-UP; DEMENTIA; INDIVIDUALS; INSULIN; COHORT; DECLINE; BETA; AGE	Background: Mild cognitive impairment (MCI) is the prodromal stage of Alzheimer's disease (AD), so identification of the related risk factors can be helpful. Although the association between type 2 diabetes mellitus (T2DM) and these modest changes in cognition is well established, whether T2DM will promote the transformation of MCI into AD is not a unified conclusion. Objective: This study aims to explore the relationship between T2DM and MCI in the elderly population living in the community in Shanghai, People's Republic of China. Methods: A total of 197 participants were included in the study. They were screened for T2DM, hyperlipidemia, traumatic brain injury, and family history of dementia. The Mini-Mental State Examination and the Montreal Cognitive Assessment were used to assess cognitive function. The diagnosis of AD was made according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, whereas the diagnosis of MCI was made according to Petersen's criteria. Then, we investigated the relation between T2DM and MCI. Results: A total of 82 (41.6%) participants had no cognitive impairment, 82 (41.6%) participants had MCI, and 33 (16.8%) participants had AD. Multivariate logistic regression models demonstrated that T2DM was a risk factor for AD (odds ratio = 49.723, 95% CI = 21.173-111.987). Conclusion: T2DM might be a risk factor for MCI progressing into AD.	[Li, Wei; Wang, Tao; Xiao, Shifu] Shanghai Jiao Tong Univ, Sch Med, Alzheimers Dis & Related Disorders Ctr, 600 South Wanping Rd, Shanghai 200030, Peoples R China; [Li, Wei; Wang, Tao; Xiao, Shifu] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Dept Geriatr Psychiat, Shanghai, Peoples R China		Xiao, SF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Alzheimers Dis & Related Disorders Ctr, 600 South Wanping Rd, Shanghai 200030, Peoples R China.	xiaoshifu@msn.com			China Ministry of Science and TechnologyMinistry of Science and Technology, China [2009BAI77B03]	This work was supported by a grant from the China Ministry of Science and Technology (2009BAI77B03).	Abbatecola AM, 2010, DIABETES CARE, V33, P1706, DOI 10.2337/dc09-2030; Almeida OP, 1999, ARQ NEURO-PSIQUIAT, V57, P421, DOI 10.1590/S0004-282X1999000300013; Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; Ates MP, 2016, NEUROSCIENCE, V325, P124, DOI 10.1016/j.neuroscience.2016.03.051; Awad N, 2004, J CLIN EXP NEUROPSYC, V26, P1044, DOI 10.1080/13803390490514875; Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2; Bruehl H, 2009, BRAIN RES, V1280, P186, DOI 10.1016/j.brainres.2009.05.032; Freude S, 2005, DIABETES, V54, P3343, DOI 10.2337/diabetes.54.12.3343; Hassing LB, 2004, J INT NEUROPSYCH SOC, V10, P599, DOI 10.1017/S1355617704104165; Hsu CC, 2011, J ALZHEIMERS DIS, V24, P485, DOI 10.3233/JAD-2011-101524; Huang CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087095; Knight EM, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0282-y; Kopf D, 2009, J ALZHEIMERS DIS, V16, P677, DOI 10.3233/JAD-2009-1011; Koran M. E. I., 2016, BRAIN IMAGING BEHAV; Korolev IO, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0138866; Kulstad JJ, 2006, NEUROLOGY, V66, P1506, DOI 10.1212/01.wnl.0000216274.58185.09; Leibson C L, 1997, Ann N Y Acad Sci, V826, P422, DOI 10.1111/j.1749-6632.1997.tb48496.x; Leibson CL, 1997, AM J EPIDEMIOL, V145, P301; Liu Y, 2011, J PATHOL, V225, P54, DOI 10.1002/path.2912; Ma F, 2015, J ALZHEIMERS DIS, V43, P1441, DOI 10.3233/JAD-141566; Mitchell AJ, 2009, ACTA PSYCHIAT SCAND, V119, P252, DOI 10.1111/j.1600-0447.2008.01326.x; Mittal K, DIABETES METAB SYNDR; Ng TP, 2016, JAMA NEUROL, V73, P456, DOI 10.1001/jamaneurol.2015.4899; O'Bryant SE, 2008, ARCH NEUROL-CHICAGO, V65, P963, DOI 10.1001/archneur.65.7.963; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Piccinin AM, 2013, J GERONTOL B-PSYCHOL, V68, P374, DOI 10.1093/geronb/gbs077; Ren RJ., 2015, MOL NEUROBIOL; Sarlus H, 2015, J ALZHEIMERS DIS, V48, P495, DOI 10.3233/JAD-143147; Sebastiao I, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00110; Sims-Robinson C, 2010, NAT REV NEUROL, V6, P551, DOI 10.1038/nrneurol.2010.130; Tiffin-Richards FE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106700; Trzepacz PT, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0103-3; Xu WL, 2004, NEUROLOGY, V63, P1181, DOI 10.1212/01.WNL.0000140291.86406.D1	35	43	43	0	12	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1178-2021			NEUROPSYCH DIS TREAT	Neuropsychiatr. Dis. Treat.		2016	12						2489	2495		10.2147/NDT.S111298			7	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	DX6JV	WOS:000384490800001	27729793	Green Published, gold			2022-02-06	
J	Margulies, S; Anderson, G; Atif, F; Badaut, J; Clark, R; Empey, P; Guseva, M; Hoane, M; Huh, J; Pauly, J; Raghupathi, R; Scheff, S; Stein, D; Tang, HL; Hicks, M				Margulies, Susan; Anderson, Gail; Atif, Fahim; Badaut, Jerome; Clark, Robert; Empey, Philip; Guseva, Maria; Hoane, Michael; Huh, Jimmy; Pauly, Jim; Raghupathi, Ramesh; Scheff, Stephen; Stein, Donald; Tang, Huiling; Hicks, Mona			Combination Therapies for Traumatic Brain Injury: Retrospective Considerations	JOURNAL OF NEUROTRAUMA			English	Article						pharmacological interventions; preclinical therapeutic development; treatments	N-TERMINAL KINASE; IMPROVES FUNCTIONAL RECOVERY; GLYCINE-PROLINE-GLUTAMATE; VITAMIN-D HORMONE; GENE-EXPRESSION; IMMATURE RAT; INTRAVENOUS-INFUSION; CLINICAL-TRIAL; AXONAL INJURY; HEAD-INJURY	Patients enrolled in clinical trials for traumatic brain injury (TBI) may present with heterogeneous features over a range of injury severity, such as diffuse axonal injury, ischemia, edema, hemorrhage, oxidative damage, mitochondrial and metabolic dysfunction, excitotoxicity, inflammation, and other pathophysiological processes. To determine whether combination therapies might be more effective than monotherapy at attenuating moderate TBI or promoting recovery, the National Institutes of Health funded six preclinical studies in adult and immature male rats to evaluate promising acute treatments alone and in combination. Each of the studies had a solid rationale for its approach based on previous research, but only one reported significant improvements in long-term outcomes across a battery of behavioral tests. Four studies had equivocal results because of a lack of sensitivity of the outcome assessments. One study demonstrated worse results with the combination in comparison with monotherapies. While specific research findings are reported elsewhere, this article provides an overview of the study designs, insights, and recommendations for future research aimed at therapy development for TBI.	[Margulies, Susan] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Anderson, Gail] Univ Washington, Dept Pharm Pharmaceut & Neurol Surg, Seattle, WA 98195 USA; [Atif, Fahim; Stein, Donald; Tang, Huiling] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; [Badaut, Jerome] Univ Bordeaux, INCIA, Bordeaux, France; [Clark, Robert] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Clark, Robert] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Empey, Philip] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA; [Guseva, Maria] Fresenius Kabi USA LLC, Lake Zurich, IL USA; [Hoane, Michael] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA; [Huh, Jimmy] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Pauly, Jim] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY USA; [Raghupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA; [Scheff, Stephen] Univ Kentucky, Ctr Aging, Lexington, KY USA; [Hicks, Mona] One Mind, Seattle, WA USA		Margulies, S (corresponding author), Univ Penn, Dept Bioengn, 210 S 33rd St,240 Skirkanich Hall, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Raghupathi, Ramesh/AAX-5538-2021; Stein, Donald/AAJ-5139-2020; Empey, Philip/L-9604-2019	Empey, Philip/0000-0001-7474-2339; Hoane, Michael/0000-0001-7779-2657	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD061944, R01 HD061946, R01 HD061963, R01 HD061966, R01 HD061971, R01 NS069247, U01 NS069545]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061963, R01HD061944, R01HD061946, R01HD061971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069247, U01NS069545] Funding Source: NIH RePORTER	We thank Beth Ansel and Michael Weinrich of the NIH for their leadership in developing and administering the research initiative that supported these studies. We also thank Stephen Ashwal, Richard Hartman, and Andre Obenaus of Loma Linda University for their thoughtful discussions. The research was supported by NIH grants R01 HD061944, R01 HD061946, R01 HD061963, R01 HD061966, R01 HD061971, R01 NS069247, and U01 NS069545.	Ajao D., 2011, SOC NEUROSCIENCE ABS, V41; Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Aminmansour Bahram, 2012, Adv Biomed Res, V1, P58, DOI 10.4103/2277-9175.100176; Anderson GD, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00021; Anderson GD, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00129; Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; Armstead WM, 2011, NEUROL RES, V33, P726, DOI 10.1179/016164110X12807570509853; Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Atif F, 2013, NEUROPHARMACOLOGY, V67, P78, DOI 10.1016/j.neuropharm.2012.10.004; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Bateman DN, 2014, LANCET, V383, P697, DOI 10.1016/S0140-6736(13)62062-0; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Behan LA, 2007, HORM RES, V68, P18, DOI 10.1159/000110466; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; Buller KM, 2009, J NEUROSCI RES, V87, P599, DOI 10.1002/jnr.21890; BURNELL JM, 1951, J CLIN INVEST, V30, P697, DOI 10.1172/JCI102482; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Chow SC, 2014, ANNU REV MED, V65, P405, DOI 10.1146/annurev-med-092012-112310; CRAWFORD IL, 1979, J PHYSIOL-LONDON, V287, P519, DOI 10.1113/jphysiol.1979.sp012674; Cruchaga C, 2013, NEURON, V78, P256, DOI 10.1016/j.neuron.2013.02.026; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Deutsch ER, 2013, BRAIN RES, V1530, P82, DOI 10.1016/j.brainres.2013.07.014; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; DiLeonardi AM, 2012, J NEUROPATH EXP NEUR, V71, P959, DOI 10.1097/NEN.0b013e31826f5876; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Fukuda AM, 2013, GENES-BASEL, V4, P435, DOI 10.3390/genes4030435; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Fukuda AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-279; Gagne JJ, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6802; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guan J, 2004, NEUROPHARMACOLOGY, V47, P892, DOI 10.1016/j.neuropharm.2004.07.002; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hammond CL, 2007, J BIOL CHEM, V282, P14337, DOI 10.1074/jbc.M611019200; Hartz AMS, 2011, CURR PHARM BIOTECHNO, V12, P656; Heard K, 2012, CURR PHARM BIOTECHNO, V13, P1917, DOI 10.2174/138920112802273146; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Michel-Monigadon D, 2010, CEREBROVASC DIS, V29, P564, DOI 10.1159/000306643; Norman AW, 2007, J STEROID BIOCHEM, V103, P204, DOI 10.1016/j.jsbmb.2006.12.071; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Peterson TC, 2015, J NEUROTRAUM, V32, P765, DOI 10.1089/neu.2014.3530; Peterson TC, 2012, J NEUROTRAUM, V29, P2823, DOI 10.1089/neu.2012.2471; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Potts Mathew B, 2006, NeuroRx, V3, P143; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; Sanders Lisa M, 2007, Nutr Today, V42, P181, DOI 10.1097/01.NT.0000286155.55343.fa; Saporito MS, 1998, NEUROSCIENCE, V86, P461, DOI 10.1016/S0306-4522(98)00059-1; SARA VR, 1993, ANN NY ACAD SCI, V692, P183; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Setkowicz Z, 2004, EPILEPSY RES, V61, P63, DOI 10.1016/j.eplepsyres.2004.06.001; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sizonenko SV, 2001, BRAIN RES, V922, P42, DOI 10.1016/S0006-8993(01)03148-1; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tang HL, 2013, HORM BEHAV, V64, P527, DOI 10.1016/j.yhbeh.2013.06.009; Tarnopolsky MA, 2001, ANN NEUROL, V49, P561, DOI 10.1002/ana.1028.abs; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Vonder Haar C, 2014, J NEUROTRAUM, V31, P961, DOI 10.1089/neu.2013.3119; WALLIMANN T, 1994, MOL CELL BIOCHEM, V133, P193, DOI 10.1007/BF01267955; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Wiegler K, 2008, CEREBROVASC DIS, V26, P360, DOI 10.1159/000151639; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yatsushige H, 2007, J NEUROSCI RES, V85, P1436, DOI 10.1002/jnr.21281; Yeatts SD, 2013, STROKE, V44, pS116, DOI 10.1161/STROKEAHA.111.000031; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	107	43	44	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					101	112		10.1089/neu.2014.3855			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200013	25970337	Green Published			2022-02-06	
J	Butler, CR; Boychuk, JA; Smith, BN				Butler, Corwin R.; Boychuk, Jeffery A.; Smith, Bret N.			Effects of Rapamycin Treatment on Neurogenesis and Synaptic Reorganization in the Dentate Gyrus after Controlled Cortical Impact Injury in Mice	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						epilepsy; trauma; hippocampus; mTOR; dentate granule cell; mossy fiber sprouting; adult neurogenesis; doublecortin	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; GRANULE CELL NEUROGENESIS; ACID-TREATED RATS; MOUSE MODEL; MAMMALIAN TARGET; HIPPOCAMPAL NEUROGENESIS; POSTTRAUMATIC EPILEPSY; ENHANCED NEUROGENESIS; RECURRENT EXCITATION	Post-traumatic epilepsy (PTE) is one consequence of traumatic brain injury (TBI). A prominent cell signaling pathway activated in animal models of both TBI and epilepsy is the mammalian target of rapamycin (mTOR). Inhibition of rnTOR with rapamycin has shown promise as a potential modulator of epileptogenesis in several animal models of epilepsy, but cellular mechanisms linking mTOR expression and epileptogenesis are unclear. In this study, the role of mTOR in modifying functional hippocampal circuit reorganization after focal TBI induced by controlled cortical impact (CCI) was investigated. Rapamycin (3 or 10 mg/kg), an inhibitor of rnTOR signaling, was administered by intraperitoneal injection beginning on the day of injury and continued daily until tissue collection. Relative to controls, rapamycin treatment reduced dentate granule cell area in the hemisphere ipsilateral to the injury two weeks post-injury. Brain injury resulted in a significant increase in doublecortin immunolabeling in the dentate gyrus ipsilateral to the injury, indicating increased neurogenesis shortly after TBI. Rapamycin treatment prevented the increase in doublecortin labeling, with no overall effect on Fluoro-Jade B staining in the ipsilateral hemisphere, suggesting that rapamycin treatment reduced posttraumatic neurogenesis but did not prevent cell loss after injury. At later times post-injury (8-13 weeks), evidence of mossy fiber sprouting and increased recurrent excitation of dentate granule cells was detected, which were attenuated by rapamycin treatment. Rapamycin treatment also diminished seizure prevalence relative to vehicle-treated controls after TBI. Collectively, these results support a role for adult neurogenesis in PTE development and suggest that suppression of epileptogenesis by mTOR inhibition includes effects on post-injury neurogenesis.	[Butler, Corwin R.; Boychuk, Jeffery A.; Smith, Bret N.] Univ Kentucky, Dept Physiol, Coll Med, Lexington, KY 40506 USA; [Boychuk, Jeffery A.; Smith, Bret N.] Univ Kentucky, Epilepsy Ctr, Lexington, KY USA; [Boychuk, Jeffery A.] Univ Kentucky, Ctr Adv Translat Stroke Sci, Lexington, KY USA; [Smith, Bret N.] Univ Kentucky, Spiul Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY USA		Smith, BN (corresponding author), Univ Kentucky, Dept Physiol, Coll Med, Lexington, KY 40506 USA.	bret.smith@uky.edu		Boychuk, Jeffery A/0000-0002-7003-1553; Butler, Corwin/0000-0001-5134-4151	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS088608] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS088608] Funding Source: Medline		ALTMAN J, 1965, NATURE, V207, P953, DOI 10.1038/207953a0; Amiri A, 2012, J NEUROSCI, V32, P5880, DOI 10.1523/JNEUROSCI.5462-11.2012; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Bhaskaran MD, 2010, EXP NEUROL, V223, P529, DOI 10.1016/j.expneurol.2010.01.021; Buckmaster PS, 2011, EPILEPSIA, V52, P2057, DOI 10.1111/j.1528-1167.2011.03253.x; Buckmaster PS, 2011, J NEUROSCI, V31, P2337, DOI 10.1523/JNEUROSCI.4852-10.2011; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Carlson SW, 2014, J NEUROPATH EXP NEUR, V73, P734, DOI 10.1097/NEN.0000000000000092; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Don ASA, 2012, DRUG DISCOV TODAY, V17, P861, DOI 10.1016/j.drudis.2012.04.010; Dudek FE, 1997, J CLIN NEUROPHYSIOL, V14, P90, DOI 10.1097/00004691-199703000-00002; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Heng K, 2013, EPILEPSIA, V54, P1535, DOI 10.1111/epi.12246; Hester MS, 2013, J NEUROSCI, V33, P8926, DOI 10.1523/JNEUROSCI.5161-12.2013; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Hunt RF, 2012, EPILEPSY RES, V99, P167, DOI 10.1016/j.eplepsyres.2011.10.011; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kron MM, 2010, J NEUROSCI, V30, P2051, DOI 10.1523/JNEUROSCI.5655-09.2010; LaSarge CL, 2015, NEUROBIOL DIS, V75, P142, DOI 10.1016/j.nbd.2014.12.029; Liu JL, 1998, J NEUROSCI, V18, P7768; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lynch M, 2000, J NEUROPHYSIOL, V83, P693, DOI 10.1152/jn.2000.83.2.693; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Parent JM, 2006, ANN NEUROL, V59, P81, DOI 10.1002/ana.20699; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 1997, CURR OPIN NEUROL, V10, P103, DOI 10.1097/00019052-199704000-00006; Parent JM, 1998, NEUROSCI LETT, V247, P9, DOI 10.1016/S0304-3940(98)00269-9; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418, DOI 10.1152/jn.1998.79.1.418; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Pun RYK, 2012, NEURON, V75, P1022, DOI 10.1016/j.neuron.2012.08.002; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sunnen CN, 2011, EPILEPSIA, V52, P2065, DOI 10.1111/j.1528-1167.2011.03280.x; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Temkin N R, 1998, Adv Neurol, V76, P179; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Wiltgen BJ, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.037.2009; Winokur RS, 2004, EPILEPSY RES, V58, P93, DOI 10.1016/j.eplepsyres.2004.01.002; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Zeng LH, 2008, ANN NEUROL, V63, P444, DOI 10.1002/ana.21331; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009	64	43	43	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5137			FRONT SYST NEUROSCI	Front. Syst. Neurosci.	NOV 27	2015	9									10.3389/fnsys.2015.00163			14	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	CZ0TK	WOS:000366818700001	26640431	Green Published, gold			2022-02-06	
J	Harris, JL; Choi, IY; Brooks, WM				Harris, Janna L.; Choi, In-Young; Brooks, William M.			Probing astrocyte metabolism in vivo: proton magnetic resonance spectroscopy in the injured and aging brain	FRONTIERS IN AGING NEUROSCIENCE			English	Article						proton magnetic resonance spectroscopy; astrocytes; traumatic brain injury (TBI); aging; myo-inositol; glutathione; glutamic acid; lactic acid	H-1 MR SPECTROSCOPY; NEUROCHEMICAL PROFILE; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; SYNAPTIC PROTEINS; TRANSGENIC MICE; MOUSE-BRAIN; HEAD-INJURY; TIME-COURSE; GLUTATHIONE	Following a brain injury, the mobilization of reactive astrocytes is part of a complex neuroinflammatory response that may have both harmful and beneficial effects. There is also evidence that astrocytes progressively accumulate in the normal aging brain, increasing in both number and size. These astrocyte changes in normal brain aging may, in the event of an injury, contribute to the exacerbated injury response and poorer outcomes observed in older traumatic brain injury (TBI) survivors. Here we present our view that proton magnetic resonance spectroscopy (H-1-MRS), a neuroimaging approach that probes brain metabolism within a defined region of interest, is a promising technique that may provide insight into astrocyte metabolic changes in the injured and aging brain in vivo. Although H-1-MRS does not specifically differentiate between cell types, it quantifies certain metabolites that are highly enriched in astrocytes (e.g., Myo-inositol, mins), or that are involved in metabolic shuttling between astrocytes and neurons (e.g., glutamate and glutamine). Here we focus on metabolites detectable by H-1-MRS that may serve as markers of astrocyte metabolic status. We review the physiological roles of these metabolites, discuss recent H-1-MRS findings in the injured and aging brain, and describe how an astrocyte metabolite profile approach might be useful in clinical medicine and clinical trials.	[Harris, Janna L.; Choi, In-Young; Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66103 USA; [Harris, Janna L.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66103 USA; [Choi, In-Young; Brooks, William M.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA; [Choi, In-Young; Brooks, William M.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66103 USA		Harris, JL (corresponding author), Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66103 USA.	jharris2@kumc.edu	Brooks, William/AAF-8299-2019	Brooks, William/0000-0001-6227-7636	U.S. National Institutes of Health through the University of Kansas Alzheimer's Center [P30 AG035982]; Heartland Institute for Clinical & Translational Research [UL1 TR000001, R21 NS091920]; KUMC Lied Endowed Basic Science; Hoglund Family Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS091920] Funding Source: NIH RePORTER	This work was supported in part by the U.S. National Institutes of Health through the University of Kansas Alzheimer's Center (P30 AG035982), Frontiers: The Heartland Institute for Clinical & Translational Research (UL1 TR000001), R21 NS091920, KUMC Lied Endowed Basic Science grants to Drs. Harris and Brooks, and the Hoglund Family Foundation. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.	Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ashwal S, 1997, ANN NEUROL, V41, P470, DOI 10.1002/ana.410410410; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/0897715042441756; Bartnik-Olson Brenda L, 2013, Front Neuroenergetics, V5, P8, DOI 10.3389/fnene.2013.00008; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; Bluml S., 2013, MR SPECTROSCOPY PEDI, P11, DOI [10.1007/978-1-4419-5864-8_2, DOI 10.1007/978-1-4419-5864-8_2]; Boumezbeur F, 2010, J CEREBR BLOOD F MET, V30, P211, DOI 10.1038/jcbfm.2009.197; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Brooks WM, 1999, MAGNET RESON MED, V41, P193, DOI 10.1002/(SICI)1522-2594(199901)41:1<193::AID-MRM27>3.3.CO;2-G; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BROWN LAS, 1994, AM J PHYSIOL, V266, pL172, DOI 10.1152/ajplung.1994.266.2.L172; Chang L, 1996, LIFE SCI, V58, P2049, DOI 10.1016/0024-3205(96)00197-X; Chang LD, 2013, J NEUROIMMUNE PHARM, V8, P576, DOI 10.1007/s11481-013-9460-x; Chen SQ, 2012, J ALZHEIMERS DIS, V28, P71, DOI 10.3233/JAD-2010-110893; Chen SQ, 2009, DEMENT GERIATR COGN, V28, P558, DOI 10.1159/000261646; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Choi IY, 2011, MULT SCLER J, V17, P289, DOI 10.1177/1352458510384010; Cotrina ML, 2002, J NEUROSCI RES, V67, P1; Di Pietro V, 2014, FREE RADICAL BIO MED, V69, P258, DOI 10.1016/j.freeradbiomed.2014.01.032; Duarte JMN, 2014, NEUROBIOL AGING, V35, P1660, DOI 10.1016/j.neurobiolaging.2014.01.135; Emir UE, 2011, NMR BIOMED, V24, P888, DOI 10.1002/nbm.1646; Filibian M, 2012, EPILEPSIA, V53, P1907, DOI 10.1111/j.1528-1167.2012.03685.x; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Harris JL, 2014, NEUROBIOL AGING, V35, P1686, DOI 10.1016/j.neurobiolaging.2014.01.018; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Hurd R, 2004, MAGNET RESON MED, V51, P435, DOI 10.1002/mrm.20007; Kaiser LG, 2005, NEUROBIOL AGING, V26, P665, DOI 10.1016/j.neurobiolaging.2004.07.001; Kierans AS, 2014, NEUROLOGY, V82, P521, DOI 10.1212/WNL.0000000000000105; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KREIS R, 1992, RADIOLOGY, V182, P19, DOI 10.1148/radiology.182.1.1345760; Lei HX, 2009, J CEREBR BLOOD F MET, V29, P811, DOI 10.1038/jcbfm.2009.8; Lescot T, 2010, J NEUROTRAUM, V27, P463, DOI 10.1089/neu.2009.0982-C; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Maher P, 2005, AGEING RES REV, V4, P288, DOI 10.1016/j.arr.2005.02.005; MICHAELIS T, 1993, RADIOLOGY, V187, P219, DOI 10.1148/radiology.187.1.8451417; Murray ME, 2014, J NEUROSCI, V34, P16247, DOI 10.1523/JNEUROSCI.2027-14.2014; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Paban V, 2010, EUR J NEUROSCI, V31, P1063, DOI 10.1111/j.1460-9568.2010.07126.x; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PETROFF OAC, 1995, MAGN RESON IMAGING, V13, P1197, DOI 10.1016/0730-725X(95)02033-P; Pfeuffer J, 1999, J MAGN RESON, V141, P104, DOI 10.1006/jmre.1999.1895; Popa-Wagner A, 2011, AGEING RES REV, V10, P71, DOI 10.1016/j.arr.2009.10.008; Rae CD, 2014, NEUROCHEM RES, V39, P1, DOI 10.1007/s11064-013-1199-5; Reyngoudt H, 2012, EUR J RADIOL, V81, pE223, DOI 10.1016/j.ejrad.2011.01.106; Rice ME, 1998, NEUROSCIENCE, V82, P1213; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rothermundt M, 2007, PROG NEURO-PSYCHOPH, V31, P361, DOI 10.1016/j.pnpbp.2006.09.013; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Sharrock M., 2015, NAT NEUR S, pA, DOI [10.1089/neu.2015.29000, DOI 10.1089/NEU.2015.29000]; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; STRANGE K, 1994, GLIA, V12, P35, DOI 10.1002/glia.440120105; Sun XJ, 2006, J BIOL CHEM, V281, P17420, DOI 10.1074/jbc.M601567200; Terpstra M, 2003, MAGN RESON MED, V50, P19, DOI 10.1002/mrm.10499; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Trabesinger AH, 2001, MAGN RESON MED, V45, P708, DOI 10.1002/mrm.1094; Urrila AS, 2004, J SLEEP RES, V13, P111, DOI 10.1111/j.1365-2869.2004.00401.x; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yokobori S, 2011, J TRAUMA, V71, P1235, DOI 10.1097/TA.0b013e3182140dd7; Zhang XR, 2013, BRAIN RES, V1507, P28, DOI 10.1016/j.brainres.2013.02.033; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	68	43	43	1	10	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	OCT 28	2015	7								202	10.5589/fnagi.2015.00202			8	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	CV3JA	WOS:000364154300001	26578948				2022-02-06	
J	Rose, NS; Rendell, PG; Hering, A; Kliegel, M; Bidelman, GM; Craik, FIM				Rose, Nathan S.; Rendell, Peter G.; Hering, Alexandra; Kliegel, Matthias; Bidelman, Gavin M.; Craik, Fergus I. M.			Cognitive and neural plasticity in older adults' prospective memory following training with the Virtual Week computer game	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						prospective memory; cognitive training; ERPs (event-related potentials); aging; activities of daily living (ADL); Virtual Week	RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; IMPLEMENTATION INTENTIONS; INSTRUMENTAL ACTIVITIES; NEUROLOGICAL DISORDERS; IMPROVING MEMORY; AGE-DIFFERENCES; CUE FOCALITY; REHABILITATION	Prospective memory (PM) - the ability to remember and successfully execute our intentions and planned activities - is critical for functional independence and declines with age, yet few studies have attempted to train PM in older adults. We developed a PM training program using the Virtual Week computer game. Trained participants played the game in 12, 1-h sessions over 1 month. Measures of neuropsychological functions, lab-based PM, event-related potentials (ERPs) during performance on a lab-based PM task, instrumental activities of daily living, and real-world PM were assessed before and after training. Performance was compared to both no-contact and active (music training) control groups. PM on the Virtual Week game dramatically improved following training relative to controls, suggesting PM plasticity is preserved in older adults. Relative to control participants, training did not produce reliable transfer to laboratory-based tasks, but was associated with a reduction of an ERP component (sustained negativity over occipito-parietal cortex) associated with processing PM cues, indicative of more automatic PM retrieval. Most importantly, training produced far transfer to real-world outcomes including improvements in performance on real world PM and activities of daily living. Real-world gains were not observed in either control group. Our findings demonstrate that short-term training with the Virtual Week game produces cognitive and neural plasticity that may result in real-world benefits to supporting functional independence in older adulthood.	[Rose, Nathan S.; Bidelman, Gavin M.; Craik, Fergus I. M.] Rotman Res Inst, Toronto, ON, Canada; [Rose, Nathan S.; Rendell, Peter G.] Australian Catholic Univ, Sch Psychol, Melbourne, Vic, Australia; [Rose, Nathan S.; Rendell, Peter G.] Univ Geneva, Fac Psychol & Sci Educ, Geneva, Switzerland; [Bidelman, Gavin M.] Univ Memphis, Inst Intelligent Syst, Memphis, TN 38152 USA; [Bidelman, Gavin M.] Univ Memphis, Sch Commun Sci & Disorders, Memphis, TN 38152 USA		Rose, NS (corresponding author), Rotman Res Inst, Toronto, ON, Canada.	nathan.rose@acu.edu.au	Hering, Alexandra/AAL-5929-2020; Bidelman, Gavin M/D-9998-2016; Rendell, Peter/E-7539-2010	Hering, Alexandra/0000-0002-7952-9032; Bidelman, Gavin M/0000-0002-1821-3261; Rendell, Peter/0000-0002-4829-4322; Kliegel, Matthias/0000-0002-2001-2522; Rose, Nathan/0000-0002-7619-4441	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; Baycrest's Centre for Brain Fitness; Australian Research CouncilAustralian Research Council; Roland Ernst foundation; Centre for Brain Fitness; Suzanna Penningroth	This research was supported in part by grants from the Natural Sciences and Engineering Research Council of Canada, Baycrest's Centre for Brain Fitness, the Australian Research Council, and the Roland Ernst foundation. We thank Sylvain Moreno for supporting the music training program for the active control group which was sponsored by the Centre for Brain Fitness, Suzanna Penningroth for providing data regarding everyday prospective memory tasks that were incorporated into the Virtual Week training program, Trevor Daniels for assistance with programming the Virtual Week training game, and Karen Lau, Brittany Murphy, and Virtual Week for their tireless efforts with data collection.	Bidelman GM, 2015, J NEUROSCI, V35, P1240, DOI 10.1523/JNEUROSCI.3292-14.2015; Bisiacchi PS, 2008, AGING CLIN EXP RES, V20, P569; Brom SS, 2014, PSYCHOL AGING, V29, P744, DOI 10.1037/a0037181; Brom SS, 2014, EUR J AGEING, V11, P89, DOI 10.1007/s10433-013-0288-2; Cona G, 2015, NEUROSCI BIOBEHAV R, V52, P21, DOI 10.1016/j.neubiorev.2015.02.007; Cona G, 2014, CEREB CORTEX, V24, P2630, DOI 10.1093/cercor/bht116; Craik FIM, 2006, MEM COGNITION, V34, P1236, DOI 10.3758/BF03193268; Craik FIM, 2012, J APPL RES MEM COGN, V1, P51, DOI 10.1016/j.jarmac.2011.12.001; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; Crawford JR, 2003, MEMORY, V11, P261, DOI 10.1080/09658210244000027; CROVITZ HF, 1984, B PSYCHONOMIC SOC, V22, P413; de Jager CA, 2003, INT J GERIATR PSYCH, V18, P318, DOI 10.1002/gps.830; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DESMOND DW, 1994, INT J GERIATR PSYCH, V9, P803, DOI 10.1002/gps.930091006; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Fish J, 2010, NEUROPSYCHOL REHABIL, V20, P161, DOI 10.1080/09602010903126029; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Gollwitzer PM, 1999, AM PSYCHOL, V54, P493, DOI 10.1037//0003-066X.54.7.493; Gross AL, 2012, AGING MENT HEALTH, V16, P722, DOI 10.1080/13607863.2012.667783; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; Hering A, 2014, PSYCHOL RES-PSYCH FO, V78, P892, DOI 10.1007/s00426-014-0566-4; Ihle A, 2013, PSYCHOL AGING, V28, P714, DOI 10.1037/a0033653; Kinsella GJ, 2009, J NEUROL NEUROSUR PS, V80, P730, DOI 10.1136/jnnp.2008.148346; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kliegel M, 2003, INT J PSYCHOL, V38, P207, DOI 10.1080/00207590344000132; Kliegel M, 2008, PSYCHOL AGING, V23, P203, DOI 10.1037/0882-7974.23.1.203; Kliegel M, 2012, J APPL RES MEM COGN, V1, P58, DOI 10.1016/j.jarmac.2012.01.002; Lee JH, 2016, BRIT J CLIN PSYCHOL, V55, P154, DOI 10.1111/bjc.12084; Leitz JR, 2009, PSYCHOPHARMACOLOGY, V205, P379, DOI 10.1007/s00213-009-1546-z; Liu LL, 2004, PSYCHOL AGING, V19, P318, DOI 10.1037/0882-7974.19.2.318; Lopez-Calderon J, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00213; McDaniel MA., 1996, PROSPECTIVE MEMORY T, P1; McDaniel MA, 2014, PSYCHOL AGING, V29, P717, DOI 10.1037/a0037363; McDaniel MA, 2012, J APPL RES MEM COGN, V1, P45, DOI 10.1016/j.jarmac.2011.11.002; McFarland CP, 2011, AGING NEUROPSYCHOL C, V18, P633, DOI 10.1080/13825585.2011.613449; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Moreno S, 2011, PSYCHOL SCI, V22, P1425, DOI 10.1177/0956797611416999; Morrison AB, 2011, PSYCHON B REV, V18, P46, DOI 10.3758/s13423-010-0034-0; Owsley C, 2002, GERONTOLOGY, V48, P254, DOI 10.1159/000058360; Penningroth SL, 2013, EUR J AGEING, V10, P211, DOI 10.1007/s10433-013-0265-9; Phillips L.H., 2008, Prospective Memory: Cognitive, Neuroscience, Developmental, and Applied; Piras F, 2011, EUR J PHYS REHAB MED, V47, P149; Radford K, 2012, J INT NEUROPSYCH SOC, V18, P738, DOI 10.1017/S1355617712000379; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Raven J., 1996, MANUAL RAVENS PROGR; Reichman WE., 2010, AGING HLTH, V6, P565, DOI [DOI 10.2217/AHE.10.54, 10.2217/ahe.10.54]; Rendell PG, 2007, J INT NEUROPSYCH SOC, V13, P410, DOI 10.1017/S1355617707070579; Rendell PG, 2011, COGNITION EMOTION, V25, P916, DOI 10.1080/02699931.2010.508610; Rendell PG, 2000, APPL COGNITIVE PSYCH, V14, pS43, DOI 10.1002/acp.770; Rose NS, 2015, CAN J EXP PSYCHOL, V69, P252, DOI 10.1037/cep0000054; Rose NS, 2010, PSYCHOL AGING, V25, P595, DOI 10.1037/a0019771; Shipley WC, 1940, J PSYCHOL, V9, P371, DOI 10.1080/00223980.1940.9917704; Shipstead Z, 2012, PSYCHOL BULL, V138, P628, DOI 10.1037/a0027473; Shum D, 2011, J REHABIL MED, V43, P216, DOI 10.2340/16501977-0647; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TERRY WS, 1988, PSYCHOL REP, V62, P299, DOI 10.2466/pr0.1988.62.1.299; Tucker-Drob EM, 2011, NEUROPSYCHOLOGY, V25, P368, DOI 10.1037/a0022348; VERHAEGHEN P, 1992, PSYCHOL AGING, V7, P242, DOI 10.1037/0882-7974.7.2.242; Wallstrom GL, 2004, INT J PSYCHOPHYSIOL, V53, P105, DOI 10.1016/j.ijpsycho.2004.03.007; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; West R, 2005, PSYCHOPHYSIOLOGY, V42, P698, DOI 10.1111/j.1469-8986.2005.00361.x; West R, 2011, NEUROPSYCHOLOGIA, V49, P2233, DOI 10.1016/j.neuropsychologia.2010.12.028; Woods SP, 2012, J INT NEUROPSYCH SOC, V18, P134, DOI 10.1017/S1355617711001263; Zachary R. A., 1986, SHIPLEY I LIVING SCA	64	43	45	5	64	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	OCT 28	2015	9									10.3389/fnhum.2015.00592			13	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	CY5ZS	WOS:000366487300002	26578936	gold, Green Published			2022-02-06	
J	Guilfoyle, MR; Carpenter, KLH; Helmy, A; Pickard, JD; Menon, DK; Hutchinson, PJA				Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Helmy, Adel; Pickard, John D.; Menon, David K.; Hutchinson, Peter J. A.			Matrix Metalloproteinase Expression in Contusional Traumatic Brain Injury: A Paired Microdialysis Study	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; extracellular matrix; microdialysis	THERAPEUTIC HYPOTHERMIA; CEREBROSPINAL-FLUID; FOCAL ISCHEMIA; MATRIX-METALLOPROTEINASE-9; INHIBITION; DOXYCYCLINE; STROKE; EDEMA; BLOOD; RATS	Matrix metalloproteinases (MMPs) are extracellular enzymes that have been implicated in the pathophysiology of blood-brain barrier (BBB) breakdown, contusion expansion, and vasogenic edema after traumatic brain injury (TBI). Specifically, in focal injury models, increased MMP-9 expression has been observed in pericontusional brain, and MMP-9 inhibitors reduce brain swelling and final lesion volume. The aim of this study was to examine whether there is a similarly localized increase of MMP concentrations in patients with contusional TBI. Paired microdialysis catheters were inserted into 12 patients with contusional TBI (with or without associated mass lesion) targeting pericontusional and radiologically normal brain defined on admission computed tomography scan. Microdialysate was pooled every 8h and analyzed for MMP-1, -2, -7, -9, and -10 using a multiplex immunoassay. Concentrations of MMP-1, -2, and -10 were similar at both monitoring sites and did not show discernible temporal trends. Overall, there was a gradual increase in MMP-7 concentrations in both normal and injured brain over the monitoring period, although this was not consistent in every patient. MMP-9 concentrations were elevated in pericontusional, compared to normal, brain, with the maximal difference at the earliest monitoring times (i.e., <24h postinjury). Repeated-measures analysis of variance showed that MMP-9 concentrations were significantly higher in pericontusional brain (p=0.03) and within the first 72h of injury, compared with later in the monitoring period (p=0.04). No significant differences were found for the other MMPs assayed. MMP-9 concentrations are increased in pericontusional brain early post-TBI and may represent a potential therapeutic target to reduce hemorrhagic progression and vasogenic edema.	[Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Helmy, Adel; Pickard, John D.; Hutchinson, Peter J. A.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Menon, David K.] Univ Cambridge, Dept Med, Div Anesthesia, Cambridge CB2 0QQ, England		Guilfoyle, MR (corresponding author), Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	mrg48@cam.ac.uk	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Hutchinson, Peter/0000-0002-2796-1835; Carpenter, Keri/0000-0001-8236-7727	National Institute for Health Research (NIHR) Academic Clinical FellowshipNational Institute for Health Research (NIHR); Royal College of Surgeons/Philip King Research Fellowship; Beverley and Raymond Sackler Fellowship; joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship; NIHR Biomedical Research Center, Cambridge; Traumatic Brain Injury NIHR Health Technology Cooperative; NIHR Senior Investigator Award; Cambridge NIHR BRCNational Institute for Health Research (NIHR); NIHR Research Professorship; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1002277] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013] Funding Source: researchfish	M.R.G. was supported by a National Institute for Health Research (NIHR) Academic Clinical Fellowship, a Royal College of Surgeons/Philip King Research Fellowship, and a Beverley and Raymond Sackler Fellowship. A.H. was supported by a joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship. K.L.H.C. is supported by the NIHR Biomedical Research Center, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). J.D.P. is supported by the Traumatic Brain Injury NIHR Health Technology Cooperative. D.K.M. is supported by an NIHR Senior Investigator Award. P.J.A.H. is supported by the Cambridge NIHR BRC and an NIHR Research Professorship.	Aoki T, 2002, STROKE, V33, P2711, DOI 10.1161/01.STR.0000033932.34467.97; Avolio C, 2003, J NEUROIMMUNOL, V136, P46, DOI 10.1016/S0165-5728(03)00006-7; Chen F, 2009, HEPATOLOGY, V50, P1914, DOI 10.1002/hep.23203; Crossley S, 2014, CRIT CARE, V18, DOI 10.1186/cc13835; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; JENNETT B, 1975, LANCET, V1, P480; Jiang XF, 2001, NEUROSCI LETT, V305, P41, DOI 10.1016/S0304-3940(01)01800-6; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lee JE, 2005, J NEUROSURG, V103, P289, DOI 10.3171/jns.2005.103.2.0289; Lindeman JHN, 2009, CIRCULATION, V119, P2209, DOI 10.1161/CIRCULATIONAHA.108.806505; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Preshaw PM, 2004, J CLIN PERIODONTOL, V31, P697, DOI 10.1111/j.1600-051X.2004.00558.x; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; Rosell A, 2008, CURR OPIN PHARMACOL, V8, P82, DOI 10.1016/j.coph.2007.12.001; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; Sparano JA, 2004, J CLIN ONCOL, V22, P4683, DOI 10.1200/JCO.2004.08.054; TEASDALE G, 1974, LANCET, V2, P81; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Vandooren J, 2013, CRIT REV BIOCHEM MOL, V48, P222, DOI 10.3109/10409238.2013.770819; Vilalta A, 2008, ACTA NEUROCHIR SUPPL, V102, P415, DOI 10.1007/978-3-211-85578-2_81; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zheng KB, 2013, NEUROL INDIA, V61, P606, DOI 10.4103/0028-3886.125258	32	43	44	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2015	32	20					1553	1559		10.1089/neu.2014.3764			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CS6VH	WOS:000362220500002	25858502	Bronze, Green Published, Green Submitted			2022-02-06	
J	Jiang, Y; Li, GY; Qian, LX; Liang, S; Destrade, M; Cao, YP				Jiang, Yi; Li, Guoyang; Qian, Lin-Xue; Liang, Si; Destrade, Michel; Cao, Yanping			Measuring the linear and nonlinear elastic properties of brain tissue with shear waves and inverse analysis	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Supersonic shear wave imaging technique; Inverse method; Brain tissue; Elastic and hyperelastic properties	IN-VIVO; MECHANICAL-PROPERTIES; 4TH-ORDER CONSTANTS; SOFT SOLIDS; EX-VIVO; ELASTOGRAPHY; BEHAVIOR; DEFORMATION; MODULUS; MODEL	We use supersonic shear wave imaging (SSI) technique to measure not only the linear but also the nonlinear elastic properties of brain matter. Here, we tested six porcine brains ex vivo and measured the velocities of the plane shear waves induced by acoustic radiation force at different states of pre-deformation when the ultrasonic probe is pushed into the soft tissue. We relied on an inverse method based on the theory governing the propagation of small-amplitude acoustic waves in deformed solids to interpret the experimental data. We found that, depending on the subjects, the resulting initial shear modulus varies from 1.8 to 3.2 kPa, the stiffening parameter of the hyperelastic Demiray-Fung model from 0.13 to 0.73, and the third- and fourth-order constants of weakly nonlinear elasticity from 1.3 to 20.6 kPa and from 3.1 to 8.7 kPa, respectively. Paired test performed on the experimental results of the left and right lobes of the brain shows no significant difference. These values are in line with those reported in the literature on brain tissue, indicating that the SSI method, combined to the inverse analysis, is an efficient and powerful tool for the mechanical characterization of brain tissue, which is of great importance for computer simulation of traumatic brain injury and virtual neurosurgery.	[Jiang, Yi; Li, Guoyang; Cao, Yanping] Tsinghua Univ, Dept Engn Mech, AML, Inst Biomech & Med Engn, Beijing 100084, Peoples R China; [Qian, Lin-Xue; Liang, Si] Capital Med Univ, Beijing Friendship Hosp, Dept Ultrasound, Beijing 100050, Peoples R China; [Destrade, Michel] Natl Univ Ireland Univ Coll Galway, Sch Math Stat & Appl Math, Galway, Ireland		Cao, YP (corresponding author), Tsinghua Univ, Dept Engn Mech, AML, Inst Biomech & Med Engn, Beijing 100084, Peoples R China.	michel.destrade@nuigalway.ie; caoyanping@tsinghua.edu.cn	Li, Guo-Yang/Q-5391-2016; cao, yanping/E-3381-2010; Destrade, Michel/O-5825-2019	Li, Guo-Yang/0000-0002-5939-9293; Destrade, Michel/0000-0002-6266-1221	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [11172155]; Tsinghua University [2012Z02103]; 973 Program of MOSTNational Basic Research Program of China [2010CB631005]	Supports from the National Natural Science Foundation of China (Grant No. 11172155), Tsinghua University (2012Z02103) and 973 Program of MOST (2010CB631005) are gratefully acknowledged. We also thank the referees for helping us improve greatly previous versions of the article.	Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Bercoff J, 2004, IEEE T ULTRASON FERR, V51, P1523, DOI 10.1109/TUFFC.2004.1367494; Bercoff J, 2004, IEEE T ULTRASON FERR, V51, P396, DOI 10.1109/TUFFC.2004.1295425; Bercoff J, 2004, APPL PHYS LETT, V84, P2202, DOI 10.1063/1.1667613; Brillouin L., 1946, TENSEURS MECANIQUE E; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; DEMIRAY H, 1972, J BIOMECH, V5, P309, DOI 10.1016/0021-9290(72)90047-4; Destrade M, 2010, J APPL MECH-T ASME, V77, DOI 10.1115/1.4001282; Destrade M, 2010, J ACOUST SOC AM, V128, P3334, DOI 10.1121/1.3505102; Destrade M, 2010, J ACOUST SOC AM, V127, P2759, DOI 10.1121/1.3372624; Destrade M, 2010, J ACOUST SOC AM, V127, P2103, DOI 10.1121/1.3337232; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gennisson JL, 2007, J ACOUST SOC AM, V122, P3211, DOI 10.1121/1.2793605; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Hamilton MF, 2004, J ACOUST SOC AM, V116, P41, DOI 10.1121/1.1736652; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Jiang Y, 2015, MED IMAGE ANAL, V20, P97, DOI 10.1016/j.media.2014.10.010; Karimi A, 2013, P I MECH ENG H, V227, P609, DOI 10.1177/0954411913476779; Kaster T, 2011, J BIOMECH, V44, P1158, DOI 10.1016/j.jbiomech.2011.01.019; Klatt D, 2007, PHYS MED BIOL, V52, P7281, DOI 10.1088/0031-9155/52/24/006; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Latorre-Ossa H, 2012, IEEE T ULTRASON FERR, V59, P833, DOI 10.1109/TUFFC.2012.2262; Mace E, 2011, IEEE T MED IMAGING, V30, P550, DOI 10.1109/TMI.2010.2079940; Miga MI, 2000, IEEE T BIO-MED ENG, V47, P266, DOI 10.1109/10.821778; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Nicolle S, 2005, BIORHEOLOGY, V42, P209; ODONNELL M, 1994, IEEE T ULTRASON FERR, V41, P314, DOI 10.1109/58.285465; Ogden RW, 2007, CISM COURSES LECT, P1; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Rashid B, 2013, J BIOMECH, V46, P1276, DOI 10.1016/j.jbiomech.2013.02.014; Renier M, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2979875; Roberts DW, 1999, NEUROSURGERY, V45, P1199, DOI 10.1097/00006123-199911000-00037; Sack I, 2009, NEUROIMAGE, V46, P652, DOI 10.1016/j.neuroimage.2009.02.040; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Streitberger KJ, 2011, NMR BIOMED, V24, P385, DOI 10.1002/nbm.1602; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang MG, 2014, J MECH PHYS SOLIDS, V68, P179, DOI 10.1016/j.jmps.2014.03.012; Zhang MG, 2014, BIOMECH MODEL MECHAN, V13, P1, DOI 10.1007/s10237-013-0481-4	47	43	46	2	56	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	OCT	2015	14	5					1119	1128		10.1007/s10237-015-0658-0			10	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	CQ8MT	WOS:000360862600013	25697960	Green Submitted			2022-02-06	
J	Ilie, G; Mann, RE; Hamilton, H; Adlaf, EM; Boak, A; Asbridge, M; Rehm, J; Cusimano, MD				Ilie, Gabriela; Mann, Robert E.; Hamilton, Hayley; Adlaf, Edward M.; Boak, Angela; Asbridge, Mark; Rehm, Juergen; Cusimano, Michael D.			Substance Use and Related Harms Among Adolescents With and Without Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescents; alcohol use; concussion; drugs; smoking; substance use; traumatic brain injury	DRUG-USE; MENTAL-HEALTH; UNITED-STATES; ALCOHOL; CANNABIS; ABUSE; CLASSIFICATION; ASSOCIATION; POPULATION; PREVALENCE	Objective: The relationship between self-reported lifetime traumatic brain injury (TBI) and drug and alcohol use and associated harms was examined using an epidemiological sample of Canadian adolescents. Settings and Design: Data were derived from a 2011 population-based cross-sectional school survey, which included 6383 Ontario 9th-12th graders who self-completed anonymous self-administered questionnaires in classrooms. Traumatic brain injury was defined as loss of consciousness for at least 5 minutes or a minimum 1-night hospital stay due to symptoms. Results: Relative to high schoolers without a history of TBI, those who acknowledged having a TBI in their lifetime had odds 2 times greater for binge drinking (5+ drinks per occasion in the past 4 weeks), 2.5 times greater for daily cigarette smoking, 2.9 times greater for nonmedical use of prescription drugs, and 2.7 times greater for consuming illegal drug in the past 12 months. Adolescents with a history of TBI had greater odds for experiencing hazardous/harmful drinking (adjusted odds ratio [aOR] = 2.3), cannabis problems (aOR = 2.4), and drug problems (aOR = 2.1), compared with adolescents who were never injured. Conclusion: There are strong and demographically stable associations between TBI and substance use. These associations may not only increase the odds of injury but impair the quality of postinjury recovery.	[Ilie, Gabriela; Cusimano, Michael D.] St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada; [Mann, Robert E.; Hamilton, Hayley; Adlaf, Edward M.; Boak, Angela; Rehm, Juergen] St Michaels Hosp, Ctr Addict & Mental Hlth, Social & Epidemiol Res, Toronto, ON M5B 1W8, Canada; [Asbridge, Mark] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada		Ilie, G (corresponding author), St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	ilieg@smh.ca	Cusimano, Michael/X-4059-2019; Ilie, Gabriela/AAM-9122-2021	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation; AUTO21; Natural Sciences and Engineering Research CouncilNatural Sciences and Engineering Research Council of Canada (NSERC); Social Sciences and Humanities Research CouncilSocial Sciences and Humanities Research Council of Canada (SSHRC); Ontario Ministry of Health and Long-Term CareMinistry of Health and Long-Term Care, Ontario	This work was financially supported by a STAIR Team Grant from the Canadian Institutes of Health Research (TIR-103946) and by the Ontario Neurotrauma Foundation. Additional funding was obtained from a grant from AUTO21, a member of the Networks of Centres of Excellence program that is administered and funded by the Natural Sciences and Engineering Research Council, the Social Sciences and Humanities Research Council, in partnership with Industry Canada, and ongoing funding support from the Ontario Ministry of Health and Long-Term Care.	Adlaf E.M., 2005, EPIDEMIOLOGY DRUG AB, P99; [Anonymous], 2012, INJ PREV CONTR TRAUM; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Becker B, 2001, DISABIL STUD Q, V21; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI [10.1089/neu.2008.0849, 10.1089/neu.2008-0849]; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; Canadian Institute for Health Information, 2006, HEAD INJ CAN DEC CHA; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ US E; Cherpitel CJ, 2007, DRUG ALCOHOL REV, V26, P201, DOI 10.1080/09595230601146686; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Courser MW, 2009, EVALUATION REV, V33, P370, DOI 10.1177/0193841X09337228; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061865; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Dicker BG, 1989, HEAD TRAUMA REHABIL, V4, P73; Dikmen S, 2003, NEUROPSYCHOLOGY, V7, P296; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Frances A, DSM 4 CLASSIFICATION; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Groves R.M., 2009, SURVEY METHODOLOGY; Groves RM, 2008, PUBLIC OPIN QUART, V72, P167, DOI 10.1093/poq/nfn011; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Heeringa SG, 2010, APPL SURVEY DATA; Ilie G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094936; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Knight JR, 2002, ARCH PEDIAT ADOL MED, V156, P607, DOI 10.1001/archpedi.156.6.607; Korn E.L., 1999, ANAL HLTH SURVEYS; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Kuipers P, 2000, J HEAD TRAUMA REHAB, V15, P1275, DOI 10.1097/00001199-200012000-00007; Laird RD, 2005, DEV PSYCHOPATHOL, V17, P127, DOI 10.1017/S0954579405050078; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Martin G, 2006, DRUG ALCOHOL DEPEN, V83, P90, DOI 10.1016/j.drugalcdep.2005.10.014; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mohler-Kuo M, 2003, J AM COLL HEALTH, V52, P17, DOI 10.1080/07448480309595719; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Institute on Drug Abuse, 2012, DRUG FACTS HIGH SCH; OuCH, 2012, OUTC FOLL CONC HOCK; Paglia-Boak A., 2011, CAMH RES DOCUMENT SE, V32; Paglia-Boak A, 2013, CAMH RES DOCUMENT SE, V36; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Patton GC, 2002, BMJ-BRIT MED J, V325, P1195, DOI 10.1136/bmj.325.7374.1195; Perle JG, 2013, J CHILD ADOLES SUBST, V22, P1, DOI 10.1080/1067828X.2012.724289; Rey JM, 2002, BRIT J PSYCHIAT, V180, P216, DOI 10.1192/bjp.180.3.216; Ryan L M, 1996, Appl Neuropsychol, V3, P49, DOI 10.1207/s15324826an0302_1; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; SHEDLER J, 1990, AM PSYCHOL, V45, P612, DOI 10.1037/0003-066X.45.5.612; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Tait RJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-171; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Turner A., 2009, HDB REHABILITATION P, P241; West BT, 2008, STATA J, V8, P520, DOI 10.1177/1536867X0800800404; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Winqvist S, 2006, J ADOLESCENT HEALTH, V39; Winqvist S, 2007, NEUROEPIDEMIOLOGY, V29, P136, DOI 10.1159/000110741; Zatzick DF, 2011, PSYCHIAT SERV, V62, P264, DOI 10.1176/ps.62.3.pss6203_0264; Zernicke R. F., 2009, Journal of Intercollegiate Sport, V2, P42	69	43	43	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2015	30	5					293	301		10.1097/HTR.0000000000000101			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DD0JE	WOS:000369605400007	25427256	Green Accepted			2022-02-06	
J	Benedict, PA; Baner, NV; Harrold, GK; Moehringer, N; Hasanaj, L; Serrano, LP; Sproul, M; Pagnotta, G; Cardone, DA; Flanagan, SR; Rucker, J; Galetta, SL; Balcer, LJ				Benedict, Peter A.; Baner, Natali V.; Harrold, G. Kyle; Moehringer, Nicholas; Hasanaj, Lisena; Serrano, Liliana P.; Sproul, Mara; Pagnotta, Geraldine; Cardone, Dennis A.; Flanagan, Steven R.; Rucker, Janet; Galetta, Steven L.; Balcer, Laura J.			Gender and age predict outcomes of cognitive, balance and vision testing in a multidisciplinary concussion center	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Concussion; Sports; SCAT2; King-Devick test; Saccades; Cognition	DORSOLATERAL PREFRONTAL CORTEX; SPORTS-RELATED CONCUSSION; VISUAL SCREENING TOOL; KING-DEVICK TEST; NORMATIVE DATA; BRAIN-INJURY; DEPRESSION; SYMPTOMS	Objective: This study examined components of the Sports Concussion Assessment Tool, 3rd Edition (SCAT3) and a vision-based test of rapid number naming (King-Devick [K-D] to evaluate sports and non-sports concussion patients in an outpatient, multidisciplinary concussion center. While the Symptom Evaluation, Standardized Assessment of Concussion (SAC), modified Balance Error Scoring System (BESS), and K-D are used typically for sideline assessment, their use in an outpatient clinical setting following concussion has not been widely investigated. Methods: K-D, BESS, SAC, and SCAT3 Symptom Evaluation scores were analyzed for 206 patients who received concussion care at the Concussion Center at NYU Langone Medical Center. Patient age, gender, referral data, mechanism of injury, time between concussive event and first concussion center appointment, and the first specialty service to evaluate each patient were also analyzed. Results: In this cohort, Symptom Evaluation scores showed a higher severity and a greater number of symptoms to be associated with older age (r = 031, P = 0.002), female gender (P = 0.002, t-test), and longer time between the concussion event and first appointment at the concussion center (r = 0.34, P = 0.008). Performance measures of K-D and BESS also showed associations of worse scores with increasing patient age (r = 0.32-0.54, P <= 0.001), but were similar among males and females and across the spectrum of duration since the concussion event. Patients with greater Symptom Severity Scores also had the greatest numbers of referrals to specialty services in the concussion center (r = 033, P = 0.0008). Worse Immediate Memory scores on SAC testing correlated with slower K-D times, potentially implicating the dorsolateral prefrontal cortex as a commonly involved brain structure. Conclusion: This study demonstrates a novel use of sideline concussion assessment tools for evaluation in the outpatient setting, and implicates age and gender as predictors of outcomes for these tests. (C) 2015 Elsevier B.V. All rights reserved.	[Benedict, Peter A.; Baner, Natali V.; Harrold, G. Kyle; Moehringer, Nicholas; Hasanaj, Lisena; Serrano, Liliana P.; Rucker, Janet; Galetta, Steven L.; Balcer, Laura J.] NYU, Dept Neurol, Sch Med, New York, NY 10016 USA; [Balcer, Laura J.] NYU, Dept Populat Hlth, Sch Med, New York, NY 10016 USA; [Rucker, Janet; Galetta, Steven L.; Balcer, Laura J.] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA; [Sproul, Mara; Pagnotta, Geraldine; Flanagan, Steven R.] NYU, Dept Rehabil Med, Sch Med, New York, NY 10016 USA; [Cardone, Dennis A.] NYU, Dept Orthopaed Sports Med, Sch Med, New York, NY 10016 USA		Balcer, LJ (corresponding author), NYU, Dept Neurol, Sch Med, 240 East 38th St,20th Floor, New York, NY 10016 USA.	peter.benedict@nyumc.org; natali.baner@nyumc.org; george.harrold@nyumc.org; nicholasmoehringer@yahoo.com; lisena.hasanaj@nyumc.org; liliana.serrano2@nyumc.org; mara.sproul@nyumc.org; geraldine.pagnotta@nyumc.org; dennis.cardone@nyumc.org; steven.flanagan@nyumc.org; janet.rucker@nyumc.org; steven.galetta@nyumc.org; laura.balcer@nyumc.org		Rucker, Janet/0000-0002-0397-0999; Harrold, G/0000-0001-6166-188X; Flanagan, Steven/0000-0001-9005-5897	NYU School of Medicine	This study was supported in part by the NYU School of Medicine.	Aoki R, 2011, NEUROSCI RES, V70, P189, DOI 10.1016/j.neures.2011.02.011; Choi W, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.01024; Dessy A, 2014, CLIN NEUROL NEUROSUR, V122, P59, DOI 10.1016/j.clineuro.2014.04.003; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEUROOPHTHALM 0218; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; Koenigs M, 2009, BEHAV BRAIN RES, V201, P239, DOI 10.1016/j.bbr.2009.03.004; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Marinides Z, 2015, NEUROL CLIN PRACT, V5, P25, DOI DOI 10.1212/CPJ.000000000; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Pierrot-Deseilligny C, 2005, ANN NY ACAD SCI, V1039, P239, DOI 10.1196/annals.1325.023; Qin SZ, 2009, BIOL PSYCHIAT, V66, P25, DOI 10.1016/j.biopsych.2009.03.006; Sturzenegger M, 2008, ACTA NEUROL SCAND, V117, P49, DOI 10.1111/j.1600-0404.2007.00939.x; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5	22	43	43	1	29	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	JUN 15	2015	353	1-2					111	115		10.1016/j.jns.2015.04.029			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK3PK	WOS:000356127800020	25953343				2022-02-06	
J	Yang, ZH; Wang, P; Morgan, D; Lin, D; Pan, JC; Lin, F; Strang, KH; Selig, TM; Perez, PD; Febo, M; Chang, BG; Rubenstein, R; Wang, KKW				Yang, Zhihui; Wang, Ping; Morgan, Drake; Lin, Dan; Pan, Jianchun; Lin, Fan; Strang, Kevin H.; Selig, Tyler M.; Perez, Pablo D.; Febo, Marcelo; Chang, Binggong; Rubenstein, Richard; Wang, Kevin K. W.			Temporal MRI characterization, neurobiochemical and neurobehavioral changes in a mouse repetitive concussive head injury model	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; COGNITIVE IMPAIRMENT; ANXIETY; HIPPOCAMPUS; DYSFUNCTION; MECHANISMS; PLAYERS; MILD	Single and repeated sports-related mild traumatic brain injury (mTBI), also referred to as concussion, can result in chronic post-concussive syndrome (PCS), neuropsychological and cognitive deficits, or chronic traumatic encephalopathy (CTE). However PCS is often difficult to diagnose using routine clinical, neuroimaging or laboratory evaluations, while CTE currently only can be definitively diagnosed postmortem. We sought to develop an animal model to simulate human repetitive concussive head injury for systematic study. In this study, mice received single or multiple head impacts by a stereotaxic impact device with a custom-made rubber tip-fitted impactor. Dynamic changes in MRI, neurobiochemical markers (Tau hyperphosphorylation and glia activation in brain tissues) and neurobehavioral functions such as anxiety, depression, motor function and cognitive function at various acute/subacute (1-7 day post-injury) and chronic (14-60 days post-injury) time points were examined. To explore the potential biomarkers of rCHI, serum levels of total Tau (T-Tau) and phosphorylated Tau (P-Tau) were also monitored at various time points. Our results show temporal dynamics of MRI consistent with structural perturbation in the acute phase and neurobiochemical changes (P-Tau and GFAP induction) in the subacute and chronic phase as well as development of chronic neurobehavioral changes, which resemble those observed in mTBI patients.	[Yang, Zhihui; Wang, Ping; Lin, Dan; Lin, Fan; Strang, Kevin H.; Selig, Tyler M.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Yang, Zhihui; Wang, Ping; Lin, Dan; Lin, Fan; Strang, Kevin H.; Selig, Tyler M.; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Dept Neurosci, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Wang, Ping; Lin, Dan] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China; [Morgan, Drake; Perez, Pablo D.; Febo, Marcelo] Univ Florida, McKnight Brain Inst, Dept Psychiat, Gainesville, FL 32611 USA; [Chang, Binggong; Rubenstein, Richard] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA		Yang, ZH (corresponding author), Univ Florida, McKnight Brain Inst, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA.	zhihuiyang@ufl.edu; drakem@ufl.edu; Richard.Rubenstein@downstate.edu; kwang@ufl.edu	Febo, Marcelo/G-5718-2011; Morgan, Drake/F-6664-2012; Febo, Marcelo/X-6769-2019	Febo, Marcelo/0000-0001-8981-4163; Bruijnzeel, Adriaan/0000-0001-8466-1970; Wang, Kevin/0000-0002-9343-6473	Florida state BSCIRTF; McKnight Brain Institute; NIH grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA019946]; National Science Foundation CooperativeNational Science Foundation (NSF) [DMR-1157490]; State of Florida; SUNY Downstate Medical Center; Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DoD) Broad Agency Announcement [W81XWH-14-2-0166, W81XWH-11-2-0069]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA019946] Funding Source: NIH RePORTER	Funding support was provided in part by Florida state BSCIRTF (K.K. Wang). M. Febo and P. D. Perez were supported by the McKnight Brain Institute and NIH grant DA019946. The imaging studies of this work were conducted in the UF McKnight Brain Institute at the National High Magnetic Field Laboratory's AMRIS Facility, which is supported by National Science Foundation Cooperative Agreement No. DMR-1157490 and the State of Florida. A portion of this work was supported by both the SUNY Downstate Medical Center (RR) and the Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DoD) Broad Agency Announcement under Award #'s W81XWH-14-2-0166 and W81XWH-11-2-0069 (BC, RR). Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the DoD. For the DoD, the U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office.	Beauquis J, 2014, HIPPOCAMPUS, V24, P257, DOI 10.1002/hipo.22219; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Cai ZY, 2010, NEUROSCI BULL, V26, P28, DOI 10.1007/s12264-010-0818-2; Can A, 2012, JOVE-J VIS EXP, DOI 10.3791/3638; Etkin A, 2012, DEPRESS ANXIETY, V29, P355, DOI 10.1002/da.21957; Etkin A, 2010, CURR TOP BEHAV NEURO, V2, P251, DOI 10.1007/7854_2009_5; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kalisch R, 2006, NEUROPSYCHOPHARMACOL, V31, P925, DOI 10.1038/sj.npp.1300910; Kepe V, 2013, J ALZHEIMERS DIS, V36, P145, DOI 10.3233/JAD-130032; Li CY, 2011, CURR ALZHEIMER RES, V8, P67; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelinka L. E., 2004, J NEUROTRAUM, V11, P1; Pineda JA, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-47; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rubenstein R., 2014, J NEUROTRAU IN PRESS; Solomon GS, 2015, BRAIN INJURY, V29, P164, DOI 10.3109/02699052.2014.965205; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang K., 2013, P SPIE, V8723; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105	29	43	43	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 10	2015	5								11178	10.1038/srep11178			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CK3AO	WOS:000356087600001	26058556	Green Published, gold			2022-02-06	
J	Donders, J; Strong, CAH				Donders, Jacobus; Strong, Carrie-Ann H.			Clinical Utility of the Wechsler Adult Intelligence Scale-Fourth Edition After Traumatic Brain Injury	ASSESSMENT			English	Article						assessment; processing speed; sensitivity; specificity	WAIS-IV; CRITERION VALIDITY; NEUROPSYCHOLOGICAL TESTS; SAMPLE; SCORES	The performance of 100 patients with traumatic brain injury (TBI) on the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) was compared with that of 100 demographically matched neurologically healthy controls. Processing Speed was the only WAIS-IV factor index that was able to discriminate between persons with moderate-severe TBI on the one hand and persons with either less severe TBI or neurologically healthy controls on the other hand. The Processing Speed index also had acceptable sensitivity and specificity when differentiating between patients with TBI who either did or did not have scores in the clinically significant range on the Trail Making Test. It is concluded that WAIS-IV Processing Speed has acceptable clinical utility in the evaluation of patients with moderate-severe TBI but that it should be supplemented with other measures to assure sufficient accuracy in the diagnostic process.	[Donders, Jacobus; Strong, Carrie-Ann H.] Mary Free Bed Rehabil Hosp, Grand Rapids, MI 49503 USA		Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Benson N, 2010, PSYCHOL ASSESSMENT, V22, P121, DOI 10.1037/a0017767; Binder LM, 2011, CLIN NEUROPSYCHOL, V25, P62, DOI 10.1080/13854046.2010.533195; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; Canivez GL, 2010, PSYCHOL ASSESSMENT, V22, P827, DOI 10.1037/a0020429; Cullen N, 2014, BRAIN INJURY, V28, P38, DOI 10.3109/02699052.2013.849005; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Donders J, 2012, ARCH CLIN NEUROPSYCH, V27, P440, DOI 10.1093/arclin/acs043; Green P., 2003, GREENS WORD MEMORY T; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Heyanka DJ, 2013, INT J NEUROSCI, V123, P526, DOI 10.3109/00207454.2013.771261; Holdnack JA, 2011, ASSESSMENT, V18, P178, DOI 10.1177/1073191110393106; HOLM S, 1979, SCAND J STAT, V6, P65; Loring DW, 2010, NEUROLOGY, V74, P685, DOI 10.1212/WNL.0b013e3181d0cd12; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; Martin TA, 2003, APPL NEUROPSYCHOL, V10, P163, DOI 10.1207/S15324826AN1003_05; Michel NM, 2013, ASSESSMENT, V20, P462, DOI 10.1177/1073191113478153; Munnoz-Moreno JA, 2013, JAIDS-J ACQ IMM DEF, V63, P585, DOI 10.1097/QAI.0b013e31829e1408; Nelson JM, 2013, PSYCHOL ASSESSMENT, V25, P618, DOI 10.1037/a0032086; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Ryan JJ, 2012, J CLIN EXP NEUROPSYC, V34, P571, DOI 10.1080/13803395.2012.666229; Stucky KJ, 2014, NEUROPSYCHOLOGY STUD, P432; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Ward LC, 2012, PSYCHOL ASSESSMENT, V24, P328, DOI 10.1037/a0025614; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wechsler D., 2008, WECHSLER ADULT INTEL; Weissberger GH, 2013, NEUROPSYCHOLOGY, V27, P343, DOI 10.1037/a0032399; Wolfson, 1993, HALSTEAD REITAN NEUR	30	43	43	0	28	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	FEB	2015	22	1					17	22		10.1177/1073191114530776			6	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	AX0LZ	WOS:000346645100002	24752385				2022-02-06	
J	Dunkley, BT; Da Costa, L; Bethune, A; Jetly, R; Pang, EW; Taylor, MJ; Doesburg, SM				Dunkley, B. T.; Da Costa, L.; Bethune, A.; Jetly, R.; Pang, E. W.; Taylor, M. J.; Doesburg, S. M.			Low-frequency connectivity is associated with mild traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Mild traumatic brain injury (mTBI); Magnetoencephalography (MEG); Resting-state; Attention; Depression; Anxiety; Functional connectivity; Neural oscillations	RESTING-STATE NETWORKS; FUNCTIONAL CONNECTIVITY; IMAGING APPROACH; PHASE SYNCHRONY; DELTA WAVES; DEPRESSION; ANXIETY; ATTENTION; MEG; OSCILLATIONS	Mild traumatic brain injury (mTBI) occurs from a closed-head impact. Often referred to as concussion, about 20% of cases complain of secondary psychological sequelae, such as disorders of attention and memory. Known as post-concussive symptoms (PCS), these problems can severely disrupt the patient's quality of life. Changes in local spectral power, particularly low-frequency amplitude increases and/or peak alpha slowing have been reported in mTBI, but large-scale connectivity metrics based on inter-regional amplitude correlations relevant for integration and segregation in functional brain networks, and their association with disorders in cognition and behaviour, remain relatively unexplored. Here, we used non-invasive neuroimaging with magnetoencephalography to examine functional connectivity in a resting-state protocol in a group with mTBI (n = 20), and a control group (n=21). We observed a trend for atypical slow-wave power changes in subcortical, temporal and parietal regions in mTBI, as well as significant long-range increases in amplitude envelope correlations among deep-source, temporal, and frontal regions in the delta, theta, and alpha bands. Subsequently, we conducted an exploratory analysis of patterns of connectivity most associated with variability in secondary symptoms of mTBI, including inattention, anxiety, and depression. Differential patterns of altered resting state neurophysiological network connectivity were found across frequency bands. This indicated that multiple network and frequency specific alterations in large scale brain connectivity may contribute to overlapping cognitive sequelae in mTBI. In conclusion, we show that local spectral power content can be supplemented with measures of correlations in amplitude to define general networks that are atypical in mTBI, and suggest that certain cognitive difficulties are mediated by disturbances in a variety of alterations in network interactions which are differentially expressed across canonical neurophysiological frequency ranges. Crown Copyright (C) 2015 Published by Elsevier Inc.	[Dunkley, B. T.; Taylor, M. J.; Doesburg, S. M.] Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada; [Dunkley, B. T.; Pang, E. W.; Taylor, M. J.; Doesburg, S. M.] Hosp Sick Children, Res Inst, Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; [Da Costa, L.; Bethune, A.] Sunnybrook Med Ctr, Div Neurosurg, Toronto, ON, Canada; [Jetly, R.] Canadian Forces Hlth Serv, Directorate Mental Hlth, Ottawa, ON, Canada; [Pang, E. W.; Taylor, M. J.] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada; [Doesburg, S. M.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Taylor, M. J.; Doesburg, S. M.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada		Dunkley, BT (corresponding author), Dept Diagnost Imaging, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	ben.dunkley@sickkids.ca	; da Costa, Leodante/F-7474-2010	Dunkley, Ben/0000-0001-6173-1171; da Costa, Leodante/0000-0002-3222-4944	Defence Research and Development Canada (DRDC); Canadian Forces Health Services [W7719-135182/001/TOR]	Thanks are given to Amanda Robertson and Marc Lalancette for their help in the data collection, and Daniel Cassel for his help with the data analysis pipeline. This work was supported by funding from Defence Research and Development Canada (DRDC) and the Canadian Forces Health Services to MJT and EWP (contract # W7719-135182/001/TOR).	BALL GJ, 1977, ELECTROEN CLIN NEURO, V43, P346, DOI 10.1016/0013-4694(77)90258-9; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BJELLAND I, 2002, J PSYCHOSOM RES, V0052; BRADY EU, 1992, PSYCHOL BULL, V111, P244, DOI 10.1037/0033-2909.111.2.244; Brookes MJ, 2011, P NATL ACAD SCI USA, V108, P16783, DOI 10.1073/pnas.1112685108; Brookes MJ, 2011, NEUROIMAGE, V56, P1082, DOI 10.1016/j.neuroimage.2011.02.054; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; CLARKE DM, 1991, AUST NZ J PSYCHIAT, V25, P322, DOI 10.3109/00048679109062632; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Dunkley BT, 2014, NEUROIMAGE-CLIN, V5, P377, DOI 10.1016/j.nicl.2014.07.017; Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038; Engel AK, 2010, CURR OPIN NEUROBIOL, V20, P156, DOI 10.1016/j.conb.2010.02.015; Fan J, 2007, J NEUROSCI, V27, P6197, DOI 10.1523/JNEUROSCI.1833-07.2007; Fan J, 2009, BRAIN COGNITION, V70, P209, DOI 10.1016/j.bandc.2009.02.002; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hari R, 2012, NEUROIMAGE, V61, P386, DOI 10.1016/j.neuroimage.2011.11.074; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hipp JF, 2012, NAT NEUROSCI, V15, P884, DOI 10.1038/nn.3101; Honey CJ, 2007, P NATL ACAD SCI USA, V104, P10240, DOI 10.1073/pnas.0701519104; Huang MX, 2007, NEUROIMAGE, V37, P731, DOI 10.1016/j.neuroimage.2007.06.002; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KLIMESCH W, 1994, ELECTROEN CLIN NEURO, V91, P428, DOI 10.1016/0013-4694(94)90164-3; Klimesch W., 1993, Brain Topography, V5, P241, DOI 10.1007/BF01128991; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Muthukumaraswamy SD, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00138; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Palva JM, 2005, J NEUROSCI, V25, P3962, DOI 10.1523/JNEUROSCI.4250-04.2005; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; Quraan MA, 2010, NEUROIMAGE, V49, P2387, DOI 10.1016/j.neuroimage.2009.10.012; Raz A, 2006, NAT REV NEUROSCI, V7, P367, DOI 10.1038/nrn1903; Raz Amir, 2004, Anatomical Record Part B:The New Anatomist, V281, P21, DOI 10.1002/ar.b.20035; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sadaghiani S, 2012, J NEUROSCI, V32, P14305, DOI 10.1523/JNEUROSCI.1358-12.2012; Schaul N, 1998, ELECTROEN CLIN NEURO, V106, P101, DOI 10.1016/S0013-4694(97)00111-9; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; Siegel M, 2012, NAT REV NEUROSCI, V13, P121, DOI 10.1038/nrn3137; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Tewarie P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069318; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vincent JL, 2007, NATURE, V447, P83, DOI 10.1038/nature05758; Wang XJ, 2010, PHYSIOL REV, V90, P1195, DOI 10.1152/physrev.00035.2008; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; WHYTE J, 1995, ARCH PHYS MED REHAB, V76, P804, DOI 10.1016/S0003-9993(95)80543-5; Wittchen HU, 2002, J CLIN PSYCHIAT, V63, P24; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zalesky A, 2012, NEUROIMAGE, V60, P1055, DOI 10.1016/j.neuroimage.2012.01.068; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	65	43	43	2	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	7						611	621		10.1016/j.nicl.2015.02.020			11	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI0GE	WOS:000373172600066	25844315	Green Published, gold			2022-02-06	
